<SEC-DOCUMENT>0001387131-20-002086.txt : 20200224
<SEC-HEADER>0001387131-20-002086.hdr.sgml : 20200224
<ACCEPTANCE-DATETIME>20200224161820
ACCESSION NUMBER:		0001387131-20-002086
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		86
CONFORMED PERIOD OF REPORT:	20191231
FILED AS OF DATE:		20200224
DATE AS OF CHANGE:		20200224

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TherapeuticsMD, Inc.
		CENTRAL INDEX KEY:			0000025743
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				870233535
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-00100
		FILM NUMBER:		20644527

	BUSINESS ADDRESS:	
		STREET 1:		951 YAMATO ROAD, SUITE 220
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33431
		BUSINESS PHONE:		561-961-1900

	MAIL ADDRESS:	
		STREET 1:		951 YAMATO ROAD, SUITE 220
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33431

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMHN, Inc.
		DATE OF NAME CHANGE:	20090930

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CROFF ENTERPRISES INC
		DATE OF NAME CHANGE:	19970915

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CROFF OIL CO
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>txmd-10k_123119.htm
<DESCRIPTION>ANNUAL REPORT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:us-roles="http://fasb.org/us-roles/2019-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:txmd="http://therapeuticsmd.com/20191231">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" /></head>
<!-- Field: Set; Name: xdx; ID: xdx_021_US%2DGAAP%2D2019 -->
<!-- Field: Set; Name: xdx; ID: xdx_03B_txmd_therapeuticsmd.com_20191231 -->
<!-- Field: Set; Name: xdx; ID: xdx_045_20190101_20191231 -->
<!-- Field: Set; Name: xdx; ID: xdx_054_edei%2D%2DEntityCentralIndexKey_0000025743 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DDocumentFiscalPeriodFocus_FY -->
<!-- Field: Set; Name: xdx; ID: xdx_05F_edei%2D%2DDocumentFiscalYearFocus_2019 -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0xMi0zMQ== -->
<!-- Field: Set; Name: xdx; ID: xdx_07D_XDX_P%2D%2D\Clients\TherapeuticsMD\2020\q20%2D00531__10%2DK\merged.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_065_EUR_0_iso4217%2D%2DEUR -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_sqft_0_utr%2D%2Dsqft -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
  <ix:hidden>
    <ix:nonNumeric contextRef="From2019-01-01to2019-12-31" name="dei:EntityCentralIndexKey">0000025743</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2019-01-01to2019-12-31" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2019-01-01to2019-12-31" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2019-01-01to2019-12-31" name="dei:DocumentFiscalYearFocus">2019</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2019-01-01to2019-12-31" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2019-01-01to2019-12-31" id="xdx2ixbrl0037" name="dei:EntityFilerCategory">Large Accelerated Filer</ix:nonNumeric>
    <ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2018-12-31" id="xdx2ixbrl0083" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2018-12-31" id="xdx2ixbrl0116" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2019-12-31" id="xdx2ixbrl0127" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2018-12-31" id="xdx2ixbrl0128" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2018-01-012018-12-31_us-gaap_LicenseAndServiceMember" id="xdx2ixbrl0180" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2017-01-012017-12-31_us-gaap_LicenseAndServiceMember" id="xdx2ixbrl0181" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2018-01-012018-12-31" id="xdx2ixbrl0224" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2017-01-012017-12-31" id="xdx2ixbrl0225" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2017-01-012017-12-31" id="xdx2ixbrl0233" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" contextRef="From2019-01-01to2019-12-31" id="xdx2ixbrl0235" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" contextRef="From2018-01-012018-12-31" id="xdx2ixbrl0236" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2019-01-01to2019-12-31" id="xdx2ixbrl0247" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2018-01-012018-12-31" id="xdx2ixbrl0248" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2017-01-012017-12-31" id="xdx2ixbrl0249" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2017-01-012017-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0276" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2017-01-012017-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0283" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2017-01-012017-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0290" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2017-01-012017-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0295" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2017-01-012017-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0297" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" contextRef="AsOf2016-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0300" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" contextRef="AsOf2016-12-31" id="xdx2ixbrl0303" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2017-01-012017-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0305" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2017-01-012017-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0306" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2018-01-012018-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0318" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2018-01-012018-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0324" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2018-01-012018-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0328" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2018-01-012018-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0330" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2018-01-012018-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0333" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2018-01-012018-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0334" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2019-01-012019-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0346" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2019-01-012019-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0352" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2019-01-012019-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0359" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-01-012019-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0362" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-01-012019-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0363" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:OtherNoncashExpense" contextRef="From2018-01-012018-12-31" id="xdx2ixbrl0395" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:OtherNoncashExpense" contextRef="From2017-01-012017-12-31" id="xdx2ixbrl0396" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="txmd:NoncashOperatingLeaseExpense" contextRef="From2018-01-012018-12-31" id="xdx2ixbrl0399" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="txmd:NoncashOperatingLeaseExpense" contextRef="From2017-01-012017-12-31" id="xdx2ixbrl0400" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2018-01-012018-12-31" id="xdx2ixbrl0407" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2017-01-012017-12-31" id="xdx2ixbrl0408" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:OtherAmortizationOfDeferredCharges" contextRef="From2018-01-012018-12-31" id="xdx2ixbrl0415" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:OtherAmortizationOfDeferredCharges" contextRef="From2017-01-012017-12-31" id="xdx2ixbrl0416" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AmortizationOfFinancingCosts" contextRef="From2017-01-012017-12-31" id="xdx2ixbrl0420" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="txmd:PaymentsToAcquireIntellectualPropertyLicense" contextRef="From2017-01-012017-12-31" id="xdx2ixbrl0456" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:IncreaseDecreaseInRestrictedCash" contextRef="From2017-01-012017-12-31" id="xdx2ixbrl0468" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" contextRef="From2018-01-012018-12-31" id="xdx2ixbrl0487" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" contextRef="From2017-01-012017-12-31" id="xdx2ixbrl0488" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt" contextRef="From2019-01-01to2019-12-31" id="xdx2ixbrl0490" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt" contextRef="From2017-01-012017-12-31" id="xdx2ixbrl0492" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:PaymentsOfFinancingCosts" contextRef="From2017-01-012017-12-31" id="xdx2ixbrl0496" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:RepaymentsOfOtherLongTermDebt" contextRef="From2018-01-012018-12-31" id="xdx2ixbrl0499" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:RepaymentsOfOtherLongTermDebt" contextRef="From2017-01-012017-12-31" id="xdx2ixbrl0500" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2017-01-012017-12-31" id="xdx2ixbrl0524" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonNumeric contextRef="From2019-01-012019-12-31_us-gaap_LandAndBuildingMember_srt_MinimumMember" id="xdx2ixbrl0553" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">P3Y</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2019-01-012019-12-31_us-gaap_LandAndBuildingMember_srt_MaximumMember" id="xdx2ixbrl0554" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">P7Y</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2019-01-012019-12-31_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_srt_MinimumMember" id="xdx2ixbrl0555" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">P5Y</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2019-01-012019-12-31_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_srt_MaximumMember" id="xdx2ixbrl0556" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">P7Y</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2019-01-012019-12-31_srt_MinimumMember" name="txmd:ReturnPeriodOfUnsalablePrescriptionProducts">P6M</ix:nonNumeric>
    <ix:nonFraction name="txmd:PrepaidManufacturing" contextRef="AsOf2018-12-31" id="xdx2ixbrl0684" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AccruedRentCurrent" contextRef="AsOf2019-12-31" id="xdx2ixbrl0846" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2018-12-31" id="xdx2ixbrl0850" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2019-01-01to2019-12-31" id="xdx2ixbrl0904" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,057,632</ix:nonFraction>
    <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" contextRef="From2017-01-012017-12-31" id="xdx2ixbrl1220" unitRef="Pure" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" contextRef="From2018-01-012018-12-31" id="xdx2ixbrl1223" unitRef="Pure" xs:nil="true"></ix:nonFraction>
    </ix:hidden>
  <ix:references>
    <link:schemaRef xlink:href="txmd-20191231.xsd" xlink:type="simple" />
    </ix:references>
  <ix:resources>
    <xbrli:context id="From2019-01-01to2019-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-06-28">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-06-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-02-17">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-02-17</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_us-gaap_ProductMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-12-31_us-gaap_ProductMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-012017-12-31_us-gaap_ProductMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_us-gaap_LicenseAndServiceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-12-31_us-gaap_LicenseAndServiceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-012017-12-31_us-gaap_LicenseAndServiceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-012017-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-012017-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-012017-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-012017-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_us-gaap_AccountsReceivableMember_custom_CustomerAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_us-gaap_AccountsReceivableMember_custom_CustomerBMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerBMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_us-gaap_AccountsReceivableMember_custom_CustomerCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_us-gaap_AccountsReceivableMember_custom_CustomerDMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerDMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-12-31_us-gaap_AccountsReceivableMember_custom_CustomerAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-12-31_us-gaap_AccountsReceivableMember_custom_CustomerBMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerBMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-12-31_us-gaap_AccountsReceivableMember_custom_CustomerCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_us-gaap_LandAndBuildingMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandAndBuildingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_us-gaap_LandAndBuildingMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandAndBuildingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_VitaminsAndImvexxyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:VitaminsAndImvexxyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_BijuvaAndAnnoveraMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:BijuvaAndAnnoveraMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-07-302018-08-06_custom_SubscriptionAgreementKnightMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">txmd:SubscriptionAgreementKnightMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-07-30</xbrli:startDate>
        <xbrli:endDate>2018-08-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-08-06_custom_SubscriptionAgreementKnightMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">txmd:SubscriptionAgreementKnightMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-08-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-08-042019-08-05_custom_LicenseAgreementTheramexMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:LicenseAgreementTheramexMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-08-04</xbrli:startDate>
        <xbrli:endDate>2019-08-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-08-032019-08-05_custom_LicenseAgreementTheramexMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:LicenseAgreementTheramexMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-08-03</xbrli:startDate>
        <xbrli:endDate>2019-08-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-06-06_custom_LicenseAgreementTheramexMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:LicenseAgreementTheramexMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-06-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-06-052019-06-06_custom_LicenseAgreementTheramexMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:LicenseAgreementTheramexMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-06-05</xbrli:startDate>
        <xbrli:endDate>2019-06-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-06-052019-06-06_custom_LicenseAgreementTheramexMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:LicenseAgreementTheramexMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-06-05</xbrli:startDate>
        <xbrli:endDate>2019-06-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-06-052019-06-06_custom_LicenseAgreementTheramexMember_custom_BijuvaAndAnnoveraMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:LicenseAgreementTheramexMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:BijuvaAndAnnoveraMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-06-05</xbrli:startDate>
        <xbrli:endDate>2019-06-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_PrescriptionVitaminsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:PrescriptionVitaminsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-12-31_custom_PrescriptionVitaminsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:PrescriptionVitaminsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-012017-12-31_custom_PrescriptionVitaminsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:PrescriptionVitaminsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_ImvexxyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:ImvexxyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-12-31_custom_ImvexxyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:ImvexxyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_BijuvaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:BijuvaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_AnnoveraMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:AnnoveraMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-012017-12-31_custom_OtcProductsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:OtcProductsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-012017-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-012017-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-12-31_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-01-02_us-gaap_AccountingStandardsUpdate201602Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-01-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-08-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-08-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_EquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_EquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_ComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_ComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ApprovedHormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ApprovedHormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_HormoneTherapyDrugCandidatePatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">txmd:HormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_MultipleTrademarksForVitaminsSupplementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">txmd:MultipleTrademarksForVitaminsSupplementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_InternetDomainNamesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InternetDomainNamesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ApprovedHormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ApprovedHormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_custom_HormoneTherapyDrugCandidatePatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">txmd:HormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_custom_MultipleTrademarksForVitaminsSupplementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">txmd:MultipleTrademarksForVitaminsSupplementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_DomesticUSPatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticUSPatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_ForeignPatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ForeignPatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_DomesticPatentsBijuvaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticPatentsBijuvaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_ForeignPatentsBijuvaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ForeignPatentsBijuvaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_DomesticPatentsNonApprovedBijuvaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticPatentsNonApprovedBijuvaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_DomesticUSPatentsImvexxyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticUSPatentsImvexxyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_DomesticUSUtilityPatentsImvexxyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticUSUtilityPatentsImvexxyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_DomesticUSDesignPatentsImvexxyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticUSDesignPatentsImvexxyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_ForeignPatentsImvexxyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ForeignPatentsImvexxyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_ForeignUtilityPatentsImvexxyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ForeignUtilityPatentsImvexxyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_ForeignDesignPatentsImvexxyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ForeignDesignPatentsImvexxyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_DomesticUSPatentsTopicalCreamMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticUSPatentsTopicalCreamMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_DomesticUtilityPatentTransdermalPatchMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticUtilityPatentTransdermalPatchMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_ForeignUtilityPatentTransdermalPatchMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ForeignUtilityPatentTransdermalPatchMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_DomesticUtilityPatentTx009HRMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticUtilityPatentTx009HRMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_DomesticPatentsProgesteroneFormulationsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticPatentsProgesteroneFormulationsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_ForeignPatentsProgesteroneFormulationsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ForeignPatentsProgesteroneFormulationsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_DomesticUtilityPatentOperaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticUtilityPatentOperaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-012019-09-30_custom_AnnoveraMember_custom_CouncilLicenseAgreement1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:AnnoveraMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreement1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-07-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_custom_AnnoveraMember_custom_CouncilLicenseAgreement1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:AnnoveraMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreement1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_AnnoveraMember_custom_CouncilLicenseAgreement1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:AnnoveraMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreement1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_CouncilLicenseAgreementStep1Member_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreementStep1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_CouncilLicenseAgreementStep1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreementStep1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_CouncilLicenseAgreementStep2Member_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreementStep2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_CouncilLicenseAgreementStep2Member_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreementStep2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_CouncilLicenseAgreementStep2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreementStep2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_CouncilLicenseAgreementStep3Member_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreementStep3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_CouncilLicenseAgreementStep3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreementStep3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_CouncilLicenseAgreement1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreement1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-04-24_us-gaap_RevolvingCreditFacilityMember_custom_FinancingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-04-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-232019-04-24_custom_FinancingAgreementMember_custom_TrancheOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="txmd:DebtTrancheAxis">txmd:TrancheOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-23</xbrli:startDate>
        <xbrli:endDate>2019-04-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-04-24_custom_FinancingAgreementMember_custom_TrancheTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="txmd:DebtTrancheAxis">txmd:TrancheTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-04-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-02-162020-02-18_custom_FinancingAgreementMember_custom_TrancheThreeMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="txmd:DebtTrancheAxis">txmd:TrancheThreeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-02-16</xbrli:startDate>
        <xbrli:endDate>2020-02-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012019-12-31_custom_ImvexxyBijuvaAndAnnoveraMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:ImvexxyBijuvaAndAnnoveraMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-232019-04-24_custom_FinancingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-23</xbrli:startDate>
        <xbrli:endDate>2019-04-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-04-24_custom_FinancingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-04-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-232019-04-24_custom_FinancingAgreementMember_us-gaap_PrimeRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-23</xbrli:startDate>
        <xbrli:endDate>2019-04-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-04-24_custom_FinancingAgreementMember_us-gaap_PrimeRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-04-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-04-24_custom_FinancingAgreementMember_custom_TrancheTwoThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="txmd:DebtTrancheAxis">txmd:TrancheTwoThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-04-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-05-01_us-gaap_SecuredDebtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-05-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-04-302018-05-01_us-gaap_SecuredDebtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-04-30</xbrli:startDate>
        <xbrli:endDate>2018-05-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-04-302018-05-01_us-gaap_RevolvingCreditFacilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-04-30</xbrli:startDate>
        <xbrli:endDate>2018-05-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-232019-04-24_custom_MidCapAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:MidCapAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-23</xbrli:startDate>
        <xbrli:endDate>2019-04-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_MidCapAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:MidCapAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_FinancingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_TrancheOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="txmd:DebtTrancheAxis">txmd:TrancheOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_FinancingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_custom_CreditAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:CreditAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-242019-10-29_custom_UnderwritingAgreementJPMorganChaseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:UnderwritingAgreementJPMorganChaseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-24</xbrli:startDate>
        <xbrli:endDate>2019-10-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-10-29_custom_UnderwritingAgreementJPMorganChaseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:UnderwritingAgreementJPMorganChaseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-10-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-08-012018-08-06_custom_UnderwritingAgreementGoldmanSachsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:UnderwritingAgreementGoldmanSachsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-08-01</xbrli:startDate>
        <xbrli:endDate>2018-08-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-08-06_custom_UnderwritingAgreementGoldmanSachsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:UnderwritingAgreementGoldmanSachsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-08-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-08-052018-08-06_custom_SubscriptionAgreementKnightMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:SubscriptionAgreementKnightMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-08-05</xbrli:startDate>
        <xbrli:endDate>2018-08-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-08-06_custom_SubscriptionAgreementKnightMember819119062">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:SubscriptionAgreementKnightMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-08-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-12-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-09-242017-09-25_custom_UnderwritingAgreementJPMorganChaseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:UnderwritingAgreementJPMorganChaseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-09-24</xbrli:startDate>
        <xbrli:endDate>2017-09-25</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-09-28_custom_UnderwritingAgreementJPMorganChaseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:UnderwritingAgreementJPMorganChaseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-09-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-09-262017-09-28_custom_UnderwritingAgreementJPMorganChaseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:UnderwritingAgreementJPMorganChaseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-09-26</xbrli:startDate>
        <xbrli:endDate>2017-09-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_WarrantsMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_WarrantsMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_OutsideConsultant2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:OutsideConsultant2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_OutsideConsultant2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:OutsideConsultant2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-12-31_custom_OutsideConsultant2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:OutsideConsultant2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_custom_OutsideConsultant2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:OutsideConsultant2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-012017-12-31_custom_OutsideConsultant2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:OutsideConsultant2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_custom_OutsideConsultant2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:OutsideConsultant2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-12-31_custom_WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-012017-12-31_custom_WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_WarrantsCashlessExerciseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantsCashlessExerciseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-012017-12-31_custom_WarrantsCashlessExerciseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantsCashlessExerciseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_LongTermIncentiveCompensationPlan2009Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:LongTermIncentiveCompensationPlan2009Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_NonQualified2012StockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:NonQualified2012StockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_NonQualified2012StockIncentivePlanMember_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:NonQualified2012StockIncentivePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_Plan2019Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:Plan2019Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_Plan2019Member_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:Plan2019Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-12-31_us-gaap_EmployeeStockOptionMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-12-31_us-gaap_EmployeeStockOptionMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-012017-12-31_us-gaap_EmployeeStockOptionMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-012017-12-31_us-gaap_EmployeeStockOptionMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-12-122018-12-13_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-12-12</xbrli:startDate>
        <xbrli:endDate>2018-12-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-292019-07-30_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-07-29</xbrli:startDate>
        <xbrli:endDate>2019-07-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_us-gaap_DomesticCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-12-31_us-gaap_DomesticCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-012017-12-31_us-gaap_DomesticCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_InternalRevenueServiceIRSMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_InternalRevenueServiceIRSMember_custom_ExpirationPeriod20YearsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">txmd:ExpirationPeriod20YearsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_us-gaap_InternalRevenueServiceIRSMember_custom_ExpirationPeriod20YearsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">txmd:ExpirationPeriod20YearsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_InternalRevenueServiceIRSMember_custom_ExpirationPeriodIndefiniteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">txmd:ExpirationPeriodIndefiniteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_srt_AffiliatedEntityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-12-31_srt_AffiliatedEntityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-012017-12-31_srt_AffiliatedEntityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_srt_AffiliatedEntityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_srt_AffiliatedEntityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_us-gaap_SupplierConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_SupplierTwoConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:SupplierTwoConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_SupplierThreeConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:SupplierThreeConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-12-31_us-gaap_SupplierConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-12-31_custom_SupplierTwoConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:SupplierTwoConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-12-31_custom_SupplierThreeConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:SupplierThreeConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-012017-12-31_us-gaap_SupplierConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-012017-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_us-gaap_SalesRevenueNetMember_custom_FourCustomersConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:FourCustomersConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-12-31_us-gaap_SalesRevenueNetMember_custom_FourCustomersConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:FourCustomersConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-012017-12-31_us-gaap_SalesRevenueNetMember_custom_FourCustomersConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:FourCustomersConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationMcKessonCorporationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationMcKessonCorporationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationPillPackRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationPillPackRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationAmerisourceBergenRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationAmerisourceBergenRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationCardinalHealthRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationCardinalHealthRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-12-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationMcKessonCorporationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationMcKessonCorporationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-12-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationPillPackRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationPillPackRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-12-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationAmerisourceBergenRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationAmerisourceBergenRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-12-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationCardinalHealthRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationCardinalHealthRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-012017-12-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationAmerisourceBergenRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationAmerisourceBergenRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-012017-12-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationMcKessonCorporationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationMcKessonCorporationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-012017-12-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationCardinalHealthRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationCardinalHealthRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-012017-12-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationPharmacyInnovationsPaRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationPharmacyInnovationsPaRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-06-302013-07-01">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-06-30</xbrli:startDate>
        <xbrli:endDate>2013-07-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-10-02">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-10-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-08-01">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-08-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-06-01">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-06-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_CatalentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">txmd:CatalentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_AnnoveraMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">txmd:AnnoveraMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-012019-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-012019-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-07-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012019-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-04-012018-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-04-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-07-012018-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-07-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-10-012018-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-10-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-012019-09-30_custom_LicenseAgreementTheramexMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:LicenseAgreementTheramexMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-07-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-02-162020-02-18_custom_FinancingAgreementMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-02-16</xbrli:startDate>
        <xbrli:endDate>2020-02-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="EUR">
      <xbrli:measure>iso4217:EUR</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="sqft">
      <xbrli:measure>utr:sqft</xbrli:measure>
    </xbrli:unit>
    </ix:resources>
  </ix:header>
</div>


<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div><div style="float: left; margin-top: 12pt; margin-bottom: 3pt"><div style="border-top: Black 4pt solid; border-bottom: Black 1pt solid; font-size: 1pt; width: 100%"></div></div></div><!-- Field: /Rule-Page -->

<p style="margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 14pt Times New Roman, Times, Serif"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 14pt Times New Roman, Times, Serif"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 12pt Times New Roman, Times, Serif"><b>Washington,
DC 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></p>
<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 20%"><div style="border-top: Black 1pt solid; font-size: 1pt"></div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 16pt Times New Roman, Times, Serif"><b>Form
<span id="xdx_902_edei--DocumentType_c20190101__20191231_zIlC0grlMiu4"><ix:nonNumeric contextRef="From2019-01-01to2019-12-31" name="dei:DocumentType">10-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 5%; font-size: 10pt"><span style="font: 12pt Times New Roman, Times, Serif"><span id="xdx_90D_edei--DocumentAnnualReport_c20190101__20191231_zMd96PHuehZ8"><ix:nonNumeric contextRef="From2019-01-01to2019-12-31" format="ixt-sec:boolballotbox" name="dei:DocumentAnnualReport">&#9746;</ix:nonNumeric></span></span></td>
    <td style="width: 95%; font-size: 10pt; text-align: justify"><span style="font: 12pt Times New Roman, Times, Serif"><b>ANNUAL
    REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></td></tr>
<tr style="vertical-align: top">
    <td style="font-size: 10pt"><span style="font: 12pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font: 12pt Times New Roman, Times, Serif"><b>For
    the fiscal year ended <span id="xdx_90B_edei--DocumentPeriodEndDate_c20190101__20191231_zaIeBJSGLCuk"><ix:nonNumeric contextRef="From2019-01-01to2019-12-31" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">December 31, 2019</ix:nonNumeric></span></b></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">or</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 5%"><span style="font: 12pt Times New Roman, Times, Serif"><b><span id="xdx_90E_edei--DocumentTransitionReport_c20190101__20191231_zU4Q00s690Rd"><ix:nonNumeric contextRef="From2019-01-01to2019-12-31" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span></b></span></td>
    <td style="width: 95%; text-align: justify"><span style="font: 12pt Times New Roman, Times, Serif"><b>TRANSITION
    REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></td></tr>
<tr style="vertical-align: top">
    <td><span style="font: 12pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font: 12pt Times New Roman, Times, Serif"><b>For the transition
    period from ______________________ to ________________________</b></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Commission
File Number <span id="xdx_90C_edei--EntityFileNumber_c20190101__20191231_zGireUUfVd4c"><ix:nonNumeric contextRef="From2019-01-01to2019-12-31" name="dei:EntityFileNumber">001-00100</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 20%"><div style="border-top: Black 1pt solid; font-size: 1pt"></div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 18pt Times New Roman, Times, Serif"><b><span id="xdx_90A_edei--EntityRegistrantName_c20190101__20191231_zxDV5CgWVHmf"><ix:nonNumeric contextRef="From2019-01-01to2019-12-31" name="dei:EntityRegistrantName">TherapeuticsMD, Inc.</ix:nonNumeric></span></b></span></p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 35%"><div style="border-top: Black 1pt solid; font-size: 1pt"></div></div><!-- Field: /Rule-Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;
<span style="font-size: 10pt"><i>(Exact Name of Registrant as Specified in Its Charter)</i></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; width: 35%; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90E_edei--EntityIncorporationStateCountryCode_c20190101__20191231_zd26Z5YGYoP8"><ix:nonNumeric contextRef="From2019-01-01to2019-12-31" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Nevada</ix:nonNumeric></span></span></td>
    <td style="width: 30%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 35%; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90F_edei--EntityTaxIdentificationNumber_c20190101__20191231_zEYCtVMRwaq5"><ix:nonNumeric contextRef="From2019-01-01to2019-12-31" name="dei:EntityTaxIdentificationNumber">87-0233535</ix:nonNumeric></span></span></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-style: italic; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(State or Other
    Jurisdiction of Incorporation or Organization)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-style: italic; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">(I.R.S. Employer
    Identification No.)</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_90A_edei--EntityAddressAddressLine1_c20190101__20191231_zVi9G5JYLNa2"><ix:nonNumeric contextRef="From2019-01-01to2019-12-31" name="dei:EntityAddressAddressLine1">951 Yamato Rd.</ix:nonNumeric></span>, <span id="xdx_90D_edei--EntityAddressAddressLine2_c20190101__20191231_znSDa9fHVgkh"><ix:nonNumeric contextRef="From2019-01-01to2019-12-31" name="dei:EntityAddressAddressLine2">Suite 220</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_903_edei--EntityAddressCityOrTown_c20190101__20191231_ziuX2wHk8XWk"><ix:nonNumeric contextRef="From2019-01-01to2019-12-31" name="dei:EntityAddressCityOrTown">Boca Raton</ix:nonNumeric></span>, <span id="xdx_903_edei--EntityAddressStateOrProvince_c20190101__20191231_zCN3a7o8U2Ef"><ix:nonNumeric contextRef="From2019-01-01to2019-12-31" name="dei:EntityAddressStateOrProvince">FL</ix:nonNumeric></span> <span id="xdx_90F_edei--EntityAddressPostalZipCode_c20190101__20191231_zzYKJuJ3XqSa"><ix:nonNumeric contextRef="From2019-01-01to2019-12-31" name="dei:EntityAddressPostalZipCode">33431</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_903_edei--CityAreaCode_c20190101__20191231_zLzOlDnCAFG1"><ix:nonNumeric contextRef="From2019-01-01to2019-12-31" name="dei:CityAreaCode">(561)</ix:nonNumeric></span>
<span id="xdx_90F_edei--LocalPhoneNumber_c20190101__20191231_zfpeSb9vnmed"><ix:nonNumeric contextRef="From2019-01-01to2019-12-31" name="dei:LocalPhoneNumber">961-1900</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><i>(Address,
including zip code, and telephone number,</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><i>including
area code, of Principal Executive Offices)</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Securities
registered pursuant to Section 12(b) of the Act:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 34%; text-align: center; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Title
        of Each Class</b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 33%; text-align: center; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Trading
        Symbol</b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 33%; text-align: center; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif"><b>Name
    of Each Exchange on Which Registered</b></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_907_edei--Security12bTitle_c20190101__20191231_zaRPSPfPTt48"><ix:nonNumeric contextRef="From2019-01-01to2019-12-31" name="dei:Security12bTitle">Common Stock, par value $0.001 per share</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90D_edei--TradingSymbol_c20190101__20191231_zkT7WTaKNLV"><ix:nonNumeric contextRef="From2019-01-01to2019-12-31" name="dei:TradingSymbol">TXMD</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_903_edei--SecurityExchangeName_c20190101__20191231_z2q24PoK5kpf"><ix:nonNumeric contextRef="From2019-01-01to2019-12-31" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">The Nasdaq Stock Market LLC</ix:nonNumeric></span></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"><b>Securities
registered pursuant to Section 12(g) of the Act: </b>None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes &#9744;&#160;&#160;&#160;&#160;&#160;<span id="xdx_906_edei--EntityWellKnownSeasonedIssuer_c20190101__20191231_z2amOBc2KBJ"><ix:nonNumeric contextRef="From2019-01-01to2019-12-31" name="dei:EntityWellKnownSeasonedIssuer">No</ix:nonNumeric></span>
&#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">Indicate
by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes &#9744;&#160;&#160;&#160;<span id="xdx_90E_edei--EntityVoluntaryFilers_c20190101__20191231_zD1bDLVTWrih"><ix:nonNumeric contextRef="From2019-01-01to2019-12-31" name="dei:EntityVoluntaryFilers">No</ix:nonNumeric></span>
&#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days. <span id="xdx_902_edei--EntityCurrentReportingStatus_c20190101__20191231_zjNfpcTFRnWe"><ix:nonNumeric contextRef="From2019-01-01to2019-12-31" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span> &#9746;&#160;&#160;&#160;&#160;&#160;No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant
to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that
the registrant was required to submit such files). <span id="xdx_90D_edei--EntityInteractiveDataCurrent_c20190101__20191231_zWY1T7pcoeM4"><ix:nonNumeric contextRef="From2019-01-01to2019-12-31" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span> &#9746;&#160;&#160;&#160;&#160;&#160;No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221;
&#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. (Check one):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 30%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90A_edei--EntityFilerCategory_c20190101__20191231_zQvux9DTRr53"><span style="-sec-ix-hidden: xdx2ixbrl0037">Large accelerated filer</span></span> &#9746;</span></td>
    <td style="width: 20%"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 30%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;Accelerated
    filer &#9744;</span></td>
    <td style="width: 20%">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;Non-accelerated
    filer &#9744;</span></td>
    <td></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">Smaller reporting
    company <span id="xdx_90F_edei--EntitySmallBusiness_c20190101__20191231_zB4s20VWijtb"><ix:nonNumeric contextRef="From2019-01-01to2019-12-31" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness">&#9744;</ix:nonNumeric></span></span></td>
    <td>&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">Emerging growth Company
    <span id="xdx_906_edei--EntityEmergingGrowthCompany_c20190101__20191231_zZg2S9je0Dn2"><ix:nonNumeric contextRef="From2019-01-01to2019-12-31" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></td>
    <td>&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes &#9744; &#160;&#160;&#160;<span id="xdx_90F_edei--EntityShellCompany_c20190101__20191231_zTzq6HocSBgf"><ix:nonNumeric contextRef="From2019-01-01to2019-12-31" format="ixt:booleanfalse" name="dei:EntityShellCompany">No</ix:nonNumeric></span>
&#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
aggregate market value of common stock held by non-affiliates of the registrant (<span id="xdx_90B_ecustom--EntityCommonStockHeldByNonaffiliates_iI_c20190628_zLwNGUZAg1z4" title="Entity Common Stock Held by Non-affiliates"><ix:nonFraction name="txmd:EntityCommonStockHeldByNonaffiliates" contextRef="AsOf2019-06-28" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">207,399,071</ix:nonFraction></span> shares) based on the closing price
of the registrant&#8217;s common stock as reported on the Nasdaq Global Select Market on June 28, 2019, which was the last business
day of the registrant&#8217;s most recently completed second fiscal quarter, was $<span id="xdx_90C_edei--EntityPublicFloat_iI_c20190628_zQcI6KPg8XTi"><ix:nonFraction name="dei:EntityPublicFloat" contextRef="AsOf2019-06-28" format="ixt:numdotdecimal" decimals="0" unitRef="USD">539,237,585</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As
of February 17, 2020, there were outstanding <span id="xdx_903_edei--EntityCommonStockSharesOutstanding_iI_c20200217_zhcV5sPLvvua"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2020-02-17" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">271,526,176</ix:nonFraction></span> shares of the registrant&#8217;s common stock, par value $0.001 per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Documents
Incorporated by Reference</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Portions
of the registrant&#8217;s definitive Proxy Statement for its 2020 Annual Meeting of Stockholders are incorporated by reference
into Part III of this Annual Report on Form 10-K where indicated. Such Proxy Statement will be filed with the Securities and Exchange
Commission no later than 120 days after the end of the registrant&#8217;s fiscal year ended December 31, 2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: Rule-Page --><div><div style="float: left; margin-top: 3pt; margin-bottom: 12pt"><div style="border-top: Black 1pt solid; border-bottom: Black 4pt solid; font-size: 1pt; width: 100%">&#160;</div></div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo --><!-- Field: /Sequence --></p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
        <span style="font: 10pt Times New Roman, Times, Serif"><b>THERAPEUTICSMD, INC.</b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
        <span style="font: 10pt Times New Roman, Times, Serif"><b>ANNUAL REPORT ON FORM 10-K</b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
        <span style="font: 10pt Times New Roman, Times, Serif"><b>Fiscal Year Ended December 31, 2019</b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
        <span style="font: 10pt Times New Roman, Times, Serif"><b>TABLE OF CONTENTS</b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
        <tr style="vertical-align: top">
            <td style="width: 9%">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="width: 87%; text-align: center">
                <span style="font: 10pt Times New Roman, Times, Serif"><a href="#txmd10ka001">PART I</a> </span>
            </td>
            <td style="width: 4%">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td>
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="text-align: center">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td>
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td>
                <span style="font: 10pt Times New Roman, Times, Serif"><a href="#txmd10ka001">Item 1.</a></span>
            </td>
            <td>
                <span style="font: 10pt Times New Roman, Times, Serif"><i><a href="#txmd10ka002">Business</a></i></span>
            </td>
            <td style="text-align: right">
                <span style="font: 10pt Times New Roman, Times, Serif">4 </span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td>
                <span style="font: 10pt Times New Roman, Times, Serif"><a href="#txmd10ka003">Item 1A.</a> </span>
            </td>
            <td>
                <span style="font: 10pt Times New Roman, Times, Serif"><i><a href="#txmd10ka003">Risk Factors</a></i></span>
            </td>
            <td style="text-align: right">
                <span style="font: 10pt Times New Roman, Times, Serif">24</span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td>
                <span style="font: 10pt Times New Roman, Times, Serif"><a href="#txmd10ka004">Item 1B.</a></span>
            </td>
            <td>
                <span style="font: 10pt Times New Roman, Times, Serif"><i><a href="#txmd10ka004">Unresolved Staff Comments</a></i></span>
            </td>
            <td style="text-align: right">
                <span style="font: 10pt Times New Roman, Times, Serif">50</span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td>
                <span style="font: 10pt Times New Roman, Times, Serif"><a href="#txmd10ka005">Item 2.</a> </span>
            </td>
            <td>
                <span style="font: 10pt Times New Roman, Times, Serif"><i><a href="#txmd10ka005">Properties</a></i></span>
            </td>
            <td style="text-align: right">
                <span style="font: 10pt Times New Roman, Times, Serif">50</span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td>
                <span style="font: 10pt Times New Roman, Times, Serif"><a href="#txmd10ka006">Item 3.</a> </span>
            </td>
            <td>
                <span style="font: 10pt Times New Roman, Times, Serif"><i><a href="#txmd10ka006">Legal Proceedings</a></i></span>
            </td>
            <td style="text-align: right">
                <span style="font: 10pt Times New Roman, Times, Serif">51</span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td>
                <span style="font: 10pt Times New Roman, Times, Serif"><a href="#txmd10ka007">Item 4.</a> </span>
            </td>
            <td>
                <span style="font: 10pt Times New Roman, Times, Serif"><i><a href="#txmd10ka007">Mine Safety Disclosures</a></i></span>
            </td>
            <td style="text-align: right">
                <span style="font: 10pt Times New Roman, Times, Serif">51</span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td>
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="text-align: center">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="text-align: right">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td>
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="text-align: center">
                <span style="font: 10pt Times New Roman, Times, Serif"><a href="#txmd10ka008">PART II</a> </span>
            </td>
            <td style="text-align: right">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td>
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="text-align: center">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="text-align: right">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td>
                <span style="font: 10pt Times New Roman, Times, Serif"><a href="#txmd10ka009">Item 5.</a> </span>
            </td>
            <td>
                <span style="font: 10pt Times New Roman, Times, Serif"><i><a href="#txmd10ka009">Market for Registrant&#x2019;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></i></span>
            </td>
            <td style="text-align: right">
                <span style="font: 10pt Times New Roman, Times, Serif">51</span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td>
                <span style="font: 10pt Times New Roman, Times, Serif"><a href="#txmd10ka010">Item 6.</a> </span>
            </td>
            <td>
                <span style="font: 10pt Times New Roman, Times, Serif"><i><a href="#txmd10ka010">Selected Financial Data</a></i></span>
            </td>
            <td style="text-align: right">
                <span style="font: 10pt Times New Roman, Times, Serif">53</span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td>
                <span style="font: 10pt Times New Roman, Times, Serif"><a href="#txmd10ka011">Item 7.</a> </span>
            </td>
            <td>
                <span style="font: 10pt Times New Roman, Times, Serif"><i><a href="#txmd10ka011">Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations</a></i></span>
            </td>
            <td style="text-align: right">
                <span style="font: 10pt Times New Roman, Times, Serif">54</span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td>
                <span style="font: 10pt Times New Roman, Times, Serif"><a href="#txmd10ka012">Item 7A.</a> </span>
            </td>
            <td>
                <span style="font: 10pt Times New Roman, Times, Serif"><i><a href="#txmd10ka012">Quantitative and Qualitative Disclosures About Market Risk</a></i></span>
            </td>
            <td style="text-align: right">
                <span style="font: 10pt Times New Roman, Times, Serif">69</span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td>
                <span style="font: 10pt Times New Roman, Times, Serif"><a href="#txmd10ka013">Item 8.</a></span>
            </td>
            <td>
                <span style="font: 10pt Times New Roman, Times, Serif"><i><a href="#txmd10ka013">Financial Statements and Supplementary Data</a></i></span>
            </td>
            <td style="text-align: right">
                <span style="font: 10pt Times New Roman, Times, Serif">69</span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td>
                <span style="font: 10pt Times New Roman, Times, Serif"><a href="#txmd10ka014">Item 9.</a> </span>
            </td>
            <td>
                <span style="font: 10pt Times New Roman, Times, Serif"><i><a href="#txmd10ka014">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</a></i></span>
            </td>
            <td style="text-align: right">
                <span style="font: 10pt Times New Roman, Times, Serif">69</span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td>
                <span style="font: 10pt Times New Roman, Times, Serif"><a href="#txmd10ka015">Item 9A.</a> </span>
            </td>
            <td>
                <span style="font: 10pt Times New Roman, Times, Serif"><i><a href="#txmd10ka015">Controls and Procedures</a></i></span>
            </td>
            <td style="text-align: right">
                <span style="font: 10pt Times New Roman, Times, Serif">69</span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td>
                <span style="font: 10pt Times New Roman, Times, Serif"><a href="#txmd10ka016">Item 9B.</a> </span>
            </td>
            <td>
                <span style="font: 10pt Times New Roman, Times, Serif"><i><a href="#txmd10ka016">Other Information</a></i></span>
            </td>
            <td style="text-align: right">
                <span style="font: 10pt Times New Roman, Times, Serif">72</span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td>
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="text-align: center">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="text-align: right">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td>
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="text-align: center">
                <span style="font: 10pt Times New Roman, Times, Serif"><a href="#txmd10ka017">PART III</a> </span>
            </td>
            <td style="text-align: right">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td>
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="text-align: center">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="text-align: right">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td>
                <span style="font: 10pt Times New Roman, Times, Serif"><a href="#txmd10ka018">Item 10.</a></span>
            </td>
            <td>
                <span style="font: 10pt Times New Roman, Times, Serif"><i><a href="#txmd10ka018">Directors, Executive Officers and Corporate Governance</a></i></span>
            </td>
            <td style="text-align: right">
                <span style="font: 10pt Times New Roman, Times, Serif">72</span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td>
                <span style="font: 10pt Times New Roman, Times, Serif"><a href="#txmd10ka019">Item 11.</a></span>
            </td>
            <td>
                <span style="font: 10pt Times New Roman, Times, Serif"><i><a href="#txmd10ka019">Executive Compensation</a></i></span>
            </td>
            <td style="text-align: right">
                <span style="font: 10pt Times New Roman, Times, Serif">72</span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td>
                <span style="font: 10pt Times New Roman, Times, Serif"><a href="#txmd10ka020">Item 12.</a></span>
            </td>
            <td>
                <span style="font: 10pt Times New Roman, Times, Serif"><i><a href="#txmd10ka020">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></i></span>
            </td>
            <td style="text-align: right">
                <span style="font: 10pt Times New Roman, Times, Serif">72</span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td>
                <span style="font: 10pt Times New Roman, Times, Serif"><a href="#txmd10ka021">Item 13.</a></span>
            </td>
            <td>
                <span style="font: 10pt Times New Roman, Times, Serif"><i><a href="#txmd10ka021">Certain Relationships and Related Transactions, and Director Independence</a></i></span>
            </td>
            <td style="text-align: right">
                <span style="font: 10pt Times New Roman, Times, Serif">72</span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td>
                <span style="font: 10pt Times New Roman, Times, Serif"><a href="#txmd10ka022">Item 14.</a></span>
            </td>
            <td>
                <span style="font: 10pt Times New Roman, Times, Serif"><i><a href="#txmd10ka022">Principal Accounting Fees and Services</a></i></span>
            </td>
            <td style="text-align: right">
                <span style="font: 10pt Times New Roman, Times, Serif">72</span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td>
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="text-align: center">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="text-align: right">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td>
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="text-align: center">
                <span style="font: 10pt Times New Roman, Times, Serif"><a href="#txmd10ka023">PART IV</a></span>
            </td>
            <td style="text-align: right">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td>
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="text-align: center">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="text-align: right">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td>
                <span style="font: 10pt Times New Roman, Times, Serif"><a href="#txmd10ka024">Item 15.</a> </span>
            </td>
            <td>
                <span style="font: 10pt Times New Roman, Times, Serif"><i><a href="#txmd10ka024">Exhibits, Financial Statement Schedules</a></i></span>
            </td>
            <td style="text-align: right">
                <span style="font: 10pt Times New Roman, Times, Serif">73</span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td>
                <span style="font: 10pt Times New Roman, Times, Serif"><a href="#txmd10ka025">Item 16.</a> </span>
            </td>
            <td>
                <span style="font: 10pt Times New Roman, Times, Serif"><i><a href="#txmd10ka025">Form 10-K Summary</a></i></span>
            </td>
            <td style="text-align: right">
                <span style="font: 10pt Times New Roman, Times, Serif">75</span>
            </td>
        </tr>
    </table>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Throughout this Annual Report, the terms &#x201C;we,&#x201D; &#x201C;us,&#x201D; &#x201C;our,&#x201D; &#x201C;TherapeuticsMD,&#x201D; or &#x201C;our company&#x201D; refer to TherapeuticsMD, Inc., a Nevada corporation, and unless specified otherwise, include our wholly owned subsidiaries, vitaMedMD, LLC, a Delaware limited liability company, or VitaMed; BocaGreenMD, Inc., a Nevada corporation, or BocaGreen; and VitaCare Prescription Services, Inc., a Florida corporation, or VitaCare.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">This Annual Report includes our trademarks, trade names and service marks, such as vitaMedMD<sup>&#xAE;</sup>, BocaGreenMD<sup>&#xAE;</sup>, IMVEXXY<sup>&#xAE;</sup>, BIJUVA<sup>&#xAE;</sup> and ANNOVERA<sup>&#xAE;</sup> which are protected under applicable intellectual property laws and are the property of, or licensed to, our company. This Annual Report also contains trademarks, trade names and service marks of other companies, which are the property of their respective owners. Solely for convenience, trademarks, trade names and service marks referred to in this Annual Report may appear without the &#xAE;, &#x2122; or SM symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the right of the applicable licensor to these trademarks, trade names and service marks. We do not intend our use or display of other parties&#x2019; trademarks, trade names or service marks to imply, and such use or display should not be construed to imply, a relationship with, or endorsement or sponsorship of us by, these other parties.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">In addition, this Annual Report includes market and industry data that we obtained from periodic industry publications, third-party studies and surveys, government-agency sources, filings of public companies in our industry, and internal-company surveys. Industry publications and surveys generally state that their information has been obtained from sources believed to be reliable. Although we believe that the industry and market data below is reliable as of the date of this Annual Report, this information could prove to be inaccurate as a result of a variety of matters.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <!-- Field: Page; Sequence: 2; Value: 1-->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt">
        <p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">
            <!-- Field: Sequence; Type: Arabic; Name: PageNo-->2<!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&#160;</p>
    </div>
    <!-- Field: /Page -->
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
        <span style="font: 10pt Times New Roman, Times, Serif"><b>Statement Regarding Forward-Looking Information</b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">This Annual Report on Form 10-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve substantial risks and uncertainties. For example, statements regarding our operations, financial position, business strategy, product development, and other plans and objectives for future operations, and assumptions and predictions about future product development and demand, research and development, marketing, expenses and sales are all forward-looking statements. These statements may be found in the items of this Annual Report entitled &#x201C;Business&#x201D; and &#x201C;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations,&#x201D; as well as in this Annual Report generally. These statements are generally accompanied by words such as &#x201C;intend,&#x201D; &#x201C;anticipate,&#x201D; &#x201C;believe,&#x201D; &#x201C;estimate,&#x201D; &#x201C;potential(ly),&#x201D; &#x201C;continue,&#x201D; &#x201C;forecast,&#x201D; &#x201C;predict,&#x201D; &#x201C;plan,&#x201D; &#x201C;may,&#x201D; &#x201C;will,&#x201D; &#x201C;could,&#x201D; &#x201C;would,&#x201D; &#x201C;should,&#x201D; &#x201C;expect,&#x201D; or the negative of such terms or other comparable terminology.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">We have based these forward-looking statements on our current expectations and projections about future events. We believe that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to us on the date of this Annual Report, but we cannot assure you that these assumptions and expectations will prove to have been correct or that we will take any action that we may presently be planning. These forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, research and product-development uncertainties, regulatory policies and approval requirements, competition from other businesses, market and general economic factors, and the other risks discussed in Item 1A of this Annual Report. This discussion should be read in conjunction with the consolidated financial statements and notes thereto included in this Annual Report.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">We have identified some of the important factors that could cause future events to differ from our current expectations and they are described in this Annual Report in the section entitled &#x201C;Risk Factors&#x201D; that you should review carefully. Please consider our forward-looking statements in light of those risks as you read this Annual Report. If one or more of these or other risks or uncertainties materialize, or if our underlying assumptions prove to be incorrect, actual results may vary materially from what we project. We do not undertake to update any forward-looking statements or to publicly announce the results of any revisions to any statements to reflect new information or future events or developments.
            <br /> </span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <!-- Field: Page; Sequence: 3; Value: 1-->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt">
        <p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">
            <!-- Field: Sequence; Type: Arabic; Name: PageNo-->3<!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&#160;</p>
    </div>
    <!-- Field: /Page -->
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
        <span style="font: 10pt Times New Roman, Times, Serif"><b><span id="txmd10ka001"></span>PART I</b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="vertical-align: top; text-align: justify">
            <td style="width: 0in"></td>
            <td style="width: 1in; text-align: left">
                <span style="font: 10pt Times New Roman, Times, Serif"><b>Item 1.</b></span>
            </td>
            <td style="text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif"><b><span id="txmd10ka002"></span>Business</b></span>
            </td>
        </tr>
    </table>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b>Overview</b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><i>Our Company</i></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">TherapeuticsMD is a women&#x2019;s healthcare company with a mission of creating and commercializing innovative products to support the lifespan of women from pregnancy prevention through menopause. At TherapeuticsMD, we combine entrepreneurial spirit, clinical expertise, and business leadership to develop and commercialize health solutions that enable new standards of care for women. Our solutions range from a patient-controlled, long-lasting contraceptive to advanced hormone therapy pharmaceutical products. We also have a portfolio of branded and generic prescription prenatal vitamins under the vitaMedMD and BocaGreenMD brands that furthers our women&#x2019;s healthcare focus.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Our portfolio of products focused on women&#x2019;s health allows us to efficiently leverage our sales and marketing plans to grow our recently approved products. During 2018, the U.S. Food and Drug Administration, or FDA, approval of our drugs has transitioned our company from predominately focused on conducting research and development to one focused on commercializing our drugs.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">In July 2018, we launched our FDA-approved product, IMVEXXY (estradiol vaginal inserts) for the treatment of moderate-to-severe dyspareunia (vaginal pain associated with sexual activity), a symptom of vulvar and vaginal atrophy, or VVA, due to menopause, which was approved by the FDA in May 2018.</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">In April 2019, we launched our FDA-approved product, BIJUVA (estradiol and progesterone) capsules, our hormone therapy combination of bio-identical 17&#xDF;-estradiol and bio-identical progesterone in a single, oral softgel capsule, for the treatment of moderate-to-severe vasomotor symptoms, or VMS, due to menopause in women with a uterus, which was approved by the FDA in October 2018.</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">In October 2019, we began a &#x201C;test and learn&#x201D; market introduction for our FDA-approved product ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system), the first and only patient-controlled, procedure-free, reversible prescription contraceptive option for women, which was approved by the FDA in August 2018 and which we have licensed for commercialization in the U.S. pursuant to an exclusive license agreement, or the Population Council License Agreement, with the Population Council, Inc., or the Population Council. We expect the full commercial launch of ANNOVERA in the first quarter of 2020.</span>
            </td>
        </tr>
    </table>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0; margin-right: 0; margin-top: 0">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">We have also entered into license agreements with strategic partners to commercialize IMVEXXY and BIJUVA outside of the U.S.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">In July 2018, we entered into a license and supply agreement with Knight Therapeutics Inc., or Knight, pursuant to which we granted Knight an exclusive license to commercialize IMVEXXY and BIJUVA in Canada and Israel.</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">In June 2019, we entered into an exclusive license and supply agreement, or the Theramex License Agreement, with Theramex HQ UK Limited, or Theramex, a leading, global specialty pharmaceutical company dedicated to women&#x2019;s health, to commercialize BIJUVA and IMVEXXY outside of the U.S., excluding Canada and Israel.</span>
            </td>
        </tr>
    </table>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0; margin-right: 0; margin-top: 0">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b>Our Business Model</b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">At TherapeuticsMD, our purposeful and continuous partnership with healthcare professionals and women is at the heart of our strategies for delivering innovative solutions for women. From pregnancy to post-menopause, we believe the only way to truly connect with and understand women and their healthcare professionals is to ask questions.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Healthcare has become increasingly consumer driven. Therefore, patients are seeking more information, control, and convenience, which places additional time and financial pressures on health care practitioners, or HCPs, and as a result HCPs are looking for improved ways to provide better service to their patients. A study by IMS Health Inc. concluded that HCPs desire fewer but more encompassing relationships with companies that can provide more valuable information, deliver more relevant services, and better respond to specific needs of their practice and patients. Our goal is to meet this challenge by focusing on the opportunities in women&#x2019;s health, specifically the OB/GYN market, to provide a better customer experience for physician, payer, pharmacist, and patient through the following means:</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">We offer HCPs a comprehensive product line of women&#x2019;s healthcare products across women&#x2019;s lifecycles.</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">Our hormone therapy pharmaceutical products are designed to respond to both healthcare professional and patient needs in the marketplace &#x2013; low dose, bio-identical and convenience where needed.</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">Our contraceptive product is the only long-lasting reversible contraceptive option that is patient-controlled and procedure-free.</span>
            </td>
        </tr>
    </table>
    <!-- Field: Page; Sequence: 4; Value: 1-->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt">
        <p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">
            <!-- Field: Sequence; Type: Arabic; Name: PageNo-->4<!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&#160;</p>
    </div>
    <!-- Field: /Page -->
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">We believe the attributes of our prenatal vitamins will result in greater consumer acceptance and satisfaction than competitive products while offering the high quality products, such as Quatrefolic<sup>&#xAE;</sup>, FOLMAX&#xAE;, FePlus&#xAE;, and pur-DHA&#x2122;. All of our prenatal vitamins are gluten-, sugar-, and lactose-free.</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">We focus on improved patient education, a high level of patient compliance, and a competitive cost of products, which can result in lower cost of care for payers and improved outcomes for patients.</span>
            </td>
        </tr>
    </table>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0; margin-right: 0; margin-top: 0">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">At the forefront of our sales approach is the philosophy that the physician should recommend or prescribe products based only on what is best for the patient. In general, a better outcome is achieved by providing patients with the best products and care at the best value. We believe having a portfolio of high-quality product options that can be recommended or prescribed by physicians, and reimbursed by either government or private third-party payers is the foundation of providing valuable options to the patient. We are dedicated to enabling healthcare professionals to advance the health of women by offering new treatment options and giving voice to women&#x2019;s needs and health concerns. We are committed to partnering with women&#x2019;s health advocacy organizations as we create and commercialize solutions to help women transform how they experience reproductive health.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Our sales model focuses on the &#x201C;4Ps&#x201D;: patient, provider, pharmacist, and payer. We market and sell our products primarily through a dedicated national sales force that calls on HCPs primarily in the OB/GYN market space. In addition, our products allow HCPs to offer an alternative to patients at a co-payment that provides patients a cost that is competitive in the marketplace. We also believe that our combination of branded and authorized generic lines of prenatal vitamins offers HCPs, women, and payers cost-effective alternatives for top-quality care. We supply our prescription products to consumers through pharmacies nationwide. Our fully staffed customer care center uses current customer relationship management software to respond to HCPs, pharmacies, and consumers via incoming and outgoing telephone calls, e-mails, and live chat.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">We believe our sales force has developed strong relationships in the OB/GYN market to sell our current products. We have established relationships with some of the largest OB/GYN practices in their respective markets. By delivering our portfolio to similar customer bases of women and OB/GYNs, we believe we can leverage our already deployed assets to increase sales of our products and achieve profitability. We leverage our existing infrastructure, including our sales force, to commercialize our VitaMedMD line of prenatal vitamins and our FDA-approved pharmaceutical products: IMVEXXY, BIJUVA, and ANNOVERA. In addition to our focus on direct selling from our sales organization, which comprises approximately 200 sales representatives, we utilize other commercial levers such as non-personal promotion to HCPs and direct-to-consumer marketing as appropriate to drive awareness and education of our product portfolio. Finally, we partner with strategic partners and licensees to commercialize our pharmaceutical products outside of the OB/GYN market and in non-U.S. markets.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">As of December 31, 2019, we marketed and sold IMVEXXY, BIJUVA, and ANNOVERA under the TherapeuticsMD brand, our prescription prenatal vitamins under our vitaMedMD brand name, and authorized generic formulations of our prescription prenatal vitamin products under our BocaGreenMD Prena1 brand name. We leverage our existing wholesale and retail partnerships to distribute and sell IMVEXXY, BIJUVA, and ANNOVERA, which enable us to drive efficiency as we drive increased volume across the portfolio.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b>Our Growth Strategy</b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">We believe that the relationships our national sales force has developed with OB/GYN&#x2019;s, through our prescription prenatal vitamin products and our FDA-approved pharmaceutical products, will continue to grow as these products offer HCPs new opportunities to serve the needs of their patients. By delivering our entire portfolio through the same sales channel and demonstrating how these products can help women as different needs emerge throughout their lifetime, we believe we can create efficiencies and synergies to further our growth.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif"><i>Exclusive Focus on Women&#x2019;s Health Issues</i>. We have steadily developed relationships with many of the largest OB/GYN practices in the country through the sales of our prenatal vitamins and our FDA-approved pharmaceutical products. We believe that our singular focus on women&#x2019;s health issues enables us to continue to build long-term relationships with women as they move through their life cycles of family planning to post-menopause.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif"><i>Focus on Hormone Therapy Products</i>. We continue our focus on the commercialization, development, and clinical trials of bio-identical hormone therapy products designed to (1) alleviate the symptoms of, and reduce the health effects resulting from, menopause-related hormone deficiencies, including VMS and VVA, and (2) fill the large unmet need in this segment of the market.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif"><i>Deepening focus on other parts of a women&#x2019;s reproductive lifecycle.</i>&#160;With the acquisition and launch of ANNOVERA, we are demonstrating our intent to provide effective and innovative products for women at all lifecycle stages.</span>
    </p>
    <!-- Field: Page; Sequence: 5; Value: 1-->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt">
        <p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">
            <!-- Field: Sequence; Type: Arabic; Name: PageNo-->5<!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&#160;</p>
    </div>
    <!-- Field: /Page -->
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif"><i>Penetrate Compounding Market with FDA-Approved Products</i>. BIJUVA is currently the only FDA-approved hormone therapy combination product that is bio-identical to the estradiol and progesterone produced by the ovaries, and will provide a proven alternative to non-FDA approved compounded bio-identical hormone therapy products, and potentially at a lower price to patients since most insurance companies do not provide coverage for compounded products, which are not FDA approved. We continue to work with independent and community-based pharmacies that currently compound bio-identical hormone therapy products to help introduce patients and prescribers to our FDA-approved products. Our BIO-IGNITE program is focused on supporting the synergistic relationships between community pharmacies and HCPs so that offering BIJUVA and IMVEXXY as appropriate treatment alternatives is economically practical for independent and community-based pharmacies. A dedicated team of sales representatives and our Key Account Management, or KAM, team are focusing their efforts on growing BIJUVA through our BIO-IGNITE partners and as of December 31, 2019, there were over 160 BIO-IGNITE compounding pharmacies that were dispensing BIJUVA.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif"><i>Multi-Channel Marketing Emphasis</i>. We continue our emphasis on large group OB/GYN practices that provide opportunities to reach large patient bases and that are receptive to the data and savings we provide. In addition, we work with strategic partners and licensees to commercialize and/or market our pharmaceutical products outside of the OB/GYN market and in non-U.S. markets.&#160; The proliferation of digital technology has dramatically increased the amount of information available to patients and providers. We believe this makes patient/provider engagement and experience a more important factor for life sciences companies and that providing patients and providers with important information on a real-time basis is a critical piece of serving this market. As an example of the impact of technology on women&#x2019;s health, products such as ANNOVERA can be prescribed to patients via online platforms, such as the PlushCare virtual health platform and other direct-to-consumer telehealth platforms. Subject to state telemedicine and prescribing laws, prescribers affiliated with PlushCare and other direct-to-consumer telehealth platforms can prescribe or offer products to patients through a convenient virtual platform.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif"><i>Multiple Distribution Partners</i>. We have multiple distribution partners, including large chain pharmacies, independent community pharmacies, mail order, and compounding and specialty pharmacies. We believe that providing a higher level of customer care through unique programs targeted at each of these distribution partners can produce better outcomes and value for the patient, provider, and payer.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif"><i>Geographical Expansion</i>. We have expanded our geographic marketing footprint in the United States and sales team to approximately 200 professionals as we continue to commercialize IMVEXXY, BIJUVA and ANNOVERA.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b>Industry and Market</b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif"><i>Women&#x2019;s Healthcare Market </i></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">According to the BBC Research report &#x201C;Pharmaceuticals for Women&#x2019;s Health: Global markets to 2023,&#x201D; post-menopausal osteoporosis, pregnancy disorders and management, menopause, endometriosis, and polycystic ovary syndrome (PCOS) are the largest segments within the global market for women&#x2019;s health therapeutics. The global market for women&#x2019;s health therapeutics reached nearly $30.5 billion in 2018 and should reach nearly $37.3 billion by 2023, at a compound annual growth rate, or CAGR, of 4.2% for the period of 2018-2023. In addition, the menopause market for women&#x2019;s health therapeutics reached $5.4 billion in 2018 and should reach $6.7 billion by 2023 at a CAGR of 4.5% through 2023. According to the GBI Research (a provider of industry-leading business intelligence solutions on a global basis) report &#x201C;Women&#x2019;s Health Therapeutic Market through 2018,&#x201D; the women&#x2019;s health therapeutics market is one of the most attractive markets in the global pharmaceutical industry.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif"><i>Menopause Market </i></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Menopause is the spontaneous and permanent cessation of menstruation, which naturally occurs in most women between the ages of 40 and 58. In the U.S., there are approximately 42 million women in this age group with an additional 6,000 women reaching menopause age every day, or over 2 million additional women per year. Classic symptoms of menopause are VMS (including hot flashes and night sweats), vulvovaginal symptoms (including dyspareunia and vaginal dryness) and sleep disturbances. These symptoms are caused by the reduced levels of circulating estrogen as ovarian production shuts down. Common treatments for menopausal VMS and vulvovaginal symptoms of menopause ranges from prescription medications, including hormone therapy and non-hormonal options, to over-the-counter supplements and lubrication options.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Hormone therapy is the most effective treatment in the United States and Canada for relief of menopausal symptoms according to the North American Menopause Society, or NAMS. Approved FDA prescriptions for menopausal hormone therapy in the United States dropped significantly following the Women&#x2019;s Health Initiative, or WHI, study results published in 2002, which found that subjects using conjugated equine estrogens plus the synthetic progestin medroxyprogesterone acetate had, among other things, a greater incidence of coronary heart disease, breast cancer, stroke, and pulmonary embolism. This study caused a significant change in hormone therapy prescribing habits. Since 2002, many women and HCPs have chosen compounded hormone therapy, a bio-identical solution for treating VMS, and the use of local vaginal therapy increased during this time. The FDA recommends that women with moderate-to-severe menopausal symptoms who want to try menopausal hormone therapy for relief use it for the shortest time needed and at the lowest effective dose.</span>
    </p>
    <!-- Field: Page; Sequence: 6; Value: 1-->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt">
        <p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">
            <!-- Field: Sequence; Type: Arabic; Name: PageNo-->6<!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&#160;</p>
    </div>
    <!-- Field: /Page -->
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b>Our Menopause Portfolio</b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif"><b>IMVEXXY</b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">In May 2018, the FDA approved the 4-&#x3BC;g and 10-&#x3BC;g doses of IMVEXXY (estradiol vaginal inserts) for the treatment of moderate-to-severe dyspareunia (vaginal pain associated with sexual activity), a symptom of VVA, due to menopause. The 4-&#x3BC;g formulation of IMVEXXY represents the lowest FDA-approved dose of vaginal estradiol available. IMVEXXY 10-&#x3BC;g became available for commercial distribution in July 2018 and both doses were commercially available in September 2018.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">IMVEXXY is a small, digitally inserted, softgel vaginal insert that dissolves completely. It is administered mess-free, without the need for an applicator, and can be used any time of day. IMVEXXY provides a mechanism of action and dosing that are familiar and comfortable for patients, with no patient education required for dose application or applicators. IMVEXXY demonstrated efficacy as early as two weeks (secondary endpoint) and maintained efficacy through week 12 in clinical studies, with no increase in systemic hormone levels beyond the normal postmenopausal range (the clinical relevance of systemic absorption rates for vaginal estrogen therapies is not known).</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">As part of the FDA&#x2019;s approval of IMVEXXY, we have committed to conduct a post-approval observational study to evaluate the risk of endometrial cancer in post-menopausal women with a uterus who use a low-dose vaginal estrogen unopposed by a progestogen. The FDA has also asked the sponsors of other vaginal estrogen products to participate in the observational study. In connection with the observational study, we will be required to provide progress reports to the FDA on an annual basis. The development of this method is underway, and we do not believe that the costs will be material on an annual basis. In addition, the FDA asked for post-approval information with respect to certain characteristics related to the product&#x2019;s specifications, which we submitted to FDA.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Based on prescription data from Symphony Health Solutions, the FDA-approved prescription market in the U.S. for the treatment of VVA symptoms includes seven products (including branded products and their generic equivalents), which generated an aggregate of approximately $1.8 billion in gross sales on approximately 5.9 million prescriptions for the 12 months ended December 31, 2019. Approximately $1.5 billion in gross sales were by three products currently on the market: PREMARIN&#xAE; cream (Pfizer), ESTRACE&#xAE; cream, both brand and generic (Allergan and Mylan), and Vagifem&#xAE; which is now mostly generic (Yuvafem by Amneal Pharmaceuticals).</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">The most commonly used product for the treatment of VVA is localized estrogen therapy, which generated an aggregate of approximately $1.7 billion in gross sales in the U.S. on approximately 5.5 million prescriptions for the 12 months ended December 31, 2019. In 2017, generic forms of Estrace and Vagifem were introduced into the U.S. market with the generic equivalents capturing the vast majority of the sales for these two products. Estrace, including its generic equivalents, was the market leader in 2019 with approximately $566 million in gross sales in the U.S. on approximately 2.1 million prescriptions. The two most recent FDA-approved product launches in this category were Osphena&#xAE; (Duchesnay USA, Inc<b>) </b>and Intrarosa&#xAE; (Amag Pharmaceuticals), each of which still has a relatively small market share.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif"><b>BIJUVA</b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">In October 2018, the FDA approved BIJUVA (estradiol and progesterone) capsules, 1 mg/100 mg, the first and only FDA-approved bioidentical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate-to-severe VMS (commonly known as hot flashes or flushes), due to menopause in women with a uterus. The estrogen and progesterone in BIJUVA have the same molecular structure as the hormones that are naturally produced in a woman&#x2019;s body. We launched BIJUVA in April 2019.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">BIJUVA offers the convenience of a single-capsule combination of two hormones (estradiol and progesterone), which may improve a user&#x2019;s compliance. The estradiol and progesterone in BIJUVA are plant-based, not animal-sourced, and contain no peanut allergens. BIJUVA provides a sustained steady state of estradiol which reduced the frequency and severity of hot flashes in clinical studies with no demonstrated impact on a patient&#x2019;s weight or blood pressure. Additionally, through clinical trials BIJUVA has demonstrated endometrial safety and greater than 90% amenorrhea rates, while providing no clinically meaningful changes in mammograms.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Estrogen (with or without a progestin) is most commonly used to treat VMS due to menopause that is a direct result of the decline in estrogen levels associated with ovarian shutdown at menopause. Estrogen is a generic term for any substance, natural or synthetic, that exerts biological effects characteristic of estrogenic hormones, such as estradiol, a natural ovarian produced estrogen. According to NAMS, the most effective treatment for VMS due to menopause is estrogen therapy.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Progestins are used in combination with estrogen in menopausal women with uteruses to avoid an increase in the incidence of endometrial hyperplasia, which is a condition caused by chronic use of estrogen alone by a woman with a uterus and is associated with an increased incidence of uterine, or endometrial, cancer. Progestins include the naturally occurring hormone progesterone and several synthetic progestin compounds that have pregestational activity. These agents are used for a variety of indications and conditions. Progestins alone are also used to treat women with secondary amenorrhea to create withdrawal bleeding in these women who have not had regular menses. Progestins are also used to treat dysfunctional uterine bleeding and endometriosis.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">According to Symphony Health Solutions, the total FDA-approved prescription market in the U.S. for all estrogen and progestin drug products for the treatment of VMS generated an aggregate of approximately $2.2 billion of gross revenue on approximately 23.9 million prescriptions for the 12 months ended December 31, 2019. The three primary hormone therapy products are estrogen, progestin, and combination of estrogen and progestin, which are produced in a variety of forms, including oral tablets or capsules, skin patches, gels, and emulsions. For the 12 months ended December 31, 2019, gross sales in the U.S. of FDA-approved branded and generic products for estrogen only amounted to an aggregate of approximately $1.4 billion on approximately 14.3 million prescriptions. For the 12 months ended December 31, 2019, gross sales in the U.S. of FDA-approved branded and generic products for progestins only amounted to an aggregate of approximately $406 million on approximately 7.6 million prescriptions. For the 12 months ended December 31, 2019, gross sales in the U.S. of FDA approved branded and generic products for estrogens/progestins combined amounted to an aggregate of approximately $463 million on approximately 2.0 million prescriptions.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <!-- Field: Page; Sequence: 7; Value: 1-->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt">
        <p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">
            <!-- Field: Sequence; Type: Arabic; Name: PageNo-->7<!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&#160;</p>
    </div>
    <!-- Field: /Page -->
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Based on the Symphony Health Solutions data and the uses of these products, we estimate that sales of FDA-approved combinations of estrogen and progestins (the addressable market for BIJUVA) were approximately $1.3 billion in the United States for the 12 months ended December 31, 2019. Based on various reports, including data recently presented at the NAMS Annual Meeting, &#x201C;Knowledge, Use, and Prescribing of Custom-Compounded Bioidentical Hormones for Menopausal Women: It&#x2019;s Not What You Think,&#x201D; by JoAnn V. Pinkerton, et al., we estimate, that U.S. sales of non-FDA-approved compounded combination addressable estradiol and progesterone products approximate $1.5 billion per year.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">We submitted a New Drug Application, or NDA, efficacy supplement for the 0.5/100 mg dose of BIJUVA to the FDA in late January 2020 for review and potential approval. The NDA efficacy supplement uses existing data from our Phase 3 REPLENISH trial for BIJUVA, for which we announced results in December 2016, together with additional information and analyses. The REPLENISH trial was the first time that a combination of bio-identical estradiol and bio-identical progesterone used in a continuous combined daily fashion demonstrated safety and efficacy data to support FDA-approval. We do not anticipate that the FDA will require any new clinical trials in connection with our submission of the NDA efficacy supplement, however, there is no assurance that will be the case. If accepted for review by the FDA, we expect that the NDA efficacy supplement will be reviewed, under current Prescription Drug User Fee Act timeline goals, within ten months of receipt by the FDA.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">With the approval of BIJUVA, the FDA required a post-approval commitment to further develop and validate our in-vitro dissolution method to show how BIJUVA is released from the capsule in an in-vitro setting for quality control assessments. The development of this method and validation were completed and submitted to the FDA as required in our approval.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Our hormone therapy pharmaceutical products are characterized by safety and efficacy profiles that can be consistently manufactured to target specifications. This provides an alternative to the non-FDA approved compounded bio-identical market. We believe that our FDA-approved pharmaceutical products offer advantages in terms of demonstrated safety and efficacy, consistency in the hormone dose, lower patient cost due to the increased likelihood of insurance coverage and improved access as a result of availability from major retail pharmacy chains rather than custom order or formulation by individual compounders.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">The largest competitors for BIJUVA in the FDA-approved market are Pfizer (PREMPRO<i>&#xAE;</i>) and Premarin, Teva and Mylan (generic estradiol, generic version of Estrace<i>&#xAE; </i>oral),&#160;with sales of PREMPRO<i>&#xAE; </i>and Premarin&#160;constituting the largest branded products. None of the competing FDA-approved drugs for the treatment of moderate-to-severe VMS due to menopause are a combination of both bio-identical estradiol and progesterone produced by the ovaries. The market for non-FDA-approved compounded hormone therapy products is generally considered very fragmented because the products are prepared and sold by individual compounding pharmacies. We believe that BIJUVA represents the first time a combination product of estradiol and progesterone that is bio-identical to the estradiol and progesterone produced by the ovaries in a single combined product has been approved in the U.S.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b>Reproductive Market</b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Contraception can be defined as the deliberate prevention of pregnancy by interfering with normal process of ovulation, fertilization and implantation through the use of barriers, drugs, medical devices, or surgical techniques. The contraceptive market includes non-hormonal methods, such as the non-hormonal intrauterine device, or IUD, contraceptive sponge, diaphragm, cervical cap or shield and condoms, and hormonal methods such as oral contraceptives, injections, implants, hormonal IUDs and vaginal ring and transdermal contraceptive products. Hormonal contraceptives can be composed of synthetic estrogens and progestins. Contraceptives containing both estrogen and a progestin are referred to as combination hormonal contraceptives, or CHCs, and contraceptives containing only progestin are referred to as progestin-only, or P-only.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman , Times, serif; margin: 0px; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">The most common synthetic estrogen approved in the U.S. for use in contraceptive products is ethinyl estradiol (EE). There are 10 different progestins that have been used in contraceptives sold in the U.S. The progestin component provides most of the contraceptive effect, while the estrogen component primarily provides cycle control, for example, minimizing bleeding or spotting between cycles. The progestin exerts its contraceptive effect by inhibiting ovulation, or release of an egg from the ovary, and by thickening cervical mucus. Thickening cervical mucus helps to prevent sperm entry into the upper genital tract. The estrogen component, in addition to providing cycle control, makes a small contribution to contraception by decreasing the maturation of the egg in the ovary. The latest data from 2015 to 2017 from the Centers for Disease Control, or CDC, indicate that approximately 65% of women aged 15 to 49 were using some type of contraceptive method. Most women who were not using contraception had reasons for not doing so, such as seeking pregnancy, being pregnant or postpartum, or not being sexually active.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <!-- Field: Page; Sequence: 8; Value: 1-->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt">
        <p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">
            <!-- Field: Sequence; Type: Arabic; Name: PageNo-->8<!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&#160;</p>
    </div>
    <!-- Field: /Page -->
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">The U.S. contraceptive market size is expected to reach at $11.6 billion by 2025 expanding at a CAGR of 5.3% over the forecast period, according to Grand View Research, Inc. Increasing awareness about long-acting reversible contraceptives, or LARCs, is expected to augment the product demand, thereby driving the market over the next few years. According to the National Center for Health and Statistics, the use of LARCs in the United States has increased nearly five-fold in the last decade among women aged 15 to 44 and we believe that this segment of the contraceptive market is attractive given its current growth trajectory. We believe that the increasing awareness about long-lasting reversible contraceptive options will grow incremental product demand, thereby driving market growth over the coming years. This is currently led by IUDs. The market leader in the IUD market is Bayer with the following products: Mirena&#xAE;, Kyleena&#xAE;, Jaydess&#xAE; and Skyla&#xAE;. The remainder of the market is dominated by oral contraceptives, which is represented by one major brand, Lo Loestrin&#xAE; Fe by Allergan, and a variety of generics led by generic manufacturers such as Teva Pharmaceuticals and Lupin Pharma.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif"><b>ANNOVERA</b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">In July 2018, we entered into an exclusive license agreement with the Population Council to commercialize in the U.S. ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system), the first and only patient-controlled, procedure-free, reversible prescription contraceptive that can prevent pregnancy for up to a total of 13 cycles (one year), which was approved by the FDA in August 2018.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">ANNOVERA was classified by the FDA as a &#x201C;new chemical entity,&#x201D; or NCE, and thus has five years of regulatory exclusivity under the Drug Price Competition and Patent Term Restoration Act of 1984, otherwise known as the Hatch-Waxman Act. ANNOVERA is a one-year ring-shaped contraceptive vaginal system, or CVS. ANNOVERA, which is made with a silicone elastomer, contains segesterone acetate, a 19-nor progesterone derivative also known as Nestorone&#xAE;, or SA, and EE. EE is an approved active ingredient in many marketed hormonal contraceptive products. Segesterone acetate, an NCE, is a potent progestin that, based on pharmacopogical studies in animals and <i>in vitro</i>, does not bind to the androgen or estrogen receptors and has no glucocorticoid activity at contraceptive doses. SA has been evaluated in 51 clinical studies across these delivery systems with more than 26,794 cycles of exposure.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">ANNOVERA can be inserted and removed by the woman herself without the aid of a healthcare provider and, unlike oral contraceptives, ANNOVERA does not require daily administration to obtain the contraceptive effect. After 21 days of use, the woman removes ANNOVERA for seven days, thereby providing a regular bleeding pattern (i.e., withdrawal/scheduled bleeding). The same CVS is then re-inserted for additional 21/7-days in/out, for up to a total of 13 cycles (one year). ANNOVERA releases daily vaginal doses of both active ingredients (SA and EE). The claimed release rate of 150 &#x3BC;g/day SA and 13/day &#x3BC;g EE is supported by the calculated average release rate from an ex vivo analysis of ANNOVERA used for 13 cycles and is also supported by data from 13 cycles of in vitro release.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">As part of the approval of ANNOVERA, the FDA has required a post-approval observational study be performed to measure the risk of venous thromboembolism. In accordance with the post-marketing requirements, the full protocol for the study was submitted to the FDA in August 2019. We have agreed to perform and pay the costs and expenses associated with this post-approval study, provided that if the costs and expenses associated with such post-approval study exceed $20 million, half of such excess will offset against royalties or other payments owed by us to the Population Council under the Population Council License Agreement. Given the observational nature of the study, we do not believe that the costs of the study will be material on an annual basis.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">In October 2019, we began a &#x201C;test and learn&#x201D; market introduction phase of launch for ANNOVERA, with 36 of our existing sales representatives, our 23 regional sales managers and 12 compounding key account managers, or KAMs, introducing ANNOVERA to top targeted healthcare practitioners. A full-scale launch of ANNOVERA is expected in the first quarter of 2020.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">We believe that ANNOVERA will compete across all the contraception options for women with focus on those women seeking a long-lasting option without a procedure.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">For patients, ANNOVERA provides a single long-lasting reversible birth control product that does not require a procedure at the doctor&#x2019;s office for insertion or removal, empowering women to be in complete control of their fertility and menstruation with a 21/7 regimen. We believe that ANNOVERA is a unique alternative for women who have previously chosen other forms of birth control. These include nulliparous women (or women who have never given birth), women who are considering an IUD but would rather not have a procedure, women who are between pregnancies but desire protection without a long-term commitment, and women who are not satisfied with oral options due to the daily usage or potential side effects.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif"><i>Prenatal Vitamin Market</i></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">According to the Centers for Disease Control and Prevention, there are approximately four million births per year in the U.S. Of women giving birth in the U.S., the U.S. Department of Health and Human Services reports that approximately 73% received early prenatal care in the first trimester, while 6% began prenatal care in the third trimester or did not receive any prenatal care. Most HCPs encourage taking a prenatal vitamin as the recommended standard of care. Prenatal vitamins are dietary supplements intended to be taken before and during pregnancy and during postnatal lactation that provide nutrients recognized by various health organizations as helpful for a healthy pregnancy outcome.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <!-- Field: Page; Sequence: 9; Value: 1-->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt">
        <p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">
            <!-- Field: Sequence; Type: Arabic; Name: PageNo-->9<!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&#160;</p>
    </div>
    <!-- Field: /Page -->
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">The prenatal vitamin market is highly fragmented, with dozens of companies selling hundreds of competitive products. Prenatal vitamin products are marketed as either nonprescription products or prescription products, with many companies marketing their products through both channels. According to Symphony Health Solutions, during the 12 months ended December 31, 2019, approximately 5.0 million prescriptions for prenatal vitamins were issued in the U.S. resulting in total sales of approximately $286 million.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif"><b><i>Our Prenatal Vitamin Products</i></b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">We continue to manufacture and distribute our prescription prenatal vitamin product lines under our vitaMedMD brand name and authorized generic formulations of some of our prescription prenatal vitamin products under our BocaGreenMD Prena1 name. We will continue to support the vitaMedMD and BocaGreenMD products as they are important products to our core customers and help provide us with continued access to sell our women&#x2019;s health portfolio. Our current prenatal vitamin product line features a unique, proprietary combination of FOLMAX&#x2122;, FePlus&#x2122;, and pur-DHA&#x2122; and includes the following products:</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif"><i>vitaTrue&#x2122;</i></span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif"><i>vitaPearl&#x2122;</i></span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif"><i>vitaMedMD One Rx Prenatal Multivitamin</i></span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif"><i>vitaMedMD RediChew&#xAE; Rx Prenatal Multivitamin</i></span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif"><i>BocaGreenMD Prena1 True</i></span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif"><i>BocaGreenMD Prena1 Pearl</i></span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif"><i>BocaGreenMD Prena1 Chew</i></span>
            </td>
        </tr>
    </table>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0; margin-right: 0; margin-top: 0">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">For the years ended December 31, 2019, 2018, and 2017, approximately 20%, 93%, and 99.9%, respectively, of our consolidated revenue was generated by our prenatal vitamin products.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b>Commercialization Model</b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">We are commercializing the products in our portfolio through a common model focused on the belief that providing good experiences for both HCPs and patients will drive profitability for TherapeuticsMD. Given that our portfolio focus is exclusively in women&#x2019;s health, we believe that each new product launch will allow us to further leverage our existing infrastructure and build out our reputation as the premier women&#x2019;s health organization in the U.S. Below is more detail on our commercialization model:</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b>HCP Education </b>- Initially, we focus on the high writing and high potential HCPs in each territory to gain a full understanding of their prescribing behavior and practices. Our focus is on driving initial prescriptions of these writers for each new product launch and utilizing the time to also pull through on our portfolio of existing products. Once regular writing is established with the initial group of HCPs, we expand our reach to a larger set of HCPs writing in the category.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">We educate HCPs on our products primarily with our field sales organization. We have defined a sales force targeting approximately 200 territories, which includes the most significant part of the addressable markets across our product portfolio. We are deploying a hybrid sales model that combines an internal sales leadership team with a fully dedicated contract sales force to call on our target HCPs.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">As of December 31, 2019, at least 17,800 HCPs had written at least one prescription of IMVEXXY and at least 5,000 HCPs had written at least one prescription of BIJUVA, the majority of which are also IMVEXXY writers demonstrating the value of portfolio and focus. In addition, although still in soft launch mode, as of December 31, 2019, at least 800 HCPs had written at least one prescription of ANNOVERA.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">In addition to our sales organization, we leverage non-personal promotion (multi-channel advertising) to targets and non-targets that drive awareness, education, and action. These efforts allow for pull through of the sales organization efforts and identification of new targets that have interest in writing prescriptions for one or more of our products. We believe this will drive increased prescribing for our products and lift the overall writing universe and our products top of mind in the HCP community.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b>BIO-IGNITE </b>- In addition to our sales organization calling on HCPs, we have a KAM team to support our BIO-IGNITE pharmacy partners and continue to build our internal capabilities to support both organizations, including compliance professionals and programs and key data support systems that provide real-time data for the sales force and KAMs. Our KAMs have national coverage and target over 1,900 community pharmacies that have a focus on compounded bio-identical hormones and the over 2,000 additional HCPs that are affiliated with these pharmacies. As of December 31, 2019, there were over 160 BIO-IGNITE compounding pharmacies that were dispensing BIJUVA.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <!-- Field: Page; Sequence: 10; Value: 1-->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt">
        <p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">
            <!-- Field: Sequence; Type: Arabic; Name: PageNo-->10<!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&#160;</p>
    </div>
    <!-- Field: /Page -->
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b>Payer Access - </b>With the ever-changing payer environment, it is critical to maximize breadth of coverage as quickly as possible to not inhibit patient access to product. We do this while working to negotiate the best possible contracts for us. Many commercial payers employ &#x201C;new-to-market blocks&#x201D; for newly launched products until the payers have the opportunity to make a coverage decision based upon their internal review of the product. When a product is not covered, the patient is responsible to pay the full price for the medication, which can significantly limit utilization of the product. As we seek to increase the number of lives covered by commercial payers, it is our objective to continue to seek unrestricted coverage. Currently, both IMVEXXY and BIJUVA are broadly available in major pharmacy chains in the U.S., as well as with our BIO-IGNITE partners, via our third-party logistics and our distribution partners. As of December 31, 2019, we have obtained coverage for the majority of commercial payers for both products and continue to seek unrestricted coverage from the remaining commercial insurance plans that we have not yet contracted with to provide affordable access for patients. For IMVEXXY, we achieved unrestricted coverage with eight of the top ten commercial payers of VVA products by commercial payer lives and we continue to sign new agreements with payers to cover IMVEXXY. In addition, as of December 31, 2019, two of the top six Medicare Part D payers of VVA products were adjudicating IMVEXXY, with additional decisions for other Medicare Part D payers expected during 2020. For BIJUVA, through December 31, 2019, we have achieved unrestricted coverage with six of the top ten commercial payers of VMS products by commercial payer lives and we continue to sign new agreements with payers to cover BIJUVA. Although Medicare is a small percentage of the VMS market, as of December 31, 2019, two of the top six Medicare Part D payers of VMS products were adjudicating BIJUVA.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">For ANNOVERA, we believe that its unique characteristics will assist us in pursuing favorable commercial payer coverage, including only one pharmacy fill fee per year and no office visit or procedure fees. We have made substantial progress in achieving unrestricted access to ANNOVERA through commercial payers, including having achieved adjudication with six of the top ten commercial payers by commercial payer lives as of December 31, 2019, and we continue to pursue discussions with several of the country&#x2019;s largest commercial insurers to further expand coverage. As of December 31, 2019, approximately 64% of the commercial payer market covered ANNOVERA with unrestricted access under pharmacy benefits and approximately 11% covered ANNOVERA with step access.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">In addition, the Patient Protection and Affordable Care Act, as amended by the Healthcare and Education Reconciliation Act of 2010, or the ACA, mandates that private health plans provide coverage for women&#x2019;s preventative services, without imposing patient cost-sharing requirements, as recommended by the Health Resources and Services Administration, or HRSA. HRSA Guidelines require private health plans to cover, without cost-sharing, at least one form of contraception, or product, in each of the methods, or classes, identified by the FDA for women in its Birth Control Guide, which currently includes 18 separate classes. For classes with more than one type of treatment, private payers need only provide no-cost coverage for one product in each class and may use reasonable medical management to determine whether and to what extent to cover other products in the class. We believe, that given no other vaginal contraceptive product offers contraceptive benefits for an entire year that it is possible that FDA could determine that ANNOVERA constitutes a new class of contraceptive, which could allow for coverage of ANNOVERA by private health plans with no out-of-pocket cost for patients. However, there is no assurance that FDA will make such a determination and it is possible that other FDA-approved products could also be included in such a new class. For instance, the FDA may find that ANNOVERA fits into the vaginal contraceptive ring class, which it would share with NuvaRing and its generic equivalents, and potentially others. To the extent ANNOVERA is not the only FDA-approved product in a designated class of contraception, private payers may choose not to cover ANNOVERA or may require patient cost-sharing obligations. Recently, some states have amended and expanded requirements to match the standard set in the ACA mandate, specifically requiring coverage for the full range of contraceptive methods, counseling and services used by women and eliminating out-of-pocket costs and limiting other health plan restrictions. As of January 2020, 29&#160;states require insurers that cover prescription drugs to provide coverage of FDA-approved prescription contraceptive drugs and devices. However, the Trump administration has implemented new policies that permit certain employers to claim a religious or moral objection to the birth control coverage mandate under the ACA. Health plans sponsored by certain exempt religious employers and non-profit religious organizations that certify they have religious objections do not need to offer contraception coverage through their health benefit plans. As of January 2020, 21 states allow certain employers and insurers to refuse to comply with the ACA&#x2019;s contraceptive coverage mandate. We anticipate that any impact on contraception coverage due to religious exemption will be low; however, healthcare reform, including potential repeal of or changes to the ACA, continues to attract significant legislative and administrative interest, legal challenges, regulatory and compliance requirements, new approaches and public attention that create uncertainty and the potential for additional changes. Healthcare reform implementation, additional legislation or regulations, and other changes in government policy or regulation may repeal the contraception coverage mandate, affect our reimbursement or impose additional coverage limitations and/or cost-sharing obligations on patients, any of which could have a material adverse effect on patient usage of ANNOVERA.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> <span style="font: 10pt Times New Roman, Times, Serif">In
    February 2020, we entered into an agreement with Afaxys Pharma, LLC, a pharmaceutical company focused on serving women in the
    public health system, to market ANNOVERA in the U.S. public health sector. As part of the Population Council License
    Agreement, we have agreed to provide significantly reduced pricing to federally designated Title X family planning clinics
    serving underrepresented women. We also have agreements to market ANNOVERA to the U.S. Department of Defense, the U.S.
    Veteran's Administration, and in Puerto Rico.</span> </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <!-- Field: Page; Sequence: 11; Value: 1-->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt">
        <p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">
            <!-- Field: Sequence; Type: Arabic; Name: PageNo-->11<!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&#160;</p>
    </div>
    <!-- Field: /Page -->
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Obtaining and maintaining favorable reimbursement can be a time-consuming and expensive process, and there is no guarantee that we will be able to negotiate or continue to negotiate reimbursement or pricing terms for our products with payers at profitable levels.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b>Supply </b>- We want to ensure our products are available in all classes of trade and delivery systems. We offer our products through traditional chain wholesalers (Cardinal, McKesson and AmerisourceBergen) and independent retail pharmacies, community compounding pharmacies with our
            <span style="text-transform: uppercase">Bio-Ignite</span> program, and mail order. We continue to develop unique opportunities to sell direct to pharmacies to streamline distribution and better control costs.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b>Patient Affordability Programs </b>- We have affordability and adherence programs in place for patients so that we can support appropriate use of our products by patients. Our co-pay assistance programs allow all patients to access our products at a reasonable cost.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">We continue to support our patient education and affordability program that allows all eligible patients who enroll to receive IMVEXXY and BIJUVA at a reasonable cost. When a product is not covered by a patient&#x2019;s commercial insurance, the patient is responsible to pay the full price for the medication, which can significantly limit a patient&#x2019;s ability to pay and subsequent utilization of the product. Starting October 1, 2019, enrolled patients pay as little as $35 for a prescription of IMVEXXY with commercial insurance coverage and pay as little as $50 for a prescription of IMVEXXY without commercial insurance coverage. For ANNOVERA, for commercially insured patients, we offer patients assistance for as low as $60 for an annual prescription. Many patients will not need a co-pay assistance program for ANNOVERA given the requirements of the ACA at the federal level and similar laws at the state level.</span>
            </td>
        </tr>
    </table>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0; margin-right: 0; margin-top: 0">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">We continue to dialogue with the FDA regarding the potential inclusion of ANNOVERA as a new class of contraception for women in the FDA&#x2019;s Birth Control Guide, which would require private health plans to cover ANNOVERA with no patient out-of-pocket costs as part of the ACA. While we are optimistic about our chances to secure a new contraception class for ANNOVERA, there is no assurance that the FDA will make such a determination and it is possible that other FDA-approved products could also be included in such a new class. The FDA may also find that ANNOVERA fits into the vaginal contraceptive ring class, which it would share with NuvaRing and its generic equivalents, and potentially others. Eight states require insurance coverage of prescription contraception with co-pay regardless of inclusion in the FDA&#x2019;s Birth Control Guide and 11 states, plus Washington D.C., require coverage of prescription contraception with no co-pay regardless of inclusion in the FDA&#x2019;s Birth Control Guide.</span>
            </td>
        </tr>
    </table>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0; margin-right: 0; margin-top: 0">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b>Patient Adherence</b> - Establishing compliance and adherence programs that make getting on a prescription medication and obtaining prescribed refills easy and convenient for the patient and HCPs is a critical lever in our commercial model. Our focus is on minimizing complications in patients filling their first prescription and engaging with them throughout the life of their treatment to ensure patients stay on and use therapy for the appropriate length of time. We have delivered effective patient engagement programs for both our prescription prenatal line and for IMVEXXY with average adherence rates above the averages in their respective categories.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b>Consumer Communication -</b> Another critical level in the commercial model is consumer communication. Our initial focus is on those patients who are already predisposed to seek treatment, such as those patients new to therapy, and those patients dissatisfied with their current therapy. Next, we are focused on expanding the market by energizing patients who are experiencing bothersome symptoms but who have not been motived to seek treatment. Methods of communication include online and offline media and span branded and unbranded communication to ensure we drive action from awareness of symptoms to desire to speak to an HCP to acquire a prescription.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b>License Agreements</b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif"><i>License Agreement with the Population Council</i></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Under the terms of the Population Council License Agreement, we paid the Population Council a milestone payment of $20,000,000 within 30 days following approval by the FDA of the NDA for ANNOVERA. The first commercial batch of ANNOVERA was released during the third quarter of 2019 and we paid the Population Council $20,000,000 as a result of the commercial batch release. The Population Council is eligible to receive additional milestone payments and royalties from commercial sales of ANNOVERA, as detailed below.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">We assumed responsibility for marketing expenses related to the commercialization of ANNOVERA.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">We are required to pay the Population Council milestone payments of $40 million upon cumulative net sales of ANNOVERA in the U.S. by us and our affiliates and permitted sublicensees of each of $200.0 million, $400.0 million and $1.0 billion.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <!-- Field: Page; Sequence: 12; Value: 1-->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt">
        <p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">
            <!-- Field: Sequence; Type: Arabic; Name: PageNo-->12<!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&#160;</p>
    </div>
    <!-- Field: /Page -->
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">In addition, we are required to pay the Population Council, on a quarterly basis, step-based royalty payments based on annual net sales of ANNOVERA in the U.S. by us and our affiliates and permitted sublicensees as follows:</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 80%; border-collapse: collapse; margin-right: auto">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt; padding-right: 5.4pt; width: 67%; vertical-align: bottom; text-align: left">
                <span style="font: 10pt Times New Roman, Times, Serif"><b>Annual Net Sales</b></span>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt; padding-right: 5.4pt; width: 12%; text-align: center">
                <span style="font: 10pt Times New Roman, Times, Serif"><b>Royalty Rate</b></span>
            </td>
        </tr>
        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #cceeff; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt; padding-right: 5.4pt; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">Less than or equal to $50.0 million</span>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt; text-align: right">
                <span style="font: 10pt Times New Roman, Times, Serif">5%</span>
            </td>
        </tr>
        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt; padding-right: 5.4pt; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">Greater than $50.0 million and less than or equal to $150.0 million</span>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt; text-align: right">
                <span style="font: 10pt Times New Roman, Times, Serif">10%</span>
            </td>
        </tr>
        <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #cceeff; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt; padding-right: 5.4pt; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">Greater than $150.0 million</span>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt; text-align: right">
                <span style="font: 10pt Times New Roman, Times, Serif">15%</span>
            </td>
        </tr>
    </table>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">The annual royalty rate will be reduced to 50% of the initial rate during the six-month period beginning on the date of the first arms-length commercial sale of a generic equivalent of ANNOVERA that is launched by a third party in the U.S., and thereafter will be reduced to 20% of the initial rate.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
        <span style="font: 10pt Times New Roman, Times, Serif">The Population Council has agreed to perform and pay the costs and expenses associated with two post-approval studies required by the FDA for ANNOVERA and we have agreed to perform and pay the costs and expenses associated with a post-approval study required by the FDA to measure risk for venous thromboembolism, provided that if the costs and expenses associated with such post-approval study exceed $20 million, half of such excess will be offset against royalties or other payments owed by us to the Population Council under the Population Council License Agreement. We and the Population Council formed a joint product committee responsible for overseeing activities under the Population Council License Agreement. We are responsible for all aspects of promotion, product positioning, pricing, education programs, publications, sales messages and any additional desired clinical studies for the one-year vaginal contraceptive system, subject to oversight and decisions made by the joint product committee.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
        <span style="font: 10pt Times New Roman, Times, Serif">Unless earlier terminated, the Population Council License Agreement will remain in effect until the later of the expiration of the last-to-expire of the Population Council&#x2019;s U.S. patents that are licensed to us, or the date following such expiration that follows a continuous period of six months during which we and our affiliates have not made a commercial sale of ANNOVERA in the U.S. The Population Council License Agreement may also be terminated for certain breach and bankruptcy-related events and by us on 180 days prior notice to the Population Council.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
        <span style="font: 10pt Times New Roman, Times, Serif">As part of the Population Council License Agreement, we have the exclusive right to negotiate co-development and U.S. marketing rights for two other investigational vaginal contraceptive systems in development by the Population Council.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
        <span style="font: 10pt Times New Roman, Times, Serif"><i>License Agreement with Knight</i></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
        <span style="font: 10pt Times New Roman, Times, Serif">In July 2018, we entered into a license and supply agreement, or the Knight License Agreement, with Knight pursuant to which we granted Knight an exclusive license to commercialize IMVEXXY and BIJUVA in Canada and Israel. Pursuant to the terms of the Knight License Agreement, Knight will pay us a milestone fee upon the first regulatory approval in Canada of each of IMVEXXY and BIJUVA, sales milestone fees based upon certain aggregate annual sales in Canada and Israel of each of IMVEXXY and BIJUVA and royalties based on aggregate annual sales of each of IMVEXXY and BIJUVA in Canada and Israel. In October 2019 and November 2019, Knight&#x2019;s New Drug Submissions for Joyesta (IMVEXXY) and BIJUVA, respectively, were accepted for review by Health Canada. Knight will be responsible for all regulatory and commercial activities in Canada and Israel related to IMVEXXY and BIJUVA. We may terminate the Knight License Agreement if Knight does not submit all regulatory applications, submissions and/or registrations required for regulatory approval to use and commercialize IMVEXXY and BIJUVA in Canada within certain specified time periods. We also may terminate the Knight License Agreement if Knight challenges our patents. Either party may terminate the Knight License Agreement for any material breach by the other party that is not cured within certain specified time periods or if the other party files for bankruptcy or other related matters.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif"><i>License Agreement with Theramex</i></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">In June 2019, we entered into a licensing and supply agreement, or the Theramex License Agreement, with Theramex pursuant to which we granted Theramex an exclusive, perpetual license to commercialize BIJUVA and IMVEXXY for human use outside of the U.S., except for Canada and Israel, or the Theramex Territory. Pursuant to the terms of the Theramex License Agreement, Theramex paid us an upfront fee of EUR 14 million in cash. We are also eligible to receive up to an additional EUR 29.5 million in cash milestone payments, comprised of (i) an aggregate of EUR 2 million in regulatory milestone payments based on regulatory approvals for each of BIJUVA and IMVEXXY in certain specified markets and (ii) an aggregate of EUR 27.5 million in sales milestone payments to be paid in escalating tranches based on Theramex first attaining certain aggregate annual net sales milestones in the Theramex Territory ranging from EUR 25 million to EUR 100 million. We are also entitled to receive quarterly royalty payments based on net sales of BIJUVA and IMVEXXY in the Theramex Territory. Theramex has agreed to submit all regulatory applications, submissions and/or registrations required for regulatory approval to use and commercialize BIJUVA and IMVEXXY in certain specified markets within certain specified time periods and we may terminate the Theramex License Agreement if Theramex does not submit certain of such regulatory applications, submissions and/or registrations. We may also terminate the Theramex License Agreement if Theramex challenges our patents. Either party may terminate the Theramex License Agreement for any material breach by the other party that is not cured within certain specified time periods or if the other party files for bankruptcy or other related matters. Theramex may sublicense its rights to commercialize BIJUVA and IMVEXXY in the Theramex Territory, except for certain specified markets. Pursuant to the terms of the Theramex License Agreement, we agreed to supply, or cause to be supplied, BIJUVA and IMVEXXY to Theramex. We and Theramex have agreed to form a joint product committee responsible for advising and overseeing activities under the Theramex License Agreement.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <!-- Field: Page; Sequence: 13; Value: 1-->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt">
        <p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">
            <!-- Field: Sequence; Type: Arabic; Name: PageNo-->13<!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&#160;</p>
    </div>
    <!-- Field: /Page -->
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><strong><span style="font: 10pt Times New Roman, Times, Serif">Preclinical Development </span></strong></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman , Times, serif; margin: 0px; text-align: justify; text-indent: 0.5in">We have four preclinical projects: a progesterone-alone transdermal cream (TX-005HR), a combination estradiol and progesterone transdermal cream (TX-006HR), and a pair of transdermal patch product candidates (TX-007HR and TX-008HR).&#160;<em>In vivo</em> and <em>in vitro</em> proof-of-concept preclinical studies were conducted to assess TX-005HR and TX-006HR with respect to penetration of the estradiol and progesterone, and successful opposition of subcutaneous estradiol on the endometrium. In addition to menopausal treatments, we are also evaluating various other indications targeted to women&#x2019;s health and wellness. We may, in the future, engage with a financing partner to advance one or more of these product candidates. We have one project in clinical development: an oral progesterone and estradiol formulation (TX-009HR).&#160; Previously, TX-009HR showed improved bioavailability in animals.&#160; In 2019, TX-009HR was tested in a Phase 1 study of healthy postmenopausal women and was well-tolerated in that study.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b>Sales Concentration</b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">We sell our prescription prenatal vitamin products and pharmaceutical products to wholesale distributors and retail pharmacy distributors. See Note 12 to the consolidated financial statements included in this Annual Report for a discussion of the concentration of sales of our products.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b>Seasonality</b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">The pharmaceutical markets in which we compete are not subject to seasonal sales fluctuation. However, our net revenues for the first quarter of each year can be negatively affected by the annual reset of high-deductible commercial insurance plans.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b>Manufacturing of Our Products</b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">We have sourced and qualified third-party contract manufacturing organizations, or CMOs, for the commercial supply of our products. The regulations for manufacturing of approved drug products are significantly more stringent than the standards for manufacturing supplements or drug product for clinical trials. Our CMOs are responsible for the manufacture of our products in accordance with our specifications and applicable regulatory requirements. We have entered into long-term supply agreements with Catalent Pharma Solutions, LLC, or Catalent, for the commercial supply of our IMVEXXY and BIJUVA, and QPharma for the supply of ANNOVERA. Under the terms of the agreements, we are obligated to purchase certain minimum annual amounts of each product. We may terminate the agreement for a particular drug for certain specified reasons. If we are unable to obtain sufficient quantities of drugs or receive raw materials in a timely manner, we could be required to delay our manufacturing and seek alternative manufacturers, which would be costly and time-consuming.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">We have a multi-faceted risk management approach to ensure continuous supply from our qualified CMOs for the commercial supply of our products. This approach includes oversight of the manufacturing processes, regular Good Manufacturing Practice, or GMP, audits, a review of their business continuity plans, management of finished product inventory and safety stock, and second sourcing as appropriate.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">We have also sourced and qualified manufacturers of the active pharmaceutical ingredient, or APIs, to be used in our drugs and drug candidates. We follow a risk management approach for our API manufacturer similar to that followed for the commercial supply of the finished drug product.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">We use third-party manufacturers to manufacture and package our vitamin and supplement products, as well as meet applicable contract and regulatory requirements. We currently obtain all of our vitaMedMD and BocaGreen products from Lang Pharma Nutrition, or Lang, a full-service, private label and corporate brand manufacturer specializing in premium health benefit driven products, including medical foods, nutritional supplements, beverages, bars, and functional foods in the dietary supplement category. As a result, we are dependent on Lang and its subcontractors for the manufacture of our vitamin and supplement products. In addition to manufacturing, Lang also provides a variety of additional services to us, including development processes, prototype development, raw materials sourcing, regulatory review, and packaging production. We believe that Lang maintains multiple supply and purchasing relationships throughout the raw materials marketplace to provide an uninterrupted supply of product to meet our manufacturing requirements.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">We have experienced no difficulties in obtaining the vitamin and supplement products we need in the amounts we require and do not anticipate those issues in the future. We believe the terms of our agreements with Lang are competitive with other suppliers and manufacturers. At present, we believe our relationship with Lang is excellent, and we intend to continue to use Lang as our third-party manufacturer for most of our vitamins and supplements. Although we anticipate continuing our relationship with Lang, we believe that we could obtain similar terms with other suppliers to provide the same services in the event our relationship with Lang terminates. Accordingly, we do not believe that such termination would have a material adverse effect on our business.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <!-- Field: Page; Sequence: 14; Value: 1-->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt">
        <p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">
            <!-- Field: Sequence; Type: Arabic; Name: PageNo-->14<!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&#160;</p>
    </div>
    <!-- Field: /Page -->
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b>Quality Control for our Products</b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Our products are required to be manufactured in accordance with the FDA&#x2019;s current Good Manufacturing Practice, or cGMPs. Our third-party suppliers and manufacturers are also responsible for continued compliance with cGMP requirements. We have executed quality agreements that delineate the responsibilities of each company in the quality assurance process. To comply with these drug commercialization standards, we have personnel with pharmaceutical development, manufacturing, and quality assurance experience who are responsible for the relationships with our suppliers. We have contracted with Catalent, an established manufacturer of softgel drug products, to manufacture the commercial supply for both IMVEXXY and BIJUVA. We have also contracted with QPharma to manufacture the commercial supply for ANNOVERA. For the prenatal vitamins, our quality assurance team collaborates with Lang to monitor the cGMP compliance of Lang&#x2019;s contracted manufacturers and packagers. Although each of Catalent, QPharma and Lang have received Form FDA 483 observations from FDA inspections in the past, we are not aware of any open FDA investigations into the manufacturing and/or packaging processes at the facilities that are used for our products.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Our quality assurance team establishes controls that are designed to document the manufacturing process and ensure that our contract manufacturers meet product specifications and that our finished products contain the correct ingredients, purity, strength, and composition in compliance with FDA regulations. Depending on their roles and activities, certain of our contractors are subject to applicable requirements to test incoming raw materials and finished goods to ensure they meet or exceed FDA and U.S. Pharmacopeia standards, including quantitative and qualitative assay and microbial and heavy metal contamination (as appropriate).</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b>Distribution of our Products</b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">We distribute our products through our third-party logistics partner, Cardinal Logistics, who ships to national wholesale distributors such as Cardinal, McKesson, and AmerisourceBergen, regional wholesalers such as Smith Drug, Anda, Value Drug and RDC, and alternate distribution partners. Wholesaler product inventory is monitored daily and sales out is monitored weekly. We are subject to compliance responsibilities under the Drug Supply Chain Security Act, or the DSCSA, and the Prescription Drug Marketing Act, or PDMA, in relation to distribution of drug products in the commercial supply and dispensing chain and drug samples to HCPs respectively, and are further subject to state laws on these topics. National and regional retail pharmacies are also an area of focus to make sure our products are purchased and dispensed properly.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b>Customer Service</b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Our goal is 100% customer satisfaction by consistently delivering superior customer experiences before, during, and after the sale. To achieve this goal, we maintain a fully staffed customer care center that uses current customer relationship management software to respond to HCPs, pharmacies, and consumers. We believe our customer service initiatives allow us to establish and maintain long-term customer relationships and facilitate repeat visits and purchases.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Our representatives receive regular training so that they can effectively and efficiently field questions from current and prospective customers and are also trained not to answer questions that should be directed to a customer&#x2019;s physician. Having a quality customer care center allows our representatives to provide an array of valuable data in the areas of sales, market research, quality assurance, lead generation, and customer retention.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
        <span style="font: 10pt Times New Roman, Times, Serif"><b>Our Return Policy</b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">We sell our prescription products through third-party logistics providers, wholesale distributors, and retail pharmacy distributors, all of whom may return a product within six months before and twelve months after the expiration date of the product. Once customers buy a prescription product from the pharmacy, the product may not be returned.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b>Our Quality Guarantee</b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">We proudly stand behind the quality of our products. We believe our guarantee makes it easy, convenient, and safe for customers to purchase our products. Under our quality guarantee, we:</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">Ensure the potency and quality of our products; and</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">Help HCPs and payers by delivering information on patient compliance and satisfaction.</span>
            </td>
        </tr>
    </table>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0; margin-right: 0; margin-top: 0">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <!-- Field: Page; Sequence: 15; Value: 1-->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt">
        <p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">
            <!-- Field: Sequence; Type: Arabic; Name: PageNo-->15<!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&#160;</p>
    </div>
    <!-- Field: /Page -->
    <p style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0; margin-right: 0; margin-top: 0">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">We value frequent communication with and feedback from our customers to continue to improve our offerings and services.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b>Research and Development</b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Our product development programs are concentrated in advanced hormone therapy pharmaceutical products. We engage in programs to provide alternatives to the FDA and non-FDA-approved compounded bio-identical market for hormone therapy. Our programs seek to bring new products to market in unique delivery systems or formats that enhance the effectiveness, safety, and reliability of existing hormone therapy alternatives.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b>Intellectual Property</b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> <span style="font: 10pt Times New Roman, Times, Serif">Our
    success depends, in part, on our ability to obtain patents, maintain trade-secret protection, and operate without infringing
    the proprietary rights of others. Our intellectual property portfolio is one way we attempt to protect our competitive
    position. We rely primarily on a combination of know-how, trade secrets, patents, trademarks, and contractual restrictions to
    protect our products and to maintain our competitive position. We are diligently seeking ways to protect our intellectual
    property through various legal mechanisms in relevant jurisdictions. Where permitted, patents for our hormone therapy drug
    products have been submitted to the Orange Book.</span> </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">As of December 31, 2019, we had 29 issued domestic patents and 30 issued foreign patents, including:</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">12 domestic patents and six foreign patents that relate to BIJUVA as well as three domestic patents that relate to estradiol and progesterone product candidates. These patents establish an important intellectual property foundation and are owned by us. The domestic patents will expire in 2032. The foreign patents will expire no earlier than 2032. In addition, we have pending patent applications relating to BIJUVA in the U.S., Argentina, Australia, Brazil, Canada, China, Europe, Israel, Japan, Mexico, New Zealand, Russia, South Africa, and South Korea;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">Six domestic patents (five utility and one design) and 13 foreign patents (three utility and ten design) that relate to IMVEXXY. These patents establish an important intellectual property foundation for IMVEXXY and are owned by us. The domestic patents will expire in 2032 or 2033. The foreign utility patents will expire no earlier than 2033. The foreign design patents provide protection expiring no earlier than 2025. In certain countries, the foreign design patents provide protection through at least 2037. In addition, we have pending patent applications related to IMVEXXY in the U.S., Argentina, Australia, Brazil, Canada, Europe, Israel, Japan, Mexico, New Zealand, Russia, South Africa, and South Korea;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">One domestic utility patent that relates to our topical-cream candidates, which is owned by us. The domestic patent will expire in 2035. We have pending patent applications with respect to our topical-cream candidates in the U.S., Argentina, Australia, Brazil, Canada, Europe, Israel, Japan, Mexico, Russia, South Africa, and South Korea;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">One domestic utility patent and seven foreign patents that relate to our transdermal-patch candidates, which are owned by us. The domestic utility patent will expire in 2032. The foreign patents will expire no earlier than 2033. We have pending patent applications with respect to our transdermal-patch candidates in the U.S., Brazil, Canada, Mexico, and South Africa;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">Three domestic utility patents that relate to TX-009HR, a progesterone and estradiol product candidate, which are owned by us and will expire in 2037. We have pending patent applications with respect to TX-009HR in the U.S., Argentina, Australia, Brazil, Canada, Europe, Israel, Japan, Mexico, New Zealand, Russia, South Africa, and South Korea;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">Two domestic and four foreign patents that relate to formulations containing progesterone, which are owned by us. The domestic patents will expire between 2032 and 2036. The foreign patents will expire no earlier than 2033. In addition, we have pending patent applications with respect formulations containing progesterone in the U.S., Argentina, Australia, Brazil, Canada, Europe, Israel, Japan, Mexico, Russia, South Africa, and South Korea; and</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">One domestic utility patent that relates to our OPERA information-technology platform, which is owned by us and will expire in 2031.</span>
            </td>
        </tr>
    </table>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0; margin-right: 0; margin-top: 0">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">The sponsor of an approved 505(b) drug product, which approval is the first permitted commercial marketing of a drug with that drug&#x2019;s active ingredient, may apply for a patent term extension (PTE) under 35 U.S.C. &#xA7; 156. The length of a PTE is calculated based on the &#x201C;regulatory review period,&#x201D; which consists of one-half of the time between the initial effective date of the Investigational New Drug, or IND, for the clinical study(ies) supporting FDA approval of the drug and the date of the NDA submission, plus the time between the submission of the NDA and the date of FDA approval. Any period of time during the regulatory review period in which the applicant is deemed to have not acted with due diligence will be deducted from regulatory review period calculation. A PTE may not exceed five years, and the remaining term of a patent as extended by a PTE will be limited as necessary such that the remaining term does not exceed 14 years from the date of the NDA approval. Only one patent may be extended based on a regulatory review period, and a patent may not receive more than one PTE. The rights provided during the term of a PTE generally are limited to the approved use(s) of the product.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">As of December 31, 2019, we had filed over 120 patent applications with the U.S. Patent and Trademark Office, or the USPTO, with respect to our technology or our hormone-therapy drugs and drug candidates, and over 189 international patent applications with respect to our technology or our hormone-therapy drugs and drug candidates, including Patent Cooperation Treaty (PCT) and national-stage filings.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <!-- Field: Page; Sequence: 16; Value: 1-->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt">
        <p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">
            <!-- Field: Sequence; Type: Arabic; Name: PageNo-->16<!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&#160;</p>
    </div>
    <!-- Field: /Page -->
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">We hold multiple U.S. trademark registrations and have numerous pending trademark applications. Issuance of a federally registered trademark creates a rebuttable presumption of ownership of the mark; however, it is subject to challenge by others claiming first use in the mark in some or all the areas in which it is used. Federally registered trademarks have a perpetual life so long as they are maintained and renewed on a timely basis and used properly as trademarks, subject to the rights of third parties to seek cancellation of the trademarks if they claim priority or confusion of usage. We believe our patents and trademarks are valuable and provide us certain benefits in marketing our products.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> <span style="font: 10pt Times New Roman, Times, Serif">We
    intend to actively protect our intellectual property with patents, trademarks, trade secrets, or other legal avenues for the
    protection of intellectual property and to aggressively prosecute, enforce, and defend our patents, trademarks, and
    proprietary technology. The loss, by expiration or otherwise, of any one patent may have a material effect on our business.
    Defense and enforcement of our intellectual property rights can be expensive and time consuming, even if the outcome is
    favorable to us. It is possible that the patents issued or licensed to us will be successfully challenged, that a court may
    find that we are infringing on validly issued patents of third parties, or that we may have to alter or discontinue the
    development of our products or pay licensing fees to account for patent rights of third parties. See &#x201C;&#x2013;
    Pharmaceutical Regulation &#x2013; Regulatory Exclusivity&#x201D; below for information regarding our intellectual property
    and challenges thereto.</span> </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">As we continue to develop proprietary intellectual property, we will expand our protection by applying for patents on future technologies. As we examine our current product offerings and new product pipeline, we are in the process of modifying and developing new formulations that will enable us to gain patent protection for these products.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">While we seek broad coverage under our patent applications, there is always a risk that an alteration to the process may provide sufficient basis for a competitor to avoid infringement claims. In addition, patents expire, and we cannot provide any assurance that any patents will be issued from our pending application or that any potentially issued patents will adequately protect our intellectual property.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b>Government Regulation</b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">In the United States, the FDA regulates pharmaceuticals, biologics, medical devices, dietary supplements, and cosmetics under the Federal Food, Drug, and Cosmetic Act, or FDCA, and its implementing regulations. These products are also subject to other federal, state, and local statutes and regulations, including federal and state consumer protection laws, laws regarding pricing transparency, laws requiring the implementation of compliance programs, laws requiring the reporting of payments or other transfers of value to HCPs or other healthcare professionals, laws protecting the privacy of health-related information, and laws prohibiting unfair and deceptive acts and trade practices.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b>Pharmaceutical Regulation</b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">The process required by the FDA before a new drug product may be marketed in the United States generally involves the following:</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">completion of or reference to extensive preclinical laboratory tests and preclinical animal studies, all performed in accordance with the FDA&#x2019;s Good Laboratory Practice, or GLP, regulations;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">submission to the FDA of an investigational new drug, or IND application under which the holder may begin conducting human clinical trials, provided that the FDA does not object; the IND must be updated annually;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">performance of adequate and well-controlled human clinical trials to establish the safety and efficacy of the drug candidate for each proposed indication; and</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">submission to the FDA of an NDA after completion of all pivotal clinical trials.</span>
            </td>
        </tr>
    </table>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0; margin-right: 0; margin-top: 0">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">An IND application is a request for authorization from the FDA to administer an investigational drug product to humans. We have submitted six INDs for our hormone therapy drug candidates. Requests to withdraw the INDs for TX-002HR and TX-003HR were submitted in December 2019. The INDs for TX-004HR, TX-001HR, TX-006HR, and TX-009HR remain active. The IND for ANNOVERA was transferred from the Population Council to us in May 2019 and is also active.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Clinical trials involve the administration of the investigational drug to human subjects under the supervision of qualified investigators in accordance with current Good Clinical Practices, or cGCPs, which include the requirement that all research subjects provide their informed consent for their participation in the clinical trial. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. Additionally, approval must also be obtained from and central or each clinical trial site&#x2019;s institutional review board, or IRB, before the trials may be initiated, and the IRB must monitor the study until completed and re-assess and approve the study at least annually. There are also requirements governing the reporting of ongoing clinical trials and clinical trial results to public registries.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <!-- Field: Page; Sequence: 17; Value: 1-->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt">
        <p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">
            <!-- Field: Sequence; Type: Arabic; Name: PageNo-->17<!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&#160;</p>
    </div>
    <!-- Field: /Page -->
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Clinical trials are usually conducted in three phases. Phase 1 clinical trials are normally conducted in small groups of healthy volunteers to assess safety, characterize pharmacokinetics, and assist in finding the potential dosing range. During Phase 2, the drug is administered to small populations of patients to look for initial signs of efficacy in treating the targeted disease or condition and to continue to assess dosing and safety. Phase 3 clinical trials are usually multi-center, double-blind, controlled trials in hundreds or even thousands of subjects to assess the safety and effectiveness of the drug.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">During a clinical trial, we are required to inform the FDA and the IRB about adverse events associated with our drug candidate. The FDA, the IRB, or the clinical trial sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects are being exposed to an unacceptable health risk. Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board or committee, or DSMB. This group reviews unblinded data from clinical trials and provides authorization for whether a trial may move forward at designated check points based on access to certain data from the study. We may also suspend or terminate a clinical trial based on evolving business objectives or competitive climates.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, detailed investigational drug product information is submitted to the FDA in the form of an NDA requesting approval to market the product for one or more indications. The application includes all relevant data available from pertinent preclinical and clinical trials, including, among other things, negative or ambiguous results as well as positive findings, together with detailed information relating to the product&#x2019;s chemistry, manufacturing, controls and proposed labeling.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Once the NDA submission has been accepted for filing, the FDA&#x2019;s goal is to review standard applications within 10 months of the 60-day filing date for new molecular entity NDA and original BLA submissions, or within 10 months of receipt for non-NME and original BLA submissions. For Original Efficacy Supplements, the FDA&#x2019;s goal is to review the application within 10 months of the receipt date. The review process can be extended by FDA requests for additional information or clarification. The FDA may refer the application to an advisory committee for review, evaluation, and recommendation as to whether the application should be approved. The FDA is not bound by the recommendation of an advisory committee, but it typically follows such recommendations.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><i>Post-Approval Regulation</i></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Since regulatory approval of some of our drug products has been obtained, we are required to comply with several post-approval requirements. As a holder of an approved NDA, we are required to report, among other things, certain adverse reactions and production problems to the FDA, to provide updated safety and efficacy information, to adhere to product sampling and distribution requirements, fulfill post-marketing study commitments, and to comply with requirements concerning advertising and promotional labeling for any of our drug products, which include, among other things, standards for direct-to-consumer advertising, restrictions that prohibit promoting products for uses or in patient populations that are not described in the product&#x2019;s approved uses or that are not otherwise consistent with the FDA-required label (known as &#x201C;off-label use&#x201D;), limitations on industry-sponsored scientific and educational activities, and requirements for promotional activities involving the internet. Although physicians may prescribe legally available products for off-label use, if they deem such use to be appropriate in their professional medical judgment, manufacturers may not market or promote such off-label uses.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Also, quality control and manufacturing procedures must continue to conform to cGMPs to ensure and preserve the long-term stability of the drug product. cGMP regulations require among other things, quality control and quality assurance as well as the corresponding maintenance of records and documentation and the obligation to investigate and correct any deviations from cGMP. Manufacturers and other entities involved in the manufacture and distribution of approved products are, depending on the nature and scope of their activities, subject to FDA and certain state agency requirements relating to establishing and maintaining product quality. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting and documentation requirements upon us and any third-party manufacturers that we may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">The FDA periodically inspects manufacturing facilities to assess compliance with cGMP, which imposes extensive procedural, substantive, and record keeping requirements. For example, Catalent, the CMO that we have contracted with for the commercial supply of our BIJUVA and IMVEXXY hormone therapy drug products, was issued a Form FDA 483 in 2019 with respect to its softgel manufacturing plant. The observations and associated corrective actions identified in Catalent&#x2019;s response to the Form FDA 483 related to our BIJUVA product. The current inspection classification status of that Form FDA 483 is that the response was adequate and Voluntary Action Indicated. Voluntary Action Indicated status indicates that objectionable conditions or practices were found but the FDA is not prepared to take or recommend any administrative or regulatory action.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <!-- Field: Page; Sequence: 18; Value: 1-->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt">
        <p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">
            <!-- Field: Sequence; Type: Arabic; Name: PageNo-->18<!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&#160;</p>
    </div>
    <!-- Field: /Page -->
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">We rely, and expect to continue to rely, on third parties to produce clinical and commercial quantities of our drugs and drug candidates. Future FDA and state inspections may identify compliance issues at our facilities or at the facilities of our contract manufacturers that may disrupt production or distribution or require substantial resources to correct. In addition, discovery of previously unknown problems (for example, through adverse events observed in the post-marketing context, or in Phase 4 / post-marketing studies) with a product or the failure to comply with applicable requirements may result in restrictions on a product, manufacturer, or holder of an approved NDA, including withdrawal or recall of the product from the market or other voluntary, FDA-initiated or judicial action that could delay or prohibit further marketing. Newly discovered or developed safety or effectiveness data may require changes to a product&#x2019;s approved labeling, including the addition of new warnings and contraindications, and may require the implementation of other risk management measures. Also, new government requirements, including those resulting from new legislation, may be established, or the FDA&#x2019;s policies may change, which could delay or prevent regulatory approval of our products under development.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><i>Regulation of Compounding Pharmacies</i></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Our hormone therapy pharmaceutical products and product candidates may compete with unapproved hormone therapy products supplied by compounding pharmacies. Pharmacy compounding is a practice in which a licensed pharmacist combines, mixes, or alters ingredients in response to a prescription to create a medication tailored to the medical needs of an individual patient. The medications created by the compounding pharmacy are not approved by the FDA and are therefore not reviewed to evaluate their safety, effectiveness, or quality.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">For approximately 50 years, the FDA left regulation of compounding pharmacies to the states. In 1992, in response to various safety concerns, the FDA issued a Compliance Policy Guide, which announced that the &#x201C;FDA may, in the exercise of its enforcement discretion, initiate federal enforcement actions...when the scope and nature of a pharmacy&#x2019;s activities raises the kinds of concerns normally associated with a manufacturer and...results in significant violations of the new drug, adulteration, or misbranding provisions of the Act.&#x201D; Thereafter, Congress enacted the Food and Drug Administration Modernization Act of 1997, or FDAMA, which sought to clarify FDA&#x2019;s regulatory authority over compounding pharmacies. FDAMA exempted &#x201C;compounded drugs&#x201D; from the FDA&#x2019;s standard drug approval requirements as long as the providers of those drugs abide by several restrictions, including that they refrain from advertising or promoting particular compounded drugs. In 2002, though, the Supreme Court declared this provision of FDAMA to be unconstitutional under the First Amendment, effectively reinstating the pre-FDAMA regime. Shortly thereafter, the FDA issued its 2002 Compliance Policy Guide 460.200, which states that the FDA will exercise enforcement discretion to exclude compounded drugs from the new drug approval requirements except where compounding pharmacies act more akin to traditional drug manufacturers.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">To further clarify the FDA&#x2019;s jurisdiction, Congress enacted and the President signed into law the Drug Quality and Security Act of 2013, which among other things, formalized the relationship between the FDA and compounding pharmacies by exempting compounding pharmacy products from the FDA approval requirements and the requirement to label products with adequate directions for use, but not the exemption from cGMP requirements. To qualify for this exemption, a compounding pharmacy must register with the FDA as an &#x201C;outsourcing facility,&#x201D; subject to FDA inspection and other requirements. The FDA does not exercise the same authority to regulate compounding pharmacies as pharmaceutical manufacturers. For example, compounding pharmacies are not required to report adverse events associated with compounded drugs, while commercial drug manufacturers are subject to stringent regulatory reporting requirements.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif"><i>Regulatory Exclusivity</i></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">A Section 505(b) NDA applicant may be eligible for its own regulatory exclusivity period, such as a five-year or three-year exclusivity. The first approved Section 505(b) NDA applicant for a drug containing an active ingredient that has not previously been approved in any other 505(b) NDA (a &#x201C;new chemical entity,&#x201D; or NCE), is eligible for a five-year NCE exclusivity period starting on the date of the NDA approval. During this period, an Abbreviated New Drug Application, or ANDA, or 505(b)(2) application for a drug containing the protected active ingredient of the NCE product generally cannot be submitted to FDA until the end of the five-year exclusivity period, except that such applications can be submitted at year four if the product is covered by an Orange Book listed patent and the ANDA or 505(b)(2) NDA includes a Paragraph IV Certification challenging such patent. Additional exclusivities may also apply.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">The first approved Section 505(b) NDA applicant for a particular condition, or a supplemental NDA approval for a change to a marketed product, such as a new extended release formulation for a previously approved product, may be eligible for a three-year Hatch-Waxman exclusivity if one or more new clinical studies, other than bioavailability or bioequivalence studies, was essential to the approval of the application and was conducted or sponsored by the applicant. Should this occur, the FDA would be precluded from granting final approval to any ANDA or 505(b)(2) application for the same condition of use or change to the marketed product that was granted exclusivity until after that three-year exclusivity period has run.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <!-- Field: Page; Sequence: 19; Value: 1-->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt">
        <p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">
            <!-- Field: Sequence; Type: Arabic; Name: PageNo-->19<!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&#160;</p>
    </div>
    <!-- Field: /Page -->
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Additionally, any ANDA or 505(b)(2) NDA that references the 505(b) product must include one of several types of patent certifications. If the Section 505(b) NDA drug has one or more unexpired patents listed in the Orange Book, an ANDA or 505(b)(2) NDA must include either a &#x201C;Paragraph III Certification&#x201D; or a &#x201C;Paragraph IV Certification.&#x201D; A Paragraph III Certification identifies the expiration date of the listed patent and requires FDA to withhold final approval until that patent has expired. A &#x201C;Paragraph IV Certification&#x201D; states that, in the applicant&#x2019;s opinion, the relevant patent is invalid, unenforceable, or would not be infringed by the commercial marketing of the proposed ANDA or 505(b)(2) NDA product. The sponsor of a Paragraph IV ANDA or 505(b)(2) NDA must also provide the holder of the marketed product NDA, and the owner of the challenged patent, with notification of the Paragraph IV filing along with a detailed statement of the reasons the applicant believes the patent is invalid, unenforceable, or would not be infringed. If the patent owner brings an infringement action against the Paragraph IV applicant within 45 days of the notification, a statutory stay is imposed which prevents FDA from granting final approval of the Paragraph IV application for 30 months from the date of the Paragraph IV Notification. Generally, no more than one 30-month stay may be applied against any specific Paragraph IV ANDA or 505(b)(2) NDA. A 30-month stay can be terminated early, and the Paragraph IV application can be immediately approved, if the district court rules in favor of the Paragraph IV applicant that the patent is invalid, unenforceable, or would not be infringed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On February 20, 2020, we received a Paragraph IV certification notice letter, or the Notice Letter, regarding an ANDA submitted to the FDA by Teva Pharmaceuticals USA, Inc., or Teva. The ANDA seeks approval from the FDA to commercially manufacture, use, or sell a generic version of the 4 mcg and 10 mcg doses of IMVEXXY. In the Notice Letter, Teva alleges that TherapeuticsMD patents listed in the FDA&#x2019;s Orange Book that claim compositions and methods of IMVEXXY, or the IMVEXXY Patents, are invalid, unenforceable, and/or will not be infringed by Teva&#x2019;s commercial manufacture, use, or sale of its proposed generic drug product. The IMVEXXY Patents identified in the Notice Letter expire in 2032 or 2033. We are currently reviewing the Notice Letter and intend to vigorously enforce our above-described intellectual property rights relating to IMVEXXY.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif"><i>Dietary Supplement Regulation</i></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Our currently marketed prenatal vitamins are regulated as dietary supplements. The processing, formulation, safety, manufacturing, packaging, labeling, advertising, and distribution of these products are subject to regulation by one or more federal agencies, including the FDA and the Federal Trade Commission, or the FTC, and by various agencies of the states and localities in which our products are sold.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Generally, our nutritional product formulations are proprietary in that in designing them, we attempt to blend an optimal combination of nutrients that are intended to have a beneficial impact in prenatal women based upon scientific literature and input from HCPs; however, we are generally prohibited from making disease treatment and prevention claims in the promotion of our products that use these formulations.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">The Dietary Supplement Health and Education Act of 1994, or DSHEA, amended the FDCA to establish a new framework governing the composition, safety, labeling, manufacturing, and marketing of dietary supplements. Generally, under the FDCA, dietary ingredients that were marketed in the United States before October 15, 1994 may be used in dietary supplements without notifying the FDA. &#x201C;New&#x201D; dietary ingredients (<i>i.e.</i>, dietary ingredients that were &#x201C;not marketed in the United States before October 15, 1994&#x201D;) must be the subject of a new dietary ingredient notification submitted to the FDA unless the ingredient has been &#x201C;present in the food supply as an article used for food&#x201D; without being &#x201C;chemically altered.&#x201D; A new dietary ingredient notification must provide the FDA evidence of a &#x201C;history of use or other evidence of safety&#x201D; establishing that use of the dietary ingredient &#x201C;will reasonably be expected to be safe.&#x201D; A new dietary ingredient notification must be submitted to the FDA at least 75 days before the initial marketing of the new dietary ingredient. The FDA may determine that a new dietary ingredient notification does not provide an adequate basis to conclude that a dietary ingredient is reasonably expected to be safe. Such a determination could prevent the marketing of such dietary ingredient. The FDA recently issued draft guidance governing the notification of new dietary ingredients. FDA guidance is not mandatory, and companies are free to use an alternative approach if the approach satisfies the requirements of applicable laws and regulations. However, FDA guidance is a strong indication of the FDA&#x2019;s &#x201C;current thinking&#x201D; on the topic discussed in the guidance, including its position on enforcement. The draft guidance on new dietary ingredients is expected to be significantly revised when published in final form. Moreover, Congress can amend the dietary supplement provisions of the FDCA to impose additional restrictions on labeling and marketing of dietary supplements. Such action would have material adverse impact on our business and growth prospects.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">The FDA or other agencies could take actions against products or product ingredients that in its determination present an unreasonable health risk to consumers that would make it illegal for us to sell such products. In addition, the FDA could issue consumer warnings with respect to the products or ingredients in such products. Such actions or warnings could be based on information received through FDCA-mandated reporting of serious adverse events. The FDCA requires that reports of serious adverse events be submitted to the FDA, and based in part on such reports, the FDA has issued public warnings to consumers to stop using certain third-party dietary supplement products.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">In addition, DSHEA provides that so-called &#x201C;third-party literature,&#x201D; such as a reprint of a peer-reviewed scientific publication linking a particular dietary ingredient with health benefits, may be used &#x201C;in connection with the sale of a dietary supplement to consumers&#x201D; without the literature being subject to regulation as labeling. The literature: (1) must not be false or misleading; (2) may not &#x201C;promote&#x201D; a particular manufacturer or brand dietary supplement; (3) must present a balanced view of the available scientific information on the subject matter; (4) if displayed in establishment, must be physically separate from the dietary supplements; and (5) should not have appended to it any information by sticker or another method. If the literature fails to satisfy each of these requirements, we may be prevented from disseminating such literature with our products, and any dissemination could subject our product to regulatory action as an illegal drug.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <!-- Field: Page; Sequence: 20; Value: 1-->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt">
        <p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">
            <!-- Field: Sequence; Type: Arabic; Name: PageNo-->20<!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&#160;</p>
    </div>
    <!-- Field: /Page -->
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">In June 2007, pursuant to the authority granted by the FDCA as amended by DSHEA, the FDA published detailed cGMP regulations that govern the manufacturing, packaging, labeling, and holding operations of dietary supplement manufacturers. The cGMP regulations, among other things, impose significant recordkeeping requirements on manufacturers. The cGMP requirements are in effect for all manufacturers, and the FDA is conducting inspections of dietary supplement manufacturers pursuant to these requirements. The failure of a manufacturing facility to comply with the cGMP regulations renders products manufactured in such facility &#x201C;adulterated,&#x201D; and subjects such products and the manufacturer to a variety of potential FDA enforcement actions. In addition, under the Food Safety Modernization Act, or FSMA, which was enacted on January 2, 2011, the manufacturing of dietary ingredients contained in dietary supplements are subject to similar or even more burdensome manufacturing requirements, which has the potential to increase the costs of dietary ingredients and subject suppliers of such ingredients to more rigorous inspections and enforcement. The FSMA also requires importers of food, including dietary supplements and dietary ingredients, to conduct verification activities to ensure that the food they might import meets applicable domestic requirements.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">The FDA has broad authority to enforce the provisions of federal law applicable to dietary supplements, including powers to issue public Warning Letters or Untitled Letters to a company, publicize information about illegal products, detain products intended for import, require the reporting of serious adverse events, request a recall of illegal or unsafe products from the market, and request that the Department of Justice initiate a seizure action, an injunction action, or a criminal prosecution in the U.S. courts. The FSMA expands the reach and regulatory powers of the FDA with respect to the production and importation of food, including dietary supplements. The expanded reach and regulatory powers include the FDA&#x2019;s ability to order mandatory recalls, administratively detain domestic products, require certification of compliance with domestic requirements for imported foods associated with safety issues and administratively revoke manufacturing facility registrations, effectively enjoining manufacturing of dietary ingredients and dietary supplements without judicial process. The regulation of dietary supplements may increase or become more restrictive in the future.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">The FTC exercises jurisdiction over the advertising of dietary supplements. In recent years, the FTC has instituted numerous enforcement actions against dietary supplement companies for making false or misleading advertising claims and for failing to adequately substantiate claims made in advertising. These enforcement actions have often resulted in consent decrees and the payment of civil penalties and/or restitution by the companies involved. The FTC also regulates other aspects of consumer purchases, including promotional offers of savings compared policies, telemarketing, continuity plans, and &#x201C;free&#x201D; offers.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">We are also subject to regulation under various state, local, and international laws that include provisions governing, among other things, the formulation, manufacturing, packaging, labeling, advertising, and distribution of dietary supplements and drugs. For example, Proposition 65 in the state of California is a list of substances deemed to pose a risk of carcinogenicity or birth defects at or above certain levels. If any such ingredient exceeds the permissible levels in a dietary supplement, cosmetic, or drug, the product may be lawfully sold in California only if accompanied by a prominent warning label alerting consumers that the product contains an ingredient linked to cancer or birth defect risk. Private attorney general actions as well as California attorney general actions may be brought against non-compliant parties and can result in substantial costs and fines.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif"><i>Other U.S. Healthcare Laws and Compliance Requirements</i></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Certain federal and state healthcare laws and regulations pertaining to fraud and abuse and patients&#x2019; rights, among other topics, are and will be applicable to our business. We are subject to regulation by both the federal government and the states in which we or our partners conduct our business. The healthcare laws and regulations that may affect our ability to operate include:</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">the federal Anti-Kickback Statute, which prohibits, among other things, any person or entity from knowingly and willfully offering, soliciting, receiving or providing any remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce either the referral of an individual or in return for the purchase, lease, or order of any good, facility item or service, for which payment may be made, in whole or in part, under federal healthcare programs such as the Medicare and Medicaid programs;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">federal civil and criminal false claims laws and civil monetary penalty laws, including, for example, the federal civil False Claims Act, which impose criminal and civil penalties, including civil whistleblower or qui tam actions, against individuals or entities for, among other things, knowingly presenting, or causing to be presented, to the federal government, including the Medicare and Medicaid programs, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created additional federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payer (e.g., public or private), knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters;</span>
            </td>
        </tr>
    </table>
    <p style="margin-bottom: 0; margin-top: 0">&#160;</p>
    <!-- Field: Page; Sequence: 21; Value: 1-->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt">
        <p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">
            <!-- Field: Sequence; Type: Arabic; Name: PageNo-->21<!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&#160;</p>
    </div>
    <!-- Field: /Page -->
    <p style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0; margin-right: 0; margin-top: 0">&#160;</p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, and their implementing regulations, which impose obligations on covered entities, including certain healthcare providers, health plans, and healthcare clearinghouses, as well as their respective business associates that create, receive, maintain or transmit individually identifiable health information for or on behalf of a covered entity, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">the federal physician sunshine requirements under the ACA, which require certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare or Medicaid to report annually to the Centers for Medicare &#38; Medicaid Services information related to payments and other transfers of value provided to physicians and teaching hospitals, and ownership and investment interests held by physicians and their immediate family members. In 2022 the Sunshine Act will be extended to payments and transfers of value to physician assistants, nurse practitioners, and other mid-level practitioners (with reporting requirements going into effect in 2022 for payments made in 2021). In addition, Section 6004 of the ACA requires annual reporting of information about drug samples that manufacturers and authorized distributors provide to healthcare providers;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">federal and state laws requiring pricing transparency or limiting price increases, which are in existence today or are anticipated to be in existence in the near future, may limit the ability to raise prices, require disclosure of price increases or require disclosure of the wholesale acquisition cost of pharmaceutical products to governmental agencies and consumers; and</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws, which may apply to items or services reimbursed by any third-party payer, including commercial insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#x2019;s voluntary compliance guidelines and the applicable compliance guidance promulgated by the federal government, or otherwise restrict payments that may be provided to healthcare providers and other potential referral sources; state laws that require drug manufacturers to report information related to payments and other transfers of value to healthcare providers or marketing expenditures; and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.</span>
            </td>
        </tr>
    </table>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0; margin-right: 0; margin-top: 0">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Pharmaceutical company interactions with HCPs, patient advocacy groups, and patients, including with respect to product and patient assistance programs and other education and support initiatives, have been and continue to be the subject of regulatory scrutiny for compliance with fraud and abuse laws.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">In addition to the fraud and abuse laws, we continue to monitor the potential impact of proposals to lower prescription drug costs at the federal and state level. For example, on May 11, 2018, President Trump laid out his administration&#x2019;s &#x201C;Blueprint&#x201D; to lower drug prices and reduce out of pocket costs of drugs, as well as additional proposals to increase drug manufacturer competition, increase the negotiating power of certain federal healthcare programs, and incentivize manufacturers to lower the list price of their products. Although some proposals related to the administration&#x2019;s Blueprint may require additional authorization to become effective, may ultimately be withdrawn, or may face challenges in the courts, the U.S. Congress and the Trump administration have indicated that they will continue to seek new legislative and administrative measures to control drug costs. Drug pricing remains a key bipartisan issue and drug pricing legislation has been introduced in both the Senate and the House. The Senate Finance Committee released &#x201C;The Prescription Drug Pricing Reduction Act of 2019&#x201D; in July 2019 which includes changes to Medicare and Medicaid drug pricing and targets certain pharmacy benefit manager (PBM) and pharmaceutical manufacturer pricing practices. In December 2019, the House passed a drug pricing bill, &#x201C;Lower Drug Costs Now Act of 2019&#x201D;, which features Medicare Parts B and D direct negotiation with manufacturers, inflationary rebates, and a restructuring of the Part D benefit. Republicans in both chambers have opposed the drug pricing bills but the Trump administration has expressed support for the Senate bill and continues to push for drug pricing controls. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws. In addition, recent healthcare reform legislation has strengthened these laws. For example, the ACA, among other things, amended the intent requirement of the federal Anti-Kickback Statute and certain criminal healthcare fraud statutes. A person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. In addition, the ACA codified case law that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Efforts to ensure that our business arrangements with third parties comply with applicable healthcare laws and regulations could be costly. Although we believe that our business practices are structured to be compliant with applicable laws, it is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations, or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our past or present operations, including activities conducted by our sales team or agents, are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal, and administrative penalties, damages, fines, exclusion from third party payer programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations. If any of the HCPs, providers, or entities with whom we do business are found to be not in compliance with applicable laws, they may be subject to criminal, civil, or administrative sanctions, including exclusion from government funded healthcare programs.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <!-- Field: Page; Sequence: 22; Value: 1-->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt">
        <p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">
            <!-- Field: Sequence; Type: Arabic; Name: PageNo-->22<!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&#160;</p>
    </div>
    <!-- Field: /Page -->
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Many aspects of these laws have not been definitively interpreted by the regulatory authorities or the courts, and their provisions are open to a variety of subjective interpretations that increases the risk of potential violations. In addition, these laws and their interpretations are subject to change. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses, divert our management&#x2019;s attention from the operation of our business, and damage our reputation.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">In addition, from time to time in the future, we may become subject to additional laws or regulations administered by the FDA, the FTC, U.S. Department of Health and Human Services, or HHS, or by other federal, state, local, or foreign regulatory authorities, or the repeal of laws or regulations that we generally consider favorable, such as DSHEA, or to more stringent interpretations of current laws or regulations. We are not able to predict the nature of such future laws, regulations, repeals, or interpretations, and we cannot predict what effect additional governmental regulation, if and when it occurs, would have on our business in the future. Such developments could, however, require reformulation of certain products to meet new standards, recalls or discontinuance of certain products not able to be reformulated, additional record-keeping requirements, increased documentation of the properties of certain products, additional or different labeling, additional scientific substantiation, additional personnel, or other new requirements. Any such developments could have a material adverse effect on our business.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">The growth and demand for eCommerce could result in more stringent consumer protection laws that impose additional compliance burdens on online retailers. These consumer protection laws could result in substantial compliance costs and could interfere with the conduct of our business. There is currently great uncertainty in many states whether or how existing laws governing issues such as property ownership, sales and other taxes, and libel and personal privacy apply to the Internet and commercial online retailers. These issues may take years to resolve. For example, tax authorities in several states, as well as a Congressional advisory commission, are currently reviewing the appropriate tax treatment of companies engaged in online commerce and new state tax regulations may subject us to additional state sales and income taxes. New legislation or regulation, the application of laws and regulations from jurisdictions whose laws do not currently apply to our business, or a change in application of existing laws and regulations to the Internet and commercial online services could result in significant additional taxes on our business. These taxes could have an adverse effect on our results of operations.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b>Employees</b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">As of December 31, 2019, we had 348 employees, six of whom are executive officers. Our sales force currently consists mainly of contract employees, with the sales management being employees. Additionally, from time to time, we hire temporary contract employees. None of our employees are covered by a collective bargaining agreement, and we are unaware of any union organizing efforts. We have never experienced a major work stoppage, strike, or dispute. We consider our relationship with our employees to be good.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
        <span style="font: 10pt Times New Roman, Times, Serif"><b>Our History</b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">On October 3, 2011, we changed our name to TherapeuticsMD, Inc. On October 4, 2011, we closed a reverse merger with VitaMedMD pursuant to which (1) all outstanding membership units of VitaMedMD were exchanged for shares of our common stock, (2) all outstanding VitaMedMD options and warrants were exchanged and converted into options and warrants to purchase shares of our common stock, and (3) VitaMedMD became our wholly owned subsidiary. As of December 31, 2011, we determined that VitaMedMD would become the sole focus of our company and services previously performed relative to the licensing agreement discussed in the following paragraph were discontinued.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">We were incorporated in Utah in 1907 under the name Croff Mining Company, or Croff. Prior to 2008, Croff&#x2019;s operations consisted entirely of oil and natural gas leases. Due to a spin-off of its operations in December 2007, Croff had no business operations or revenue source and had reduced its operations to a minimal level although it continued to file reports required under the Securities Exchange Act of 1934, or the Exchange Act. As a result of the spin-off, Croff was a &#x201C;shell company&#x201D; under the rules of the Securities and Exchange Commission, or the SEC. In July 2009, Croff (i) closed a transaction to acquire America&#x2019;s Minority Health Network, Inc. as a wholly owned subsidiary, (ii) ceased being a shell company, and (iii) experienced a change in control in which the former stockholders of America&#x2019;s Minority Health Network, Inc. acquired control of our company. On June 11, 2010, we closed a transaction to acquire Spectrum Health Network, Inc. as a wholly owned subsidiary. On July 20, 2010, we filed Articles of Conversion and Articles of Incorporation to redomicile in the state of Nevada. On July 31, 2010, we transferred the assets of America&#x2019;s Minority Health Network, Inc. to a secured noteholder in exchange for the satisfaction of certain associated debt. On February 15, 2011, we transferred the assets of Spectrum Health Network, Inc. to a secured noteholder in exchange for the satisfaction of associated debt and in exchange for a licensing agreement under which we subsequently sold subscription services and advertising on the Spectrum Health Network for commissions.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <!-- Field: Page; Sequence: 23; Value: 1-->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt">
        <p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">
            <!-- Field: Sequence; Type: Arabic; Name: PageNo-->23<!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&#160;</p>
    </div>
    <!-- Field: /Page -->
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b>Available Information</b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">We are a Nevada corporation. We maintain our principal executive offices at 951 Yamato Road, Suite 220, Boca Raton, Florida 33431. Our telephone number is (561) 961-1900. We maintain a corporate website at <i>www.therapeuticsmd.com&#160;</i>as well as various product websites.&#160;The information contained on our websites or that can be accessed through our websites is not incorporated by reference into this Annual Report or in any other report or document we file with the SEC.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">We file reports with the SEC, including Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and any other filings required by the SEC. Through our website, we make available free of charge our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, other filings required by the SEC, and all amendments to those reports, as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC.&#160; These reports may also be obtained directly from the SEC&#x2019;s website at <i>www.sec.gov</i>.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
        <span style="font: 10pt Times New Roman, Times, Serif"><b>Risk Factors</b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 1in">
                <span style="font: 10pt Times New Roman, Times, Serif"><b>Item 1A.</b></span>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif"><b><span id="txmd10ka003"></span>Risk Factors</b></span>
            </td>
        </tr>
    </table>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0; margin-right: 0; margin-top: 0">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif"><i>Investing in our common stock involves a high degree of risk. You should carefully consider the following risk factors, together with all of the information included in this Annual Report and our other filings with the SEC, before you decide to purchase shares of our common stock. We believe the risks and uncertainties described below are the most significant we face. Additional risks and uncertainties of which we are unaware, or that we currently deem immaterial, also may become important factors that affect us. If any of the following risks occur, our business, financial condition, or results of operations could be materially and adversely affected. In that case, the trading price of our common stock could decline, and you may lose all or part of your investment.</i></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
        <span style="font: 10pt Times New Roman, Times, Serif"><b><i>Risks Related to Our Business</i></b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b><i>We have incurred significant operating losses since inception and anticipate that we will incur continued losses for the foreseeable future.</i></b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">We have incurred recurring net losses, including net losses of approximately $176 million, $133 million, and $77 million for the years ended December 31, 2019, 2018, and 2017, respectively. As of December 31, 2019, we had an accumulated deficit of approximately $695 million. We have generated limited revenue and have funded our operations to date primarily from public and private sales of equity and private sales of debt securities. We may incur substantial additional losses over the next few years because of our commercialization, research, development, and clinical trial activities. As a result, we may never achieve or maintain profitability, even if we successfully commercialize all of our pharmaceutical products. If we continue to incur substantial losses and are unable to secure additional financing, we could be forced to discontinue or curtail our business operations, sell assets at unfavorable prices, refinance then-existing debt obligations on terms unfavorable to us, or merge, consolidate, or combine with a company with greater financial resources in a transaction that might be unfavorable to us.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b><i>We currently derive all of our revenue from sales or licenses of our women&#x2019;s healthcare products, and our failure to maintain or increase sales of these products could have a material adverse effect on our business, financial condition, results of operations, and growth prospects.</i></b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">In 2019, we derived all of our revenue from sales or licenses of our women&#x2019;s healthcare products, including patient-controlled, long-acting contraceptive, hormone therapy pharmaceutical products, prenatal and women&#x2019;s multi-vitamins, and iron supplements. We cannot assure you that we will be able to sustain such sales or that such sales will grow. In addition to other risks described herein, our ability to maintain or increase existing product sales is subject to several risks and uncertainties, including the following:</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">the presence of new or existing competing products, including non-authorized generic copies of our products;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">supply or distribution problems arising with any of our manufacturing and distribution partners;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">changed or increased regulatory restrictions or regulatory actions by the FDA;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">changes in healthcare laws and policy, including changes in requirements for drug pricing, rebates, reimbursement, and coverage by federal healthcare programs and commercial payers;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">the impact or efficacy of any price increases we may implement in the future;</span>
            </td>
        </tr>
    </table>
    <p style="margin-bottom: 0; margin-top: 0">&#160;</p>
    <!-- Field: Page; Sequence: 24; Value: 1-->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt">
        <p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">
            <!-- Field: Sequence; Type: Arabic; Name: PageNo-->24<!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&#160;</p>
    </div>
    <!-- Field: /Page -->
    <p style="margin-bottom: 0; margin-top: 0">&#160;</p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">changes to our labels and labeling, including new safety warnings or changes to our boxed warnings, that further restrict how we market and sell our products; and</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">acceptance of our products as safe and effective by physicians and patients.</span>
            </td>
        </tr>
    </table>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0; margin-right: 0; margin-top: 0">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">If revenue from sales of our products does not increase, we may be required to reduce our operating expenses or to seek to raise additional funds, which could have a material adverse effect on our business, financial condition, results of operations, and growth prospects, or we may not be able to commercialize all of our pharmaceutical products or commence or continue clinical trials to seek approval for any other products we may choose to develop in the future.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b><i>The commercial success of our existing products and other pharmaceutical products that we may develop, if approved in the future, will depend upon gaining and retaining significant market acceptance of these products among physicians and payers.</i></b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Physicians may not prescribe our products, which would prevent us from generating revenue or becoming profitable. Market acceptance of our products, including our hormone therapy pharmaceutical products and patient-controlled, long-acting contraceptive, by physicians, patients, and payers, will depend on a number of factors, many of which are beyond our control, including the following:</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">the clinical indications for which our hormone therapy pharmaceutical products and patient-controlled, long-acting contraceptive are approved;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">acceptance by physicians and payers of each product as a safe and effective treatment;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">the cost of treatment in relation to alternative treatments, including numerous generic pharmaceutical products;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">the relative convenience and ease of administration of our products in the treatment of the symptoms for which they are intended;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">the availability and efficacy of competitive drugs and devices;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">the effectiveness of our sales force and marketing efforts;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">the extent to which the product is approved for inclusion on formularies of hospitals and managed care organizations;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">the potential inclusion of a new category for one-year multi-cycle hormonal birth control methods in the FDA Birth Control Guide, which payers may rely upon as guidance for coverage;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">the availability of coverage and adequate reimbursement by third parties, such as insurance companies and other healthcare payers, or by government healthcare programs, including Medicare and Medicaid;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">limitations or warnings contained in a product&#x2019;s FDA-approved labeling; and</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">prevalence and severity of adverse side effects.</span>
            </td>
        </tr>
    </table>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0; margin-right: 0; margin-top: 0">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Even if the medical community accepts that our products are safe and effective for their approved indications, physicians may not immediately be receptive to their use or may be slow to adopt our products as an accepted treatment for the symptoms for which they are intended. Labeling approved by the FDA may not permit us to promote our products as being superior to competing products. If our products do not achieve an adequate level of acceptance by physicians and payers, we may not generate sufficient or any revenue from these products and we may not become profitable. In addition, our efforts to educate the medical community and third-party payers on the benefits of our products may require significant resources and may never be successful.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b><i>Our business may be affected by unfavorable publicity or lack of consumer acceptance. </i></b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">We are highly dependent upon consumer acceptance of the safety and quality of our products, as well as similar products distributed by other companies. Consumer acceptance of a product can be significantly influenced by scientific research or findings, national media attention, and other publicity about product use, products themselves, or marketing campaigns for our products. A product may be received favorably, resulting in high sales associated with that product that may not be sustainable as consumer preferences change. Future scientific research or publicity could be unfavorable to our industry or any of our products and may not be consistent with earlier favorable research or publicity. A future research report or publicity that is perceived by consumers as less than favorable or that may question earlier favorable research or publicity could have a material adverse effect on sales of our products and our ability to generate revenue. Adverse publicity in the form of published scientific research, statements by regulatory authorities or otherwise, whether or not accurate, that associates use of our products or any other similar products with illness or other adverse effects, or that questions the benefits of our products or similar products, or that claims that such products do not have the effect intended, or that question the marketing of our products, could have a material adverse effect on our business, reputation, financial condition, or results of operations.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <!-- Field: Page; Sequence: 25; Value: 1-->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt">
        <p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">
            <!-- Field: Sequence; Type: Arabic; Name: PageNo-->25<!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&#160;</p>
    </div>
    <!-- Field: /Page -->
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b><i>Our success depends on how efficiently we respond to changing consumer preferences and demand.</i></b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Our success depends, in part, on our ability to anticipate and respond to changing consumer trends and preferences. We may not be able to respond in a timely or commercially appropriate manner to these changes. Our failure to accurately predict these trends could negatively impact our inventory levels, sales, and consumer opinion of us as a source for the latest product. The success of our new product offerings depends upon several factors, including our ability to achieve the following:</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">accurately anticipate consumer needs;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">innovate and develop new products;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">successfully commercialize new products in a timely manner;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">competitively price our products in the market;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">procure and maintain products in sufficient volumes and in a timely manner; and</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">differentiate our product offerings from those of our competitors.</span>
            </td>
        </tr>
    </table>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0; margin-right: 0; margin-top: 0">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">If we do not introduce new products, make enhancements to existing products, or maintain the appropriate inventory levels of our existing products to meet consumers&#x2019; demand in a timely manner, our business, results of operations, and financial condition could be materially and adversely affected.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b><i>We may not be able to complete the commercialization of our pharmaceutical products and development of future product candidates if we fail to obtain additional financing.</i></b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">We need substantial amounts of cash to complete the commercialization of IMVEXXY, BIJUVA and ANNOVERA and the clinical development and commercialization of future pharmaceutical product candidates. Our existing cash may not be sufficient to fund these requirements. In addition, changing circumstances may cause us to consume funds significantly faster than we currently anticipate, and we may need to spend more money than currently expected on these programs. We may attempt to raise additional capital from the issuance of equity securities, collaborations with third parties, licensing of rights to our products, the issuance of debt securities and the incurrence of debt, in each case to the extent permitted under the Financing Agreement, dated as of April 24, 2019, as amended, with TPG Specialty Lending, Inc., as administrative agent, or the Administrative Agent or Sixth Street, various lenders from time to time party thereto, and certain of our subsidiaries party thereto from time to time as guarantors, or the Financing Agreement, or other means, or a combination of any of the foregoing. Securing additional financing will require a substantial amount of time and attention from our management and may divert a disproportionate amount of management&#x2019;s attention away from our day-to-day activities, which may adversely affect our ability to conduct our day-to-day operations.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">We cannot guarantee that future debt or equity financing will be available in sufficient amounts or on terms acceptable to us, if at all. If we are unable to raise additional capital when required or on acceptable terms, we may be required to significantly delay, scale back, or discontinue our commercialization and product development efforts.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">The Financing Agreement does, and any agreements governing future debt financing, if available, may, include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our existing stockholders will be diluted, and the terms of these new securities may include liquidation or other preferences that adversely affect the rights of our existing stockholders. If we raise additional funds through collaborations, strategic alliances, or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs, or proposed products or grant licenses on terms that may not be favorable to us.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we will be prevented from pursuing commercialization and development efforts, and our ability to generate revenue and achieve or sustain profitability will be substantially harmed.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
        <span style="font: 10pt Times New Roman, Times, Serif"><b><i>We are subject to extensive and costly government regulation.</i></b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">The products we currently commercializing, including IMVEXXY, BIJUVA and ANNOVERA and our prenatal vitamins, and the pharmaceutical products we are developing and planning to develop in the future, are subject to extensive and rigorous domestic government regulation, including regulation by the FDA, the Centers for Medicare &#38; Medicaid Services, or CMS, other divisions of the U.S. Department of Health and Human Services, including its Office of Inspector General, the U.S. Department of Justice, the Departments of Defense and Veterans Affairs, to the extent our products are paid for directly or indirectly by those departments, state and local governments, and their respective foreign equivalents. The FDA regulates dietary supplements, cosmetics, and drugs under different regulatory schemes. For example, the FDA regulates the processing, formulation, safety, manufacturing, packaging, labeling, and distribution of dietary supplements and cosmetics under its dietary supplement and cosmetic authority, respectively. The FDA also regulates the research, development, pre-clinical and clinical testing, manufacture, safety, effectiveness, record keeping, reporting, labeling, storage, approval, advertising, promotion, sale, distribution, import, and export of pharmaceutical products under various regulatory provisions. If any pharmaceutical products we develop are tested or marketed abroad, they will also be subject to extensive regulation by foreign governments, whether or not we have obtained FDA approval for a given product and its uses. Such foreign regulation may be equally or more demanding than corresponding U.S. regulation.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <!-- Field: Page; Sequence: 26; Value: 1-->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt">
        <p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">
            <!-- Field: Sequence; Type: Arabic; Name: PageNo-->26<!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&#160;</p>
    </div>
    <!-- Field: /Page -->
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">We are also subject to additional healthcare regulation and enforcement by the federal government and the states in which we conduct our business. Applicable federal and state healthcare laws and regulations include the following:</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">The federal healthcare Anti-Kickback Statute, or AKS, prohibits, among other things, persons and entities, including pharmaceutical manufacturers, from knowingly and willfully soliciting, offering, receiving, or providing remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, lease, order, or recommendation of, any good or service reimbursable, in whole or in part, for which payment may be made under federal healthcare programs, such as Medicare, Medicaid, TRICARE , and the State Children&#x2019;s Health Insurance Program. This statute has been interpreted broadly to apply to, among other things, arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers and formulary managers on the other hand. The term &#x201C;remuneration&#x201D; includes kickbacks, bribes or rebates and also has been broadly interpreted to include anything of value, including, for example, gifts, discounts, waivers of payment, ownership interest and providing anything at less than its fair market value. There are a number of statutory exceptions and regulatory safe harbors protecting certain common activities from prosecution or other regulatory sanctions, however, the exceptions and safe harbors are drawn narrowly, and practices that do not fit squarely within an exception or safe harbor may be subject to scrutiny. The failure to meet the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the AKS. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all of its facts and circumstances. Our practices may not meet the criteria for safe harbor protection from AKS liability in all cases. Liability may be established without proving actual knowledge of the statute or specific intent to violate it to have committed a violation. In addition, federal law provides that the government may assert that a claim including items or services resulting from a violation of the AKS constitutes a false or fraudulent claim for purposes of the False Claims Act, or FCA, described below. Violations of the AKS carry potentially significant civil and criminal penalties, including imprisonment, fines, administrative civil monetary penalties, and exclusion from participation in government healthcare programs.</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">The Ethics in Patient Referrals Act of 1989, commonly referred to as the Stark Law, and its corresponding regulations, prohibit physicians from referring patients for designated health services, including outpatient drugs, reimbursed under the Medicare or Medicaid programs to entities with which the physicians or their immediate family members have a financial relationship or an ownership interest, subject to narrow regulatory exceptions, and prohibits those entities from submitting claims to Medicare or Medicaid for payment of items or services provided to a referred beneficiary.</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">The federal civil and criminal false claims laws and civil monetary penalty laws, including the FCA imposes criminal and civil penalties, and authorizes civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, claims for payment to, or approval by federally funded health care programs that are false, fictitious or fraudulent or knowingly making, using, or causing to be made to be used, a false record or statement material to a false or fraudulent claim to avoid, decrease, or conceal an obligation to pay money with respect to a federal program. As a result of a modification made by the Fraud Enforcement and Recovery Act of 2009, a claim includes "any request or demand" for money or property presented to the federal government. Although we do not submit claims directly to payers, manufacturers can be held liable under these laws if they are deemed to "cause" the submission of false or fraudulent claims by, for example, providing inaccurate billing or coding information to customers, promoting a product off-label, marketing products of sub-standard quality, or, as noted above, paying a kickback that results in a claim for items or services. In addition, our activities relating to the reporting of wholesaler or estimated retail prices for our products, the reporting of prices used to calculate Medicaid rebate information and other information affecting federal, state and third-party reimbursement for our products, and the sale and marketing of our products, are subject to scrutiny under this law. For example, several pharmaceutical and other healthcare companies have faced enforcement actions under these laws for allegedly inflating drug prices they report to pricing services, which in turn were used by the government to set Medicare and Medicaid reimbursement rates, and for allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product. The FCA prohibits knowingly and willfully falsifying, concealing, or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items, or services. Government enforcement agencies and private whistleblowers have asserted liability under the FCA for, among other things, claims for items or services not provided as claimed, with inaccurate coding or for medically unnecessary items or services, kickbacks, promotion of off-label uses, and misreporting of drug prices to federal agencies. In addition, AKS violations and certain marketing practices, including off-label promotion, may also implicate the FCA. Although the FCA is a civil statute, conduct that results in a FCA violation may also implicate various federal criminal statutes.</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">Health Insurance Portability and Accountability Act of 1996, or HIPAA, imposes criminal and civil liability for knowingly and willfully executing or attempting to execute a scheme to defraud or to obtain, by means of false or fraudulent pretenses, representations or promises, any money or property owned by, or under the control or custody of, any healthcare benefit program, including third-party private payers, knowingly and willfully falsifying, concealing, or covering up by trick, scheme, or device, a material fact or making any materially false, fictitious, or fraudulent statements in connection with the delivery of or payment for healthcare benefits, items, or services. HIPAA also imposes obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security, and transmission of individually identifiable health information. Similar to the AKS, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it to have committed a violation. State laws may also govern the privacy and security of health information or other personal information in certain circumstances.</span>
            </td>
        </tr>
    </table>
    <p style="margin-bottom: 0; margin-top: 0">&#160;</p>
    <!-- Field: Page; Sequence: 27; Value: 1-->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt">
        <p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">
            <!-- Field: Sequence; Type: Arabic; Name: PageNo-->27<!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&#160;</p>
    </div>
    <!-- Field: /Page -->
    <p style="margin-bottom: 0; margin-top: 0">&#160;</p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their respective implementing regulations, including the Final Omnibus Rule published on January 25, 2013, impose, among other things, obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information held by certain healthcare providers, health plans and healthcare clearinghouses, known as covered entities, and business associates. Among other things, HITECH made certain aspects of HIPAA's rules (notably the Security Rule) directly applicable to business associates - independent contractors or agents of covered entities that receive or obtain individually identifiable health information in connection with providing a service on behalf of a covered entity. HITECH also created four new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal court to enforce the federal HIPAA laws and seek attorney's fees and costs associated with pursuing federal civil actions. The Department of Health and Human Services Office of Civil Rights, or the OCR, has increased its focus on compliance and continues to train state attorneys general for enforcement purposes. The OCR has recently increased both its efforts to audit HIPAA compliance and its level of enforcement, with one recent penalty exceeding $5 million.</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">According to the U.S. Federal Trade Commission, or the FTC, failing to take appropriate steps to keep consumers' personal information secure constitutes unfair acts or practices in or affecting commerce in violation of Section 5(a) of the Federal Trade Commission Act. The FTC expects a company's data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. Medical data is considered sensitive data that merits stronger safeguards. The FTC's guidance for appropriately securing consumers' personal information is similar to what is required by the HIPAA Security Rule.</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">Federal laws require pharmaceutical manufacturers to report certain calculated product prices to the government or provide certain discounts or rebates to government authorities or private entities, often as a condition of reimbursement under government healthcare programs.</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">The Physician Payments Sunshine Act, enacted as part of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or the ACA, and its implementing regulations, imposes annual reporting requirements for certain manufacturers of drugs, devices, biologics, and medical supplies for which payment is available under certain government healthcare programs (with certain exceptions) to annually report to CMS information related to certain payments or other &#x201C;transfers of value&#x201D; made or provided to physicians and teaching hospitals, or to other entities or individuals at the request of, or designated on behalf of, the physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. Numerous state laws may also require disclosure of transfers of value to healthcare providers, pharmaceutical pricing information and marketing expenditures. On October 25, 2018, President Trump signed into law the &#x201C;Substance Use-Disorder Prevention that Promoted Opioid Recovery and Treatment for Patients and Communities Act.&#x201D; This law, in part (under a provision entitled &#x201C;Fighting the Opioid Epidemic with Sunshine&#x201D;), will extend the Sunshine Act to payments and transfers of value to physician assistants, nurse practitioners, and other mid-level healthcare providers (with reporting requirements going into effect in 2022 for payments made in 2021).</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">Analogous state laws and regulations, such as state anti-kickback and false claims laws, and other state laws addressing the pharmaceutical and healthcare industries, may apply to interactions between pharmaceutical manufacturers and healthcare providers, sales or marketing arrangements, and claims involving healthcare items or services reimbursed by commercial third-party payers, including private healthcare insurers and health maintenance organizations, and in some cases that may apply regardless of payer, i.e., even if reimbursement is not available; further, some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#x2019;s voluntary compliance program guidelines (the PhRMA Code) and the relevant compliance guidance promulgated by the federal government (HHS-OIG) in addition to requiring drug manufacturers to report pricing and marketing information, including, among other things, information related to gifts, payments, or other remuneration to physicians and other healthcare providers or marketing expenditures, state and local laws that require the registration of pharmaceutical sales representatives, and state laws governing the privacy and security of health information and the use of prescriber-identifiable data in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. For example, California enacted legislation &#x2013; the California Consumer Privacy Act, or CCPA &#x2013; which went into effect January 1, 2020 and, among other things, creates new data privacy obligations for covered companies and provides new privacy rights to California residents, including the right to opt out of certain disclosures of their information, and creates a private right of action with statutory damages for certain data breaches, thereby potentially increasing risks associated with a data breach; the California Attorney General will issue final regulations, and although the law includes limited exceptions, including for certain information collected as part of clinical trials as specified in the law, it may regulate or impact our processing of personal information depending on the context, and it remains unclear what language the final Attorney General regulations will contain or how the statute and regulations will be interpreted.</span>
            </td>
        </tr>
    </table>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0; margin-right: 0; margin-top: 0">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <!-- Field: Page; Sequence: 28; Value: 1-->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt">
        <p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">
            <!-- Field: Sequence; Type: Arabic; Name: PageNo-->28<!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&#160;</p>
    </div>
    <!-- Field: /Page -->
    <p style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0; margin-right: 0; margin-top: 0">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Many aspects of these laws have not been definitively interpreted by the regulatory authorities or the courts, and their provisions are open to a variety of subjective interpretations that increases the risk of potential violations. In addition, these laws and their interpretations are subject to change. Many state laws differ from each other in significant ways and often are not preempted by federal laws, thus complicating compliance efforts. Moreover, the number and complexity of both federal and state laws continues to increase, and additional governmental resources are being used to enforce these laws and to prosecute companies and individuals who are believed to be violating them. In particular, the ACA includes a number of provisions aimed at strengthening the government&#x2019;s ability to pursue AKS and FCA cases against pharmaceutical manufacturers and other healthcare entities, including substantially increased funding for healthcare fraud enforcement activities, enhanced investigative powers, and amendments to the FCA that make it easier for the government and whistleblowers to pursue cases for alleged kickback and false claim violations. We anticipate that government scrutiny of pharmaceutical sales and marketing practices will continue for the foreseeable future and subject us to the risk of government investigations and enforcement actions. For example, federal enforcement agencies recently have shown interest in pharmaceutical companies&#x2019; product and patient assistance programs, including manufacturer reimbursement support services and relationships with specialty pharmacies. Some of these investigations have resulted in significant civil and criminal settlements.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Efforts to ensure that our operations, including our business arrangements with third parties, comply with applicable healthcare laws and regulations could be costly. In connection with the commercial launches of IMVEXXY, BIJUVA and ANNOVERA, we have grown our compliance program and are in the process of developing a program based on industry best practices and tailored to evolving risks as we launch additional products, identify new distribution channels and target new patient types. As this program has not yet been tested and the requirements in this area are constantly evolving, our program may not eliminate all areas of potential exposure. Although effective compliance programs can help mitigate the risk of investigation, regulatory and enforcement actions, and prosecution for violations of these laws, the risks cannot be entirely eliminated. Moreover, achieving and sustaining compliance with applicable federal and state fraud, privacy, security, and reporting laws may prove costly. Although we believe that our business practices are structured to be compliant with applicable laws, it is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations, or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our past or present operations, including activities conducted by our sales team or agents, are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal, and administrative penalties, damages, fines, exclusion from government healthcare programs, and the curtailment or restructuring of our operations. If any of the physicians, providers, or entities with whom we do business are found to be not in compliance with applicable laws, they may be subject to criminal, civil, or administrative sanctions, including exclusion from government healthcare programs. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses, divert our management&#x2019;s attention from the operation of our business, and damage our reputation. In addition, even if we are not determined to have violated these laws, government investigations into these issues typically require the expenditure of significant resources and generate negative publicity, and could result in related stockholder suits, any of which could also have an adverse effect on our business, financial condition and results of operations.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">In addition, from time to time in the future, we may become subject to additional laws or regulations administered by the FDA, the FTC, or by other federal, state, local, or foreign regulatory authorities, to the repeal of laws or regulations that we generally consider favorable, such as the Dietary Supplement Health and Education Act of 1994, or to more stringent interpretations of current laws or regulations. We are not able to predict the nature of such future laws, regulations, repeals, or interpretations, and we cannot predict what effect additional governmental regulation, if it occurs, would have on our business in the future. Such developments could, however, require reformulation of certain products to meet new standards, recalls or discontinuance of certain products not able to be reformulated, additional record-keeping requirements, increased documentation of the properties of certain products, additional or different labeling, additional scientific substantiation, additional personnel, or other new requirements. Any such developments could have a material adverse effect on our business.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b><i>Coverage and reimbursement may not be available for our products, which could make it difficult for us to sell our products profitably, or if available, government mandated rebates may be too high and may adversely affect our profitability.</i></b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Market acceptance and sales of our products, including IMVEXXY, BIJUVA and ANNOVERA, and our prescription vitamins, will depend on coverage and reimbursement policies and may be affected by healthcare reform measures. Government healthcare programs and third-party payers decide which prescription pharmaceutical products they will pay for and establish reimbursement levels. Payers generally do not cover OTC products, and coverage for prescription vitamins and dietary supplements varies. Many private third-party payers, such as managed care plans, manage access to pharmaceutical products&#x2019; coverage partly to control costs to their plans, and may use drug formularies and medical policies to limit their exposure. Factors considered by these payers include product efficacy, cost effectiveness, and safety, as well as the availability of other treatments including generic prescription drugs. Our ability to commercialize IMVEXXY, BIJUVA and ANNOVERA successfully depends on coverage and reimbursement levels set by government healthcare programs and third-party private payers. Obtaining and maintaining favorable reimbursement can be a time-consuming and expensive process, and we may not be able to negotiate or continue to negotiate reimbursement or pricing terms for our products with payers at levels that are profitable to us, or at all.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <!-- Field: Page; Sequence: 29; Value: 1-->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt">
        <p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">
            <!-- Field: Sequence; Type: Arabic; Name: PageNo-->29<!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&#160;</p>
    </div>
    <!-- Field: /Page -->
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">In both the U.S. and some foreign jurisdictions, there have been several legislative and regulatory proposals to change the healthcare system in ways that could affect our ability to sell our products profitably. In the U.S., the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, also called the Medicare Modernization Act, or MMA, changed the way Medicare covers and pays for pharmaceutical products. The legislation expanded Medicare coverage for drug purchases by the elderly and certain others by establishing a new Part D to the Medicare program. However, unlike Medicare Part A and Part B&#x2014;through which Medicare provides coverage for certain drugs in certain circumstances&#x2014;coverage under Part D is provided by private insurers operating under contract with CMS. In addition, this legislation provided authority for limiting the number of certain outpatient drugs that will be covered in any therapeutic class. Because of this legislation and the expansion of federal coverage of pharmaceutical products, we expect that there will be additional pressure to contain and reduce costs. These and future cost-reduction initiatives could decrease the coverage and price that we receive for our products from Medicare, if any, including IMVEXXY, BIJUVA and ANNOVERA, and could significantly harm our business. It was historically unclear whether products approved to treat moderate-to-severe dyspareunia, a symptom of vulvar and vaginal atrophy due to menopause, such as IMVEXXY, were excluded under Medicare Part D, which resulted in limited Medicare coverage for such products. Recent clarification issued by CMS in May 2018 indicated that drugs, such as IMVEXXY, that are approved for the treatment of moderate-to-severe dyspareunia (as well as drugs approved for the treatment of moderate-to-severe symptoms of vulvar and vaginal atrophy associated with menopause) are not excluded from Medicare Part D coverage. CMS&#x2019;s clarification, however, is no guarantee that such coverage will be obtained for IMVEXXY and obtaining Medicare or other government healthcare program reimbursement for any new pharmaceutical products may take up to several years following FDA approval. While the MMA applies only to drug benefits for Medicare beneficiaries, third-party payers often follow Medicare coverage policies and payment limitations in setting their own reimbursement rates, and any reduction in reimbursement under Medicare may result in a similar reduction in payments from third-party payers.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Our ability to commercialize ANNOVERA depends on coverage and reimbursement levels set by government healthcare programs and third-party private payers. The ACA mandates that private health plans provide coverage for women&#x2019;s preventative services, without imposing patient cost-sharing requirements, as recommended by HRSA. HRSA Guidelines require private health plans to cover, with no patient out-of-pocket costs, at least one form of treatment (e.g., one product) in each of the methods (e.g., classes of contraception) identified by the FDA for women in its Birth Control Guide. To the extent ANNOVERA is deemed a new class of contraception by the FDA, such a designation could allow for coverage by private health plans with no patient out-of-pocket costs. However, there is no guarantee that such coverage will be obtained, and it is possible that other FDA-approved products could also be included in this new class. For instance, the FDA may find that ANNOVERA fits into the vaginal contraceptive ring class, which it would share with NuvaRing and its generic equivalents, and potentially others. Pursuant to HRSA Guidelines, private payers need only provide no-cost coverage for one product in each class and may use reasonable medical management to determine whether and to what extent to cover other products in the class. Private payers may interpret the statute and its associated rules in ways in which they decline to cover ANNOVERA, even if we believe ANNOVERA should be covered without cost sharing under the ACA framework. To the extent ANNOVERA is not the only FDA-approved product in a designated class of contraception, private payers may choose not to cover our one-year vaginal contraceptive system or may require patient cost-sharing obligations. Recently, some states have amended and expanded requirements to match the standard set in the ACA mandate, specifically requiring coverage for the full range of contraceptive methods, counseling and services used by women and eliminating out-of-pocket costs and limiting other health plan restrictions. Despite this favorable development, there is no guarantee that other states will follow and no guarantee that states will retain this mandate, particularly if the ACA mandate is repealed or otherwise eroded. The Trump administration has implemented new policies that permit certain employers to claim a religious or moral objection to the birth control coverage mandate under the ACA. Health plans sponsored by certain exempt religious employers and non-profit religious organizations that certify they have religious objections do not need to offer contraception coverage through their health benefit plans. Further, despite our progress with commercial payers, there is no guarantee that we will be able to retain these agreements or obtain new agreements or that we will be able to negotiate favorable reimbursement or pricing terms for our products in the future. In addition, healthcare reform, including potential repeal of or changes to the ACA, continues to attract significant legislative and administrative interest, legal challenges, regulatory and compliance requirements, new approaches and public attention that create uncertainty and the potential for additional changes. Healthcare reform implementation, additional legislation or regulations, and other changes in government policy or regulation may repeal the contraception coverage mandate, affect our reimbursement or impose additional coverage limitations and/or cost-sharing obligations on patients, any of which could have a material adverse effect on coverage and reimbursement of our products, and our business, financial condition, results of operations, and prospects could be harmed.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">To the extent we obtain coverage for our products by state Medicaid programs, we may be required to pay a rebate to each state Medicaid program for any covered outpatient drugs that are dispensed to Medicaid beneficiaries and paid for by a state Medicaid program, and to comply with all Medicaid rebate requirements of the Omnibus Budget Reconciliation Act of 1990 and the Veterans Healthcare Act of 1992. Moreover, federal law requires that any company participating in the Medicaid Drug Rebate program also participate in the Public Health Service&#x2019;s 340B Program, which impose additional reporting requirements and price concessions. Manufacturer compliance with 340B Program requirements can be costly. In addition, if our products are made available to authorized users of the Federal Supply Schedule of the General Services Administration or to low income patients of certain hospitals, additional laws and requirements may apply.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <!-- Field: Page; Sequence: 30; Value: 1-->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt">
        <p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">
            <!-- Field: Sequence; Type: Arabic; Name: PageNo-->30<!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&#160;</p>
    </div>
    <!-- Field: /Page -->
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">We expect to experience pricing pressures in connection with the sale of our products generally due to the trend toward managed healthcare, the increasing influence of health maintenance organizations, the scrutiny of pharmaceutical pricing, the ongoing debates on reducing government spending and additional legislative proposals. As discussed more below, the goal of the ACA, as enacted in 2010, was to reduce the cost of healthcare and substantially change the way healthcare is financed by both government healthcare programs and third-party payers. Among other measures, the ACA increased rebates on manufacturers for certain covered pharmaceutical products reimbursed by state Medicaid programs. While we cannot predict the full effect that the ACA will have on government healthcare programs&#x2019; reimbursement policies in general or on our business specifically, the ACA may result in downward pressure on drug reimbursement, which could negatively affect market acceptance of our products. In addition, we cannot predict whether new proposals will be made or adopted, when they may be adopted, or what impact they may have on us if they are adopted.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">The availability of generic products at lower prices than branded products may substantially reduce the likelihood of reimbursement for branded products, such as IMVEXXY, BIJUVA and ANNOVERA.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">If we fail to successfully secure and maintain adequate coverage and reimbursement for our products or are significantly delayed in doing so, we could have difficulty achieving market acceptance of our products and our business, financial condition, results of operations, and prospects could be harmed.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b><i>Future legislation or regulations may adversely affect reimbursement from government healthcare programs and third-party payers.</i></b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Legislative changes have been proposed and adopted since the ACA was enacted. In August 2011, President Obama signed into law the Budget Control Act of 2011, which, among other things, created the Joint Select Committee on Deficit Reduction to recommend to Congress proposals in spending reductions. The Joint Select Committee did not achieve a targeted deficit reduction, triggering the legislation&#x2019;s automatic reduction of several government programs. This includes aggregate reductions to Medicare payments to healthcare providers of up to 2.0% per fiscal year, starting in 2013. In January 2013, President Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, reduced Medicare payments to several categories of healthcare providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. Under the Trump administration, there have been ongoing efforts to modify or repeal all or certain provisions of the ACA. On December 14, 2018, the U.S. District Court for the Northern District of Texas struck down the ACA in <i>Texas v. Azar</i>, deeming it unconstitutional given that Congress repealed the individual mandate in 2017; on July 9, 2019, the U.S. Court of Appeals for the Fifth Circuit heard arguments on appeal in this matter. On December 15, 2019, the Fifth Circuit struck down the ACA in its entirety given that the TCJA eliminated the tax penalty associated with the individual mandate and therefore it was unconstitutional. The Fifth Circuit further remanded the case to the U.S. District Court for the Northern District of Texas to further analyze whether the other provisions of the ACA are serverable as they currently exist under the law. If the ACA or parts of it are repealed, it is unclear what impact that would have on drug reimbursements or coverage and it is also unclear what programs, if any, Congress might enact to replace the repealed portions of the ACA. The Trump administration may also take executive action in the absence of legislative action. For example, in October 2017, the President announced that the administration will withhold the cost-sharing subsidies paid to health insurance exchange plans serving low-income enrollees. With respect to IMVEXXY, BIJUVA and ANNOVERA, and to the extent we ever obtain regulatory approval and commercialization of our other pharmaceutical product candidates, these new laws and policies (as well as proposed legislation, if enacted) may result in additional reductions in Medicare and other healthcare funding, which could have a material adverse effect on our customers and accordingly, our financial operations.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">On December 13, 2016, President Obama signed into law the 21st Century Cures Act, which, among other things, may increase the types of clinical trial designs that would be acceptable to support an NDA. It is unclear, at this time, how these provisions will be implemented or whether they would have any effect on our company. Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on our pharmaceutical products and product candidates may be.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">There have also been efforts by government officials or legislators to implement measures to regulate prices or payment for pharmaceutical products, including legislation on drug importation. For example, on December 23, 2019, the Trump administration released a Notice for Proposed Rulemaking to amend the FDA regulations regarding the importation of certain prescription drugs from Canada. If this rule is finalized as proposed, states and certain other non-federal governmental entities would be able to submit important program proposed to the FDA for review and authorization. Proposals to the FDA would need to demonstrate that any drug importation program does not pose any additional risk to the public&#x2019;s health and safety and an explanation of any results in significant reduction in the cost of covered products to consumers. Additionally, there has recently been considerable public and government scrutiny of pharmaceutical pricing and proposals to address the perceived high cost of pharmaceuticals; proposed and enacted legislation generally have focused on increasing transparency around drug costs or limiting drug prices, including drug rebates. For instance, on May 11, 2018, President Trump laid out his administration&#x2019;s &#x201C;Blueprint&#x201D; to lower drug prices and reduce out of pocket costs of drugs, as well as additional proposals to increase drug manufacturer competition, increase the negotiating power of certain federal healthcare programs, and incentivize manufacturers to lower the list price of their products. Although some proposals related to the administration&#x2019;s Blueprint may require additional authorization to become effective, may ultimately be withdrawn, or may face challenges in the courts, the U.S. Congress and the Trump administration have each indicated that they will continue to seek new legislative and administrative measures to control drug costs, including by addressing the role of pharmacy benefit managers in the supply chain.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>
    <!-- Field: Page; Sequence: 31; Value: 1-->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt">
        <p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">
            <!-- Field: Sequence; Type: Arabic; Name: PageNo-->31<!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&#160;</p>
    </div>
    <!-- Field: /Page -->
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, rebate transparency, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. We are unable to predict the future course of federal or state healthcare legislation in the U.S. directed at broadening the availability of healthcare and containing or lowering the cost of healthcare. The ACA and any further changes in the law or regulatory framework that reduce our revenue or increase our costs could also have a material and adverse effect on our business, financial condition and results of operations. For example, in 2017, California enacted a new law, which went into effect on January 1, 2018, to facilitate greater transparency in brand-name and generic drug pricing through the implementation of specific price reporting requirements for pharmaceutical manufacturers. If adequate reimbursement levels are not maintained by government and third-party payers for our products, our ability to sell our products may be limited and/or our ability to establish acceptable pricing levels may be impaired, thereby reducing anticipated revenues and profitability.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Further, if a federal government shutdown were to occur for a prolonged period, federal government payment obligations, including its obligations under Medicaid and Medicare, may be delayed. Similarly, if state government shutdowns were to occur, state payment obligations may be delayed. If the federal or state governments fail to make payments under these programs on a timely basis, our ability to sell our products to government payers may be limited and/or our ability to establish acceptable pricing levels may be impaired, thereby reducing anticipated revenues and profitability.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b><i>Our dependence upon third parties for the manufacture and supply of our existing women&#x2019;s healthcare products and our pharmaceutical product candidates may cause delays in, or prevent us from, successfully developing, commercializing, and marketing our products.</i></b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">We do not currently have, nor do we currently plan to build or acquire, the infrastructure or capability to internally manufacture our existing women&#x2019;s healthcare products, IMVEXXY, BIJUVA and ANNOVERA, or our pharmaceutical product candidates. We have relied, and will continue to rely, on third parties to manufacture these products in accordance with our specifications and in compliance with applicable regulatory requirements, including cGMPs. We have entered into long-term supply agreements with Catalent for the commercial supply of IMVEXXY and BIJUVA. Under the terms of the agreements, we are obligated to purchase certain minimum annual amounts of each product. We have also entered into a long-term supply contract with QPharma AB for ANNOVERA. Under the terms of the QPharma agreement, we are obligated to purchase certain minimum annual amounts of ANNOVERA. We depend on Lang, a full-service, private label and corporate brand manufacturer, to supply our vitaMedMD and BocaGreen products. We do not have long-term contracts for the commercial supply of our vitaMedMD and BocaGreen products, however, in certain circumstances, including our failure to satisfy our production forecasts to Lang, we may be obligated to reimburse Lang for the costs of excess raw materials purchased by Lang that it cannot use in another product category that it then sells.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman , Times, serif; margin: 0px; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Regulatory requirements could pose barriers to the manufacture of our women&#x2019;s healthcare products and our pharmaceutical product candidates. Holders of NDAs, or other forms of FDA approvals or clearances, or those distributing a regulated product under their own name, are ultimately responsible for compliance with manufacturing obligations even if the manufacturing is conducted by a third-party contract manufacturing organization, or CMO. All of our existing products are manufactured by CMOs. These CMOs are required by the terms of our contracts to manufacture our products in compliance with the applicable regulatory requirements. The CMO that manufactures IMVEXXY and BIJUVA has previously been inspected by the FDA and received Form 483 observations with respect to its softgel manufacturing plant that is used for the manufacture of the commercial supply of IMVEXXY and BIJUVA. The CMO that manufactures ANNOVERA, has previously been inspected by the FDA and received Form 483 observations with respect to its facility that will be used for the commercial supply of ANNOVERA. We believe that corrective actions to address the compliance issues identified in the referenced Forms 483 have been implemented by the CMOs; however, the FDA has not yet reinspected the CMOs to confirm that the corrective actions were implemented as described to the agency in the respective Form 483 responses.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">If our manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA and any applicable foreign regulatory authority, our regulatory submissions may be delayed or disapproved, and our marketed products may be affected. If these facilities are not in compliance for the manufacture of our products, we may need to find alternative manufacturing facilities, which would result in substantial disruptions of our sales of existing products and significant delays of up to several years in obtaining approval for our pharmaceutical product candidates. In addition, our manufacturers will be subject to ongoing periodic unannounced inspections by the FDA and corresponding state and foreign agencies for compliance with cGMPs and similar regulatory requirements. Failure by any of our manufacturers to comply with applicable cGMP regulations or other applicable requirements could result in sanctions being imposed on us, including fines, injunctions, civil penalties, violation letters, delays, suspensions or withdrawals of approvals, operating restrictions, interruptions in supply, recalls, withdrawals, issuance of safety alerts, and criminal prosecutions, any of which could have a material adverse impact on our business, financial condition, results of operations, and prospects. We do not currently have alternative manufacturers, and we may not be able to enter into a long-term agreement with alternative manufacturers, or do so on commercially reasonable terms, and if we do enter into agreements with alternative manufacturers, those alternative manufacturers may not be approved by the FDA, any of which could have a material adverse impact on our business. Finally, we also could experience manufacturing delays if our CMOs give greater priority to the supply of other products over our products and proposed products to the delay or other detriment of our products and proposed products, or otherwise do not satisfactorily perform according to the terms of their agreements with us.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <!-- Field: Page; Sequence: 32; Value: 1-->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt">
        <p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">
            <!-- Field: Sequence; Type: Arabic; Name: PageNo-->32<!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&#160;</p>
    </div>
    <!-- Field: /Page -->
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">We also do not have long-term contracts for the supply of the active pharmaceutical ingredient, or API, used in IMVEXXY, BIJUVA and ANNOVERA. If any supplier of the API or other products used in our products or pharmaceutical product candidates experiences any significant difficulties in its respective manufacturing processes, does not comply with the terms of an agreement between us, or does not devote sufficient time, energy, and care to providing our manufacturing needs, we could experience significant interruptions in the supply of our products or pharmaceutical product candidates, which could impair our ability to supply our products or pharmaceutical product candidates at the levels required for commercialization and prevent or delay their successful commercialization.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b><i>Even after the approval of IMVEXXY, BIJUVA and ANNOVERA, and even if we obtain regulatory approval for other pharmaceutical product candidates, we will still face extensive, ongoing regulatory requirements and review, and our products may face future development and regulatory difficulties.</i></b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">With respect to IMVEXXY, BIJUVA and ANNOVERA, the FDA may still impose significant restrictions on a product&#x2019;s indicated uses or marketing or to the conditions for approval or impose ongoing requirements for potentially costly post-approval studies, including phase 4 clinical trials or post-market surveillance. As a condition to granting marketing approval of a product, the FDA may require a company to conduct additional clinical trials. The results generated in these post-approval clinical trials could result in loss of marketing approval, changes in product labeling, or new or increased concerns about side effects or efficacy of a product. For example, the labeling for IMVEXXY, BIJUVA and ANNOVERA contains restrictions on use and warnings. The Food and Drug Administration Amendments Act of 2007, or FDAAA, gives the FDA enhanced post-market authority, including the Risk Evaluation and Mitigation Strategy, or REMS, explicit authority to require post-market studies and clinical trials, labeling changes based on new safety information, and compliance with FDA-approved REMS programs. IMVEXXY, BIJUVA and ANNOVERA will also be subject to ongoing FDA requirements governing the manufacturing, labeling, packaging, storage, distribution, safety surveillance, advertising, promotion, record keeping, and reporting of safety and other post-market information. The FDA&#x2019;s exercise of its authority could result in delays or increased costs during product development, clinical trials and regulatory review, increased costs to comply with additional post-approval regulatory requirements, and potential restrictions on sales of approved products. As part of the FDA&#x2019;s approval of IMVEXXY, we have committed to conduct a post-approval observational study to evaluate the risk of endometrial cancer in post-menopausal women with a uterus who use a low-dose vaginal estrogen unopposed by a progestogen such as IMVEXXY. As part of the FDA&#x2019;s approval of ANNOVERA, the FDA has required a post-approval observational study be performed to measure the risk of venous thromboembolism. Foreign regulatory agencies often have similar authority and may impose comparable costs. Post-marketing studies, whether conducted by us or by others and whether mandated by regulatory agencies or voluntary, and other emerging data about marketed products, such as adverse event reports, may also adversely affect sales of our pharmaceutical product candidates once approved, and potentially our other marketed products. Further, the discovery of significant problems with a product similar to one of our products that implicate (or are perceived to implicate) an entire class of products could have an adverse effect on sales of our approved products. Accordingly, new data about our products could negatively affect demand because of real or perceived side effects or uncertainty regarding efficacy and, in some cases, could result in product withdrawal or recall. Furthermore, new data and information, including information about product misuse, may lead government agencies, professional societies, and practice management groups or organizations involved with various diseases to publish guidelines or recommendations related to the use of our products or the use of related therapies or place restrictions on sales. Such guidelines or recommendations may lead to lower sales of our products.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">The holder of an approved NDA also is subject to obligations to monitor and report adverse events and instances of the failure of a product to meet the specifications in the NDA. Application holders must submit new or supplemental applications and obtain FDA approval for certain changes to the approved product, product labeling, or manufacturing process. Application holders must also submit advertising and other promotional material to the FDA and report on ongoing clinical trials. Legal requirements have also been enacted to require disclosure of certain clinical trial results on a publicly available database.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">In addition, manufacturers of pharmaceutical products and their facilities are subject to continual review and periodic inspections by the FDA and other regulatory authorities for compliance with the FDA&#x2019;s cGMP regulations and other regulatory requirements, such as adverse event reporting. If we or a regulatory agency discovers problems with a product, such as adverse events of unanticipated severity or frequency or problems with the facility where the product is manufactured, a regulatory agency may impose restrictions on that product, the manufacturing facility, or us, including requiring recall or withdrawal of the product from the market or suspension of manufacturing, requiring new warnings or other labeling changes to limit use of the drug, requiring that we conduct additional clinical trials, imposing new monitoring requirements, or requiring that we establish a REMS program. Advertising and promotional materials must comply with FDA rules in addition to other potentially applicable federal and state laws, and are subject to review by FDA. If the FDA raises concerns regarding our promotional materials or messages, we may be required to modify or discontinue using them and may be required to provide corrective information. Should we fail to comply with these requirements, we may be subject to significant liability including civil and administrative actions as well as criminal sanctions.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <!-- Field: Page; Sequence: 33; Value: 1-->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt">
        <p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">
            <!-- Field: Sequence; Type: Arabic; Name: PageNo-->33<!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&#160;</p>
    </div>
    <!-- Field: /Page -->
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Commercial products must now meet the requirements of the Drug Supply Chain Security Act, or DSCSA, which imposes obligations on manufacturers of prescription pharmaceutical products for commercial distribution, regulating the distribution of the products at the federal level, and sets certain standards for federal or state registration and compliance of entities in the supply chain (manufacturers and re-packagers, wholesale distributors, third-party logistics providers, and dispensers). The DSCSA preempts previously enacted state pedigree laws and the pedigree requirements of the Prescription Drug Marketing Act, or PDMA, and its implementing regulations. Trading partners within the drug supply chain must now ensure certain product tracing requirements are met that they are doing business with other authorized trading partners; and they are required to exchange transaction information, transaction history, and transaction statements. Further, the DSCSA limits the distribution of prescription pharmaceutical products and imposes requirements to ensure overall accountability and security in the drug supply chain. As of November 27, 2018, product identifier information (an aspect of the product tracing scheme) is required. Although the PDMA no longer mandates pedigree requirements, manufacturers must follow the requirements pertaining to drug samples for health care professionals. Some states also have their own regulations on drug samples and related interactions with health care professionals.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Our activities are also potentially subject to federal and state consumer protection and unfair competition laws. If we or our third-party suppliers fail to comply with applicable regulatory requirements, a regulatory agency may take any of the following actions:</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">conduct an investigation into our practices and any alleged violation of law;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">issue warning letters or untitled letters asserting that we are in violation of the law;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">seek an injunction or impose civil or criminal penalties or monetary fines;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">suspend or withdraw regulatory approval;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">require that we suspend or terminate any ongoing clinical trials;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">refuse to approve pending applications or supplements to applications filed by us;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">suspend or impose restrictions on operations, including costly new manufacturing requirements;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">seize or detain products, refuse to permit the import or export of products, or require us to initiate a product recall; or</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">exclude us from providing our products to those participating in government healthcare programs, such as Medicare and Medicaid, and refuse to allow us to enter into supply contracts, including government contracts.</span>
            </td>
        </tr>
    </table>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0; margin-right: 0; margin-top: 0">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b><i>We may initiate product recalls or withdrawals or may be subject to regulatory enforcement actions that could negatively affect our business.</i></b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">We may be subject to product recalls, withdrawals, or seizures if any of the products we formulate, manufacture, or sell are believed to cause injury or illness or if we are alleged to have violated governmental regulations in the manufacture, labeling, promotion, sale, or distribution of any of our products. A recall, withdrawal, or seizure of any of our products could materially and adversely affect consumer confidence in our brands and lead to decreased demand for our products. In addition, a recall, withdrawal, or seizure of any of our products would require significant management attention, would likely result in substantial and unexpected expenditures, and could materially and adversely affect our business, financial condition, and results of operations.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b><i>Recent government enforcement has targeted pharmaceutical companies for violations of fraud, abuse and other laws.</i></b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">The AKS has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand and prescribers, purchasers, pharmacies, and formulary managers on the other. Although there are several statutory exemptions and regulatory safe harbors protecting certain common activities from prosecution, the exemptions and safe harbors are drawn narrowly and practices that involve remuneration to those who prescribe, purchase, or recommend pharmaceutical products, including certain discounts, or engagement of speakers or consultants, may be subject to scrutiny if they do not fit squarely within an exemption or safe harbor. Our practices with respect to interactions with healthcare professionals, including but not limited to consultant relationships, speaker programs, advisory boards, and scientific/educational grant programs, as well as our arrangements with pharmacies, may not in all cases meet all of the criteria for safe harbor protection from AKS liability. Moreover, there are no safe harbors for many common practices, such as educational and research grants or patient assistance programs. In addition, several states have recently enacted legislation requiring pharmaceutical companies to establish marketing and promotional compliance programs or codes of conduct and/or to file periodic reports with the state or make periodic public disclosures on sales, marketing, pricing, clinical trials, and other activities. Several states have also adopted laws that prohibit or limit certain marketing-related activities, including the provision of gifts, meals or other items to certain healthcare providers.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
        <span style="font: 10pt Times New Roman, Times, Serif">The FDA also strictly regulates marketing, labeling, advertising, and promotion of products that are placed on the market. A company can make only those claims relating to safety and efficacy, purity, and potency that are approved by the FDA. Physicians, in their independent professional medical judgment, may prescribe legally available products for unapproved indications that are not described in the product&#x2019;s labeling and that differ from those tested and approved by the FDA. Pharmaceutical companies, however, are required to promote their pharmaceutical products only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off label uses may be subject to significant liability, including, but not limited to, criminal and civil penalties under the FDCA and the FCA, exclusion from participation in federal healthcare programs, mandatory compliance programs under corporate integrity agreements, debarment, and refusal of government contracts.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <!-- Field: Page; Sequence: 34; Value: 1-->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt">
        <p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">
            <!-- Field: Sequence; Type: Arabic; Name: PageNo-->34<!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&#160;</p>
    </div>
    <!-- Field: /Page -->
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27.35pt">
        <span style="font: 10pt Times New Roman, Times, Serif">We cannot ensure that our compliance controls, policies and procedures will be sufficient to protect against acts of our employees, business partners or vendors that may violate federal or state fraud and abuse laws or other applicable requirements.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27.35pt">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
        <span style="font: 10pt Times New Roman, Times, Serif">Federal enforcement agencies and private whistleblowers recently have shown interest in pharmaceutical companies&#x2019; product and patient assistance programs (PAPs), including reimbursement support, co-pay support, nursing, adherence and educational services, referrals to other providers, donations to independent patient assistance charities, and relationships with specialty pharmacies. Co-pay assistance programs are intended to assist qualified patients with private insurance with any out-of-pocket financial obligations but must exclude any government healthcare program beneficiaries. Several investigations into patient assistance practices have resulted in significant civil and criminal settlements. We offer co-pay assistance for our vitamin products and IMVEXXY and BIJUVA, including co-pay assistance and free drug sample packs for IMVEXXY and BIJUVA, and potentially will enter into similar programs for ANNOVERA. While the HHS Office of Inspector General (OIG) has approved certain independent charitable PAPs that help financially needy beneficiaries, advisory opinions on this issue have primarily focused on charities that provide assistance to patients who cannot afford cost-sharing obligations for prescription drugs. A key element for the OIG has been whether the charities are sufficiently independent from drug manufacturer donors. In May 2014, the OIG issued a Supplemental Special Advisory Bulletin regarding Independent Charity Patient Assistance Programs, or the 2014 Special Advisory Bulletin, which updated its 2005 Special Advisory Bulletin relating to PAPs. In the 2014 Special Advisory Bulletin, the OIG stated that although PAPs provide important safety net assistance to financially needy patients, these programs also present a risk of fraud, waste, and abuse with respect to federal health care programs. One of the three factors set forth in the revised guidance was that the PAP could not limit assistance to a single product. In September of 2014, the OIG also released a Special Advisory Bulletin on pharmaceutical manufacturer copayment coupons, specifically stating that manufacturers that did not comply with the law may be subject to sanctions if they fail to take appropriate steps to ensure that such coupons do not induce the purchase of Federal health care program items or services, including, but not limited to, drugs paid for by Medicare Part D.&#160; Failure to take such steps may be evidence of intent to induce the purchase of drugs paid for by these programs, in violations of the AKS. PAPs have also been the subject of recent Congressional review. If we fail to structure our patient assistance and support programs to comply with applicable law, we risk becoming subject to government investigations, and potentially, facing penalties or consequences for violations under fraud and abuse laws. Although we believe that our business practices are structured to be compliant with applicable laws, it is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations, or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our past or present operations, including activities conducted by our sales team or agents, are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal, and administrative penalties, damages, fines, exclusion from government healthcare programs, and the curtailment or restructuring of our operations. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses, divert our management&#x2019;s attention from the operation of our business, and damage our reputation. In addition, even if we are not determined to have violated these laws, government investigations into these issues typically require the expenditure of significant resources and generate negative publicity, which could also have an adverse effect on our business, financial condition and results of operations. In addition, to the extent we, our subsidiary, VitaCare Prescription Services, or our other contractors or agents receive or obtain individually identifiable health information from patients, healthcare professionals, pharmacies, or other individuals or entities, we could be subject to criminal penalties if we mishandle individually identifiable health information in a manner that is not authorized or permitted by HIPAA. Claims that we have violated individuals&#x2019; privacy rights or breached our contractual obligations, even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business. In addition, VitaCare Prescription Services' activities could be subject to regulation and enforcement by the federal government and the states in which VitaCare conducts its business, including state licensing of pharmacies and pharmacists and as a result of potential increased scrutiny of innovation in hub services.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.35pt">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">The occurrence of any of the foregoing events or penalties may force us to expend significant amounts of time and money and may significantly inhibit our ability to bring to market or continue to market our products and generate revenue. Similar regulations apply in foreign jurisdictions.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Some of our products can be prescribed to patients via virtual health platform, such as PlushCare, a direct-to-consumer telehealth platform offering primary care medical services, subject to state telemedicine and prescribing laws. The federal Ryan Haight Act substantially limits the ability of prescribers to prescribe controlled substances via telehealth. While this federal law applies only to federally controlled substances, the permissibility of prescribing other non-controlled substances via a telehealth encounter is addressed at the state level. Constant changes to the telemedicine laws and regulations as well as state pharmacy and prescribing laws and emerging enforcement priorities by state legislatures, licensing bodies, and attorney generals&#x2019; offices, make it difficult to predict our ability to effectively penetrate the market for our products via virtual care offerings. We cannot guarantee that prescribers will be able, or willing, to prescribe our products to patients via a telehealth encounter and any limitations on such remote prescribing at the state level may impede our ability to expand access to our products.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <!-- Field: Page; Sequence: 35; Value: 1-->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt">
        <p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">
            <!-- Field: Sequence; Type: Arabic; Name: PageNo-->35<!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&#160;</p>
    </div>
    <!-- Field: /Page -->
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b><i>Licensing of intellectual property involves complex legal, business and scientific issues, and disputes could jeopardize our rights under such agreements. Additionally, our current licensing agreements contain limitations and restrictions that could limit or adversely affect our ability to develop and commercialize other products in the future.</i></b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">We are currently and may in the future be a party to license agreements of importance to our business and to our products and product candidates. Disputes may arise between us and any of these counterparties regarding intellectual property subject to and each parties&#x2019; obligations under such agreements, including:</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of our product and product candidates, and what activities satisfy those diligence obligations;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">the scope of rights granted under the agreement and other interpretation-related issues;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">our obligations to make milestone, royalty, or other payments under those agreements;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the agreement;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">our right to sublicense patent and other rights to third parties:</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">the ownership of inventions and know-how arising under the agreement or resulting from the joint creation or use of intellectual property by our licensors and us and our partners;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">our right to transfer or assign the license; and</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">the effects of termination.</span>
            </td>
        </tr>
    </table>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0; margin-right: 0; margin-top: 0">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">These or other disputes over our obligations or intellectual property that we have licensed may prevent or impair our ability to maintain our current arrangements on acceptable terms, or may impair the value of the arrangement to us. Any such dispute could have an adverse effect on our business.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">If we fail to meet our obligations under a license agreement in a material respect, the respective licensor could have the right to terminate the respective agreement and upon the effective date of such termination, have the right to re-obtain the related technology as well as, potentially, aspects of any intellectual property controlled by us and developed during the period the agreement was in force that relate to the applicable technology. This means that the licensor to each of these agreements could effectively take control of the development and commercialization of the applicable product or product candidate after an uncured, material breach of the agreement by us. This may also be the case if we voluntarily terminate the relevant agreement. Any uncured, material breach under a license agreement could result in our loss of exclusive rights and may lead to a complete termination of our product development and any commercialization efforts for the applicable product or product candidates.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">In July 2018, we entered into a license agreement with the Population Council to obtain exclusive U.S. rights to commercialize ANNOVERA. The agreement requires us to commercialize this product and enter into certain manufacturing agreements, make timely milestone and other payments, provide certain information regarding our activities under the agreement, and indemnify the other party with respect to our development and commercialization activities under the terms of the agreements.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">In addition, our current licensing agreement with the Population Council contains limitations and restrictions, including limitations that could limit or adversely affect our ability to develop and commercialize this or other product candidates including the following:</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">we cannot sublicense the rights licensed to us without the consent of the Population Council;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">neither we nor the Population Council may develop a competitive product (as defined with respect to each party in the agreement) for six years from the date of the agreement;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">currently there are no Orange Book listable patents covering ANNOVERA; and</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">the Population Council owns any program improvements, as defined in the agreement.</span>
            </td>
        </tr>
    </table>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0; margin-right: 0; margin-top: 0">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
        <span style="font: 10pt Times New Roman, Times, Serif">We have also entered into licensing and supply agreements with Knight pursuant to which we granted Knight an exclusive license to commercialize IMVEXXY and BIJUVA&#160;in Canada and Israel and with Theramex pursuant to which we granted Theramex an exclusive license to commercialize BIJUVA and IMVEXXY outside of the U.S., except for Canada and Israel.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
        <span style="font: 10pt Times New Roman, Times, Serif">Sales of our products in the U.S. and our rights to receive royalties with respect to our products sold outside the U.S. could be adversely affected if products manufactured outside of the U.S. or for sale outside of the U.S. under the terms of these licensing and supply agreements are reimported and sold in the U.S. In addition, our rights to receive royalties with respect to our products sold outside the U.S. could be adversely affected if our licensees fail to diligently pursue approval of our products, or opt not to sell our products, in certain jurisdictions where they are not required to do so.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <!-- Field: Page; Sequence: 36; Value: 1-->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt">
        <p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">
            <!-- Field: Sequence; Type: Arabic; Name: PageNo-->36<!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&#160;</p>
    </div>
    <!-- Field: /Page -->
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b><i>Our level of indebtedness and the terms of the Financing Agreement could adversely affect our operations and limit our ability to plan for or respond to changes in our business. If we are unable to satisfy certain conditions in our Financing Agreement, we will be unable to draw down the remaining the facility and if we are unable to comply with restrictions in the Financing Agreement, the repayment of our existing indebtedness could be accelerated.</i></b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Under the Financing Agreement, we have incurred a substantial amount of debt, which could adversely affect our business. In April 2019, we drew down the first tranche of $200.0 million under the Financing Agreement and in February 2020 we drew down the second tranche of $50.0 million under the Financing Agreement. We intend to draw an additional $50.0 million tranche under the terms of the Financing Agreement, when and if the conditions precedent to such tranche have been met; however, the Administrative Agent has the sole and absolute discretion to make this additional $50.0 million tranche available to us and there is no assurance that the Administrative Agent will do so. Our high level of indebtedness could affect our business in the following ways, among other things: make it more difficult for us to satisfy our contractual and commercial commitments; require us to use a substantial portion of our cash flow from operations to pay interest and principal, which would reduce funds available for working capital, capital expenditures and other general corporate purposes; limit our ability to obtain additional financing for working capital, capital expenditures, acquisitions and other investments or general corporate purposes; heighten our vulnerability to downturns in our business, our industry or in the general economy; place us at a disadvantage compared to those of our competitors that may have proportionately less debt; limit management&#x2019;s discretion in operating our business; and limit our flexibility in planning for, or reacting to, changes in our business, the industry in which we operate or the general economy.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">We must satisfy certain conditions to be eligible to draw down the third tranche of $50.0 million under the Financing Agreement. The third tranche may be drawn by us on or before September 22, 2020 (or such later date as may be consented to by the lenders in their sole discretion) in TPG&#x2019;s sole and absolute discretion either contemporaneously with the delivery of our financial statements for the fiscal quarter ending June 30, 2020 or at such earlier date as TPG shall have consented to. If we are unable to satisfy those conditions, we would not be able to draw down the tranche of financing and may not be able to obtain alternative financing on commercially reasonable terms or at all.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">The Financing Agreement requires us to make certain payments of principal and interest over time and contains several other restrictive covenants. Among other requirements of the Financing Agreement, we and our subsidiaries party to the Financing Agreement must (i) maintain a minimum unrestricted cash balance of $50.0 million, which amount increased to $60.0 million when we drew done the second tranche of the facility, and (ii) achieve certain minimum consolidated net revenue amounts attributable to commercial sales of our products beginning with the fourth quarter of 2020. The Financing Agreement also contains covenants that limit, among other things, the ability of us and our subsidiaries party to the Financing Agreement to (i) incur indebtedness, (ii) incur liens on our property, (iii) pay dividends or make other distributions, (iv) sell our assets, (v) make certain loans or investments, (vi) merge or consolidate, (vii) voluntarily repay or prepay certain permitted indebtedness and (viii) enter into transactions with affiliates, in each case subject to certain exceptions. These and other terms in the Financing Agreement have to be monitored closely for compliance and could restrict our ability to grow our business or enter into transactions that we believe would be beneficial to our business.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Our business may not generate cash flow from operations in the future sufficient to service our debt and support our growth strategies. If we are unable to generate such cash flow, we may be required to adopt one or more alternatives, such as selling assets, restructuring debt or obtaining additional equity capital on terms that may be onerous or highly dilutive. Our ability to refinance our indebtedness will depend on the capital markets and our financial condition at such time. We may not be able to engage in any of these activities or engage in these activities on desirable terms, which could result in a default on our debt obligations, including under our current debt obligations.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b><i>If our dietary supplement</i></b>, <b><i>hormone therapy pharmaceutical products or patient-controlled, long-acting contraceptive products do not have the effects intended or cause undesirable side effects, our business may suffer.</i></b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Although many of the ingredients in our dietary supplement products are vitamins, minerals, and other substances for which there is a long history of human consumption, they also contain innovative ingredients or combinations of ingredients. Furthermore, our hormone therapy or patient-controlled, long-acting contraceptive pharmaceutical products have been approved by the FDA based on its assessment of the safety and efficacy of these products. While we believe that all of these products and the combinations of ingredients in them are safe when taken as directed, the products could have certain undesirable side effects if not taken as directed or if taken by a consumer who has certain medical conditions. In addition, these products may not have the effect intended if they are not taken in accordance with certain instructions, which include certain dietary or other labeling restrictions. Furthermore, there can be no assurance that any of the products, even when used as directed, will have the effects intended or will not have harmful side effects in an unforeseen way or on an unforeseen cohort. If any of our products or products we develop or commercialize in the future are shown to be harmful or generate negative publicity from perceived harmful effects, our business, financial condition, results of operations, and prospects could be harmed significantly.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <!-- Field: Page; Sequence: 37; Value: 1-->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt">
        <p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">
            <!-- Field: Sequence; Type: Arabic; Name: PageNo-->37<!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&#160;</p>
    </div>
    <!-- Field: /Page -->
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b><i>Even following regulatory approval for our hormone therapy pharmaceutical products and patient-controlled, long-acting contraceptive, we will still face extensive, ongoing regulatory requirements and review, and our products may face future development and regulatory difficulties.</i></b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Even following regulatory approval for our pharmaceutical products in the U. S., the FDA may still impose significant restrictions on a product&#x2019;s doses, indicated uses, or marketing, or to the conditions for approval, or impose ongoing requirements for potentially costly post-approval studies, including Phase 4 clinical trials or post-market surveillance. For example, as part of the FDA&#x2019;s approval of IMVEXXY, we have committed to conducting a post-approval observational study to evaluate the risk of endometrial cancer in post-menopausal women with a uterus who use a low-dose vaginal estrogen unopposed by a progestogen such as IMVEXXY. As part of the FDA&#x2019;s approval of ANNOVERA, the FDA has required a post-approval observational study be performed to measure the risk of venous thromboembolism. As a condition to granting marketing approval of a product, the FDA may require a company to conduct additional clinical trials. The data generated in these post-approval clinical trials could result in loss of marketing approval, changes in product labeling, or new or increased concerns about side effects or efficacy of a product. For example, the labeling for our pharmaceutical products includes restrictions on use or warnings. The Food and Drug Administration Amendments Act of 2007, or FDAAA, gives the FDA enhanced post-market authority, including the explicit authority to require post-market studies and clinical trials, labeling changes based on new safety information, and compliance with FDA-approved REMS programs. Our pharmaceutical products are also be subject to ongoing FDA requirements governing the manufacturing, labeling, packaging, storage, distribution, safety surveillance, advertising, promotion, record keeping, and reporting of safety and other post-market information. The FDA&#x2019;s exercise of its authority could result in delays or increased costs during product development, clinical trials and regulatory review, increased costs to comply with additional post-approval regulatory requirements, and potential restrictions on sales of approved products. Foreign regulatory agencies often have similar authority and may impose comparable requirements and related costs. Post-marketing studies, whether conducted by us or by others and whether mandated by regulatory agencies or voluntary, and other emerging data about marketed products, such as adverse event reports, may also adversely affect sales of our pharmaceutical products, and potentially our other marketed products. Further, the discovery of significant problems with a product similar to one of our products that implicate (or are perceived to implicate) an entire class of products could have an adverse effect on sales of our approved products. Accordingly, new data about our products could negatively affect demand because of real or perceived side effects or uncertainty regarding efficacy and, in some cases, could result in product withdrawal or recall. Furthermore, new data and information, including information about product misuse, may lead government agencies, professional societies, and practice management groups or organizations involved with various diseases to publish guidelines or recommendations related to the use of our products or the use of related therapies or place restrictions on sales. Such guidelines or recommendations may lead to lower sales of our products.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">The holder of an approved NDA also is subject to obligations to monitor and report adverse events and instances of the failure of a product to meet the specifications in the NDA. Application holders must submit new or supplemental applications and obtain FDA approval for certain changes to the approved product, product labeling, or manufacturing process. Application holders must also submit advertising and other promotional material to the FDA and report on ongoing clinical trials. Legal requirements have also been enacted to require disclosure of clinical trial results on publicly available databases.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">In addition, manufacturers of pharmaceutical products and their facilities are subject to continual review and periodic inspections by the FDA and other regulatory authorities for compliance with the FDA&#x2019;s cGMP regulations. If we or a regulatory agency discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency or problems with the facility where the product is manufactured, a regulatory agency may impose restrictions on that product, the manufacturing facility, or us, including requiring recall or withdrawal of the product from the market or suspension of manufacturing, requiring new warnings or other labeling changes to limit use of the drug, requiring that we conduct additional clinical trials, imposing new monitoring requirements, or requiring that we establish a REMS program. Advertising and promotional materials must comply with FDA rules in addition to other potentially applicable federal and state laws. The distribution of product samples to physicians must comply with the requirements of the PDMA. Sales, marketing, and scientific/educational grant programs must comply with the anti-fraud and abuse provisions of the Social Security Act, the FCA, and similar state laws. We would also be required under the Sunshine provision of the ACA to report annually to CMS on payments that we make to physicians and teaching hospitals and ownerships interests in the company held by physicians. Pricing and rebate programs must comply with the Medicaid rebate requirements of the Omnibus Budget Reconciliation Act of 1990 and the Veterans Healthcare Act of 1992. If products are made available to authorized users of the Federal Supply Schedule of the General Services Administration and to low income patients of certain hospitals, additional laws and requirements apply. Our activities are also potentially subject to federal and state consumer protection and unfair competition laws. If we or our third-party collaborators fail to comply with applicable regulatory requirements, a regulatory agency may take any of the following actions:</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">conduct an investigation into our practices and any alleged violation of law;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">issue warning letters or untitled letters asserting that we are in violation of the law;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">seek an injunction or impose civil or criminal penalties or monetary fines;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">suspend or withdraw regulatory approval;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">require that we suspend or terminate any ongoing clinical trials;</span>
            </td>
        </tr>
    </table>
    <!-- Field: Page; Sequence: 38; Value: 1-->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt">
        <p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">
            <!-- Field: Sequence; Type: Arabic; Name: PageNo-->38<!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&#160;</p>
    </div>
    <!-- Field: /Page -->
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">refuse to approve pending applications or supplements to applications filed by us;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">suspend or impose restrictions on operations, including costly new manufacturing requirements;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">seize or detain products, refuse to permit the import or export of products, or require us to initiate a product recall; or</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">exclude us from providing our products to those participating in government healthcare programs, such as Medicare and Medicaid, and refuse to allow us to enter into supply contracts, including government contracts.</span>
            </td>
        </tr>
    </table>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0; margin-right: 0; margin-top: 0">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">The occurrence of any of the foregoing events or penalties may force us to expend significant amounts of time and money and may significantly inhibit our ability to bring to market or continue to market our products and generate revenue. Similar regulations apply in foreign jurisdictions.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b><i>Our products face significant competition from branded and generic products, and our operating results will suffer if we fail to compete effectively.</i></b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Development and awareness of our brand will depend largely upon our success in increasing our consumer base and maintaining adequate pricing through our exclusivities. The pharmaceutical and dietary supplement industries are intensely competitive and subject to rapid and significant technological change. Our products face intense competition, including from major multinational pharmaceutical and dietary supplement companies, established biotechnology companies, specialty pharmaceutical, and generic drug companies. Many of these companies have greater financial and other resources, such as larger research and development staffs and more experienced marketing and manufacturing organizations. As a result, these companies may obtain regulatory approval more rapidly and may be more effective in selling and marketing their products. They also may invest heavily to accelerate discovery and development of novel compounds or to in-license novel compounds that could make the products that we sell or develop obsolete. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies. If we are unable to economically promote or maintain our brand, our business, results of operations and financial condition could be severely harmed. In addition, our efforts to provide an alternative to the non-FDA-approved compound bioidentical market for estradiol and progesterone products sold by compounding pharmacies may not be successful. Finally, loss of exclusivity may provide opportunity for competing products, particularly generics, to erode pricing and siphon off our consumers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On February 20, 2020, we received the Notice Letter regarding an ANDA submitted to the FDA by Teva. The ANDA seeks approval from the FDA to commercially manufacture, use, or sell a generic version of the 4 mcg and 10 mcg doses of IMVEXXY. In the Notice Letter, Teva alleges that IMVEXXY Patents listed in the FDA&#x2019;s Orange Book that claim compositions and methods of IMVEXXY are invalid, unenforceable, and/or will not be infringed by Teva&#x2019;s commercial manufacture, use, or sale of its proposed generic drug product. The IMVEXXY Patents identified in the Notice Letter expire in 2032 or 2033. We are currently reviewing the Notice Letter and intend to vigorously enforce our intellectual property rights relating to IMVEXXY. Under the Hatch-Waxman Act, we have 45 days from receipt of the Notice Letter to initiate a patent infringement lawsuit against Teva. Such a lawsuit would automatically preclude the FDA from approving Teva&#x2019;s ANDA until the earlier of 30 months or entry of a district court decision finding the IMVEXXY Patents invalid, unenforceable, or not infringed. We cannot assure you that any patent infringement lawsuit that we may file will prevent the introduction of a generic version of IMVEXXY for any particular length of time, or at all. If Teva&#x2019;s ANDA is approved, and a generic version of IMVEXXY is introduced, our sales of IMVEXXY could be adversely affected. In addition, we cannot predict what additional ANDAs could be filed by Teva or other potential generic competitors requesting approval to market generic forms of our products, which could require us to incur significant additional expense and result in distraction for our management team, and if approved, result in significant decreases in the revenue derived from sales of our marketed products and thereby materially harm our business and financial condition.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b><i>Failure to obtain regulatory approval outside the U.S. will prevent our licensees from marketing our hormone therapy pharmaceutical products in non-U.S. markets.</i></b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">We have entered into licensing and supply agreements with Knight and Theramex to commercialize IMVEXXY and BIJUVA in non-U.S. markets. To market these products in the European Union and many other non-U.S. jurisdictions, our licensees must obtain separate regulatory approvals. We have had limited interactions with non-U.S. regulatory authorities, the approval procedures vary among countries and can involve additional testing, and the time required to obtain approval may differ from that required to obtain FDA approval or clearance. Approval or clearance by the FDA does not ensure approval by regulatory authorities in other countries, and approval by one or more non-U.S. regulatory authorities does not ensure approval by other regulatory authorities in other countries or by the FDA. The non-U.S. regulatory approval process may include all of the risks associated with obtaining FDA approval or clearance. For these non-U.S. regulatory approvals, our licensees may not obtain them on a timely basis, if at all. Our licensees&#x2019; failure to receive necessary non-U.S. regulatory approvals to commercialize IMVEXXY and BIJUVA in a given market could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">In addition, by seeking to obtain approval to market IMVEXXY and BIJUVA in one or more non-U.S. markets, we and/or our licensees will be subject to rules and regulations in those markets relating to our products. In some countries, particularly countries of the European Union, each of which has developed its own rules and regulations, pricing is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of regulatory approval for a drug. To obtain reimbursement or pricing approval in some countries, our licensees may be required to conduct a clinical trial that compares the cost-effectiveness of our pharmaceutical product to other available products. If reimbursement of our pharmaceutical product is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our licensees may be unable to generate revenues and achieve or sustain profitability with respect to any given market, which could have a material adverse effect on our business, financial condition, results of operations, and prospects. If our licensees obtain approval to market IMVEXXY or BIJUVA in one or more non-U.S. markets, we will have additional pharmacovigilance reporting requirements for our products. To the extent that the non-U.S. markets in which our licensees distribute our products have different pharmacovigilance reporting requirements than the U.S., there is a risk that the marketing of our drugs in those countries may increase the number of adverse events reported for our products.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>
    <!-- Field: Page; Sequence: 39; Value: 1-->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt">
        <p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">
            <!-- Field: Sequence; Type: Arabic; Name: PageNo-->39<!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&#160;</p>
    </div>
    <!-- Field: /Page -->
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b><i>Product liability lawsuits could divert our resources, result in substantial liabilities and reduce the commercial potential of our products.</i></b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">We face an inherent risk of product liability claims as a result of the commercial availability of our current products and the clinical testing of our pharmaceutical product candidates despite obtaining appropriate informed consents from our clinical trial participants. Additionally, in light of the history of product liability claims related to other hormone therapy products and contraceptives, we will face an even greater risk through commercialization of our products. For example, we may be sued if any product we develop allegedly causes injury or is found to be otherwise unsuitable during clinical testing, manufacturing, marketing, or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, failures to warn of dangers associated with the use of the product, negligence, strict liability, or breaches of warranties. Claims could also be asserted under state consumer fraud and protection statutes. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our existing products or pharmaceutical product candidates. Regardless of the merits or eventual outcome, product liability claims may result in any of the following:</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">the inability to commercialize our products or pharmaceutical product candidates;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">difficulty recruiting subjects for clinical trials or withdrawal of these subjects before a trial is completed;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">labeling, marketing, or promotional changes and/or restrictions;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">product recalls or withdrawals;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">decreased demand for our products or products that we may develop in the future;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">loss of revenue;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">injury to our reputation;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">initiation of investigations by regulators or actions by state attorney generals or the U.S. Department of Justice;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">costs to defend the related litigation;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">a diversion of management&#x2019;s time and our resources;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">substantial monetary awards to trial participants or patients;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">exhaustion of any available insurance and our capital resources; and</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">a decline in our stock price.</span>
            </td>
        </tr>
    </table>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0; margin-right: 0; margin-top: 0">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Although we maintain general liability insurance and clinical trial liability insurance for our products and product candidates, this insurance may not fully cover potential liabilities. The cost of any product liability litigation or other proceeding, even if resolved in our favor, could be substantial. In addition, our inability to obtain or maintain sufficient insurance coverage at an acceptable cost or to otherwise protect against potential product liability claims could prevent or inhibit the development and commercial production and sale of our products, which could adversely affect our business, financial condition, results of operations, and prospects.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b><i>If we use hazardous materials in a manner that causes injury or violates applicable law, we may be liable for damages.</i></b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Our manufacturing and research and development activities involve the controlled use of potentially hazardous substances, including chemical, biological, and radioactive materials. In addition, our operations produce hazardous waste products. Federal, state, and local laws and regulations in the U.S. govern the use, manufacture, storage, handling, and disposal of hazardous materials. Although we believe that our procedures for use, handling, storing, and disposing of these materials (all of which only occur at third-party sites operated by our contractors) comply with legally prescribed standards, we may incur significant additional costs to comply with applicable laws in the future. We also cannot predict the impact on our business of new or amended environmental laws or regulations or any changes in the way existing and future laws and regulations are interpreted or enforced. Also, even if we are in compliance with applicable laws, we cannot completely eliminate the risk of contamination or injury resulting from hazardous materials, and we may incur liability as a result of any such contamination or injury. In the event of an accident, we could be held liable for damages or penalized with fines, and the liability could exceed our resources, and we do not carry liability insurance covering the use of hazardous materials. If we fail to comply with applicable requirements, we could incur substantial costs, including civil or criminal fines and penalties, clean-up costs, or capital expenditures for control equipment or operational changes necessary to achieve or maintain compliance. Compliance with applicable environmental laws and regulations is expensive, and current or future environmental regulations may impair our research, development and production efforts, and may adversely affect our business, financial condition, results of operations, and prospects.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b><i>If we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.</i></b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Our ability to compete in the highly competitive pharmaceutical industry depends in large part on our ability to attract and retain highly qualified managerial, scientific, and medical personnel. To induce valuable employees to remain with us, we have, among other things, provided stock-based compensation that vests over time. The value to employees of stock-based compensation will be significantly affected by movements in our stock price that we cannot control and may at any time be insufficient to counteract more lucrative offers from other companies. Despite our efforts to retain valuable employees, members of our management, scientific, and medical teams may terminate their employment with us on short notice. Although we have employment agreements with several of our key employees, most employees are employed on an at-will basis, which means that any of these employees could leave our employment at any time, with or without notice, and may go to work for a competitor. The loss of the services of any of our executive officers or other key employees could potentially harm our business, operating results, and financial condition. Our success also depends on our ability to continue to attract, retain, and motivate highly skilled scientific and medical personnel.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <!-- Field: Page; Sequence: 40; Value: 1-->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt">
        <p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">
            <!-- Field: Sequence; Type: Arabic; Name: PageNo-->40<!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&#160;</p>
    </div>
    <!-- Field: /Page -->
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b><i>Our success is tied to our distribution channels.</i></b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">We sell our products to wholesale distributors and retail pharmacy distributors. During 2019, four customers each generated more than 10% of our total revenues; revenue generated from these four customers combined accounted for approximately 73% of our total revenue during 2019. Our business would be harmed if any of these customers refused to distribute our products or refused to purchase our products on commercially favorable terms to us.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b><i>A failure to maintain optimal inventory levels to meet commercial demand for our products could harm our reputation and subject us to financial losses.</i></b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Our ability to maintain optimal inventory levels to meet commercial demand depends on the performance of third-party contract manufacturers. In some instances, our products have unique ingredients used under license arrangements. If our manufacturers are unsuccessful in obtaining raw materials, if we are unable to manufacture and release inventory on a timely and consistent basis, if we fail to maintain an adequate level of product inventory, if inventory is destroyed or damaged, or if our inventory reaches its expiration date, patients might not have access to our products, our reputation and brands could be harmed, and physicians may be less likely to recommend our products in the future, each of which could have a material adverse effect on our business, financial condition, results of operations, and cash flows.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b><i>Delays in clinical trials are common for many reasons, and any such delays could result in increased costs to us and jeopardize or delay our ability to obtain regulatory approval or commence or continue product sales.</i></b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">We may experience delays in future clinical trials for our pharmaceutical product candidates or required post-approval clinical trials for our approved products. Clinical trials might not begin on time; may be interrupted, delayed, suspended, or terminated once commenced; might need to be amended or redesigned; might not enroll enough patients; or might not be completed on schedule, if at all. Clinical trials can be delayed for a variety of reasons, including the following:</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">delays in obtaining regulatory approval to commence a trial;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">imposition of a clinical hold following an inspection of clinical trial operations or trial sites by the FDA, or other regulatory authorities;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">imposition of a clinical hold because of safety or efficacy concerns by the DSMB, FDA, or IRB, or us;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">delays in reaching agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical trial sites;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">delays in obtaining required central or local IRB approval for each clinical site;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">delays in identifying, recruiting, and training suitable clinical investigators;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">delays in recruiting suitable patients to participate in a trial;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">delays in having patients&#x2019; complete participation in a trial or return for post-treatment follow-up;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">clinical sites dropping out of a trial to the detriment of enrollment or due to a lack of ability to enroll a certain number of patients in a trial;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">time required to add new sites;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">delays in obtaining sufficient supplies of clinical trial materials, including suitable API; or</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">delays resulting from negative or equivocal findings of DSMB for a trial.</span>
            </td>
        </tr>
    </table>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0; margin-right: 0; margin-top: 0">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Patient enrollment, a significant factor in the timing of clinical trials, is affected by many factors, including the size and nature of the patient population, the proximity of patients to clinical sites, the eligibility criteria for the trial, the design of the clinical trial, competing clinical trials, and clinicians&#x2019; and patients&#x2019; perceptions as to the potential advantages of the drug being studied in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating. Any of these delays in completing future clinical trials could increase our costs, slow down our product development and approval process, and jeopardize our ability to commence product sales and generate revenue from our pharmaceutical product candidates, or continue to generate revenue from our approved products subject to post-approval clinical trials for our approved products, subject to the trial.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b><i>Clinical trials are lengthy and expensive with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results</i>.</b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Clinical trials are expensive, can take many years to complete and have highly uncertain outcomes. Failure can occur at any time during the clinical trial process because of inadequate performance of a drug, inadequate adherence by patients or investigators to clinical trial protocols, or other factors. New drugs in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through earlier clinical trials. Several companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials as a result of a lack of efficacy or adverse safety profiles, despite promising results in earlier trials. Our future clinical trials may not be successful or may be more expensive or time-consuming than we currently expect. Before approving a new drug, the FDA generally requires that the safety and efficacy of the drug be demonstrated in two adequate and well-controlled clinical trials. In some situations, the FDA approves drugs based on a single well-controlled clinical trial. If clinical trials for any of our pharmaceutical product candidates fail to demonstrate safety or efficacy to the satisfaction of the FDA, the FDA will not approve those product candidates and we will not be able to commercialize, which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <!-- Field: Page; Sequence: 41; Value: 1-->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt">
        <p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">
            <!-- Field: Sequence; Type: Arabic; Name: PageNo-->41<!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&#160;</p>
    </div>
    <!-- Field: /Page -->
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b><i>Future legislation, or the absence of such legislation, regulations, and policies adopted by the FDA or other regulatory authorities may increase the time and cost required for us to conduct and complete clinical trials for our pharmaceutical product candidates.</i></b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">The FDA has established regulations, guidelines, and policies to govern the drug development and approval process, as have foreign regulatory authorities. Any change in regulatory requirements resulting from the adoption of new legislation, regulations, or policies may require us to amend existing clinical trial protocols or add new clinical trials to comply with these changes. Such amendments to existing protocols or clinical trial applications or the need for new ones, may significantly and adversely affect the cost, timing, and completion of the clinical trials for our pharmaceutical product candidates.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">In addition, the FDA&#x2019;s policies may change and additional government regulations may be issued that could prevent, limit, or delay regulatory approval of our pharmaceutical product candidates, or impose more stringent product labeling and post-marketing testing and other requirements. For example, in the past the FDA has indicated it would regulate prenatal vitamins containing greater than 0.8 mg of folic acid as a drug under the FDCA. More recently the FDA indicated that there is no specified upper limit on the amount of folic acid permitted in a dietary supplement. If the FDA were to seek to regulate products with higher amounts of folic acid as drugs, it may require us to stop selling certain of our dietary supplement products and otherwise adversely affect our business. If we are slow or unable to adapt to any such changes, our business, prospects, and ability to achieve or sustain profitability could be adversely affected.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b><i>We may be required to suspend or discontinue clinical trials because of adverse side effects or other safety risks that could preclude approval of our pharmaceutical product candidates.</i></b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Clinical trials may be suspended or terminated at any time for many reasons. A clinical trial may be suspended or terminated by us, our collaborators, the FDA, or other regulatory authorities because of a failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, presentation of unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using the investigational drug, changes in governmental regulations or administrative actions, lack of adequate funding to continue the clinical trial, or negative or equivocal findings of the DSMB or the IRB for a clinical trial. An IRB may also suspend or terminate our clinical trials for failure to protect patient safety or patient rights. We may voluntarily suspend or terminate our clinical trials if at any time we believe that they present an unacceptable risk to participants. In addition, regulatory agencies may order the temporary or permanent discontinuation of our clinical trials at any time if they believe the clinical trials are not being conducted in accordance with applicable regulatory requirements or present an unacceptable safety risk to participants. If we elect or are forced to suspend or terminate any clinical trial of any proposed product that we develop, the commercial prospects of such proposed product will be harmed and our ability to generate product revenue from any of these proposed products will be delayed or eliminated. Any of these occurrences may harm our business, financial condition, results of operations, and prospects significantly.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b><i>We rely on third parties to conduct our research and development activities, including our clinical trials, and we may experience delays in obtaining or may be unsuccessful in obtaining regulatory approval for, or in commercializing, our pharmaceutical product candidates if these third parties do not successfully carry out their contractual duties or meet expected deadlines.</i></b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">We do not have the resources to independently conduct research and development activities. Therefore, we have relied, and plan to continue to rely, on various third-party CROs to conduct our research and development activities and to recruit patients and monitor and manage data for our on-going clinical programs for our pharmaceutical product candidates, as well as for the execution of clinical studies. Although we control only certain aspects of our CROs&#x2019; activities, we are ultimately responsible for ensuring that each of our studies is conducted in accordance with the applicable protocol, legal, regulatory, and scientific standards and our reliance on the CROs does not relieve us of our regulatory responsibilities. We cannot assure you that the CROs will conduct the research properly or in a timely manner, or that the results will be reproducible. We and our CROs are required to comply with the FDA&#x2019;s Good Clinical Practice, or cGCP, regulations and guidelines enforced by the FDA for all of our products in clinical development. The FDA enforces these cGCPs through periodic and pre-approval inspections of trial sponsors, principal investigators, and clinical trial sites. If we or our CROs fail to comply with applicable cGCPs, the clinical data generated in our clinical trials may be deemed unreliable or invalid, and the FDA may require us to perform additional clinical trials before approving our proposed products. We cannot assure you that, upon inspection, the FDA will determine that any of our clinical trials comply with cGCPs. In addition, to evaluate the safety and effectiveness compared to placebo of our pharmaceutical product candidates to a statistically significant degree, our clinical trials will require an adequately large number of test subjects. Any clinical trial that a CRO conducts abroad on our behalf is subject to similar regulation. Accordingly, if our CROs fail to comply with these regulations or recruit enough patients, we may be required to repeat clinical trials, which would delay the regulatory approval process.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <!-- Field: Page; Sequence: 42; Value: 1-->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt">
        <p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">
            <!-- Field: Sequence; Type: Arabic; Name: PageNo-->42<!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&#160;</p>
    </div>
    <!-- Field: /Page -->
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">In addition, we do not employ the personnel of our CROs, and, except for remedies available to us under our agreements with such organizations, we cannot control whether or not they will devote sufficient time and resources to our on-going clinical and pre-clinical programs. Our CROs may also have relationships with other commercial entities, including one or more of our competitors, for which they may also be conducting clinical studies or other drug development activities, which could impede their ability to devote appropriate time to our clinical programs. If our CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced, or if the quality or accuracy of the clinical data they obtain is compromised because of the failure to adhere to our clinical protocols or regulatory requirements, or for other reasons, our clinical trials may be extended, delayed, or terminated, and we may not be able to obtain regulatory approval for or successfully commercialize our pharmaceutical product candidates that we seek to develop. As a result, our financial results and the commercial prospects for our pharmaceutical product candidates that we seek to develop could be harmed, our costs could increase, and our ability to generate revenue could be delayed or end.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">We typically engage one or more CROs on a project-by-project basis for each study or trial. While we have developed and plan to maintain our relationships with CROs that we have previously engaged, we also expect to enter into agreements with other CROs to obtain additional resources and expertise to accelerate our progress with regard to on-going clinical programs and, specifically, the compilation of clinical trial data for submission with an NDA for each of our pharmaceutical product candidates. If any of our relationships with these third parties terminate, we may not be able to enter into arrangements with alternative CROs or do so on commercially reasonable terms. Switching or entering into new relationships with CROs involves substantial cost and requires extensive management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can materially affect our ability to meet our desired clinical development timelines and can increase our costs significantly. Although we try to carefully manage our relationships with our CROs, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition, results of operations, or prospects.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b><i>Our ability to utilize net operating loss carryforwards may be limited.</i></b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">As of December 31, 2019, we had federal net operating loss carryforwards, or NOLs, of approximately $620.4 million. Subject to applicable limitations, these NOLs may be used to offset future taxable income, to the extent we generate any taxable income, and thereby reduce our future federal income taxes otherwise payable.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Section 382 of the Internal Revenue Code of 1986, as amended, imposes limitations on a corporation&#x2019;s ability to utilize NOLs if it experiences an ownership change as defined in Section 382. In general terms, an ownership change may result from transactions increasing the ownership of certain stockholders in the stock of a corporation by more than 50 percent over a three-year period. If an ownership change has occurred, or were to occur, utilization of our NOLs would be subject to an annual limitation under Section 382 determined by multiplying the value of our stock at the time of the ownership change by the applicable long-term tax-exempt rate. Any unused annual limitation may be carried over to later years. We may be found to have experienced an ownership change under Section 382 because of events in the past or the issuance of shares of our common stock in the future. If so, the use of our NOLs, or a portion thereof, against our future taxable income may be subject to an annual limitation under Section 382.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">On December 22, 2017, the U.S. federal government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act, or the Tax Act. The Tax Act makes broad and complex changes to the U.S. federal tax code, including, but not limited to reducing the U.S. federal corporate tax rate from 34 percent to 21 percent and imposing new restrictions on the use of NOLs. The Tax Act reduces the corporate tax rate to 21 percent, effective January 1, 2018.&#160; Management assessed the valuation allowance analyses with respect to our NOLs as affected by various aspects of the Tax Act and determined that a full valuation allowance continues to be appropriate. Furthermore, the Tax Act limits the NOL carryover deduction in a taxable year to the lesser of the NOL carryforward or 80 percent of the taxpayer&#x2019;s taxable income (before considering any deduction on account of such NOLs), which may restrict our ability to offset future taxable income with NOLs and increase our future federal income taxes otherwise payable.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b><i>Our business may be impacted by new or changing tax laws or regulations and actions by federal, state, and/or local agencies, or how judicial authorities apply tax laws.</i></b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">In connection with the products we sell and intend to sell, we calculate, collect, and remit various federal, state, and local taxes, surcharges and regulatory fees, or taxes, to numerous federal, state and local governmental authorities. In addition, we incur and pay state and local taxes and fees on purchases of goods and services used in our business.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Tax laws are dynamic and subject to change as new laws are passed and new interpretations of the law are issued or applied. In many cases, the application of tax laws (including the recently enacted Tax Act) is uncertain and subject to differing interpretations, especially when evaluated against new technologies and services. The impact of this tax reform on holders of our common stock is also uncertain and could be adverse.&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <!-- Field: Page; Sequence: 43; Value: 1-->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt">
        <p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">
            <!-- Field: Sequence; Type: Arabic; Name: PageNo-->43<!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&#160;</p>
    </div>
    <!-- Field: /Page -->
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">If we have incorrectly described, disclosed, calculated, assessed, or remitted amounts that were due to governmental authorities, we could be subject to additional taxes, fines, penalties, or other adverse actions, which could materially impact our business, results of operations, and financial condition.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b><i>Our operations are concentrated in Boca Raton, Florida and interruptions affecting us or our suppliers due to natural disasters or other unforeseen events could materially and adversely affect our operations.</i></b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Our current operations are concentrated in Boca Raton, Florida. A hurricane or other disaster or unforeseen event resulting in significant damage to our facilities could significantly disrupt or curtail or require us to cease our operations. It would be difficult, costly and time-consuming to transfer resources from one facility to another or to repair or replace our facility if it is significantly damaged. In addition, our insurance may be insufficient to cover all of our losses and may not continue to be available to us on acceptable terms, or at all. In addition, if one of our suppliers, such as Catalent at its manufacturing facility in St. Petersburg, Florida, experiences a similar disaster or unforeseen event, we could face significant delays in obtaining our products. Any significant uninsured loss, prolonged or repeated disruption to operations or inability to operate, experienced by us or by our suppliers, could materially and adversely affect our business, financial condition and results of operations.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b><i>Any failure to adequately maintain a sales force will impede our growth.</i></b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">We are substantially dependent on a sales force &#x2013; both those directly employed by us and those engaged through our contract sales organization &#x2013; to attract new business and to manage existing customer relationships. We believe that there is significant competition for qualified, productive direct sales personnel with advanced sales skills and technical knowledge. Our ability to achieve significant growth in revenue in the future will depend, in large part, on our success in recruiting, training, and retaining direct sales personnel. New and future sales personnel may not become as productive as expected, and we may be unable to hire or engage enough qualified individuals in the future in the markets in which we do business. If we are unable to hire, engage and develop enough productive sales personnel or are required to hire or engage more sales personnel than we expect our business prospects could suffer. In addition to utilizing a contract sales organization for part of our sales force, we also utilize this organization for certain sales support functions, such as fleet and sample management.&#160; We currently intend to insource at least some of these functions and personnel in the future.&#160; If we are unsuccessful in insourcing these functions or personnel, we may face delays or additional costs in commercializing our pharmaceutical products, which could materially and adversely affect our business, financial condition and results of operations.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Other pharmaceutical companies with which we compete for qualified personnel may have greater financial and other resources, different risk profiles, and longer histories than we do. They also may provide more diverse opportunities and better chances for career advancement. Some of these characteristics may be more appealing to high-quality candidates than what we offer. If we are unable to continue to attract and retain high-quality personnel, our ability to commercialize IMVEXXY, BIJUVA and ANNOVERA may be limited.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b><i>We will need to grow our organization, and we may experience difficulties in managing this growth, which could disrupt our operations.</i></b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">As of December 31, 2019, we had 348 employees. As our development and commercialization plans and strategies develop, we expect to expand our employee base for managerial, operational, financial, sales and marketing, and other resources. Future growth would impose significant added responsibilities on members of management, including the need to identify, recruit, maintain, motivate, and integrate additional employees. Also, our management may need to divert a disproportionate amount of its attention away from their day-to-day activities and devote a substantial amount of time to managing these growth activities. We may not be able to effectively manage the expansion of our operations, which may result in weaknesses in our infrastructure, give rise to operational mistakes, loss of business opportunities, loss of employees and reduced productivity among remaining employees. Our growth could require significant capital expenditures and may divert financial resources from other projects, such as the development of additional pharmaceutical product candidates. If we are unable to effectively manage our expected growth, our expenses may increase more than expected, our ability to increase revenue could be reduced and we may not be able to implement our business strategy. Our future financial performance and our ability to commercialize our pharmaceutical products and compete effectively will depend, in part, on our ability to effectively manage any future growth in our organization.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b><i>We may not be able to maintain effective and efficient information systems or properly safeguard our information systems.</i></b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Our operations are dependent on uninterrupted performance of our information systems. Failure to maintain reliable information systems, disruptions in our existing information systems or the implementation of new systems could cause disruptions in our business operations, including violations of patient privacy and confidentiality requirements and other regulatory requirements, increased administrative expenses and other adverse consequences.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">In addition, information security risks have generally increased in recent years because of new technologies and the increased activities of perpetrators of cyber-attacks resulting in the theft of protected health, business, or financial information. Despite our layered security controls, experienced computer programmers and hackers may be able to penetrate our information systems and misappropriate or compromise sensitive patient or personnel information or proprietary or confidential information, create system disruptions or cause shutdowns. They also may be able to develop and deploy viruses, worms and other malicious software programs that disable our systems or otherwise exploit any security vulnerabilities. Outside parties may also attempt to fraudulently induce employees to take actions, including the release of confidential or sensitive information or to make fraudulent payments, through illegal electronic spamming, phishing, or other tactics.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <!-- Field: Page; Sequence: 44; Value: 1-->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt">
        <p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">
            <!-- Field: Sequence; Type: Arabic; Name: PageNo-->44<!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&#160;</p>
    </div>
    <!-- Field: /Page -->
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">A failure in or breach of our information systems because of cyber-attacks or other tactics could disrupt our business, result in the release or misuse of protected health information, or PHI, confidential or proprietary business information or financial loss, damage our reputation, increase our administrative expenses, and expose us to additional risk of liability to federal or state governments or individuals. Although we believe that we have robust information security procedures and other safeguards in place, as cyber threats continue to evolve, we may be required to expend additional resources to continue to enhance our information security measures or to investigate and remediate any information security vulnerabilities. Our remediation efforts may not be successful and could result in interruptions, delays or cessation of service and loss of existing or potential patients and disruption of our operations. In addition, breaches of our security measures and the unauthorized dissemination of patient healthcare and other sensitive information, proprietary or confidential information about us or other third-parties could expose such persons&#x2019; private information to the risk of financial or medical identity theft or expose us or such persons to a risk of loss or misuse of this information, result in litigation and potential liability for us, damage our brand and reputation or otherwise harm our business. Any of these disruptions or breaches of security could have a material adverse effect on our business, financial condition, and results of operations.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b><i>Our failure to comply with foreign data protection laws and regulations could lead to government enforcement actions and significant penalties against us, and adversely impact our operating results.</i></b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">European Union member states and other foreign jurisdictions, including Switzerland, have adopted data protection laws and regulations which impose significant compliance obligations. Moreover, the collection and use of personal health data in the European Union, which was formerly governed by the provisions of the European Union Data Protection Directive, was replaced with the European Union General Data Protection Regulation, or the GDPR, in May 2018. The GDPR, which is wide-ranging in scope, imposes several requirements relating to the consent of the individuals to whom the personal data relates, the information provided to the individuals, the security and confidentiality of the personal data, data breach notification and the use of third party processors in connection with the processing of personal data. The GDPR also imposes strict rules on the transfer of personal data out of the European Union to the U.S., provides an enforcement authority and imposes large penalties for noncompliance, including the potential for fines of up to &#x20AC;20 million or 4% of the annual global revenues of the non-compliant company, whichever is greater. The recent implementation of the GDPR has increased our responsibility and liability in relation to personal data that we process, including in clinical trials, and we may in the future be required to put in place additional mechanisms to ensure compliance with the GDPR, which could divert management's attention and increase our cost of doing business. In addition, new regulation or legislative actions regarding data privacy and security (together with applicable industry standards) may increase our costs of doing business. In this regard, we expect that there will continue to be new proposed laws, regulations and industry standards relating to privacy and data protection in the U.S., the European Union and other jurisdictions, and we cannot determine the impact such future laws, regulations and standards may have on our business.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b><i>Our employees and business partners may not appropriately secure and protect confidential information in their possession.</i></b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Each of our employees and business partners is responsible for the security of the information in our systems or under our control and to ensure that private and financial information is kept confidential. Should an employee or business partner not follow appropriate security measures, including those related to cyber threats or attacks or other tactics, as well as our privacy and security policies and procedures, the improper release of personal information, including PHI, or confidential business or financial information, or misappropriation of assets could result. The release of such information or misappropriation of assets could have a material adverse effect on our business, financial condition, and results of operations.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b><i>Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading.</i></b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include intentional failures to comply with FDA regulations, to provide accurate information to the FDA, to comply with federal and state healthcare fraud and abuse laws and regulations, to report financial information or data accurately, or to disclose unauthorized activities to us. In particular, sales, marketing, and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing, and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs, and other business arrangements. Employee misconduct could also involve the improper use of information obtained during clinical trials, which could result in regulatory sanctions and serious harm to our reputation. We have adopted a Code of Conduct and Ethics, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <!-- Field: Page; Sequence: 45; Value: 1-->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt">
        <p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">
            <!-- Field: Sequence; Type: Arabic; Name: PageNo-->45<!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&#160;</p>
    </div>
    <!-- Field: /Page -->
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
        <span style="font: 10pt Times New Roman, Times, Serif"><b><i>Risks Related to our Intellectual Property</i></b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b><i>Another party could develop competing pharmaceutical products and obtain FDA regulatory exclusivity in the U.S. before we do, potentially preventing our ability to commercialize our pharmaceutical products and other products in development.</i></b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">We plan to seek to obtain market exclusivity for our pharmaceutical products and any other pharmaceutical product candidates we develop in the future. To the extent that patent protection is not available or has expired, FDA exclusivity may be the only available form of exclusivity available for these proposed products. These FDA exclusivities can delay the submission or the approval of certain drug applications. Potentially competitive products may also be seeking FDA exclusivities and may be in various stages of development, including some more advanced than us. We cannot predict with certainty the timing of FDA approval or whether FDA approval will be granted, nor can we predict with certainty the timing of FDA approval for competing products or whether such approval will be granted. It is possible that competing products may obtain FDA approval with exclusivities before we do, which could delay our ability to submit an application or obtain necessary regulatory approvals, result in lost market opportunities with respect to our pharmaceutical product candidates, and materially adversely affect our business, financial condition, and results of operations.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b><i>If our efforts to protect the proprietary nature of the intellectual property covering our hormone therapy pharmaceutical products and other products are not adequate, we may not be able to compete effectively in our market.</i></b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Our commercial success will depend in part on our ability to obtain additional patents and protect our existing patent positions as well as our ability to maintain adequate protection of other intellectual property for our hormone therapy pharmaceutical products and other products. If we do not adequately protect our intellectual property, competitors may be able to use our technologies and erode or negate any competitive advantage we may have, which could harm our business and ability to achieve profitability. The patent positions of pharmaceutical companies are highly uncertain. The legal principles applicable to patents are in transition due to changing court precedent and legislative action, and we cannot be certain that the historical legal standards surrounding questions of validity will continue to be applied or that current defenses relating to issued patents in these fields will be sufficient in the future. Changes in patent laws in the U.S., such as the America Invents Act of 2011, may affect the scope, strength, and enforceability of our patent rights or the nature of proceedings that may be brought by us related to our patent rights. In addition, the laws of some foreign countries do not protect proprietary rights to the same extent as the laws of the U.S., and we may encounter significant problems in protecting our proprietary rights in these countries. We will be able to protect our proprietary rights from unauthorized use by third parties only to the extent that our proprietary technologies are covered by valid and enforceable patents or are effectively maintained as trade secrets.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">These risks include the possibility of the following:</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">the patent applications that we have filed may fail to result in issued patents in the U.S. or in foreign jurisdictions;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">patents issued or licensed to us or our partners may be challenged or discovered to have been issued on the basis of insufficient, incomplete, or incorrect information, and thus held to be invalid or unenforceable;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">the scope of any patent protection may be too narrow to exclude competitors from developing or designing around these patents;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">we or our licensors were not the first to make the inventions covered by each of our issued patents and pending patent applications;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">we or our licensors may not have been the first inventors to invent or file patent applications for these technologies in the U.S. or were not the first to file patent applications directed to these technologies abroad;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">we may fail to comply with procedural, documentary, fee payment, and other similar provisions during the patent application process, which can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">future pharmaceutical product candidates may not be patentable;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">others may claim rights or ownership regarding patents and other proprietary rights that we hold or license;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">delays in development, testing, clinical trials, and regulatory review may reduce the period during which we could market our pharmaceutical products under patent protection; and</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">we may fail to timely apply for patents on our technologies or products.</span>
            </td>
        </tr>
    </table>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0; margin-right: 0; margin-top: 0">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">While we apply for patents covering our technologies and products, as we deem appropriate, many third parties may already have filed patent applications or have received patents in our areas of product development. These entities&#x2019; applications, patents, and other intellectual property rights may conflict with patent applications to which we have rights and could prevent us from obtaining patents or could call into question the validity of any of our patents, if issued, or could otherwise adversely affect our ability to develop, manufacture, or commercialize our pharmaceutical products. In addition, if third parties file patent applications in the technologies that also claim technology to which we have rights, we may have to participate in interference, derivation, or other proceedings with the USPTO or foreign patent regulatory authorities to determine our rights in the technologies, which may be time-consuming and expensive. Moreover, issued patents may be challenged in the courts or in post-grant proceedings at the USPTO, or in similar proceedings in foreign countries. These proceedings may result in loss of patent claims or adverse changes to the scope of the claims.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <!-- Field: Page; Sequence: 46; Value: 1-->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt">
        <p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">
            <!-- Field: Sequence; Type: Arabic; Name: PageNo-->46<!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&#160;</p>
    </div>
    <!-- Field: /Page -->
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">If we, our licensors, or our strategic partners fail to obtain and maintain patent protection for our products, or our proprietary technologies and their uses, companies may be dissuaded from collaborating with us. In such event, our ability to commercialize our pharmaceutical products may be threatened, we could lose our competitive advantage, and the competition we face could increase, all of which could adversely affect our business, financial condition, results of operations, and prospects.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition, mechanisms exist in much of the world permitting some form of challenge by generic drug marketers to our patents before, or immediately following, the expiration of any regulatory exclusivity, and generic companies are increasingly employing aggressive strategies, such as &#x201C;at risk&#x201D; launches to challenge relevant patent rights.On February 20, 2020, we received the Notice Letter regarding an ANDA submitted to the FDA by Teva. The ANDA seeks approval from the FDA to commercially manufacture, use, or sell a generic version of the 4 mcg and 10 mcg doses of IMVEXXY. In the Notice Letter, Teva alleges that IMVEXXY Patents listed in the FDA&#x2019;s Orange Book that claim compositions and methods of IMVEXXY are invalid, unenforceable, and/or will not be infringed by Teva&#x2019;s commercial manufacture, use, or sale of its proposed generic drug product. The IMVEXXY Patents identified in the Notice Letter expire in 2032 or 2033. We are currently reviewing the Notice Letter and intend to vigorously enforce our intellectual property rights relating to IMVEXXY. Under the Hatch-Waxman Act, we have 45 days from receipt of the Notice Letter to initiate a patent infringement lawsuit against Teva. Such a lawsuit would automatically preclude the FDA from approving Teva&#x2019;s ANDA until the earlier of 30 months or entry of a district court decision finding the IMVEXXY Patents invalid, unenforceable, or not infringed. We cannot assure you that any patent infringement lawsuit that we may file will prevent the introduction of a generic version of IMVEXXY for any particular length of time, or at all. If Teva&#x2019;s ANDA is approved, and a generic version of IMVEXXY is introduced, our sales of IMVEXXY could be adversely affected. In addition, we cannot predict what additional ANDAs could be filed by Teva or other potential generic competitors requesting approval to market generic forms of our products, which could require us to incur significant additional expense and result in distraction for our management team, and if approved, result in significant decreases in the revenue derived from sales of our marketed products and thereby materially harm our business and financial condition.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Our business also may rely on unpatented proprietary technology, know-how, and trade secrets. If the confidentiality of this intellectual property is breached, it could adversely impact our business.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b><i>If we are sued for infringing intellectual property rights of third parties, litigation will be costly and time consuming and could prevent or delay us from developing or commercializing our pharmaceutical product candidates.</i></b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Our commercial success depends, in part, on our not infringing the patents and proprietary rights of other parties and not breaching any collaboration or other agreements we have entered into with regard to our technologies and products. We are aware of numerous third-party U.S. and non-U.S. issued patents and pending applications that exist in the technical areas of our pharmaceutical products, including compounds, formulations, treatment methods, and synthetic processes, which may be applied towards the synthesis of hormones, for example. Patent applications are confidential when filed and remain confidential until publication, approximately 18 months after initial filing, while some patent applications remain unpublished until issuance. As such, there may be other third-party patents and pending applications of which we are currently unaware with claims directed towards composition of matter, formulations, methods of manufacture, or methods for treatment related to the use or manufacture of our products or product candidates. Therefore, we cannot ever know with certainty the nature or existence of every third-party patent filing. We cannot provide assurances that we or our partners will be free to manufacture or market our product candidates as planned or that we or our licensors&#x2019; and partners&#x2019; patents will not be opposed or litigated by third parties. If any third-party patent was held by a court of competent jurisdiction to cover aspects of our materials, formulations, methods of manufacture, or methods of treatment related to the use or manufacture of any of our product candidates, the holders of any such patent may be able to block our ability to develop and commercialize the applicable product candidate unless we obtained a license or until such patent expires or is finally determined to be held invalid or unenforceable. There can be no assurances that we will be able to obtain a license to such patent on favorable terms or at all. Failure to obtain such license may have a material adverse effect on our business.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">There is a substantial amount of litigation involving intellectual property in the pharmaceutical industry generally. If a third party asserts that we infringe its patents or other proprietary rights, we could face many risks that could adversely affect our business, financial condition, results of operations, and prospects, including the following:</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">infringement and other intellectual property claims, which would be costly and time-consuming to defend, whether or not we are ultimately successful, which in turn could delay the regulatory approval process, consume our capital, and divert management&#x2019;s attention from our business;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">substantial damages for past infringement, which we may have to pay if a court determines that our products or technologies infringe a competitor&#x2019;s patent or other proprietary rights;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">a court prohibiting us from selling or licensing our technologies or future products unless the third party licenses its patents or other proprietary rights to us on commercially reasonable terms, which it is not required to do;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">if a license is available from a third party, we may have to pay substantial royalties or lump sum payments or grant cross licenses to our patents or other proprietary rights to obtain that license; or</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">redesigning our products so they do not infringe, which may not be possible or may require substantial monetary expenditures and time.</span>
            </td>
        </tr>
    </table>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0; margin-right: 0; margin-top: 0">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">We are party from time-to-time to legal proceedings relating to our intellectual property, and third parties in the future may file claims asserting that our technologies, processes, or products infringe on their intellectual property. We cannot predict whether third parties will assert these claims against us or our strategic partners or against the licensors of technology licensed to us, or whether those claims will harm our business. In addition, the outcome of intellectual property litigation is subject to uncertainties that cannot be adequately quantified in advance. If we or our partners were to face infringement claims or challenges by third parties relating to our pharmaceutical product candidates, an adverse outcome could subject us to significant liabilities to such third parties, and force us or our partners to curtail or cease the development of some or all of our pharmaceutical product candidates, which could adversely affect our business, financial condition, results of operations, and prospects.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <!-- Field: Page; Sequence: 47; Value: 1-->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt">
        <p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">
            <!-- Field: Sequence; Type: Arabic; Name: PageNo-->47<!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&#160;</p>
    </div>
    <!-- Field: /Page -->
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b><i>We may be required to file lawsuits or take other actions to protect or enforce our patents or the patents of our licensors, which could be expensive and time-consuming.</i></b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Competitors may infringe our patents or the patents of our licensors. To counter infringement or unauthorized use, we may be required to file infringement claims, including with respect to Teva's ANDA and Notice Letter, which can be expensive and time-consuming. Moreover, there can be no assurance that we will have sufficient financial or other resources to file and pursue such infringement claims, which typically last for years before they are concluded. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to pharmaceuticals, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">In addition, in an infringement proceeding, a court may decide that a patent of ours or our licensors is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents, or those of our licensors, do not cover the technology in question or on other grounds. An adverse result in any litigation or defense proceedings could put one or more of our patents, or those of our licensors, at risk of being invalidated, held unenforceable, or interpreted narrowly and could put our patent applications, or those of our licensors, at risk of not issuing. Moreover, we may not be able to prevent, alone or with our licensors, misappropriation of our proprietary rights, particularly in countries in which the laws may not protect those rights as fully as in the U.S. or in those countries in which we do not file national phase patent applications. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, if securities analysts or investors perceive public announcements of the results of hearings, motions, or other interim proceedings or developments to be negative, the price of our common stock could be adversely affected. The occurrence of any of the above could adversely affect our business, financial condition, results of operations, and prospects.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
        <span style="font: 10pt Times New Roman, Times, Serif"><b><i>If we are unable to protect the confidentiality of certain information, the value of our products and technology could be materially adversely affected.</i></b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">We also rely on trade secrets, know-how, and continuing technological advancement to develop and maintain our competitive position. To protect this competitive position, we regularly enter into confidentiality and proprietary information agreements with third parties, including employees, independent contractors, suppliers, and collaborators. We cannot, however, ensure that these protective arrangements will be honored by third parties, and we may not have adequate remedies if these arrangements are breached. In addition, enforcement of claims that a third party has illegally obtained and is using trade secrets, know-how, or technological advancements is expensive, time-consuming, and uncertain. Non-U.S. courts are sometimes less willing than U.S. courts to protect this information. Moreover, our trade secrets, know-how, and technological advancements may otherwise become known or be independently developed by competitors in a manner providing us with no practical recourse against the competing parties. If any such events were to occur, they could adversely affect our business, financial condition, results of operations, and prospects.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b><i>We may be subject to claims that our employees have wrongfully used or disclosed alleged trade secrets of their former employers or of other third parties with whom we have obligations of confidentiality.</i></b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">As is common in the pharmaceutical industry, we employ individuals who were previously employed at other biotechnology or pharmaceutical companies, including our competitors or potential competitors. We may be subject to claims that these employees, or we, have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers. Litigation may be necessary to defend against these claims. Such claims may lead to material costs for us, or an inability to protect or use valuable intellectual property rights, which could adversely affect our business, financial condition, results of operations, and prospects.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
        <span style="font: 10pt Times New Roman, Times, Serif"><b><i>Risks Related to Ownership of Our Common Stock</i></b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b><i>The market price of our common stock may be highly volatile, and you could lose all or part of your investment.</i></b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">The trading price of our common stock on Nasdaq is likely to be volatile. This volatility may prevent you from being able to sell your shares at or above the price you paid for your shares. Our stock price could be subject to wide fluctuations in response to a variety of factors, which include the following:</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">changes in laws or regulations applicable to our products or proposed products, including clinical trial requirements for approvals;</span>
            </td>
        </tr>
    </table>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0; margin-right: 0; margin-top: 0">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <!-- Field: Page; Sequence: 48; Value: 1-->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt">
        <p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">
            <!-- Field: Sequence; Type: Arabic; Name: PageNo-->48<!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&#160;</p>
    </div>
    <!-- Field: /Page -->
    <p style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0; margin-right: 0; margin-top: 0">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">unanticipated serious safety concerns related to the use of our products;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">a decision to initiate a clinical trial, not to initiate a clinical trial, or to terminate an existing clinical trial;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">adverse results or delays in clinical trials;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">the inability to obtain adequate supply for our products or the inability to do so at acceptable prices;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">adverse regulatory decisions;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">the introduction of new products or technologies offered by us or our competitors;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">the effectiveness of our or our licensees&#x2019; commercialization efforts;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">the perception of the pharmaceutical industry by the public, legislatures, regulators, and the investment community;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">disputes or other developments relating to proprietary rights, including patents, litigation matters, and our ability to obtain patent protection for our technologies;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">the inability to effectively manage our growth;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">actual or anticipated variations in quarterly operating results;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">the failure to meet or exceed the estimates and projections of the investment community;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">the overall performance of the U.S. equity markets and general political and economic conditions;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">announcements of significant acquisitions, strategic partnerships, joint ventures, or capital commitments by us or our competitors;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">additions or departures of key scientific or management personnel;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">adverse market reaction to any indebtedness we may incur or securities we may issue in the future;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">sales of our common stock by us or our stockholders in the future;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">significant lawsuits, including patent or stockholder litigation;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">changes in the market valuations of similar companies;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">the trading volume of our common stock;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">increases in our common stock available for sale upon expiration of lock-up agreements;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">effects of natural or man-made catastrophic events or other business interruptions; and</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">other events or factors, many of which are beyond our control.</span>
            </td>
        </tr>
    </table>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0; margin-right: 0; margin-top: 0">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">In addition, the stock market in general and the stock of biotechnology companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b><i>Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.</i></b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">As of December 31, 2019, our executive officers, directors, holders of 5% or more of our stock, and their affiliates beneficially owned approximately 51% of our common stock, inclusive of vested options and warrants to acquire shares of our common stock. These stockholders may be able to determine the outcome of all matters requiring stockholder approval. For example, these stockholders may be able to control elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may feel are in your best interest as one of our stockholders.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b><i>If we fail to maintain proper internal controls, our ability to produce accurate financial statements or comply with applicable regulations could be impaired.</i></b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Pursuant to Section 404 of the Sarbanes-Oxley Act, our management is required annually to deliver a report that assesses the effectiveness of our internal control over financial reporting and our independent registered public accounting firm is required annually to deliver an attestation report on the effectiveness of our internal control over financial reporting. If we are unable to maintain effective internal control over financial reporting or if our independent auditors are unwilling or unable to provide us with an attestation report on the effectiveness of internal control over financial reporting for future periods as required by Section 404 of the Sarbanes-Oxley Act, we may not be able to produce accurate financial statements, and investors may therefore lose confidence in our operating results, our stock price could decline and we may be subject to litigation or regulatory enforcement actions.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b><i>If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.</i></b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">The trading market for our common stock will depend in part on the research and reports that securities or industry analysts publish about us or our business. If one or more of the analysts who cover us downgrade our stock or publish inaccurate or unfavorable research about our business, our stock price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which might cause our stock price and trading volume to decline.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <!-- Field: Page; Sequence: 49; Value: 1-->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt">
        <p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">
            <!-- Field: Sequence; Type: Arabic; Name: PageNo-->49<!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&#160;</p>
    </div>
    <!-- Field: /Page -->
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
        <span style="font: 10pt Times New Roman, Times, Serif"><b><i>Future sales and issuances of equity securities, convertible securities or other securities could result in additional dilution of the percentage ownership of holders of our common stock.</i></b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Our stockholders may experience dilution upon future equity issuances, including convertible debt or equity securities we may issue in the future, the exercise of stock options to purchase common stock granted to our employees, consultants and directors, including options to purchase common stock granted under our stock option and equity incentive plans or the issuance of common stock in settlement of previously issued awards under our stock option and equity incentive plans that may vest in the future.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that additional capital will be needed in the future to continue our planned operations. To raise capital, we may sell
equity securities, convertible securities or other securities in one or more transactions at prices and in a manner we determine
from time to time. If we sell equity securities, convertible securities or other securities current investors may be materially
diluted by subsequent sales. We may also need our stockholders to authorize the issuance of additional shares of common stock
under our articles of incorporation if we do not have sufficient authorized shares to raise such additional capital or issue future
awards under our stock option and equity incentive plans. New investors could also gain rights, preferences and privileges senior
to those of holders of our existing equity securities.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b><i>We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock.</i></b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">We have never declared or paid any cash dividends on our common stock. We currently anticipate that we will retain any future earnings for the development, operation, and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. In addition, the terms of the Financing Agreement preclude us from paying dividends, and any future debt agreements may also preclude us from paying dividends. Any return to stockholders will be limited to the capital appreciation, if any, of their stock.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b><i>Some provisions of our charter documents and Nevada law may have anti-takeover effects that could discourage an acquisition of us by others, even if an acquisition would be beneficial to our stockholders and may prevent attempts by our stockholders to replace or remove our current management.</i></b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Provisions in our articles of incorporation and bylaws, as well as certain provisions of Nevada law, could make it more difficult for a third party to acquire us or increase the cost of acquiring us, even if an acquisition would benefit our stockholders, and could also make it more difficult to remove our current management. These provisions in our articles of incorporation and bylaws include the following:</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">authorizing the issuance of &#x201C;blank check&#x201D; preferred stock that could be issued by our board of directors to increase the number of outstanding shares and thwart a takeover attempt;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">prohibiting cumulative voting in the election of directors, which would otherwise allow less than a majority of stockholders to elect director candidates; and</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">advance notice provisions in connection with stockholder proposals that may prevent or hinder any attempt by our stockholders to bring business to be considered by our stockholders at a meeting or replace our board of directors.</span>
            </td>
        </tr>
    </table>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0; margin-right: 0; margin-top: 0">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">In addition, we are subject to Nevada&#x2019;s Combination with Interested Stockholders statute (Nevada Revised Statute Sections 78.411 - 78.444), which prohibits an &#x201C;interested stockholder&#x201D; from entering into a &#x201C;combination&#x201D; with a company, unless certain conditions are met. An &#x201C;interested stockholder&#x201D; is a person who, together with affiliates and associates, beneficially owns (or within the prior two years, did beneficially own) 10% or more of the corporation&#x2019;s capital stock entitled to vote.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="vertical-align: top; text-align: justify">
            <td style="width: 0in"></td>
            <td style="width: 1in; text-align: left">
                <span style="font: 10pt Times New Roman, Times, Serif"><b>Item 1B</b></span>
            </td>
            <td style="text-align: justify"><span id="txmd10ka004"></span>
                <span style="font: 10pt Times New Roman, Times, Serif"><b>Unresolved Staff Comments</b></span>
            </td>
        </tr>
    </table>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">None.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="vertical-align: top; text-align: justify">
            <td style="width: 0in"></td>
            <td style="width: 1in; text-align: left">
                <span style="font: 10pt Times New Roman, Times, Serif"><b>Item 2.</b></span>
            </td>
            <td style="text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif"><b><span id="txmd10ka005"></span>Properties</b></span>
            </td>
        </tr>
    </table>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #212529; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">In October 2018, we entered into a lease for new corporate headquarter offices in Boca Raton, Florida. The lease includes 56,212 rentable square feet, or the full premises, of which the lease on 7,561 square feet commenced in 2018 and the lease on the remaining 48,651 square feet commenced in August 2019, or the full premises commencement date. The lease will expire 11 years after the full premises commencement date, unless terminated earlier in accordance with the terms of the lease. We have the option to extend the term of the lease for two additional consecutive periods of five years. The extension option is not included in the determination of the lease term as it is not reasonably certain to be exercised. The term of the lease includes escalating rent and free rent periods. We are also responsible for certain other operating costs under the lease, including electricity and utility expenses. In June 2019, we entered into an agreement with the same lessors to lease additional 6,536 square feet of administrative office space in the same location, pursuant to an addendum to such lease, which is expected to commence as soon as the first quarter of 2020.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #212529; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <!-- Field: Page; Sequence: 50; Value: 1-->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt">
        <p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">
            <!-- Field: Sequence; Type: Arabic; Name: PageNo-->50<!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&#160;</p>
    </div>
    <!-- Field: /Page -->
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #212529; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="vertical-align: top; text-align: justify">
            <td style="width: 0in"></td>
            <td style="width: 1in; text-align: left">
                <span style="font: 10pt Times New Roman, Times, Serif"><b>Item 3.</b></span>
            </td>
            <td style="text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif"><b><span id="txmd10ka006"></span>Legal Proceedings</b></span>
            </td>
        </tr>
    </table>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">From time to time, we are involved in litigation and proceedings in the ordinary course of our business. We are not currently involved in any legal proceeding that we believe would have a material effect on our business or financial condition.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="vertical-align: top; text-align: justify">
            <td style="width: 0in"></td>
            <td style="width: 1in; text-align: left">
                <span style="font: 10pt Times New Roman, Times, Serif"><b>Item 4.</b></span>
            </td>
            <td style="text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif"><b><span id="txmd10ka007"></span>Mine Safety Disclosures</b></span>
            </td>
        </tr>
    </table>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Not applicable.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
        <span style="font: 10pt Times New Roman, Times, Serif"><b><span id="txmd10ka008"></span>PART II</b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 1in">
                <span style="font: 10pt Times New Roman, Times, Serif"><b>Item 5.</b></span>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif">
                <span style="font: 10pt Times New Roman, Times, Serif"><b><span id="txmd10ka009"></span>Market for Registrant&#x2019;s Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities</b></span>
            </td>
        </tr>
    </table>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0; margin-right: 0; margin-top: 0">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
        <span style="font: 10pt Times New Roman, Times, Serif"><b>Market Information on Common Stock</b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Since October 9, 2017, our common stock has been listed on the Nasdaq Global Select Market of the Nasdaq Stock Market LLC under the symbol &#x201C;TXMD.&#x201D; From April 23, 2013 to October 6, 2017, our common stock was listed on the NYSE American under the symbol &#x201C;TXMD.&#x201D; Before that time, our common stock was quoted on the OTCQB.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">As of February 3, 2020, there were approximately 192 record holders and 25,445 beneficial owners of our common stock.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b>Dividends</b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Historically, we have not paid dividends on our common stock, and we currently do not intend to pay any dividends on our common stock in the foreseeable future. We currently plan to retain any earnings to finance the growth of our business rather than to pay cash dividends. Payments of any cash dividends in the future will depend on our financial condition, results of operations, and capital requirements as well as other factors deemed relevant by our board of directors. In addition, the Credit Agreement contains covenants that limit our ability to pay dividends or make other distributions on our common stock.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b>Performance Graph </b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">The following line graph compares cumulative total stockholder return for the five years ended December 31, 2019 for (i) our common stock; (ii) Nasdaq Pharmaceutical Index; and (iii) Nasdaq Stock Market (U.S. companies). The graph assumes $100 invested on December 31, 2014 and includes reinvestment of dividends. Measurement points are at December 31, 2014 and the last trading day of the fiscal years ended December 31, 2015, 2016, 2017, 2018, and 2019. The stock price performance on the following graph is not necessarily indicative of future stock price performance.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; color: red; margin-bottom: 0; margin-top: 0; text-align: center"><img alt="" src="txmd10k001.jpg" /></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: red; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <!-- Field: Page; Sequence: 51; Value: 1-->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt">
        <p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">
            <!-- Field: Sequence; Type: Arabic; Name: PageNo-->51<!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&#160;</p>
    </div>
    <!-- Field: /Page -->
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: red; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">The following line graph compares cumulative total stockholder return for the five years ended December 31, 2019 for (i) our common stock; (ii) Nasdaq Pharmaceutical Index; and (iii) Nasdaq Stock Market (U.S. companies). The graph assumes $100 invested on December 31, 2014 and includes reinvestment of dividends. Measurement points are December 31, 2014 and the last trading day of the fiscal years ended December 31, 2019, 2018, 2017, 2016, and 2015 and each of the following quarters ended therein. The stock price performance on the following graph is not necessarily indicative of future stock price performance.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; color: red; margin-bottom: 0; margin-top: 0; text-align: center"><img alt="" src="txmd10k002.jpg" /></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: red; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">The performance graphs shall not be deemed &#x201C;filed&#x201D; for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that section. The performance graphs will not be deemed incorporated by reference into any filing of our company under the Exchange Act or the Securities Act of 1933, as amended, or the Securities Act.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b>Recent Sales of Unregistered Equity Securities </b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">During the year ended December 31, 2019, warrants to purchase an aggregate of 1,250,000 shares of our common stock that were previously issued to an outside service provider were exercised pursuant to the warrants&#x2019; cashless exercise provisions, which resulted in 471,184 shares of our common stock being issued. The shares of common stock were issued in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <!-- Field: Page; Sequence: 52; Value: 1-->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt">
        <p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">
            <!-- Field: Sequence; Type: Arabic; Name: PageNo-->52<!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&#160;</p>
    </div>
    <!-- Field: /Page -->
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="vertical-align: top; text-align: justify">
            <td style="width: 0in"></td>
            <td style="width: 1in; text-align: left">
                <span style="font: 10pt Times New Roman, Times, Serif"><b>Item 6.</b></span>
            </td>
            <td style="text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif"><b><span id="txmd10ka010"></span>Selected Financial Data</b></span>
            </td>
        </tr>
    </table>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">The following table sets forth selected consolidated financial and other data as of and for the periods indicated. You should read the following information together with the more detailed information contained in &#x201C;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations&#x201D; and our consolidated financial statements and the related notes included elsewhere in this Annual Report. The consolidated statements of operations for the years ended December 31, 2019, 2018, and 2017 and the consolidated balance sheet data as of December 31, 2019 and 2018 are derived from our audited consolidated financial statements included in this Annual Report. The consolidated statements of operations for the years ended December 31, 2016 and 2015, and the consolidated balance sheet data as of December 31, 2017, 2016, and 2015 are derived from our audited consolidated financial statements not included in this Annual Report.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0; margin-top: 0; text-align: center">
        <span style="font: 10pt Times New Roman, Times, Serif"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0; margin-top: 0; text-align: center">
        <span style="font: 10pt Times New Roman, Times, Serif"><b>(in thousands, except per share data)</b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
        <tr style="vertical-align: bottom">
            <td style="padding-left: 15pt; text-align: justify; text-indent: -10pt">&#160;</td>
            <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
            <td colspan="18" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Year Ended December 31,</td>
            <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
        </tr>
        <tr style="vertical-align: bottom">
            <td style="border-bottom: Black 1pt solid; padding-left: 15pt; text-align: justify; text-indent: -10pt; font-weight: bold">Consolidated Statements of Operations Data</td>
            <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2019</td>
            <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
            <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2018</td>
            <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
            <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2017</td>
            <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
            <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2016</td>
            <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
            <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2015</td>
            <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="padding-left: 15pt; width: 35%; text-align: justify; text-indent: -10pt">Product revenue, net</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">$</td>
            <td style="width: 10%; text-align: right">34,141</td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">$</td>
            <td style="width: 10%; text-align: right">16,099</td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">$</td>
            <td style="width: 10%; text-align: right">16,778</td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">$</td>
            <td style="width: 10%; text-align: right">19,356</td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">$</td>
            <td style="width: 10%; text-align: right">20,143</td>
            <td style="width: 1%; text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td style="padding-left: 15pt; text-align: justify; text-indent: -10pt">License revenue</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">15,506</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#x2014;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#x2014;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#x2014;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#x2014;</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="padding-bottom: 1pt; padding-left: 15pt; text-align: justify; text-indent: -10pt">Cost of goods sold</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">6,335</td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">2,737</td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">2,637</td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">4,185</td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">4,506</td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td style="padding-bottom: 1pt; padding-left: 15pt; text-align: justify; text-indent: -10pt">Gross profit</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">43,312</td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">13,362</td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">14,141</td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">15,171</td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">15,637</td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="padding-left: 15pt; text-align: justify; text-indent: -10pt">Operating expenses:</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td style="padding-left: 15pt; text-align: justify; text-indent: -10pt">Sales, general, and administration</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">174,113</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">115,989</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">57,703</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">51,348</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">28,721</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="padding-left: 15pt; text-align: justify; text-indent: -10pt">Research and development</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">19,792</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">27,299</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">33,853</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">53,943</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">72,043</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td style="padding-bottom: 1pt; padding-left: 15pt; text-align: justify; text-indent: -10pt">Depreciation and amortization</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">613</td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">294</td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">213</td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">133</td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">63</td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="padding-bottom: 1pt; padding-left: 15pt; text-align: justify; text-indent: -10pt">Total operating expense</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">194,518</td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">143,582</td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">91,769</td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">105,424</td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">100,827</td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td style="padding-left: 15pt; text-align: justify; text-indent: -10pt">Operating loss</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">(151,206</td>
            <td style="text-align: left">)</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">(130,220</td>
            <td style="text-align: left">)</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">(77,628</td>
            <td style="text-align: left">)</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">(90,253</td>
            <td style="text-align: left">)</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">(85,190</td>
            <td style="text-align: left">)</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="padding-bottom: 1pt; padding-left: 15pt; text-align: justify; text-indent: -10pt">Other (expense) income, net</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">(24,939</td>
            <td style="padding-bottom: 1pt; text-align: left">)</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">(2,397</td>
            <td style="padding-bottom: 1pt; text-align: left">)</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">703</td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">378</td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">113</td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td style="padding-bottom: 2pt; padding-left: 15pt; text-align: justify; text-indent: -10pt">Net loss</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: left">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right">(176,145</td>
            <td style="padding-bottom: 2pt; text-align: left">)</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: left">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right">(132,617</td>
            <td style="padding-bottom: 2pt; text-align: left">))</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: left">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right">(76,925</td>
            <td style="padding-bottom: 2pt; text-align: left">)</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: left">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right">(89,875</td>
            <td style="padding-bottom: 2pt; text-align: left">)</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: left">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right">(85,077</td>
            <td style="padding-bottom: 2pt; text-align: left">)</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="padding-left: 15pt; text-align: justify; text-indent: -10pt">Net loss per share, basic and diluted</td>
            <td>&#160;</td>
            <td style="text-align: left">$</td>
            <td style="text-align: right">(0.72</td>
            <td style="text-align: left">)</td>
            <td>&#160;</td>
            <td style="text-align: left">$</td>
            <td style="text-align: right">(0.59</td>
            <td style="text-align: left">)</td>
            <td>&#160;</td>
            <td style="text-align: left">$</td>
            <td style="text-align: right">(0.37</td>
            <td style="text-align: left">)</td>
            <td>&#160;</td>
            <td style="text-align: left">$</td>
            <td style="text-align: right">(0.46</td>
            <td style="text-align: left">)</td>
            <td>&#160;</td>
            <td style="text-align: left">$</td>
            <td style="text-align: right">(0.49</td>
            <td style="text-align: left">)</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td style="padding-left: 15pt; text-align: justify; text-indent: -10pt">Weighted average number of common shares outstanding, basic and diluted</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">246,353</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">225,026</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">205,523</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">196,088</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">173,174</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="padding-left: 15pt; text-align: justify; text-indent: -10pt">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; padding-left: 5pt; text-align: justify">
                <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0">
                    <span style="font: 10pt Times New Roman, Times, Serif"><b>Consolidated Balance Sheet Date</b></span>
                </p>
                <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in">
                    <span style="font: 10pt Times New Roman, Times, Serif"><b>(at end of period)</b></span>
                </p>
            </td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="padding-left: 15pt; text-align: justify; text-indent: -10pt">Total assets</td>
            <td>&#160;</td>
            <td style="text-align: left">$</td>
            <td style="text-align: right">265,986</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">$</td>
            <td style="text-align: right">211,984</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">$</td>
            <td style="text-align: right">143,230</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">$</td>
            <td style="text-align: right">142,472</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">$</td>
            <td style="text-align: right">73,729</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td style="padding-left: 15pt; text-align: justify; text-indent: -10pt">Total liabilities</td>
            <td>&#160;</td>
            <td style="text-align: left">$</td>
            <td style="text-align: right">256,785</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">$</td>
            <td style="text-align: right">114,460</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">$</td>
            <td style="text-align: right">13,321</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">$</td>
            <td style="text-align: right">14,983</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">$</td>
            <td style="text-align: right">10,666</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="padding-left: 15pt; text-align: justify; text-indent: -10pt">Total stockholders&#x2019; equity</td>
            <td>&#160;</td>
            <td style="text-align: left">$</td>
            <td style="text-align: right">9,201</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">$</td>
            <td style="text-align: right">97,524</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">$</td>
            <td style="text-align: right">129,909</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">$</td>
            <td style="text-align: right">127,489</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">$</td>
            <td style="text-align: right">63,063</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td style="padding-left: 15pt; text-align: justify; text-indent: -10pt; font-weight: bold">Other Data:</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="padding-left: 15pt; text-align: justify; text-indent: -10pt">Capital expenditures (for the period)</td>
            <td>&#160;</td>
            <td style="text-align: left">$</td>
            <td style="text-align: right">3,892</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">$</td>
            <td style="text-align: right">1,322</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">$</td>
            <td style="text-align: right">827</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">$</td>
            <td style="text-align: right">1,241</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">$</td>
            <td style="text-align: right">584</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td style="padding-left: 15pt; text-align: justify; text-indent: -10pt">Working capital (at the end of the period)</td>
            <td>&#160;</td>
            <td style="text-align: left">$</td>
            <td style="text-align: right">155,411</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">$</td>
            <td style="text-align: right">145,700</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">$</td>
            <td style="text-align: right">126,233</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">$</td>
            <td style="text-align: right">124,428</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">$</td>
            <td style="text-align: right">60,014</td>
            <td style="text-align: left">&#160;</td>
        </tr>
    </table>
    <p style="margin-bottom: 0; margin-top: 0">&#160;</p>
    <!-- Field: Page; Sequence: 53; Value: 1-->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt">
        <p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">
            <!-- Field: Sequence; Type: Arabic; Name: PageNo-->53<!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&#160;</p>
    </div>
    <!-- Field: /Page -->
    <p style="margin-bottom: 0; margin-top: 0">&#160;</p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="vertical-align: top; text-align: justify">
            <td style="width: 0in"></td>
            <td style="width: 1in; text-align: left">
                <span style="font: 10pt Times New Roman, Times, Serif"><b>Item 7.</b></span>
            </td>
            <td style="text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif"><b><span id="txmd10ka011"></span>Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations</b></span>
            </td>
        </tr>
    </table>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif"><i>You should read the following discussion and analysis in conjunction with the information set forth under &#x201C;Selected Financial Data&#x201D; and our consolidated financial statements and the notes to those financial statements included elsewhere in this Annual Report. This discussion contains forward-looking statements based upon current expectations that involve risks and uncertainties. See &#x201C;Statement Regarding Forward-Looking Information.&#x201D; Our actual results may differ materially from those contained in or implied by any forward-looking statements as a result of various factors, including, but not limited to, the risks and uncertainties described under &#x201C;Risk Factors&#x201D; elsewhere in this Annual Report.</i></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b>Company Overview</b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">TherapeuticsMD is a women&#x2019;s healthcare company with a mission of creating and commercializing innovative products to support the lifespan of women from pregnancy prevention through menopause. At TherapeuticsMD, we combine entrepreneurial spirit, clinical expertise, and business leadership to develop and commercialize health solutions that enable new standards of care for women. Our solutions range from a patient-controlled, long-lasting contraceptive to advanced hormone therapy pharmaceutical products. We also have a portfolio of branded and generic prescription prenatal vitamins under the vitaMedMD and BocaGreenMD brands that furthers our women&#x2019;s healthcare focus.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Our portfolio of products focused on women&#x2019;s health allows us to efficiently leverage our sales and marketing plan to grow our recently approved products. During 2018, the U.S. Food and Drug Administration, or FDA, approval of our drugs has transitioned our company from predominately focused on conducting research and development to one focused on commercializing our drugs.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">In July 2018, we launched our FDA-approved product, IMVEXXY (estradiol vaginal inserts) for the treatment of moderate-to-severe dyspareunia (vaginal pain associated with sexual activity), a symptom of vulvar and vaginal atrophy, or VVA, due to menopause, which was approved by the FDA in May 2018.</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">In April 2019, we launched our FDA-approved product, BIJUVA (estradiol and progesterone) capsules, our hormone therapy combination of bio-identical 17&#xDF;-estradiol and bio-identical progesterone in a single, oral softgel capsule, for the treatment of moderate-to-severe vasomotor symptoms, or VMS, due to menopause in women with a uterus, which was approved by the FDA in October 2018.</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">In October 2019, we began a &#x201C;test and learn&#x201D; market introduction for our FDA-approved product ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system), the first and only patient-controlled, procedure-free, reversible prescription contraceptive option for women, which was approved by the FDA in
                    <span style="color: #212529">August 2018 and which we have licensed for commercialization in the U.S. pursuant to </span>an exclusive license agreement, or the Population Council License Agreement, with the Population Council, Inc., or the Population Council
                    <span style="color: #212529">. We expect the full commercial launch of ANNOVERA in the first quarter of 2020.</span>
                </span>
            </td>
        </tr>
    </table>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0; margin-right: 0; margin-top: 0">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">We have also entered into license agreements with strategic partners to commercialize IMVEXXY and BIJUVA outside of the U.S.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">In July 2018, we entered into a license and supply agreement with Knight Therapeutics Inc., or Knight, pursuant to which we granted Knight an exclusive license to commercialize IMVEXXY and BIJUVA in Canada and Israel.</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">In June 2019, we entered into an exclusive license and supply agreement, or the Theramex License Agreement, with Theramex HQ UK Limited, or Theramex, a leading, global specialty pharmaceutical company dedicated to women&#x2019;s health, to commercialize BIJUVA and IMVEXXY outside of the U.S., excluding Canada and Israel.</span>
            </td>
        </tr>
    </table>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0; margin-right: 0; margin-top: 0">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><i>Product Portfolio</i></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">We are focused on activities necessary for commercialization of IMVEXXY, BIJUVA and ANNOVERA. We continue to manufacture and distribute our prescription prenatal vitamin product lines, consisting of branded prenatal vitamins under vitaMedMD and authorized generic formulations of some of our prescription prenatal vitamin products under BocaGreenMD. All of our prenatal vitamins are&#160;</span>
        <span style="font: 10pt Times New Roman, Times, Serif">gluten-, sugar-, and lactose-free. A prenatal vitamin option that is both vegan and kosher is also available for women with special dietary needs. We believe our product attributes result in greater consumer acceptance and satisfaction than competitive products while offering the highest quality and patented ingredients.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif"><i>BIJUVA</i></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">In October 2018, the FDA approved BIJUVA (estradiol and progesterone) capsules, 1 mg/100 mg, the first and only FDA-approved bioidentical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate-to-severe VMS (commonly known as hot flashes or flushes) due to menopause in women with a uterus.&#160;The estrogen and progesterone in BIJUVA have the same chemical and molecular structure as the hormones that are naturally produced in a woman&#x2019;s body. We launched BIJUVA in April 2019.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <!-- Field: Page; Sequence: 54; Value: 1-->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt">
        <p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">
            <!-- Field: Sequence; Type: Arabic; Name: PageNo-->54<!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&#160;</p>
    </div>
    <!-- Field: /Page -->
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Following meetings with the FDA, we submitted a New Drug Application, or NDA, efficacy supplement for the 0.5/100 mg dose of BIJUVA to the FDA in late January 2020 for review and potential approval. The NDA efficacy supplement uses existing data from our Phase 3 REPLENISH trial for BIJUVA, for which we announced results in December 2016, together with additional information and analyses. The REPLENISH trial was the first time that a combination of bio-identical estradiol and bio-identical progesterone used in a continuous combined daily fashion demonstrated safety and efficacy data to support FDA-approval. We do not anticipate that the FDA will require any new clinical trials in connection with our submission of the NDA efficacy supplement, however, there is no assurance that will be the case. If accepted for review by the FDA, we expect that the NDA efficacy supplement will be reviewed, under current Prescription Drug User Fee Act timeline goals, within ten months of receipt by the FDA.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif"><i>IMVEXXY</i></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">In May 2018, the FDA approved the 4-&#x3BC;g and 10-&#x3BC;g doses of IMVEXXY (estradiol vaginal inserts) for the treatment of moderate-to-severe dyspareunia (vaginal pain associated with sexual activity), a symptom of VVA, due to menopause. The 4-&#x3BC;g formulation of IMVEXXY represents the lowest FDA-approved dose of vaginal estradiol available. IMVEXXY 10-&#x3BC;g became available for commercial distribution in July 2018 and both doses were commercially available by September 2018<i>.</i></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">As part of the FDA&#x2019;s approval of IMVEXXY, we have committed to conduct a post-approval observational study to evaluate the risk of endometrial cancer in post-menopausal women with a uterus who use a low-dose vaginal estrogen unopposed by a progestogen. In connection with the observational study, we are required to provide progress reports to the FDA on an annual basis. The development of this method is underway, and we do not believe that the costs will be material.&#160;In addition, the FDA asked for post-approval information with respect to certain characteristics related to the product&#x2019;s specifications, which we submitted to FDA in November 2018.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif"><i>ANNOVERA</i></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">In July 2018, we entered into an exclusive license agreement with the Population Council to commercialize in the U.S. ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system), the first and only patient-controlled, procedure-free, reversible prescription contraceptive that can prevent pregnancy for up to a total of 13 cycles (one year), which was approved by the FDA in August 2018. ANNOVERA was classified by the FDA as an NCE and thus has five years of regulatory exclusivity under the Drug Price Competition and Patent Term Restoration Act of 1984, otherwise known as the Hatch-Waxman Act.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">ANNOVERA is a one-year ring-shaped contraceptive vaginal system, or CVS. ANNOVERA, which is made with a silicone elastomer, contains segesterone acetate, a 19-nor progesterone derivative also known as SA and EE. EE is an approved active ingredient in many marketed hormonal contraceptive products. Segesterone acetate, an NCE, is a potent progestin and ANNOVERA is the only product with segesterone acetate. Segesterone acetate also does not bind to the androgen or estrogen receptors and has no glucocorticoid effects at contraceptive doses. SA has been evaluated in 51 clinical studies across these delivery systems with more than 26,794 cycles of exposure.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">ANNOVERA can be inserted and removed by the woman herself without the aid of a healthcare provider and, unlike oral contraceptives, or OCs, ANNOVERA does not require daily administration to obtain the contraceptive effect. After 21 days of use, the woman removes ANNOVERA for seven days, thereby providing a regular bleeding pattern (i.e., withdrawal/scheduled bleeding). The same CVS is then re-inserted for additional 21/7-days in/out, for up to a total of 13 cycles (one year).</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">ANNOVERA releases daily vaginal doses of both active ingredients (SA and EE). The claimed release rate of 150 &#x3BC;g/day SA and 13/day &#x3BC;g EE is supported by the calculated average release rate from an ex vivo analysis of ANNOVERA used for 13 cycles and is also supported by data from 13 cycles of in vitro release.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">As part of the approval of ANNOVERA, the FDA has required a post-approval observational study be performed to measure the risk of venous thromboembolism. In accordance with the post-marketing requirements, the full protocol for the study was submitted to the FDA in August 2019. We have agreed to perform and pay the costs and expenses associated with this post-approval study, provided that if the costs and expenses associated with such post-approval study exceed $20,000,000, half of such excess will offset against royalties or other payments owed by us to the Population Council under the Population Council License Agreement. Given the observational nature of the study, we do not believe that the costs of the study will be material on an annual basis. The Population Council has agreed to perform and pay the costs and expenses associated with two post-approval studies required by the FDA for ANNOVERA.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <!-- Field: Page; Sequence: 55; Value: 1-->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt">
        <p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">
            <!-- Field: Sequence; Type: Arabic; Name: PageNo-->55<!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&#160;</p>
    </div>
    <!-- Field: /Page -->
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">In October 2019, we began a &#x201C;test and learn&#x201D; market introduction phase of launch for ANNOVERA, with 36 of our existing sales representatives currently promoting ANNOVERA in addition to our other products, and our 23 regional sales managers and 12 compounding key account managers, or KAMs, introducing ANNOVERA to top targeted healthcare practitioners outside of these 36 territories. A full-scale launch of ANNOVERA is expected in the first quarter of 2020.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif"><i>License Agreement with the Population Council</i></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Under the terms of the Population Council License Agreement, we paid the Population Council a milestone payment of $20,000,000 within 30 days following approval by the FDA of the NDA for ANNOVERA. The first commercial batch of ANNOVERA was released during the third quarter of 2019 and we paid the Population Council $20,000,000 as a result of the commercial batch release. The Population Council is eligible to receive additional milestone payments and royalties from commercial sales of ANNOVERA, as detailed below.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">We assumed responsibility for marketing expenses related to the commercialization of ANNOVERA.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">We are required to pay the Population Council, on a quarterly basis, step-based royalty payments based on annual net sales of ANNOVERA in the U.S. by us and our affiliates and permitted sublicensees as follows:</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 80%; border-collapse: collapse; margin-right: auto">
        <tr style="vertical-align: bottom">
            <td style="border-bottom: Black 1pt solid; text-align: justify; font-weight: bold">Annual Net Sales</td>
            <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Royalty Rate</td>
            <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="padding-left: 5.4pt; width: 87%; text-align: justify">Less than or equal to $50.0 million</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td style="width: 10%; text-align: right">5</td>
            <td style="width: 1%; text-align: left">%</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td style="padding-left: 5.4pt; text-align: justify">Greater than $50.0 million and less than or equal to $150.0 million</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">10</td>
            <td style="text-align: left">%</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="padding-left: 5.4pt; text-align: justify">Greater than $150.0 million</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">15</td>
            <td style="text-align: left">%</td>
        </tr>
    </table>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">The annual royalty rate will be reduced to 50% of the initial rate during the six-month period beginning on the date of the first arms-length commercial sale of a generic equivalent of ANNOVERA that is launched by a third party in the U.S., and thereafter will be reduced to 20% of the initial rate.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Unless earlier terminated, the Population Council License Agreement will remain in effect until the later of the expiration of the last-to-expire of the Population Council&#x2019;s U.S. patents that are licensed to us, or the date following such expiration that follows a continuous period of six months during which we and our affiliates have not made a commercial sale of ANNOVERA in the U.S. The Population Council License Agreement may also be terminated for certain breach and bankruptcy-related events and by us on 180 days prior notice to the Population Council.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">As part of the Population Council License Agreement, we have the exclusive right to negotiate co-development and U.S. marketing rights for two other investigational vaginal contraceptive systems in development by the Population Council.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
        <span style="font: 10pt Times New Roman, Times, Serif"><i>License Agreement with Knight</i></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
        <span style="font: 10pt Times New Roman, Times, Serif">In July 2018, we entered into the Knight License Agreement with Knight pursuant to which we granted Knight an exclusive license to commercialize IMVEXXY and BIJUVA in Canada and Israel. Pursuant to the terms of the Knight License Agreement, Knight will pay us a milestone fee upon the first regulatory approval in Canada of each of IMVEXXY and BIJUVA, sales milestone fees based upon certain aggregate annual sales in Canada and Israel of each of IMVEXXY and BIJUVA and royalties based on aggregate annual sales of each of IMVEXXY and BIJUVA in Canada and Israel. In October 2019 and November 2019, Knight&#x2019;s New Drug Submissions for Joyesta (IMVEXXY) and BIJUVA, respectively, were accepted for review by Health Canada. Knight will be responsible for all regulatory and commercial activities in Canada and Israel related to IMVEXXY and BIJUVA. We may terminate the Knight License Agreement if Knight does not submit all regulatory applications, submissions and/or registrations required for regulatory approval to use and commercialize IMVEXXY and BIJUVA in Canada within certain specified time periods. We also may terminate the Knight License Agreement if Knight challenges our patents. Either party may terminate the Knight License Agreement for any material breach by the other party that is not cured within certain specified time periods or if the other party files for bankruptcy or other related matters.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif"><i>License Agreement with Theramex</i></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">In June 2019, we entered into the Theramex License Agreement with Theramex pursuant to which we granted Theramex an exclusive, perpetual license to commercialize BIJUVA and IMVEXXY for human use outside of the Theramex Territory. Pursuant to the terms of the Theramex License Agreement, Theramex paid us an upfront fee of EUR 14 million in cash. We are also eligible to receive up to an additional EUR 29.5 million in cash milestone payments, comprised of (i) an aggregate of EUR 2 million in regulatory milestone payments based on regulatory approvals for each of BIJUVA and IMVEXXY in certain specified markets and (ii) an aggregate of EUR 27.5 million in sales milestone payments to be paid in escalating tranches based on Theramex first attaining certain aggregate annual net sales milestones in the Theramex Territory ranging from EUR 25 million to EUR 100 million. We are also entitled to receive quarterly royalty payments based on net sales of BIJUVA and IMVEXXY in the Theramex Territory. Theramex has agreed to submit all regulatory applications, submissions and/or registrations required for regulatory approval to use and commercialize BIJUVA and IMVEXXY in certain specified markets within certain specified time periods and we may terminate the Theramex License Agreement if Theramex does not submit certain of such regulatory applications, submissions and/or registrations. We may also terminate the Theramex License Agreement if Theramex challenges our patents. Either party may terminate the Theramex License Agreement for any material breach by the other party that is not cured within certain specified time periods or if the other party files for bankruptcy or other related matters. Theramex may sublicense its rights to commercialize BIJUVA and IMVEXXY in the Theramex Territory, except for certain specified markets. Pursuant to the terms of the Theramex License Agreement, we agreed to supply, or cause to be supplied, BIJUVA and IMVEXXY to Theramex. We and Theramex have agreed to form a joint product committee responsible for advising and overseeing activities under the Theramex License Agreement.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <!-- Field: Page; Sequence: 56; Value: 1-->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt">
        <p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">
            <!-- Field: Sequence; Type: Arabic; Name: PageNo-->56<!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&#160;</p>
    </div>
    <!-- Field: /Page -->
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
        <span style="font: 10pt Times New Roman, Times, Serif"><b>Research and Development Expenses</b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">A significant portion of our historical operating expenses have been incurred in research and development activities. Research and development expenses relate primarily to the discovery and development of our drug candidates. Our research and development expenses consist primarily of expenses incurred under agreements with contract research organizations, or CROs, and consultants that conduct our clinical and preclinical studies; employee-related expenses, which include salaries and benefits, and non-cash share-based compensation; the cost of developing our chemistry, manufacturing, and controls capabilities, and costs associated with other research activities and regulatory approvals. Other research and development costs listed below consist of costs incurred with respect to drug candidates that have not received Investigational New Drug Application approval from the FDA.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">The following table indicates our research and development expense by project for the periods indicated:</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 80%; border-collapse: collapse; margin-right: auto">
        <tr style="vertical-align: bottom">
            <td style="text-align: justify">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center">Years Ended December 31,</td>
            <td style="padding-bottom: 1pt">&#160;</td>
        </tr>
        <tr style="vertical-align: bottom">
            <td style="text-align: justify">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2019</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2018</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2017</td>
            <td style="padding-bottom: 1pt">&#160;</td>
        </tr>
        <tr style="vertical-align: bottom">
            <td style="padding-bottom: 1pt; text-align: justify">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center">&#160;</td>
            <td colspan="9" style="border-bottom: Black 1pt solid; text-align: center">(000s)</td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="width: 41%; text-align: justify">TX 001-HR (BIJUVA)</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">$</td>
            <td style="width: 10%; text-align: right">3,848</td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">$</td>
            <td style="width: 10%; text-align: right">11,790</td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">$</td>
            <td style="width: 10%; text-align: right">19,381</td>
            <td style="width: 1%; text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td style="text-align: justify">TX 004-HR (IMVEXXY)</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">2,522</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">4,890</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">8,043</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="text-align: justify">ANNOVERA</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">2,637</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#x2014;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#x2014;</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td style="padding-bottom: 1pt; text-align: justify">Other research and development</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">10,785</td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">10,619</td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">6,429</td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="padding-bottom: 2pt; text-align: justify">Total</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: left">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right">19,792</td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: left">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right">27,299</td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: left">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right">33,853</td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
        </tr>
    </table>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Research and development expenditures will continue to be incurred as we continue development of our drug candidates and advance the development of our proprietary pipeline of novel drug candidates. We expect to incur ongoing research and development costs as we develop our drug pipeline, continue stability testing and validation on our drug candidates, prepare regulatory submissions and work with regulatory authorities on existing submissions.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">The costs of clinical trials may vary significantly over the life of a project owing to factors that include, but are not limited to, the following: per patient trial costs; the number of patients that participate in the trials; the number of sites included in the trials; the length of time each patient is enrolled in the trial; the number of doses that patients receive; the drop-out or discontinuation rates of patients; the amount of time required to recruit patients for the trial; the duration of patient follow-up; and the efficacy and safety profile of the drug candidate. We base our expenses related to clinical trials on estimates that are based on our experience and estimates from CROs and other third parties. Research and development expenditures for the drug candidates will continue after the trial completes for on-going stability and laboratory testing, regulatory submission and response work.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b>Results of Operations</b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
        <span style="font: 10pt Times New Roman, Times, Serif"><b><i>Comparison of Years Ended December 31, 2019, 2018, and 2017:</i></b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">Year ended December 31, 2019 compared with year ended December 31, 2018</span></i></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 80%; border-collapse: collapse; margin-right: auto">
        <tr style="vertical-align: bottom">
            <td style="text-align: justify">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Years Ended December 31,</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td colspan="2" style="text-align: justify">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
        </tr>
        <tr style="vertical-align: bottom">
            <td style="text-align: justify">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2019</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2018</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Change</td>
            <td style="padding-bottom: 1pt">&#160;</td>
        </tr>
        <tr style="vertical-align: bottom">
            <td style="padding-bottom: 1pt; text-align: justify">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td colspan="9" style="border-bottom: Black 1pt solid; text-align: center">(000s)</td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="width: 61%; text-align: justify">Product revenue, net</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">$</td>
            <td style="width: 10%; text-align: right">34,141</td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">$</td>
            <td style="width: 10%; text-align: right">16,099</td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">$</td>
            <td style="width: 10%; text-align: right">18,042</td>
            <td style="width: 1%; text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td style="text-align: justify">License revenue</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">15,506</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#x2014;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">15,506</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="text-align: justify">Cost of goods sold</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">6,335</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">2,737</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">3,598</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td style="padding-bottom: 1pt; text-align: justify">Operating expenses</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">194,518</td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">143,582</td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">50,936</td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="padding-left: 0.125in; text-align: justify">Operating loss</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">(151,206</td>
            <td style="text-align: left">)</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">(130,220</td>
            <td style="text-align: left">)</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">(20,986</td>
            <td style="text-align: left">)</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td style="padding-bottom: 1pt; text-align: justify">Other (expense) income, net</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">(24,939</td>
            <td style="padding-bottom: 1pt; text-align: left">)</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">(2,397</td>
            <td style="padding-bottom: 1pt; text-align: left">)</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">(22,542</td>
            <td style="padding-bottom: 1pt; text-align: left">)</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="padding-bottom: 2pt; text-align: justify">Net loss</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: left">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right">(176,145</td>
            <td style="padding-bottom: 2pt; text-align: left">)</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: left">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right">(132,617</td>
            <td style="padding-bottom: 2pt; text-align: left">)</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: left">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right">(43,528</td>
            <td style="padding-bottom: 2pt; text-align: left">)</td>
        </tr>
    </table>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
    <!-- Field: Page; Sequence: 57; Value: 1-->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt">
        <p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">
            <!-- Field: Sequence; Type: Arabic; Name: PageNo-->57<!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&#160;</p>
    </div>
    <!-- Field: /Page -->
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><i>Revenue</i></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Product revenue is recorded net of sales discounts, chargebacks, wholesaler fees, customer rebates, coupons and estimated returns. Product revenue for the year ended December 31, 2019 increased approximately $18,042,000, or 112%, to approximately $34,141,000, compared with approximately $16,099,000 for the year ended December 31, 2018. Product revenue increased primarily due to an increase in sales of approximately $15,194,000 of IMVEXXY in the current period, partially offset by a decrease in prenatal vitamin sales of approximately $5,155,000. Product revenue for the year ended December 31, 2019 also included sales of BIJUVA of approximately $1,836,000 and sales of ANNOVERA of approximately $6,167,000. The revenue decrease related to our prenatal vitamins was primarily affected by lower number of units sold as compared to the prior year period. We launched IMVEXXY in the third quarter of 2018 and BIJUVA in the second quarter of 2019. We started selling ANNOVERA in the third quarter of 2019
            <span style="color: #212529">and we expect the full commercial launch of ANNOVERA in the first quarter of 2020.</span> Since the launches, revenues related to IMVEXXY and BIJUVA have been greatly affected by the co-pay assistance programs that we introduced to launch these products, which allow eligible enrolled patients to access the products at a reasonable cost regardless of insurance coverage. We expect our product revenue to improve as commercial and Medicare payer coverage increases, and plans complete the process needed to adjudicate IMVEXXY, BIJUVA and ANNOVERA prescriptions at pharmacies. In addition to our product revenue, during the year ended December 31, 2019, we recognized license revenue of approximately $15,506,000 from the upfront fee, which was a non-refundable payment, paid to us by Theramex under the terms of the Theramex License Agreement, which we recognized at the point in time when Theramex was able to use and benefit from the license, which was when the knowledge transfer of regulatory documents occurred.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><i>Cost of Goods Sold</i></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Cost of goods sold increased by approximately $3,598,000, or 131%, to approximately $6,335,000 for the year ended December 31, 2019, compared with approximately $2,737,000 for the year ended December 31, 2018, primarily related to product costs attributable to our prescription pharmaceutical products, as well as royalty fees of $308,328 and the amortization of our license fee of $778,692 related to ANNOVERA. Our gross margin related to our prescription pharmaceutical products was 81% for the year ended December 31, 2019 as compared to 83% for the year ended December 31, 2018. The change in our gross margin is primarily related to the change in product mix between the two periods.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><i>Operating Expenses</i></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Our principal operating costs included the following items as a percentage of total operating expenses.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; width: 80%; border-collapse: collapse">
        <tr style="vertical-align: bottom">
            <td style="text-align: justify">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Years Ended
                <br />December 31,</td>
            <td style="padding-bottom: 1pt">&#160;</td>
        </tr>
        <tr style="vertical-align: bottom">
            <td style="text-align: justify">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2019</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2018</td>
            <td style="padding-bottom: 1pt">&#160;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="width: 74%; text-align: justify">Sales and marketing costs, excluding human resource costs</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td style="width: 10%; text-align: right">45</td>
            <td style="width: 1%; text-align: left">%</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td style="width: 10%; text-align: right">43</td>
            <td style="width: 1%; text-align: left">%</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td style="text-align: justify">Human resource related costs</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">28</td>
            <td style="text-align: left">%</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">25</td>
            <td style="text-align: left">%</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="text-align: justify">Product research and development costs</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">10</td>
            <td style="text-align: left">%</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">19</td>
            <td style="text-align: left">%</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td style="text-align: justify">Professional fees and consulting costs</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">7</td>
            <td style="text-align: left">%</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">5</td>
            <td style="text-align: left">%</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="text-align: justify">Other operating expenses</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">10</td>
            <td style="text-align: left">%</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">8</td>
            <td style="text-align: left">%</td>
        </tr>
    </table>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Operating expenses increased by approximately $50,936,000, or 35%, to approximately $194,518,000 for the year ended December 31, 2019, compared with approximately $143,582,000 for the year ended December 31, 2018, as a result of the following items:</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 80%; border-collapse: collapse; margin-right: auto">
        <tr style="vertical-align: bottom">
            <td style="text-align: justify">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Years Ended December 31,</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td colspan="2" style="text-align: justify">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
        </tr>
        <tr style="vertical-align: bottom">
            <td style="text-align: justify">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2019</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2018</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Change</td>
            <td style="padding-bottom: 1pt">&#160;</td>
        </tr>
        <tr style="vertical-align: bottom">
            <td style="padding-bottom: 1pt; text-align: justify">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center">(000s)</td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="width: 41%; text-align: justify">Sales and marketing, excluding human resources costs</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">$</td>
            <td style="width: 10%; text-align: right">86,459</td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">$</td>
            <td style="width: 10%; text-align: right">61,845</td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">$</td>
            <td style="width: 10%; text-align: right">24,614</td>
            <td style="width: 1%; text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td style="text-align: justify">Human resources related costs</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">54,120</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">35,003</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">19,117</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="text-align: justify">Research and development costs</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">19,792</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">27,299</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">(7,507</td>
            <td style="text-align: left">)</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td style="text-align: left">Professional and consulting costs</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">13,913</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">7,661</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">6,252</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="padding-bottom: 1pt; text-align: justify">Other operating expenses</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">20,234</td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">11,774</td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">8,460</td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td style="padding-bottom: 2pt; text-align: justify">Total operating expenses</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: left">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right">194,518</td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: left">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right">143,582</td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: left">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right">50,936</td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
        </tr>
    </table>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Sales and marketing costs increased by approximately $24,614,000 or 40%, to approximately $86,459,000 for the year ended December 31, 2019, compared with approximately $61,845,000 for the year ended December 31, 2018, primarily as a result of increased expenses associated with sales and marketing efforts to support launch and commercialization of our pharmaceutical products, including an increase of $7.4 million related to advertising expenses related to our pharmaceutical products, an increase of $6.5 million in consulting projects including costs for outsourced sales personnel and their related expenses, an increase of $6.0 million in marketing initiatives related to the launch of our pharmaceutical products as well as an increase in costs related to physician education, conferences and travel expenses related to product commercialization. We expect sales and marketing expenses to continue to increase as we continue to support the commercialization of our pharmaceutical products.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <!-- Field: Page; Sequence: 58; Value: 1-->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt">
        <p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">
            <!-- Field: Sequence; Type: Arabic; Name: PageNo-->58<!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&#160;</p>
    </div>
    <!-- Field: /Page -->
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Human resource related costs, including salaries and benefits increased by approximately $19,117,000, or 55%, to approximately $54,120,000 for the year ended December 31, 2019, compared with approximately $35,003,000 for the year ended December 31, 2018, primarily as a result of an increase of approximately $16,844,000 primarily due to higher employee count which increased from 241 in 2018 to 348 in 2019 primarily in sales, marketing and regulatory areas to support commercialization of our pharmaceutical products and an increase in non-cash compensation expense included in this category of approximately $2,273,000 related to employee stock option amortization during 2019 as compared to 2018.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Research and development costs decreased by approximately $7,507,000, or 27%, to approximately $19,792,000 for the year ended December 31, 2019, compared with approximately $27,299,000 for the year ended December 31, 2018. Research and development costs include costs related to manufacturing validation and early development trials, as well as salaries, wages, non-cash compensation and benefits of personnel involved in research and development activities. Research and development costs decreased primarily as a result of certain employees and activities that were previously classified as research and development being transferred into operations as they began to support commercial and launch efforts after the FDA approvals of IMVEXXY and BIJUVA.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#x25CF; Since the project&#x2019;s inception in February 2013, we have incurred approximately $131,035,000 in research and development costs with respect to BIJUVA.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#x25CF; Since the project&#x2019;s inception in August 2014, we have incurred approximately $48,261,000 in research and development costs with respect to IMVEXXY.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">For a discussion of the nature of efforts and steps necessary to complete these projects, see &#x201C;Item 1. Business &#x2014; Research and Development.&#x201D; For a discussion of the risks and uncertainties associated with completing development of our products, see &#x201C;Item 1A. Risk Factors &#x2014; Risks Related to Our Business.&#x201D; For a discussion of the extent and nature of additional resources that we may need to obtain if our current liquidity is not expected to be sufficient to complete these projects, see &#x201C;&#x2014; Liquidity and Capital Resources.&#x201D; For a discussion as to whether a future milestone such as completion of a development phase, date of filing an NDA with a regulatory agency or approval from a regulatory agency can be reliably determined, see &#x201C;Item 1. Business &#x2014; Pharmaceutical Regulation.&#x201D; Future milestones, including NDA submission dates, are not easily determinable as such milestones are dependent on various factors related to our clinical trials, including the timing of ongoing patient recruitment efforts to find eligible subjects for the applicable trials.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Professional and consulting costs increased by approximately $6,252,000, or 82%, for the year ended December 31, 2019, to approximately $13,913,000 compared with approximately $7,661,000 for the year December 31, 2018, primarily as a result of increased medical safety consulting fees to support commercialization of our pharmaceutical products.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">All other costs increased by approximately $8,460,000, or 72%, to approximately $20,234,000 for the year ended December 31, 2019, compared with approximately $11,774,000 for the year ended December 31, 2018, as a result of increased contract labor, dues and subscriptions, information technology, travel, insurance and other office expenses primarily to support commercialization of our new drugs.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><i>Operating Loss</i></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">As a result of the foregoing, our operating loss increased approximately $20,986,000, or 16%, to approximately $151,206,000 for the year ended December 31, 2019, compared with approximately $130,220,000 for the year ended December 31, 2018, primarily as a result of an increase in total operating expenses to support commercialization of our pharmaceutical products, partially offset by increased total net revenue.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">We anticipate that we will continue to have operating losses for the near future until we successfully commercialize IMVEXXY, BIJUVA and ANNOVERA, although there is no assurance that any commercialization of IMVEXXY, BIJUVA and ANNOVERA will be successful.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif"><i>Other (Expense) Income, net</i></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Other non-operating (expense) income, net changed by approximately $22,542,000, or 940%, to an expense of approximately $24,939,000 for the year ended December 31, 2019 compared with an expense of approximately $2,397,000 for 2018, primarily as a result of a one-time charge of $10.1 million in loss on extinguishment of debt and increased interest expense related to our Financing Agreement that we recorded in 2019 as compared to 2018.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <!-- Field: Page; Sequence: 59; Value: 1-->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt">
        <p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">
            <!-- Field: Sequence; Type: Arabic; Name: PageNo-->59<!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&#160;</p>
    </div>
    <!-- Field: /Page -->
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><i>Net Loss</i></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Because of the net effects of the foregoing, net loss increased approximately $43,528,000, or 33%, to approximately $176,145,000 for the year ended December 31, 2019, compared with approximately $132,617,000 for the year ended December 31, 2018. Net loss per share of common stock, basic and diluted, was ($0.72) for the year ended December 31, 2019, compared with ($0.59) per share of common stock for the year ended December 31, 2018.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">Year ended December 31, 2018 compared with year ended December 31, 2017</span></i></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 80%; border-collapse: collapse; margin-right: auto">
        <tr style="vertical-align: bottom">
            <td style="text-align: justify">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Years Ended December 31,</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td colspan="2" style="text-align: justify">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
        </tr>
        <tr style="vertical-align: bottom">
            <td style="text-align: justify">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2018</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2017</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Change</td>
            <td style="padding-bottom: 1pt">&#160;</td>
        </tr>
        <tr style="vertical-align: bottom">
            <td style="padding-bottom: 1pt; text-align: justify">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td colspan="9" style="border-bottom: Black 1pt solid; text-align: center">(000s)</td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="width: 41%; text-align: justify">Product revenue, net</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">$</td>
            <td style="width: 10%; text-align: right">16,099</td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">$</td>
            <td style="width: 10%; text-align: right">16,778</td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">$</td>
            <td style="width: 10%; text-align: right">(679</td>
            <td style="width: 1%; text-align: left">)</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td style="text-align: justify">Cost of goods sold</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">2,737</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">2,637</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">100</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="padding-bottom: 1pt; text-align: justify">Operating expenses</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">143,582</td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">91,769</td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">51,813</td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td style="padding-left: 0.125in; text-align: justify">Operating loss</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">(130,220</td>
            <td style="text-align: left">)</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">(77,628</td>
            <td style="text-align: left">)</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">(52,592</td>
            <td style="text-align: left">)</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="padding-bottom: 1pt; text-align: justify">Other (expense) income</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">(2,397</td>
            <td style="padding-bottom: 1pt; text-align: left">)</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">703</td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">(3,100</td>
            <td style="padding-bottom: 1pt; text-align: left">)</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td style="padding-bottom: 2pt; text-align: justify">Net loss</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: left">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right">(132,617</td>
            <td style="padding-bottom: 2pt; text-align: left">)</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: left">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right">(76,925</td>
            <td style="padding-bottom: 2pt; text-align: left">)</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: left">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right">(55,692</td>
            <td style="padding-bottom: 2pt; text-align: left">)</td>
        </tr>
    </table>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><i>Revenue</i></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Product revenue is recorded net of sales discounts, chargebacks, wholesaler fees, customer rebates, coupons, and estimated returns. Product revenue for the year ended December 31, 2018 decreased by approximately $679,000, or 4%, to approximately $16,099,000, compared with approximately $16,778,000 for the year ended December 31, 2017. Product revenue decreased primarily due to a decrease in prenatal vitamin sales of approximately $1,737,000 partially offset by sales of IMVEXXY of approximately $1,058,000. The product revenue decrease related to our prenatal vitamins was primarily affected by lower number of units sold and higher utilization of coupons offered to customers during the year ended December 31, 2018 as compared to the prior year. We launched sales of IMVEXXY in the third quarter of 2018. During this launch period, product revenue related to our newly approved drug were greatly affected by the co-pay assistance program that we introduced to launch IMVEXXY, which allowed patients to access the product at a reasonable cost regardless of insurance coverage. We expect our product revenue related to IMVEXXY to improve as commercial payer coverage for IMVEXXY increases.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><i>Cost of Goods Sold</i></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Cost of goods sold increased by approximately $100,000, or 4%, to approximately $2,737,000 for the year ended December 31, 2018, compared with approximately $2,637,000 for the year ended December 31, 2017 primarily related to product costs attributable to IMVEXXY, partially offset by lower royalty fees attributable to prenatal vitamins, and lower shipping costs. Our gross margin was 83% for the year ended December 31, 2018 as compared to 84% for the year ended December 31, 2017. The decrease in gross margin percentage was primarily attributable to higher utilization of coupons/co-pay assistance offered in 2018 as compared with 2017.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><i>Operating Expenses</i></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Our principal operating costs included the following items as a percentage of total operating expenses.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 90%; border-collapse: collapse; margin-right: auto">
        <tr style="vertical-align: bottom">
            <td style="text-align: justify">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Years Ended
                <br />December 31,</td>
            <td style="padding-bottom: 1pt">&#160;</td>
        </tr>
        <tr style="vertical-align: bottom">
            <td style="text-align: justify">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2018</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2017</td>
            <td style="padding-bottom: 1pt">&#160;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="width: 64%; text-align: justify">Sales and marketing costs, excluding human resource costs</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td style="width: 10%; text-align: right">43</td>
            <td style="width: 1%; text-align: left">%</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td style="width: 10%; text-align: right">22</td>
            <td style="width: 1%; text-align: left">%</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td style="text-align: justify">Human resource related costs</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">25</td>
            <td style="text-align: left">%</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">27</td>
            <td style="text-align: left">%</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="text-align: justify">Product research and development costs</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">19</td>
            <td style="text-align: left">%</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">37</td>
            <td style="text-align: left">%</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td style="text-align: justify">Professional fees and consulting costs</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">5</td>
            <td style="text-align: left">%</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">6</td>
            <td style="text-align: left">%</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="text-align: justify">Other operating expenses</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">8</td>
            <td style="text-align: left">%</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">8</td>
            <td style="text-align: left">%</td>
        </tr>
    </table>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <!-- Field: Page; Sequence: 60; Value: 1-->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt">
        <p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">
            <!-- Field: Sequence; Type: Arabic; Name: PageNo-->60<!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&#160;</p>
    </div>
    <!-- Field: /Page -->
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Operating expenses increased by approximately $51,813,000, or 56%, to approximately $143,582,000 for the year ended December 31, 2018, compared with approximately $91,769,000 for the year ended December 31, 2017, as a result of the following items:</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 80%; border-collapse: collapse; margin-right: auto">
        <tr style="vertical-align: bottom">
            <td style="text-align: justify">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Years Ended December 31,</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td colspan="2" style="text-align: justify">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
        </tr>
        <tr style="vertical-align: bottom">
            <td style="text-align: justify">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2018</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2017</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Change</td>
            <td style="padding-bottom: 1pt">&#160;</td>
        </tr>
        <tr style="vertical-align: bottom">
            <td style="padding-bottom: 1pt; text-align: justify">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: center">&#160;</td>
            <td colspan="9" style="border-bottom: Black 1pt solid; text-align: center">(000s)</td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="width: 41%; text-align: justify">Sales and marketing, excluding human resources costs</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">$</td>
            <td style="width: 10%; text-align: right">61,845</td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">$</td>
            <td style="width: 10%; text-align: right">19,614</td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">$</td>
            <td style="width: 10%; text-align: right">42,231</td>
            <td style="width: 1%; text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td style="text-align: justify">Human resources related costs</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">35,003</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">24,720</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">10,283</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="text-align: justify">Research and development costs</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">27,299</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">33,853</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">(6,554</td>
            <td style="text-align: left">)</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td style="text-align: left">Professional and consulting costs</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">7,661</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">5,859</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">1,802</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="padding-bottom: 1pt; text-align: justify">Other operating expenses</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">11,774</td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">7,723</td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">4,051</td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td style="padding-bottom: 2pt; text-align: justify">Total operating expenses</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: left">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right">143,582</td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: left">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right">91,769</td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: left">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right">51,813</td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
        </tr>
    </table>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Sales and marketing costs increased by approximately $42,231,000, or 215%, to approximately $61,845,000 for the year ended December 31, 2018, compared with approximately $19,614,000 for the year ended December 31, 2017, primarily as a result of increased expenses associated with sales and marketing efforts to support launch and commercialization of IMVEXXY and BIJUVA, including costs related to outsourced sales personnel and their related expenses, physician education and product samples, advertising, and travel expenses related to product commercialization. We expect sales and marketing expenses to continue to increase as we continue the launch of BIJUVA, prepare for the launch of ANNOVERA, and continue to support our growing business and commercialization of our products.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Human resource related costs, including salaries and benefits increased by approximately $10,283,000, or 42%, to approximately $35,003,000 for the year ended December 31, 2018, compared with approximately $24,720,000 for the year ended December 31, 2017, primarily as a result of an increase of approximately $7,975,000 in personnel costs in sales, marketing and regulatory areas to support commercialization of our new drugs and an increase in non-cash compensation expense included in this category of approximately $2,308,000 related to employee stock option amortization during 2018 as compared to 2017.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Research and development costs decreased by approximately $6,554,000, or 19%, to approximately $27,299,000 for the year ended December 31, 2018, compared with approximately $33,853,000 for the year ended December 31, 2017, primarily as a result of the completion of the REPLENISH Trial for BIJUVA and FDA approval of IMVEXXY and BIJUVA, partially offset by scale-up and manufacturing activities for BIJUVA before FDA approval as well as increased pre-clinical work to support our product pipeline. Research and development costs in 2017 included approximately $2,400,000 in NDA submission fees related to BIJUVA and a write-off of approximately $1,000,000 of prepaid manufacturing costs. Research and developments costs during the year ended December 31, 2018 included the following research and development projects:</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">During the year ended December 31, 2018 and since the project&#x2019;s inception in February 2013, we have incurred approximately $11,790,000 and $127,187,000, respectively, in research and development costs with respect to BIJUVA.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">During the year ended December 31, 2018 and since the project&#x2019;s inception in April 2013, we have incurred approximately $0 and $2,525,000, respectively, in research and development costs with respect to TX-002HR, our progesterone only drug candidate.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">During the year ended December 31, 2018 and since the project&#x2019;s inception in August 2014, we have incurred approximately $4,890,000 and $45,739,000, respectively, in research and development costs with respect to IMVEXXY.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">For a discussion of the nature of efforts and steps necessary to complete these projects, see &#x201C;Item 1. Business &#x2014; Research and Development.&#x201D; For a discussion of the risks and uncertainties associated with completing development of our products, see &#x201C;Item 1A. Risk Factors &#x2014; Risks Related to Our Business.&#x201D; For a discussion of the extent and nature of additional resources that we may need to obtain if our current liquidity is not expected to be sufficient to complete these projects, see &#x201C;&#x2014; Liquidity and Capital Resources.&#x201D; For a discussion as to whether a future milestone such as completion of a development phase, date of filing an NDA with a regulatory agency or approval from a regulatory agency can be reliably determined, see &#x201C;Item 1. Business &#x2014; Pharmaceutical Regulation.&#x201D; Future milestones, including NDA submission dates, are not easily determinable as such milestones are dependent on various factors related to our clinical trials, including the timing of ongoing patient recruitment efforts to find eligible subjects for the applicable trials.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Professional and consulting costs increased by approximately $1,802,000, or 31%, for the year ended December 31, 2018, to approximately $7,661,000 compared with approximately $5,859,000 for the year December 31, 2017, primarily as a result of increased legal, consulting and recruiting fees.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <!-- Field: Page; Sequence: 61; Value: 1-->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt">
        <p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">
            <!-- Field: Sequence; Type: Arabic; Name: PageNo-->61<!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&#160;</p>
    </div>
    <!-- Field: /Page -->
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">All other costs increased by approximately $4,051,000, or 52%, to approximately $11,774,000 for the year ended December 31, 2018, compared with approximately $7,723,000 for the year ended December 31, 2017, as a result of increased information technology, travel, allowance for bad debt expense, insurance and other office expenses primarily to support commercialization of our new drugs.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><i>Operating Loss</i></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">As a result of the foregoing, our operating loss increased approximately $52,592,000, or 68%, to approximately $130,220,000 for the year ended December 31, 2018, compared with approximately $77,628,000 for the year ended December 31, 2017, primarily as a result of increased personnel costs, sales and marketing expenses to support commercialization of IMVEXXY and BIJUVA, including costs related to outsourced sales personnel and their related expenses, professional fees and other operating expenses, as well a decrease in revenue, partially offset by a decrease in research and development costs.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">We anticipate that we will continue to have operating losses for the near future until we successfully commercialize IMVEXXY, BIJUVA and ANNOVERA, although there is no assurance that any commercialization of IMVEXXY and BIJUVA and ANNOVERA will be successful.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><i>Other (Expense) Income</i></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Other non-operating income changed by approximately $3,100,000, or 441%, to an expense of approximately $2,397,000 for the year ended December 31, 2018 compared with an income of approximately $703,000 for 2017, primarily as a result of increased interest expense related to our term loan that we obtained in 2018 partially offset by increased interest income in 2018 as compared to 2017.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><i>Net Loss</i></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Because of the net effects of the foregoing, net loss increased approximately $55,692,000, or 72%, to approximately $132,617,000 for the year ended December 31, 2018, compared with approximately $76,925,000 for the year ended December 31, 2017. Net loss per share of common stock, basic and diluted, was ($0.59) for the year ended December 31, 2018, compared with ($0.37) per share of common stock for the year ended December 31, 2017.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b>Liquidity and Capital Resources</b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">We have funded our operations primarily through public offerings of our common stock and private placements of equity and debt securities. For the three-year period ending December 31, 2019, we received approximately $236,000,000 in net proceeds from the issuance of shares of our common stock. As of December 31, 2019, we had a cash balance of approximately $160,830,000, however, changing circumstances may cause us to consume funds significantly faster than we currently anticipate, and we may need to spend more money than currently expected because of circumstances beyond our control.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">On October 29, 2019, we closed an underwritten public offering of 29,900,000 shares of our common stock at a price to the public of $2.75 per share, inclusive of the underwriters&#x2019; option to purchase additional shares of common stock, which option was exercised in full. We received net proceeds from the offering of approximately $77.0 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by us.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">On June 6, 2019, we entered into the Theramex License Agreement with Theramex, a leading, global specialty pharmaceutical company dedicated to women&#x2019;s health, to commercialize BIJUVA and IMVEXXY for human use outside of the U.S., except for Canada and Israel, or the Theramex Territory. Under the terms of the Theramex License Agreement, Theramex paid us EUR 14 million in cash as an upfront fee on August 5, 2019. Within thirty days of signing the Theramex License Agreement, we provided Theramex the regulatory materials and clinical data that were necessary for Theramex to obtain marketing authorizations and other applicable regulatory approvals for commercializing BIJUVA and IMVEXXY. We recognized the revenue related to the upfront fee, which was a nonrefundable payment, during the third quarter of 2019, at a point in time when Theramex was able to use and benefit from the license which was when the knowledge transfer of regulatory documents occurred. We are eligible to receive additional milestone payments comprised of (i) up to an aggregate of EUR 2 million in regulatory milestone payments based on regulatory approvals for BIJUVA and IMVEXXY in certain specified markets and (ii) up to an aggregate of EUR 27.5 million in sales milestone payments to be paid in escalating tranches based on Theramex first attaining certain aggregate annual net sales milestones of BIJUVA and IMVEXXY in the Theramex Territory ranging from EUR 25 million to EUR 100 million. We are also entitled to receive quarterly royalty payments on net sales of BIJUVA and IMVEXXY in the Theramex Territory. Theramex will be responsible for all regulatory and commercial activities for BIJUVA and IMVEXXY in the Theramex Territory. Theramex may sublicense its rights to commercialize BIJUVA and IMVEXXY in the Theramex Territory, except for certain specified markets. We may terminate the Theramex License Agreement if Theramex does not submit all regulatory applications, submissions and/or registrations required for regulatory approval to use and commercialize BIJUVA and IMVEXXY within certain specified time periods. We also may terminate the Theramex License Agreement if Theramex challenges our patents. Either party may terminate the Theramex License Agreement for any material breach by the other party that is not cured within certain specified time periods or if the other party files for bankruptcy or other related matters.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <!-- Field: Page; Sequence: 62; Value: 1-->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt">
        <p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">
            <!-- Field: Sequence; Type: Arabic; Name: PageNo-->62<!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&#160;</p>
    </div>
    <!-- Field: /Page -->
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">On April 24, 2019, we entered into a Financing Agreement, as amended on December 27, 2019, or the Financing Agreement, with TPG Specialty Lending, Inc., as administrative agent, or the Administrative Agent, various lenders from time to time party thereto, and certain of our subsidiaries party thereto from time to time as guarantors, which provides us with a $300,000,000 first lien secured term loan credit facility, or the Facility. The Facility provides for availability to us in three tranches: (i) $200,000,000 was drawn upon entering into the Financing Agreement; (ii) $50,000,000 was drawn on February 18, 2020; and (iii) $50,000,000 will be available to us in the Administrative Agent&#x2019;s sole and absolute discretion either contemporaneously with the delivery of our financial statements for the fiscal quarter ending June 30, 2020 or at such earlier date as the Administrative Agent shall have consented to. Borrowings under the Facility accrue interest at either (i) 3-month LIBOR plus 7.75%, subject to a LIBOR floor of 2.70% or (ii) the prime rate plus 6.75%, subject to a prime rate floor of 5.20% as selected by us. Interest on amounts borrowed under the Facility is payable quarterly. The outstanding principal amount of the Facility is payable in four equal quarterly installments beginning on June 30, 2023, with the Facility maturing on March 31, 2024. A portion of the initial tranche of borrowing under the Facility in the amount of approximately $81,661,000 was used to repay all amounts outstanding under our prior financing agreement with MidCap Financial Trust, or the MidCap Agreement. As a result of the termination of the MidCap Agreement, we recorded $10,057,632 in loss on extinguishment of debt in our unaudited consolidated financial statements.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">We believe that our existing cash and availability under the Facility will allow us to fund our operating plan through at least the next 12 months from the date of this Annual Report. However, if the commercialization of IMVEXXY, BIJUVA, or ANNOVERA is delayed, our existing cash and availability under the Facility, if we are able to access such funds, may be insufficient to satisfy our liquidity requirements until we are able to commercialize IMVEXXY, BIJUVA and ANNOVERA and we may not be able to access funds under the Facility. If our available cash is insufficient to satisfy our liquidity requirements, we may curtail our sales, marketing and other commercialization efforts and we may seek to sell additional equity or debt securities. Our ability to sell equity securities will be limited by the authorized shares that we have available to issue. Our ability to sell debt securities or obtain additional debt financing is restricted pursuant to the Financing Agreement. To the extent that we raise additional capital through the sale of equity or convertible debt securities, to the extent permitted under the Financing Agreement, the ownership interests of our existing stockholders will be diluted, and the terms of these new securities may include liquidation or other preferences that adversely affect the rights of our existing stockholders. If we raise additional funds through collaborations, strategic alliances, or licensing arrangements with third parties, certain of which are restricted under the Financing Agreement, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs, or proposed products, if permitted under the Financing Agreement. Additionally, we may have to grant licenses on terms that may not be favorable to us.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Our net days sales outstanding, or net DSO, is calculated by dividing gross accounts receivable less the reserve for doubtful accounts, chargebacks and payment discounts divided by the average daily net revenues during the fourth quarter of 2019. We also disclose gross DSO, which includes the calculation of gross accounts receivable divided by the average daily gross revenues to distributors during the fourth quarter of 2019. For the quarter ended December 31, 2019, our gross DSO was 55 days compared to 77 days for the quarter ended December 31, 2018 and our net DSO was 141 days for the quarter ended December 31, 2019 compared to 200 days for the quarter ended December 31, 2018. Our DSO decreased primarily due to more favorable arrangements with customers that we entered into in the second quarter of 2019. We anticipate that our DSO will fluctuate in the future based upon a variety of factors, including longer payment terms associated with the launch of IMVEXXY, BIJUVA and ANNOVERA and changes in the healthcare industry.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">We need substantial amounts of cash to complete the launch and commercialization of our hormone therapy and contraceptive drugs. The following table sets forth the primary sources and uses of cash for each of the periods set forth below:</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b>Summary of (Uses) and Sources of Cash</b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 80%; border-collapse: collapse; margin-right: auto">
        <tr style="vertical-align: bottom">
            <td style="text-align: justify">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center">Years Ended December 31,</td>
            <td style="padding-bottom: 1pt">&#160;</td>
        </tr>
        <tr style="vertical-align: bottom">
            <td style="text-align: justify">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2019</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2018</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2017</td>
            <td style="padding-bottom: 1pt">&#160;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="width: 61%; text-align: justify">Net cash used in operating activities</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">$</td>
            <td style="width: 10%; text-align: right">(165,697,595</td>
            <td style="width: 1%; text-align: left">)</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">$</td>
            <td style="width: 10%; text-align: right">(106,811,781</td>
            <td style="width: 1%; text-align: left">)</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">$</td>
            <td style="width: 10%; text-align: right">(76,155,614</td>
            <td style="width: 1%; text-align: left">)</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td style="text-align: justify">Net cash used in investing activities</td>
            <td>&#160;</td>
            <td style="text-align: left">$</td>
            <td style="text-align: right">(23,912,694</td>
            <td style="text-align: left">)</td>
            <td>&#160;</td>
            <td style="text-align: left">$</td>
            <td style="text-align: right">(21,497,857</td>
            <td style="text-align: left">)</td>
            <td>&#160;</td>
            <td style="text-align: left">$</td>
            <td style="text-align: right">(827,108</td>
            <td style="text-align: left">)</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="padding-left: 12.6pt; text-align: justify; text-indent: -12.6pt">Net cash provided by financing activities</td>
            <td>&#160;</td>
            <td style="text-align: left">$</td>
            <td style="text-align: right">188,826,925</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">$</td>
            <td style="text-align: right">162,787,087</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">$</td>
            <td style="text-align: right">72,584,249</td>
            <td style="text-align: left">&#160;</td>
        </tr>
    </table>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><i>Operating Activities</i></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">The principal use of cash in operating activities for the year ended December 31, 2019 was to fund our current expenses primarily related to supporting commercialization activities for IMVEXXY, BIJUVA and ANNOVERA, sales, marketing, scale-up and manufacturing activities and clinical development, adjusted for non-cash items. The increase of approximately $58,886,000 in cash used in operating activities for the year ended December 31, 2019 in comparison to the year ended December 31, 2018 was due primarily to an increase in our net loss coupled with changes in the components of working capital which were primarily due to the launch and commercialization of our pharmaceutical products.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <!-- Field: Page; Sequence: 63; Value: 1-->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt">
        <p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">
            <!-- Field: Sequence; Type: Arabic; Name: PageNo-->63<!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&#160;</p>
    </div>
    <!-- Field: /Page -->
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">The principal use of cash in operating activities for the year ended December 31, 2018 was to fund our current expenses primarily related to supporting commercialization activities for IMVEXXY, BIJUVA and ANNOVERA, sales, marketing, scale-up and manufacturing activities and clinical development, adjusted for non-cash items. The increase of approximately $30,656,000 in cash used in operating activities for the year ended December 31, 2018 in comparison to the year ended December 31, 2017 was due primarily to an increase in our net loss and non-cash compensation expense coupled with changes in the components of working capital.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><i>Investing Activities</i></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">During the year ended December 31, 2019, we paid $20,000,000 to the Population Council in connection with the commercial batch release of ANNOVERA, based on the Population Council License Agreement. In addition, an increase in spending on fixed assets, patents and trademarks resulted in an increase in cash used in investing activities for the year ended December 31, 2019 compared with the same period in 2018.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">During the year ended December 31, 2018, we paid $20,000,000 to the Population Council, upon FDA approval of ANNOVERA, based on the Population Council License Agreement. In addition, an increase in spending on patents and trademarks resulted in an increase in cash used in investing activities for the year ended December 31, 2018 compared with the same period in 2017.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><i>Financing Activities</i></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Financing activities represent the principal source of our cash flow. Our financing activities for the year ended December 31, 2019 provided net cash of approximately $188,827,000. The cash provided by financing activities during the year ended December 31, 2019 included approximately $77,031,000 in proceeds from the sale of our common stock and approximately $109,000 in proceeds from the exercise of options as well as funding from our Financing Agreement of approximately $200,000,000 partially offset by the payment of financing fees of approximately $6,652,000 in connection with the Financing Agreement and the repayment of the MidCap Agreement of $81,661,000.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">On October 29, 2019, we closed an underwritten public offering of 29,900,000 shares of our common stock at a price to the public of $2.75 per share, inclusive of the underwriters&#x2019; option to purchase additional shares of common stock, which option was exercised in full. We received net proceeds from the offering of approximately $77.0 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by us.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Our financing activities for the year ended December 31, 2018 provided net cash of approximately $162,787,000. The cash provided by financing activities during the year ended December 31, 2018 included approximately $89,908,000 in proceeds from the sale of our common stock and approximately $1,666,000 in proceeds from the exercise of options, as well as funding from the MidCap Agreement of approximately $75,000,000, partially offset by the payment of financing fees of approximately $3,787,000 in connection with the MidCap Agreement.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">On August 6, 2018, we closed an underwritten public offering of 14,656,862 shares of our common stock at a price to the public of $5.10 per share, inclusive of the underwriters&#x2019; option to purchase additional shares of common stock. The net proceeds to us from the offering were approximately $69,908,000, after deducting the underwriting discount and offering expenses payable by us. In connection with the Knight License Agreement, Knight entered into a subscription agreement with us pursuant to which Knight purchased 3,921,568 shares of our common stock concurrently with the closing of the underwritten public offering of common stock at a price of $5.10 per share, for proceeds to us of $20,000,000.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b>Critical Accounting Policies and New Accounting Pronouncements</b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><i>Critical Accounting Policies</i></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">The preparation of financial statements in accordance with accounting principles generally accepted in the United States, or GAAP, requires us to make estimates and assumptions that affect reported amounts and related disclosures in the financial statements. We consider an accounting estimate to be critical if:</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">it requires assumptions to be made that were uncertain at the time the estimate was made, and</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">changes in the estimate or different estimates that could have been selected could have a material impact on our results of operations or financial condition.</span>
            </td>
        </tr>
    </table>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0; margin-right: 0; margin-top: 0">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <!-- Field: Page; Sequence: 64; Value: 1-->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt">
        <p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">
            <!-- Field: Sequence; Type: Arabic; Name: PageNo-->64<!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&#160;</p>
    </div>
    <!-- Field: /Page -->
    <p style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0; margin-right: 0; margin-top: 0">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">We base our estimates and judgments on our experience, our current knowledge, our beliefs of what could occur in the future, our observation of trends in the industry, information provided by our customers, and information available from other sources. Actual results may differ from these estimates under different assumptions or conditions. We have identified the following accounting policies and estimates as those that we believe are most critical to our financial condition and results of operations and that require our most subjective and complex judgments in estimating the effect of inherent uncertainties: share-based compensation expense and income taxes.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><i>Revenue Recognition. </i>We recognize revenue on arrangements in accordance with ASC 606, <em>Revenue from Contracts with Customers</em>, or ASC 606. In accordance with ASC 606, revenue is recognized when a customer obtains control of promised goods or services. The amount of revenue recognized reflects the consideration to which we expect to be entitled to receive in exchange for these goods or services. The provisions of ASC 606 include a five-step process by which we determine revenue recognition, depicting the transfer of goods or services to customers in amounts reflecting the payment to which we expect to be entitled in exchange for those goods or services. ASC 606 requires us to apply the following steps: (1) identify the contract with the customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when, or as, we satisfy the performance obligation.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #212529; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">As of December 31, 2019, our products consisted primarily of prescription vitamins and our FDA-approved products: IMVEXXY, which we began selling during the third quarter of 2018 and BIJUVA, which we began selling in the second quarter of 2019. We started selling ANNOVERA in the third quarter of 2019 and we expect the full commercial launch of ANNOVERA in the first quarter of 2020. We sell our name brand and generic prescription products primarily through wholesale distributors and retail pharmacies. We have one performance obligation related to prescription products sold through wholesale distributors, which is to transfer promised goods to a customer, and two performance obligations related to products sold through retail pharmacies, which are to: (1) transfer promised goods and (2) provide customer service for an immaterial fee. We treat shipping as a fulfillment activity rather than as a separate obligation. We recognize prescription revenue only when we satisfy performance obligations by transferring a promised good or service to a customer. A good or service is considered to be transferred when the customer receives the goods or service or obtains control. Control refers to the customer&#x2019;s ability to direct the use of, and obtain substantially all of the remaining benefits from, an asset. Based on our contracts, we invoice customers once our performance obligations have been satisfied, at which point payment is unconditional. We disclose receivables from contracts with customers separately in the statement of financial position. Payment for goods or services sold by us is typically due between 30 and 60 days after an invoice is sent to the customer.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #212529; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #212529; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">The transaction price of a contract is the amount of consideration which we expect to be entitled to in exchange for transferring promised goods or services to a customer. Prescription products are sold at fixed wholesale acquisition cost determined based on our list price. However, the total transaction price is variable as it is calculated net of estimated product returns, chargebacks, rebates, coupons, discounts and wholesaler fees. These estimates are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the customer) or a current liability (if the amount is payable to a party other than a customer). In order to determine the transaction price, we estimate the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract or each variable consideration. The estimated amount of variable consideration is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. In determining amounts of variable consideration to include in a contract&#x2019;s transaction price, we rely on our historical experience and other evidence that supports our qualitative assessment of whether revenue would be subject to a significant reversal. We consider all the facts and circumstances associated with both the risk of a revenue reversal arising from an uncertain future event and the magnitude of the reversal if that uncertain event were to occur. Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our original estimates, we will adjust these estimates, which would affect net product revenue and earnings in the period such changes in estimates become known.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #212529; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <!-- Field: Page; Sequence: 65; Value: 1-->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt">
        <p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">
            <!-- Field: Sequence; Type: Arabic; Name: PageNo-->65<!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&#160;</p>
    </div>
    <!-- Field: /Page -->
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><i>Share-Based Compensation. </i>We measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees are required to provide services. Share-based compensation arrangements may include options, restricted stock, restricted stock units, performance-based awards, and share appreciation rights. We amortize such compensation amounts, if any, over the respective service periods of the award. We use the Black-Scholes-Merton option pricing model, or the Black-Scholes Model, an acceptable model in accordance with ASC 718, <i>Compensation-Stock Compensation</i>, to value options. Option valuation models require the input of assumptions, including the expected life of the stock-based awards, the estimated stock price volatility, the risk-free interest rate, and the expected dividend yield. The risk-free interest rate assumption is based upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the term of the instrument. Estimated volatility is a measure of the amount by which our stock price is expected to fluctuate each year during the term of the award. Before January 1, 2017, the expected volatility of share options was estimated based on a historical volatility analysis of peer entities whose stock prices were publicly available that were similar to our company with respect to industry, stage of life cycle, market capitalization, and financial leverage. On January 1, 2017, we began using our own stock price in our volatility calculation along with two other peer entities whose stock prices were publicly available that were similar to our company. Our calculation of estimated volatility is based on historical stock prices over a period equal to the expected term of the awards. The average expected life of warrants is based on the contractual terms of the awards. The average expected life of options is based on the contractual terms of the stock option using the simplified method. We utilize a dividend yield of zero based on the fact that we have never paid cash dividends and have no current intention to pay cash dividends. Calculating share-based compensation expense requires the input of highly subjective judgment and assumptions, estimates of expected life of the share-based award, stock price volatility and risk-free interest rates. The assumptions used in calculating the fair value of share-based awards represent our best estimates, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change and we use different assumptions, our share-based compensation expense could be materially different in the future.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">We generally recognize the compensation expense on a straight-line basis over the employee&#x2019;s requisite service period. Effective January 1, 2017, we account for forfeitures when they occur. On January 1, 2019, we adopted ASU 2018-07 which simplified the accounting for share-based payments to nonemployees by aligning it with the accounting for share-based payments to employees, with certain exceptions. The new guidance expanded the scope of ASC 718 to include share-based payments granted to nonemployees in exchange for goods or services used or consumed in an entity&#x2019;s own operations and superseded the guidance in ASC 505-50. Prior to January 1, 2019, equity instruments issued to non-employees were recorded on a fair value basis, as required by ASC 505, Equity - Based Payments to Non-Employees.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><i>Income Taxes. </i>We account for income taxes under the asset and liability method. We recognize deferred tax assets and liabilities for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. We measure deferred tax assets and liabilities using enacted tax rates expected to apply to taxable income in the years in which the related temporary differences are expected to be recovered or settled. We recognize the effect on deferred tax assets and liabilities of a change in tax rates when the rate change is enacted. Valuation allowances are recorded to reduce deferred tax assets to the amount that will more likely than not be realized.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">In accordance with ASC 740, <i>Income Taxes</i>, we recognize the effect of uncertain income tax positions only if the positions are more likely than not of being sustained in an audit, based on the technical merits of the position. We measure recognized uncertain income tax positions using the largest amount that has a likelihood of being realized that is greater than 50%. Changes in recognition or measurement are reflected in the period in which those changes in judgment occur. We recognize both interest and penalties related to uncertain tax positions as part of the income tax provision. At December 31, 2019 and 2018, we had no tax positions relating to open tax returns that were considered to be uncertain. Our tax returns are subject to review by the Internal Revenue Service three years after they are filed. Our U.S. federal and state tax returns since 2011, which was the first year we generated net operating losses, remain open to examination.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">The determination of our provision for income taxes requires significant judgment, the use of estimates, and the interpretation and application of complex tax laws. In the ordinary course of our business, there are transactions and calculations for which the ultimate tax determination is uncertain. In spite of our belief that we have appropriate support for all the positions taken on our tax returns, we acknowledge that certain positions may be successfully challenged by the taxing authorities. We determine the tax benefits more likely than not to be recognized with respect to uncertain tax positions. Although we believe our recorded tax assets and liabilities are reasonable, tax laws and regulations are subject to interpretation and inherent uncertainty; therefore, our assessments can involve both a series of complex judgments about future events and rely on estimates and assumptions. Although we believe these estimates and assumptions are reasonable, the final determination could be materially different than that which is reflected in our provision for income taxes and recorded tax assets and liabilities.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <!-- Field: Page; Sequence: 66; Value: 1-->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt">
        <p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">
            <!-- Field: Sequence; Type: Arabic; Name: PageNo-->66<!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&#160;</p>
    </div>
    <!-- Field: /Page -->
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">On December 22, 2017, the U.S. federal government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act, or the Tax Act. The Tax Act makes broad and complex changes to the U.S. federal tax code, including, but not limited to reducing the U.S. federal corporate tax rate from 34 percent to 21 percent, effective January 1, 2018. As the result of our initial analysis of the impact of the Tax Act, we recorded a provisional amount of net tax expense of $46.7 million in 2017 related to the remeasurement of our deferred tax balances and other effects. We completed our accounting for the income tax effects of the Tax Act in 2018, and no material adjustments were required to the provisional amounts initially recorded.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><i>Segment Reporting. </i>We are managed and operated as one business, which is focused on creating and commercializing products targeted exclusively for women. Our business operations are managed by a single management team that reports to the President of our Company. We do not operate separate lines of business with respect to any of our products and we do not prepare discrete financial information with respect to separate products. All product sales are derived from sales in the United States. Accordingly, we view our business as one reportable operating segment.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><i>New Accounting Pronouncements</i>. In August 2018, the Financial Accounting Standards Board, or the FASB, issued Accounting Standards Update, or ASU, 2018-13, which eliminates certain disclosure requirements for fair value measurements for all entities, requires public entities to disclose certain new information and modifies some disclosure requirements. The FASB developed the amendments to Accounting Standards Codification, or ASC, 820 as part of its broader disclosure framework project, which aims to improve the effectiveness of disclosures in the notes to financial statements by focusing on requirements that clearly communicate the most important information to users of the financial statements. The new guidance is effective for all entities for fiscal years beginning after December 15, 2019 and for interim periods within those fiscal years. An entity is permitted to early adopt either the entire standard or only the provisions that eliminate or modify requirements. We do not expect that the adoption of this standard will have a material effect on our disclosures.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman , Times, serif; margin: 0px; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">In June 2018, the FASB issued ASU 2018-07 to simplify the accounting for share-based payments to nonemployees by aligning it with the accounting for share-based payments to employees, with certain exceptions. The new guidance expands the scope of ASC 718 to include share-based payments granted to nonemployees in exchange for goods or services used or consumed in an entity&#x2019;s own operations and supersedes the guidance in ASC 505-50. The guidance is effective for public business entities in annual periods beginning after December 15, 2018, and interim periods within those annual periods. Early adoption is permitted, including in an interim period for which financial statements have not been issued, but not before an entity adopts ASC 606. We adopted this standard on January 1, 2019 and the adoption of this standard did not have a material effect on our consolidated financial statements.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman , Times, serif; margin: 0px; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">In February 2016, the FASB issued ASU 2016-02, Leases. This guidance requires lessees to record most leases on their balance sheets while recognizing expenses on their income statements in a manner similar to current accounting. The guidance also eliminates current real estate-specific provisions for all entities. For lessors, the guidance modifies the classification criteria and the accounting for sales-type and direct financing leases. The standard was effective for public business entities for annual periods beginning after December 15, 2018, and interim periods within those years. In July 2018, the FASB amended the new leases standard and issued ASU 2018-11, Leases, (Topic 842): Targeted Improvements to give entities another option for transition and to provide lessors with a practical expedient. We adopted ASU 2016-02 on January 1, 2019 utilizing the alternative transition method allowed for under ASU 2018-11 and we recorded a $3.8 million right of use asset and a $4.1 million liability related to adoption of this standard. In addition, upon commencement of additional lease space in the third quarter of 2019 (as disclosed in Note 13), we recorded an additional $7.4 million right of use asset and an additional $7.2 million liability related to our new lease space. Comparative financial information was not adjusted and will continue to be reported under ASC 840. We also elected the transition relief package of practical expedients and as a result we did not assess (1) whether existing or expired contracts contain leases, (2) lease classification for any existing or expired leases, and (3) whether lease origination costs qualified as initial direct costs. We elected the short-term lease practical expedient by establishing an accounting policy to exclude leases with a term of 12 months or less. We elected not to separate lease components from non-lease components for our specified asset classes. Additionally, the adoption of the new standard resulted in increased disclosure requirements in our quarterly and annual filings.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman , Times, serif; margin: 0px; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants and the SEC did not, and are not expected to, have a material effect on our results of operations or financial position.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b>Off-Balance Sheet Arrangements</b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">As of December 31, 2019, 2018, and 2017, we had no off-balance sheet arrangements that have had or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">In the ordinary course of business, we enter into agreements with third parties that include indemnification provisions, which, in our judgment, are normal and customary for companies in our industry sector. These agreements are typically with business partners, clinical sites, and suppliers. Pursuant to these agreements, we generally agree to indemnify, hold harmless, and reimburse indemnified parties for losses suffered or incurred by the indemnified parties with respect to our drugs or drug candidates, use of such drugs or drug candidates, or other actions taken or omitted by us. The maximum potential amount of future payments we could be required to make under these indemnification provisions is sometimes unlimited. We have not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. As a result, the estimated fair value of liabilities relating to these provisions is minimal. Accordingly, we have no liabilities recorded for these provisions as of December 31, 2019, 2018, and 2017.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <!-- Field: Page; Sequence: 67; Value: 1-->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt">
        <p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">
            <!-- Field: Sequence; Type: Arabic; Name: PageNo-->67<!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&#160;</p>
    </div>
    <!-- Field: /Page -->
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">In the normal course of business, we may be confronted with issues or events that may result in a contingent liability. These generally relate to lawsuits, claims, environmental actions or the actions of various regulatory agencies. We consult with counsel and other appropriate experts to assess the claim. If, in our opinion, we have incurred a probable loss as set forth by GAAP, an estimate is made of the loss and the appropriate accounting entries are reflected in our financial statements.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b>Effects of Inflation</b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">For each of the fiscal years ended December 31, 2019, 2018, and 2017, our business and operations have not been materially affected by inflation.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b>Contractual Obligations</b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">A summary of contractual obligations as of December 31, 2019 is as follows:</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; width: 92%; border-collapse: collapse">
        <tr style="vertical-align: bottom">
            <td style="text-align: justify">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td colspan="2" style="text-align: center">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td colspan="14" style="border-bottom: Black 1pt solid; text-align: center">Payments Due by Period</td>
            <td style="padding-bottom: 1pt">&#160;</td>
        </tr>
        <tr style="vertical-align: bottom">
            <td style="text-align: justify">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Total</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Less than 1 Year</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">1-3 Years</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">3-5 Years</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">More than 5 Years</td>
            <td style="padding-bottom: 1pt">&#160;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="width: 35%; text-align: justify">Operating lease obligations</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">$</td>
            <td style="width: 10%; text-align: right">15,684,456</td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">$</td>
            <td style="width: 10%; text-align: right">1,566,617</td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">$</td>
            <td style="width: 10%; text-align: right">3,460,843</td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">$</td>
            <td style="width: 10%; text-align: right">2,620,065</td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">$</td>
            <td style="width: 10%; text-align: right">8,036,931</td>
            <td style="width: 1%; text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td style="text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">Debt payments <sup>(1)</sup></span>
            </td>
            <td>&#160;</td>
            <td style="text-align: left"></td>
            <td style="text-align: right">200,000,000</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#x2014;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#x2014;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">200,000,000</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#x2014;</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">Interest payment <sup>(2)</sup></span>
            </td>
            <td>&#160;</td>
            <td style="text-align: left"></td>
            <td style="text-align: right">80,929,444</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">20,900,000</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">41,800,000</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">18,229,444</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#x2014;</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td style="padding-bottom: 1pt; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">Purchase commitments <sup>(3)</sup></span>
            </td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">34,671,190</td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">6,700,603</td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">9,643,326</td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">13,204,246</td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">5,123,015</td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="padding-bottom: 2pt; text-align: justify">Total</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: left">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right">331,285,090</td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: left">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right">29,167,220</td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: left">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right">54,904,169</td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: left">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right">234,053,755</td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: left">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right">13,159,946</td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
        </tr>
    </table>
    <p style="margin-bottom: 0; margin-top: 0">&#160;</p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">
                <span style="font: 10pt Times New Roman, Times, Serif">(1)</span>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif; color: #212529">The outstanding principal amount of the Financing Agreement is payable in four equal quarterly installments beginning on June 30, 2023, with the Financing Agreement maturing on March 31, 2024. </span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">
                <span style="font: 10pt Times New Roman, Times, Serif">(2)</span>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">Interest calculation is based on interest rates in place on December 31, 2019.</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">
                <span style="font: 10pt Times New Roman, Times, Serif">(3)</span>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">Includes manufacturing purchase commitments described below.&#160;The amounts presented here represent our estimates of the minimum required payments under our agreements.</span>
            </td>
        </tr>
    </table>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0; margin-right: 0; margin-top: 0">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b>Intellectual Property Licenses</b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">We have license agreements with third parties that provide for minimum royalty, license, and exclusivity payments to be paid by us for access to certain technologies. In addition, we pay royalties as a percent of revenue as described in Note 6, Intangible Assets, to these consolidated financial statements.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b>Purchase Commitments</b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">We have manufacturing and supply agreements whereby we are required to purchase from Catalent a minimum number of softgels during the first contract year and a higher number or softgels after the first contract year. If the minimum order quantities of specific products are not met, we are required to pay Catalent 50% of the difference between the total amount we would have paid to Catalent if the minimum requirement had been fulfilled and the sum of all purchases of our products from Catalent during the contract year.&#160;
            <span style="color: #212529">In addition, we</span> have a manufacturing and supply agreement whereby we are required to purchase a minimum number of units of ANNOVERA during a contract year.
            <span style="color: #212529">As of December 31, 2019, we have met our minimum purchase commitments with our manufacturers related to fiscal year 2019.</span>
        </span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b>Legal Proceedings</b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">From time to time, we are involved in litigation and proceedings in the ordinary course of business. We are not currently involved in any legal proceeding that we believe would have a material effect on our consolidated financial condition, results of operations, or cash flows.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <!-- Field: Page; Sequence: 68; Value: 1-->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt">
        <p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">
            <!-- Field: Sequence; Type: Arabic; Name: PageNo-->68<!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&#160;</p>
    </div>
    <!-- Field: /Page -->
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b>Employment Agreements</b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">We have entered into employment agreements with certain of our executives that provide for compensation and certain other benefits. Under certain circumstances, including a change in control, some of these agreements provide for severance or other payments, if those circumstances occur during the term of the employment agreement.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b>Seasonality</b></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The specialty pharmaceutical industry component of women&#x2019;s health is not subject to seasonal sales fluctuation, however, we anticipate that high deductible and annual prescription copay resets under commercial insurance plans at the beginning of the calendar year will affect our first quarter net revenue.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="vertical-align: top; text-align: justify">
            <td style="width: 0in"></td>
            <td style="width: 1in; text-align: left">
                <span style="font: 10pt Times New Roman, Times, Serif"><b>Item 7A</b></span>
            </td>
            <td style="text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif"><b><span id="txmd10ka012"></span>Quantitative and Qualitative Disclosures About Market Risk</b></span>
            </td>
        </tr>
    </table>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">We had a cash balance of approximately $160,830,000 as of December 31, 2019. We hold certain portions of our cash balances in overnight money market placements all of which are fully available to us to support our cash flow requirements. The primary objective of our investment policy is to preserve principal and maintain proper liquidity to meet operating needs. Our investment policy specifies credit quality standards for our investments and limits the amount of credit exposure to any single issue, issuer or type of investment. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates. To minimize this risk, we intend to maintain an investment portfolio that may include cash, cash equivalents and investment securities available-for-sale in a variety of securities which may include money market funds, government and non-government debt securities and commercial paper, all with various maturity dates. Due to the low risk profile of our investments, an immediate 100 basis point change in interest rates would not have a material effect on the fair market value of our portfolio.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">As of April 24, 2019, we repaid all amounts outstanding under the MidCap Agreement and became subject to market risk in connection with borrowings under the Financing Agreement. Amounts borrowed under the Financing Agreement will accrue interest at either (i) 3-month LIBOR plus 7.75%, subject to a LIBOR floor of 2.70% or (ii) the prime rate plus 6.75%, subject to a prime rate floor of 5.20%. Considering the total outstanding principal balance under the Financing Agreement of approximately $200,000,000 at December 31, 2019, a 1.0% change in interest rates would result in an impact to income before income taxes of approximately $2,000,000 per year.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="vertical-align: top; text-align: justify">
            <td style="width: 0in"></td>
            <td style="width: 1in; text-align: left">
                <span style="font: 10pt Times New Roman, Times, Serif"><b>Item 8.</b></span>
            </td>
            <td style="text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif"><b><span id="txmd10ka013"></span>Financial Statements and Supplementary Data</b></span>
            </td>
        </tr>
    </table>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Reference is made to the financial statements, the notes thereto, and the reports thereon, commencing on page F-1 of this Annual Report, which financial statements, notes, and reports are incorporated herein by reference.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="vertical-align: top; text-align: justify">
            <td style="width: 0in"></td>
            <td style="width: 1in; text-align: left">
                <span style="font: 10pt Times New Roman, Times, Serif"><b>Item 9.</b></span>
            </td>
            <td style="text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif"><b><span id="txmd10ka014"></span>Change in and Disagreements With Accountants on Accounting and Financial Disclosure</b></span>
            </td>
        </tr>
    </table>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">None.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="vertical-align: top; text-align: justify">
            <td style="width: 0in"></td>
            <td style="width: 1in; text-align: left">
                <span style="font: 10pt Times New Roman, Times, Serif"><b>Item 9A.</b></span>
            </td>
            <td style="text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif"><b><span id="txmd10ka015"></span>Controls and Procedures</b></span>
            </td>
        </tr>
    </table>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><i>Evaluation of Disclosure Controls and Procedures</i></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in the Securities Exchange Act of 1934 Rules 13a-15(e) or 15d-15(e)) as of the end of the period covered by this Annual Report on Form 10-K. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of December 31, 2019, our disclosure controls and procedures were effective to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act is (i) recorded, processed, summarized, and reported within the time periods specified in the SEC rules and forms, and (ii) is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><i>Changes in Internal Control over Financial Reporting</i></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">There was no change in our internal control over financial reporting during our most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><i>Inherent Limitations on Effectiveness of Controls</i></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal controls will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefit of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues, misstatements, errors, and instances of fraud, if any, within our company have been or will be prevented or detected. Further, internal controls may become inadequate because of changes in conditions, or through the deterioration of the degree of compliance with policies or procedures.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <!-- Field: Page; Sequence: 69; Value: 1-->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt">
        <p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">
            <!-- Field: Sequence; Type: Arabic; Name: PageNo-->69<!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&#160;</p>
    </div>
    <!-- Field: /Page -->
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><i>Management&#x2019;s Annual Report on Internal Control over Financial Reporting</i></span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined under Exchange Act Rules 13a-15(f) and 15d-15(f). Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP. Internal control over financial reporting includes those policies and procedures that:</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets;</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and</span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#x25CF;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif">provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of our assets that could have a material effect on the financial statements.</span>
            </td>
        </tr>
    </table>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0; margin-right: 0; margin-top: 0">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Our management assessed the effectiveness of our internal control over financial reporting as of December 31, 2019. In making this assessment, our management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control&#x2014;Integrated Framework (2013). Management&#x2019;s assessment included an evaluation of the design of our internal control over financial reporting and testing of the operational effectiveness of its internal control over financial reporting. Based on management&#x2019;s assessment, we believe that our internal controls over financial reporting were effective as of December 31, 2019.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">The effectiveness of our internal control over financial reporting as of December 31, 2019 has been audited by Grant Thornton LLP, an independent registered public accounting firm, as stated in their Report of Independent Registered Public Accounting Firm on Internal Control Over Financial Reporting as of December 31, 2019, which appears below.</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>
    <!-- Field: Page; Sequence: 70; Value: 1-->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt">
        <p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">
            <!-- Field: Sequence; Type: Arabic; Name: PageNo-->70<!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&#160;</p>
    </div>
    <!-- Field: /Page -->
    <p style="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif"><b>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></span>
    </p>
    <p style="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman,serif; margin: 0pt 0">
        <span style="font: 10pt Times New Roman, Times, Serif">Board of Directors and Stockholders
            <br /> TherapeuticsMD, Inc.</span>
    </p>
    <p style="font: 10pt Times New Roman,serif; margin: 0pt 0">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <h2 style="margin-top: 0in; line-height: 14pt"><span style="font-size: 10pt"><strong>Opinion on internal control over financial reporting</strong></span></h2>
    <p style="text-align: justify">We have audited the internal control over financial reporting of TherapeuticsMD, Inc. (a Nevada corporation) and subsidiaries (the &#x201C;Company&#x201D;) as of December 31, 2019, based on criteria established in the 2013 <em>Internal Control&#x2014;Integrated Framework</em> issued by the Committee of Sponsoring Organizations of the Treadway Commission (&#x201C;COSO&#x201D;). In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2019, based on criteria established in the 2013 <em>Internal Control&#x2014;Integrated Framework</em> issued by COSO.</p>
    <p style="text-align: justify">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (&#x201C;PCAOB&#x201D;), the consolidated financial statements of the Company as of and for the year ended December 31, 2019, and our report dated February 24, 2020 expressed an unqualified opinion on those financial statements.</p>
    <h2 style="margin-top: 0in; line-height: 14pt"><span style="font-size: 10pt"><strong>Basis for opinion</strong></span></h2>
    <p style="text-align: justify">The Company&#x2019;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management&#x2019;s Annual Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#x2019;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>
    <p style="text-align: justify">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</p>
    <h2 style="margin-top: 0in; line-height: 14pt"><span style="font-size: 10pt"><strong>Definition and limitations of internal control over financial reporting</strong></span></h2>
    <p style="text-align: justify">A company&#x2019;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#x2019;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#x2019;s assets that could have a material effect on the financial statements.</p>
    <p style="text-align: justify">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</p>
    <p style="font: 10pt Times New Roman,serif; margin: 0pt 0">
        <span style="font: 10pt Times New Roman, Times, Serif">/s/ GRANT THORNTON LLP</span>
    </p>
    <p style="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman,serif; margin: 0pt 0">
        <span style="font: 10pt Times New Roman, Times, Serif">Fort Lauderdale, Florida&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman,serif; margin: 0pt 0">
        <span style="font: 10pt Times New Roman, Times, Serif">February 24, 2020</span>
    </p>
    <p style="font: 10pt Times New Roman,serif; margin: 0pt 0">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <!-- Field: Page; Sequence: 71; Value: 1-->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt">
        <p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">
            <!-- Field: Sequence; Type: Arabic; Name: PageNo-->71<!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&#160;</p>
    </div>
    <!-- Field: /Page -->
    <p style="font: 10pt Times New Roman,serif; margin: 0pt 0">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman,serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="vertical-align: top">
            <td style="width: 1in">
                <span style="font: 10pt Times New Roman, Times, Serif"><b>Item 9B.</b></span>
            </td>
            <td style="text-align: justify">
                <span style="font: 10pt Times New Roman, Times, Serif"><b><span id="txmd10ka016"></span>Other Information</b></span>
            </td>
        </tr>
    </table>
    <p style="font: 10pt Times New Roman,serif; margin-bottom: 0pt; margin-top: 0pt">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="margin-top: 0pt; text-align: justify; margin-bottom: 0pt; text-indent: 0.5in">On February 20, 2020, following its fourth quarter 2019 earnings call, TherapeuticsMD received a Paragraph IV certification notice letter (the &#x201C;Notice Letter&#x201D;), regarding an Abbreviated New Drug Application (&#x201C;ANDA&#x201D;) submitted to the U.S. Food and Drug Administration (the &#x201C;FDA&#x201D;) by Teva Pharmaceuticals USA, Inc. (&#x201C;Teva&#x201D;). The ANDA seeks approval from the FDA to commercially manufacture, use, or sell a generic version of the 4 mcg and 10 mcg doses of IMVEXXY&#xAE; (estradiol vaginal inserts). In the Notice Letter, Teva alleges that TherapeuticsMD patents listed in the FDA&#x2019;s Orange Book that claim compositions and methods of IMVEXXY (the &#x201C;IMVEXXY Patents&#x201D;) are invalid, unenforceable, and/or will not be infringed by Teva&#x2019;s commercial manufacture, use, or sale of its proposed generic drug product. The IMVEXXY Patents identified in the Notice Letter expire in 2032 or 2033.</p>

<p style="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
    <p style="margin-top: 0pt; text-align: justify; margin-bottom: 0pt; text-indent: 0.5in">TherapeuticsMD is currently reviewing the Notice Letter and intends to vigorously enforce its intellectual property rights relating to IMVEXXY. Under the Hatch-Waxman Act, TherapeuticsMD has 45 days from receipt of the Notice Letter to initiate a patent infringement lawsuit
against Teva. Such a lawsuit would automatically preclude the FDA from approving Teva&#x2019;s ANDA until the earlier of
30 months or entry of a district court decision finding the IMVEXXY Patents invalid, unenforceable, or not infringed.<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="margin-top: 0pt; text-align: justify; margin-bottom: 0pt; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
    <p style="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: center">
        <span style="font: 10pt Times New Roman, Times, Serif"><b><span id="txmd10ka017"></span>PART III</b></span>
    </p>
    <p style="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: center">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman,serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="vertical-align: top">
            <td style="width: 1in; text-align: left">
                <span style="font: 10pt Times New Roman, Times, Serif"><b>Item 10.&#160;</b></span>
            </td>
            <td>
                <span style="font: 10pt Times New Roman, Times, Serif"><b><span id="txmd10ka018"></span>Directors, Executive Officers, and Corporate Governance</b></span>
            </td>
        </tr>
    </table>
    <p style="font: 10pt Times New Roman,serif; margin: 0pt 0">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">The information required by this Item relating to our directors and corporate governance is incorporated herein by reference to the definitive Proxy Statement to be filed pursuant to Regulation 14A of the Exchange Act for our 2020 Annual Meeting of Stockholders.</span>
    </p>
    <p style="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman,serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="vertical-align: top">
            <td style="width: 1in; text-align: left">
                <span style="font: 10pt Times New Roman, Times, Serif"><b>Item 11.&#160;</b></span>
            </td>
            <td>
                <span style="font: 10pt Times New Roman, Times, Serif"><b><span id="txmd10ka019"></span>Executive Compensation</b></span>
            </td>
        </tr>
    </table>
    <p style="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">The information required by this Item is incorporated herein by reference to the definitive Proxy Statement to be filed pursuant to Regulation 14A of the Exchange Act for our 2020 Annual Meeting of Stockholders.</span>
    </p>
    <p style="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman,serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="vertical-align: top">
            <td style="width: 1in; text-align: left">
                <span style="font: 10pt Times New Roman, Times, Serif"><b>Item 12.&#160;</b></span>
            </td>
            <td>
                <span style="font: 10pt Times New Roman, Times, Serif"><b><span id="txmd10ka020"></span>Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</b></span>
            </td>
        </tr>
    </table>
    <p style="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">The information required by this Item is incorporated herein by reference to the definitive Proxy Statement to be filed pursuant to Regulation 14A of the Exchange Act for our 2020 Annual Meeting of Stockholders.</span>
    </p>
    <p style="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman,serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="vertical-align: top">
            <td style="width: 1in; text-align: left">
                <span style="font: 10pt Times New Roman, Times, Serif"><b>Item 13.&#160;</b></span>
            </td>
            <td>
                <span style="font: 10pt Times New Roman, Times, Serif"><b><span id="txmd10ka021"></span>Certain Relationships and Related Transactions, and Director Independence</b></span>
            </td>
        </tr>
    </table>
    <p style="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">The information required by this Item is incorporated herein by reference to the definitive Proxy Statements to be filed pursuant to Regulation 14A of the Exchange Act for our 2020 Annual Meeting of Stockholders.</span>
    </p>
    <p style="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman,serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="vertical-align: top">
            <td style="width: 1in; text-align: left">
                <span style="font: 10pt Times New Roman, Times, Serif"><b>Item 14.&#160;</b></span>
            </td>
            <td>
                <span style="font: 10pt Times New Roman, Times, Serif"><b><span id="txmd10ka022"></span>Principal Accounting Fees and Services</b></span>
            </td>
        </tr>
    </table>
    <p style="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">The information required by this Item is incorporated herein by reference to the definitive Proxy Statements to be filed pursuant to Regulation 14A of the Exchange Act for our 2020 Annual Meeting of Stockholders.</span>
    </p>
    <p style="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <!-- Field: Page; Sequence: 72; Value: 1-->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt">
        <p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">
            <!-- Field: Sequence; Type: Arabic; Name: PageNo-->72<!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&#160;</p>
    </div>
    <!-- Field: /Page -->
    <p style="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif"><b><span id="txmd10ka023"></span>PART IV</b></span>
    </p>
    <p style="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman,serif; margin-bottom: 0pt; margin-top: 0pt; width: 100%">
        <tr style="vertical-align: top">
            <td style="width: 1in; text-align: left">
                <span style="font: 10pt Times New Roman, Times, Serif"><b>Item 15.&#160;</b></span>
            </td>
            <td>
                <span style="font: 10pt Times New Roman, Times, Serif"><b><span id="txmd10ka024"></span>Exhibits and Financial Statement Schedules</b></span>
            </td>
        </tr>
    </table>
    <p style="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; border-collapse: collapse">
        <tr>
            <td style="width: 0.5in; vertical-align: top; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">(a)</span>
            </td>
            <td style="vertical-align: top; text-align: justify; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif"><b>Financial Statements and Financial Statements Schedules</b></span>
            </td>
        </tr>
    </table>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; border-collapse: collapse">
        <tr style="vertical-align: top">
            <td style="width: 0.5in; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="width: 0.5in; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">(1)</span>
            </td>
            <td style="text-align: justify; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">Financial Statements are listed in the Index to Consolidated Financial Statements on page F-1 of this Annual Report. &#160; &#160;</span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td style="text-align: justify; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="text-align: justify; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td style="text-align: justify; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">(2)</span>
            </td>
            <td style="text-align: justify; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">No financial statement schedules are included because such schedules are not applicable, are not required, or because required information is included in the consolidated financial statements or notes thereto.</span>
            </td>
        </tr>
    </table>
    <p style="margin: 0">&#160;</p>
    <table cellpadding="0" cellspacing="0" style="font: 9pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
        <tr style="vertical-align: top">
            <td style="width: 1%; font-size: 9pt">&#160;</td>
            <td style="width: 6%; font-size: 9pt">
                <span style="font-size: 9pt">(b)</span>
            </td>
            <td style="width: 93%; text-align: justify; font-size: 9pt">
                <span style="font-size: 9pt"><b>Exhibits</b></span>
            </td>
        </tr>
    </table>
    <p style="margin: 0">&#160;</p>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; border-collapse: collapse">
        <tr style="vertical-align: top">
            <td style="width: 4%; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="border-bottom: black 1pt solid; width: 8%; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif"><b>Exhibit</b></span>
            </td>
            <td style="width: 1%; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="border-bottom: black 1pt solid; width: 18%; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif"><b>Date</b></span>
            </td>
            <td style="width: 1%; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="border-bottom: black 1pt solid; width: 68%; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif"><b>Description</b></span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/25743/000101968709002459/croff_8k-ex0201.htm">2.1</a></span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">July 6, 2009</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">Agreement and Plan of Reorganization among Croff Enterprises, Inc., AMHN Acquisition Corp., America&#x2019;s Minority Health Network, Inc., and the Major Shareholders <sup>(1)</sup></span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/25743/000119312510138955/dex101.htm">2.2</a></span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">June 11, 2010</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">Agreement and Plan of Reorganization among AMHN, Inc., SHN Acquisition Corp., Spectrum Health Network, Inc., and the Sole Shareholder of Spectrum Health Network, Inc. <sup>(2)</sup></span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/25743/000135601808000256/ex332.htm">2.3</a></span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">October 25, 2007</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">Croff Enterprises, Inc. Plan of Corporate Division and Reorganization <sup>(3)</sup></span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713111001316/ex-10_01.htm">2.4</a></span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">July 18, 2011</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">Agreement and Plan of Merger among VitaMedMD, LLC, AMHN, Inc., and VitaMed Acquisition, LLC <sup>(4)</sup></span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/25743/000119312510175462/dex34.htm">3.1</a></span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">July 20, 2010</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">Articles of Conversion of AMHN, Inc. filed in the State of Nevada<sup>(5)</sup></span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/25743/000119312510175462/dex35.htm">3.2</a></span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">July 20, 2010</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">Articles of Incorporation of AMHN, Inc. filed in the State of Nevada<sup>(5)</sup></span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713115002352/ex3-1.htm">3.3</a></span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">n/a</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">Composite Amended and Restated Articles of Incorporation of the Company, as amended <sup>(6)</sup></span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/25743/000119312510149198/ddef14c.htm">3.4</a></span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">n/a</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">Bylaws of AMHN, Inc. <sup>(7)</sup></span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713115003704/ex3-1.htm">3.5</a></span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">December 17, 2015</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">First Amendment to Bylaws of the Company <sup>(8)</sup></span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713113000166/ex4-2.htm">4.1</a></span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">n/a</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">Form of Certificate of Common Stock <sup>(9)</sup></span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif"><a href="ex4-2.htm">4.2</a>&#x2020;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">n/a</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">Description of Securities of the Company</span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713111002213/ex-10_3.htm">10.1</a></span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">n/a</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">Form of Common Stock Purchase Warrant <sup>(10)</sup></span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713111002213/ex-10_2.htm">10.2</a>*</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">n/a</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">Form of Non-Qualified Stock Option Agreement <sup>(10)</sup></span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713119004545/ex99-1.htm">10.3</a>*</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">n/a</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">TherapeuticsMD, Inc. 2019 Stock Incentive Plan <sup>(11)</sup></span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713113003145/ex10-34.htm">10.4</a>*</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">n/a</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">Amended and Restated 2012 Stock Incentive Plan <sup>(12)</sup></span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/25743/000119312513399924/d611784dex991.htm">10.5</a>*</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">n/a</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">2009 Long Term Incentive Compensation Plan, as amended <sup>(13)</sup></span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713111002306/ex10_7.htm">10.6</a></span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">October 23, 2011</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">Common Stock Purchase Warrant to Lang Naturals, Inc. <sup>(14)</sup></span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713112000490/ex-10_3.htm">10.7</a></span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">February 24, 2012</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">Form of Common Stock Purchase Warrant <sup>(15)</sup></span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713119005935/ex10-1.htm">10.8</a>***</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">April 24, 2019</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">Financing Agreement, by and among TherapeuticsMD, Inc., VitaMedMD, LLC, BocagreenMD, Inc., VitaCare Prescription Services, Inc., TPG Specialty Lending, Inc., Top IV Talents, LLC and Tao Talents, LLC <sup>(18)</sup></span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713119005935/ex10-2.htm">10.9</a>***</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">April 24, 2019</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">Pledge and Security Agreement, by and among TherapeuticsMD, Inc., VitaMedMD, LLC, BocagreenMD, Inc., VitaCare Prescription Services, Inc. and TPG Specialty Lending, Inc. <sup>(18)</sup></span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713112003625/ex10-28.htm">10.10</a>*</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">November 8, 2012</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">Form of Employment Agreement <sup>(19)</sup></span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713113000292/ex10_1.htm">10.11</a></span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">January 31, 2013</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">Common Stock Purchase Warrant, issued to Plato &#38; Associates, LLC <sup>(20)</sup></span>
            </td>
        </tr>
<tr style="vertical-align: top">
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713119008469/ex10-1.htm">10.12</a>***</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">September 28, 2018</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">Commercial Supply Agreement by and between TherapeuticsMD, Inc. and QPharma AB<sup>(23)</sup></span>
            </td>
        </tr>
<tr style="vertical-align: top">
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713113001675/ex10-31.htm">10.13</a>*</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">May 8, 2013</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">Agreement to Forfeit Non-Qualified Stock Options between the Company and Robert G. Finizio <sup>(22)</sup></span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713119008469/ex10-2.htm">10.14</a>***</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">October 5, 2018</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">Lease by and between 951 Yamato Acquisition Company, LLC and TherapeuticsMD, Inc. <sup>(23)</sup></span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713118003401/ex10-1.htm">10.15</a>**</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">April 20, 2016</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">Softgel Commercial Supply Agreement by and between TherapeuticsMD, Inc. and Catalent Pharma Solutions, LLC <sup>(16)</sup></span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713119001471/ex10-20.htm">10.16</a>**</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">June 24, 2016</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">Softgel Commercial Supply Agreement by and between TherapeuticsMD, Inc. and Catalent Pharma Solutions, LLC <sup>(17)</sup></span>
            </td>
        </tr>
    </table>
    <p style="margin: 0">&#160;</p>
    <!-- Field: Page; Sequence: 73; Value: 1-->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt">
        <p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">
            <!-- Field: Sequence; Type: Arabic; Name: PageNo-->73<!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&#160;</p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0">&#160;</p>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; border-collapse: collapse">
        <tr style="vertical-align: top">
            <td style="width: 4%; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="width: 8%; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713118005976/ex10-1.htm">10.17</a>**</span>
            </td>
            <td style="width: 1%; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="width: 18%; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">July 30, 2018</span>
            </td>
            <td style="width: 1%; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="width: 68%; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">Population Council License Agreement by and between TherapeuticsMD, Inc. and The Population Council, Inc. <sup>(21)</sup></span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif"><a href="ex10-18.htm">10.18</a>&#x2020;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">December 27, 2019</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">Amendment No. 1 to the Financing Agreement, by and among TherapeuticsMD, Inc., VitaMedMD, LLC, BocagreenMD, Inc., VitaCare Prescription Services, Inc., TPG Specialty Lending, Inc., Top IV Talents, LLC and Tao Talents, LLC </span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713115003704/ex10-1.htm">10.19</a>*</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">December 17, 2015</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">Employment Agreement between the Company and Brian Bernick<sup>(8)</sup></span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713115003704/ex10-2.htm">10.20</a>*</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">December 17, 2015</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">Employment Agreement between the Company and Michael Donegan <sup>(8)</sup></span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713115003704/ex10-3.htm">10.21</a>*</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">December 17, 2015</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">Employment Agreement between the Company and Mitchell Krassan <sup>(8)</sup></span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713119005935/ex10-3.htm">10.22</a>***</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">June 6, 2019</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">License and Supply Agreement, by and between TherapeuticsMD, Inc. and Theramex HQ UK Limited <sup>(18)</sup></span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <a href="ex21-1.htm">
                    <span style="font: 10pt Times New Roman, Times, Serif">21.1&#x2020;</span>
                </a>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">February 24, 2020</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">Subsidiaries of the Company</span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <a href="ex23-1.htm">
                    <span style="font: 10pt Times New Roman, Times, Serif">23.1&#x2020;</span>
                </a>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">February 24, 2020</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">Consent of Grant Thornton LLP</span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <a href="ex31-1.htm">
                    <span style="font: 10pt Times New Roman, Times, Serif">31.1&#x2020;</span>
                </a>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">February 24, 2020</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">Certification of Chief Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a), promulgated under the Securities Exchange Act of 1934, as amended</span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <a href="ex31-2.htm">
                    <span style="font: 10pt Times New Roman, Times, Serif">31.2&#x2020;</span>
                </a>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">February 24, 2020</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif"> <span style="font: 10pt Times New Roman, Times, Serif">Certification of Chief
            Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a), promulgated under the Securities Exchange Act of 1934, as
            amended</span> </td>
        </tr>
        <tr style="vertical-align: top">
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <a href="ex32-1.htm">
                    <span style="font: 10pt Times New Roman, Times, Serif">32.1&#x2020;&#x2020;</span>
                </a>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">February 24, 2020</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">Certification pursuant to U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <a href="ex32-2.htm">
                    <span style="font: 10pt Times New Roman, Times, Serif">32.2&#x2020;&#x2020;</span>
                </a>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">February 24, 2020</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">101.INS&#x2020;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">n/a</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">XBRL Instance Document &#x2013; the instance document does not appear in the Interactive Data file because its XBRL tags are embedded within the Inline XBRL document</span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">101.SCH&#x2020;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">n/a</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">XBRL Taxonomy Extension Schema Document</span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">101.CAL&#x2020;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">n/a</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">XBRL Taxonomy Extension Calculation Linkbase Document</span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">101.DEF&#x2020;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">n/a</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">XBRL Taxonomy Extension Definition Linkbase Instance Document</span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">101.LAB&#x2020;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">n/a</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">XBRL Taxonomy Extension Label Linkbase Instance Document</span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">101.PRE&#x2020;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">n/a&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">XBRL Taxonomy Extension Presentation Linkbase Instance Document&#160;</span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">104&#x2020;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">n/a</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">Cover Page Interactive Data File (formatted as Inline XBRL and Contained in Exhibit 101)</span>
            </td>
        </tr>
    </table>
    <p style="margin: 0">&#160;</p>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; border-collapse: collapse">
        <tr style="vertical-align: top">
            <td style="width: 4%; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">*</span>
            </td>
            <td style="width: 96%; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">Indicates a contract with management or compensatory plan or arrangement.</span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">**</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">Certain confidential material contained in the document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been granted with respect to this omitted information.</span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">***</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">Portions of this exhibit have been redacted in compliance with Regulation S-K Item 601(b)(10). The omitted information is not material and would likely cause competitive harm to the Company if publicly disclosed.</span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#x2020;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">Filed herewith.</span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#x2020;&#x2020;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">Furnished herewith.</span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif"><sup>(1)</sup></span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">Filed as an exhibit to Form 8-K filed with the Commission on July 10, 2009 and incorporated herein by reference (SEC File No. 000-16731).</span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif"><sup>(2)</sup></span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">Filed as an exhibit to Form 8-K filed with the Commission on June 14, 2010 and incorporated herein by reference (SEC File No. 000-16731).</span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif"><sup>(3)</sup></span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">Filed as an exhibit to Form 10-K for the year ended December 31, 2007 filed with the Commission on May 1, 2008 and incorporated herein by reference (SEC File No. 000-16731).</span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif"><sup>(4)</sup></span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">Filed as an exhibit to Form 8-K filed with the Commission on July 21, 2011 and incorporated herein by reference (SEC File No. 000-16731).</span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif"><sup>(5)</sup></span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2010 filed with the Commission on August 3, 2010 and incorporated herein by reference (SEC File No. 000-16731).</span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif"><sup>(6)</sup></span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2015 filed with the Commission on August 7, 2015 and incorporated herein by reference (SEC File No. 001-00100).</span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif"><sup>(7)</sup></span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">Filed as an exhibit to Definitive 14C Information Statement filed with the Commission on June 29, 2010 and incorporated herein by reference (SEC File No. 000-16731).</span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif"><sup>(8)</sup></span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">Filed as an exhibit to Form 8-K filed with the Commission on December 22, 2015 and incorporated herein by reference (SEC File No. 001-00100).</span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif"><sup>(9)</sup></span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">Filed as an exhibit to Form S-3 filed with the Commission on January 25, 2013 and incorporated hereby by reference (SEC File No. 333-186189).</span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif"><sup>(10)</sup></span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">Filed as an exhibit to Form 8-K filed with the Commission on October 11, 2011 and incorporated herein by reference (SEC File No. 000-16731).</span>
            </td>
        </tr>
    </table>
    <p style="margin: 0">&#160;</p>
    <!-- Field: Page; Sequence: 74; Value: 1-->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt">
        <p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">
            <!-- Field: Sequence; Type: Arabic; Name: PageNo-->74<!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&#160;</p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0">&#160;</p>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; border-collapse: collapse">
        <tr style="vertical-align: top">
            <td style="width: 4%; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif"><sup>(11)</sup></span>
            </td>
            <td style="width: 96%; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">Filed as an exhibit to Form S-8 filed with the Commission on June 21, 2019 and incorporated herein by reference (SEC File No. 333-232268).</span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif"><sup>(12)</sup></span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">Filed as an exhibit to Form 8-K filed with the Commission on August 22, 2013 and incorporated herein by reference (SEC File No. 001-00100).</span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif"><sup>(13)</sup></span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">Filed as an exhibit to Registration Statement on Form S-8 filed with the Commission on October 15, 2013 and incorporated herein by reference (SEC File No. 333-191730).</span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif"><sup>(14)</sup></span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">Filed as an exhibit to Form 8-K filed with the Commission on October 24, 2011 and incorporated herein by reference (SEC File No. 000-16731).</span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif"><sup>(15)</sup></span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">Filed as an exhibit to Form 8-K filed with the Commission on February 24, 2012 and incorporated herein by reference (SEC File No. 000-16731).</span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif"><sup>(16)</sup></span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2018 filed with the Commission on July 30, 2018 and incorporated herein by reference (SEC File No. 001-00100).</span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif"><sup>(17)</sup></span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">Filed as an exhibit to Form 10-K for the year ended December 31, 2018 filed with the Commission on February 27, 2019 and incorporated herein by reference (SEC File No. 001-00100).</span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif"><sup>(18)</sup></span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2019 filed with the Commission on August 9, 2019 and incorporated herein by reference (SEC File No. 001-00100).</span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif"><sup>(19)</sup></span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">Filed as an exhibit to Form 10-Q for the quarter ended September 30, 2012 filed with the Commission on November 13, 2012 and incorporated herein by reference (SEC File No. 000-16731).</span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif"><sup>(20)</sup></span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">Filed as an exhibit to Form 8-K filed with the Commission on February 6, 2013 and incorporated herein by reference (SEC File No. 000-16731).</span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif"><sup>(21)</sup></span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">Filed as an exhibit to Form 10-Q for the quarter ended September 30, 2018 filed with the Commission on November 8, 2018 and incorporated herein by reference (SEC File No. 001-00100).</span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif"><sup>(22)</sup></span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2013 filed with the Commission on May 10, 2013 and incorporated herein by reference (SEC File No. 001-00100).</span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif"><sup>(23)</sup></span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">Filed as an exhibit to Form 10-Q for the quarter ended September 30, 2019 filed with the Commission on November 8, 2019 and incorporated herein by reference (SEC File No. 001-00100).</span>
            </td>
        </tr>
    </table>
    <p style="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman,serif; margin-bottom: 0; margin-top: 0; width: 100%">
        <tr style="vertical-align: top">
            <td style="width: 1in; text-align: left">
                <span style="font: 10pt Times New Roman, Times, Serif"><b>Item 16.&#160;</b></span>
            </td>
            <td>
                <span style="font: 10pt Times New Roman, Times, Serif"><b><span id="txmd10ka025"></span>Form 10-K Summary</b></span>
            </td>
        </tr>
    </table>
    <p style="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">None.</span>
    </p>
    <p style="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <!-- Field: Page; Sequence: 75; Value: 1-->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt">
        <p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">
            <!-- Field: Sequence; Type: Arabic; Name: PageNo-->75<!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&#160;</p>
    </div>
    <!-- Field: /Page -->
    <p style="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: center">
        <span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span>
    </p>
    <p style="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: center">
        <span style="font: 10pt Times New Roman, Times, Serif"><b>SIGNATURES</b></span>
    </p>
    <p style="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: center">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span>
    </p>
    <p style="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; border-collapse: collapse">
        <tr style="vertical-align: top">
            <td style="width: 60%; text-align: justify; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">Date: February 24, 2020</span>
            </td>
            <td style="width: 40%; text-align: justify; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif"><b>THERAPEUTICSMD, INC.</b></span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td style="text-align: justify; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="text-align: justify; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td style="text-align: justify; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="border-bottom: black 1pt solid; text-align: justify; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif"><i>/s/ Robert G. Finizio</i></span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td style="text-align: justify; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="text-align: justify; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">Robert G. Finizio</span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td style="text-align: justify; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="text-align: justify; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">Chief Executive Officer</span>
            </td>
        </tr>
    </table>
    <p style="font: 10pt Times New Roman,serif; margin: 0pt 0; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman,serif; margin: 0pt 0; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the date indicated.</span>
    </p>
    <p style="font: 10pt Times New Roman,serif; margin: 0pt 0; text-indent: 0.5in">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; border-collapse: collapse">
        <tr style="vertical-align: top">
            <td style="padding-left: 5.4pt; padding-right: 5.4pt; width: 12%; text-align: center; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="border-bottom: black 1pt solid; padding-left: 5.4pt; padding-right: 5.4pt; width: 9%; text-align: center; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif"><b>Signature</b></span>
            </td>
            <td style="padding-left: 5.4pt; padding-right: 5.4pt; width: 12%; text-align: center; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="width: 1%; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="padding-left: 5.4pt; padding-right: 5.4pt; width: 18%; text-align: center; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="border-bottom: black 1pt solid; padding-left: 5.4pt; padding-right: 5.4pt; width: 8%; text-align: center; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif"><b>Capacity</b></span>
            </td>
            <td style="padding-left: 5.4pt; padding-right: 5.4pt; width: 18%; text-align: center; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="width: 1%; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="padding-left: 5.4pt; padding-right: 5.4pt; width: 8%; text-align: center; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="border-bottom: black 1pt solid; padding-left: 5.4pt; padding-right: 5.4pt; width: 5%; text-align: center; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif"><b>Date</b></span>
            </td>
            <td style="padding-left: 5.4pt; padding-right: 5.4pt; width: 8%; text-align: center; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
        </tr>
        <tr>
            <td colspan="3" style="border-bottom: black 1pt solid; padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: bottom; text-align: center; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif"><i>/s/ Robert G. Finizio</i></span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td colspan="3" rowspan="2" style="padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: top; text-align: center; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">Chief Executive Officer, Director
                    <br /> (Principal Executive Officer)</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td colspan="3" rowspan="2" style="padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: top; text-align: center; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">February 24, 2020</span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td colspan="3" style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">Robert G. Finizio</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td colspan="3" style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td colspan="3" style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td colspan="3" style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
        </tr>
        <tr>
            <td colspan="3" style="border-bottom: black 1pt solid; padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: bottom; text-align: center; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif"><i>/s/ John C.K. Milligan, IV</i></span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td colspan="3" rowspan="2" style="padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: top; text-align: center; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">President, Secretary, Director</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td colspan="3" rowspan="2" style="padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: top; text-align: center; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">February 24, 2020</span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td colspan="3" style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">John C.K. Milligan, IV</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
        </tr>
        <tr>
            <td colspan="3" style="padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: bottom; text-align: center; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td colspan="3" style="padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: top; text-align: center; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td colspan="3" style="padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: top; text-align: center; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td colspan="3" style="border-bottom: black 1pt solid; padding-left: 5.4pt; padding-right: 5.4pt; text-align: center; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif"><i>/s/ Daniel A. Cartwright</i></span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td colspan="3" rowspan="2" style="padding-left: 5.4pt; padding-right: 5.4pt">
                <p style="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: center">
                    <span style="font: 10pt Times New Roman, Times, Serif">Chief Financial Officer, Treasurer&#160;</span>
                </p>
                <p style="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: center">
                    <span style="font: 10pt Times New Roman, Times, Serif">(Principal Financial and Accounting Officer)</span>
                </p>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td colspan="3" rowspan="2" style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">February 24, 2020</span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td colspan="3" style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">Daniel A. Cartwright</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
        </tr>
        <tr>
            <td colspan="3" style="padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: bottom; text-align: center; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td colspan="3" style="padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: top; text-align: center; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td colspan="3" style="padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: top; text-align: center; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
        </tr>
        <tr>
            <td colspan="3" style="border-bottom: black 1pt solid; padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: bottom; text-align: center; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif"><i>/s/ Tommy G. Thompson</i></span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td colspan="3" rowspan="2" style="padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: top; text-align: center; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">Chairman</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td colspan="3" rowspan="2" style="vertical-align: top; text-align: center; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">February 24, 2020</span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td colspan="3" style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">Tommy G. Thompson </span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
        </tr>
        <tr>
            <td colspan="3" style="padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: bottom; text-align: center; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td colspan="3" style="padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: top; text-align: center; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td colspan="3" style="padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: top; text-align: center; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
        </tr>
        <tr>
            <td colspan="3" style="border-bottom: black 1pt solid; padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: bottom; text-align: center; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif"><i>/s/ Brian Bernick </i></span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td colspan="3" rowspan="2" style="padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: top; text-align: center; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">Director</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td colspan="3" rowspan="2" style="vertical-align: top; text-align: center; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">February 24, 2020</span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td colspan="3" style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">Brian Bernick </span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
        </tr>
        <tr>
            <td colspan="3" style="padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: bottom; text-align: center; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td colspan="3" style="padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: top; text-align: center; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td colspan="3" style="padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: top; text-align: center; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
        </tr>
        <tr>
            <td colspan="3" style="border-bottom: Black 1pt solid; padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: bottom; text-align: center; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif"><i>/s/ Jane F. Barlow</i></span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td colspan="3" rowspan="2" style="padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: top; text-align: center; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">Director</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td colspan="3" rowspan="2" style="padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: top; text-align: center; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">February 24, 2020</span>
            </td>
        </tr>
        <tr>
            <td colspan="3" style="padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: bottom; text-align: center; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">Jane F. Barlow</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
        </tr>
        <tr>
            <td colspan="3" style="padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: bottom; text-align: center; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td colspan="3" style="padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: top; text-align: center; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td colspan="3" style="padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: top; text-align: center; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td colspan="3" style="border-bottom: black 1pt solid; padding-left: 5.4pt; padding-right: 5.4pt; text-align: center; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif"><i>/s/ J. Martin Carroll</i></span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td colspan="3" rowspan="2" style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">Director</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td colspan="3" rowspan="2" style="text-align: center; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">February 24, 2020</span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td colspan="3" style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;J. Martin Carroll</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td colspan="3" style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td colspan="3" style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td colspan="3" style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td colspan="3" style="border-bottom: black 1pt solid; padding-left: 5.4pt; padding-right: 5.4pt; text-align: center; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif"><i>/s/ Cooper C. Collins</i></span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td colspan="3" rowspan="2" style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">Director</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td colspan="3" rowspan="2" style="text-align: center; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">February 24, 2020</span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td colspan="3" style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;Cooper C. Collins</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td colspan="3" style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td colspan="3" style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td colspan="3" style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
        </tr>
        <tr>
            <td colspan="3" style="border-bottom: black 1pt solid; padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: bottom; text-align: center; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif"><i>/s/ Robert V. LaPenta, Jr.</i></span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td colspan="3" rowspan="2" style="padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: top; text-align: center; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">Director</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td colspan="3" rowspan="2" style="vertical-align: top; text-align: center; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">February 24, 2020</span>
            </td>
        </tr>
        <tr style="vertical-align: bottom">
            <td colspan="3" style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">Robert V. LaPenta, Jr </span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
        </tr>
        <tr>
            <td colspan="3" style="padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: bottom; text-align: center; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td colspan="3" style="padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: top; text-align: center; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td colspan="3" style="padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: top; text-align: center; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
        </tr>
        <tr>
            <td colspan="3" style="border-bottom: black 1pt solid; padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: bottom; text-align: center; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif"><i>/s/ Jules Musing</i></span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td colspan="3" rowspan="2" style="padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: top; text-align: center; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">Director</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td colspan="3" rowspan="2" style="vertical-align: top; text-align: center; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">February 24, 2020</span>
            </td>
        </tr>
        <tr style="vertical-align: bottom">
            <td colspan="3" style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">Jules Musing</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
        </tr>
        <tr>
            <td colspan="3" style="padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: bottom; text-align: center; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td colspan="3" style="padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: top; text-align: center; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td colspan="3" style="padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: top; text-align: center; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
        </tr>
        <tr>
            <td colspan="3" style="border-bottom: black 1pt solid; padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: bottom; text-align: center; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif"><i>/s/ Angus C. Russell</i></span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td colspan="3" style="padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: top; text-align: center; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">Director</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td colspan="3" style="padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: top; text-align: center; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">February 24, 2020</span>
            </td>
        </tr>
        <tr>
            <td colspan="3" style="padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: bottom; text-align: center; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">Angus C. Russell</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td colspan="3" style="padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: top; text-align: center; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td colspan="3" style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
        </tr>
        <tr>
            <td colspan="3" style="padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: bottom; text-align: center; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td colspan="3" style="padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: top; text-align: center; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td colspan="3" style="padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: top; text-align: center; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
        </tr>
        <tr>
            <td colspan="3" style="border-bottom: black 1pt solid; padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: bottom; text-align: center; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif"><i>/s/ Nicholas Segal </i></span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td colspan="3" rowspan="2" style="padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: top; text-align: center; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">Director</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td colspan="3" rowspan="2" style="vertical-align: top; text-align: center; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">February 24, 2020</span>
            </td>
        </tr>
        <tr style="vertical-align: bottom">
            <td colspan="3" style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center; font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">Nicholas Segal</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
            <td style="font-family: Times New Roman,serif">
                <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
            </td>
        </tr>
    </table>
    <p>
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>

<!-- Field: Page; Sequence: 76 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"><tr style="vertical-align: top; text-align: center"><td style="font: 10pt Times New Roman, Times, Serif; width: 25%; white-space: nowrap"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%"></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<p style="margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>INDEX
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: bottom; background-color: white">
    <td style="white-space: nowrap; width: 88%; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; width: 2%; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 10%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Page</span></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#REPORT">Report of Independent Registered Public Accounting Firm</a></span></td>
    <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">F-2</span></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#txmdb001">Consolidated
    Balance Sheets as of December 31, 2019 and 2018</a></span></td>
    <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">F-3</span></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#txmdb002">Consolidated
    Statements of Operations for the years ended December 31, 2019, 2018 and 2017</a></span></td>
    <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">F-4</span></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#txmdb003">Consolidated
    Statements of Stockholders&#8217; Equity for the years ended December 31, 2019, 2018 and 2017</a></span></td>
    <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">F-5</span></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#txmdb004">Consolidated
    Statements of Cash Flows for the years ended December 31, 2019, 2018 and 2017</a></span></td>
    <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">F-6</span></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#txmdb005">Notes
    to Consolidated Financial Statements</a></span></td>
    <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">F-7</span></td></tr>
</table>

<p style="margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: Page; Sequence: 77; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="REPORT"></span>REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>


<p style="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-left: 0"></p>

<p style="font: 9pt Arial, Helvetica, Sans-Serif; margin: 0 0 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Board
of Directors and Shareholders<br />
TherapeuticsMD, Inc.</span></p>

<p style="font: 9pt Arial, Helvetica, Sans-Serif; margin: 0 0 8pt"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<p style="font: 9pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Opinion
on the financial statements </b></span></p>

<p style="text-align: justify; font: 9pt Arial, Helvetica, Sans-Serif; margin: 0 0 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited the accompanying consolidated balance sheets of TherapeuticsMD, Inc. (a Nevada corporation) and subsidiaries (the
&#8220;Company&#8221;) as of December 31, 2019 and 2018, the related consolidated statements of operations, stockholders&#8217;
equity, and cash flows for each of the three years in the period ended December 31, 2019, and the related notes (collectively
referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material
respects, the financial position of the Company as of December 31, 2019 and 2018, and the results of its operations and its cash
flows for each of the three years in the period ended December 31, 2019, in conformity with accounting principles generally accepted
in the United States of America.</span></p>

<p style="font: 9pt Arial, Helvetica, Sans-Serif; margin: 0 0 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;),
the Company&#8217;s internal control over financial reporting as of December 31, 2019, based on criteria established in the 2013
<i>Internal Control&#8212;Integrated Framework</i> issued by the Committee of Sponsoring Organizations of the Treadway Commission
(&#8220;COSO&#8221;), and our report dated February 24, 2020 expressed an unqualified opinion.</span></p>

<p style="font: 9pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Change
in accounting principle</b></span></p>

<p style="text-align: justify; font: 9pt Arial, Helvetica, Sans-Serif; margin: 0 0 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
discussed in Note 13 to the consolidated financial statements, the Company has changed its method of accounting for leases due
to the adoption of Accounting Standard Update No. 2016-02 &#8220;Leases (Topic 842).&#8221;</span></p>

<p style="font: 9pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis
for opinion </b></span></p>

<p style="text-align: justify; font: 9pt Arial, Helvetica, Sans-Serif; margin: 0 0 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on
the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are
required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable
rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>

<p style="text-align: justify; font: 9pt Arial, Helvetica, Sans-Serif; margin: 0 0 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit
to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error
or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements,
whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a
test basis, evidence supporting the amounts and disclosures in the financial statements. Our audits also included evaluating the
accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the
financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></p>

<p style="font: 9pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical
audit matter </b></span></p>

<p style="font: 9pt Arial, Helvetica, Sans-Serif; margin: 0 0 8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was
communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material
to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of
critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by
communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or
disclosures to which it relates.</span></p>

<p style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration:underline;">Calculation
of variable consideration related to sales deductions</p>

<p style="font: 9pt Arial, Helvetica, Sans-Serif; margin: 0 0 8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
described further in Note 2 to the consolidated financial statements, the transaction price of the Company&#8217;s revenue contracts
is variable as it is calculated net of estimated product returns, chargebacks, rebates, coupons, discounts and wholesaler fees
(collectively &#8220;sales deductions&#8221;). We identified the calculation of variable consideration related to sales deductions
as a critical audit matter.</span></p>

<p style="font: 9pt Arial, Helvetica, Sans-Serif; margin: 0 0 8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
principal consideration for our determination that the calculation of variable consideration related to sales deductions is a
critical audit matter is that auditing the estimation of variable consideration requires significant judgement and the amounts
are material to the financial statements taken as a whole. These estimates require the consideration of key assumptions such as
expected return rates, estimated levels of inventory in the distribution channel, expected coupon utilization, and expected insurance
coverage levels, all of which have estimation uncertainty.</span></p>

<p style="font: 9pt Arial, Helvetica, Sans-Serif; margin: 0 0 8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audit procedures related to testing the calculation of variable consideration related to sales deductions included the following,
among others:</span></p>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 9pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 6pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8226;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                         tested the design and operating effectiveness of controls relating to management&#8217;s
                                         calculation and review of variable consideration related to sales deductions by verifying
                                         management&#8217;s controls over the completeness of the input data, mathematical accuracy
                                         of the calculations and evaluating the reasonableness of key assumptions used in the
                                         calculations.</span></td></tr></table>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 9pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 6pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8226;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                         tested management&#8217;s estimates by performing one of the following procedures based
                                         on the sales deduction being tested, (1) developing independent expectations to corroborate
                                         the reasonableness of management&#8217;s estimate, (2) testing management&#8217;s process
                                         to develop the estimate, or (3) reviewing subsequent events or transactions. Our procedures
                                         included reviewing subsequent data to estimate levels of inventory in the distribution
                                         channel for which coupons would be redeemed and subsequent information related to coupon
                                         and rebate settlements. We used historical sales and return data in developing our independent
                                         expectations and testing management&#8217;s process. We tested the completeness and accuracy
                                         of the historical sales and return data used in the calculations by agreeing total sales
                                         to accounting records and tracing a sample of individual sale transactions to supporting
                                         audit evidence, such as purchase orders, shipping documents and invoices. We also evaluated
                                         the average assistance paid in the co-pay assistance program by testing a sample of transactions
                                         settled during the year to source documentation.</span></td></tr></table>

<p style="font: 9pt Arial, Helvetica, Sans-Serif; margin: 0 0 8pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 9pt Arial, Helvetica, Sans-Serif; margin: 0 0 14.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
GRANT THORNTON LLP</span></p>

<p style="font: 9pt Arial, Helvetica, Sans-Serif; margin: 0 0 14.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have served as the Company&#8217;s auditor since 2015.</span></p>

<p style="font: 9pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fort
Lauderdale, Florida</span></p>

<p style="font: 9pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
24, 2020</span></p>

<p style="font: 9pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<!-- Field: Page; Sequence: 78 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; padding-top: 6pt; padding-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>THERAPEUTICSMD,
INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="txmdb001"></span><b>CONSOLIDATED
BALANCE SHEETS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_302_111_zV7rKUDeFrya" summary="xdx: Statement - CONSOLIDATED BALANCE SHEETS" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td id="xdx_49C_20191231_zuTkA5lfJe16" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td id="xdx_498_20181231_z22imD1YWlhd" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>December
    31,</b></span></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>2019</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>2018</b></span></td></tr>
<tr id="xdx_407_eus-gaap--AssetsAbstract_iB_zU9AAhKrFDu3" style="vertical-align: bottom">
    <td colspan="9" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">ASSETS</span></td></tr>
<tr id="xdx_406_eus-gaap--AssetsCurrentAbstract_i01B_zbUrsUdjpAs4" style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -8.65pt; padding-left: 8.65pt"><span style="font: 10pt Times New Roman, Times, Serif">Current
    Assets:</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_405_eus-gaap--Cash_i02I_maACzX3U_zMil8GsL49v4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 70%; text-indent: -8.65pt; padding-left: 17.3pt"><span style="font: 10pt Times New Roman, Times, Serif">Cash</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">160,829,713</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">161,613,077</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_407_eus-gaap--AccountsReceivableNetCurrent_i02I_maACzX3U_zvR3KnzZ1f2a" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -8.65pt; padding-left: 17.3pt"><span style="font: 10pt Times New Roman, Times, Serif">Accounts
    receivable, net of allowance for doubtful accounts of $<span id="xdx_90F_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_c20191231_zsAxN7D8NlU2" title="Allowance for doubtful accounts"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">904,040</ix:nonFraction></span> and $<span id="xdx_90C_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_c20181231_zHcVGMtx9jul"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">596,602</ix:nonFraction></span>, respectively</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,395,958</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,063,821</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_408_eus-gaap--InventoryNet_i02I_maACzX3U_zp127knlirBl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -8.65pt; padding-left: 17.3pt"><span style="font: 10pt Times New Roman, Times, Serif">Inventory</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,860,716</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,267,670</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_400_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_maACzX3U_zrHtjStXmWQg" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; text-indent: -8.65pt; padding-left: 17.3pt"><span style="font: 10pt Times New Roman, Times, Serif">Other
    current assets</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,329,793</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,834,693</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40A_eus-gaap--AssetsCurrent_i02TI_mtACzX3U_maAzdKj_zp50K2lXGpD9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; text-indent: -8.65pt; padding-left: 25.9pt"><span style="font: 10pt Times New Roman, Times, Serif">Total
    current assets</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">208,416,180</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">186,779,261</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-indent: -8.65pt; padding-left: 8.65pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"></span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentNet_i01I_maAzdKj_zkoUrS3olLIh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; text-indent: -8.65pt; padding-left: 8.65pt"><span style="font: 10pt Times New Roman, Times, Serif">Fixed
    assets, net</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,507,775</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">472,683</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-indent: -8.65pt; padding-left: 8.65pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_406_eus-gaap--OtherAssetsAbstract_i01B_z2zhQVx61sCe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -8.65pt; padding-left: 8.65pt"><span style="font: 10pt Times New Roman, Times, Serif">Other
    Assets:</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"></span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40E_ecustom--LicenseRights_i02I_maANzoSD_zZORhS2SYJA5" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -8.65pt; padding-left: 17.3pt"><span style="font: 10pt Times New Roman, Times, Serif">License
    rights, net</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="txmd:LicenseRights" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">39,221,308</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="txmd:LicenseRights" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,000,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_402_eus-gaap--IntangibleAssetsNetExcludingGoodwill_i02I_maANzoSD_z1EElUKxjuBk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -8.65pt; padding-left: 17.3pt"><span style="font: 10pt Times New Roman, Times, Serif">Intangible
    assets, net</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,258,211</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,092,679</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_406_eus-gaap--OperatingLeaseRightOfUseAsset_i02I_maANzoSD_zmNeWvKbMz8d" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -8.65pt; padding-left: 17.3pt"><span style="font: 10pt Times New Roman, Times, Serif">Right
    of use asset</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,109,154</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0083">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_401_eus-gaap--OtherAssetsMiscellaneousNoncurrent_i02I_maANzoSD_zdKts8VAzQ9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; text-indent: -8.65pt; padding-left: 17.3pt"><span style="font: 10pt Times New Roman, Times, Serif">Other assets</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OtherAssetsMiscellaneousNoncurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">473,009</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OtherAssetsMiscellaneousNoncurrent" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">639,301</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40C_eus-gaap--OtherAssetsNoncurrent_i02TI_mtANzoSD_maAzdKj_z8cCj9o6g4w4" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; text-indent: -8.65pt; padding-left: 25.9pt"><span style="font: 10pt Times New Roman, Times, Serif">Total
    other assets</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">55,061,682</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,731,980</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40A_eus-gaap--Assets_i01TI_mtAzdKj_zO5hx1x6iGB9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; text-indent: -8.65pt; padding-left: 34.55pt"><span style="font: 10pt Times New Roman, Times, Serif">Total
    assets</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">265,985,637</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">211,983,924</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-indent: -8.65pt; padding-left: 8.65pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_403_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zITWOKWiFLHb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td colspan="9" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">LIABILITIES
    AND STOCKHOLDERS&#8217; EQUITY</span></td></tr>
<tr id="xdx_40B_eus-gaap--LiabilitiesCurrentAbstract_i01B_zgzlLFwukY24" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -8.65pt; padding-left: 8.65pt"><span style="font: 10pt Times New Roman, Times, Serif">Current
    Liabilities:</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_407_eus-gaap--AccountsPayableCurrent_i02I_maLCzQKb_z9nR0GIVXlu3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -8.65pt; padding-left: 17.3pt"><span style="font: 10pt Times New Roman, Times, Serif">Accounts
    payable</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,181,212</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,743,841</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_406_eus-gaap--OtherLiabilitiesCurrent_i02I_maLCzQKb_zRzFrZbxQQNd" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; text-indent: -8.65pt; padding-left: 17.3pt"><span style="font: 10pt Times New Roman, Times, Serif">Other
    current liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">33,823,613</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,334,948</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_404_eus-gaap--LiabilitiesCurrent_i02TI_mtLCzQKb_maLz0dX_zQHlvdvaw6o1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; text-indent: -8.65pt; padding-left: 25.9pt"><span style="font: 10pt Times New Roman, Times, Serif">Total
    current liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">53,004,825</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">41,078,789</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-indent: -8.65pt; padding-left: 8.65pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_403_eus-gaap--LongTermDebtNoncurrentAbstract_i01B_zER851oYhdXj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -8.65pt; padding-left: 8.65pt"><span style="font: 10pt Times New Roman, Times, Serif">Long-Term
    Liabilities:</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_400_eus-gaap--LongTermDebtNoncurrent_i02I_maLz0dX_zPEA18Q8O7wh" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -8.65pt; padding-left: 17.3pt"><span style="font: 10pt Times New Roman, Times, Serif">Long-term
    debt</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LongTermDebtNoncurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">194,634,643</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LongTermDebtNoncurrent" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">73,381,014</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_405_eus-gaap--OperatingLeaseLiabilityNoncurrent_i02I_maLz0dX_zW6FZY1edCQj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; text-indent: -8.65pt; padding-left: 17.3pt"><span style="font: 10pt Times New Roman, Times, Serif">Operating
    lease liability</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,145,049</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0116">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_409_eus-gaap--Liabilities_i01TI_mtLz0dX_maLASEz5d0_zy7en9qnh6pe" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; text-indent: -8.65pt; padding-left: 34.55pt"><span style="font: 10pt Times New Roman, Times, Serif">Total
    liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">256,784,517</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">114,459,803</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-indent: -8.65pt; padding-left: 8.65pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_403_eus-gaap--CommitmentsAndContingencies_i01I_zS1lTBfA671e" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -8.65pt; padding-left: 8.65pt"><span style="font: 10pt Times New Roman, Times, Serif">Commitments
    and Contingencies - See Note 13</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-indent: -8.65pt; padding-left: 8.65pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40F_eus-gaap--StockholdersEquityAbstract_i01B_zbkRdiyj7qTd" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -8.65pt; padding-left: 8.65pt"><span style="font: 10pt Times New Roman, Times, Serif">Stockholders&#8217;
    Equity:</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_401_eus-gaap--PreferredStockValue_i02I_maSEzu5O_zz80cJK8jd41" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -8.65pt; padding-left: 17.3pt"><span style="font: 10pt Times New Roman, Times, Serif">Preferred
    stock - par value $<span id="xdx_904_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20191231_zEgxPM0vBonc" title="Preferred Stock, Par or Stated Value Per Share"><span id="xdx_905_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20181231_zSs8SShrSZZd" title="Preferred Stock, Par or Stated Value Per Share"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span>; <span id="xdx_908_eus-gaap--PreferredStockSharesAuthorized_iI_c20191231_zYVmXXRc1q9b" title="Preferred Stock, Shares Authorized"><span id="xdx_903_eus-gaap--PreferredStockSharesAuthorized_iI_c20181231_zuvE00Fbd7U6" title="Preferred Stock, Shares Authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized; <span id="xdx_90C_eus-gaap--PreferredStockSharesIssued_iI_do_c20191231_zU5MY20JxHLh" title="Preferred Stock, Shares Issued"><span id="xdx_903_eus-gaap--PreferredStockSharesIssued_iI_do_c20181231_z2FHhny67ia" title="Preferred Stock, Shares Issued"><span id="xdx_902_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20191231_z3Yok5QvNPu9" title="Preferred Stock, Shares Outstanding"><span id="xdx_907_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20181231_zasTiW0zLUB7" title="Preferred Stock, Shares Outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2019-12-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2018-12-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2019-12-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2018-12-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> shares issued and outstanding</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0127">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0128">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_403_eus-gaap--CommonStockValue_i02I_maSEzu5O_z4yftpntxIH1" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -8.65pt; padding-left: 17.3pt"><span style="font: 10pt Times New Roman, Times, Serif">Common
    stock - par value $<span id="xdx_902_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20191231_zTuipMkfayzj" title="Common Stock, Par or Stated Value Per Share"><span id="xdx_909_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20181231_zANEIV0RgZng" title="Common Stock, Par or Stated Value Per Share"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span>; <span id="xdx_901_eus-gaap--CommonStockSharesAuthorized_iI_c20191231_zvdfImNamk9e" title="Common Stock, Shares Authorized"><span id="xdx_901_eus-gaap--CommonStockSharesAuthorized_iI_c20181231_z99l8kIrPxil" title="Common Stock, Shares Authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized: <span id="xdx_901_eus-gaap--CommonStockSharesIssued_iI_c20191231_zWD2iIlyHUeb" title="Common Stock, Shares, Issued"><span id="xdx_90D_eus-gaap--CommonStockSharesOutstanding_iI_c20191231_zuPaTK8eklL1" title="Common Stock, Shares, Outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">271,177,076</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_907_eus-gaap--CommonStockSharesIssued_iI_c20181231_zHnCvJYVa3C" title="Common Stock, Shares, Issued"><span id="xdx_909_eus-gaap--CommonStockSharesOutstanding_iI_c20181231_zOXPQCG0Be4a" title="Common Stock, Shares, Outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">240,462,439</ix:nonFraction></ix:nonFraction></span></span> issued and outstanding, respectively</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">271,177</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">240,463</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40A_eus-gaap--AdditionalPaidInCapitalCommonStock_i02I_maSEzu5O_zf1mrZ1b3ZGe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -8.65pt; padding-left: 17.3pt"><span style="font: 10pt Times New Roman, Times, Serif">Additional
    paid-in capital</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">704,351,222</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">616,559,938</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40E_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_maSEzu5O_z19d3IIC9bUl" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; text-indent: -8.65pt; padding-left: 17.3pt"><span style="font: 10pt Times New Roman, Times, Serif">Accumulated
    deficit</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">695,421,279</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">519,276,280</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_40B_eus-gaap--StockholdersEquity_i02TI_mtSEzu5O_maLASEz5d0_zbU14ajuhXSl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; text-indent: -8.65pt; padding-left: 25.9pt"><span style="font: 10pt Times New Roman, Times, Serif">Total
    stockholders&#8217; equity</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,201,120</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">97,524,121</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40D_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_mtLASEz5d0_zUfXIDFSf6k4" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; text-indent: -8.65pt; padding-left: 34.55pt"><span style="font: 10pt Times New Roman, Times, Serif">Total
    liabilities and stockholders&#8217; equity</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">265,985,637</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">211,983,924</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<p style="margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">The
accompanying footnotes are an integral part of these consolidated financial statements.</span></p>

<p style="margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 79; Options: NewSection; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>THERAPEUTICSMD,
INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="txmdb002"></span><b>CONSOLIDATED
STATEMENTS OF OPERATIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30A_113_zzzcp5zRwNWc" summary="xdx: Statement - CONSOLIDATED STATEMENTS OF OPERATIONS" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td id="xdx_494_20190101__20191231_zxXl5qNdvYvb" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td id="xdx_49D_20180101__20181231_zv0qnQNShMla" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td id="xdx_49E_20170101__20171231_zbY4niyZ7BU8" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="11" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Year
    Ended December 31,</b></span></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>2019</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>2018</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>2017</b></span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 55%; text-align: left; text-indent: -8.65pt; padding-left: 8.65pt"><span style="font: 10pt Times New Roman, Times, Serif">Product
    revenues, net</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ProductOrServiceAxis__us-gaap--ProductMember_zoubYvsJxiI" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2019-01-012019-12-31_us-gaap_ProductMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">34,140,537</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180101__20181231__srt--ProductOrServiceAxis__us-gaap--ProductMember_zfaBhTRSezN7" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2018-01-012018-12-31_us-gaap_ProductMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,099,460</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20170101__20171231__srt--ProductOrServiceAxis__us-gaap--ProductMember_z8BuUWMW2e59" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2017-01-012017-12-31_us-gaap_ProductMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,777,713</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; text-indent: -8.65pt; padding-left: 8.65pt"><span style="font: 10pt Times New Roman, Times, Serif">License
    revenue</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ProductOrServiceAxis__us-gaap--LicenseAndServiceMember_z9Ka5yosdcL9" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2019-01-012019-12-31_us-gaap_LicenseAndServiceMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,506,400</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180101__20181231__srt--ProductOrServiceAxis__us-gaap--LicenseAndServiceMember_zbPhB5k0rG47" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0180">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20170101__20171231__srt--ProductOrServiceAxis__us-gaap--LicenseAndServiceMember_zTk7UBsEG0hi" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0181">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_maGPzhxd_zdBRpgv6dyYi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -8.65pt; padding-left: 17.3pt"><span style="font: 10pt Times New Roman, Times, Serif">Total
    revenue, net</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2019-01-01to2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">49,646,937</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,099,460</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2017-01-012017-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,777,713</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-indent: -8.65pt; padding-left: 8.65pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_406_eus-gaap--CostOfGoodsAndServicesSold_msGPzhxd_zDEby5ImamV1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; text-indent: -8.65pt; padding-left: 8.65pt"><span style="font: 10pt Times New Roman, Times, Serif">Cost
    of goods sold</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2019-01-01to2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,334,585</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,737,652</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2017-01-012017-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,636,943</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-indent: -8.65pt; padding-left: 8.65pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_406_eus-gaap--GrossProfit_iT_mtGPzhxd_maOILzhju_zcFxy25Irtpl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; text-indent: -8.65pt; padding-left: 8.65pt"><span style="font: 10pt Times New Roman, Times, Serif">Gross
    profit</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2019-01-01to2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">43,312,352</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,361,808</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2017-01-012017-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,140,770</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-indent: -8.65pt; padding-left: 8.65pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_404_eus-gaap--OperatingExpensesAbstract_iB_zzLP56MmwTG5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -8.65pt; padding-left: 8.65pt"><span style="font: 10pt Times New Roman, Times, Serif">Operating
    expenses:</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40C_eus-gaap--SellingGeneralAndAdministrativeExpense_i01_maOEzkWI_zHpZtbLtT6Pi" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -8.65pt; padding-left: 17.3pt"><span style="font: 10pt Times New Roman, Times, Serif">Sales,
    general, and administrative</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2019-01-01to2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">174,112,612</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">115,988,954</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2017-01-012017-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">57,703,370</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_405_eus-gaap--ResearchAndDevelopmentExpense_i01_maOEzkWI_zgLj4qtPg792" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -8.65pt; padding-left: 17.3pt"><span style="font: 10pt Times New Roman, Times, Serif">Research
    and development</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2019-01-01to2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,792,212</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,299,138</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2017-01-012017-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">33,852,993</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_400_eus-gaap--DepreciationAndAmortization_i01_maOEzkWI_zkbgm7WgScNd" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; text-indent: -8.65pt; padding-left: 17.3pt"><span style="font: 10pt Times New Roman, Times, Serif">Depreciation
    and amortization</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2019-01-01to2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">612,786</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">293,886</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2017-01-012017-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">213,117</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_407_eus-gaap--OperatingExpenses_i01T_mtOEzkWI_msOILzhju_zncUrawcstG3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; text-indent: -8.65pt; padding-left: 25.9pt"><span style="font: 10pt Times New Roman, Times, Serif">Total
    operating expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2019-01-01to2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">194,517,610</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">143,581,978</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2017-01-012017-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">91,769,480</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-indent: -8.65pt; padding-left: 8.65pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_402_eus-gaap--OperatingIncomeLoss_iT_mtOILzhju_maILFCOzYaL_z0TGCM1Q1rI3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; text-indent: -8.65pt; padding-left: 8.65pt"><span style="font: 10pt Times New Roman, Times, Serif">Operating
    loss</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2019-01-01to2019-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">151,205,258</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">130,220,170</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2017-01-012017-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">77,628,710</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-indent: -8.65pt; padding-left: 8.65pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40D_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_zoWFGh0z72q6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -8.65pt; padding-left: 8.65pt"><span style="font: 10pt Times New Roman, Times, Serif">Other
    (expense) income</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40A_eus-gaap--GainsLossesOnExtinguishmentOfDebt_i01_maNIEzSk6_zo3b2pPL9mjg" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -8.65pt; padding-left: 17.3pt"><span style="font: 10pt Times New Roman, Times, Serif">Loss
    on extinguishment of debt</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2019-01-01to2019-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,057,632</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0224">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0225">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40A_eus-gaap--OtherNonoperatingIncome_i01_maNIEzSk6_zVUUDGD3KQtl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -8.65pt; padding-left: 17.3pt"><span style="font: 10pt Times New Roman, Times, Serif">Miscellaneous
    income</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OtherNonoperatingIncome" contextRef="From2019-01-01to2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,500,106</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OtherNonoperatingIncome" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,280,844</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OtherNonoperatingIncome" contextRef="From2017-01-012017-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">695,631</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_405_eus-gaap--InterestExpense_i01N_di_msNIEzSk6_zX34XcG5WEYh" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -8.65pt; padding-left: 17.3pt"><span style="font: 10pt Times New Roman, Times, Serif">Interest
    expense</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2019-01-01to2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,382,215</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,677,834</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0233">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_405_eus-gaap--InvestmentIncomeNetAmortizationOfDiscountAndPremium_i01_maNIEzSk6_zbhQUoxYmmS4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; text-indent: -8.65pt; padding-left: 17.3pt"><span style="font: 10pt Times New Roman, Times, Serif">Accreted
    interest</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0235">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0236">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" contextRef="From2017-01-012017-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,699</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40D_eus-gaap--NonoperatingIncomeExpense_i01T_mtNIEzSk6_maILFCOzYaL_zOPMHDFGyzP8" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; text-indent: -8.65pt; padding-left: 25.9pt"><span style="font: 10pt Times New Roman, Times, Serif">Total
    other (expense) income</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2019-01-01to2019-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">24,939,741</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,396,990</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2017-01-012017-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">703,330</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-indent: -8.65pt; padding-left: 8.65pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_409_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_mtILFCOzYaL_maNILzxKc_zP1oaZkXsqv5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -8.65pt; padding-left: 8.65pt"><span style="font: 10pt Times New Roman, Times, Serif">Loss
    before income taxes</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2019-01-01to2019-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">176,144,999</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">132,617,160</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2017-01-012017-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">76,925,380</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-indent: -8.65pt; padding-left: 8.65pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_409_eus-gaap--IncomeTaxExpenseBenefit_msNILzxKc_zrLJL4eDNU76" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; text-indent: -8.65pt; padding-left: 8.65pt"><span style="font: 10pt Times New Roman, Times, Serif">Provision
    for income taxes</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0247">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0248">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0249">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-indent: -8.65pt; padding-left: 8.65pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40D_eus-gaap--NetIncomeLoss_iT_mtNILzxKc_zHUI2oZZrrek" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; text-indent: -8.65pt; padding-left: 8.65pt"><span style="font: 10pt Times New Roman, Times, Serif">Net
    loss</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-01-01to2019-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">176,144,999</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">132,617,160</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2017-01-012017-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">76,925,380</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-indent: -8.65pt; padding-left: 8.65pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40C_eus-gaap--EarningsPerShareAbstract_iB_zjefu4qFQRIi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -8.65pt; padding-left: 8.65pt"><span style="font: 10pt Times New Roman, Times, Serif">Loss
    per share, basic and diluted:</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-indent: -8.65pt; padding-left: 8.65pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_403_eus-gaap--EarningsPerShareBasicAndDiluted_i01_zSvoizl3Slp6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; text-indent: -8.65pt; padding-left: 8.65pt"><span style="font: 10pt Times New Roman, Times, Serif">Net
    loss per share, basic and diluted</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="From2019-01-01to2019-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.72</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.59</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="From2017-01-012017-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.37</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-indent: -8.65pt; padding-left: 8.65pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_406_eus-gaap--WeightedAverageNumberOfShareOutstandingBasicAndDiluted_zsOizO5fPQa9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; text-indent: -8.65pt; padding-left: 8.65pt"><span style="font: 10pt Times New Roman, Times, Serif">Weighted
    average number of common shares outstanding, basic and diluted</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="From2019-01-01to2019-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">246,353,318</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">225,026,300</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="From2017-01-012017-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">205,523,288</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<p style="margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">The
accompanying footnotes are an integral part of these consolidated financial statements.</span></p>

<p style="margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 80; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>THERAPEUTICSMD,
INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="txmdb003"></span><b>CONSOLIDATED
STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>FOR
THE YEARS ENDED DECEMBER 31, 2019, 2018 AND 2017</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30D_114_zgqFONka1Dc4" summary="xdx: Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS&apos; EQUITY" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td id="xdx_4BB_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zbtPsSaej8H4" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" id="xdx_4BC_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zrrAqc4sjRH7" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" id="xdx_4B4_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_z3NbGIHwiMq9" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" id="xdx_4B9_zG7WqXpv2FG" style="font-size: 10pt; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Common
    Stock</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Additional
    <br />Paid in</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Accumulated</b></span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="3" style="font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Shares</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Amount</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Capital</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Deficit</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Total</b></span></td></tr>
<tr id="xdx_43E_c20170101__20171231_eus-gaap--StockholdersEquity_iS_zUX5r483EgCf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 25%; text-indent: -8.65pt; padding-left: 8.65pt"><span style="font: 10pt Times New Roman, Times, Serif">Balance,
    January 1, 2017</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--CommonStockSharesOutstanding_iS_c20170101__20171231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zGnEwVa7tTp2" title="Beginning balance (in shares)" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2016-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">196,688,222</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2016-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">196,688</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2016-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">436,995,052</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2016-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">309,702,319</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">$<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2016-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">127,489,421</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-indent: -8.65pt; padding-left: 8.65pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_407_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zXXdfJGXBe99" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -8.65pt; padding-left: 8.65pt"><span style="font: 10pt Times New Roman, Times, Serif">Shares
    issued in offerings, net of cost</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20170101__20171231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zzGucPHdYxHk" title="Shares issued in offerings, net of cost (in shares)" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2017-01-012017-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,400,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2017-01-012017-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,400</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2017-01-012017-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">68,560,235</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0276">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2017-01-012017-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">68,572,635</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_404_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_zpgVNDHOLxb4" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -8.65pt; padding-left: 8.65pt"><span style="font: 10pt Times New Roman, Times, Serif">Shares
    issued for exercise of options, net</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20170101__20171231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zhd8LdzM825c" title="Shares issued for exercise of options, net (in shares)" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2017-01-012017-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">102,546</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2017-01-012017-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">103</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2017-01-012017-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">212,512</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0283">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2017-01-012017-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">212,615</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40F_eus-gaap--StockIssuedDuringPeriodValueOther_znzAhhVFHFm" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -8.65pt; padding-left: 8.65pt"><span style="font: 10pt Times New Roman, Times, Serif">Shares
    issued for exercise of warrants, net</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesOther_c20170101__20171231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zWtBcUASIk8f" title="Shares issued for exercise of warrants, net (in shares)" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2017-01-012017-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,238,874</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2017-01-012017-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,239</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2017-01-012017-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,791,760</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0290">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2017-01-012017-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,798,999</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_402_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zsaartjBm9S1" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -8.65pt; padding-left: 8.65pt"><span style="font: 10pt Times New Roman, Times, Serif">Share-based
    compensation</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0295">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2017-01-012017-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,760,425</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0297">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2017-01-012017-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,760,425</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_400_eus-gaap--CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_iS_zLrO4Xee7IVj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -8.65pt; padding-left: 8.65pt"><span style="font: 10pt Times New Roman, Times, Serif">Adoption
    of ASU 2016-09</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0300">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" contextRef="AsOf2016-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31,421</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" contextRef="AsOf2016-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">31,421</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0303">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_408_eus-gaap--NetIncomeLoss_zubkzV92k8N" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; text-indent: -8.65pt; padding-left: 8.65pt"><span style="font: 10pt Times New Roman, Times, Serif">Net
    loss</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0305">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0306">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2017-01-012017-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">76,925,380</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2017-01-012017-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">76,925,380</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-indent: -8.65pt; padding-left: 8.65pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_439_c20180101__20181231_eus-gaap--StockholdersEquity_iS_zpxL4c4JHfw6" style="vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-indent: -8.65pt; padding-left: 8.65pt"><span style="font: 10pt Times New Roman, Times, Serif">Balance,
    December 31, 2017</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--CommonStockSharesOutstanding_iS_c20180101__20181231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2Zg5qRZs7Ya" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2017-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">216,429,642</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2017-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">216,430</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2017-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">516,351,405</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2017-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">386,659,120</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2017-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">129,908,715</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-indent: -8.65pt; padding-left: 8.65pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_407_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zYLLbFf0fTX1" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -8.65pt; padding-left: 8.65pt"><span style="font: 10pt Times New Roman, Times, Serif">Shares
    issued in offerings, net of cost</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20180101__20181231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zH80eKcB4guf" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2018-01-012018-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">18,578,430</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2018-01-012018-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,578</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2018-01-012018-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">89,889,219</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0318">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">89,907,797</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_404_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_zSN5AETC6Rpe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -8.65pt; padding-left: 8.65pt"><span style="font: 10pt Times New Roman, Times, Serif">Shares
    issued for exercise of options, net</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20180101__20181231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z39a09Qhk0Ya" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2018-01-012018-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,454,367</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2018-01-012018-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,455</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2018-01-012018-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,660,753</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0324">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,666,208</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_402_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zDDkawsxOKf6" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -8.65pt; padding-left: 8.65pt"><span style="font: 10pt Times New Roman, Times, Serif">Share-based
    compensation</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0328">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2018-01-012018-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,658,561</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0330">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,658,561</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_408_eus-gaap--NetIncomeLoss_z2EarrQbmaJi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; text-indent: -8.65pt; padding-left: 8.65pt"><span style="font: 10pt Times New Roman, Times, Serif">Net
    loss</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0333">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0334">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2018-01-012018-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">132,617,160</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">132,617,160</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-indent: -8.65pt; padding-left: 8.65pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_43E_c20190101__20191231_eus-gaap--StockholdersEquity_iS_zb3Ns4QlBine" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-indent: -8.65pt; padding-left: 8.65pt"><span style="font: 10pt Times New Roman, Times, Serif">Balance,
    December 31, 2018</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--CommonStockSharesOutstanding_iS_c20190101__20191231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zloQh1SnODl3" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2018-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">240,462,439</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2018-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">240,463</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2018-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">616,559,938</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2018-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">519,276,280</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">97,524,121</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-indent: -8.65pt; padding-left: 8.65pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_407_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zHN75r1mOFQb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -8.65pt; padding-left: 8.65pt"><span style="font: 10pt Times New Roman, Times, Serif">Shares
    issued in offerings, net of cost</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20190101__20191231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z4RbxXQpkqzc" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2019-01-012019-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">29,900,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2019-01-012019-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,900</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2019-01-012019-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">77,001,358</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0346">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2019-01-01to2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">77,031,258</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_400_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensation_zddHT7tl0rak" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -8.65pt; padding-left: 8.65pt"><span style="font: 10pt Times New Roman, Times, Serif">Shares
    issued for exercise of options and warrants, net</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_c20190101__20191231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zuoLP8cyufjk" title="Shares issued for exercise of options and warrants, net (in shares)" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="From2019-01-012019-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">814,637</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2019-01-012019-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">814</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2019-01-012019-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">107,842</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0352">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2019-01-01to2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">108,656</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_402_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zLvV2RUMLQx4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -8.65pt; padding-left: 8.65pt"><span style="font: 10pt Times New Roman, Times, Serif">Share-based
    compensation</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2019-01-012019-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,682,084</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0359">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2019-01-01to2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,682,084</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_408_eus-gaap--NetIncomeLoss_zmk5mgcxLKPh" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -8.65pt; padding-left: 8.65pt; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Net
    loss</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0362">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0363">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-01-012019-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">176,144,999</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-01-01to2019-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">176,144,999</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_430_c20190101__20191231_eus-gaap--StockholdersEquity_iE_zcw9RPTcA6da" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-indent: -8.65pt; padding-left: 8.65pt"><span style="font: 10pt Times New Roman, Times, Serif">Balance,
    December 31, 2019</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--CommonStockSharesOutstanding_iE_c20190101__20191231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zfdRLkulax24" title="Ending balance (in shares)" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2019-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">271,177,076</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">271,177</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">704,351,222</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">695,421,279</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,201,120</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<p style="margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">The
accompanying footnotes are an integral part of these consolidated financial statements.</span></p>

<p style="margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 81; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>THERAPEUTICSMD,
INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="txmdb004"></span><b>CONSOLIDATED
STATEMENTS OF CASH FLOWS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30B_112_zeIDyGLhHBY9" summary="xdx: Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td id="xdx_49C_20190101__20191231_z1bX7gF0dXwk" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td id="xdx_49D_20180101__20181231_zQvqpXHiq8xc" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td id="xdx_49A_20170101__20171231_ze8HTXqJmpg5" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="11" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Year
    Ended December, 31,</b></span></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>2019</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>2018</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>2017</b></span></td></tr>
<tr id="xdx_402_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zIRc66WH6mo3" style="vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -8.65pt; padding-left: 8.65pt"><span style="font: 10pt Times New Roman, Times, Serif">CASH
    FLOWS FROM OPERATING ACTIVITIES</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_401_eus-gaap--NetIncomeLoss_i01_mascfops_zSULir5JDUKf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 55%; text-align: left; text-indent: -8.65pt; padding-left: 25.9pt"><span style="font: 10pt Times New Roman, Times, Serif">Net
    loss</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-01-01to2019-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">176,144,999</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">132,617,160</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2017-01-012017-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">76,925,380</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_40D_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_z4HnvJ9IPkj2" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -8.65pt; padding-left: 34.55pt"><span style="font: 10pt Times New Roman, Times, Serif">Adjustments
    to reconcile net loss to net cash used in operating activities:</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_400_eus-gaap--Depreciation_i02_mascfops_zwVAhwd4Wgy9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -8.65pt; padding-left: 0.6in"><span style="font: 10pt Times New Roman, Times, Serif">Depreciation
    of fixed assets</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2019-01-01to2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">415,193</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">181,412</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2017-01-012017-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">141,601</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_406_eus-gaap--AmortizationOfIntangibleAssets_i02_mascfops_zRajvcNeBhUb" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -8.65pt; padding-left: 0.6in"><span style="font: 10pt Times New Roman, Times, Serif">Amortization
    of intangible assets</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2019-01-01to2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">197,593</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">112,474</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2017-01-012017-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">71,516</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_408_eus-gaap--OtherNoncashExpense_i02_mascfops_zt6QlfEWgGYd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -8.65pt; padding-left: 0.6in"><span style="font: 10pt Times New Roman, Times, Serif">Write
    off of patent and trademark cost</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OtherNoncashExpense" contextRef="From2019-01-01to2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">78,864</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0395">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0396">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_405_ecustom--NoncashOperatingLeaseExpense_i02_mascfops_zRuzQ53Bn2T3" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -8.65pt; padding-left: 0.6in"><span style="font: 10pt Times New Roman, Times, Serif">Non-cash
    operating lease expense</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="txmd:NoncashOperatingLeaseExpense" contextRef="From2019-01-01to2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,062,318</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0399">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0400">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_409_eus-gaap--ProvisionForDoubtfulAccounts_i02_mascfops_zSNhV6zLTGqj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -8.65pt; padding-left: 0.6in"><span style="font: 10pt Times New Roman, Times, Serif">Provision
    for doubtful accounts</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="From2019-01-01to2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">307,438</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">216,022</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="From2017-01-012017-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,206</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40F_eus-gaap--GainsLossesOnExtinguishmentOfDebt_i02N_di_msscfops_zc9R18rFgva6" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -8.65pt; padding-left: 0.6in"><span style="font: 10pt Times New Roman, Times, Serif">Loss
    of extinguishment of debt</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2019-01-01to2019-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,057,632</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0407">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0408">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_400_eus-gaap--ShareBasedCompensation_i02_mascfops_z2wmZXCYLcxh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -8.65pt; padding-left: 0.6in"><span style="font: 10pt Times New Roman, Times, Serif">Share-based
    compensation</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2019-01-01to2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,693,662</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,661,967</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2017-01-012017-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,889,323</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40D_eus-gaap--OtherAmortizationOfDeferredCharges_i02_mascfops_z5q9SR3X0J9f" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -8.65pt; padding-left: 0.6in"><span style="font: 10pt Times New Roman, Times, Serif">Amortization
    of intellectual property license fee</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OtherAmortizationOfDeferredCharges" contextRef="From2019-01-01to2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">778,692</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0415">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0416">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_400_eus-gaap--AmortizationOfFinancingCosts_i02_mascfops_zrCQSYfVpGXc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -8.65pt; padding-left: 0.6in"><span style="font: 10pt Times New Roman, Times, Serif">Amortization
    of deferred financing costs</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCosts" contextRef="From2019-01-01to2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">856,302</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCosts" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">269,859</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0420">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_406_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i02B_zL68iPBOpRKa" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -8.65pt; padding-left: 0.6in"><span style="font: 10pt Times New Roman, Times, Serif">Changes
    in operating assets and liabilities:</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_401_eus-gaap--IncreaseDecreaseInAccountsReceivable_i03N_di_msscfops_zHG6HXPsgkZg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -8.65pt; padding-left: 51.85pt"><span style="font: 10pt Times New Roman, Times, Serif">Accounts
    receivable</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2019-01-01to2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,639,575</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,951,041</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2017-01-012017-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">167,691</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40D_eus-gaap--IncreaseDecreaseInInventories_i03N_di_msscfops_z4SK1iEhcAX4" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -8.65pt; padding-left: 51.85pt"><span style="font: 10pt Times New Roman, Times, Serif">Inventory</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2019-01-01to2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,593,046</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,782,312</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2017-01-012017-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">409,037</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_401_eus-gaap--IncreaseDecreaseInOtherOperatingAssets_i03N_di_msscfops_zq8LVoiOrpwj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -8.65pt; padding-left: 51.85pt"><span style="font: 10pt Times New Roman, Times, Serif">Other
    assets</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" contextRef="From2019-01-01to2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,880,048</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,657,190</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" contextRef="From2017-01-012017-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,434,130</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_40F_eus-gaap--IncreaseDecreaseInAccountsPayable_i03_mascfops_zBzOPQz9nNdc" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -8.65pt; padding-left: 51.85pt"><span style="font: 10pt Times New Roman, Times, Serif">Accounts
    payable</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2019-01-01to2019-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,562,629</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,646,241</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2017-01-012017-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,260,914</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_401_eus-gaap--IncreaseDecreaseInOtherCurrentLiabilities_i03_mascfops_zM8h7whVVtli" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; text-indent: -8.65pt; padding-left: 51.85pt"><span style="font: 10pt Times New Roman, Times, Serif">Accrued
    expenses and other liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" contextRef="From2019-01-01to2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,675,008</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,107,947</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" contextRef="From2017-01-012017-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,599,510</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-indent: -8.65pt; padding-left: 8.65pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_408_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_mtscfops_maCCERCzuTH_z8hbAW55V7zi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; text-indent: -8.65pt; padding-left: 17.3pt"><span style="font: 10pt Times New Roman, Times, Serif">Net
    cash used in operating activities</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2019-01-01to2019-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">165,697,595</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">106,811,781</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2017-01-012017-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">76,155,614</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-indent: -8.65pt; padding-left: 8.65pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40A_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_zkod7Iu04uPd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -8.65pt; padding-left: 8.65pt"><span style="font: 10pt Times New Roman, Times, Serif">CASH
    FLOWS FROM INVESTING ACTIVITIES</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_403_ecustom--PaymentsToAcquireIntellectualPropertyLicense_i01N_di_msNCPBUzecP_zcAHMWMBqZQa" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -8.65pt; padding-left: 25.9pt"><span style="font: 10pt Times New Roman, Times, Serif">Payment
    for intellectual property license</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="txmd:PaymentsToAcquireIntellectualPropertyLicense" contextRef="From2019-01-01to2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,000,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="txmd:PaymentsToAcquireIntellectualPropertyLicense" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,000,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0456">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40E_eus-gaap--PaymentsToAcquireIntangibleAssets_i01N_di_msNCPBUzecP_z29MaPpC4h93" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -8.65pt; padding-left: 25.9pt"><span style="font: 10pt Times New Roman, Times, Serif">Patent
    costs</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="From2019-01-01to2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,441,989</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,105,407</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="From2017-01-012017-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">765,291</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_408_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_i01N_di_msNCPBUzecP_zqiHLZYRT8re" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -8.65pt; padding-left: 25.9pt"><span style="font: 10pt Times New Roman, Times, Serif">Purchase
    of fixed assets</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2019-01-01to2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,450,285</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">217,040</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2017-01-012017-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">61,817</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_40B_eus-gaap--IncreaseDecreaseInRestrictedCash_i01N_di_msNCPBUzecP_zWeQA9tPz0zb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; text-indent: -8.65pt; padding-left: 25.9pt"><span style="font: 10pt Times New Roman, Times, Serif">Payment
    of security deposit</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInRestrictedCash" contextRef="From2019-01-01to2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,420</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInRestrictedCash" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">175,410</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0468">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-indent: -8.65pt; padding-left: 8.65pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40D_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_mtNCPBUzecP_maCCERCzuTH_zixO1XCnXOr" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; text-indent: -8.65pt; padding-left: 17.3pt"><span style="font: 10pt Times New Roman, Times, Serif">Net
    cash used in investing activities</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2019-01-01to2019-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">23,912,694</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">21,497,857</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2017-01-012017-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">827,108</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-indent: -8.65pt; padding-left: 8.65pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_402_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zY1w6PoRxhI5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -8.65pt; padding-left: 8.65pt"><span style="font: 10pt Times New Roman, Times, Serif">CASH
    FLOWS FROM FINANCING ACTIVITIES</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-indent: -8.65pt; padding-left: 8.65pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_405_eus-gaap--ProceedsFromStockOptionsExercised_i01_maNCPBUzaoj_zp9bYOuUgsG8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -8.65pt; padding-left: 25.9pt"><span style="font: 10pt Times New Roman, Times, Serif">Proceeds
    from exercise of options and warrants</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2019-01-01to2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">108,656</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,666,208</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2017-01-012017-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,011,614</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40F_eus-gaap--ProceedsFromIssuanceOfCommonStock_i01_maNCPBUzaoj_zwJdvwJRvTvc" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -8.65pt; padding-left: 25.9pt"><span style="font: 10pt Times New Roman, Times, Serif">Proceeds
    from sale of common stock, net of costs</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2019-01-01to2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">77,031,258</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">89,907,797</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2017-01-012017-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">68,572,635</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_405_eus-gaap--ProceedsFromLinesOfCredit_i01_maNCPBUzaoj_zAIh9FktvFKc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -8.65pt; padding-left: 25.9pt"><span style="font: 10pt Times New Roman, Times, Serif">Proceeds
    from Financing Agreement</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" contextRef="From2019-01-01to2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">200,000,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0487">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0488">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40B_eus-gaap--ProceedsFromIssuanceOfOtherLongTermDebt_i01_maNCPBUzaoj_zbZJ6fmzwhfa" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -8.65pt; padding-left: 25.9pt"><span style="font: 10pt Times New Roman, Times, Serif">Proceeds
    from Credit Agreement</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0490">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">75,000,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0492">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_404_eus-gaap--PaymentsOfFinancingCosts_i01N_di_msNCPBUzaoj_zzqHYRNByYf5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -8.65pt; padding-left: 25.9pt"><span style="font: 10pt Times New Roman, Times, Serif">Payment
    of deferred financing fees</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:PaymentsOfFinancingCosts" contextRef="From2019-01-01to2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,652,270</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:PaymentsOfFinancingCosts" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,786,918</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0496">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_404_eus-gaap--RepaymentsOfOtherLongTermDebt_i01N_di_msNCPBUzaoj_z2xHF2aeIRGl" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; text-indent: -8.65pt; padding-left: 25.9pt"><span style="font: 10pt Times New Roman, Times, Serif">Repayment
    of Credit Agreement</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:RepaymentsOfOtherLongTermDebt" contextRef="From2019-01-01to2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">81,660,719</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0499">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0500">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-indent: -8.65pt; padding-left: 8.65pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_401_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_mtNCPBUzaoj_maCCERCzuTH_zqT2AOSShPBi" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; text-indent: -8.65pt; padding-left: 17.3pt"><span style="font: 10pt Times New Roman, Times, Serif">Net
    cash provided by financing activities</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2019-01-01to2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">188,826,925</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">162,787,087</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2017-01-012017-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">72,584,249</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-indent: -8.65pt; padding-left: 8.65pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40E_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_iT_mtCCERCzuTH_zJmd13sJZqc4" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -8.65pt; padding-left: 17.3pt"><span style="font: 10pt Times New Roman, Times, Serif">(Decrease)
    increase in cash</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2019-01-01to2019-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">783,364</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">34,477,449</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2017-01-012017-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,398,473</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_403_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iS_zl47TWE5HJU" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-indent: -8.65pt; padding-left: 17.3pt"><span style="font: 10pt Times New Roman, Times, Serif">Cash,
    beginning of period</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">161,613,077</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2017-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">127,135,628</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2016-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">131,534,101</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40B_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iE_zQFgKp1XI927" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-indent: -8.65pt; padding-left: 17.3pt"><span style="font: 10pt Times New Roman, Times, Serif">Cash,
    end of period</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">160,829,713</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">161,613,077</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2017-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">127,135,628</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-indent: -8.65pt; padding-left: 8.65pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_406_eus-gaap--SupplementalCashFlowInformationAbstract_iB_zjJoRSUOmzWa" style="vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -8.65pt; padding-left: 8.65pt"><span style="font: 10pt Times New Roman, Times, Serif">Supplemental
    disclosure of cash flow information</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_402_eus-gaap--InterestPaidNet_i01_zEQjPA4ubHG8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; text-indent: -8.65pt; padding-left: 17.3pt"><span style="font: 10pt Times New Roman, Times, Serif">Interest
    paid</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2019-01-01to2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,787,903</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,890,166</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0524">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>



<p style="margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin-top: 0; text-align: center; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">The
accompanying footnotes are an integral part of these consolidated financial statements.</span></p>

<p style="margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: Page; Sequence: 82; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b><span id="txmdb005"></span>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<ix:nonNumeric contextRef="From2019-01-01to2019-12-31" escape="true" name="us-gaap:NatureOfOperations"><p id="xdx_80D_eus-gaap--NatureOfOperations_z13SIeAOJBxd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b><span style="text-decoration: underline"><b>NOTE 1 &#8211; <span id="xdx_822_zBs3fazlAubl">THE COMPANY</span></b></span></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">TherapeuticsMD,
Inc., a Nevada corporation, or TherapeuticsMD or the Company, has <span id="xdx_900_ecustom--NumberOfSubsidiaries_iI_dc_uPure_c20191231_zj683O4X4lTg" title="Number of subsidiaires"><ix:nonFraction name="txmd:NumberOfSubsidiaries" contextRef="AsOf2019-12-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Pure">three</ix:nonFraction></span> wholly owned subsidiaries, vitaMedMD, LLC, a Delaware
limited liability company, or VitaMed; BocaGreenMD, Inc., a Nevada corporation, or BocaGreen; and VitaCare Prescription Services,
Inc., a Florida corporation, or VitaCare. Unless the context otherwise requires, TherapeuticsMD, VitaMed, BocaGreen, and VitaCare
collectively are sometimes referred to as &#8220;our company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; or &#8220;us.&#8221;
TherapeuticsMD &#174;, vitaMedMD &#174;, BocaGreenMD &#174;, IMVEXXY &#174; and BIJUVA &#174; are registered trademarks of our
company and ANNOVERA&#8482; is a licensed trademark of our company. </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: black"><span style="text-decoration: underline"><span style="color: black">Nature of Business</span></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">We are a women&#x2019;s healthcare company with a mission of creating and commercializing innovative products to support the lifespan of women from pregnancy prevention through menopause. At TherapeuticsMD, we combine entrepreneurial spirit, clinical expertise, and business leadership to develop and commercialize health solutions that enable new standards of care for women. Our solutions range from a patient-controlled, long-lasting contraceptive to advanced hormone therapy pharmaceutical products. We also manufacture and distribute branded and generic prescription prenatal vitamins under the vitaMedMD and BocaGreenMD brands. Our portfolio of products focused on women&#x2019;s health allows us to efficiently leverage our sales and marketing plan to grow our recently approved products. During 2018, the U.S. Food and Drug Administration, or FDA, approval of our pharmaceutical products has transitioned our company from predominately focused on conducting research and development to one focused on commercializing our pharmaceutical products. In July 2018, we launched our FDA-approved product, IMVEXXY (estradiol vaginal inserts) for the treatment of moderate-to-severe dyspareunia (vaginal pain associated with sexual activity), a symptom of vulvar and vaginal atrophy, or VVA, due to menopause. In April 2019, we launched our FDA-approved product BIJUVA (estradiol and progesterone) capsules<span style="text-align: justify">, our hormone therapy combination of bio-identical 17&#223;-estradiol and bio-identical progesterone in a single, oral softgel capsule, for the treatment of moderate-to-severe vasomotor symptoms, or VMS, due to menopause in women with a uterus. In October 2019, we began a test and learn market introduction for our FDA-approved product ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system), the first and only patient-controlled, procedure-free, reversible prescription contraceptive option for women. We expect the full commercial launch of ANNOVERA in the first quarter of 2020. On July 30, 2018, we entered into an exclusive license agreement, or the Population Council License Agreement, with the Population Council, Inc., or the Population Council, to commercialize ANNOVERA in the U.S. In addition, on July 30, 2018, we entered into a license and supply agreement</span><span style="color: #212529">, or the Knight License Agreement,</span> with Knight Therapeutics Inc., or Knight, pursuant to which we granted Knight an exclusive license to commercialize IMVEXXY and BIJUVA in Canada and Israel. On June 6, 2019, we entered into an exclusive license and supply agreement, or the Theramex License Agreement, with Theramex HQ UK Limited, or Theramex, to commercialize BIJUVA and IMVEXXY outside of the U.S., excluding Canada and Israel, or the Theramex Territory. </span></p>
</ix:nonNumeric><p id="xdx_815_zpnjJTMYMROj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<ix:nonNumeric contextRef="From2019-01-01to2019-12-31" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_808_eus-gaap--SignificantAccountingPoliciesTextBlock_zO2vOpZycVy9" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><b><span style="text-decoration: underline"><b>NOTE 2 &#8211; <span id="xdx_827_zZNBdZzlNhJd">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></span></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<ix:nonNumeric contextRef="From2019-01-01to2019-12-31" escape="true" name="us-gaap:ConsolidationPolicyTextBlock"><p id="xdx_840_eus-gaap--ConsolidationPolicyTextBlock_z9mbbq84TDpk" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="text-decoration: underline">Principles of Consolidation</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">The accompanying consolidated financial statements include the accounts of our company and our wholly owned subsidiaries, VitaMed, BocaGreen and VitaCare. All intercompany balances and transactions have been eliminated in consolidation.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</ix:nonNumeric><ix:nonNumeric contextRef="From2019-01-01to2019-12-31" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_84E_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zPuRMhgGn9n9" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: black"><span style="text-decoration: underline"><span style="color: black">Cash</span></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">We maintain cash at financial institutions that at times may exceed the Federal Deposit Insurance Corporation, or the FDIC, insured limits of $<span id="xdx_907_eus-gaap--CashFDICInsuredAmount_iI_c20191231_zArZMLyhjRi2" title="Federal insurance limits"><ix:nonFraction name="us-gaap:CashFDICInsuredAmount" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span> per bank. We have never experienced any losses related to these funds.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</ix:nonNumeric><ix:nonNumeric contextRef="From2019-01-01to2019-12-31" escape="true" name="us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy"><p id="xdx_842_eus-gaap--ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_z4vfyE0pmWgg" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: black"><span style="text-decoration: underline"><span style="color: black">Trade Accounts Receivable and Allowance for Doubtful Accounts</span></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">Trade accounts receivable are customer obligations due under normal trade terms. We review accounts receivable for uncollectible accounts and credit card chargebacks and provide an allowance for doubtful accounts, which is based upon a review of outstanding receivables, historical collection information, and existing economic conditions. We evaluate trade accounts receivable aged more than 90 days for delinquency. We write off delinquent receivables against our allowance for doubtful accounts based on individual credit evaluations, the results of collection efforts, and specific circumstances of customers. We record recoveries of accounts previously written off when received as an increase in the allowance for doubtful accounts. To the extent data we use to calculate these estimates does not accurately reflect bad debts, adjustments to these reserves may be required. At December 31, 2019, four different customers represented <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_dp_c20190101__20191231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerAMember_zKF3b71cwfz1" title="Concentration risk"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2019-01-012019-12-31_us-gaap_AccountsReceivableMember_custom_CustomerAMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">36</ix:nonFraction></span>%, <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_dp_c20190101__20191231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerBMember_zmEFfWdMZjDg"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2019-01-012019-12-31_us-gaap_AccountsReceivableMember_custom_CustomerBMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21</ix:nonFraction></span>%, <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_dp_c20190101__20191231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerCMember_zntJnZicuVGl"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2019-01-012019-12-31_us-gaap_AccountsReceivableMember_custom_CustomerCMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">16</ix:nonFraction></span>% and <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_dp_c20190101__20191231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerDMember_zO8dfd3KrK6h"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2019-01-012019-12-31_us-gaap_AccountsReceivableMember_custom_CustomerDMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">11</ix:nonFraction></span>% of our gross accounts receivable. At December 31, 2018, three different customers represented <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_dp_c20180101__20181231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerAMember_zupQyt5giKMl"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2018-01-012018-12-31_us-gaap_AccountsReceivableMember_custom_CustomerAMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">42</ix:nonFraction></span>%, <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20180101__20181231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerBMember_zpzmvrRmdsO9"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2018-01-012018-12-31_us-gaap_AccountsReceivableMember_custom_CustomerBMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">24</ix:nonFraction></span>% and <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_c20180101__20181231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerCMember_zyUQ7PV5Sc6d"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2018-01-012018-12-31_us-gaap_AccountsReceivableMember_custom_CustomerCMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">13</ix:nonFraction></span>% of our gross accounts receivable.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<ix:exclude><!-- Field: Page; Sequence: 83; Value: 3 -->
    <div id="xdx_235_zk7dHjpTKyDd" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_23B_zmY0My168PSc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div>
    <div id="xdx_23E_z6ZJRcMuJWC1" style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>
<ix:exclude><p id="xdx_23F_zr0iDygant3l" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2019-01-01to2019-12-31" escape="true" name="us-gaap:InventoryPolicyTextBlock"><p id="xdx_841_eus-gaap--InventoryPolicyTextBlock_zJMMUrzk2Is1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: black"><span style="text-decoration: underline"><span style="color: black">Inventories</span></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">Inventories represent pharmaceutical products, packaged vitamins and raw materials which are valued at the lower of cost or net realizable value. Our pharmaceutical products are valued using first in first out method and our vitamins are valued using the average-cost method. We review our inventory for excess or obsolete inventory and write-down obsolete or otherwise unmarketable inventory to its estimated net realizable value. Obsolescence may occur due to product expiring or product improvements rendering previous versions obsolete.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black"><i><span style="text-decoration: underline"><span style="color: black"><i>Pre-Launch Inventory</i></span></span></i></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">Pre-launch
inventory costs associated with product candidates that have not yet received regulatory approval are capitalized if we
believe there is probable future commercial use and future economic benefit. If the probability of future commercial use and
future economic benefit cannot be reasonably determined, then pre-launch inventory costs associated with such product
candidates are expensed as research and development expenses during the period the costs are incurred. We have not
capitalized any pre-launch inventory to date.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</ix:nonNumeric><ix:nonNumeric contextRef="From2019-01-01to2019-12-31" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><p id="xdx_840_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zVTVNsWARLG6" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: black"><span style="text-decoration: underline"><span style="color: black">Fixed Assets</span></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">We state fixed assets at cost, net of accumulated depreciation. We charge maintenance costs, which do not significantly extend the useful lives of the respective assets, and repair costs to operating expenses as incurred. We compute depreciation using the straight-line method over the estimated useful lives of the related assets, which range from <span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dxL_c20190101__20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LandAndBuildingMember__srt--RangeAxis__srt--MinimumMember_zJS38w4WoxI7" title="Useful life of assets::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl0553">three</span></span> to <span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dxL_c20190101__20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LandAndBuildingMember__srt--RangeAxis__srt--MaximumMember_zlggfZdrMU98" title="::XDX::P7Y"><span style="-sec-ix-hidden: xdx2ixbrl0554">seven</span></span> years. Leasehold improvements are depreciated over the shorter of their useful life or the term of the lease.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">We capitalize software and software development costs incurred to create and acquire computer software for internal use, principally related to software coding and application development. We begin to capitalize software development costs when both the preliminary project stage is completed and it is probable that the software will be used as intended. Capitalized software costs include only external direct costs and services utilized in developing or obtaining computer software. Capitalized software costs are amortized on a straight-line basis when placed into service over the estimated useful life, generally <span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dxL_c20190101__20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember__srt--RangeAxis__srt--MinimumMember_zld1rcASVmyj" title="::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl0555">five</span></span> to <span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dxL_c20190101__20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember__srt--RangeAxis__srt--MaximumMember_zbWzKwyxIev5" title="::XDX::P7Y"><span style="-sec-ix-hidden: xdx2ixbrl0556">seven</span></span> years.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</ix:nonNumeric><ix:nonNumeric contextRef="From2019-01-01to2019-12-31" escape="true" name="us-gaap:IntangibleAssetsFiniteLivedPolicy"><p id="xdx_840_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zkbInhjBzxL3" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: black"><span style="text-decoration: underline"><span style="color: black">Intangible Assets</span></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">We have adopted the provisions of Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, 350, <i><span style="color: black">Intangibles - Goodwill and Other</span></i>, or ASC 350. Capitalized patent costs, net of accumulated amortization, include outside legal costs incurred for patent applications. In accordance with ASC 350, once a patent is granted, we amortize the capitalized patent costs over the remaining life of the patent using the straight-line method. If the patent is not granted, we write-off any capitalized patent costs at that time. As of December 31, 2019, we had <span id="xdx_904_ecustom--NumberOfIssuedPatentsDomestic_iI_uPure_c20191231_zN9Aevq2rkUe" title="Number of issued patents domestic."><ix:nonFraction name="txmd:NumberOfIssuedPatentsDomestic" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">29</ix:nonFraction></span> issued domestic, or U.S., patents and <span id="xdx_907_ecustom--NumberOfIssuedPatentsForeign_iI_uPure_c20191231_zxTQdtMts3r5" title="Number of issued patents foreign"><ix:nonFraction name="txmd:NumberOfIssuedPatentsForeign" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">30</ix:nonFraction></span> issued foreign patents (See Note 6). We capitalize external costs, consisting primarily of legal costs, related to securing our trademarks. Trademarks are perpetual and are not amortized. We review intangible assets for impairment annually or when events or circumstances indicate that their carrying amount may not be recoverable.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</ix:nonNumeric><ix:nonNumeric contextRef="From2019-01-01to2019-12-31" escape="true" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"><p id="xdx_84C_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zX0rxQcb4Caj" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="text-decoration: underline">Impairment of Long-Lived Assets</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">We review the carrying values of fixed assets and long-lived intangible assets to be held and used for impairment whenever events or changes in circumstances indicate that their carrying values may not be recoverable. Such events or circumstances may include, among others, the following:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%; width: 100%">

<tr>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">significant declines in an asset&#x2019;s market price;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%; width: 100%">

<tr>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">significant deterioration in an asset&#x2019;s physical condition;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%; width: 100%">

<tr>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">significant changes in the nature or extent of an asset&#x2019;s use or operation;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%; width: 100%">

<tr>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">significant adverse changes in the business climate that could impact an asset&#x2019;s value, including adverse actions or assessments by regulators;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%; width: 100%">

<tr>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">accumulation of costs significantly in excess of original expectations related to the acquisition or construction of an asset;</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%; width: 100%">

<tr>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">current-period operating or cash flow losses combined with a history of such losses or a forecast that demonstrates continuing losses associated with an asset&#x2019;s use; and</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%; width: 100%">

<tr>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">expectations that it is more likely than not that an asset will be sold or otherwise disposed of significantly before the end of its previously estimated useful life.</p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<ix:exclude><!-- Field: Page; Sequence: 84; Value: 3 -->
    <div id="xdx_238_zqMJPU2RP4la" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_239_zgQqjPyoA8R8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div>
    <div id="xdx_232_zJVPnYj000g8" style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>
<ix:exclude><p id="xdx_23B_zwvJWAOrNvPh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></ix:exclude>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">If impairment indicators are present, we determine whether an impairment loss should be recognized by testing the applicable asset or asset group&#x2019;s carrying value for recoverability. This test requires long-lived assets to be grouped at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities, the determination of which requires judgment. We estimate the undiscounted future cash flows expected to be generated from the use and eventual disposal of the assets and compare that estimate to the respective carrying values in order to determine if such carrying values are recoverable. This assessment requires the exercise of judgment in assessing the future use of and projected value to be derived from the eventual disposal of the assets to be held and used. In our assessments, we also consider changes in asset utilization, including, if applicable, the temporary idling of capacity and the expected timing for placing this capacity back into production. If the carrying value of the assets is not recoverable, then we record a loss for the difference between the assets&#x2019; fair value and respective carrying values. We determine the fair value of the assets using an &#8220;income approach&#8221; based upon a forecast of all the expected discounted future net cash flows associated with the subject assets. Some of the more significant estimates and assumptions include market size and growth, market share, projected selling prices, manufacturing cost, and discount rate. We base estimates upon historical experience, our commercial relationships, market conditions, and available external information about future trends. We believe our current assumptions and estimates are reasonable and appropriate. Unanticipated events and changes in market conditions, however, could affect such estimates, resulting in the need for an impairment charge in future periods. There was no impairment of long-lived assets to be held and used during the years ended December 31, 2019, 2018, and 2017.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">We perform impairment tests for intangible assets with indefinite useful lives annually, in the fourth quarter, or more frequently if events occur or circumstances change that would more likely than not reduce the fair value of an intangible asset below its carrying value. The impairment test for assets with indefinite lives consists of a comparison of the fair value of the asset with its carrying amount. If the carrying amount of an intangible asset exceeds its fair value, an impairment loss is recognized in an amount equal to that excess. </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: #212529">We also evaluate the remaining useful life of intangible assets subject to amortization on a periodic basis to determine whether events and circumstances would indicate impairment or warrant a revision to the remaining useful life. If the estimate of an intangible asset&#x2019;s remaining useful life is changed, we will amortize the remaining carrying value of the intangible asset prospectively over the revised remaining useful life.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</ix:nonNumeric><ix:nonNumeric contextRef="From2019-01-01to2019-12-31" escape="true" name="us-gaap:FairValueOfFinancialInstrumentsPolicy"><p id="xdx_843_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zcmWXNTLtxO5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: black"><span style="text-decoration: underline"><span style="color: black">Fair Value of Financial Instruments</span></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">Our financial instruments consist primarily of cash, accounts receivable, accounts payable, accrued expenses and long term debt. The carrying amount of cash, accounts receivable, accounts payable and accrued expenses approximates their fair value because of the short-term maturity of such instruments, which are considered Level 1 assets under the fair value hierarchy.&#160; T<span style="color: #212529">he carrying amount for long-term debt as of December 31, 2019 and 2018 (as disclosed in Note 8), approximates fair value based on market activity for other debt instruments with similar characteristics and comparable risk (Level 2).</span></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">We
categorize our assets and liabilities that are valued at fair value on a recurring basis into a three-level fair value
hierarchy as defined by ASC 820, <i><span style="color: black">Fair Value Measurements</span></i>, or ASC 820. The fair value
hierarchy gives the highest priority to quoted prices in active markets for identical assets and liabilities (Level 1) and
lowest priority to unobservable inputs (Level 3). Assets and liabilities recorded in the consolidated balance sheet at fair
value are categorized based on a hierarchy of inputs, as follows: </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
    <td style="width: 4%">&#160;</td>
    <td style="text-align: justify; width: 6%"><b>Level 1</b></td>
    <td style="text-align: justify; width: 90%">unadjusted quoted prices in active markets for identical assets or liabilities;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><b>Level 2</b></td>
    <td style="text-align: justify">quoted prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument; and</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><b>Level 3</b></td>
    <td style="text-align: justify">unobservable inputs for the assets or liabilities.</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">At December 31, 2019 and 2018, we had no assets or liabilities that were valued at fair value on a recurring basis.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">The fair value of indefinite-lived assets is measured on a non-recurring basis using significant unobservable inputs (Level 3) in connection with any required impairment test. During the year ended December 31, 2019, we wrote off $78,864 in costs related to trademarks and patents, including the net carrying amount of our OPERA software patent. There was no impairment of intangible assets during the years ended December 31, 2018, and 2017.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</ix:nonNumeric><ix:nonNumeric contextRef="From2019-01-01to2019-12-31" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_845_eus-gaap--IncomeTaxPolicyTextBlock_zXcE6tElWSuf" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="text-decoration: underline">Income Taxes</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">We account for income taxes under the asset and liability method. We recognize deferred tax assets and liabilities for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. We measure deferred tax assets and liabilities using enacted tax rates expected to apply to taxable income in the years in which the related temporary differences are expected to be recovered or settled. We recognize the effect on deferred tax assets and liabilities of a change in tax rates when the rate change is enacted. Valuation allowances are recorded to reduce deferred tax assets to the amount that will more likely than not be realized.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<ix:exclude><!-- Field: Page; Sequence: 85; Value: 3 -->
    <div id="xdx_239_zM53xVG7ARB3" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_239_ze2MpeJHtiCc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div>
    <div id="xdx_232_zpAb9ShEDvO7" style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>
<ix:exclude><p id="xdx_239_zUBX0mz740m7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></ix:exclude>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">In accordance with ASC 740, <i><span style="color: black">Income Taxes</span></i>, we recognize the effect of uncertain income tax positions only if the positions are more likely than not of being sustained in an audit, based on the technical merits of the position. We measure recognized uncertain income tax positions using the largest amount that has a likelihood of being realized that is greater than 50%. Changes in recognition or measurement are reflected in the period in which those changes in judgment occur.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">We recognize both interest and penalties related to uncertain tax positions as part of the income tax provision. At December 31, 2019 and 2018, we had no tax positions relating to open tax returns that were considered to be uncertain.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">Our U.S. federal and state tax returns since 2011, which was the first year we generated net operating losses, remain open to examination.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</ix:nonNumeric><ix:nonNumeric contextRef="From2019-01-01to2019-12-31" escape="true" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy"><p id="xdx_84D_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zZ67QJ5XmZpg" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="text-decoration: underline">Share-Based Compensation</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">We measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees are required to provide services. Share-based compensation arrangements include options, restricted stock, restricted stock units, performance-based awards, share appreciation rights, and employee share purchase plans. We amortize such compensation amounts, if any, over the respective service periods of the award. We use the Black-Scholes-Merton option pricing model, or the Black-Scholes Model, an acceptable model in accordance with ASC 718, Compensation-Stock Compensation, to value options. Option valuation models require the input of assumptions, including the expected life of the stock-based awards, the estimated stock price volatility, the risk-free interest rate, and the expected dividend yield. The risk-free interest rate assumption is based upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the term of the instrument. Estimated volatility is a measure of the amount by which our stock price is expected to fluctuate each year during the term of the award. On January 1, 2017, we began using our own stock price in our volatility calculation along with the other peer entities whose stock prices were publicly available that were similar to our company and in 2019 we started using only our own stock price in the volatility calculation. Our calculation of estimated volatility is based on historical stock prices over a period equal to the expected term of the awards. The average expected life of options is based on the contractual terms of the stock option using the simplified method. We utilize a dividend yield of zero based on the fact that we have never paid cash dividends and have no current intention to pay cash dividends. Calculating share-based compensation expense requires the input of highly subjective judgment and assumptions, estimates of expected life of the share-based award, stock price volatility and risk-free interest rates. The assumptions used in calculating the fair value of share-based awards represent our best estimates, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change and we use different assumptions, our share-based compensation expense could be materially different in the future. We recognize the compensation expense for share-based compensation granted based on the grant date fair value estimated in accordance with ASC 718. We generally recognize the compensation expense on a straight-line basis over the employee&#x2019;s requisite service period. Effective January 1, 2017, we account for forfeitures when they occur. On January 1, 2019, we adopted ASU 2018-07 which simplified the accounting for share-based payments to non-employees by aligning it with the accounting for share-based payments to employees, with certain exceptions. The new guidance expanded the scope of ASC 718 to include share-based payments granted to non-employees in exchange for goods or services used or consumed in an entity&#x2019;s own operations and superseded the guidance in ASC 505-50. Prior to January 1, 2019, equity instruments issued to non-employees were recorded on a fair value basis, as required by ASC 505, Equity - Based Payments to Non-Employees.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</ix:nonNumeric><ix:nonNumeric contextRef="From2019-01-01to2019-12-31" escape="true" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock"><p id="xdx_845_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zX9Q9Tx5SIq5" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: black"><span style="text-decoration: underline"><span style="color: black">Revenue Recognition</span></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">We
adopted ASC 606, <i>Revenue from Contracts with Customers</i>, or ASC 606, on January 1, 2018 using the modified retrospective
method for all contracts not completed as of the date of adoption. ASC 606 states that a contract is considered &#8220;completed&#8221;
if all (or substantially all) of the revenue was recognized in accordance with revenue guidance that was in effect before the
date of initial application. Because all (or substantially all) of the revenue related to sales of our products was recognized
under ASC 605 prior to the date of initial application of the new standard, the contracts were considered completed under ASC
606. Based on our evaluation of ASC 606, we concluded that a cumulative adjustment was not necessary upon implementation of ASC
606 on January 1, 2018. In accordance with ASC 606, revenue is recognized when a customer obtains control of promised goods or
services. The amount of revenue recognized reflects the consideration to which we expect to be entitled to receive in exchange
for these goods or services. The provisions of ASC 606 include a five-step process by which we determine revenue recognition,
depicting the transfer of goods or services to customers in amounts reflecting the payment to which we expect to be entitled in
exchange for those goods or services. ASC 606 requires us to apply the following steps: (1) identify the contract with the customer;
(2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price
to the performance obligations in the contract; and (5) recognize revenue when, or as, we satisfy the performance obligation.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<ix:exclude><!-- Field: Page; Sequence: 86; Value: 3 -->
    <div id="xdx_230_zg1wDST2y5Nb" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_238_zORn9YqWI0Q1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div>
    <div id="xdx_23C_zEhayVPbVGZ" style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>
<ix:exclude><p id="xdx_23A_zC9Fnymf9EG2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></ix:exclude>
<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 36pt; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black"><i><span style="text-decoration: underline"><span style="color: black"><i>Prescription Products</i></span></span></i></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: #212529">As of December 31, 2019, our products consisted primarily of prescription vitamins and our FDA-approved products: IMVEXXY, which we began selling during the third quarter of 2018, and BIJUVA, which we began selling in the second quarter of 2019. We started selling ANNOVERA in the third quarter of 2019 and we expect the full commercial launch of ANNOVERA in the first quarter of 2020. We sell our name brand and generic prescription products primarily through wholesale distributors and retail pharmacies. We have one performance obligation related to prescription products sold through wholesale distributors, which is to transfer promised goods to a customer, and two performance obligations related to products sold through retail pharmacies, which are to: (1) transfer promised goods and (2) provide customer service for an immaterial fee. We treat shipping as a fulfillment activity rather than as a separate obligation. We recognize prescription revenue only when we satisfy performance obligations by transferring a promised good or service to a customer. A good or service is considered to be transferred when the customer receives the goods or service or obtains control. Control refers to the customer&#x2019;s ability to direct the use of, and obtain substantially all of the remaining benefits from, an asset. Based on our contracts, we invoice customers once our performance obligations have been satisfied, at which point payment is unconditional. We disclose receivables from contracts with customers separately in the statement of financial position. Payment for goods or services sold by us is typically due between 30 and 60 days after an invoice is sent to the customer. </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: #212529">The transaction price of a contract is the amount of consideration which we expect to be entitled to in exchange for transferring promised goods or services to a customer. Prescription products are sold at fixed wholesale acquisition cost, or WAC, determined based on our list price. However, the total transaction price is variable as it is calculated net of estimated product returns, chargebacks, rebates, coupons, discounts and wholesaler fees. These estimates are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the customer) or a current liability (if the amount is payable to a party other than a customer). In order to determine the transaction price, we estimate the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract or each variable consideration. The estimated amount of variable consideration is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. In determining amounts of variable consideration to include in a contract&#x2019;s transaction price, we rely on our historical experience and other evidence that supports our qualitative assessment of whether revenue would be subject to a significant reversal. We consider all the facts and circumstances associated with both the risk of a revenue reversal arising from an uncertain future event and the magnitude of the reversal if that uncertain event were to occur. Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our original estimates, we will adjust these estimates, which would affect net product revenue and earnings in the period such changes in estimates become known. </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: #212529">We accept returns of unsalable prescription products sold through wholesale distributors within a return period of <span id="xdx_90B_ecustom--ReturnPeriodOfUnsalablePrescriptionProducts_dxH_c20190101__20191231__srt--RangeAxis__srt--MinimumMember_zwmQaTTYNKK" title="Return period of unsalable prescription products::XDX::P6M">six</span> months prior to and up to <span id="xdx_908_ecustom--ReturnPeriodOfUnsalablePrescriptionProducts_dtM_c20190101__20191231__srt--RangeAxis__srt--MaximumMember_zpQUNXhwWkQ1"><ix:nonNumeric contextRef="From2019-01-012019-12-31_srt_MaximumMember" format="ixt-sec:durmonth" name="txmd:ReturnPeriodOfUnsalablePrescriptionProducts">12</ix:nonNumeric></span> months following product expiration. Our vitamins and IMVEXXY currently have a shelf life of <span id="xdx_907_ecustom--ShelfLifeOfPrescriptionProducts_dtM_c20190101__20191231__srt--ProductOrServiceAxis__custom--VitaminsAndImvexxyMember_zdk5medOaIY1" title="Shelf life of prescription products following product expiration"><ix:nonNumeric contextRef="From2019-01-012019-12-31_custom_VitaminsAndImvexxyMember" format="ixt-sec:durmonth" name="txmd:ShelfLifeOfPrescriptionProducts">24</ix:nonNumeric></span> months from the date of manufacture and BIJUVA and ANNOVERA currently have a shelf life of <span id="xdx_905_ecustom--ShelfLifeOfPrescriptionProducts_dtM_c20190101__20191231__srt--ProductOrServiceAxis__custom--BijuvaAndAnnoveraMember_zykSpchkSjok"><ix:nonNumeric contextRef="From2019-01-012019-12-31_custom_BijuvaAndAnnoveraMember" format="ixt-sec:durmonth" name="txmd:ShelfLifeOfPrescriptionProducts">18</ix:nonNumeric></span> months from the date of manufacture. We do not allow product returns for prescription products that have been dispensed to a patient. We estimate the amount of our product sales that may be returned by our customers and record this estimate as a reduction of revenue in the period the related product revenue is recognized. Where historical rates of return exist, we use history as a basis to establish a returns reserve for products shipped to wholesalers. For our newly launched products, for which the right of return exists but for which we currently do not have history of product returns, we estimate returns based on available industry data, our own sales information and our visibility into the inventory remaining in the distribution channel. At the end of each reporting period, we may decide to constrain revenue for product returns based on information from various sources, including channel inventory levels and dating and sell-through data, the expiration dates of products currently being shipped, price changes of competitive products and any introductions of generic products. We recognize the amount of expected returns as a refund liability, representing the obligation to return the customer&#x2019;s consideration. Since our returns primarily consist of expired and short dated products that will not be resold, we do not record a return asset for the right to recover the goods returned by the customer at the time of the initial sale (when recognition of revenue is deferred due to the anticipated return). Return estimates are recorded in accrued expenses and other current liabilities on the consolidated balance sheet.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: #212529">We offer various rebate and discount programs in an effort to maintain a competitive position in the marketplace and to promote sales and customer loyalty. We estimate the allowance for consumer rebates and coupons that we have offered based on our experience and industry averages, which is reviewed, and adjusted if necessary, on a quarterly basis. Estimates relating to these rebates and coupons are deducted from gross product revenues at the time the revenues are recognized. We record distributor fees based on amounts stated in contracts. Rebate and coupon estimates and distributor fees are recorded in accrued expenses and other current liabilities on the consolidated balance sheet. We estimate chargebacks based on number of units sold during the period taking into account prices stated in contracts and our historical experience. Estimates related to distributors fees, rebates, coupons and returns are disclosed in Note 7. We provide invoice discounts to our customers for prompt payment. Estimates relating to invoice discounts and chargebacks are deducted from gross product revenues at the time the revenues are recognized. </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: #212529">As part of commercial launches for our FDA-approved prescription products, we introduced a co-pay assistance program for eligible enrolled patients whose out of pocket costs are reduced to a more affordable price. This allows patients to access the product at a reasonable cost and is in line with our responsible pricing approach. We reimburse pharmacies for this discount through third-party vendors. We consider certain payments as consideration paid to the customer and reflect such payments as a reduction of the transaction price as we do not receive a distinct good or service related to these payments. The variable consideration is estimated based on contract prices, the estimated percentage of patients that will utilize the copay assistance, the average assistance paid, the estimated levels of inventory in the distribution channel and the current level of prescriptions covered by patients&#x2019; insurance. Payers may change coverage levels for our prescription products positively or negatively, at any time up to the time that we have formally contracted coverage with the payer. As such, the net transaction price of our prescription products is susceptible to such changes in coverage levels, which are outside the influence of the Company. As a result, we constrain variable consideration for our prescription products to an amount that will not result in a significant revenue reversal in future periods. Our ability to estimate the net transaction price for our prescription products is constrained by our estimates of the amount to be paid for the co-pay assistance program which is directly related to the level of prescriptions paid for by insurance. As such, we record an accrual to reduce gross sales for the estimated co-pay and other patient assistance based on currently available third-party data and our internal analyses. We re-evaluate variable consideration each reporting period.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<ix:exclude><!-- Field: Page; Sequence: 87; Value: 3 -->
    <div id="xdx_23E_zXTv4tPv1Koc" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_230_z4tPNE4sk9m6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div>
    <div id="xdx_23A_zypQtbkxn5ye" style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>
<ix:exclude><p id="xdx_231_zn9S8160JWOg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></ix:exclude>
<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 36pt; margin-top: 0pt; margin-bottom: 0pt"><span style="color: #212529"><i><span style="text-decoration: underline"><span style="color: #212529"><i>License Revenue</i></span></span></i></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: #212529">License
arrangements may consist of non-refundable upfront license fees, exclusive licensed rights to patented or patent pending
technology, and various performance or sales milestones and future product royalty payments. Some of these arrangements may
include multiple performance obligations. Non-refundable up-front fees that are not contingent on any future performance by
us, and do not require continuing involvement on our part, are recognized as revenue when the right to use functional IP is transferred to the customer.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #212529"><span style="text-decoration: underline"><span style="color: #212529">License Agreement with Knight Therapeutics Inc.</span></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: #212529">On July 30, 2018, we entered into the Knight License Agreement with Knight pursuant to which we granted Knight an exclusive license to commercialize IMVEXXY and BIJUVA in Canada and Israel. Pursuant to the terms of the Knight License Agreement, Knight will pay us a milestone fee upon first regulatory approval in Canada of each of IMVEXXY and BIJUVA, sales milestone fees based upon certain aggregate annual sales in Canada and Israel of each of IMVEXXY and BIJUVA and royalties based on aggregate annual sales of each of IMVEXXY and BIJUVA in Canada and Israel. Knight will be responsible for all regulatory and commercial activities in Canada and Israel related to IMVEXXY and BIJUVA. We may terminate the Knight License Agreement if Knight does not submit all regulatory applications, submissions and/or registrations required for regulatory approval to use and commercialize IMVEXXY and BIJUVA in Canada and Israel within certain specified time periods. We also may terminate the Knight License Agreement if Knight challenges our patents. Either party may terminate the Knight License Agreement for any material breach by the other party that is not cured within certain specified time periods or if the other party files for bankruptcy or other related matters. In connection with the Knight License Agreement, Knight entered into a subscription agreement with us, pursuant to which Knight purchased <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20180730__20180806__us-gaap--SubsidiarySaleOfStockAxis__custom--SubscriptionAgreementKnightMember_zPi7HFxxKJK7"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2018-07-302018-08-06_custom_SubscriptionAgreementKnightMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,921,568</ix:nonFraction></span> shares of our Common Stock concurrent with the closing of the underwritten public offering of Common Stock on August 6, 2018 at a price of $<span id="xdx_90C_eus-gaap--SaleOfStockPricePerShare_iI_c20180806__us-gaap--SubsidiarySaleOfStockAxis__custom--SubscriptionAgreementKnightMember_zA6xYqBlf9gh"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2018-08-06_custom_SubscriptionAgreementKnightMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.10</ix:nonFraction></span>, for proceeds of $<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20180730__20180806__us-gaap--SubsidiarySaleOfStockAxis__custom--SubscriptionAgreementKnightMember_zE3Vbx4PtVqb"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2018-07-302018-08-06_custom_SubscriptionAgreementKnightMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,000,000</ix:nonFraction></span>.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #212529"><span style="text-decoration: underline"><span style="color: #212529">License Agreement with Theramex</span></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: #212529">On
June 6, 2019, we entered into the Theramex License Agreement with Theramex to commercialize BIJUVA and IMVEXXY in the <span style="color: black">Theramex </span>Territory.
Under the terms of the Theramex License Agreement, Theramex paid us EUR <span id="xdx_90E_ecustom--CashUpfrontPaymentReceived_dm_uEUR_c20190804__20190805__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember_zhZ8Q0Jom5W"><ix:nonFraction name="txmd:CashUpfrontPaymentReceived" contextRef="From2019-08-042019-08-05_custom_LicenseAgreementTheramexMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="EUR">14</ix:nonFraction>
million</span>, or $<span id="xdx_904_ecustom--CashUpfrontPaymentReceived_uUSD_c20190803__20190805__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember_z1NgfBwzHIz7"><ix:nonFraction name="txmd:CashUpfrontPaymentReceived" contextRef="From2019-08-032019-08-05_custom_LicenseAgreementTheramexMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,506,400</ix:nonFraction></span>,
in cash as an upfront fee on August 5, 2019. Within thirty days of signing the Theramex License Agreement, we provided
Theramex the regulatory materials and clinical data that were necessary for Theramex to obtain marketing authorizations and
other applicable regulatory approvals for commercializing BIJUVA and IMVEXXY. We recognized the revenue related to the
upfront fee, which was a non-refundable payment, during the third quarter of 2019, at a point in time when Theramex was able
to use and benefit from the license which was when the knowledge transfer of regulatory documents occurred. We are eligible
to receive additional milestone payments comprised of (i) up to an aggregate of EUR <span id="xdx_907_ecustom--RegulatoryMilestoneAdditionalPayment_iI_dm_uEUR_c20190606__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember__srt--RangeAxis__srt--MaximumMember_zebOAlMYfGdc"><ix:nonFraction name="txmd:RegulatoryMilestoneAdditionalPayment" contextRef="AsOf2019-06-06_custom_LicenseAgreementTheramexMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="EUR">2</ix:nonFraction>
million</span> in regulatory milestone payments based on regulatory approvals for BIJUVA and IMVEXXY in certain specified
markets and (ii) up to an aggregate of EUR <span id="xdx_906_ecustom--SalesMilestonePaymentsInTranches_iI_dm_uEUR_c20190606__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember__srt--RangeAxis__srt--MaximumMember_zTkMgkY5IUa4"><ix:nonFraction name="txmd:SalesMilestonePaymentsInTranches" contextRef="AsOf2019-06-06_custom_LicenseAgreementTheramexMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="EUR">27.5</ix:nonFraction>
million</span> in sales milestone payments to be paid in escalating tranches based on Theramex first attaining certain
aggregate annual net sales milestones of BIJUVA and IMVEXXY in the <span style="color: black">Theramex </span>Territory
ranging from EUR <span id="xdx_90C_ecustom--AnnualNetSalesMilestone_dm_uEUR_c20190605__20190606__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember__srt--RangeAxis__srt--MinimumMember_z1X49D80mEN1" title="Sales milestone"><ix:nonFraction name="txmd:AnnualNetSalesMilestone" contextRef="From2019-06-052019-06-06_custom_LicenseAgreementTheramexMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="EUR">25</ix:nonFraction>
million</span> to EUR <span id="xdx_909_ecustom--AnnualNetSalesMilestone_dm_uEUR_c20190605__20190606__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember__srt--RangeAxis__srt--MaximumMember_zfL5UAQPZVef"><ix:nonFraction name="txmd:AnnualNetSalesMilestone" contextRef="From2019-06-052019-06-06_custom_LicenseAgreementTheramexMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="EUR">100</ix:nonFraction>
million</span>. We are also entitled to receive quarterly royalty payments at a rate of <span id="xdx_90D_ecustom--QuarterlyRoyaltyPaymentsPercentage_dp_c20190605__20190606__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember__srt--ProductOrServiceAxis__custom--BijuvaAndAnnoveraMember_zNWu2klcrb31" title="Quarterly royalty payments percentage"><ix:nonFraction name="txmd:QuarterlyRoyaltyPaymentsPercentage" contextRef="From2019-06-052019-06-06_custom_LicenseAgreementTheramexMember_custom_BijuvaAndAnnoveraMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction></span>% on net sales of BIJUVA and
IMVEXXY in the <span style="color: black">Theramex </span>Territory. Theramex is responsible for all regulatory
and commercial activities for BIJUVA and IMVEXXY in the <span style="color: black">Theramex </span>Territory. Theramex
may sublicense its rights to commercialize BIJUVA and IMVEXXY in the <span style="color: black">Theramex </span>Territory,
except for certain specified markets. We may terminate the Theramex License Agreement if Theramex does not submit
all regulatory applications, submissions and/or registrations required for regulatory approval to use and commercialize
BIJUVA and IMVEXXY within certain specified time periods. We also may terminate the Theramex License Agreement if
Theramex challenges our patents. Either party may terminate the Theramex License Agreement for any material breach by the
other party that is not cured within certain specified time periods or if the other party files for bankruptcy or other
related matters. </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 36pt; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black"><i><span style="text-decoration: underline"><span style="color: black"><i>Disaggregation of revenue</i></span></span></i></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<ix:nonNumeric contextRef="From2019-01-01to2019-12-31" escape="true" name="us-gaap:DisaggregationOfRevenueTableTextBlock"><p id="xdx_890_eus-gaap--DisaggregationOfRevenueTableTextBlock_z8OEeqjDg4wl" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">The following table provides information about disaggregated revenue by product mix for the years ended December 31, 2019, 2018, and 2017:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellspacing="0" cellpadding="0" style="margin-right: auto; margin-left: auto; float: none; width: 80%">

<tr>
<td style="vertical-align: top; padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b></b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-right: Black medium none; border-left: Black medium none; padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b></b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-right: Black medium none; border-left: Black medium none; padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b></b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="10" style="border-bottom: black 1pt solid; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>For the Years
Ended December 31,</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-bottom: black 1pt solid; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2019</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-right: Black medium none; border-bottom: Black 1pt solid; border-left: Black medium none; padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2018</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-right: Black medium none; border-bottom: Black 1pt solid; border-left: Black medium none; padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2017</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; width: 55%; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt; text-align: justify; text-indent: 0pt">Prescription vitamins</p>
</td>
<td style="width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 12%">
<p id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_zTCn7GWquVDa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2019-01-012019-12-31_custom_PrescriptionVitaminsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,885,493</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 12%">
<p id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180101__20181231__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_zeoacSq302Jd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2018-01-012018-12-31_custom_PrescriptionVitaminsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,041,259</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 12%">
<p id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20170101__20171231__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_zFufrbuEnuIj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2017-01-012017-12-31_custom_PrescriptionVitaminsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,744,831</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt; text-align: justify; text-indent: 0pt">IMVEXXY</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ProductOrServiceAxis__custom--ImvexxyMember_zYDRVsbMXUX2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2019-01-012019-12-31_custom_ImvexxyMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,252,045</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180101__20181231__srt--ProductOrServiceAxis__custom--ImvexxyMember_z6BPbXQEuVA8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2018-01-012018-12-31_custom_ImvexxyMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,058,201</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#8212;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt; text-align: justify; text-indent: 0pt">BIJUVA</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ProductOrServiceAxis__custom--BijuvaMember_zTDhU6TAWyd9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2019-01-012019-12-31_custom_BijuvaMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,836,443</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#8212;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#8212;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt; text-align: justify; text-indent: 0pt">ANNOVERA</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ProductOrServiceAxis__custom--AnnoveraMember_zNVeDXdoxc1h" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2019-01-012019-12-31_custom_AnnoveraMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,166,556</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#8212;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#8212;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt; text-align: justify; text-indent: 0pt">License revenue</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ProductOrServiceAxis__us-gaap--LicenseAndServiceMember_zsZ6QSDNh8v1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2019-01-012019-12-31_us-gaap_LicenseAndServiceMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,506,400</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#8212;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#8212;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt; text-align: justify; text-indent: 0pt">OTC products</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#8212;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#8212;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20170101__20171231__srt--ProductOrServiceAxis__custom--OtcProductsMember_zFoKtnjjbps5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2017-01-012017-12-31_custom_OtcProductsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">32,882</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 0pt 16px; text-indent: 0pt">Net revenue</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom">
<p id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231_ziaaFJ1sWOfe" title="Net revenue" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2019-01-01to2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">49,646,937</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom">
<p id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180101__20181231_z38IF71YI67g" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,099,460</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom">
<p id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20170101__20171231_zq8rzdspFESg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2017-01-012017-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,777,713</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
</table>
</ix:nonNumeric><p id="xdx_8A1_z2enxXr8rRi1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: black"><span style="text-decoration: underline"><span style="color: black">Shipping and Handling Costs</span></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">We expense all shipping and handling costs as incurred. We include these costs in cost of goods sold on the accompanying consolidated financial statements.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</ix:nonNumeric><ix:nonNumeric contextRef="From2019-01-01to2019-12-31" escape="true" name="us-gaap:SegmentReportingPolicyPolicyTextBlock"><p id="xdx_84B_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zh34nsSoyXzj" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: black"><span style="text-decoration: underline"><span style="color: black">Segment Reporting</span></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">We are managed and operated as <span id="xdx_901_eus-gaap--NumberOfReportableSegments_dc_uPure_c20190101__20191231_zfTscoqBJ7ng" title="Number of operating segments"><ix:nonFraction name="us-gaap:NumberOfReportableSegments" contextRef="From2019-01-01to2019-12-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Pure">one</ix:nonFraction></span> business, which is focused on creating and commercializing products targeted exclusively for women. Our business operations are managed by a single management team that reports to the President of our company. We do not operate separate lines of business with respect to any of our products and we do not prepare discrete financial information with respect to separate products. All product sales are derived from sales in the United States. Accordingly, we view our business as one reportable operating segment.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 88; Value: 3 -->
    <div id="xdx_23E_zl0QzaMsWLJ4" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_239_zsL2M27WhxO6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div>
    <div id="xdx_23A_zZmC9UAh0gN" style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>
<ix:exclude><p id="xdx_232_zl2oCzh88Fxg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></ix:exclude>
</ix:nonNumeric><ix:nonNumeric contextRef="From2019-01-01to2019-12-31" escape="true" name="us-gaap:CostOfSalesPolicyTextBlock"><p id="xdx_848_eus-gaap--CostOfSalesPolicyTextBlock_zBqUjo09XUGh" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: black"><span style="text-decoration: underline"><span style="color: black">Cost of Sales </span></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">Cost
of sales includes the cost of inventory, manufacturing, manufacturing overhead and supply chain costs, and product shipping
and handling costs. The Population Council License Agreement requires payment of royalties based on the sale of future
products. Such royalties are recorded as a component of cost of sales. Additionally, the amortization of license fees or
milestone payments related to licensed products are classified as components of cost of sales to the extent such payments
become due in the future.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2019-01-01to2019-12-31" escape="true" name="us-gaap:AdvertisingCostsPolicyTextBlock"><p id="xdx_845_eus-gaap--AdvertisingCostsPolicyTextBlock_zwHL0Geta6pj" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="text-decoration: underline">Advertising Costs</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">We expense advertising costs when incurred. Advertising costs were $<span id="xdx_900_eus-gaap--AdvertisingExpense_c20190101__20191231_zPOagYG9VJZh" title="Advertising costs"><ix:nonFraction name="us-gaap:AdvertisingExpense" contextRef="From2019-01-01to2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,045,571</ix:nonFraction></span>, $<span id="xdx_90C_eus-gaap--AdvertisingExpense_c20180101__20181231_zaOsot7eExva"><ix:nonFraction name="us-gaap:AdvertisingExpense" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,682,746</ix:nonFraction></span> and $<span id="xdx_900_eus-gaap--AdvertisingExpense_c20170101__20171231_zWaOTgdOA1Jf"><ix:nonFraction name="us-gaap:AdvertisingExpense" contextRef="From2017-01-012017-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">448,288</ix:nonFraction></span> during the years ended December 31, 2019, 2018, and 2017, respectively.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2019-01-01to2019-12-31" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p id="xdx_845_eus-gaap--ResearchAndDevelopmentExpensePolicy_zIzh16fKypj9" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="text-decoration: underline">Research and Development Expenses</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">Research and development, or R&#38;D, expenses include internal R&#38;D activities, services of external contract research organizations, or CROs, costs of their clinical research sites, manufacturing, scale-up and validation costs, and other activities. Internal R&#38;D activity expenses include laboratory supplies, salaries, benefits, and non-cash share-based compensation expenses. CRO activity expenses include preclinical laboratory experiments and clinical trial studies. Other activity expenses include regulatory consulting and other costs. The activities undertaken by our regulatory consultants that were classified as R&#38;D expenses include assisting, consulting with, and advising our in-house staff with respect to various FDA submission processes, clinical trial processes, and scientific writing matters, including preparing protocols and FDA submissions. These consulting expenses were direct costs associated with preparing, reviewing, and undertaking work for our clinical trials and investigative drugs. We charge internal R&#38;D activities and other activity expenses to operations as incurred. We make payments to CROs based on agreed-upon terms, which may include payments in advance of a study starting date. We expense nonrefundable advance payments for goods and services that will be used in future R&#38;D activities when the activity has been performed or when the goods have been received rather than when the payment is made. We review and accrue CRO expenses and clinical trial study expenses based on services performed and rely on estimates of those costs applicable to the completion stage of a study as provided by CROs. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. We charge revisions to expenses in the period in which the facts that give rise to the revision become known.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</ix:nonNumeric><ix:nonNumeric contextRef="From2019-01-01to2019-12-31" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_841_eus-gaap--EarningsPerSharePolicyTextBlock_zai2UEwH7ehf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="text-decoration: underline">Earnings Per Share</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">We calculate earnings per share, or EPS, in accordance with ASC 260, <i><span style="color: black">Earnings Per Share</span></i>, which requires the computation and disclosure of two EPS amounts: basic and diluted. We compute basic EPS based on the weighted-average number of shares of common stock, par value $0.001 per share, or Common Stock, outstanding during the period. We compute diluted EPS based on the weighted-average number of shares of our Common Stock outstanding plus all potentially dilutive shares of our Common Stock outstanding during the period. Such potentially dilutive shares of our Common Stock consist of options, warrants and restricted stock awards and were excluded from the calculation of diluted earnings per share because their effect would have been anti-dilutive due to the net loss reported by us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">&#160;</span></p>

<ix:nonNumeric contextRef="From2019-01-01to2019-12-31" escape="true" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"><p id="xdx_892_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zjMWR87JAaTl" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">The table below presents potentially dilutive securities that could affect our calculation of diluted net loss per share allocable to common stockholders for the periods presented.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellspacing="0" cellpadding="0" style="margin-right: auto; margin-left: auto; float: none; width: 80%">

<tr>
<td style="vertical-align: top; padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt"><b>&#160;</b></td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b></b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-right: Black medium none; border-left: Black medium none; padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b></b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-right: Black medium none; border-left: Black medium none; padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b></b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top"></td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="10" style="border-bottom: black 1pt solid; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>As of December
31,</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top"><b>&#160;</b></td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-bottom: black 1pt solid; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2019</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-right: Black medium none; border-bottom: Black 1pt solid; border-left: Black medium none; padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2018</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-right: Black medium none; border-bottom: Black 1pt solid; border-left: Black medium none; padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2017</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; width: 55%; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Stock options</p>
</td>
<td style="width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 12%">
<p id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zwwment6okci" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,030,234</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 12%">
<p id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z4Udu7FwKRBd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2018-01-012018-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,872,824</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 12%">
<p id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20170101__20171231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zLOgdFIRfWz1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2017-01-012017-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">23,365,225</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Warrants</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zn1G1tvZMjg2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2019-01-012019-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,832,571</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20180101__20181231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zJuxJ8RNShMk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2018-01-012018-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,007,571</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20170101__20171231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z1nPiuQRWDX3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2017-01-012017-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,115,905</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Restricted stock awards</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zed2bsYYVwWh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2019-01-012019-12-31_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,240,000</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zIyxoJjJmrO6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2018-01-012018-12-31_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,040,000</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#8212;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top">&#160;</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom">
<p id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20190101__20191231_zD9Rt6prp5r" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2019-01-01to2019-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">28,102,805</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom">
<p id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20180101__20181231_zP5dRly8IJff" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">24,920,395</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom">
<p id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20170101__20171231_zBwVIKCXZx59" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2017-01-012017-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">26,481,130</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>

</table>
</ix:nonNumeric><p id="xdx_8A5_znRoDQXLLwAh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</ix:nonNumeric><ix:nonNumeric contextRef="From2019-01-01to2019-12-31" escape="true" name="us-gaap:ConcentrationRiskCreditRisk"><p id="xdx_840_eus-gaap--ConcentrationRiskCreditRisk_z3qPnllrsXji" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="text-decoration: underline">Concentration of Credit Risk and other Risks and Uncertainties</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">Financial instruments that potentially expose us to concentrations of credit risk consist primarily of cash and trade accounts receivable. Cash is on deposit with financial institutions in the United States and these deposits generally exceed the amount of insurance provided by the FDIC. We have not experienced any historical losses on our deposits of cash.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">Concentration of credit risk with respect to our trade accounts receivable from our customers is primarily limited to drug wholesalers and retail pharmacy distributors. Credit is extended to our customers based on an evaluation of a customer&#x2019;s financial condition, and collateral is not required.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</ix:nonNumeric><ix:nonNumeric contextRef="From2019-01-01to2019-12-31" escape="true" name="us-gaap:UseOfEstimates"><p id="xdx_84F_eus-gaap--UseOfEstimates_zsMyrC5LdsBg" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="text-decoration: underline">Use of Estimates</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">Our consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP. The preparation of these financial statements requires us to make significant estimates and judgments that affect the reported amounts of assets, liabilities, revenue, expenses, and related disclosure of contingent assets and liabilities. We evaluate our estimates, including those related to contingencies, on an ongoing basis. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ, at times in material amounts, from these estimates under different assumptions or conditions.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 89; Value: 3 -->
    <div id="xdx_231_z3CJIh7t2Pkb" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_232_zkjyCCqmxWy3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div>
    <div id="xdx_23D_zrTquGBoG5V" style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>
<ix:exclude><p id="xdx_234_zEuix7ajezB8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></ix:exclude>
</ix:nonNumeric><ix:nonNumeric contextRef="From2019-01-01to2019-12-31" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_84B_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zjxi7fQvxgc2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="text-decoration: underline">Recently Issued Accounting Pronouncements</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="color: black">In August 2018, the FASB issued Accounting Standards Update, or ASU, 2018-13, which eliminates certain disclosure requirements for fair value measurements for all entities, requires public entities to disclose certain new information and modifies some disclosure requirements. The FASB developed the amendments to ASC 820 as part of its broader disclosure framework project, which aims to improve the effectiveness of disclosures in the notes to financial statements by focusing on requirements that clearly communicate the most important information to users of the financial statements. The new guidance is effective for all entities for fiscal years beginning after December 15, 2019 and for interim periods within those fiscal years. An entity is permitted to early adopt either the entire standard or only the provisions that eliminate or modify requirements. We do not expect that the adoption of this standard will have a material effect on our disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="color: black">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="color: black">In June 2018, the FASB issued ASU 2018-07 to simplify the accounting for share-based payments to non-employees by aligning it with the accounting for share-based payments to employees, with certain exceptions. The new guidance expands the scope of ASC 718 to include share-based payments granted to non-employees in exchange for goods or services used or consumed in an entity&#x2019;s own operations and supersedes the guidance in ASC 505-50. The guidance is effective for public business entities in annual periods beginning after December 15, 2018, and interim periods within those annual periods. Early adoption is permitted, including in an interim period for which financial statements have not been issued, but not before an entity adopts ASC 606. We adopted this standard on January 1, 2019 and the adoption of this standard did not have a material effect on our consolidated financial statements. </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="color: black">In February 2016, the FASB issued ASU 2016-02, Leases. This guidance requires lessees to record most leases on their balance sheets while recognizing expenses on their income statements in a manner similar to current accounting. The guidance also eliminates current real estate-specific provisions for all entities. For lessors, the guidance modifies the classification criteria and the accounting for sales-type and direct financing leases. The standard was effective for public business entities for annual periods beginning after December 15, 2018, and interim periods within those years. In July 2018, the FASB amended the new leases standard and issued ASU 2018-11, Leases, (Topic 842): Targeted Improvements to give entities another option for transition and to provide lessors with a practical expedient. We adopted ASU 2016-02 on January 1, 2019 utilizing the alternative transition method allowed for under ASU 2018-11 and we recorded a $<span id="xdx_903_eus-gaap--OperatingLeaseRightOfUseAsset_iI_dm_c20190102__us-gaap--AdjustmentsForNewAccountingPronouncementsAxis__us-gaap--AccountingStandardsUpdate201602Member_zlV7DDjFbRp3" title="Right of use asset"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2019-01-02_us-gaap_AccountingStandardsUpdate201602Member" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">3.8</ix:nonFraction> million</span> right of use asset and a $<span id="xdx_903_eus-gaap--OperatingLeaseLiability_iI_dm_c20190102__us-gaap--AdjustmentsForNewAccountingPronouncementsAxis__us-gaap--AccountingStandardsUpdate201602Member_zthkuShkZZq9" title="Lease liability"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2019-01-02_us-gaap_AccountingStandardsUpdate201602Member" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">4.1</ix:nonFraction> million</span> liability related to adoption of this standard. In addition, upon commencement of additional leased space in the third quarter of 2019 (as disclosed in Note 13), we recorded an additional $<span id="xdx_903_eus-gaap--OperatingLeaseRightOfUseAsset_iI_dm_c20190831_zkKApmrsrDpd"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2019-08-31" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">7.4</ix:nonFraction> million</span> right of use asset and an additional $<span id="xdx_90A_eus-gaap--OperatingLeaseLiability_iI_dm_c20190831_zd4NiSL1yiF4"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2019-08-31" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">7.2</ix:nonFraction> million</span> liability related to our new leased space. Comparative financial information was not adjusted and will continue to be reported under ASC 840. We also elected the transition relief package of practical expedients and as a result we did not assess (1) whether existing or expired contracts contain leases, (2) lease classification for any existing or expired leases, and (3) whether lease origination costs qualified as initial direct costs. We elected the short-term lease practical expedient by establishing an accounting policy to exclude leases with a term of 12 months or less. We elected not to separate lease components from non-lease components for our specified asset classes. Additionally, the adoption of the new standard resulted in increased disclosure requirements in our quarterly and annual filings. </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants and the SEC did not, and are not expected to, have a material effect on our results of operations or financial position.</span></p>

</ix:nonNumeric><p id="xdx_850_zrLqpYk9J5Xh" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black"></span></p>
</ix:nonNumeric><p id="xdx_811_zIkcUDQWjgq5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<ix:nonNumeric contextRef="From2019-01-01to2019-12-31" escape="true" name="us-gaap:InventoryDisclosureTextBlock"><p id="xdx_80F_eus-gaap--InventoryDisclosureTextBlock_zXRuhSKOS16e" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b><span style="text-decoration: underline"><b>NOTE 3 &#8211; <span id="xdx_82E_zgeF1IYPHMS">INVENTORY</span></b></span></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<ix:nonNumeric contextRef="From2019-01-01to2019-12-31" escape="true" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock"><p id="xdx_89E_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zI6A9EX6leu8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Inventory consists of the following:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellspacing="0" cellpadding="0" style="margin-right: auto; margin-left: auto; float: none; width: 60%">

<tr>
<td style="vertical-align: top; padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" id="xdx_49B_20191231_zMjb20GpLqN8" style="vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b></b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" id="xdx_49F_20181231_znBjvoHo4Cn2" style="border-right: Black medium none; border-left: Black medium none; padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b></b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="6" style="border-bottom: black 1pt solid; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>December 31,</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-bottom: black 1pt solid; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2019</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-right: Black medium none; border-bottom: Black 1pt solid; border-left: Black medium none; padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2018</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr id="xdx_40C_eus-gaap--InventoryFinishedGoods_iI_maINzas5_zJI8TeByDyvk" style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; width: 64%; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Finished products</p>
</td>
<td style="width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 15%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:InventoryFinishedGoods" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,976,910</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 15%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:InventoryFinishedGoods" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,908,958</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_407_eus-gaap--InventoryWorkInProcess_iI_maINzas5_zL7THiYBMq0d">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Work in process</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:InventoryWorkInProcess" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,182,059</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:InventoryWorkInProcess" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">339,312</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_40B_eus-gaap--InventoryRawMaterialsAndSupplies_iI_maINzas5_zmfSP9XEzOJ1" style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Raw materials</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:InventoryRawMaterialsAndSupplies" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,701,747</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:InventoryRawMaterialsAndSupplies" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,400</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_40D_eus-gaap--InventoryNet_iTI_mtINzas5_zQw4JmfiOGD5">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">TOTAL INVENTORY</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,860,716</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,267,670</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>

</table>
</ix:nonNumeric></ix:nonNumeric><p id="xdx_814_zHcudjguEUme" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p id="xdx_8A8_z8ZRm9aHB2Og" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<ix:nonNumeric contextRef="From2019-01-01to2019-12-31" escape="true" name="us-gaap:OtherCurrentAssetsTextBlock"><p id="xdx_803_eus-gaap--OtherCurrentAssetsTextBlock_zRNYmDDXc6Sd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b><span style="text-decoration: underline"><b>NOTE 4 &#8211; <span id="xdx_823_zdSaMndaGqag">OTHER CURRENT ASSETS</span></b></span></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<ix:nonNumeric contextRef="From2019-01-01to2019-12-31" escape="true" name="us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock"><p id="xdx_896_eus-gaap--ScheduleOfOtherCurrentAssetsTableTextBlock_zjwlCufIbUAf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Other current assets consist of the following:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellspacing="0" cellpadding="0" style="margin-right: auto; margin-left: auto; float: none; width: 70%">

<tr>
<td style="vertical-align: top; padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" id="xdx_499_20191231_zfyPdyJN7dKb" style="vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b></b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" id="xdx_49F_20181231_zAm9YV72nO92" style="border-right: Black medium none; border-left: Black medium none; padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b></b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="6" style="border-bottom: black 1pt solid; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>December 31,</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-bottom: black 1pt solid; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2019</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-right: Black medium none; border-bottom: Black 1pt solid; border-left: Black medium none; padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2018</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr id="xdx_400_ecustom--PrepaidSalesAndMarketingCostsCurrent_iI_maPEAOAz0Eh_zXRJw45hyjOi" style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; width: 64%; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Prepaid sales and marketing costs</p>
</td>
<td style="width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 15%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="txmd:PrepaidSalesAndMarketingCostsCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,583,698</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 15%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="txmd:PrepaidSalesAndMarketingCostsCurrent" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,148,789</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_400_eus-gaap--DeferredFinanceCostsCurrentNet_iI_maPEAOAz0Eh_z7DIMLHNXcG9">
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Debt financing fees on undrawn&#160;<span style="font-size: 10pt">tranches (Note 8)</span></p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredFinanceCostsCurrentNet" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">550,757</ix:nonFraction></span></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredFinanceCostsCurrentNet" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,898,074</ix:nonFraction></span></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_404_eus-gaap--PrepaidInsurance_iI_maPEAOAz0Eh_zW7ZnRxvUVCe" style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Prepaid insurance</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:PrepaidInsurance" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,812,135</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:PrepaidInsurance" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">790,465</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_40F_ecustom--PrepaidManufacturing_iI_maPEAOAz0Eh_zF5VxublHLfc">
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Prepaid manufacturing</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="txmd:PrepaidManufacturing" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,595,721</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0684">&#8212;</span></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_40A_eus-gaap--OtherPrepaidExpenseCurrent_iI_maPEAOAz0Eh_zFDbJpAstKWb" style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Other prepaid costs</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,787,482</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,997,365</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_404_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_mtPEAOAz0Eh_zKXE2iVJ8S0d">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">TOTAL OTHER CURRENT ASSETS</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,329,793</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,834,693</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>

</table>
</ix:nonNumeric></ix:nonNumeric><p id="xdx_81F_z7vkGbBhyHH2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p id="xdx_8A3_zQmiAUKsKDqd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<!-- Field: Page; Sequence: 90; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<ix:nonNumeric contextRef="From2019-01-01to2019-12-31" escape="true" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock"><p id="xdx_802_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zgpcaKalwq28" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b><span style="text-decoration: underline"><b>NOTE 5 &#8211; <span id="xdx_82C_zBqY9axhRcNa">FIXED ASSETS, NET</span></b></span></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<ix:nonNumeric contextRef="From2019-01-01to2019-12-31" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock"><p id="xdx_89B_eus-gaap--PropertyPlantAndEquipmentTextBlock_zkVVpSXENsMa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Fixed assets, net consist of the following:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellspacing="0" cellpadding="0" style="margin-right: auto; margin-left: auto; float: none; width: 70%">

<tr>
<td style="vertical-align: top; padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" id="xdx_49F_20191231_zo6Y5dD1EH68" style="vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b></b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" id="xdx_49F_20181231_z6v1oWzlTnve" style="border-right: Black medium none; border-left: Black medium none; padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b></b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="6" style="border-bottom: black 1pt solid; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>December 31,</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-bottom: black 1pt solid; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2019</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-right: Black medium none; border-bottom: Black 1pt solid; border-left: Black medium none; padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2018</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; width: 64%; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Accounting system</p>
</td>
<td style="width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 15%">
<p id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_z32a40lMwwJi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2019-12-31_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">301,096</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 15%">
<p id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20181231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_zpnLXAPVVO9f" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2018-12-31_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">301,096</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Equipment</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zeGpIGjrLzE4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2019-12-31_us-gaap_EquipmentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,619,646</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20181231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zKDf4Ta867He" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2018-12-31_us-gaap_EquipmentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">490,576</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Furniture and fixtures</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_98B_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_ziLZ4fHvEgv6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2019-12-31_us-gaap_FurnitureAndFixturesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,406,858</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20181231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zLgqLDpc7EO8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2018-12-31_us-gaap_FurnitureAndFixturesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">116,542</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Computer hardware</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_982_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_z5rCbLMkY4i2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2019-12-31_us-gaap_ComputerEquipmentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">80,211</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_989_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20181231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zz9tXHiawG8b" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2018-12-31_us-gaap_ComputerEquipmentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">80,211</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Leasehold improvements</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zsAmJrFQWzC9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2019-12-31_us-gaap_LeaseholdImprovementsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">68,788</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20181231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zaf7Hky3Dwz6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2018-12-31_us-gaap_LeaseholdImprovementsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">37,888</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_402_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzht4_zdZloV6xL9N7">
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">TOTAL FIXED ASSETS</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,476,599</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,026,313</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_403_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzht4_zHboRH6WJLq6" style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Accumulated depreciation</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">968,824</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">553,630</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
</tr>
<tr id="xdx_409_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzht4_z5pGWjrUNNpb">
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">TOTAL FIXED ASSETS, NET</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,507,775</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">472,683</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>

</table>
</ix:nonNumeric><p id="xdx_8A0_zytXFyuyQPDb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Depreciation expense for the years ended December 31, 2019, 2018, and 2017 was $<span id="xdx_90A_eus-gaap--Depreciation_c20190101__20191231_zyVSxuNunUb3" title="Depreciation expense"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2019-01-01to2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">415,193</ix:nonFraction></span>, $<span id="xdx_902_eus-gaap--Depreciation_c20180101__20181231_zft8t8kpKb9j"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">181,412</ix:nonFraction></span>, and $<span id="xdx_909_eus-gaap--Depreciation_c20170101__20171231_zfY4ZFLq3AL1"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2017-01-012017-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">141,601</ix:nonFraction></span>, respectively.</p>
</ix:nonNumeric><p id="xdx_811_z5PNpA4LByBf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<ix:nonNumeric contextRef="From2019-01-01to2019-12-31" escape="true" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock"><p id="xdx_806_eus-gaap--GoodwillAndIntangibleAssetsDisclosureTextBlock_zdGQyxM7RIa2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b><span style="text-decoration: underline"><b>NOTE 6 &#8211; <span id="xdx_827_zbdlCzYrVrkk">INTANGIBLE ASSETS, NET</span></b></span></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<ix:nonNumeric contextRef="From2019-01-01to2019-12-31" escape="true" name="txmd:ScheduleOfIntangibleAssetsTableTextBlock"><p id="xdx_89E_ecustom--ScheduleOfIntangibleAssetsTableTextBlock_zSsNxgQCmCKk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of December 31, 2019 and 2018:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse: collapse; width: 100%; width: 100%">

<tr>
<td style="padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top">&#160;</td>
<td>&#160;</td>
<td style="border-top-style: none; border-right-style: none; border-left-style: none; vertical-align: top">&#160;</td>
<td style="border-top-style: none; border-right-style: none; border-left-style: none; vertical-align: top">&#160;</td>
<td style="border-top-style: none; border-right-style: none; border-left-style: none; vertical-align: top">&#160;</td>
<td style="border-top-style: none; border-right-style: none; border-left-style: none; vertical-align: top">&#160;</td>
<td style="border-top-style: none; border-right-style: none; border-left-style: none; vertical-align: top">&#160;</td>
<td style="border-top-style: none; border-right-style: none; border-left-style: none; vertical-align: top">&#160;</td>
<td style="border-top-style: none; border-right-style: none; border-left-style: none; vertical-align: top">&#160;</td>
<td style="border-top-style: none; border-right-style: none; border-left-style: none; vertical-align: top">&#160;</td>
<td style="border-top-style: none; border-right-style: none; border-left-style: none; vertical-align: top">&#160;</td>
<td style="border-top-style: none; border-right-style: none; border-left-style: none; vertical-align: top">&#160;</td>
<td style="border-top-style: none; border-right-style: none; border-left-style: none; vertical-align: top">&#160;</td>
<td style="border-top-style: none; border-right-style: none; border-left-style: none; vertical-align: top">&#160;</td>
<td style="border-top-style: none; border-right-style: none; border-left-style: none; vertical-align: top">&#160;</td>
<td style="border-top-style: none; border-right-style: none; border-left-style: none; vertical-align: top">&#160;</td>
<td style="vertical-align: bottom; width: 1%">&#160;</td></tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top"></td>
<td><p style="margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="14" style="border-bottom: black 1pt none; border-top-style: none; border-right-style: none; border-left-style: none; border-bottom-style: solid; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>December 31,
2019</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; width: 40%; vertical-align: top"><b>&#160;</b></td>
<td><p style="margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-bottom: black 1pt solid; text-align: center; width: 10%; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Gross Carrying
Amount</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td style="width: 1%; width: 1%"><p style="margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-bottom: black 1pt solid; text-align: center; width: 10%; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Accumulated Amortization</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td style="width: 1%; width: 1%"><p style="margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-bottom: black 1pt solid; text-align: center; width: 10%; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Net<br />Amount</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td style="width: 1%; width: 1%"><p style="margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-bottom: black 1pt solid; text-align: center; width: 10%; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Weighted-<br />Average<br />Remaining
Amortization<br />Period (yrs.)</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; width: 40%; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Amortizable intangible assets:</p>
</td>
<td style="width: 3%">
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 10%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 3%">
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 10%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 3%">
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 10%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 3%">
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 10%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: rgb(204,238,255)">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Approved hormone</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: rgb(204,238,255)">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.15in; margin-top: 0pt; margin-bottom: 0pt">therapy drug</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: rgb(204,238,255)">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.15in; margin-top: 0pt; margin-bottom: 0pt">candidate patents</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zZ45m8aW3pgf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2019-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,463,082</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zvgJ9pOvKXK1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2019-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">478,983</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zrPdY8Onobyb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2019-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,984,099</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_dtY_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_z2oQJxvGOrE"><ix:nonNumeric contextRef="From2019-01-012019-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">13</ix:nonNumeric></span></p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: White">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Hormone therapy drug</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.15in; margin-top: 0pt; margin-bottom: 0pt">candidate patents</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: White">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.15in; margin-top: 0pt; margin-bottom: 0pt">(pending)</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20191231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_zGbZuhcyXZ41" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2019-12-31_custom_HormoneTherapyDrugCandidatePatentsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,979,299</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#8212;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20191231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_zw6A1cByWgMe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2019-12-31_custom_HormoneTherapyDrugCandidatePatentsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,979,299</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">n/a</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: rgb(204,238,255)">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Non-amortizable intangible</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: rgb(204,238,255)">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.15in; margin-top: 0pt; margin-bottom: 0pt">assets:</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: White">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Multiple trademarks</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_984_eus-gaap--IndefiniteLivedTrademarks_iI_c20191231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksForVitaminsSupplementsMember_znQmUqz0u694" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:IndefiniteLivedTrademarks" contextRef="AsOf2019-12-31_custom_MultipleTrademarksForVitaminsSupplementsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">294,813</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#8212;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_98A_eus-gaap--IndefiniteLivedIntangibleAssetsExcludingGoodwill_iI_c20191231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksForVitaminsSupplementsMember_zocGRvUhihv6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="AsOf2019-12-31_custom_MultipleTrademarksForVitaminsSupplementsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">294,813</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">indefinite</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: rgb(204,238,255)">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">TOTAL</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom">
<p id="xdx_984_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_c20191231_zrPXHNejo0C2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,737,194</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom">
<p id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_c20191231_zIYygBuIkRkd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">478,983</ix:nonFraction></p>
</td>
<td style="padding-bottom: 2pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom">
<p id="xdx_98D_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20191231_zUtdcezNgmUh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,258,211</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<ix:exclude><!-- Field: Page; Sequence: 91; Value: 3 -->
    <div id="xdx_23C_zoqtDnVy8XIf" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_234_zsHYao2WdFoa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div>
    <div id="xdx_230_zj8IwaWvqZyj" style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>
<ix:exclude><p id="xdx_237_zdu0DGUhaDh1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></ix:exclude>
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse: collapse; width: 100%; width: 100%">

<tr>
<td style="padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top">&#160;</td>
<td>&#160;</td>
<td style="border-top-style: none; border-right-style: none; border-left-style: none; border-image: initial; vertical-align: top">&#160;</td>
<td style="border-top-style: none; border-right-style: none; border-left-style: none; border-image: initial; vertical-align: top">&#160;</td>
<td style="border-top-style: none; border-right-style: none; border-left-style: none; border-image: initial; vertical-align: top">&#160;</td>
<td style="border-top-style: none; border-right-style: none; border-left-style: none; border-image: initial; vertical-align: top">&#160;</td>
<td style="border-top-style: none; border-right-style: none; border-left-style: none; border-image: initial; vertical-align: top">&#160;</td>
<td style="border-top-style: none; border-right-style: none; border-left-style: none; border-image: initial; vertical-align: top">&#160;</td>
<td style="border-top-style: none; border-right-style: none; border-left-style: none; border-image: initial; vertical-align: top">&#160;</td>
<td style="border-top-style: none; border-right-style: none; border-left-style: none; border-image: initial; vertical-align: top">&#160;</td>
<td style="border-top-style: none; border-right-style: none; border-left-style: none; border-image: initial; vertical-align: top">&#160;</td>
<td style="border-top-style: none; border-right-style: none; border-left-style: none; border-image: initial; vertical-align: top">&#160;</td>
<td style="border-top-style: none; border-right-style: none; border-left-style: none; border-image: initial; vertical-align: top">&#160;</td>
<td style="border-top-style: none; border-right-style: none; border-left-style: none; border-image: initial; vertical-align: top">&#160;</td>
<td style="border-top-style: none; border-right-style: none; border-left-style: none; border-image: initial; vertical-align: top">&#160;</td>
<td style="border-top-style: none; border-right-style: none; border-left-style: none; border-image: initial; vertical-align: top">&#160;</td>
<td style="vertical-align: bottom; width: 1%">&#160;</td></tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top"></td>
<td><p style="margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="14" style="border-bottom: black 1pt solid; border-top-style: none; border-right-style: none; border-left-style: none; border-image: initial; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>December 31,
2018</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; text-align: center; vertical-align: top"><b>&#160;</b></td>
<td><p style="margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-bottom: black 1pt solid; text-align: center; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Gross Carrying
Amount</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td style="width: 1%; width: 1%"><p style="margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-bottom: black 1pt solid; text-align: center; width: 10%; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Accumulated Amortization</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td style="width: 1%; width: 1%"><p style="margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-bottom: black 1pt solid; text-align: center; width: 10%; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Net<br />Amount</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td style="width: 1%; width: 1%"><p style="margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-bottom: black 1pt solid; text-align: center; width: 10%; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Weighted- Average<br />Remaining
Amortization Period (yrs.)</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; width: 40%; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Amortizable intangible assets:</p>
</td>
<td style="width: 3%">
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 10%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 3%">
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 10%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 3%">
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 10%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 3%">
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 10%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">OPERA software patent</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--ComputerSoftwareIntangibleAssetMember_zuH4Ob72Oyq2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2018-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31,951</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_c20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--ComputerSoftwareIntangibleAssetMember_zLmvoUYIi4ub" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2018-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,484</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--ComputerSoftwareIntangibleAssetMember_zaOasLYxHcb9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2018-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,467</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_dtY_c20180101__20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--ComputerSoftwareIntangibleAssetMember_zB2Ja4HDIBf8"><ix:nonNumeric contextRef="From2018-01-012018-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">10.75</ix:nonNumeric></span></p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Development costs of</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.15in; margin-top: 0pt; margin-bottom: 0pt">corporate website</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InternetDomainNamesMember_zSYk6Y2UUw96" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2018-12-31_us-gaap_InternetDomainNamesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">91,743</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_c20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InternetDomainNamesMember_zHtL9OMHqBJ1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2018-12-31_us-gaap_InternetDomainNamesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">91,743</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#8212;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">n/a</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: rgb(204,238,255)">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Approved hormone</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: rgb(204,238,255)">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.15in; margin-top: 0pt; margin-bottom: 0pt">therapy drug</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: rgb(204,238,255)">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.15in; margin-top: 0pt; margin-bottom: 0pt">candidate patents</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zO6DdncI1wfe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2018-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,234,129</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_c20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zawuCBN6mu5l" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2018-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">282,485</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zDHtmBT3FTW7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2018-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,951,644</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_dtY_c20180101__20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_z9dfucABmOri"><ix:nonNumeric contextRef="From2018-01-012018-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">14</ix:nonNumeric></span></p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: White">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Hormone therapy drug</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.15in; margin-top: 0pt; margin-bottom: 0pt">candidate patents</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: White">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.15in; margin-top: 0pt; margin-bottom: 0pt">(pending)</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20181231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_zhWshXYSDvVh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2018-12-31_custom_HormoneTherapyDrugCandidatePatentsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,855,279</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#8212;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20181231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_zUuP8vFYS5Fl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2018-12-31_custom_HormoneTherapyDrugCandidatePatentsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,855,279</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">n/a</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: rgb(204,238,255)">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Non-amortizable intangible</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: rgb(204,238,255)">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.15in; margin-top: 0pt; margin-bottom: 0pt">assets:</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: White">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Multiple trademarks</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_988_eus-gaap--IndefiniteLivedTrademarks_iI_c20181231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksForVitaminsSupplementsMember_zyYy112mUFnl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:IndefiniteLivedTrademarks" contextRef="AsOf2018-12-31_custom_MultipleTrademarksForVitaminsSupplementsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">264,289</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#8212;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_988_eus-gaap--IndefiniteLivedIntangibleAssetsExcludingGoodwill_iI_c20181231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksForVitaminsSupplementsMember_zvLuDgt0SQh7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="AsOf2018-12-31_custom_MultipleTrademarksForVitaminsSupplementsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">264,289</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">indefinite</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: rgb(204,238,255)">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">TOTAL</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom">
<p id="xdx_982_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_c20181231_z7iwKFoMeZTl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,477,391</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom">
<p id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_c20181231_zPbzzNlfWeZ2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">384,712</ix:nonFraction></p>
</td>
<td style="padding-bottom: 2pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom">
<p id="xdx_984_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20181231_zNnLUsOkkZ89" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,092,679</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>

</table>
</ix:nonNumeric><p id="xdx_8AD_zQXuyGeRuVb8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">We capitalize external costs, consisting primarily of legal costs, related to securing our patents and trademarks. Once a patent is granted, we amortize the approved hormone therapy drug candidate patents using the straight-line method over the estimated useful life of approximately <span id="xdx_908_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zEe9VmrPiLYb"><ix:nonNumeric contextRef="From2019-01-012019-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">20</ix:nonNumeric></span> years, which is the life of intellectual property patents. If the patent is not granted, we write-off any capitalized patent costs at that time. Trademarks are perpetual and are not amortized. During the year ended December 31, 2019, we wrote off $<span id="xdx_909_eus-gaap--ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_c20190101__20191231_zAi4ok0xPne"><ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" contextRef="From2019-01-01to2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">78,864</ix:nonFraction></span> in costs related to trademarks and patents, including the net carrying amount of the OPERA patent. </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">As of December 31, 2019, we had <span id="xdx_901_ecustom--NumberOfIssuedPatents_iI_uPure_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUSPatentsMember_zcAXHfpAAxz8"><ix:nonFraction name="txmd:NumberOfIssuedPatents" contextRef="AsOf2019-12-31_custom_DomesticUSPatentsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">29</ix:nonFraction></span> issued domestic &#160;patents and <span id="xdx_907_ecustom--NumberOfIssuedPatents_iI_uPure_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignPatentsMember_zmFxdUJsHDC"><ix:nonFraction name="txmd:NumberOfIssuedPatents" contextRef="AsOf2019-12-31_custom_ForeignPatentsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">30</ix:nonFraction></span> issued foreign patents, including: </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%; width: 100%">

<tr>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">&#9679;</span></p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black"><span id="xdx_907_ecustom--NumberOfIssuedPatents_iI_uPure_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticPatentsBijuvaMember_zfHJygFwRv7h" title="Number of issued patents"><ix:nonFraction name="txmd:NumberOfIssuedPatents" contextRef="AsOf2019-12-31_custom_DomesticPatentsBijuvaMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">12</ix:nonFraction></span> domestic patents and <span id="xdx_908_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignPatentsBijuvaMember_zH34gBx8H73f"><ix:nonFraction name="txmd:NumberOfIssuedPatents" contextRef="AsOf2019-12-31_custom_ForeignPatentsBijuvaMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Pure">six</ix:nonFraction></span> foreign patents that relate to BIJUVA as well as <span id="xdx_902_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticPatentsNonApprovedBijuvaMember_zuIweFRntojg"><ix:nonFraction name="txmd:NumberOfIssuedPatents" contextRef="AsOf2019-12-31_custom_DomesticPatentsNonApprovedBijuvaMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Pure">three</ix:nonFraction></span> domestic patents that relate to estradiol and progesterone product candidates. These patents establish an important intellectual property foundation and are owned by us. The domestic patents will expire in 2032. The foreign patents will expire no earlier than 2032. In addition, we have pending patent applications relating to BIJUVA in the U.S., Argentina, Australia, Brazil, Canada, China, Europe, Israel, Japan, Mexico, New Zealand, Russia, South Africa, and South Korea; </span></p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%; width: 100%">

<tr>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">&#9679;</span></p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span id="xdx_90D_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUSPatentsImvexxyMember_zPub0tWlzhoj"><ix:nonFraction name="txmd:NumberOfIssuedPatents" contextRef="AsOf2019-12-31_custom_DomesticUSPatentsImvexxyMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Pure">Six</ix:nonFraction></span><span style="color: black"> domestic patents (</span><span id="xdx_90F_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUSUtilityPatentsImvexxyMember_zeK62XpJvJ97"><ix:nonFraction name="txmd:NumberOfIssuedPatents" contextRef="AsOf2019-12-31_custom_DomesticUSUtilityPatentsImvexxyMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Pure">five</ix:nonFraction></span> <span style="color: black">utility and <span id="xdx_905_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUSDesignPatentsImvexxyMember_zNiqvZkjaRL"><ix:nonFraction name="txmd:NumberOfIssuedPatents" contextRef="AsOf2019-12-31_custom_DomesticUSDesignPatentsImvexxyMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Pure">one</ix:nonFraction></span> design) and <span id="xdx_90D_ecustom--NumberOfIssuedPatents_iI_uPure_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignPatentsImvexxyMember_zYTzRR8sspCa"><ix:nonFraction name="txmd:NumberOfIssuedPatents" contextRef="AsOf2019-12-31_custom_ForeignPatentsImvexxyMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">13</ix:nonFraction></span> foreign patents (<span id="xdx_90A_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignUtilityPatentsImvexxyMember_zLRJQMRCTJW1"><ix:nonFraction name="txmd:NumberOfIssuedPatents" contextRef="AsOf2019-12-31_custom_ForeignUtilityPatentsImvexxyMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Pure">three</ix:nonFraction></span> utility and <span id="xdx_905_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignDesignPatentsImvexxyMember_z8IZymKPqmu4"><ix:nonFraction name="txmd:NumberOfIssuedPatents" contextRef="AsOf2019-12-31_custom_ForeignDesignPatentsImvexxyMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Pure">ten</ix:nonFraction></span> design) that relate to IMVEXXY. These patents establish an important intellectual property foundation for IMVEXXY and are owned by us. The domestic patents will expire in 2032 or 2033. The foreign utility patents will expire no earlier than 2033. The foreign design patents provide protection expiring no earlier than 2025. In certain countries, the foreign design patents provide protection through at least 2037. In addition, we have pending patent applications related to IMVEXXY in the U.S., Argentina, Australia, Brazil, Canada, Europe, Israel, Japan, Mexico, New Zealand, Russia, South Africa, and South Korea; </span></p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%; width: 100%">

<tr>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">&#9679;</span></p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black"><span id="xdx_908_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUSPatentsTopicalCreamMember_zSE6pfEuadbc"><ix:nonFraction name="txmd:NumberOfIssuedPatents" contextRef="AsOf2019-12-31_custom_DomesticUSPatentsTopicalCreamMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Pure">One</ix:nonFraction></span> domestic utility patent that relates to our topical-cream candidates, which is owned by us. The domestic patent will expire in 2035. We have pending patent applications with respect to our topical-cream candidates in the U.S., Argentina, Australia, Brazil, Canada, Europe, Israel, Japan, Mexico, Russia, South Africa, and South Korea; </span></p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%; width: 100%">

<tr>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">&#9679;</span></p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black"><span id="xdx_904_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUtilityPatentTransdermalPatchMember_z4tmsEJeDbqe"><ix:nonFraction name="txmd:NumberOfIssuedPatents" contextRef="AsOf2019-12-31_custom_DomesticUtilityPatentTransdermalPatchMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Pure">One</ix:nonFraction></span> domestic utility patent and </span><span id="xdx_902_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignUtilityPatentTransdermalPatchMember_znk2ICZ9uEif"><ix:nonFraction name="txmd:NumberOfIssuedPatents" contextRef="AsOf2019-12-31_custom_ForeignUtilityPatentTransdermalPatchMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Pure">seven</ix:nonFraction></span><span style="color: black"> foreign patents that relate to our transdermal-patch candidates, which are owned by us. The domestic utility patent will expire in 2032. The foreign patents will expire no earlier than 2033. We have pending patent applications with respect to our transdermal-patch candidates in the U.S., Brazil, Canada, Mexico, and South Africa; </span></p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%; width: 100%">

<tr>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">&#9679;</span></p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span id="xdx_909_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUtilityPatentTx009HRMember_zRjys56gHOK5"><ix:nonFraction name="txmd:NumberOfIssuedPatents" contextRef="AsOf2019-12-31_custom_DomesticUtilityPatentTx009HRMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Pure">Three</ix:nonFraction></span><span style="color: black"> domestic utility patents that relate to TX-009HR, a progesterone and estradiol product candidate, which are owned by us and will expire in 2037. We have pending patent applications with respect to TX-009HR in the U.S., Argentina, Australia, Brazil, Canada, Europe, Israel, Japan, Mexico, New Zealand, Russia, South Africa, and South Korea.</span></p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%; width: 100%">

<tr>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">&#9679;</span></p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span id="xdx_90D_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticPatentsProgesteroneFormulationsMember_zdkLx1njb5ng"><ix:nonFraction name="txmd:NumberOfIssuedPatents" contextRef="AsOf2019-12-31_custom_DomesticPatentsProgesteroneFormulationsMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Pure">Two</ix:nonFraction></span><span style="color: black"> domestic and <span id="xdx_900_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignPatentsProgesteroneFormulationsMember_zEQ5E1kS3jW2"><ix:nonFraction name="txmd:NumberOfIssuedPatents" contextRef="AsOf2019-12-31_custom_ForeignPatentsProgesteroneFormulationsMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Pure">four</ix:nonFraction></span> foreign patents that relate to formulations containing progesterone, which are owned by us. The domestic patent</span>s<span style="color: black"> will expire </span>between <span style="color: black">2032</span> and 2036<span style="color: black">. The foreign patents will expire no earlier than 2033. In addition, we have pending patent applications with respect formulations containing progesterone in the U.S., Argentina, Australia, Brazil, Canada, Europe, Israel, Japan, Mexico, Russia, South Africa, and South Korea; </span></p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%; width: 100%">

<tr>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">&#9679;</span></p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black"><span id="xdx_904_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUtilityPatentOperaMember_zOGUFxyameRe"><ix:nonFraction name="txmd:NumberOfIssuedPatents" contextRef="AsOf2019-12-31_custom_DomesticUtilityPatentOperaMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Pure">One</ix:nonFraction></span> domestic utility patent that relates to our OPERA information-technology platform, which is owned by us and will expire in 2031; </span></p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<ix:exclude><!-- Field: Page; Sequence: 92; Value: 3 -->
    <div id="xdx_23E_zaR02W77oD3b" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_23C_zWH9R7FwtQQh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div>
    <div id="xdx_237_z3WQ260fENSj" style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>
<ix:exclude><p id="xdx_233_zj9xczlpcuCj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></ix:exclude>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="background-color: white">Amortization expense was $<span id="xdx_90F_eus-gaap--AmortizationOfIntangibleAssets_c20190101__20191231_z7iwZ5ZuQTC9"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2019-01-01to2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">197,593</ix:nonFraction></span>, $<span id="xdx_908_eus-gaap--AmortizationOfIntangibleAssets_c20180101__20181231_z7N1ETmlU4z5"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">112,474</ix:nonFraction></span>, and $<span id="xdx_90D_eus-gaap--AmortizationOfIntangibleAssets_c20170101__20171231_zKi5baRkOisj"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2017-01-012017-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">71,516</ix:nonFraction></span> for the years ended December 31, 2019, 2018, and 2017, respectively.</span></p>

<ix:nonNumeric contextRef="From2019-01-01to2019-12-31" escape="true" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"><p id="xdx_897_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zrznKYBF3tWd" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="background-color: white">Estimated amortization expense, based on current patent cost being amortized, for the next five years is as follows:</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellspacing="0" cellpadding="0" style="margin-right: auto; margin-left: auto; float: none; width: 40%">

<tr>
<td style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; width: 49%; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Year Ending<br />December
31,</b></p>
</td>
<td style="padding: 0pt 5.4pt; width: 2%; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td id="xdx_49E_20191231_zsxdHn6Z4B7k" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; vertical-align: top; width: 49%"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Estimated<br />Amortization</b></p>
</td>
</tr>
<tr id="xdx_400_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_z5zAjuA6YVph" style="background-color: rgb(204,238,255)">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">2020</p>
</td>
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">$<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">229,546</ix:nonFraction></p>
</td>
</tr>
<tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_zggNowtaQ5kb" style="background-color: White">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">2021</p>
</td>
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">$<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">229,546</ix:nonFraction></p>
</td>
</tr>
<tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_zUDpMMLkGDl7" style="background-color: rgb(204,238,255)">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">2022</p>
</td>
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">$<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">229,546</ix:nonFraction></p>
</td>
</tr>
<tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_zlthq9FvAC15" style="background-color: White">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">2023</p>
</td>
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">$<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">229,546</ix:nonFraction></p>
</td>
</tr>
<tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_ztTQzfSmEsS7" style="background-color: rgb(204,238,255)">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">2024</p>
</td>
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">$<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">229,546</ix:nonFraction></p>
</td>
</tr>
<tr style="background-color: White">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>

</table>
</ix:nonNumeric><p id="xdx_8AB_zW8i29NaJY2f" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #212529"><span style="text-decoration: underline"><span style="color: #212529">License Agreement with the Population Council</span></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: #212529">On July 30, 2018, we entered into the Population Council License Agreement to commercialize ANNOVERA in the U.S. ANNOVERA became commercially available in the third quarter of 2019 and we expect the full commercial launch of ANNOVERA in the first quarter of 2020.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: #212529">Under the terms of the Population Council License Agreement, we paid the Population Council a milestone payment of $<span id="xdx_907_ecustom--MilestonePaymentUponFDAApproval_c20190701__20190930__srt--ProductOrServiceAxis__custom--AnnoveraMember__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreement1Member_zZi7oSOg8Tg1" title="Milestone payment upon FDA Approval"><ix:nonFraction name="txmd:MilestonePaymentUponFDAApproval" contextRef="From2019-07-012019-09-30_custom_AnnoveraMember_custom_CouncilLicenseAgreement1Member" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,000,000</ix:nonFraction></span> within 30 days following the approval by the FDA of the new drug application, or NDA, for ANNOVERA and $<span id="xdx_900_ecustom--MilestonePaymentsAfterReleaseOfFirstCommercialBatch_iI_c20190930__srt--ProductOrServiceAxis__custom--AnnoveraMember__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreement1Member_z1gyEedlxhHb" title="Milestone payments (payment after release of first commercial batch)"><ix:nonFraction name="txmd:MilestonePaymentsAfterReleaseOfFirstCommercialBatch" contextRef="AsOf2019-09-30_custom_AnnoveraMember_custom_CouncilLicenseAgreement1Member" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,000,000</ix:nonFraction></span> within 30 days following the first commercial batch release of ANNOVERA. Both milestone payments of $<span id="xdx_90F_eus-gaap--FinitelivedIntangibleAssetsAcquired1_c20190701__20190930__srt--ProductOrServiceAxis__custom--AnnoveraMember__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreement1Member_z24YlW0jZZ2c" title="License rights acquired"><ix:nonFraction name="us-gaap:FinitelivedIntangibleAssetsAcquired1" contextRef="From2019-07-012019-09-30_custom_AnnoveraMember_custom_CouncilLicenseAgreement1Member" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,000,000</ix:nonFraction></span> were recorded as license rights in the consolidated balance sheets. We started amortizing the license rights in the third quarter of 2019 once ANNOVERA became commercially available for use. The cost is amortized over the remaining useful life over which the license rights will contribute directly or indirectly to our cash flows, which is estimated to be the remaining patent life of the product, which expires in December 2032. The cost is amortized using the straight-line method as the pattern of economic benefit cannot be reliably determined. During the year ended December 31, 2019, we recorded $<span id="xdx_90F_eus-gaap--OtherAmortizationOfDeferredCharges_c20190101__20191231__srt--ProductOrServiceAxis__custom--AnnoveraMember__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreement1Member_z8S5vUF488U3" title="Amortization of Other Deferred Charges"><ix:nonFraction name="us-gaap:OtherAmortizationOfDeferredCharges" contextRef="From2019-01-012019-12-31_custom_AnnoveraMember_custom_CouncilLicenseAgreement1Member" format="ixt:numdotdecimal" decimals="0" unitRef="USD">778,692</ix:nonFraction></span> in amortization expense related to the license fee which was recorded as a component of cost of sales.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: #212529">The
Population Council is also eligible to receive milestone payments and royalties from commercial sales of ANNOVERA. We are
responsible for marketing expenses related to the commercialization of ANNOVERA. In addition, we are required to pay the
Population Council, on a quarterly basis, step-based royalty payments based on annual net sales of ANNOVERA in the U.S. by
the Company and its affiliates and permitted licensees as follows: (i) if annual net sales are less than or equal to $<span id="xdx_902_ecustom--NetSalesAmountPerStepbasedRoyalty_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep1Member__srt--RangeAxis__srt--MaximumMember_zrTYygEARfQi" title="Net sales amount per step-based royalty"><ix:nonFraction name="txmd:NetSalesAmountPerStepbasedRoyalty" contextRef="From2019-01-012019-12-31_custom_CouncilLicenseAgreementStep1Member_srt_MaximumMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000,000</ix:nonFraction></span>,
a royalty of <span id="xdx_90D_ecustom--RoyaltyPercent_dp_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep1Member_zkNUJsk4roz3" title="Royalty (percent)"><ix:nonFraction name="txmd:RoyaltyPercent" contextRef="From2019-01-012019-12-31_custom_CouncilLicenseAgreementStep1Member" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction></span>%
of net sales; (ii) for annual net sales greater than $<span id="xdx_902_ecustom--NetSalesAmountPerStepbasedRoyalty_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep2Member__srt--RangeAxis__srt--MinimumMember_zpPxhCHKYSua"><ix:nonFraction name="txmd:NetSalesAmountPerStepbasedRoyalty" contextRef="From2019-01-012019-12-31_custom_CouncilLicenseAgreementStep2Member_srt_MinimumMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000,000</ix:nonFraction></span>
and less than or equal to $<span id="xdx_903_ecustom--NetSalesAmountPerStepbasedRoyalty_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep2Member__srt--RangeAxis__srt--MaximumMember_zb8M2Ena4km4"><ix:nonFraction name="txmd:NetSalesAmountPerStepbasedRoyalty" contextRef="From2019-01-012019-12-31_custom_CouncilLicenseAgreementStep2Member_srt_MaximumMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">150,000,000</ix:nonFraction></span>,
a royalty of <span id="xdx_90D_ecustom--RoyaltyPercent_dp_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep2Member_zxZPuiOOFrC1"><ix:nonFraction name="txmd:RoyaltyPercent" contextRef="From2019-01-012019-12-31_custom_CouncilLicenseAgreementStep2Member" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction></span>%
of such net sales; and (iii) for net sales greater than $<span id="xdx_903_ecustom--NetSalesAmountPerStepbasedRoyalty_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep3Member__srt--RangeAxis__srt--MinimumMember_zvrDgk1VqKRc"><ix:nonFraction name="txmd:NetSalesAmountPerStepbasedRoyalty" contextRef="From2019-01-012019-12-31_custom_CouncilLicenseAgreementStep3Member_srt_MinimumMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">150,000,000</ix:nonFraction></span>,
a royalty of <span id="xdx_903_ecustom--RoyaltyPercent_dp_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep3Member_zjcM4N5IFwbe"><ix:nonFraction name="txmd:RoyaltyPercent" contextRef="From2019-01-012019-12-31_custom_CouncilLicenseAgreementStep3Member" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">15</ix:nonFraction></span>%
of such net sales. The annual royalty rate will be reduced to <span id="xdx_905_ecustom--AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent_dp_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreement1Member_zXXunlGnhwqf" title="Annual royalty rate reduction of initial rate during the six-month period from commercial sale of a generic equivalent"><ix:nonFraction name="txmd:AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent" contextRef="From2019-01-012019-12-31_custom_CouncilLicenseAgreement1Member" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">50</ix:nonFraction></span>%
of the initial rate during the six-month period beginning on the date of the first arms-length commercial sale of a generic
equivalent of the one-year vaginal contraceptive system that is launched by a third party in the U.S., and thereafter will be
reduced to <span id="xdx_902_ecustom--AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent_dp_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreement1Member_zAfLDRuaPx5e" title="Annual royalty rate reduction of initial rate after the six-month period from commercial sale of a generic equivalent"><ix:nonFraction name="txmd:AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent" contextRef="From2019-01-012019-12-31_custom_CouncilLicenseAgreement1Member" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">20</ix:nonFraction></span>%
of the initial rate. We are required to pay the Population Council milestone payments of $<span id="xdx_90A_ecustom--RequiredMilestonePaymentsUponCumulativeNetSalesOfSpecifiedLevels_dm_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreement1Member_z3WB7dveZctb" title="Required milestone payments upon cumulative net sales of specified levels"><ix:nonFraction name="txmd:RequiredMilestonePaymentsUponCumulativeNetSalesOfSpecifiedLevels" contextRef="From2019-01-012019-12-31_custom_CouncilLicenseAgreement1Member" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">40</ix:nonFraction>
million</span> upon cumulative net sales of ANNOVERA in the U.S. by us and our affiliates and permitted sublicensees of each
of $<span id="xdx_902_ecustom--SpecifiedLevelOneOfCumulativeNetSalesForRequiredMilestonePayments_dm_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreement1Member_zPOga3TS5ZBa" title="Specified level one of cumulative net sales for required milestone payments"><ix:nonFraction name="txmd:SpecifiedLevelOneOfCumulativeNetSalesForRequiredMilestonePayments" contextRef="From2019-01-012019-12-31_custom_CouncilLicenseAgreement1Member" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">200</ix:nonFraction>
million</span>, $<span id="xdx_904_ecustom--SpecifiedLevelTwoOfCumulativeNetSalesForRequiredMilestonePayments_dm_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreement1Member_zRgYvIBzPUZa" title="Specified level two of cumulative net sales for required milestone payments"><ix:nonFraction name="txmd:SpecifiedLevelTwoOfCumulativeNetSalesForRequiredMilestonePayments" contextRef="From2019-01-012019-12-31_custom_CouncilLicenseAgreement1Member" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">400</ix:nonFraction>
million</span> and $<span id="xdx_906_ecustom--SpecifiedLevelThreeOfCumulativeNetSalesForRequiredMilestonePayments_dm_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreement1Member_zwGmMDa1Sdvg" title="Specified level three of cumulative net sales for required milestone payments"><ix:nonFraction name="txmd:SpecifiedLevelThreeOfCumulativeNetSalesForRequiredMilestonePayments" contextRef="From2019-01-012019-12-31_custom_CouncilLicenseAgreement1Member" format="ixt:numdotdecimal" decimals="0" scale="9" unitRef="USD">1</ix:nonFraction>
billion</span>. The Population Council has agreed to perform and pay the costs and expenses associated with four
post-approval studies required by the FDA for ANNOVERA and we have agreed to perform and pay the costs and expenses
associated with a post approval study required by the FDA to measure risk for venous thromboembolism, provided that if the
costs and expenses associated with such post-approval study exceed $<span id="xdx_90A_ecustom--MaximumCostsAndExpensesForPostApprovalStudyToBePaid_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreement1Member_zagFFOU168tg" title="Maximum costs and expenses for post approval"><ix:nonFraction name="txmd:MaximumCostsAndExpensesForPostApprovalStudyToBePaid" contextRef="From2019-01-012019-12-31_custom_CouncilLicenseAgreement1Member" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,000,000</ix:nonFraction></span>,
half of such excess will be offset against royalties or other payments owed by us to the Population Council under the
Population Council License Agreement. We and the Population Council have agreed to form a joint product committee responsible
for overseeing activities under the Population Council License Agreement. We will be responsible for all aspects of
promotion, product positioning, pricing, education programs, publications, sales messages and any additional desired clinical
studies for the one-year vaginal contraceptive system, subject to oversight and decisions made by the joint product
committee. The Population Council License Agreement includes exclusive rights for us to negotiate co-development of two other
investigational vaginal contraceptive systems in development by the Population Council. </span></p>
</ix:nonNumeric><p id="xdx_818_zrbNfSIUUSI2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<!-- Field: Page; Sequence: 93; Value: 3 -->
    <div id="xdx_239_zYVaYxqNW9M3" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_239_zcCMxOKo8LQg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div>
    <div id="xdx_236_z3JIaQnegvy" style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->
<p id="xdx_239_z8DsfDj7waBi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<ix:nonNumeric contextRef="From2019-01-01to2019-12-31" escape="true" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"><p id="xdx_805_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_zjt8xYAJDmTd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b><span style="text-decoration: underline"><b>NOTE 7 &#8211; <span id="xdx_82F_zx9XuzG1nPx2">OTHER CURRENT LIABILITIES</span></b></span></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<ix:nonNumeric contextRef="From2019-01-01to2019-12-31" escape="true" name="us-gaap:OtherCurrentLiabilitiesTableTextBlock"><p id="xdx_89B_eus-gaap--OtherCurrentLiabilitiesTableTextBlock_zV63QVGAs9w6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Other current liabilities consist of the following:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellspacing="0" cellpadding="0" style="margin-right: auto; margin-left: auto; float: none; width: 80%">

<tr>
<td style="vertical-align: top; padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" id="xdx_491_20191231_zjFOD0PPjSWf" style="vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b></b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" id="xdx_499_20181231_zUKRCWRTVVHa" style="vertical-align: top; padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b></b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="6" style="border-bottom: black 1pt none; border-top-style: none; border-right-style: none; border-left-style: none; border-bottom-style: solid; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>December 31,</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-bottom: black 1pt solid; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2019</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2018</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr id="xdx_40E_eus-gaap--AccruedSalariesCurrent_iI_maOLCzU7z_zOuIA4I6TjVl" style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; width: 70%; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Accrued payroll, bonuses and commission costs</p>
</td>
<td style="width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 12%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:AccruedSalariesCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,040,278</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 12%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:AccruedSalariesCurrent" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,854,002</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_404_ecustom--SalesDiscountsReturnsAndAllowancesGoods1_iI_maOLCzU7z_zWEOrv5FWwFh">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Allowance for coupons and returns</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="txmd:SalesDiscountsReturnsAndAllowancesGoods1" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,316,298</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="txmd:SalesDiscountsReturnsAndAllowancesGoods1" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,294,120</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_404_eus-gaap--AccruedMarketingCostsCurrent_iI_maOLCzU7z_zzKoU8WkETQe" style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Accrued sales and marketing costs</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:AccruedMarketingCostsCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,285,662</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:AccruedMarketingCostsCurrent" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,288,028</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_40D_eus-gaap--AccruedVacationCurrent_iI_maOLCzU7z_zdVTD5Z7jHQ4">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Accrued compensated absences</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:AccruedVacationCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,463,878</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:AccruedVacationCurrent" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,178,110</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_408_ecustom--AllowanceForWholesaleDistributorFeesCurrent_iI_maOLCzU7z_zYhKDbjcucVf" style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Allowance for wholesale distributor fees</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="txmd:AllowanceForWholesaleDistributorFeesCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,347,122</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="txmd:AllowanceForWholesaleDistributorFeesCurrent" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">792,891</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_40B_eus-gaap--AccruedProfessionalFeesCurrent_iI_maOLCzU7z_zzjV5ZgsadF7">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Accrued legal and accounting expense</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">422,336</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">385,824</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_40B_ecustom--AccruedResearchAndDevelopment_iI_maOLCzU7z_zoBcexnUN7A7" style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Accrued research and development</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="txmd:AccruedResearchAndDevelopment" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,049,603</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="txmd:AccruedResearchAndDevelopment" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">388,675</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_400_eus-gaap--AccruedRentCurrent_iI_maOLCzU7z_zSS2ihVlbIv6">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Accrued rent</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0846">&#8212;</span></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:AccruedRentCurrent" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">365,155</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_407_eus-gaap--OperatingLeaseLiabilityCurrent_iI_maOLCzU7z_zfwx69kp59ad" style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Operating lease liability</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,501,539</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0850">&#8212;</span></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_405_ecustom--AccruedRebates_iI_maOLCzU7z_zMCf1hCKBMif">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Accrued rebates</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="txmd:AccruedRebates" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,916,672</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="txmd:AccruedRebates" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">412,570</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_407_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_maOLCzU7z_zH8gZSYDqck8" style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Other accrued expenses</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,480,225</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">375,573</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_405_eus-gaap--OtherLiabilitiesCurrent_iTI_mtOLCzU7z_ziorxVunc4d3">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">TOTAL OTHER CURRENT LIABILITIES</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">33,823,613</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,334,948</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>

</table>
</ix:nonNumeric></ix:nonNumeric><p id="xdx_810_zEtHQjHPX7T1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p id="xdx_8AF_zFdTPawyC5Jh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<ix:nonNumeric contextRef="From2019-01-01to2019-12-31" escape="true" name="us-gaap:LongTermDebtTextBlock"><p id="xdx_805_eus-gaap--LongTermDebtTextBlock_zSiEv2AIkhag" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><b><span style="text-decoration: underline"><b>NOTE 8 &#8211; <span id="xdx_826_zaOePHCOSkxk">DEBT</span></b></span></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: #212529">On April 24, 2019, we entered into a Financing Agreement, as amended on December 27, 2019, or the Financing Agreement, with TPG Specialty Lending, Inc., as administrative agent, or the Administrative Agent, various lenders from time to time party thereto, and certain of our subsidiaries party thereto from time to time as guarantors, which provides us with a $<span id="xdx_904_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20190424__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_ztKq30bxEfr9"><ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="AsOf2019-04-24_us-gaap_RevolvingCreditFacilityMember_custom_FinancingAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">300,000,000</ix:nonFraction></span> first lien secured term loan credit facility, or the Facility. The Facility provides for availability to us in three tranches: (i) $<span id="xdx_909_eus-gaap--ProceedsFromLinesOfCredit_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__custom--DebtTrancheAxis__custom--TrancheOneMember_zi0swcfjdzkc"><ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" contextRef="From2019-04-232019-04-24_custom_FinancingAgreementMember_custom_TrancheOneMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">200,000,000</ix:nonFraction></span> was drawn upon entering into the Financing Agreement; (ii) $<span id="xdx_90A_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__custom--DebtTrancheAxis__custom--TrancheTwoMember_z9hMwRzstg49"><ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="AsOf2019-04-24_custom_FinancingAgreementMember_custom_TrancheTwoMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000,000</ix:nonFraction></span> will be available to us in the Administrative Agent&#x2019;s sole and absolute discretion either contemporaneously with the delivery of our financial statements for the fiscal quarter ending June 30, 2020 or at such earlier date as the Administrative Agent shall have consented to; and (iii) $<span id="xdx_909_eus-gaap--ProceedsFromLinesOfCredit_c20200216__20200218__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__custom--DebtTrancheAxis__custom--TrancheThreeMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_znOd6IYgJich"><ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" contextRef="From2020-02-162020-02-18_custom_FinancingAgreementMember_custom_TrancheThreeMember_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000,000</ix:nonFraction></span> was drawn on February 18, 2020 following our achievement of more than $<span id="xdx_90A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20191001__20191231__srt--ProductOrServiceAxis__custom--ImvexxyBijuvaAndAnnoveraMember__srt--RangeAxis__srt--MinimumMember_zfv3TjGl8LZ1" title="Net revenue"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2019-10-012019-12-31_custom_ImvexxyBijuvaAndAnnoveraMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,000,000</ix:nonFraction></span> in net revenues from IMVEXXY, BIJUVA and ANNOVERA for the fourth quarter of 2019. Borrowings under the Facility accrue interest at either (i) <span id="xdx_90B_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zKJYtF79CaQd"><ix:nonNumeric contextRef="From2019-04-232019-04-24_custom_FinancingAgreementMember" name="us-gaap:DebtInstrumentDescriptionOfVariableRateBasis">3-month LIBOR</ix:nonNumeric></span> plus <span id="xdx_902_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_dp_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zp1LBXSYs8ve"><ix:nonFraction name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="From2019-04-232019-04-24_custom_FinancingAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7.75</ix:nonFraction></span>%, subject to a LIBOR floor of <span id="xdx_902_ecustom--LiborFloorRate_iI_dp_c20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zOd7HYmfzNdi" title="LIBOR floor rate"><ix:nonFraction name="txmd:LiborFloorRate" contextRef="AsOf2019-04-24_custom_FinancingAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.70</ix:nonFraction></span>% or (ii) the <span id="xdx_90A_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__us-gaap--VariableRateAxis__us-gaap--PrimeRateMember_zjeOahoIjjzg"><ix:nonNumeric contextRef="From2019-04-232019-04-24_custom_FinancingAgreementMember_us-gaap_PrimeRateMember" name="us-gaap:DebtInstrumentDescriptionOfVariableRateBasis">prime rate</ix:nonNumeric></span> plus <span id="xdx_908_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_dp_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__us-gaap--VariableRateAxis__us-gaap--PrimeRateMember_z7ZeM62wYHf9"><ix:nonFraction name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="From2019-04-232019-04-24_custom_FinancingAgreementMember_us-gaap_PrimeRateMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6.75</ix:nonFraction></span>%, subject to a prime rate floor of <span id="xdx_901_ecustom--LiborFloorRate_iI_dp_c20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__us-gaap--VariableRateAxis__us-gaap--PrimeRateMember_zm98sOE82Djj"><ix:nonFraction name="txmd:LiborFloorRate" contextRef="AsOf2019-04-24_custom_FinancingAgreementMember_us-gaap_PrimeRateMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5.2</ix:nonFraction></span>% as selected by us. Interest on amounts borrowed under the Facility is payable quarterly. The outstanding principal amount of the Facility is payable in <span id="xdx_903_ecustom--NumberOfInstallmentPayments_iI_dc_uPure_c20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zo00bHzWivZ7" title="Number of quarterly principal installment payments"><ix:nonFraction name="txmd:NumberOfInstallmentPayments" contextRef="AsOf2019-04-24_custom_FinancingAgreementMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Pure">four</ix:nonFraction></span> equal quarterly installments beginning on June 30, 2023, with the Facility maturing on March 31, 2024. We have the right to prepay borrowings under the Facility in whole or in part at any time, subject to a prepayment fee on the principal amount being prepaid of (i) <span id="xdx_908_ecustom--PrepaymentFeeForFirstTwoYearsFundingPercent_dp_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zBKqDSL2LShj" title="Prepayment fee for first two years funding (percent)"><ix:nonFraction name="txmd:PrepaymentFeeForFirstTwoYearsFundingPercent" contextRef="From2019-04-232019-04-24_custom_FinancingAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">30.0</ix:nonFraction></span>% for the first two years following the initial funding date of the applicable borrowing, (ii) <span id="xdx_900_ecustom--PrepaymentFeeThirdYearFundingPercent_dp_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zXjZ1JE5xuIi" title="Prepayment fee third year funding (percent)"><ix:nonFraction name="txmd:PrepaymentFeeThirdYearFundingPercent" contextRef="From2019-04-232019-04-24_custom_FinancingAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5.0</ix:nonFraction></span>% for the third year following the initial funding date of the applicable borrowing, (iii) <span id="xdx_90E_ecustom--PrepaymentFeeFourthYearFundingPercent_dp_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_z072mbMfrW8h" title="Prepayment fee fourth year funding (percent)"><ix:nonFraction name="txmd:PrepaymentFeeFourthYearFundingPercent" contextRef="From2019-04-232019-04-24_custom_FinancingAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.0</ix:nonFraction></span>% for the fourth year following the initial funding date of the applicable borrowing and (iv) <span id="xdx_902_ecustom--PrepaymentFeeFifthYearFundingPercent_dp_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_z5dW3FwW1X3c" title="Prepayment fee fifth year funding (percent)"><ix:nonFraction name="txmd:PrepaymentFeeFifthYearFundingPercent" contextRef="From2019-04-232019-04-24_custom_FinancingAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.0</ix:nonFraction></span>% for the fifth year following the initial funding date of the applicable borrowing but prior to March 31, 2024. In connection with the initial borrowing under the Facility, we paid, for the benefit of the lenders, a facility fee equal to <span id="xdx_90E_ecustom--FacilityFeePaidPercent_dp_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_z1LrXhir0wBk" title="Facility fee paid (percent)"><ix:nonFraction name="txmd:FacilityFeePaidPercent" contextRef="From2019-04-232019-04-24_custom_FinancingAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.5</ix:nonFraction></span>% of the initial amount borrowed and will be required to pay such a facility fee in connection with any subsequent borrowings under the Facility. We are also required to pay the Administrative Agent and the lenders an annual administrative fee in addition to other fees and expenses. The Financing Agreement contains customary mandatory prepayments, restrictions and covenants applicable to us that are customary for financings of this type. Among other requirements, we are required to (i) maintain a minimum unrestricted cash balance of $<span id="xdx_90E_ecustom--MinimumCashBalanceRequirementUnderCreditAgreement_iI_c20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zcVtCOGqCjMc" title="Minimum cash balance requirement under credit agreement"><ix:nonFraction name="txmd:MinimumCashBalanceRequirementUnderCreditAgreement" contextRef="AsOf2019-04-24_custom_FinancingAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000,000</ix:nonFraction></span>, which will increase to $<span id="xdx_90C_ecustom--MinimumCashBalanceRequirementUnderCreditAgreement_iI_c20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__custom--DebtTrancheAxis__custom--TrancheTwoThreeMember_zapjg0M2A454"><ix:nonFraction name="txmd:MinimumCashBalanceRequirementUnderCreditAgreement" contextRef="AsOf2019-04-24_custom_FinancingAgreementMember_custom_TrancheTwoThreeMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">60,000,000</ix:nonFraction></span> if we draw either the second or third tranche of the Facility, and (ii) achieve certain minimum consolidated net revenue amounts attributable to commercial sales of our IMVEXXY, BIJUVA and ANNOVERA products beginning with the fiscal quarter ending December 31, 2020. The Financing Agreement also includes other representations, warranties, indemnities and events of default that are customary for financings of this type, including an event of default relating to a change of control of the Company. Upon or after an event of default, the Administrative Agent and the lenders may declare all or a portion of our obligations under the Financing Agreement to be immediately due and payable and exercise other rights and remedies provided for under the Financing Agreement. The obligations of our company and its subsidiaries under the Financing Agreement are secured, subject to customary permitted liens and other agreed upon exceptions, by a first priority perfected security interest in all existing and after acquired assets of our company and its subsidiaries. The obligations under the Financing Agreement will be guaranteed by each of our future direct and indirect subsidiaries, subject to certain exceptions. </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<ix:exclude><!-- Field: Page; Sequence: 94; Value: 3 -->
    <div id="xdx_234_zQaUGYcIFR7l" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_235_zYbaRjcJGEoh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div>
    <div id="xdx_23C_zOgNXkIUtbl9" style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>
<ix:exclude><p id="xdx_23C_zjernuvkCGrf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></ix:exclude>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: #212529">On May 1, 2018, we entered into a Credit and Security Agreement, or the Credit Agreement, with MidCap Financial Trust, or MidCap, as agent, or Agent, and as lender, and the additional lenders party thereto from time to time (together with MidCap as a lender, the Lenders), as amended. The Credit Agreement provided a secured term loan facility in an aggregate principal amount of up to $<span id="xdx_90B_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20180501__us-gaap--CreditFacilityAxis__us-gaap--SecuredDebtMember_zthRxExVWBUe"><ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="AsOf2018-05-01_us-gaap_SecuredDebtMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">200,000,000</ix:nonFraction></span>, or the Term Loan. Under the terms of the Credit Agreement, the Term Loan was available to be made in <span id="xdx_902_ecustom--NumberOfTranchesUnderTermLoanFacility_iI_dc_uPure_c20180501__us-gaap--CreditFacilityAxis__us-gaap--SecuredDebtMember_zPPGETTdoyd1" title="Number of tranches under term loan facility"><ix:nonFraction name="txmd:NumberOfTranchesUnderTermLoanFacility" contextRef="AsOf2018-05-01_us-gaap_SecuredDebtMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Pure">three</ix:nonFraction></span> separate tranches, with each tranche to be made available to us, at our option, upon our achievement of certain milestones. Amounts borrowed under the Term Loan bore interest at a rate equal to the sum of (i) <span id="xdx_90C_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20180430__20180501__us-gaap--CreditFacilityAxis__us-gaap--SecuredDebtMember_zniw2imzgvIj"><ix:nonNumeric contextRef="From2018-04-302018-05-01_us-gaap_SecuredDebtMember" name="us-gaap:DebtInstrumentDescriptionOfVariableRateBasis">one-month LIBOR</ix:nonNumeric></span> (subject to a LIBOR floor of <span id="xdx_905_ecustom--LiborFloorRate_iI_dp_c20180501__us-gaap--CreditFacilityAxis__us-gaap--SecuredDebtMember_zNdCgj9HmMG8"><ix:nonFraction name="txmd:LiborFloorRate" contextRef="AsOf2018-05-01_us-gaap_SecuredDebtMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.50</ix:nonFraction></span>%) plus (ii) <span id="xdx_903_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_dp_c20180430__20180501__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zwDyyLP7pB0b"><ix:nonFraction name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="From2018-04-302018-05-01_us-gaap_RevolvingCreditFacilityMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7.75</ix:nonFraction></span>% per annum.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: #212529">On April 24, 2019, we terminated the Credit Agreement. A portion of the initial tranche of borrowing under the Financing Agreement in the amount of approximately $<span id="xdx_902_ecustom--RepaymentOfDebtWithNewCreditFacility_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--MidCapAgreementMember_zRCxWeLxaQee" title="Repayment of debt with new credit facility"><ix:nonFraction name="txmd:RepaymentOfDebtWithNewCreditFacility" contextRef="From2019-04-232019-04-24_custom_MidCapAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">81,661,000</ix:nonFraction></span> was used to repay all amounts outstanding under the Credit Agreement, which included a prepayment fee of <span id="xdx_906_ecustom--PrepaymentFeePercentage_dp_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--MidCapAgreementMember_z1tr3iVx9Ax2" title="Prepayment fee percentage"><ix:nonFraction name="txmd:PrepaymentFeePercentage" contextRef="From2019-04-232019-04-24_custom_MidCapAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4</ix:nonFraction></span>%, a repayment fee of <span id="xdx_907_ecustom--RepaymentFeePercentage_dp_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--MidCapAgreementMember_zW5eRlDCh8gb" title="Repayment fee percentage"><ix:nonFraction name="txmd:RepaymentFeePercentage" contextRef="From2019-04-232019-04-24_custom_MidCapAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4</ix:nonFraction></span>% and other fees and expenses payable to the lenders under the Credit Agreement. As a result of the termination of the Credit Agreement, we recorded $<span id="xdx_903_eus-gaap--GainsLossesOnExtinguishmentOfDebt_dxL_c20190101__20191231_zAdxzVLUPBZb" title="Loss on extinguishment of debt::XDX::-10%2C057%2C632"><span style="-sec-ix-hidden: xdx2ixbrl0904">10,057,632</span></span> in loss on extinguishment of debt in the accompanying consolidated financial statements. Interest on amounts borrowed under the Term Loan was due and payable monthly in arrears. Interest expense for the year ending December 31, 2019 related to the Credit Agreement was $<span id="xdx_90A_eus-gaap--InterestExpenseDebt_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--MidCapAgreementMember_zZu0N2x7r0pi"><ix:nonFraction name="us-gaap:InterestExpenseDebt" contextRef="From2019-01-012019-12-31_custom_MidCapAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,816,747</ix:nonFraction></span>. During the year ended December 31, 2019, and prior to the repayment of the Credit Agreement, we amortized $<span id="xdx_907_eus-gaap--AmortizationOfFinancingCosts_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--MidCapAgreementMember_z6DStLq8Xyw7" title="Amortization of Debt Issuance Costs"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCosts" contextRef="From2019-01-012019-12-31_custom_MidCapAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">120,146</ix:nonFraction></span> of deferred financing fees <span style="color: black">as interest expense in our accompanying consolidated financial statements</span> and d<span style="color: black">uring the year ended December 31, 2018, we amortized $<span id="xdx_90A_eus-gaap--AmortizationOfFinancingCosts_c20180101__20181231_zEiH8OzHEhJ5"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCosts" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">269,859</ix:nonFraction></span>, of debt issuance costs as interest expense in our accompanying consolidated financial statements. </span></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: #212529; background-color: white">As of December 31, 2019, we had $<span id="xdx_901_eus-gaap--DebtInstrumentCarryingAmount_iI_c20191231__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_z9VcDs7KUOp4"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2019-12-31_custom_FinancingAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">200,000,000</ix:nonFraction></span> in borrowings outstanding under the Financing Agreement, which are classified as long-term debt in the accompanying consolidated financial statements. During the year ended December 31, 2019, we incurred $<span id="xdx_90E_eus-gaap--PaymentsOfFinancingCosts_c20190101__20191231_zUmKALfTitQ4"><ix:nonFraction name="us-gaap:PaymentsOfFinancingCosts" contextRef="From2019-01-01to2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,652,270</ix:nonFraction></span> in deferred financing fees related to the Financing Agreement. Deferred financing fees related to the entire Financing Agreement have been allocated pro rata between the funded and unfunded portions of each tranche. Allocated deferred financing fees related to the first tranche of borrowings of $<span id="xdx_906_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20191231_zr98Xubaf61j"><ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,101,513</ix:nonFraction></span> have been reflected as a debt discount and are accreted to interest expense using the effective interest method. Deferred financing fees associated with unfunded tranches were deferred as assets until the respective tranche has been drawn. As of December 31, 2019, deferred financing fees related to the unfunded tranches were included in other current assets in the accompanying consolidated financial statements. During the year ended December 31, 2019, we amortized $<span id="xdx_902_eus-gaap--AmortizationOfFinancingCosts_c20190101__20191231__custom--DebtTrancheAxis__custom--TrancheOneMember_zlblebXkXWC4"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCosts" contextRef="From2019-01-012019-12-31_custom_TrancheOneMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">736,156</ix:nonFraction></span><span style="background-color: white"> of deferred financing fees related to the first tranche as interest expense in the accompanying consolidated financial statements. Interest on amounts borrowed under the Financing Agreement is due and payable quarterly in arrears. Interest expense for the year ended December 31, 2019 was $</span><span id="xdx_909_eus-gaap--InterestExpenseBorrowings_c20190101__20191231__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_zabZC7kgd36h"><ix:nonFraction name="us-gaap:InterestExpenseBorrowings" contextRef="From2019-01-012019-12-31_custom_FinancingAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,709,166</ix:nonFraction></span><span style="background-color: white">. The overall effective interest rate under the Financing Agreement was approximately </span><span id="xdx_906_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_dp_c20191231_zQGVlNDMVn2e"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">11</ix:nonFraction></span><span style="background-color: white">% as of December 31, </span>2019.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<ix:nonNumeric contextRef="From2019-01-01to2019-12-31" escape="true" name="us-gaap:ScheduleOfDebtTableTextBlock"><p id="xdx_89D_eus-gaap--ScheduleOfDebtTableTextBlock_zhYPUVgRaRm2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: #212529">As
of December 31, 2019 and 2018, the carrying value of our debt consisted of the following:</span></p>
<table border="0" cellspacing="0" cellpadding="0" style="margin-right: auto; margin-left: auto; float: none; width: 90%">

<tr>
<td style="vertical-align: top; padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" id="xdx_494_20191231_zlUsomLypRM8" style="vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b></b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" id="xdx_499_20181231_zzTEfz2tgvEe" style="vertical-align: top; padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b></b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="6" style="border-bottom: black 1pt none; border-top-style: none; border-right-style: none; border-left-style: none; border-bottom-style: solid; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>As of December
31,</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-bottom: black 1pt solid; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2019</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2018</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; width: 70%; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Financing Agreement</p>
</td>
<td style="width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 12%">
<p id="xdx_98E_eus-gaap--DebtInstrumentCarryingAmount_iI_c20191231__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_zbE9M3lpQTMk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2019-12-31_custom_FinancingAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">200,000,000</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 12%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#8212;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Credit Agreement</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#8212;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_98E_eus-gaap--DebtInstrumentCarryingAmount_iI_c20181231__us-gaap--LongtermDebtTypeAxis__custom--CreditAgreementMember_zphlZAFEh85c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2018-12-31_custom_CreditAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">75,000,000</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_40C_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iNI_di_ze8D0Pviiowe" style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Debt discount and financing fees</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(<ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,365,357</ix:nonFraction></p>
</td>
<td style="padding-bottom: 1pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(<ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,618,986</ix:nonFraction></p>
</td>
<td style="padding-bottom: 1pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
</tr>
<tr id="xdx_40A_eus-gaap--LongTermDebtNoncurrent_iI_zm5RcpFdX4U3">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">TOTAL LONG-TERM DEBT</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:LongTermDebtNoncurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">194,634,643</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:LongTermDebtNoncurrent" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">73,381,014</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>

</table>
</ix:nonNumeric></ix:nonNumeric><p id="xdx_818_zbE2RcFQDyR9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p id="xdx_8A8_zPdIgI5MwNad" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<!-- Field: Page; Sequence: 95; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<ix:nonNumeric contextRef="From2019-01-01to2019-12-31" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_80C_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zr1lbX2Y9D4d" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b><span style="text-decoration: underline"><b>NOTE 9 &#8211; <span id="xdx_82E_zBXGNpIYmxl4">STOCKHOLDERS&#x2019; EQUITY</span></b></span></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="text-decoration: underline">Preferred Stock</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">At December 31, 2019, we had <span id="xdx_905_eus-gaap--PreferredStockSharesAuthorized_iI_c20191231_zTOAgJVpXB2g"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000,000</ix:nonFraction></span> shares of Preferred Stock, par value $<span id="xdx_902_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20191231_zq0hLf08FHNg"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span>, authorized for issuance, of which <span id="xdx_906_eus-gaap--PreferredStockSharesIssued_iI_do_c20191231_zHQwzEDAM63k"><span id="xdx_907_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20191231_zmy7r9Nyhwn1"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2019-12-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2019-12-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></ix:nonFraction></span></span> shares of Preferred Stock were issued or outstanding.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="text-decoration: underline">Common Stock</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">At December 31, 2019, we had <span id="xdx_901_eus-gaap--CommonStockSharesAuthorized_iI_c20191231_zPs3uhMuk7Ij"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,000,000</ix:nonFraction></span> shares of Common Stock authorized for issuance, of which <span id="xdx_908_eus-gaap--CommonStockSharesIssued_iI_c20191231_zTuOXU3PkOVg"><span id="xdx_90A_eus-gaap--CommonStockSharesOutstanding_iI_c20191231_zWdNBpqcNWx8"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">271,177,076</ix:nonFraction></ix:nonFraction></span></span> shares of&#160; Common Stock were issued and outstanding.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black"><i><span style="text-decoration: underline"><span style="color: black"><i>Issuances During 2019</i></span></span></i></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">On October 24, 2019, we entered into an underwriting agreement with J.P. Morgan Securities LLC, as representative of the underwriters, relating to an underwritten public offering of <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20191024__20191029__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementJPMorganChaseMember_zzhYHMosfdY1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2019-10-242019-10-29_custom_UnderwritingAgreementJPMorganChaseMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">26,000,000</ix:nonFraction></span> shares of our Common Stock at a public offering price of $<span id="xdx_90A_eus-gaap--SharesIssuedPricePerShare_iI_c20191029__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementJPMorganChaseMember_zAjg4lFbLlf1"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2019-10-29_custom_UnderwritingAgreementJPMorganChaseMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.75</ix:nonFraction></span> per share. We granted the underwriters an option, exercisable for a period of <span id="xdx_901_ecustom--PeriodExercisableUnderwritersOption_dt_c20191024__20191029__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementJPMorganChaseMember_zkPs2rK7it54" title="Period exercisable underwriters option"><ix:nonNumeric contextRef="From2019-10-242019-10-29_custom_UnderwritingAgreementJPMorganChaseMember" format="ixt-sec:durwordsen" name="txmd:PeriodExercisableUnderwritersOption">30 days</ix:nonNumeric></span>, to purchase up to <span id="xdx_904_ecustom--UnderwritersOptionGrantedInPeriodShares_c20191024__20191029__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementJPMorganChaseMember_zyOo1tRWgXP5" title="Underwriters option granted in period shares"><ix:nonFraction name="txmd:UnderwritersOptionGrantedInPeriodShares" contextRef="From2019-10-242019-10-29_custom_UnderwritingAgreementJPMorganChaseMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,900,000</ix:nonFraction></span> additional shares of Common Stock, which was exercised in full. The net proceeds to us from the offering were approximately $<span id="xdx_907_ecustom--ProceedsFromIssuancePublicOffering_c20191024__20191029__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementJPMorganChaseMember_zSAbRt90BdY"><ix:nonFraction name="txmd:ProceedsFromIssuancePublicOffering" contextRef="From2019-10-242019-10-29_custom_UnderwritingAgreementJPMorganChaseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">77,031,000</ix:nonFraction></span>, after deducting the underwriting discount and offering expenses payable by us. The offering closed on October 29, 2019. </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">During the year ended December 31, 2019, certain individuals exercised stock options to purchase an aggregate of <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zxMNGDGgvUGf"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2019-01-012019-12-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">331,619</ix:nonFraction></span> shares of Common Stock for $<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zMfvCCpwzZV9"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2019-01-012019-12-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">108,656</ix:nonFraction></span> in cash.&#160; Also, during the year ended December 31, 2019, stock options to purchase an aggregate of <span id="xdx_901_ecustom--NumberOfStockOptionsExercisedInCashlessExercise_c20190101__20191231_z7Ts4oYk1wC7" title="Number of stock options exercised in cashless exercise (in shares)"><ix:nonFraction name="txmd:NumberOfStockOptionsExercisedInCashlessExercise" contextRef="From2019-01-01to2019-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,097</ix:nonFraction></span> shares of Common Stock were exercised pursuant to the options&#x2019; cashless exercise provisions, which resulted in <span id="xdx_90D_ecustom--NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares_c20190101__20191231_zjDIqaErDoVk" title="Number of common stock issued during period for stock options exercised in cashless exercise (in shares)"><ix:nonFraction name="txmd:NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares" contextRef="From2019-01-01to2019-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,834</ix:nonFraction></span> shares of Common Stock being issued.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black"><i><span style="text-decoration: underline"><span style="color: black"><i>Issuances During 2018</i></span></span></i></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">On August 1, 2018, we entered into an underwriting agreement with Goldman Sachs &#38; Co. LLC, as representative of the underwriters, relating to an underwritten public offering of <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20180801__20180806__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementGoldmanSachsMember_zDGtMyIi9AQd"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2018-08-012018-08-06_custom_UnderwritingAgreementGoldmanSachsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,745,098</ix:nonFraction></span> shares of our Common Stock at a price of $<span id="xdx_909_eus-gaap--SharesIssuedPricePerShare_iI_c20180806__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementGoldmanSachsMember_zYGCWawnhbJd"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2018-08-06_custom_UnderwritingAgreementGoldmanSachsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.10</ix:nonFraction></span> per share. We granted the underwriters an option, exercisable for a period of <span id="xdx_906_ecustom--PeriodExercisableUnderwritersOption_dt_c20180801__20180806__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementGoldmanSachsMember_zVsKieBFw9di"><ix:nonNumeric contextRef="From2018-08-012018-08-06_custom_UnderwritingAgreementGoldmanSachsMember" format="ixt-sec:durwordsen" name="txmd:PeriodExercisableUnderwritersOption">30 days</ix:nonNumeric></span>, to purchase up to <span id="xdx_90E_ecustom--UnderwritersOptionGrantedInPeriodShares_c20180801__20180806__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementGoldmanSachsMember_zqVUpBiKm7Rf"><ix:nonFraction name="txmd:UnderwritersOptionGrantedInPeriodShares" contextRef="From2018-08-012018-08-06_custom_UnderwritingAgreementGoldmanSachsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,911,764</ix:nonFraction></span> additional shares of Common Stock. On August 2, 2018, the underwriters exercised the option in full. The net proceeds to us from the offering, including the exercise of the option to purchase additional shares, were approximately $<span id="xdx_90D_ecustom--ProceedsFromIssuancePublicOffering_c20180801__20180806__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementGoldmanSachsMember_zgBjkcLXYwjh"><ix:nonFraction name="txmd:ProceedsFromIssuancePublicOffering" contextRef="From2018-08-012018-08-06_custom_UnderwritingAgreementGoldmanSachsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">69,908,000</ix:nonFraction></span>, after deducting the underwriting discount and offering expenses payable by us. The offering closed on August 6, 2018. In connection with the Knight License Agreement, on August 6, 2018, Knight entered into a subscription agreement with us, pursuant to which Knight purchased <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20180805__20180806__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementKnightMember_zNIGC8ShI0o7"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2018-08-052018-08-06_custom_SubscriptionAgreementKnightMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,921,568</ix:nonFraction></span> of shares of our Common Stock concurrently with the closing of the underwritten public offering of Common Stock at a price of $<span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_c20180806__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementKnightMember_za7hGPU9otw1"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2018-08-06_custom_SubscriptionAgreementKnightMember819119062" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.10</ix:nonFraction></span>, for proceeds to us of $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20180805__20180806__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementKnightMember_zRHfKZ7dNtr5"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2018-08-052018-08-06_custom_SubscriptionAgreementKnightMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,000,000</ix:nonFraction></span>.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">During the year ended December 31, 2018, certain individuals exercised stock options to purchase an aggregate of <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zHiowcES30lj"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2018-01-012018-12-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,444,526</ix:nonFraction></span> shares of Common Stock for $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z36gE29D3pWf"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2018-01-012018-12-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,666,208</ix:nonFraction></span> in cash. Also, during the year ended December 31, 2018, stock options to purchase an aggregate of <span id="xdx_90C_ecustom--NumberOfStockOptionsExercisedInCashlessExercise_c20180101__20181231_zDVr4ebv9s65"><ix:nonFraction name="txmd:NumberOfStockOptionsExercisedInCashlessExercise" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000</ix:nonFraction></span> shares of Common Stock were exercised pursuant to the options&#x2019; cashless exercise provisions, wherein <span id="xdx_90C_ecustom--NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares_c20180101__20181231_zhbndHLPqPIk"><ix:nonFraction name="txmd:NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,841</ix:nonFraction></span> shares of Common Stock were issued.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black"><i><span style="text-decoration: underline"><span style="color: black"><i>Issuances During 2017</i></span></span></i></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">On September 25, 2017, we entered into an underwriting agreement with J.P. Morgan Securities LLC relating to an underwritten public offering of <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20170924__20170925__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementJPMorganChaseMember_zl9ka8C4mkWg"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2017-09-242017-09-25_custom_UnderwritingAgreementJPMorganChaseMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,400,000</ix:nonFraction></span> shares of our Common Stock at a price of $<span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_c20170928__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementJPMorganChaseMember_z8vw2S1Nm17l"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2017-09-28_custom_UnderwritingAgreementJPMorganChaseMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.55</ix:nonFraction></span> per share. The net proceeds to us from the offering were approximately $<span id="xdx_909_ecustom--ProceedsFromIssuancePublicOffering_c20170926__20170928__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementJPMorganChaseMember_z9zXHJcsmL3e"><ix:nonFraction name="txmd:ProceedsFromIssuancePublicOffering" contextRef="From2017-09-262017-09-28_custom_UnderwritingAgreementJPMorganChaseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">68,573,000</ix:nonFraction></span>, after deducting estimated offering expenses payable by us. The offering closed on September 28, 2017 and we issued <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20170926__20170928__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementJPMorganChaseMember_zstftbLH5yVi"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2017-09-262017-09-28_custom_UnderwritingAgreementJPMorganChaseMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,400,000</ix:nonFraction></span> shares of Common Stock.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">During the year ended December 31, 2017, certain individuals exercised stock options to purchase an aggregate of <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20170101__20171231_zVXD8ygZBgl7"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2017-01-012017-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">102,546</ix:nonFraction></span> shares of Common Stock for $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_c20170101__20171231_zHUJqh1806O2"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2017-01-012017-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">212,615</ix:nonFraction></span> in cash.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="text-decoration: underline">Warrants to Purchase Common Stock</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">As of December 31, 2019, we had warrants outstanding to purchase an aggregate of <span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstanding_iI_c20191231_zprfMzJQxKz5"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,832,571</ix:nonFraction></span> shares of Common Stock with a weighted-average contractual remaining life of approximately <span id="xdx_90B_ecustom--WarrantsAndRightsWeightedAverageContractualRemainingLife_dtY_c20190101__20191231_zIkIuyjKCTgk" title="Weighted-average contractual remaining life"><ix:nonNumeric contextRef="From2019-01-01to2019-12-31" format="ixt-sec:duryear" name="txmd:WarrantsAndRightsWeightedAverageContractualRemainingLife">1.95</ix:nonNumeric></span> years, and exercise prices ranging from $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20191231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__srt--RangeAxis__srt--MinimumMember_zhCByUX9fQF7"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2019-12-31_custom_WarrantsMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.24</ix:nonFraction></span> to $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20191231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__srt--RangeAxis__srt--MaximumMember_z22OGQ9JMSV"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2019-12-31_custom_WarrantsMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.20</ix:nonFraction></span> per share, resulting in a weighted average exercise price of $<span id="xdx_902_ecustom--WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice_iI_c20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zPwuUL5vRlt7" title="Weighted average exercise price of warrants (in dollars per share)"><ix:nonFraction name="txmd:WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice" contextRef="AsOf2019-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.62</ix:nonFraction></span> per share.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<ix:exclude><!-- Field: Page; Sequence: 96; Value: 3 -->
    <div id="xdx_233_zq7CDP7BxS64" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_230_zYidYQxYOuI5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div>
    <div id="xdx_239_zm3wOwa38gja" style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>
<ix:exclude><p id="xdx_23C_zNye6bWNhzcf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></ix:exclude>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">The valuation methodology used to determine the fair value of our warrants is the Black-Scholes Model. The Black-Scholes Model requires the use of a number of assumptions, including volatility of the stock price, the risk-free interest rate, dividend yield and the term of the warrant. During the year ended December 31, 2019, we granted warrants to purchase an aggregate of <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_ziSNle1y4PYe" title="Warrants granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2019-01-012019-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">75,000</ix:nonFraction></span> shares of Common Stock to outside consultants which vest ratably over a <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtM_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zyKQ8jRcazDd" title="Warrants vesting period"><ix:nonNumeric contextRef="From2019-01-012019-12-31_custom_OutsideConsultant2Member" format="ixt-sec:durmonth" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">12</ix:nonNumeric></span>-month period and have an expiration date of <span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20191231__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zSvqSCMF2X54" title="Warrants expiration date"><ix:nonNumeric contextRef="AsOf2019-12-31_custom_OutsideConsultant2Member" format="ixt:datemonthdayyearen" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">February 13, 2024</ix:nonNumeric></span>. During the year ended December 31, 2018, we granted warrants to purchase an aggregate of <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20180101__20181231__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_z0HEhH7p5PG8"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2018-01-012018-12-31_custom_OutsideConsultant2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">175,000</ix:nonFraction></span> shares of Common Stock to outside consultants which vest ratably over a <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtM_c20180101__20181231__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zBb69z51ovd1"><ix:nonNumeric contextRef="From2018-01-012018-12-31_custom_OutsideConsultant2Member" format="ixt-sec:durmonth" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">12</ix:nonNumeric></span>-month period and have an expiration date of <span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20181231__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zMvAlTL440fh"><ix:nonNumeric contextRef="AsOf2018-12-31_custom_OutsideConsultant2Member" format="ixt:datemonthdayyearen" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">March 15, 2023</ix:nonNumeric></span>. During the year ended December 31, 2017, we granted warrants to purchase an aggregate of <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20170101__20171231__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zg7KzW5gyPkk"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2017-01-012017-12-31_custom_OutsideConsultant2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">125,000</ix:nonFraction></span> shares of Common Stock to outside consultants which vest ratably over a <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtM_c20170101__20171231__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zNLaO6dpnahg"><ix:nonNumeric contextRef="From2017-01-012017-12-31_custom_OutsideConsultant2Member" format="ixt-sec:durmonth" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">12</ix:nonNumeric></span>-month period and have an expiration date of <span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20171231__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zvVlHAs2Dvpj"><ix:nonNumeric contextRef="AsOf2017-12-31_custom_OutsideConsultant2Member" format="ixt:datemonthdayyearen" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">March 15, 2022</ix:nonNumeric></span>.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">We recorded share-based compensation expense related to warrants previously issued of $<span id="xdx_90E_eus-gaap--ShareBasedCompensation_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zi8eIr5qpsQ6"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2019-01-012019-12-31_custom_WarrantsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">254,970</ix:nonFraction></span>, $<span id="xdx_90D_eus-gaap--ShareBasedCompensation_c20180101__20181231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_z83PpEbF6tGg"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2018-01-012018-12-31_custom_WarrantsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">494,136</ix:nonFraction></span>, and $<span id="xdx_905_eus-gaap--ShareBasedCompensation_c20170101__20171231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zbXY56uq74e5"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2017-01-012017-12-31_custom_WarrantsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">313,271</ix:nonFraction></span> for the years ended December 31, 2019, 2018 and 2017, respectively, in the accompanying consolidated financial statements. At December 31, 2019, total unrecognized estimated compensation expense related to unvested warrants was approximately $<span id="xdx_909_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20191231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zh1okmWOz9y6"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="AsOf2019-12-31_custom_WarrantsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,446</ix:nonFraction></span> which is expected to be recognized over weighted-average period of <span id="xdx_903_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zDGx8e3Shs69"><ix:nonNumeric contextRef="From2019-01-012019-12-31_custom_WarrantsMember" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">0.1</ix:nonNumeric></span> years.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<ix:nonNumeric contextRef="From2019-01-01to2019-12-31" escape="true" name="txmd:ScheduleOfWarrantRollForwardTableTextBlock"><p id="xdx_89E_ecustom--ScheduleOfWarrantRollForwardTableTextBlock_zOwm3dSdLZ89" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><i>Summary of our Warrant activity during the year ended December 31, 2019:</i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse: collapse; width: 100%; width: 100%">

<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Number of Shares
Under Warrants</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; width: 13%; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Weighted Average
Exercise Price</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; width: 13%; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Weighted Average
Remaining Contractual Life in Years</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; width: 13%; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Aggregate Intrinsic
Value</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; width: 40%; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Balance at December 31, 2018</p>
</td>
<td style="width: 3%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 10%">
<p id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zzsiNoEzQ4Jk" title="Number of shares under warrants outstanding beginning" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2018-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,007,571</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 3%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 10%">
<p id="xdx_984_ecustom--WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice_iS_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z5INwx1jqVf5" title="Weighted average exercise price warrants outstanding beginning" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="txmd:WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice" contextRef="AsOf2018-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.78</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 3%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 10%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20180101__20181231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zxjwyr8ZK2H1" title="Weighted average remaining contractual life, warrants outstanding"><ix:nonNumeric contextRef="From2018-01-012018-12-31_us-gaap_WarrantMember" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">1.58</ix:nonNumeric></span></p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 3%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 10%">
<p id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iS_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z0MUPG1iCvga" title="Aggregate intrinsic value, warrants outstanding beginning" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" contextRef="AsOf2018-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,826,403</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 16px">Granted</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zdeXaontc7rh" title="Number of shares under warrants granted" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2019-01-012019-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">75,000</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_987_ecustom--WarrantsGrantedOtherThanOptionsWeightedAverageExercisePrice_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z5RsyebWvcFl" title="Weighted average exercise price warrants granted" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="txmd:WarrantsGrantedOtherThanOptionsWeightedAverageExercisePrice" contextRef="From2019-01-012019-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.63</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 16px">Exercised</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zmBuFPFCyj0j" title="Number of shares under warrants exercised" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2019-01-012019-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,250,000</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_984_ecustom--WarrantsExercisedOtherThanOptionsWeightedAverageExercisePrice_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zbvjQGVArDqj" title="Weighted average exercise price warrants exercised" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="txmd:WarrantsExercisedOtherThanOptionsWeightedAverageExercisePrice" contextRef="From2019-01-012019-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.20</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z5B44HXAAYx4" title="Aggregate intrinsic value, warrants exercised" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue" contextRef="From2019-01-012019-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,420,000</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 16px">Expired</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#8212;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#8212;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#8212;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 16px">Cancelled/Forfeited</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#8212;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#8212;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#8212;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Balance at December 31, 2019</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 2pt double; vertical-align: bottom">
<p id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zHJWqHZEIubc" title="Number of shares under warrants outstanding ending" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2019-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,832,571</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_98D_ecustom--WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice_iE_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zodK7rurjHp1" title="Weighted average exercise price warrants outstanding ending" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="txmd:WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice" contextRef="AsOf2019-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.62</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zebKN0rLMd8k"><ix:nonNumeric contextRef="From2019-01-012019-12-31_us-gaap_WarrantMember" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">1.95</ix:nonNumeric></span></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iE_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z6mE2IQurG9l" title="Aggregate intrinsic value, warrants outstanding ending" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" contextRef="AsOf2019-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,447,929</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Vested and Exercisable at December 31, 2019</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zPmH3SiLrHOg" title="Number of shares under warrants vested and exercisable ending" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" contextRef="AsOf2019-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,820,071</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_986_ecustom--WarrantsOutstandingVestedAndExercisable_iE_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zSPukOwepEHb" title="Weighted average exercise price warrants vested and exercisable ending" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="txmd:WarrantsOutstandingVestedAndExercisable" contextRef="AsOf2019-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.60</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExercisableWeightedAverageRemainingContractualTerms_dtY_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z1B6TVrIP1s6" title="Weighted average remaining contractual life, vested and exercisable ending"><ix:nonNumeric contextRef="From2019-01-012019-12-31_us-gaap_WarrantMember" format="ixt-sec:duryear" name="txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExercisableWeightedAverageRemainingContractualTerms">1.90</ix:nonNumeric></span></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue_iE_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zXaS840m905d" title="Aggregate intrinsic value, vested and exercisable ending" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue" contextRef="AsOf2019-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,447,929</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Unvested at December 31, 2019</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zSGOyx4fGjaa" title="Number of shares under warrants unvested ending" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2019-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,500</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_98C_ecustom--WarrantsUnvestedWeightedAverageExercisePrice_iE_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zB54OIysC6p" title="Weighted average exercise price warrants unvested ending" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="txmd:WarrantsUnvestedWeightedAverageExercisePrice" contextRef="AsOf2019-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.63</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms_dtY_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zBJ5gIVdV1C2" title="Weighted average remaining contractual life, warrants unvested ending"><ix:nonNumeric contextRef="From2019-01-012019-12-31_us-gaap_WarrantMember" format="ixt-sec:duryear" name="txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms">9.13</ix:nonNumeric></span></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#8212;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>

</table>
</ix:nonNumeric><p id="xdx_8AE_zd4TbJcoRQbj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<ix:nonNumeric contextRef="From2019-01-01to2019-12-31" escape="true" name="txmd:ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock"><p id="xdx_890_ecustom--ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock_zZ8D5rUScNI1" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">The weighted average fair value per share of warrants issued and the assumptions used in the Black-Scholes Model during the years ended December 31, 2019, 2018, and 2017 are set forth in the table below.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellspacing="0" cellpadding="0" style="margin-right: auto; margin-left: auto; float: none; width: 80%">

<tr>
<td style="padding: 0pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td id="xdx_496_20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zG5JtLMRyJz3" colspan="2" style="border-bottom: black 1pt solid; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2019</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td id="xdx_496_20180101__20181231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zxQ5G1Vw01fk" colspan="2" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2018</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td id="xdx_49C_20170101__20171231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zyNqzjHzKqhc" colspan="2" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2017</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr id="xdx_405_ecustom--WeightedAverageExercisePriceOtherThanOptions_zuNoq8ji79a8" style="background-color: #cceeff">
<td style="padding: 0pt; width: 55%; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Weighted average exercise price</p>
</td>
<td style="width: 3%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 10%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="txmd:WeightedAverageExercisePriceOtherThanOptions" contextRef="From2019-01-012019-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.63</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 3%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 10%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="txmd:WeightedAverageExercisePriceOtherThanOptions" contextRef="From2018-01-012018-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.16</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 3%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 10%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="txmd:WeightedAverageExercisePriceOtherThanOptions" contextRef="From2017-01-012017-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.83</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_40A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_zP3RmzYosxR3">
<td style="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Weighted average grant date fair value</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2019-01-012019-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.00</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2018-01-012018-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.79</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2017-01-012017-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.67</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_409_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_za8qxKPEG6y3" style="background-color: #cceeff">
<td style="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Risk-free interest rate</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2019-01-012019-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.52</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">%</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2018-01-012018-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.36</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">%</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2017-01-012017-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.47</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">%</p>
</td>
</tr>
<tr id="xdx_404_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_zYjoJ5E78zph">
<td style="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Volatility</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2019-01-012019-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">60.8</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">%</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2018-01-012018-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">62.12</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">%</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2017-01-012017-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">63.24</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">%</p>
</td>
</tr>
<tr style="background-color: #cceeff">
<td style="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Term (in years)</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zftNEFwHtlHk" title="Term"><ix:nonNumeric contextRef="From2019-01-012019-12-31_us-gaap_WarrantMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5</ix:nonNumeric></span></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20180101__20181231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zunPuguZCAy5"><ix:nonNumeric contextRef="From2018-01-012018-12-31_us-gaap_WarrantMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5</ix:nonNumeric></span></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20170101__20171231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zMZ3YxBRyp91"><ix:nonNumeric contextRef="From2017-01-012017-12-31_us-gaap_WarrantMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5</ix:nonNumeric></span></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_406_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_zoarFoj8iWm9">
<td style="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Dividend yield</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2019-01-012019-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.00</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">%</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2018-01-012018-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.00</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">%</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2017-01-012017-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.00</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">%</p>
</td>
</tr>

</table>
</ix:nonNumeric><p id="xdx_8A2_zF5PmUHoAiBa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black"><i><span style="text-decoration: underline"><span style="color: black"><i>Warrant exercises</i></span></span></i></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">During the year ended December 31, 2019, warrants to purchase an aggregate of <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zYwnH775sK0j" title="Warrants exercised"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2019-01-012019-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,250,000</ix:nonFraction></span> shares of Common Stock were exercised pursuant to the warrants&#x2019; cashless exercise provisions, which resulted in <span id="xdx_90F_ecustom--NumberOfStockIssuedInCashlessExerciseOfWarrants_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsCashlessExerciseMember_zcLcDd2VOyBf" title="Number of stock issued in cashless exercise of warrants"><ix:nonFraction name="txmd:NumberOfStockIssuedInCashlessExerciseOfWarrants" contextRef="From2019-01-012019-12-31_custom_WarrantsCashlessExerciseMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">471,184</ix:nonFraction></span> shares of Common Stock being issued. During the year ended December 31, 2018, <span id="xdx_90F_ecustom--NumberOfStockIssuedInCashlessExerciseOfWarrants_do_c20180101__20181231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zus9aF77sbfd"><ix:nonFraction name="txmd:NumberOfStockIssuedInCashlessExerciseOfWarrants" contextRef="From2018-01-012018-12-31_custom_WarrantsMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></span> warrants were exercised.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">During the year ended December 31, 2017, certain individuals exercised warrants to purchase an aggregate of <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20170101__20171231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zAKZFvqTBQMd"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2017-01-012017-12-31_custom_WarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,476,666</ix:nonFraction></span> shares of Common Stock for $<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueOther_c20170101__20171231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zWNlfkzO8DL1" title="Shares issued for exercise of warrants, net"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2017-01-012017-12-31_custom_WarrantsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,798,999</ix:nonFraction></span> in cash. In addition, during the year ended December 31, 2017, certain individuals exercised warrants to purchase an aggregate of <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20170101__20171231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsCashlessExerciseMember_zPTJ96mXW0se"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2017-01-012017-12-31_custom_WarrantsCashlessExerciseMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,590,000</ix:nonFraction></span> shares of Common Stock pursuant to the warrants&#x2019; cashless exercise provisions, which resulted in <span id="xdx_900_ecustom--NumberOfStockIssuedInCashlessExerciseOfWarrants_c20170101__20171231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsCashlessExerciseMember_z2jrqc8PYIUl"><ix:nonFraction name="txmd:NumberOfStockIssuedInCashlessExerciseOfWarrants" contextRef="From2017-01-012017-12-31_custom_WarrantsCashlessExerciseMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,762,208</ix:nonFraction></span> shares of Common Stock being issued.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: black"><span style="text-decoration: underline"><span style="color: black">Options to Purchase Common Stock of the Company</span></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">In 2009, we adopted the 2009 Long Term Incentive Compensation Plan, or the 2009 Plan, to provide financial incentives to employees, directors, advisers, and consultants of our company who are able to contribute towards the creation of or who have created stockholder value by providing them stock options and other stock and cash incentives, or the Awards. As of December 31, 2019, there were non-qualified stock options to purchase an aggregate of <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20191231__us-gaap--PlanNameAxis__custom--LongTermIncentiveCompensationPlan2009Member_zA9WJyJtOZnf"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2019-12-31_custom_LongTermIncentiveCompensationPlan2009Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,017,759</ix:nonFraction></span> shares of Common Stock outstanding under the 2009 Plan. Effective upon our adoption of the TherapeuticsMD, Inc. 2019 Stock Incentive Plan, or the 2019 Plan, on June 20, 2019, no future awards may be made under the 2009 Plan. </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<ix:exclude><!-- Field: Page; Sequence: 97; Value: 3 -->
    <div id="xdx_233_zikomoYTa3L6" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_235_zAe9WasyLnS2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div>
    <div id="xdx_231_zmEnvm7B7F8f" style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>
<ix:exclude><p id="xdx_23F_zOlPUZlCg401" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></ix:exclude>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">In 2012, we adopted the 2012 Stock Incentive Plan, or the 2012 Plan, a non-qualified plan that was amended in August 2013. The 2012 Plan was designed to serve as an incentive for retaining qualified and competent key employees, officers, directors, and certain consultants and advisors of our company. As of December 31, 2019, there were non-qualified stock options to purchase an aggregate of <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20191231__us-gaap--PlanNameAxis__custom--NonQualified2012StockIncentivePlanMember_zdi2FH3pvyx6"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2019-12-31_custom_NonQualified2012StockIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,316,474</ix:nonFraction></span> shares of Common Stock outstanding and an aggregate of <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20191231__us-gaap--PlanNameAxis__custom--NonQualified2012StockIncentivePlanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zjwuaexHuYlb"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2019-12-31_custom_NonQualified2012StockIncentivePlanMember_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,040,000</ix:nonFraction></span> restricted stock awards under the 2012 Plan. Effective upon our adoption of the 2019 Plan, no future awards may be made under the 2012 Plan. </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">On June 20, 2019, we adopted the 2019 Plan to serve as an incentive for retaining qualified and competent key employees, officers, directors, and certain consultants and advisors of our company. The Awards available under the 2019 Plan consist of stock options, stock appreciation rights, restricted stock, restricted stock units, performance stock, performance units, and other stock or cash awards as described in the 2019 Plan. Generally, the options vest annually over four years or as determined by our board of directors, upon each option grant. Options may be exercised by paying the price for shares or on a cashless exercise basis after they have vested and prior to the specified expiration date provided and applicable exercise conditions are met, if any. The expiration date is generally ten years from the date the option is issued. </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">As of December 31, 2019, there were <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20191231__us-gaap--PlanNameAxis__custom--Plan2019Member_z3hKaGDLkKI"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2019-12-31_custom_Plan2019Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,599,382</ix:nonFraction></span> shares of Common Stock available for issuance under the 2019 Plan, consisting of (i) <span id="xdx_90E_ecustom--PlanAwardsNumberOfNewShares_iI_c20191231__us-gaap--PlanNameAxis__custom--Plan2019Member_zTQ3oZu0sPsf" title="Plan awards number of new shares"><ix:nonFraction name="txmd:PlanAwardsNumberOfNewShares" contextRef="AsOf2019-12-31_custom_Plan2019Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,103,999</ix:nonFraction></span> new shares, (ii) <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20191231__us-gaap--PlanNameAxis__custom--NonQualified2012StockIncentivePlanMember_z91vULZqs2He"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2019-12-31_custom_NonQualified2012StockIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,395,333</ix:nonFraction></span> unallocated shares previously available for issuance under the 2012 Plan that were not then subject to outstanding &#8220;Awards&#8221; (as defined in the 2012 Plan), and (iii) <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20191231__us-gaap--PlanNameAxis__custom--LongTermIncentiveCompensationPlan2009Member_zr71Tt1aKAD"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2019-12-31_custom_LongTermIncentiveCompensationPlan2009Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,050</ix:nonFraction></span> unallocated shares previously available for issuance under the 2009 Plan that were not then subject to outstanding &#8220;Awards&#8221; (as defined in the 2009 Plan). Any shares subject to outstanding options or other equity &#8220;Awards&#8221; under the 2019 Plan, the 2012 Plan and the 2009 Plan that are forfeited, expire or otherwise terminate without issuance of the underlying shares, or if any such Award is settled for cash or otherwise does not result in the issuance of all or a portion of the shares subject to such Award (other than shares tendered or withheld in connection with the exercise of an Award or the satisfaction of withholding tax liabilities), the shares to which those Awards were subject, shall, to the extent of such forfeiture, expiration, termination, cash settlement or non-issuance, again be available for delivery with respect to Awards under the 2019 Plan. As of December 31, 2019, there were non-qualified stock options to purchase <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20191231__us-gaap--PlanNameAxis__custom--Plan2019Member_zPNlniOuGUG7"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2019-12-31_custom_Plan2019Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,696,001</ix:nonFraction></span> shares of Common Stock outstanding under the 2019 Plan and <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20191231__us-gaap--PlanNameAxis__custom--Plan2019Member__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zKf9prgmmQbc"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2019-12-31_custom_Plan2019Member_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">200,000</ix:nonFraction></span> restricted stock awards outstanding under the 2019 Plan.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">The valuation methodology used to determine the fair value of stock options is the Black-Scholes Model. The Black-Scholes Model requires the use of a number of assumptions including volatility of the stock price, the risk-free interest rate, and the expected life of the stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">&#160;</span></p>

<ix:nonNumeric contextRef="From2019-01-01to2019-12-31" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><p id="xdx_895_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zCEi1KljRvq9" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">The ranges of assumptions used in the Black-Scholes Model during the years ended December 31, 2019, 2018, and 2017 are set forth in the table below.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellspacing="0" cellpadding="0" style="margin-right: auto; margin-left: auto; float: none; width: 90%">

<tr>
<td style="padding: 0pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td id="xdx_49C_20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zjKyY1ZaOy42" colspan="2" style="border-bottom: black 1pt solid; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2019</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td id="xdx_497_20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z58HCy3xTEeg" colspan="2" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2018</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td id="xdx_49C_20170101__20171231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zqVe4ECcgasl" colspan="2" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2017</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr style="background-color: #cceeff">
<td style="padding: 0pt; width: 55%; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Weighted average exercise price</p>
</td>
<td style="width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 12%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zgkqeDYPMqIg" title="Weighted average exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="AsOf2019-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.10</ix:nonFraction></span></p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 12%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zFo2BcoH7fjj"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="AsOf2018-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.45</ix:nonFraction></span></p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 12%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20171231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zbG85QwG2Ocb"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="AsOf2017-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.60</ix:nonFraction></span></p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_402_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_zc1CMM4er3qi">
<td style="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Weighted average grant date fair value</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.82</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2018-01-012018-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.24</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2017-01-012017-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.82</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: #cceeff">
<td style="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Risk-free interest rate</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_dp_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z72SaZuA7mYf" title="Risk-free interest rate - minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.64</ix:nonFraction></span>-<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_dp_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zMBIDOEQmA3g" title="Risk-free interest rate - maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.54</ix:nonFraction></span></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">%</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_dp_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zWMdjkfx1yJ5"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="From2018-01-012018-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.38</ix:nonFraction></span>-<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_dp_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zber2qjmMZ7h"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="From2018-01-012018-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.89</ix:nonFraction></span></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">%</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_dp_c20170101__20171231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zQKM7FnmrT82"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="From2017-01-012017-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.84</ix:nonFraction></span>-<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_dp_c20170101__20171231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zPWhETmvYVph"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="From2017-01-012017-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.05</ix:nonFraction></span></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">%</p>
</td>
</tr>
<tr>
<td style="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Volatility</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_dp_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zvNe48pIuEr3" title="Volatility - minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">61.25</ix:nonFraction></span>-<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_dp_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zPSoEKeatYTa" title="Volatility - maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">64.49</ix:nonFraction></span></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">%</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_dp_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zgeecMMVU1w"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="From2018-01-012018-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">59.45</ix:nonFraction></span>-<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_dp_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zTEHa0V1Z9Of"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="From2018-01-012018-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">64.04</ix:nonFraction></span></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">%</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_dp_c20170101__20171231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zWtayHZ5UV75"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="From2017-01-012017-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">61.56</ix:nonFraction></span>-<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_dp_c20170101__20171231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zoMIKAINnb18"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="From2017-01-012017-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">64.25</ix:nonFraction></span></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">%</p>
</td>
</tr>
<tr style="background-color: #cceeff">
<td style="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Term (in years)</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zqaof0desl1f" title="Term"><ix:nonNumeric contextRef="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember_srt_MinimumMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.5</ix:nonNumeric></span>-<span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zZGWEqvOCNH2"><ix:nonNumeric contextRef="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember_srt_MaximumMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">6.5</ix:nonNumeric></span></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_z9Gj3SsGjeLf"><ix:nonNumeric contextRef="From2018-01-012018-12-31_us-gaap_EmployeeStockOptionMember_srt_MinimumMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.1</ix:nonNumeric></span>-<span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_z3js9QZdKgci"><ix:nonNumeric contextRef="From2018-01-012018-12-31_us-gaap_EmployeeStockOptionMember_srt_MaximumMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">6.25</ix:nonNumeric></span></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20170101__20171231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_z0KPl6IbB7Mk"><ix:nonNumeric contextRef="From2017-01-012017-12-31_us-gaap_EmployeeStockOptionMember_srt_MinimumMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.5</ix:nonNumeric></span>-<span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20170101__20171231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zewgrtLkYuD5"><ix:nonNumeric contextRef="From2017-01-012017-12-31_us-gaap_EmployeeStockOptionMember_srt_MaximumMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">6.25</ix:nonNumeric></span></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_403_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_zzaNpbW6kdKi">
<td style="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Dividend yield</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.00</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">%</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2018-01-012018-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.00</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">%</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2017-01-012017-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.00</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">%</p>
</td>
</tr>

</table>
</ix:nonNumeric><p id="xdx_8A1_zfVnekqikrOe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<ix:nonNumeric contextRef="From2019-01-01to2019-12-31" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><p id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zqkCBu3wAa76" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">A summary of activity under the 2009, 2012 and 2019 Plans and related information during the year ended December 31, 2019 is as follows:</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse: collapse; width: 100%; width: 100%">

<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Number of Shares
Under Options</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; width: 13%; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Weighted Average
Exercise Price</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; width: 13%; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Weighted Average
Remaining Contractual Life in Years</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; width: 13%; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Aggregate Intrinsic
Value</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; width: 40%; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Balance at December 31, 2018</p>
</td>
<td style="width: 3%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 10%">
<p id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z1WbCCkctj24" title="Number of shares under options, beginning" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2018-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,872,824</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 3%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 10%">
<p id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zbL3OIGB26O6" title="Weighted average exercise price, beginning" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2018-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.93</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 3%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 10%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zEKbZ2w6uHi1" title="Weighted average remaining contractual life"><ix:nonNumeric contextRef="From2018-01-012018-12-31_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">5.94</ix:nonNumeric></span></p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 3%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 10%">
<p id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zzIu12iiUYNh" title="Aggregate intrinsic value, beginning" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2018-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,239,876</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 16px">Granted</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z14SZQE1hUE2" title="Number of shares under options, granted" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,620,501</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z3iADKoLUTN3" title="Weighted average exercise price, granted" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.10</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 16px">Exercised</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zvxmSZSdljxe" title="Number of shares under options, exercised" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">343,716</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zs2Pw0YxQ17i" title="Weighted average exercise price, exercised" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.32</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zNKbPT57DNg1" title="Aggregate intrinsic value, exercised" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,426,828</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 16px">Expired</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z3ZQUPGssbIb" title="Number of shares under options, expired" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">26,375</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zqBowh4gmwK2" title="Weighted average exercise price, expired" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.57</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 16px">Cancelled/Forfeited</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zo67pKgkpwuf" title="Number of shares under options, cancelled forfeited" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">93,000</ix:nonFraction></p>
</td>
<td style="padding-bottom: 1pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_znaQMmEOcu31" title="Weighted average exercise price, cancelled forfeited" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.16</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Balance at December 31, 2019</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 2pt double; vertical-align: bottom">
<p id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zT5qwoFAhF85" title="Number of shares under options, ending" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2019-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,030,234</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zrkPEZKJ1B2k" title="Weighted average exercise price, ending" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2019-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.65</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zwnfeDj2mMFa"><ix:nonNumeric contextRef="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">5.84</ix:nonNumeric></span></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zEN2HI5oFGGd" title="Aggregate intrinsic value, ending" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2019-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,668,171</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Vested and Exercisable at December 31, 2019</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zXjGY5zRJRXg" title="Number of shares under options, vested and exercisable ending" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="AsOf2019-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">18,025,819</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zf7B2nc4VWn7" title="Weighted average exercise price, vested and exercisable ending" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="AsOf2019-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.88</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zGU2IlSsl7Pb" title="Weighted average remaining contractual life, vested and exercisable"><ix:nonNumeric contextRef="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">4.62</ix:nonNumeric></span></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zstAPNlwDEl3" title="Aggregate intrinsic value, vested and exercisable ending" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2019-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,319,621</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Unvested at December 31, 2019</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zhRoTf6JPxce" title="Number of shares under options, unvested ending" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" contextRef="AsOf2019-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,004,415</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_iE_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z0meePN4hQb4" title="Weighted average exercise price, unvested ending" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" contextRef="AsOf2019-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.05</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms_dtY_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zO4CzDUTSACc" title="Weighted average remaining contractual life, unvested"><ix:nonNumeric contextRef="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear" name="txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms">8.96</ix:nonNumeric></span></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue_iE_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zKiil2Vlg8Bk" title="Aggregate intrinsic value, unvested ending" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue" contextRef="AsOf2019-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">348,550</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>

</table>
</ix:nonNumeric><p id="xdx_8A9_zHz2fz1qH2h3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">At December 31, 2019, our outstanding options had exercise prices ranging from $<span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice_iI_c20191231__srt--RangeAxis__srt--MinimumMember_zjJKNZmujqd8" title="Range - exercise price of options"><ix:nonFraction name="txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice" contextRef="AsOf2019-12-31_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.19</ix:nonFraction></span> to $<span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice_iI_c20191231__srt--RangeAxis__srt--MaximumMember_zFiacbDPeo4"><ix:nonFraction name="txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice" contextRef="AsOf2019-12-31_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.92</ix:nonFraction></span> per share. Share-based compensation expense related to options recognized in our results of operations for the years ended December 31, 2019, 2018, and 2017 was approximately $<span id="xdx_909_eus-gaap--AllocatedShareBasedCompensationExpense_c20190101__20191231_zuudtJB3bdZc"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2019-01-01to2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,798,707</ix:nonFraction></span>, $<span id="xdx_902_eus-gaap--AllocatedShareBasedCompensationExpense_c20180101__20181231_zDGum8ymDev8"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,091,294</ix:nonFraction></span>, and $<span id="xdx_908_eus-gaap--AllocatedShareBasedCompensationExpense_c20170101__20171231_zGiej39Pfm6"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2017-01-012017-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,447,154</ix:nonFraction></span>, respectively, and it is based on awards vested. At December 31, 2019, total unrecognized estimated compensation expense related to unvested options was approximately $<span id="xdx_906_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_c20191231_z2Ux47Ts9Ou6"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,460,000</ix:nonFraction></span>, which may be adjusted for future changes in forfeitures. This cost is expected to be recognized over a weighted-average period of <span id="xdx_904_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zlAyk1aeJjwg"><ix:nonNumeric contextRef="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">2.4</ix:nonNumeric></span> years. No tax benefit was realized due to a continued pattern of operating losses.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<ix:exclude><!-- Field: Page; Sequence: 98; Value: 3 -->
    <div id="xdx_237_zkn4o9SWSlLk" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_23C_zYLV8bzrTJsl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div>
    <div id="xdx_23E_zlCjpfzlRmYi" style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>
<ix:exclude><p id="xdx_232_zqe2vJd5y2Pk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></ix:exclude>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: black"><span style="text-decoration: underline"><span style="color: black">Restricted Stock</span></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">Restricted stock awards granted under our 2009, 2012 and 2019 Plans entitle the holder to receive, at the end of vesting period, a specified number of shares of our Common Stock. Share-based compensation expense is measured by the market value of our Common Stock on the day of the grant. The shares vest ratably over the period specified in the grant. There is no partial vesting and any unvested portion is forfeited.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: #212529">On
December 13, 2018, we granted an aggregate of <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20181212__20181213__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zgyqMYPzPxZ8"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2018-12-122018-12-13_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,040,000</ix:nonFraction></span>
restricted stock units to certain executive employees which will vest at the end of the third year. The grant date fair
value was $<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20181212__20181213__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zk4XlYgflu0j"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2018-12-122018-12-13_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.06</ix:nonFraction></span>
per unit. At December 31, 2019, <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zJKhH2kS0VNa"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="From2019-01-012019-12-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">150,000</ix:nonFraction></span>
of those restricted stock units vested due to an employment termination.&#160; On July 30, 2019, we granted an aggregate of <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20190729__20190730__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zUL9Y3i4m4w7"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2019-07-292019-07-30_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">200,000</ix:nonFraction></span>
restricted stock units to certain executive employees which will vest on January 31, 2022. The grant date fair value
was $<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20190729__20190730__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zpo5CUmdIRlk"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2019-07-292019-07-30_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.18</ix:nonFraction></span>
per unit. During the year ended December 31, 2019 and 2018, we recorded $<span id="xdx_90F_eus-gaap--RestrictedStockExpense_c20190101__20191231_zymqTdrvGDi9"><ix:nonFraction name="us-gaap:RestrictedStockExpense" contextRef="From2019-01-01to2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,628,407</ix:nonFraction></span>
and $<span id="xdx_901_eus-gaap--RestrictedStockExpense_c20180101__20181231_z3CUBmKVNeYc"><ix:nonFraction name="us-gaap:RestrictedStockExpense" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">73,132</ix:nonFraction></span>, respectively,
in share-based compensation expense related to restricted stock units. At December 31, 2019, total unrecognized
estimated compensation expense related to unvested restricted stock units was approximately $<span id="xdx_903_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_iI_c20191231_zKm9R7UpC4d5"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,711,000</ix:nonFraction></span>,
which may be adjusted for future changes in forfeitures. This cost is expected to be recognized over a
weighted-average period of <span id="xdx_909_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zHYC7rxV3Vnj"><ix:nonNumeric contextRef="From2019-01-012019-12-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">2.0</ix:nonNumeric></span>
years. At December 31, 2019, we had <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zBExi3hHJUia"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2019-12-31_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,240,000</ix:nonFraction></span>
restricted stock awards outstanding.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: black"><span style="text-decoration: underline"><span style="color: black">Cash-Settled Stock Appreciation Rights (SARs)</span></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">On July 1, 2018, we issued cash-settled SARs to certain consultants and employees. The SARs plan year began on July 1, 2018 and ended on or immediately following June 30, 2019. SARs were granted with a grant price equal to the market value of a share of our Common Stock on the date of grant. Cash-settled SARs provided for the cash payment of the excess of the fair market value of our Common Stock on June 30, 2019 over the grant price. Cash-settled SARs have no effect on dilutive shares or shares outstanding as any appreciation of our Common Stock over the grant price is paid in cash and not in Common Stock. </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">Cash
settled SARs were recorded in our consolidated balance sheets as a liability until the date of exercise. The fair value of each
SAR award was estimated using the Black-Scholes valuation model. In accordance with ASC Topic 718, <i>Stock Compensation</i>,
the fair value of each SAR award was recalculated at the end of each reporting period and the liability and expense adjusted based
on the new fair value and the percent vested. At June 30, 2019, the fair market value of our Common Stock was lower than the grant
price of the SARs and, as a result, the recorded liability was reversed and no cash payment was made.</span></p>
</ix:nonNumeric><p id="xdx_811_zzSfFDGeqCa3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<ix:nonNumeric contextRef="From2019-01-01to2019-12-31" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock"><p id="xdx_804_eus-gaap--IncomeTaxDisclosureTextBlock_zL6wTaqLV84c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b><span style="text-decoration: underline"><b>NOTE 10 &#8211; <span id="xdx_82E_z7q5de6Oj7qg">INCOME TAXES</span> </b></span></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<ix:nonNumeric contextRef="From2019-01-01to2019-12-31" escape="true" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"><p id="xdx_894_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zADi8hHgCXHf" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">For financial reporting purposes, income before taxes includes the following components:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellspacing="0" cellpadding="0" style="margin-right: auto; margin-left: auto; float: none; width: 90%">

<tr>
<td style="padding: 0pt; vertical-align: top"></td>
<td><p style="margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-bottom: black 1pt solid; text-align: center; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>2019</b></p>
</td>
<td style="vertical-align: bottom"><p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td><p style="margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; text-align: center; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>2018</b></p>
</td>
<td style="vertical-align: bottom"><p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td><p style="margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; text-align: center; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>2017</b></p>
</td>
<td style="vertical-align: bottom"><p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr style="background-color: #cceeff">
<td style="padding: 0pt; width: 55%; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">United States</p>
</td>
<td style="width: 1%">
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; width: 1%; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="border-bottom: black 1pt solid; width: 12%; vertical-align: bottom">
<p id="xdx_98D_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_c20190101__20191231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zdcjS9MuxK97" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="From2019-01-012019-12-31_us-gaap_DomesticCountryMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">176,144,999</ix:nonFraction></p>
</td>
<td style="padding-bottom: 1pt; width: 1%; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
<td style="width: 1%">
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; width: 1%; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="border-bottom: black 1pt solid; width: 12%; vertical-align: bottom">
<p id="xdx_98B_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_c20180101__20181231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zZVgfVuMkwYi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="From2018-01-012018-12-31_us-gaap_DomesticCountryMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">132,617,160</ix:nonFraction></p>
</td>
<td style="padding-bottom: 1pt; width: 1%; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
<td style="width: 1%">
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; width: 1%; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="border-bottom: black 1pt solid; width: 12%; vertical-align: bottom">
<p id="xdx_98A_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_c20170101__20171231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zbqcESBZjJO9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="From2017-01-012017-12-31_us-gaap_DomesticCountryMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">76,925,380</ix:nonFraction></p>
</td>
<td style="padding-bottom: 1pt; width: 1%; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
</tr>
<tr>
<td style="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Total</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="border-bottom: black 2pt double; vertical-align: bottom">
<p id="xdx_986_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_c20190101__20191231_zA2uptl6PhHa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="From2019-01-01to2019-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">176,144,999</ix:nonFraction></p>
</td>
<td style="padding-bottom: 2pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="border-bottom: black 2pt double; vertical-align: bottom">
<p id="xdx_982_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_c20180101__20181231_zAAncojzdhd4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">132,617,160</ix:nonFraction></p>
</td>
<td style="padding-bottom: 2pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="border-bottom: black 2pt double; vertical-align: bottom">
<p id="xdx_988_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_c20170101__20171231_zH3ExzahCWS5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="From2017-01-012017-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">76,925,380</ix:nonFraction></p>
</td>
<td style="padding-bottom: 2pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
</tr>

</table>
</ix:nonNumeric><p id="xdx_8AE_zhvkruLPKWMe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black; background-color: white">For the years ended December 31, 2019, 2018, and 2017, there was no provision for income taxes, current or deferred. At December 31, 2019, we had a federal net operating loss carry forward of approximately $<span id="xdx_90F_eus-gaap--OperatingLossCarryforwards_iI_c20191231__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--InternalRevenueServiceIRSMember_z8l9AyTYnsX3" title="Net operating loss carry forward"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2019-12-31_us-gaap_InternalRevenueServiceIRSMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">620,354,163</ix:nonFraction></span>. Approximately $<span id="xdx_903_eus-gaap--OperatingLossCarryforwards_iI_c20191231__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--InternalRevenueServiceIRSMember__us-gaap--TaxPeriodAxis__custom--ExpirationPeriod20YearsMember_zSB1hNG2rK4b"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2019-12-31_us-gaap_InternalRevenueServiceIRSMember_custom_ExpirationPeriod20YearsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">338,775,332</ix:nonFraction></span> of the federal net operating loss carry forward can be carried forward for <span id="xdx_90F_ecustom--NolCarryForwardPeriod_dt_c20190101__20191231__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--InternalRevenueServiceIRSMember__us-gaap--TaxPeriodAxis__custom--ExpirationPeriod20YearsMember_z7jOQqaAF0S8" title="NOL carry forward period"><ix:nonNumeric contextRef="From2019-01-012019-12-31_us-gaap_InternalRevenueServiceIRSMember_custom_ExpirationPeriod20YearsMember" format="ixt-sec:durwordsen" name="txmd:NolCarryForwardPeriod">20 years</ix:nonNumeric></span> and will begin to expire in <span id="xdx_90F_ecustom--OperatingLossCarryforwardsExpirationYear_c20190101__20191231__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--InternalRevenueServiceIRSMember__us-gaap--TaxPeriodAxis__custom--ExpirationPeriod20YearsMember_zABw0O4Z2etk" title="NOL carry forward expiration year"><ix:nonNumeric contextRef="From2019-01-012019-12-31_us-gaap_InternalRevenueServiceIRSMember_custom_ExpirationPeriod20YearsMember" name="txmd:OperatingLossCarryforwardsExpirationYear">2031</ix:nonNumeric></span>.&#160; The remaining $<span id="xdx_90A_eus-gaap--OperatingLossCarryforwards_iI_c20191231__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--InternalRevenueServiceIRSMember__us-gaap--TaxPeriodAxis__custom--ExpirationPeriodIndefiniteMember_zVwMshszB345"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2019-12-31_us-gaap_InternalRevenueServiceIRSMember_custom_ExpirationPeriodIndefiniteMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">281,578,831</ix:nonFraction></span> can be carried forward indefinitely.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<ix:nonNumeric contextRef="From2019-01-01to2019-12-31" escape="true" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"><p id="xdx_89F_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zoefKqWPnWmd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">A reconciliation between taxes computed at the federal statutory rate and the consolidated effective tax rate is as follows: </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellspacing="0" cellpadding="0" style="margin-right: auto; margin-left: auto; float: none; width: 90%">

<tr>
<td style="padding: 0pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td id="xdx_49B_20190101__20191231_zdXEdo8l0Qa5" colspan="2" style="border-bottom: black 1pt solid; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2019</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td id="xdx_49A_20180101__20181231_zx7mVGnraWRd" colspan="2" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2018</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td id="xdx_49A_20170101__20171231_ztGnIkT0Ayyf" colspan="2" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2017</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr id="xdx_40E_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_matax_zWW9DKxQYQX9" style="background-color: #cceeff">
<td style="padding: 0pt; width: 55%; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Federal statutory tax rate</p>
</td>
<td style="width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 10%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2019-01-01to2019-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21.0</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom; width: 3%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">%</p>
</td>
<td style="width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 10%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21.0</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom; width: 3%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">%</p>
</td>
<td style="width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 10%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2017-01-012017-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">34.0</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom; width: 3%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">%</p>
</td>
</tr>
<tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_matax_z9UZ52KqppS6">
<td style="padding: 0pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">State tax rate, net of federal tax benefit</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2019-01-01to2019-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.0</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">%</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5.2</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">%</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2017-01-012017-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5.0</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">%</p>
</td>
</tr>
<tr id="xdx_40E_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_matax_zMXUfxWLY9Yg" style="background-color: #cceeff">
<td style="padding: 0pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Adjustment in valuation allowances</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2019-01-01to2019-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">22.5</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)%</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">31.2</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)%</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2017-01-012017-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">22.6</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">%</p>
</td>
</tr>
<tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_dp_matax_zi11CB4dc9Q4">
<td style="padding: 0pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Excess stock benefits</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" contextRef="From2019-01-01to2019-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.2</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">%</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5.3</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">%</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1220">&#8212;</span></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">%</p>
</td>
</tr>
<tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_dp_matax_z8hJGHsZqqnf" style="background-color: #cceeff">
<td style="padding: 0pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Federal income tax rate change</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" contextRef="From2019-01-01to2019-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">%</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1223">&#8212;</span></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">%</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" contextRef="From2017-01-012017-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">60.8</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)%</p>
</td>
</tr>
<tr id="xdx_40C_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_dp_matax_zltD2WQnmse2">
<td style="padding: 0pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Permanent and other differences</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="From2019-01-01to2019-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">2.7</ix:nonFraction></p>
</td>
<td style="padding-bottom: 1pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)%</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">0.3</ix:nonFraction></p>
</td>
<td style="padding-bottom: 1pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)%</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="From2017-01-012017-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">0.8</ix:nonFraction></p>
</td>
<td style="padding-bottom: 1pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)%</p>
</td>
</tr>
<tr id="xdx_40C_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_dp0_mttax_zOznacZATEnc" style="background-color: #cceeff">
<td style="padding: 0pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Provision (benefit) for income taxes</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2019-01-01to2019-12-31" format="ixt:zerodash" decimals="INF" scale="-2" unitRef="Pure">&#8212;</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2018-01-012018-12-31" format="ixt:zerodash" decimals="INF" scale="-2" unitRef="Pure">&#8212;</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2017-01-012017-12-31" format="ixt:zerodash" decimals="INF" scale="-2" unitRef="Pure">&#8212;</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>

</table>
</ix:nonNumeric><p id="xdx_8AE_zVKLUAFWiqjf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<ix:exclude><!-- Field: Page; Sequence: 99; Value: 3 -->
    <div id="xdx_234_ztxSzDTq6cX4" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_234_zAx4aNEtIY2k" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div>
    <div id="xdx_23B_zQqCNz8hFEtd" style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>
<ix:exclude><p id="xdx_235_zKQbeMmtewB9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></ix:exclude>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">Deferred income taxes result from temporary differences between the amount of assets and liabilities recognized for financial reporting and tax purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">&#160;</span></p>

<ix:nonNumeric contextRef="From2019-01-01to2019-12-31" escape="true" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><p id="xdx_89A_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zw9h4532cjri" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">The components of the net deferred income tax asset as of December 31, 2019, 2018, and 2017 are as follows:</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellspacing="0" cellpadding="0" style="margin-right: auto; margin-left: auto; float: none; width: 90%">

<tr>
<td style="padding: 0pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td id="xdx_492_20191231_zHBuwuSiDfbg" colspan="2" style="border-bottom: black 1pt solid; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2019</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td id="xdx_49A_20181231_zYKgdQSBRIp5" colspan="2" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2018</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td id="xdx_493_20171231_z7FXwxCHEeCg" colspan="2" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2017</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr id="xdx_409_eus-gaap--DeferredTaxAssetsNetAbstract_iB_zLYeykKKz84c">
<td style="padding: 0pt; width: 55%; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Deferred Income Tax Assets:</p>
</td>
<td style="width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 12%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 12%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 12%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_406_eus-gaap--DeferredTaxAssetsOtherLossCarryforwards_i01I_maDTAGz9uv_za087dA6m2l5" style="background-color: #cceeff">
<td style="padding: 0pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 16px">Net operating losses</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOtherLossCarryforwards" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">180,520,709</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOtherLossCarryforwards" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">140,891,764</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOtherLossCarryforwards" contextRef="AsOf2017-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">99,596,321</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_40A_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_i01I_maDTAGz9uv_zESHYbMQgsW4">
<td style="padding: 0pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 16px">R&#38;D Credit</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">186,347</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">186,347</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="AsOf2017-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">186,347</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_408_eus-gaap--DeferredTaxAssetsGross_i01TI_mtDTAGz9uv_maDTANzNCq_zpGMbiJ1dNX5" style="background-color: #cceeff">
<td style="padding: 0pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 16px">Total deferred income tax asset</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">180,707,056</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">141,078,111</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2017-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">99,782,668</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_40B_eus-gaap--DeferredTaxAssetsValuationAllowance_i01NI_di_msDTANzNCq_zBSejEMW9Ygf">
<td style="padding: 0pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 16px">Valuation allowance</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">180,707,056</ix:nonFraction></p>
</td>
<td style="padding-bottom: 1pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">141,078,111</ix:nonFraction></p>
</td>
<td style="padding-bottom: 1pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2017-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">99,782,668</ix:nonFraction></p>
</td>
<td style="padding-bottom: 1pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
</tr>
<tr id="xdx_40B_eus-gaap--DeferredTaxAssetsNet_i01TI_d0_mtDTANzNCq_zkFTcoIvc2gh" style="background-color: #cceeff">
<td style="padding: 0pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Deferred income tax assets, net</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2019-12-31" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2018-12-31" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2017-12-31" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>

</table>
</ix:nonNumeric><p id="xdx_8AE_zrUihzAMpL77" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">We believe that it is more likely than not that we will not generate sufficient future taxable income to realize the tax benefits related to the deferred tax assets on our balance sheet and as such, a valuation allowance has been established against the deferred tax assets for the period ended December 31, 2019.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black"><i><span style="color: black">Unrecognized Tax Benefits</span></i></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">As of the period ended December 31, 2019, we have no unrecognized tax benefits.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">On December 22, 2017, the U.S. federal government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act, or the Tax Act. The Tax Act makes broad and complex changes to the U.S. federal tax code, including, but not limited to reducing the U.S. federal corporate tax rate from <span id="xdx_90E_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_c20170101__20171231_zKlQ7fsuZXhb" title="Federal statutory tax rate"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2017-01-012017-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">34</ix:nonFraction></span> percent to <span id="xdx_90E_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_c20180101__20181231_zy9HW51Z2pw7"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21</ix:nonFraction></span> percent, effective January 1, 2018. As the result of our initial analysis of the impact of the Tax Act, we recorded a provisional amount of net tax expense of $<span id="xdx_900_eus-gaap--TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalIncomeTaxExpenseBenefit_dm_c20170101__20171231_zJ5V3RumQlxh" title="Tax Cuts and Jobs Act, provisional net tax expense"><ix:nonFraction name="us-gaap:TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalIncomeTaxExpenseBenefit" contextRef="From2017-01-012017-12-31" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">46.7</ix:nonFraction> million</span> in 2017 related to the remeasurement of our deferred tax balances and other effects. We completed our accounting for the income tax effects of the Tax Act in 2018, and no material adjustments were required to the provisional amounts initially recorded.</span></p>
</ix:nonNumeric><p id="xdx_816_zlWgm0bCiqA8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<ix:nonNumeric contextRef="From2019-01-01to2019-12-31" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p id="xdx_804_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zgie4KeD5Cpb" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><b><span style="text-decoration: underline"><span style="color: black"><b>NOTE 11 &#8211; <span id="xdx_826_zjDJXeBkIIZa">RELATED PARTIES</span></b></span></span></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: #212529; background-color: white">In July 2015, J. Martin Carroll, a director of our company, was appointed to the board of directors of Catalent, Inc. From time to time, we have entered into agreements with Catalent, Inc. and its affiliates, or Catalent, in the normal course of business. Agreements with Catalent have been reviewed by independent directors of our Company, or a committee consisting of independent directors of our company, since July 2015. During the years ended December 31, 2019, 2018 and 2017, we were billed by Catalent approximately $<span id="xdx_908_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20190101__20191231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--AffiliatedEntityMember_zKi3t8phY5Nb" title="Amount billed"><ix:nonFraction name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" contextRef="From2019-01-012019-12-31_srt_AffiliatedEntityMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,101,000</ix:nonFraction></span>, <span style="background-color: white">$</span><span id="xdx_904_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20180101__20181231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--AffiliatedEntityMember_zqPDCCoK5juk"><ix:nonFraction name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" contextRef="From2018-01-012018-12-31_srt_AffiliatedEntityMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,111,000</ix:nonFraction></span> and $<span id="xdx_90C_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20170101__20171231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--AffiliatedEntityMember_zfStqqRfrYNg"><ix:nonFraction name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" contextRef="From2017-01-012017-12-31_srt_AffiliatedEntityMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,646,000</ix:nonFraction></span><span style="background-color: white">, respectively, for manufacturing activities related to our clinical trials, scale-up, registration batches, stability and validation testing.&#160; As of December 31, 2019 and 2018, there were amounts due to Catalent of approximately $</span><span id="xdx_906_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_c20191231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--AffiliatedEntityMember_zKzmEpKGPUv2" title="Amounts due to related party"><ix:nonFraction name="us-gaap:AccountsPayableRelatedPartiesCurrent" contextRef="AsOf2019-12-31_srt_AffiliatedEntityMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">35,000</ix:nonFraction></span><span style="background-color: white"> and $</span><span id="xdx_902_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_c20181231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--AffiliatedEntityMember_z9yX0r34phrf"><ix:nonFraction name="us-gaap:AccountsPayableRelatedPartiesCurrent" contextRef="AsOf2018-12-31_srt_AffiliatedEntityMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">88,000</ix:nonFraction></span><span style="background-color: white">, respectively. In addition, we have minimum purchase requirements in place with Catalent as disclosed in Note 13, Commitments and Contingencies.</span></span></p>
</ix:nonNumeric><p id="xdx_81F_z99suYLtqBI7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<ix:nonNumeric contextRef="From2019-01-01to2019-12-31" escape="true" name="us-gaap:ConcentrationRiskDisclosureTextBlock"><p id="xdx_804_eus-gaap--ConcentrationRiskDisclosureTextBlock_ztnMgYnmrbt1" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><b><span style="text-decoration: underline"><span style="color: black"><b>NOTE
12 &#8211; <span id="xdx_823_zIV8oz54AaXc">BUSINESS CONCENTRATIONS</span></b></span></span></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">We purchase our prescription products from several suppliers with approximately <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20190101__20191231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_z4ACyvGjFMlg"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2019-01-012019-12-31_us-gaap_SupplierConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">24</ix:nonFraction></span>%, <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20190101__20191231__us-gaap--ConcentrationRiskByTypeAxis__custom--SupplierTwoConcentrationRiskMember_z5oVDkWgDQn1"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2019-01-012019-12-31_custom_SupplierTwoConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">27</ix:nonFraction></span>% and <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20190101__20191231__us-gaap--ConcentrationRiskByTypeAxis__custom--SupplierThreeConcentrationRiskMember_zv7GggoSt8Nh"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2019-01-012019-12-31_custom_SupplierThreeConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">35</ix:nonFraction></span>% of our purchases supplied by <span id="xdx_90C_ecustom--NumberOfVendors_dc_uPure_c20190101__20191231_z41LJnJ0NjX8" title="Number of vendors - suppliers"><ix:nonFraction name="txmd:NumberOfVendors" contextRef="From2019-01-01to2019-12-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Pure">three</ix:nonFraction></span> vendors each, respectively, during the year ended December 31, 2019, <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20180101__20181231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_z8oAQnqHYkZ1"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2018-01-012018-12-31_us-gaap_SupplierConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">43</ix:nonFraction></span>%, <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20180101__20181231__us-gaap--ConcentrationRiskByTypeAxis__custom--SupplierTwoConcentrationRiskMember_zJ4hU7XGgkK1"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2018-01-012018-12-31_custom_SupplierTwoConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">33</ix:nonFraction></span>% and <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20180101__20181231__us-gaap--ConcentrationRiskByTypeAxis__custom--SupplierThreeConcentrationRiskMember_zjhDFKrG2zmk"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2018-01-012018-12-31_custom_SupplierThreeConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">24</ix:nonFraction></span>% of our purchases supplied by <span id="xdx_90D_ecustom--NumberOfVendors_dc_uPure_c20180101__20181231_zumjp0mpdYwa"><ix:nonFraction name="txmd:NumberOfVendors" contextRef="From2018-01-012018-12-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Pure">three</ix:nonFraction></span> vendors each, respectively, during the year ended December 31, 2018, and <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20170101__20171231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zNSnALCZBzvi" title="Concentration risk"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2017-01-012017-12-31_us-gaap_SupplierConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span>% of our purchases supplied by <span id="xdx_907_ecustom--NumberOfVendors_dc_uPure_c20170101__20171231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zaY3nRzejjhe"><ix:nonFraction name="txmd:NumberOfVendors" contextRef="From2017-01-012017-12-31_us-gaap_SupplierConcentrationRiskMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Pure">one</ix:nonFraction></span> vendor for the year ended December 31, 2017.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">We sell our prescription products to wholesale distributors, specialty pharmacies, specialty distributors, and chain drug stores that generally sell products to retail pharmacies, hospitals, and other institutional customers. During each of the years ended December 31, 2019, 2018 and 2017, <span id="xdx_90F_ecustom--NumberOfCustomers_dc_uPure_c20190101__20191231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z1X1VboSYu6h" title="Number of customers - revenue"><span id="xdx_90A_ecustom--NumberOfCustomers_dc_uPure_c20180101__20181231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zi7PzsIWif4c" title="Number of customers - revenue"><span id="xdx_906_ecustom--NumberOfCustomers_dc_uPure_c20170101__20171231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zGcfmoUvIDsk" title="Number of customers - revenue"><ix:nonFraction name="txmd:NumberOfCustomers" contextRef="From2019-01-012019-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Pure"><ix:nonFraction name="txmd:NumberOfCustomers" contextRef="From2018-01-012018-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Pure"><ix:nonFraction name="txmd:NumberOfCustomers" contextRef="From2017-01-012017-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Pure">four</ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span> customers each accounted for more than <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20190101__20191231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zM8332bQqgaf" title="Concentration risk"><span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_dp_c20180101__20181231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zATBihi25Tvd" title="Concentration risk"><span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_c20170101__20171231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zeeZfSn6OJTl" title="Concentration risk"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2019-01-012019-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2018-01-012018-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2017-01-012017-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span>% of our total prescription revenues. Prescription revenue from the four customers combined accounted for approximately <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_c20190101__20191231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--FourCustomersConcentrationRiskMember_zruN4QGI5ak2" title="Concentration risk"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2019-01-012019-12-31_us-gaap_SalesRevenueNetMember_custom_FourCustomersConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">73</ix:nonFraction></span>%, <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20180101__20181231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--FourCustomersConcentrationRiskMember_z8MeQGtPnKQa"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2018-01-012018-12-31_us-gaap_SalesRevenueNetMember_custom_FourCustomersConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">76</ix:nonFraction></span>%, and <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_c20170101__20171231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--FourCustomersConcentrationRiskMember_zzPbH3qgXd03"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2017-01-012017-12-31_us-gaap_SalesRevenueNetMember_custom_FourCustomersConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">59</ix:nonFraction></span>% of our prescription revenue for the years ended December 31, 2019, 2018 and 2017, respectively.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">During the year ended December 31, 2019, McKesson Corporation accounted for approximately $<span id="xdx_905_eus-gaap--Revenues_c20190101__20191231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationMcKessonCorporationRiskMember_zPhuxuhWrRhf" title="Revenues"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2019-01-012019-12-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationMcKessonCorporationRiskMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,911,000</ix:nonFraction></span> of our prescription revenue, Pillpack, Inc. accounted for approximately $<span id="xdx_90A_eus-gaap--Revenues_c20190101__20191231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationPillPackRiskMember_zPOwABWNHa3g"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2019-01-012019-12-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationPillPackRiskMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,676,000</ix:nonFraction></span> of our prescription revenue, AmerisourceBergen accounted for approximately $<span id="xdx_906_eus-gaap--Revenues_c20190101__20191231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationAmerisourceBergenRiskMember_zsmOBn6Tv5Hh"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2019-01-012019-12-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationAmerisourceBergenRiskMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,927,000</ix:nonFraction></span> of our prescription revenue and Cardinal Health accounted for approximately $<span id="xdx_904_eus-gaap--Revenues_c20190101__20191231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationCardinalHealthRiskMember_zPrNCg3EbDrd"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2019-01-012019-12-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationCardinalHealthRiskMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,551,000</ix:nonFraction></span> of our prescription revenue.&#160; During the year ended December 31, 2018, McKesson Corporation accounted for approximately $<span id="xdx_903_eus-gaap--Revenues_c20180101__20181231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationMcKessonCorporationRiskMember_zy9iziJlFeC8"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2018-01-012018-12-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationMcKessonCorporationRiskMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,610,000</ix:nonFraction></span> of our prescription revenue, Pillpack, Inc. accounted for approximately $<span id="xdx_90F_eus-gaap--Revenues_c20180101__20181231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationPillPackRiskMember_zEue5CDdiVt2"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2018-01-012018-12-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationPillPackRiskMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,075,000</ix:nonFraction></span> of our prescription revenue, AmerisourceBergen accounted for approximately $<span id="xdx_905_eus-gaap--Revenues_c20180101__20181231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationAmerisourceBergenRiskMember_zdhm7OySa9Ra"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2018-01-012018-12-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationAmerisourceBergenRiskMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,246,000</ix:nonFraction></span> of our prescription revenue and Cardinal Health accounted for approximately $<span id="xdx_902_eus-gaap--Revenues_c20180101__20181231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationCardinalHealthRiskMember_zQoUJjkaWr4b"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2018-01-012018-12-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationCardinalHealthRiskMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,308,000</ix:nonFraction></span> of our prescription revenue. During the year ended December 31, 2017, AmerisourceBergen accounted for approximately $<span id="xdx_907_eus-gaap--Revenues_c20170101__20171231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationAmerisourceBergenRiskMember_zBdhMO7IGyYh"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2017-01-012017-12-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationAmerisourceBergenRiskMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,667,000</ix:nonFraction></span> of our prescription revenue; McKesson Corporation accounted for approximately $<span id="xdx_901_eus-gaap--Revenues_c20170101__20171231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationMcKessonCorporationRiskMember_zYFac21scak2"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2017-01-012017-12-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationMcKessonCorporationRiskMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,959,000</ix:nonFraction></span> of our prescription revenue; Cardinal Health accounted for approximately $<span id="xdx_90C_eus-gaap--Revenues_c20170101__20171231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationCardinalHealthRiskMember_zkhPsGnM1J13"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2017-01-012017-12-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationCardinalHealthRiskMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,559,000</ix:nonFraction></span> of our prescription revenue and Pharmacy Innovations PA accounted for approximately $<span id="xdx_90B_eus-gaap--Revenues_c20170101__20171231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationPharmacyInnovationsPaRiskMember_zsXZhx6YsbLc"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2017-01-012017-12-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationPharmacyInnovationsPaRiskMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,715,000</ix:nonFraction></span> of our prescription revenue. </span></p>
</ix:nonNumeric><p id="xdx_81A_zfXLOmEQmWRd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<!-- Field: Page; Sequence: 100; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<ix:nonNumeric contextRef="From2019-01-01to2019-12-31" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_80A_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zhJAHfjpgEEi" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><b><span style="text-decoration: underline"><span style="color: black"><b>NOTE 13 &#8211; <span id="xdx_82A_zcIGsXKuPa46">COMMITMENTS AND CONTINGENCIES</span></b></span></span></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: black"><span style="text-decoration: underline"><span style="color: black">Operating Leases</span></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: #212529">We adopted ASC 842 effective January 1, 2019. Substantially all our operating lease right-of-use assets and operating lease liabilities represent leases for office space used to conduct our business. Upon adoption, we recognized a right-of-use asset and a lease liability for all leases that have commenced as of January 1, 2019. The right-of-use assets represent the right to use the leased asset for the lease term. The lease liabilities represent the present value of the lease payments under the lease. The right-of-use asset is initially measured at cost, which primarily comprises the initial amount of the lease liability, plus any initial direct costs incurred, less any lease incentives received. All right-of-use assets are reviewed for impairment. The lease liability is initially measured at the present value of the lease payments, discounted using our secured incremental borrowing rate for the same term as the underlying lease because the rates are not implicit in the leases. Some of our leases contain variable lease payments, including payments based on an index or rate. Variable lease payments based on an index or rate are initially measured using the index or rate in effect at lease commencement. Additional payments based on the change in an index or rate, or payments based on a change in our portion of the operating expenses are recorded as a period expense when incurred. Lease modifications result in remeasurement of the lease liability. Included in lease expense are any variable lease payments incurred in the period that were not included in the initial lease liability.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: #212529">We lease administrative office space in Boca Raton, Florida pursuant to a non-cancelable operating lease that commenced on July 1, 2013 and originally provided for a <span id="xdx_90E_ecustom--CapitalLeaseObligationsTerm_dtM_c20130630__20130701_zdVg4IsOI4U9" title="Non-cancelable operating lease term"><ix:nonNumeric contextRef="From2013-06-302013-07-01" format="ixt-sec:durmonth" name="txmd:CapitalLeaseObligationsTerm">63</ix:nonNumeric></span>-month term. On February 18, 2015, we entered into an agreement with the same lessors to lease additional administrative office space in the same location, pursuant to an addendum to such lease. In addition, on April 26, 2016, we entered into an agreement with the same lessors to lease additional administrative office space in the same location. This agreement was effective beginning May 1, 2016 and extended the original expiration of the lease term to October 31, 2021. On October 4, 2016, we entered into an agreement with the same lessors to lease additional administrative office space in the same location, pursuant to an addendum to such lease. This addendum became effective beginning November 1, 2016.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: #212529">In October 2018, we entered into a lease for new corporate offices in Boca Raton, Florida. The lease includes <span id="xdx_90F_ecustom--NetRentableAreaLease_iI_usqft_c20181002_zNtE8ApWI0tg" title="Net rentable area"><ix:nonFraction name="txmd:NetRentableAreaLease" contextRef="AsOf2018-10-02" format="ixt:numdotdecimal" decimals="INF" unitRef="sqft">56,212</ix:nonFraction></span> rentable square feet, or the full premises, of which the lease on <span id="xdx_90C_ecustom--RentedAreaLease_iI_usqft_c20181002_zAHNPk4lOrF2" title="Rented area lease"><ix:nonFraction name="txmd:RentedAreaLease" contextRef="AsOf2018-10-02" format="ixt:numdotdecimal" decimals="INF" unitRef="sqft">7,561</ix:nonFraction></span> square feet commenced in 2018 and the lease on the remaining <span id="xdx_907_ecustom--AdditionalAreaOfLeaseOccupied_iI_usqft_c20190801_zKJzAhT76tnj" title="Additional area of lease occupied"><ix:nonFraction name="txmd:AdditionalAreaOfLeaseOccupied" contextRef="AsOf2019-08-01" format="ixt:numdotdecimal" decimals="INF" unitRef="sqft">48,651</ix:nonFraction></span> square feet commenced in August 2019, or the full premises commencement date. The lease will expire <span id="xdx_902_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dt_c20190801_zCw6gyvl9XJ5"><ix:nonNumeric contextRef="AsOf2019-08-01" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseTermOfContract">11 years</ix:nonNumeric></span> after the full premises commencement date, unless terminated earlier in accordance with the terms of the lease. We have the option to extend the term of the lease for <span id="xdx_908_ecustom--LesseeFinanceLeaseExistenceOfOptionToExtendNumber_dc_uPure_c20190101__20191231_zfGD4K7SGNJg" title="Number of options to extend lease"><ix:nonFraction name="txmd:LesseeFinanceLeaseExistenceOfOptionToExtendNumber" contextRef="From2019-01-01to2019-12-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Pure">two</ix:nonFraction></span> additional consecutive periods of <span id="xdx_907_eus-gaap--LesseeFinanceLeaseRenewalTerm1_iI_dt_c20191231_z1H6WTPH41m4" title="Lease renewal term"><ix:nonNumeric contextRef="AsOf2019-12-31" format="ixt-sec:durwordsen" name="us-gaap:LesseeFinanceLeaseRenewalTerm1">five years</ix:nonNumeric></span>. The extension option is not included in the determination of the lease term as it is not reasonably certain to be exercised. The term of the lease includes escalating rent and free rent periods. We are also responsible for certain other operating costs under the lease, including electricity and utility expenses. In June 2019, we entered into an agreement with the same lessors to lease additional <span id="xdx_905_ecustom--LesseeOperatingLeaseLeaseNotYetCommencedArea_iI_usqft_c20190601_zVHqmxRLq306" title="Lease not yet commenced (area)"><ix:nonFraction name="txmd:LesseeOperatingLeaseLeaseNotYetCommencedArea" contextRef="AsOf2019-06-01" format="ixt:numdotdecimal" decimals="INF" unitRef="sqft">6,536</ix:nonFraction></span> square feet of administrative office space in the same location, pursuant to an addendum to such lease, which is expected to commence as soon as the first quarter of 2020.</span></p>
<ix:nonNumeric contextRef="From2019-01-01to2019-12-31" escape="true" name="txmd:ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock"><p id="xdx_897_ecustom--ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock_z48rBQgEI9Lj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellspacing="0" cellpadding="0" style="margin-right: auto; margin-left: auto; float: none; width: 80%">

<tr>
<td style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><span id="xdx_8BC_zTCvqPmJs8xf">Supplemental lease information</span> at December 31, 2019</b></p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td colspan="2" style="vertical-align: top">&#160;</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; width: 85%; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Right-of-use asset</p>
</td>
<td style="width: 1%">
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 12%">
<p id="xdx_984_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20191231_z8a7pYazUhbk" title="Right-of-use asset" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,109,154</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Short-term operating lease liability (included in Other current liabilities)</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_985_eus-gaap--OperatingLeaseLiabilityCurrent_iI_c20191231_zERKcgVqrAr9" title="Short-term operating lease liability (included in Other current liabilities)" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,501,539</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Long-term operating lease liability</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_98D_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_c20191231_zjW5hGBbmrn3" title="Long-term operating lease liability" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,145,049</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Weighted average remaining term</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_987_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dt_c20191231_zbwYMEXG2Mhg" title="Weighted average remaining term" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonNumeric contextRef="AsOf2019-12-31" format="ixt-sec:durwordsen" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">9 Years</ix:nonNumeric></p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Weighted average discount rate</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_987_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20191231_zSn2Lds4H9O3" title="Weighted average discount rate" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8.25</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">%</p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellspacing="0" cellpadding="0" style="margin-right: auto; margin-left: auto; float: none; width: 80%">

<tr>
<td style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Supplemental cash flow information for the year ended</b><br />
<b>December 31, 2019</b></p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td colspan="2" style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; width: 85%; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Cash paid for amounts included in the measurement of lease liabilities for operating lease</p>
</td>
<td style="width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 12%">
<p id="xdx_989_eus-gaap--OperatingLeasePayments_c20190101__20191231_zSvPYRerMxW8" title="Cash paid for amounts included in the measurement of lease liabilities for operating lease" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2019-01-01to2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,164,234</ix:nonFraction></span></p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Right-of-use assets obtained in exchange for lease obligation</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_982_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_c20190101__20191231_z7S1xqMVFat6" title="Right-of-use assets obtained in exchange for lease obligation" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="From2019-01-01to2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,171,471</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>

</table>
</ix:nonNumeric><p id="xdx_8AE_zl1S0NCrW1T1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<ix:exclude><!-- Field: Page; Sequence: 101; Value: 3 -->
    <div id="xdx_23C_zKFGKIFNfpli" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_23F_zh7sXszKDiW7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div>
    <div id="xdx_23C_zVfjjd0AinT9" style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>
<ix:exclude><p id="xdx_236_zT3kKyplqZP8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></ix:exclude>
<ix:nonNumeric contextRef="From2019-01-01to2019-12-31" escape="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock"><p id="xdx_895_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_z2GX5VLIpZ6e" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: #212529">The following table reconciles the undiscounted cash flows for all operating leases at December 31, 2019 to the operating lease liabilities recorded on the balance sheet:</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellspacing="0" cellpadding="0" style="margin-right: auto; margin-left: auto; float: none; width: 50%">

<tr>
<td style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>Years Ending December
31,</b></p>
</td>
<td><p style="margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" id="xdx_49A_20191231_zoZfKDWyM5Ni" style="vertical-align: top"><b>&#160;</b></td>
<td style="vertical-align: bottom"><p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPznhG_zCShR9Y0XsZ5" style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; width: 77%; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">2020</p>
</td>
<td style="width: 1%">
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 20%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,566,617</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPznhG_zpb6wZo9RsZ5">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">2021</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,198,541</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPznhG_zjgMVTsisXS9" style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">2022</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,262,302</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPznhG_zVUB6N03Ccyh">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">2023</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,293,859</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_maLOLLPznhG_zNj4npP2OcX6" style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">2024</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,326,206</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_maLOLLPznhG_zMsI9KHAuEv1">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Thereafter</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,036,931</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPznhG_zXKl3OVd0UV1" style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Total undiscounted lease payments</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,684,456</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zWmQOGk1qPQk">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Less: imputed interest</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,037,868</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
</tr>
<tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iI_zRqM9FEjWdl4" style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Present value of lease payments</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,646,588</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>

</table>
</ix:nonNumeric><p id="xdx_8AE_zEmzow5b22Q7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: #212529; background-color: white">During the year ended December 31, 2019, operating lease expense related to our real estate leases was $<span id="xdx_900_eus-gaap--OperatingLeaseExpense_c20190101__20191231_z4qcml6WorJ4" title="Operating lease expense"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2019-01-01to2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,558,794</ix:nonFraction></span><span style="background-color: white">, and variable lease expense was insignificant.&#160; </span><span style="color: black">The rental expense during the years ended December 31, 2018 and 2017 was $<span id="xdx_901_eus-gaap--LeaseAndRentalExpense_c20180101__20181231_zs2WHRxallCe" title="Rental expense"><ix:nonFraction name="us-gaap:LeaseAndRentalExpense" contextRef="From2018-01-012018-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,068,275</ix:nonFraction></span> and $<span id="xdx_90B_eus-gaap--LeaseAndRentalExpense_c20170101__20171231_zL5faYMzAg6d"><ix:nonFraction name="us-gaap:LeaseAndRentalExpense" contextRef="From2017-01-012017-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,029,205</ix:nonFraction></span>, respectively.</span></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: black"><span style="text-decoration: underline"><span style="color: black">Intellectual Property Licenses</span></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">The Population Council License Agreement provides for future milestone payments to be paid by us for access to certain technologies. In addition, we pay royalties as a percent of revenue as described in Note 6, Intangible Assets, to these consolidated financial statements.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: black"><span style="text-decoration: underline"><span style="color: black">Purchase Commitments</span></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: #212529; background-color: white">We
have manufacturing and supply agreements whereby we are required to purchase from Catalent a minimum number of
softgels during the first contract year and a higher number of softgels after the first contract year. If the minimum order
quantities of specific products are not met, we are required to pay Catalent <span id="xdx_90B_ecustom--SignificantSupplyCommitmentPercentagePayable_iI_dp_c20191231_zPWjHoUUPya8" title="Significant supply commitment percentage payable"><ix:nonFraction name="txmd:SignificantSupplyCommitmentPercentagePayable" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">50</ix:nonFraction></span>%
of the difference between the total amount we would have paid to Catalent if the minimum requirement had been fulfilled
and the sum of all purchases of our products from Catalent during the contract year. Minimum purchase commitments for
Catalent for the next five years are as follows: 2020 &#8211; $<span id="xdx_906_eus-gaap--RecordedUnconditionalPurchaseObligationDueWithinOneYear_iI_c20191231__us-gaap--RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis__custom--CatalentMember_zShCViTpvU7d" title="Minimum purchase commitment, 2020"><ix:nonFraction name="us-gaap:RecordedUnconditionalPurchaseObligationDueWithinOneYear" contextRef="AsOf2019-12-31_custom_CatalentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,650,853</ix:nonFraction></span>;
2021 &#8211; $<span id="xdx_904_eus-gaap--RecordedUnconditionalPurchaseObligationDueInSecondYear_iI_c20191231__us-gaap--RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis__custom--CatalentMember_z6U7SNDCL1Cj" title="Minimum purchase commitment, 2021"><ix:nonFraction name="us-gaap:RecordedUnconditionalPurchaseObligationDueInSecondYear" contextRef="AsOf2019-12-31_custom_CatalentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,000,035</ix:nonFraction></span>;
2022 &#8211; $<span id="xdx_900_eus-gaap--RecordedUnconditionalPurchaseObligationDueInThirdYear_iI_c20191231__us-gaap--RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis__custom--CatalentMember_zdAVDHPZdg33" title="Minimum purchase commitment, 2022"><ix:nonFraction name="us-gaap:RecordedUnconditionalPurchaseObligationDueInThirdYear" contextRef="AsOf2019-12-31_custom_CatalentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,643,291</ix:nonFraction></span>;
2023 &#8211; $<span id="xdx_90D_eus-gaap--RecordedUnconditionalPurchaseObligationDueInFourthYear_iI_c20191231__us-gaap--RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis__custom--CatalentMember_zAXPQP8fqCDh" title="Minimum purchase commitment, 2023"><ix:nonFraction name="us-gaap:RecordedUnconditionalPurchaseObligationDueInFourthYear" contextRef="AsOf2019-12-31_custom_CatalentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,445,301</ix:nonFraction></span>
and 2024 &#8211; $<span id="xdx_90D_eus-gaap--RecordedUnconditionalPurchaseObligationDueInFifthYear_iI_c20191231__us-gaap--RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis__custom--CatalentMember_zZAH1Pv4dl41" title="Minimum purchase commitment, 2024"><ix:nonFraction name="us-gaap:RecordedUnconditionalPurchaseObligationDueInFifthYear" contextRef="AsOf2019-12-31_custom_CatalentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,758,945</ix:nonFraction></span>.
In addition, we have a manufacturing and supply agreement whereby we are required to purchase a minimum number of units of
ANNOVERA during a contract year. The minimum purchase commitment for ANNOVERA for 2020 is approximately $<span id="xdx_904_eus-gaap--RecordedUnconditionalPurchaseObligationDueWithinOneYear_iI_c20191231__us-gaap--RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis__custom--AnnoveraMember_zmcDDsZ0PtD5"><ix:nonFraction name="us-gaap:RecordedUnconditionalPurchaseObligationDueWithinOneYear" contextRef="AsOf2019-12-31_custom_AnnoveraMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,049,750</ix:nonFraction></span>.
As of December 31, 2019, we have met our minimum purchase commitments with our manufacturers related to fiscal
year 2019.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: #212529; background-color: white">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: black"><span style="text-decoration: underline"><span style="color: black">Legal Proceedings</span></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">From time to time, we are involved in litigation and proceedings in the ordinary course of business. We are not currently involved in any legal proceeding that we believe would have a material effect on our consolidated financial condition, results of operations, or cash flows.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: black"><span style="text-decoration: underline"><span style="color: black">Off-Balance Sheet Arrangements</span></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">As of December 31, 2019, 2018, and 2017, we had no off-balance sheet arrangements that have had or are reasonably likely to have current or future effects on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: black"><span style="text-decoration: underline"><span style="color: black">Employment Agreements</span></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">We have entered into employment agreements with certain of our executives that provide for compensation and certain other benefits. Under certain circumstances, including a change in control, some of these agreements provide for severance or other payments, if those circumstances occur during the term of the employment agreement.</span></p>
</ix:nonNumeric><p id="xdx_81C_zAsNLkVQRsNi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<!-- Field: Page; Sequence: 102; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<ix:nonNumeric contextRef="From2019-01-01to2019-12-31" escape="true" name="us-gaap:QuarterlyFinancialInformationTextBlock"><p id="xdx_80C_eus-gaap--QuarterlyFinancialInformationTextBlock_zMrP0NpM9FIb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b><span style="text-decoration: underline"><b>NOTE 14 &#8211; <span id="xdx_82E_z2svtgrXJTu7">SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)</span></b></span></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<ix:nonNumeric contextRef="From2019-01-01to2019-12-31" escape="true" name="us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock"><p id="xdx_896_eus-gaap--ScheduleOfQuarterlyFinancialInformationTableTextBlock_zEn63kaxapc7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Summarized quarterly financial data for fiscal years 2019 and 2018 is as follows:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse: collapse; width: 100%; width: 100%">

<tr>
<td style="padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom">&#160;</td>
<td>&#160;</td>
<td style="vertical-align: top">&#160;</td>
<td id="xdx_497_20190101__20190331_zvWkYbBag85e" style="vertical-align: top">&#160;</td>
<td style="vertical-align: top">&#160;</td>
<td style="vertical-align: top">&#160;</td>
<td style="vertical-align: top">&#160;</td>
<td id="xdx_49C_20190401__20190630_zRMMfDXcFPna" style="vertical-align: top">&#160;</td>
<td style="vertical-align: top">&#160;</td>
<td style="vertical-align: top">&#160;</td>
<td style="vertical-align: top">&#160;</td>
<td id="xdx_49D_20190701__20190930_z4bm4UwCuShi" style="vertical-align: top">&#160;</td>
<td style="vertical-align: top">&#160;</td>
<td style="vertical-align: top">&#160;</td>
<td style="vertical-align: top">&#160;</td>
<td id="xdx_49D_20191001__20191231_zmCEIBgmbA5a" style="vertical-align: top">&#160;</td>
<td style="vertical-align: bottom; width: 1%">&#160;</td></tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="14" style="border-bottom: black 1pt solid; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2019</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><i>(In thousands,
except per share)</i></b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>First <br />Quarter</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-right: Black medium none; border-bottom: Black 1pt solid; border-left: Black medium none; padding: 0pt 5.4pt; width: 13%; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Second Quarter<sup>(1)</sup></b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-right: Black medium none; border-bottom: Black 1pt solid; border-left: Black medium none; padding: 0pt 5.4pt; width: 13%; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Third <br />Quarter<sup>(2)</sup></b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-right: Black medium none; border-bottom: Black 1pt solid; border-left: Black medium none; padding: 0pt 5.4pt; width: 13%; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Fourth Quarter</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr id="xdx_408_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zqinRDBQgOW3" style="background-color: #cceeff">
<td style="border-top: black 1pt solid; padding: 0pt 5.4pt; width: 40%; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Revenues</p>
</td>
<td style="width: 3%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 10%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2019-01-012019-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,947</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 3%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 10%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2019-04-012019-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,079</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 3%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 10%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2019-07-012019-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">23,719</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 3%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 10%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2019-10-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15,902</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_402_eus-gaap--GrossProfit_pn3n3_zBFlFQ2EDn5j">
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Gross profit</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2019-01-012019-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,184</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2019-04-012019-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,830</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2019-07-012019-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">22,275</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2019-10-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">13,023</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_40D_eus-gaap--NetIncomeLoss_pn3n3_zdUt4Odpg7nj" style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Net loss</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-01-012019-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">39,506</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-04-012019-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">55,237</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-07-012019-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">31,967</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-10-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">49,435</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_40E_eus-gaap--EarningsPerShareBasicAndDiluted_zrq0GfU2BD15" style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Loss per common share, basic and diluted</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="From2019-01-012019-03-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.16</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="From2019-04-012019-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.23</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="From2019-07-012019-09-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.13</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="From2019-10-012019-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.19</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse: collapse; width: 100%; width: 100%">

<tr>
<td style="padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom">&#160;</td>
<td>&#160;</td>
<td style="vertical-align: top">&#160;</td>
<td id="xdx_49A_20180101__20180331_zxU5UFNBPt84" style="vertical-align: top">&#160;</td>
<td style="vertical-align: top">&#160;</td>
<td style="vertical-align: top">&#160;</td>
<td style="vertical-align: top">&#160;</td>
<td id="xdx_492_20180401__20180630_zQ4tjR4tcunj" style="vertical-align: top">&#160;</td>
<td style="vertical-align: top">&#160;</td>
<td style="vertical-align: top">&#160;</td>
<td style="vertical-align: top">&#160;</td>
<td id="xdx_49D_20180701__20180930_zeEuUP8H4Ijj" style="vertical-align: top">&#160;</td>
<td style="vertical-align: top">&#160;</td>
<td style="vertical-align: top">&#160;</td>
<td style="vertical-align: top">&#160;</td>
<td id="xdx_49D_20181001__20181231_zMiJBlQwGAw8" style="vertical-align: top">&#160;</td>
<td style="vertical-align: bottom; width: 1%">&#160;</td></tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="14" style="border-bottom: black 1pt solid; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2018</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><i>(In thousands,
except per share)</i></b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>First <br />Quarter</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-right: Black medium none; border-bottom: Black 1pt solid; border-left: Black medium none; padding: 0pt 5.4pt; width: 13%; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Second Quarter</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-right: Black medium none; border-bottom: Black 1pt solid; border-left: Black medium none; padding: 0pt 5.4pt; width: 13%; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Third <br />Quarter</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-right: Black medium none; border-bottom: Black 1pt solid; border-left: Black medium none; padding: 0pt 5.4pt; width: 13%; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Fourth Quarter</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr id="xdx_408_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zOdIA16Nbnk8" style="background-color: #cceeff">
<td style="border-top: black 1pt solid; padding: 0pt 5.4pt; width: 40%; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Revenues</p>
</td>
<td style="width: 3%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 10%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2018-01-012018-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,773</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 3%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 10%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2018-04-012018-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,763</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 3%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 10%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2018-07-012018-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,474</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 3%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 10%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2018-10-012018-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,089</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_402_eus-gaap--GrossProfit_pn3n3_zwxv5YtJecw3">
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Gross profit</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2018-01-012018-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,139</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2018-04-012018-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,309</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2018-07-012018-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,775</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2018-10-012018-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,139</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_40D_eus-gaap--NetIncomeLoss_pn3n3_zI3UO2OHCzL1" style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Net loss</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2018-01-012018-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">24,402</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2018-04-012018-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">33,219</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2018-07-012018-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">35,605</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2018-10-012018-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">39,391</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_40E_eus-gaap--EarningsPerShareBasicAndDiluted_zHw2xdXE9Tfh" style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Loss per common share, basic and diluted</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="From2018-01-012018-03-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.11</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="From2018-04-012018-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.15</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="From2018-07-012018-09-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.16</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="From2018-10-012018-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.17</ix:nonFraction></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(1)</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">During the second quarter of 2019, we recorded $<span id="xdx_909_eus-gaap--GainsLossesOnExtinguishmentOfDebt_iN_pn3p0_dmi_c20190401__20190630_zxZ3LQ9oEMs4" title="Loss on extinguishment of debt"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2019-04-012019-06-30" format="ixt:numdotdecimal" decimals="-3" scale="6" sign="-" unitRef="USD">10.1</ix:nonFraction> million</span> in loss on extinguishment of debt related to the repayment of the Credit Agreement. Refer to discussion in Note 8-Debt.</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%; width: 100%">

<tr>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(2)</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">During the third quarter of 2019, we recorded $<span id="xdx_90A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_dm_c20190701__20190930__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember_zdrB7jeaTC48" title="Revenues"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2019-07-012019-09-30_custom_LicenseAgreementTheramexMember" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">15.5</ix:nonFraction> million</span> in license revenue related to the <span style="color: black">Theramex License Agreement</span>. Refer to discussion in Note 2-Summary of Significant Accounting Policies.</p>
</td>
</tr>

</table>
</ix:nonNumeric></ix:nonNumeric><p id="xdx_81D_zsRrWeAAZTT1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p id="xdx_8A9_zqKElXRSjqMd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<ix:nonNumeric contextRef="From2019-01-01to2019-12-31" escape="true" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_807_eus-gaap--SubsequentEventsTextBlock_z4Sms2OiHi83" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b><span style="text-decoration: underline"><b>NOTE 15 &#8211; <span id="xdx_822_zIc69mhC26cg">SUBSEQUENT EVENTS</span></b></span></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="color: #212529">On February 18, 2020, we received $<span id="xdx_906_eus-gaap--ProceedsFromLinesOfCredit_c20200216__20200218__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z4ARTyqNNAG5" title="Proceeds from Financing Agreement"><ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" contextRef="From2020-02-162020-02-18_custom_FinancingAgreementMember_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000,000</ix:nonFraction></span> under the Financing Agreement following our achievement of more than $<span id="xdx_901_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20191001__20191231__srt--ProductOrServiceAxis__custom--ImvexxyBijuvaAndAnnoveraMember__srt--RangeAxis__srt--MinimumMember_zrZC4J9F7YIi" title="Net revenue"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2019-10-012019-12-31_custom_ImvexxyBijuvaAndAnnoveraMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,000,000</ix:nonFraction></span> in net revenues from IMVEXXY, BIJUVA and ANNOVERA for the fourth quarter of 2019 (refer to discussion in Note 8-Debt).</span></p>

</ix:nonNumeric><p id="xdx_819_z6KhM8LVKEt" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="color: #212529">&#160;</span></p>
<!-- Field: Page; Sequence: 103; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div>
    <!-- Field: /Page -->


</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>2
<FILENAME>ex4-2.htm
<DESCRIPTION>DESCRIPTION OF SECURITIES OF THE COMPANY
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>
<div style="margin-bottom: 0; margin-top: 0; width: 100%;">
        <div style="border-bottom: Black 1pt solid; border-top: Black 2pt solid; font-size: 1pt;">&nbsp;</div>
    </div>
    <p style="margin: 0pt 0; text-align: left; font: 10pt Times New Roman,serif;"><a href="txmd-10k_123119.htm">TherapeuticsMD, Inc. 10-K</a></p>
    <p style="margin: 0pt 0; text-align: right; font: 10pt Times New Roman,serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: right; font: 10pt Times New Roman,serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>Exhibit 4.2</b></font>
    </p>
    <P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: left">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>DESCRIPTION OF THE REGISTRANT&rsquo;S SECURITIES
REGISTERED PURSUANT TO SECTION 12 <BR>
OF THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">As of December 31, 2019, the only class of securities of TherapeuticsMD,
Inc., a Nevada corporation (the &ldquo;Company&rdquo;), registered under Section 12 of the Securities Exchange Act of 1934, as
amended, is common stock, par value $0.001 per share (&ldquo;common stock&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><U>Overview</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">This section describes the general terms of the Company&rsquo;s
common stock. The Company&rsquo;s common stock and the rights of the holders of its common stock are subject to the applicable
provisions of the Nevada Private Corporation Code, which is referred to herein as &ldquo;Nevada law,&rdquo; the Company&rsquo;s
amended and restated articles of incorporation, as amended, the Company&rsquo;s bylaws, as amended, and the rights of the holders
of the Company&rsquo;s preferred stock, if any, as well as some of the terms of the Company&rsquo;s outstanding indebtedness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Under the Company&rsquo;s amended and restated articles of incorporation,
as amended, the Company has the authority to issue 350,000,000 shares of common stock, par value $0.001 per share. As of February
17, 2020, there were 271,526,176 shares of common stock outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The following description of the Company&rsquo;s common stock may
not be complete and is subject to, and qualified in its entirety by reference to, Nevada law and the actual terms and provisions
contained in the Company&rsquo;s amended and restated articles of incorporation and the Company&rsquo;s bylaws, each as amended
from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0"><B>Voting Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0">Each outstanding share of the Company&rsquo;s common stock
is entitled to one vote per share of record on all matters submitted to a vote of stockholders and to vote together as a single
class for the election of directors and in respect of other corporate matters. At a meeting of stockholders at which a quorum is
present, for all matters other than the election of directors, an affirmative vote of the majority of shares entitled to vote on
a matter and that are represented either in person or by proxy at a meeting of stockholders decides all questions, unless the matter
is one upon which a different vote is required by express provision of law or the Company&rsquo;s amended and restated articles
incorporation or the Company&rsquo;s bylaws, each as may be amended from time to time. Directors will be elected by a plurality
of the votes of the shares present at a meeting. Holders of shares of common stock do not have cumulative voting rights with respect
to the election of directors or any other matter. The Company has adopted a majority voting policy as part of its Corporate Governance
Guidelines. The majority voting policy is applicable solely to uncontested elections, which are those elections in which the number
of nominees for election is less than or equal to the number of directors to be elected. Under the majority voting policy, any
nominee for director who receives more &ldquo;withheld&rdquo; votes than &ldquo;for&rdquo; votes in an uncontested election must
submit a written offer to resign as director. Any such resignation will be reviewed by the Nominating and Corporate Governance
Committee and, within 90 days after the election, the independent members of the Company&rsquo;s board of directors will determine
whether to accept, reject or take other appropriate action with respect to, the resignation, in furtherance of the best interests
of the Company and its stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0"><B>Dividends</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0">Holders of the Company&rsquo;s common stock are entitled to
receive dividends or other distributions when, as and if declared by the Company&rsquo;s board of directors. The right of the Company&rsquo;s
board of directors to declare dividends, however, is subject to any rights of the holders of other classes of the Company&rsquo;s
capital stock, any indebtedness outstanding from time to time and the availability of sufficient funds, as determined under Nevada
law, to pay dividends.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0"><B>Preemptive Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0">The holders of the Company&rsquo;s common stock do not have
preemptive rights to purchase or subscribe for any of the Company&rsquo;s capital stock or other securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0"><B>Redemption</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0">Shares of the Company&rsquo;s common stock are not subject
to redemption by operation of a sinking fund or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; padding-top: 6pt; padding-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0"><B>Liquidation Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0">In the event of any liquidation, dissolution, or winding up
of the Company, subject to the rights, if any, of the holders of other classes of the Company&rsquo;s capital stock, the holders
of shares of the Company&rsquo;s common stock are entitled to receive any of the Company&rsquo;s assets available for distribution
to its stockholders ratably in proportion to the number of shares held by them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0"><B>Options and Other Stock-Based Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0">From time to time, the Company has issued and expect to continue
to issue options and other stock-based rights to various lenders, investors, consultants, employees, officers and directors of
the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0"><B>Listing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0">The Company&rsquo;s common stock is listed on the Nasdaq Global
Select Market of the Nasdaq Stock Market LLC under the symbol &ldquo;TXMD.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0"><B>Transfer Agent and Registrar</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0">The transfer agent and registrar for the Company&rsquo;s common
stock is Computershare Trust Company, N.A.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><U>Certain Provisions of Nevada Law and the Company&rsquo;s Articles
of Incorporation and Bylaws</U></B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The following paragraphs summarize certain provisions of Nevada
law and the Company&rsquo;s amended and restated articles of incorporation, as amended, and bylaws, as amended. The summary does
not purport to be complete and is subject to and qualified in its entirety by reference to Nevada law and to the Company&rsquo;s
amended and restated articles of incorporation, as amended, and bylaws, as amended, copies of which are on file with the Securities
and Exchange Commission as exhibits to reports previously filed by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>General</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Certain provisions of the Company&rsquo;s amended and restated articles
of incorporation, as amended, and bylaws, as amended, and Nevada law could make an acquisition of the Company by a third party,
a change in the Company&rsquo;s incumbent management, or a similar change in control more difficult, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD><FONT STYLE="font-size: 10pt">an acquisition of the Company by means of a tender or exchange offer;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD><FONT STYLE="font-size: 10pt">an acquisition of the Company by means of a proxy contest or otherwise; or</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD><FONT STYLE="font-size: 10pt">the removal of a majority or all of the Company&rsquo;s incumbent officers and directors.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">These provisions, which are summarized below, are likely to discourage
certain types of coercive takeover practices and inadequate takeover bids. These provisions are also designed to encourage persons
seeking to acquire control of the Company to first negotiate with the Company&rsquo;s board of directors. The Company believes
that these provisions help to protect its potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal
to acquire or restructure the Company, and that this benefit outweighs the potential disadvantages of discouraging such a proposal
because the Company&rsquo;s ability to negotiate with the proponent could result in an improvement of the terms of the proposal.
The existence of these provisions which are described below could limit the price that investors might otherwise pay in the future
for the Company&rsquo;s securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Articles of Incorporation and Bylaws</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="background-color: white"><I>Authorized But Unissued
Capital Stock.&nbsp;</I>The Company has shares of common stock and preferred stock available for future issuance without stockholder
approval, subject to any limitations imposed by the listing standards of any securities exchange on which </FONT>the Company&rsquo;s
<FONT STYLE="background-color: white">stock may be listed. The Company may utilize these additional shares for a variety of corporate
purposes, including for future public offerings to raise additional capital or facilitate corporate acquisitions or for payment
as a dividend on </FONT>the Company&rsquo;s <FONT STYLE="background-color: white">capital stock. The existence of unissued and
unreserved common stock and preferred stock may enable </FONT>the Company&rsquo;s <FONT STYLE="background-color: white">board of
directors to issue shares to persons friendly to current management or to issue preferred stock with terms that could have the
effect of making it more difficult for a third party to acquire, or could discourage a third party from seeking to acquire, a controlling
interest in </FONT>the Company <FONT STYLE="background-color: white">by means of a merger, tender offer, proxy contest, or otherwise.
In addition, if </FONT>the Company <FONT STYLE="background-color: white">issues preferred stock, the issuance could adversely affect
the voting power of holders of common stock and the likelihood that such holders will receive dividend payments and payments upon
liquidation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="background-color: white"></FONT></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; padding-top: 6pt; padding-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="background-color: white"><I>Blank Check Preferred Stock</I>.
The Company&rsquo;s board of directors, without stockholder approval, has the authority under the Company&rsquo;s amended and restated
articles of incorporation, as amended, to issue preferred stock with rights superior to the rights of the holders of common stock.
As a result, preferred stock could be issued quickly and easily, could impair the rights of holders of common stock, and could
be issued with terms calculated to delay or prevent a change in control or make removal of management more difficult.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="background-color: white"><I>Election of Directors</I>.
The Company&rsquo;s bylaws provide that a majority of directors then in office may fill any vacancy occurring on the Company&rsquo;s
board of directors, even though less than a quorum may then be in office. These provisions may discourage a third party from voting
to remove incumbent directors and simultaneously gaining control of the Company&rsquo;s board of directors by filling the vacancies
created by that removal with its own nominees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="background-color: white"><I>Removal of Directors</I>.
Except in certain cases for directors elected by the holders of any series of preferred stock, a director may be removed only by
the affirmative vote of two-thirds or more of the combined voting power of the then issued and outstanding shares of the Company&rsquo;s
capital stock entitled to vote in the election of directors, voting together as a single class.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="background-color: white"><I>Stockholder Meetings</I>.
The Company&rsquo;s bylaws do not permit stockholders to call a special meeting of stockholders. Rather, only the Company&rsquo;s
board of directors or such person or persons authorized by the Company&rsquo;s board of directors will be able to call special
meetings of stockholders. This provision may discourage another person or entity from making a tender offer, even if it acquired
a majority of the Company&rsquo;s outstanding voting stock, because the person or entity could only take action at a duly called
stockholders&rsquo; meeting or by written consent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Anti-takeover Effects of Nevada Law</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="background-color: white"><I>Business Combinations with
Interested Stockholders</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The &ldquo;business combination with interested stockholders&rdquo;
provisions of Sections 78.411 to 78.444, inclusive, of the Nevada Revised Statutes, or NRS, generally prohibit a Nevada corporation
with at least 200 stockholders of record from engaging in various &ldquo;combination&rdquo; transactions with any interested stockholder
for a period of two years after the date of the transaction in which the person became an interested stockholder, unless the combination
is approved by the Company&rsquo;s board of directors prior to the date the interested stockholder obtained such status or the
combination is approved by the Company&rsquo;s board of directors and at such time or thereafter is approved at a meeting of the
stockholders by the affirmative vote of stockholders representing at least 60% of the outstanding voting power held by disinterested
stockholders, and extends beyond the expiration of the two-year period, unless:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD><FONT STYLE="font-size: 10pt">the combination was approved by the Company&rsquo;s board of directors prior to the person becoming
an interested stockholder or the transaction by which the person first became an interested stockholder was approved by the Company&rsquo;s
board of directors before the person became an interested stockholder or the combination is later approved by a majority of the
voting power held by disinterested stockholders; or</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD><FONT STYLE="font-size: 10pt">if the consideration to be paid by the interested stockholder is at least equal to the highest
of: (a) the highest price per share paid by the interested stockholder within the two years immediately preceding the date of the
announcement of the combination or in the transaction in which it became an interested stockholder, whichever is higher; (b) the
market value per share of common stock on the date of announcement of the combination and the date the interested stockholder acquired
the shares, whichever is higher; or (c) for holders of preferred stock, the highest liquidation value of the preferred stock, if
it is higher.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Notwithstanding the foregoing, NRS 78.411 to 78.444, inclusive,
do not apply to any combination of a resident domestic corporation with an interested stockholder after the expiration of four
years after the person first became an interested stockholder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; padding-top: 6pt; padding-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">A &ldquo;combination&rdquo; is generally defined to include mergers
or consolidations or any sale, lease exchange, mortgage, pledge, transfer, or other disposition, in one transaction or a series
of transactions, with an &ldquo;interested stockholder&rdquo; having: (a)&nbsp;an aggregate market value equal to more than 5%
of the aggregate market value of the assets of the corporation, (b)&nbsp;an aggregate market value equal to more than 5% of the
aggregate market value of all outstanding voting shares of the corporation, (c)&nbsp;more than 10% of the earning power or net
income of the corporation, and (d)&nbsp;certain other transactions with an interested stockholder or an affiliate or associate
of an interested stockholder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In general, an &ldquo;interested stockholder&rdquo; is a person
who, together with affiliates and associates, owns (or within two years, did own) 10% or more of a corporation&rsquo;s voting stock.
The statute could prohibit or delay mergers or other takeover or change in control attempts and, accordingly, may discourage attempts
to acquire the Company even though such a transaction may offer the Company&rsquo;s stockholders the opportunity to sell their
stock at a price above the prevailing market price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><I>Control Share Acquisitions</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">The &ldquo;control share&rdquo; provisions
of Sections 78.378 to 78.3793, inclusive, of the NRS apply to &ldquo;issuing corporations&rdquo; that are Nevada corporations with
at least 200 stockholders of record, including at least 100 stockholders of record who are Nevada residents, and that conduct business
directly or indirectly in Nevada. The control share statute prohibits an acquirer, under certain circumstances, from voting its
shares of a target corporation&rsquo;s stock after crossing certain ownership threshold percentages, unless the acquirer obtains
approval of the target corporation&rsquo;s disinterested stockholders. The statute specifies three thresholds: one-fifth or more
but less than one-third, one-third but less than a majority, and a majority or more, of the outstanding voting power. Generally,
once an acquirer crosses one of the above thresholds, those shares in an offer or acquisition and acquired within 90 days thereof
become &ldquo;control shares&rdquo; and such control shares are deprived of the right to vote until disinterested stockholders
restore the right. These provisions also provide that if control shares are accorded full voting rights and the acquiring person
has acquired a majority or more of all voting power, all other stockholders who do not vote in favor of authorizing voting rights
to the control shares are entitled to demand payment for the fair value of their shares in accordance with statutory procedures
established for dissenters&rsquo; rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">A corporation may elect to not be governed
by, or &ldquo;opt out&rdquo; of, the control share provisions by making an election in its articles of incorporation or bylaws,
provided that the opt-out election must be in place on the 10th&nbsp;day following the date an acquiring person has acquired a
controlling interest, that is, crossing any of the three thresholds described above. The Company has not opted out of the control
share statutes, and will be subject to these statutes if we are an &ldquo;issuing corporation&rdquo; as defined in such statutes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">The effect of the Nevada control share
statutes is that the acquiring person, and those acting in association with the acquiring person, will obtain only such voting
rights in the control shares as are conferred by a resolution of the stockholders at an annual or special meeting. The Nevada control
share law, if applicable, could have the effect of discouraging takeovers of the Company.</P>



<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; padding-top: 6pt; padding-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.18
<SEQUENCE>3
<FILENAME>ex10-18.htm
<DESCRIPTION>AMENDMENT NO. 1 TO THE FINANCING AGREEMENT
<TEXT>
<html>
<head>
     <title></title>
</head>
<body style="font: 10pt Times New Roman, Times, Serif">

<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="txmd-10k_123119.htm">TherapeuticsMD, Inc. 10-K</a></font></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: right">Exhibit 10.18<font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AMENDMENT
NO. 1<br>
TO FINANCING AGREEMENT</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AMENDMENT
NO. 1 TO FINANCING AGREEMENT</b>, dated as of December 27, 2019 (this &quot;<u>Amendment</u>&quot;), to the Financing Agreement,
dated as of April 24, 2019 (as amended, restated, supplemented or otherwise modified from time to time, the &quot;<u>Financing
Agreement</u>&quot;), by and among THERAPEUTICSMD, INC., a Nevada corporation (&quot;<u>Company</u>&quot; or &quot;<u>Borrower</u>&quot;),
certain Subsidiaries of Borrower, as Guarantors, the Lenders from time to time party thereto, and TPG SPECIALTY LENDING, INC.,
a Delaware corporation (&quot;<u>TSL</u>&quot;), as administrative agent for the Lenders (in such capacity, together with its
successors and assigns in such capacity, the &quot;<u>Administrative Agent</u>&quot;).</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>WHEREAS</b>,
the Loan Parties have requested that the Administrative Agent and the Lenders amend certain terms and conditions of the Financing
Agreement; and</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>WHEREAS</b>,
the Administrative Agent and the Lenders are willing to amend such terms and conditions of the Financing Agreement on the terms
and conditions set forth herein.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOW
THEREFORE</b>, in consideration of the premises and other good and valuable consideration, the receipt and sufficiency of which
are hereby acknowledged, the parties hereto hereby agree as follows:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 -11pt; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">1.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1.25in"><font style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase"></font><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>Definitions</u>.
All terms used herein that are defined in the Financing Agreement and not otherwise defined herein shall have the meanings assigned
to them in the Financing Agreement.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 -11pt; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">2.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1.25in"><font style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase"></font><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>Amendments</u>.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 -11pt; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 2in"><font style="font: 10pt Times New Roman, Times, Serif"><u>New Definitions</u>. <u>Section 1.01</u> of the Financing Agreement is hereby amended by
adding the following definitions, in appropriate alphabetical order:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 -11pt; text-align: justify; text-indent: 2in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 2.5in"><font style="font: 10pt Times New Roman, Times, Serif">&quot;&quot;<u>Amendment
No. 1</u>&quot; means Amendment No. 1 to Financing Agreement, dated as of December 27, 2019, by and among the Loan Parties, the
Administrative Agent and the Lenders.&quot;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 -11pt; text-align: justify; text-indent: 2in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 2.5in"><font style="font: 10pt Times New Roman, Times, Serif">&quot;&quot;<u>Amendment
No. 1 Effective Date</u>&quot; means the &quot;Amendment Effective Date&quot; as set forth in Amendment No. 1.&quot;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 -11pt; text-align: justify; text-indent: 2in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 2.5in"><font style="font: 10pt Times New Roman, Times, Serif">&quot;&quot;<u>DD
A-1 Request Date</u>&quot; has the meaning set forth in Section 3.2(a)(v).&quot;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 -11pt; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 2in"><font style="font: 10pt Times New Roman, Times, Serif"><u>Existing Definitions</u>. The following definitions in <u>Section 1.01</u> of the Financing
Agreement are hereby amended as follows:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 -11pt; text-align: justify; text-indent: 2in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 2.5in"><font style="font: 10pt Times New Roman, Times, Serif">Delayed
Draw Commitment Termination Date is hereby amended and restated in its entirety to read as follows:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></font></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&nbsp;<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><font style="font: 10pt Times New Roman, Times, Serif">&quot;<u>Delayed
Draw Term Loan Commitment Termination Date</u>&quot; means the earliest to occur of (a) the date the Term Loan Commitments are
permanently reduced to zero in accordance with and pursuant to <u>Section 2.12(b)</u> or <u>2.13</u>, (b) the date of the termination
of the Term Loan Commitments in accordance with and pursuant to <u>Section 8.1</u>, (c) solely in the case of the Delayed Draw
A-1 Term Loan Commitment, September 22, 2020 (or such later date as may be consented to by the Required Lenders in their sole
discretion) and (d) solely in the case of the Delayed Draw A-2 Term Loan Commitment, March 31, 2020 (or such later date as may
be consented to by the Required Lenders in their sole discretion).&quot;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 -11pt; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 2in"><font style="font: 10pt Times New Roman, Times, Serif"><u>Section 3.2 (Conditions to Each Credit Extension)</u>. <u>Section 3.2(a)</u> of the Financing
Agreement is hereby amended by amending and restating clause (v) therein in its entirety to read as follows:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 -11pt; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&quot;(v)</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1.25in"><font style="font: 10pt Times New Roman, Times, Serif">solely
in respect of any Delayed Draw A-1 Term Loan, (A) Company shall deliver a Funding Notice in respect of the Delayed Draw A-1 Term
Loan either contemporaneously with the delivery of financial statements under <u>Section 5.1(b)</u> in respect of the fiscal quarter
ending June 30, 2020 or at such earlier date as the Administrative Agent shall have consented to in its sole and absolute discretion
(the &quot;<u>DD A-1 Request Date</u>&quot;), (B) the Administrative Agent shall have consented to make such Loan in its sole
and absolute discretion on or before the date that is 10 Business Days after the DD A-1 Request Date, and (C) if the Administrative
Agent consents to make such Loan in accordance with preceding clause (B), such Loan is made on or before the Delayed Draw Commitment
Termination Date; and&quot;.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 -11pt; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">3.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1.25in"><font style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase"></font><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>Conditions
to Effectiveness</u>. This Amendment shall become effective only upon satisfaction in full, in a manner satisfactory to the Administrative
Agent, of the following conditions precedent (the first date upon which all such conditions shall have been satisfied being hereinafter
referred to as the &quot;<u>Amendment Effective Date</u>&quot;):</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 -11pt; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 2in"><font style="font: 10pt Times New Roman, Times, Serif"><u>Payment of Fees, Etc</u>. The Borrowers shall have paid on or before the Amendment Effective
Date all fees, costs, expenses and taxes then payable, if any, pursuant to <u>Section 2.7</u> or <u>10.2</u> of the Financing
Agreement.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 -11pt; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 2in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>Representations
and Warranties</u>. The representations and warranties contained in this Amendment and in <u>Article&nbsp;IV</u> of the Financing
Agreement and in each other Loan Document shall be true and correct in all material respects (except that such materiality qualifier
shall not be applicable to any representations or warranties that already are qualified or modified as to &quot;materiality&quot;
or &quot;Material Adverse Effect&quot; in the text thereof, which representations and warranties shall be true and correct in
all respects subject to such qualification) on and as the Amendment Effective Date to the same extent as though made on and as
of that date, except to the extent such representations and warranties specifically relate to an earlier date, in which case such
representations and warranties shall have been true and correct in all material respects (except that such materiality qualifier
shall not be applicable to any representations or warranties that already are qualified or modified as to &quot;materiality&quot;
or &quot;Material Adverse Effect&quot; in the text thereof, which representations and warranties shall be true and correct in
all respects subject to such qualification) on and as of such earlier date.</font></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 2in"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 -11pt; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 2in"><font style="font: 10pt Times New Roman, Times, Serif"><u>No Default; Event of Default</u>. No Default or Event of Default shall have occurred and
be continuing on the Amendment Effective Date or result from this Amendment becoming effective in accordance with its terms.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 -11pt; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 2in"><font style="font: 10pt Times New Roman, Times, Serif"><u>Delivery of Documents</u>. The Administrative Agent shall have received on or before the
Amendment Effective Date this Amendment, duly executed by the Loan Parties and the Administrative Agent and the Lenders.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 -11pt; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 2in"><font style="font: 10pt Times New Roman, Times, Serif"><u>Material Adverse Effect</u>. The Administrative Agent shall have determined, in its reasonable
judgment, that no event or development shall have occurred since December 31, 2018, which could reasonably be expected to have
a Material Adverse Effect.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 -11pt; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 2in"><font style="font: 10pt Times New Roman, Times, Serif"><u>Liens; Priority</u>. The Administrative Agent shall be satisfied that the Administrative
Agent has been granted, and holds, for the benefit of the Administrative Agent and the Lenders, a perfected, first priority Lien
on and security interest in all of the Collateral, subject only to Permitted Liens, to the extent such Liens and security interests
are required pursuant to the Loan Documents to be granted or perfected on or before the Amendment Effective Date.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 -11pt; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 2in"><font style="font: 10pt Times New Roman, Times, Serif"><u>Approvals</u>. All consents, authorizations and approvals of, and filings and registrations
with, and all other actions in respect of, any Governmental Authority or other Person required in connection with any Loan Document
or the transactions contemplated thereby or the conduct of the Loan Parties'</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">business
shall have been obtained or made and shall be in full force and effect. There shall exist no claim, action, suit, investigation,
litigation or proceeding (including, without limitation, shareholder or derivative litigation) pending or, to the knowledge of
any Loan Party, threatened in any court or before any arbitrator or Governmental Authority which (i)&nbsp;relates to the Loan
Documents or the transactions contemplated thereby or (ii)&nbsp;could reasonably be expected to have a Material Adverse Effect.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 -11pt; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">4.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1.25in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>Continued
Effectiveness of the Financing Agreement and Other Loan Documents</u>. Each Loan Party hereby (a) acknowledges and consents to
this Amendment, (b)&nbsp;confirms and agrees that the Financing Agreement and each other Loan Document to which it is a party
is, and shall continue to be, in full force and effect and is hereby ratified and confirmed in all respects, except that on and
after the Amendment Effective Date, all references in any such Loan Document to &quot;the Financing Agreement&quot;, the &quot;Agreement&quot;,
&quot;thereto&quot;, &quot;thereof&quot;, &quot;thereunder&quot; or words of like import referring to the Financing Agreement
shall mean the Financing Agreement as amended by this Amendment, and (c)&nbsp;confirms and agrees that, to the extent that any
such Loan Document purports to assign or pledge to the Administrative Agent, for the benefit of the Administrative Agent and the
Lenders, or to grant to the Administrative Agent, for the benefit of the Administrative Agent and the Lenders, a security interest
in or Lien on any Collateral as security for the Obligations of the Loan Parties from time to time existing in respect of the
Financing Agreement (as amended hereby) and the other Loan Documents, such pledge, assignment and/or grant of the security interest
or Lien is hereby ratified and confirmed in all respects. This Amendment does not and shall not affect any of the obligations
of the Loan Parties, other than as expressly provided herein, including, without limitation, the Loan Parties' obligations to
repay the Loans in accordance with the terms of Financing Agreement or the obligations of the Loan Parties under any Loan Document
to which they are a party, all of which obligations shall remain in full force and effect. Except as expressly provided herein,
the execution, delivery and effectiveness of this Amendment shall not operate as a waiver of any right, power or remedy of Administrative
Agent or any Lender under the Financing Agreement or any other Loan Document nor constitute a waiver of any provision of the Financing
Agreement or any other Loan Document.</font></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1.25in"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 -11pt; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">5.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1.25in"><font style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase"></font><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>No Novation</u>.
Nothing herein contained shall be construed as a substitution or novation of the Obligations outstanding under the Financing Agreement
or instruments securing the same, which shall remain in full force and effect, except as modified hereby.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 -11pt; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">6.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1.25in"><font style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase"></font><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>No Representations
by Administrative Agent or Lenders</u>. Each Loan Party hereby acknowledges that it has not relied on any representation, written
or oral, express or implied, by Administrative Agent or any Lender, other than those expressly contained herein, in entering into
this Amendment.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 -11pt; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">7.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1.25in"><font style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase"></font><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>Release</u>.
Each Loan Party hereby acknowledges and agrees that: (a) neither it nor any of its Subsidiaries has any claim or cause of action
against Administrative Agent or any Lender (or any of the directors, officers, employees, agents, attorneys or consultants of
any of the foregoing) and (b) the Administrative Agent and the Lenders have heretofore properly performed and satisfied in a timely
manner all of their obligations to the Loan Parties, and all of their Subsidiaries and Affiliates. Notwithstanding the foregoing,
the Administrative Agent and the Lenders wish (and the Loan Parties agree) to eliminate any possibility that any past conditions,
acts, omissions, events or circumstances would impair or otherwise adversely affect any of their rights, interests, security and/or
remedies. Accordingly, for and in consideration of the agreements contained in this Amendment and other good and valuable consideration,
each Loan Party (for itself and its Subsidiaries and Affiliates and the successors, assigns, heirs and representatives of each
of the foregoing) (collectively, the &quot;<u>Releasors</u>&quot;) does hereby fully, finally, unconditionally and irrevocably
release, waive and forever discharge the Administrative Agent and the Lenders, together with their respective Affiliates and Related
Funds, and each of the directors, officers, employees, agents, attorneys and consultants of each of the foregoing (collectively,
the &quot;<u>Released Parties</u>&quot;), from any and all debts, claims, allegations, obligations, damages, costs, attorneys'
fees, suits, demands, liabilities, actions, proceedings and causes of action, in each case, whether known or unknown, contingent
or fixed, direct or indirect, and of whatever nature or description, and whether in law or in equity, under contract, tort, statute
or otherwise, which any Releasor has heretofore had or now or hereafter can, shall or may have against any Released Party by reason
of any act, omission or thing whatsoever done or omitted to be done, in each case, on or prior to the Amendment Effective Date
directly arising out of, connected with or related to this Amendment, the Financing Agreement or any other Loan Document, or any
act, event or transaction related or attendant thereto, or the agreements of Administrative Agent or any Lender contained therein,
or the possession, use, operation or control of any of the assets of any Loan Party, or the making of any Loans or other advances,
or the management of such Loans or other advances or the Collateral. </font><font style="font: 10pt Times New Roman, Times, Serif">Each
Loan Party represents and warrants that it has no knowledge of any claim by any Releasor against any Released Party or of any
facts or acts or omissions of any Released Party which on the date hereof would be the basis of a claim by any Releasor against
any Released Party which would not be released hereby.</font></p>


<!-- Field: Page; Sequence: 4 -->
    <div style="margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 -11pt; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">8.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1.25in"><font style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase"></font><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>Further
Assurances.</u> The Loan Parties shall execute any and all further documents, agreements and instruments, and take all further
actions, as may be required under applicable law or as Administrative Agent may reasonably request, in order to effect the purposes
of this Amendment.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 -11pt; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">9.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1.25in"><font style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase"></font><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>Disclosure</u>.
Promptly (but in no event later than 4 Business Days) following the Amendment Effective Date, the Loan Parties shall disclose
the terms of this Amendment in a Form 8-K current report, which report shall be in form and substance reasonably satisfactory
to the Administrative Agent. The Loan Parties (a) agree that any press release in respect of this Amendment shall be consented
to by the Administrative Agent prior to the release thereof, and (b) acknowledge and confirm that any other or further disclosure
of this Amendment is subject to <u>Section 10.17</u> of the Financing Agreement.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 -11pt; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">10.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1.25in"><font style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase"></font><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>Miscellaneous</u>.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 -11pt; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 2in"><font style="font: 10pt Times New Roman, Times, Serif">This Amendment may be executed in any number of counterparts and by different parties
hereto in separate counterparts, each of which shall be deemed to be an original but all of which taken together shall constitute
one and the same agreement. Delivery of an executed counterpart of this Amendment by facsimile or electronic mail shall be equally
effective as delivery of an original executed counterpart of this Amendment.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 -11pt; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 2in"><font style="font: 10pt Times New Roman, Times, Serif">Section and paragraph headings herein are included for convenience of reference only
and shall not constitute a part of this Amendment for any other purpose.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 -11pt; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 2in"><font style="font: 10pt Times New Roman, Times, Serif">This Amendment shall be governed by, and construed in accordance with, the laws of the
State of New York.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 -11pt; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 2in"><font style="font: 10pt Times New Roman, Times, Serif">Each Loan Party hereby acknowledges and agrees that this Amendment constitutes a &quot;Loan
Document&quot; under the Financing Agreement. Accordingly, it shall be an immediate Event of Default under the Financing Agreement
if (i) any representation or warranty made by any Loan Party under or in connection with this Amendment shall have been incorrect
in any respect when made or deemed made, or (ii) any Loan Party shall fail to perform or observe any term, covenant or agreement
contained in this Amendment.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 -11pt; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 2in"><font style="font: 10pt Times New Roman, Times, Serif">Any provision of this Amendment that is prohibited or unenforceable in any jurisdiction
shall, as to such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the
remaining portions hereof or affecting the validity or enforceability of such provision in any other jurisdiction.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[<i>Remainder
of page intentionally left blank.</i>]</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>


<!-- Field: Page; Sequence: 5 -->
    <div style="margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->-</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the parties hereto have caused this Amendment to be executed and delivered as of the date set forth on the first
page hereof.</font></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BORROWER:</font></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THERAPEUTICSMD,
        INC.</font></p></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</font></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 44%; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Daniel A. Cartwright</font></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Daniel A. Cartwright</font></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer and Treasurer</font></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td></tr>
</table>

<p style="margin: 0"></p>

<p style="margin: 0"></p>

<p style="margin: 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GUARANTORS:</font></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">VITAMEDMD,
        LLC</font></p></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</font></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 44%; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Daniel A. Cartwright</font></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Daniel A. Cartwright</font></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer and Treasurer</font></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td></tr>
</table>
<p style="margin: 0"></p>

<p style="margin: 0"></p>

<p style="margin: 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BOCAGREENMD,
        INC.</font></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></font></p></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</font></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 44%; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Daniel A. Cartwright</font></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Daniel A. Cartwright</font></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer and Treasurer</font></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td></tr>
</table>
<p style="margin: 0"></p>

<p style="margin: 0">&nbsp;</p>

<p style="margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">VITACARE
        PRESCRIPTION SERVICES, INC.</font></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></font></p></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</font></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 44%; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Daniel A. Cartwright</font></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Daniel A. Cartwright</font></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer and Assistant Treasurer</font></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td></tr>
</table>
<p style="margin: 0"></p>

<p style="margin: 0"></p>

<p style="margin: 0"></p>

<p style="margin: 0">&nbsp;</p>


<!-- Field: Page; Sequence: 6 -->
    <div style="margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</div>
    <div style="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 24pt 0 0 3in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></font></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TPG
SPECIALTY LENDING, INC., as</font></p>
                                                                     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Administrative Agent and Lender</font></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></font></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></font></p></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</font></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 44%; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Joshua Easterly</font></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joshua Easterly</font></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CEO</font></td></tr>
</table>

<p style="margin-top: 0; margin-bottom: 0">&nbsp;</p>

<p style="margin-top: 0; margin-bottom: 0">&nbsp;</p>


<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TOP
IV TALENTS, LLC, as Lender</font></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></font></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></font></p></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</font></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 44%; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Joshua Peck</font></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joshua Peck</font></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vice President</font></td></tr>
</table>

<p style="margin-top: 0; margin-bottom: 0">&nbsp;</p>

<p style="margin-top: 0; margin-bottom: 0">&nbsp;</p>


<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TAO
TALENTS, LLC, as Lender</font></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></font></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></font></p></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</font></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 44%; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Joshua Peck</font></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joshua Peck</font></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vice President</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 24pt 0 0 3in"></p>



<!-- Field: Page; Sequence: 7; Options: Last -->
    <div style="margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>4
<FILENAME>ex21-1.htm
<DESCRIPTION>SUBSIDIARIES OF THE COMPANY
<TEXT>
<HTML>

<HEAD>
    <TITLE></TITLE>
</HEAD>

<BODY style="font: 10pt Times New Roman, Times, Serif">
    <!-- Edge Version : NotProvided -->
    <div style="margin-bottom: 0; margin-top: 0; width: 100%;">
        <div style="border-bottom: Black 1pt solid; border-top: Black 2pt solid; font-size: 1pt;">&nbsp;</div>
    </div>
    <p style="margin: 0pt 0; text-align: left; font: 10pt Times New Roman,serif;"><a href="txmd-10k_123119.htm">TherapeuticsMD, Inc. 10-K</a></p>
    <p style="margin: 0pt 0; text-align: right; font: 10pt Times New Roman,serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: right; font: 10pt Times New Roman,serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>Exhibit 21.1</b></font>
    </p>
    <p style="margin: 0pt 0; text-align: right; font: 10pt Times New Roman,serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman,serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><u>Subsidiaries of the Company</u></b></font>
    </p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman,serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <table style="width: 100%; font-size: 10pt; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr>
            <td style="border-bottom: Black 1pt solid; width: 48%; vertical-align: bottom; text-align: center; font-family: Times New Roman,serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>Name</b></font>
            </td>
            <td style="width: 1%; vertical-align: top; text-align: center; font-family: Times New Roman,serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; width: 51%; vertical-align: bottom; text-align: center; font-family: Times New Roman,serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>State or Jurisdiction of Incorporation or Organization</b></font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td style="text-align: center; font-family: Times New Roman,serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">VitaMedMD, LLC</font>
            </td>
            <td style="text-align: center; font-family: Times New Roman,serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: center; font-family: Times New Roman,serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Delaware</font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td style="text-align: center; font-family: Times New Roman,serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">BocagreenMD, Inc.</font>
            </td>
            <td style="text-align: center; font-family: Times New Roman,serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: center; font-family: Times New Roman,serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Nevada</font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td style="text-align: center; font-family: Times New Roman,serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">VitaCare Prescription Services, Inc.</font>
            </td>
            <td style="text-align: center; font-family: Times New Roman,serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="text-align: center; font-family: Times New Roman,serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Florida</font>
            </td>
        </tr>
    </table>
    <p style="margin: 0;">&nbsp;</p>
    <!-- Field: Page; Sequence: 1; Options: NewSection; Value: 77-->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; Type: Arabic; Name: PageNo-->77
            <!-- Field: /Sequence -->
        </p>
    </div>
    <!-- Field: /Page -->
</BODY>

</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>ex23-1.htm
<DESCRIPTION>CONSENT OF GRANT THORNTON LLP
<TEXT>
<HTML>

<HEAD>
    <TITLE></TITLE>
</HEAD>

<BODY style="font: 10pt Times New Roman, Times, Serif">
    <!-- Edge Version : NotProvided -->
    <div style="margin-bottom: 0; margin-top: 0; width: 100%;">
        <div style="border-bottom: Black 1pt solid; border-top: Black 2pt solid; font-size: 1pt;">&nbsp;</div>
    </div>
    <p style="margin: 0pt 0; text-align: left; font: 10pt Times New Roman,serif;"><a href="txmd-10k_123119.htm">TherapeuticsMD, Inc. 10-K</a></p>
    <p style="margin: 0pt 0; text-align: right; font: 10pt Times New Roman,serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: right; font: 10pt Times New Roman,serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>Exhibit 23.1</b></font>
    </p>
    <p style="margin: 0pt 0; text-align: right; font: 10pt Times New Roman,serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman,serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></font>
    </p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman,serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
    <p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">We have issued our reports dated
    February 24, 2020, with respect to the consolidated financial statements and internal control over financial reporting
    included in the Annual Report of TherapeuticsMD, Inc. (a Nevada Corporation) on Form 10-K for the year ended December 31,
    2019. We consent to the incorporation by reference of said reports in the Registration Statements of TherapeuticsMD, Inc. on
    Form S-3 (File No. 333-226452) and on Forms S-8 (File No. 333-191730 and File No. 333-232268).</p>
    <p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman,serif;"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    <FONT STYLE="text-transform: uppercase">Grant Thornton</FONT> LLP</FONT></p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman,serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman,serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Fort Lauderdale, Florida&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman,serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">February 24, 2020</font>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman,serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <!-- Field: Page; Sequence: 1; Options: NewSection; Value: 78-->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; Type: Arabic; Name: PageNo-->78
            <!-- Field: /Sequence -->
        </p>
    </div>
    <!-- Field: /Page -->
</BODY>

</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>ex31-1.htm
<DESCRIPTION>CERTIFICATION OF CHIEF EXECUTIVE OFFICER
<TEXT>
<HTML>

<HEAD>
    <TITLE>ex31-1.htm</TITLE>
</HEAD>

<BODY style="font: 10pt Times New Roman, Times, Serif">
    <!-- Edge Version : NotProvided -->
    <div style="margin-bottom: 0; margin-top: 0; width: 100%;">
        <div style="border-bottom: Black 1pt solid; border-top: Black 2pt solid; font-size: 1pt;">&nbsp;</div>
    </div>
    <p style="margin: 0pt 0; text-align: left; font: 10pt Times New Roman,serif;"><a href="txmd-10k_123119.htm">TherapeuticsMD, Inc. 10-K</a></p>
    <p style="margin: 0pt 0; text-align: right; font: 10pt Times New Roman,serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: right; font: 10pt Times New Roman,serif;">
        <font style="font: 10pt Times New Roman, Times, Serif;"><b>Exhibit 31.1</b></font>
    </p>
    <p style="margin: 0pt 0; text-align: right; font: 10pt Times New Roman,serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman,serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>CERTIFICATIONS OF CHIEF EXECUTIVE OFFICER</b></font>
    </p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman,serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman,serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">I, Robert G. Finizio, certify that:</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman,serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman,serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">(1) I have reviewed this annual report on Form 10-K of TherapeuticsMD, Inc.;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman,serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman,serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">(2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman,serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman,serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">(3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman,serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman,serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">(4) The registrant&#x2019;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman,serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0 0pt 0.5in; text-align: justify; font: 10pt Times New Roman,serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">(a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font>
    </p>
    <p style="margin: 0pt 0 0pt 0.5in; text-align: justify; font: 10pt Times New Roman,serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">(b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font>
    </p>
    <p style="margin: 0pt 0 0pt 0.5in; text-align: justify; font: 10pt Times New Roman,serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">(c) evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font>
    </p>
    <p style="margin: 0pt 0 0pt 0.5in; text-align: justify; font: 10pt Times New Roman,serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">(d) disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting.</font>
    </p>
    <p style="margin: 0pt 0 0pt 0.5in; text-align: justify; font: 10pt Times New Roman,serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman,serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">(5) The registrant&#x2019;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman,serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0 0pt 0.5in; text-align: justify; font: 10pt Times New Roman,serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">(a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font>
    </p>
    <p style="margin: 0pt 0 0pt 0.5in; text-align: justify; font: 10pt Times New Roman,serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">(b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font>
    </p>
    <p style="margin: 0pt 0 0pt 0.5in; text-align: justify; font: 10pt Times New Roman,serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman,serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Date: February 24, 2020</font>
    </p>
    <table style="width: 100%; font-size: 10pt; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top;">
            <td style="width: 50%; font-family: Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; width: 50%; font-family: Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">/s/ Robert G. Finizio</font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td style="font-family: Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font-family: Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Robert G. Finizio</font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td style="font-family: Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font-family: Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Chief Executive Officer</font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td style="font-family: Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font-family: Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">(Principal Executive Officer)</font>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0 0pt 4.5in; text-indent: 0.5in; font: 10pt Times New Roman,serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <!-- Field: Page; Sequence: 1; Options: NewSection; Value: 79-->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; Type: Arabic; Name: PageNo-->79
            <!-- Field: /Sequence -->
        </p>
    </div>
    <!-- Field: /Page -->
</BODY>

</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>ex31-2.htm
<DESCRIPTION>CERTIFICATION OF CHIEF FINANCIAL OFFICER
<TEXT>
<HTML>

<HEAD>
    <TITLE>ex31-2.htm</TITLE>
</HEAD>

<BODY style="font: 10pt Times New Roman, Times, Serif">
    <!-- Edge Version : NotProvided -->
    <div style="margin-bottom: 0; margin-top: 0; width: 100%;">
        <div style="border-bottom: Black 1pt solid; border-top: Black 2pt solid; font-size: 1pt;">&nbsp;</div>
    </div>
    <p style="margin: 0pt 0; text-align: left; font: 10pt Times New Roman,serif;"><a href="txmd-10k_123119.htm">TherapeuticsMD, Inc. 10-K</a></p>
    <p style="margin: 0pt 0; text-align: right; font: 10pt Times New Roman,serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: right; font: 10pt Times New Roman,serif;">
        <font style="font: 10pt Times New Roman, Times, Serif;"><b>Exhibit 31.2</b></font>
    </p>
    <p style="margin: 0pt 0; text-align: right; font: 10pt Times New Roman,serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman,serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>CERTIFICATIONS OF CHIEF FINANCIAL OFFICER</b></font>
    </p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman,serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman,serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">I, Daniel A. Cartwright, certify that:</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman,serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman,serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">(1) I have reviewed this annual report on Form 10-K of TherapeuticsMD, Inc.;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman,serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman,serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">(2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman,serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman,serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">(3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman,serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman,serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">(4) The registrant&#x2019;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman,serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0 0pt 0.5in; text-align: justify; font: 10pt Times New Roman,serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">(a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font>
    </p>
    <p style="margin: 0pt 0 0pt 0.5in; text-align: justify; font: 10pt Times New Roman,serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">(b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font>
    </p>
    <p style="margin: 0pt 0 0pt 0.5in; text-align: justify; font: 10pt Times New Roman,serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">(c) evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font>
    </p>
    <p style="margin: 0pt 0 0pt 0.5in; text-align: justify; font: 10pt Times New Roman,serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">(d) disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting.</font>
    </p>
    <p style="margin: 0pt 0 0pt 0.5in; text-align: justify; font: 10pt Times New Roman,serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman,serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">(5) The registrant&#x2019;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman,serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0 0pt 0.5in; text-align: justify; font: 10pt Times New Roman,serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">(a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font>
    </p>
    <p style="margin: 0pt 0 0pt 0.5in; text-align: justify; font: 10pt Times New Roman,serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">(b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font>
    </p>
    <p style="margin: 0pt 0 0pt 0.5in; text-align: justify; font: 10pt Times New Roman,serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman,serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Date: February 24, 2020&nbsp;</font>
    </p>
    <table style="width: 100%; font-size: 10pt; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top;">
            <td style="width: 50%; font-family: Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; width: 50%; font-family: Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">/s/ Daniel A. Cartwright</font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td style="font-family: Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font-family: Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Daniel A. Cartwright</font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td style="font-family: Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font-family: Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Chief Financial Officer</font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td style="font-family: Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font-family: Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">(Principal Financial and Accounting Officer)</font>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0 0pt 4.5in; text-indent: 0.5in; font: 10pt Times New Roman,serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <!-- Field: Page; Sequence: 1; Options: NewSection; Value: 80-->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; Type: Arabic; Name: PageNo-->80
            <!-- Field: /Sequence -->
        </p>
    </div>
    <!-- Field: /Page -->
</BODY>

</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>ex32-1.htm
<DESCRIPTION>CERTIFICATION OF CHIEF EXECUTIVE OFFICER
<TEXT>
<HTML>

<HEAD>
    <TITLE>ex32-1.htm</TITLE>
</HEAD>

<BODY style="font: 10pt Times New Roman, Times, Serif">
    <!-- Edge Version : NotProvided -->
    <div style="margin-bottom: 0; margin-top: 0; width: 100%;">
        <div style="border-bottom: Black 1pt solid; border-top: Black 2pt solid; font-size: 1pt;">&nbsp;</div>
    </div>
    <p style="margin: 0pt 0; text-align: left; font: 10pt Times New Roman,serif;"><a href="txmd-10k_123119.htm">TherapeuticsMD, Inc. 10-K</a></p>
    <p style="margin: 0pt 0; text-align: right; font: 10pt Times New Roman,serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: right; font: 10pt Times New Roman,serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>Exhibit 32.1</b></font>
    </p>
    <p style="margin: 0pt 0; text-align: right; font: 10pt Times New Roman,serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman,serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>SECTION 1350 CERTIFICATION OF CHIEF EXECUTIVE OFFICER</b></font>
    </p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman,serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman,serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">In connection with the annual report of TherapeuticsMD, Inc. (the &#x201C;Company&#x201D;) on Form 10-K for the year ended December 31, 2019 as filed with the Securities and Exchange Commission on the date hereof (the &#x201C;Report&#x201D;), I, Robert G. Finizio, Chief Executive Officer of the Company, certify, to my best knowledge and belief, pursuant to 18 U.S.C. &#xA7; 1350, as adopted pursuant to &#xA7; 906 of the Sarbanes-Oxley Act of 2002, that:</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman,serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <table style="margin-bottom: 0pt; margin-top: 0pt; font: 12pt Times New Roman,serif;" cellpadding="0" cellspacing="0" width="100%">
        <tr style="vertical-align: top;">
            <td style="width: 0.5in;"></td>
            <td style="width: 0.25in;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">(1)</font>
            </td>
            <td style="text-align: justify;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m(a) or 78o(d)); and</font>
            </td>
        </tr>
    </table>
    <p style="margin-bottom: 0pt; margin-top: 0pt; font: 12pt Times New Roman,serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <table style="margin-bottom: 0pt; margin-top: 0pt; font: 12pt Times New Roman,serif;" cellpadding="0" cellspacing="0" width="100%">
        <tr style="vertical-align: top;">
            <td style="width: 0.5in;"></td>
            <td style="width: 0.25in;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">(2)</font>
            </td>
            <td style="text-align: justify;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font>
            </td>
        </tr>
    </table>
    <p style="margin-bottom: 0pt; margin-top: 0pt; font: 12pt Times New Roman,serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman,serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">February 24, 2020</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman,serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <table style="width: 100%; font-size: 10pt; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top;">
            <td style="width: 50%; font-family: Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; width: 50%; font-family: Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i>/s/ Robert G. Finizio</i></font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td style="font-family: Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font-family: Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Robert G. Finizio</font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td style="font-family: Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font-family: Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Chief Executive Officer</font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td style="font-family: Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font-family: Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">(Principal Executive Officer)</font>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 5in; font: 10pt Times New Roman,serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman,serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">A signed original of this certification has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman,serif;">
        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
    </p>
    <!-- Field: Page; Sequence: 1; Options: NewSection; Value: 81-->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; Type: Arabic; Name: PageNo-->81
            <!-- Field: /Sequence -->
        </p>
    </div>
    <!-- Field: /Page -->
</BODY>

</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>9
<FILENAME>ex32-2.htm
<DESCRIPTION>CERTIFICATION OF CHIEF FINANCIAL OFFICER
<TEXT>
<HTML>

<HEAD>
    <TITLE>ex32-2.htm</TITLE>
</HEAD>

<BODY style="font: 10pt Times New Roman, Times, Serif">
    <!-- Edge Version : NotProvided -->
    <div style="margin-bottom: 0; margin-top: 0; width: 100%;">
        <div style="border-bottom: Black 1pt solid; border-top: Black 2pt solid; font-size: 1pt;">&nbsp;</div>
    </div>
    <p style="margin: 0pt 0; text-align: left; font: 10pt Times New Roman,serif;"><a href="txmd-10k_123119.htm">TherapeuticsMD, Inc. 10-K</a></p>
    <p style="margin: 0pt 0; text-align: right; font: 10pt Times New Roman,serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: right; font: 10pt Times New Roman,serif;"><b>Exhibit 32.2</b></p>
    <p style="margin: 0pt 0; text-align: right; font: 10pt Times New Roman,serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman,serif;"><b>SECTION 1350 CERTIFICATION OF CHIEF FINANCIAL OFFICER</b></p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman,serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman,serif;">In connection with the annual report of TherapeuticsMD, Inc. (the &#x201C;Company&#x201D;) on Form 10-K for the year ended December 31, 2019 as filed with the Securities and Exchange Commission on the date hereof (the &#x201C;Report&#x201D;), I, Daniel A. Cartwright, Chief Financial Officer of the Company, certify, to my best knowledge and belief, pursuant to 18 U.S.C. &#xA7; 1350, as adopted pursuant to &#xA7; 906 of the Sarbanes-Oxley Act of 2002, that:</p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman,serif;">&nbsp;</p>
    <table style="margin-bottom: 0pt; margin-top: 0pt; font: 12pt Times New Roman,serif;" cellpadding="0" cellspacing="0" width="100%">
        <tr style="vertical-align: top;">
            <td style="width: 0.5in;"></td>
            <td style="width: 0.25in;">
                <font style="font-size: 10pt;">(3)</font>
            </td>
            <td style="text-align: justify;">
                <font style="font-size: 10pt;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m(a) or 78o(d)); and</font>
            </td>
        </tr>
    </table>
    <p style="margin-bottom: 0pt; margin-top: 0pt; font: 12pt Times New Roman,serif;">&nbsp;</p>
    <table style="margin-bottom: 0pt; margin-top: 0pt; font: 12pt Times New Roman,serif;" cellpadding="0" cellspacing="0" width="100%">
        <tr style="vertical-align: top;">
            <td style="width: 0.5in;"></td>
            <td style="width: 0.25in;">
                <font style="font-size: 10pt;">(4)</font>
            </td>
            <td style="text-align: justify;">
                <font style="font-size: 10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font>
            </td>
        </tr>
    </table>
    <p style="margin-bottom: 0pt; margin-top: 0pt; font: 12pt Times New Roman,serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman,serif;">February 24, 2020</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman,serif;">&nbsp;</p>
    <table style="width: 100%; font-size: 10pt; border-collapse: collapse;" cellpadding="0" cellspacing="0">
        <tr style="vertical-align: top;">
            <td style="width: 50%; font-family: Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="border-bottom: Black 1pt solid; width: 50%; font-family: Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i>/s/ Daniel A. Cartwright</i></font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td style="font-family: Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font-family: Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Daniel A. Cartwright</font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td style="font-family: Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font-family: Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Chief Financial Officer</font>
            </td>
        </tr>
        <tr style="vertical-align: top;">
            <td style="font-family: Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&nbsp;</font>
            </td>
            <td style="font-family: Times New Roman, Times, Serif;">
                <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">(Principal Financial and Accounting Officer)</font>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 5in; font: 10pt Times New Roman,serif;">&nbsp;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman,serif;">A signed original of this certification has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman,serif;">&nbsp;</p>
    <!-- Field: Page; Sequence: 1; Options: NewSection; Value: 82-->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; Type: Arabic; Name: PageNo-->82
            <!-- Field: /Sequence -->
        </p>
    </div>
    <!-- Field: /Page -->
</BODY>

</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>txmd10k001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 txmd10k001.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@!9P*C P$1  (1 0,1 ?_$ ,0  0 " P$! 0
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M/^Q*1[3S>B-Y'M;-9%F#(T#.9-G>R_"L[X#H+K?IBD>I1_1) 68
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M9^]OQK\M 6=UOTQ2/4H_HD@+,
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M5ARC/NVGP$ O+LW&JU&H]9IT-\X9SX4=$1W/./9N:4<VWWK5F:BM<L.TN'A
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MX=G<X>$!TON^NA,NT4QE9F45]J&I"#>6]_N4,9,I?UAF99;EA_" [
M                              !S/WM^-?EH"SNM^F*1ZE']$D!9@
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M%?:33JF^X3RUFXRE;R,\1%EDAP_DX.X [,
M              !S/WM^-?EH"SNM^F*1ZE']$D!9@
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MM!J41I(K/V (DCWOW5<B.N1XDI3R6E*C:3&6TTHS;6XR1N&1Y*7C:42#[ID
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MR:8;2TV5MB$$24E:=IX" 9@
M   .9^]OQK\M 6=UOTQ2/4H_HD@+,
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M\:_+0%G=;],4CU*/Z)("S
M
M           ',_>WXU^6@+.ZWZ8I'J4?T20%F
M
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M)F M]U+N]@:XCQ@&ZEW>P-<1XP#=2[O8&N(\8!NI=WL#7$>, W4N[V!KB/&
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MXCQ@&ZEW>P-<1XP#=2[O8&N(\8!NI=WL#7$>, W4N[V!KB/& ;J7=[ UQ'C
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M^6@+.ZWZ8I'J4?T20%F   "%7?Z)4/5GO1F CW3_ $M1_4H_HD@+4
M                %7(O'36*@B$M?AG@6X7B(5W"48I,_G^FQ:B,$SOZ9Z(G
MJG^-R930Y+8^>(6A&1E:7 +N)0P
M                                          %10/M-7]=5Z- "!][?
MC7Y: L[K?IBD>I1_1) 68   (5=_HE0]6>]&8"/=/]+4?U*/Z)("U
M               &F9,8AQER'U9+:"P]\S[A%\)B-J]53!CG)>=E8_C8Z8L5
MLEHK7BYDKJ/3U*G.J3%4^:G"C$FW)MPIROC^D/&?_P Q?56G/:8QS?;/+LX=
M6W_R6_[E&..2/>V;MO\ 'U+NEU(W%'!E(*/.9+"T7BJ26 E-]\AZ3R[S#FGP
M,L<F:D<.B8ZZ]GV*_48-GOUGFI/\;)6(N$0
M                                                 %10/M-7]=5Z
M- "!][?C7Y: L[K?IBD>I1_1) 68   (5=_HE0]6>]&8"/=/]+4?U*/Z)("U
M                     8N.(;0IQQ1)0DC-2CX"(AI>]:5FUIV1#-:S,[(5
M$1M=6E)GOI,H+)VPF3^F?.J+_A%!IJ3KLL9[Q_AI^G7K_//_ (I^2T8*\E>_
M/>GJ[/:N1Z)7H=2IC,UM-IFV^V>4P^G I"O@^#X!7Z_R^FHK'X;UWUM'&)_C
MH=\&HG'/76>,=;13ZD]G] J!$W-25J%%XCR2^DC]Y"-H?,+\_@9_=S1PGHO'
M7'WPZYM/&SGQ[Z?7'I68N4,
M                                    5% ^TU?UU7HT ('WM^-?EH"S
MNM^F*1ZE']$D!9@   A5W^B5#U9[T9@(]T_TM1_4H_HD@+4
M       !2NFJM2C80=E+CJ^O67^LX7T"_LEW1YS),^89>2/_ )J3[T_';X8_
M+'2L*Q\O7FG]2W#\L=?I724DDB2DK"+ 1%P$0]%$1$;(X*^9!D $:H4Z/.8S
M;MI*2>4TZG M"BX%),0M=H,>IIRVXQPF.-9ZX=L&>V.=L>KK0X-1D,2"I]2L
M*0?V>06!#Q%\RN^0@:/79,=XT^I[_P"&W1>/NMUP[YL%;5\3'W>F/A_DM1>(
M0
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M]G:Y"<0!H$'L[7(3B - @]G:Y"<0!H$'L[7(3B - @]G:Y"<0!H$'L[7(3B
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MV=KD)Q &@0>SM<A.( T"#V=KD)Q &@0>SM<A.( T"#V=KD)Q &@0>SM<A.(
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M.ZWZ8I'J4?T20%F   "%7?Z)4/5GO1F CW3_ $M1_4H_HD@+4
M    &F;,8AQER'U9+:"^4S[A%\)B-J]533XYR7G96/XV.F+%;):*QQ0:9#?>
M?.ISDV27"L89/@9;/N?Q'W16^7:6^2_S.?\ 4MW:_!7VSTI.HRUK'AT[L<9Z
MY]BT%VA            ,7&VW&U-N)):%%8I)X2,C&F3'6]9K:-L2S6TQ.V.*
MF(WJ&NP\IVD*/ ?"J.9_.CYAY^)OY=._;;2S],X_;7[%ANU$=67_ /7\UTA:
M'$)6A1*0HK4J+"1D8]#2\6B+5G;$J^8F)V2]&S
M                         *RIWBID!9,+6;\M7B1&"SCIG_"7!\H"%F+S
M5;[0OV1"5_HM&2Y*B_M+\5'R +*F4.F4U)E$9)+BOYCRO"<4??4L\)@)P
M           J*!]IJ_KJO1H 0/O;\:_+0%G=;],4CU*/Z)("S   !"KO]$J'
MJSWHS 1[I_I:C^I1_1) 6H              Q<<0VVIQQ1)0@C-2CX"(AIDR
M5I6;6G9$,UK,SLA41&UU:4F>^DR@LG;!95](^=47_"*'2TG798SWC_#7].O7
M^>?N3\EHP5Y*]^>]/W>U<CT*O              !XI*5)-*B(TG@,CPD9#%J
MQ,;)X,Q.Q2K;?HCANL)4[2E':ZP6%3)GPJ1WT]\AYV^._EUIM2)MIIXUZ:=M
M?R]<+"+1J(V6W9.B?B]/:N&7FGVDNM+);:RM2HL)&0O\66N2L6I.VL]*!>DU
MG9.Z68Z-0                                          5=2O'38+N
MCY2I,U7B1(Y9QPS^$B\7Y0$/1;R5;#+=]DPE?_78,E2%%_:<X$_W0%G3:+3:
M:@TQ&"0I7CN'X2U'WU+/"8":                 J*!]IJ_KJO1H 0/O;\:
M_+0%G=;],4CU*/Z)("S   !"KO\ 1*AZL]Z,P$>Z?Z6H_J4?T20%J
M       *5TU5J4;"#_\ Y4=7URR_UG"^@7]DNZ/.9)GS#+R1_P#-2?>GX[?#
M_3'2L*Q\O7;/ZEN'Y8Z_2NB(DD1$5A%@(B[P]%$1$;(5\R#(
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MFRL2DHK_  <@6^#!3%2*4C96J+>\WM-IXRV;U4SFY6JO^8.S0WJIG-RM5?\
M, -ZJ9S<K57_ # #>JF<W*U5_P P WJIG-RM5?\ , -ZJ9S<K57_ # #>JF<
MW*U5_P P WJIG-RM5?\ , -ZJ9S<K57_ # #>JF<W*U5_P P WJIG-RM5?\
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M)4IBY<M#BWG+",\XHBL(K"(B[@"UA0V8<1J*SE9IE.2C+,U'87PF W
M                  J*#]IJ_KJO1H 0/O;\:_+0%G=;],4CU*/Z)("S   !
M"KO]$J'JSWHS 1[I_I:C^I1_1) 6H          AU.HIA,D9)SDAT\B.R7"M
M9_N[XK_,=?&GINCFR6W5KUS[.M(T^"<D]58XSU,*53E1DK?D*SDZ1X4AWYDI
M_LI'/RW03AB;Y)YLU]]I^Z.R&=3GB^R*[J5X>U/%HC
M       "LGTUY+_M"G&2)A%]8V>!#R2^BKX>\8I=;Y?>+^/I]V7ICHO'5/;U
M2F8<\37DR;Z?7#V+>"GO*::<7F)3AFA3#F!25EPD?[AG3^>:?)-:6GDR3NY9
MXQ/5/W=;&319*[9C?6.E9"Y1&)N-EPJ(OC,:3DK'&89BLL%2XB?&>;+XU$7[
MQSMJL4<;5]<-HQ6GHEJ55:8GQI31?WTXQPMYGIJ\<E/]4-XTV2?PSZD=^\M
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M5P&/4Z/SJD[,>?\ Q9NF+;HF>R>"MRZ.=]J>]3L^]:D9&5I< O(E"
M                                 5% ^TU?UU7HT ('WM^-?EH"SNM^
MF*1ZE']$D!9@   A5W^B5#U9[T9@(]T_TM1_4H_HD@+4        !IFS&(<9
M<A]5B$%\IGW"+X3$;5ZJFGQSDO.Z/XV.F+%;):*QQ0:7#?=?.ISBLDN%8PR?
M RV?<_B/NBM\NTE[W^9S_J6[M?@KU>F>E)U&6L1X=.['&>N5H+M"
M                    <Q5+I/2JJ4AMZQAX\I\U':I!EY/?^#O#Q7F7_%[Y
M]5XE;>Y:=MMO&/1]W4N-/YE%,7+,;XX+(KLTSZ9O+_B=6?[Q<1_Q[3=///IO
M;VHGS^3HV1]$($YNYD#P92F\YW&LM3BS_ND9F-X_X]HX_!M],S[6/G\WQ(J<
MW*P4J[V4D^"1,(F4?'DG:LQUKY'HX_VJ^IK.MS3^*6]%TYLHO]_):8;/ACP6
MDME\1N*(U"17RW35X8Z?Z8<IU&2?Q3ZUE3[K4* 9*8B(-SG7/#7QJM$RM8K&
MR(V0YS.WBM";07 DB^(AB*5CA!MEZ-F        &N1%CR6S;?;2ZV?"E16CC
MGT^/-7ER5BT=K>F2U)VUG9*L.CS(?A4J2:$=E?M6U\A^,D4T^59L&_2Y-D?!
M?WJ_1TPE_-4O^K7Z8W2]17LPHFJHPJ&L\!.^,R?Q++@^4;5\Z\.>74TG%/7Q
MI/\ =[6)T?-&W'/-'U^I:-N-N();:B6@^!23M(^(75,E;QMK.V.Q#M68G9+(
M;L                                    *B@?::OZZKT: $#[V_&ORT
M!9W6_3%(]2C^B2 LP   0J[_ $2H>K/>C,!'NG^EJ/ZE']$D!:@       Q<
M<0VVIQQ1)0@C-2CX"(AIDR5I6;6G9$,UK,SLCBJ(C:ZM*34'TF4)D[8+*OI'
MSJB_X10Z7'.NRQGO'^&OZ=>O\\_<GY;1AKX=>_/>G[O:N1Z%7@
M           9D16F=A?" CN5" U_,DM(L\I:2^<P$-V]%W6L"Z@Q;WB62OFM
M :%7SN__ *;ZWO\ I-.*^9(#S>QE?V>GSGOB8-)?XC(!Y[?K"_Y-"D'WC=6V
MW\YF Y*N7VJS=9:+)1$5"-276<O.H-2RL/+R;+<D@'4M4"54&T/5&K/2FG")
M26H_U#)D>$O%\(R^4!:0*)28!?[2*VTKNK(K5'\:CM,!-
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MH_J4?T20%J       "E<-5:E&RG^E1U?7++_ %G"^@7]E/='G,DSYAEY(_\
MFQS[T_';J_ICI6%8^7KMG]2W#\L=?I71$22(B*PBP$1=X>BB(B-D*^9!D
M   S(N$[ &M4F.CQG4)^-1$ TKJU+;\>6RGXW$XP9V(SEY[O-^//9+^];\P&
MQ%=OS=5KQJ@W\F5B!K-HCC,.>D>]%)2S6Q#4N UEDHS4DE.D7BK2? DO@,:[
M=SC&6TUFVSAPWQOCKVK]J]4F0RV[&HTQU#B24E5B$I,E%;@4:L)#9VK;;$2R
M]K7F<_E47(+N&](07[$D8,A/7T<X(\%C^);BS+B(@#0[X.>/48S)?\M@U?\
M&8!["K;G\ZNO_"33;:/W& ;J(7]HJ<Y[O_7&DO\ "1 /4W,H/^HVZ\?_ #7G
M%?Y@&]NZMW6\*:>S;WU)RO\ BM 3&Z936OY<1E%GDMI+]P"0E"4E8DB(O@*P
M!Z  -"H$%2C4J,TI2CM49H29F?PX &Y*4I224D24E@))8"(@'H
M            K9-!AN.&_'-4.3SS!Y-O\2> Q3ZCR7#>W/CVXLGQ4W>N.$I>
M/67B-EO>KU2U:76H."4R4V.7^NP5CA%_:;[OR#A\SK--^K7QJ?%3O?37V-_#
MPY.[/);JGAZTV%5(,TK8[I*47C-G@67QI/"++2>8X-1'^.VV>KICZ.*/ET]\
M?>A*$UQ                8N.-MIRG%$A/?49$7[08F8CBJYM[KKPOM55BM
M&7<-U!GQ$9F-)R5CC*-DUV"G>O7UJISWGW1MR8KSTY7<3$CNNV_*2;!IX]46
M?.,'X9FWHB98'?FJO_TZZ]2?(_%6\E$9/^-5H>+/166/W&]NYBO/IW/DGO)K
M-YEWI<5+0]2WC9:_V;3ZEI)-AV'E(L3:?=$3-:>;?N>5\WU&><WO1-)V1NB7
MUGW2OOO7&@N/N+=<-3MJW#-2L#A]U6$2]//N0]3Y):9TU9GCO^UV [+8
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MZP WA=V3/Z)'6 &\+NR9_1(ZP WA=V3/Z)'6 &\+NR9_1(ZP WA=V3/Z)'6
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M(S&:L]+KC\VT]MW-LGMW?:Z"/+BR49<=Y#R/*;42BXR,QTB4^MZVX3M;1EL
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M ('WM^-?EH"SNM^F*1ZE']$D!9@   A5W^B5#U9[T9@(]T_TM1_4H_HD@+4
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M^6@+.ZWZ8I'J4?T20%F   "%7?Z)4/5GO1F CW3_ $M1_4H_HD@+4
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M;N6K;ZI2XM4I\K[/(0L_)([%<1X18:;S+3Y_T[UGZ=_J<,FGR4[T3"4)KB
M              J*!]IJ_KJO1H 0/O;\:_+0%G=;],4CU*/Z)("S   !"KO]
M$J'JSWHS 1[I_I:C^I1_1) 6H
M                                                (<JD4R5A>CH4
MKRR+)5QE88K]3Y5ILW?I69Z^$^N'?'JLE.$RB^Q9+&&#/=:(N!IVQU'^+#^T
M0OVC)B_0S7KV6]^OU[W;YNMN_2)]&Z32KP1OY\5N6@OIL*R5<E0?,Z_#W\=<
ML==)V3ZI/#P7X6FOI]L,V[Q4[*R)&7$<\E])H_;P#>GGVGV\N3FQ6ZKQL^O@
MQ;0Y.-=EH[%BT\TZG*:6E:3^DDR,OV"VQY:WC;68F.Q%M68W3&QD.C4
M     %10/M-7]=5Z- "!][?C7Y: L[K?IBD>I1_1) 68   (5=_HE0]6>]&8
M"/=/]+4?U*/Z)("U
M                                           !BXTVXG)<02TGPI41
M&7[1IDQUO&RT1,=K-;3&^%<Y=VFFK+82J*YY;"C1^PL J,GD.FF>:D3CMUTF
M:_R2ZZ[)PGWH[=[#1*]&_D3$2D%_IR$V*Y:1I\KKL/Z>6N2.J\;_ /5#/BX+
M]ZLU_I]DGMF8Q@G4]ULBX76;'4?LPA^[9L7Z^&]>VOOQ]6\^5I;N7B?3N82;
MV4AE+:DK-TUJL4E)&2D%W341V#EJ/^4:3'%9B>;;/1QCMG:WQ^6Y;3.[8MF7
MFGFDNM*);:RM2HL)&0OL66N2L6K.VL]*#:LUG9/%F.C4     5% ^TU?UU7H
MT ('WM^-?EH"SNM^F*1ZE']$D!\DJCU79O'>55/??G3I"9)R39:F-2:?&0I%
MA(RU&PLEMD9(-M.5;A(!9L5%2;H5N+1Y$U5&.6A=-7:^J3[,2IE,U3*W"SQH
M2I3EA\/#8 HY<EXHJR;DU0J2E,L[CK;5)RG)1.H)DC/QUEPDWGL&1: ^O7@<
MJ2;LR3;90]).*LGTK7FR+ZH\HR,DJ[H"NNO+O*5VJ22*='4@H<?)/23*TLTG
M_EF L],O/LV-K1]4 :9>?9L;6CZH TR\^S8VM'U0!IEY]FQM:/J@#3+S[-C:
MT?5 &F7GV;&UH^J -,O/LV-K1]4 :9>?9L;6CZH TR\^S8VM'U0!IEY]FQM:
M/J@#3+S[-C:T?5 &F7GV;&UH^J -,O/LV-K1]4 :9>?9L;6CZH TR\^S8VM'
MU0!IEY]FQM:/J@#3+S[-C:T?5 &F7GV;&UH^J -,O/LV-K1]4 :9>?9L;6CZ
MH TR\^S8VM'U0!IEY]FQM:/J@#3+S[-C:T?5 &F7GV;&UH^J -,O/LV-K1]4
M :9>?9L;6CZH TR\^S8VM'U0!IEY]FQM:/J@#3+S[-C:T?5 &F7GV;&UH^J
M-,O/LV-K1]4 :9>?9L;6CZH TR\^S8VM'U0!IEY]FQM:/J@#3+S[-C:T?5 &
MF7GV;&UH^J -,O/LV-K1]4 :9>?9L;6CZH TR\^S8VM'U0!IEY]FQM:/J@#3
M+S[-C:T?5 &F7GV;&UH^J -,O/LV-K1]4 :9>?9L;6CZH TR\^S8VM'U0!IE
MY]FQM:/J@#3+S[-C:T?5 &F7GV;&UH^J -,O/LV-K1]4 :9>?9L;6CZH TR\
M^S8VM'U0!IEY]FQM:/J@#3+S[-C:T?5 &F7GV;&UH^J -,O/LV-K1]4 :9>?
M9L;6CZH TR\^S8VM'U0!IEY]FQM:/J@#3+S[-C:T?5 &F7GV;&UH^J -,O/L
MV-K1]4 :9>?9L;6CZH TR\^S8VM'U0!IEY]FQM:/J@#3+S[-C:T?5 &F7GV;
M&UH^J -,O/LV-K1]4 :9>?9L;6CZH TR\^S8VM'U0!IEY]FQM:/J@%/6*+7*
MBZA[V?'9=(R)U29*O"3WOY7#\(\]YM_QW%K+Q?;R6Z>V/;VI^EU]L43'&%G%
M5>"*PAABEQD-(*Q*=*5U0NM-IJ8:1CI&RL(>3):]IM;C+;IEY]FQM:/JAW:&
MF7GV;&UH^J -,O/LV-K1]4 :9>?9L;6CZH TR\^S8VM'U0#5==4A2JHJ2VEI
M\YJ\MM"LM)?5HX%6)MX@$7[V_&ORT!9W6_3%(]2C^B2 LP   0J[_1*AZL]Z
M,P$>Z?Z6H_J4?T20%J
M
M*B@?::OZZKT: $#[V_&ORT!9W6_3%(]2C^B2 LP   0J[_1*AZL]Z,P$>Z?Z
M6H_J4?T20%J
M                                                     *B@?::O
MZZKT: $#[V_&ORT!9W6_3%(]2C^B2 LP   0J[_1*AZL]Z,P$>Z?Z6H_J4?T
M20%J
M                                              *B@?::OZZKT: $
M#[V_&ORT!9W6_3%(]2C^B2 LP   0J[_ $2H>K/>C,!'NG^EJ/ZE']$D!:@
M
M                                        "HH'VFK^NJ]&@! ^]OQK
M\M 6=UOTQ2/4H_HD@+,!BEUM;9.)6E39E:2R,C*SOV@/,^SDH5G$Y+EA-JM*
MQ1GA+)[X"+7?Z)4/5GO1F CW3_2U']2C^B2 M0
M
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MM -#O_M*G:J[UH!H=_\ :5.U5WK0#0[_ .TJ=JKO6@&AW_VE3M5=ZT T._\
MM*G:J[UH"9=RDU* W,749:)<J9(5(4;39M-H(TI22$I-2C^C;A,! ^]OQK\M
M 6=UOTQ2/4H_HD@+,           '%7HO%>6EWEBMPWHLF&LLMRCI:6J2<="
M%*?DN/Y62T2#(B01I\(\'" H]_+[QZ-.?44"9,<I;%<@J(EM-,,/K-*FG"(U
MFX:"3X)E9E& L9_O/8;O]1KK,.QT9]9M5//91.FZY&-YE#"> ^YE*^0!]
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MV_&ORT!9W6_3%(]2C^B2 LP   0:]_0ZCZL]Z,P&RD_TJ%_T&O\ @(!*
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MJ4647>[X"+*]X=Z:I>&52FU.E SK2TDF.N.\PMB:TV;9F1J/)6@SMR\)EAX
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M!Q@-BK\7ID.7C9E.EI%(D,OTTXK:DLE9*)HHZUG8I2W$JL-"T_"6 !]?
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$80'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>txmd10k002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 txmd10k002.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@!=@*W P$1  (1 0,1 ?_$ ,   0 " P$! 0
M       %!@(#! <!" $!  (# 0$               0% @,& 0<0  $# @,"
M"@8%" D#! ,!  (! P0 !1$2!B$3,4$BTI,45)05!U%AT=-5%C)2(W2T<4)R
MLC,T-3:!D:%BDE.S)'6QP8)#<R47X:)CPA$!  (! @0#!04&!00" @,   $"
M Q$$(3$2!4%187$B,A,&@9'!0B/PH;'14A3A8G*")/$S0Q53%I*BLL)C_]H
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M<;)#;-$(#%<45%VHJ*E!]H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H%!%:C_=HGWZ'^("@PTC_ "Y"_1+]<J"8H% H% H% H% H% H% H% H%
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MN))02FFM5ZAEZBM[TJ:V[!O;LYA+.C8B</J7T2WB<LB7# \WI3"@]&H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H%!%:C_=HGWZ'^("@PTC_
M "Y"_1+]<J"8H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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MY43!:N^TY?F;7';_ "PA;JG3EM'J[*L&@H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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MFFOC.OX^"VS;2^/;Z>NLK-79JA%:D3+":D)PQWVG,?5FP7_K5%]01IAKD_\
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MDQSK6?VXO<V&V.W3;FZF?+^P,NBZTL@#'@(7B%?ZQP6I34[?E6U_7D]Y?Y]
M^5;7]>3WE_GT#Y5M?UY/>7^?0??E:V?YDKO3_/H'RM;/\R5WI_GT'SY5M?UY
M/>7^?0/E6U_7D]Y?Y]!K9T]8WE-&7WW%;+*X@RGUP+T+RZTXMQCR3,4M%NF=
M)T\)9VQVKIK&FK9\JVOZ\GO+_/K<P0NIK<S;66UB]:0G%_>>LO*@8<6"DNU?
M77,?4W=,VUQ1&*-.K\WEZ>V5CV[;4R6UM/+P\W/"MEPG6]'(S+P.(FR2<M],
MRIQB"EA_VJ)MNX]QW>U_3I6)TTZYG29]D?BVY-OM\63WIU]/YONG;._-E/#*
M-T&&%5'6A=<;+>%QX H^CCJ)](TW-<EXM.E(^*L\^K]N;;W6<<UK,?%X3Z+#
M\JVOZ\GO+_/KO5(?*MK^O)[R_P ^@Y+MI,3@N!;77@EE@@&[)?441>%<,RX[
M*")L&A;E#EKUUY"AF*Y@8==:+.GT2Y.7'^F@L/RK:_KR>\O\^@?*MK^O)[R_
MSZ!\JVOZ\GO+_/H'RK:_KR>\O\^@?*MK^O)[R_SZ!\JVOZ\GO+_/H'RK:_KR
M>\O\^@?*MK^O)[R_SZ!\JVOZ\GO+_/H'RK:_KR>\O\^@?*MK^O)[R_SZ!\JV
MOZ\GO+_/H'RK:_KR>\O\^@?*MK^O)[R_SZ!\JVOZ\GO+_/H.&9984&ZV=U@G
ME-9)#]H\XXF"M'^:9$E!(ZC_ ':)]^A_B H,-(_RY"_1+]<J"8H% H%!6M ?
MPB9_R,[\05!9:!0*"O:CU(_;Y 1HX?:)@;AFG)4?JC[:Y'Z@^H;[7)&/''O<
MYF>6GE'\UKL=A&6LVM/!ML\9+B@W6<N]</'<,DF#;0\')1>%5]-2>U;?^[B-
MUG]ZT_#73W:QZ1X^UKW63Y7Z5.$>,^,_MY)B/&8C-(TPVC;:8X"*8)MJ_P &
MWQX:]%(BM?*$&^2UYUM.LME;F!0*#X2D@JHIF)$7 >#%?16-IF(G3C+V.:BQ
M+W<(=Y?<<:4 <<594;;@*8X9O5AZ:^9;7O&XV^\O:U=*VM[]?"/7[//Q='EV
MF/)AB(GE'"5S2X05!HT?!1?7*TN9.4OH2OHG]_@TK/772_P\>:@^1?68TGAS
M;G76V6R==) ;!,2)=B(E2,N6N.LVM.E8YRPK6;3I'-%6$DE.S+EPC(<R,K__
M #;3!/ZZHNR6C-;+N?\ Y+:5_P!->$)F\CHBN/\ ICC[92]= @E H-$XG!AO
M*VUOSR+E:5<,VS@J-O)M&&W37KMI/N^;9AB.N-9TC7FIE@D7I]Y;>PZ;4?'[
M4L,5:%.(5+Z/HKYUV//O<MYV]+6KC_-_DCTUY>3H-[3#6/F3$3;P]5@725J5
MYEU4,E;55<S+FWB^D\:ZN?I?:S>MIUGIYZSKU?ZE7_[++I,>?[O8FD1$1$1,
M$38B)711$1&D*^9*]"@4"@4"@4$1;?\ 8W.1;5V,NXR(GHP)>6*?D7;5!V__
M (VYOMY^"WOT^WXH^R4[/^ICC)XQ[MOPE*NNMM-DXX2 V"8D2[$1$J\RY:XZ
MS:TZ5A#K6;3I'-PVJ^0;DK@L*J&VJ\@MBJ/$2>JJSMO><&\ZHI/&OA/EYI&X
MV=\6G5XI"K9%?"(13$E04X,5V<-8VM$<9G1[$:H2_.>(8VB(BG(54)XT7 &A
M3ZZIZ?17-][R?W7_ !,7&_.T^%8_S?R6.SK\K]6W"OAYS[/YL-,Z??MY./R3
MP=/$4:%>3EQX5]*UJ^G>Q7VDS?)/O3PTCEIZO=_O:Y=*UC@G7 %P";+@,514
M]2[*ZC)2+UFL\IC16UG2=4#;[S$MMD!9IJ"1WEB+QKFS8#_95/\ 3^29VW1/
M/'::?=/\DO?Q^IK'YHB71<]5V. !YY0./"BJ++:YR5>).3CA_35VAH73VO67
M(BC=$<ZR!$I&TV1CD5<1QRHN&'!0= Z_A.7)Z*PPY)!!'JJLBJFX?YPY5PP1
M*"OZLN>I)\IEI8#L48I(\V (KBY\,14B%,,4]5!MO$6Y/:=8FG/E./25078[
MY;L1X<PHVB)CP5!W_<<.TIUY9TCEP;L&"V6=*FB+)'DE,:F,,N$@(K+A)G,%
M79L%=F%:>W=YV^\F8Q3.M?.-&>?:9,6G5XI:!Y=LPIC,MFX/(ZR:&G)%,?2B
M^I:M$9;Z"#U?%9>MPD6._%P1CHB\)FN&"I7,_5.UIDV\3.O7%HBOK,\%CVS)
M-<GIIQ^QRP[7<K#'*4T02!44*6PN**F7C O54':=MW/;,<Y:36\::WK[/Z9;
M\NXQ[FW3.M?*?YOMLUBW(G$S)!&67%1&#QX%]!KZZ][=]65S9YIDCHI;X9\O
M:\W':YK36LZS'/\ P3KUPA,N--NO")OK@TBKPUU&7?8<=JUM:(F_+U5M<%[1
M,Q'+FZ*EM10*!0<UPN$6!'5^064$V(B;55?0B5#WV^Q;7'UY)TC]\^QNPX+9
M+=-49-O*3F%BVG.](>%,70Y(M(OUB7@7U52[ONW]SCG%M-;9+Q\4<(K[9\_1
M+Q;7Y=NK+I%8\//V(G3=NFPKVK4DRCEE)4#A%Y$7!<%]7#5#]/[#-M][TY)F
MDZ3P\+_MS3M_GIDPZU][_P#JN5?1% AKD W"ZQ[<29H[(]8E#Q+Q *_]:Y[N
M%8W6ZIMYXXZ1UW_A6$_;S\K%.3\T\(_%,  @" "((BF BFQ$1*OZ4BL1$1I$
M(,S,SK**<_VNHVSX&Y[2@7_N-;4__6J._P"CW&L_ES4T_P!U>7[DVOO[>8\:
M3^Z4M5\@E H% H% H% H% H% H% H% H% H(B]_Q"S?>E_T3H,M1_NT3[]#_
M ! 4&&D?Y<A?HE^N5!,4"@4"@K6@/X1,_P"1G?B"H++0*!00)16+U=73?'/"
M@KNFTX$-W'$U]:)P5R]MM3N.ZM:\:X</NQZV_-]D<EE&2=OBB(^._'V1X)X1
M$1013 43!$3@1*Z>M8B-(Y*Z9U*]>% H% H,-PSO"<R#O#3*98)BJ)Q+6OY-
M.J;:1U3&DSZ,NN=-->"HWS2TM9XN00167R^@G)1LN-?R5P/>?IK+.>+8(]R\
M\N73/\EYL^XUZ-+\X_>[[AIN>_;U;Z^Z^Z*(J-'@@$J<7LQJSW_T]GR;?I^=
M>]H\)^&?V\-4;!OZ5OKT1$?O=&F+/)M\4ED&N\>P56,<1#_\^FI?TYVK)M,4
M_,GWK?E\(_Q:NX;JN6WNQPCQ\TU72*\H% H, 9:;(R $$G%S&J)@JKZ5K73%
M6LS-8B)MS]64VF><\F=;&)0*!0*!0*!0*"KZT>E-=5<:!0%M55)0K@HDNS+L
MX,:XGZORY:?+M2-(K/QQSB?)<=JK6>J)GGX-D*%=+U!$KF\349<,K("@D>'
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MZUIU6GEQE*)I>"Z(G-(Y,K,ANO$N&;#\W#B'U5=__6\-XB<TSDR:ZS;S]/\
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M !6M/;9G:YK;6WP_%C]GC7[&>XCYE(RQSY6]OG]J8KH$ H% H% H% H% H%
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M6<W0$<^4AQ(D1,R8;4]*5T<9+>;Y3BW^XF\1UVY^<KOJKRIUS.O+DEM6)PF
M8R!W48<43:(M)P(-;KX;S.O-;;_LNZRY9MK%_7A'[ESTKY;6[Y0BVO45O:66
M#INNY"Y2EF7*JN!@J\E:VTPQTZ6A<;+M-/[>*9:QU:_MQ3=I\OM(VIUUV';P
M$G@W;F=5<115<<,#5:V5Q5KRA.V_;L.&9FE=-8T&O+O1#3@.MV>.+C9(0%@N
MQ17%%X:\^33R8U[5MHG6*0\ZU]Y7:EN>J)4VSPF!@NB"C@X#>)(.!KEV;<:T
M9<-IMK')S_=.RYLN:;8ZQTS[(<T[R=OWRY;4BQD6\HX[X@!/CNT#%=WEQY/!
MPX5C."VD>;#+V'+."L1'OZSK[W!NTQY-W)8US&_10%]6<+8HO(HH]@6TLF.S
M'"LJ8)XZLMEV')%;QDC29CW>/CZZ-6G_ "<U9!OEOF2EBE'CO@X\*&I8B*XJ
MF"CMKRN"T3$L=IV#/CRUO/3I$^;V7PJU]C8Z,/94UV:OZO\ +NT:E8C-&:P>
MK&1H4< 12S)A@6RM63%UJ[N/;J[J(BTS'2A8ODW9;?:[FRT77Y4ME0BE+$<&
MG$1<I"HIBFU:PC;Q$3XH%.P8L=+Q'O6M'#7P4^T^2FK6KE$<E/,-, X*O.LN
M*K@BB[5!%'!5_+6FNWMK"JP?3V>N2)F8B-?">*GZGLEPCZAN3",R)*-2'!20
MK2HKF"_27*F7;ZJTWKQE4[[;Y(S6CWK<>:_/^4%PN]DLTJ%.R.E&%9 3,>3F
M%%$6Q >2@^NI$X)F(TE>7['?-BI,6G7I_-X>Q8]%^5B6RT76W7LF907%1%#8
M14,01-J(:IBF*^BMF/!I$Q/BL.W]E^5CO3)I;J\DE:_*?1MMGLSH\=U7F%S
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M>+V.=W5WV4#YGB]CG=U=]E ^9XO8YW=7?90/F>+V.=W5WV4#YGB]CG=U=]E
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M51P7P4MN&(T%TTQ8"L<25#1_?1W);\F,*CE5MN0:N;OUY2(MM!+FX#8*;A(
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MI+[:F9.&0M;]IK8#JO,"O*-<-O'07FQ:8L5B;=;M,,(HODA.Y<5QPV"F)*N
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M>*8\,5J*\\:*['E%C%?M["#NUZNJ?;*JXXHN/%07"-H=ZYWF+>KZ,;D1R!R
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MDQOS<>;?%D3%I'76-ZO(5UL5V@FV@PC:DT!(NT."-N<;2>TJQFW@?;E$^+J
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M)D3@[P7!P16<K>"@FT$1<*"P[C37A#=K4;CN&YB3D+J[V;>H]O\ #')]'/\
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MO]-&]Y0/%;O\%?Z:-[R@>*W?X*_TT;WE \5N_P %?Z:-[R@>*W?X*_TT;WE
M\5N_P5_IHWO*!XK=_@K_ $T;WE \5N_P5_IHWO*!XK=_@K_31O>4#Q6[_!7^
MFC>\H'BMW^"O]-&]Y0/%;O\ !7^FC>\H'BMW^"O]-&]Y0/%;O\%?Z:-[R@>*
MW?X*_P!-&]Y0/%;O\%?Z:-[R@>*W?X*_TT;WE \5N_P5_IHWO*!XK=_@K_31
MO>4#Q6[_  5_IHWO*!XK=_@K_31O>4#Q6[_!7^FC>\H'BMW^"O\ 31O>4#Q6
M[_!7^FC>\H'BMW^"O]-&]Y0/%;O\%?Z:-[R@>*W?X*_TT;WE \5N_P %?Z:-
M[R@>*W?X*_TT;WE \5N_P5_IHWO*!XK=_@K_ $T;WE \5N_P5_IHWO*!XK=_
M@K_31O>4#Q6[_!7^FC>\H'BMW^"O]-&]Y01M]N5T./&0[2\VB3(JHI.L*BJC
-PJ@\DUVDNQ/[:#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>12
<FILENAME>txmd-20191231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.1d -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +6spw7xRiXhun8uCbn1MSaSMGbP9w5dzielBtm9xHTk6HyEsez5NQSTSudf2IaEN -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:txmd="http://therapeuticsmd.com/20191231" elementFormDefault="qualified" targetNamespace="http://therapeuticsmd.com/20191231">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheets" id="ConsolidatedBalanceSheets">
	  <link:definition>00000002 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical" id="ConsolidatedBalanceSheetsParenthetical">
	  <link:definition>00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations" id="ConsolidatedStatementsOfOperations">
	  <link:definition>00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquity" id="ConsolidatedStatementsOfStockholdersEquity">
	  <link:definition>00000005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows" id="ConsolidatedStatementsOfCashFlows">
	  <link:definition>00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Company" id="Company">
	  <link:definition>00000007 - Disclosure - THE COMPANY</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
	  <link:definition>00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Inventory" id="Inventory">
	  <link:definition>00000009 - Disclosure - INVENTORY</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/OtherCurrentAssets" id="OtherCurrentAssets">
	  <link:definition>00000010 - Disclosure - OTHER CURRENT ASSETS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/FixedAssetsNet" id="FixedAssetsNet">
	  <link:definition>00000011 - Disclosure - FIXED ASSETS, NET</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/IntangibleAssetsNet" id="IntangibleAssetsNet">
	  <link:definition>00000012 - Disclosure - INTANGIBLE ASSETS, NET</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilities" id="OtherCurrentLiabilities">
	  <link:definition>00000013 - Disclosure - OTHER CURRENT LIABILITIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Debt" id="Debt">
	  <link:definition>00000014 - Disclosure - DEBT</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/StockholdersEquity" id="StockholdersEquity">
	  <link:definition>00000015 - Disclosure - STOCKHOLDERS&#8217; EQUITY</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/IncomeTaxes" id="IncomeTaxes">
	  <link:definition>00000016 - Disclosure - INCOME TAXES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/RelatedParties" id="RelatedParties">
	  <link:definition>00000017 - Disclosure - RELATED PARTIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/BusinessConcentrations" id="BusinessConcentrations">
	  <link:definition>00000018 - Disclosure - BUSINESS CONCENTRATIONS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
	  <link:definition>00000019 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialData" id="SelectedQuarterlyFinancialData">
	  <link:definition>00000020 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/SubsequentEvents" id="SubsequentEvents">
	  <link:definition>00000021 - Disclosure - SUBSEQUENT EVENTS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
	  <link:definition>00000022 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
	  <link:definition>00000023 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/InventoryTables" id="InventoryTables">
	  <link:definition>00000024 - Disclosure - INVENTORY (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/OtherCurrentAssetsTables" id="OtherCurrentAssetsTables">
	  <link:definition>00000025 - Disclosure - OTHER CURRENT ASSETS (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/FixedAssetsNetTables" id="FixedAssetsNetTables">
	  <link:definition>00000026 - Disclosure - FIXED ASSETS, NET (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/IntangibleAssetsNetTables" id="IntangibleAssetsNetTables">
	  <link:definition>00000027 - Disclosure - INTANGIBLE ASSETS, NET (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesTables" id="OtherCurrentLiabilitiesTables">
	  <link:definition>00000028 - Disclosure - OTHER CURRENT LIABILITIES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/DebtTables" id="DebtTables">
	  <link:definition>00000029 - Disclosure - DEBT (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/StockholdersEquityTables" id="StockholdersEquityTables">
	  <link:definition>00000030 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
	  <link:definition>00000031 - Disclosure - INCOME TAXES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
	  <link:definition>00000032 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialDataTables" id="SelectedQuarterlyFinancialDataTables">
	  <link:definition>00000033 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/CompanyDetailsNarrative" id="CompanyDetailsNarrative">
	  <link:definition>00000034 - Disclosure - THE COMPANY (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueByProductMixForYearsEndedDecember3120192018And2017Details" id="FollowingTableProvidesInformationAboutDisaggregatedRevenueByProductMixForYearsEndedDecember3120192018And2017Details">
	  <link:definition>00000035 - Disclosure - The following table provides information about disaggregated revenue by product mix for the years ended December 31, 2019, 2018, and 2017: (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/TableBelowPresentsPotentiallyDilutiveSecuritiesThatCouldAffectOurCalculationOfDilutedNetLossPerShareAllocableToCommonStockholdersForPeriodsPresented.Details" id="TableBelowPresentsPotentiallyDilutiveSecuritiesThatCouldAffectOurCalculationOfDilutedNetLossPerShareAllocableToCommonStockholdersForPeriodsPresented.Details">
	  <link:definition>00000036 - Disclosure - The table below presents potentially dilutive securities that could affect our calculation of diluted net loss per share allocable to common stockholders for the periods presented. (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" id="SummaryOfSignificantAccountingPoliciesDetailsNarrative">
	  <link:definition>00000037 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/InventoryConsistsOfFollowingDetails" id="InventoryConsistsOfFollowingDetails">
	  <link:definition>00000038 - Disclosure - Inventory consists of the following: (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails" id="OtherCurrentAssetsConsistOfFollowingDetails">
	  <link:definition>00000039 - Disclosure - Other current assets consist of the following: (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails" id="FixedAssetsNetConsistOfFollowingDetails">
	  <link:definition>00000040 - Disclosure - Fixed assets, net consist of the following: (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/FixedAssetsNetDetailsNarrative" id="FixedAssetsNetDetailsNarrative">
	  <link:definition>00000041 - Disclosure - FIXED ASSETS, NET (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfDecember312019And2018Details" id="FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfDecember312019And2018Details">
	  <link:definition>00000042 - Disclosure - The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of December 31, 2019 and 2018: (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/EstimatedAmortizationExpenseBasedOnCurrentPatentCostBeingAmortizedForNextFiveYearsIsAsFollowsDetails" id="EstimatedAmortizationExpenseBasedOnCurrentPatentCostBeingAmortizedForNextFiveYearsIsAsFollowsDetails">
	  <link:definition>00000043 - Disclosure - Estimated amortization expense, based on current patent cost being amortized, for the next five years is as follows: (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative" id="IntangibleAssetsNetDetailsNarrative">
	  <link:definition>00000044 - Disclosure - INTANGIBLE ASSETS, NET (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails" id="OtherCurrentLiabilitiesConsistOfFollowingDetails">
	  <link:definition>00000045 - Disclosure - Other current liabilities consist of the following: (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/AsOfDecember312019And2018CarryingValueOfOurDebtConsistedOfFollowingDetails" id="AsOfDecember312019And2018CarryingValueOfOurDebtConsistedOfFollowingDetails">
	  <link:definition>00000046 - Disclosure - As of December 31, 2019 and 2018, the carrying value of our debt consisted of the following: (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/DebtDetailsNarrative" id="DebtDetailsNarrative">
	  <link:definition>00000047 - Disclosure - DEBT (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/SummaryOfOurWarrantActivityDuringYearEndedDecember312019Details" id="SummaryOfOurWarrantActivityDuringYearEndedDecember312019Details">
	  <link:definition>00000048 - Disclosure - Summary of our Warrant activity during the year ended December 31, 2019: (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/WeightedAverageFairValuePerShareOfWarrantsIssuedAndAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120192018And2017AreSetForthInTableBelow.Details" id="WeightedAverageFairValuePerShareOfWarrantsIssuedAndAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120192018And2017AreSetForthInTableBelow.Details">
	  <link:definition>00000049 - Disclosure - The weighted average fair value per share of warrants issued and the assumptions used in the Black-Scholes Model during the years ended December 31, 2019, 2018, and 2017 are set forth in the table below. (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/RangesOfAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120192018And2017AreSetForthInTableBelow.Details" id="RangesOfAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120192018And2017AreSetForthInTableBelow.Details">
	  <link:definition>00000050 - Disclosure - The ranges of assumptions used in the Black-Scholes Model during the years ended December 31, 2019, 2018, and 2017 are set forth in the table below. (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringYearEndedDecember312019IsAsFollowsDetails" id="SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringYearEndedDecember312019IsAsFollowsDetails">
	  <link:definition>00000051 - Disclosure - A summary of activity under the 2009, 2012 and 2019 Plans and related information during the year ended December 31, 2019 is as follows: (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative" id="StockholdersEquityDetailsNarrative">
	  <link:definition>00000052 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/ForFinancialReportingPurposesIncomeBeforeTaxesIncludesFollowingComponentsDetails" id="ForFinancialReportingPurposesIncomeBeforeTaxesIncludesFollowingComponentsDetails">
	  <link:definition>00000053 - Disclosure - For financial reporting purposes, income before taxes includes the following components: (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/ReconciliationBetweenTaxesComputedAtFederalStatutoryRateAndConsolidatedEffectiveTaxRateIsAsFollowsDetails" id="ReconciliationBetweenTaxesComputedAtFederalStatutoryRateAndConsolidatedEffectiveTaxRateIsAsFollowsDetails">
	  <link:definition>00000054 - Disclosure - A reconciliation between taxes computed at the federal statutory rate and the consolidated effective tax rate is as follows: (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/ComponentsOfNetDeferredIncomeTaxAssetAsOfDecember3120192018And2017AreAsFollowsDetails" id="ComponentsOfNetDeferredIncomeTaxAssetAsOfDecember3120192018And2017AreAsFollowsDetails">
	  <link:definition>00000055 - Disclosure - The components of the net deferred income tax asset as of December 31, 2019, 2018, and 2017 are as follows: (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/IncomeTaxesDetailsNarrative" id="IncomeTaxesDetailsNarrative">
	  <link:definition>00000056 - Disclosure - INCOME TAXES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative" id="RelatedPartiesDetailsNarrative">
	  <link:definition>00000057 - Disclosure - RELATED PARTIES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative" id="BusinessConcentrationsDetailsNarrative">
	  <link:definition>00000058 - Disclosure - BUSINESS CONCENTRATIONS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/SupplementalLeaseInformationDetails" id="SupplementalLeaseInformationDetails">
	  <link:definition>00000059 - Disclosure - Supplemental lease information (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtDecember312019ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails" id="FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtDecember312019ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails">
	  <link:definition>00000060 - Disclosure - The following table reconciles the undiscounted cash flows for all operating leases at December 31, 2019 to the operating lease liabilities recorded on the balance sheet: (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
	  <link:definition>00000061 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/SummarizedQuarterlyFinancialDataForFiscalYears2019And2018IsAsFollowsDetails" id="SummarizedQuarterlyFinancialDataForFiscalYears2019And2018IsAsFollowsDetails">
	  <link:definition>00000062 - Disclosure - Summarized quarterly financial data for fiscal years 2019 and 2018 is as follows: (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
	  <link:definition>00000063 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="txmd-20191231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="txmd-20191231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="txmd-20191231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="txmd-20191231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" />
    <import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
    <import namespace="http://fasb.org/srt/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd" />
    <element id="txmd_CustomerAMember" name="CustomerAMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CustomerBMember" name="CustomerBMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CustomerCMember" name="CustomerCMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CustomerDMember" name="CustomerDMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_VitaminsAndImvexxyMember" name="VitaminsAndImvexxyMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_BijuvaAndAnnoveraMember" name="BijuvaAndAnnoveraMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_SubscriptionAgreementKnightMember" name="SubscriptionAgreementKnightMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_LicenseAgreementTheramexMember" name="LicenseAgreementTheramexMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PrescriptionVitaminsMember" name="PrescriptionVitaminsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ImvexxyMember" name="ImvexxyMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_BijuvaMember" name="BijuvaMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_AnnoveraMember" name="AnnoveraMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_OtcProductsMember" name="OtcProductsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" name="ApprovedHormoneTherapyDrugCandidatePatentsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_HormoneTherapyDrugCandidatePatentsMember" name="HormoneTherapyDrugCandidatePatentsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_MultipleTrademarksForVitaminsSupplementsMember" name="MultipleTrademarksForVitaminsSupplementsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DomesticUSPatentsMember" name="DomesticUSPatentsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ForeignPatentsMember" name="ForeignPatentsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DomesticPatentsBijuvaMember" name="DomesticPatentsBijuvaMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ForeignPatentsBijuvaMember" name="ForeignPatentsBijuvaMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DomesticPatentsNonApprovedBijuvaMember" name="DomesticPatentsNonApprovedBijuvaMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DomesticUSPatentsImvexxyMember" name="DomesticUSPatentsImvexxyMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DomesticUSUtilityPatentsImvexxyMember" name="DomesticUSUtilityPatentsImvexxyMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DomesticUSDesignPatentsImvexxyMember" name="DomesticUSDesignPatentsImvexxyMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ForeignPatentsImvexxyMember" name="ForeignPatentsImvexxyMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ForeignUtilityPatentsImvexxyMember" name="ForeignUtilityPatentsImvexxyMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ForeignDesignPatentsImvexxyMember" name="ForeignDesignPatentsImvexxyMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DomesticUSPatentsTopicalCreamMember" name="DomesticUSPatentsTopicalCreamMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DomesticUtilityPatentTransdermalPatchMember" name="DomesticUtilityPatentTransdermalPatchMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ForeignUtilityPatentTransdermalPatchMember" name="ForeignUtilityPatentTransdermalPatchMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DomesticUtilityPatentTx009HRMember" name="DomesticUtilityPatentTx009HRMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DomesticPatentsProgesteroneFormulationsMember" name="DomesticPatentsProgesteroneFormulationsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ForeignPatentsProgesteroneFormulationsMember" name="ForeignPatentsProgesteroneFormulationsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DomesticUtilityPatentOperaMember" name="DomesticUtilityPatentOperaMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CouncilLicenseAgreement1Member" name="CouncilLicenseAgreement1Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CouncilLicenseAgreementStep1Member" name="CouncilLicenseAgreementStep1Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CouncilLicenseAgreementStep2Member" name="CouncilLicenseAgreementStep2Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CouncilLicenseAgreementStep3Member" name="CouncilLicenseAgreementStep3Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_FinancingAgreementMember" name="FinancingAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_TrancheOneMember" name="TrancheOneMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_TrancheTwoMember" name="TrancheTwoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_TrancheThreeMember" name="TrancheThreeMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ImvexxyBijuvaAndAnnoveraMember" name="ImvexxyBijuvaAndAnnoveraMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_TrancheTwoThreeMember" name="TrancheTwoThreeMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_MidCapAgreementMember" name="MidCapAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CreditAgreementMember" name="CreditAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_UnderwritingAgreementJPMorganChaseMember" name="UnderwritingAgreementJPMorganChaseMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_UnderwritingAgreementGoldmanSachsMember" name="UnderwritingAgreementGoldmanSachsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WarrantsMember" name="WarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_OutsideConsultant2Member" name="OutsideConsultant2Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WarrantsCashlessExerciseMember" name="WarrantsCashlessExerciseMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_LongTermIncentiveCompensationPlan2009Member" name="LongTermIncentiveCompensationPlan2009Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NonQualified2012StockIncentivePlanMember" name="NonQualified2012StockIncentivePlanMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_Plan2019Member" name="Plan2019Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ExpirationPeriod20YearsMember" name="ExpirationPeriod20YearsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ExpirationPeriodIndefiniteMember" name="ExpirationPeriodIndefiniteMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_SupplierTwoConcentrationRiskMember" name="SupplierTwoConcentrationRiskMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_SupplierThreeConcentrationRiskMember" name="SupplierThreeConcentrationRiskMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_FourCustomersConcentrationRiskMember" name="FourCustomersConcentrationRiskMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CustomerConcentrationMcKessonCorporationRiskMember" name="CustomerConcentrationMcKessonCorporationRiskMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CustomerConcentrationPillPackRiskMember" name="CustomerConcentrationPillPackRiskMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CustomerConcentrationAmerisourceBergenRiskMember" name="CustomerConcentrationAmerisourceBergenRiskMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CustomerConcentrationCardinalHealthRiskMember" name="CustomerConcentrationCardinalHealthRiskMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CustomerConcentrationPharmacyInnovationsPaRiskMember" name="CustomerConcentrationPharmacyInnovationsPaRiskMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CatalentMember" name="CatalentMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_EntityCommonStockHeldByNonaffiliates" name="EntityCommonStockHeldByNonaffiliates" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_LicenseRights" name="LicenseRights" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NoncashOperatingLeaseExpense" name="NoncashOperatingLeaseExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PaymentsToAcquireIntellectualPropertyLicense" name="PaymentsToAcquireIntellectualPropertyLicense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ScheduleOfIntangibleAssetsTableTextBlock" name="ScheduleOfIntangibleAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ScheduleOfWarrantRollForwardTableTextBlock" name="ScheduleOfWarrantRollForwardTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock" name="ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock" name="ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NumberOfSubsidiaries" name="NumberOfSubsidiaries" nillable="true" xbrli:periodType="instant" type="xbrli:integerItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NumberOfIssuedPatentsDomestic" name="NumberOfIssuedPatentsDomestic" nillable="true" xbrli:periodType="instant" type="xbrli:integerItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NumberOfIssuedPatentsForeign" name="NumberOfIssuedPatentsForeign" nillable="true" xbrli:periodType="instant" type="xbrli:integerItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ReturnPeriodOfUnsalablePrescriptionProducts" name="ReturnPeriodOfUnsalablePrescriptionProducts" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ShelfLifeOfPrescriptionProducts" name="ShelfLifeOfPrescriptionProducts" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CashUpfrontPaymentReceived" name="CashUpfrontPaymentReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_RegulatoryMilestoneAdditionalPayment" name="RegulatoryMilestoneAdditionalPayment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_SalesMilestonePaymentsInTranches" name="SalesMilestonePaymentsInTranches" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_AnnualNetSalesMilestone" name="AnnualNetSalesMilestone" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_QuarterlyRoyaltyPaymentsPercentage" name="QuarterlyRoyaltyPaymentsPercentage" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PrepaidSalesAndMarketingCostsCurrent" name="PrepaidSalesAndMarketingCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PrepaidManufacturing" name="PrepaidManufacturing" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NumberOfIssuedPatents" name="NumberOfIssuedPatents" nillable="true" xbrli:periodType="instant" type="xbrli:integerItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_MilestonePaymentUponFDAApproval" name="MilestonePaymentUponFDAApproval" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch" name="MilestonePaymentsAfterReleaseOfFirstCommercialBatch" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NetSalesAmountPerStepbasedRoyalty" name="NetSalesAmountPerStepbasedRoyalty" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_RoyaltyPercent" name="RoyaltyPercent" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent" name="AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent" name="AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_RequiredMilestonePaymentsUponCumulativeNetSalesOfSpecifiedLevels" name="RequiredMilestonePaymentsUponCumulativeNetSalesOfSpecifiedLevels" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_SpecifiedLevelOneOfCumulativeNetSalesForRequiredMilestonePayments" name="SpecifiedLevelOneOfCumulativeNetSalesForRequiredMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_SpecifiedLevelTwoOfCumulativeNetSalesForRequiredMilestonePayments" name="SpecifiedLevelTwoOfCumulativeNetSalesForRequiredMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_SpecifiedLevelThreeOfCumulativeNetSalesForRequiredMilestonePayments" name="SpecifiedLevelThreeOfCumulativeNetSalesForRequiredMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid" name="MaximumCostsAndExpensesForPostApprovalStudyToBePaid" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_SalesDiscountsReturnsAndAllowancesGoods1" name="SalesDiscountsReturnsAndAllowancesGoods1" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_AllowanceForWholesaleDistributorFeesCurrent" name="AllowanceForWholesaleDistributorFeesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_AccruedResearchAndDevelopment" name="AccruedResearchAndDevelopment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_AccruedRebates" name="AccruedRebates" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DebtTrancheAxis" name="DebtTrancheAxis" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" />
    <element id="txmd_DebtTrancheDomain" name="DebtTrancheDomain" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_LiborFloorRate" name="LiborFloorRate" nillable="true" xbrli:periodType="instant" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NumberOfInstallmentPayments" name="NumberOfInstallmentPayments" nillable="true" xbrli:periodType="instant" type="xbrli:integerItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PrepaymentFeeForFirstTwoYearsFundingPercent" name="PrepaymentFeeForFirstTwoYearsFundingPercent" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PrepaymentFeeThirdYearFundingPercent" name="PrepaymentFeeThirdYearFundingPercent" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PrepaymentFeeFourthYearFundingPercent" name="PrepaymentFeeFourthYearFundingPercent" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PrepaymentFeeFifthYearFundingPercent" name="PrepaymentFeeFifthYearFundingPercent" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_FacilityFeePaidPercent" name="FacilityFeePaidPercent" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_MinimumCashBalanceRequirementUnderCreditAgreement" name="MinimumCashBalanceRequirementUnderCreditAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NumberOfTranchesUnderTermLoanFacility" name="NumberOfTranchesUnderTermLoanFacility" nillable="true" xbrli:periodType="instant" type="xbrli:integerItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_RepaymentOfDebtWithNewCreditFacility" name="RepaymentOfDebtWithNewCreditFacility" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PrepaymentFeePercentage" name="PrepaymentFeePercentage" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_RepaymentFeePercentage" name="RepaymentFeePercentage" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice" name="WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WarrantsGrantedOtherThanOptionsWeightedAverageExercisePrice" name="WarrantsGrantedOtherThanOptionsWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WarrantsExercisedOtherThanOptionsWeightedAverageExercisePrice" name="WarrantsExercisedOtherThanOptionsWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WarrantsOutstandingVestedAndExercisable" name="WarrantsOutstandingVestedAndExercisable" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExercisableWeightedAverageRemainingContractualTerms" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExercisableWeightedAverageRemainingContractualTerms" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WarrantsUnvestedWeightedAverageExercisePrice" name="WarrantsUnvestedWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WeightedAverageExercisePriceOtherThanOptions" name="WeightedAverageExercisePriceOtherThanOptions" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PeriodExercisableUnderwritersOption" name="PeriodExercisableUnderwritersOption" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_UnderwritersOptionGrantedInPeriodShares" name="UnderwritersOptionGrantedInPeriodShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ProceedsFromIssuancePublicOffering" name="ProceedsFromIssuancePublicOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NumberOfStockOptionsExercisedInCashlessExercise" name="NumberOfStockOptionsExercisedInCashlessExercise" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares" name="NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife" name="WarrantsAndRightsWeightedAverageContractualRemainingLife" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NumberOfStockIssuedInCashlessExerciseOfWarrants" name="NumberOfStockIssuedInCashlessExerciseOfWarrants" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PlanAwardsNumberOfNewShares" name="PlanAwardsNumberOfNewShares" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NolCarryForwardPeriod" name="NolCarryForwardPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_OperatingLossCarryforwardsExpirationYear" name="OperatingLossCarryforwardsExpirationYear" nillable="true" xbrli:periodType="duration" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NumberOfVendors" name="NumberOfVendors" nillable="true" xbrli:periodType="duration" type="xbrli:integerItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NumberOfCustomers" name="NumberOfCustomers" nillable="true" xbrli:periodType="duration" type="xbrli:integerItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CapitalLeaseObligationsTerm" name="CapitalLeaseObligationsTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NetRentableAreaLease" name="NetRentableAreaLease" nillable="true" xbrli:periodType="instant" type="num:areaItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_RentedAreaLease" name="RentedAreaLease" nillable="true" xbrli:periodType="instant" type="num:areaItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_AdditionalAreaOfLeaseOccupied" name="AdditionalAreaOfLeaseOccupied" nillable="true" xbrli:periodType="instant" type="num:areaItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_LesseeFinanceLeaseExistenceOfOptionToExtendNumber" name="LesseeFinanceLeaseExistenceOfOptionToExtendNumber" nillable="true" xbrli:periodType="duration" type="xbrli:integerItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_LesseeOperatingLeaseLeaseNotYetCommencedArea" name="LesseeOperatingLeaseLeaseNotYetCommencedArea" nillable="true" xbrli:periodType="instant" type="num:areaItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_SignificantSupplyCommitmentPercentagePayable" name="SignificantSupplyCommitmentPercentagePayable" nillable="true" xbrli:periodType="instant" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DomesticUtilityPatentDLimoneneMember" name="DomesticUtilityPatentDLimoneneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ThreeCustomersConcentrationRiskMember" name="ThreeCustomersConcentrationRiskMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CustomerConcentrationPIServicesRiskMember" name="CustomerConcentrationPIServicesRiskMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_RevenueRequirementToDrawOnTermLoan" name="RevenueRequirementToDrawOnTermLoan" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsTextBlock" name="BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NumberOfStockOptionsExercised" name="NumberOfStockOptionsExercised" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_AccruedIntellectualLicenseFee" name="AccruedIntellectualLicenseFee" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WarrantsExpiredOtherThanOptionsWeightedAverageExercisePrice" name="WarrantsExpiredOtherThanOptionsWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>13
<FILENAME>txmd-20191231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.1d -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Cover" xlink:href="txmd-20191231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheets" xlink:href="txmd-20191231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="txmd-20191231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations" xlink:href="txmd-20191231.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:href="txmd-20191231.xsd#ConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="txmd-20191231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Company" xlink:href="txmd-20191231.xsd#Company" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="txmd-20191231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Inventory" xlink:href="txmd-20191231.xsd#Inventory" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentAssets" xlink:href="txmd-20191231.xsd#OtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsNet" xlink:href="txmd-20191231.xsd#FixedAssetsNet" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsNet" xlink:href="txmd-20191231.xsd#IntangibleAssetsNet" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilities" xlink:href="txmd-20191231.xsd#OtherCurrentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Debt" xlink:href="txmd-20191231.xsd#Debt" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquity" xlink:href="txmd-20191231.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IncomeTaxes" xlink:href="txmd-20191231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/RelatedParties" xlink:href="txmd-20191231.xsd#RelatedParties" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/BusinessConcentrations" xlink:href="txmd-20191231.xsd#BusinessConcentrations" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingencies" xlink:href="txmd-20191231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialData" xlink:href="txmd-20191231.xsd#SelectedQuarterlyFinancialData" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SubsequentEvents" xlink:href="txmd-20191231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="txmd-20191231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="txmd-20191231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/InventoryTables" xlink:href="txmd-20191231.xsd#InventoryTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentAssetsTables" xlink:href="txmd-20191231.xsd#OtherCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsNetTables" xlink:href="txmd-20191231.xsd#FixedAssetsNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsNetTables" xlink:href="txmd-20191231.xsd#IntangibleAssetsNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesTables" xlink:href="txmd-20191231.xsd#OtherCurrentLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/DebtTables" xlink:href="txmd-20191231.xsd#DebtTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityTables" xlink:href="txmd-20191231.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IncomeTaxesTables" xlink:href="txmd-20191231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables" xlink:href="txmd-20191231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialDataTables" xlink:href="txmd-20191231.xsd#SelectedQuarterlyFinancialDataTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CompanyDetailsNarrative" xlink:href="txmd-20191231.xsd#CompanyDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueByProductMixForYearsEndedDecember3120192018And2017Details" xlink:href="txmd-20191231.xsd#FollowingTableProvidesInformationAboutDisaggregatedRevenueByProductMixForYearsEndedDecember3120192018And2017Details" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/TableBelowPresentsPotentiallyDilutiveSecuritiesThatCouldAffectOurCalculationOfDilutedNetLossPerShareAllocableToCommonStockholdersForPeriodsPresented.Details" xlink:href="txmd-20191231.xsd#TableBelowPresentsPotentiallyDilutiveSecuritiesThatCouldAffectOurCalculationOfDilutedNetLossPerShareAllocableToCommonStockholdersForPeriodsPresented.Details" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="txmd-20191231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/InventoryConsistsOfFollowingDetails" xlink:href="txmd-20191231.xsd#InventoryConsistsOfFollowingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails" xlink:href="txmd-20191231.xsd#OtherCurrentAssetsConsistOfFollowingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails" xlink:href="txmd-20191231.xsd#FixedAssetsNetConsistOfFollowingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsNetDetailsNarrative" xlink:href="txmd-20191231.xsd#FixedAssetsNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfDecember312019And2018Details" xlink:href="txmd-20191231.xsd#FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfDecember312019And2018Details" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/EstimatedAmortizationExpenseBasedOnCurrentPatentCostBeingAmortizedForNextFiveYearsIsAsFollowsDetails" xlink:href="txmd-20191231.xsd#EstimatedAmortizationExpenseBasedOnCurrentPatentCostBeingAmortizedForNextFiveYearsIsAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative" xlink:href="txmd-20191231.xsd#IntangibleAssetsNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails" xlink:href="txmd-20191231.xsd#OtherCurrentLiabilitiesConsistOfFollowingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/AsOfDecember312019And2018CarryingValueOfOurDebtConsistedOfFollowingDetails" xlink:href="txmd-20191231.xsd#AsOfDecember312019And2018CarryingValueOfOurDebtConsistedOfFollowingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/DebtDetailsNarrative" xlink:href="txmd-20191231.xsd#DebtDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfOurWarrantActivityDuringYearEndedDecember312019Details" xlink:href="txmd-20191231.xsd#SummaryOfOurWarrantActivityDuringYearEndedDecember312019Details" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/WeightedAverageFairValuePerShareOfWarrantsIssuedAndAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120192018And2017AreSetForthInTableBelow.Details" xlink:href="txmd-20191231.xsd#WeightedAverageFairValuePerShareOfWarrantsIssuedAndAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120192018And2017AreSetForthInTableBelow.Details" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/RangesOfAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120192018And2017AreSetForthInTableBelow.Details" xlink:href="txmd-20191231.xsd#RangesOfAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120192018And2017AreSetForthInTableBelow.Details" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringYearEndedDecember312019IsAsFollowsDetails" xlink:href="txmd-20191231.xsd#SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringYearEndedDecember312019IsAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative" xlink:href="txmd-20191231.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ForFinancialReportingPurposesIncomeBeforeTaxesIncludesFollowingComponentsDetails" xlink:href="txmd-20191231.xsd#ForFinancialReportingPurposesIncomeBeforeTaxesIncludesFollowingComponentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ReconciliationBetweenTaxesComputedAtFederalStatutoryRateAndConsolidatedEffectiveTaxRateIsAsFollowsDetails" xlink:href="txmd-20191231.xsd#ReconciliationBetweenTaxesComputedAtFederalStatutoryRateAndConsolidatedEffectiveTaxRateIsAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ComponentsOfNetDeferredIncomeTaxAssetAsOfDecember3120192018And2017AreAsFollowsDetails" xlink:href="txmd-20191231.xsd#ComponentsOfNetDeferredIncomeTaxAssetAsOfDecember3120192018And2017AreAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IncomeTaxesDetailsNarrative" xlink:href="txmd-20191231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative" xlink:href="txmd-20191231.xsd#RelatedPartiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative" xlink:href="txmd-20191231.xsd#BusinessConcentrationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SupplementalLeaseInformationDetails" xlink:href="txmd-20191231.xsd#SupplementalLeaseInformationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtDecember312019ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails" xlink:href="txmd-20191231.xsd#FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtDecember312019ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="txmd-20191231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummarizedQuarterlyFinancialDataForFiscalYears2019And2018IsAsFollowsDetails" xlink:href="txmd-20191231.xsd#SummarizedQuarterlyFinancialDataForFiscalYears2019And2018IsAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SubsequentEventsDetailsNarrative" xlink:href="txmd-20191231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedBalanceSheets" xlink:title="00000002 - Statement - CONSOLIDATED BALANCE SHEETS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCash" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_LicenseRights" xlink:label="loc_txmdLicenseRights" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherAssetsNoncurrent" xlink:to="loc_txmdLicenseRights" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherAssetsNoncurrent" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherAssetsNoncurrent" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:label="loc_us-gaapOtherAssetsMiscellaneousNoncurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherAssetsNoncurrent" xlink:to="loc_us-gaapOtherAssetsMiscellaneousNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaapLongTermDebtNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLongTermDebtNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaapCostOfGoodsAndServicesSold" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapCostOfGoodsAndServicesSold" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaapOtherNonoperatingIncome" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapOtherNonoperatingIncome" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:label="loc_us-gaapInvestmentIncomeNetAmortizationOfDiscountAndPremium" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:title="00000005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS&apos; EQUITY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows" xlink:title="00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncashExpense" xlink:label="loc_us-gaapOtherNoncashExpense" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapOtherNoncashExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_NoncashOperatingLeaseExpense" xlink:label="loc_txmdNoncashOperatingLeaseExpense" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_txmdNoncashOperatingLeaseExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaapProvisionForDoubtfulAccounts" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapProvisionForDoubtfulAccounts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAmortizationOfDeferredCharges" xlink:label="loc_us-gaapOtherAmortizationOfDeferredCharges" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapOtherAmortizationOfDeferredCharges" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaapAmortizationOfFinancingCosts" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAmortizationOfFinancingCosts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" />
      <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_PaymentsToAcquireIntellectualPropertyLicense" xlink:label="loc_txmdPaymentsToAcquireIntellectualPropertyLicense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_txmdPaymentsToAcquireIntellectualPropertyLicense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="loc_us-gaapIncreaseDecreaseInRestrictedCash" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInRestrictedCash" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaapProceedsFromLinesOfCredit" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromLinesOfCredit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xlink:label="loc_us-gaapProceedsFromIssuanceOfOtherLongTermDebt" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfOtherLongTermDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaapPaymentsOfFinancingCosts" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsOfFinancingCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfOtherLongTermDebt" xlink:label="loc_us-gaapRepaymentsOfOtherLongTermDebt" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfOtherLongTermDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Company" xlink:title="00000007 - Disclosure - THE COMPANY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Inventory" xlink:title="00000009 - Disclosure - INVENTORY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssets" xlink:title="00000010 - Disclosure - OTHER CURRENT ASSETS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsNet" xlink:title="00000011 - Disclosure - FIXED ASSETS, NET" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsNet" xlink:title="00000012 - Disclosure - INTANGIBLE ASSETS, NET" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilities" xlink:title="00000013 - Disclosure - OTHER CURRENT LIABILITIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Debt" xlink:title="00000014 - Disclosure - DEBT" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquity" xlink:title="00000015 - Disclosure - STOCKHOLDERS&#8217; EQUITY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IncomeTaxes" xlink:title="00000016 - Disclosure - INCOME TAXES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/RelatedParties" xlink:title="00000017 - Disclosure - RELATED PARTIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/BusinessConcentrations" xlink:title="00000018 - Disclosure - BUSINESS CONCENTRATIONS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingencies" xlink:title="00000019 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialData" xlink:title="00000020 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SubsequentEvents" xlink:title="00000021 - Disclosure - SUBSEQUENT EVENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000022 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000023 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/InventoryTables" xlink:title="00000024 - Disclosure - INVENTORY (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssetsTables" xlink:title="00000025 - Disclosure - OTHER CURRENT ASSETS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsNetTables" xlink:title="00000026 - Disclosure - FIXED ASSETS, NET (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsNetTables" xlink:title="00000027 - Disclosure - INTANGIBLE ASSETS, NET (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesTables" xlink:title="00000028 - Disclosure - OTHER CURRENT LIABILITIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/DebtTables" xlink:title="00000029 - Disclosure - DEBT (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityTables" xlink:title="00000030 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IncomeTaxesTables" xlink:title="00000031 - Disclosure - INCOME TAXES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables" xlink:title="00000032 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialDataTables" xlink:title="00000033 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CompanyDetailsNarrative" xlink:title="00000034 - Disclosure - THE COMPANY (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueByProductMixForYearsEndedDecember3120192018And2017Details" xlink:title="00000035 - Disclosure - The following table provides information about disaggregated revenue by product mix for the years ended December 31, 2019, 2018, and 2017: (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/TableBelowPresentsPotentiallyDilutiveSecuritiesThatCouldAffectOurCalculationOfDilutedNetLossPerShareAllocableToCommonStockholdersForPeriodsPresented.Details" xlink:title="00000036 - Disclosure - The table below presents potentially dilutive securities that could affect our calculation of diluted net loss per share allocable to common stockholders for the periods presented. (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000037 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/InventoryConsistsOfFollowingDetails" xlink:title="00000038 - Disclosure - Inventory consists of the following: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaapInventoryFinishedGoods" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapInventoryNet" xlink:to="loc_us-gaapInventoryFinishedGoods" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaapInventoryWorkInProcess" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapInventoryNet" xlink:to="loc_us-gaapInventoryWorkInProcess" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterialsAndSupplies" xlink:label="loc_us-gaapInventoryRawMaterialsAndSupplies" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapInventoryNet" xlink:to="loc_us-gaapInventoryRawMaterialsAndSupplies" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails" xlink:title="00000039 - Disclosure - Other current assets consist of the following: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_PrepaidSalesAndMarketingCostsCurrent" xlink:label="loc_txmdPrepaidSalesAndMarketingCostsCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_txmdPrepaidSalesAndMarketingCostsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFinanceCostsCurrentNet" xlink:label="loc_us-gaapDeferredFinanceCostsCurrentNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaapDeferredFinanceCostsCurrentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaapPrepaidInsurance" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaapPrepaidInsurance" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_PrepaidManufacturing" xlink:label="loc_txmdPrepaidManufacturing" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_txmdPrepaidManufacturing" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails" xlink:title="00000040 - Disclosure - Fixed assets, net consist of the following: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsNetDetailsNarrative" xlink:title="00000041 - Disclosure - FIXED ASSETS, NET (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfDecember312019And2018Details" xlink:title="00000042 - Disclosure - The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of December 31, 2019 and 2018: (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/EstimatedAmortizationExpenseBasedOnCurrentPatentCostBeingAmortizedForNextFiveYearsIsAsFollowsDetails" xlink:title="00000043 - Disclosure - Estimated amortization expense, based on current patent cost being amortized, for the next five years is as follows: (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative" xlink:title="00000044 - Disclosure - INTANGIBLE ASSETS, NET (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails" xlink:title="00000045 - Disclosure - Other current liabilities consist of the following: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="loc_us-gaapAccruedSalariesCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedSalariesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_SalesDiscountsReturnsAndAllowancesGoods1" xlink:label="loc_txmdSalesDiscountsReturnsAndAllowancesGoods1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_txmdSalesDiscountsReturnsAndAllowancesGoods1" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedMarketingCostsCurrent" xlink:label="loc_us-gaapAccruedMarketingCostsCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedMarketingCostsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedVacationCurrent" xlink:label="loc_us-gaapAccruedVacationCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedVacationCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_AllowanceForWholesaleDistributorFeesCurrent" xlink:label="loc_txmdAllowanceForWholesaleDistributorFeesCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_txmdAllowanceForWholesaleDistributorFeesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaapAccruedProfessionalFeesCurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedProfessionalFeesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_AccruedResearchAndDevelopment" xlink:label="loc_txmdAccruedResearchAndDevelopment" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_txmdAccruedResearchAndDevelopment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedRentCurrent" xlink:label="loc_us-gaapAccruedRentCurrent" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedRentCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_AccruedRebates" xlink:label="loc_txmdAccruedRebates" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_txmdAccruedRebates" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/AsOfDecember312019And2018CarryingValueOfOurDebtConsistedOfFollowingDetails" xlink:title="00000046 - Disclosure - As of December 31, 2019 and 2018, the carrying value of our debt consisted of the following: (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/DebtDetailsNarrative" xlink:title="00000047 - Disclosure - DEBT (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfOurWarrantActivityDuringYearEndedDecember312019Details" xlink:title="00000048 - Disclosure - Summary of our Warrant activity during the year ended December 31, 2019: (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/WeightedAverageFairValuePerShareOfWarrantsIssuedAndAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120192018And2017AreSetForthInTableBelow.Details" xlink:title="00000049 - Disclosure - The weighted average fair value per share of warrants issued and the assumptions used in the Black-Scholes Model during the years ended December 31, 2019, 2018, and 2017 are set forth in the table below. (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/RangesOfAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120192018And2017AreSetForthInTableBelow.Details" xlink:title="00000050 - Disclosure - The ranges of assumptions used in the Black-Scholes Model during the years ended December 31, 2019, 2018, and 2017 are set forth in the table below. (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringYearEndedDecember312019IsAsFollowsDetails" xlink:title="00000051 - Disclosure - A summary of activity under the 2009, 2012 and 2019 Plans and related information during the year ended December 31, 2019 is as follows: (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000052 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ForFinancialReportingPurposesIncomeBeforeTaxesIncludesFollowingComponentsDetails" xlink:title="00000053 - Disclosure - For financial reporting purposes, income before taxes includes the following components: (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ReconciliationBetweenTaxesComputedAtFederalStatutoryRateAndConsolidatedEffectiveTaxRateIsAsFollowsDetails" xlink:title="00000054 - Disclosure - A reconciliation between taxes computed at the federal statutory rate and the consolidated effective tax rate is as follows: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ComponentsOfNetDeferredIncomeTaxAssetAsOfDecember3120192018And2017AreAsFollowsDetails" xlink:title="00000055 - Disclosure - The components of the net deferred income tax asset as of December 31, 2019, 2018, and 2017 are as follows: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOtherLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOtherLossCarryforwards" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsOtherLossCarryforwards" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000056 - Disclosure - INCOME TAXES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative" xlink:title="00000057 - Disclosure - RELATED PARTIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative" xlink:title="00000058 - Disclosure - BUSINESS CONCENTRATIONS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SupplementalLeaseInformationDetails" xlink:title="00000059 - Disclosure - Supplemental lease information (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtDecember312019ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails" xlink:title="00000060 - Disclosure - The following table reconciles the undiscounted cash flows for all operating leases at December 31, 2019 to the operating lease liabilities recorded on the balance sheet: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000061 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummarizedQuarterlyFinancialDataForFiscalYears2019And2018IsAsFollowsDetails" xlink:title="00000062 - Disclosure - Summarized quarterly financial data for fiscal years 2019 and 2018 is as follows: (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000063 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>14
<FILENAME>txmd-20191231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.1d -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Cover" xlink:href="txmd-20191231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheets" xlink:href="txmd-20191231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="txmd-20191231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations" xlink:href="txmd-20191231.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:href="txmd-20191231.xsd#ConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="txmd-20191231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Company" xlink:href="txmd-20191231.xsd#Company" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="txmd-20191231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Inventory" xlink:href="txmd-20191231.xsd#Inventory" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentAssets" xlink:href="txmd-20191231.xsd#OtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsNet" xlink:href="txmd-20191231.xsd#FixedAssetsNet" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsNet" xlink:href="txmd-20191231.xsd#IntangibleAssetsNet" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilities" xlink:href="txmd-20191231.xsd#OtherCurrentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Debt" xlink:href="txmd-20191231.xsd#Debt" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquity" xlink:href="txmd-20191231.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IncomeTaxes" xlink:href="txmd-20191231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/RelatedParties" xlink:href="txmd-20191231.xsd#RelatedParties" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/BusinessConcentrations" xlink:href="txmd-20191231.xsd#BusinessConcentrations" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingencies" xlink:href="txmd-20191231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialData" xlink:href="txmd-20191231.xsd#SelectedQuarterlyFinancialData" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SubsequentEvents" xlink:href="txmd-20191231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="txmd-20191231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="txmd-20191231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/InventoryTables" xlink:href="txmd-20191231.xsd#InventoryTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentAssetsTables" xlink:href="txmd-20191231.xsd#OtherCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsNetTables" xlink:href="txmd-20191231.xsd#FixedAssetsNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsNetTables" xlink:href="txmd-20191231.xsd#IntangibleAssetsNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesTables" xlink:href="txmd-20191231.xsd#OtherCurrentLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/DebtTables" xlink:href="txmd-20191231.xsd#DebtTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityTables" xlink:href="txmd-20191231.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IncomeTaxesTables" xlink:href="txmd-20191231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables" xlink:href="txmd-20191231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialDataTables" xlink:href="txmd-20191231.xsd#SelectedQuarterlyFinancialDataTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CompanyDetailsNarrative" xlink:href="txmd-20191231.xsd#CompanyDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueByProductMixForYearsEndedDecember3120192018And2017Details" xlink:href="txmd-20191231.xsd#FollowingTableProvidesInformationAboutDisaggregatedRevenueByProductMixForYearsEndedDecember3120192018And2017Details" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/TableBelowPresentsPotentiallyDilutiveSecuritiesThatCouldAffectOurCalculationOfDilutedNetLossPerShareAllocableToCommonStockholdersForPeriodsPresented.Details" xlink:href="txmd-20191231.xsd#TableBelowPresentsPotentiallyDilutiveSecuritiesThatCouldAffectOurCalculationOfDilutedNetLossPerShareAllocableToCommonStockholdersForPeriodsPresented.Details" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="txmd-20191231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/InventoryConsistsOfFollowingDetails" xlink:href="txmd-20191231.xsd#InventoryConsistsOfFollowingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails" xlink:href="txmd-20191231.xsd#OtherCurrentAssetsConsistOfFollowingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails" xlink:href="txmd-20191231.xsd#FixedAssetsNetConsistOfFollowingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsNetDetailsNarrative" xlink:href="txmd-20191231.xsd#FixedAssetsNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfDecember312019And2018Details" xlink:href="txmd-20191231.xsd#FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfDecember312019And2018Details" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/EstimatedAmortizationExpenseBasedOnCurrentPatentCostBeingAmortizedForNextFiveYearsIsAsFollowsDetails" xlink:href="txmd-20191231.xsd#EstimatedAmortizationExpenseBasedOnCurrentPatentCostBeingAmortizedForNextFiveYearsIsAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative" xlink:href="txmd-20191231.xsd#IntangibleAssetsNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails" xlink:href="txmd-20191231.xsd#OtherCurrentLiabilitiesConsistOfFollowingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/AsOfDecember312019And2018CarryingValueOfOurDebtConsistedOfFollowingDetails" xlink:href="txmd-20191231.xsd#AsOfDecember312019And2018CarryingValueOfOurDebtConsistedOfFollowingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/DebtDetailsNarrative" xlink:href="txmd-20191231.xsd#DebtDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfOurWarrantActivityDuringYearEndedDecember312019Details" xlink:href="txmd-20191231.xsd#SummaryOfOurWarrantActivityDuringYearEndedDecember312019Details" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/WeightedAverageFairValuePerShareOfWarrantsIssuedAndAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120192018And2017AreSetForthInTableBelow.Details" xlink:href="txmd-20191231.xsd#WeightedAverageFairValuePerShareOfWarrantsIssuedAndAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120192018And2017AreSetForthInTableBelow.Details" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/RangesOfAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120192018And2017AreSetForthInTableBelow.Details" xlink:href="txmd-20191231.xsd#RangesOfAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120192018And2017AreSetForthInTableBelow.Details" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringYearEndedDecember312019IsAsFollowsDetails" xlink:href="txmd-20191231.xsd#SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringYearEndedDecember312019IsAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative" xlink:href="txmd-20191231.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ForFinancialReportingPurposesIncomeBeforeTaxesIncludesFollowingComponentsDetails" xlink:href="txmd-20191231.xsd#ForFinancialReportingPurposesIncomeBeforeTaxesIncludesFollowingComponentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ReconciliationBetweenTaxesComputedAtFederalStatutoryRateAndConsolidatedEffectiveTaxRateIsAsFollowsDetails" xlink:href="txmd-20191231.xsd#ReconciliationBetweenTaxesComputedAtFederalStatutoryRateAndConsolidatedEffectiveTaxRateIsAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ComponentsOfNetDeferredIncomeTaxAssetAsOfDecember3120192018And2017AreAsFollowsDetails" xlink:href="txmd-20191231.xsd#ComponentsOfNetDeferredIncomeTaxAssetAsOfDecember3120192018And2017AreAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IncomeTaxesDetailsNarrative" xlink:href="txmd-20191231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative" xlink:href="txmd-20191231.xsd#RelatedPartiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative" xlink:href="txmd-20191231.xsd#BusinessConcentrationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SupplementalLeaseInformationDetails" xlink:href="txmd-20191231.xsd#SupplementalLeaseInformationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtDecember312019ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails" xlink:href="txmd-20191231.xsd#FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtDecember312019ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="txmd-20191231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummarizedQuarterlyFinancialDataForFiscalYears2019And2018IsAsFollowsDetails" xlink:href="txmd-20191231.xsd#SummarizedQuarterlyFinancialDataForFiscalYears2019And2018IsAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SubsequentEventsDetailsNarrative" xlink:href="txmd-20191231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedBalanceSheets" xlink:title="00000002 - Statement - CONSOLIDATED BALANCE SHEETS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaapProductMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapProductMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="loc_us-gaapLicenseAndServiceMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapLicenseAndServiceMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaapCostOfGoodsAndServicesSold_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCostOfGoodsAndServicesSold_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGrossProfit_100" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingExpensesAbstract_100" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_100" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense_100" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_100" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_100" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_100" xlink:to="loc_us-gaapDepreciationAndAmortization_100" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_100" xlink:to="loc_us-gaapOperatingExpenses_100" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingIncomeLoss_100" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract_100" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_100" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_100" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaapOtherNonoperatingIncome_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_100" xlink:to="loc_us-gaapOtherNonoperatingIncome_100" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_100" xlink:to="loc_us-gaapInterestExpense_100" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:label="loc_us-gaapInvestmentIncomeNetAmortizationOfDiscountAndPremium_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_100" xlink:to="loc_us-gaapInvestmentIncomeNetAmortizationOfDiscountAndPremium_100" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_100" xlink:to="loc_us-gaapNonoperatingIncomeExpense_100" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_100" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit_100" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_100" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareAbstract_100" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaapEarningsPerShareBasicAndDiluted_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEarningsPerShareAbstract_100" xlink:to="loc_us-gaapEarningsPerShareBasicAndDiluted_100" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted_100" xlink:type="arc" order="20" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:title="00000005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS&apos; EQUITY">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaapCumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_50" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_50" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:label="loc_us-gaapStockGrantedDuringPeriodValueSharebasedCompensation_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockGrantedDuringPeriodValueSharebasedCompensation_50" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation_50" xlink:type="arc" order="13" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows" xlink:title="00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Company" xlink:title="00000007 - Disclosure - THE COMPANY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Inventory" xlink:title="00000009 - Disclosure - INVENTORY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssets" xlink:title="00000010 - Disclosure - OTHER CURRENT ASSETS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsNet" xlink:title="00000011 - Disclosure - FIXED ASSETS, NET" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsNet" xlink:title="00000012 - Disclosure - INTANGIBLE ASSETS, NET" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilities" xlink:title="00000013 - Disclosure - OTHER CURRENT LIABILITIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Debt" xlink:title="00000014 - Disclosure - DEBT" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquity" xlink:title="00000015 - Disclosure - STOCKHOLDERS&#8217; EQUITY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IncomeTaxes" xlink:title="00000016 - Disclosure - INCOME TAXES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/RelatedParties" xlink:title="00000017 - Disclosure - RELATED PARTIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/BusinessConcentrations" xlink:title="00000018 - Disclosure - BUSINESS CONCENTRATIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingencies" xlink:title="00000019 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialData" xlink:title="00000020 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SubsequentEvents" xlink:title="00000021 - Disclosure - SUBSEQUENT EVENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000022 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000023 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/InventoryTables" xlink:title="00000024 - Disclosure - INVENTORY (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssetsTables" xlink:title="00000025 - Disclosure - OTHER CURRENT ASSETS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsNetTables" xlink:title="00000026 - Disclosure - FIXED ASSETS, NET (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsNetTables" xlink:title="00000027 - Disclosure - INTANGIBLE ASSETS, NET (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesTables" xlink:title="00000028 - Disclosure - OTHER CURRENT LIABILITIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/DebtTables" xlink:title="00000029 - Disclosure - DEBT (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityTables" xlink:title="00000030 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IncomeTaxesTables" xlink:title="00000031 - Disclosure - INCOME TAXES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables" xlink:title="00000032 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialDataTables" xlink:title="00000033 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CompanyDetailsNarrative" xlink:title="00000034 - Disclosure - THE COMPANY (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueByProductMixForYearsEndedDecember3120192018And2017Details" xlink:title="00000035 - Disclosure - The following table provides information about disaggregated revenue by product mix for the years ended December 31, 2019, 2018, and 2017: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaapProductInformationLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaapScheduleOfProductInformationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapScheduleOfProductInformationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_PrescriptionVitaminsMember" xlink:label="loc_txmdPrescriptionVitaminsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_txmdPrescriptionVitaminsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_ImvexxyMember" xlink:label="loc_txmdImvexxyMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_txmdImvexxyMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_BijuvaMember" xlink:label="loc_txmdBijuvaMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_txmdBijuvaMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_AnnoveraMember" xlink:label="loc_txmdAnnoveraMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_txmdAnnoveraMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="loc_us-gaapLicenseAndServiceMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapLicenseAndServiceMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_OtcProductsMember" xlink:label="loc_txmdOtcProductsMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_txmdOtcProductsMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_130" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/TableBelowPresentsPotentiallyDilutiveSecuritiesThatCouldAffectOurCalculationOfDilutedNetLossPerShareAllocableToCommonStockholdersForPeriodsPresented.Details" xlink:title="00000036 - Disclosure - The table below presents potentially dilutive securities that could affect our calculation of diluted net loss per share allocable to common stockholders for the periods presented. (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_us-gaapWarrantMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_120" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000037 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaapProductInformationLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaapScheduleOfProductInformationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapScheduleOfProductInformationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaapAccountsReceivableMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapAccountsReceivableMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_CustomerAMember" xlink:label="loc_txmdCustomerAMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerAMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_CustomerBMember" xlink:label="loc_txmdCustomerBMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerBMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_CustomerCMember" xlink:label="loc_txmdCustomerCMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerCMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_CustomerDMember" xlink:label="loc_txmdCustomerDMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerDMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LandAndBuildingMember" xlink:label="loc_us-gaapLandAndBuildingMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLandAndBuildingMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="loc_us-gaapSoftwareAndSoftwareDevelopmentCostsMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapSoftwareAndSoftwareDevelopmentCostsMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_90" xlink:type="arc" order="92" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_VitaminsAndImvexxyMember" xlink:label="loc_txmdVitaminsAndImvexxyMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_txmdVitaminsAndImvexxyMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_BijuvaAndAnnoveraMember" xlink:label="loc_txmdBijuvaAndAnnoveraMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_txmdBijuvaAndAnnoveraMember_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_SubscriptionAgreementKnightMember" xlink:label="loc_txmdSubscriptionAgreementKnightMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_txmdSubscriptionAgreementKnightMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_LicenseAgreementTheramexMember" xlink:label="loc_txmdLicenseAgreementTheramexMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdLicenseAgreementTheramexMember_180" xlink:type="arc" order="181" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaapAdjustmentsForNewAccountingPronouncementsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapAdjustmentsForNewAccountingPronouncementsAxis" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaapTypeOfAdoptionMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAdjustmentsForNewAccountingPronouncementsAxis" xlink:to="loc_us-gaapTypeOfAdoptionMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaapTypeOfAdoptionMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAdjustmentsForNewAccountingPronouncementsAxis" xlink:to="loc_us-gaapTypeOfAdoptionMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaapAccountingStandardsUpdate201602Member_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTypeOfAdoptionMember" xlink:to="loc_us-gaapAccountingStandardsUpdate201602Member_270" xlink:type="arc" order="271" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapCashFDICInsuredAmount_300" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1_300" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_300" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_NumberOfIssuedPatentsDomestic" xlink:label="loc_txmdNumberOfIssuedPatentsDomestic_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_txmdNumberOfIssuedPatentsDomestic_300" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_NumberOfIssuedPatentsForeign" xlink:label="loc_txmdNumberOfIssuedPatentsForeign_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_txmdNumberOfIssuedPatentsForeign_300" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_ReturnPeriodOfUnsalablePrescriptionProducts" xlink:label="loc_txmdReturnPeriodOfUnsalablePrescriptionProducts_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_txmdReturnPeriodOfUnsalablePrescriptionProducts_300" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_ShelfLifeOfPrescriptionProducts" xlink:label="loc_txmdShelfLifeOfPrescriptionProducts_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_txmdShelfLifeOfPrescriptionProducts_300" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_300" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare_300" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_300" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_CashUpfrontPaymentReceived" xlink:label="loc_txmdCashUpfrontPaymentReceived_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_txmdCashUpfrontPaymentReceived_300" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_RegulatoryMilestoneAdditionalPayment" xlink:label="loc_txmdRegulatoryMilestoneAdditionalPayment_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_txmdRegulatoryMilestoneAdditionalPayment_300" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_SalesMilestonePaymentsInTranches" xlink:label="loc_txmdSalesMilestonePaymentsInTranches_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_txmdSalesMilestonePaymentsInTranches_300" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_AnnualNetSalesMilestone" xlink:label="loc_txmdAnnualNetSalesMilestone_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_txmdAnnualNetSalesMilestone_300" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_QuarterlyRoyaltyPaymentsPercentage" xlink:label="loc_txmdQuarterlyRoyaltyPaymentsPercentage_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_txmdQuarterlyRoyaltyPaymentsPercentage_300" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaapNumberOfReportableSegments_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapNumberOfReportableSegments_300" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdvertisingExpense" xlink:label="loc_us-gaapAdvertisingExpense_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapAdvertisingExpense_300" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_300" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapOperatingLeaseLiability_300" xlink:type="arc" order="18" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/InventoryConsistsOfFollowingDetails" xlink:title="00000038 - Disclosure - Inventory consists of the following: (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails" xlink:title="00000039 - Disclosure - Other current assets consist of the following: (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails" xlink:title="00000040 - Disclosure - Fixed assets, net consist of the following: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="loc_us-gaapSoftwareAndSoftwareDevelopmentCostsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapSoftwareAndSoftwareDevelopmentCostsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaapEquipmentMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapEquipmentMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_130" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsNetDetailsNarrative" xlink:title="00000041 - Disclosure - FIXED ASSETS, NET (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfDecember312019And2018Details" xlink:title="00000042 - Disclosure - The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of December 31, 2019 and 2018: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:label="loc_txmdApprovedHormoneTherapyDrugCandidatePatentsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdApprovedHormoneTherapyDrugCandidatePatentsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="loc_us-gaapComputerSoftwareIntangibleAssetMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapComputerSoftwareIntangibleAssetMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InternetDomainNamesMember" xlink:label="loc_us-gaapInternetDomainNamesMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapInternetDomainNamesMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_HormoneTherapyDrugCandidatePatentsMember" xlink:label="loc_txmdHormoneTherapyDrugCandidatePatentsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdHormoneTherapyDrugCandidatePatentsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_MultipleTrademarksForVitaminsSupplementsMember" xlink:label="loc_txmdMultipleTrademarksForVitaminsSupplementsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdMultipleTrademarksForVitaminsSupplementsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross_140" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_140" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet_140" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_140" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedTrademarks" xlink:label="loc_us-gaapIndefiniteLivedTrademarks_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapIndefiniteLivedTrademarks_140" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwill_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwill_140" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsGrossExcludingGoodwill_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapIntangibleAssetsGrossExcludingGoodwill_140" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill_140" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/EstimatedAmortizationExpenseBasedOnCurrentPatentCostBeingAmortizedForNextFiveYearsIsAsFollowsDetails" xlink:title="00000043 - Disclosure - Estimated amortization expense, based on current patent cost being amortized, for the next five years is as follows: (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative" xlink:title="00000044 - Disclosure - INTANGIBLE ASSETS, NET (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:label="loc_txmdApprovedHormoneTherapyDrugCandidatePatentsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdApprovedHormoneTherapyDrugCandidatePatentsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_DomesticUSPatentsMember" xlink:label="loc_txmdDomesticUSPatentsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticUSPatentsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_ForeignPatentsMember" xlink:label="loc_txmdForeignPatentsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdForeignPatentsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_DomesticPatentsBijuvaMember" xlink:label="loc_txmdDomesticPatentsBijuvaMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticPatentsBijuvaMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_ForeignPatentsBijuvaMember" xlink:label="loc_txmdForeignPatentsBijuvaMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdForeignPatentsBijuvaMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_DomesticPatentsNonApprovedBijuvaMember" xlink:label="loc_txmdDomesticPatentsNonApprovedBijuvaMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticPatentsNonApprovedBijuvaMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_DomesticUSPatentsImvexxyMember" xlink:label="loc_txmdDomesticUSPatentsImvexxyMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticUSPatentsImvexxyMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_DomesticUSUtilityPatentsImvexxyMember" xlink:label="loc_txmdDomesticUSUtilityPatentsImvexxyMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticUSUtilityPatentsImvexxyMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_DomesticUSDesignPatentsImvexxyMember" xlink:label="loc_txmdDomesticUSDesignPatentsImvexxyMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticUSDesignPatentsImvexxyMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_ForeignPatentsImvexxyMember" xlink:label="loc_txmdForeignPatentsImvexxyMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdForeignPatentsImvexxyMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_ForeignUtilityPatentsImvexxyMember" xlink:label="loc_txmdForeignUtilityPatentsImvexxyMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdForeignUtilityPatentsImvexxyMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_ForeignDesignPatentsImvexxyMember" xlink:label="loc_txmdForeignDesignPatentsImvexxyMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdForeignDesignPatentsImvexxyMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_DomesticUSPatentsTopicalCreamMember" xlink:label="loc_txmdDomesticUSPatentsTopicalCreamMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticUSPatentsTopicalCreamMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_DomesticUtilityPatentTransdermalPatchMember" xlink:label="loc_txmdDomesticUtilityPatentTransdermalPatchMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticUtilityPatentTransdermalPatchMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_ForeignUtilityPatentTransdermalPatchMember" xlink:label="loc_txmdForeignUtilityPatentTransdermalPatchMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdForeignUtilityPatentTransdermalPatchMember_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_DomesticUtilityPatentTx009HRMember" xlink:label="loc_txmdDomesticUtilityPatentTx009HRMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticUtilityPatentTx009HRMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_DomesticPatentsProgesteroneFormulationsMember" xlink:label="loc_txmdDomesticPatentsProgesteroneFormulationsMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticPatentsProgesteroneFormulationsMember_170" xlink:type="arc" order="171" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_ForeignPatentsProgesteroneFormulationsMember" xlink:label="loc_txmdForeignPatentsProgesteroneFormulationsMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdForeignPatentsProgesteroneFormulationsMember_180" xlink:type="arc" order="181" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_DomesticUtilityPatentOperaMember" xlink:label="loc_txmdDomesticUtilityPatentOperaMember_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticUtilityPatentOperaMember_190" xlink:type="arc" order="191" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_AnnoveraMember" xlink:label="loc_txmdAnnoveraMember_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_txmdAnnoveraMember_220" xlink:type="arc" order="221" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_CouncilLicenseAgreement1Member" xlink:label="loc_txmdCouncilLicenseAgreement1Member_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdCouncilLicenseAgreement1Member_220" xlink:type="arc" order="222" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_CouncilLicenseAgreementStep1Member" xlink:label="loc_txmdCouncilLicenseAgreementStep1Member_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdCouncilLicenseAgreementStep1Member_250" xlink:type="arc" order="251" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_CouncilLicenseAgreementStep2Member" xlink:label="loc_txmdCouncilLicenseAgreementStep2Member_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdCouncilLicenseAgreementStep2Member_270" xlink:type="arc" order="271" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_CouncilLicenseAgreementStep3Member" xlink:label="loc_txmdCouncilLicenseAgreementStep3Member_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdCouncilLicenseAgreementStep3Member_300" xlink:type="arc" order="301" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_250" xlink:type="arc" order="252" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_270" xlink:type="arc" order="272" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_340" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="loc_us-gaapImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_340" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_NumberOfIssuedPatents" xlink:label="loc_txmdNumberOfIssuedPatents_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_txmdNumberOfIssuedPatents_340" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets_340" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_MilestonePaymentUponFDAApproval" xlink:label="loc_txmdMilestonePaymentUponFDAApproval_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_txmdMilestonePaymentUponFDAApproval_340" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch" xlink:label="loc_txmdMilestonePaymentsAfterReleaseOfFirstCommercialBatch_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_txmdMilestonePaymentsAfterReleaseOfFirstCommercialBatch_340" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:label="loc_us-gaapFinitelivedIntangibleAssetsAcquired1_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFinitelivedIntangibleAssetsAcquired1_340" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAmortizationOfDeferredCharges" xlink:label="loc_us-gaapOtherAmortizationOfDeferredCharges_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapOtherAmortizationOfDeferredCharges_340" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_NetSalesAmountPerStepbasedRoyalty" xlink:label="loc_txmdNetSalesAmountPerStepbasedRoyalty_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_txmdNetSalesAmountPerStepbasedRoyalty_340" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_RoyaltyPercent" xlink:label="loc_txmdRoyaltyPercent_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_txmdRoyaltyPercent_340" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent" xlink:label="loc_txmdAnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_txmdAnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent_340" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent" xlink:label="loc_txmdAnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_txmdAnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent_340" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_RequiredMilestonePaymentsUponCumulativeNetSalesOfSpecifiedLevels" xlink:label="loc_txmdRequiredMilestonePaymentsUponCumulativeNetSalesOfSpecifiedLevels_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_txmdRequiredMilestonePaymentsUponCumulativeNetSalesOfSpecifiedLevels_340" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_SpecifiedLevelOneOfCumulativeNetSalesForRequiredMilestonePayments" xlink:label="loc_txmdSpecifiedLevelOneOfCumulativeNetSalesForRequiredMilestonePayments_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_txmdSpecifiedLevelOneOfCumulativeNetSalesForRequiredMilestonePayments_340" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_SpecifiedLevelTwoOfCumulativeNetSalesForRequiredMilestonePayments" xlink:label="loc_txmdSpecifiedLevelTwoOfCumulativeNetSalesForRequiredMilestonePayments_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_txmdSpecifiedLevelTwoOfCumulativeNetSalesForRequiredMilestonePayments_340" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_SpecifiedLevelThreeOfCumulativeNetSalesForRequiredMilestonePayments" xlink:label="loc_txmdSpecifiedLevelThreeOfCumulativeNetSalesForRequiredMilestonePayments_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_txmdSpecifiedLevelThreeOfCumulativeNetSalesForRequiredMilestonePayments_340" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid" xlink:label="loc_txmdMaximumCostsAndExpensesForPostApprovalStudyToBePaid_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_txmdMaximumCostsAndExpensesForPostApprovalStudyToBePaid_340" xlink:type="arc" order="16" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails" xlink:title="00000045 - Disclosure - Other current liabilities consist of the following: (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/AsOfDecember312019And2018CarryingValueOfOurDebtConsistedOfFollowingDetails" xlink:title="00000046 - Disclosure - As of December 31, 2019 and 2018, the carrying value of our debt consisted of the following: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_FinancingAgreementMember" xlink:label="loc_txmdFinancingAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdFinancingAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_CreditAgreementMember" xlink:label="loc_txmdCreditAgreementMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdCreditAgreementMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaapDebtInstrumentCarryingAmount_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentCarryingAmount_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaapLongTermDebtNoncurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLongTermDebtNoncurrent_50" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/DebtDetailsNarrative" xlink:title="00000047 - Disclosure - DEBT (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaapCreditFacilityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapCreditFacilityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaapCreditFacilityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapCreditFacilityAxis" xlink:to="loc_us-gaapCreditFacilityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaapCreditFacilityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCreditFacilityAxis" xlink:to="loc_us-gaapCreditFacilityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaapRevolvingCreditFacilityMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCreditFacilityDomain" xlink:to="loc_us-gaapRevolvingCreditFacilityMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="loc_us-gaapSecuredDebtMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCreditFacilityDomain" xlink:to="loc_us-gaapSecuredDebtMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_FinancingAgreementMember" xlink:label="loc_txmdFinancingAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdFinancingAgreementMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_MidCapAgreementMember" xlink:label="loc_txmdMidCapAgreementMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdMidCapAgreementMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_DebtTrancheAxis" xlink:label="loc_txmdDebtTrancheAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_txmdDebtTrancheAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_DebtTrancheDomain" xlink:label="loc_txmdDebtTrancheDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_txmdDebtTrancheAxis" xlink:to="loc_txmdDebtTrancheDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_DebtTrancheDomain" xlink:label="loc_txmdDebtTrancheDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_txmdDebtTrancheAxis" xlink:to="loc_txmdDebtTrancheDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_TrancheOneMember" xlink:label="loc_txmdTrancheOneMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdDebtTrancheDomain" xlink:to="loc_txmdTrancheOneMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_TrancheTwoMember" xlink:label="loc_txmdTrancheTwoMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdDebtTrancheDomain" xlink:to="loc_txmdTrancheTwoMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_TrancheThreeMember" xlink:label="loc_txmdTrancheThreeMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdDebtTrancheDomain" xlink:to="loc_txmdTrancheThreeMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_TrancheTwoThreeMember" xlink:label="loc_txmdTrancheTwoThreeMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdDebtTrancheDomain" xlink:to="loc_txmdTrancheTwoThreeMember_90" xlink:type="arc" order="92" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_30" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_ImvexxyBijuvaAndAnnoveraMember" xlink:label="loc_txmdImvexxyBijuvaAndAnnoveraMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_txmdImvexxyBijuvaAndAnnoveraMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaapVariableRateAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapVariableRateAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaapVariableRateDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapVariableRateAxis" xlink:to="loc_us-gaapVariableRateDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaapVariableRateDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapVariableRateAxis" xlink:to="loc_us-gaapVariableRateDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrimeRateMember" xlink:label="loc_us-gaapPrimeRateMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVariableRateDomain" xlink:to="loc_us-gaapPrimeRateMember_70" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_FinancingAgreementMember" xlink:label="loc_txmdFinancingAgreementMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdFinancingAgreementMember_170" xlink:type="arc" order="171" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity_220" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaapProceedsFromLinesOfCredit_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapProceedsFromLinesOfCredit_220" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_220" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:label="loc_us-gaapDebtInstrumentDescriptionOfVariableRateBasis_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentDescriptionOfVariableRateBasis_220" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaapDebtInstrumentBasisSpreadOnVariableRate1_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentBasisSpreadOnVariableRate1_220" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_LiborFloorRate" xlink:label="loc_txmdLiborFloorRate_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdLiborFloorRate_220" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_NumberOfInstallmentPayments" xlink:label="loc_txmdNumberOfInstallmentPayments_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdNumberOfInstallmentPayments_220" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_PrepaymentFeeForFirstTwoYearsFundingPercent" xlink:label="loc_txmdPrepaymentFeeForFirstTwoYearsFundingPercent_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdPrepaymentFeeForFirstTwoYearsFundingPercent_220" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_PrepaymentFeeThirdYearFundingPercent" xlink:label="loc_txmdPrepaymentFeeThirdYearFundingPercent_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdPrepaymentFeeThirdYearFundingPercent_220" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_PrepaymentFeeFourthYearFundingPercent" xlink:label="loc_txmdPrepaymentFeeFourthYearFundingPercent_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdPrepaymentFeeFourthYearFundingPercent_220" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_PrepaymentFeeFifthYearFundingPercent" xlink:label="loc_txmdPrepaymentFeeFifthYearFundingPercent_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdPrepaymentFeeFifthYearFundingPercent_220" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_FacilityFeePaidPercent" xlink:label="loc_txmdFacilityFeePaidPercent_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdFacilityFeePaidPercent_220" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_MinimumCashBalanceRequirementUnderCreditAgreement" xlink:label="loc_txmdMinimumCashBalanceRequirementUnderCreditAgreement_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdMinimumCashBalanceRequirementUnderCreditAgreement_220" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_NumberOfTranchesUnderTermLoanFacility" xlink:label="loc_txmdNumberOfTranchesUnderTermLoanFacility_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdNumberOfTranchesUnderTermLoanFacility_220" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_RepaymentOfDebtWithNewCreditFacility" xlink:label="loc_txmdRepaymentOfDebtWithNewCreditFacility_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdRepaymentOfDebtWithNewCreditFacility_220" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_PrepaymentFeePercentage" xlink:label="loc_txmdPrepaymentFeePercentage_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdPrepaymentFeePercentage_220" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_RepaymentFeePercentage" xlink:label="loc_txmdRepaymentFeePercentage_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdRepaymentFeePercentage_220" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_220" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaapInterestExpenseDebt_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapInterestExpenseDebt_220" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaapAmortizationOfFinancingCosts_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapAmortizationOfFinancingCosts_220" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaapDebtInstrumentCarryingAmount_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentCarryingAmount_220" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaapPaymentsOfFinancingCosts_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapPaymentsOfFinancingCosts_220" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscount_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscount_220" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseBorrowings" xlink:label="loc_us-gaapInterestExpenseBorrowings_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapInterestExpenseBorrowings_220" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage_220" xlink:type="arc" order="24" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfOurWarrantActivityDuringYearEndedDecember312019Details" xlink:title="00000048 - Disclosure - Summary of our Warrant activity during the year ended December 31, 2019: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice" xlink:label="loc_txmdWarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdWarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_WarrantsGrantedOtherThanOptionsWeightedAverageExercisePrice" xlink:label="loc_txmdWarrantsGrantedOtherThanOptionsWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdWarrantsGrantedOtherThanOptionsWeightedAverageExercisePrice_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_WarrantsExercisedOtherThanOptionsWeightedAverageExercisePrice" xlink:label="loc_txmdWarrantsExercisedOtherThanOptionsWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdWarrantsExercisedOtherThanOptionsWeightedAverageExercisePrice_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_50" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_WarrantsOutstandingVestedAndExercisable" xlink:label="loc_txmdWarrantsOutstandingVestedAndExercisable_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdWarrantsOutstandingVestedAndExercisable_50" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExercisableWeightedAverageRemainingContractualTerms" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExercisableWeightedAverageRemainingContractualTerms_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExercisableWeightedAverageRemainingContractualTerms_50" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue_50" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_50" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_WarrantsUnvestedWeightedAverageExercisePrice" xlink:label="loc_txmdWarrantsUnvestedWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdWarrantsUnvestedWeightedAverageExercisePrice_50" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms_50" xlink:type="arc" order="18" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/WeightedAverageFairValuePerShareOfWarrantsIssuedAndAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120192018And2017AreSetForthInTableBelow.Details" xlink:title="00000049 - Disclosure - The weighted average fair value per share of warrants issued and the assumptions used in the Black-Scholes Model during the years ended December 31, 2019, 2018, and 2017 are set forth in the table below. (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_WeightedAverageExercisePriceOtherThanOptions" xlink:label="loc_txmdWeightedAverageExercisePriceOtherThanOptions_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdWeightedAverageExercisePriceOtherThanOptions_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_40" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/RangesOfAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120192018And2017AreSetForthInTableBelow.Details" xlink:title="00000050 - Disclosure - The ranges of assumptions used in the Black-Scholes Model during the years ended December 31, 2019, 2018, and 2017 are set forth in the table below. (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_70" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_130" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_130" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_130" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_130" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_130" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_130" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringYearEndedDecember312019IsAsFollowsDetails" xlink:title="00000051 - Disclosure - A summary of activity under the 2009, 2012 and 2019 Plans and related information during the year ended December 31, 2019 is as follows: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_50" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_50" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_50" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_50" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_50" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_50" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_50" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_50" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_50" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms_50" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue_50" xlink:type="arc" order="23" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000052 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_UnderwritingAgreementJPMorganChaseMember" xlink:label="loc_txmdUnderwritingAgreementJPMorganChaseMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdUnderwritingAgreementJPMorganChaseMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_UnderwritingAgreementGoldmanSachsMember" xlink:label="loc_txmdUnderwritingAgreementGoldmanSachsMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdUnderwritingAgreementGoldmanSachsMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_SubscriptionAgreementKnightMember" xlink:label="loc_txmdSubscriptionAgreementKnightMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdSubscriptionAgreementKnightMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapStockOptionMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember_330" xlink:type="arc" order="332" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_380" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_380" xlink:type="arc" order="381" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_390" xlink:type="arc" order="391" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_WarrantsMember" xlink:label="loc_txmdWarrantsMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdWarrantsMember_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_us-gaapWarrantMember_170" xlink:type="arc" order="171" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_OutsideConsultant2Member" xlink:label="loc_txmdOutsideConsultant2Member_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdOutsideConsultant2Member_190" xlink:type="arc" order="191" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_WarrantsCashlessExerciseMember" xlink:label="loc_txmdWarrantsCashlessExerciseMember_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdWarrantsCashlessExerciseMember_290" xlink:type="arc" order="291" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_150" xlink:type="arc" order="152" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_160" xlink:type="arc" order="162" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_LongTermIncentiveCompensationPlan2009Member" xlink:label="loc_txmdLongTermIncentiveCompensationPlan2009Member_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_txmdLongTermIncentiveCompensationPlan2009Member_310" xlink:type="arc" order="311" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_NonQualified2012StockIncentivePlanMember" xlink:label="loc_txmdNonQualified2012StockIncentivePlanMember_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_txmdNonQualified2012StockIncentivePlanMember_320" xlink:type="arc" order="321" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_Plan2019Member" xlink:label="loc_txmdPlan2019Member_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_txmdPlan2019Member_340" xlink:type="arc" order="341" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_440" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_440" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_440" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_440" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_440" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_440" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_440" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_440" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_440" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_PeriodExercisableUnderwritersOption" xlink:label="loc_txmdPeriodExercisableUnderwritersOption_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdPeriodExercisableUnderwritersOption_440" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_UnderwritersOptionGrantedInPeriodShares" xlink:label="loc_txmdUnderwritersOptionGrantedInPeriodShares_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdUnderwritersOptionGrantedInPeriodShares_440" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_ProceedsFromIssuancePublicOffering" xlink:label="loc_txmdProceedsFromIssuancePublicOffering_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdProceedsFromIssuancePublicOffering_440" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_440" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_440" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_NumberOfStockOptionsExercisedInCashlessExercise" xlink:label="loc_txmdNumberOfStockOptionsExercisedInCashlessExercise_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdNumberOfStockOptionsExercisedInCashlessExercise_440" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares" xlink:label="loc_txmdNumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdNumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares_440" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_440" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding_440" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife" xlink:label="loc_txmdWarrantsAndRightsWeightedAverageContractualRemainingLife_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdWarrantsAndRightsWeightedAverageContractualRemainingLife_440" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_440" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice" xlink:label="loc_txmdWarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdWarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice_440" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_440" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_440" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate_440" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensation_440" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_440" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_440" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_440" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_NumberOfStockIssuedInCashlessExerciseOfWarrants" xlink:label="loc_txmdNumberOfStockIssuedInCashlessExerciseOfWarrants_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdNumberOfStockIssuedInCashlessExerciseOfWarrants_440" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther_440" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_440" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_440" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_440" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_PlanAwardsNumberOfNewShares" xlink:label="loc_txmdPlanAwardsNumberOfNewShares_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdPlanAwardsNumberOfNewShares_440" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_440" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice_440" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_440" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_440" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_440" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_440" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_440" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockExpense" xlink:label="loc_us-gaapRestrictedStockExpense_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapRestrictedStockExpense_440" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_440" xlink:type="arc" order="42" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ForFinancialReportingPurposesIncomeBeforeTaxesIncludesFollowingComponentsDetails" xlink:title="00000053 - Disclosure - For financial reporting purposes, income before taxes includes the following components: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaapOperatingLossCarryforwardsLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaapOperatingLossCarryforwardsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwardsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaapDomesticCountryMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapDomesticCountryMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_70" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ReconciliationBetweenTaxesComputedAtFederalStatutoryRateAndConsolidatedEffectiveTaxRateIsAsFollowsDetails" xlink:title="00000054 - Disclosure - A reconciliation between taxes computed at the federal statutory rate and the consolidated effective tax rate is as follows: (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ComponentsOfNetDeferredIncomeTaxAssetAsOfDecember3120192018And2017AreAsFollowsDetails" xlink:title="00000055 - Disclosure - The components of the net deferred income tax asset as of December 31, 2019, 2018, and 2017 are as follows: (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000056 - Disclosure - INCOME TAXES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaapOperatingLossCarryforwardsLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaapOperatingLossCarryforwardsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwardsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapIncomeTaxAuthorityNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeTaxAuthorityNameAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeTaxAuthorityNameAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="loc_us-gaapInternalRevenueServiceIRSMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityNameDomain" xlink:to="loc_us-gaapInternalRevenueServiceIRSMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaapTaxPeriodAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapTaxPeriodAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaapTaxPeriodDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTaxPeriodAxis" xlink:to="loc_us-gaapTaxPeriodDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaapTaxPeriodDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTaxPeriodAxis" xlink:to="loc_us-gaapTaxPeriodDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_ExpirationPeriod20YearsMember" xlink:label="loc_txmdExpirationPeriod20YearsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTaxPeriodDomain" xlink:to="loc_txmdExpirationPeriod20YearsMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_ExpirationPeriodIndefiniteMember" xlink:label="loc_txmdExpirationPeriodIndefiniteMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTaxPeriodDomain" xlink:to="loc_txmdExpirationPeriodIndefiniteMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_NolCarryForwardPeriod" xlink:label="loc_txmdNolCarryForwardPeriod_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_txmdNolCarryForwardPeriod_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_OperatingLossCarryforwardsExpirationYear" xlink:label="loc_txmdOperatingLossCarryforwardsExpirationYear_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_txmdOperatingLossCarryforwardsExpirationYear_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapTaxCutsAndJobsActOf2017IncompleteAccountingProvisionalIncomeTaxExpenseBenefit_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapTaxCutsAndJobsActOf2017IncompleteAccountingProvisionalIncomeTaxExpenseBenefit_70" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative" xlink:title="00000057 - Disclosure - RELATED PARTIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_AffiliatedEntityMember" xlink:label="loc_srtAffiliatedEntityMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_srtAffiliatedEntityMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:label="loc_us-gaapRelatedPartyTransactionPurchasesFromRelatedParty_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionPurchasesFromRelatedParty_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="loc_us-gaapAccountsPayableRelatedPartiesCurrent_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapAccountsPayableRelatedPartiesCurrent_60" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative" xlink:title="00000058 - Disclosure - BUSINESS CONCENTRATIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaapConcentrationRiskLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaapConcentrationRiskTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapConcentrationRiskTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:label="loc_us-gaapSupplierConcentrationRiskMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapSupplierConcentrationRiskMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_SupplierTwoConcentrationRiskMember" xlink:label="loc_txmdSupplierTwoConcentrationRiskMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdSupplierTwoConcentrationRiskMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_SupplierThreeConcentrationRiskMember" xlink:label="loc_txmdSupplierThreeConcentrationRiskMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdSupplierThreeConcentrationRiskMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaapCustomerConcentrationRiskMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapCustomerConcentrationRiskMember_90" xlink:type="arc" order="92" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_FourCustomersConcentrationRiskMember" xlink:label="loc_txmdFourCustomersConcentrationRiskMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdFourCustomersConcentrationRiskMember_120" xlink:type="arc" order="122" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_CustomerConcentrationMcKessonCorporationRiskMember" xlink:label="loc_txmdCustomerConcentrationMcKessonCorporationRiskMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerConcentrationMcKessonCorporationRiskMember_150" xlink:type="arc" order="152" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_CustomerConcentrationPillPackRiskMember" xlink:label="loc_txmdCustomerConcentrationPillPackRiskMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerConcentrationPillPackRiskMember_160" xlink:type="arc" order="162" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_CustomerConcentrationAmerisourceBergenRiskMember" xlink:label="loc_txmdCustomerConcentrationAmerisourceBergenRiskMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerConcentrationAmerisourceBergenRiskMember_170" xlink:type="arc" order="172" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_CustomerConcentrationCardinalHealthRiskMember" xlink:label="loc_txmdCustomerConcentrationCardinalHealthRiskMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerConcentrationCardinalHealthRiskMember_180" xlink:type="arc" order="182" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_CustomerConcentrationPharmacyInnovationsPaRiskMember" xlink:label="loc_txmdCustomerConcentrationPharmacyInnovationsPaRiskMember_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerConcentrationPharmacyInnovationsPaRiskMember_260" xlink:type="arc" order="262" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaapSalesRevenueNetMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapSalesRevenueNetMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1_280" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_NumberOfVendors" xlink:label="loc_txmdNumberOfVendors_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_txmdNumberOfVendors_280" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_NumberOfCustomers" xlink:label="loc_txmdNumberOfCustomers_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_txmdNumberOfCustomers_280" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapRevenues_280" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SupplementalLeaseInformationDetails" xlink:title="00000059 - Disclosure - Supplemental lease information (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtDecember312019ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails" xlink:title="00000060 - Disclosure - The following table reconciles the undiscounted cash flows for all operating leases at December 31, 2019 to the operating lease liabilities recorded on the balance sheet: (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000061 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RecordedUnconditionalPurchaseObligationLineItems" xlink:label="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RecordedUnconditionalPurchaseObligationTable" xlink:label="loc_us-gaapRecordedUnconditionalPurchaseObligationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_us-gaapRecordedUnconditionalPurchaseObligationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:label="loc_us-gaapRecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationTable" xlink:to="loc_us-gaapRecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:label="loc_us-gaapUnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:to="loc_us-gaapUnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:label="loc_us-gaapUnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:to="loc_us-gaapUnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_CatalentMember" xlink:label="loc_txmdCatalentMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapUnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:to="loc_txmdCatalentMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_AnnoveraMember" xlink:label="loc_txmdAnnoveraMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapUnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:to="loc_txmdAnnoveraMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_CapitalLeaseObligationsTerm" xlink:label="loc_txmdCapitalLeaseObligationsTerm_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_txmdCapitalLeaseObligationsTerm_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_NetRentableAreaLease" xlink:label="loc_txmdNetRentableAreaLease_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_txmdNetRentableAreaLease_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_RentedAreaLease" xlink:label="loc_txmdRentedAreaLease_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_txmdRentedAreaLease_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_AdditionalAreaOfLeaseOccupied" xlink:label="loc_txmdAdditionalAreaOfLeaseOccupied_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_txmdAdditionalAreaOfLeaseOccupied_110" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaapLesseeOperatingLeaseTermOfContract_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseTermOfContract_110" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_LesseeFinanceLeaseExistenceOfOptionToExtendNumber" xlink:label="loc_txmdLesseeFinanceLeaseExistenceOfOptionToExtendNumber_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_txmdLesseeFinanceLeaseExistenceOfOptionToExtendNumber_110" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:label="loc_us-gaapLesseeFinanceLeaseRenewalTerm1_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_us-gaapLesseeFinanceLeaseRenewalTerm1_110" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_LesseeOperatingLeaseLeaseNotYetCommencedArea" xlink:label="loc_txmdLesseeOperatingLeaseLeaseNotYetCommencedArea_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_txmdLesseeOperatingLeaseLeaseNotYetCommencedArea_110" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaapOperatingLeaseExpense_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_us-gaapOperatingLeaseExpense_110" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaapLeaseAndRentalExpense_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_us-gaapLeaseAndRentalExpense_110" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_SignificantSupplyCommitmentPercentagePayable" xlink:label="loc_txmdSignificantSupplyCommitmentPercentagePayable_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_txmdSignificantSupplyCommitmentPercentagePayable_110" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RecordedUnconditionalPurchaseObligationDueWithinOneYear" xlink:label="loc_us-gaapRecordedUnconditionalPurchaseObligationDueWithinOneYear_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_us-gaapRecordedUnconditionalPurchaseObligationDueWithinOneYear_110" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RecordedUnconditionalPurchaseObligationDueInSecondYear" xlink:label="loc_us-gaapRecordedUnconditionalPurchaseObligationDueInSecondYear_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_us-gaapRecordedUnconditionalPurchaseObligationDueInSecondYear_110" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RecordedUnconditionalPurchaseObligationDueInThirdYear" xlink:label="loc_us-gaapRecordedUnconditionalPurchaseObligationDueInThirdYear_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_us-gaapRecordedUnconditionalPurchaseObligationDueInThirdYear_110" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RecordedUnconditionalPurchaseObligationDueInFourthYear" xlink:label="loc_us-gaapRecordedUnconditionalPurchaseObligationDueInFourthYear_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_us-gaapRecordedUnconditionalPurchaseObligationDueInFourthYear_110" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RecordedUnconditionalPurchaseObligationDueInFifthYear" xlink:label="loc_us-gaapRecordedUnconditionalPurchaseObligationDueInFifthYear_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_us-gaapRecordedUnconditionalPurchaseObligationDueInFifthYear_110" xlink:type="arc" order="15" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummarizedQuarterlyFinancialDataForFiscalYears2019And2018IsAsFollowsDetails" xlink:title="00000062 - Disclosure - Summarized quarterly financial data for fiscal years 2019 and 2018 is as follows: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_LicenseAgreementTheramexMember" xlink:label="loc_txmdLicenseAgreementTheramexMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdLicenseAgreementTheramexMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapGrossProfit_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapNetIncomeLoss_100" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaapEarningsPerShareBasicAndDiluted_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapEarningsPerShareBasicAndDiluted_100" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_100" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000063 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSubsequentEventTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_FinancingAgreementMember" xlink:label="loc_txmdFinancingAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdFinancingAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_ImvexxyBijuvaAndAnnoveraMember" xlink:label="loc_txmdImvexxyBijuvaAndAnnoveraMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_txmdImvexxyBijuvaAndAnnoveraMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaapProceedsFromLinesOfCredit_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapProceedsFromLinesOfCredit_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_30" xlink:type="arc" order="1" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>15
<FILENAME>txmd-20191231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.1d -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductMember" xlink:to="us-gaap_ProductMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductMember_lbl" xml:lang="en-US">Product [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseAndServiceMember" xlink:to="us-gaap_LicenseAndServiceMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicenseAndServiceMember_lbl" xml:lang="en-US">License and Service [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableMember_lbl" xml:lang="en-US">Accounts Receivable [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_CustomerAMember" xlink:label="txmd_CustomerAMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerAMember" xlink:to="txmd_CustomerAMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CustomerAMember_lbl" xml:lang="en-US">Customer A [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_CustomerBMember" xlink:label="txmd_CustomerBMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerBMember" xlink:to="txmd_CustomerBMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CustomerBMember_lbl" xml:lang="en-US">Customer B [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_CustomerCMember" xlink:label="txmd_CustomerCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerCMember" xlink:to="txmd_CustomerCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CustomerCMember_lbl" xml:lang="en-US">Customer C [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_CustomerDMember" xlink:label="txmd_CustomerDMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerDMember" xlink:to="txmd_CustomerDMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CustomerDMember_lbl" xml:lang="en-US">Customer D [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LandAndBuildingMember" xlink:label="us-gaap_LandAndBuildingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LandAndBuildingMember" xlink:to="us-gaap_LandAndBuildingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LandAndBuildingMember_lbl" xml:lang="en-US">Land and Building [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl" xml:lang="en-US">Software and Software Development Costs [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_VitaminsAndImvexxyMember" xlink:label="txmd_VitaminsAndImvexxyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_VitaminsAndImvexxyMember" xlink:to="txmd_VitaminsAndImvexxyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_VitaminsAndImvexxyMember_lbl" xml:lang="en-US">Vitamins and IMVEXXY [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_BijuvaAndAnnoveraMember" xlink:label="txmd_BijuvaAndAnnoveraMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_BijuvaAndAnnoveraMember" xlink:to="txmd_BijuvaAndAnnoveraMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_BijuvaAndAnnoveraMember_lbl" xml:lang="en-US">BIJUVA and ANNOVERA [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_SubscriptionAgreementKnightMember" xlink:label="txmd_SubscriptionAgreementKnightMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SubscriptionAgreementKnightMember" xlink:to="txmd_SubscriptionAgreementKnightMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_SubscriptionAgreementKnightMember_lbl" xml:lang="en-US">Subscription Agreement Knight [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_LicenseAgreementTheramexMember" xlink:label="txmd_LicenseAgreementTheramexMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LicenseAgreementTheramexMember" xlink:to="txmd_LicenseAgreementTheramexMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_LicenseAgreementTheramexMember_lbl" xml:lang="en-US">License Agreement Theramex</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_PrescriptionVitaminsMember" xlink:label="txmd_PrescriptionVitaminsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrescriptionVitaminsMember" xlink:to="txmd_PrescriptionVitaminsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PrescriptionVitaminsMember_lbl" xml:lang="en-US">Prescription Vitamins [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_ImvexxyMember" xlink:label="txmd_ImvexxyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ImvexxyMember" xlink:to="txmd_ImvexxyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ImvexxyMember_lbl" xml:lang="en-US">Imvexxy [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_BijuvaMember" xlink:label="txmd_BijuvaMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_BijuvaMember" xlink:to="txmd_BijuvaMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_BijuvaMember_lbl" xml:lang="en-US">BIJUVA [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_AnnoveraMember" xlink:label="txmd_AnnoveraMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AnnoveraMember" xlink:to="txmd_AnnoveraMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AnnoveraMember_lbl" xml:lang="en-US">ANNOVERA [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_OtcProductsMember" xlink:label="txmd_OtcProductsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_OtcProductsMember" xlink:to="txmd_OtcProductsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_OtcProductsMember_lbl" xml:lang="en-US">OTC Products [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US">Restricted Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201602Member" xlink:to="us-gaap_AccountingStandardsUpdate201602Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xml:lang="en-US">Accounting Standards Update 2016-02 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US">Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US">Computer Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:label="txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:to="txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember_lbl" xml:lang="en-US">Approved Hormone Therapy Drug Candidate Patents [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_HormoneTherapyDrugCandidatePatentsMember" xlink:label="txmd_HormoneTherapyDrugCandidatePatentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_HormoneTherapyDrugCandidatePatentsMember" xlink:to="txmd_HormoneTherapyDrugCandidatePatentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_HormoneTherapyDrugCandidatePatentsMember_lbl" xml:lang="en-US">Hormone Therapy Drug Candidate Patents - (Pending) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_MultipleTrademarksForVitaminsSupplementsMember" xlink:label="txmd_MultipleTrademarksForVitaminsSupplementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MultipleTrademarksForVitaminsSupplementsMember" xlink:to="txmd_MultipleTrademarksForVitaminsSupplementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_MultipleTrademarksForVitaminsSupplementsMember_lbl" xml:lang="en-US">Multiple Trademarks [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl" xml:lang="en-US">Computer Software, Intangible Asset [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InternetDomainNamesMember" xlink:label="us-gaap_InternetDomainNamesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InternetDomainNamesMember" xlink:to="us-gaap_InternetDomainNamesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InternetDomainNamesMember_lbl" xml:lang="en-US">Internet Domain Names [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_DomesticUSPatentsMember" xlink:label="txmd_DomesticUSPatentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticUSPatentsMember" xlink:to="txmd_DomesticUSPatentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DomesticUSPatentsMember_lbl" xml:lang="en-US">Domestic US Patents</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_ForeignPatentsMember" xlink:label="txmd_ForeignPatentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ForeignPatentsMember" xlink:to="txmd_ForeignPatentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ForeignPatentsMember_lbl" xml:lang="en-US">Foreign Patents Member</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_DomesticPatentsBijuvaMember" xlink:label="txmd_DomesticPatentsBijuvaMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticPatentsBijuvaMember" xlink:to="txmd_DomesticPatentsBijuvaMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DomesticPatentsBijuvaMember_lbl" xml:lang="en-US">Domestic Patents BIJUVA</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_ForeignPatentsBijuvaMember" xlink:label="txmd_ForeignPatentsBijuvaMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ForeignPatentsBijuvaMember" xlink:to="txmd_ForeignPatentsBijuvaMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ForeignPatentsBijuvaMember_lbl" xml:lang="en-US">Foreign Patents BIJUVA</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_DomesticPatentsNonApprovedBijuvaMember" xlink:label="txmd_DomesticPatentsNonApprovedBijuvaMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticPatentsNonApprovedBijuvaMember" xlink:to="txmd_DomesticPatentsNonApprovedBijuvaMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DomesticPatentsNonApprovedBijuvaMember_lbl" xml:lang="en-US">Domestic Patents NonApproved BIJUVA</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_DomesticUSPatentsImvexxyMember" xlink:label="txmd_DomesticUSPatentsImvexxyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticUSPatentsImvexxyMember" xlink:to="txmd_DomesticUSPatentsImvexxyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DomesticUSPatentsImvexxyMember_lbl" xml:lang="en-US">Domestic US Patents IMVEXXY</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_DomesticUSUtilityPatentsImvexxyMember" xlink:label="txmd_DomesticUSUtilityPatentsImvexxyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticUSUtilityPatentsImvexxyMember" xlink:to="txmd_DomesticUSUtilityPatentsImvexxyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DomesticUSUtilityPatentsImvexxyMember_lbl" xml:lang="en-US">Domestic US Utility Patents IMVEXXY</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_DomesticUSDesignPatentsImvexxyMember" xlink:label="txmd_DomesticUSDesignPatentsImvexxyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticUSDesignPatentsImvexxyMember" xlink:to="txmd_DomesticUSDesignPatentsImvexxyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DomesticUSDesignPatentsImvexxyMember_lbl" xml:lang="en-US">Domestic US Design Patents IMVEXXY</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_ForeignPatentsImvexxyMember" xlink:label="txmd_ForeignPatentsImvexxyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ForeignPatentsImvexxyMember" xlink:to="txmd_ForeignPatentsImvexxyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ForeignPatentsImvexxyMember_lbl" xml:lang="en-US">Foreign Patents IMVEXXY</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_ForeignUtilityPatentsImvexxyMember" xlink:label="txmd_ForeignUtilityPatentsImvexxyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ForeignUtilityPatentsImvexxyMember" xlink:to="txmd_ForeignUtilityPatentsImvexxyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ForeignUtilityPatentsImvexxyMember_lbl" xml:lang="en-US">Foreign Utility Patents IMVEXXY</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_ForeignDesignPatentsImvexxyMember" xlink:label="txmd_ForeignDesignPatentsImvexxyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ForeignDesignPatentsImvexxyMember" xlink:to="txmd_ForeignDesignPatentsImvexxyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ForeignDesignPatentsImvexxyMember_lbl" xml:lang="en-US">Foreign Design Patents IMVEXXY</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_DomesticUSPatentsTopicalCreamMember" xlink:label="txmd_DomesticUSPatentsTopicalCreamMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticUSPatentsTopicalCreamMember" xlink:to="txmd_DomesticUSPatentsTopicalCreamMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DomesticUSPatentsTopicalCreamMember_lbl" xml:lang="en-US">Domestic US Patents Topical Cream</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_DomesticUtilityPatentTransdermalPatchMember" xlink:label="txmd_DomesticUtilityPatentTransdermalPatchMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticUtilityPatentTransdermalPatchMember" xlink:to="txmd_DomesticUtilityPatentTransdermalPatchMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DomesticUtilityPatentTransdermalPatchMember_lbl" xml:lang="en-US">Domestic Utility Patent Transdermal Patch</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_ForeignUtilityPatentTransdermalPatchMember" xlink:label="txmd_ForeignUtilityPatentTransdermalPatchMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ForeignUtilityPatentTransdermalPatchMember" xlink:to="txmd_ForeignUtilityPatentTransdermalPatchMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ForeignUtilityPatentTransdermalPatchMember_lbl" xml:lang="en-US">Foreign Utility Patent Transdermal Patch</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_DomesticUtilityPatentTx009HRMember" xlink:label="txmd_DomesticUtilityPatentTx009HRMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticUtilityPatentTx009HRMember" xlink:to="txmd_DomesticUtilityPatentTx009HRMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DomesticUtilityPatentTx009HRMember_lbl" xml:lang="en-US">Domestic Utility Patent TX009HR</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_DomesticPatentsProgesteroneFormulationsMember" xlink:label="txmd_DomesticPatentsProgesteroneFormulationsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticPatentsProgesteroneFormulationsMember" xlink:to="txmd_DomesticPatentsProgesteroneFormulationsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DomesticPatentsProgesteroneFormulationsMember_lbl" xml:lang="en-US">Domestic Patents Progesterone Formulations</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_ForeignPatentsProgesteroneFormulationsMember" xlink:label="txmd_ForeignPatentsProgesteroneFormulationsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ForeignPatentsProgesteroneFormulationsMember" xlink:to="txmd_ForeignPatentsProgesteroneFormulationsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ForeignPatentsProgesteroneFormulationsMember_lbl" xml:lang="en-US">Foreign Patents Progesterone Formulations</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_DomesticUtilityPatentOperaMember" xlink:label="txmd_DomesticUtilityPatentOperaMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticUtilityPatentOperaMember" xlink:to="txmd_DomesticUtilityPatentOperaMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DomesticUtilityPatentOperaMember_lbl" xml:lang="en-US">Domestic Utility Patent Opera</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_CouncilLicenseAgreement1Member" xlink:label="txmd_CouncilLicenseAgreement1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CouncilLicenseAgreement1Member" xlink:to="txmd_CouncilLicenseAgreement1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CouncilLicenseAgreement1Member_lbl" xml:lang="en-US">Council License Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_CouncilLicenseAgreementStep1Member" xlink:label="txmd_CouncilLicenseAgreementStep1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CouncilLicenseAgreementStep1Member" xlink:to="txmd_CouncilLicenseAgreementStep1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CouncilLicenseAgreementStep1Member_lbl" xml:lang="en-US">Council License Agreement Step 1</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_CouncilLicenseAgreementStep2Member" xlink:label="txmd_CouncilLicenseAgreementStep2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CouncilLicenseAgreementStep2Member" xlink:to="txmd_CouncilLicenseAgreementStep2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CouncilLicenseAgreementStep2Member_lbl" xml:lang="en-US">Council License Agreement Step 2</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_CouncilLicenseAgreementStep3Member" xlink:label="txmd_CouncilLicenseAgreementStep3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CouncilLicenseAgreementStep3Member" xlink:to="txmd_CouncilLicenseAgreementStep3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CouncilLicenseAgreementStep3Member_lbl" xml:lang="en-US">Council License Agreement Step 3</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CreditFacilityAxis_lbl" xml:lang="en-US">Credit Facility [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="us-gaap_RevolvingCreditFacilityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevolvingCreditFacilityMember" xlink:to="us-gaap_RevolvingCreditFacilityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevolvingCreditFacilityMember_lbl" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_FinancingAgreementMember" xlink:label="txmd_FinancingAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_FinancingAgreementMember" xlink:to="txmd_FinancingAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_FinancingAgreementMember_lbl" xml:lang="en-US">Financing Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_DebtTrancheAxis" xlink:label="txmd_DebtTrancheAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DebtTrancheAxis" xlink:to="txmd_DebtTrancheAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DebtTrancheAxis_lbl" xml:lang="en-US">Debt Tranche [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_TrancheOneMember" xlink:label="txmd_TrancheOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_TrancheOneMember" xlink:to="txmd_TrancheOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_TrancheOneMember_lbl" xml:lang="en-US">Tranche 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_TrancheTwoMember" xlink:label="txmd_TrancheTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_TrancheTwoMember" xlink:to="txmd_TrancheTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_TrancheTwoMember_lbl" xml:lang="en-US">Tranche Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_TrancheThreeMember" xlink:label="txmd_TrancheThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_TrancheThreeMember" xlink:to="txmd_TrancheThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_TrancheThreeMember_lbl" xml:lang="en-US">Tranche 3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_ImvexxyBijuvaAndAnnoveraMember" xlink:label="txmd_ImvexxyBijuvaAndAnnoveraMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ImvexxyBijuvaAndAnnoveraMember" xlink:to="txmd_ImvexxyBijuvaAndAnnoveraMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ImvexxyBijuvaAndAnnoveraMember_lbl" xml:lang="en-US">IMVEXXY, BIJUVA and ANNOVERA [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableRateAxis_lbl" xml:lang="en-US">Variable Rate [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrimeRateMember" xlink:label="us-gaap_PrimeRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrimeRateMember" xlink:to="us-gaap_PrimeRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrimeRateMember_lbl" xml:lang="en-US">Prime Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_TrancheTwoThreeMember" xlink:label="txmd_TrancheTwoThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_TrancheTwoThreeMember" xlink:to="txmd_TrancheTwoThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_TrancheTwoThreeMember_lbl" xml:lang="en-US">Tranche Two Three Member</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="us-gaap_SecuredDebtMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecuredDebtMember" xlink:to="us-gaap_SecuredDebtMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecuredDebtMember_lbl" xml:lang="en-US">Secured Debt [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_MidCapAgreementMember" xlink:label="txmd_MidCapAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MidCapAgreementMember" xlink:to="txmd_MidCapAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_MidCapAgreementMember_lbl" xml:lang="en-US">Credit Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_CreditAgreementMember" xlink:label="txmd_CreditAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CreditAgreementMember" xlink:to="txmd_CreditAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CreditAgreementMember_lbl" xml:lang="en-US">Credit Agreement Member</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_UnderwritingAgreementJPMorganChaseMember" xlink:label="txmd_UnderwritingAgreementJPMorganChaseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_UnderwritingAgreementJPMorganChaseMember" xlink:to="txmd_UnderwritingAgreementJPMorganChaseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_UnderwritingAgreementJPMorganChaseMember_lbl" xml:lang="en-US">Underwriting Agreement JP Morgan Chase</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Equity Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_UnderwritingAgreementGoldmanSachsMember" xlink:label="txmd_UnderwritingAgreementGoldmanSachsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_UnderwritingAgreementGoldmanSachsMember" xlink:to="txmd_UnderwritingAgreementGoldmanSachsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_UnderwritingAgreementGoldmanSachsMember_lbl" xml:lang="en-US">Underwriting Agreement Goldman Sachs [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_WarrantsMember" xlink:label="txmd_WarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsMember" xlink:to="txmd_WarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WarrantsMember_lbl" xml:lang="en-US">Warrants Member</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_OutsideConsultant2Member" xlink:label="txmd_OutsideConsultant2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_OutsideConsultant2Member" xlink:to="txmd_OutsideConsultant2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_OutsideConsultant2Member_lbl" xml:lang="en-US">Outside Consultants Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_WarrantsCashlessExerciseMember" xlink:label="txmd_WarrantsCashlessExerciseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsCashlessExerciseMember" xlink:to="txmd_WarrantsCashlessExerciseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WarrantsCashlessExerciseMember_lbl" xml:lang="en-US">Warrants - Cashless Exercise [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_LongTermIncentiveCompensationPlan2009Member" xlink:label="txmd_LongTermIncentiveCompensationPlan2009Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LongTermIncentiveCompensationPlan2009Member" xlink:to="txmd_LongTermIncentiveCompensationPlan2009Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_LongTermIncentiveCompensationPlan2009Member_lbl" xml:lang="en-US">2009 Long Term Incentive Compensation Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_NonQualified2012StockIncentivePlanMember" xlink:label="txmd_NonQualified2012StockIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NonQualified2012StockIncentivePlanMember" xlink:to="txmd_NonQualified2012StockIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NonQualified2012StockIncentivePlanMember_lbl" xml:lang="en-US">2012 Stock Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_Plan2019Member" xlink:label="txmd_Plan2019Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_Plan2019Member" xlink:to="txmd_Plan2019Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_Plan2019Member_lbl" xml:lang="en-US">Plan 2019 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis_lbl" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="us-gaap_InternalRevenueServiceIRSMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InternalRevenueServiceIRSMember" xlink:to="us-gaap_InternalRevenueServiceIRSMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InternalRevenueServiceIRSMember_lbl" xml:lang="en-US">Internal Revenue Service (IRS) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxPeriodAxis_lbl" xml:lang="en-US">Tax Period [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_ExpirationPeriod20YearsMember" xlink:label="txmd_ExpirationPeriod20YearsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ExpirationPeriod20YearsMember" xlink:to="txmd_ExpirationPeriod20YearsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ExpirationPeriod20YearsMember_lbl" xml:lang="en-US">Expiration Period 20 Years [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_ExpirationPeriodIndefiniteMember" xlink:label="txmd_ExpirationPeriodIndefiniteMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ExpirationPeriodIndefiniteMember" xlink:to="txmd_ExpirationPeriodIndefiniteMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ExpirationPeriodIndefiniteMember_lbl" xml:lang="en-US">Expiration Period Indefinite [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_AffiliatedEntityMember" xlink:label="srt_AffiliatedEntityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_AffiliatedEntityMember" xlink:to="srt_AffiliatedEntityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_AffiliatedEntityMember_lbl" xml:lang="en-US">Affiliated Entity [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:label="us-gaap_SupplierConcentrationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplierConcentrationRiskMember" xlink:to="us-gaap_SupplierConcentrationRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplierConcentrationRiskMember_lbl" xml:lang="en-US">Supplier Concentration Risk [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_SupplierTwoConcentrationRiskMember" xlink:label="txmd_SupplierTwoConcentrationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SupplierTwoConcentrationRiskMember" xlink:to="txmd_SupplierTwoConcentrationRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_SupplierTwoConcentrationRiskMember_lbl" xml:lang="en-US">Supplier 2</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_SupplierThreeConcentrationRiskMember" xlink:label="txmd_SupplierThreeConcentrationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SupplierThreeConcentrationRiskMember" xlink:to="txmd_SupplierThreeConcentrationRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_SupplierThreeConcentrationRiskMember_lbl" xml:lang="en-US">Supplier 3</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_FourCustomersConcentrationRiskMember" xlink:label="txmd_FourCustomersConcentrationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_FourCustomersConcentrationRiskMember" xlink:to="txmd_FourCustomersConcentrationRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_FourCustomersConcentrationRiskMember_lbl" xml:lang="en-US">Four Customers Concentration Risk Member</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_CustomerConcentrationMcKessonCorporationRiskMember" xlink:label="txmd_CustomerConcentrationMcKessonCorporationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerConcentrationMcKessonCorporationRiskMember" xlink:to="txmd_CustomerConcentrationMcKessonCorporationRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CustomerConcentrationMcKessonCorporationRiskMember_lbl" xml:lang="en-US">McKesson Corporation - Major Customer</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_CustomerConcentrationPillPackRiskMember" xlink:label="txmd_CustomerConcentrationPillPackRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerConcentrationPillPackRiskMember" xlink:to="txmd_CustomerConcentrationPillPackRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CustomerConcentrationPillPackRiskMember_lbl" xml:lang="en-US">PillPack - Major Customer</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_CustomerConcentrationAmerisourceBergenRiskMember" xlink:label="txmd_CustomerConcentrationAmerisourceBergenRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerConcentrationAmerisourceBergenRiskMember" xlink:to="txmd_CustomerConcentrationAmerisourceBergenRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CustomerConcentrationAmerisourceBergenRiskMember_lbl" xml:lang="en-US">AmerisourceBergen - Major Customer</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_CustomerConcentrationCardinalHealthRiskMember" xlink:label="txmd_CustomerConcentrationCardinalHealthRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerConcentrationCardinalHealthRiskMember" xlink:to="txmd_CustomerConcentrationCardinalHealthRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CustomerConcentrationCardinalHealthRiskMember_lbl" xml:lang="en-US">Cardinal Health - Major Customer</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_CustomerConcentrationPharmacyInnovationsPaRiskMember" xlink:label="txmd_CustomerConcentrationPharmacyInnovationsPaRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerConcentrationPharmacyInnovationsPaRiskMember" xlink:to="txmd_CustomerConcentrationPharmacyInnovationsPaRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CustomerConcentrationPharmacyInnovationsPaRiskMember_lbl" xml:lang="en-US">Pharmacy Innovations PA - Major Customer</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:label="us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_lbl" xml:lang="en-US">Recorded Unconditional Purchase Obligation by Category of Item Purchased [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_CatalentMember" xlink:label="txmd_CatalentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CatalentMember" xlink:to="txmd_CatalentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CatalentMember_lbl" xml:lang="en-US">Catalent [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_EntityCommonStockHeldByNonaffiliates" xlink:label="txmd_EntityCommonStockHeldByNonaffiliates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_EntityCommonStockHeldByNonaffiliates" xlink:to="txmd_EntityCommonStockHeldByNonaffiliates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_EntityCommonStockHeldByNonaffiliates_lbl" xml:lang="en-US">Entity Common Stock Held by Non-affiliates</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current Assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable, net of allowance for doubtful accounts of $904,040 and $596,602, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Fixed assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsAbstract" xlink:label="us-gaap_OtherAssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_OtherAssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsAbstract_lbl" xml:lang="en-US">Other Assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_LicenseRights" xlink:label="txmd_LicenseRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LicenseRights" xlink:to="txmd_LicenseRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_LicenseRights_lbl" xml:lang="en-US">License rights, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Intangible assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Right of use asset</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:label="us-gaap_OtherAssetsMiscellaneousNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:to="us-gaap_OtherAssetsMiscellaneousNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsMiscellaneousNoncurrent_lbl" xml:lang="en-US">Other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Total other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrentAbstract" xlink:label="us-gaap_LongTermDebtNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrentAbstract" xlink:to="us-gaap_LongTermDebtNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtNoncurrentAbstract_lbl" xml:lang="en-US">Long-Term Liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xml:lang="en-US">Long-term debt</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies - See Note 13</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; Equity:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock - par value $0.001; 10,000,000 shares authorized; no shares issued and outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock - par value $0.001; 350,000,000 shares authorized: 271,177,076 and 240,462,439 issued and outstanding, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xml:lang="en-US">Allowance for doubtful accounts</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US">Total revenue, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xml:lang="en-US">Cost of goods sold</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross profit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Sales, general, and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other (expense) income</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Loss on extinguishment of debt</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="us-gaap_OtherNonoperatingIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US">Miscellaneous income</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:to="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_lbl" xml:lang="en-US">Accreted interest</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other (expense) income</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Loss before income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Provision for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Loss per share, basic and diluted:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Net loss per share, basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Weighted average number of common shares outstanding, basic and diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Beginning balance, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_2_lbl" xml:lang="en-US">Beginning balance (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Shares issued in offerings, net of cost</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Shares issued in offerings, net of cost (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Shares issued for exercise of options, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Shares issued for exercise of options, net (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Shares issued for exercise of warrants, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Shares issued for exercise of warrants, net (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Share-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:to="us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_lbl" xml:lang="en-US">Adoption of ASU 2016-09</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:label="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:to="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_lbl" xml:lang="en-US">Shares issued for exercise of options and warrants, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xml:lang="en-US">Shares issued for exercise of options and warrants, net (in shares)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Ending balance, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_3_lbl" xml:lang="en-US">Ending balance (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation of fixed assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization of intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncashExpense" xlink:label="us-gaap_OtherNoncashExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashExpense" xlink:to="us-gaap_OtherNoncashExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncashExpense_lbl" xml:lang="en-US">Write off of patent and trademark cost</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_NoncashOperatingLeaseExpense" xlink:label="txmd_NoncashOperatingLeaseExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NoncashOperatingLeaseExpense" xlink:to="txmd_NoncashOperatingLeaseExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NoncashOperatingLeaseExpense_lbl" xml:lang="en-US">Non-cash operating lease expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForDoubtfulAccounts" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl" xml:lang="en-US">Provision for doubtful accounts</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_2_lbl" xml:lang="en-US">Loss of extinguishment of debt</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAmortizationOfDeferredCharges" xlink:label="us-gaap_OtherAmortizationOfDeferredCharges" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAmortizationOfDeferredCharges" xlink:to="us-gaap_OtherAmortizationOfDeferredCharges_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAmortizationOfDeferredCharges_lbl" xml:lang="en-US">Amortization of intellectual property license fee</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xml:lang="en-US">Amortization of deferred financing costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xml:lang="en-US">Other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl" xml:lang="en-US">Accrued expenses and other liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_PaymentsToAcquireIntellectualPropertyLicense" xlink:label="txmd_PaymentsToAcquireIntellectualPropertyLicense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PaymentsToAcquireIntellectualPropertyLicense" xlink:to="txmd_PaymentsToAcquireIntellectualPropertyLicense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="txmd_PaymentsToAcquireIntellectualPropertyLicense_lbl" xml:lang="en-US">Payment for intellectual property license</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US">Patent costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of fixed assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash_lbl" xml:lang="en-US">Payment of security deposit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from exercise of options and warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from sale of common stock, net of costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="us-gaap_ProceedsFromLinesOfCredit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLinesOfCredit" xlink:to="us-gaap_ProceedsFromLinesOfCredit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromLinesOfCredit_lbl" xml:lang="en-US">Proceeds from Financing Agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_lbl" xml:lang="en-US">Proceeds from Credit Agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfFinancingCosts" xlink:to="us-gaap_PaymentsOfFinancingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xml:lang="en-US">Payment of deferred financing fees</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfOtherLongTermDebt" xlink:label="us-gaap_RepaymentsOfOtherLongTermDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfOtherLongTermDebt" xlink:to="us-gaap_RepaymentsOfOtherLongTermDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfOtherLongTermDebt_lbl" xml:lang="en-US">Repayment of Credit Agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">(Decrease) increase in cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xml:lang="en-US">Cash, end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosure of cash flow information</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest paid</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US">THE COMPANY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">INVENTORY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentAssetsTextBlock" xlink:label="us-gaap_OtherCurrentAssetsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentAssetsTextBlock" xlink:to="us-gaap_OtherCurrentAssetsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCurrentAssetsTextBlock_lbl" xml:lang="en-US">OTHER CURRENT ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">FIXED ASSETS, NET</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">INTANGIBLE ASSETS, NET</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xml:lang="en-US">OTHER CURRENT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="us-gaap_LongTermDebtTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtTextBlock" xlink:to="us-gaap_LongTermDebtTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtTextBlock_lbl" xml:lang="en-US">DEBT</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">INCOME TAXES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">RELATED PARTIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="us-gaap_RisksAndUncertaintiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RisksAndUncertaintiesAbstract_lbl" xml:lang="en-US">Risks and Uncertainties [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl" xml:lang="en-US">BUSINESS CONCENTRATIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_lbl" xml:lang="en-US">Quarterly Financial Information Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_QuarterlyFinancialInformationTextBlock" xlink:to="us-gaap_QuarterlyFinancialInformationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock_lbl" xml:lang="en-US">SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Principles of Consolidation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:label="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:to="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_lbl" xml:lang="en-US">Trade Accounts Receivable and Allowance for Doubtful Accounts</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US">Inventories</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Fixed Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xml:lang="en-US">Intangible Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Share-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment Reporting</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="us-gaap_CostOfSalesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesPolicyTextBlock" xlink:to="us-gaap_CostOfSalesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfSalesPolicyTextBlock_lbl" xml:lang="en-US">Cost of Sales</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="us-gaap_AdvertisingCostsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock_lbl" xml:lang="en-US">Advertising Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Earnings Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration of Credit Risk and other Risks and Uncertainties</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently Issued Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xml:lang="en-US">The following table provides information about disaggregated revenue by product mix for the years ended December 31, 2019, 2018, and 2017:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">The table below presents potentially dilutive securities that could affect our calculation of diluted net loss per share allocable to common stockholders for the periods presented.</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Inventory consists of the following:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl" xml:lang="en-US">Other current assets consist of the following:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Fixed assets, net consist of the following:</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_ScheduleOfIntangibleAssetsTableTextBlock" xlink:label="txmd_ScheduleOfIntangibleAssetsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ScheduleOfIntangibleAssetsTableTextBlock" xlink:to="txmd_ScheduleOfIntangibleAssetsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ScheduleOfIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US">The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of December 31, 2019 and 2018:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US">Estimated amortization expense, based on current patent cost being amortized, for the next five years is as follows:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:label="us-gaap_OtherCurrentLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:to="us-gaap_OtherCurrentLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCurrentLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Other current liabilities consist of the following:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xml:lang="en-US">As of December 31, 2019 and 2018, the carrying value of our debt consisted of the following:</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_ScheduleOfWarrantRollForwardTableTextBlock" xlink:label="txmd_ScheduleOfWarrantRollForwardTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ScheduleOfWarrantRollForwardTableTextBlock" xlink:to="txmd_ScheduleOfWarrantRollForwardTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ScheduleOfWarrantRollForwardTableTextBlock_lbl" xml:lang="en-US">Summary of our Warrant activity during the year ended December 31, 2019:</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock" xlink:label="txmd_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock" xlink:to="txmd_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">The weighted average fair value per share of warrants issued and the assumptions used in the Black-Scholes Model during the years ended December 31, 2019, 2018, and 2017 are set forth in the table below.</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">The ranges of assumptions used in the Black-Scholes Model during the years ended December 31, 2019, 2018, and 2017 are set forth in the table below.</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">A summary of activity under the 2009, 2012 and 2019 Plans and related information during the year ended December 31, 2019 is as follows:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xml:lang="en-US">For financial reporting purposes, income before taxes includes the following components:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">A reconciliation between taxes computed at the federal statutory rate and the consolidated effective tax rate is as follows:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">The components of the net deferred income tax asset as of December 31, 2019, 2018, and 2017 are as follows:</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock" xlink:label="txmd_ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock" xlink:to="txmd_ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock_lbl" xml:lang="en-US">Supplemental lease information</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">The following table reconciles the undiscounted cash flows for all operating leases at December 31, 2019 to the operating lease liabilities recorded on the balance sheet:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:to="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl" xml:lang="en-US">Summarized quarterly financial data for fiscal years 2019 and 2018 is as follows:</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_NumberOfSubsidiaries" xlink:label="txmd_NumberOfSubsidiaries" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfSubsidiaries" xlink:to="txmd_NumberOfSubsidiaries_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NumberOfSubsidiaries_lbl" xml:lang="en-US">Number of subsidiaires</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="us-gaap_ScheduleOfProductInformationTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfProductInformationTable" xlink:to="us-gaap_ScheduleOfProductInformationTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfProductInformationTable_lbl" xml:lang="en-US">Schedule of Product Information [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductInformationLineItems" xlink:label="us-gaap_ProductInformationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductInformationLineItems" xlink:to="us-gaap_ProductInformationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductInformationLineItems_lbl" xml:lang="en-US">Product Information [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2_lbl" xml:lang="en-US">Net revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xml:lang="en-US">Federal insurance limits</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US">Concentration risk</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Useful life of assets</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_NumberOfIssuedPatentsDomestic" xlink:label="txmd_NumberOfIssuedPatentsDomestic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfIssuedPatentsDomestic" xlink:to="txmd_NumberOfIssuedPatentsDomestic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NumberOfIssuedPatentsDomestic_lbl" xml:lang="en-US">Number of issued patents domestic.</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_NumberOfIssuedPatentsForeign" xlink:label="txmd_NumberOfIssuedPatentsForeign" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfIssuedPatentsForeign" xlink:to="txmd_NumberOfIssuedPatentsForeign_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NumberOfIssuedPatentsForeign_lbl" xml:lang="en-US">Number of issued patents foreign</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_ReturnPeriodOfUnsalablePrescriptionProducts" xlink:label="txmd_ReturnPeriodOfUnsalablePrescriptionProducts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ReturnPeriodOfUnsalablePrescriptionProducts" xlink:to="txmd_ReturnPeriodOfUnsalablePrescriptionProducts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ReturnPeriodOfUnsalablePrescriptionProducts_lbl" xml:lang="en-US">Return period of unsalable prescription products</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_ShelfLifeOfPrescriptionProducts" xlink:label="txmd_ShelfLifeOfPrescriptionProducts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShelfLifeOfPrescriptionProducts" xlink:to="txmd_ShelfLifeOfPrescriptionProducts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ShelfLifeOfPrescriptionProducts_lbl" xml:lang="en-US">Shelf life of prescription products following product expiration</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_CashUpfrontPaymentReceived" xlink:label="txmd_CashUpfrontPaymentReceived" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CashUpfrontPaymentReceived" xlink:to="txmd_CashUpfrontPaymentReceived_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CashUpfrontPaymentReceived_lbl" xml:lang="en-US">Cash upfront payment received</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_RegulatoryMilestoneAdditionalPayment" xlink:label="txmd_RegulatoryMilestoneAdditionalPayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RegulatoryMilestoneAdditionalPayment" xlink:to="txmd_RegulatoryMilestoneAdditionalPayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_RegulatoryMilestoneAdditionalPayment_lbl" xml:lang="en-US">Regulatory milestone payments</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_SalesMilestonePaymentsInTranches" xlink:label="txmd_SalesMilestonePaymentsInTranches" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SalesMilestonePaymentsInTranches" xlink:to="txmd_SalesMilestonePaymentsInTranches_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_SalesMilestonePaymentsInTranches_lbl" xml:lang="en-US">Sales milestone payment</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_AnnualNetSalesMilestone" xlink:label="txmd_AnnualNetSalesMilestone" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AnnualNetSalesMilestone" xlink:to="txmd_AnnualNetSalesMilestone_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AnnualNetSalesMilestone_lbl" xml:lang="en-US">Sales milestone</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_QuarterlyRoyaltyPaymentsPercentage" xlink:label="txmd_QuarterlyRoyaltyPaymentsPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_QuarterlyRoyaltyPaymentsPercentage" xlink:to="txmd_QuarterlyRoyaltyPaymentsPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_QuarterlyRoyaltyPaymentsPercentage_lbl" xml:lang="en-US">Quarterly royalty payments percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xml:lang="en-US">Number of operating segments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdvertisingExpense" xlink:label="us-gaap_AdvertisingExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingExpense" xlink:to="us-gaap_AdvertisingExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdvertisingExpense_lbl" xml:lang="en-US">Advertising costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xml:lang="en-US">Finished products</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="us-gaap_InventoryWorkInProcess" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcess" xlink:to="us-gaap_InventoryWorkInProcess_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWorkInProcess_lbl" xml:lang="en-US">Work in process</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterialsAndSupplies" xlink:label="us-gaap_InventoryRawMaterialsAndSupplies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterialsAndSupplies" xlink:to="us-gaap_InventoryRawMaterialsAndSupplies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterialsAndSupplies_lbl" xml:lang="en-US">Raw materials</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryNet_2_lbl" xml:lang="en-US">TOTAL INVENTORY</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_PrepaidSalesAndMarketingCostsCurrent" xlink:label="txmd_PrepaidSalesAndMarketingCostsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidSalesAndMarketingCostsCurrent" xlink:to="txmd_PrepaidSalesAndMarketingCostsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PrepaidSalesAndMarketingCostsCurrent_lbl" xml:lang="en-US">Prepaid sales and marketing costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFinanceCostsCurrentNet" xlink:label="us-gaap_DeferredFinanceCostsCurrentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsCurrentNet" xlink:to="us-gaap_DeferredFinanceCostsCurrentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFinanceCostsCurrentNet_lbl" xml:lang="en-US">Debt financing fees on undrawn&#160;tranches (Note 8)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidInsurance_lbl" xml:lang="en-US">Prepaid insurance</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_PrepaidManufacturing" xlink:label="txmd_PrepaidManufacturing" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidManufacturing" xlink:to="txmd_PrepaidManufacturing_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PrepaidManufacturing_lbl" xml:lang="en-US">Prepaid manufacturing</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US">Other prepaid costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2_lbl" xml:lang="en-US">TOTAL OTHER CURRENT ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">TOTAL FIXED ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Accumulated depreciation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xml:lang="en-US">TOTAL FIXED ASSETS, NET</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Depreciation_2_lbl" xml:lang="en-US">Depreciation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:to="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Remaining Amortization Period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedTrademarks" xlink:label="us-gaap_IndefiniteLivedTrademarks" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedTrademarks" xlink:to="us-gaap_IndefiniteLivedTrademarks_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedTrademarks_lbl" xml:lang="en-US">Indefinite-Lived Trademarks</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsGrossExcludingGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill_lbl" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_2_lbl" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US">2020</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US">2021</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US">2022</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xml:lang="en-US">2023</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xml:lang="en-US">2024</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_lbl" xml:lang="en-US">Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_NumberOfIssuedPatents" xlink:label="txmd_NumberOfIssuedPatents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfIssuedPatents" xlink:to="txmd_NumberOfIssuedPatents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NumberOfIssuedPatents_lbl" xml:lang="en-US">Number of issued patents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_2_lbl" xml:lang="en-US">Amortization of Intangible Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_MilestonePaymentUponFDAApproval" xlink:label="txmd_MilestonePaymentUponFDAApproval" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MilestonePaymentUponFDAApproval" xlink:to="txmd_MilestonePaymentUponFDAApproval_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_MilestonePaymentUponFDAApproval_lbl" xml:lang="en-US">Milestone payment upon FDA Approval</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch" xlink:label="txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch" xlink:to="txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch_lbl" xml:lang="en-US">Milestone payments (payment after release of first commercial batch)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:label="us-gaap_FinitelivedIntangibleAssetsAcquired1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:to="us-gaap_FinitelivedIntangibleAssetsAcquired1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinitelivedIntangibleAssetsAcquired1_lbl" xml:lang="en-US">License rights acquired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAmortizationOfDeferredCharges" xlink:to="us-gaap_OtherAmortizationOfDeferredCharges_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherAmortizationOfDeferredCharges_2_lbl" xml:lang="en-US">Amortization of Other Deferred Charges</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_NetSalesAmountPerStepbasedRoyalty" xlink:label="txmd_NetSalesAmountPerStepbasedRoyalty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NetSalesAmountPerStepbasedRoyalty" xlink:to="txmd_NetSalesAmountPerStepbasedRoyalty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NetSalesAmountPerStepbasedRoyalty_lbl" xml:lang="en-US">Net sales amount per step-based royalty</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_RoyaltyPercent" xlink:label="txmd_RoyaltyPercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RoyaltyPercent" xlink:to="txmd_RoyaltyPercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_RoyaltyPercent_lbl" xml:lang="en-US">Royalty (percent)</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent" xlink:label="txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent" xlink:to="txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent_lbl" xml:lang="en-US">Annual royalty rate reduction of initial rate during the six-month period from commercial sale of a generic equivalent</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent" xlink:label="txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent" xlink:to="txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent_lbl" xml:lang="en-US">Annual royalty rate reduction of initial rate after the six-month period from commercial sale of a generic equivalent</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_RequiredMilestonePaymentsUponCumulativeNetSalesOfSpecifiedLevels" xlink:label="txmd_RequiredMilestonePaymentsUponCumulativeNetSalesOfSpecifiedLevels" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RequiredMilestonePaymentsUponCumulativeNetSalesOfSpecifiedLevels" xlink:to="txmd_RequiredMilestonePaymentsUponCumulativeNetSalesOfSpecifiedLevels_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_RequiredMilestonePaymentsUponCumulativeNetSalesOfSpecifiedLevels_lbl" xml:lang="en-US">Required milestone payments upon cumulative net sales of specified levels</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_SpecifiedLevelOneOfCumulativeNetSalesForRequiredMilestonePayments" xlink:label="txmd_SpecifiedLevelOneOfCumulativeNetSalesForRequiredMilestonePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SpecifiedLevelOneOfCumulativeNetSalesForRequiredMilestonePayments" xlink:to="txmd_SpecifiedLevelOneOfCumulativeNetSalesForRequiredMilestonePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_SpecifiedLevelOneOfCumulativeNetSalesForRequiredMilestonePayments_lbl" xml:lang="en-US">Specified level one of cumulative net sales for required milestone payments</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_SpecifiedLevelTwoOfCumulativeNetSalesForRequiredMilestonePayments" xlink:label="txmd_SpecifiedLevelTwoOfCumulativeNetSalesForRequiredMilestonePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SpecifiedLevelTwoOfCumulativeNetSalesForRequiredMilestonePayments" xlink:to="txmd_SpecifiedLevelTwoOfCumulativeNetSalesForRequiredMilestonePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_SpecifiedLevelTwoOfCumulativeNetSalesForRequiredMilestonePayments_lbl" xml:lang="en-US">Specified level two of cumulative net sales for required milestone payments</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_SpecifiedLevelThreeOfCumulativeNetSalesForRequiredMilestonePayments" xlink:label="txmd_SpecifiedLevelThreeOfCumulativeNetSalesForRequiredMilestonePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SpecifiedLevelThreeOfCumulativeNetSalesForRequiredMilestonePayments" xlink:to="txmd_SpecifiedLevelThreeOfCumulativeNetSalesForRequiredMilestonePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_SpecifiedLevelThreeOfCumulativeNetSalesForRequiredMilestonePayments_lbl" xml:lang="en-US">Specified level three of cumulative net sales for required milestone payments</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid" xlink:label="txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid" xlink:to="txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid_lbl" xml:lang="en-US">Maximum costs and expenses for post approval</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedSalariesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedSalariesCurrent_lbl" xml:lang="en-US">Accrued payroll, bonuses and commission costs</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_SalesDiscountsReturnsAndAllowancesGoods1" xlink:label="txmd_SalesDiscountsReturnsAndAllowancesGoods1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SalesDiscountsReturnsAndAllowancesGoods1" xlink:to="txmd_SalesDiscountsReturnsAndAllowancesGoods1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_SalesDiscountsReturnsAndAllowancesGoods1_lbl" xml:lang="en-US">Allowance for coupons and returns</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedMarketingCostsCurrent" xlink:label="us-gaap_AccruedMarketingCostsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedMarketingCostsCurrent" xlink:to="us-gaap_AccruedMarketingCostsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedMarketingCostsCurrent_lbl" xml:lang="en-US">Accrued sales and marketing costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedVacationCurrent" xlink:label="us-gaap_AccruedVacationCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedVacationCurrent" xlink:to="us-gaap_AccruedVacationCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedVacationCurrent_lbl" xml:lang="en-US">Accrued compensated absences</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_AllowanceForWholesaleDistributorFeesCurrent" xlink:label="txmd_AllowanceForWholesaleDistributorFeesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AllowanceForWholesaleDistributorFeesCurrent" xlink:to="txmd_AllowanceForWholesaleDistributorFeesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AllowanceForWholesaleDistributorFeesCurrent_lbl" xml:lang="en-US">Allowance for wholesale distributor fees</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US">Accrued legal and accounting expense</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_AccruedResearchAndDevelopment" xlink:label="txmd_AccruedResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AccruedResearchAndDevelopment" xlink:to="txmd_AccruedResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AccruedResearchAndDevelopment_lbl" xml:lang="en-US">Accrued research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedRentCurrent" xlink:label="us-gaap_AccruedRentCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedRentCurrent" xlink:to="us-gaap_AccruedRentCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedRentCurrent_lbl" xml:lang="en-US">Accrued rent</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_AccruedRebates" xlink:label="txmd_AccruedRebates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AccruedRebates" xlink:to="txmd_AccruedRebates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AccruedRebates_lbl" xml:lang="en-US">Accrued rebates</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other accrued expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_2_lbl" xml:lang="en-US">TOTAL OTHER CURRENT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US">Long-term Debt, Gross</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xml:lang="en-US">Debt discount and financing fees</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermDebtNoncurrent_2_lbl" xml:lang="en-US">TOTAL LONG-TERM DEBT</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLinesOfCredit" xlink:to="us-gaap_ProceedsFromLinesOfCredit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromLinesOfCredit_2_lbl" xml:lang="en-US">Proceeds from Lines of Credit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:label="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:to="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_lbl" xml:lang="en-US">Debt Instrument, Description of Variable Rate Basis</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_LiborFloorRate" xlink:label="txmd_LiborFloorRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LiborFloorRate" xlink:to="txmd_LiborFloorRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_LiborFloorRate_lbl" xml:lang="en-US">LIBOR floor rate</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_NumberOfInstallmentPayments" xlink:label="txmd_NumberOfInstallmentPayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfInstallmentPayments" xlink:to="txmd_NumberOfInstallmentPayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NumberOfInstallmentPayments_lbl" xml:lang="en-US">Number of quarterly principal installment payments</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_PrepaymentFeeForFirstTwoYearsFundingPercent" xlink:label="txmd_PrepaymentFeeForFirstTwoYearsFundingPercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaymentFeeForFirstTwoYearsFundingPercent" xlink:to="txmd_PrepaymentFeeForFirstTwoYearsFundingPercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PrepaymentFeeForFirstTwoYearsFundingPercent_lbl" xml:lang="en-US">Prepayment fee for first two years funding (percent)</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_PrepaymentFeeThirdYearFundingPercent" xlink:label="txmd_PrepaymentFeeThirdYearFundingPercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaymentFeeThirdYearFundingPercent" xlink:to="txmd_PrepaymentFeeThirdYearFundingPercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PrepaymentFeeThirdYearFundingPercent_lbl" xml:lang="en-US">Prepayment fee third year funding (percent)</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_PrepaymentFeeFourthYearFundingPercent" xlink:label="txmd_PrepaymentFeeFourthYearFundingPercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaymentFeeFourthYearFundingPercent" xlink:to="txmd_PrepaymentFeeFourthYearFundingPercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PrepaymentFeeFourthYearFundingPercent_lbl" xml:lang="en-US">Prepayment fee fourth year funding (percent)</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_PrepaymentFeeFifthYearFundingPercent" xlink:label="txmd_PrepaymentFeeFifthYearFundingPercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaymentFeeFifthYearFundingPercent" xlink:to="txmd_PrepaymentFeeFifthYearFundingPercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PrepaymentFeeFifthYearFundingPercent_lbl" xml:lang="en-US">Prepayment fee fifth year funding (percent)</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_FacilityFeePaidPercent" xlink:label="txmd_FacilityFeePaidPercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_FacilityFeePaidPercent" xlink:to="txmd_FacilityFeePaidPercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_FacilityFeePaidPercent_lbl" xml:lang="en-US">Facility fee paid (percent)</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_MinimumCashBalanceRequirementUnderCreditAgreement" xlink:label="txmd_MinimumCashBalanceRequirementUnderCreditAgreement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MinimumCashBalanceRequirementUnderCreditAgreement" xlink:to="txmd_MinimumCashBalanceRequirementUnderCreditAgreement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_MinimumCashBalanceRequirementUnderCreditAgreement_lbl" xml:lang="en-US">Minimum cash balance requirement under credit agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_NumberOfTranchesUnderTermLoanFacility" xlink:label="txmd_NumberOfTranchesUnderTermLoanFacility" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfTranchesUnderTermLoanFacility" xlink:to="txmd_NumberOfTranchesUnderTermLoanFacility_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NumberOfTranchesUnderTermLoanFacility_lbl" xml:lang="en-US">Number of tranches under term loan facility</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_RepaymentOfDebtWithNewCreditFacility" xlink:label="txmd_RepaymentOfDebtWithNewCreditFacility" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RepaymentOfDebtWithNewCreditFacility" xlink:to="txmd_RepaymentOfDebtWithNewCreditFacility_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_RepaymentOfDebtWithNewCreditFacility_lbl" xml:lang="en-US">Repayment of debt with new credit facility</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_PrepaymentFeePercentage" xlink:label="txmd_PrepaymentFeePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaymentFeePercentage" xlink:to="txmd_PrepaymentFeePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PrepaymentFeePercentage_lbl" xml:lang="en-US">Prepayment fee percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_RepaymentFeePercentage" xlink:label="txmd_RepaymentFeePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RepaymentFeePercentage" xlink:to="txmd_RepaymentFeePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_RepaymentFeePercentage_lbl" xml:lang="en-US">Repayment fee percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US">Interest Expense, Debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AmortizationOfFinancingCosts_2_lbl" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfFinancingCosts" xlink:to="us-gaap_PaymentsOfFinancingCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfFinancingCosts_2_lbl" xml:lang="en-US">Payments of Financing Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseBorrowings" xlink:label="us-gaap_InterestExpenseBorrowings" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseBorrowings" xlink:to="us-gaap_InterestExpenseBorrowings_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseBorrowings_lbl" xml:lang="en-US">Interest Expense, Borrowings</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xml:lang="en-US">Number of shares under warrants outstanding beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice" xlink:label="txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice" xlink:to="txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price warrants outstanding beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xml:lang="en-US">Weighted average remaining contractual life, warrants outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl" xml:lang="en-US">Aggregate intrinsic value, warrants outstanding beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xml:lang="en-US">Number of shares under warrants granted</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_WarrantsGrantedOtherThanOptionsWeightedAverageExercisePrice" xlink:label="txmd_WarrantsGrantedOtherThanOptionsWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsGrantedOtherThanOptionsWeightedAverageExercisePrice" xlink:to="txmd_WarrantsGrantedOtherThanOptionsWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WarrantsGrantedOtherThanOptionsWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price warrants granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xml:lang="en-US">Number of shares under warrants exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_WarrantsExercisedOtherThanOptionsWeightedAverageExercisePrice" xlink:label="txmd_WarrantsExercisedOtherThanOptionsWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsExercisedOtherThanOptionsWeightedAverageExercisePrice" xlink:to="txmd_WarrantsExercisedOtherThanOptionsWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WarrantsExercisedOtherThanOptionsWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price warrants exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US">Aggregate intrinsic value, warrants exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xml:lang="en-US">Number of shares under warrants outstanding ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice" xlink:to="txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted average exercise price warrants outstanding ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_2_lbl" xml:lang="en-US">Aggregate intrinsic value, warrants outstanding ending</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_lbl" xml:lang="en-US">Number of shares under warrants vested and exercisable ending</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_WarrantsOutstandingVestedAndExercisable" xlink:label="txmd_WarrantsOutstandingVestedAndExercisable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsOutstandingVestedAndExercisable" xlink:to="txmd_WarrantsOutstandingVestedAndExercisable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="txmd_WarrantsOutstandingVestedAndExercisable_lbl" xml:lang="en-US">Weighted average exercise price warrants vested and exercisable ending</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExercisableWeightedAverageRemainingContractualTerms" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExercisableWeightedAverageRemainingContractualTerms" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExercisableWeightedAverageRemainingContractualTerms" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExercisableWeightedAverageRemainingContractualTerms_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExercisableWeightedAverageRemainingContractualTerms_lbl" xml:lang="en-US">Weighted average remaining contractual life, vested and exercisable ending</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue_lbl" xml:lang="en-US">Aggregate intrinsic value, vested and exercisable ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Number of shares under warrants unvested ending</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_WarrantsUnvestedWeightedAverageExercisePrice" xlink:label="txmd_WarrantsUnvestedWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsUnvestedWeightedAverageExercisePrice" xlink:to="txmd_WarrantsUnvestedWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="txmd_WarrantsUnvestedWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price warrants unvested ending</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms_lbl" xml:lang="en-US">Weighted average remaining contractual life, warrants unvested ending</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_WeightedAverageExercisePriceOtherThanOptions" xlink:label="txmd_WeightedAverageExercisePriceOtherThanOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WeightedAverageExercisePriceOtherThanOptions" xlink:to="txmd_WeightedAverageExercisePriceOtherThanOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WeightedAverageExercisePriceOtherThanOptions_lbl" xml:lang="en-US">Weighted average exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant date fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Term</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant date fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US">Risk-free interest rate - minimum</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US">Risk-free interest rate - maximum</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US">Volatility - minimum</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US">Volatility - maximum</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of shares under options, beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted average remaining contractual life</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate intrinsic value, beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of shares under options, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xml:lang="en-US">Number of shares under options, exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US">Aggregate intrinsic value, exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US">Number of shares under options, expired</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, expired</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Number of shares under options, cancelled forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, cancelled forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Number of shares under options, ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted average exercise price, ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xml:lang="en-US">Aggregate intrinsic value, ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Number of shares under options, vested and exercisable ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, vested and exercisable ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted average remaining contractual life, vested and exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate intrinsic value, vested and exercisable ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xml:lang="en-US">Number of shares under options, unvested ending</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, unvested ending</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms_lbl" xml:lang="en-US">Weighted average remaining contractual life, unvested</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US">Aggregate intrinsic value, unvested ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Shares Issued, Price Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_PeriodExercisableUnderwritersOption" xlink:label="txmd_PeriodExercisableUnderwritersOption" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PeriodExercisableUnderwritersOption" xlink:to="txmd_PeriodExercisableUnderwritersOption_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PeriodExercisableUnderwritersOption_lbl" xml:lang="en-US">Period exercisable underwriters option</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_UnderwritersOptionGrantedInPeriodShares" xlink:label="txmd_UnderwritersOptionGrantedInPeriodShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_UnderwritersOptionGrantedInPeriodShares" xlink:to="txmd_UnderwritersOptionGrantedInPeriodShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_UnderwritersOptionGrantedInPeriodShares_lbl" xml:lang="en-US">Underwriters option granted in period shares</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_ProceedsFromIssuancePublicOffering" xlink:label="txmd_ProceedsFromIssuancePublicOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ProceedsFromIssuancePublicOffering" xlink:to="txmd_ProceedsFromIssuancePublicOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ProceedsFromIssuancePublicOffering_lbl" xml:lang="en-US">Proceeds from issuance public offering</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_2_lbl" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_NumberOfStockOptionsExercisedInCashlessExercise" xlink:label="txmd_NumberOfStockOptionsExercisedInCashlessExercise" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfStockOptionsExercisedInCashlessExercise" xlink:to="txmd_NumberOfStockOptionsExercisedInCashlessExercise_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NumberOfStockOptionsExercisedInCashlessExercise_lbl" xml:lang="en-US">Number of stock options exercised in cashless exercise (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares" xlink:label="txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares" xlink:to="txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares_lbl" xml:lang="en-US">Number of common stock issued during period for stock options exercised in cashless exercise (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US">Warrants and Rights Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife" xlink:label="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife" xlink:to="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife_lbl" xml:lang="en-US">Weighted-average contractual remaining life</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice" xlink:to="txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Weighted average exercise price of warrants (in dollars per share)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_2_lbl" xml:lang="en-US">Warrants granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Warrants vesting period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xml:lang="en-US">Warrants expiration date</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_2_lbl" xml:lang="en-US">Warrants exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_NumberOfStockIssuedInCashlessExerciseOfWarrants" xlink:label="txmd_NumberOfStockIssuedInCashlessExerciseOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfStockIssuedInCashlessExerciseOfWarrants" xlink:to="txmd_NumberOfStockIssuedInCashlessExerciseOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NumberOfStockIssuedInCashlessExerciseOfWarrants_lbl" xml:lang="en-US">Number of stock issued in cashless exercise of warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_PlanAwardsNumberOfNewShares" xlink:label="txmd_PlanAwardsNumberOfNewShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PlanAwardsNumberOfNewShares" xlink:to="txmd_PlanAwardsNumberOfNewShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PlanAwardsNumberOfNewShares_lbl" xml:lang="en-US">Plan awards number of new shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice_lbl" xml:lang="en-US">Range - exercise price of options</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockExpense" xlink:label="us-gaap_RestrictedStockExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockExpense" xlink:to="us-gaap_RestrictedStockExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockExpense_lbl" xml:lang="en-US">Restricted Stock or Unit Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Federal statutory tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State tax rate, net of federal tax benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Adjustment in valuation allowances</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_lbl" xml:lang="en-US">Excess stock benefits</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xml:lang="en-US">Federal income tax rate change</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US">Permanent and other differences</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Provision (benefit) for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xml:lang="en-US">Deferred Income Tax Assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOtherLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOtherLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOtherLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOtherLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOtherLossCarryforwards_lbl" xml:lang="en-US">Net operating losses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US">R Credit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Total deferred income tax asset</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Deferred income tax assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carry forward</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_NolCarryForwardPeriod" xlink:label="txmd_NolCarryForwardPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NolCarryForwardPeriod" xlink:to="txmd_NolCarryForwardPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NolCarryForwardPeriod_lbl" xml:lang="en-US">NOL carry forward period</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_OperatingLossCarryforwardsExpirationYear" xlink:label="txmd_OperatingLossCarryforwardsExpirationYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_OperatingLossCarryforwardsExpirationYear" xlink:to="txmd_OperatingLossCarryforwardsExpirationYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_OperatingLossCarryforwardsExpirationYear_lbl" xml:lang="en-US">NOL carry forward expiration year</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalIncomeTaxExpenseBenefit" xlink:label="us-gaap_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalIncomeTaxExpenseBenefit" xlink:to="us-gaap_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Tax Cuts and Jobs Act, provisional net tax expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl" xml:lang="en-US">Amount billed</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:to="us-gaap_AccountsPayableRelatedPartiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrent_lbl" xml:lang="en-US">Amounts due to related party</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTable_lbl" xml:lang="en-US">Concentration Risk [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_NumberOfVendors" xlink:label="txmd_NumberOfVendors" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfVendors" xlink:to="txmd_NumberOfVendors_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NumberOfVendors_lbl" xml:lang="en-US">Number of vendors - suppliers</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_NumberOfCustomers" xlink:label="txmd_NumberOfCustomers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfCustomers" xlink:to="txmd_NumberOfCustomers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NumberOfCustomers_lbl" xml:lang="en-US">Number of customers - revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xml:lang="en-US">Right-of-use asset</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xml:lang="en-US">Short-term operating lease liability (included in Other current liabilities)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xml:lang="en-US">Long-term operating lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted average remaining term</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted average discount rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities for operating lease</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Right-of-use assets obtained in exchange for lease obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2020</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2021</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2022</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">2023</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US">2024</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US">Thereafter</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total undiscounted lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: imputed interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiability_2_lbl" xml:lang="en-US">Present value of lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RecordedUnconditionalPurchaseObligationTable" xlink:label="us-gaap_RecordedUnconditionalPurchaseObligationTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationTable" xlink:to="us-gaap_RecordedUnconditionalPurchaseObligationTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RecordedUnconditionalPurchaseObligationTable_lbl" xml:lang="en-US">Recorded Unconditional Purchase Obligation [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RecordedUnconditionalPurchaseObligationLineItems" xlink:label="us-gaap_RecordedUnconditionalPurchaseObligationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationLineItems" xlink:to="us-gaap_RecordedUnconditionalPurchaseObligationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RecordedUnconditionalPurchaseObligationLineItems_lbl" xml:lang="en-US">Recorded Unconditional Purchase Obligation [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_CapitalLeaseObligationsTerm" xlink:label="txmd_CapitalLeaseObligationsTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CapitalLeaseObligationsTerm" xlink:to="txmd_CapitalLeaseObligationsTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CapitalLeaseObligationsTerm_lbl" xml:lang="en-US">Non-cancelable operating lease term</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_NetRentableAreaLease" xlink:label="txmd_NetRentableAreaLease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NetRentableAreaLease" xlink:to="txmd_NetRentableAreaLease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NetRentableAreaLease_lbl" xml:lang="en-US">Net rentable area</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_RentedAreaLease" xlink:label="txmd_RentedAreaLease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RentedAreaLease" xlink:to="txmd_RentedAreaLease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_RentedAreaLease_lbl" xml:lang="en-US">Rented area lease</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_AdditionalAreaOfLeaseOccupied" xlink:label="txmd_AdditionalAreaOfLeaseOccupied" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AdditionalAreaOfLeaseOccupied" xlink:to="txmd_AdditionalAreaOfLeaseOccupied_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AdditionalAreaOfLeaseOccupied_lbl" xml:lang="en-US">Additional area of lease occupied</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_LesseeFinanceLeaseExistenceOfOptionToExtendNumber" xlink:label="txmd_LesseeFinanceLeaseExistenceOfOptionToExtendNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LesseeFinanceLeaseExistenceOfOptionToExtendNumber" xlink:to="txmd_LesseeFinanceLeaseExistenceOfOptionToExtendNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_LesseeFinanceLeaseExistenceOfOptionToExtendNumber_lbl" xml:lang="en-US">Number of options to extend lease</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:label="us-gaap_LesseeFinanceLeaseRenewalTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:to="us-gaap_LesseeFinanceLeaseRenewalTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeFinanceLeaseRenewalTerm1_lbl" xml:lang="en-US">Lease renewal term</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_LesseeOperatingLeaseLeaseNotYetCommencedArea" xlink:label="txmd_LesseeOperatingLeaseLeaseNotYetCommencedArea" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LesseeOperatingLeaseLeaseNotYetCommencedArea" xlink:to="txmd_LesseeOperatingLeaseLeaseNotYetCommencedArea_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_LesseeOperatingLeaseLeaseNotYetCommencedArea_lbl" xml:lang="en-US">Lease not yet commenced (area)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US">Operating lease expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAndRentalExpense" xlink:to="us-gaap_LeaseAndRentalExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xml:lang="en-US">Rental expense</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_SignificantSupplyCommitmentPercentagePayable" xlink:label="txmd_SignificantSupplyCommitmentPercentagePayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SignificantSupplyCommitmentPercentagePayable" xlink:to="txmd_SignificantSupplyCommitmentPercentagePayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_SignificantSupplyCommitmentPercentagePayable_lbl" xml:lang="en-US">Significant supply commitment percentage payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RecordedUnconditionalPurchaseObligationDueWithinOneYear" xlink:label="us-gaap_RecordedUnconditionalPurchaseObligationDueWithinOneYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationDueWithinOneYear" xlink:to="us-gaap_RecordedUnconditionalPurchaseObligationDueWithinOneYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RecordedUnconditionalPurchaseObligationDueWithinOneYear_lbl" xml:lang="en-US">Minimum purchase commitment, 2020</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RecordedUnconditionalPurchaseObligationDueInSecondYear" xlink:label="us-gaap_RecordedUnconditionalPurchaseObligationDueInSecondYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationDueInSecondYear" xlink:to="us-gaap_RecordedUnconditionalPurchaseObligationDueInSecondYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RecordedUnconditionalPurchaseObligationDueInSecondYear_lbl" xml:lang="en-US">Minimum purchase commitment, 2021</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RecordedUnconditionalPurchaseObligationDueInThirdYear" xlink:label="us-gaap_RecordedUnconditionalPurchaseObligationDueInThirdYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationDueInThirdYear" xlink:to="us-gaap_RecordedUnconditionalPurchaseObligationDueInThirdYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RecordedUnconditionalPurchaseObligationDueInThirdYear_lbl" xml:lang="en-US">Minimum purchase commitment, 2022</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RecordedUnconditionalPurchaseObligationDueInFourthYear" xlink:label="us-gaap_RecordedUnconditionalPurchaseObligationDueInFourthYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationDueInFourthYear" xlink:to="us-gaap_RecordedUnconditionalPurchaseObligationDueInFourthYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RecordedUnconditionalPurchaseObligationDueInFourthYear_lbl" xml:lang="en-US">Minimum purchase commitment, 2023</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RecordedUnconditionalPurchaseObligationDueInFifthYear" xlink:label="us-gaap_RecordedUnconditionalPurchaseObligationDueInFifthYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RecordedUnconditionalPurchaseObligationDueInFifthYear" xlink:to="us-gaap_RecordedUnconditionalPurchaseObligationDueInFifthYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RecordedUnconditionalPurchaseObligationDueInFifthYear_lbl" xml:lang="en-US">Minimum purchase commitment, 2024</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3_lbl" xml:lang="en-US">Revenues</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_2_lbl" xml:lang="en-US">Gross profit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_2_lbl" xml:lang="en-US">Loss per common share, basic and diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_3_lbl" xml:lang="en-US">Loss on extinguishment of debt</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ImvexxyMember" xlink:to="txmd_ImvexxyMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ImvexxyMember_doc" xml:lang="en-US">Information about ImvexxyTm.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_HormoneTherapyDrugCandidatePatentsMember" xlink:to="txmd_HormoneTherapyDrugCandidatePatentsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_HormoneTherapyDrugCandidatePatentsMember_doc" xml:lang="en-US">Hormone Therapy Drug Candidate Patents Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:to="txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember_doc" xml:lang="en-US">Hormone Therapy Drug Candidate Patents Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MultipleTrademarksForVitaminsSupplementsMember" xlink:to="txmd_MultipleTrademarksForVitaminsSupplementsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_MultipleTrademarksForVitaminsSupplementsMember_doc" xml:lang="en-US">Multiple Trademarks For Vitamins Supplements Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticUSPatentsMember" xlink:to="txmd_DomesticUSPatentsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DomesticUSPatentsMember_doc" xml:lang="en-US">Domestic US Patents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ForeignPatentsMember" xlink:to="txmd_ForeignPatentsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ForeignPatentsMember_doc" xml:lang="en-US">Foreign Patents Member</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticPatentsBijuvaMember" xlink:to="txmd_DomesticPatentsBijuvaMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DomesticPatentsBijuvaMember_doc" xml:lang="en-US">Domestic Patents Bijuva</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ForeignPatentsBijuvaMember" xlink:to="txmd_ForeignPatentsBijuvaMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ForeignPatentsBijuvaMember_doc" xml:lang="en-US">Foreign Patents BIJUVA</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticPatentsNonApprovedBijuvaMember" xlink:to="txmd_DomesticPatentsNonApprovedBijuvaMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DomesticPatentsNonApprovedBijuvaMember_doc" xml:lang="en-US">Domestic Patents NonApproved Bijuva</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticUSPatentsImvexxyMember" xlink:to="txmd_DomesticUSPatentsImvexxyMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DomesticUSPatentsImvexxyMember_doc" xml:lang="en-US">Domestic US Patents IMVEXXY</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticUSUtilityPatentsImvexxyMember" xlink:to="txmd_DomesticUSUtilityPatentsImvexxyMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DomesticUSUtilityPatentsImvexxyMember_doc" xml:lang="en-US">Domestic US Utility Patents IMVEXXY</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticUSDesignPatentsImvexxyMember" xlink:to="txmd_DomesticUSDesignPatentsImvexxyMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DomesticUSDesignPatentsImvexxyMember_doc" xml:lang="en-US">Domestic US Design Patents IMVEXXY</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ForeignPatentsImvexxyMember" xlink:to="txmd_ForeignPatentsImvexxyMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ForeignPatentsImvexxyMember_doc" xml:lang="en-US">Foreign Patents IMVEXXY</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ForeignUtilityPatentsImvexxyMember" xlink:to="txmd_ForeignUtilityPatentsImvexxyMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ForeignUtilityPatentsImvexxyMember_doc" xml:lang="en-US">Foreign Utility Patents IMVEXXY</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ForeignDesignPatentsImvexxyMember" xlink:to="txmd_ForeignDesignPatentsImvexxyMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ForeignDesignPatentsImvexxyMember_doc" xml:lang="en-US">Foreign Design Patents IMVEXXY</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticUSPatentsTopicalCreamMember" xlink:to="txmd_DomesticUSPatentsTopicalCreamMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DomesticUSPatentsTopicalCreamMember_doc" xml:lang="en-US">Domestic US Patents Topical Cream</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticUtilityPatentTransdermalPatchMember" xlink:to="txmd_DomesticUtilityPatentTransdermalPatchMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DomesticUtilityPatentTransdermalPatchMember_doc" xml:lang="en-US">Domestic Utility Patent Transdermal Patch</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ForeignUtilityPatentTransdermalPatchMember" xlink:to="txmd_ForeignUtilityPatentTransdermalPatchMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ForeignUtilityPatentTransdermalPatchMember_doc" xml:lang="en-US">Foreign Utility Patent Transdermal Patch</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_DomesticUtilityPatentDLimoneneMember" xlink:label="txmd_DomesticUtilityPatentDLimoneneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticUtilityPatentDLimoneneMember" xlink:to="txmd_DomesticUtilityPatentDLimoneneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DomesticUtilityPatentDLimoneneMember_doc" xml:lang="en-US">Domestic Utility Patent DLimonene</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticUtilityPatentOperaMember" xlink:to="txmd_DomesticUtilityPatentOperaMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DomesticUtilityPatentOperaMember_doc" xml:lang="en-US">Domestic Utility Patent Opera</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticUtilityPatentTx009HRMember" xlink:to="txmd_DomesticUtilityPatentTx009HRMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DomesticUtilityPatentTx009HRMember_doc" xml:lang="en-US">Domestic Utility Patent TX009HR</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CouncilLicenseAgreement1Member" xlink:to="txmd_CouncilLicenseAgreement1Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CouncilLicenseAgreement1Member_doc" xml:lang="en-US">Information about agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AnnoveraMember" xlink:to="txmd_AnnoveraMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AnnoveraMember_doc" xml:lang="en-US">The drug name.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CouncilLicenseAgreementStep1Member" xlink:to="txmd_CouncilLicenseAgreementStep1Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CouncilLicenseAgreementStep1Member_doc" xml:lang="en-US">Council License Agreement Step 1</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RoyaltyPercent" xlink:to="txmd_RoyaltyPercent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_RoyaltyPercent_doc" xml:lang="en-US">The percent of the net sales to be paid as royalty per license agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CouncilLicenseAgreementStep2Member" xlink:to="txmd_CouncilLicenseAgreementStep2Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CouncilLicenseAgreementStep2Member_doc" xml:lang="en-US">Council License Agreement Step 2</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CouncilLicenseAgreementStep3Member" xlink:to="txmd_CouncilLicenseAgreementStep3Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CouncilLicenseAgreementStep3Member_doc" xml:lang="en-US">Council License Agreement Step 3</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent" xlink:to="txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent_doc" xml:lang="en-US">The reduction in royalty rate of the initial rate during the six-month period beginning on the date of the first arms-length commercial sale of a generic equivalent of the one-year vaginal contraceptive system that is launched by a third party in the U.S.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent" xlink:to="txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent_doc" xml:lang="en-US">The reduction in royalty rate of initial rate six-months after the first arms-length commercial sale of a generic equivalent of the one-year vaginal contraceptive system that is launched by a third party in the U.S.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid" xlink:to="txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid_doc" xml:lang="en-US">The maximum amount of costs and expenses associated with a post approval study required by the FDA to measure risk for venous thromboembolism to be paid by the Company before any such excess will be offset against royalties or other payments owed by us to the Population Council under the Council License Agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SubscriptionAgreementKnightMember" xlink:to="txmd_SubscriptionAgreementKnightMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_SubscriptionAgreementKnightMember_doc" xml:lang="en-US">Subscription Agreement</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RegulatoryMilestoneAdditionalPayment" xlink:to="txmd_RegulatoryMilestoneAdditionalPayment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_RegulatoryMilestoneAdditionalPayment_doc" xml:lang="en-US">Amount of regulatory milestone payments based on regulatory approvals for each of BIJUVA and IMVEXXY in certain specified markets.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SalesMilestonePaymentsInTranches" xlink:to="txmd_SalesMilestonePaymentsInTranches_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_SalesMilestonePaymentsInTranches_doc" xml:lang="en-US">Amount of sales milestone payments per licensing agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SalesDiscountsReturnsAndAllowancesGoods1" xlink:to="txmd_SalesDiscountsReturnsAndAllowancesGoods1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_SalesDiscountsReturnsAndAllowancesGoods1_doc" xml:lang="en-US">Aggregate allowance consisting of: (i) sales discounts given by the entity, including, but not limited to, early payments of accounts due, (ii) the total deduction from sales during the period arising from goods returned by customers (other than under warranty provisions), and (iii) price reductions (allowance, price protection agreements) given by the entity. Discounts, returns and allowances are a deduction from gross revenue in arriving at net revenue.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AllowanceForWholesaleDistributorFeesCurrent" xlink:to="txmd_AllowanceForWholesaleDistributorFeesCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AllowanceForWholesaleDistributorFeesCurrent_doc" xml:lang="en-US">Carrying value as of the balance sheet date of the obligations incurred through that date and payable for wholesale distributor fees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AccruedResearchAndDevelopment" xlink:to="txmd_AccruedResearchAndDevelopment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AccruedResearchAndDevelopment_doc" xml:lang="en-US">Carrying value as of the balance sheet date of the obligations incurred through that date and payable for research and development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AccruedRebates" xlink:to="txmd_AccruedRebates_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AccruedRebates_doc" xml:lang="en-US">Carrying value as of the balance sheet date of the obligations incurred through that date and payable forrebates. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CreditAgreementMember" xlink:to="txmd_CreditAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CreditAgreementMember_doc" xml:lang="en-US">CreditAgreementMember</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_FinancingAgreementMember" xlink:to="txmd_FinancingAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_FinancingAgreementMember_doc" xml:lang="en-US">Represents member of financing agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SupplierTwoConcentrationRiskMember" xlink:to="txmd_SupplierTwoConcentrationRiskMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_SupplierTwoConcentrationRiskMember_doc" xml:lang="en-US">Supplier Two Concentration Risk Member</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SupplierThreeConcentrationRiskMember" xlink:to="txmd_SupplierThreeConcentrationRiskMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_SupplierThreeConcentrationRiskMember_doc" xml:lang="en-US">Supplier Three Concentration Risk Member</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_ThreeCustomersConcentrationRiskMember" xlink:label="txmd_ThreeCustomersConcentrationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ThreeCustomersConcentrationRiskMember" xlink:to="txmd_ThreeCustomersConcentrationRiskMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ThreeCustomersConcentrationRiskMember_doc" xml:lang="en-US">Three Customers Concentration Risk Member</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_FourCustomersConcentrationRiskMember" xlink:to="txmd_FourCustomersConcentrationRiskMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_FourCustomersConcentrationRiskMember_doc" xml:lang="en-US">Four Customers Concentration Risk Member</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerConcentrationPillPackRiskMember" xlink:to="txmd_CustomerConcentrationPillPackRiskMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CustomerConcentrationPillPackRiskMember_doc" xml:lang="en-US">Major customers in concentration of sales.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerConcentrationAmerisourceBergenRiskMember" xlink:to="txmd_CustomerConcentrationAmerisourceBergenRiskMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CustomerConcentrationAmerisourceBergenRiskMember_doc" xml:lang="en-US">Custome rConcentration AmerisourceBergen Risk Member</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerConcentrationCardinalHealthRiskMember" xlink:to="txmd_CustomerConcentrationCardinalHealthRiskMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CustomerConcentrationCardinalHealthRiskMember_doc" xml:lang="en-US">Customer Concentration Cardinal Health Risk Member</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NetRentableAreaLease" xlink:to="txmd_NetRentableAreaLease_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NetRentableAreaLease_doc" xml:lang="en-US">Net rentable area as defined in lease.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RentedAreaLease" xlink:to="txmd_RentedAreaLease_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_RentedAreaLease_doc" xml:lang="en-US">Rented area as defined in lease.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LesseeOperatingLeaseLeaseNotYetCommencedArea" xlink:to="txmd_LesseeOperatingLeaseLeaseNotYetCommencedArea_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_LesseeOperatingLeaseLeaseNotYetCommencedArea_doc" xml:lang="en-US">Future rented area to be occupied for administrative office space as defined in lease.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfStockOptionsExercisedInCashlessExercise" xlink:to="txmd_NumberOfStockOptionsExercisedInCashlessExercise_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NumberOfStockOptionsExercisedInCashlessExercise_doc" xml:lang="en-US">Number of options exercised in the cashless transaction.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares" xlink:to="txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares_doc" xml:lang="en-US">Number of shares of common stock issued attributable to stock options exercised in cashless transaction.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife" xlink:to="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife_doc" xml:lang="en-US">This item provides the weighted-average contractual remaining life of warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsMember" xlink:to="txmd_WarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_WarrantsMember_doc" xml:lang="en-US">Warrants Member</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice" xlink:to="txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice_doc" xml:lang="en-US">Weighted average price at which warrant holders can acquire the shares reserved for issuance.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_OutsideConsultant2Member" xlink:to="txmd_OutsideConsultant2Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_OutsideConsultant2Member_doc" xml:lang="en-US">A person who provides consutling services to the Company.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfStockIssuedInCashlessExerciseOfWarrants" xlink:to="txmd_NumberOfStockIssuedInCashlessExerciseOfWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NumberOfStockIssuedInCashlessExerciseOfWarrants_doc" xml:lang="en-US">Number of shares of common stock issued attributable to warrants exercised in cashless transaction.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LongTermIncentiveCompensationPlan2009Member" xlink:to="txmd_LongTermIncentiveCompensationPlan2009Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_LongTermIncentiveCompensationPlan2009Member_doc" xml:lang="en-US">Long Term Incentive Compensation Plan 2009 Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NonQualified2012StockIncentivePlanMember" xlink:to="txmd_NonQualified2012StockIncentivePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NonQualified2012StockIncentivePlanMember_doc" xml:lang="en-US">Non Qualified 2012 Stock Incentive Plan Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PlanAwardsNumberOfNewShares" xlink:to="txmd_PlanAwardsNumberOfNewShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PlanAwardsNumberOfNewShares_doc" xml:lang="en-US">Number of new shares authorized for stock awards.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_Plan2019Member" xlink:to="txmd_Plan2019Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_Plan2019Member_doc" xml:lang="en-US">New 2019 Plan.</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_CustomerConcentrationPIServicesRiskMember" xlink:label="txmd_CustomerConcentrationPIServicesRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerConcentrationPIServicesRiskMember" xlink:to="txmd_CustomerConcentrationPIServicesRiskMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CustomerConcentrationPIServicesRiskMember_doc" xml:lang="en-US">PI Services</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AdditionalAreaOfLeaseOccupied" xlink:to="txmd_AdditionalAreaOfLeaseOccupied_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AdditionalAreaOfLeaseOccupied_doc" xml:lang="en-US">Additional rented area occupied under the lease.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SignificantSupplyCommitmentPercentagePayable" xlink:to="txmd_SignificantSupplyCommitmentPercentagePayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_SignificantSupplyCommitmentPercentagePayable_doc" xml:lang="en-US">Percent of the difference between the total amount we would have paid to supplier if the minimum requirement had been fulfilled and the sum of all purchases of our products from supplier during the contract year, required to be paid to supplier.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_UnderwritingAgreementGoldmanSachsMember" xlink:to="txmd_UnderwritingAgreementGoldmanSachsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_UnderwritingAgreementGoldmanSachsMember_doc" xml:lang="en-US">Underwriter Agrrement GoldmanSachs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PeriodExercisableUnderwritersOption" xlink:to="txmd_PeriodExercisableUnderwritersOption_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PeriodExercisableUnderwritersOption_doc" xml:lang="en-US">The period the option is exercisable per agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_UnderwritersOptionGrantedInPeriodShares" xlink:to="txmd_UnderwritersOptionGrantedInPeriodShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_UnderwritersOptionGrantedInPeriodShares_doc" xml:lang="en-US">The number of shares available to be purchased per underwriter's option.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DebtTrancheAxis" xlink:to="txmd_DebtTrancheAxis_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DebtTrancheAxis_doc" xml:lang="en-US">Portions of the Credit and Security Agreement to draw funds.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_TrancheOneMember" xlink:to="txmd_TrancheOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_TrancheOneMember_doc" xml:lang="en-US">Tranche of the Credit Facility Agreement to draw funds.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_TrancheTwoMember" xlink:to="txmd_TrancheTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_TrancheTwoMember_doc" xml:lang="en-US">Tranche Two as defined in financing agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_TrancheThreeMember" xlink:to="txmd_TrancheThreeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_TrancheThreeMember_doc" xml:lang="en-US">Tranche Three as defined in financing agreement.</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_RevenueRequirementToDrawOnTermLoan" xlink:label="txmd_RevenueRequirementToDrawOnTermLoan" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RevenueRequirementToDrawOnTermLoan" xlink:to="txmd_RevenueRequirementToDrawOnTermLoan_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_RevenueRequirementToDrawOnTermLoan_doc" xml:lang="en-US">The amount of consolidated net revenue attributable to commercial sales of TX-001HR and TX-004HR during the twelve-month period ending immediately prior to the funding of Tranche 3.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LiborFloorRate" xlink:to="txmd_LiborFloorRate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_LiborFloorRate_doc" xml:lang="en-US">Represents libor floor rate.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaymentFeeForFirstTwoYearsFundingPercent" xlink:to="txmd_PrepaymentFeeForFirstTwoYearsFundingPercent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PrepaymentFeeForFirstTwoYearsFundingPercent_doc" xml:lang="en-US">The prepayment fee expressed as a percentage of the funding being repaid for first two years following the initial funding date of the applicable borrowing.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaymentFeeThirdYearFundingPercent" xlink:to="txmd_PrepaymentFeeThirdYearFundingPercent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PrepaymentFeeThirdYearFundingPercent_doc" xml:lang="en-US">The prepayment fee expressed as a percentage of the funding being repaid for third year following the initial funding date of the applicable borrowing.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaymentFeeFourthYearFundingPercent" xlink:to="txmd_PrepaymentFeeFourthYearFundingPercent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PrepaymentFeeFourthYearFundingPercent_doc" xml:lang="en-US">The prepayment fee expressed as a percentage of the funding being repaid for fourth year following the initial funding date of the applicable borrowing.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaymentFeeFifthYearFundingPercent" xlink:to="txmd_PrepaymentFeeFifthYearFundingPercent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PrepaymentFeeFifthYearFundingPercent_doc" xml:lang="en-US">The prepayment fee expressed as a percentage of the funding being repaid for fifth year following the initial funding date of the applicable borrowing.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_FacilityFeePaidPercent" xlink:to="txmd_FacilityFeePaidPercent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_FacilityFeePaidPercent_doc" xml:lang="en-US">The facility fee expressed as a percentage paid or payable to the Agent for the benefit of lenders, under the terms of Credit Agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MinimumCashBalanceRequirementUnderCreditAgreement" xlink:to="txmd_MinimumCashBalanceRequirementUnderCreditAgreement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_MinimumCashBalanceRequirementUnderCreditAgreement_doc" xml:lang="en-US">The minimum cash balance the Borrower must maintain under the credit and secuirty agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_TrancheTwoThreeMember" xlink:to="txmd_TrancheTwoThreeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_TrancheTwoThreeMember_doc" xml:lang="en-US">Tranche Two Three Member</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfTranchesUnderTermLoanFacility" xlink:to="txmd_NumberOfTranchesUnderTermLoanFacility_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NumberOfTranchesUnderTermLoanFacility_doc" xml:lang="en-US">The number of seperate tranches under terms of the Credit Agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RepaymentFeePercentage" xlink:to="txmd_RepaymentFeePercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_RepaymentFeePercentage_doc" xml:lang="en-US">The repayment fee, expressed as a percentage of the tranche funding being repaid,</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MidCapAgreementMember" xlink:to="txmd_MidCapAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_MidCapAgreementMember_doc" xml:lang="en-US">Represents member of Mid Cap agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LesseeFinanceLeaseExistenceOfOptionToExtendNumber" xlink:to="txmd_LesseeFinanceLeaseExistenceOfOptionToExtendNumber_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_LesseeFinanceLeaseExistenceOfOptionToExtendNumber_doc" xml:lang="en-US">Number of options to extend lease.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MilestonePaymentUponFDAApproval" xlink:to="txmd_MilestonePaymentUponFDAApproval_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_MilestonePaymentUponFDAApproval_doc" xml:lang="en-US">The amount of milestone payments upon FDA approval.</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsTextBlock" xlink:label="txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsTextBlock" xlink:to="txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsTextBlock_doc" xml:lang="en-US">The entire disclosure of the basis of accounting and adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_BijuvaMember" xlink:to="txmd_BijuvaMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_BijuvaMember_doc" xml:lang="en-US">BIJUVA [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CapitalLeaseObligationsTerm" xlink:to="txmd_CapitalLeaseObligationsTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CapitalLeaseObligationsTerm_doc" xml:lang="en-US">The total term (in months) of the company's outstanding lease obligation.</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_DebtTrancheDomain" xlink:label="txmd_DebtTrancheDomain" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DebtTrancheDomain" xlink:to="txmd_DebtTrancheDomain_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DebtTrancheDomain_doc" xml:lang="en-US">DebtTrancheDomain</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LicenseRights" xlink:to="txmd_LicenseRights_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_LicenseRights_doc" xml:lang="en-US">The amount of license rights.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch" xlink:to="txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch_doc" xml:lang="en-US">The amount of milestone payments payable after release of first commercial batch.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NetSalesAmountPerStepbasedRoyalty" xlink:to="txmd_NetSalesAmountPerStepbasedRoyalty_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NetSalesAmountPerStepbasedRoyalty_doc" xml:lang="en-US">The net sales amount as defined in license agreement for step-based royalty payments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NoncashOperatingLeaseExpense" xlink:to="txmd_NoncashOperatingLeaseExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NoncashOperatingLeaseExpense_doc" xml:lang="en-US">Amount of expense related to operating lease costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfInstallmentPayments" xlink:to="txmd_NumberOfInstallmentPayments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NumberOfInstallmentPayments_doc" xml:lang="en-US">Number of principal installment payments under credit and security agreement.</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_NumberOfStockOptionsExercised" xlink:label="txmd_NumberOfStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfStockOptionsExercised" xlink:to="txmd_NumberOfStockOptionsExercised_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NumberOfStockOptionsExercised_doc" xml:lang="en-US">Number of share options (or share units) exercised during the current period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidSalesAndMarketingCostsCurrent" xlink:to="txmd_PrepaidSalesAndMarketingCostsCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PrepaidSalesAndMarketingCostsCurrent_doc" xml:lang="en-US">It refers to the amount of prepaid sales and marketing costs incurred.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrescriptionVitaminsMember" xlink:to="txmd_PrescriptionVitaminsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PrescriptionVitaminsMember_doc" xml:lang="en-US">Information about Prescription Vitamins.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RepaymentOfDebtWithNewCreditFacility" xlink:to="txmd_RepaymentOfDebtWithNewCreditFacility_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_RepaymentOfDebtWithNewCreditFacility_doc" xml:lang="en-US">Amount of the repayment of debt including all fees by borrowing funds from a new credit facility.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ScheduleOfIntangibleAssetsTableTextBlock" xlink:to="txmd_ScheduleOfIntangibleAssetsTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ScheduleOfIntangibleAssetsTableTextBlock_doc" xml:lang="en-US">Tabular disclosure of intangible assets, which may be broken down by major class.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms_doc" xml:lang="en-US">Weighted average remaining contractual term for unvested options, in 'PnYnMnDTnHnMnS' format,</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue_doc" xml:lang="en-US">Amount by which the current fair value of the underlying stock exceeds the exercise price of options unvested.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_doc" xml:lang="en-US">Weighted average price at which grantees can acquire unvested shares reserved for issuance.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PaymentsToAcquireIntellectualPropertyLicense" xlink:to="txmd_PaymentsToAcquireIntellectualPropertyLicense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PaymentsToAcquireIntellectualPropertyLicense_doc" xml:lang="en-US">The cash outlow for payments to acquir intellectual property license.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfVendors" xlink:to="txmd_NumberOfVendors_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NumberOfVendors_doc" xml:lang="en-US">Number of vendors.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfCustomers" xlink:to="txmd_NumberOfCustomers_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NumberOfCustomers_doc" xml:lang="en-US">Number of customers.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LicenseAgreementTheramexMember" xlink:to="txmd_LicenseAgreementTheramexMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_LicenseAgreementTheramexMember_doc" xml:lang="en-US">License Agreement Theramex</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AnnualNetSalesMilestone" xlink:to="txmd_AnnualNetSalesMilestone_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AnnualNetSalesMilestone_doc" xml:lang="en-US">Annual net sale milestones in the Territory per license agreement.</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_AccruedIntellectualLicenseFee" xlink:label="txmd_AccruedIntellectualLicenseFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AccruedIntellectualLicenseFee" xlink:to="txmd_AccruedIntellectualLicenseFee_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AccruedIntellectualLicenseFee_doc" xml:lang="en-US">Amount of expenses incurred but not yet paid for intellectual license fee, due within one year or the normal operating cycle, if longer.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CashUpfrontPaymentReceived" xlink:to="txmd_CashUpfrontPaymentReceived_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CashUpfrontPaymentReceived_doc" xml:lang="en-US">The cash inflow from license agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaymentFeePercentage" xlink:to="txmd_PrepaymentFeePercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PrepaymentFeePercentage_doc" xml:lang="en-US">The prepayment fee, expressed as a percentage of the tranche funding being repaid,</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfSubsidiaries" xlink:to="txmd_NumberOfSubsidiaries_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NumberOfSubsidiaries_doc" xml:lang="en-US">Number of subsidiaires for period reported.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfIssuedPatents" xlink:to="txmd_NumberOfIssuedPatents_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NumberOfIssuedPatents_doc" xml:lang="en-US">Number of issued patents.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock" xlink:to="txmd_ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock_doc" xml:lang="en-US">Disclosure of supplementary lease and cash flow information.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_UnderwritingAgreementJPMorganChaseMember" xlink:to="txmd_UnderwritingAgreementJPMorganChaseMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_UnderwritingAgreementJPMorganChaseMember_doc" xml:lang="en-US">Underwriting Agreement JP Morgan Chase Member</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ProceedsFromIssuancePublicOffering" xlink:to="txmd_ProceedsFromIssuancePublicOffering_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ProceedsFromIssuancePublicOffering_doc" xml:lang="en-US">The cash inflow associated with the amount received from entity's raising of capital by public offering.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ScheduleOfWarrantRollForwardTableTextBlock" xlink:to="txmd_ScheduleOfWarrantRollForwardTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ScheduleOfWarrantRollForwardTableTextBlock_doc" xml:lang="en-US">Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for warrants that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of warrants that were granted, exercised, forfeited, and expired during the year.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock" xlink:to="txmd_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock_doc" xml:lang="en-US">Tabular disclosure of the significant assumptions used during the year to estimate the fair value of warrants, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_OtcProductsMember" xlink:to="txmd_OtcProductsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_OtcProductsMember_doc" xml:lang="en-US">OTC Products</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidManufacturing" xlink:to="txmd_PrepaidManufacturing_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PrepaidManufacturing_doc" xml:lang="en-US">Prepaid manufacturing costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsGrantedOtherThanOptionsWeightedAverageExercisePrice" xlink:to="txmd_WarrantsGrantedOtherThanOptionsWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_WarrantsGrantedOtherThanOptionsWeightedAverageExercisePrice_doc" xml:lang="en-US">Weighted average per share amount at which warrant holders can acquire shares of common stock by exercise of warrants.</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_WarrantsExpiredOtherThanOptionsWeightedAverageExercisePrice" xlink:label="txmd_WarrantsExpiredOtherThanOptionsWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsExpiredOtherThanOptionsWeightedAverageExercisePrice" xlink:to="txmd_WarrantsExpiredOtherThanOptionsWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_WarrantsExpiredOtherThanOptionsWeightedAverageExercisePrice_doc" xml:lang="en-US">Weighted average price at which warrant holders could have acquired the underlying shares with respect to warrants that expired.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsOutstandingVestedAndExercisable" xlink:to="txmd_WarrantsOutstandingVestedAndExercisable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_WarrantsOutstandingVestedAndExercisable_doc" xml:lang="en-US">Weighted-average exercise price, at which warrant holders can acquire shares reserved for issuance, for fully vested and exercisable warrants outstanding.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsUnvestedWeightedAverageExercisePrice" xlink:to="txmd_WarrantsUnvestedWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_WarrantsUnvestedWeightedAverageExercisePrice_doc" xml:lang="en-US">The weighted-average price as of the balance sheet date at which warrant holders can acquire the shares reserved for issuance on warrants outstanding and unvested.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExercisableWeightedAverageRemainingContractualTerms" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExercisableWeightedAverageRemainingContractualTerms_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExercisableWeightedAverageRemainingContractualTerms_doc" xml:lang="en-US">Weighted average remaining contractual term for vested and exercisable equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format,</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms_doc" xml:lang="en-US">Weighted average remaining contractual term for unvested equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format,</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue_doc" xml:lang="en-US">Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on warrants exercised (or share units converted) into shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue_doc" xml:lang="en-US">Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of warrants vested and exercisable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WeightedAverageExercisePriceOtherThanOptions" xlink:to="txmd_WeightedAverageExercisePriceOtherThanOptions_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_WeightedAverageExercisePriceOtherThanOptions_doc" xml:lang="en-US">Intrinsic value of unvested equity-based compensation awards outstanding. Excludes stock and unit options.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_doc" xml:lang="en-US">The number of shares into which vested non option equity instruments outstanding as of the balance sheet date can be currently converted.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerBMember" xlink:to="txmd_CustomerBMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CustomerBMember_doc" xml:lang="en-US">Customer B</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerCMember" xlink:to="txmd_CustomerCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CustomerCMember_doc" xml:lang="en-US">Customer C</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerDMember" xlink:to="txmd_CustomerDMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CustomerDMember_doc" xml:lang="en-US">Customer D</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerAMember" xlink:to="txmd_CustomerAMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CustomerAMember_doc" xml:lang="en-US">Customer A</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfIssuedPatentsDomestic" xlink:to="txmd_NumberOfIssuedPatentsDomestic_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NumberOfIssuedPatentsDomestic_doc" xml:lang="en-US">Number of issued patents domestic.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfIssuedPatentsForeign" xlink:to="txmd_NumberOfIssuedPatentsForeign_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NumberOfIssuedPatentsForeign_doc" xml:lang="en-US">Number of issued patents foreign.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ReturnPeriodOfUnsalablePrescriptionProducts" xlink:to="txmd_ReturnPeriodOfUnsalablePrescriptionProducts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ReturnPeriodOfUnsalablePrescriptionProducts_doc" xml:lang="en-US">Period the company accepts returns of unsalable prescription products from customers following product expiration.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShelfLifeOfPrescriptionProducts" xlink:to="txmd_ShelfLifeOfPrescriptionProducts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ShelfLifeOfPrescriptionProducts_doc" xml:lang="en-US">Period shelf life of prescription products from date of manufacture.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_VitaminsAndImvexxyMember" xlink:to="txmd_VitaminsAndImvexxyMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_VitaminsAndImvexxyMember_doc" xml:lang="en-US">Vitamins and IMVEXXY</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_BijuvaAndAnnoveraMember" xlink:to="txmd_BijuvaAndAnnoveraMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_BijuvaAndAnnoveraMember_doc" xml:lang="en-US">BIJUVA and ANNOVERA</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticPatentsProgesteroneFormulationsMember" xlink:to="txmd_DomesticPatentsProgesteroneFormulationsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DomesticPatentsProgesteroneFormulationsMember_doc" xml:lang="en-US">Domestic Patents Progesterone Formulations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ForeignPatentsProgesteroneFormulationsMember" xlink:to="txmd_ForeignPatentsProgesteroneFormulationsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ForeignPatentsProgesteroneFormulationsMember_doc" xml:lang="en-US">Foreign Patents Progesterone Formulations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ExpirationPeriod20YearsMember" xlink:to="txmd_ExpirationPeriod20YearsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ExpirationPeriod20YearsMember_doc" xml:lang="en-US">Expiration Period 20 Years</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ExpirationPeriodIndefiniteMember" xlink:to="txmd_ExpirationPeriodIndefiniteMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ExpirationPeriodIndefiniteMember_doc" xml:lang="en-US">Expiration Period Indefinite</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_OperatingLossCarryforwardsExpirationYear" xlink:to="txmd_OperatingLossCarryforwardsExpirationYear_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_OperatingLossCarryforwardsExpirationYear_doc" xml:lang="en-US">Expiration year of operating loss carryforward.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NolCarryForwardPeriod" xlink:to="txmd_NolCarryForwardPeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NolCarryForwardPeriod_doc" xml:lang="en-US">Expiration period of operating loss carryforward included in operating loss carryforward.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerConcentrationMcKessonCorporationRiskMember" xlink:to="txmd_CustomerConcentrationMcKessonCorporationRiskMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CustomerConcentrationMcKessonCorporationRiskMember_doc" xml:lang="en-US">McKesson Corporation - Major Customer</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerConcentrationPharmacyInnovationsPaRiskMember" xlink:to="txmd_CustomerConcentrationPharmacyInnovationsPaRiskMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CustomerConcentrationPharmacyInnovationsPaRiskMember_doc" xml:lang="en-US">Pharmacy Innovations PA - Major Customer</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ImvexxyBijuvaAndAnnoveraMember" xlink:to="txmd_ImvexxyBijuvaAndAnnoveraMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ImvexxyBijuvaAndAnnoveraMember_doc" xml:lang="en-US">IMVEXXY, BIJUVA and ANNOVERA</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsCashlessExerciseMember" xlink:to="txmd_WarrantsCashlessExerciseMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_WarrantsCashlessExerciseMember_doc" xml:lang="en-US">Warrants - Cashless Exercise</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice_doc" xml:lang="en-US">The exercise price as of the balance sheet date at which grantees can acquire the shares for options outstanding.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CatalentMember" xlink:to="txmd_CatalentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CatalentMember_doc" xml:lang="en-US">Catalent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_EntityCommonStockHeldByNonaffiliates" xlink:to="txmd_EntityCommonStockHeldByNonaffiliates_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_EntityCommonStockHeldByNonaffiliates_doc" xml:lang="en-US">Number of shares or other units held by non-affiliates of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_QuarterlyRoyaltyPaymentsPercentage" xlink:to="txmd_QuarterlyRoyaltyPaymentsPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_QuarterlyRoyaltyPaymentsPercentage_doc" xml:lang="en-US">The percentage of quarterly royalty payments on net sales which the company is entitled to receive.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RequiredMilestonePaymentsUponCumulativeNetSalesOfSpecifiedLevels" xlink:to="txmd_RequiredMilestonePaymentsUponCumulativeNetSalesOfSpecifiedLevels_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_RequiredMilestonePaymentsUponCumulativeNetSalesOfSpecifiedLevels_doc" xml:lang="en-US">The amount of required milestone payments upon cumulative net sales of specified levels by the company and affiliates and permitted sublicensees.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SpecifiedLevelOneOfCumulativeNetSalesForRequiredMilestonePayments" xlink:to="txmd_SpecifiedLevelOneOfCumulativeNetSalesForRequiredMilestonePayments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_SpecifiedLevelOneOfCumulativeNetSalesForRequiredMilestonePayments_doc" xml:lang="en-US">The first level of net sales by the company and affiliates and permitted sublicensees related to required milestone payments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SpecifiedLevelTwoOfCumulativeNetSalesForRequiredMilestonePayments" xlink:to="txmd_SpecifiedLevelTwoOfCumulativeNetSalesForRequiredMilestonePayments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_SpecifiedLevelTwoOfCumulativeNetSalesForRequiredMilestonePayments_doc" xml:lang="en-US">The second level of net sales by the company and affiliates and permitted sublicensees related to required milestone payments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SpecifiedLevelThreeOfCumulativeNetSalesForRequiredMilestonePayments" xlink:to="txmd_SpecifiedLevelThreeOfCumulativeNetSalesForRequiredMilestonePayments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_SpecifiedLevelThreeOfCumulativeNetSalesForRequiredMilestonePayments_doc" xml:lang="en-US">The third level of net sales by the company and affiliates and permitted sublicensees related to required milestone payments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsExercisedOtherThanOptionsWeightedAverageExercisePrice" xlink:to="txmd_WarrantsExercisedOtherThanOptionsWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_WarrantsExercisedOtherThanOptionsWeightedAverageExercisePrice_doc" xml:lang="en-US">Weighted average per share amount at which warrant holders can acquire shares of common stock with respect to warrants that were exercised.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_2_lbl" xml:lang="en-US">Other Assets, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_2_lbl" xml:lang="en-US">Interest Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:to="us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_2_lbl" xml:lang="en-US">Cumulative Effect of New Accounting Principle in Period of Adoption</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_2_lbl" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PaymentsToAcquireIntellectualPropertyLicense" xlink:to="txmd_PaymentsToAcquireIntellectualPropertyLicense_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PaymentsToAcquireIntellectualPropertyLicense_3_lbl" xml:lang="en-US">Payments to acquire intellectual property license</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_2_lbl" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash_2_lbl" xml:lang="en-US">Increase (Decrease) in Restricted Cash</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfOtherLongTermDebt" xlink:to="us-gaap_RepaymentsOfOtherLongTermDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfOtherLongTermDebt_2_lbl" xml:lang="en-US">Repayments of Other Long-term Debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_2_lbl" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_2_lbl" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_3_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsOutstandingVestedAndExercisable" xlink:to="txmd_WarrantsOutstandingVestedAndExercisable_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WarrantsOutstandingVestedAndExercisable_3_lbl" xml:lang="en-US">Warrants Outstanding Vested And Exercisable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue_3_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Non Options Exercisable Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsUnvestedWeightedAverageExercisePrice" xlink:to="txmd_WarrantsUnvestedWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WarrantsUnvestedWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Warrants Unvested Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Outstanding Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue_3_lbl" xml:lang="en-US">Outstanding Aggregate Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_2_lbl" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_2_lbl" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Two</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Three</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Four</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Five</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>16
<FILENAME>txmd-20191231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.1d -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Cover" xlink:href="txmd-20191231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheets" xlink:href="txmd-20191231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="txmd-20191231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations" xlink:href="txmd-20191231.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:href="txmd-20191231.xsd#ConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="txmd-20191231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Company" xlink:href="txmd-20191231.xsd#Company" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="txmd-20191231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Inventory" xlink:href="txmd-20191231.xsd#Inventory" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentAssets" xlink:href="txmd-20191231.xsd#OtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsNet" xlink:href="txmd-20191231.xsd#FixedAssetsNet" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsNet" xlink:href="txmd-20191231.xsd#IntangibleAssetsNet" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilities" xlink:href="txmd-20191231.xsd#OtherCurrentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Debt" xlink:href="txmd-20191231.xsd#Debt" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquity" xlink:href="txmd-20191231.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IncomeTaxes" xlink:href="txmd-20191231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/RelatedParties" xlink:href="txmd-20191231.xsd#RelatedParties" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/BusinessConcentrations" xlink:href="txmd-20191231.xsd#BusinessConcentrations" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingencies" xlink:href="txmd-20191231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialData" xlink:href="txmd-20191231.xsd#SelectedQuarterlyFinancialData" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SubsequentEvents" xlink:href="txmd-20191231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="txmd-20191231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="txmd-20191231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/InventoryTables" xlink:href="txmd-20191231.xsd#InventoryTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentAssetsTables" xlink:href="txmd-20191231.xsd#OtherCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsNetTables" xlink:href="txmd-20191231.xsd#FixedAssetsNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsNetTables" xlink:href="txmd-20191231.xsd#IntangibleAssetsNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesTables" xlink:href="txmd-20191231.xsd#OtherCurrentLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/DebtTables" xlink:href="txmd-20191231.xsd#DebtTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityTables" xlink:href="txmd-20191231.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IncomeTaxesTables" xlink:href="txmd-20191231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables" xlink:href="txmd-20191231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialDataTables" xlink:href="txmd-20191231.xsd#SelectedQuarterlyFinancialDataTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CompanyDetailsNarrative" xlink:href="txmd-20191231.xsd#CompanyDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueByProductMixForYearsEndedDecember3120192018And2017Details" xlink:href="txmd-20191231.xsd#FollowingTableProvidesInformationAboutDisaggregatedRevenueByProductMixForYearsEndedDecember3120192018And2017Details" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/TableBelowPresentsPotentiallyDilutiveSecuritiesThatCouldAffectOurCalculationOfDilutedNetLossPerShareAllocableToCommonStockholdersForPeriodsPresented.Details" xlink:href="txmd-20191231.xsd#TableBelowPresentsPotentiallyDilutiveSecuritiesThatCouldAffectOurCalculationOfDilutedNetLossPerShareAllocableToCommonStockholdersForPeriodsPresented.Details" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="txmd-20191231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/InventoryConsistsOfFollowingDetails" xlink:href="txmd-20191231.xsd#InventoryConsistsOfFollowingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails" xlink:href="txmd-20191231.xsd#OtherCurrentAssetsConsistOfFollowingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails" xlink:href="txmd-20191231.xsd#FixedAssetsNetConsistOfFollowingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsNetDetailsNarrative" xlink:href="txmd-20191231.xsd#FixedAssetsNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfDecember312019And2018Details" xlink:href="txmd-20191231.xsd#FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfDecember312019And2018Details" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/EstimatedAmortizationExpenseBasedOnCurrentPatentCostBeingAmortizedForNextFiveYearsIsAsFollowsDetails" xlink:href="txmd-20191231.xsd#EstimatedAmortizationExpenseBasedOnCurrentPatentCostBeingAmortizedForNextFiveYearsIsAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative" xlink:href="txmd-20191231.xsd#IntangibleAssetsNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails" xlink:href="txmd-20191231.xsd#OtherCurrentLiabilitiesConsistOfFollowingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/AsOfDecember312019And2018CarryingValueOfOurDebtConsistedOfFollowingDetails" xlink:href="txmd-20191231.xsd#AsOfDecember312019And2018CarryingValueOfOurDebtConsistedOfFollowingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/DebtDetailsNarrative" xlink:href="txmd-20191231.xsd#DebtDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfOurWarrantActivityDuringYearEndedDecember312019Details" xlink:href="txmd-20191231.xsd#SummaryOfOurWarrantActivityDuringYearEndedDecember312019Details" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/WeightedAverageFairValuePerShareOfWarrantsIssuedAndAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120192018And2017AreSetForthInTableBelow.Details" xlink:href="txmd-20191231.xsd#WeightedAverageFairValuePerShareOfWarrantsIssuedAndAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120192018And2017AreSetForthInTableBelow.Details" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/RangesOfAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120192018And2017AreSetForthInTableBelow.Details" xlink:href="txmd-20191231.xsd#RangesOfAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120192018And2017AreSetForthInTableBelow.Details" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringYearEndedDecember312019IsAsFollowsDetails" xlink:href="txmd-20191231.xsd#SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringYearEndedDecember312019IsAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative" xlink:href="txmd-20191231.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ForFinancialReportingPurposesIncomeBeforeTaxesIncludesFollowingComponentsDetails" xlink:href="txmd-20191231.xsd#ForFinancialReportingPurposesIncomeBeforeTaxesIncludesFollowingComponentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ReconciliationBetweenTaxesComputedAtFederalStatutoryRateAndConsolidatedEffectiveTaxRateIsAsFollowsDetails" xlink:href="txmd-20191231.xsd#ReconciliationBetweenTaxesComputedAtFederalStatutoryRateAndConsolidatedEffectiveTaxRateIsAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ComponentsOfNetDeferredIncomeTaxAssetAsOfDecember3120192018And2017AreAsFollowsDetails" xlink:href="txmd-20191231.xsd#ComponentsOfNetDeferredIncomeTaxAssetAsOfDecember3120192018And2017AreAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IncomeTaxesDetailsNarrative" xlink:href="txmd-20191231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative" xlink:href="txmd-20191231.xsd#RelatedPartiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative" xlink:href="txmd-20191231.xsd#BusinessConcentrationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SupplementalLeaseInformationDetails" xlink:href="txmd-20191231.xsd#SupplementalLeaseInformationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtDecember312019ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails" xlink:href="txmd-20191231.xsd#FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtDecember312019ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="txmd-20191231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummarizedQuarterlyFinancialDataForFiscalYears2019And2018IsAsFollowsDetails" xlink:href="txmd-20191231.xsd#SummarizedQuarterlyFinancialDataForFiscalYears2019And2018IsAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SubsequentEventsDetailsNarrative" xlink:href="txmd-20191231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_EntityCommonStockHeldByNonaffiliates" xlink:label="loc_txmdEntityCommonStockHeldByNonaffiliates" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_txmdEntityCommonStockHeldByNonaffiliates" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedBalanceSheets" xlink:title="00000002 - Statement - CONSOLIDATED BALANCE SHEETS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsAbstract" xlink:label="loc_us-gaapOtherAssetsAbstract" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOtherAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_LicenseRights" xlink:label="loc_txmdLicenseRights" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_txmdLicenseRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:label="loc_us-gaapOtherAssetsMiscellaneousNoncurrent" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_us-gaapOtherAssetsMiscellaneousNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrentAbstract" xlink:label="loc_us-gaapLongTermDebtNoncurrentAbstract" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLongTermDebtNoncurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaapLongTermDebtNoncurrent" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongTermDebtNoncurrentAbstract" xlink:to="loc_us-gaapLongTermDebtNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongTermDebtNoncurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivable" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtProductOrServiceAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaapProductMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapProductMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="loc_us-gaapLicenseAndServiceMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapLicenseAndServiceMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaapCostOfGoodsAndServicesSold" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCostOfGoodsAndServicesSold" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaapOtherNonoperatingIncome" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapOtherNonoperatingIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:label="loc_us-gaapInvestmentIncomeNetAmortizationOfDiscountAndPremium" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaapEarningsPerShareBasicAndDiluted" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareBasicAndDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:title="00000005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS&apos; EQUITY">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaapCumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:label="loc_us-gaapStockGrantedDuringPeriodValueSharebasedCompensation" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockGrantedDuringPeriodValueSharebasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_2" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows" xlink:title="00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncashExpense" xlink:label="loc_us-gaapOtherNoncashExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapOtherNoncashExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_NoncashOperatingLeaseExpense" xlink:label="loc_txmdNoncashOperatingLeaseExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_txmdNoncashOperatingLeaseExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaapProvisionForDoubtfulAccounts" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapProvisionForDoubtfulAccounts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAmortizationOfDeferredCharges" xlink:label="loc_us-gaapOtherAmortizationOfDeferredCharges" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapOtherAmortizationOfDeferredCharges" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaapAmortizationOfFinancingCosts" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfFinancingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_PaymentsToAcquireIntellectualPropertyLicense" xlink:label="loc_txmdPaymentsToAcquireIntellectualPropertyLicense" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_txmdPaymentsToAcquireIntellectualPropertyLicense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="loc_us-gaapIncreaseDecreaseInRestrictedCash" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInRestrictedCash" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaapProceedsFromLinesOfCredit" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromLinesOfCredit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xlink:label="loc_us-gaapProceedsFromIssuanceOfOtherLongTermDebt" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfOtherLongTermDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaapPaymentsOfFinancingCosts" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsOfFinancingCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfOtherLongTermDebt" xlink:label="loc_us-gaapRepaymentsOfOtherLongTermDebt" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapRepaymentsOfOtherLongTermDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapInterestPaidNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Company" xlink:title="00000007 - Disclosure - THE COMPANY">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaapNatureOfOperations" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapNatureOfOperations" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Inventory" xlink:title="00000009 - Disclosure - INVENTORY">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaapInventoryDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssets" xlink:title="00000010 - Disclosure - OTHER CURRENT ASSETS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentAssetsTextBlock" xlink:label="loc_us-gaapOtherCurrentAssetsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapOtherCurrentAssetsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsNet" xlink:title="00000011 - Disclosure - FIXED ASSETS, NET">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsNet" xlink:title="00000012 - Disclosure - INTANGIBLE ASSETS, NET">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilities" xlink:title="00000013 - Disclosure - OTHER CURRENT LIABILITIES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="loc_us-gaapAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Debt" xlink:title="00000014 - Disclosure - DEBT">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="loc_us-gaapLongTermDebtTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapLongTermDebtTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquity" xlink:title="00000015 - Disclosure - STOCKHOLDERS&#8217; EQUITY">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IncomeTaxes" xlink:title="00000016 - Disclosure - INCOME TAXES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/RelatedParties" xlink:title="00000017 - Disclosure - RELATED PARTIES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/BusinessConcentrations" xlink:title="00000018 - Disclosure - BUSINESS CONCENTRATIONS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaapRisksAndUncertaintiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="loc_us-gaapConcentrationRiskDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRisksAndUncertaintiesAbstract" xlink:to="loc_us-gaapConcentrationRiskDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingencies" xlink:title="00000019 - Disclosure - COMMITMENTS AND CONTINGENCIES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialData" xlink:title="00000020 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaapQuarterlyFinancialInformationDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="loc_us-gaapQuarterlyFinancialInformationTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapQuarterlyFinancialInformationDisclosureAbstract" xlink:to="loc_us-gaapQuarterlyFinancialInformationTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SubsequentEvents" xlink:title="00000021 - Disclosure - SUBSEQUENT EVENTS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000022 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaapConsolidationPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConsolidationPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:label="loc_us-gaapReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaapInventoryPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapInventoryPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="loc_us-gaapIntangibleAssetsFiniteLivedPolicy" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIntangibleAssetsFiniteLivedPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaapRevenueFromContractWithCustomerPolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="loc_us-gaapCostOfSalesPolicyTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCostOfSalesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="loc_us-gaapAdvertisingCostsPolicyTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapAdvertisingCostsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaapConcentrationRiskCreditRisk" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConcentrationRiskCreditRisk" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000023 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaapDisaggregationOfRevenueTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapDisaggregationOfRevenueTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/InventoryTables" xlink:title="00000024 - Disclosure - INVENTORY (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaapScheduleOfInventoryCurrentTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssetsTables" xlink:title="00000025 - Disclosure - OTHER CURRENT ASSETS (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:label="loc_us-gaapScheduleOfOtherCurrentAssetsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfOtherCurrentAssetsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsNetTables" xlink:title="00000026 - Disclosure - FIXED ASSETS, NET (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsNetTables" xlink:title="00000027 - Disclosure - INTANGIBLE ASSETS, NET (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_ScheduleOfIntangibleAssetsTableTextBlock" xlink:label="loc_txmdScheduleOfIntangibleAssetsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_txmdScheduleOfIntangibleAssetsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesTables" xlink:title="00000028 - Disclosure - OTHER CURRENT LIABILITIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:label="loc_us-gaapOtherCurrentLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapOtherCurrentLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/DebtTables" xlink:title="00000029 - Disclosure - DEBT (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="loc_us-gaapScheduleOfDebtTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDebtTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityTables" xlink:title="00000030 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_ScheduleOfWarrantRollForwardTableTextBlock" xlink:label="loc_txmdScheduleOfWarrantRollForwardTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_txmdScheduleOfWarrantRollForwardTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock" xlink:label="loc_txmdScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_txmdScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IncomeTaxesTables" xlink:title="00000031 - Disclosure - INCOME TAXES (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="loc_us-gaapScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables" xlink:title="00000032 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock" xlink:label="loc_txmdScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_txmdScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialDataTables" xlink:title="00000033 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaapQuarterlyFinancialInformationDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="loc_us-gaapScheduleOfQuarterlyFinancialInformationTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapQuarterlyFinancialInformationDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CompanyDetailsNarrative" xlink:title="00000034 - Disclosure - THE COMPANY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_NumberOfSubsidiaries" xlink:label="loc_txmdNumberOfSubsidiaries" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_txmdNumberOfSubsidiaries" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueByProductMixForYearsEndedDecember3120192018And2017Details" xlink:title="00000035 - Disclosure - The following table provides information about disaggregated revenue by product mix for the years ended December 31, 2019, 2018, and 2017: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaapScheduleOfProductInformationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfProductInformationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaapProductInformationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapProductInformationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtProductOrServiceAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_PrescriptionVitaminsMember" xlink:label="loc_txmdPrescriptionVitaminsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_txmdPrescriptionVitaminsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_ImvexxyMember" xlink:label="loc_txmdImvexxyMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_txmdImvexxyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_BijuvaMember" xlink:label="loc_txmdBijuvaMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_txmdBijuvaMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_AnnoveraMember" xlink:label="loc_txmdAnnoveraMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_txmdAnnoveraMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="loc_us-gaapLicenseAndServiceMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapLicenseAndServiceMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_OtcProductsMember" xlink:label="loc_txmdOtcProductsMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_txmdOtcProductsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/TableBelowPresentsPotentiallyDilutiveSecuritiesThatCouldAffectOurCalculationOfDilutedNetLossPerShareAllocableToCommonStockholdersForPeriodsPresented.Details" xlink:title="00000036 - Disclosure - The table below presents potentially dilutive securities that could affect our calculation of diluted net loss per share allocable to common stockholders for the periods presented. (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000037 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaapScheduleOfProductInformationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfProductInformationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaapProductInformationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapProductInformationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaapAccountsReceivableMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapAccountsReceivableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_CustomerAMember" xlink:label="loc_txmdCustomerAMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerAMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_CustomerBMember" xlink:label="loc_txmdCustomerBMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerBMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_CustomerCMember" xlink:label="loc_txmdCustomerCMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_CustomerDMember" xlink:label="loc_txmdCustomerDMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerDMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LandAndBuildingMember" xlink:label="loc_us-gaapLandAndBuildingMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLandAndBuildingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="loc_us-gaapSoftwareAndSoftwareDevelopmentCostsMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapSoftwareAndSoftwareDevelopmentCostsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtRangeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtProductOrServiceAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_VitaminsAndImvexxyMember" xlink:label="loc_txmdVitaminsAndImvexxyMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_txmdVitaminsAndImvexxyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_BijuvaAndAnnoveraMember" xlink:label="loc_txmdBijuvaAndAnnoveraMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_txmdBijuvaAndAnnoveraMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_SubscriptionAgreementKnightMember" xlink:label="loc_txmdSubscriptionAgreementKnightMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_txmdSubscriptionAgreementKnightMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_LicenseAgreementTheramexMember" xlink:label="loc_txmdLicenseAgreementTheramexMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdLicenseAgreementTheramexMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaapAdjustmentsForNewAccountingPronouncementsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapAdjustmentsForNewAccountingPronouncementsAxis" order="80" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaapTypeOfAdoptionMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsForNewAccountingPronouncementsAxis" xlink:to="loc_us-gaapTypeOfAdoptionMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaapAccountingStandardsUpdate201602Member" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfAdoptionMember" xlink:to="loc_us-gaapAccountingStandardsUpdate201602Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapCashFDICInsuredAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_NumberOfIssuedPatentsDomestic" xlink:label="loc_txmdNumberOfIssuedPatentsDomestic" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_txmdNumberOfIssuedPatentsDomestic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_NumberOfIssuedPatentsForeign" xlink:label="loc_txmdNumberOfIssuedPatentsForeign" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_txmdNumberOfIssuedPatentsForeign" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_ReturnPeriodOfUnsalablePrescriptionProducts" xlink:label="loc_txmdReturnPeriodOfUnsalablePrescriptionProducts" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_txmdReturnPeriodOfUnsalablePrescriptionProducts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_ShelfLifeOfPrescriptionProducts" xlink:label="loc_txmdShelfLifeOfPrescriptionProducts" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_txmdShelfLifeOfPrescriptionProducts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_CashUpfrontPaymentReceived" xlink:label="loc_txmdCashUpfrontPaymentReceived" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_txmdCashUpfrontPaymentReceived" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_RegulatoryMilestoneAdditionalPayment" xlink:label="loc_txmdRegulatoryMilestoneAdditionalPayment" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_txmdRegulatoryMilestoneAdditionalPayment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_SalesMilestonePaymentsInTranches" xlink:label="loc_txmdSalesMilestonePaymentsInTranches" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_txmdSalesMilestonePaymentsInTranches" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_AnnualNetSalesMilestone" xlink:label="loc_txmdAnnualNetSalesMilestone" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_txmdAnnualNetSalesMilestone" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_QuarterlyRoyaltyPaymentsPercentage" xlink:label="loc_txmdQuarterlyRoyaltyPaymentsPercentage" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_txmdQuarterlyRoyaltyPaymentsPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaapNumberOfReportableSegments" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapNumberOfReportableSegments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdvertisingExpense" xlink:label="loc_us-gaapAdvertisingExpense" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapAdvertisingExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/InventoryConsistsOfFollowingDetails" xlink:title="00000038 - Disclosure - Inventory consists of the following: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaapInventoryFinishedGoods" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryFinishedGoods" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaapInventoryWorkInProcess" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryWorkInProcess" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterialsAndSupplies" xlink:label="loc_us-gaapInventoryRawMaterialsAndSupplies" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryRawMaterialsAndSupplies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails" xlink:title="00000039 - Disclosure - Other current assets consist of the following: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_PrepaidSalesAndMarketingCostsCurrent" xlink:label="loc_txmdPrepaidSalesAndMarketingCostsCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_txmdPrepaidSalesAndMarketingCostsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFinanceCostsCurrentNet" xlink:label="loc_us-gaapDeferredFinanceCostsCurrentNet" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapDeferredFinanceCostsCurrentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaapPrepaidInsurance" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapPrepaidInsurance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_PrepaidManufacturing" xlink:label="loc_txmdPrepaidManufacturing" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_txmdPrepaidManufacturing" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails" xlink:title="00000040 - Disclosure - Fixed assets, net consist of the following: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="loc_us-gaapSoftwareAndSoftwareDevelopmentCostsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapSoftwareAndSoftwareDevelopmentCostsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaapEquipmentMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsNetDetailsNarrative" xlink:title="00000041 - Disclosure - FIXED ASSETS, NET (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfDecember312019And2018Details" xlink:title="00000042 - Disclosure - The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of December 31, 2019 and 2018: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:label="loc_txmdApprovedHormoneTherapyDrugCandidatePatentsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="loc_us-gaapComputerSoftwareIntangibleAssetMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapComputerSoftwareIntangibleAssetMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InternetDomainNamesMember" xlink:label="loc_us-gaapInternetDomainNamesMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapInternetDomainNamesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_HormoneTherapyDrugCandidatePatentsMember" xlink:label="loc_txmdHormoneTherapyDrugCandidatePatentsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdHormoneTherapyDrugCandidatePatentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_MultipleTrademarksForVitaminsSupplementsMember" xlink:label="loc_txmdMultipleTrademarksForVitaminsSupplementsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdMultipleTrademarksForVitaminsSupplementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedTrademarks" xlink:label="loc_us-gaapIndefiniteLivedTrademarks" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapIndefiniteLivedTrademarks" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwill" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsGrossExcludingGoodwill" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapIntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/EstimatedAmortizationExpenseBasedOnCurrentPatentCostBeingAmortizedForNextFiveYearsIsAsFollowsDetails" xlink:title="00000043 - Disclosure - Estimated amortization expense, based on current patent cost being amortized, for the next five years is as follows: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative" xlink:title="00000044 - Disclosure - INTANGIBLE ASSETS, NET (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:label="loc_txmdApprovedHormoneTherapyDrugCandidatePatentsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_DomesticUSPatentsMember" xlink:label="loc_txmdDomesticUSPatentsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticUSPatentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_ForeignPatentsMember" xlink:label="loc_txmdForeignPatentsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdForeignPatentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_DomesticPatentsBijuvaMember" xlink:label="loc_txmdDomesticPatentsBijuvaMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticPatentsBijuvaMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_ForeignPatentsBijuvaMember" xlink:label="loc_txmdForeignPatentsBijuvaMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdForeignPatentsBijuvaMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_DomesticPatentsNonApprovedBijuvaMember" xlink:label="loc_txmdDomesticPatentsNonApprovedBijuvaMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticPatentsNonApprovedBijuvaMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_DomesticUSPatentsImvexxyMember" xlink:label="loc_txmdDomesticUSPatentsImvexxyMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticUSPatentsImvexxyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_DomesticUSUtilityPatentsImvexxyMember" xlink:label="loc_txmdDomesticUSUtilityPatentsImvexxyMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticUSUtilityPatentsImvexxyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_DomesticUSDesignPatentsImvexxyMember" xlink:label="loc_txmdDomesticUSDesignPatentsImvexxyMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticUSDesignPatentsImvexxyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_ForeignPatentsImvexxyMember" xlink:label="loc_txmdForeignPatentsImvexxyMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdForeignPatentsImvexxyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_ForeignUtilityPatentsImvexxyMember" xlink:label="loc_txmdForeignUtilityPatentsImvexxyMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdForeignUtilityPatentsImvexxyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_ForeignDesignPatentsImvexxyMember" xlink:label="loc_txmdForeignDesignPatentsImvexxyMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdForeignDesignPatentsImvexxyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_DomesticUSPatentsTopicalCreamMember" xlink:label="loc_txmdDomesticUSPatentsTopicalCreamMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticUSPatentsTopicalCreamMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_DomesticUtilityPatentTransdermalPatchMember" xlink:label="loc_txmdDomesticUtilityPatentTransdermalPatchMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticUtilityPatentTransdermalPatchMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_ForeignUtilityPatentTransdermalPatchMember" xlink:label="loc_txmdForeignUtilityPatentTransdermalPatchMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdForeignUtilityPatentTransdermalPatchMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_DomesticUtilityPatentTx009HRMember" xlink:label="loc_txmdDomesticUtilityPatentTx009HRMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticUtilityPatentTx009HRMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_DomesticPatentsProgesteroneFormulationsMember" xlink:label="loc_txmdDomesticPatentsProgesteroneFormulationsMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticPatentsProgesteroneFormulationsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_ForeignPatentsProgesteroneFormulationsMember" xlink:label="loc_txmdForeignPatentsProgesteroneFormulationsMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdForeignPatentsProgesteroneFormulationsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_DomesticUtilityPatentOperaMember" xlink:label="loc_txmdDomesticUtilityPatentOperaMember" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticUtilityPatentOperaMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_srtProductOrServiceAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_AnnoveraMember" xlink:label="loc_txmdAnnoveraMember" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_txmdAnnoveraMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_CouncilLicenseAgreement1Member" xlink:label="loc_txmdCouncilLicenseAgreement1Member" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdCouncilLicenseAgreement1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_CouncilLicenseAgreementStep1Member" xlink:label="loc_txmdCouncilLicenseAgreementStep1Member" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdCouncilLicenseAgreementStep1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_CouncilLicenseAgreementStep2Member" xlink:label="loc_txmdCouncilLicenseAgreementStep2Member" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdCouncilLicenseAgreementStep2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_CouncilLicenseAgreementStep3Member" xlink:label="loc_txmdCouncilLicenseAgreementStep3Member" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdCouncilLicenseAgreementStep3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_srtRangeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="loc_us-gaapImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_NumberOfIssuedPatents" xlink:label="loc_txmdNumberOfIssuedPatents" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_txmdNumberOfIssuedPatents" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_MilestonePaymentUponFDAApproval" xlink:label="loc_txmdMilestonePaymentUponFDAApproval" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_txmdMilestonePaymentUponFDAApproval" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch" xlink:label="loc_txmdMilestonePaymentsAfterReleaseOfFirstCommercialBatch" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_txmdMilestonePaymentsAfterReleaseOfFirstCommercialBatch" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:label="loc_us-gaapFinitelivedIntangibleAssetsAcquired1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFinitelivedIntangibleAssetsAcquired1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAmortizationOfDeferredCharges" xlink:label="loc_us-gaapOtherAmortizationOfDeferredCharges" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapOtherAmortizationOfDeferredCharges" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_NetSalesAmountPerStepbasedRoyalty" xlink:label="loc_txmdNetSalesAmountPerStepbasedRoyalty" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_txmdNetSalesAmountPerStepbasedRoyalty" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_RoyaltyPercent" xlink:label="loc_txmdRoyaltyPercent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_txmdRoyaltyPercent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent" xlink:label="loc_txmdAnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_txmdAnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent" xlink:label="loc_txmdAnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_txmdAnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_RequiredMilestonePaymentsUponCumulativeNetSalesOfSpecifiedLevels" xlink:label="loc_txmdRequiredMilestonePaymentsUponCumulativeNetSalesOfSpecifiedLevels" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_txmdRequiredMilestonePaymentsUponCumulativeNetSalesOfSpecifiedLevels" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_SpecifiedLevelOneOfCumulativeNetSalesForRequiredMilestonePayments" xlink:label="loc_txmdSpecifiedLevelOneOfCumulativeNetSalesForRequiredMilestonePayments" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_txmdSpecifiedLevelOneOfCumulativeNetSalesForRequiredMilestonePayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_SpecifiedLevelTwoOfCumulativeNetSalesForRequiredMilestonePayments" xlink:label="loc_txmdSpecifiedLevelTwoOfCumulativeNetSalesForRequiredMilestonePayments" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_txmdSpecifiedLevelTwoOfCumulativeNetSalesForRequiredMilestonePayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_SpecifiedLevelThreeOfCumulativeNetSalesForRequiredMilestonePayments" xlink:label="loc_txmdSpecifiedLevelThreeOfCumulativeNetSalesForRequiredMilestonePayments" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_txmdSpecifiedLevelThreeOfCumulativeNetSalesForRequiredMilestonePayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid" xlink:label="loc_txmdMaximumCostsAndExpensesForPostApprovalStudyToBePaid" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_txmdMaximumCostsAndExpensesForPostApprovalStudyToBePaid" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails" xlink:title="00000045 - Disclosure - Other current liabilities consist of the following: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="loc_us-gaapAccruedSalariesCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedSalariesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_SalesDiscountsReturnsAndAllowancesGoods1" xlink:label="loc_txmdSalesDiscountsReturnsAndAllowancesGoods1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_txmdSalesDiscountsReturnsAndAllowancesGoods1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedMarketingCostsCurrent" xlink:label="loc_us-gaapAccruedMarketingCostsCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedMarketingCostsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedVacationCurrent" xlink:label="loc_us-gaapAccruedVacationCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedVacationCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_AllowanceForWholesaleDistributorFeesCurrent" xlink:label="loc_txmdAllowanceForWholesaleDistributorFeesCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_txmdAllowanceForWholesaleDistributorFeesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaapAccruedProfessionalFeesCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedProfessionalFeesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_AccruedResearchAndDevelopment" xlink:label="loc_txmdAccruedResearchAndDevelopment" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_txmdAccruedResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedRentCurrent" xlink:label="loc_us-gaapAccruedRentCurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedRentCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_AccruedRebates" xlink:label="loc_txmdAccruedRebates" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_txmdAccruedRebates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/AsOfDecember312019And2018CarryingValueOfOurDebtConsistedOfFollowingDetails" xlink:title="00000046 - Disclosure - As of December 31, 2019 and 2018, the carrying value of our debt consisted of the following: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtInstrumentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapDebtInstrumentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_FinancingAgreementMember" xlink:label="loc_txmdFinancingAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdFinancingAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_CreditAgreementMember" xlink:label="loc_txmdCreditAgreementMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdCreditAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaapDebtInstrumentCarryingAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentCarryingAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaapLongTermDebtNoncurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLongTermDebtNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/DebtDetailsNarrative" xlink:title="00000047 - Disclosure - DEBT (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtInstrumentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapDebtInstrumentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaapCreditFacilityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapCreditFacilityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaapCreditFacilityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCreditFacilityAxis" xlink:to="loc_us-gaapCreditFacilityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaapRevolvingCreditFacilityMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCreditFacilityDomain" xlink:to="loc_us-gaapRevolvingCreditFacilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="loc_us-gaapSecuredDebtMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCreditFacilityDomain" xlink:to="loc_us-gaapSecuredDebtMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_FinancingAgreementMember" xlink:label="loc_txmdFinancingAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdFinancingAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_MidCapAgreementMember" xlink:label="loc_txmdMidCapAgreementMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdMidCapAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_DebtTrancheAxis" xlink:label="loc_txmdDebtTrancheAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_txmdDebtTrancheAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_DebtTrancheDomain" xlink:label="loc_txmdDebtTrancheDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDebtTrancheAxis" xlink:to="loc_txmdDebtTrancheDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_TrancheOneMember" xlink:label="loc_txmdTrancheOneMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDebtTrancheDomain" xlink:to="loc_txmdTrancheOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_TrancheTwoMember" xlink:label="loc_txmdTrancheTwoMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDebtTrancheDomain" xlink:to="loc_txmdTrancheTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_TrancheThreeMember" xlink:label="loc_txmdTrancheThreeMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDebtTrancheDomain" xlink:to="loc_txmdTrancheThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_TrancheTwoThreeMember" xlink:label="loc_txmdTrancheTwoThreeMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDebtTrancheDomain" xlink:to="loc_txmdTrancheTwoThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_srtProductOrServiceAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_ImvexxyBijuvaAndAnnoveraMember" xlink:label="loc_txmdImvexxyBijuvaAndAnnoveraMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_txmdImvexxyBijuvaAndAnnoveraMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_srtRangeAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaapVariableRateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapVariableRateAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaapVariableRateDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVariableRateAxis" xlink:to="loc_us-gaapVariableRateDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrimeRateMember" xlink:label="loc_us-gaapPrimeRateMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVariableRateDomain" xlink:to="loc_us-gaapPrimeRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" order="80" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_FinancingAgreementMember" xlink:label="loc_txmdFinancingAgreementMember_2" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdFinancingAgreementMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaapProceedsFromLinesOfCredit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapProceedsFromLinesOfCredit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:label="loc_us-gaapDebtInstrumentDescriptionOfVariableRateBasis" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentDescriptionOfVariableRateBasis" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaapDebtInstrumentBasisSpreadOnVariableRate1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_LiborFloorRate" xlink:label="loc_txmdLiborFloorRate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdLiborFloorRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_NumberOfInstallmentPayments" xlink:label="loc_txmdNumberOfInstallmentPayments" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdNumberOfInstallmentPayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_PrepaymentFeeForFirstTwoYearsFundingPercent" xlink:label="loc_txmdPrepaymentFeeForFirstTwoYearsFundingPercent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdPrepaymentFeeForFirstTwoYearsFundingPercent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_PrepaymentFeeThirdYearFundingPercent" xlink:label="loc_txmdPrepaymentFeeThirdYearFundingPercent" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdPrepaymentFeeThirdYearFundingPercent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_PrepaymentFeeFourthYearFundingPercent" xlink:label="loc_txmdPrepaymentFeeFourthYearFundingPercent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdPrepaymentFeeFourthYearFundingPercent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_PrepaymentFeeFifthYearFundingPercent" xlink:label="loc_txmdPrepaymentFeeFifthYearFundingPercent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdPrepaymentFeeFifthYearFundingPercent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_FacilityFeePaidPercent" xlink:label="loc_txmdFacilityFeePaidPercent" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdFacilityFeePaidPercent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_MinimumCashBalanceRequirementUnderCreditAgreement" xlink:label="loc_txmdMinimumCashBalanceRequirementUnderCreditAgreement" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdMinimumCashBalanceRequirementUnderCreditAgreement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_NumberOfTranchesUnderTermLoanFacility" xlink:label="loc_txmdNumberOfTranchesUnderTermLoanFacility" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdNumberOfTranchesUnderTermLoanFacility" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_RepaymentOfDebtWithNewCreditFacility" xlink:label="loc_txmdRepaymentOfDebtWithNewCreditFacility" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdRepaymentOfDebtWithNewCreditFacility" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_PrepaymentFeePercentage" xlink:label="loc_txmdPrepaymentFeePercentage" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdPrepaymentFeePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_RepaymentFeePercentage" xlink:label="loc_txmdRepaymentFeePercentage" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdRepaymentFeePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaapInterestExpenseDebt" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapInterestExpenseDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaapAmortizationOfFinancingCosts" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapAmortizationOfFinancingCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaapDebtInstrumentCarryingAmount" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentCarryingAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaapPaymentsOfFinancingCosts" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapPaymentsOfFinancingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscount" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseBorrowings" xlink:label="loc_us-gaapInterestExpenseBorrowings" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapInterestExpenseBorrowings" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfOurWarrantActivityDuringYearEndedDecember312019Details" xlink:title="00000048 - Disclosure - Summary of our Warrant activity during the year ended December 31, 2019: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice" xlink:label="loc_txmdWarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdWarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_WarrantsGrantedOtherThanOptionsWeightedAverageExercisePrice" xlink:label="loc_txmdWarrantsGrantedOtherThanOptionsWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdWarrantsGrantedOtherThanOptionsWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_WarrantsExercisedOtherThanOptionsWeightedAverageExercisePrice" xlink:label="loc_txmdWarrantsExercisedOtherThanOptionsWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdWarrantsExercisedOtherThanOptionsWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice" xlink:label="loc_txmdWarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice_2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdWarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_WarrantsOutstandingVestedAndExercisable" xlink:label="loc_txmdWarrantsOutstandingVestedAndExercisable" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdWarrantsOutstandingVestedAndExercisable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExercisableWeightedAverageRemainingContractualTerms" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExercisableWeightedAverageRemainingContractualTerms" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExercisableWeightedAverageRemainingContractualTerms" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_WarrantsUnvestedWeightedAverageExercisePrice" xlink:label="loc_txmdWarrantsUnvestedWeightedAverageExercisePrice" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdWarrantsUnvestedWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/WeightedAverageFairValuePerShareOfWarrantsIssuedAndAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120192018And2017AreSetForthInTableBelow.Details" xlink:title="00000049 - Disclosure - The weighted average fair value per share of warrants issued and the assumptions used in the Black-Scholes Model during the years ended December 31, 2019, 2018, and 2017 are set forth in the table below. (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_WeightedAverageExercisePriceOtherThanOptions" xlink:label="loc_txmdWeightedAverageExercisePriceOtherThanOptions" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdWeightedAverageExercisePriceOtherThanOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/RangesOfAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120192018And2017AreSetForthInTableBelow.Details" xlink:title="00000050 - Disclosure - The ranges of assumptions used in the Black-Scholes Model during the years ended December 31, 2019, 2018, and 2017 are set forth in the table below. (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringYearEndedDecember312019IsAsFollowsDetails" xlink:title="00000051 - Disclosure - A summary of activity under the 2009, 2012 and 2019 Plans and related information during the year ended December 31, 2019 is as follows: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000052 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_UnderwritingAgreementJPMorganChaseMember" xlink:label="loc_txmdUnderwritingAgreementJPMorganChaseMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdUnderwritingAgreementJPMorganChaseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_UnderwritingAgreementGoldmanSachsMember" xlink:label="loc_txmdUnderwritingAgreementGoldmanSachsMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdUnderwritingAgreementGoldmanSachsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_SubscriptionAgreementKnightMember" xlink:label="loc_txmdSubscriptionAgreementKnightMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdSubscriptionAgreementKnightMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_WarrantsMember" xlink:label="loc_txmdWarrantsMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_OutsideConsultant2Member" xlink:label="loc_txmdOutsideConsultant2Member" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdOutsideConsultant2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_WarrantsCashlessExerciseMember" xlink:label="loc_txmdWarrantsCashlessExerciseMember" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdWarrantsCashlessExerciseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_srtRangeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapPlanNameAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_LongTermIncentiveCompensationPlan2009Member" xlink:label="loc_txmdLongTermIncentiveCompensationPlan2009Member" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_txmdLongTermIncentiveCompensationPlan2009Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_NonQualified2012StockIncentivePlanMember" xlink:label="loc_txmdNonQualified2012StockIncentivePlanMember" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_txmdNonQualified2012StockIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_Plan2019Member" xlink:label="loc_txmdPlan2019Member" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_txmdPlan2019Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_PeriodExercisableUnderwritersOption" xlink:label="loc_txmdPeriodExercisableUnderwritersOption" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdPeriodExercisableUnderwritersOption" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_UnderwritersOptionGrantedInPeriodShares" xlink:label="loc_txmdUnderwritersOptionGrantedInPeriodShares" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdUnderwritersOptionGrantedInPeriodShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_ProceedsFromIssuancePublicOffering" xlink:label="loc_txmdProceedsFromIssuancePublicOffering" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdProceedsFromIssuancePublicOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_NumberOfStockOptionsExercisedInCashlessExercise" xlink:label="loc_txmdNumberOfStockOptionsExercisedInCashlessExercise" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdNumberOfStockOptionsExercisedInCashlessExercise" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares" xlink:label="loc_txmdNumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdNumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife" xlink:label="loc_txmdWarrantsAndRightsWeightedAverageContractualRemainingLife" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdWarrantsAndRightsWeightedAverageContractualRemainingLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice" xlink:label="loc_txmdWarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdWarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_NumberOfStockIssuedInCashlessExerciseOfWarrants" xlink:label="loc_txmdNumberOfStockIssuedInCashlessExerciseOfWarrants" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdNumberOfStockIssuedInCashlessExerciseOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_PlanAwardsNumberOfNewShares" xlink:label="loc_txmdPlanAwardsNumberOfNewShares" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdPlanAwardsNumberOfNewShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockExpense" xlink:label="loc_us-gaapRestrictedStockExpense" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapRestrictedStockExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ForFinancialReportingPurposesIncomeBeforeTaxesIncludesFollowingComponentsDetails" xlink:title="00000053 - Disclosure - For financial reporting purposes, income before taxes includes the following components: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaapOperatingLossCarryforwardsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapOperatingLossCarryforwardsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaapOperatingLossCarryforwardsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapOperatingLossCarryforwardsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaapDomesticCountryMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapDomesticCountryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ReconciliationBetweenTaxesComputedAtFederalStatutoryRateAndConsolidatedEffectiveTaxRateIsAsFollowsDetails" xlink:title="00000054 - Disclosure - A reconciliation between taxes computed at the federal statutory rate and the consolidated effective tax rate is as follows: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ComponentsOfNetDeferredIncomeTaxAssetAsOfDecember3120192018And2017AreAsFollowsDetails" xlink:title="00000055 - Disclosure - The components of the net deferred income tax asset as of December 31, 2019, 2018, and 2017 are as follows: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="loc_us-gaapDeferredTaxAssetsNetAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOtherLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOtherLossCarryforwards" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOtherLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000056 - Disclosure - INCOME TAXES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaapOperatingLossCarryforwardsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapOperatingLossCarryforwardsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaapOperatingLossCarryforwardsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapOperatingLossCarryforwardsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapIncomeTaxAuthorityNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityNameAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="loc_us-gaapInternalRevenueServiceIRSMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityNameDomain" xlink:to="loc_us-gaapInternalRevenueServiceIRSMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaapTaxPeriodAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapTaxPeriodAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaapTaxPeriodDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTaxPeriodAxis" xlink:to="loc_us-gaapTaxPeriodDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_ExpirationPeriod20YearsMember" xlink:label="loc_txmdExpirationPeriod20YearsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTaxPeriodDomain" xlink:to="loc_txmdExpirationPeriod20YearsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_ExpirationPeriodIndefiniteMember" xlink:label="loc_txmdExpirationPeriodIndefiniteMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTaxPeriodDomain" xlink:to="loc_txmdExpirationPeriodIndefiniteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_NolCarryForwardPeriod" xlink:label="loc_txmdNolCarryForwardPeriod" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_txmdNolCarryForwardPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_OperatingLossCarryforwardsExpirationYear" xlink:label="loc_txmdOperatingLossCarryforwardsExpirationYear" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_txmdOperatingLossCarryforwardsExpirationYear" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapTaxCutsAndJobsActOf2017IncompleteAccountingProvisionalIncomeTaxExpenseBenefit" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapTaxCutsAndJobsActOf2017IncompleteAccountingProvisionalIncomeTaxExpenseBenefit" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative" xlink:title="00000057 - Disclosure - RELATED PARTIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_AffiliatedEntityMember" xlink:label="loc_srtAffiliatedEntityMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_srtAffiliatedEntityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:label="loc_us-gaapRelatedPartyTransactionPurchasesFromRelatedParty" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionPurchasesFromRelatedParty" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="loc_us-gaapAccountsPayableRelatedPartiesCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapAccountsPayableRelatedPartiesCurrent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative" xlink:title="00000058 - Disclosure - BUSINESS CONCENTRATIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaapRisksAndUncertaintiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaapConcentrationRiskTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRisksAndUncertaintiesAbstract" xlink:to="loc_us-gaapConcentrationRiskTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaapConcentrationRiskLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:label="loc_us-gaapSupplierConcentrationRiskMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapSupplierConcentrationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_SupplierTwoConcentrationRiskMember" xlink:label="loc_txmdSupplierTwoConcentrationRiskMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdSupplierTwoConcentrationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_SupplierThreeConcentrationRiskMember" xlink:label="loc_txmdSupplierThreeConcentrationRiskMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdSupplierThreeConcentrationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaapCustomerConcentrationRiskMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapCustomerConcentrationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_FourCustomersConcentrationRiskMember" xlink:label="loc_txmdFourCustomersConcentrationRiskMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdFourCustomersConcentrationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_CustomerConcentrationMcKessonCorporationRiskMember" xlink:label="loc_txmdCustomerConcentrationMcKessonCorporationRiskMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerConcentrationMcKessonCorporationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_CustomerConcentrationPillPackRiskMember" xlink:label="loc_txmdCustomerConcentrationPillPackRiskMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerConcentrationPillPackRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_CustomerConcentrationAmerisourceBergenRiskMember" xlink:label="loc_txmdCustomerConcentrationAmerisourceBergenRiskMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerConcentrationAmerisourceBergenRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_CustomerConcentrationCardinalHealthRiskMember" xlink:label="loc_txmdCustomerConcentrationCardinalHealthRiskMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerConcentrationCardinalHealthRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_CustomerConcentrationPharmacyInnovationsPaRiskMember" xlink:label="loc_txmdCustomerConcentrationPharmacyInnovationsPaRiskMember" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerConcentrationPharmacyInnovationsPaRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaapSalesRevenueNetMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapSalesRevenueNetMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_NumberOfVendors" xlink:label="loc_txmdNumberOfVendors" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_txmdNumberOfVendors" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_NumberOfCustomers" xlink:label="loc_txmdNumberOfCustomers" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_txmdNumberOfCustomers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapRevenues" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SupplementalLeaseInformationDetails" xlink:title="00000059 - Disclosure - Supplemental lease information (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeasePayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaapRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtDecember312019ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails" xlink:title="00000060 - Disclosure - The following table reconciles the undiscounted cash flows for all operating leases at December 31, 2019 to the operating lease liabilities recorded on the balance sheet: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000061 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RecordedUnconditionalPurchaseObligationTable" xlink:label="loc_us-gaapRecordedUnconditionalPurchaseObligationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapRecordedUnconditionalPurchaseObligationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RecordedUnconditionalPurchaseObligationLineItems" xlink:label="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationTable" xlink:to="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:label="loc_us-gaapRecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationTable" xlink:to="loc_us-gaapRecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:label="loc_us-gaapUnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:to="loc_us-gaapUnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_CatalentMember" xlink:label="loc_txmdCatalentMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapUnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:to="loc_txmdCatalentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_AnnoveraMember" xlink:label="loc_txmdAnnoveraMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapUnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:to="loc_txmdAnnoveraMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_CapitalLeaseObligationsTerm" xlink:label="loc_txmdCapitalLeaseObligationsTerm" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_txmdCapitalLeaseObligationsTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_NetRentableAreaLease" xlink:label="loc_txmdNetRentableAreaLease" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_txmdNetRentableAreaLease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_RentedAreaLease" xlink:label="loc_txmdRentedAreaLease" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_txmdRentedAreaLease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_AdditionalAreaOfLeaseOccupied" xlink:label="loc_txmdAdditionalAreaOfLeaseOccupied" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_txmdAdditionalAreaOfLeaseOccupied" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaapLesseeOperatingLeaseTermOfContract" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseTermOfContract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_LesseeFinanceLeaseExistenceOfOptionToExtendNumber" xlink:label="loc_txmdLesseeFinanceLeaseExistenceOfOptionToExtendNumber" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_txmdLesseeFinanceLeaseExistenceOfOptionToExtendNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:label="loc_us-gaapLesseeFinanceLeaseRenewalTerm1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_us-gaapLesseeFinanceLeaseRenewalTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_LesseeOperatingLeaseLeaseNotYetCommencedArea" xlink:label="loc_txmdLesseeOperatingLeaseLeaseNotYetCommencedArea" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_txmdLesseeOperatingLeaseLeaseNotYetCommencedArea" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaapOperatingLeaseExpense" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_us-gaapOperatingLeaseExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaapLeaseAndRentalExpense" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_us-gaapLeaseAndRentalExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_SignificantSupplyCommitmentPercentagePayable" xlink:label="loc_txmdSignificantSupplyCommitmentPercentagePayable" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_txmdSignificantSupplyCommitmentPercentagePayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RecordedUnconditionalPurchaseObligationDueWithinOneYear" xlink:label="loc_us-gaapRecordedUnconditionalPurchaseObligationDueWithinOneYear" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_us-gaapRecordedUnconditionalPurchaseObligationDueWithinOneYear" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RecordedUnconditionalPurchaseObligationDueInSecondYear" xlink:label="loc_us-gaapRecordedUnconditionalPurchaseObligationDueInSecondYear" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_us-gaapRecordedUnconditionalPurchaseObligationDueInSecondYear" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RecordedUnconditionalPurchaseObligationDueInThirdYear" xlink:label="loc_us-gaapRecordedUnconditionalPurchaseObligationDueInThirdYear" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_us-gaapRecordedUnconditionalPurchaseObligationDueInThirdYear" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RecordedUnconditionalPurchaseObligationDueInFourthYear" xlink:label="loc_us-gaapRecordedUnconditionalPurchaseObligationDueInFourthYear" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_us-gaapRecordedUnconditionalPurchaseObligationDueInFourthYear" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RecordedUnconditionalPurchaseObligationDueInFifthYear" xlink:label="loc_us-gaapRecordedUnconditionalPurchaseObligationDueInFifthYear" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_us-gaapRecordedUnconditionalPurchaseObligationDueInFifthYear" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummarizedQuarterlyFinancialDataForFiscalYears2019And2018IsAsFollowsDetails" xlink:title="00000062 - Disclosure - Summarized quarterly financial data for fiscal years 2019 and 2018 is as follows: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaapQuarterlyFinancialInformationDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapQuarterlyFinancialInformationDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_LicenseAgreementTheramexMember" xlink:label="loc_txmdLicenseAgreementTheramexMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdLicenseAgreementTheramexMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaapEarningsPerShareBasicAndDiluted" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapEarningsPerShareBasicAndDiluted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000063 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_FinancingAgreementMember" xlink:label="loc_txmdFinancingAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdFinancingAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_srtProductOrServiceAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20191231.xsd#txmd_ImvexxyBijuvaAndAnnoveraMember" xlink:label="loc_txmdImvexxyBijuvaAndAnnoveraMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_txmdImvexxyBijuvaAndAnnoveraMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_srtRangeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaapProceedsFromLinesOfCredit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapProceedsFromLinesOfCredit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>17
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M_O"["H?.^;W_Q\8705/#K[LP7U!+ P04    " !(@EA0F5R<(Q &  "<)P
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M_*4)_#<@*.*QM$>64+,P$?-YF-A?&,'DJ[50U;';$:B]G;Z4W7;$Y.ZXZ_#
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MKZK6.HENWL71T>:[VT5A]VWW5;OO]7 *-5RTU64\84MNQWRK_P!02P,$%
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MH3.!+0DN<VU+T;T*N:!+!N<\ PA;F?2,8FQ-=%82!C@N$XSE5 8XQV9@4M!
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MV7A\V=C_QA@/*&5WA2/4X0=;# F-#\>/>+;3F$V&-_W\@]CRC<O?4$L#!!0
M   ( $B"6%"&+[60M $  -(#   8    >&PO=V]R:W-H965T<R]S:&5E=#DN
M>&UL?5-A;]L@$/TKB!]0$I*U661;:CI-F[1)4:=MGXE]ME&!\P#'W;\?8-?S
M6FM?@#ONO7MW'-F ]LFU )X\:V5<3EOONR-CKFQ!"W>#'9AP4Z/5P@?3-LQU
M%D250%HQOMG<,BVDH466?&=;9-A[)0V<+7&]UL+^/H'"(:=;^N)XE$WKHX,5
M62<:^ ;^>W>VP6(S2R4U&"?1$ MU3N^WQ],^QJ> 'Q(&MSB36,D%\2D:GZN<
M;J(@4%#ZR"#"=H4'4"H2!1F_)DXZIXS Y?F%_6.J/=1R$0X>4/V4E6]S>J"D
M@EKTRC_B\ FF>MY1,A7_!:Z@0GA4$G*4J%Q:2=D[CWIB"5*T>!YW:=(^C#<[
M/L'6 7P"\!EP2'G8F"@I_R"\*#*+ [%C[SL1GWA[Y*$W972F5J2[(-X%[[78
MOK_-V#4233&G,88O8^8(%MCG%'PMQ8F_@?-U^&Y5X2[!=_\HO%LGV*\2[!/!
M_K\EKL4<7B5ABYYJL$V:)D=*[$V:Y(5W'MC[](CL;_@X[5^%;:1QY((^O&SJ
M?XWH(4C9W(01:L,'FPT%M8_'NW"VXYB-AL=N^D%L_L;%'U!+ P04    " !(
M@EA0Z "XY;4!  #2 P  &0   'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q]
M4]MNW" 0_17$!P0ON^DF*]M2-E'42JVT2M7FF;7'-@IX7,#K].\+V'&MQ,H+
M,,,Y9RX,Z8#FQ38 CKQJU=J,-LYU!\9LT8 6]@H[:/U-A48+YTU3,]L9$&4D
M:<5XDGQA6LB6YFGTG4R>8N^4;.%DB.VU%N;O$10.&=W0-\>3K!L7'"Q/.U'#
M3W"_NI/Q%IM52JFAM1);8J#*Z-WF<-P%? 3\EC#8Q9F$2LZ(+\'X5F8T"0F!
M@L(%!>&W"]R#4D'(I_%GTJ1SR$!<GM_4'V/MOI:SL'"/ZEF6KLGH#24E5*)7
M[@F'KS#5<TW)5/QWN(#R\)")CU&@LG$E16\=ZDG%IZ+%Z[C+-N[#>+/?3[1U
M I\(?";<Q#AL#!0S?Q!.Y*G!@9BQ]YT(3[PY<-^;(CAC*^*=3]YZ[R7?W-ZF
M[!*$)LQQQ/ E9D8PKSZ'X&LACOP#G:_3MZL9;B-]NZ0GR;K ;E5@%P5VGY;X
M$<.3]T6R14\UF#I.DR4%]FV<Y(5W'M@['M_D/WR<]A_"U+*UY(S.OVSL?X7H
MP*>27/D1:OP'FPT%E0O'O3^;<<Q&PV$W_2 V?^/\'U!+ P04    " !(@EA0
MKM/<.K0!  #2 P  &0   'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q]4V%O
MW" ,_2N('U 2+MVJ4Q*IUVK:I$TZ==KZF4N<!!5"!N32_?L9DF;9%NT+8./W
M_&Q,/AG[XCH 3UZUZEU!.^^'(V.NZD +=V,&Z/&F,58+CZ9MF1LLB#J"M&(\
M2=XQ+61/RSSZSK;,S>B5[.%LB1NU%O;G"929"IK2-\>3;#L?'*S,!]'"5_#?
MAK-%BZTLM=30.VEZ8J$IZ'UZ/&4A/@9\ES"YS9F$2B[&O 3C4UW0) @"!94/
M# *W*SR 4H$(9?Q8..F:,@"WYS?V#[%VK.4B'#P8]2QKWQ7TCI(:&C$J_V2F
MC[#4<TO)4OQGN(+"\* $<U1&N;B2:G3>Z(4%I6CQ.N^RC_LTWV3I ML'\ 7
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M\(/-AH+*A^,-GNTX9J/A33?](#9_X_P#4$L#!!0    ( $B"6%!=]_$9M0$
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M-ISM-&:3X;&??Q!;OG'Y"U!+ P04    " !(@EA0O*<>Y[4!  #2 P  &0
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M/+YL[']CC =,);G!$>KP@ZV&@L:'XWL\VWG,9L.;8?E!;/W&Y5]02P,$%
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MV^OI+4^!5?T\IF3YKRC^ E!+ P04    " !(@EA0SKKPS[D!  #2 P  &0
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MN/=G,X[9:#CLIA_$YF^<OP%02P,$%     @ 2()84/'H*W"V 0  T@,  !D
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MSW8<L]'PIIM^$)N_<?X?4$L#!!0    ( $B"6%!;!6QTMP$  -(#   9
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M;HKG0$!E_?;.[?7XEL? JFX:4S+_5^0?4$L#!!0    ( $B"6%!9F(IXMP$
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MV&(HJ%TX?O9G,XW99#CLYQ_$EF]<O %02P,$%     @ 2()84(RDMS.T 0
MT@,  !D   !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL=5-M;YLP$/XKEG]
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MN6#>>]N,:S8Z#KOI!;'Y&>=_ %!+ P04    " !(@EA0UO]MQ-X!   !!0
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M+9QW3<OL8$#4D:05XTGREFDA>UKF,78V98ZC4[*'LR%VU%J8/R=0.!4TI;?
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M@L[?;)Q_@^C EY(\^!7J_ -;'06-"^8[;YMYS6;'X;"\(+8^X_(O4$L#!!0
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M,KG5]6UH[LOVA-@^:'7H3K]!?P1?_ 502P,$%     @ 2()84&+*][2) @
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MW2"[J.=SG2:KPTF6OE;-H:V/B^Y[8G=2Y?O^6^GL\,%V\1]02P,$%     @
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MKA%2106<J@?10F-.SD)RJHTI2Z1:"?3D2)RA.(I2Q&G=A'GF? >99^*B6=W
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M7/H3Z1=:C/-E@Y<;K_H#4$L#!!0    ( $B"6%!#%K/IP 4  $0D   9
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M3/T2@R8GJ#>)09.@ =E0'P]&%P\N,8=)#*-$,!(SJ<*(J0GB36%P% (G>A/
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MT"0)FKAZ(QE&I!Z0,\.(]-NWT:C>S$@14^HE Y(DVKS6>"!*Q%1RR3 D*88
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M_;BI^$&99:;773_8]ALEVF%HC\9_#NM_4$L#!!0    ( $B"6%"+&#/#:@(
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M9*:5'6.2*H]1H*IZ4!/O^%#3G=2WN;KG_=C7/TC6#2-M.,[5RS]02P,$%
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M[.X>1?/U$RL1>XQPBE $(\)N\%&TJ"EEA'C(2'&44(0!0MA6*5*3[^,#G!2
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M&$4TTSI@E-R8'C18 &=JEK8#&#^^EFBPU2*<<I$6 7&UQ0=ID8;5$HCB62+
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M[LM#NS>;Y=/E[IM1X]>O9UW]'U!+ P04    " !(@EA0Q\'-."("   R!@
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M^PK&)*A"O0=58Z4&^!@0**3>)FK/^S'6!Y*UPX1&XV<B^P]02P,$%     @
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MQE*LYPH([R757!(&^:0!"G(BC9RDD3&([TACMT'L-(B-07)GD%A1!TUJ--U
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M5(W2M+,38Y(J0^Z3LE*JD3AM:GJ2>AFI-1_FPK"1K!MGGC,-WNP_4$L#!!0
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MW@SO[$-#R8/Y'HG&CZ+%7U!+ P04    " !(@EA0 L5X!^8#  #;$   &0
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MR$]>T4ZV0US/:7IG5=9XW=K4?O.EK=;2MKZ.(BX'P6MMJ6/&+<.N&,["/K.
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M4>]=6\X%DZ[@2OKMY0FV:^1L*]0MD?=U>XQK&X)7YH@:=.?DV5]02P,$%
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ME]NV<7[>'YP/^]6O+],R*8\PPC8.K@^[99Q7G^CU^N?P7Z^&1?+J7?R8(*K
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MF!BF:$)*=F7!9(1/\08-S@"N+?# 6*P(&0(7K5LT.TI6,0%N#^(MOO28 \7
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M#R?!H!_T)T&_'XP&P6 4](>!QL\A0-W/YL4VX1QC9U>_$A(:[0O/,X^> P0
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M"!-X" KQ(]-TVT"=EH%PD[@ENKD8M@WK08LULCATE!-Q)/.%0"]X"7K%865
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M-);\ L31N<)H@6B2Z%0D&TEJE=SO9+<\8-JQM0R)PSHI+!57AD%&P'.6[.&
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MYX?'PJT+?N)6U^^/@TRVO+=D0GL,>@=XXB4-X#5WM5G@,^MS4J%)Z5?;KE-
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M^\='-HB>]X<JB)N6C(6QZ3O8*Q?+RM-.MNK.*2EH'$I:J2)T#$M4F\+6L."
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M^7U<4I]UL="[,O =MSLZNU_<%6],6+3KMQ(#%$IWYX4.!$^3\MLBR!LE@$^
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M;Q=2/G&[SG5]S3QS6\V!1EW]!%(:H#B$=2'IU=>U*TK4JS\#U0ENXK1'K8A
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M.7P\I&Q#64DULGCKN1GM@U^MKT8#17"NE#<5Z80795\%D,)?<@N%@YDN*'^
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MH0JE<-+ZN?A<DO?!P>L5J[7)U2>UAC&_3X&8HHTD[IR[425<X[LP[NL(#9A
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M$?1^8,\6.XV=A-O62H?Q=VFBQ5S3TH1U#<1.@V9;*QT&XK+-'LY$+RU#'O$
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M_WB+0!_CGXC['J1=51 F['6N1\4V@[XV1<9VB+#]XW[_])?_ U!+ P04
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MMG+PQ *)9%(A;4[>* LL4MVY<. \>RDZ'DZ%5&UM5\']+KKI6X'>LP(I8X/
M"79 ')9$:U#BRCCMY!;\(80Z>[XJC<)<D54P.<5C0CN8(@NI4E!#F0#W4!PR
MR*P<1?/"CEJ6G@UJ+;DQ4DIR*4BKH<_H#$.; &,W]HOYE&UP-QER<^R1^!A9
M%;UI5MV9XZGYK>1U-L>]3KL;+RKI4NJWM5F.:'U[<>!:04:;UF^R08!A)V7)
M5F\8S04'MYA'"P8[%HQ#TM=!A53TSO#9JY(8 !1&2U":)NO(%T7*.32ZOTY-
MMJOFR1YJ?NI]SD& (FQ=M+G[SWF7_[-BVUO^6G/[M[*M^ E%3L^>OT;;1_=
MY&P?1.[!<4_/_[%&KVN-:_UWH_L.*%K4E&DJ.K4%35-P>NSS)\(?[;N+;?3
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MYIUI^M^2/%F[_IS/QG]=+=X 4$L! A0#%     @ 2()84!\CSP/     $P(
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M4$L! A0#%     @ 2()84&@.\Y5= @  4@@  !@              ( !(A$
M 'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( $B"6%  S;@C
M?00  /(3   8              "  ;43  !X;"]W;W)K<VAE971S+W-H965T
M-"YX;6Q02P$"% ,4    " !(@EA0:BM3Y1<%  !]&   &
M@ %H&   >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ 2()8
M4/4>Q;SZ!0  \QP  !@              ( !M1T  'AL+W=O<FMS:&5E=',O
M<VAE970V+GAM;%!+ 0(4 Q0    ( $B"6%!VT@7GKP$  -(#   8
M      "  >4C  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4
M" !(@EA0L7:')+0!  #2 P  &               @ '*)0  >&PO=V]R:W-H
M965T<R]S:&5E=#@N>&UL4$L! A0#%     @ 2()84(8OM9"T 0  T@,  !@
M             ( !M"<  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4
M Q0    ( $B"6%#H +CEM0$  -(#   9              "  9XI  !X;"]W
M;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ 2()84*[3W#JT 0
MT@,  !D              ( !BBL  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX
M;6Q02P$"% ,4    " !(@EA0CL]QSK4!  #2 P  &0              @ %U
M+0  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( $B"6%!=
M]_$9M0$  -(#   9              "  6$O  !X;"]W;W)K<VAE971S+W-H
M965T,3,N>&UL4$L! A0#%     @ 2()84'J.KC>S 0  T@,  !D
M     ( !33$  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( $B"6%!,;;.EM $  -(#   9              "
M >0Z  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ 2()8
M4);,L.>T 0  T@,  !D              ( !SSP  'AL+W=O<FMS:&5E=',O
M<VAE970R,"YX;6Q02P$"% ,4    " !(@EA0NP;6-;0!  #2 P  &0
M        @ &Z/@  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0
M   ( $B"6%"Z;W7GJ@(  !,+   9              "  :5   !X;"]W;W)K
M<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ 2()84'0>)?+" 0  -P0
M !D              ( !AD,  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q0
M2P$"% ,4    " !(@EA0SKKPS[D!  #2 P  &0              @ %_10
M>&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( $B"6%#QZ"MP
MM@$  -(#   9              "  6]'  !X;"]W;W)K<VAE971S+W-H965T
M,C4N>&UL4$L! A0#%     @ 2()84%L%;'2W 0  T@,  !D
M ( !7$D  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " !(
M@EA0W#PQ(,(!   W!   &0              @ %*2P  >&PO=V]R:W-H965T
M<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( $B"6%!9F(IXMP$  -(#   9
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M970S,BYX;6Q02P$"% ,4    " !(@EA0>@6\U;$!  #2 P  &0
M    @ $Q5P  >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    (
M $B"6%!=(L))F@$  %8#   9              "  1E9  !X;"]W;W)K<VAE
M971S+W-H965T,S0N>&UL4$L! A0#%     @ 2()84+@5),&( P  C@\  !D
M             ( !ZEH  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"
M% ,4    " !(@EA08LKWM(D"  "$"   &0              @ &I7@  >&PO
M=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( $B"6% C4&=F*P4
M +P=   9              "  6EA  !X;"]W;W)K<VAE971S+W-H965T,S<N
M>&UL4$L! A0#%     @ 2()84([SN=@0 @  B04  !D              ( !
MRV8  'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4    " !(@EA0
M<@I=+#\"  "H!@  &0              @ $2:0  >&PO=V]R:W-H965T<R]S
M:&5E=#,Y+GAM;%!+ 0(4 Q0    ( $B"6%#8NS@;L@(  &L*   9
M      "  8AK  !X;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%
M  @ 2()84$@3/T?W 0  Y 0  !D              ( !<6X  'AL+W=O<FMS
M:&5E=',O<VAE970T,2YX;6Q02P$"% ,4    " !(@EA0UL(V>'D#   [#P
M&0              @ &?<   >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+
M 0(4 Q0    ( $B"6%"S@6O)U@$  /T$   9              "  4]T  !X
M;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ 2()84$,6L^G
M!0  1"0  !D              ( !7'8  'AL+W=O<FMS:&5E=',O<VAE970T
M-"YX;6Q02P$"% ,4    " !(@EA0SC3[Z-D"   9"@  &0
M@ %3?   >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( $B"
M6%!/H^5Y' (  $L&   9              "  6-_  !X;"]W;W)K<VAE971S
M+W-H965T-#8N>&UL4$L! A0#%     @ 2()84,Y!K@SH!0  T"(  !D
M         ( !MH$  'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"% ,4
M    " !(@EA0WJY3$1<#  !%#   &0              @ '5AP  >&PO=V]R
M:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( $B"6%"+&#/#:@(  #\(
M   9              "  2.+  !X;"]W;W)K<VAE971S+W-H965T-#DN>&UL
M4$L! A0#%     @ 2()84$^8PWO6 @  8PL  !D              ( !Q(T
M 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"% ,4    " !(@EA0 M=P
M:+$#  "K#P  &0              @ '1D   >&PO=V]R:W-H965T<R]S:&5E
M=#4Q+GAM;%!+ 0(4 Q0    ( $B"6%#E3:@ST @  *HU   9
M  "  ;F4  !X;"]W;W)K<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @
M2()84,?!S3@B @  ,@8  !D              ( !P)T  'AL+W=O<FMS:&5E
M=',O<VAE970U,RYX;6Q02P$"% ,4    " !(@EA0&NF<_W@"  #M"   &0
M            @ $9H   >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4
M Q0    ( $B"6%"X!@D1/P(  #8'   9              "  <BB  !X;"]W
M;W)K<VAE971S+W-H965T-34N>&UL4$L! A0#%     @ 2()84"V,(S") @
MZ0@  !D              ( !/J4  'AL+W=O<FMS:&5E=',O<VAE970U-BYX
M;6Q02P$"% ,4    " !(@EA0J#'#C@T"  !T!0  &0              @ '^
MIP  >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4 Q0    ( $B"6%#/
M.,]UE0,  & 1   9              "  4*J  !X;"]W;W)K<VAE971S+W-H
M965T-3@N>&UL4$L! A0#%     @ 2()84.WET_1> @  A <  !D
M     ( !#JX  'AL+W=O<FMS:&5E=',O<VAE970U.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( $B"6%"NQL^%CI@  #(V @ 4              "
M :2]  !X;"]S:&%R9613=')I;F=S+GAM;%!+ 0(4 Q0    ( $B"6% ((!0#
M5@(  'X+   -              "  616 0!X;"]S='EL97,N>&UL4$L! A0#
M%     @ 2()84(CV;ZG&!0  E"D   \              ( !Y5@! 'AL+W=O
M<FMB;V]K+GAM;%!+ 0(4 Q0    ( $B"6%"X]0,.(P(  !(F   :
M      "  =A> 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0
M   ( $B"6%!U'BN_[P$  'TE   3              "  3-A 0!;0V]N=&5N
B=%]4>7!E<UTN>&UL4$L%!@    !( $@ JA,  %-C 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6807053920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTIES (Details Narrative) - Affiliated Entity [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty', window );">Amount billed</a></td>
<td class="nump">$ 6,101,000<span></span>
</td>
<td class="nump">$ 4,111,000<span></span>
</td>
<td class="nump">$ 3,646,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableRelatedPartiesCurrent', window );">Amounts due to related party</a></td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="nump">$ 88,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6814304544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>For financial reporting purposes, income before taxes includes the following components: (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Income (Loss) from Continuing Operations before Income Taxes, Domestic</a></td>
<td class="num">$ (176,144,999)<span></span>
</td>
<td class="num">$ (132,617,160)<span></span>
</td>
<td class="num">$ (76,925,380)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Income (Loss) from Continuing Operations before Income Taxes, Domestic</a></td>
<td class="num">$ (176,144,999)<span></span>
</td>
<td class="num">$ (132,617,160)<span></span>
</td>
<td class="num">$ (76,925,380)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6800134592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock', window );">Supplemental lease information</a></td>
<td class="text"><p id="xdx_897_ecustom--ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock_z48rBQgEI9Lj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="margin-right: auto; margin-left: auto; float: none; width: 80%">

<tr>
<td style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><span id="xdx_8BC_zTCvqPmJs8xf">Supplemental lease information</span> at December 31, 2019</b></p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td colspan="2" style="vertical-align: top">&#160;</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; width: 85%; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Right-of-use asset</p>
</td>
<td style="width: 1%">
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 12%">
<p id="xdx_984_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20191231_z8a7pYazUhbk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Right-of-use asset">10,109,154</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Short-term operating lease liability (included in Other current liabilities)</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_985_eus-gaap--OperatingLeaseLiabilityCurrent_iI_c20191231_zERKcgVqrAr9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Short-term operating lease liability (included in Other current liabilities)">1,501,539</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Long-term operating lease liability</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_98D_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_c20191231_zjW5hGBbmrn3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Long-term operating lease liability">9,145,049</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Weighted average remaining term</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_987_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dt_c20191231_zbwYMEXG2Mhg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Weighted average remaining term">9 Years</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Weighted average discount rate</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_987_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20191231_zSn2Lds4H9O3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Weighted average discount rate">8.25</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">%</p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="margin-right: auto; margin-left: auto; float: none; width: 80%">

<tr>
<td style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Supplemental cash flow information for the year ended</b><br/>
<b>December 31, 2019</b></p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td colspan="2" style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; width: 85%; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Cash paid for amounts included in the measurement of lease liabilities for operating lease</p>
</td>
<td style="width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 12%">
<p id="xdx_989_eus-gaap--OperatingLeasePayments_c20190101__20191231_zSvPYRerMxW8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Cash paid for amounts included in the measurement of lease liabilities for operating lease"><span style="font-size: 10pt">1,164,234</span></p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Right-of-use assets obtained in exchange for lease obligation</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_982_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_c20190101__20191231_z7S1xqMVFat6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Right-of-use assets obtained in exchange for lease obligation">11,171,471</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>

</table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">The following table reconciles the undiscounted cash flows for all operating leases at December 31, 2019 to the operating lease liabilities recorded on the balance sheet:</a></td>
<td class="text"><p id="xdx_895_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_z2GX5VLIpZ6e" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: #212529">The following table reconciles the undiscounted cash flows for all operating leases at December 31, 2019 to the operating lease liabilities recorded on the balance sheet:</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="margin-right: auto; margin-left: auto; float: none; width: 50%">

<tr>
<td style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>Years Ending December
31,</b></p>
</td>
<td><p style="margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" id="xdx_49A_20191231_zoZfKDWyM5Ni" style="vertical-align: top"><b>&#160;</b></td>
<td style="vertical-align: bottom"><p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPznhG_zCShR9Y0XsZ5" style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; width: 77%; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">2020</p>
</td>
<td style="width: 1%">
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 20%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">1,566,617</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPznhG_zpb6wZo9RsZ5">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">2021</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">2,198,541</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPznhG_zjgMVTsisXS9" style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">2022</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">1,262,302</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPznhG_zVUB6N03Ccyh">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">2023</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">1,293,859</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_maLOLLPznhG_zNj4npP2OcX6" style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">2024</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">1,326,206</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_maLOLLPznhG_zMsI9KHAuEv1">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Thereafter</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">8,036,931</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPznhG_zXKl3OVd0UV1" style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Total undiscounted lease payments</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">15,684,456</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zWmQOGk1qPQk">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Less: imputed interest</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(5,037,868</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
</tr>
<tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iI_zRqM9FEjWdl4" style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Present value of lease payments</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">10,646,588</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>

</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of supplementary lease and cash flow information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6803748256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue, net</a></td>
<td class="nump">$ 49,646,937<span></span>
</td>
<td class="nump">$ 16,099,460<span></span>
</td>
<td class="nump">$ 16,777,713<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">6,334,585<span></span>
</td>
<td class="nump">2,737,652<span></span>
</td>
<td class="nump">2,636,943<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">43,312,352<span></span>
</td>
<td class="nump">13,361,808<span></span>
</td>
<td class="nump">14,140,770<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Sales, general, and administrative</a></td>
<td class="nump">174,112,612<span></span>
</td>
<td class="nump">115,988,954<span></span>
</td>
<td class="nump">57,703,370<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">19,792,212<span></span>
</td>
<td class="nump">27,299,138<span></span>
</td>
<td class="nump">33,852,993<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">612,786<span></span>
</td>
<td class="nump">293,886<span></span>
</td>
<td class="nump">213,117<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">194,517,610<span></span>
</td>
<td class="nump">143,581,978<span></span>
</td>
<td class="nump">91,769,480<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(151,205,258)<span></span>
</td>
<td class="num">(130,220,170)<span></span>
</td>
<td class="num">(77,628,710)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other (expense) income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="num">(10,057,632)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Miscellaneous income</a></td>
<td class="nump">2,500,106<span></span>
</td>
<td class="nump">2,280,844<span></span>
</td>
<td class="nump">695,631<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(17,382,215)<span></span>
</td>
<td class="num">(4,677,834)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium', window );">Accreted interest</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">7,699<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other (expense) income</a></td>
<td class="num">(24,939,741)<span></span>
</td>
<td class="num">(2,396,990)<span></span>
</td>
<td class="nump">703,330<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(176,144,999)<span></span>
</td>
<td class="num">(132,617,160)<span></span>
</td>
<td class="num">(76,925,380)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (176,144,999)<span></span>
</td>
<td class="num">$ (132,617,160)<span></span>
</td>
<td class="num">$ (76,925,380)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Loss per share, basic and diluted:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted</a></td>
<td class="num">$ (0.72)<span></span>
</td>
<td class="num">$ (0.59)<span></span>
</td>
<td class="num">$ (0.37)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average number of common shares outstanding, basic and diluted</a></td>
<td class="nump">246,353,318<span></span>
</td>
<td class="nump">225,026,300<span></span>
</td>
<td class="nump">205,523,288<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue, net</a></td>
<td class="nump">$ 34,140,537<span></span>
</td>
<td class="nump">$ 16,099,460<span></span>
</td>
<td class="nump">$ 16,777,713<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember', window );">License and Service [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue, net</a></td>
<td class="nump">$ 15,506,400<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6805542272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The table below presents potentially dilutive securities that could affect our calculation of diluted net loss per share allocable to common stockholders for the periods presented. (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">28,102,805<span></span>
</td>
<td class="nump">24,920,395<span></span>
</td>
<td class="nump">26,481,130<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">1,832,571<span></span>
</td>
<td class="nump">3,007,571<span></span>
</td>
<td class="nump">3,115,905<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">25,030,234<span></span>
</td>
<td class="nump">20,872,824<span></span>
</td>
<td class="nump">23,365,225<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">1,240,000<span></span>
</td>
<td class="nump">1,040,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6800221168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p id="xdx_808_eus-gaap--SignificantAccountingPoliciesTextBlock_zO2vOpZycVy9" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><b><span style="text-decoration: underline"><b>NOTE 2 &#8211; <span id="xdx_827_zZNBdZzlNhJd">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></span></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p id="xdx_840_eus-gaap--ConsolidationPolicyTextBlock_z9mbbq84TDpk" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="text-decoration: underline">Principles of Consolidation</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">The accompanying consolidated financial statements include the accounts of our company and our wholly owned subsidiaries, VitaMed, BocaGreen and VitaCare. All intercompany balances and transactions have been eliminated in consolidation.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p id="xdx_84E_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zPuRMhgGn9n9" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: black"><span style="text-decoration: underline"><span style="color: black">Cash</span></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">We maintain cash at financial institutions that at times may exceed the Federal Deposit Insurance Corporation, or the FDIC, insured limits of $<span id="xdx_907_eus-gaap--CashFDICInsuredAmount_iI_c20191231_zArZMLyhjRi2" title="Federal insurance limits">250,000</span> per bank. We have never experienced any losses related to these funds.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p id="xdx_842_eus-gaap--ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_z4vfyE0pmWgg" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: black"><span style="text-decoration: underline"><span style="color: black">Trade Accounts Receivable and Allowance for Doubtful Accounts</span></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">Trade accounts receivable are customer obligations due under normal trade terms. We review accounts receivable for uncollectible accounts and credit card chargebacks and provide an allowance for doubtful accounts, which is based upon a review of outstanding receivables, historical collection information, and existing economic conditions. We evaluate trade accounts receivable aged more than 90 days for delinquency. We write off delinquent receivables against our allowance for doubtful accounts based on individual credit evaluations, the results of collection efforts, and specific circumstances of customers. We record recoveries of accounts previously written off when received as an increase in the allowance for doubtful accounts. To the extent data we use to calculate these estimates does not accurately reflect bad debts, adjustments to these reserves may be required. At December 31, 2019, four different customers represented <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_dp_c20190101__20191231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerAMember_zKF3b71cwfz1" title="Concentration risk">36</span>%, <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_dp_c20190101__20191231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerBMember_zmEFfWdMZjDg">21</span>%, <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_dp_c20190101__20191231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerCMember_zntJnZicuVGl">16</span>% and <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_dp_c20190101__20191231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerDMember_zO8dfd3KrK6h">11</span>% of our gross accounts receivable. At December 31, 2018, three different customers represented <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_dp_c20180101__20181231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerAMember_zupQyt5giKMl">42</span>%, <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20180101__20181231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerBMember_zpzmvrRmdsO9">24</span>% and <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_c20180101__20181231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerCMember_zyUQ7PV5Sc6d">13</span>% of our gross accounts receivable.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>



<p id="xdx_841_eus-gaap--InventoryPolicyTextBlock_zJMMUrzk2Is1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: black"><span style="text-decoration: underline"><span style="color: black">Inventories</span></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">Inventories represent pharmaceutical products, packaged vitamins and raw materials which are valued at the lower of cost or net realizable value. Our pharmaceutical products are valued using first in first out method and our vitamins are valued using the average-cost method. We review our inventory for excess or obsolete inventory and write-down obsolete or otherwise unmarketable inventory to its estimated net realizable value. Obsolescence may occur due to product expiring or product improvements rendering previous versions obsolete.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black"><i><span style="text-decoration: underline"><span style="color: black"><i>Pre-Launch Inventory</i></span></span></i></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">Pre-launch
inventory costs associated with product candidates that have not yet received regulatory approval are capitalized if we
believe there is probable future commercial use and future economic benefit. If the probability of future commercial use and
future economic benefit cannot be reasonably determined, then pre-launch inventory costs associated with such product
candidates are expensed as research and development expenses during the period the costs are incurred. We have not
capitalized any pre-launch inventory to date.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p id="xdx_840_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zVTVNsWARLG6" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: black"><span style="text-decoration: underline"><span style="color: black">Fixed Assets</span></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">We state fixed assets at cost, net of accumulated depreciation. We charge maintenance costs, which do not significantly extend the useful lives of the respective assets, and repair costs to operating expenses as incurred. We compute depreciation using the straight-line method over the estimated useful lives of the related assets, which range from <span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dxL_c20190101__20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LandAndBuildingMember__srt--RangeAxis__srt--MinimumMember_zJS38w4WoxI7" title="Useful life of assets::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl0553">three</span></span> to <span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dxL_c20190101__20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LandAndBuildingMember__srt--RangeAxis__srt--MaximumMember_zlggfZdrMU98" title="::XDX::P7Y"><span style="-sec-ix-hidden: xdx2ixbrl0554">seven</span></span> years. Leasehold improvements are depreciated over the shorter of their useful life or the term of the lease.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">We capitalize software and software development costs incurred to create and acquire computer software for internal use, principally related to software coding and application development. We begin to capitalize software development costs when both the preliminary project stage is completed and it is probable that the software will be used as intended. Capitalized software costs include only external direct costs and services utilized in developing or obtaining computer software. Capitalized software costs are amortized on a straight-line basis when placed into service over the estimated useful life, generally <span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dxL_c20190101__20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember__srt--RangeAxis__srt--MinimumMember_zld1rcASVmyj" title="::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl0555">five</span></span> to <span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dxL_c20190101__20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember__srt--RangeAxis__srt--MaximumMember_zbWzKwyxIev5" title="::XDX::P7Y"><span style="-sec-ix-hidden: xdx2ixbrl0556">seven</span></span> years.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p id="xdx_840_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zkbInhjBzxL3" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: black"><span style="text-decoration: underline"><span style="color: black">Intangible Assets</span></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">We have adopted the provisions of Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, 350, <i><span style="color: black">Intangibles - Goodwill and Other</span></i>, or ASC 350. Capitalized patent costs, net of accumulated amortization, include outside legal costs incurred for patent applications. In accordance with ASC 350, once a patent is granted, we amortize the capitalized patent costs over the remaining life of the patent using the straight-line method. If the patent is not granted, we write-off any capitalized patent costs at that time. As of December 31, 2019, we had <span id="xdx_904_ecustom--NumberOfIssuedPatentsDomestic_iI_uPure_c20191231_zN9Aevq2rkUe" title="Number of issued patents domestic.">29</span> issued domestic, or U.S., patents and <span id="xdx_907_ecustom--NumberOfIssuedPatentsForeign_iI_uPure_c20191231_zxTQdtMts3r5" title="Number of issued patents foreign">30</span> issued foreign patents (See Note 6). We capitalize external costs, consisting primarily of legal costs, related to securing our trademarks. Trademarks are perpetual and are not amortized. We review intangible assets for impairment annually or when events or circumstances indicate that their carrying amount may not be recoverable.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p id="xdx_84C_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zX0rxQcb4Caj" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="text-decoration: underline">Impairment of Long-Lived Assets</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">We review the carrying values of fixed assets and long-lived intangible assets to be held and used for impairment whenever events or changes in circumstances indicate that their carrying values may not be recoverable. Such events or circumstances may include, among others, the following:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; width: 100%">

<tr>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">significant declines in an asset&#8217;s market price;</p>
</td>
</tr>

</table>
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; width: 100%">

<tr>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">significant deterioration in an asset&#8217;s physical condition;</p>
</td>
</tr>

</table>
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; width: 100%">

<tr>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">significant changes in the nature or extent of an asset&#8217;s use or operation;</p>
</td>
</tr>

</table>
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; width: 100%">

<tr>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">significant adverse changes in the business climate that could impact an asset&#8217;s value, including adverse actions or assessments by regulators;</p>
</td>
</tr>

</table>
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; width: 100%">

<tr>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">accumulation of costs significantly in excess of original expectations related to the acquisition or construction of an asset;</p>
</td>
</tr>

</table>
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; width: 100%">

<tr>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">current-period operating or cash flow losses combined with a history of such losses or a forecast that demonstrates continuing losses associated with an asset&#8217;s use; and</p>
</td>
</tr>

</table>
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; width: 100%">

<tr>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">expectations that it is more likely than not that an asset will be sold or otherwise disposed of significantly before the end of its previously estimated useful life.</p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">If impairment indicators are present, we determine whether an impairment loss should be recognized by testing the applicable asset or asset group&#8217;s carrying value for recoverability. This test requires long-lived assets to be grouped at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities, the determination of which requires judgment. We estimate the undiscounted future cash flows expected to be generated from the use and eventual disposal of the assets and compare that estimate to the respective carrying values in order to determine if such carrying values are recoverable. This assessment requires the exercise of judgment in assessing the future use of and projected value to be derived from the eventual disposal of the assets to be held and used. In our assessments, we also consider changes in asset utilization, including, if applicable, the temporary idling of capacity and the expected timing for placing this capacity back into production. If the carrying value of the assets is not recoverable, then we record a loss for the difference between the assets&#8217; fair value and respective carrying values. We determine the fair value of the assets using an &#8220;income approach&#8221; based upon a forecast of all the expected discounted future net cash flows associated with the subject assets. Some of the more significant estimates and assumptions include market size and growth, market share, projected selling prices, manufacturing cost, and discount rate. We base estimates upon historical experience, our commercial relationships, market conditions, and available external information about future trends. We believe our current assumptions and estimates are reasonable and appropriate. Unanticipated events and changes in market conditions, however, could affect such estimates, resulting in the need for an impairment charge in future periods. There was no impairment of long-lived assets to be held and used during the years ended December 31, 2019, 2018, and 2017.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">We perform impairment tests for intangible assets with indefinite useful lives annually, in the fourth quarter, or more frequently if events occur or circumstances change that would more likely than not reduce the fair value of an intangible asset below its carrying value. The impairment test for assets with indefinite lives consists of a comparison of the fair value of the asset with its carrying amount. If the carrying amount of an intangible asset exceeds its fair value, an impairment loss is recognized in an amount equal to that excess. </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: #212529">We also evaluate the remaining useful life of intangible assets subject to amortization on a periodic basis to determine whether events and circumstances would indicate impairment or warrant a revision to the remaining useful life. If the estimate of an intangible asset&#8217;s remaining useful life is changed, we will amortize the remaining carrying value of the intangible asset prospectively over the revised remaining useful life.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p id="xdx_843_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zcmWXNTLtxO5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: black"><span style="text-decoration: underline"><span style="color: black">Fair Value of Financial Instruments</span></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">Our financial instruments consist primarily of cash, accounts receivable, accounts payable, accrued expenses and long term debt. The carrying amount of cash, accounts receivable, accounts payable and accrued expenses approximates their fair value because of the short-term maturity of such instruments, which are considered Level 1 assets under the fair value hierarchy.&#160; T<span style="color: #212529">he carrying amount for long-term debt as of December 31, 2019 and 2018 (as disclosed in Note 8), approximates fair value based on market activity for other debt instruments with similar characteristics and comparable risk (Level 2).</span></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">We
categorize our assets and liabilities that are valued at fair value on a recurring basis into a three-level fair value
hierarchy as defined by ASC 820, <i><span style="color: black">Fair Value Measurements</span></i>, or ASC 820. The fair value
hierarchy gives the highest priority to quoted prices in active markets for identical assets and liabilities (Level 1) and
lowest priority to unobservable inputs (Level 3). Assets and liabilities recorded in the consolidated balance sheet at fair
value are categorized based on a hierarchy of inputs, as follows: </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
    <td style="width: 4%">&#160;</td>
    <td style="text-align: justify; width: 6%"><b>Level 1</b></td>
    <td style="text-align: justify; width: 90%">unadjusted quoted prices in active markets for identical assets or liabilities;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><b>Level 2</b></td>
    <td style="text-align: justify">quoted prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument; and</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><b>Level 3</b></td>
    <td style="text-align: justify">unobservable inputs for the assets or liabilities.</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">At December 31, 2019 and 2018, we had no assets or liabilities that were valued at fair value on a recurring basis.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">The fair value of indefinite-lived assets is measured on a non-recurring basis using significant unobservable inputs (Level 3) in connection with any required impairment test. During the year ended December 31, 2019, we wrote off $78,864 in costs related to trademarks and patents, including the net carrying amount of our OPERA software patent. There was no impairment of intangible assets during the years ended December 31, 2018, and 2017.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p id="xdx_845_eus-gaap--IncomeTaxPolicyTextBlock_zXcE6tElWSuf" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="text-decoration: underline">Income Taxes</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">We account for income taxes under the asset and liability method. We recognize deferred tax assets and liabilities for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. We measure deferred tax assets and liabilities using enacted tax rates expected to apply to taxable income in the years in which the related temporary differences are expected to be recovered or settled. We recognize the effect on deferred tax assets and liabilities of a change in tax rates when the rate change is enacted. Valuation allowances are recorded to reduce deferred tax assets to the amount that will more likely than not be realized.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">In accordance with ASC 740, <i><span style="color: black">Income Taxes</span></i>, we recognize the effect of uncertain income tax positions only if the positions are more likely than not of being sustained in an audit, based on the technical merits of the position. We measure recognized uncertain income tax positions using the largest amount that has a likelihood of being realized that is greater than 50%. Changes in recognition or measurement are reflected in the period in which those changes in judgment occur.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">We recognize both interest and penalties related to uncertain tax positions as part of the income tax provision. At December 31, 2019 and 2018, we had no tax positions relating to open tax returns that were considered to be uncertain.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">Our U.S. federal and state tax returns since 2011, which was the first year we generated net operating losses, remain open to examination.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p id="xdx_84D_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zZ67QJ5XmZpg" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="text-decoration: underline">Share-Based Compensation</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">We measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees are required to provide services. Share-based compensation arrangements include options, restricted stock, restricted stock units, performance-based awards, share appreciation rights, and employee share purchase plans. We amortize such compensation amounts, if any, over the respective service periods of the award. We use the Black-Scholes-Merton option pricing model, or the Black-Scholes Model, an acceptable model in accordance with ASC 718, Compensation-Stock Compensation, to value options. Option valuation models require the input of assumptions, including the expected life of the stock-based awards, the estimated stock price volatility, the risk-free interest rate, and the expected dividend yield. The risk-free interest rate assumption is based upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the term of the instrument. Estimated volatility is a measure of the amount by which our stock price is expected to fluctuate each year during the term of the award. On January 1, 2017, we began using our own stock price in our volatility calculation along with the other peer entities whose stock prices were publicly available that were similar to our company and in 2019 we started using only our own stock price in the volatility calculation. Our calculation of estimated volatility is based on historical stock prices over a period equal to the expected term of the awards. The average expected life of options is based on the contractual terms of the stock option using the simplified method. We utilize a dividend yield of zero based on the fact that we have never paid cash dividends and have no current intention to pay cash dividends. Calculating share-based compensation expense requires the input of highly subjective judgment and assumptions, estimates of expected life of the share-based award, stock price volatility and risk-free interest rates. The assumptions used in calculating the fair value of share-based awards represent our best estimates, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change and we use different assumptions, our share-based compensation expense could be materially different in the future. We recognize the compensation expense for share-based compensation granted based on the grant date fair value estimated in accordance with ASC 718. We generally recognize the compensation expense on a straight-line basis over the employee&#8217;s requisite service period. Effective January 1, 2017, we account for forfeitures when they occur. On January 1, 2019, we adopted ASU 2018-07 which simplified the accounting for share-based payments to non-employees by aligning it with the accounting for share-based payments to employees, with certain exceptions. The new guidance expanded the scope of ASC 718 to include share-based payments granted to non-employees in exchange for goods or services used or consumed in an entity&#8217;s own operations and superseded the guidance in ASC 505-50. Prior to January 1, 2019, equity instruments issued to non-employees were recorded on a fair value basis, as required by ASC 505, Equity - Based Payments to Non-Employees.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p id="xdx_845_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zX9Q9Tx5SIq5" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: black"><span style="text-decoration: underline"><span style="color: black">Revenue Recognition</span></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">We
adopted ASC 606, <i>Revenue from Contracts with Customers</i>, or ASC 606, on January 1, 2018 using the modified retrospective
method for all contracts not completed as of the date of adoption. ASC 606 states that a contract is considered &#8220;completed&#8221;
if all (or substantially all) of the revenue was recognized in accordance with revenue guidance that was in effect before the
date of initial application. Because all (or substantially all) of the revenue related to sales of our products was recognized
under ASC 605 prior to the date of initial application of the new standard, the contracts were considered completed under ASC
606. Based on our evaluation of ASC 606, we concluded that a cumulative adjustment was not necessary upon implementation of ASC
606 on January 1, 2018. In accordance with ASC 606, revenue is recognized when a customer obtains control of promised goods or
services. The amount of revenue recognized reflects the consideration to which we expect to be entitled to receive in exchange
for these goods or services. The provisions of ASC 606 include a five-step process by which we determine revenue recognition,
depicting the transfer of goods or services to customers in amounts reflecting the payment to which we expect to be entitled in
exchange for those goods or services. ASC 606 requires us to apply the following steps: (1) identify the contract with the customer;
(2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price
to the performance obligations in the contract; and (5) recognize revenue when, or as, we satisfy the performance obligation.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 36pt; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black"><i><span style="text-decoration: underline"><span style="color: black"><i>Prescription Products</i></span></span></i></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: #212529">As of December 31, 2019, our products consisted primarily of prescription vitamins and our FDA-approved products: IMVEXXY, which we began selling during the third quarter of 2018, and BIJUVA, which we began selling in the second quarter of 2019. We started selling ANNOVERA in the third quarter of 2019 and we expect the full commercial launch of ANNOVERA in the first quarter of 2020. We sell our name brand and generic prescription products primarily through wholesale distributors and retail pharmacies. We have one performance obligation related to prescription products sold through wholesale distributors, which is to transfer promised goods to a customer, and two performance obligations related to products sold through retail pharmacies, which are to: (1) transfer promised goods and (2) provide customer service for an immaterial fee. We treat shipping as a fulfillment activity rather than as a separate obligation. We recognize prescription revenue only when we satisfy performance obligations by transferring a promised good or service to a customer. A good or service is considered to be transferred when the customer receives the goods or service or obtains control. Control refers to the customer&#8217;s ability to direct the use of, and obtain substantially all of the remaining benefits from, an asset. Based on our contracts, we invoice customers once our performance obligations have been satisfied, at which point payment is unconditional. We disclose receivables from contracts with customers separately in the statement of financial position. Payment for goods or services sold by us is typically due between 30 and 60 days after an invoice is sent to the customer. </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: #212529">The transaction price of a contract is the amount of consideration which we expect to be entitled to in exchange for transferring promised goods or services to a customer. Prescription products are sold at fixed wholesale acquisition cost, or WAC, determined based on our list price. However, the total transaction price is variable as it is calculated net of estimated product returns, chargebacks, rebates, coupons, discounts and wholesaler fees. These estimates are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the customer) or a current liability (if the amount is payable to a party other than a customer). In order to determine the transaction price, we estimate the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract or each variable consideration. The estimated amount of variable consideration is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. In determining amounts of variable consideration to include in a contract&#8217;s transaction price, we rely on our historical experience and other evidence that supports our qualitative assessment of whether revenue would be subject to a significant reversal. We consider all the facts and circumstances associated with both the risk of a revenue reversal arising from an uncertain future event and the magnitude of the reversal if that uncertain event were to occur. Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our original estimates, we will adjust these estimates, which would affect net product revenue and earnings in the period such changes in estimates become known. </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: #212529">We accept returns of unsalable prescription products sold through wholesale distributors within a return period of <span id="xdx_90B_ecustom--ReturnPeriodOfUnsalablePrescriptionProducts_dxH_c20190101__20191231__srt--RangeAxis__srt--MinimumMember_zwmQaTTYNKK" title="Return period of unsalable prescription products::XDX::P6M">six</span> months prior to and up to <span id="xdx_908_ecustom--ReturnPeriodOfUnsalablePrescriptionProducts_dtM_c20190101__20191231__srt--RangeAxis__srt--MaximumMember_zpQUNXhwWkQ1">12</span> months following product expiration. Our vitamins and IMVEXXY currently have a shelf life of <span id="xdx_907_ecustom--ShelfLifeOfPrescriptionProducts_dtM_c20190101__20191231__srt--ProductOrServiceAxis__custom--VitaminsAndImvexxyMember_zdk5medOaIY1" title="Shelf life of prescription products following product expiration">24</span> months from the date of manufacture and BIJUVA and ANNOVERA currently have a shelf life of <span id="xdx_905_ecustom--ShelfLifeOfPrescriptionProducts_dtM_c20190101__20191231__srt--ProductOrServiceAxis__custom--BijuvaAndAnnoveraMember_zykSpchkSjok">18</span> months from the date of manufacture. We do not allow product returns for prescription products that have been dispensed to a patient. We estimate the amount of our product sales that may be returned by our customers and record this estimate as a reduction of revenue in the period the related product revenue is recognized. Where historical rates of return exist, we use history as a basis to establish a returns reserve for products shipped to wholesalers. For our newly launched products, for which the right of return exists but for which we currently do not have history of product returns, we estimate returns based on available industry data, our own sales information and our visibility into the inventory remaining in the distribution channel. At the end of each reporting period, we may decide to constrain revenue for product returns based on information from various sources, including channel inventory levels and dating and sell-through data, the expiration dates of products currently being shipped, price changes of competitive products and any introductions of generic products. We recognize the amount of expected returns as a refund liability, representing the obligation to return the customer&#8217;s consideration. Since our returns primarily consist of expired and short dated products that will not be resold, we do not record a return asset for the right to recover the goods returned by the customer at the time of the initial sale (when recognition of revenue is deferred due to the anticipated return). Return estimates are recorded in accrued expenses and other current liabilities on the consolidated balance sheet.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: #212529">We offer various rebate and discount programs in an effort to maintain a competitive position in the marketplace and to promote sales and customer loyalty. We estimate the allowance for consumer rebates and coupons that we have offered based on our experience and industry averages, which is reviewed, and adjusted if necessary, on a quarterly basis. Estimates relating to these rebates and coupons are deducted from gross product revenues at the time the revenues are recognized. We record distributor fees based on amounts stated in contracts. Rebate and coupon estimates and distributor fees are recorded in accrued expenses and other current liabilities on the consolidated balance sheet. We estimate chargebacks based on number of units sold during the period taking into account prices stated in contracts and our historical experience. Estimates related to distributors fees, rebates, coupons and returns are disclosed in Note 7. We provide invoice discounts to our customers for prompt payment. Estimates relating to invoice discounts and chargebacks are deducted from gross product revenues at the time the revenues are recognized. </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: #212529">As part of commercial launches for our FDA-approved prescription products, we introduced a co-pay assistance program for eligible enrolled patients whose out of pocket costs are reduced to a more affordable price. This allows patients to access the product at a reasonable cost and is in line with our responsible pricing approach. We reimburse pharmacies for this discount through third-party vendors. We consider certain payments as consideration paid to the customer and reflect such payments as a reduction of the transaction price as we do not receive a distinct good or service related to these payments. The variable consideration is estimated based on contract prices, the estimated percentage of patients that will utilize the copay assistance, the average assistance paid, the estimated levels of inventory in the distribution channel and the current level of prescriptions covered by patients&#8217; insurance. Payers may change coverage levels for our prescription products positively or negatively, at any time up to the time that we have formally contracted coverage with the payer. As such, the net transaction price of our prescription products is susceptible to such changes in coverage levels, which are outside the influence of the Company. As a result, we constrain variable consideration for our prescription products to an amount that will not result in a significant revenue reversal in future periods. Our ability to estimate the net transaction price for our prescription products is constrained by our estimates of the amount to be paid for the co-pay assistance program which is directly related to the level of prescriptions paid for by insurance. As such, we record an accrual to reduce gross sales for the estimated co-pay and other patient assistance based on currently available third-party data and our internal analyses. We re-evaluate variable consideration each reporting period.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 36pt; margin-top: 0pt; margin-bottom: 0pt"><span style="color: #212529"><i><span style="text-decoration: underline"><span style="color: #212529"><i>License Revenue</i></span></span></i></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: #212529">License
arrangements may consist of non-refundable upfront license fees, exclusive licensed rights to patented or patent pending
technology, and various performance or sales milestones and future product royalty payments. Some of these arrangements may
include multiple performance obligations. Non-refundable up-front fees that are not contingent on any future performance by
us, and do not require continuing involvement on our part, are recognized as revenue when the right to use functional IP is transferred to the customer.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #212529"><span style="text-decoration: underline"><span style="color: #212529">License Agreement with Knight Therapeutics Inc.</span></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: #212529">On July 30, 2018, we entered into the Knight License Agreement with Knight pursuant to which we granted Knight an exclusive license to commercialize IMVEXXY and BIJUVA in Canada and Israel. Pursuant to the terms of the Knight License Agreement, Knight will pay us a milestone fee upon first regulatory approval in Canada of each of IMVEXXY and BIJUVA, sales milestone fees based upon certain aggregate annual sales in Canada and Israel of each of IMVEXXY and BIJUVA and royalties based on aggregate annual sales of each of IMVEXXY and BIJUVA in Canada and Israel. Knight will be responsible for all regulatory and commercial activities in Canada and Israel related to IMVEXXY and BIJUVA. We may terminate the Knight License Agreement if Knight does not submit all regulatory applications, submissions and/or registrations required for regulatory approval to use and commercialize IMVEXXY and BIJUVA in Canada and Israel within certain specified time periods. We also may terminate the Knight License Agreement if Knight challenges our patents. Either party may terminate the Knight License Agreement for any material breach by the other party that is not cured within certain specified time periods or if the other party files for bankruptcy or other related matters. In connection with the Knight License Agreement, Knight entered into a subscription agreement with us, pursuant to which Knight purchased <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20180730__20180806__us-gaap--SubsidiarySaleOfStockAxis__custom--SubscriptionAgreementKnightMember_zPi7HFxxKJK7">3,921,568</span> shares of our Common Stock concurrent with the closing of the underwritten public offering of Common Stock on August 6, 2018 at a price of $<span id="xdx_90C_eus-gaap--SaleOfStockPricePerShare_iI_c20180806__us-gaap--SubsidiarySaleOfStockAxis__custom--SubscriptionAgreementKnightMember_zA6xYqBlf9gh">5.10</span>, for proceeds of $<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20180730__20180806__us-gaap--SubsidiarySaleOfStockAxis__custom--SubscriptionAgreementKnightMember_zE3Vbx4PtVqb">20,000,000</span>.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #212529"><span style="text-decoration: underline"><span style="color: #212529">License Agreement with Theramex</span></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: #212529">On
June 6, 2019, we entered into the Theramex License Agreement with Theramex to commercialize BIJUVA and IMVEXXY in the <span style="color: black">Theramex </span>Territory.
Under the terms of the Theramex License Agreement, Theramex paid us EUR <span id="xdx_90E_ecustom--CashUpfrontPaymentReceived_dm_uEUR_c20190804__20190805__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember_zhZ8Q0Jom5W">14
million</span>, or $<span id="xdx_904_ecustom--CashUpfrontPaymentReceived_uUSD_c20190803__20190805__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember_z1NgfBwzHIz7">15,506,400</span>,
in cash as an upfront fee on August 5, 2019. Within thirty days of signing the Theramex License Agreement, we provided
Theramex the regulatory materials and clinical data that were necessary for Theramex to obtain marketing authorizations and
other applicable regulatory approvals for commercializing BIJUVA and IMVEXXY. We recognized the revenue related to the
upfront fee, which was a non-refundable payment, during the third quarter of 2019, at a point in time when Theramex was able
to use and benefit from the license which was when the knowledge transfer of regulatory documents occurred. We are eligible
to receive additional milestone payments comprised of (i) up to an aggregate of EUR <span id="xdx_907_ecustom--RegulatoryMilestoneAdditionalPayment_iI_dm_uEUR_c20190606__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember__srt--RangeAxis__srt--MaximumMember_zebOAlMYfGdc">2
million</span> in regulatory milestone payments based on regulatory approvals for BIJUVA and IMVEXXY in certain specified
markets and (ii) up to an aggregate of EUR <span id="xdx_906_ecustom--SalesMilestonePaymentsInTranches_iI_dm_uEUR_c20190606__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember__srt--RangeAxis__srt--MaximumMember_zTkMgkY5IUa4">27.5
million</span> in sales milestone payments to be paid in escalating tranches based on Theramex first attaining certain
aggregate annual net sales milestones of BIJUVA and IMVEXXY in the <span style="color: black">Theramex </span>Territory
ranging from EUR <span id="xdx_90C_ecustom--AnnualNetSalesMilestone_dm_uEUR_c20190605__20190606__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember__srt--RangeAxis__srt--MinimumMember_z1X49D80mEN1" title="Sales milestone">25
million</span> to EUR <span id="xdx_909_ecustom--AnnualNetSalesMilestone_dm_uEUR_c20190605__20190606__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember__srt--RangeAxis__srt--MaximumMember_zfL5UAQPZVef">100
million</span>. We are also entitled to receive quarterly royalty payments at a rate of <span id="xdx_90D_ecustom--QuarterlyRoyaltyPaymentsPercentage_dp_c20190605__20190606__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember__srt--ProductOrServiceAxis__custom--BijuvaAndAnnoveraMember_zNWu2klcrb31" title="Quarterly royalty payments percentage">5</span>% on net sales of BIJUVA and
IMVEXXY in the <span style="color: black">Theramex </span>Territory. Theramex is responsible for all regulatory
and commercial activities for BIJUVA and IMVEXXY in the <span style="color: black">Theramex </span>Territory. Theramex
may sublicense its rights to commercialize BIJUVA and IMVEXXY in the <span style="color: black">Theramex </span>Territory,
except for certain specified markets. We may terminate the Theramex License Agreement if Theramex does not submit
all regulatory applications, submissions and/or registrations required for regulatory approval to use and commercialize
BIJUVA and IMVEXXY within certain specified time periods. We also may terminate the Theramex License Agreement if
Theramex challenges our patents. Either party may terminate the Theramex License Agreement for any material breach by the
other party that is not cured within certain specified time periods or if the other party files for bankruptcy or other
related matters. </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 36pt; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black"><i><span style="text-decoration: underline"><span style="color: black"><i>Disaggregation of revenue</i></span></span></i></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p id="xdx_890_eus-gaap--DisaggregationOfRevenueTableTextBlock_z8OEeqjDg4wl" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">The following table provides information about disaggregated revenue by product mix for the years ended December 31, 2019, 2018, and 2017:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="margin-right: auto; margin-left: auto; float: none; width: 80%">

<tr>
<td style="vertical-align: top; padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b/></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-right: Black medium none; border-left: Black medium none; padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b/></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-right: Black medium none; border-left: Black medium none; padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b/></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="10" style="border-bottom: black 1pt solid; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>For the Years
Ended December 31,</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-bottom: black 1pt solid; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2019</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-right: Black medium none; border-bottom: Black 1pt solid; border-left: Black medium none; padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2018</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-right: Black medium none; border-bottom: Black 1pt solid; border-left: Black medium none; padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2017</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; width: 55%; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt; text-align: justify; text-indent: 0pt">Prescription vitamins</p>
</td>
<td style="width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 12%">
<p id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_zTCn7GWquVDa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">9,885,493</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 12%">
<p id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180101__20181231__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_zeoacSq302Jd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">15,041,259</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 12%">
<p id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20170101__20171231__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_zFufrbuEnuIj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">16,744,831</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt; text-align: justify; text-indent: 0pt">IMVEXXY</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ProductOrServiceAxis__custom--ImvexxyMember_zYDRVsbMXUX2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">16,252,045</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180101__20181231__srt--ProductOrServiceAxis__custom--ImvexxyMember_z6BPbXQEuVA8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">1,058,201</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#8212;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt; text-align: justify; text-indent: 0pt">BIJUVA</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ProductOrServiceAxis__custom--BijuvaMember_zTDhU6TAWyd9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">1,836,443</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#8212;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#8212;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt; text-align: justify; text-indent: 0pt">ANNOVERA</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ProductOrServiceAxis__custom--AnnoveraMember_zNVeDXdoxc1h" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">6,166,556</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#8212;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#8212;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt; text-align: justify; text-indent: 0pt">License revenue</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ProductOrServiceAxis__us-gaap--LicenseAndServiceMember_zsZ6QSDNh8v1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">15,506,400</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#8212;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#8212;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt; text-align: justify; text-indent: 0pt">OTC products</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#8212;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#8212;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20170101__20171231__srt--ProductOrServiceAxis__custom--OtcProductsMember_zFoKtnjjbps5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">32,882</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 0pt 16px; text-indent: 0pt">Net revenue</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom">
<p id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231_ziaaFJ1sWOfe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Net revenue">49,646,937</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom">
<p id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180101__20181231_z38IF71YI67g" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">16,099,460</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom">
<p id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20170101__20171231_zq8rzdspFESg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">16,777,713</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
</table>
<p id="xdx_8A1_z2enxXr8rRi1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: black"><span style="text-decoration: underline"><span style="color: black">Shipping and Handling Costs</span></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">We expense all shipping and handling costs as incurred. We include these costs in cost of goods sold on the accompanying consolidated financial statements.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p id="xdx_84B_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zh34nsSoyXzj" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: black"><span style="text-decoration: underline"><span style="color: black">Segment Reporting</span></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">We are managed and operated as <span id="xdx_901_eus-gaap--NumberOfReportableSegments_dc_uPure_c20190101__20191231_zfTscoqBJ7ng" title="Number of operating segments">one</span> business, which is focused on creating and commercializing products targeted exclusively for women. Our business operations are managed by a single management team that reports to the President of our company. We do not operate separate lines of business with respect to any of our products and we do not prepare discrete financial information with respect to separate products. All product sales are derived from sales in the United States. Accordingly, we view our business as one reportable operating segment.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>



<p id="xdx_848_eus-gaap--CostOfSalesPolicyTextBlock_zBqUjo09XUGh" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: black"><span style="text-decoration: underline"><span style="color: black">Cost of Sales </span></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">Cost
of sales includes the cost of inventory, manufacturing, manufacturing overhead and supply chain costs, and product shipping
and handling costs. The Population Council License Agreement requires payment of royalties based on the sale of future
products. Such royalties are recorded as a component of cost of sales. Additionally, the amortization of license fees or
milestone payments related to licensed products are classified as components of cost of sales to the extent such payments
become due in the future.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p id="xdx_845_eus-gaap--AdvertisingCostsPolicyTextBlock_zwHL0Geta6pj" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="text-decoration: underline">Advertising Costs</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">We expense advertising costs when incurred. Advertising costs were $<span id="xdx_900_eus-gaap--AdvertisingExpense_c20190101__20191231_zPOagYG9VJZh" title="Advertising costs">9,045,571</span>, $<span id="xdx_90C_eus-gaap--AdvertisingExpense_c20180101__20181231_zaOsot7eExva">1,682,746</span> and $<span id="xdx_900_eus-gaap--AdvertisingExpense_c20170101__20171231_zWaOTgdOA1Jf">448,288</span> during the years ended December 31, 2019, 2018, and 2017, respectively.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p id="xdx_845_eus-gaap--ResearchAndDevelopmentExpensePolicy_zIzh16fKypj9" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="text-decoration: underline">Research and Development Expenses</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">Research and development, or R&amp;D, expenses include internal R&amp;D activities, services of external contract research organizations, or CROs, costs of their clinical research sites, manufacturing, scale-up and validation costs, and other activities. Internal R&amp;D activity expenses include laboratory supplies, salaries, benefits, and non-cash share-based compensation expenses. CRO activity expenses include preclinical laboratory experiments and clinical trial studies. Other activity expenses include regulatory consulting and other costs. The activities undertaken by our regulatory consultants that were classified as R&amp;D expenses include assisting, consulting with, and advising our in-house staff with respect to various FDA submission processes, clinical trial processes, and scientific writing matters, including preparing protocols and FDA submissions. These consulting expenses were direct costs associated with preparing, reviewing, and undertaking work for our clinical trials and investigative drugs. We charge internal R&amp;D activities and other activity expenses to operations as incurred. We make payments to CROs based on agreed-upon terms, which may include payments in advance of a study starting date. We expense nonrefundable advance payments for goods and services that will be used in future R&amp;D activities when the activity has been performed or when the goods have been received rather than when the payment is made. We review and accrue CRO expenses and clinical trial study expenses based on services performed and rely on estimates of those costs applicable to the completion stage of a study as provided by CROs. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. We charge revisions to expenses in the period in which the facts that give rise to the revision become known.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p id="xdx_841_eus-gaap--EarningsPerSharePolicyTextBlock_zai2UEwH7ehf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="text-decoration: underline">Earnings Per Share</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">We calculate earnings per share, or EPS, in accordance with ASC 260, <i><span style="color: black">Earnings Per Share</span></i>, which requires the computation and disclosure of two EPS amounts: basic and diluted. We compute basic EPS based on the weighted-average number of shares of common stock, par value $0.001 per share, or Common Stock, outstanding during the period. We compute diluted EPS based on the weighted-average number of shares of our Common Stock outstanding plus all potentially dilutive shares of our Common Stock outstanding during the period. Such potentially dilutive shares of our Common Stock consist of options, warrants and restricted stock awards and were excluded from the calculation of diluted earnings per share because their effect would have been anti-dilutive due to the net loss reported by us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">&#160;</span></p>

<p id="xdx_892_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zjMWR87JAaTl" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">The table below presents potentially dilutive securities that could affect our calculation of diluted net loss per share allocable to common stockholders for the periods presented.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="margin-right: auto; margin-left: auto; float: none; width: 80%">

<tr>
<td style="vertical-align: top; padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt"><b>&#160;</b></td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b/></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-right: Black medium none; border-left: Black medium none; padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b/></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-right: Black medium none; border-left: Black medium none; padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b/></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top"/>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="10" style="border-bottom: black 1pt solid; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>As of December
31,</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top"><b>&#160;</b></td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-bottom: black 1pt solid; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2019</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-right: Black medium none; border-bottom: Black 1pt solid; border-left: Black medium none; padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2018</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-right: Black medium none; border-bottom: Black 1pt solid; border-left: Black medium none; padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2017</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; width: 55%; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Stock options</p>
</td>
<td style="width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 12%">
<p id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zwwment6okci" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">25,030,234</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 12%">
<p id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z4Udu7FwKRBd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">20,872,824</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 12%">
<p id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20170101__20171231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zLOgdFIRfWz1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">23,365,225</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Warrants</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zn1G1tvZMjg2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">1,832,571</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20180101__20181231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zJuxJ8RNShMk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">3,007,571</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20170101__20171231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z1nPiuQRWDX3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">3,115,905</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Restricted stock awards</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zed2bsYYVwWh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">1,240,000</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zIyxoJjJmrO6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">1,040,000</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#8212;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top">&#160;</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom">
<p id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20190101__20191231_zD9Rt6prp5r" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">28,102,805</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom">
<p id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20180101__20181231_zP5dRly8IJff" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">24,920,395</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom">
<p id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20170101__20171231_zBwVIKCXZx59" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">26,481,130</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>

</table>
<p id="xdx_8A5_znRoDQXLLwAh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p id="xdx_840_eus-gaap--ConcentrationRiskCreditRisk_z3qPnllrsXji" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="text-decoration: underline">Concentration of Credit Risk and other Risks and Uncertainties</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">Financial instruments that potentially expose us to concentrations of credit risk consist primarily of cash and trade accounts receivable. Cash is on deposit with financial institutions in the United States and these deposits generally exceed the amount of insurance provided by the FDIC. We have not experienced any historical losses on our deposits of cash.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">Concentration of credit risk with respect to our trade accounts receivable from our customers is primarily limited to drug wholesalers and retail pharmacy distributors. Credit is extended to our customers based on an evaluation of a customer&#8217;s financial condition, and collateral is not required.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p id="xdx_84F_eus-gaap--UseOfEstimates_zsMyrC5LdsBg" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="text-decoration: underline">Use of Estimates</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">Our consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP. The preparation of these financial statements requires us to make significant estimates and judgments that affect the reported amounts of assets, liabilities, revenue, expenses, and related disclosure of contingent assets and liabilities. We evaluate our estimates, including those related to contingencies, on an ongoing basis. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ, at times in material amounts, from these estimates under different assumptions or conditions.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>



<p id="xdx_84B_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zjxi7fQvxgc2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="text-decoration: underline">Recently Issued Accounting Pronouncements</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="color: black">In August 2018, the FASB issued Accounting Standards Update, or ASU, 2018-13, which eliminates certain disclosure requirements for fair value measurements for all entities, requires public entities to disclose certain new information and modifies some disclosure requirements. The FASB developed the amendments to ASC 820 as part of its broader disclosure framework project, which aims to improve the effectiveness of disclosures in the notes to financial statements by focusing on requirements that clearly communicate the most important information to users of the financial statements. The new guidance is effective for all entities for fiscal years beginning after December 15, 2019 and for interim periods within those fiscal years. An entity is permitted to early adopt either the entire standard or only the provisions that eliminate or modify requirements. We do not expect that the adoption of this standard will have a material effect on our disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="color: black">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="color: black">In June 2018, the FASB issued ASU 2018-07 to simplify the accounting for share-based payments to non-employees by aligning it with the accounting for share-based payments to employees, with certain exceptions. The new guidance expands the scope of ASC 718 to include share-based payments granted to non-employees in exchange for goods or services used or consumed in an entity&#8217;s own operations and supersedes the guidance in ASC 505-50. The guidance is effective for public business entities in annual periods beginning after December 15, 2018, and interim periods within those annual periods. Early adoption is permitted, including in an interim period for which financial statements have not been issued, but not before an entity adopts ASC 606. We adopted this standard on January 1, 2019 and the adoption of this standard did not have a material effect on our consolidated financial statements. </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="color: black">In February 2016, the FASB issued ASU 2016-02, Leases. This guidance requires lessees to record most leases on their balance sheets while recognizing expenses on their income statements in a manner similar to current accounting. The guidance also eliminates current real estate-specific provisions for all entities. For lessors, the guidance modifies the classification criteria and the accounting for sales-type and direct financing leases. The standard was effective for public business entities for annual periods beginning after December 15, 2018, and interim periods within those years. In July 2018, the FASB amended the new leases standard and issued ASU 2018-11, Leases, (Topic 842): Targeted Improvements to give entities another option for transition and to provide lessors with a practical expedient. We adopted ASU 2016-02 on January 1, 2019 utilizing the alternative transition method allowed for under ASU 2018-11 and we recorded a $<span id="xdx_903_eus-gaap--OperatingLeaseRightOfUseAsset_iI_dm_c20190102__us-gaap--AdjustmentsForNewAccountingPronouncementsAxis__us-gaap--AccountingStandardsUpdate201602Member_zlV7DDjFbRp3" title="Right of use asset">3.8 million</span> right of use asset and a $<span id="xdx_903_eus-gaap--OperatingLeaseLiability_iI_dm_c20190102__us-gaap--AdjustmentsForNewAccountingPronouncementsAxis__us-gaap--AccountingStandardsUpdate201602Member_zthkuShkZZq9" title="Lease liability">4.1 million</span> liability related to adoption of this standard. In addition, upon commencement of additional leased space in the third quarter of 2019 (as disclosed in Note 13), we recorded an additional $<span id="xdx_903_eus-gaap--OperatingLeaseRightOfUseAsset_iI_dm_c20190831_zkKApmrsrDpd">7.4 million</span> right of use asset and an additional $<span id="xdx_90A_eus-gaap--OperatingLeaseLiability_iI_dm_c20190831_zd4NiSL1yiF4">7.2 million</span> liability related to our new leased space. Comparative financial information was not adjusted and will continue to be reported under ASC 840. We also elected the transition relief package of practical expedients and as a result we did not assess (1) whether existing or expired contracts contain leases, (2) lease classification for any existing or expired leases, and (3) whether lease origination costs qualified as initial direct costs. We elected the short-term lease practical expedient by establishing an accounting policy to exclude leases with a term of 12 months or less. We elected not to separate lease components from non-lease components for our specified asset classes. Additionally, the adoption of the new standard resulted in increased disclosure requirements in our quarterly and annual filings. </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants and the SEC did not, and are not expected to, have a material effect on our results of operations or financial position.</span></p>

<p id="xdx_850_zrLqpYk9J5Xh" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black"/></p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6808768624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="text"><p id="xdx_80C_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zr1lbX2Y9D4d" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b><span style="text-decoration: underline"><b>NOTE 9 &#8211; <span id="xdx_82E_zBXGNpIYmxl4">STOCKHOLDERS&#8217; EQUITY</span></b></span></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="text-decoration: underline">Preferred Stock</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">At December 31, 2019, we had <span id="xdx_905_eus-gaap--PreferredStockSharesAuthorized_iI_c20191231_zTOAgJVpXB2g">10,000,000</span> shares of Preferred Stock, par value $<span id="xdx_902_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20191231_zq0hLf08FHNg">0.001</span>, authorized for issuance, of which <span id="xdx_906_eus-gaap--PreferredStockSharesIssued_iI_do_c20191231_zHQwzEDAM63k"><span id="xdx_907_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20191231_zmy7r9Nyhwn1">no</span></span> shares of Preferred Stock were issued or outstanding.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="text-decoration: underline">Common Stock</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">At December 31, 2019, we had <span id="xdx_901_eus-gaap--CommonStockSharesAuthorized_iI_c20191231_zPs3uhMuk7Ij">350,000,000</span> shares of Common Stock authorized for issuance, of which <span id="xdx_908_eus-gaap--CommonStockSharesIssued_iI_c20191231_zTuOXU3PkOVg"><span id="xdx_90A_eus-gaap--CommonStockSharesOutstanding_iI_c20191231_zWdNBpqcNWx8">271,177,076</span></span> shares of&#160; Common Stock were issued and outstanding.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black"><i><span style="text-decoration: underline"><span style="color: black"><i>Issuances During 2019</i></span></span></i></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">On October 24, 2019, we entered into an underwriting agreement with J.P. Morgan Securities LLC, as representative of the underwriters, relating to an underwritten public offering of <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20191024__20191029__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementJPMorganChaseMember_zzhYHMosfdY1">26,000,000</span> shares of our Common Stock at a public offering price of $<span id="xdx_90A_eus-gaap--SharesIssuedPricePerShare_iI_c20191029__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementJPMorganChaseMember_zAjg4lFbLlf1">2.75</span> per share. We granted the underwriters an option, exercisable for a period of <span id="xdx_901_ecustom--PeriodExercisableUnderwritersOption_dt_c20191024__20191029__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementJPMorganChaseMember_zkPs2rK7it54" title="Period exercisable underwriters option">30 days</span>, to purchase up to <span id="xdx_904_ecustom--UnderwritersOptionGrantedInPeriodShares_c20191024__20191029__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementJPMorganChaseMember_zyOo1tRWgXP5" title="Underwriters option granted in period shares">3,900,000</span> additional shares of Common Stock, which was exercised in full. The net proceeds to us from the offering were approximately $<span id="xdx_907_ecustom--ProceedsFromIssuancePublicOffering_c20191024__20191029__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementJPMorganChaseMember_zSAbRt90BdY">77,031,000</span>, after deducting the underwriting discount and offering expenses payable by us. The offering closed on October 29, 2019. </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">During the year ended December 31, 2019, certain individuals exercised stock options to purchase an aggregate of <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zxMNGDGgvUGf">331,619</span> shares of Common Stock for $<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zMfvCCpwzZV9">108,656</span> in cash.&#160; Also, during the year ended December 31, 2019, stock options to purchase an aggregate of <span id="xdx_901_ecustom--NumberOfStockOptionsExercisedInCashlessExercise_c20190101__20191231_z7Ts4oYk1wC7" title="Number of stock options exercised in cashless exercise (in shares)">12,097</span> shares of Common Stock were exercised pursuant to the options&#8217; cashless exercise provisions, which resulted in <span id="xdx_90D_ecustom--NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares_c20190101__20191231_zjDIqaErDoVk" title="Number of common stock issued during period for stock options exercised in cashless exercise (in shares)">11,834</span> shares of Common Stock being issued.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black"><i><span style="text-decoration: underline"><span style="color: black"><i>Issuances During 2018</i></span></span></i></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">On August 1, 2018, we entered into an underwriting agreement with Goldman Sachs &amp; Co. LLC, as representative of the underwriters, relating to an underwritten public offering of <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20180801__20180806__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementGoldmanSachsMember_zDGtMyIi9AQd">12,745,098</span> shares of our Common Stock at a price of $<span id="xdx_909_eus-gaap--SharesIssuedPricePerShare_iI_c20180806__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementGoldmanSachsMember_zYGCWawnhbJd">5.10</span> per share. We granted the underwriters an option, exercisable for a period of <span id="xdx_906_ecustom--PeriodExercisableUnderwritersOption_dt_c20180801__20180806__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementGoldmanSachsMember_zVsKieBFw9di">30 days</span>, to purchase up to <span id="xdx_90E_ecustom--UnderwritersOptionGrantedInPeriodShares_c20180801__20180806__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementGoldmanSachsMember_zqVUpBiKm7Rf">1,911,764</span> additional shares of Common Stock. On August 2, 2018, the underwriters exercised the option in full. The net proceeds to us from the offering, including the exercise of the option to purchase additional shares, were approximately $<span id="xdx_90D_ecustom--ProceedsFromIssuancePublicOffering_c20180801__20180806__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementGoldmanSachsMember_zgBjkcLXYwjh">69,908,000</span>, after deducting the underwriting discount and offering expenses payable by us. The offering closed on August 6, 2018. In connection with the Knight License Agreement, on August 6, 2018, Knight entered into a subscription agreement with us, pursuant to which Knight purchased <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20180805__20180806__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementKnightMember_zNIGC8ShI0o7">3,921,568</span> of shares of our Common Stock concurrently with the closing of the underwritten public offering of Common Stock at a price of $<span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_c20180806__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementKnightMember_za7hGPU9otw1">5.10</span>, for proceeds to us of $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20180805__20180806__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementKnightMember_zRHfKZ7dNtr5">20,000,000</span>.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">During the year ended December 31, 2018, certain individuals exercised stock options to purchase an aggregate of <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zHiowcES30lj">5,444,526</span> shares of Common Stock for $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z36gE29D3pWf">1,666,208</span> in cash. Also, during the year ended December 31, 2018, stock options to purchase an aggregate of <span id="xdx_90C_ecustom--NumberOfStockOptionsExercisedInCashlessExercise_c20180101__20181231_zDVr4ebv9s65">10,000</span> shares of Common Stock were exercised pursuant to the options&#8217; cashless exercise provisions, wherein <span id="xdx_90C_ecustom--NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares_c20180101__20181231_zhbndHLPqPIk">9,841</span> shares of Common Stock were issued.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black"><i><span style="text-decoration: underline"><span style="color: black"><i>Issuances During 2017</i></span></span></i></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">On September 25, 2017, we entered into an underwriting agreement with J.P. Morgan Securities LLC relating to an underwritten public offering of <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20170924__20170925__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementJPMorganChaseMember_zl9ka8C4mkWg">12,400,000</span> shares of our Common Stock at a price of $<span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_c20170928__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementJPMorganChaseMember_z8vw2S1Nm17l">5.55</span> per share. The net proceeds to us from the offering were approximately $<span id="xdx_909_ecustom--ProceedsFromIssuancePublicOffering_c20170926__20170928__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementJPMorganChaseMember_z9zXHJcsmL3e">68,573,000</span>, after deducting estimated offering expenses payable by us. The offering closed on September 28, 2017 and we issued <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20170926__20170928__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementJPMorganChaseMember_zstftbLH5yVi">12,400,000</span> shares of Common Stock.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">During the year ended December 31, 2017, certain individuals exercised stock options to purchase an aggregate of <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20170101__20171231_zVXD8ygZBgl7">102,546</span> shares of Common Stock for $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_c20170101__20171231_zHUJqh1806O2">212,615</span> in cash.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="text-decoration: underline">Warrants to Purchase Common Stock</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">As of December 31, 2019, we had warrants outstanding to purchase an aggregate of <span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstanding_iI_c20191231_zprfMzJQxKz5">1,832,571</span> shares of Common Stock with a weighted-average contractual remaining life of approximately <span id="xdx_90B_ecustom--WarrantsAndRightsWeightedAverageContractualRemainingLife_dtY_c20190101__20191231_zIkIuyjKCTgk" title="Weighted-average contractual remaining life">1.95</span> years, and exercise prices ranging from $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20191231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__srt--RangeAxis__srt--MinimumMember_zhCByUX9fQF7">0.24</span> to $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20191231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__srt--RangeAxis__srt--MaximumMember_z22OGQ9JMSV">8.20</span> per share, resulting in a weighted average exercise price of $<span id="xdx_902_ecustom--WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice_iI_c20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zPwuUL5vRlt7" title="Weighted average exercise price of warrants (in dollars per share)">2.62</span> per share.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">The valuation methodology used to determine the fair value of our warrants is the Black-Scholes Model. The Black-Scholes Model requires the use of a number of assumptions, including volatility of the stock price, the risk-free interest rate, dividend yield and the term of the warrant. During the year ended December 31, 2019, we granted warrants to purchase an aggregate of <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_ziSNle1y4PYe" title="Warrants granted">75,000</span> shares of Common Stock to outside consultants which vest ratably over a <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtM_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zyKQ8jRcazDd" title="Warrants vesting period">12</span>-month period and have an expiration date of <span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20191231__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zSvqSCMF2X54" title="Warrants expiration date">February 13, 2024</span>. During the year ended December 31, 2018, we granted warrants to purchase an aggregate of <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20180101__20181231__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_z0HEhH7p5PG8">175,000</span> shares of Common Stock to outside consultants which vest ratably over a <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtM_c20180101__20181231__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zBb69z51ovd1">12</span>-month period and have an expiration date of <span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20181231__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zMvAlTL440fh">March 15, 2023</span>. During the year ended December 31, 2017, we granted warrants to purchase an aggregate of <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20170101__20171231__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zg7KzW5gyPkk">125,000</span> shares of Common Stock to outside consultants which vest ratably over a <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtM_c20170101__20171231__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zNLaO6dpnahg">12</span>-month period and have an expiration date of <span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20171231__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zvVlHAs2Dvpj">March 15, 2022</span>.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">We recorded share-based compensation expense related to warrants previously issued of $<span id="xdx_90E_eus-gaap--ShareBasedCompensation_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zi8eIr5qpsQ6">254,970</span>, $<span id="xdx_90D_eus-gaap--ShareBasedCompensation_c20180101__20181231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_z83PpEbF6tGg">494,136</span>, and $<span id="xdx_905_eus-gaap--ShareBasedCompensation_c20170101__20171231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zbXY56uq74e5">313,271</span> for the years ended December 31, 2019, 2018 and 2017, respectively, in the accompanying consolidated financial statements. At December 31, 2019, total unrecognized estimated compensation expense related to unvested warrants was approximately $<span id="xdx_909_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20191231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zh1okmWOz9y6">26,446</span> which is expected to be recognized over weighted-average period of <span id="xdx_903_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zDGx8e3Shs69">0.1</span> years.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p id="xdx_89E_ecustom--ScheduleOfWarrantRollForwardTableTextBlock_zOwm3dSdLZ89" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><i>Summary of our Warrant activity during the year ended December 31, 2019:</i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; width: 100%">

<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Number of Shares
Under Warrants</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; width: 13%; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Weighted Average
Exercise Price</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; width: 13%; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Weighted Average
Remaining Contractual Life in Years</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; width: 13%; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Aggregate Intrinsic
Value</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; width: 40%; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Balance at December 31, 2018</p>
</td>
<td style="width: 3%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 10%">
<p id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zzsiNoEzQ4Jk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Number of shares under warrants outstanding beginning">3,007,571</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 3%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 10%">
<p id="xdx_984_ecustom--WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice_iS_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z5INwx1jqVf5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Weighted average exercise price warrants outstanding beginning">2.78</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 3%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 10%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20180101__20181231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zxjwyr8ZK2H1" title="Weighted average remaining contractual life, warrants outstanding">1.58</span></p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 3%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 10%">
<p id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iS_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z0MUPG1iCvga" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Aggregate intrinsic value, warrants outstanding beginning">4,826,403</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 16px">Granted</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zdeXaontc7rh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Number of shares under warrants granted">75,000</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_987_ecustom--WarrantsGrantedOtherThanOptionsWeightedAverageExercisePrice_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z5RsyebWvcFl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Weighted average exercise price warrants granted">5.63</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 16px">Exercised</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zmBuFPFCyj0j" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Number of shares under warrants exercised">(1,250,000</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_984_ecustom--WarrantsExercisedOtherThanOptionsWeightedAverageExercisePrice_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zbvjQGVArDqj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Weighted average exercise price warrants exercised">3.20</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z5B44HXAAYx4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Aggregate intrinsic value, warrants exercised">2,420,000</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 16px">Expired</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#8212;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#8212;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#8212;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 16px">Cancelled/Forfeited</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#8212;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#8212;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#8212;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Balance at December 31, 2019</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 2pt double; vertical-align: bottom">
<p id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zHJWqHZEIubc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Number of shares under warrants outstanding ending">1,832,571</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_98D_ecustom--WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice_iE_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zodK7rurjHp1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Weighted average exercise price warrants outstanding ending">2.62</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zebKN0rLMd8k">1.95</span></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iE_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z6mE2IQurG9l" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Aggregate intrinsic value, warrants outstanding ending">2,447,929</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Vested and Exercisable at December 31, 2019</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zPmH3SiLrHOg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Number of shares under warrants vested and exercisable ending">1,820,071</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_986_ecustom--WarrantsOutstandingVestedAndExercisable_iE_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zSPukOwepEHb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Weighted average exercise price warrants vested and exercisable ending">2.60</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExercisableWeightedAverageRemainingContractualTerms_dtY_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z1B6TVrIP1s6" title="Weighted average remaining contractual life, vested and exercisable ending">1.90</span></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue_iE_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zXaS840m905d" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Aggregate intrinsic value, vested and exercisable ending">2,447,929</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Unvested at December 31, 2019</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zSGOyx4fGjaa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Number of shares under warrants unvested ending">12,500</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_98C_ecustom--WarrantsUnvestedWeightedAverageExercisePrice_iE_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zB54OIysC6p" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Weighted average exercise price warrants unvested ending">5.63</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms_dtY_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zBJ5gIVdV1C2" title="Weighted average remaining contractual life, warrants unvested ending">9.13</span></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#8212;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>

</table>
<p id="xdx_8AE_zd4TbJcoRQbj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p id="xdx_890_ecustom--ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock_zZ8D5rUScNI1" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">The weighted average fair value per share of warrants issued and the assumptions used in the Black-Scholes Model during the years ended December 31, 2019, 2018, and 2017 are set forth in the table below.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="margin-right: auto; margin-left: auto; float: none; width: 80%">

<tr>
<td style="padding: 0pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" id="xdx_496_20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zG5JtLMRyJz3" style="border-bottom: black 1pt solid; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2019</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" id="xdx_496_20180101__20181231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zxQ5G1Vw01fk" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2018</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" id="xdx_49C_20170101__20171231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zyNqzjHzKqhc" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2017</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr id="xdx_405_ecustom--WeightedAverageExercisePriceOtherThanOptions_zuNoq8ji79a8" style="background-color: #cceeff">
<td style="padding: 0pt; width: 55%; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Weighted average exercise price</p>
</td>
<td style="width: 3%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 10%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">5.63</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 3%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 10%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">5.16</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 3%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 10%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">6.83</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_40A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_zP3RmzYosxR3">
<td style="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Weighted average grant date fair value</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">3.00</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">2.79</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">3.67</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_409_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_za8qxKPEG6y3" style="background-color: #cceeff">
<td style="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Risk-free interest rate</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">2.52</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">%</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">2.36</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">%</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">1.47</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">%</p>
</td>
</tr>
<tr id="xdx_404_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_zYjoJ5E78zph">
<td style="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Volatility</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">60.8</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">%</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">62.12</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">%</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">63.24</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">%</p>
</td>
</tr>
<tr style="background-color: #cceeff">
<td style="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Term (in years)</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zftNEFwHtlHk" title="Term">5</span></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20180101__20181231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zunPuguZCAy5">5</span></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20170101__20171231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zMZ3YxBRyp91">5</span></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_406_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_zoarFoj8iWm9">
<td style="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Dividend yield</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">0.00</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">%</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">0.00</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">%</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">0.00</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">%</p>
</td>
</tr>

</table>
<p id="xdx_8A2_zF5PmUHoAiBa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black"><i><span style="text-decoration: underline"><span style="color: black"><i>Warrant exercises</i></span></span></i></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">During the year ended December 31, 2019, warrants to purchase an aggregate of <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zYwnH775sK0j" title="Warrants exercised">1,250,000</span> shares of Common Stock were exercised pursuant to the warrants&#8217; cashless exercise provisions, which resulted in <span id="xdx_90F_ecustom--NumberOfStockIssuedInCashlessExerciseOfWarrants_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsCashlessExerciseMember_zcLcDd2VOyBf" title="Number of stock issued in cashless exercise of warrants">471,184</span> shares of Common Stock being issued. During the year ended December 31, 2018, <span id="xdx_90F_ecustom--NumberOfStockIssuedInCashlessExerciseOfWarrants_do_c20180101__20181231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zus9aF77sbfd">no</span> warrants were exercised.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">During the year ended December 31, 2017, certain individuals exercised warrants to purchase an aggregate of <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20170101__20171231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zAKZFvqTBQMd">2,476,666</span> shares of Common Stock for $<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueOther_c20170101__20171231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zWNlfkzO8DL1" title="Shares issued for exercise of warrants, net">3,798,999</span> in cash. In addition, during the year ended December 31, 2017, certain individuals exercised warrants to purchase an aggregate of <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20170101__20171231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsCashlessExerciseMember_zPTJ96mXW0se">6,590,000</span> shares of Common Stock pursuant to the warrants&#8217; cashless exercise provisions, which resulted in <span id="xdx_900_ecustom--NumberOfStockIssuedInCashlessExerciseOfWarrants_c20170101__20171231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsCashlessExerciseMember_z2jrqc8PYIUl">4,762,208</span> shares of Common Stock being issued.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: black"><span style="text-decoration: underline"><span style="color: black">Options to Purchase Common Stock of the Company</span></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">In 2009, we adopted the 2009 Long Term Incentive Compensation Plan, or the 2009 Plan, to provide financial incentives to employees, directors, advisers, and consultants of our company who are able to contribute towards the creation of or who have created stockholder value by providing them stock options and other stock and cash incentives, or the Awards. As of December 31, 2019, there were non-qualified stock options to purchase an aggregate of <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20191231__us-gaap--PlanNameAxis__custom--LongTermIncentiveCompensationPlan2009Member_zA9WJyJtOZnf">15,017,759</span> shares of Common Stock outstanding under the 2009 Plan. Effective upon our adoption of the TherapeuticsMD, Inc. 2019 Stock Incentive Plan, or the 2019 Plan, on June 20, 2019, no future awards may be made under the 2009 Plan. </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">In 2012, we adopted the 2012 Stock Incentive Plan, or the 2012 Plan, a non-qualified plan that was amended in August 2013. The 2012 Plan was designed to serve as an incentive for retaining qualified and competent key employees, officers, directors, and certain consultants and advisors of our company. As of December 31, 2019, there were non-qualified stock options to purchase an aggregate of <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20191231__us-gaap--PlanNameAxis__custom--NonQualified2012StockIncentivePlanMember_zdi2FH3pvyx6">6,316,474</span> shares of Common Stock outstanding and an aggregate of <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20191231__us-gaap--PlanNameAxis__custom--NonQualified2012StockIncentivePlanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zjwuaexHuYlb">1,040,000</span> restricted stock awards under the 2012 Plan. Effective upon our adoption of the 2019 Plan, no future awards may be made under the 2012 Plan. </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">On June 20, 2019, we adopted the 2019 Plan to serve as an incentive for retaining qualified and competent key employees, officers, directors, and certain consultants and advisors of our company. The Awards available under the 2019 Plan consist of stock options, stock appreciation rights, restricted stock, restricted stock units, performance stock, performance units, and other stock or cash awards as described in the 2019 Plan. Generally, the options vest annually over four years or as determined by our board of directors, upon each option grant. Options may be exercised by paying the price for shares or on a cashless exercise basis after they have vested and prior to the specified expiration date provided and applicable exercise conditions are met, if any. The expiration date is generally ten years from the date the option is issued. </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">As of December 31, 2019, there were <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20191231__us-gaap--PlanNameAxis__custom--Plan2019Member_z3hKaGDLkKI">13,599,382</span> shares of Common Stock available for issuance under the 2019 Plan, consisting of (i) <span id="xdx_90E_ecustom--PlanAwardsNumberOfNewShares_iI_c20191231__us-gaap--PlanNameAxis__custom--Plan2019Member_zTQ3oZu0sPsf" title="Plan awards number of new shares">11,103,999</span> new shares, (ii) <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20191231__us-gaap--PlanNameAxis__custom--NonQualified2012StockIncentivePlanMember_z91vULZqs2He">2,395,333</span> unallocated shares previously available for issuance under the 2012 Plan that were not then subject to outstanding &#8220;Awards&#8221; (as defined in the 2012 Plan), and (iii) <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20191231__us-gaap--PlanNameAxis__custom--LongTermIncentiveCompensationPlan2009Member_zr71Tt1aKAD">100,050</span> unallocated shares previously available for issuance under the 2009 Plan that were not then subject to outstanding &#8220;Awards&#8221; (as defined in the 2009 Plan). Any shares subject to outstanding options or other equity &#8220;Awards&#8221; under the 2019 Plan, the 2012 Plan and the 2009 Plan that are forfeited, expire or otherwise terminate without issuance of the underlying shares, or if any such Award is settled for cash or otherwise does not result in the issuance of all or a portion of the shares subject to such Award (other than shares tendered or withheld in connection with the exercise of an Award or the satisfaction of withholding tax liabilities), the shares to which those Awards were subject, shall, to the extent of such forfeiture, expiration, termination, cash settlement or non-issuance, again be available for delivery with respect to Awards under the 2019 Plan. As of December 31, 2019, there were non-qualified stock options to purchase <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20191231__us-gaap--PlanNameAxis__custom--Plan2019Member_zPNlniOuGUG7">3,696,001</span> shares of Common Stock outstanding under the 2019 Plan and <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20191231__us-gaap--PlanNameAxis__custom--Plan2019Member__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zKf9prgmmQbc">200,000</span> restricted stock awards outstanding under the 2019 Plan.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">The valuation methodology used to determine the fair value of stock options is the Black-Scholes Model. The Black-Scholes Model requires the use of a number of assumptions including volatility of the stock price, the risk-free interest rate, and the expected life of the stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">&#160;</span></p>

<p id="xdx_895_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zCEi1KljRvq9" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">The ranges of assumptions used in the Black-Scholes Model during the years ended December 31, 2019, 2018, and 2017 are set forth in the table below.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="margin-right: auto; margin-left: auto; float: none; width: 90%">

<tr>
<td style="padding: 0pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" id="xdx_49C_20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zjKyY1ZaOy42" style="border-bottom: black 1pt solid; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2019</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" id="xdx_497_20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z58HCy3xTEeg" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2018</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" id="xdx_49C_20170101__20171231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zqVe4ECcgasl" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2017</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr style="background-color: #cceeff">
<td style="padding: 0pt; width: 55%; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Weighted average exercise price</p>
</td>
<td style="width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 12%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zgkqeDYPMqIg" title="Weighted average exercise price">3.10</span></p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 12%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zFo2BcoH7fjj">5.45</span></p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 12%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20171231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zbG85QwG2Ocb">6.60</span></p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_402_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_zc1CMM4er3qi">
<td style="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Weighted average grant date fair value</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">1.82</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">3.24</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">3.82</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: #cceeff">
<td style="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Risk-free interest rate</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_dp_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z72SaZuA7mYf" title="Risk-free interest rate - minimum">1.64</span>-<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_dp_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zMBIDOEQmA3g" title="Risk-free interest rate - maximum">2.54</span></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">%</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_dp_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zWMdjkfx1yJ5">2.38</span>-<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_dp_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zber2qjmMZ7h">2.89</span></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">%</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_dp_c20170101__20171231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zQKM7FnmrT82">1.84</span>-<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_dp_c20170101__20171231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zPWhETmvYVph">2.05</span></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">%</p>
</td>
</tr>
<tr>
<td style="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Volatility</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_dp_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zvNe48pIuEr3" title="Volatility - minimum">61.25</span>-<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_dp_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zPSoEKeatYTa" title="Volatility - maximum">64.49</span></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">%</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_dp_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zgeecMMVU1w">59.45</span>-<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_dp_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zTEHa0V1Z9Of">64.04</span></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">%</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_dp_c20170101__20171231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zWtayHZ5UV75">61.56</span>-<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_dp_c20170101__20171231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zoMIKAINnb18">64.25</span></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">%</p>
</td>
</tr>
<tr style="background-color: #cceeff">
<td style="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Term (in years)</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zqaof0desl1f" title="Term">5.5</span>-<span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zZGWEqvOCNH2">6.5</span></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_z9Gj3SsGjeLf">5.1</span>-<span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_z3js9QZdKgci">6.25</span></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20170101__20171231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_z0KPl6IbB7Mk">5.5</span>-<span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20170101__20171231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zewgrtLkYuD5">6.25</span></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_403_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_zzaNpbW6kdKi">
<td style="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Dividend yield</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">0.00</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">%</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">0.00</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">%</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">0.00</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">%</p>
</td>
</tr>

</table>
<p id="xdx_8A1_zfVnekqikrOe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zqkCBu3wAa76" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">A summary of activity under the 2009, 2012 and 2019 Plans and related information during the year ended December 31, 2019 is as follows:</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; width: 100%">

<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Number of Shares
Under Options</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; width: 13%; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Weighted Average
Exercise Price</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; width: 13%; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Weighted Average
Remaining Contractual Life in Years</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; width: 13%; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Aggregate Intrinsic
Value</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; width: 40%; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Balance at December 31, 2018</p>
</td>
<td style="width: 3%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 10%">
<p id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z1WbCCkctj24" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Number of shares under options, beginning">20,872,824</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 3%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 10%">
<p id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zbL3OIGB26O6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Weighted average exercise price, beginning">4.93</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 3%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 10%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zEKbZ2w6uHi1" title="Weighted average remaining contractual life">5.94</span></p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 3%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 10%">
<p id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zzIu12iiUYNh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Aggregate intrinsic value, beginning">12,239,876</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 16px">Granted</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z14SZQE1hUE2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Number of shares under options, granted">4,620,501</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z3iADKoLUTN3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Weighted average exercise price, granted">3.10</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 16px">Exercised</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zvxmSZSdljxe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Number of shares under options, exercised">(343,716</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zs2Pw0YxQ17i" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Weighted average exercise price, exercised">0.32</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zNKbPT57DNg1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Aggregate intrinsic value, exercised">1,426,828</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 16px">Expired</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z3ZQUPGssbIb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Number of shares under options, expired">(26,375</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zqBowh4gmwK2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Weighted average exercise price, expired">5.57</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 16px">Cancelled/Forfeited</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zo67pKgkpwuf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Number of shares under options, cancelled forfeited">(93,000</p>
</td>
<td style="padding-bottom: 1pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_znaQMmEOcu31" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Weighted average exercise price, cancelled forfeited">5.16</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Balance at December 31, 2019</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 2pt double; vertical-align: bottom">
<p id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zT5qwoFAhF85" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Number of shares under options, ending">25,030,234</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zrkPEZKJ1B2k" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Weighted average exercise price, ending">4.65</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zwnfeDj2mMFa">5.84</span></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zEN2HI5oFGGd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Aggregate intrinsic value, ending">3,668,171</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Vested and Exercisable at December 31, 2019</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zXjGY5zRJRXg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Number of shares under options, vested and exercisable ending">18,025,819</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zf7B2nc4VWn7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Weighted average exercise price, vested and exercisable ending">4.88</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zGU2IlSsl7Pb" title="Weighted average remaining contractual life, vested and exercisable">4.62</span></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zstAPNlwDEl3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Aggregate intrinsic value, vested and exercisable ending">3,319,621</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Unvested at December 31, 2019</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zhRoTf6JPxce" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Number of shares under options, unvested ending">7,004,415</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_iE_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z0meePN4hQb4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Weighted average exercise price, unvested ending">4.05</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms_dtY_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zO4CzDUTSACc" title="Weighted average remaining contractual life, unvested">8.96</span></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue_iE_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zKiil2Vlg8Bk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Aggregate intrinsic value, unvested ending">348,550</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>

</table>
<p id="xdx_8A9_zHz2fz1qH2h3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">At December 31, 2019, our outstanding options had exercise prices ranging from $<span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice_iI_c20191231__srt--RangeAxis__srt--MinimumMember_zjJKNZmujqd8" title="Range - exercise price of options">0.19</span> to $<span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice_iI_c20191231__srt--RangeAxis__srt--MaximumMember_zFiacbDPeo4">8.92</span> per share. Share-based compensation expense related to options recognized in our results of operations for the years ended December 31, 2019, 2018, and 2017 was approximately $<span id="xdx_909_eus-gaap--AllocatedShareBasedCompensationExpense_c20190101__20191231_zuudtJB3bdZc">8,798,707</span>, $<span id="xdx_902_eus-gaap--AllocatedShareBasedCompensationExpense_c20180101__20181231_zDGum8ymDev8">8,091,294</span>, and $<span id="xdx_908_eus-gaap--AllocatedShareBasedCompensationExpense_c20170101__20171231_zGiej39Pfm6">6,447,154</span>, respectively, and it is based on awards vested. At December 31, 2019, total unrecognized estimated compensation expense related to unvested options was approximately $<span id="xdx_906_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_c20191231_z2Ux47Ts9Ou6">11,460,000</span>, which may be adjusted for future changes in forfeitures. This cost is expected to be recognized over a weighted-average period of <span id="xdx_904_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zlAyk1aeJjwg">2.4</span> years. No tax benefit was realized due to a continued pattern of operating losses.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: black"><span style="text-decoration: underline"><span style="color: black">Restricted Stock</span></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">Restricted stock awards granted under our 2009, 2012 and 2019 Plans entitle the holder to receive, at the end of vesting period, a specified number of shares of our Common Stock. Share-based compensation expense is measured by the market value of our Common Stock on the day of the grant. The shares vest ratably over the period specified in the grant. There is no partial vesting and any unvested portion is forfeited.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: #212529">On
December 13, 2018, we granted an aggregate of <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20181212__20181213__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zgyqMYPzPxZ8">1,040,000</span>
restricted stock units to certain executive employees which will vest at the end of the third year. The grant date fair
value was $<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20181212__20181213__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zk4XlYgflu0j">4.06</span>
per unit. At December 31, 2019, <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zJKhH2kS0VNa">150,000</span>
of those restricted stock units vested due to an employment termination.&#160; On July 30, 2019, we granted an aggregate of <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20190729__20190730__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zUL9Y3i4m4w7">200,000</span>
restricted stock units to certain executive employees which will vest on January 31, 2022. The grant date fair value
was $<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20190729__20190730__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zpo5CUmdIRlk">2.18</span>
per unit. During the year ended December 31, 2019 and 2018, we recorded $<span id="xdx_90F_eus-gaap--RestrictedStockExpense_c20190101__20191231_zymqTdrvGDi9">1,628,407</span>
and $<span id="xdx_901_eus-gaap--RestrictedStockExpense_c20180101__20181231_z3CUBmKVNeYc">73,132</span>, respectively,
in share-based compensation expense related to restricted stock units. At December 31, 2019, total unrecognized
estimated compensation expense related to unvested restricted stock units was approximately $<span id="xdx_903_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_iI_c20191231_zKm9R7UpC4d5">2,711,000</span>,
which may be adjusted for future changes in forfeitures. This cost is expected to be recognized over a
weighted-average period of <span id="xdx_909_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zHYC7rxV3Vnj">2.0</span>
years. At December 31, 2019, we had <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zBExi3hHJUia">1,240,000</span>
restricted stock awards outstanding.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: black"><span style="text-decoration: underline"><span style="color: black">Cash-Settled Stock Appreciation Rights (SARs)</span></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">On July 1, 2018, we issued cash-settled SARs to certain consultants and employees. The SARs plan year began on July 1, 2018 and ended on or immediately following June 30, 2019. SARs were granted with a grant price equal to the market value of a share of our Common Stock on the date of grant. Cash-settled SARs provided for the cash payment of the excess of the fair market value of our Common Stock on June 30, 2019 over the grant price. Cash-settled SARs have no effect on dilutive shares or shares outstanding as any appreciation of our Common Stock over the grant price is paid in cash and not in Common Stock. </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">Cash
settled SARs were recorded in our consolidated balance sheets as a liability until the date of exercise. The fair value of each
SAR award was estimated using the Black-Scholes valuation model. In accordance with ASC Topic 718, <i>Stock Compensation</i>,
the fair value of each SAR award was recalculated at the end of each reporting period and the liability and expense adjusted based
on the new fair value and the percent vested. At June 30, 2019, the fair market value of our Common Stock was lower than the grant
price of the SARs and, as a result, the recorded liability was reversed and no cash payment was made.</span></p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6808827632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FIXED ASSETS, NET<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">FIXED ASSETS, NET</a></td>
<td class="text"><p id="xdx_802_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zgpcaKalwq28" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b><span style="text-decoration: underline"><b>NOTE 5 &#8211; <span id="xdx_82C_zBqY9axhRcNa">FIXED ASSETS, NET</span></b></span></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p id="xdx_89B_eus-gaap--PropertyPlantAndEquipmentTextBlock_zkVVpSXENsMa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Fixed assets, net consist of the following:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="margin-right: auto; margin-left: auto; float: none; width: 70%">

<tr>
<td style="vertical-align: top; padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" id="xdx_49F_20191231_zo6Y5dD1EH68" style="vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b/></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" id="xdx_49F_20181231_z6v1oWzlTnve" style="border-right: Black medium none; border-left: Black medium none; padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b/></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="6" style="border-bottom: black 1pt solid; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>December 31,</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-bottom: black 1pt solid; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2019</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-right: Black medium none; border-bottom: Black 1pt solid; border-left: Black medium none; padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2018</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; width: 64%; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Accounting system</p>
</td>
<td style="width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 15%">
<p id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_z32a40lMwwJi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">301,096</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 15%">
<p id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20181231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_zpnLXAPVVO9f" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">301,096</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Equipment</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zeGpIGjrLzE4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">1,619,646</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20181231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zKDf4Ta867He" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">490,576</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Furniture and fixtures</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_98B_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_ziLZ4fHvEgv6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">1,406,858</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20181231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zLgqLDpc7EO8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">116,542</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Computer hardware</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_982_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_z5rCbLMkY4i2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">80,211</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_989_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20181231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zz9tXHiawG8b" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">80,211</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Leasehold improvements</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zsAmJrFQWzC9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">68,788</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20181231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zaf7Hky3Dwz6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">37,888</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_402_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzht4_zdZloV6xL9N7">
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">TOTAL FIXED ASSETS</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">3,476,599</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">1,026,313</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_403_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzht4_zHboRH6WJLq6" style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Accumulated depreciation</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(968,824</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(553,630</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
</tr>
<tr id="xdx_409_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzht4_z5pGWjrUNNpb">
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">TOTAL FIXED ASSETS, NET</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">2,507,775</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">472,683</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>

</table>
<p id="xdx_8A0_zytXFyuyQPDb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Depreciation expense for the years ended December 31, 2019, 2018, and 2017 was $<span id="xdx_90A_eus-gaap--Depreciation_c20190101__20191231_zyVSxuNunUb3" title="Depreciation expense">415,193</span>, $<span id="xdx_902_eus-gaap--Depreciation_c20180101__20181231_zft8t8kpKb9j">181,412</span>, and $<span id="xdx_909_eus-gaap--Depreciation_c20170101__20171231_zfY4ZFLq3AL1">141,601</span>, respectively.</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.19.3.a.u2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>246</ContextCount>
  <ElementCount>447</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>100</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="txmd-10k_123119.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="txmd-10k_123119.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="txmd-10k_123119.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="txmd-10k_123119.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="txmd-10k_123119.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="txmd-10k_123119.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="txmd-10k_123119.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Disclosure - THE COMPANY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Company</Role>
      <ShortName>THE COMPANY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="txmd-10k_123119.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="txmd-10k_123119.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - INVENTORY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Inventory</Role>
      <ShortName>INVENTORY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="txmd-10k_123119.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - OTHER CURRENT ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/OtherCurrentAssets</Role>
      <ShortName>OTHER CURRENT ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="txmd-10k_123119.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - FIXED ASSETS, NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/FixedAssetsNet</Role>
      <ShortName>FIXED ASSETS, NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="txmd-10k_123119.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - INTANGIBLE ASSETS, NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/IntangibleAssetsNet</Role>
      <ShortName>INTANGIBLE ASSETS, NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="txmd-10k_123119.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - OTHER CURRENT LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/OtherCurrentLiabilities</Role>
      <ShortName>OTHER CURRENT LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="txmd-10k_123119.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - DEBT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Debt</Role>
      <ShortName>DEBT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="txmd-10k_123119.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - STOCKHOLDERS??? EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/StockholdersEquity</Role>
      <ShortName>STOCKHOLDERS??? EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="txmd-10k_123119.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/IncomeTaxes</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="txmd-10k_123119.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - RELATED PARTIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/RelatedParties</Role>
      <ShortName>RELATED PARTIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="txmd-10k_123119.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - BUSINESS CONCENTRATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/BusinessConcentrations</Role>
      <ShortName>BUSINESS CONCENTRATIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="txmd-10k_123119.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/CommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="txmd-10k_123119.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/SelectedQuarterlyFinancialData</Role>
      <ShortName>SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="txmd-10k_123119.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/SubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="txmd-10k_123119.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="txmd-10k_123119.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="txmd-10k_123119.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - INVENTORY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/InventoryTables</Role>
      <ShortName>INVENTORY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/Inventory</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="txmd-10k_123119.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - OTHER CURRENT ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/OtherCurrentAssetsTables</Role>
      <ShortName>OTHER CURRENT ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/OtherCurrentAssets</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="txmd-10k_123119.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - FIXED ASSETS, NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/FixedAssetsNetTables</Role>
      <ShortName>FIXED ASSETS, NET (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/FixedAssetsNet</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="txmd-10k_123119.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - INTANGIBLE ASSETS, NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/IntangibleAssetsNetTables</Role>
      <ShortName>INTANGIBLE ASSETS, NET (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/IntangibleAssetsNet</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="txmd-10k_123119.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - OTHER CURRENT LIABILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/OtherCurrentLiabilitiesTables</Role>
      <ShortName>OTHER CURRENT LIABILITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/OtherCurrentLiabilities</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="txmd-10k_123119.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - DEBT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/DebtTables</Role>
      <ShortName>DEBT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/Debt</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="txmd-10k_123119.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - STOCKHOLDERS??? EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/StockholdersEquityTables</Role>
      <ShortName>STOCKHOLDERS??? EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/StockholdersEquity</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="txmd-10k_123119.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/IncomeTaxesTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/IncomeTaxes</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="txmd-10k_123119.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="txmd-10k_123119.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/SelectedQuarterlyFinancialDataTables</Role>
      <ShortName>SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/SelectedQuarterlyFinancialData</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="txmd-10k_123119.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - THE COMPANY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/CompanyDetailsNarrative</Role>
      <ShortName>THE COMPANY (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/Company</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="txmd-10k_123119.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - The following table provides information about disaggregated revenue by product mix for the years ended December 31, 2019, 2018, and 2017: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueByProductMixForYearsEndedDecember3120192018And2017Details</Role>
      <ShortName>The following table provides information about disaggregated revenue by product mix for the years ended December 31, 2019, 2018, and 2017: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="txmd-10k_123119.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - The table below presents potentially dilutive securities that could affect our calculation of diluted net loss per share allocable to common stockholders for the periods presented. (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/TableBelowPresentsPotentiallyDilutiveSecuritiesThatCouldAffectOurCalculationOfDilutedNetLossPerShareAllocableToCommonStockholdersForPeriodsPresented.Details</Role>
      <ShortName>The table below presents potentially dilutive securities that could affect our calculation of diluted net loss per share allocable to common stockholders for the periods presented. (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="txmd-10k_123119.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="txmd-10k_123119.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>00000038 - Disclosure - Inventory consists of the following: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/InventoryConsistsOfFollowingDetails</Role>
      <ShortName>Inventory consists of the following: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="txmd-10k_123119.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>00000039 - Disclosure - Other current assets consist of the following: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails</Role>
      <ShortName>Other current assets consist of the following: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="txmd-10k_123119.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>00000040 - Disclosure - Fixed assets, net consist of the following: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails</Role>
      <ShortName>Fixed assets, net consist of the following: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="txmd-10k_123119.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>00000041 - Disclosure - FIXED ASSETS, NET (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/FixedAssetsNetDetailsNarrative</Role>
      <ShortName>FIXED ASSETS, NET (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/FixedAssetsNetTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="txmd-10k_123119.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>00000042 - Disclosure - The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of December 31, 2019 and 2018: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfDecember312019And2018Details</Role>
      <ShortName>The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of December 31, 2019 and 2018: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="txmd-10k_123119.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>00000043 - Disclosure - Estimated amortization expense, based on current patent cost being amortized, for the next five years is as follows: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/EstimatedAmortizationExpenseBasedOnCurrentPatentCostBeingAmortizedForNextFiveYearsIsAsFollowsDetails</Role>
      <ShortName>Estimated amortization expense, based on current patent cost being amortized, for the next five years is as follows: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="txmd-10k_123119.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>00000044 - Disclosure - INTANGIBLE ASSETS, NET (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative</Role>
      <ShortName>INTANGIBLE ASSETS, NET (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/IntangibleAssetsNetTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="txmd-10k_123119.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>00000045 - Disclosure - Other current liabilities consist of the following: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails</Role>
      <ShortName>Other current liabilities consist of the following: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="txmd-10k_123119.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>00000046 - Disclosure - As of December 31, 2019 and 2018, the carrying value of our debt consisted of the following: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/AsOfDecember312019And2018CarryingValueOfOurDebtConsistedOfFollowingDetails</Role>
      <ShortName>As of December 31, 2019 and 2018, the carrying value of our debt consisted of the following: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="txmd-10k_123119.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>00000047 - Disclosure - DEBT (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/DebtDetailsNarrative</Role>
      <ShortName>DEBT (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/DebtTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="txmd-10k_123119.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>00000048 - Disclosure - Summary of our Warrant activity during the year ended December 31, 2019: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/SummaryOfOurWarrantActivityDuringYearEndedDecember312019Details</Role>
      <ShortName>Summary of our Warrant activity during the year ended December 31, 2019: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="txmd-10k_123119.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>00000049 - Disclosure - The weighted average fair value per share of warrants issued and the assumptions used in the Black-Scholes Model during the years ended December 31, 2019, 2018, and 2017 are set forth in the table below. (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/WeightedAverageFairValuePerShareOfWarrantsIssuedAndAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120192018And2017AreSetForthInTableBelow.Details</Role>
      <ShortName>The weighted average fair value per share of warrants issued and the assumptions used in the Black-Scholes Model during the years ended December 31, 2019, 2018, and 2017 are set forth in the table below. (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="txmd-10k_123119.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>00000050 - Disclosure - The ranges of assumptions used in the Black-Scholes Model during the years ended December 31, 2019, 2018, and 2017 are set forth in the table below. (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/RangesOfAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120192018And2017AreSetForthInTableBelow.Details</Role>
      <ShortName>The ranges of assumptions used in the Black-Scholes Model during the years ended December 31, 2019, 2018, and 2017 are set forth in the table below. (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="txmd-10k_123119.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>00000051 - Disclosure - A summary of activity under the 2009, 2012 and 2019 Plans and related information during the year ended December 31, 2019 is as follows: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringYearEndedDecember312019IsAsFollowsDetails</Role>
      <ShortName>A summary of activity under the 2009, 2012 and 2019 Plans and related information during the year ended December 31, 2019 is as follows: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="txmd-10k_123119.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>00000052 - Disclosure - STOCKHOLDERS??? EQUITY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative</Role>
      <ShortName>STOCKHOLDERS??? EQUITY (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/StockholdersEquityTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="txmd-10k_123119.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>00000053 - Disclosure - For financial reporting purposes, income before taxes includes the following components: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/ForFinancialReportingPurposesIncomeBeforeTaxesIncludesFollowingComponentsDetails</Role>
      <ShortName>For financial reporting purposes, income before taxes includes the following components: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="txmd-10k_123119.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>00000054 - Disclosure - A reconciliation between taxes computed at the federal statutory rate and the consolidated effective tax rate is as follows: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/ReconciliationBetweenTaxesComputedAtFederalStatutoryRateAndConsolidatedEffectiveTaxRateIsAsFollowsDetails</Role>
      <ShortName>A reconciliation between taxes computed at the federal statutory rate and the consolidated effective tax rate is as follows: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="txmd-10k_123119.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>00000055 - Disclosure - The components of the net deferred income tax asset as of December 31, 2019, 2018, and 2017 are as follows: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/ComponentsOfNetDeferredIncomeTaxAssetAsOfDecember3120192018And2017AreAsFollowsDetails</Role>
      <ShortName>The components of the net deferred income tax asset as of December 31, 2019, 2018, and 2017 are as follows: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="txmd-10k_123119.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>00000056 - Disclosure - INCOME TAXES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/IncomeTaxesDetailsNarrative</Role>
      <ShortName>INCOME TAXES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/IncomeTaxesTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="txmd-10k_123119.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>00000057 - Disclosure - RELATED PARTIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative</Role>
      <ShortName>RELATED PARTIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/RelatedParties</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="txmd-10k_123119.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>00000058 - Disclosure - BUSINESS CONCENTRATIONS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative</Role>
      <ShortName>BUSINESS CONCENTRATIONS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/BusinessConcentrations</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="txmd-10k_123119.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>00000059 - Disclosure - Supplemental lease information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/SupplementalLeaseInformationDetails</Role>
      <ShortName>Supplemental lease information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="txmd-10k_123119.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>00000060 - Disclosure - The following table reconciles the undiscounted cash flows for all operating leases at December 31, 2019 to the operating lease liabilities recorded on the balance sheet: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtDecember312019ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails</Role>
      <ShortName>The following table reconciles the undiscounted cash flows for all operating leases at December 31, 2019 to the operating lease liabilities recorded on the balance sheet: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="txmd-10k_123119.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>00000061 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="txmd-10k_123119.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>00000062 - Disclosure - Summarized quarterly financial data for fiscal years 2019 and 2018 is as follows: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/SummarizedQuarterlyFinancialDataForFiscalYears2019And2018IsAsFollowsDetails</Role>
      <ShortName>Summarized quarterly financial data for fiscal years 2019 and 2018 is as follows: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="txmd-10k_123119.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>00000063 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>SUBSEQUENT EVENTS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/SubsequentEvents</ParentRole>
      <Position>63</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="txmd-10k_123119.htm">txmd-10k_123119.htm</File>
    <File>ex10-18.htm</File>
    <File>ex21-1.htm</File>
    <File>ex23-1.htm</File>
    <File>ex31-1.htm</File>
    <File>ex31-2.htm</File>
    <File>ex32-1.htm</File>
    <File>ex32-2.htm</File>
    <File>ex4-2.htm</File>
    <File>txmd-20191231.xsd</File>
    <File>txmd-20191231_cal.xml</File>
    <File>txmd-20191231_def.xml</File>
    <File>txmd-20191231_lab.xml</File>
    <File>txmd-20191231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>txmd10k001.jpg</File>
    <File>txmd10k002.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6798341136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zhJAHfjpgEEi" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><b><span style="text-decoration: underline"><span style="color: black"><b>NOTE 13 &#8211; <span id="xdx_82A_zcIGsXKuPa46">COMMITMENTS AND CONTINGENCIES</span></b></span></span></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: black"><span style="text-decoration: underline"><span style="color: black">Operating Leases</span></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: #212529">We adopted ASC 842 effective January 1, 2019. Substantially all our operating lease right-of-use assets and operating lease liabilities represent leases for office space used to conduct our business. Upon adoption, we recognized a right-of-use asset and a lease liability for all leases that have commenced as of January 1, 2019. The right-of-use assets represent the right to use the leased asset for the lease term. The lease liabilities represent the present value of the lease payments under the lease. The right-of-use asset is initially measured at cost, which primarily comprises the initial amount of the lease liability, plus any initial direct costs incurred, less any lease incentives received. All right-of-use assets are reviewed for impairment. The lease liability is initially measured at the present value of the lease payments, discounted using our secured incremental borrowing rate for the same term as the underlying lease because the rates are not implicit in the leases. Some of our leases contain variable lease payments, including payments based on an index or rate. Variable lease payments based on an index or rate are initially measured using the index or rate in effect at lease commencement. Additional payments based on the change in an index or rate, or payments based on a change in our portion of the operating expenses are recorded as a period expense when incurred. Lease modifications result in remeasurement of the lease liability. Included in lease expense are any variable lease payments incurred in the period that were not included in the initial lease liability.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: #212529">We lease administrative office space in Boca Raton, Florida pursuant to a non-cancelable operating lease that commenced on July 1, 2013 and originally provided for a <span id="xdx_90E_ecustom--CapitalLeaseObligationsTerm_dtM_c20130630__20130701_zdVg4IsOI4U9" title="Non-cancelable operating lease term">63</span>-month term. On February 18, 2015, we entered into an agreement with the same lessors to lease additional administrative office space in the same location, pursuant to an addendum to such lease. In addition, on April 26, 2016, we entered into an agreement with the same lessors to lease additional administrative office space in the same location. This agreement was effective beginning May 1, 2016 and extended the original expiration of the lease term to October 31, 2021. On October 4, 2016, we entered into an agreement with the same lessors to lease additional administrative office space in the same location, pursuant to an addendum to such lease. This addendum became effective beginning November 1, 2016.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: #212529">In October 2018, we entered into a lease for new corporate offices in Boca Raton, Florida. The lease includes <span id="xdx_90F_ecustom--NetRentableAreaLease_iI_usqft_c20181002_zNtE8ApWI0tg" title="Net rentable area">56,212</span> rentable square feet, or the full premises, of which the lease on <span id="xdx_90C_ecustom--RentedAreaLease_iI_usqft_c20181002_zAHNPk4lOrF2" title="Rented area lease">7,561</span> square feet commenced in 2018 and the lease on the remaining <span id="xdx_907_ecustom--AdditionalAreaOfLeaseOccupied_iI_usqft_c20190801_zKJzAhT76tnj" title="Additional area of lease occupied">48,651</span> square feet commenced in August 2019, or the full premises commencement date. The lease will expire <span id="xdx_902_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dt_c20190801_zCw6gyvl9XJ5">11 years</span> after the full premises commencement date, unless terminated earlier in accordance with the terms of the lease. We have the option to extend the term of the lease for <span id="xdx_908_ecustom--LesseeFinanceLeaseExistenceOfOptionToExtendNumber_dc_uPure_c20190101__20191231_zfGD4K7SGNJg" title="Number of options to extend lease">two</span> additional consecutive periods of <span id="xdx_907_eus-gaap--LesseeFinanceLeaseRenewalTerm1_iI_dt_c20191231_z1H6WTPH41m4" title="Lease renewal term">five years</span>. The extension option is not included in the determination of the lease term as it is not reasonably certain to be exercised. The term of the lease includes escalating rent and free rent periods. We are also responsible for certain other operating costs under the lease, including electricity and utility expenses. In June 2019, we entered into an agreement with the same lessors to lease additional <span id="xdx_905_ecustom--LesseeOperatingLeaseLeaseNotYetCommencedArea_iI_usqft_c20190601_zVHqmxRLq306" title="Lease not yet commenced (area)">6,536</span> square feet of administrative office space in the same location, pursuant to an addendum to such lease, which is expected to commence as soon as the first quarter of 2020.</span></p>
<p id="xdx_897_ecustom--ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock_z48rBQgEI9Lj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="margin-right: auto; margin-left: auto; float: none; width: 80%">

<tr>
<td style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><span id="xdx_8BC_zTCvqPmJs8xf">Supplemental lease information</span> at December 31, 2019</b></p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td colspan="2" style="vertical-align: top">&#160;</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; width: 85%; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Right-of-use asset</p>
</td>
<td style="width: 1%">
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 12%">
<p id="xdx_984_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20191231_z8a7pYazUhbk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Right-of-use asset">10,109,154</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Short-term operating lease liability (included in Other current liabilities)</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_985_eus-gaap--OperatingLeaseLiabilityCurrent_iI_c20191231_zERKcgVqrAr9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Short-term operating lease liability (included in Other current liabilities)">1,501,539</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Long-term operating lease liability</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_98D_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_c20191231_zjW5hGBbmrn3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Long-term operating lease liability">9,145,049</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Weighted average remaining term</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_987_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dt_c20191231_zbwYMEXG2Mhg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Weighted average remaining term">9 Years</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Weighted average discount rate</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_987_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20191231_zSn2Lds4H9O3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Weighted average discount rate">8.25</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">%</p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="margin-right: auto; margin-left: auto; float: none; width: 80%">

<tr>
<td style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Supplemental cash flow information for the year ended</b><br/>
<b>December 31, 2019</b></p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td colspan="2" style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; width: 85%; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Cash paid for amounts included in the measurement of lease liabilities for operating lease</p>
</td>
<td style="width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 12%">
<p id="xdx_989_eus-gaap--OperatingLeasePayments_c20190101__20191231_zSvPYRerMxW8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Cash paid for amounts included in the measurement of lease liabilities for operating lease"><span style="font-size: 10pt">1,164,234</span></p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Right-of-use assets obtained in exchange for lease obligation</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_982_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_c20190101__20191231_z7S1xqMVFat6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Right-of-use assets obtained in exchange for lease obligation">11,171,471</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>

</table>
<p id="xdx_8AE_zl1S0NCrW1T1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>


<p id="xdx_895_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_z2GX5VLIpZ6e" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: #212529">The following table reconciles the undiscounted cash flows for all operating leases at December 31, 2019 to the operating lease liabilities recorded on the balance sheet:</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="margin-right: auto; margin-left: auto; float: none; width: 50%">

<tr>
<td style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>Years Ending December
31,</b></p>
</td>
<td><p style="margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" id="xdx_49A_20191231_zoZfKDWyM5Ni" style="vertical-align: top"><b>&#160;</b></td>
<td style="vertical-align: bottom"><p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPznhG_zCShR9Y0XsZ5" style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; width: 77%; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">2020</p>
</td>
<td style="width: 1%">
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 20%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">1,566,617</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPznhG_zpb6wZo9RsZ5">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">2021</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">2,198,541</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPznhG_zjgMVTsisXS9" style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">2022</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">1,262,302</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPznhG_zVUB6N03Ccyh">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">2023</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">1,293,859</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_maLOLLPznhG_zNj4npP2OcX6" style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">2024</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">1,326,206</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_maLOLLPznhG_zMsI9KHAuEv1">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Thereafter</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">8,036,931</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPznhG_zXKl3OVd0UV1" style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Total undiscounted lease payments</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">15,684,456</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zWmQOGk1qPQk">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Less: imputed interest</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(5,037,868</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
</tr>
<tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iI_zRqM9FEjWdl4" style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Present value of lease payments</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">10,646,588</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>

</table>
<p id="xdx_8AE_zEmzow5b22Q7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: #212529; background-color: white">During the year ended December 31, 2019, operating lease expense related to our real estate leases was $<span id="xdx_900_eus-gaap--OperatingLeaseExpense_c20190101__20191231_z4qcml6WorJ4" title="Operating lease expense">1,558,794</span><span style="background-color: white">, and variable lease expense was insignificant.&#160; </span><span style="color: black">The rental expense during the years ended December 31, 2018 and 2017 was $<span id="xdx_901_eus-gaap--LeaseAndRentalExpense_c20180101__20181231_zs2WHRxallCe" title="Rental expense">1,068,275</span> and $<span id="xdx_90B_eus-gaap--LeaseAndRentalExpense_c20170101__20171231_zL5faYMzAg6d">1,029,205</span>, respectively.</span></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: black"><span style="text-decoration: underline"><span style="color: black">Intellectual Property Licenses</span></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">The Population Council License Agreement provides for future milestone payments to be paid by us for access to certain technologies. In addition, we pay royalties as a percent of revenue as described in Note 6, Intangible Assets, to these consolidated financial statements.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: black"><span style="text-decoration: underline"><span style="color: black">Purchase Commitments</span></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: #212529; background-color: white">We
have manufacturing and supply agreements whereby we are required to purchase from Catalent a minimum number of
softgels during the first contract year and a higher number of softgels after the first contract year. If the minimum order
quantities of specific products are not met, we are required to pay Catalent <span id="xdx_90B_ecustom--SignificantSupplyCommitmentPercentagePayable_iI_dp_c20191231_zPWjHoUUPya8" title="Significant supply commitment percentage payable">50</span>%
of the difference between the total amount we would have paid to Catalent if the minimum requirement had been fulfilled
and the sum of all purchases of our products from Catalent during the contract year. Minimum purchase commitments for
Catalent for the next five years are as follows: 2020 &#8211; $<span id="xdx_906_eus-gaap--RecordedUnconditionalPurchaseObligationDueWithinOneYear_iI_c20191231__us-gaap--RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis__custom--CatalentMember_zShCViTpvU7d" title="Minimum purchase commitment, 2020">5,650,853</span>;
2021 &#8211; $<span id="xdx_904_eus-gaap--RecordedUnconditionalPurchaseObligationDueInSecondYear_iI_c20191231__us-gaap--RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis__custom--CatalentMember_z6U7SNDCL1Cj" title="Minimum purchase commitment, 2021">4,000,035</span>;
2022 &#8211; $<span id="xdx_900_eus-gaap--RecordedUnconditionalPurchaseObligationDueInThirdYear_iI_c20191231__us-gaap--RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis__custom--CatalentMember_zdAVDHPZdg33" title="Minimum purchase commitment, 2022">5,643,291</span>;
2023 &#8211; $<span id="xdx_90D_eus-gaap--RecordedUnconditionalPurchaseObligationDueInFourthYear_iI_c20191231__us-gaap--RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis__custom--CatalentMember_zAXPQP8fqCDh" title="Minimum purchase commitment, 2023">6,445,301</span>
and 2024 &#8211; $<span id="xdx_90D_eus-gaap--RecordedUnconditionalPurchaseObligationDueInFifthYear_iI_c20191231__us-gaap--RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis__custom--CatalentMember_zZAH1Pv4dl41" title="Minimum purchase commitment, 2024">6,758,945</span>.
In addition, we have a manufacturing and supply agreement whereby we are required to purchase a minimum number of units of
ANNOVERA during a contract year. The minimum purchase commitment for ANNOVERA for 2020 is approximately $<span id="xdx_904_eus-gaap--RecordedUnconditionalPurchaseObligationDueWithinOneYear_iI_c20191231__us-gaap--RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis__custom--AnnoveraMember_zmcDDsZ0PtD5">1,049,750</span>.
As of December 31, 2019, we have met our minimum purchase commitments with our manufacturers related to fiscal
year 2019.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: #212529; background-color: white">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"/>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: black"><span style="text-decoration: underline"><span style="color: black">Legal Proceedings</span></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">From time to time, we are involved in litigation and proceedings in the ordinary course of business. We are not currently involved in any legal proceeding that we believe would have a material effect on our consolidated financial condition, results of operations, or cash flows.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: black"><span style="text-decoration: underline"><span style="color: black">Off-Balance Sheet Arrangements</span></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">As of December 31, 2019, 2018, and 2017, we had no off-balance sheet arrangements that have had or are reasonably likely to have current or future effects on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: black"><span style="text-decoration: underline"><span style="color: black">Employment Agreements</span></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">We have entered into employment agreements with certain of our executives that provide for compensation and certain other benefits. Under certain circumstances, including a change in control, some of these agreements provide for severance or other payments, if those circumstances occur during the term of the employment agreement.</span></p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6808771712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS, NET (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ScheduleOfIntangibleAssetsTableTextBlock', window );">The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of December 31, 2019 and 2018:</a></td>
<td class="text"><p id="xdx_89E_ecustom--ScheduleOfIntangibleAssetsTableTextBlock_zSsNxgQCmCKk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of December 31, 2019 and 2018:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; width: 100%">

<tr>
<td style="padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top">&#160;</td>
<td>&#160;</td>
<td style="border-top-style: none; border-right-style: none; border-left-style: none; vertical-align: top">&#160;</td>
<td style="border-top-style: none; border-right-style: none; border-left-style: none; vertical-align: top">&#160;</td>
<td style="border-top-style: none; border-right-style: none; border-left-style: none; vertical-align: top">&#160;</td>
<td style="border-top-style: none; border-right-style: none; border-left-style: none; vertical-align: top">&#160;</td>
<td style="border-top-style: none; border-right-style: none; border-left-style: none; vertical-align: top">&#160;</td>
<td style="border-top-style: none; border-right-style: none; border-left-style: none; vertical-align: top">&#160;</td>
<td style="border-top-style: none; border-right-style: none; border-left-style: none; vertical-align: top">&#160;</td>
<td style="border-top-style: none; border-right-style: none; border-left-style: none; vertical-align: top">&#160;</td>
<td style="border-top-style: none; border-right-style: none; border-left-style: none; vertical-align: top">&#160;</td>
<td style="border-top-style: none; border-right-style: none; border-left-style: none; vertical-align: top">&#160;</td>
<td style="border-top-style: none; border-right-style: none; border-left-style: none; vertical-align: top">&#160;</td>
<td style="border-top-style: none; border-right-style: none; border-left-style: none; vertical-align: top">&#160;</td>
<td style="border-top-style: none; border-right-style: none; border-left-style: none; vertical-align: top">&#160;</td>
<td style="border-top-style: none; border-right-style: none; border-left-style: none; vertical-align: top">&#160;</td>
<td style="vertical-align: bottom; width: 1%">&#160;</td></tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top"/>
<td><p style="margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="14" style="border-bottom: black 1pt none; border-top-style: none; border-right-style: none; border-left-style: none; border-bottom-style: solid; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>December 31,
2019</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; width: 40%; vertical-align: top"><b>&#160;</b></td>
<td><p style="margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-bottom: black 1pt solid; text-align: center; width: 10%; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Gross Carrying
Amount</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td style="width: 1%; width: 1%"><p style="margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-bottom: black 1pt solid; text-align: center; width: 10%; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Accumulated Amortization</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td style="width: 1%; width: 1%"><p style="margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-bottom: black 1pt solid; text-align: center; width: 10%; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Net<br/>Amount</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td style="width: 1%; width: 1%"><p style="margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-bottom: black 1pt solid; text-align: center; width: 10%; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Weighted-<br/>Average<br/>Remaining
Amortization<br/>Period (yrs.)</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; width: 40%; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Amortizable intangible assets:</p>
</td>
<td style="width: 3%">
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 10%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 3%">
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 10%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 3%">
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 10%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 3%">
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 10%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: rgb(204,238,255)">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Approved hormone</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: rgb(204,238,255)">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.15in; margin-top: 0pt; margin-bottom: 0pt">therapy drug</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: rgb(204,238,255)">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.15in; margin-top: 0pt; margin-bottom: 0pt">candidate patents</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zZ45m8aW3pgf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">3,463,082</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zvgJ9pOvKXK1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(478,983</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zrPdY8Onobyb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">2,984,099</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_dtY_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_z2oQJxvGOrE">13</span></p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: White">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Hormone therapy drug</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.15in; margin-top: 0pt; margin-bottom: 0pt">candidate patents</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: White">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.15in; margin-top: 0pt; margin-bottom: 0pt">(pending)</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20191231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_zGbZuhcyXZ41" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">1,979,299</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#8212;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20191231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_zw6A1cByWgMe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">1,979,299</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">n/a</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: rgb(204,238,255)">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Non-amortizable intangible</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: rgb(204,238,255)">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.15in; margin-top: 0pt; margin-bottom: 0pt">assets:</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: White">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Multiple trademarks</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_984_eus-gaap--IndefiniteLivedTrademarks_iI_c20191231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksForVitaminsSupplementsMember_znQmUqz0u694" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">294,813</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#8212;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_98A_eus-gaap--IndefiniteLivedIntangibleAssetsExcludingGoodwill_iI_c20191231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksForVitaminsSupplementsMember_zocGRvUhihv6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">294,813</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">indefinite</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: rgb(204,238,255)">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">TOTAL</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom">
<p id="xdx_984_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_c20191231_zrPXHNejo0C2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">5,737,194</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom">
<p id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_c20191231_zIYygBuIkRkd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(478,983</p>
</td>
<td style="padding-bottom: 2pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom">
<p id="xdx_98D_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20191231_zUtdcezNgmUh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">5,258,211</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; width: 100%">

<tr>
<td style="padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top">&#160;</td>
<td>&#160;</td>
<td style="border-top-style: none; border-right-style: none; border-left-style: none; border-image: initial; vertical-align: top">&#160;</td>
<td style="border-top-style: none; border-right-style: none; border-left-style: none; border-image: initial; vertical-align: top">&#160;</td>
<td style="border-top-style: none; border-right-style: none; border-left-style: none; border-image: initial; vertical-align: top">&#160;</td>
<td style="border-top-style: none; border-right-style: none; border-left-style: none; border-image: initial; vertical-align: top">&#160;</td>
<td style="border-top-style: none; border-right-style: none; border-left-style: none; border-image: initial; vertical-align: top">&#160;</td>
<td style="border-top-style: none; border-right-style: none; border-left-style: none; border-image: initial; vertical-align: top">&#160;</td>
<td style="border-top-style: none; border-right-style: none; border-left-style: none; border-image: initial; vertical-align: top">&#160;</td>
<td style="border-top-style: none; border-right-style: none; border-left-style: none; border-image: initial; vertical-align: top">&#160;</td>
<td style="border-top-style: none; border-right-style: none; border-left-style: none; border-image: initial; vertical-align: top">&#160;</td>
<td style="border-top-style: none; border-right-style: none; border-left-style: none; border-image: initial; vertical-align: top">&#160;</td>
<td style="border-top-style: none; border-right-style: none; border-left-style: none; border-image: initial; vertical-align: top">&#160;</td>
<td style="border-top-style: none; border-right-style: none; border-left-style: none; border-image: initial; vertical-align: top">&#160;</td>
<td style="border-top-style: none; border-right-style: none; border-left-style: none; border-image: initial; vertical-align: top">&#160;</td>
<td style="border-top-style: none; border-right-style: none; border-left-style: none; border-image: initial; vertical-align: top">&#160;</td>
<td style="vertical-align: bottom; width: 1%">&#160;</td></tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top"/>
<td><p style="margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="14" style="border-bottom: black 1pt solid; border-top-style: none; border-right-style: none; border-left-style: none; border-image: initial; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>December 31,
2018</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; text-align: center; vertical-align: top"><b>&#160;</b></td>
<td><p style="margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-bottom: black 1pt solid; text-align: center; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Gross Carrying
Amount</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td style="width: 1%; width: 1%"><p style="margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-bottom: black 1pt solid; text-align: center; width: 10%; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Accumulated Amortization</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td style="width: 1%; width: 1%"><p style="margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-bottom: black 1pt solid; text-align: center; width: 10%; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Net<br/>Amount</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td style="width: 1%; width: 1%"><p style="margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-bottom: black 1pt solid; text-align: center; width: 10%; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Weighted- Average<br/>Remaining
Amortization Period (yrs.)</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; width: 40%; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Amortizable intangible assets:</p>
</td>
<td style="width: 3%">
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 10%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 3%">
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 10%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 3%">
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 10%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 3%">
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 10%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">OPERA software patent</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--ComputerSoftwareIntangibleAssetMember_zuH4Ob72Oyq2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">31,951</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_c20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--ComputerSoftwareIntangibleAssetMember_zLmvoUYIi4ub" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(10,484</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--ComputerSoftwareIntangibleAssetMember_zaOasLYxHcb9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">21,467</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_dtY_c20180101__20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--ComputerSoftwareIntangibleAssetMember_zB2Ja4HDIBf8">10.75</span></p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Development costs of</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.15in; margin-top: 0pt; margin-bottom: 0pt">corporate website</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InternetDomainNamesMember_zSYk6Y2UUw96" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">91,743</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_c20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InternetDomainNamesMember_zHtL9OMHqBJ1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(91,743</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#8212;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">n/a</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: rgb(204,238,255)">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Approved hormone</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: rgb(204,238,255)">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.15in; margin-top: 0pt; margin-bottom: 0pt">therapy drug</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: rgb(204,238,255)">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.15in; margin-top: 0pt; margin-bottom: 0pt">candidate patents</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zO6DdncI1wfe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">2,234,129</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_c20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zawuCBN6mu5l" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(282,485</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zDHtmBT3FTW7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">1,951,644</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_dtY_c20180101__20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_z9dfucABmOri">14</span></p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: White">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Hormone therapy drug</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.15in; margin-top: 0pt; margin-bottom: 0pt">candidate patents</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: White">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.15in; margin-top: 0pt; margin-bottom: 0pt">(pending)</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20181231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_zhWshXYSDvVh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">1,855,279</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#8212;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20181231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_zUuP8vFYS5Fl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">1,855,279</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">n/a</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: rgb(204,238,255)">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Non-amortizable intangible</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: rgb(204,238,255)">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.15in; margin-top: 0pt; margin-bottom: 0pt">assets:</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: White">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Multiple trademarks</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_988_eus-gaap--IndefiniteLivedTrademarks_iI_c20181231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksForVitaminsSupplementsMember_zyYy112mUFnl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">264,289</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#8212;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_988_eus-gaap--IndefiniteLivedIntangibleAssetsExcludingGoodwill_iI_c20181231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksForVitaminsSupplementsMember_zvLuDgt0SQh7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">264,289</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">indefinite</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: rgb(204,238,255)">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">TOTAL</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom">
<p id="xdx_982_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_c20181231_z7iwKFoMeZTl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">4,477,391</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom">
<p id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_c20181231_zPbzzNlfWeZ2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(384,712</p>
</td>
<td style="padding-bottom: 2pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom">
<p id="xdx_984_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20181231_zNnLUsOkkZ89" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">4,092,679</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>

</table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Estimated amortization expense, based on current patent cost being amortized, for the next five years is as follows:</a></td>
<td class="text"><p id="xdx_897_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zrznKYBF3tWd" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="background-color: white">Estimated amortization expense, based on current patent cost being amortized, for the next five years is as follows:</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="margin-right: auto; margin-left: auto; float: none; width: 40%">

<tr>
<td style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; width: 49%; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Year Ending<br/>December
31,</b></p>
</td>
<td style="padding: 0pt 5.4pt; width: 2%; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td id="xdx_49E_20191231_zsxdHn6Z4B7k" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; vertical-align: top; width: 49%"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Estimated<br/>Amortization</b></p>
</td>
</tr>
<tr id="xdx_400_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_z5zAjuA6YVph" style="background-color: rgb(204,238,255)">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">2020</p>
</td>
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">$229,546</p>
</td>
</tr>
<tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_zggNowtaQ5kb" style="background-color: White">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">2021</p>
</td>
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">$229,546</p>
</td>
</tr>
<tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_zUDpMMLkGDl7" style="background-color: rgb(204,238,255)">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">2022</p>
</td>
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">$229,546</p>
</td>
</tr>
<tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_zlthq9FvAC15" style="background-color: White">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">2023</p>
</td>
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">$229,546</p>
</td>
</tr>
<tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_ztTQzfSmEsS7" style="background-color: rgb(204,238,255)">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">2024</p>
</td>
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">$229,546</p>
</td>
</tr>
<tr style="background-color: White">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>

</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ScheduleOfIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of intangible assets, which may be broken down by major class.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ScheduleOfIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6814262064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">The following table provides information about disaggregated revenue by product mix for the years ended December 31, 2019, 2018, and 2017:</a></td>
<td class="text"><p id="xdx_890_eus-gaap--DisaggregationOfRevenueTableTextBlock_z8OEeqjDg4wl" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">The following table provides information about disaggregated revenue by product mix for the years ended December 31, 2019, 2018, and 2017:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="margin-right: auto; margin-left: auto; float: none; width: 80%">

<tr>
<td style="vertical-align: top; padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b/></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-right: Black medium none; border-left: Black medium none; padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b/></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-right: Black medium none; border-left: Black medium none; padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b/></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="10" style="border-bottom: black 1pt solid; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>For the Years
Ended December 31,</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-bottom: black 1pt solid; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2019</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-right: Black medium none; border-bottom: Black 1pt solid; border-left: Black medium none; padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2018</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-right: Black medium none; border-bottom: Black 1pt solid; border-left: Black medium none; padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2017</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; width: 55%; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt; text-align: justify; text-indent: 0pt">Prescription vitamins</p>
</td>
<td style="width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 12%">
<p id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_zTCn7GWquVDa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">9,885,493</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 12%">
<p id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180101__20181231__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_zeoacSq302Jd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">15,041,259</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 12%">
<p id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20170101__20171231__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_zFufrbuEnuIj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">16,744,831</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt; text-align: justify; text-indent: 0pt">IMVEXXY</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ProductOrServiceAxis__custom--ImvexxyMember_zYDRVsbMXUX2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">16,252,045</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180101__20181231__srt--ProductOrServiceAxis__custom--ImvexxyMember_z6BPbXQEuVA8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">1,058,201</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#8212;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt; text-align: justify; text-indent: 0pt">BIJUVA</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ProductOrServiceAxis__custom--BijuvaMember_zTDhU6TAWyd9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">1,836,443</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#8212;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#8212;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt; text-align: justify; text-indent: 0pt">ANNOVERA</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ProductOrServiceAxis__custom--AnnoveraMember_zNVeDXdoxc1h" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">6,166,556</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#8212;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#8212;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt; text-align: justify; text-indent: 0pt">License revenue</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ProductOrServiceAxis__us-gaap--LicenseAndServiceMember_zsZ6QSDNh8v1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">15,506,400</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#8212;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#8212;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt; text-align: justify; text-indent: 0pt">OTC products</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#8212;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#8212;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20170101__20171231__srt--ProductOrServiceAxis__custom--OtcProductsMember_zFoKtnjjbps5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">32,882</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 0pt 16px; text-indent: 0pt">Net revenue</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom">
<p id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231_ziaaFJ1sWOfe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Net revenue">49,646,937</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom">
<p id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180101__20181231_z38IF71YI67g" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">16,099,460</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom">
<p id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20170101__20171231_zq8rzdspFESg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">16,777,713</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
</table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">The table below presents potentially dilutive securities that could affect our calculation of diluted net loss per share allocable to common stockholders for the periods presented.</a></td>
<td class="text"><p id="xdx_892_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zjMWR87JAaTl" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">The table below presents potentially dilutive securities that could affect our calculation of diluted net loss per share allocable to common stockholders for the periods presented.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="margin-right: auto; margin-left: auto; float: none; width: 80%">

<tr>
<td style="vertical-align: top; padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt"><b>&#160;</b></td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b/></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-right: Black medium none; border-left: Black medium none; padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b/></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-right: Black medium none; border-left: Black medium none; padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b/></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top"/>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="10" style="border-bottom: black 1pt solid; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>As of December
31,</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top"><b>&#160;</b></td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-bottom: black 1pt solid; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2019</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-right: Black medium none; border-bottom: Black 1pt solid; border-left: Black medium none; padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2018</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-right: Black medium none; border-bottom: Black 1pt solid; border-left: Black medium none; padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2017</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; width: 55%; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Stock options</p>
</td>
<td style="width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 12%">
<p id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zwwment6okci" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">25,030,234</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 12%">
<p id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z4Udu7FwKRBd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">20,872,824</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 12%">
<p id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20170101__20171231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zLOgdFIRfWz1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">23,365,225</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Warrants</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zn1G1tvZMjg2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">1,832,571</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20180101__20181231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zJuxJ8RNShMk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">3,007,571</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20170101__20171231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z1nPiuQRWDX3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">3,115,905</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Restricted stock awards</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zed2bsYYVwWh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">1,240,000</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zIyxoJjJmrO6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">1,040,000</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#8212;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top">&#160;</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom">
<p id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20190101__20191231_zD9Rt6prp5r" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">28,102,805</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom">
<p id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20180101__20181231_zP5dRly8IJff" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">24,920,395</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom">
<p id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20170101__20171231_zBwVIKCXZx59" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">26,481,130</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>

</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6807210272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 01, 2013</div></th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 01, 2019 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Jun. 01, 2019 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Oct. 02, 2018 </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RecordedUnconditionalPurchaseObligationLineItems', window );"><strong>Recorded Unconditional Purchase Obligation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_CapitalLeaseObligationsTerm', window );">Non-cancelable operating lease term</a></td>
<td class="text">63 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NetRentableAreaLease', window );">Net rentable area | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,212<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_RentedAreaLease', window );">Rented area lease | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,561<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AdditionalAreaOfLeaseOccupied', window );">Additional area of lease occupied | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,651<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, Operating Lease, Term of Contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">11 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_LesseeFinanceLeaseExistenceOfOptionToExtendNumber', window );">Number of options to extend lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseRenewalTerm1', window );">Lease renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_LesseeOperatingLeaseLeaseNotYetCommencedArea', window );">Lease not yet commenced (area) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,558,794<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Rental expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,068,275<span></span>
</td>
<td class="nump">$ 1,029,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_SignificantSupplyCommitmentPercentagePayable', window );">Significant supply commitment percentage payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=txmd_CatalentMember', window );">Catalent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RecordedUnconditionalPurchaseObligationLineItems', window );"><strong>Recorded Unconditional Purchase Obligation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RecordedUnconditionalPurchaseObligationDueWithinOneYear', window );">Minimum purchase commitment, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,650,853<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RecordedUnconditionalPurchaseObligationDueInSecondYear', window );">Minimum purchase commitment, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RecordedUnconditionalPurchaseObligationDueInThirdYear', window );">Minimum purchase commitment, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,643,291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RecordedUnconditionalPurchaseObligationDueInFourthYear', window );">Minimum purchase commitment, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,445,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RecordedUnconditionalPurchaseObligationDueInFifthYear', window );">Minimum purchase commitment, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,758,945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=txmd_AnnoveraMember', window );">ANNOVERA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RecordedUnconditionalPurchaseObligationLineItems', window );"><strong>Recorded Unconditional Purchase Obligation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RecordedUnconditionalPurchaseObligationDueWithinOneYear', window );">Minimum purchase commitment, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,049,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AdditionalAreaOfLeaseOccupied">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional rented area occupied under the lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_AdditionalAreaOfLeaseOccupied</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_CapitalLeaseObligationsTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total term (in months) of the company's outstanding lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_CapitalLeaseObligationsTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_LesseeFinanceLeaseExistenceOfOptionToExtendNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options to extend lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_LesseeFinanceLeaseExistenceOfOptionToExtendNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_LesseeOperatingLeaseLeaseNotYetCommencedArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future rented area to be occupied for administrative office space as defined in lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_LesseeOperatingLeaseLeaseNotYetCommencedArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NetRentableAreaLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net rentable area as defined in lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NetRentableAreaLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_RentedAreaLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rented area as defined in lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_RentedAreaLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_SignificantSupplyCommitmentPercentagePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percent of the difference between the total amount we would have paid to supplier if the minimum requirement had been fulfilled and the sum of all purchases of our products from supplier during the contract year, required to be paid to supplier.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_SignificantSupplyCommitmentPercentagePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseRenewalTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's finance lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseRenewalTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RecordedUnconditionalPurchaseObligationDueInFifthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the recorded unconditional purchase obligation maturing in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77896938&amp;loc=d3e25383-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RecordedUnconditionalPurchaseObligationDueInFifthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RecordedUnconditionalPurchaseObligationDueInFourthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the recorded unconditional purchase obligation maturing in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77896938&amp;loc=d3e25383-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RecordedUnconditionalPurchaseObligationDueInFourthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RecordedUnconditionalPurchaseObligationDueInSecondYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the recorded unconditional purchase obligation maturing in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77896938&amp;loc=d3e25383-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RecordedUnconditionalPurchaseObligationDueInSecondYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RecordedUnconditionalPurchaseObligationDueInThirdYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the recorded unconditional purchase obligation maturing in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77896938&amp;loc=d3e25383-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RecordedUnconditionalPurchaseObligationDueInThirdYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RecordedUnconditionalPurchaseObligationDueWithinOneYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the recorded unconditional purchase obligation maturing in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77896938&amp;loc=d3e25383-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RecordedUnconditionalPurchaseObligationDueWithinOneYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RecordedUnconditionalPurchaseObligationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RecordedUnconditionalPurchaseObligationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=txmd_CatalentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=txmd_CatalentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=txmd_AnnoveraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=txmd_AnnoveraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6805598080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of December 31, 2019 and 2018: (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-Lived Intangible Assets, Accumulated Amortization</a></td>
<td class="num">$ (478,983)<span></span>
</td>
<td class="num">$ (384,712)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Intangible Assets, Gross (Excluding Goodwill)</a></td>
<td class="nump">5,737,194<span></span>
</td>
<td class="nump">4,477,391<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible Assets, Net (Excluding Goodwill)</a></td>
<td class="nump">5,258,211<span></span>
</td>
<td class="nump">4,092,679<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=txmd_HormoneTherapyDrugCandidatePatentsMember', window );">Hormone Therapy Drug Candidate Patents - (Pending) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-Lived Intangible Assets, Gross</a></td>
<td class="nump">1,979,299<span></span>
</td>
<td class="nump">1,855,279<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-Lived Intangible Assets, Net</a></td>
<td class="nump">1,979,299<span></span>
</td>
<td class="nump">1,855,279<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=txmd_MultipleTrademarksForVitaminsSupplementsMember', window );">Multiple Trademarks [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedTrademarks', window );">Indefinite-Lived Trademarks</a></td>
<td class="nump">294,813<span></span>
</td>
<td class="nump">264,289<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite-lived Intangible Assets (Excluding Goodwill)</a></td>
<td class="nump">294,813<span></span>
</td>
<td class="nump">264,289<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember', window );">Approved Hormone Therapy Drug Candidate Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-Lived Intangible Assets, Gross</a></td>
<td class="nump">3,463,082<span></span>
</td>
<td class="nump">2,234,129<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-Lived Intangible Assets, Accumulated Amortization</a></td>
<td class="num">(478,983)<span></span>
</td>
<td class="num">(282,485)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-Lived Intangible Assets, Net</a></td>
<td class="nump">$ 2,984,099<span></span>
</td>
<td class="nump">$ 1,951,644<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Finite-Lived Intangible Assets, Remaining Amortization Period</a></td>
<td class="text">13 years<span></span>
</td>
<td class="text">14 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Computer Software, Intangible Asset [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-Lived Intangible Assets, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,951<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-Lived Intangible Assets, Accumulated Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,484)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-Lived Intangible Assets, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,467<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Finite-Lived Intangible Assets, Remaining Amortization Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years 9 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InternetDomainNamesMember', window );">Internet Domain Names [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-Lived Intangible Assets, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 91,743<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-Lived Intangible Assets, Accumulated Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (91,743)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedTrademarks">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (original costs adjusted for previously recognized amortization and impairment) as of the balance sheet date for the rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style for a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedTrademarks</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=txmd_HormoneTherapyDrugCandidatePatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=txmd_HormoneTherapyDrugCandidatePatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=txmd_MultipleTrademarksForVitaminsSupplementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=txmd_MultipleTrademarksForVitaminsSupplementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InternetDomainNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InternetDomainNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6804041056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>As of December 31, 2019 and 2018, the carrying value of our debt consisted of the following: (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Debt discount and financing fees</a></td>
<td class="num">$ (5,365,357)<span></span>
</td>
<td class="num">$ (1,618,986)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">TOTAL LONG-TERM DEBT</a></td>
<td class="nump">194,634,643<span></span>
</td>
<td class="nump">73,381,014<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementMember', window );">Financing Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term Debt, Gross</a></td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=txmd_CreditAgreementMember', window );">Credit Agreement Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term Debt, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=txmd_CreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=txmd_CreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6808758944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FIXED ASSETS, NET (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Fixed assets, net consist of the following:</a></td>
<td class="text"><p id="xdx_89B_eus-gaap--PropertyPlantAndEquipmentTextBlock_zkVVpSXENsMa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Fixed assets, net consist of the following:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="margin-right: auto; margin-left: auto; float: none; width: 70%">

<tr>
<td style="vertical-align: top; padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" id="xdx_49F_20191231_zo6Y5dD1EH68" style="vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b/></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" id="xdx_49F_20181231_z6v1oWzlTnve" style="border-right: Black medium none; border-left: Black medium none; padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b/></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="6" style="border-bottom: black 1pt solid; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>December 31,</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-bottom: black 1pt solid; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2019</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-right: Black medium none; border-bottom: Black 1pt solid; border-left: Black medium none; padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2018</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; width: 64%; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Accounting system</p>
</td>
<td style="width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 15%">
<p id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_z32a40lMwwJi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">301,096</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 15%">
<p id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20181231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_zpnLXAPVVO9f" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">301,096</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Equipment</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zeGpIGjrLzE4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">1,619,646</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20181231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zKDf4Ta867He" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">490,576</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Furniture and fixtures</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_98B_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_ziLZ4fHvEgv6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">1,406,858</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20181231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zLgqLDpc7EO8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">116,542</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Computer hardware</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_982_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_z5rCbLMkY4i2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">80,211</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_989_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20181231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zz9tXHiawG8b" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">80,211</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Leasehold improvements</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zsAmJrFQWzC9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">68,788</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20181231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zaf7Hky3Dwz6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">37,888</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_402_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzht4_zdZloV6xL9N7">
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">TOTAL FIXED ASSETS</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">3,476,599</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">1,026,313</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_403_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzht4_zHboRH6WJLq6" style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Accumulated depreciation</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(968,824</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(553,630</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
</tr>
<tr id="xdx_409_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzht4_z5pGWjrUNNpb">
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">TOTAL FIXED ASSETS, NET</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">2,507,775</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">472,683</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>

</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6805382592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p id="xdx_840_eus-gaap--ConsolidationPolicyTextBlock_z9mbbq84TDpk" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="text-decoration: underline">Principles of Consolidation</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">The accompanying consolidated financial statements include the accounts of our company and our wholly owned subsidiaries, VitaMed, BocaGreen and VitaCare. All intercompany balances and transactions have been eliminated in consolidation.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zPuRMhgGn9n9" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: black"><span style="text-decoration: underline"><span style="color: black">Cash</span></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">We maintain cash at financial institutions that at times may exceed the Federal Deposit Insurance Corporation, or the FDIC, insured limits of $<span id="xdx_907_eus-gaap--CashFDICInsuredAmount_iI_c20191231_zArZMLyhjRi2" title="Federal insurance limits">250,000</span> per bank. We have never experienced any losses related to these funds.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy', window );">Trade Accounts Receivable and Allowance for Doubtful Accounts</a></td>
<td class="text"><p id="xdx_842_eus-gaap--ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_z4vfyE0pmWgg" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: black"><span style="text-decoration: underline"><span style="color: black">Trade Accounts Receivable and Allowance for Doubtful Accounts</span></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">Trade accounts receivable are customer obligations due under normal trade terms. We review accounts receivable for uncollectible accounts and credit card chargebacks and provide an allowance for doubtful accounts, which is based upon a review of outstanding receivables, historical collection information, and existing economic conditions. We evaluate trade accounts receivable aged more than 90 days for delinquency. We write off delinquent receivables against our allowance for doubtful accounts based on individual credit evaluations, the results of collection efforts, and specific circumstances of customers. We record recoveries of accounts previously written off when received as an increase in the allowance for doubtful accounts. To the extent data we use to calculate these estimates does not accurately reflect bad debts, adjustments to these reserves may be required. At December 31, 2019, four different customers represented <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_dp_c20190101__20191231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerAMember_zKF3b71cwfz1" title="Concentration risk">36</span>%, <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_dp_c20190101__20191231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerBMember_zmEFfWdMZjDg">21</span>%, <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_dp_c20190101__20191231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerCMember_zntJnZicuVGl">16</span>% and <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_dp_c20190101__20191231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerDMember_zO8dfd3KrK6h">11</span>% of our gross accounts receivable. At December 31, 2018, three different customers represented <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_dp_c20180101__20181231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerAMember_zupQyt5giKMl">42</span>%, <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20180101__20181231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerBMember_zpzmvrRmdsO9">24</span>% and <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_c20180101__20181231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerCMember_zyUQ7PV5Sc6d">13</span>% of our gross accounts receivable.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>



<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><p id="xdx_841_eus-gaap--InventoryPolicyTextBlock_zJMMUrzk2Is1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: black"><span style="text-decoration: underline"><span style="color: black">Inventories</span></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">Inventories represent pharmaceutical products, packaged vitamins and raw materials which are valued at the lower of cost or net realizable value. Our pharmaceutical products are valued using first in first out method and our vitamins are valued using the average-cost method. We review our inventory for excess or obsolete inventory and write-down obsolete or otherwise unmarketable inventory to its estimated net realizable value. Obsolescence may occur due to product expiring or product improvements rendering previous versions obsolete.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black"><i><span style="text-decoration: underline"><span style="color: black"><i>Pre-Launch Inventory</i></span></span></i></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">Pre-launch
inventory costs associated with product candidates that have not yet received regulatory approval are capitalized if we
believe there is probable future commercial use and future economic benefit. If the probability of future commercial use and
future economic benefit cannot be reasonably determined, then pre-launch inventory costs associated with such product
candidates are expensed as research and development expenses during the period the costs are incurred. We have not
capitalized any pre-launch inventory to date.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Fixed Assets</a></td>
<td class="text"><p id="xdx_840_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zVTVNsWARLG6" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: black"><span style="text-decoration: underline"><span style="color: black">Fixed Assets</span></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">We state fixed assets at cost, net of accumulated depreciation. We charge maintenance costs, which do not significantly extend the useful lives of the respective assets, and repair costs to operating expenses as incurred. We compute depreciation using the straight-line method over the estimated useful lives of the related assets, which range from <span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dxL_c20190101__20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LandAndBuildingMember__srt--RangeAxis__srt--MinimumMember_zJS38w4WoxI7" title="Useful life of assets::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl0553">three</span></span> to <span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dxL_c20190101__20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LandAndBuildingMember__srt--RangeAxis__srt--MaximumMember_zlggfZdrMU98" title="::XDX::P7Y"><span style="-sec-ix-hidden: xdx2ixbrl0554">seven</span></span> years. Leasehold improvements are depreciated over the shorter of their useful life or the term of the lease.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">We capitalize software and software development costs incurred to create and acquire computer software for internal use, principally related to software coding and application development. We begin to capitalize software development costs when both the preliminary project stage is completed and it is probable that the software will be used as intended. Capitalized software costs include only external direct costs and services utilized in developing or obtaining computer software. Capitalized software costs are amortized on a straight-line basis when placed into service over the estimated useful life, generally <span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dxL_c20190101__20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember__srt--RangeAxis__srt--MinimumMember_zld1rcASVmyj" title="::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl0555">five</span></span> to <span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dxL_c20190101__20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember__srt--RangeAxis__srt--MaximumMember_zbWzKwyxIev5" title="::XDX::P7Y"><span style="-sec-ix-hidden: xdx2ixbrl0556">seven</span></span> years.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Assets</a></td>
<td class="text"><p id="xdx_840_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zkbInhjBzxL3" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: black"><span style="text-decoration: underline"><span style="color: black">Intangible Assets</span></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">We have adopted the provisions of Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, 350, <i><span style="color: black">Intangibles - Goodwill and Other</span></i>, or ASC 350. Capitalized patent costs, net of accumulated amortization, include outside legal costs incurred for patent applications. In accordance with ASC 350, once a patent is granted, we amortize the capitalized patent costs over the remaining life of the patent using the straight-line method. If the patent is not granted, we write-off any capitalized patent costs at that time. As of December 31, 2019, we had <span id="xdx_904_ecustom--NumberOfIssuedPatentsDomestic_iI_uPure_c20191231_zN9Aevq2rkUe" title="Number of issued patents domestic.">29</span> issued domestic, or U.S., patents and <span id="xdx_907_ecustom--NumberOfIssuedPatentsForeign_iI_uPure_c20191231_zxTQdtMts3r5" title="Number of issued patents foreign">30</span> issued foreign patents (See Note 6). We capitalize external costs, consisting primarily of legal costs, related to securing our trademarks. Trademarks are perpetual and are not amortized. We review intangible assets for impairment annually or when events or circumstances indicate that their carrying amount may not be recoverable.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zX0rxQcb4Caj" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="text-decoration: underline">Impairment of Long-Lived Assets</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">We review the carrying values of fixed assets and long-lived intangible assets to be held and used for impairment whenever events or changes in circumstances indicate that their carrying values may not be recoverable. Such events or circumstances may include, among others, the following:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; width: 100%">

<tr>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">significant declines in an asset&#8217;s market price;</p>
</td>
</tr>

</table>
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; width: 100%">

<tr>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">significant deterioration in an asset&#8217;s physical condition;</p>
</td>
</tr>

</table>
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; width: 100%">

<tr>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">significant changes in the nature or extent of an asset&#8217;s use or operation;</p>
</td>
</tr>

</table>
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; width: 100%">

<tr>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">significant adverse changes in the business climate that could impact an asset&#8217;s value, including adverse actions or assessments by regulators;</p>
</td>
</tr>

</table>
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; width: 100%">

<tr>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">accumulation of costs significantly in excess of original expectations related to the acquisition or construction of an asset;</p>
</td>
</tr>

</table>
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; width: 100%">

<tr>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">current-period operating or cash flow losses combined with a history of such losses or a forecast that demonstrates continuing losses associated with an asset&#8217;s use; and</p>
</td>
</tr>

</table>
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; width: 100%">

<tr>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">expectations that it is more likely than not that an asset will be sold or otherwise disposed of significantly before the end of its previously estimated useful life.</p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">If impairment indicators are present, we determine whether an impairment loss should be recognized by testing the applicable asset or asset group&#8217;s carrying value for recoverability. This test requires long-lived assets to be grouped at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities, the determination of which requires judgment. We estimate the undiscounted future cash flows expected to be generated from the use and eventual disposal of the assets and compare that estimate to the respective carrying values in order to determine if such carrying values are recoverable. This assessment requires the exercise of judgment in assessing the future use of and projected value to be derived from the eventual disposal of the assets to be held and used. In our assessments, we also consider changes in asset utilization, including, if applicable, the temporary idling of capacity and the expected timing for placing this capacity back into production. If the carrying value of the assets is not recoverable, then we record a loss for the difference between the assets&#8217; fair value and respective carrying values. We determine the fair value of the assets using an &#8220;income approach&#8221; based upon a forecast of all the expected discounted future net cash flows associated with the subject assets. Some of the more significant estimates and assumptions include market size and growth, market share, projected selling prices, manufacturing cost, and discount rate. We base estimates upon historical experience, our commercial relationships, market conditions, and available external information about future trends. We believe our current assumptions and estimates are reasonable and appropriate. Unanticipated events and changes in market conditions, however, could affect such estimates, resulting in the need for an impairment charge in future periods. There was no impairment of long-lived assets to be held and used during the years ended December 31, 2019, 2018, and 2017.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">We perform impairment tests for intangible assets with indefinite useful lives annually, in the fourth quarter, or more frequently if events occur or circumstances change that would more likely than not reduce the fair value of an intangible asset below its carrying value. The impairment test for assets with indefinite lives consists of a comparison of the fair value of the asset with its carrying amount. If the carrying amount of an intangible asset exceeds its fair value, an impairment loss is recognized in an amount equal to that excess. </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: #212529">We also evaluate the remaining useful life of intangible assets subject to amortization on a periodic basis to determine whether events and circumstances would indicate impairment or warrant a revision to the remaining useful life. If the estimate of an intangible asset&#8217;s remaining useful life is changed, we will amortize the remaining carrying value of the intangible asset prospectively over the revised remaining useful life.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p id="xdx_843_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zcmWXNTLtxO5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: black"><span style="text-decoration: underline"><span style="color: black">Fair Value of Financial Instruments</span></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">Our financial instruments consist primarily of cash, accounts receivable, accounts payable, accrued expenses and long term debt. The carrying amount of cash, accounts receivable, accounts payable and accrued expenses approximates their fair value because of the short-term maturity of such instruments, which are considered Level 1 assets under the fair value hierarchy.&#160; T<span style="color: #212529">he carrying amount for long-term debt as of December 31, 2019 and 2018 (as disclosed in Note 8), approximates fair value based on market activity for other debt instruments with similar characteristics and comparable risk (Level 2).</span></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">We
categorize our assets and liabilities that are valued at fair value on a recurring basis into a three-level fair value
hierarchy as defined by ASC 820, <i><span style="color: black">Fair Value Measurements</span></i>, or ASC 820. The fair value
hierarchy gives the highest priority to quoted prices in active markets for identical assets and liabilities (Level 1) and
lowest priority to unobservable inputs (Level 3). Assets and liabilities recorded in the consolidated balance sheet at fair
value are categorized based on a hierarchy of inputs, as follows: </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
    <td style="width: 4%">&#160;</td>
    <td style="text-align: justify; width: 6%"><b>Level 1</b></td>
    <td style="text-align: justify; width: 90%">unadjusted quoted prices in active markets for identical assets or liabilities;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><b>Level 2</b></td>
    <td style="text-align: justify">quoted prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument; and</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><b>Level 3</b></td>
    <td style="text-align: justify">unobservable inputs for the assets or liabilities.</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">At December 31, 2019 and 2018, we had no assets or liabilities that were valued at fair value on a recurring basis.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">The fair value of indefinite-lived assets is measured on a non-recurring basis using significant unobservable inputs (Level 3) in connection with any required impairment test. During the year ended December 31, 2019, we wrote off $78,864 in costs related to trademarks and patents, including the net carrying amount of our OPERA software patent. There was no impairment of intangible assets during the years ended December 31, 2018, and 2017.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_845_eus-gaap--IncomeTaxPolicyTextBlock_zXcE6tElWSuf" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="text-decoration: underline">Income Taxes</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">We account for income taxes under the asset and liability method. We recognize deferred tax assets and liabilities for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. We measure deferred tax assets and liabilities using enacted tax rates expected to apply to taxable income in the years in which the related temporary differences are expected to be recovered or settled. We recognize the effect on deferred tax assets and liabilities of a change in tax rates when the rate change is enacted. Valuation allowances are recorded to reduce deferred tax assets to the amount that will more likely than not be realized.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">In accordance with ASC 740, <i><span style="color: black">Income Taxes</span></i>, we recognize the effect of uncertain income tax positions only if the positions are more likely than not of being sustained in an audit, based on the technical merits of the position. We measure recognized uncertain income tax positions using the largest amount that has a likelihood of being realized that is greater than 50%. Changes in recognition or measurement are reflected in the period in which those changes in judgment occur.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">We recognize both interest and penalties related to uncertain tax positions as part of the income tax provision. At December 31, 2019 and 2018, we had no tax positions relating to open tax returns that were considered to be uncertain.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">Our U.S. federal and state tax returns since 2011, which was the first year we generated net operating losses, remain open to examination.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zZ67QJ5XmZpg" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="text-decoration: underline">Share-Based Compensation</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">We measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees are required to provide services. Share-based compensation arrangements include options, restricted stock, restricted stock units, performance-based awards, share appreciation rights, and employee share purchase plans. We amortize such compensation amounts, if any, over the respective service periods of the award. We use the Black-Scholes-Merton option pricing model, or the Black-Scholes Model, an acceptable model in accordance with ASC 718, Compensation-Stock Compensation, to value options. Option valuation models require the input of assumptions, including the expected life of the stock-based awards, the estimated stock price volatility, the risk-free interest rate, and the expected dividend yield. The risk-free interest rate assumption is based upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the term of the instrument. Estimated volatility is a measure of the amount by which our stock price is expected to fluctuate each year during the term of the award. On January 1, 2017, we began using our own stock price in our volatility calculation along with the other peer entities whose stock prices were publicly available that were similar to our company and in 2019 we started using only our own stock price in the volatility calculation. Our calculation of estimated volatility is based on historical stock prices over a period equal to the expected term of the awards. The average expected life of options is based on the contractual terms of the stock option using the simplified method. We utilize a dividend yield of zero based on the fact that we have never paid cash dividends and have no current intention to pay cash dividends. Calculating share-based compensation expense requires the input of highly subjective judgment and assumptions, estimates of expected life of the share-based award, stock price volatility and risk-free interest rates. The assumptions used in calculating the fair value of share-based awards represent our best estimates, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change and we use different assumptions, our share-based compensation expense could be materially different in the future. We recognize the compensation expense for share-based compensation granted based on the grant date fair value estimated in accordance with ASC 718. We generally recognize the compensation expense on a straight-line basis over the employee&#8217;s requisite service period. Effective January 1, 2017, we account for forfeitures when they occur. On January 1, 2019, we adopted ASU 2018-07 which simplified the accounting for share-based payments to non-employees by aligning it with the accounting for share-based payments to employees, with certain exceptions. The new guidance expanded the scope of ASC 718 to include share-based payments granted to non-employees in exchange for goods or services used or consumed in an entity&#8217;s own operations and superseded the guidance in ASC 505-50. Prior to January 1, 2019, equity instruments issued to non-employees were recorded on a fair value basis, as required by ASC 505, Equity - Based Payments to Non-Employees.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p id="xdx_845_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zX9Q9Tx5SIq5" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: black"><span style="text-decoration: underline"><span style="color: black">Revenue Recognition</span></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">We
adopted ASC 606, <i>Revenue from Contracts with Customers</i>, or ASC 606, on January 1, 2018 using the modified retrospective
method for all contracts not completed as of the date of adoption. ASC 606 states that a contract is considered &#8220;completed&#8221;
if all (or substantially all) of the revenue was recognized in accordance with revenue guidance that was in effect before the
date of initial application. Because all (or substantially all) of the revenue related to sales of our products was recognized
under ASC 605 prior to the date of initial application of the new standard, the contracts were considered completed under ASC
606. Based on our evaluation of ASC 606, we concluded that a cumulative adjustment was not necessary upon implementation of ASC
606 on January 1, 2018. In accordance with ASC 606, revenue is recognized when a customer obtains control of promised goods or
services. The amount of revenue recognized reflects the consideration to which we expect to be entitled to receive in exchange
for these goods or services. The provisions of ASC 606 include a five-step process by which we determine revenue recognition,
depicting the transfer of goods or services to customers in amounts reflecting the payment to which we expect to be entitled in
exchange for those goods or services. ASC 606 requires us to apply the following steps: (1) identify the contract with the customer;
(2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price
to the performance obligations in the contract; and (5) recognize revenue when, or as, we satisfy the performance obligation.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 36pt; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black"><i><span style="text-decoration: underline"><span style="color: black"><i>Prescription Products</i></span></span></i></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: #212529">As of December 31, 2019, our products consisted primarily of prescription vitamins and our FDA-approved products: IMVEXXY, which we began selling during the third quarter of 2018, and BIJUVA, which we began selling in the second quarter of 2019. We started selling ANNOVERA in the third quarter of 2019 and we expect the full commercial launch of ANNOVERA in the first quarter of 2020. We sell our name brand and generic prescription products primarily through wholesale distributors and retail pharmacies. We have one performance obligation related to prescription products sold through wholesale distributors, which is to transfer promised goods to a customer, and two performance obligations related to products sold through retail pharmacies, which are to: (1) transfer promised goods and (2) provide customer service for an immaterial fee. We treat shipping as a fulfillment activity rather than as a separate obligation. We recognize prescription revenue only when we satisfy performance obligations by transferring a promised good or service to a customer. A good or service is considered to be transferred when the customer receives the goods or service or obtains control. Control refers to the customer&#8217;s ability to direct the use of, and obtain substantially all of the remaining benefits from, an asset. Based on our contracts, we invoice customers once our performance obligations have been satisfied, at which point payment is unconditional. We disclose receivables from contracts with customers separately in the statement of financial position. Payment for goods or services sold by us is typically due between 30 and 60 days after an invoice is sent to the customer. </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: #212529">The transaction price of a contract is the amount of consideration which we expect to be entitled to in exchange for transferring promised goods or services to a customer. Prescription products are sold at fixed wholesale acquisition cost, or WAC, determined based on our list price. However, the total transaction price is variable as it is calculated net of estimated product returns, chargebacks, rebates, coupons, discounts and wholesaler fees. These estimates are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the customer) or a current liability (if the amount is payable to a party other than a customer). In order to determine the transaction price, we estimate the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract or each variable consideration. The estimated amount of variable consideration is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. In determining amounts of variable consideration to include in a contract&#8217;s transaction price, we rely on our historical experience and other evidence that supports our qualitative assessment of whether revenue would be subject to a significant reversal. We consider all the facts and circumstances associated with both the risk of a revenue reversal arising from an uncertain future event and the magnitude of the reversal if that uncertain event were to occur. Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our original estimates, we will adjust these estimates, which would affect net product revenue and earnings in the period such changes in estimates become known. </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: #212529">We accept returns of unsalable prescription products sold through wholesale distributors within a return period of <span id="xdx_90B_ecustom--ReturnPeriodOfUnsalablePrescriptionProducts_dxH_c20190101__20191231__srt--RangeAxis__srt--MinimumMember_zwmQaTTYNKK" title="Return period of unsalable prescription products::XDX::P6M">six</span> months prior to and up to <span id="xdx_908_ecustom--ReturnPeriodOfUnsalablePrescriptionProducts_dtM_c20190101__20191231__srt--RangeAxis__srt--MaximumMember_zpQUNXhwWkQ1">12</span> months following product expiration. Our vitamins and IMVEXXY currently have a shelf life of <span id="xdx_907_ecustom--ShelfLifeOfPrescriptionProducts_dtM_c20190101__20191231__srt--ProductOrServiceAxis__custom--VitaminsAndImvexxyMember_zdk5medOaIY1" title="Shelf life of prescription products following product expiration">24</span> months from the date of manufacture and BIJUVA and ANNOVERA currently have a shelf life of <span id="xdx_905_ecustom--ShelfLifeOfPrescriptionProducts_dtM_c20190101__20191231__srt--ProductOrServiceAxis__custom--BijuvaAndAnnoveraMember_zykSpchkSjok">18</span> months from the date of manufacture. We do not allow product returns for prescription products that have been dispensed to a patient. We estimate the amount of our product sales that may be returned by our customers and record this estimate as a reduction of revenue in the period the related product revenue is recognized. Where historical rates of return exist, we use history as a basis to establish a returns reserve for products shipped to wholesalers. For our newly launched products, for which the right of return exists but for which we currently do not have history of product returns, we estimate returns based on available industry data, our own sales information and our visibility into the inventory remaining in the distribution channel. At the end of each reporting period, we may decide to constrain revenue for product returns based on information from various sources, including channel inventory levels and dating and sell-through data, the expiration dates of products currently being shipped, price changes of competitive products and any introductions of generic products. We recognize the amount of expected returns as a refund liability, representing the obligation to return the customer&#8217;s consideration. Since our returns primarily consist of expired and short dated products that will not be resold, we do not record a return asset for the right to recover the goods returned by the customer at the time of the initial sale (when recognition of revenue is deferred due to the anticipated return). Return estimates are recorded in accrued expenses and other current liabilities on the consolidated balance sheet.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: #212529">We offer various rebate and discount programs in an effort to maintain a competitive position in the marketplace and to promote sales and customer loyalty. We estimate the allowance for consumer rebates and coupons that we have offered based on our experience and industry averages, which is reviewed, and adjusted if necessary, on a quarterly basis. Estimates relating to these rebates and coupons are deducted from gross product revenues at the time the revenues are recognized. We record distributor fees based on amounts stated in contracts. Rebate and coupon estimates and distributor fees are recorded in accrued expenses and other current liabilities on the consolidated balance sheet. We estimate chargebacks based on number of units sold during the period taking into account prices stated in contracts and our historical experience. Estimates related to distributors fees, rebates, coupons and returns are disclosed in Note 7. We provide invoice discounts to our customers for prompt payment. Estimates relating to invoice discounts and chargebacks are deducted from gross product revenues at the time the revenues are recognized. </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: #212529">As part of commercial launches for our FDA-approved prescription products, we introduced a co-pay assistance program for eligible enrolled patients whose out of pocket costs are reduced to a more affordable price. This allows patients to access the product at a reasonable cost and is in line with our responsible pricing approach. We reimburse pharmacies for this discount through third-party vendors. We consider certain payments as consideration paid to the customer and reflect such payments as a reduction of the transaction price as we do not receive a distinct good or service related to these payments. The variable consideration is estimated based on contract prices, the estimated percentage of patients that will utilize the copay assistance, the average assistance paid, the estimated levels of inventory in the distribution channel and the current level of prescriptions covered by patients&#8217; insurance. Payers may change coverage levels for our prescription products positively or negatively, at any time up to the time that we have formally contracted coverage with the payer. As such, the net transaction price of our prescription products is susceptible to such changes in coverage levels, which are outside the influence of the Company. As a result, we constrain variable consideration for our prescription products to an amount that will not result in a significant revenue reversal in future periods. Our ability to estimate the net transaction price for our prescription products is constrained by our estimates of the amount to be paid for the co-pay assistance program which is directly related to the level of prescriptions paid for by insurance. As such, we record an accrual to reduce gross sales for the estimated co-pay and other patient assistance based on currently available third-party data and our internal analyses. We re-evaluate variable consideration each reporting period.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 36pt; margin-top: 0pt; margin-bottom: 0pt"><span style="color: #212529"><i><span style="text-decoration: underline"><span style="color: #212529"><i>License Revenue</i></span></span></i></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: #212529">License
arrangements may consist of non-refundable upfront license fees, exclusive licensed rights to patented or patent pending
technology, and various performance or sales milestones and future product royalty payments. Some of these arrangements may
include multiple performance obligations. Non-refundable up-front fees that are not contingent on any future performance by
us, and do not require continuing involvement on our part, are recognized as revenue when the right to use functional IP is transferred to the customer.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #212529"><span style="text-decoration: underline"><span style="color: #212529">License Agreement with Knight Therapeutics Inc.</span></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: #212529">On July 30, 2018, we entered into the Knight License Agreement with Knight pursuant to which we granted Knight an exclusive license to commercialize IMVEXXY and BIJUVA in Canada and Israel. Pursuant to the terms of the Knight License Agreement, Knight will pay us a milestone fee upon first regulatory approval in Canada of each of IMVEXXY and BIJUVA, sales milestone fees based upon certain aggregate annual sales in Canada and Israel of each of IMVEXXY and BIJUVA and royalties based on aggregate annual sales of each of IMVEXXY and BIJUVA in Canada and Israel. Knight will be responsible for all regulatory and commercial activities in Canada and Israel related to IMVEXXY and BIJUVA. We may terminate the Knight License Agreement if Knight does not submit all regulatory applications, submissions and/or registrations required for regulatory approval to use and commercialize IMVEXXY and BIJUVA in Canada and Israel within certain specified time periods. We also may terminate the Knight License Agreement if Knight challenges our patents. Either party may terminate the Knight License Agreement for any material breach by the other party that is not cured within certain specified time periods or if the other party files for bankruptcy or other related matters. In connection with the Knight License Agreement, Knight entered into a subscription agreement with us, pursuant to which Knight purchased <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20180730__20180806__us-gaap--SubsidiarySaleOfStockAxis__custom--SubscriptionAgreementKnightMember_zPi7HFxxKJK7">3,921,568</span> shares of our Common Stock concurrent with the closing of the underwritten public offering of Common Stock on August 6, 2018 at a price of $<span id="xdx_90C_eus-gaap--SaleOfStockPricePerShare_iI_c20180806__us-gaap--SubsidiarySaleOfStockAxis__custom--SubscriptionAgreementKnightMember_zA6xYqBlf9gh">5.10</span>, for proceeds of $<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20180730__20180806__us-gaap--SubsidiarySaleOfStockAxis__custom--SubscriptionAgreementKnightMember_zE3Vbx4PtVqb">20,000,000</span>.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #212529"><span style="text-decoration: underline"><span style="color: #212529">License Agreement with Theramex</span></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: #212529">On
June 6, 2019, we entered into the Theramex License Agreement with Theramex to commercialize BIJUVA and IMVEXXY in the <span style="color: black">Theramex </span>Territory.
Under the terms of the Theramex License Agreement, Theramex paid us EUR <span id="xdx_90E_ecustom--CashUpfrontPaymentReceived_dm_uEUR_c20190804__20190805__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember_zhZ8Q0Jom5W">14
million</span>, or $<span id="xdx_904_ecustom--CashUpfrontPaymentReceived_uUSD_c20190803__20190805__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember_z1NgfBwzHIz7">15,506,400</span>,
in cash as an upfront fee on August 5, 2019. Within thirty days of signing the Theramex License Agreement, we provided
Theramex the regulatory materials and clinical data that were necessary for Theramex to obtain marketing authorizations and
other applicable regulatory approvals for commercializing BIJUVA and IMVEXXY. We recognized the revenue related to the
upfront fee, which was a non-refundable payment, during the third quarter of 2019, at a point in time when Theramex was able
to use and benefit from the license which was when the knowledge transfer of regulatory documents occurred. We are eligible
to receive additional milestone payments comprised of (i) up to an aggregate of EUR <span id="xdx_907_ecustom--RegulatoryMilestoneAdditionalPayment_iI_dm_uEUR_c20190606__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember__srt--RangeAxis__srt--MaximumMember_zebOAlMYfGdc">2
million</span> in regulatory milestone payments based on regulatory approvals for BIJUVA and IMVEXXY in certain specified
markets and (ii) up to an aggregate of EUR <span id="xdx_906_ecustom--SalesMilestonePaymentsInTranches_iI_dm_uEUR_c20190606__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember__srt--RangeAxis__srt--MaximumMember_zTkMgkY5IUa4">27.5
million</span> in sales milestone payments to be paid in escalating tranches based on Theramex first attaining certain
aggregate annual net sales milestones of BIJUVA and IMVEXXY in the <span style="color: black">Theramex </span>Territory
ranging from EUR <span id="xdx_90C_ecustom--AnnualNetSalesMilestone_dm_uEUR_c20190605__20190606__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember__srt--RangeAxis__srt--MinimumMember_z1X49D80mEN1" title="Sales milestone">25
million</span> to EUR <span id="xdx_909_ecustom--AnnualNetSalesMilestone_dm_uEUR_c20190605__20190606__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember__srt--RangeAxis__srt--MaximumMember_zfL5UAQPZVef">100
million</span>. We are also entitled to receive quarterly royalty payments at a rate of <span id="xdx_90D_ecustom--QuarterlyRoyaltyPaymentsPercentage_dp_c20190605__20190606__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember__srt--ProductOrServiceAxis__custom--BijuvaAndAnnoveraMember_zNWu2klcrb31" title="Quarterly royalty payments percentage">5</span>% on net sales of BIJUVA and
IMVEXXY in the <span style="color: black">Theramex </span>Territory. Theramex is responsible for all regulatory
and commercial activities for BIJUVA and IMVEXXY in the <span style="color: black">Theramex </span>Territory. Theramex
may sublicense its rights to commercialize BIJUVA and IMVEXXY in the <span style="color: black">Theramex </span>Territory,
except for certain specified markets. We may terminate the Theramex License Agreement if Theramex does not submit
all regulatory applications, submissions and/or registrations required for regulatory approval to use and commercialize
BIJUVA and IMVEXXY within certain specified time periods. We also may terminate the Theramex License Agreement if
Theramex challenges our patents. Either party may terminate the Theramex License Agreement for any material breach by the
other party that is not cured within certain specified time periods or if the other party files for bankruptcy or other
related matters. </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 36pt; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black"><i><span style="text-decoration: underline"><span style="color: black"><i>Disaggregation of revenue</i></span></span></i></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p id="xdx_890_eus-gaap--DisaggregationOfRevenueTableTextBlock_z8OEeqjDg4wl" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">The following table provides information about disaggregated revenue by product mix for the years ended December 31, 2019, 2018, and 2017:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="margin-right: auto; margin-left: auto; float: none; width: 80%">

<tr>
<td style="vertical-align: top; padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b/></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-right: Black medium none; border-left: Black medium none; padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b/></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-right: Black medium none; border-left: Black medium none; padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b/></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="10" style="border-bottom: black 1pt solid; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>For the Years
Ended December 31,</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-bottom: black 1pt solid; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2019</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-right: Black medium none; border-bottom: Black 1pt solid; border-left: Black medium none; padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2018</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-right: Black medium none; border-bottom: Black 1pt solid; border-left: Black medium none; padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2017</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; width: 55%; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt; text-align: justify; text-indent: 0pt">Prescription vitamins</p>
</td>
<td style="width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 12%">
<p id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_zTCn7GWquVDa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">9,885,493</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 12%">
<p id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180101__20181231__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_zeoacSq302Jd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">15,041,259</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 12%">
<p id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20170101__20171231__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_zFufrbuEnuIj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">16,744,831</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt; text-align: justify; text-indent: 0pt">IMVEXXY</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ProductOrServiceAxis__custom--ImvexxyMember_zYDRVsbMXUX2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">16,252,045</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180101__20181231__srt--ProductOrServiceAxis__custom--ImvexxyMember_z6BPbXQEuVA8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">1,058,201</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#8212;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt; text-align: justify; text-indent: 0pt">BIJUVA</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ProductOrServiceAxis__custom--BijuvaMember_zTDhU6TAWyd9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">1,836,443</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#8212;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#8212;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt; text-align: justify; text-indent: 0pt">ANNOVERA</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ProductOrServiceAxis__custom--AnnoveraMember_zNVeDXdoxc1h" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">6,166,556</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#8212;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#8212;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt; text-align: justify; text-indent: 0pt">License revenue</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ProductOrServiceAxis__us-gaap--LicenseAndServiceMember_zsZ6QSDNh8v1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">15,506,400</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#8212;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#8212;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt; text-align: justify; text-indent: 0pt">OTC products</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#8212;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#8212;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20170101__20171231__srt--ProductOrServiceAxis__custom--OtcProductsMember_zFoKtnjjbps5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">32,882</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 0pt 16px; text-indent: 0pt">Net revenue</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom">
<p id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231_ziaaFJ1sWOfe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Net revenue">49,646,937</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom">
<p id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180101__20181231_z38IF71YI67g" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">16,099,460</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom">
<p id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20170101__20171231_zq8rzdspFESg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">16,777,713</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
</table>
<p id="xdx_8A1_z2enxXr8rRi1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: black"><span style="text-decoration: underline"><span style="color: black">Shipping and Handling Costs</span></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">We expense all shipping and handling costs as incurred. We include these costs in cost of goods sold on the accompanying consolidated financial statements.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zh34nsSoyXzj" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: black"><span style="text-decoration: underline"><span style="color: black">Segment Reporting</span></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">We are managed and operated as <span id="xdx_901_eus-gaap--NumberOfReportableSegments_dc_uPure_c20190101__20191231_zfTscoqBJ7ng" title="Number of operating segments">one</span> business, which is focused on creating and commercializing products targeted exclusively for women. Our business operations are managed by a single management team that reports to the President of our company. We do not operate separate lines of business with respect to any of our products and we do not prepare discrete financial information with respect to separate products. All product sales are derived from sales in the United States. Accordingly, we view our business as one reportable operating segment.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>



<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of Sales</a></td>
<td class="text"><p id="xdx_848_eus-gaap--CostOfSalesPolicyTextBlock_zBqUjo09XUGh" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: black"><span style="text-decoration: underline"><span style="color: black">Cost of Sales </span></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">Cost
of sales includes the cost of inventory, manufacturing, manufacturing overhead and supply chain costs, and product shipping
and handling costs. The Population Council License Agreement requires payment of royalties based on the sale of future
products. Such royalties are recorded as a component of cost of sales. Additionally, the amortization of license fees or
milestone payments related to licensed products are classified as components of cost of sales to the extent such payments
become due in the future.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising Costs</a></td>
<td class="text"><p id="xdx_845_eus-gaap--AdvertisingCostsPolicyTextBlock_zwHL0Geta6pj" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="text-decoration: underline">Advertising Costs</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">We expense advertising costs when incurred. Advertising costs were $<span id="xdx_900_eus-gaap--AdvertisingExpense_c20190101__20191231_zPOagYG9VJZh" title="Advertising costs">9,045,571</span>, $<span id="xdx_90C_eus-gaap--AdvertisingExpense_c20180101__20181231_zaOsot7eExva">1,682,746</span> and $<span id="xdx_900_eus-gaap--AdvertisingExpense_c20170101__20171231_zWaOTgdOA1Jf">448,288</span> during the years ended December 31, 2019, 2018, and 2017, respectively.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><p id="xdx_845_eus-gaap--ResearchAndDevelopmentExpensePolicy_zIzh16fKypj9" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="text-decoration: underline">Research and Development Expenses</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">Research and development, or R&amp;D, expenses include internal R&amp;D activities, services of external contract research organizations, or CROs, costs of their clinical research sites, manufacturing, scale-up and validation costs, and other activities. Internal R&amp;D activity expenses include laboratory supplies, salaries, benefits, and non-cash share-based compensation expenses. CRO activity expenses include preclinical laboratory experiments and clinical trial studies. Other activity expenses include regulatory consulting and other costs. The activities undertaken by our regulatory consultants that were classified as R&amp;D expenses include assisting, consulting with, and advising our in-house staff with respect to various FDA submission processes, clinical trial processes, and scientific writing matters, including preparing protocols and FDA submissions. These consulting expenses were direct costs associated with preparing, reviewing, and undertaking work for our clinical trials and investigative drugs. We charge internal R&amp;D activities and other activity expenses to operations as incurred. We make payments to CROs based on agreed-upon terms, which may include payments in advance of a study starting date. We expense nonrefundable advance payments for goods and services that will be used in future R&amp;D activities when the activity has been performed or when the goods have been received rather than when the payment is made. We review and accrue CRO expenses and clinical trial study expenses based on services performed and rely on estimates of those costs applicable to the completion stage of a study as provided by CROs. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. We charge revisions to expenses in the period in which the facts that give rise to the revision become known.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share</a></td>
<td class="text"><p id="xdx_841_eus-gaap--EarningsPerSharePolicyTextBlock_zai2UEwH7ehf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="text-decoration: underline">Earnings Per Share</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">We calculate earnings per share, or EPS, in accordance with ASC 260, <i><span style="color: black">Earnings Per Share</span></i>, which requires the computation and disclosure of two EPS amounts: basic and diluted. We compute basic EPS based on the weighted-average number of shares of common stock, par value $0.001 per share, or Common Stock, outstanding during the period. We compute diluted EPS based on the weighted-average number of shares of our Common Stock outstanding plus all potentially dilutive shares of our Common Stock outstanding during the period. Such potentially dilutive shares of our Common Stock consist of options, warrants and restricted stock awards and were excluded from the calculation of diluted earnings per share because their effect would have been anti-dilutive due to the net loss reported by us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">&#160;</span></p>

<p id="xdx_892_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zjMWR87JAaTl" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">The table below presents potentially dilutive securities that could affect our calculation of diluted net loss per share allocable to common stockholders for the periods presented.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="margin-right: auto; margin-left: auto; float: none; width: 80%">

<tr>
<td style="vertical-align: top; padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt"><b>&#160;</b></td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b/></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-right: Black medium none; border-left: Black medium none; padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b/></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-right: Black medium none; border-left: Black medium none; padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b/></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top"/>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="10" style="border-bottom: black 1pt solid; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>As of December
31,</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top"><b>&#160;</b></td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-bottom: black 1pt solid; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2019</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-right: Black medium none; border-bottom: Black 1pt solid; border-left: Black medium none; padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2018</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-right: Black medium none; border-bottom: Black 1pt solid; border-left: Black medium none; padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2017</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; width: 55%; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Stock options</p>
</td>
<td style="width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 12%">
<p id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zwwment6okci" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">25,030,234</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 12%">
<p id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z4Udu7FwKRBd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">20,872,824</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 12%">
<p id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20170101__20171231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zLOgdFIRfWz1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">23,365,225</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Warrants</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zn1G1tvZMjg2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">1,832,571</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20180101__20181231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zJuxJ8RNShMk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">3,007,571</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20170101__20171231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z1nPiuQRWDX3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">3,115,905</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Restricted stock awards</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zed2bsYYVwWh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">1,240,000</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zIyxoJjJmrO6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">1,040,000</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#8212;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top">&#160;</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom">
<p id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20190101__20191231_zD9Rt6prp5r" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">28,102,805</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom">
<p id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20180101__20181231_zP5dRly8IJff" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">24,920,395</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom">
<p id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20170101__20171231_zBwVIKCXZx59" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">26,481,130</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>

</table>
<p id="xdx_8A5_znRoDQXLLwAh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk and other Risks and Uncertainties</a></td>
<td class="text"><p id="xdx_840_eus-gaap--ConcentrationRiskCreditRisk_z3qPnllrsXji" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="text-decoration: underline">Concentration of Credit Risk and other Risks and Uncertainties</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">Financial instruments that potentially expose us to concentrations of credit risk consist primarily of cash and trade accounts receivable. Cash is on deposit with financial institutions in the United States and these deposits generally exceed the amount of insurance provided by the FDIC. We have not experienced any historical losses on our deposits of cash.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">Concentration of credit risk with respect to our trade accounts receivable from our customers is primarily limited to drug wholesalers and retail pharmacy distributors. Credit is extended to our customers based on an evaluation of a customer&#8217;s financial condition, and collateral is not required.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p id="xdx_84F_eus-gaap--UseOfEstimates_zsMyrC5LdsBg" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="text-decoration: underline">Use of Estimates</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">Our consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP. The preparation of these financial statements requires us to make significant estimates and judgments that affect the reported amounts of assets, liabilities, revenue, expenses, and related disclosure of contingent assets and liabilities. We evaluate our estimates, including those related to contingencies, on an ongoing basis. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ, at times in material amounts, from these estimates under different assumptions or conditions.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>



<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zjxi7fQvxgc2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="text-decoration: underline">Recently Issued Accounting Pronouncements</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="color: black">In August 2018, the FASB issued Accounting Standards Update, or ASU, 2018-13, which eliminates certain disclosure requirements for fair value measurements for all entities, requires public entities to disclose certain new information and modifies some disclosure requirements. The FASB developed the amendments to ASC 820 as part of its broader disclosure framework project, which aims to improve the effectiveness of disclosures in the notes to financial statements by focusing on requirements that clearly communicate the most important information to users of the financial statements. The new guidance is effective for all entities for fiscal years beginning after December 15, 2019 and for interim periods within those fiscal years. An entity is permitted to early adopt either the entire standard or only the provisions that eliminate or modify requirements. We do not expect that the adoption of this standard will have a material effect on our disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="color: black">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="color: black">In June 2018, the FASB issued ASU 2018-07 to simplify the accounting for share-based payments to non-employees by aligning it with the accounting for share-based payments to employees, with certain exceptions. The new guidance expands the scope of ASC 718 to include share-based payments granted to non-employees in exchange for goods or services used or consumed in an entity&#8217;s own operations and supersedes the guidance in ASC 505-50. The guidance is effective for public business entities in annual periods beginning after December 15, 2018, and interim periods within those annual periods. Early adoption is permitted, including in an interim period for which financial statements have not been issued, but not before an entity adopts ASC 606. We adopted this standard on January 1, 2019 and the adoption of this standard did not have a material effect on our consolidated financial statements. </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="color: black">In February 2016, the FASB issued ASU 2016-02, Leases. This guidance requires lessees to record most leases on their balance sheets while recognizing expenses on their income statements in a manner similar to current accounting. The guidance also eliminates current real estate-specific provisions for all entities. For lessors, the guidance modifies the classification criteria and the accounting for sales-type and direct financing leases. The standard was effective for public business entities for annual periods beginning after December 15, 2018, and interim periods within those years. In July 2018, the FASB amended the new leases standard and issued ASU 2018-11, Leases, (Topic 842): Targeted Improvements to give entities another option for transition and to provide lessors with a practical expedient. We adopted ASU 2016-02 on January 1, 2019 utilizing the alternative transition method allowed for under ASU 2018-11 and we recorded a $<span id="xdx_903_eus-gaap--OperatingLeaseRightOfUseAsset_iI_dm_c20190102__us-gaap--AdjustmentsForNewAccountingPronouncementsAxis__us-gaap--AccountingStandardsUpdate201602Member_zlV7DDjFbRp3" title="Right of use asset">3.8 million</span> right of use asset and a $<span id="xdx_903_eus-gaap--OperatingLeaseLiability_iI_dm_c20190102__us-gaap--AdjustmentsForNewAccountingPronouncementsAxis__us-gaap--AccountingStandardsUpdate201602Member_zthkuShkZZq9" title="Lease liability">4.1 million</span> liability related to adoption of this standard. In addition, upon commencement of additional leased space in the third quarter of 2019 (as disclosed in Note 13), we recorded an additional $<span id="xdx_903_eus-gaap--OperatingLeaseRightOfUseAsset_iI_dm_c20190831_zkKApmrsrDpd">7.4 million</span> right of use asset and an additional $<span id="xdx_90A_eus-gaap--OperatingLeaseLiability_iI_dm_c20190831_zd4NiSL1yiF4">7.2 million</span> liability related to our new leased space. Comparative financial information was not adjusted and will continue to be reported under ASC 840. We also elected the transition relief package of practical expedients and as a result we did not assess (1) whether existing or expired contracts contain leases, (2) lease classification for any existing or expired leases, and (3) whether lease origination costs qualified as initial direct costs. We elected the short-term lease practical expedient by establishing an accounting policy to exclude leases with a term of 12 months or less. We elected not to separate lease components from non-lease components for our specified asset classes. Additionally, the adoption of the new standard resulted in increased disclosure requirements in our quarterly and annual filings. </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants and the SEC did not, and are not expected to, have a material effect on our results of operations or financial position.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=116822174&amp;loc=d3e355033-122828<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=116822174&amp;loc=d3e355100-122828<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 705<br> -URI http://asc.fasb.org/topic&amp;trid=2122478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32247-109318<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32280-109318<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116846552&amp;loc=d3e543-108305<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118936363&amp;loc=d3e5144-111524<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>36
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "txmd-10k_123119.htm": {
   "axisCustom": 1,
   "axisStandard": 23,
   "contextCount": 246,
   "dts": {
    "calculationLink": {
     "local": [
      "txmd-20191231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "txmd-20191231_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "txmd-10k_123119.htm"
     ]
    },
    "labelLink": {
     "local": [
      "txmd-20191231_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "txmd-20191231_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "txmd-20191231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd",
      "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 619,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2019-01-31": 59,
    "http://therapeuticsmd.com/20191231": 5,
    "http://xbrl.sec.gov/dei/2019-01-31": 6,
    "total": 70
   },
   "keyCustom": 82,
   "keyStandard": 365,
   "memberCustom": 65,
   "memberStandard": 32,
   "nsprefix": "txmd",
   "nsuri": "http://therapeuticsmd.com/20191231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "From2019-01-01to2019-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://therapeuticsmd.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "From2019-01-01to2019-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "From2019-01-01to2019-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000010 - Disclosure - OTHER CURRENT ASSETS",
     "role": "http://therapeuticsmd.com/role/OtherCurrentAssets",
     "shortName": "OTHER CURRENT ASSETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "From2019-01-01to2019-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "From2019-01-01to2019-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000011 - Disclosure - FIXED ASSETS, NET",
     "role": "http://therapeuticsmd.com/role/FixedAssetsNet",
     "shortName": "FIXED ASSETS, NET",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "From2019-01-01to2019-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "From2019-01-01to2019-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000012 - Disclosure - INTANGIBLE ASSETS, NET",
     "role": "http://therapeuticsmd.com/role/IntangibleAssetsNet",
     "shortName": "INTANGIBLE ASSETS, NET",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "From2019-01-01to2019-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "From2019-01-01to2019-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000013 - Disclosure - OTHER CURRENT LIABILITIES",
     "role": "http://therapeuticsmd.com/role/OtherCurrentLiabilities",
     "shortName": "OTHER CURRENT LIABILITIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "From2019-01-01to2019-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "From2019-01-01to2019-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000014 - Disclosure - DEBT",
     "role": "http://therapeuticsmd.com/role/Debt",
     "shortName": "DEBT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "From2019-01-01to2019-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "From2019-01-01to2019-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000015 - Disclosure - STOCKHOLDERS\u2019 EQUITY",
     "role": "http://therapeuticsmd.com/role/StockholdersEquity",
     "shortName": "STOCKHOLDERS\u2019 EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "From2019-01-01to2019-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "From2019-01-01to2019-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000016 - Disclosure - INCOME TAXES",
     "role": "http://therapeuticsmd.com/role/IncomeTaxes",
     "shortName": "INCOME TAXES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "From2019-01-01to2019-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "From2019-01-01to2019-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000017 - Disclosure - RELATED PARTIES",
     "role": "http://therapeuticsmd.com/role/RelatedParties",
     "shortName": "RELATED PARTIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "From2019-01-01to2019-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "From2019-01-01to2019-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000018 - Disclosure - BUSINESS CONCENTRATIONS",
     "role": "http://therapeuticsmd.com/role/BusinessConcentrations",
     "shortName": "BUSINESS CONCENTRATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "From2019-01-01to2019-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "From2019-01-01to2019-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000019 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "role": "http://therapeuticsmd.com/role/CommitmentsAndContingencies",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "From2019-01-01to2019-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "AsOf2019-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Cash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000002 - Statement - CONSOLIDATED BALANCE SHEETS",
     "role": "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "AsOf2019-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Cash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "From2019-01-01to2019-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:QuarterlyFinancialInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000020 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)",
     "role": "http://therapeuticsmd.com/role/SelectedQuarterlyFinancialData",
     "shortName": "SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "From2019-01-01to2019-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:QuarterlyFinancialInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "From2019-01-01to2019-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000021 - Disclosure - SUBSEQUENT EVENTS",
     "role": "http://therapeuticsmd.com/role/SubsequentEvents",
     "shortName": "SUBSEQUENT EVENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "From2019-01-01to2019-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "From2019-01-01to2019-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000022 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "role": "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "From2019-01-01to2019-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "From2019-01-01to2019-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000023 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "role": "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "From2019-01-01to2019-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "From2019-01-01to2019-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000024 - Disclosure - INVENTORY (Tables)",
     "role": "http://therapeuticsmd.com/role/InventoryTables",
     "shortName": "INVENTORY (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "From2019-01-01to2019-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:OtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "From2019-01-01to2019-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000025 - Disclosure - OTHER CURRENT ASSETS (Tables)",
     "role": "http://therapeuticsmd.com/role/OtherCurrentAssetsTables",
     "shortName": "OTHER CURRENT ASSETS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:OtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "From2019-01-01to2019-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "From2019-01-01to2019-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000026 - Disclosure - FIXED ASSETS, NET (Tables)",
     "role": "http://therapeuticsmd.com/role/FixedAssetsNetTables",
     "shortName": "FIXED ASSETS, NET (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "From2019-01-01to2019-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "From2019-01-01to2019-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "txmd:ScheduleOfIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000027 - Disclosure - INTANGIBLE ASSETS, NET (Tables)",
     "role": "http://therapeuticsmd.com/role/IntangibleAssetsNetTables",
     "shortName": "INTANGIBLE ASSETS, NET (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "From2019-01-01to2019-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "txmd:ScheduleOfIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "From2019-01-01to2019-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000028 - Disclosure - OTHER CURRENT LIABILITIES (Tables)",
     "role": "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesTables",
     "shortName": "OTHER CURRENT LIABILITIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "From2019-01-01to2019-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LongTermDebtTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "From2019-01-01to2019-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000029 - Disclosure - DEBT (Tables)",
     "role": "http://therapeuticsmd.com/role/DebtTables",
     "shortName": "DEBT (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LongTermDebtTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "From2019-01-01to2019-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "AsOf2019-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "AsOf2019-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "From2019-01-01to2019-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "txmd:ScheduleOfWarrantRollForwardTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000030 - Disclosure - STOCKHOLDERS\u2019 EQUITY (Tables)",
     "role": "http://therapeuticsmd.com/role/StockholdersEquityTables",
     "shortName": "STOCKHOLDERS\u2019 EQUITY (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "From2019-01-01to2019-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "txmd:ScheduleOfWarrantRollForwardTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "From2019-01-01to2019-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000031 - Disclosure - INCOME TAXES (Tables)",
     "role": "http://therapeuticsmd.com/role/IncomeTaxesTables",
     "shortName": "INCOME TAXES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "From2019-01-01to2019-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "From2019-01-01to2019-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "txmd:ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000032 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)",
     "role": "http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "From2019-01-01to2019-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "txmd:ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:QuarterlyFinancialInformationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "From2019-01-01to2019-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000033 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) (Tables)",
     "role": "http://therapeuticsmd.com/role/SelectedQuarterlyFinancialDataTables",
     "shortName": "SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:QuarterlyFinancialInformationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "From2019-01-01to2019-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:NatureOfOperations",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "AsOf2019-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "txmd:NumberOfSubsidiaries",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000034 - Disclosure - THE COMPANY (Details Narrative)",
     "role": "http://therapeuticsmd.com/role/CompanyDetailsNarrative",
     "shortName": "THE COMPANY (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:NatureOfOperations",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "AsOf2019-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "txmd:NumberOfSubsidiaries",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "us-gaap:QuarterlyFinancialInformationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "From2019-10-012019-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000035 - Disclosure - The following table provides information about disaggregated revenue by product mix for the years ended December 31, 2019, 2018, and 2017: (Details)",
     "role": "http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueByProductMixForYearsEndedDecember3120192018And2017Details",
     "shortName": "The following table provides information about disaggregated revenue by product mix for the years ended December 31, 2019, 2018, and 2017: (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "From2019-01-012019-12-31_custom_PrescriptionVitaminsMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "From2019-01-01to2019-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000036 - Disclosure - The table below presents potentially dilutive securities that could affect our calculation of diluted net loss per share allocable to common stockholders for the periods presented. (Details)",
     "role": "http://therapeuticsmd.com/role/TableBelowPresentsPotentiallyDilutiveSecuritiesThatCouldAffectOurCalculationOfDilutedNetLossPerShareAllocableToCommonStockholdersForPeriodsPresented.Details",
     "shortName": "The table below presents potentially dilutive securities that could affect our calculation of diluted net loss per share allocable to common stockholders for the periods presented. (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "From2019-01-01to2019-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "AsOf2019-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashFDICInsuredAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000037 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "role": "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "AsOf2019-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashFDICInsuredAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "AsOf2019-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryFinishedGoods",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000038 - Disclosure - Inventory consists of the following: (Details)",
     "role": "http://therapeuticsmd.com/role/InventoryConsistsOfFollowingDetails",
     "shortName": "Inventory consists of the following: (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "AsOf2019-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryFinishedGoods",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "AsOf2019-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "txmd:PrepaidSalesAndMarketingCostsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000039 - Disclosure - Other current assets consist of the following: (Details)",
     "role": "http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails",
     "shortName": "Other current assets consist of the following: (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "AsOf2019-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "txmd:PrepaidSalesAndMarketingCostsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "From2019-01-01to2019-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS",
     "role": "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "From2019-01-01to2019-12-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "AsOf2019-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000040 - Disclosure - Fixed assets, net consist of the following: (Details)",
     "role": "http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails",
     "shortName": "Fixed assets, net consist of the following: (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "AsOf2019-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "From2019-01-01to2019-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000041 - Disclosure - FIXED ASSETS, NET (Details Narrative)",
     "role": "http://therapeuticsmd.com/role/FixedAssetsNetDetailsNarrative",
     "shortName": "FIXED ASSETS, NET (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "txmd:ScheduleOfIntangibleAssetsTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "AsOf2019-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000042 - Disclosure - The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of December 31, 2019 and 2018: (Details)",
     "role": "http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfDecember312019And2018Details",
     "shortName": "The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of December 31, 2019 and 2018: (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "txmd:ScheduleOfIntangibleAssetsTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "AsOf2019-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "AsOf2019-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000043 - Disclosure - Estimated amortization expense, based on current patent cost being amortized, for the next five years is as follows: (Details)",
     "role": "http://therapeuticsmd.com/role/EstimatedAmortizationExpenseBasedOnCurrentPatentCostBeingAmortizedForNextFiveYearsIsAsFollowsDetails",
     "shortName": "Estimated amortization expense, based on current patent cost being amortized, for the next five years is as follows: (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "AsOf2019-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "From2019-01-01to2019-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000044 - Disclosure - INTANGIBLE ASSETS, NET (Details Narrative)",
     "role": "http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative",
     "shortName": "INTANGIBLE ASSETS, NET (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "From2019-01-01to2019-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "AsOf2019-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedSalariesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000045 - Disclosure - Other current liabilities consist of the following: (Details)",
     "role": "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails",
     "shortName": "Other current liabilities consist of the following: (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "AsOf2019-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedSalariesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "us-gaap:LongTermDebtTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "AsOf2019-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000046 - Disclosure - As of December 31, 2019 and 2018, the carrying value of our debt consisted of the following: (Details)",
     "role": "http://therapeuticsmd.com/role/AsOfDecember312019And2018CarryingValueOfOurDebtConsistedOfFollowingDetails",
     "shortName": "As of December 31, 2019 and 2018, the carrying value of our debt consisted of the following: (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "us-gaap:LongTermDebtTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "AsOf2019-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "From2019-01-01to2019-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromLinesOfCredit",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000047 - Disclosure - DEBT (Details Narrative)",
     "role": "http://therapeuticsmd.com/role/DebtDetailsNarrative",
     "shortName": "DEBT (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:LongTermDebtTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "From2019-01-012019-12-31_custom_FinancingAgreementMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:InterestExpenseBorrowings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "txmd:ScheduleOfWarrantRollForwardTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "AsOf2018-12-31_us-gaap_WarrantMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000048 - Disclosure - Summary of our Warrant activity during the year ended December 31, 2019: (Details)",
     "role": "http://therapeuticsmd.com/role/SummaryOfOurWarrantActivityDuringYearEndedDecember312019Details",
     "shortName": "Summary of our Warrant activity during the year ended December 31, 2019: (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "txmd:ScheduleOfWarrantRollForwardTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "From2019-01-012019-12-31_us-gaap_WarrantMember",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "txmd:ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "From2019-01-012019-12-31_us-gaap_WarrantMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "txmd:WeightedAverageExercisePriceOtherThanOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000049 - Disclosure - The weighted average fair value per share of warrants issued and the assumptions used in the Black-Scholes Model during the years ended December 31, 2019, 2018, and 2017 are set forth in the table below. (Details)",
     "role": "http://therapeuticsmd.com/role/WeightedAverageFairValuePerShareOfWarrantsIssuedAndAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120192018And2017AreSetForthInTableBelow.Details",
     "shortName": "The weighted average fair value per share of warrants issued and the assumptions used in the Black-Scholes Model during the years ended December 31, 2019, 2018, and 2017 are set forth in the table below. (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "txmd:ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "From2019-01-012019-12-31_us-gaap_WarrantMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "txmd:WeightedAverageExercisePriceOtherThanOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "AsOf2016-12-31_us-gaap_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "role": "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquity",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "AsOf2016-12-31_us-gaap_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "AsOf2019-12-31_us-gaap_EmployeeStockOptionMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000050 - Disclosure - The ranges of assumptions used in the Black-Scholes Model during the years ended December 31, 2019, 2018, and 2017 are set forth in the table below. (Details)",
     "role": "http://therapeuticsmd.com/role/RangesOfAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120192018And2017AreSetForthInTableBelow.Details",
     "shortName": "The ranges of assumptions used in the Black-Scholes Model during the years ended December 31, 2019, 2018, and 2017 are set forth in the table below. (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "AsOf2019-12-31_us-gaap_EmployeeStockOptionMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "From2017-01-012017-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000051 - Disclosure - A summary of activity under the 2009, 2012 and 2019 Plans and related information during the year ended December 31, 2019 is as follows: (Details)",
     "role": "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringYearEndedDecember312019IsAsFollowsDetails",
     "shortName": "A summary of activity under the 2009, 2012 and 2019 Plans and related information during the year ended December 31, 2019 is as follows: (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "AsOf2019-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000052 - Disclosure - STOCKHOLDERS\u2019 EQUITY (Details Narrative)",
     "role": "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative",
     "shortName": "STOCKHOLDERS\u2019 EQUITY (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "From2019-01-01to2019-12-31",
      "decimals": "INF",
      "lang": null,
      "name": "txmd:NumberOfStockOptionsExercisedInCashlessExercise",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "From2019-01-01to2019-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000053 - Disclosure - For financial reporting purposes, income before taxes includes the following components: (Details)",
     "role": "http://therapeuticsmd.com/role/ForFinancialReportingPurposesIncomeBeforeTaxesIncludesFollowingComponentsDetails",
     "shortName": "For financial reporting purposes, income before taxes includes the following components: (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "From2019-01-01to2019-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "From2019-01-01to2019-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000054 - Disclosure - A reconciliation between taxes computed at the federal statutory rate and the consolidated effective tax rate is as follows: (Details)",
     "role": "http://therapeuticsmd.com/role/ReconciliationBetweenTaxesComputedAtFederalStatutoryRateAndConsolidatedEffectiveTaxRateIsAsFollowsDetails",
     "shortName": "A reconciliation between taxes computed at the federal statutory rate and the consolidated effective tax rate is as follows: (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "From2019-01-01to2019-12-31",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "AsOf2019-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOtherLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000055 - Disclosure - The components of the net deferred income tax asset as of December 31, 2019, 2018, and 2017 are as follows: (Details)",
     "role": "http://therapeuticsmd.com/role/ComponentsOfNetDeferredIncomeTaxAssetAsOfDecember3120192018And2017AreAsFollowsDetails",
     "shortName": "The components of the net deferred income tax asset as of December 31, 2019, 2018, and 2017 are as follows: (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "AsOf2019-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOtherLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "From2019-01-01to2019-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000056 - Disclosure - INCOME TAXES (Details Narrative)",
     "role": "http://therapeuticsmd.com/role/IncomeTaxesDetailsNarrative",
     "shortName": "INCOME TAXES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "From2017-01-012017-12-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalIncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "From2019-01-012019-12-31_srt_AffiliatedEntityMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000057 - Disclosure - RELATED PARTIES (Details Narrative)",
     "role": "http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative",
     "shortName": "RELATED PARTIES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "From2019-01-012019-12-31_srt_AffiliatedEntityMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:ConcentrationRiskDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "From2019-01-01to2019-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "txmd:NumberOfVendors",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000058 - Disclosure - BUSINESS CONCENTRATIONS (Details Narrative)",
     "role": "http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative",
     "shortName": "BUSINESS CONCENTRATIONS (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:ConcentrationRiskDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "From2019-01-01to2019-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "txmd:NumberOfVendors",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "AsOf2019-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000059 - Disclosure - Supplemental lease information (Details)",
     "role": "http://therapeuticsmd.com/role/SupplementalLeaseInformationDetails",
     "shortName": "Supplemental lease information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "txmd:ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "AsOf2019-12-31",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "From2019-01-01to2019-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "From2019-01-01to2019-12-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:OtherNoncashExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "AsOf2019-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000060 - Disclosure - The following table reconciles the undiscounted cash flows for all operating leases at December 31, 2019 to the operating lease liabilities recorded on the balance sheet: (Details)",
     "role": "http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtDecember312019ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails",
     "shortName": "The following table reconciles the undiscounted cash flows for all operating leases at December 31, 2019 to the operating lease liabilities recorded on the balance sheet: (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "AsOf2019-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "From2013-06-302013-07-01",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "txmd:CapitalLeaseObligationsTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000061 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "role": "http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "From2013-06-302013-07-01",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "txmd:CapitalLeaseObligationsTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "us-gaap:QuarterlyFinancialInformationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "From2019-10-012019-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000062 - Disclosure - Summarized quarterly financial data for fiscal years 2019 and 2018 is as follows: (Details)",
     "role": "http://therapeuticsmd.com/role/SummarizedQuarterlyFinancialDataForFiscalYears2019And2018IsAsFollowsDetails",
     "shortName": "Summarized quarterly financial data for fiscal years 2019 and 2018 is as follows: (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "us-gaap:QuarterlyFinancialInformationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "From2019-10-012019-12-31",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:GrossProfit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "From2019-01-01to2019-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromLinesOfCredit",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000063 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)",
     "role": "http://therapeuticsmd.com/role/SubsequentEventsDetailsNarrative",
     "shortName": "SUBSEQUENT EVENTS (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "From2019-01-01to2019-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000007 - Disclosure - THE COMPANY",
     "role": "http://therapeuticsmd.com/role/Company",
     "shortName": "THE COMPANY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "From2019-01-01to2019-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "From2019-01-01to2019-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "role": "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPolicies",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "From2019-01-01to2019-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "From2019-01-01to2019-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000009 - Disclosure - INVENTORY",
     "role": "http://therapeuticsmd.com/role/Inventory",
     "shortName": "INVENTORY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10k_123119.htm",
      "contextRef": "From2019-01-01to2019-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 100,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The start date of the period covered in the document, in CCYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r345"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r339"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r342"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r341"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "srt_AffiliatedEntityMember": {
     "auth_ref": [
      "r194",
      "r291",
      "r292",
      "r337"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Affiliated Entity [Member]"
       }
      }
     },
     "localname": "AffiliatedEntityMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative",
      "http://therapeuticsmd.com/role/RangesOfAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120192018And2017AreSetForthInTableBelow.Details",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative",
      "http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative",
      "http://therapeuticsmd.com/role/RangesOfAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120192018And2017AreSetForthInTableBelow.Details",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/SubsequentEventsDetailsNarrative",
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r127",
      "r188",
      "r190",
      "r331",
      "r332"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations",
      "http://therapeuticsmd.com/role/DebtDetailsNarrative",
      "http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueByProductMixForYearsEndedDecember3120192018And2017Details",
      "http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative",
      "http://therapeuticsmd.com/role/SubsequentEventsDetailsNarrative",
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [],
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations",
      "http://therapeuticsmd.com/role/DebtDetailsNarrative",
      "http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueByProductMixForYearsEndedDecember3120192018And2017Details",
      "http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative",
      "http://therapeuticsmd.com/role/SubsequentEventsDetailsNarrative",
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative",
      "http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative",
      "http://therapeuticsmd.com/role/RangesOfAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120192018And2017AreSetForthInTableBelow.Details",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/SubsequentEventsDetailsNarrative",
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [],
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative",
      "http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative",
      "http://therapeuticsmd.com/role/RangesOfAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120192018And2017AreSetForthInTableBelow.Details",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/SubsequentEventsDetailsNarrative",
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_AccruedRebates": {
     "auth_ref": [],
     "calculation": {
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable forrebates. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued rebates"
       }
      }
     },
     "localname": "AccruedRebates",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_AccruedResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for research and development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued research and development"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopment",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_AdditionalAreaOfLeaseOccupied": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additional rented area occupied under the lease.",
        "label": "Additional area of lease occupied"
       }
      }
     },
     "localname": "AdditionalAreaOfLeaseOccupied",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "areaItemType"
    },
    "txmd_AllowanceForWholesaleDistributorFeesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for wholesale distributor fees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Allowance for wholesale distributor fees"
       }
      }
     },
     "localname": "AllowanceForWholesaleDistributorFeesCurrent",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_AnnoveraMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The drug name.",
        "label": "ANNOVERA [Member]"
       }
      }
     },
     "localname": "AnnoveraMember",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueByProductMixForYearsEndedDecember3120192018And2017Details",
      "http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_AnnualNetSalesMilestone": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Annual net sale milestones in the Territory per license agreement.",
        "label": "Sales milestone"
       }
      }
     },
     "localname": "AnnualNetSalesMilestone",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The reduction in royalty rate of initial rate six-months after the first arms-length commercial sale of a generic equivalent of the one-year vaginal contraceptive system that is launched by a third party in the U.S.",
        "label": "Annual royalty rate reduction of initial rate after the six-month period from commercial sale of a generic equivalent"
       }
      }
     },
     "localname": "AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The reduction in royalty rate of the initial rate during the six-month period beginning on the date of the first arms-length commercial sale of a generic equivalent of the one-year vaginal contraceptive system that is launched by a third party in the U.S.",
        "label": "Annual royalty rate reduction of initial rate during the six-month period from commercial sale of a generic equivalent"
       }
      }
     },
     "localname": "AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Hormone Therapy Drug Candidate Patents Member.",
        "label": "Approved Hormone Therapy Drug Candidate Patents [Member]"
       }
      }
     },
     "localname": "ApprovedHormoneTherapyDrugCandidatePatentsMember",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfDecember312019And2018Details",
      "http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_BijuvaAndAnnoveraMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "BIJUVA and ANNOVERA",
        "label": "BIJUVA and ANNOVERA [Member]"
       }
      }
     },
     "localname": "BijuvaAndAnnoveraMember",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_BijuvaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "BIJUVA [Member]",
        "label": "BIJUVA [Member]"
       }
      }
     },
     "localname": "BijuvaMember",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueByProductMixForYearsEndedDecember3120192018And2017Details"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_CapitalLeaseObligationsTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The total term (in months) of the company's outstanding lease obligation.",
        "label": "Non-cancelable operating lease term"
       }
      }
     },
     "localname": "CapitalLeaseObligationsTerm",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "txmd_CashUpfrontPaymentReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from license agreement.",
        "label": "Cash upfront payment received"
       }
      }
     },
     "localname": "CashUpfrontPaymentReceived",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_CatalentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Catalent",
        "label": "Catalent [Member]"
       }
      }
     },
     "localname": "CatalentMember",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_CouncilLicenseAgreement1Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information about agreement.",
        "label": "Council License Agreement [Member]"
       }
      }
     },
     "localname": "CouncilLicenseAgreement1Member",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_CouncilLicenseAgreementStep1Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Council License Agreement Step 1",
        "label": "Council License Agreement Step 1"
       }
      }
     },
     "localname": "CouncilLicenseAgreementStep1Member",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_CouncilLicenseAgreementStep2Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Council License Agreement Step 2",
        "label": "Council License Agreement Step 2"
       }
      }
     },
     "localname": "CouncilLicenseAgreementStep2Member",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_CouncilLicenseAgreementStep3Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Council License Agreement Step 3",
        "label": "Council License Agreement Step 3"
       }
      }
     },
     "localname": "CouncilLicenseAgreementStep3Member",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_CreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "CreditAgreementMember",
        "label": "Credit Agreement Member"
       }
      }
     },
     "localname": "CreditAgreementMember",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/AsOfDecember312019And2018CarryingValueOfOurDebtConsistedOfFollowingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_CustomerAMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Customer A",
        "label": "Customer A [Member]"
       }
      }
     },
     "localname": "CustomerAMember",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_CustomerBMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Customer B",
        "label": "Customer B [Member]"
       }
      }
     },
     "localname": "CustomerBMember",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_CustomerCMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Customer C",
        "label": "Customer C [Member]"
       }
      }
     },
     "localname": "CustomerCMember",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_CustomerConcentrationAmerisourceBergenRiskMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Custome rConcentration AmerisourceBergen Risk Member",
        "label": "AmerisourceBergen - Major Customer"
       }
      }
     },
     "localname": "CustomerConcentrationAmerisourceBergenRiskMember",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_CustomerConcentrationCardinalHealthRiskMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Customer Concentration Cardinal Health Risk Member",
        "label": "Cardinal Health - Major Customer"
       }
      }
     },
     "localname": "CustomerConcentrationCardinalHealthRiskMember",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_CustomerConcentrationMcKessonCorporationRiskMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "McKesson Corporation - Major Customer",
        "label": "McKesson Corporation - Major Customer"
       }
      }
     },
     "localname": "CustomerConcentrationMcKessonCorporationRiskMember",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_CustomerConcentrationPharmacyInnovationsPaRiskMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pharmacy Innovations PA - Major Customer",
        "label": "Pharmacy Innovations PA - Major Customer"
       }
      }
     },
     "localname": "CustomerConcentrationPharmacyInnovationsPaRiskMember",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_CustomerConcentrationPillPackRiskMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Major customers in concentration of sales.",
        "label": "PillPack - Major Customer"
       }
      }
     },
     "localname": "CustomerConcentrationPillPackRiskMember",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_CustomerDMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Customer D",
        "label": "Customer D [Member]"
       }
      }
     },
     "localname": "CustomerDMember",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_DebtTrancheAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Portions of the Credit and Security Agreement to draw funds.",
        "label": "Debt Tranche [Axis]"
       }
      }
     },
     "localname": "DebtTrancheAxis",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "txmd_DebtTrancheDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "DebtTrancheDomain"
       }
      }
     },
     "localname": "DebtTrancheDomain",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_DomesticPatentsBijuvaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Domestic Patents Bijuva",
        "label": "Domestic Patents BIJUVA"
       }
      }
     },
     "localname": "DomesticPatentsBijuvaMember",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_DomesticPatentsNonApprovedBijuvaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Domestic Patents NonApproved Bijuva",
        "label": "Domestic Patents NonApproved BIJUVA"
       }
      }
     },
     "localname": "DomesticPatentsNonApprovedBijuvaMember",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_DomesticPatentsProgesteroneFormulationsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Domestic Patents Progesterone Formulations",
        "label": "Domestic Patents Progesterone Formulations"
       }
      }
     },
     "localname": "DomesticPatentsProgesteroneFormulationsMember",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_DomesticUSDesignPatentsImvexxyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Domestic US Design Patents IMVEXXY",
        "label": "Domestic US Design Patents IMVEXXY"
       }
      }
     },
     "localname": "DomesticUSDesignPatentsImvexxyMember",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_DomesticUSPatentsImvexxyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Domestic US Patents IMVEXXY",
        "label": "Domestic US Patents IMVEXXY"
       }
      }
     },
     "localname": "DomesticUSPatentsImvexxyMember",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_DomesticUSPatentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Domestic US Patents",
        "label": "Domestic US Patents"
       }
      }
     },
     "localname": "DomesticUSPatentsMember",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_DomesticUSPatentsTopicalCreamMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Domestic US Patents Topical Cream",
        "label": "Domestic US Patents Topical Cream"
       }
      }
     },
     "localname": "DomesticUSPatentsTopicalCreamMember",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_DomesticUSUtilityPatentsImvexxyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Domestic US Utility Patents IMVEXXY",
        "label": "Domestic US Utility Patents IMVEXXY"
       }
      }
     },
     "localname": "DomesticUSUtilityPatentsImvexxyMember",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_DomesticUtilityPatentOperaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Domestic Utility Patent Opera",
        "label": "Domestic Utility Patent Opera"
       }
      }
     },
     "localname": "DomesticUtilityPatentOperaMember",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_DomesticUtilityPatentTransdermalPatchMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Domestic Utility Patent Transdermal Patch",
        "label": "Domestic Utility Patent Transdermal Patch"
       }
      }
     },
     "localname": "DomesticUtilityPatentTransdermalPatchMember",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_DomesticUtilityPatentTx009HRMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Domestic Utility Patent TX009HR",
        "label": "Domestic Utility Patent TX009HR"
       }
      }
     },
     "localname": "DomesticUtilityPatentTx009HRMember",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_EntityCommonStockHeldByNonaffiliates": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares or other units held by non-affiliates of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report.",
        "label": "Entity Common Stock Held by Non-affiliates"
       }
      }
     },
     "localname": "EntityCommonStockHeldByNonaffiliates",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "txmd_ExpirationPeriod20YearsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expiration Period 20 Years",
        "label": "Expiration Period 20 Years [Member]"
       }
      }
     },
     "localname": "ExpirationPeriod20YearsMember",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_ExpirationPeriodIndefiniteMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expiration Period Indefinite",
        "label": "Expiration Period Indefinite [Member]"
       }
      }
     },
     "localname": "ExpirationPeriodIndefiniteMember",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_FacilityFeePaidPercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The facility fee expressed as a percentage paid or payable to the Agent for the benefit of lenders, under the terms of Credit Agreement.",
        "label": "Facility fee paid (percent)"
       }
      }
     },
     "localname": "FacilityFeePaidPercent",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "txmd_FinancingAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents member of financing agreement.",
        "label": "Financing Agreement [Member]"
       }
      }
     },
     "localname": "FinancingAgreementMember",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/AsOfDecember312019And2018CarryingValueOfOurDebtConsistedOfFollowingDetails",
      "http://therapeuticsmd.com/role/DebtDetailsNarrative",
      "http://therapeuticsmd.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_ForeignDesignPatentsImvexxyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Foreign Design Patents IMVEXXY",
        "label": "Foreign Design Patents IMVEXXY"
       }
      }
     },
     "localname": "ForeignDesignPatentsImvexxyMember",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_ForeignPatentsBijuvaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Foreign Patents BIJUVA",
        "label": "Foreign Patents BIJUVA"
       }
      }
     },
     "localname": "ForeignPatentsBijuvaMember",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_ForeignPatentsImvexxyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Foreign Patents IMVEXXY",
        "label": "Foreign Patents IMVEXXY"
       }
      }
     },
     "localname": "ForeignPatentsImvexxyMember",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_ForeignPatentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Foreign Patents Member",
        "label": "Foreign Patents Member"
       }
      }
     },
     "localname": "ForeignPatentsMember",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_ForeignPatentsProgesteroneFormulationsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Foreign Patents Progesterone Formulations",
        "label": "Foreign Patents Progesterone Formulations"
       }
      }
     },
     "localname": "ForeignPatentsProgesteroneFormulationsMember",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_ForeignUtilityPatentTransdermalPatchMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Foreign Utility Patent Transdermal Patch",
        "label": "Foreign Utility Patent Transdermal Patch"
       }
      }
     },
     "localname": "ForeignUtilityPatentTransdermalPatchMember",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_ForeignUtilityPatentsImvexxyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Foreign Utility Patents IMVEXXY",
        "label": "Foreign Utility Patents IMVEXXY"
       }
      }
     },
     "localname": "ForeignUtilityPatentsImvexxyMember",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_FourCustomersConcentrationRiskMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Four Customers Concentration Risk Member",
        "label": "Four Customers Concentration Risk Member"
       }
      }
     },
     "localname": "FourCustomersConcentrationRiskMember",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_HormoneTherapyDrugCandidatePatentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Hormone Therapy Drug Candidate Patents Member.",
        "label": "Hormone Therapy Drug Candidate Patents - (Pending) [Member]"
       }
      }
     },
     "localname": "HormoneTherapyDrugCandidatePatentsMember",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfDecember312019And2018Details"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_ImvexxyBijuvaAndAnnoveraMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "IMVEXXY, BIJUVA and ANNOVERA",
        "label": "IMVEXXY, BIJUVA and ANNOVERA [Member]"
       }
      }
     },
     "localname": "ImvexxyBijuvaAndAnnoveraMember",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative",
      "http://therapeuticsmd.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_ImvexxyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information about ImvexxyTm.",
        "label": "Imvexxy [Member]"
       }
      }
     },
     "localname": "ImvexxyMember",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueByProductMixForYearsEndedDecember3120192018And2017Details"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_LesseeFinanceLeaseExistenceOfOptionToExtendNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options to extend lease.",
        "label": "Number of options to extend lease"
       }
      }
     },
     "localname": "LesseeFinanceLeaseExistenceOfOptionToExtendNumber",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "integerItemType"
    },
    "txmd_LesseeOperatingLeaseLeaseNotYetCommencedArea": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Future rented area to be occupied for administrative office space as defined in lease.",
        "label": "Lease not yet commenced (area)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedArea",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "areaItemType"
    },
    "txmd_LiborFloorRate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents libor floor rate.",
        "label": "LIBOR floor rate"
       }
      }
     },
     "localname": "LiborFloorRate",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "txmd_LicenseAgreementTheramexMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "License Agreement Theramex",
        "label": "License Agreement Theramex"
       }
      }
     },
     "localname": "LicenseAgreementTheramexMember",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/SummarizedQuarterlyFinancialDataForFiscalYears2019And2018IsAsFollowsDetails",
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_LicenseRights": {
     "auth_ref": [],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of license rights.",
        "label": "License rights, net"
       }
      }
     },
     "localname": "LicenseRights",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_LongTermIncentiveCompensationPlan2009Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Long Term Incentive Compensation Plan 2009 Member.",
        "label": "2009 Long Term Incentive Compensation Plan [Member]"
       }
      }
     },
     "localname": "LongTermIncentiveCompensationPlan2009Member",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum amount of costs and expenses associated with a post approval study required by the FDA to measure risk for venous thromboembolism to be paid by the Company before any such excess will be offset against royalties or other payments owed by us to the Population Council under the Council License Agreement.",
        "label": "Maximum costs and expenses for post approval"
       }
      }
     },
     "localname": "MaximumCostsAndExpensesForPostApprovalStudyToBePaid",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_MidCapAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents member of Mid Cap agreement.",
        "label": "Credit Agreement [Member]"
       }
      }
     },
     "localname": "MidCapAgreementMember",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_MilestonePaymentUponFDAApproval": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of milestone payments upon FDA approval.",
        "label": "Milestone payment upon FDA Approval"
       }
      }
     },
     "localname": "MilestonePaymentUponFDAApproval",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of milestone payments payable after release of first commercial batch.",
        "label": "Milestone payments (payment after release of first commercial batch)"
       }
      }
     },
     "localname": "MilestonePaymentsAfterReleaseOfFirstCommercialBatch",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_MinimumCashBalanceRequirementUnderCreditAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The minimum cash balance the Borrower must maintain under the credit and secuirty agreement.",
        "label": "Minimum cash balance requirement under credit agreement"
       }
      }
     },
     "localname": "MinimumCashBalanceRequirementUnderCreditAgreement",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_MultipleTrademarksForVitaminsSupplementsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Multiple Trademarks For Vitamins Supplements Member.",
        "label": "Multiple Trademarks [Member]"
       }
      }
     },
     "localname": "MultipleTrademarksForVitaminsSupplementsMember",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfDecember312019And2018Details"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_NetRentableAreaLease": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Net rentable area as defined in lease.",
        "label": "Net rentable area"
       }
      }
     },
     "localname": "NetRentableAreaLease",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "areaItemType"
    },
    "txmd_NetSalesAmountPerStepbasedRoyalty": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net sales amount as defined in license agreement for step-based royalty payments.",
        "label": "Net sales amount per step-based royalty"
       }
      }
     },
     "localname": "NetSalesAmountPerStepbasedRoyalty",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_NolCarryForwardPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expiration period of operating loss carryforward included in operating loss carryforward.",
        "label": "NOL carry forward period"
       }
      }
     },
     "localname": "NolCarryForwardPeriod",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "txmd_NonQualified2012StockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Non Qualified 2012 Stock Incentive Plan Member.",
        "label": "2012 Stock Incentive Plan [Member]"
       }
      }
     },
     "localname": "NonQualified2012StockIncentivePlanMember",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_NoncashOperatingLeaseExpense": {
     "auth_ref": [],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense related to operating lease costs.",
        "label": "Non-cash operating lease expense"
       }
      }
     },
     "localname": "NoncashOperatingLeaseExpense",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock issued attributable to stock options exercised in cashless transaction.",
        "label": "Number of common stock issued during period for stock options exercised in cashless exercise (in shares)"
       }
      }
     },
     "localname": "NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "txmd_NumberOfCustomers": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of customers.",
        "label": "Number of customers - revenue"
       }
      }
     },
     "localname": "NumberOfCustomers",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "integerItemType"
    },
    "txmd_NumberOfInstallmentPayments": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of principal installment payments under credit and security agreement.",
        "label": "Number of quarterly principal installment payments"
       }
      }
     },
     "localname": "NumberOfInstallmentPayments",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "integerItemType"
    },
    "txmd_NumberOfIssuedPatents": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of issued patents.",
        "label": "Number of issued patents"
       }
      }
     },
     "localname": "NumberOfIssuedPatents",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "integerItemType"
    },
    "txmd_NumberOfIssuedPatentsDomestic": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of issued patents domestic.",
        "label": "Number of issued patents domestic."
       }
      }
     },
     "localname": "NumberOfIssuedPatentsDomestic",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "integerItemType"
    },
    "txmd_NumberOfIssuedPatentsForeign": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of issued patents foreign.",
        "label": "Number of issued patents foreign"
       }
      }
     },
     "localname": "NumberOfIssuedPatentsForeign",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "integerItemType"
    },
    "txmd_NumberOfStockIssuedInCashlessExerciseOfWarrants": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock issued attributable to warrants exercised in cashless transaction.",
        "label": "Number of stock issued in cashless exercise of warrants"
       }
      }
     },
     "localname": "NumberOfStockIssuedInCashlessExerciseOfWarrants",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "txmd_NumberOfStockOptionsExercisedInCashlessExercise": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options exercised in the cashless transaction.",
        "label": "Number of stock options exercised in cashless exercise (in shares)"
       }
      }
     },
     "localname": "NumberOfStockOptionsExercisedInCashlessExercise",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "txmd_NumberOfSubsidiaries": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of subsidiaires for period reported.",
        "label": "Number of subsidiaires"
       }
      }
     },
     "localname": "NumberOfSubsidiaries",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/CompanyDetailsNarrative"
     ],
     "xbrltype": "integerItemType"
    },
    "txmd_NumberOfTranchesUnderTermLoanFacility": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of seperate tranches under terms of the Credit Agreement.",
        "label": "Number of tranches under term loan facility"
       }
      }
     },
     "localname": "NumberOfTranchesUnderTermLoanFacility",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "integerItemType"
    },
    "txmd_NumberOfVendors": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of vendors.",
        "label": "Number of vendors - suppliers"
       }
      }
     },
     "localname": "NumberOfVendors",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "integerItemType"
    },
    "txmd_OperatingLossCarryforwardsExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expiration year of operating loss carryforward.",
        "label": "NOL carry forward expiration year"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsExpirationYear",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "gYearItemType"
    },
    "txmd_OtcProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "OTC Products",
        "label": "OTC Products [Member]"
       }
      }
     },
     "localname": "OtcProductsMember",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueByProductMixForYearsEndedDecember3120192018And2017Details"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_OutsideConsultant2Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A person who provides consutling services to the Company.",
        "label": "Outside Consultants Warrants [Member]"
       }
      }
     },
     "localname": "OutsideConsultant2Member",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_PaymentsToAcquireIntellectualPropertyLicense": {
     "auth_ref": [],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outlow for payments to acquir intellectual property license.",
        "label": "Payments to acquire intellectual property license",
        "negatedLabel": "Payment for intellectual property license"
       }
      }
     },
     "localname": "PaymentsToAcquireIntellectualPropertyLicense",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_PeriodExercisableUnderwritersOption": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The period the option is exercisable per agreement.",
        "label": "Period exercisable underwriters option"
       }
      }
     },
     "localname": "PeriodExercisableUnderwritersOption",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "txmd_Plan2019Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "New 2019 Plan.",
        "label": "Plan 2019 [Member]"
       }
      }
     },
     "localname": "Plan2019Member",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_PlanAwardsNumberOfNewShares": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of new shares authorized for stock awards.",
        "label": "Plan awards number of new shares"
       }
      }
     },
     "localname": "PlanAwardsNumberOfNewShares",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "txmd_PrepaidManufacturing": {
     "auth_ref": [],
     "calculation": {
      "http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Prepaid manufacturing costs.",
        "label": "Prepaid manufacturing"
       }
      }
     },
     "localname": "PrepaidManufacturing",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_PrepaidSalesAndMarketingCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "It refers to the amount of prepaid sales and marketing costs incurred.",
        "label": "Prepaid sales and marketing costs"
       }
      }
     },
     "localname": "PrepaidSalesAndMarketingCostsCurrent",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_PrepaymentFeeFifthYearFundingPercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The prepayment fee expressed as a percentage of the funding being repaid for fifth year following the initial funding date of the applicable borrowing.",
        "label": "Prepayment fee fifth year funding (percent)"
       }
      }
     },
     "localname": "PrepaymentFeeFifthYearFundingPercent",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "txmd_PrepaymentFeeForFirstTwoYearsFundingPercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The prepayment fee expressed as a percentage of the funding being repaid for first two years following the initial funding date of the applicable borrowing.",
        "label": "Prepayment fee for first two years funding (percent)"
       }
      }
     },
     "localname": "PrepaymentFeeForFirstTwoYearsFundingPercent",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "txmd_PrepaymentFeeFourthYearFundingPercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The prepayment fee expressed as a percentage of the funding being repaid for fourth year following the initial funding date of the applicable borrowing.",
        "label": "Prepayment fee fourth year funding (percent)"
       }
      }
     },
     "localname": "PrepaymentFeeFourthYearFundingPercent",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "txmd_PrepaymentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The prepayment fee, expressed as a percentage of the tranche funding being repaid,",
        "label": "Prepayment fee percentage"
       }
      }
     },
     "localname": "PrepaymentFeePercentage",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "txmd_PrepaymentFeeThirdYearFundingPercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The prepayment fee expressed as a percentage of the funding being repaid for third year following the initial funding date of the applicable borrowing.",
        "label": "Prepayment fee third year funding (percent)"
       }
      }
     },
     "localname": "PrepaymentFeeThirdYearFundingPercent",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "txmd_PrescriptionVitaminsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information about Prescription Vitamins.",
        "label": "Prescription Vitamins [Member]"
       }
      }
     },
     "localname": "PrescriptionVitaminsMember",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueByProductMixForYearsEndedDecember3120192018And2017Details"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_ProceedsFromIssuancePublicOffering": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital by public offering.",
        "label": "Proceeds from issuance public offering"
       }
      }
     },
     "localname": "ProceedsFromIssuancePublicOffering",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_QuarterlyRoyaltyPaymentsPercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The percentage of quarterly royalty payments on net sales which the company is entitled to receive.",
        "label": "Quarterly royalty payments percentage"
       }
      }
     },
     "localname": "QuarterlyRoyaltyPaymentsPercentage",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "txmd_RegulatoryMilestoneAdditionalPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of regulatory milestone payments based on regulatory approvals for each of BIJUVA and IMVEXXY in certain specified markets.",
        "label": "Regulatory milestone payments"
       }
      }
     },
     "localname": "RegulatoryMilestoneAdditionalPayment",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_RentedAreaLease": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Rented area as defined in lease.",
        "label": "Rented area lease"
       }
      }
     },
     "localname": "RentedAreaLease",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "areaItemType"
    },
    "txmd_RepaymentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The repayment fee, expressed as a percentage of the tranche funding being repaid,",
        "label": "Repayment fee percentage"
       }
      }
     },
     "localname": "RepaymentFeePercentage",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "txmd_RepaymentOfDebtWithNewCreditFacility": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the repayment of debt including all fees by borrowing funds from a new credit facility.",
        "label": "Repayment of debt with new credit facility"
       }
      }
     },
     "localname": "RepaymentOfDebtWithNewCreditFacility",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_RequiredMilestonePaymentsUponCumulativeNetSalesOfSpecifiedLevels": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of required milestone payments upon cumulative net sales of specified levels by the company and affiliates and permitted sublicensees.",
        "label": "Required milestone payments upon cumulative net sales of specified levels"
       }
      }
     },
     "localname": "RequiredMilestonePaymentsUponCumulativeNetSalesOfSpecifiedLevels",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_ReturnPeriodOfUnsalablePrescriptionProducts": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period the company accepts returns of unsalable prescription products from customers following product expiration.",
        "label": "Return period of unsalable prescription products"
       }
      }
     },
     "localname": "ReturnPeriodOfUnsalablePrescriptionProducts",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "txmd_RoyaltyPercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The percent of the net sales to be paid as royalty per license agreement.",
        "label": "Royalty (percent)"
       }
      }
     },
     "localname": "RoyaltyPercent",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "txmd_SalesDiscountsReturnsAndAllowancesGoods1": {
     "auth_ref": [],
     "calculation": {
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate allowance consisting of: (i) sales discounts given by the entity, including, but not limited to, early payments of accounts due, (ii) the total deduction from sales during the period arising from goods returned by customers (other than under warranty provisions), and (iii) price reductions (allowance, price protection agreements) given by the entity. Discounts, returns and allowances are a deduction from gross revenue in arriving at net revenue.",
        "label": "Allowance for coupons and returns"
       }
      }
     },
     "localname": "SalesDiscountsReturnsAndAllowancesGoods1",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_SalesMilestonePaymentsInTranches": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of sales milestone payments per licensing agreement.",
        "label": "Sales milestone payment"
       }
      }
     },
     "localname": "SalesMilestonePaymentsInTranches",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_ScheduleOfIntangibleAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of intangible assets, which may be broken down by major class.",
        "label": "The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of December 31, 2019 and 2018:"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetsTableTextBlock",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "txmd_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of warrants, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "The weighted average fair value per share of warrants issued and the assumptions used in the Black-Scholes Model during the years ended December 31, 2019, 2018, and 2017 are set forth in the table below."
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "txmd_ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of supplementary lease and cash flow information.",
        "label": "Supplemental lease information"
       }
      }
     },
     "localname": "ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "txmd_ScheduleOfWarrantRollForwardTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for warrants that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of warrants that were granted, exercised, forfeited, and expired during the year.",
        "label": "Summary of our Warrant activity during the year ended December 31, 2019:"
       }
      }
     },
     "localname": "ScheduleOfWarrantRollForwardTableTextBlock",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for unvested options, in 'PnYnMnDTnHnMnS' format,",
        "label": "Weighted average remaining contractual life, unvested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringYearEndedDecember312019IsAsFollowsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for unvested equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format,",
        "label": "Weighted average remaining contractual life, warrants unvested ending"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfOurWarrantActivityDuringYearEndedDecember312019Details"
     ],
     "xbrltype": "durationItemType"
    },
    "txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExercisableWeightedAverageRemainingContractualTerms": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested and exercisable equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format,",
        "label": "Weighted average remaining contractual life, vested and exercisable ending"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExercisableWeightedAverageRemainingContractualTerms",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfOurWarrantActivityDuringYearEndedDecember312019Details"
     ],
     "xbrltype": "durationItemType"
    },
    "txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares into which vested non option equity instruments outstanding as of the balance sheet date can be currently converted.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Number",
        "periodEndLabel": "Number of shares under warrants vested and exercisable ending"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfOurWarrantActivityDuringYearEndedDecember312019Details"
     ],
     "xbrltype": "sharesItemType"
    },
    "txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of warrants vested and exercisable.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Non Options Exercisable Intrinsic Value",
        "periodEndLabel": "Aggregate intrinsic value, vested and exercisable ending"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfOurWarrantActivityDuringYearEndedDecember312019Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exercise price as of the balance sheet date at which grantees can acquire the shares for options outstanding.",
        "label": "Range - exercise price of options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire unvested shares reserved for issuance.",
        "label": "Outstanding Weighted Average Exercise Price",
        "periodEndLabel": "Weighted average exercise price, unvested ending"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringYearEndedDecember312019IsAsFollowsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options unvested.",
        "label": "Outstanding Aggregate Intrinsic Value",
        "periodEndLabel": "Aggregate intrinsic value, unvested ending"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringYearEndedDecember312019IsAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on warrants exercised (or share units converted) into shares.",
        "label": "Aggregate intrinsic value, warrants exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfOurWarrantActivityDuringYearEndedDecember312019Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_ShelfLifeOfPrescriptionProducts": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period shelf life of prescription products from date of manufacture.",
        "label": "Shelf life of prescription products following product expiration"
       }
      }
     },
     "localname": "ShelfLifeOfPrescriptionProducts",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "txmd_SignificantSupplyCommitmentPercentagePayable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percent of the difference between the total amount we would have paid to supplier if the minimum requirement had been fulfilled and the sum of all purchases of our products from supplier during the contract year, required to be paid to supplier.",
        "label": "Significant supply commitment percentage payable"
       }
      }
     },
     "localname": "SignificantSupplyCommitmentPercentagePayable",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "txmd_SpecifiedLevelOneOfCumulativeNetSalesForRequiredMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The first level of net sales by the company and affiliates and permitted sublicensees related to required milestone payments.",
        "label": "Specified level one of cumulative net sales for required milestone payments"
       }
      }
     },
     "localname": "SpecifiedLevelOneOfCumulativeNetSalesForRequiredMilestonePayments",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_SpecifiedLevelThreeOfCumulativeNetSalesForRequiredMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The third level of net sales by the company and affiliates and permitted sublicensees related to required milestone payments.",
        "label": "Specified level three of cumulative net sales for required milestone payments"
       }
      }
     },
     "localname": "SpecifiedLevelThreeOfCumulativeNetSalesForRequiredMilestonePayments",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_SpecifiedLevelTwoOfCumulativeNetSalesForRequiredMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The second level of net sales by the company and affiliates and permitted sublicensees related to required milestone payments.",
        "label": "Specified level two of cumulative net sales for required milestone payments"
       }
      }
     },
     "localname": "SpecifiedLevelTwoOfCumulativeNetSalesForRequiredMilestonePayments",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_SubscriptionAgreementKnightMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Subscription Agreement",
        "label": "Subscription Agreement Knight [Member]"
       }
      }
     },
     "localname": "SubscriptionAgreementKnightMember",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_SupplierThreeConcentrationRiskMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Supplier Three Concentration Risk Member",
        "label": "Supplier 3"
       }
      }
     },
     "localname": "SupplierThreeConcentrationRiskMember",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_SupplierTwoConcentrationRiskMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Supplier Two Concentration Risk Member",
        "label": "Supplier 2"
       }
      }
     },
     "localname": "SupplierTwoConcentrationRiskMember",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_TrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tranche of the Credit Facility Agreement to draw funds.",
        "label": "Tranche 1 [Member]"
       }
      }
     },
     "localname": "TrancheOneMember",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_TrancheThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tranche Three as defined in financing agreement.",
        "label": "Tranche 3 [Member]"
       }
      }
     },
     "localname": "TrancheThreeMember",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_TrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tranche Two as defined in financing agreement.",
        "label": "Tranche Two [Member]"
       }
      }
     },
     "localname": "TrancheTwoMember",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_TrancheTwoThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tranche Two Three Member",
        "label": "Tranche Two Three Member"
       }
      }
     },
     "localname": "TrancheTwoThreeMember",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_UnderwritersOptionGrantedInPeriodShares": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares available to be purchased per underwriter's option.",
        "label": "Underwriters option granted in period shares"
       }
      }
     },
     "localname": "UnderwritersOptionGrantedInPeriodShares",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "txmd_UnderwritingAgreementGoldmanSachsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Underwriter Agrrement GoldmanSachs",
        "label": "Underwriting Agreement Goldman Sachs [Member]"
       }
      }
     },
     "localname": "UnderwritingAgreementGoldmanSachsMember",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_UnderwritingAgreementJPMorganChaseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Underwriting Agreement JP Morgan Chase Member",
        "label": "Underwriting Agreement JP Morgan Chase"
       }
      }
     },
     "localname": "UnderwritingAgreementJPMorganChaseMember",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_VitaminsAndImvexxyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Vitamins and IMVEXXY",
        "label": "Vitamins and IMVEXXY [Member]"
       }
      }
     },
     "localname": "VitaminsAndImvexxyMember",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item provides the weighted-average contractual remaining life of warrants.",
        "label": "Weighted-average contractual remaining life"
       }
      }
     },
     "localname": "WarrantsAndRightsWeightedAverageContractualRemainingLife",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "txmd_WarrantsCashlessExerciseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Warrants - Cashless Exercise",
        "label": "Warrants - Cashless Exercise [Member]"
       }
      }
     },
     "localname": "WarrantsCashlessExerciseMember",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_WarrantsExercisedOtherThanOptionsWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average per share amount at which warrant holders can acquire shares of common stock with respect to warrants that were exercised.",
        "label": "Weighted average exercise price warrants exercised"
       }
      }
     },
     "localname": "WarrantsExercisedOtherThanOptionsWeightedAverageExercisePrice",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfOurWarrantActivityDuringYearEndedDecember312019Details"
     ],
     "xbrltype": "perShareItemType"
    },
    "txmd_WarrantsGrantedOtherThanOptionsWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average per share amount at which warrant holders can acquire shares of common stock by exercise of warrants.",
        "label": "Weighted average exercise price warrants granted"
       }
      }
     },
     "localname": "WarrantsGrantedOtherThanOptionsWeightedAverageExercisePrice",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfOurWarrantActivityDuringYearEndedDecember312019Details"
     ],
     "xbrltype": "perShareItemType"
    },
    "txmd_WarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Warrants Member",
        "label": "Warrants Member"
       }
      }
     },
     "localname": "WarrantsMember",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which warrant holders can acquire the shares reserved for issuance.",
        "label": "Weighted average exercise price of warrants (in dollars per share)",
        "periodEndLabel": "Weighted average exercise price warrants outstanding ending",
        "periodStartLabel": "Weighted average exercise price warrants outstanding beginning"
       }
      }
     },
     "localname": "WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/SummaryOfOurWarrantActivityDuringYearEndedDecember312019Details"
     ],
     "xbrltype": "perShareItemType"
    },
    "txmd_WarrantsOutstandingVestedAndExercisable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted-average exercise price, at which warrant holders can acquire shares reserved for issuance, for fully vested and exercisable warrants outstanding.",
        "label": "Warrants Outstanding Vested And Exercisable",
        "periodEndLabel": "Weighted average exercise price warrants vested and exercisable ending"
       }
      }
     },
     "localname": "WarrantsOutstandingVestedAndExercisable",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfOurWarrantActivityDuringYearEndedDecember312019Details"
     ],
     "xbrltype": "perShareItemType"
    },
    "txmd_WarrantsUnvestedWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which warrant holders can acquire the shares reserved for issuance on warrants outstanding and unvested.",
        "label": "Warrants Unvested Weighted Average Exercise Price",
        "periodEndLabel": "Weighted average exercise price warrants unvested ending"
       }
      }
     },
     "localname": "WarrantsUnvestedWeightedAverageExercisePrice",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfOurWarrantActivityDuringYearEndedDecember312019Details"
     ],
     "xbrltype": "perShareItemType"
    },
    "txmd_WeightedAverageExercisePriceOtherThanOptions": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Intrinsic value of unvested equity-based compensation awards outstanding. Excludes stock and unit options.",
        "label": "Weighted average exercise price"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOtherThanOptions",
     "nsuri": "http://therapeuticsmd.com/20191231",
     "presentation": [
      "http://therapeuticsmd.com/role/WeightedAverageFairValuePerShareOfWarrantsIssuedAndAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120192018And2017AreSetForthInTableBelow.Details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).",
        "label": "Accounting Standards Update 2016-02 [Member]"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201602Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.",
        "label": "OTHER CURRENT LIABILITIES"
       }
      }
     },
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/OtherCurrentLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableRelatedPartiesCurrent": {
     "auth_ref": [
      "r35",
      "r95",
      "r291",
      "r292",
      "r293"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Amounts due to related party"
       }
      }
     },
     "localname": "AccountsPayableRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r1",
      "r18",
      "r128",
      "r129",
      "r189"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts receivable, net of allowance for doubtful accounts of $904,040 and $596,602, respectively"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedMarketingCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for the marketing, trade and selling of the entity's goods and services.   Marketing costs would include expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services; costs of public relations and corporate promotions; and obligations incurred and payable for sales discounts, rebates, price protection programs, etc. offered to customers and under government programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued sales and marketing costs"
       }
      }
     },
     "localname": "AccruedMarketingCostsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r38"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued legal and accounting expense"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedRentCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r38"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for contractual rent under lease arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued rent"
       }
      }
     },
     "localname": "AccruedRentCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedSalariesCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r38"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued payroll, bonuses and commission costs"
       }
      }
     },
     "localname": "AccruedSalariesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedVacationCurrent": {
     "auth_ref": [
      "r8",
      "r38",
      "r193"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued compensated absences"
       }
      }
     },
     "localname": "AccruedVacationCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r33",
      "r162"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by new accounting pronouncement.",
        "label": "Adjustments for New Accounting Pronouncements [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r196",
      "r198",
      "r232",
      "r233"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Share-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for advertising cost.",
        "label": "Advertising Costs"
       }
      }
     },
     "localname": "AdvertisingCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdvertisingExpense": {
     "auth_ref": [
      "r237"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.",
        "label": "Advertising costs"
       }
      }
     },
     "localname": "AdvertisingExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r198",
      "r226",
      "r231"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "auth_ref": [
      "r130",
      "r133",
      "r134",
      "r136"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable.",
        "label": "Allowance for doubtful accounts"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r59",
      "r78",
      "r277"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of deferred financing costs",
        "verboseLabel": "Amortization of Debt Issuance Costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows",
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r78",
      "r145",
      "r153"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of intangible assets",
        "verboseLabel": "Amortization of Intangible Assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows",
      "http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/TableBelowPresentsPotentiallyDilutiveSecuritiesThatCouldAffectOurCalculationOfDilutedNetLossPerShareAllocableToCommonStockholdersForPeriodsPresented.Details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative",
      "http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/SummarizedQuarterlyFinancialDataForFiscalYears2019And2018IsAsFollowsDetails",
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r125",
      "r313",
      "r324"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r6",
      "r50"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Current Assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r199",
      "r228"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/RangesOfAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120192018And2017AreSetForthInTableBelow.Details",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringYearEndedDecember312019IsAsFollowsDetails",
      "http://therapeuticsmd.com/role/TableBelowPresentsPotentiallyDilutiveSecuritiesThatCouldAffectOurCalculationOfDilutedNetLossPerShareAllocableToCommonStockholdersForPeriodsPresented.Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Cash": {
     "auth_ref": [
      "r30",
      "r334",
      "r335"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r12",
      "r81",
      "r84"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "verboseLabel": "Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r74",
      "r80",
      "r83"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, end of period",
        "periodStartLabel": "Cash, beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r74",
      "r273"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "(Decrease) increase in cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFDICInsuredAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.",
        "label": "Federal insurance limits"
       }
      }
     },
     "localname": "CashFDICInsuredAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r94",
      "r185",
      "r197"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/SummaryOfOurWarrantActivityDuringYearEndedDecember312019Details",
      "http://therapeuticsmd.com/role/TableBelowPresentsPotentiallyDilutiveSecuritiesThatCouldAffectOurCalculationOfDilutedNetLossPerShareAllocableToCommonStockholdersForPeriodsPresented.Details",
      "http://therapeuticsmd.com/role/WeightedAverageFairValuePerShareOfWarrantsIssuedAndAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120192018And2017AreSetForthInTableBelow.Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [
      "r87"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/SummaryOfOurWarrantActivityDuringYearEndedDecember312019Details",
      "http://therapeuticsmd.com/role/TableBelowPresentsPotentiallyDilutiveSecuritiesThatCouldAffectOurCalculationOfDilutedNetLossPerShareAllocableToCommonStockholdersForPeriodsPresented.Details",
      "http://therapeuticsmd.com/role/WeightedAverageFairValuePerShareOfWarrantsIssuedAndAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120192018And2017AreSetForthInTableBelow.Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/SummaryOfOurWarrantActivityDuringYearEndedDecember312019Details",
      "http://therapeuticsmd.com/role/WeightedAverageFairValuePerShareOfWarrantsIssuedAndAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120192018And2017AreSetForthInTableBelow.Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r87",
      "r185",
      "r197"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/SummaryOfOurWarrantActivityDuringYearEndedDecember312019Details",
      "http://therapeuticsmd.com/role/WeightedAverageFairValuePerShareOfWarrantsIssuedAndAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120192018And2017AreSetForthInTableBelow.Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummarizedQuarterlyFinancialDataForFiscalYears2019And2018IsAsFollowsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r42",
      "r169",
      "r316",
      "r328"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies - See Note 13"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r168",
      "r170"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r17",
      "r179"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common stock - par value $0.001; 350,000,000 shares authorized: 271,177,076 and 240,462,439 issued and outstanding, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ComputerSoftwareIntangibleAssetMember": {
     "auth_ref": [
      "r146",
      "r151",
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks.",
        "label": "Computer Software, Intangible Asset [Member]"
       }
      }
     },
     "localname": "ComputerSoftwareIntangibleAssetMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfDecember312019And2018Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r114",
      "r115",
      "r270",
      "r271"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative",
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r114",
      "r115",
      "r270",
      "r271",
      "r333"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative",
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r114",
      "r115",
      "r270",
      "r271",
      "r333"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative",
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r109",
      "r322"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration of Credit Risk and other Risks and Uncertainties"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskDisclosureTextBlock": {
     "auth_ref": [
      "r120"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.",
        "label": "BUSINESS CONCENTRATIONS"
       }
      }
     },
     "localname": "ConcentrationRiskDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/BusinessConcentrations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r114",
      "r115",
      "r270",
      "r271"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration risk"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative",
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r112",
      "r114",
      "r115",
      "r116",
      "r270",
      "r272"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r114",
      "r115",
      "r270",
      "r271"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative",
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r84",
      "r264",
      "r265",
      "r266"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "auth_ref": [
      "r192"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered.",
        "label": "Cost of Sales"
       }
      }
     },
     "localname": "CostOfSalesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.",
        "label": "Cumulative Effect of New Accounting Principle in Period of Adoption",
        "periodStartLabel": "Adoption of ASU 2016-09"
       }
      }
     },
     "localname": "CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r15",
      "r172",
      "r314",
      "r323"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/AsOfDecember312019And2018CarryingValueOfOurDebtConsistedOfFollowingDetails",
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentDescriptionOfVariableRateBasis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The reference rate for the variable rate of the debt instrument, such as LIBOR or the US Treasury rate and the maturity of the reference rate used, such as three months or six months LIBOR.",
        "label": "Debt Instrument, Description of Variable Rate Basis"
       }
      }
     },
     "localname": "DebtInstrumentDescriptionOfVariableRateBasis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r40",
      "r174",
      "r276"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/AsOfDecember312019And2018CarryingValueOfOurDebtConsistedOfFollowingDetails",
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r41",
      "r89",
      "r180",
      "r181",
      "r182",
      "r183",
      "r275",
      "r276",
      "r278",
      "r321"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/AsOfDecember312019And2018CarryingValueOfOurDebtConsistedOfFollowingDetails",
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r275",
      "r278"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt Instrument, Unamortized Discount"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r173",
      "r277"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "negatedLabel": "Debt discount and financing fees"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/AsOfDecember312019And2018CarryingValueOfOurDebtConsistedOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredFinanceCostsCurrentNet": {
     "auth_ref": [
      "r49",
      "r277"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs classified as current. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt financing fees on undrawn\u00a0tranches (Note 8)"
       }
      }
     },
     "localname": "DeferredFinanceCostsCurrentNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r247"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ComponentsOfNetDeferredIncomeTaxAssetAsOfDecember3120192018And2017AreAsFollowsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred income tax asset"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ComponentsOfNetDeferredIncomeTaxAssetAsOfDecember3120192018And2017AreAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r239",
      "r254",
      "r255"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ComponentsOfNetDeferredIncomeTaxAssetAsOfDecember3120192018And2017AreAsFollowsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "R Credit"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ComponentsOfNetDeferredIncomeTaxAssetAsOfDecember3120192018And2017AreAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r248"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ComponentsOfNetDeferredIncomeTaxAssetAsOfDecember3120192018And2017AreAsFollowsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Deferred income tax assets, net"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ComponentsOfNetDeferredIncomeTaxAssetAsOfDecember3120192018And2017AreAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Deferred Income Tax Assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ComponentsOfNetDeferredIncomeTaxAssetAsOfDecember3120192018And2017AreAsFollowsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOtherLossCarryforwards": {
     "auth_ref": [
      "r239",
      "r254",
      "r255"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ComponentsOfNetDeferredIncomeTaxAssetAsOfDecember3120192018And2017AreAsFollowsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible loss carryforwards, classified as other.",
        "label": "Net operating losses"
       }
      }
     },
     "localname": "DeferredTaxAssetsOtherLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ComponentsOfNetDeferredIncomeTaxAssetAsOfDecember3120192018And2017AreAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r249"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ComponentsOfNetDeferredIncomeTaxAssetAsOfDecember3120192018And2017AreAsFollowsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ComponentsOfNetDeferredIncomeTaxAssetAsOfDecember3120192018And2017AreAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r78",
      "r160"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation of fixed assets",
        "verboseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows",
      "http://therapeuticsmd.com/role/FixedAssetsNetDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r78",
      "r160"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r188"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "The following table provides information about disaggregated revenue by product mix for the years ended December 31, 2019, 2018, and 2017:"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ForFinancialReportingPurposesIncomeBeforeTaxesIncludesFollowingComponentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Loss per share, basic and diluted:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Net loss per share, basic and diluted",
        "verboseLabel": "Loss per common share, basic and diluted"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations",
      "http://therapeuticsmd.com/role/SummarizedQuarterlyFinancialDataForFiscalYears2019And2018IsAsFollowsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r84",
      "r100",
      "r101",
      "r102"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r92",
      "r242",
      "r243"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ReconciliationBetweenTaxesComputedAtFederalStatutoryRateAndConsolidatedEffectiveTaxRateIsAsFollowsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Provision (benefit) for income taxes"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ReconciliationBetweenTaxesComputedAtFederalStatutoryRateAndConsolidatedEffectiveTaxRateIsAsFollowsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r242",
      "r243",
      "r256"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ReconciliationBetweenTaxesComputedAtFederalStatutoryRateAndConsolidatedEffectiveTaxRateIsAsFollowsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Federal statutory tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/IncomeTaxesDetailsNarrative",
      "http://therapeuticsmd.com/role/ReconciliationBetweenTaxesComputedAtFederalStatutoryRateAndConsolidatedEffectiveTaxRateIsAsFollowsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r242",
      "r243",
      "r256"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ReconciliationBetweenTaxesComputedAtFederalStatutoryRateAndConsolidatedEffectiveTaxRateIsAsFollowsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Adjustment in valuation allowances"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ReconciliationBetweenTaxesComputedAtFederalStatutoryRateAndConsolidatedEffectiveTaxRateIsAsFollowsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": {
     "auth_ref": [
      "r242",
      "r243",
      "r256"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ReconciliationBetweenTaxesComputedAtFederalStatutoryRateAndConsolidatedEffectiveTaxRateIsAsFollowsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.",
        "label": "Federal income tax rate change"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ReconciliationBetweenTaxesComputedAtFederalStatutoryRateAndConsolidatedEffectiveTaxRateIsAsFollowsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r242",
      "r243",
      "r256"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ReconciliationBetweenTaxesComputedAtFederalStatutoryRateAndConsolidatedEffectiveTaxRateIsAsFollowsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Permanent and other differences"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ReconciliationBetweenTaxesComputedAtFederalStatutoryRateAndConsolidatedEffectiveTaxRateIsAsFollowsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent": {
     "auth_ref": [
      "r235",
      "r242"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ReconciliationBetweenTaxesComputedAtFederalStatutoryRateAndConsolidatedEffectiveTaxRateIsAsFollowsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Excess stock benefits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ReconciliationBetweenTaxesComputedAtFederalStatutoryRateAndConsolidatedEffectiveTaxRateIsAsFollowsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r242",
      "r243",
      "r256"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ReconciliationBetweenTaxesComputedAtFederalStatutoryRateAndConsolidatedEffectiveTaxRateIsAsFollowsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "State tax rate, net of federal tax benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ReconciliationBetweenTaxesComputedAtFederalStatutoryRateAndConsolidatedEffectiveTaxRateIsAsFollowsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r227"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r227"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r227"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r225"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/RangesOfAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120192018And2017AreSetForthInTableBelow.Details",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringYearEndedDecember312019IsAsFollowsDetails",
      "http://therapeuticsmd.com/role/TableBelowPresentsPotentiallyDilutiveSecuritiesThatCouldAffectOurCalculationOfDilutedNetLossPerShareAllocableToCommonStockholdersForPeriodsPresented.Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r179"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r84",
      "r268",
      "r269"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r152"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Finite-Lived Intangible Assets, Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfDecember312019And2018Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r154"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "2020"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/EstimatedAmortizationExpenseBasedOnCurrentPatentCostBeingAmortizedForNextFiveYearsIsAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r154"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/EstimatedAmortizationExpenseBasedOnCurrentPatentCostBeingAmortizedForNextFiveYearsIsAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r154"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/EstimatedAmortizationExpenseBasedOnCurrentPatentCostBeingAmortizedForNextFiveYearsIsAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r154"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/EstimatedAmortizationExpenseBasedOnCurrentPatentCostBeingAmortizedForNextFiveYearsIsAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r154"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "2021"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/EstimatedAmortizationExpenseBasedOnCurrentPatentCostBeingAmortizedForNextFiveYearsIsAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r146",
      "r149",
      "r152",
      "r156",
      "r299"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfDecember312019And2018Details",
      "http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r152",
      "r299"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfDecember312019And2018Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfDecember312019And2018Details",
      "http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r146",
      "r151"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfDecember312019And2018Details",
      "http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r152"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfDecember312019And2018Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Assets, Remaining Amortization Period"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfDecember312019And2018Details"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FinitelivedIntangibleAssetsAcquired1": {
     "auth_ref": [
      "r147"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.",
        "label": "License rights acquired"
       }
      }
     },
     "localname": "FinitelivedIntangibleAssetsAcquired1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r78",
      "r176",
      "r177"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Loss on extinguishment of debt",
        "negatedLabel": "Loss of extinguishment of debt",
        "negatedTerseLabel": "Loss on extinguishment of debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows",
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations",
      "http://therapeuticsmd.com/role/DebtDetailsNarrative",
      "http://therapeuticsmd.com/role/SummarizedQuarterlyFinancialDataForFiscalYears2019And2018IsAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r158"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "INTANGIBLE ASSETS, NET"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross profit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations",
      "http://therapeuticsmd.com/role/SummarizedQuarterlyFinancialDataForFiscalYears2019And2018IsAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": {
     "auth_ref": [
      "r78",
      "r157"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.",
        "label": "Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r84",
      "r159",
      "r164"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r91"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ForFinancialReportingPurposesIncomeBeforeTaxesIncludesFollowingComponentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r56",
      "r98",
      "r312",
      "r317",
      "r330"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ForFinancialReportingPurposesIncomeBeforeTaxesIncludesFollowingComponentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ForFinancialReportingPurposesIncomeBeforeTaxesIncludesFollowingComponentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by name of taxing authority.",
        "label": "Income Tax Authority, Name [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r86",
      "r124",
      "r258"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r53",
      "r84",
      "r240",
      "r241",
      "r245",
      "r246",
      "r251",
      "r259",
      "r336"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in current liabilities classified as other.",
        "label": "Accrued expenses and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherCurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInRestrictedCash": {
     "auth_ref": [
      "r66",
      "r68"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net cash inflow or outflow for the increase (decrease) associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as investing activities.",
        "label": "Increase (Decrease) in Restricted Cash",
        "negatedLabel": "Payment of security deposit"
       }
      }
     },
     "localname": "IncreaseDecreaseInRestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r148",
      "r155"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfDecember312019And2018Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r155"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfDecember312019And2018Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r148",
      "r155"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company."
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfDecember312019And2018Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IndefiniteLivedTrademarks": {
     "auth_ref": [
      "r155"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount (original costs adjusted for previously recognized amortization and impairment) as of the balance sheet date for the rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style for a projected indefinite period of benefit.",
        "label": "Indefinite-Lived Trademarks"
       }
      }
     },
     "localname": "IndefiniteLivedTrademarks",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfDecember312019And2018Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "auth_ref": [
      "r84",
      "r151"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.",
        "label": "Intangible Assets"
       }
      }
     },
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Intangible Assets, Gross (Excluding Goodwill)"
       }
      }
     },
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfDecember312019And2018Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r144",
      "r150"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible assets, net",
        "verboseLabel": "Intangible Assets, Net (Excluding Goodwill)"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets",
      "http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfDecember312019And2018Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r54",
      "r123",
      "r274",
      "r277",
      "r320"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseBorrowings": {
     "auth_ref": [
      "r319"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate amount of interest expense on all borrowings.",
        "label": "Interest Expense, Borrowings"
       }
      }
     },
     "localname": "InterestExpenseBorrowings",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r65",
      "r175"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r73",
      "r75",
      "r82"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InternalRevenueServiceIRSMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity.",
        "label": "Internal Revenue Service (IRS) [Member]"
       }
      }
     },
     "localname": "InternalRevenueServiceIRSMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InternetDomainNamesMember": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "String of typographic characters used to describe the location of a specific individual, business, computer, or piece of information online. Formally known as the Uniform Resource Locator or URL, it is often considered to be the address of a certain World Wide Web site.",
        "label": "Internet Domain Names [Member]"
       }
      }
     },
     "localname": "InternetDomainNamesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfDecember312019And2018Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r141"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "INVENTORY"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Inventory"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/InventoryConsistsOfFollowingDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Finished products"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/InventoryConsistsOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r0",
      "r47",
      "r138"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://therapeuticsmd.com/role/InventoryConsistsOfFollowingDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory",
        "totalLabel": "TOTAL INVENTORY"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets",
      "http://therapeuticsmd.com/role/InventoryConsistsOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r11",
      "r48",
      "r84",
      "r103",
      "r139",
      "r140"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventories"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterialsAndSupplies": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/InventoryConsistsOfFollowingDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed.",
        "label": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsAndSupplies",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/InventoryConsistsOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/InventoryConsistsOfFollowingDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/InventoryConsistsOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.",
        "label": "Accreted interest"
       }
      }
     },
     "localname": "InvestmentIncomeNetAmortizationOfDiscountAndPremium",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LandAndBuildingMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Real estate held for productive use and structures used in the conduct of business, including but not limited to, office, production, storage and distribution facilities.",
        "label": "Land and Building [Member]"
       }
      }
     },
     "localname": "LandAndBuildingMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseAndRentalExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "Rental expense"
       }
      }
     },
     "localname": "LeaseAndRentalExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r161"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeFinanceLeaseRenewalTerm1": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's finance lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lease renewal term"
       }
      }
     },
     "localname": "LesseeFinanceLeaseRenewalTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "The following table reconciles the undiscounted cash flows for all operating leases at December 31, 2019 to the operating lease liabilities recorded on the balance sheet:"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r289"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtDecember312019ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due",
        "totalLabel": "Total undiscounted lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtDecember312019ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r289"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtDecember312019ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.",
        "label": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtDecember312019ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r289"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtDecember312019ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months",
        "verboseLabel": "2020"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtDecember312019ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r289"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtDecember312019ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Five",
        "verboseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtDecember312019ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r289"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtDecember312019ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four",
        "verboseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtDecember312019ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r289"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtDecember312019ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three",
        "verboseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtDecember312019ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r289"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtDecember312019ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two",
        "verboseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtDecember312019ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r289"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtDecember312019ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r23",
      "r315",
      "r326"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Current Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseAndServiceMember": {
     "auth_ref": [
      "r190"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Right to use intangible asset and performance of related service. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License and Service [Member]"
       }
      }
     },
     "localname": "LicenseAndServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations",
      "http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueByProductMixForYearsEndedDecember3120192018And2017Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r36"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term debt",
        "verboseLabel": "TOTAL LONG-TERM DEBT"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/AsOfDecember312019And2018CarryingValueOfOurDebtConsistedOfFollowingDetails",
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Long-Term Liabilities:"
       }
      }
     },
     "localname": "LongTermDebtNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebtTextBlock": {
     "auth_ref": [
      "r178"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for long-term debt.",
        "label": "DEBT"
       }
      }
     },
     "localname": "LongTermDebtTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Debt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/AsOfDecember312019And2018CarryingValueOfOurDebtConsistedOfFollowingDetails",
      "http://therapeuticsmd.com/role/DebtDetailsNarrative",
      "http://therapeuticsmd.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r41",
      "r171"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/AsOfDecember312019And2018CarryingValueOfOurDebtConsistedOfFollowingDetails",
      "http://therapeuticsmd.com/role/DebtDetailsNarrative",
      "http://therapeuticsmd.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r106",
      "r120"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "THE COMPANY"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Company"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "CASH FLOWS FROM FINANCING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "CASH FLOWS FROM INVESTING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r74",
      "r76",
      "r79"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "CASH FLOWS FROM OPERATING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r51",
      "r52",
      "r57",
      "r79",
      "r101",
      "r318",
      "r329"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows",
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations",
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://therapeuticsmd.com/role/SummarizedQuarterlyFinancialDataForFiscalYears2019And2018IsAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "Recently Issued Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other (expense) income"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other (expense) income"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r282"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating lease expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r281"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Lease liability",
        "verboseLabel": "Present value of lease payments"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtDecember312019ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails",
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r281"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Short-term operating lease liability (included in Other current liabilities)",
        "verboseLabel": "Operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails",
      "http://therapeuticsmd.com/role/SupplementalLeaseInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r281"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating lease liability",
        "verboseLabel": "Long-term operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets",
      "http://therapeuticsmd.com/role/SupplementalLeaseInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r283",
      "r285"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Cash paid for amounts included in the measurement of lease liabilities for operating lease"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SupplementalLeaseInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r280"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Right of use asset",
        "verboseLabel": "Right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets",
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://therapeuticsmd.com/role/SupplementalLeaseInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r288",
      "r290"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Weighted average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SupplementalLeaseInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r287",
      "r290"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Weighted average remaining term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SupplementalLeaseInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r252"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Net operating loss carry forward"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ForFinancialReportingPurposesIncomeBeforeTaxesIncludesFollowingComponentsDetails",
      "http://therapeuticsmd.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ForFinancialReportingPurposesIncomeBeforeTaxesIncludesFollowingComponentsDetails",
      "http://therapeuticsmd.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r10",
      "r38"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails": {
       "order": 11.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other accrued expenses"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAmortizationOfDeferredCharges": {
     "auth_ref": [
      "r62",
      "r78"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization of other deferred costs recognized in the income statement.",
        "label": "Amortization of intellectual property license fee",
        "verboseLabel": "Amortization of Other Deferred Charges"
       }
      }
     },
     "localname": "OtherAmortizationOfDeferredCharges",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows",
      "http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other Assets:"
       }
      }
     },
     "localname": "OtherAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAssetsMiscellaneousNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of other miscellaneous assets expected to be realized or consumed after one year or normal operating cycle, if longer.",
        "label": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsMiscellaneousNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "totalLabel": "Total other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentAssetsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for other current assets.",
        "label": "OTHER CURRENT ASSETS"
       }
      }
     },
     "localname": "OtherCurrentAssetsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/OtherCurrentAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of other current liabilities.",
        "label": "Other current liabilities consist of the following:"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r38"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other current liabilities",
        "totalLabel": "TOTAL OTHER CURRENT LIABILITIES"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets",
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashExpense": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense or loss included in net income that result in no cash flow, classified as other.",
        "label": "Write off of patent and trademark cost"
       }
      }
     },
     "localname": "OtherNoncashExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncome": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income related to nonoperating activities, classified as other.",
        "label": "Miscellaneous income"
       }
      }
     },
     "localname": "OtherNonoperatingIncome",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "auth_ref": [
      "r2",
      "r5"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Other prepaid costs"
       }
      }
     },
     "localname": "OtherPrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsOfFinancingCosts": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for loan and debt issuance costs.",
        "label": "Payments of Financing Costs",
        "negatedLabel": "Payment of deferred financing fees"
       }
      }
     },
     "localname": "PaymentsOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows",
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments to Acquire Intangible Assets",
        "negatedLabel": "Patent costs"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of fixed assets"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r199",
      "r228"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred stock - par value $0.001; 10,000,000 shares authorized; no shares issued and outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r4",
      "r28",
      "r29"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Other current assets",
        "totalLabel": "TOTAL OTHER CURRENT ASSETS"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets",
      "http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidInsurance": {
     "auth_ref": [
      "r3",
      "r5",
      "r142",
      "r143"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid insurance"
       }
      }
     },
     "localname": "PrepaidInsurance",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrimeRateMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers.",
        "label": "Prime Rate [Member]"
       }
      }
     },
     "localname": "PrimeRateMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from sale of common stock, net of costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of long-term debt classified as other.",
        "label": "Proceeds from Credit Agreement"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfOtherLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLinesOfCredit": {
     "auth_ref": [
      "r70",
      "r90"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Proceeds from Financing Agreement",
        "verboseLabel": "Proceeds from Lines of Credit"
       }
      }
     },
     "localname": "ProceedsFromLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows",
      "http://therapeuticsmd.com/role/DebtDetailsNarrative",
      "http://therapeuticsmd.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r69",
      "r229"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from exercise of options and warrants"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Product Information [Line Items]"
       }
      }
     },
     "localname": "ProductInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueByProductMixForYearsEndedDecember3120192018And2017Details",
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r190"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r33",
      "r163"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails",
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r165"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.",
        "label": "FIXED ASSETS, NET"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FixedAssetsNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r32",
      "r161"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "TOTAL FIXED ASSETS"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r13",
      "r14",
      "r163",
      "r327"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Fixed assets, net",
        "totalLabel": "TOTAL FIXED ASSETS, NET"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets",
      "http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r31",
      "r84",
      "r163"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.",
        "label": "Fixed Assets"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r13",
      "r163"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Fixed assets, net consist of the following:"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FixedAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r13",
      "r161"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails",
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Useful life of assets"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r58",
      "r135"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Provision for doubtful accounts"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_QuarterlyFinancialInformationDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Quarterly Financial Information Disclosure [Abstract]"
       }
      }
     },
     "localname": "QuarterlyFinancialInformationDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_QuarterlyFinancialInformationTextBlock": {
     "auth_ref": [
      "r105"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.",
        "label": "SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)"
       }
      }
     },
     "localname": "QuarterlyFinancialInformationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SelectedQuarterlyFinancialData"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy": {
     "auth_ref": [
      "r24",
      "r84",
      "r131"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.",
        "label": "Trade Accounts Receivable and Allowance for Doubtful Accounts"
       }
      }
     },
     "localname": "ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis": {
     "auth_ref": [
      "r166",
      "r167"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pertinent information about recorded unconditional purchase arrangements to acquire goods or services, by category of goods or services.",
        "label": "Recorded Unconditional Purchase Obligation by Category of Item Purchased [Axis]"
       }
      }
     },
     "localname": "RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RecordedUnconditionalPurchaseObligationDueInFifthYear": {
     "auth_ref": [
      "r167"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the recorded unconditional purchase obligation maturing in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Minimum purchase commitment, 2024"
       }
      }
     },
     "localname": "RecordedUnconditionalPurchaseObligationDueInFifthYear",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RecordedUnconditionalPurchaseObligationDueInFourthYear": {
     "auth_ref": [
      "r167"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the recorded unconditional purchase obligation maturing in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Minimum purchase commitment, 2023"
       }
      }
     },
     "localname": "RecordedUnconditionalPurchaseObligationDueInFourthYear",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RecordedUnconditionalPurchaseObligationDueInSecondYear": {
     "auth_ref": [
      "r167"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the recorded unconditional purchase obligation maturing in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Minimum purchase commitment, 2021"
       }
      }
     },
     "localname": "RecordedUnconditionalPurchaseObligationDueInSecondYear",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RecordedUnconditionalPurchaseObligationDueInThirdYear": {
     "auth_ref": [
      "r167"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the recorded unconditional purchase obligation maturing in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Minimum purchase commitment, 2022"
       }
      }
     },
     "localname": "RecordedUnconditionalPurchaseObligationDueInThirdYear",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RecordedUnconditionalPurchaseObligationDueWithinOneYear": {
     "auth_ref": [
      "r167"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the recorded unconditional purchase obligation maturing in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Minimum purchase commitment, 2020"
       }
      }
     },
     "localname": "RecordedUnconditionalPurchaseObligationDueWithinOneYear",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RecordedUnconditionalPurchaseObligationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Recorded Unconditional Purchase Obligation [Line Items]"
       }
      }
     },
     "localname": "RecordedUnconditionalPurchaseObligationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RecordedUnconditionalPurchaseObligationTable": {
     "auth_ref": [
      "r166",
      "r167"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Describes each recorded unconditional purchase obligation arrangement to purchase goods and services that extend over multiple periods, any assets pledged to secure payment, and the fixed or determinable amount of payments due in each of the next five years and thereafter.",
        "label": "Recorded Unconditional Purchase Obligation [Table]"
       }
      }
     },
     "localname": "RecordedUnconditionalPurchaseObligationTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Amount billed"
       }
      }
     },
     "localname": "RelatedPartyTransactionPurchasesFromRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r194",
      "r291",
      "r292",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "RELATED PARTIES"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/RelatedParties"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfOtherLongTermDebt": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow for the payment of debt classified as other, maturing after one year or the operating cycle, if longer.",
        "label": "Repayments of Other Long-term Debt",
        "negatedLabel": "Repayment of Credit Agreement"
       }
      }
     },
     "localname": "RepaymentsOfOtherLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r238",
      "r338"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r84",
      "r238"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedStockExpense": {
     "auth_ref": [
      "r78"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for award of restricted stock or unit under share-based payment arrangement.",
        "label": "Restricted Stock or Unit Expense"
       }
      }
     },
     "localname": "RestrictedStockExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/TableBelowPresentsPotentiallyDilutiveSecuritiesThatCouldAffectOurCalculationOfDilutedNetLossPerShareAllocableToCommonStockholdersForPeriodsPresented.Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r20",
      "r184",
      "r325"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r187",
      "r188"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Total revenue, net",
        "terseLabel": "Revenues",
        "verboseLabel": "Net revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations",
      "http://therapeuticsmd.com/role/DebtDetailsNarrative",
      "http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueByProductMixForYearsEndedDecember3120192018And2017Details",
      "http://therapeuticsmd.com/role/SubsequentEventsDetailsNarrative",
      "http://therapeuticsmd.com/role/SummarizedQuarterlyFinancialDataForFiscalYears2019And2018IsAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r85",
      "r191"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r55",
      "r121",
      "r122",
      "r126"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r286",
      "r290"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-use assets obtained in exchange for lease obligation"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SupplementalLeaseInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RisksAndUncertaintiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Risks and Uncertainties [Abstract]"
       }
      }
     },
     "localname": "RisksAndUncertaintiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "The table below presents potentially dilutive securities that could affect our calculation of diluted net loss per share allocable to common stockholders for the periods presented."
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummarizedQuarterlyFinancialDataForFiscalYears2019And2018IsAsFollowsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.",
        "label": "As of December 31, 2019 and 2018, the carrying value of our debt consisted of the following:"
       }
      }
     },
     "localname": "ScheduleOfDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "The components of the net deferred income tax asset as of December 31, 2019, 2018, and 2017 are as follows:"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "A reconciliation between taxes computed at the federal statutory rate and the consolidated effective tax rate is as follows:"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r146",
      "r151"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfDecember312019And2018Details",
      "http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "For financial reporting purposes, income before taxes includes the following components:"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r11",
      "r25",
      "r26",
      "r27"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Inventory consists of the following:"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/InventoryTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amounts of other current assets.",
        "label": "Other current assets consist of the following:"
       }
      }
     },
     "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/OtherCurrentAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfProductInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule detailing quantitative information concerning products or product lines by product or product line.",
        "label": "Schedule of Product Information [Table]"
       }
      }
     },
     "localname": "ScheduleOfProductInformationTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueByProductMixForYearsEndedDecember3120192018And2017Details",
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r33",
      "r163"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.",
        "label": "Summarized quarterly financial data for fiscal years 2019 and 2018 is as follows:"
       }
      }
     },
     "localname": "ScheduleOfQuarterlyFinancialInformationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SelectedQuarterlyFinancialDataTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r88",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r199",
      "r228"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/RangesOfAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120192018And2017AreSetForthInTableBelow.Details",
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringYearEndedDecember312019IsAsFollowsDetails",
      "http://therapeuticsmd.com/role/TableBelowPresentsPotentiallyDilutiveSecuritiesThatCouldAffectOurCalculationOfDilutedNetLossPerShareAllocableToCommonStockholdersForPeriodsPresented.Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r204",
      "r215",
      "r218"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "A summary of activity under the 2009, 2012 and 2019 Plans and related information during the year ended December 31, 2019 is as follows:"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "The ranges of assumptions used in the Black-Scholes Model during the years ended December 31, 2019, 2018, and 2017 are set forth in the table below."
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Estimated amortization expense, based on current patent cost being amortized, for the next five years is as follows:"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/IntangibleAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuredDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.",
        "label": "Secured Debt [Member]"
       }
      }
     },
     "localname": "SecuredDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r84"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r63",
      "r137"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Sales, general, and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Warrants vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Weighted average grant date fair value",
        "verboseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/WeightedAverageFairValuePerShareOfWarrantsIssuedAndAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120192018And2017AreSetForthInTableBelow.Details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Number of shares under warrants unvested ending"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/SummaryOfOurWarrantActivityDuringYearEndedDecember312019Details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Weighted average remaining contractual life, warrants outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfOurWarrantActivityDuringYearEndedDecember312019Details"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price",
        "verboseLabel": "Weighted average exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/RangesOfAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120192018And2017AreSetForthInTableBelow.Details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/RangesOfAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120192018And2017AreSetForthInTableBelow.Details",
      "http://therapeuticsmd.com/role/WeightedAverageFairValuePerShareOfWarrantsIssuedAndAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120192018And2017AreSetForthInTableBelow.Details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/WeightedAverageFairValuePerShareOfWarrantsIssuedAndAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120192018And2017AreSetForthInTableBelow.Details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Volatility - maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/RangesOfAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120192018And2017AreSetForthInTableBelow.Details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Volatility - minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/RangesOfAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120192018And2017AreSetForthInTableBelow.Details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/WeightedAverageFairValuePerShareOfWarrantsIssuedAndAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120192018And2017AreSetForthInTableBelow.Details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Risk-free interest rate - maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/RangesOfAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120192018And2017AreSetForthInTableBelow.Details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Risk-free interest rate - minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/RangesOfAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120192018And2017AreSetForthInTableBelow.Details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/RangesOfAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120192018And2017AreSetForthInTableBelow.Details",
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringYearEndedDecember312019IsAsFollowsDetails",
      "http://therapeuticsmd.com/role/TableBelowPresentsPotentiallyDilutiveSecuritiesThatCouldAffectOurCalculationOfDilutedNetLossPerShareAllocableToCommonStockholdersForPeriodsPresented.Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "auth_ref": [
      "r209"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of non-option equity instruments exercised by participants.",
        "label": "Warrants exercised",
        "negatedLabel": "Number of shares under warrants exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/SummaryOfOurWarrantActivityDuringYearEndedDecember312019Details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Net number of non-option equity instruments granted to participants.",
        "label": "Number of shares under warrants granted",
        "verboseLabel": "Warrants granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/SummaryOfOurWarrantActivityDuringYearEndedDecember312019Details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "auth_ref": [
      "r205",
      "r207"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number",
        "periodEndLabel": "Number of shares under warrants outstanding ending",
        "periodStartLabel": "Number of shares under warrants outstanding beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/SummaryOfOurWarrantActivityDuringYearEndedDecember312019Details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r217"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Aggregate intrinsic value, exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringYearEndedDecember312019IsAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period",
        "negatedLabel": "Number of shares under options, expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringYearEndedDecember312019IsAsFollowsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Number of shares under options, cancelled forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringYearEndedDecember312019IsAsFollowsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Number of shares under options, granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringYearEndedDecember312019IsAsFollowsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r216"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Weighted average grant date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/RangesOfAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120192018And2017AreSetForthInTableBelow.Details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r228"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Aggregate intrinsic value, ending",
        "periodStartLabel": "Aggregate intrinsic value, beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringYearEndedDecember312019IsAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r206",
      "r228"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number of shares under options, ending",
        "periodStartLabel": "Number of shares under options, beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringYearEndedDecember312019IsAsFollowsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted average exercise price, ending",
        "periodStartLabel": "Weighted average exercise price, beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringYearEndedDecember312019IsAsFollowsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "periodEndLabel": "Number of shares under options, vested and exercisable ending"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringYearEndedDecember312019IsAsFollowsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted average exercise price, vested and exercisable ending"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringYearEndedDecember312019IsAsFollowsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r197",
      "r202"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/RangesOfAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120192018And2017AreSetForthInTableBelow.Details",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringYearEndedDecember312019IsAsFollowsDetails",
      "http://therapeuticsmd.com/role/TableBelowPresentsPotentiallyDilutiveSecuritiesThatCouldAffectOurCalculationOfDilutedNetLossPerShareAllocableToCommonStockholdersForPeriodsPresented.Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Weighted average exercise price, exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringYearEndedDecember312019IsAsFollowsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Weighted average exercise price, expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringYearEndedDecember312019IsAsFollowsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Weighted average exercise price, cancelled forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringYearEndedDecember312019IsAsFollowsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Weighted average exercise price, granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringYearEndedDecember312019IsAsFollowsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r84",
      "r199",
      "r203"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding",
        "periodEndLabel": "Aggregate intrinsic value, warrants outstanding ending",
        "periodStartLabel": "Aggregate intrinsic value, warrants outstanding beginning"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfOurWarrantActivityDuringYearEndedDecember312019Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r221",
      "r230"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/RangesOfAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120192018And2017AreSetForthInTableBelow.Details",
      "http://therapeuticsmd.com/role/WeightedAverageFairValuePerShareOfWarrantsIssuedAndAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120192018And2017AreSetForthInTableBelow.Details"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r228"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "periodEndLabel": "Aggregate intrinsic value, vested and exercisable ending"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringYearEndedDecember312019IsAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Weighted average remaining contractual life, vested and exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringYearEndedDecember312019IsAsFollowsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of non-vested options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares",
        "periodEndLabel": "Number of shares under options, unvested ending"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringYearEndedDecember312019IsAsFollowsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Weighted average remaining contractual life"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringYearEndedDecember312019IsAsFollowsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.",
        "label": "Software and Software Development Costs [Member]"
       }
      }
     },
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails",
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r43",
      "r179"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations",
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations",
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation": {
     "auth_ref": [
      "r195",
      "r234"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value, after forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares issued for exercise of options and warrants, net"
       }
      }
     },
     "localname": "StockGrantedDuringPeriodValueSharebasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r16",
      "r17",
      "r179",
      "r184"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Shares issued in offerings, net of cost (in shares)",
        "verboseLabel": "Stock Issued During Period, Shares, New Issues"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of stock issued attributable to transactions classified as other.",
        "label": "Shares issued for exercise of warrants, net (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesOther",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r16",
      "r17",
      "r179",
      "r184"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares issued for exercise of options and warrants, net (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r16",
      "r17",
      "r179",
      "r184",
      "r209"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Shares issued for exercise of options, net (in shares)",
        "negatedLabel": "Number of shares under options, exercised",
        "verboseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationDuringYearEndedDecember312019IsAsFollowsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r16",
      "r17",
      "r179",
      "r184"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Shares issued in offerings, net of cost",
        "verboseLabel": "Stock Issued During Period, Value, New Issues"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of shares of stock issued attributable to transactions classified as other.",
        "label": "Shares issued for exercise of warrants, net"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueOther",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r43",
      "r179",
      "r184"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Shares issued for exercise of options, net",
        "verboseLabel": "Stock Issued During Period, Value, Stock Options Exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r17",
      "r21",
      "r22",
      "r132"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance, value",
        "periodStartLabel": "Beginning balance, value",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets",
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders\u2019 Equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r186"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative",
      "http://therapeuticsmd.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative",
      "http://therapeuticsmd.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative",
      "http://therapeuticsmd.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Supplemental disclosure of cash flow information"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplierConcentrationRiskMember": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reflects the percentage that purchases in the period from one or more significant suppliers is to cost of goods or services, as defined by the entity, such as total cost of sales or services, product line cost of sales or services, segment cost of sales or services. Risk is the materially adverse effects of loss of a material supplier or a supplier of critically needed goods or services.",
        "label": "Supplier Concentration Risk [Member]"
       }
      }
     },
     "localname": "SupplierConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r257"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of reasonable estimate for income tax expense (benefit) for which accounting for tax effect is incomplete pursuant to Tax Cuts and Jobs Act.",
        "label": "Tax Cuts and Jobs Act, provisional net tax expense"
       }
      }
     },
     "localname": "TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxPeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information about the period subject to enacted tax laws.",
        "label": "Tax Period [Axis]"
       }
      }
     },
     "localname": "TaxPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxPeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identified tax period."
       }
      }
     },
     "localname": "TaxPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Adoption and early adoption of sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues Accounting Standards Updates to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy."
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative",
      "http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative",
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/SummarizedQuarterlyFinancialDataForFiscalYears2019And2018IsAsFollowsDetails",
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain": {
     "auth_ref": [
      "r167"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "General description of the goods or services to be purchased from the counterparty to the unconditional purchase arrangement."
       }
      }
     },
     "localname": "UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r107",
      "r108",
      "r110",
      "r111",
      "r117",
      "r118",
      "r119"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index."
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/SummaryOfOurWarrantActivityDuringYearEndedDecember312019Details",
      "http://therapeuticsmd.com/role/TableBelowPresentsPotentiallyDilutiveSecuritiesThatCouldAffectOurCalculationOfDilutedNetLossPerShareAllocableToCommonStockholdersForPeriodsPresented.Details",
      "http://therapeuticsmd.com/role/WeightedAverageFairValuePerShareOfWarrantsIssuedAndAssumptionsUsedInBlack-scholesModelDuringYearsEndedDecember3120192018And2017AreSetForthInTableBelow.Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "auth_ref": [
      "r94"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.",
        "label": "Warrants and Rights Outstanding"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingMaturityDate": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in CCYY-MM-DD format.",
        "label": "Warrants expiration date"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted average number of common shares outstanding, basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e7018-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e543-108305"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=118952077&loc=d3e1280-108306"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "270",
   "URI": "http://asc.fasb.org/topic&trid=2126967"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4428-111522"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4531-111522"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5074-111524"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5144-111524"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955202&loc=SL82895884-210446"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116846819&loc=d3e3927-108312"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5865-108316"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=77896938&loc=d3e25287-109308"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=77896938&loc=d3e25383-109308"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6036836-161870"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6036836-161870"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12317-112629"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12355-112629"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "705",
   "URI": "http://asc.fasb.org/topic&trid=2122478"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "http://asc.fasb.org/extlink&oid=6409733&loc=d3e19396-108361"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116855757&loc=d3e3913-113898"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116855982&loc=d3e4534-113899"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=SL79508275-113901"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11149-113907"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11178-113907"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116859318&loc=d3e15009-113911"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "740",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=117330312&loc=d3e23163-113944"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(b)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32247-109318"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32280-109318"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.EE.Q2(b))",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=SL116722634-122817"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "30",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=65884525&loc=d3e40913-109327"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5263-128473"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5504-128473"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3A-02)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355033-122828"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3A-03)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355100-122828"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13279-108611"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13531-108611"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=119364159&loc=SL77916155-209984"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918638-209977"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.7,8)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r339": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r341": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r342": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r343": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r344": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r345": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r346": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  },
  "r347": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r348": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-13"
  },
  "r349": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r351": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r352": {
   "Name": "Forms 10-K, 20-F, 40-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d-1"
  },
  "r353": {
   "Name": "Forms 20-F, 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220 and 240",
   "Subsection": "f"
  },
  "r354": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r355": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r356": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r357": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(4),(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6787-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6904-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3367-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4273-108586"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(i)(4))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6805909488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>The following table reconciles the undiscounted cash flows for all operating leases at December 31, 2019 to the operating lease liabilities recorded on the balance sheet: (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Aug. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2020</a></td>
<td class="nump">$ 1,566,617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2021</a></td>
<td class="nump">2,198,541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2022</a></td>
<td class="nump">1,262,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2023</a></td>
<td class="nump">1,293,859<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2024</a></td>
<td class="nump">1,326,206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">8,036,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted lease payments</a></td>
<td class="nump">15,684,456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(5,037,868)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease payments</a></td>
<td class="nump">$ 10,646,588<span></span>
</td>
<td class="nump">$ 7,200,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6808815744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Estimated amortization expense, based on current patent cost being amortized, for the next five years is as follows: (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2020</a></td>
<td class="nump">$ 229,546<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2021</a></td>
<td class="nump">229,546<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2022</a></td>
<td class="nump">229,546<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2023</a></td>
<td class="nump">229,546<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2024</a></td>
<td class="nump">$ 229,546<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6819637136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Feb. 18, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 24, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 01, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from Lines of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,902,000<span></span>
</td>
<td class="nump">$ 23,719,000<span></span>
</td>
<td class="nump">$ 6,079,000<span></span>
</td>
<td class="nump">$ 3,947,000<span></span>
</td>
<td class="nump">$ 5,089,000<span></span>
</td>
<td class="nump">$ 3,474,000<span></span>
</td>
<td class="nump">$ 3,763,000<span></span>
</td>
<td class="nump">$ 3,773,000<span></span>
</td>
<td class="nump">49,646,937<span></span>
</td>
<td class="nump">16,099,460<span></span>
</td>
<td class="nump">16,777,713<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (10,100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,057,632)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of Debt Issuance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">856,302<span></span>
</td>
<td class="nump">269,859<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Payments of Financing Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,652,270<span></span>
</td>
<td class="nump">$ 3,786,918<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt Instrument, Unamortized Discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,101,513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,101,513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt Instrument, Interest Rate, Effective Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementMember', window );">Financing Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term Debt, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseBorrowings', window );">Interest Expense, Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,709,166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=txmd_ImvexxyBijuvaAndAnnoveraMember', window );">IMVEXXY, BIJUVA and ANNOVERA [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Financing Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from Lines of Credit</a></td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_DebtTrancheAxis=txmd_TrancheOneMember', window );">Tranche 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of Debt Issuance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">736,156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_FinancingAgreementMember', window );">Financing Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis', window );">Debt Instrument, Description of Variable Rate Basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3-month LIBOR<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt Instrument, Basis Spread on Variable Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_LiborFloorRate', window );">LIBOR floor rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfInstallmentPayments', window );">Number of quarterly principal installment payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrepaymentFeeForFirstTwoYearsFundingPercent', window );">Prepayment fee for first two years funding (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrepaymentFeeThirdYearFundingPercent', window );">Prepayment fee third year funding (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrepaymentFeeFourthYearFundingPercent', window );">Prepayment fee fourth year funding (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrepaymentFeeFifthYearFundingPercent', window );">Prepayment fee fifth year funding (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_FacilityFeePaidPercent', window );">Facility fee paid (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_MinimumCashBalanceRequirementUnderCreditAgreement', window );">Minimum cash balance requirement under credit agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_FinancingAgreementMember', window );">Financing Agreement [Member] | Prime Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis', window );">Debt Instrument, Description of Variable Rate Basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">prime rate<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt Instrument, Basis Spread on Variable Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_LiborFloorRate', window );">LIBOR floor rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_FinancingAgreementMember', window );">Financing Agreement [Member] | Tranche 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from Lines of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_FinancingAgreementMember', window );">Financing Agreement [Member] | Tranche Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of Credit Facility, Maximum Borrowing Capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_FinancingAgreementMember', window );">Financing Agreement [Member] | Tranche 3 [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from Lines of Credit</a></td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_FinancingAgreementMember', window );">Financing Agreement [Member] | Tranche Two Three Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_MinimumCashBalanceRequirementUnderCreditAgreement', window );">Minimum cash balance requirement under credit agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_MidCapAgreementMember', window );">Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_RepaymentOfDebtWithNewCreditFacility', window );">Repayment of debt with new credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81,661,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrepaymentFeePercentage', window );">Prepayment fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_RepaymentFeePercentage', window );">Repayment fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest Expense, Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,816,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of Debt Issuance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt Instrument, Basis Spread on Variable Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility [Member] | Financing Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of Credit Facility, Maximum Borrowing Capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember', window );">Secured Debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of Credit Facility, Maximum Borrowing Capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis', window );">Debt Instrument, Description of Variable Rate Basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one-month LIBOR<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_LiborFloorRate', window );">LIBOR floor rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfTranchesUnderTermLoanFacility', window );">Number of tranches under term loan facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_FacilityFeePaidPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The facility fee expressed as a percentage paid or payable to the Agent for the benefit of lenders, under the terms of Credit Agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_FacilityFeePaidPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_LiborFloorRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents libor floor rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_LiborFloorRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_MinimumCashBalanceRequirementUnderCreditAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum cash balance the Borrower must maintain under the credit and secuirty agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_MinimumCashBalanceRequirementUnderCreditAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NumberOfInstallmentPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of principal installment payments under credit and security agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NumberOfInstallmentPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NumberOfTranchesUnderTermLoanFacility">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of seperate tranches under terms of the Credit Agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NumberOfTranchesUnderTermLoanFacility</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PrepaymentFeeFifthYearFundingPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The prepayment fee expressed as a percentage of the funding being repaid for fifth year following the initial funding date of the applicable borrowing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_PrepaymentFeeFifthYearFundingPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PrepaymentFeeForFirstTwoYearsFundingPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The prepayment fee expressed as a percentage of the funding being repaid for first two years following the initial funding date of the applicable borrowing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_PrepaymentFeeForFirstTwoYearsFundingPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PrepaymentFeeFourthYearFundingPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The prepayment fee expressed as a percentage of the funding being repaid for fourth year following the initial funding date of the applicable borrowing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_PrepaymentFeeFourthYearFundingPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PrepaymentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The prepayment fee, expressed as a percentage of the tranche funding being repaid,</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_PrepaymentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PrepaymentFeeThirdYearFundingPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The prepayment fee expressed as a percentage of the funding being repaid for third year following the initial funding date of the applicable borrowing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_PrepaymentFeeThirdYearFundingPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_RepaymentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The repayment fee, expressed as a percentage of the tranche funding being repaid,</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_RepaymentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_RepaymentOfDebtWithNewCreditFacility">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the repayment of debt including all fees by borrowing funds from a new credit facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_RepaymentOfDebtWithNewCreditFacility</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The reference rate for the variable rate of the debt instrument, such as LIBOR or the US Treasury rate and the maturity of the reference rate used, such as three months or six months LIBOR.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDescriptionOfVariableRateBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate amount of interest expense on all borrowings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.7,8)<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=txmd_ImvexxyBijuvaAndAnnoveraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=txmd_ImvexxyBijuvaAndAnnoveraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_DebtTrancheAxis=txmd_TrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_DebtTrancheAxis=txmd_TrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=txmd_FinancingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=txmd_FinancingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_PrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_PrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_DebtTrancheAxis=txmd_TrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_DebtTrancheAxis=txmd_TrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_DebtTrancheAxis=txmd_TrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_DebtTrancheAxis=txmd_TrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_DebtTrancheAxis=txmd_TrancheTwoThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_DebtTrancheAxis=txmd_TrancheTwoThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=txmd_MidCapAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=txmd_MidCapAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6806372384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalIncomeTaxExpenseBenefit', window );">Tax Cuts and Jobs Act, provisional net tax expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,700,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Internal Revenue Service (IRS) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carry forward</a></td>
<td class="nump">$ 620,354,163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Internal Revenue Service (IRS) [Member] | Expiration Period 20 Years [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carry forward</a></td>
<td class="nump">$ 338,775,332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NolCarryForwardPeriod', window );">NOL carry forward period</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_OperatingLossCarryforwardsExpirationYear', window );">NOL carry forward expiration year</a></td>
<td class="text">2031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Internal Revenue Service (IRS) [Member] | Expiration Period Indefinite [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carry forward</a></td>
<td class="nump">$ 281,578,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NolCarryForwardPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiration period of operating loss carryforward included in operating loss carryforward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NolCarryForwardPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_OperatingLossCarryforwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiration year of operating loss carryforward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_OperatingLossCarryforwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of reasonable estimate for income tax expense (benefit) for which accounting for tax effect is incomplete pursuant to Tax Cuts and Jobs Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2A<br> -Subparagraph (SAB Topic 5.EE.Q2(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=SL116722634-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=txmd_ExpirationPeriod20YearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=txmd_ExpirationPeriod20YearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=txmd_ExpirationPeriodIndefiniteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=txmd_ExpirationPeriodIndefiniteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6816915264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 29, 2019</div></th>
<th class="th"><div>Jul. 30, 2019</div></th>
<th class="th"><div>Dec. 13, 2018</div></th>
<th class="th"><div>Aug. 06, 2018</div></th>
<th class="th"><div>Aug. 06, 2018</div></th>
<th class="th"><div>Sep. 28, 2017</div></th>
<th class="th"><div>Sep. 25, 2017</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, Shares Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">271,177,076<span></span>
</td>
<td class="nump">240,462,439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">271,177,076<span></span>
</td>
<td class="nump">240,462,439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,546<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock Issued During Period, Value, Stock Options Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,666,208<span></span>
</td>
<td class="nump">$ 212,615<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfStockOptionsExercisedInCashlessExercise', window );">Number of stock options exercised in cashless exercise (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,097<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares', window );">Number of common stock issued during period for stock options exercised in cashless exercise (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,834<span></span>
</td>
<td class="nump">9,841<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77,031,258<span></span>
</td>
<td class="nump">$ 89,907,797<span></span>
</td>
<td class="nump">68,572,635<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants and Rights Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,832,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife', window );">Weighted-average contractual remaining life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 11 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based Payment Arrangement, Noncash Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,693,662<span></span>
</td>
<td class="nump">8,661,967<span></span>
</td>
<td class="nump">6,889,323<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Shares issued for exercise of warrants, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,798,999<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based Payment Arrangement, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,798,707<span></span>
</td>
<td class="nump">8,091,294<span></span>
</td>
<td class="nump">6,447,154<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,460,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedStockExpense', window );">Restricted Stock or Unit Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,628,407<span></span>
</td>
<td class="nump">73,132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,711,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=txmd_LongTermIncentiveCompensationPlan2009Member', window );">2009 Long Term Incentive Compensation Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,017,759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=txmd_NonQualified2012StockIncentivePlanMember', window );">2012 Stock Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,316,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,395,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=txmd_Plan2019Member', window );">Plan 2019 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,696,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,599,382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PlanAwardsNumberOfNewShares', window );">Plan awards number of new shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,103,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice', window );">Range - exercise price of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice', window );">Range - exercise price of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_WarrantsMember', window );">Warrants Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based Payment Arrangement, Noncash Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 254,970<span></span>
</td>
<td class="nump">$ 494,136<span></span>
</td>
<td class="nump">$ 313,271<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,476,666<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfStockIssuedInCashlessExerciseOfWarrants', window );">Number of stock issued in cashless exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Shares issued for exercise of warrants, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,798,999<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_WarrantsMember', window );">Warrants Member | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_WarrantsMember', window );">Warrants Member | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice', window );">Weighted average exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.62<span></span>
</td>
<td class="nump">$ 2.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Warrants granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,832,571<span></span>
</td>
<td class="nump">3,007,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="nump">$ 2.79<span></span>
</td>
<td class="nump">$ 3.67<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_OutsideConsultant2Member', window );">Outside Consultants Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Warrants granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,000<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Warrants vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">12 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Warrants expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb. 13,  2024<span></span>
</td>
<td class="text">Mar. 15,  2023<span></span>
</td>
<td class="text">Mar. 15,  2022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_WarrantsCashlessExerciseMember', window );">Warrants - Cashless Exercise [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,590,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfStockIssuedInCashlessExerciseOfWarrants', window );">Number of stock issued in cashless exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">471,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,762,208<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">Equity Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">331,619<span></span>
</td>
<td class="nump">5,444,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock Issued During Period, Value, Stock Options Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 108,656<span></span>
</td>
<td class="nump">$ 1,666,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,240,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member] | 2012 Stock Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,040,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member] | Plan 2019 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">343,716<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,030,234<span></span>
</td>
<td class="nump">20,872,824<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">1,040,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.18<span></span>
</td>
<td class="nump">$ 4.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_UnderwritingAgreementJPMorganChaseMember', window );">Underwriting Agreement JP Morgan Chase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="nump">26,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,400,000<span></span>
</td>
<td class="nump">12,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="nump">$ 2.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PeriodExercisableUnderwritersOption', window );">Period exercisable underwriters option</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_UnderwritersOptionGrantedInPeriodShares', window );">Underwriters option granted in period shares</a></td>
<td class="nump">3,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ProceedsFromIssuancePublicOffering', window );">Proceeds from issuance public offering</a></td>
<td class="nump">$ 77,031,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 68,573,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_UnderwritingAgreementGoldmanSachsMember', window );">Underwriting Agreement Goldman Sachs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,745,098<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.10<span></span>
</td>
<td class="nump">$ 5.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PeriodExercisableUnderwritersOption', window );">Period exercisable underwriters option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_UnderwritersOptionGrantedInPeriodShares', window );">Underwriters option granted in period shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,911,764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ProceedsFromIssuancePublicOffering', window );">Proceeds from issuance public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 69,908,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_SubscriptionAgreementKnightMember', window );">Subscription Agreement Knight [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,921,568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.10<span></span>
</td>
<td class="nump">$ 5.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock issued attributable to stock options exercised in cashless transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NumberOfStockIssuedInCashlessExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock issued attributable to warrants exercised in cashless transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NumberOfStockIssuedInCashlessExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NumberOfStockOptionsExercisedInCashlessExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options exercised in the cashless transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NumberOfStockOptionsExercisedInCashlessExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PeriodExercisableUnderwritersOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The period the option is exercisable per agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_PeriodExercisableUnderwritersOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PlanAwardsNumberOfNewShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new shares authorized for stock awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_PlanAwardsNumberOfNewShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ProceedsFromIssuancePublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital by public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ProceedsFromIssuancePublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exercise price as of the balance sheet date at which grantees can acquire the shares for options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_UnderwritersOptionGrantedInPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares available to be purchased per underwriter's option.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_UnderwritersOptionGrantedInPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item provides the weighted-average contractual remaining life of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which warrant holders can acquire the shares reserved for issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedStockExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for award of restricted stock or unit under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedStockExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=txmd_LongTermIncentiveCompensationPlan2009Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=txmd_LongTermIncentiveCompensationPlan2009Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=txmd_NonQualified2012StockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=txmd_NonQualified2012StockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=txmd_Plan2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=txmd_Plan2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=txmd_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_OutsideConsultant2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=txmd_OutsideConsultant2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_WarrantsCashlessExerciseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=txmd_WarrantsCashlessExerciseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=txmd_UnderwritingAgreementJPMorganChaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=txmd_UnderwritingAgreementJPMorganChaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=txmd_UnderwritingAgreementGoldmanSachsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=txmd_UnderwritingAgreementGoldmanSachsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=txmd_SubscriptionAgreementKnightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=txmd_SubscriptionAgreementKnightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6808827632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORY</a></td>
<td class="text"><p id="xdx_80F_eus-gaap--InventoryDisclosureTextBlock_zXRuhSKOS16e" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b><span style="text-decoration: underline"><b>NOTE 3 &#8211; <span id="xdx_82E_zgeF1IYPHMS">INVENTORY</span></b></span></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p id="xdx_89E_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zI6A9EX6leu8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Inventory consists of the following:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="margin-right: auto; margin-left: auto; float: none; width: 60%">

<tr>
<td style="vertical-align: top; padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" id="xdx_49B_20191231_zMjb20GpLqN8" style="vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b/></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" id="xdx_49F_20181231_znBjvoHo4Cn2" style="border-right: Black medium none; border-left: Black medium none; padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b/></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="6" style="border-bottom: black 1pt solid; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>December 31,</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-bottom: black 1pt solid; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2019</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-right: Black medium none; border-bottom: Black 1pt solid; border-left: Black medium none; padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2018</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr id="xdx_40C_eus-gaap--InventoryFinishedGoods_iI_maINzas5_zJI8TeByDyvk" style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; width: 64%; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Finished products</p>
</td>
<td style="width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 15%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">4,976,910</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 15%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">2,908,958</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_407_eus-gaap--InventoryWorkInProcess_iI_maINzas5_zL7THiYBMq0d">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Work in process</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">1,182,059</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">339,312</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_40B_eus-gaap--InventoryRawMaterialsAndSupplies_iI_maINzas5_zmfSP9XEzOJ1" style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Raw materials</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">5,701,747</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">19,400</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_40D_eus-gaap--InventoryNet_iTI_mtINzas5_zQw4JmfiOGD5">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">TOTAL INVENTORY</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">11,860,716</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">3,267,670</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>

</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6805210288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock', window );">Summarized quarterly financial data for fiscal years 2019 and 2018 is as follows:</a></td>
<td class="text"><p id="xdx_896_eus-gaap--ScheduleOfQuarterlyFinancialInformationTableTextBlock_zEn63kaxapc7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Summarized quarterly financial data for fiscal years 2019 and 2018 is as follows:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; width: 100%">

<tr>
<td style="padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom">&#160;</td>
<td>&#160;</td>
<td style="vertical-align: top">&#160;</td>
<td id="xdx_497_20190101__20190331_zvWkYbBag85e" style="vertical-align: top">&#160;</td>
<td style="vertical-align: top">&#160;</td>
<td style="vertical-align: top">&#160;</td>
<td style="vertical-align: top">&#160;</td>
<td id="xdx_49C_20190401__20190630_zRMMfDXcFPna" style="vertical-align: top">&#160;</td>
<td style="vertical-align: top">&#160;</td>
<td style="vertical-align: top">&#160;</td>
<td style="vertical-align: top">&#160;</td>
<td id="xdx_49D_20190701__20190930_z4bm4UwCuShi" style="vertical-align: top">&#160;</td>
<td style="vertical-align: top">&#160;</td>
<td style="vertical-align: top">&#160;</td>
<td style="vertical-align: top">&#160;</td>
<td id="xdx_49D_20191001__20191231_zmCEIBgmbA5a" style="vertical-align: top">&#160;</td>
<td style="vertical-align: bottom; width: 1%">&#160;</td></tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="14" style="border-bottom: black 1pt solid; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2019</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><i>(In thousands,
except per share)</i></b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>First <br/>Quarter</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-right: Black medium none; border-bottom: Black 1pt solid; border-left: Black medium none; padding: 0pt 5.4pt; width: 13%; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Second Quarter<sup>(1)</sup></b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-right: Black medium none; border-bottom: Black 1pt solid; border-left: Black medium none; padding: 0pt 5.4pt; width: 13%; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Third <br/>Quarter<sup>(2)</sup></b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-right: Black medium none; border-bottom: Black 1pt solid; border-left: Black medium none; padding: 0pt 5.4pt; width: 13%; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Fourth Quarter</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr id="xdx_408_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zqinRDBQgOW3" style="background-color: #cceeff">
<td style="border-top: black 1pt solid; padding: 0pt 5.4pt; width: 40%; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Revenues</p>
</td>
<td style="width: 3%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 10%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">3,947</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 3%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 10%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">6,079</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 3%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 10%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">23,719</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 3%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 10%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">15,902</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_402_eus-gaap--GrossProfit_pn3n3_zBFlFQ2EDn5j">
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Gross profit</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">3,184</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">4,830</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">22,275</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">13,023</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_40D_eus-gaap--NetIncomeLoss_pn3n3_zdUt4Odpg7nj" style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Net loss</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(39,506</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(55,237</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(31,967</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(49,435</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_40E_eus-gaap--EarningsPerShareBasicAndDiluted_zrq0GfU2BD15" style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Loss per common share, basic and diluted</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(0.16</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(0.23</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(0.13</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(0.19</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; width: 100%">

<tr>
<td style="padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom">&#160;</td>
<td>&#160;</td>
<td style="vertical-align: top">&#160;</td>
<td id="xdx_49A_20180101__20180331_zxU5UFNBPt84" style="vertical-align: top">&#160;</td>
<td style="vertical-align: top">&#160;</td>
<td style="vertical-align: top">&#160;</td>
<td style="vertical-align: top">&#160;</td>
<td id="xdx_492_20180401__20180630_zQ4tjR4tcunj" style="vertical-align: top">&#160;</td>
<td style="vertical-align: top">&#160;</td>
<td style="vertical-align: top">&#160;</td>
<td style="vertical-align: top">&#160;</td>
<td id="xdx_49D_20180701__20180930_zeEuUP8H4Ijj" style="vertical-align: top">&#160;</td>
<td style="vertical-align: top">&#160;</td>
<td style="vertical-align: top">&#160;</td>
<td style="vertical-align: top">&#160;</td>
<td id="xdx_49D_20181001__20181231_zMiJBlQwGAw8" style="vertical-align: top">&#160;</td>
<td style="vertical-align: bottom; width: 1%">&#160;</td></tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="14" style="border-bottom: black 1pt solid; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2018</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><i>(In thousands,
except per share)</i></b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>First <br/>Quarter</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-right: Black medium none; border-bottom: Black 1pt solid; border-left: Black medium none; padding: 0pt 5.4pt; width: 13%; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Second Quarter</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-right: Black medium none; border-bottom: Black 1pt solid; border-left: Black medium none; padding: 0pt 5.4pt; width: 13%; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Third <br/>Quarter</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-right: Black medium none; border-bottom: Black 1pt solid; border-left: Black medium none; padding: 0pt 5.4pt; width: 13%; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Fourth Quarter</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr id="xdx_408_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zOdIA16Nbnk8" style="background-color: #cceeff">
<td style="border-top: black 1pt solid; padding: 0pt 5.4pt; width: 40%; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Revenues</p>
</td>
<td style="width: 3%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 10%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">3,773</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 3%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 10%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">3,763</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 3%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 10%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">3,474</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 3%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 10%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">5,089</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_402_eus-gaap--GrossProfit_pn3n3_zwxv5YtJecw3">
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Gross profit</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">3,139</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">3,309</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">2,775</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">4,139</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_40D_eus-gaap--NetIncomeLoss_pn3n3_zI3UO2OHCzL1" style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Net loss</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(24,402</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(33,219</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(35,605</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(39,391</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_40E_eus-gaap--EarningsPerShareBasicAndDiluted_zHw2xdXE9Tfh" style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Loss per common share, basic and diluted</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(0.11</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(0.15</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(0.16</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(0.17</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(1)</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">During the second quarter of 2019, we recorded $<span id="xdx_909_eus-gaap--GainsLossesOnExtinguishmentOfDebt_iN_pn3p0_dmi_c20190401__20190630_zxZ3LQ9oEMs4" title="Loss on extinguishment of debt">10.1 million</span> in loss on extinguishment of debt related to the repayment of the Credit Agreement. Refer to discussion in Note 8-Debt.</p>
</td>
</tr>

</table>
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; width: 100%">

<tr>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(2)</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">During the third quarter of 2019, we recorded $<span id="xdx_90A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_dm_c20190701__20190930__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember_zdrB7jeaTC48" title="Revenues">15.5 million</span> in license revenue related to the <span style="color: black">Theramex License Agreement</span>. Refer to discussion in Note 2-Summary of Significant Accounting Policies.</p>
</td>
</tr>

</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118952077&amp;loc=d3e1280-108306<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6803687328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Dec. 31, 2016</a></td>
<td class="nump">$ 196,688<span></span>
</td>
<td class="nump">$ 436,995,052<span></span>
</td>
<td class="num">$ (309,702,319)<span></span>
</td>
<td class="nump">$ 127,489,421<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2016</a></td>
<td class="nump">196,688,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued in offerings, net of cost</a></td>
<td class="nump">$ 12,400<span></span>
</td>
<td class="nump">68,560,235<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">68,572,635<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued in offerings, net of cost (in shares)</a></td>
<td class="nump">12,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Shares issued for exercise of options, net</a></td>
<td class="nump">$ 103<span></span>
</td>
<td class="nump">212,512<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 212,615<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares issued for exercise of options, net (in shares)</a></td>
<td class="nump">102,546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,546<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Shares issued for exercise of warrants, net</a></td>
<td class="nump">$ 7,239<span></span>
</td>
<td class="nump">3,791,760<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 3,798,999<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Shares issued for exercise of warrants, net (in shares)</a></td>
<td class="nump">7,238,874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">6,760,425<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,760,425<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Adoption of ASU 2016-09 at Dec. 31, 2016</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">31,421<span></span>
</td>
<td class="num">(31,421)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(76,925,380)<span></span>
</td>
<td class="num">(76,925,380)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Dec. 31, 2017</a></td>
<td class="nump">$ 216,430<span></span>
</td>
<td class="nump">516,351,405<span></span>
</td>
<td class="num">(386,659,120)<span></span>
</td>
<td class="nump">129,908,715<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2017</a></td>
<td class="nump">216,429,642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued in offerings, net of cost</a></td>
<td class="nump">$ 18,578<span></span>
</td>
<td class="nump">89,889,219<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">89,907,797<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued in offerings, net of cost (in shares)</a></td>
<td class="nump">18,578,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Shares issued for exercise of options, net</a></td>
<td class="nump">$ 5,455<span></span>
</td>
<td class="nump">1,660,753<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,666,208<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares issued for exercise of options, net (in shares)</a></td>
<td class="nump">5,454,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">8,658,561<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">8,658,561<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(132,617,160)<span></span>
</td>
<td class="num">(132,617,160)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Dec. 31, 2018</a></td>
<td class="nump">$ 240,463<span></span>
</td>
<td class="nump">616,559,938<span></span>
</td>
<td class="num">(519,276,280)<span></span>
</td>
<td class="nump">$ 97,524,121<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2018</a></td>
<td class="nump">240,462,439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">240,462,439<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued in offerings, net of cost</a></td>
<td class="nump">$ 29,900<span></span>
</td>
<td class="nump">77,001,358<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 77,031,258<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued in offerings, net of cost (in shares)</a></td>
<td class="nump">29,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,682,084<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">10,682,084<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(176,144,999)<span></span>
</td>
<td class="num">(176,144,999)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation', window );">Shares issued for exercise of options and warrants, net</a></td>
<td class="nump">$ 814<span></span>
</td>
<td class="nump">107,842<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">108,656<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares issued for exercise of options and warrants, net (in shares)</a></td>
<td class="nump">814,637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Dec. 31, 2019</a></td>
<td class="nump">$ 271,177<span></span>
</td>
<td class="nump">$ 704,351,222<span></span>
</td>
<td class="num">$ (695,421,279)<span></span>
</td>
<td class="nump">$ 9,201,120<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2019</a></td>
<td class="nump">271,177,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">271,177,076<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116855982&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 30<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=116855757&amp;loc=d3e3913-113898<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116859318&amp;loc=d3e15009-113911<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6817845280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)<br></strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 05, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 05, 2019 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jun. 06, 2019 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Aug. 06, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 02, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Federal insurance limits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatentsDomestic', window );">Number of issued patents domestic.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatentsForeign', window );">Number of issued patents foreign</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77,031,258<span></span>
</td>
<td class="nump">$ 89,907,797<span></span>
</td>
<td class="nump">$ 68,572,635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of operating segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,045,571<span></span>
</td>
<td class="nump">1,682,746<span></span>
</td>
<td class="nump">$ 448,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,109,154<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,646,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">Accounting Standards Update 2016-02 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,800,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_LicenseAgreementTheramexMember', window );">License Agreement Theramex</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_CashUpfrontPaymentReceived', window );">Cash upfront payment received</a></td>
<td class="nump">$ 15,506,400<span></span>
</td>
<td class="nump">&#8364; 14,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=txmd_SubscriptionAgreementKnightMember', window );">Subscription Agreement Knight [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,921,568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of Stock, Price Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=txmd_VitaminsAndImvexxyMember', window );">Vitamins and IMVEXXY [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShelfLifeOfPrescriptionProducts', window );">Shelf life of prescription products following product expiration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=txmd_BijuvaAndAnnoveraMember', window );">BIJUVA and ANNOVERA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShelfLifeOfPrescriptionProducts', window );">Shelf life of prescription products following product expiration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=txmd_BijuvaAndAnnoveraMember', window );">BIJUVA and ANNOVERA [Member] | License Agreement Theramex</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_QuarterlyRoyaltyPaymentsPercentage', window );">Quarterly royalty payments percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ReturnPeriodOfUnsalablePrescriptionProducts', window );">Return period of unsalable prescription products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | License Agreement Theramex</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AnnualNetSalesMilestone', window );">Sales milestone | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ReturnPeriodOfUnsalablePrescriptionProducts', window );">Return period of unsalable prescription products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | License Agreement Theramex</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_RegulatoryMilestoneAdditionalPayment', window );">Regulatory milestone payments | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_SalesMilestonePaymentsInTranches', window );">Sales milestone payment | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AnnualNetSalesMilestone', window );">Sales milestone | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandAndBuildingMember', window );">Land and Building [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandAndBuildingMember', window );">Land and Building [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Software and Software Development Costs [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Software and Software Development Costs [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable [Member] | Customer A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36.00%<span></span>
</td>
<td class="nump">42.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable [Member] | Customer B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable [Member] | Customer C [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable [Member] | Customer D [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AnnualNetSalesMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual net sale milestones in the Territory per license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_AnnualNetSalesMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_CashUpfrontPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_CashUpfrontPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NumberOfIssuedPatentsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of issued patents domestic.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NumberOfIssuedPatentsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NumberOfIssuedPatentsForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of issued patents foreign.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NumberOfIssuedPatentsForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_QuarterlyRoyaltyPaymentsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of quarterly royalty payments on net sales which the company is entitled to receive.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_QuarterlyRoyaltyPaymentsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_RegulatoryMilestoneAdditionalPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of regulatory milestone payments based on regulatory approvals for each of BIJUVA and IMVEXXY in certain specified markets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_RegulatoryMilestoneAdditionalPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ReturnPeriodOfUnsalablePrescriptionProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the company accepts returns of unsalable prescription products from customers following product expiration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ReturnPeriodOfUnsalablePrescriptionProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_SalesMilestonePaymentsInTranches">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of sales milestone payments per licensing agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_SalesMilestonePaymentsInTranches</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ShelfLifeOfPrescriptionProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period shelf life of prescription products from date of manufacture.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ShelfLifeOfPrescriptionProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13537-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=txmd_LicenseAgreementTheramexMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=txmd_LicenseAgreementTheramexMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=txmd_SubscriptionAgreementKnightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=txmd_SubscriptionAgreementKnightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=txmd_VitaminsAndImvexxyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=txmd_VitaminsAndImvexxyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=txmd_BijuvaAndAnnoveraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=txmd_BijuvaAndAnnoveraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandAndBuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandAndBuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6803557648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Feb. 17, 2020</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-00100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">TherapeuticsMD, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000025743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">87-0233535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">951 Yamato Rd.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Boca Raton<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">FL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">33431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(561)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">961-1900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">TXMD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 539,237,585<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">271,526,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_EntityCommonStockHeldByNonaffiliates', window );">Entity Common Stock Held by Non-affiliates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">207,399,071<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 20-F, 40-F<br> -Number 240<br> -Section 15<br> -Subsection d-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_EntityCommonStockHeldByNonaffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares or other units held by non-affiliates of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_EntityCommonStockHeldByNonaffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6808908272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BUSINESS CONCENTRATIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>Risks and Uncertainties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskDisclosureTextBlock', window );">BUSINESS CONCENTRATIONS</a></td>
<td class="text"><p id="xdx_804_eus-gaap--ConcentrationRiskDisclosureTextBlock_ztnMgYnmrbt1" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><b><span style="text-decoration: underline"><span style="color: black"><b>NOTE
12 &#8211; <span id="xdx_823_zIV8oz54AaXc">BUSINESS CONCENTRATIONS</span></b></span></span></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">We purchase our prescription products from several suppliers with approximately <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20190101__20191231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_z4ACyvGjFMlg">24</span>%, <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20190101__20191231__us-gaap--ConcentrationRiskByTypeAxis__custom--SupplierTwoConcentrationRiskMember_z5oVDkWgDQn1">27</span>% and <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20190101__20191231__us-gaap--ConcentrationRiskByTypeAxis__custom--SupplierThreeConcentrationRiskMember_zv7GggoSt8Nh">35</span>% of our purchases supplied by <span id="xdx_90C_ecustom--NumberOfVendors_dc_uPure_c20190101__20191231_z41LJnJ0NjX8" title="Number of vendors - suppliers">three</span> vendors each, respectively, during the year ended December 31, 2019, <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20180101__20181231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_z8oAQnqHYkZ1">43</span>%, <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20180101__20181231__us-gaap--ConcentrationRiskByTypeAxis__custom--SupplierTwoConcentrationRiskMember_zJ4hU7XGgkK1">33</span>% and <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20180101__20181231__us-gaap--ConcentrationRiskByTypeAxis__custom--SupplierThreeConcentrationRiskMember_zjhDFKrG2zmk">24</span>% of our purchases supplied by <span id="xdx_90D_ecustom--NumberOfVendors_dc_uPure_c20180101__20181231_zumjp0mpdYwa">three</span> vendors each, respectively, during the year ended December 31, 2018, and <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20170101__20171231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zNSnALCZBzvi" title="Concentration risk">100</span>% of our purchases supplied by <span id="xdx_907_ecustom--NumberOfVendors_dc_uPure_c20170101__20171231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zaY3nRzejjhe">one</span> vendor for the year ended December 31, 2017.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">We sell our prescription products to wholesale distributors, specialty pharmacies, specialty distributors, and chain drug stores that generally sell products to retail pharmacies, hospitals, and other institutional customers. During each of the years ended December 31, 2019, 2018 and 2017, <span id="xdx_90F_ecustom--NumberOfCustomers_dc_uPure_c20190101__20191231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z1X1VboSYu6h" title="Number of customers - revenue"><span id="xdx_90A_ecustom--NumberOfCustomers_dc_uPure_c20180101__20181231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zi7PzsIWif4c" title="Number of customers - revenue"><span id="xdx_906_ecustom--NumberOfCustomers_dc_uPure_c20170101__20171231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zGcfmoUvIDsk" title="Number of customers - revenue">four</span></span></span> customers each accounted for more than <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20190101__20191231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zM8332bQqgaf" title="Concentration risk"><span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_dp_c20180101__20181231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zATBihi25Tvd" title="Concentration risk"><span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_c20170101__20171231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zeeZfSn6OJTl" title="Concentration risk">10</span></span></span>% of our total prescription revenues. Prescription revenue from the four customers combined accounted for approximately <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_c20190101__20191231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--FourCustomersConcentrationRiskMember_zruN4QGI5ak2" title="Concentration risk">73</span>%, <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20180101__20181231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--FourCustomersConcentrationRiskMember_z8MeQGtPnKQa">76</span>%, and <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_c20170101__20171231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--FourCustomersConcentrationRiskMember_zzPbH3qgXd03">59</span>% of our prescription revenue for the years ended December 31, 2019, 2018 and 2017, respectively.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">During the year ended December 31, 2019, McKesson Corporation accounted for approximately $<span id="xdx_905_eus-gaap--Revenues_c20190101__20191231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationMcKessonCorporationRiskMember_zPhuxuhWrRhf" title="Revenues">3,911,000</span> of our prescription revenue, Pillpack, Inc. accounted for approximately $<span id="xdx_90A_eus-gaap--Revenues_c20190101__20191231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationPillPackRiskMember_zPOwABWNHa3g">12,676,000</span> of our prescription revenue, AmerisourceBergen accounted for approximately $<span id="xdx_906_eus-gaap--Revenues_c20190101__20191231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationAmerisourceBergenRiskMember_zsmOBn6Tv5Hh">3,927,000</span> of our prescription revenue and Cardinal Health accounted for approximately $<span id="xdx_904_eus-gaap--Revenues_c20190101__20191231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationCardinalHealthRiskMember_zPrNCg3EbDrd">4,551,000</span> of our prescription revenue.&#160; During the year ended December 31, 2018, McKesson Corporation accounted for approximately $<span id="xdx_903_eus-gaap--Revenues_c20180101__20181231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationMcKessonCorporationRiskMember_zy9iziJlFeC8">1,610,000</span> of our prescription revenue, Pillpack, Inc. accounted for approximately $<span id="xdx_90F_eus-gaap--Revenues_c20180101__20181231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationPillPackRiskMember_zEue5CDdiVt2">5,075,000</span> of our prescription revenue, AmerisourceBergen accounted for approximately $<span id="xdx_905_eus-gaap--Revenues_c20180101__20181231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationAmerisourceBergenRiskMember_zdhm7OySa9Ra">3,246,000</span> of our prescription revenue and Cardinal Health accounted for approximately $<span id="xdx_902_eus-gaap--Revenues_c20180101__20181231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationCardinalHealthRiskMember_zQoUJjkaWr4b">2,308,000</span> of our prescription revenue. During the year ended December 31, 2017, AmerisourceBergen accounted for approximately $<span id="xdx_907_eus-gaap--Revenues_c20170101__20171231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationAmerisourceBergenRiskMember_zBdhMO7IGyYh">2,667,000</span> of our prescription revenue; McKesson Corporation accounted for approximately $<span id="xdx_901_eus-gaap--Revenues_c20170101__20171231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationMcKessonCorporationRiskMember_zYFac21scak2">1,959,000</span> of our prescription revenue; Cardinal Health accounted for approximately $<span id="xdx_90C_eus-gaap--Revenues_c20170101__20171231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationCardinalHealthRiskMember_zkhPsGnM1J13">2,559,000</span> of our prescription revenue and Pharmacy Innovations PA accounted for approximately $<span id="xdx_90B_eus-gaap--Revenues_c20170101__20171231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationPharmacyInnovationsPaRiskMember_zsXZhx6YsbLc">2,715,000</span> of our prescription revenue. </span></p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RisksAndUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6808773312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">DEBT</a></td>
<td class="text"><p id="xdx_805_eus-gaap--LongTermDebtTextBlock_zSiEv2AIkhag" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><b><span style="text-decoration: underline"><b>NOTE 8 &#8211; <span id="xdx_826_zaOePHCOSkxk">DEBT</span></b></span></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: #212529">On April 24, 2019, we entered into a Financing Agreement, as amended on December 27, 2019, or the Financing Agreement, with TPG Specialty Lending, Inc., as administrative agent, or the Administrative Agent, various lenders from time to time party thereto, and certain of our subsidiaries party thereto from time to time as guarantors, which provides us with a $<span id="xdx_904_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20190424__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_ztKq30bxEfr9">300,000,000</span> first lien secured term loan credit facility, or the Facility. The Facility provides for availability to us in three tranches: (i) $<span id="xdx_909_eus-gaap--ProceedsFromLinesOfCredit_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__custom--DebtTrancheAxis__custom--TrancheOneMember_zi0swcfjdzkc">200,000,000</span> was drawn upon entering into the Financing Agreement; (ii) $<span id="xdx_90A_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__custom--DebtTrancheAxis__custom--TrancheTwoMember_z9hMwRzstg49">50,000,000</span> will be available to us in the Administrative Agent&#8217;s sole and absolute discretion either contemporaneously with the delivery of our financial statements for the fiscal quarter ending June 30, 2020 or at such earlier date as the Administrative Agent shall have consented to; and (iii) $<span id="xdx_909_eus-gaap--ProceedsFromLinesOfCredit_c20200216__20200218__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__custom--DebtTrancheAxis__custom--TrancheThreeMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_znOd6IYgJich">50,000,000</span> was drawn on February 18, 2020 following our achievement of more than $<span id="xdx_90A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20191001__20191231__srt--ProductOrServiceAxis__custom--ImvexxyBijuvaAndAnnoveraMember__srt--RangeAxis__srt--MinimumMember_zfv3TjGl8LZ1" title="Net revenue">11,000,000</span> in net revenues from IMVEXXY, BIJUVA and ANNOVERA for the fourth quarter of 2019. Borrowings under the Facility accrue interest at either (i) <span id="xdx_90B_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zKJYtF79CaQd">3-month LIBOR</span> plus <span id="xdx_902_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_dp_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zp1LBXSYs8ve">7.75</span>%, subject to a LIBOR floor of <span id="xdx_902_ecustom--LiborFloorRate_iI_dp_c20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zOd7HYmfzNdi" title="LIBOR floor rate">2.70</span>% or (ii) the <span id="xdx_90A_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__us-gaap--VariableRateAxis__us-gaap--PrimeRateMember_zjeOahoIjjzg">prime rate</span> plus <span id="xdx_908_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_dp_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__us-gaap--VariableRateAxis__us-gaap--PrimeRateMember_z7ZeM62wYHf9">6.75</span>%, subject to a prime rate floor of <span id="xdx_901_ecustom--LiborFloorRate_iI_dp_c20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__us-gaap--VariableRateAxis__us-gaap--PrimeRateMember_zm98sOE82Djj">5.2</span>% as selected by us. Interest on amounts borrowed under the Facility is payable quarterly. The outstanding principal amount of the Facility is payable in <span id="xdx_903_ecustom--NumberOfInstallmentPayments_iI_dc_uPure_c20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zo00bHzWivZ7" title="Number of quarterly principal installment payments">four</span> equal quarterly installments beginning on June 30, 2023, with the Facility maturing on March 31, 2024. We have the right to prepay borrowings under the Facility in whole or in part at any time, subject to a prepayment fee on the principal amount being prepaid of (i) <span id="xdx_908_ecustom--PrepaymentFeeForFirstTwoYearsFundingPercent_dp_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zBKqDSL2LShj" title="Prepayment fee for first two years funding (percent)">30.0</span>% for the first two years following the initial funding date of the applicable borrowing, (ii) <span id="xdx_900_ecustom--PrepaymentFeeThirdYearFundingPercent_dp_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zXjZ1JE5xuIi" title="Prepayment fee third year funding (percent)">5.0</span>% for the third year following the initial funding date of the applicable borrowing, (iii) <span id="xdx_90E_ecustom--PrepaymentFeeFourthYearFundingPercent_dp_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_z072mbMfrW8h" title="Prepayment fee fourth year funding (percent)">3.0</span>% for the fourth year following the initial funding date of the applicable borrowing and (iv) <span id="xdx_902_ecustom--PrepaymentFeeFifthYearFundingPercent_dp_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_z5dW3FwW1X3c" title="Prepayment fee fifth year funding (percent)">1.0</span>% for the fifth year following the initial funding date of the applicable borrowing but prior to March 31, 2024. In connection with the initial borrowing under the Facility, we paid, for the benefit of the lenders, a facility fee equal to <span id="xdx_90E_ecustom--FacilityFeePaidPercent_dp_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_z1LrXhir0wBk" title="Facility fee paid (percent)">2.5</span>% of the initial amount borrowed and will be required to pay such a facility fee in connection with any subsequent borrowings under the Facility. We are also required to pay the Administrative Agent and the lenders an annual administrative fee in addition to other fees and expenses. The Financing Agreement contains customary mandatory prepayments, restrictions and covenants applicable to us that are customary for financings of this type. Among other requirements, we are required to (i) maintain a minimum unrestricted cash balance of $<span id="xdx_90E_ecustom--MinimumCashBalanceRequirementUnderCreditAgreement_iI_c20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zcVtCOGqCjMc" title="Minimum cash balance requirement under credit agreement">50,000,000</span>, which will increase to $<span id="xdx_90C_ecustom--MinimumCashBalanceRequirementUnderCreditAgreement_iI_c20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__custom--DebtTrancheAxis__custom--TrancheTwoThreeMember_zapjg0M2A454">60,000,000</span> if we draw either the second or third tranche of the Facility, and (ii) achieve certain minimum consolidated net revenue amounts attributable to commercial sales of our IMVEXXY, BIJUVA and ANNOVERA products beginning with the fiscal quarter ending December 31, 2020. The Financing Agreement also includes other representations, warranties, indemnities and events of default that are customary for financings of this type, including an event of default relating to a change of control of the Company. Upon or after an event of default, the Administrative Agent and the lenders may declare all or a portion of our obligations under the Financing Agreement to be immediately due and payable and exercise other rights and remedies provided for under the Financing Agreement. The obligations of our company and its subsidiaries under the Financing Agreement are secured, subject to customary permitted liens and other agreed upon exceptions, by a first priority perfected security interest in all existing and after acquired assets of our company and its subsidiaries. The obligations under the Financing Agreement will be guaranteed by each of our future direct and indirect subsidiaries, subject to certain exceptions. </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: #212529">On May 1, 2018, we entered into a Credit and Security Agreement, or the Credit Agreement, with MidCap Financial Trust, or MidCap, as agent, or Agent, and as lender, and the additional lenders party thereto from time to time (together with MidCap as a lender, the Lenders), as amended. The Credit Agreement provided a secured term loan facility in an aggregate principal amount of up to $<span id="xdx_90B_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20180501__us-gaap--CreditFacilityAxis__us-gaap--SecuredDebtMember_zthRxExVWBUe">200,000,000</span>, or the Term Loan. Under the terms of the Credit Agreement, the Term Loan was available to be made in <span id="xdx_902_ecustom--NumberOfTranchesUnderTermLoanFacility_iI_dc_uPure_c20180501__us-gaap--CreditFacilityAxis__us-gaap--SecuredDebtMember_zPPGETTdoyd1" title="Number of tranches under term loan facility">three</span> separate tranches, with each tranche to be made available to us, at our option, upon our achievement of certain milestones. Amounts borrowed under the Term Loan bore interest at a rate equal to the sum of (i) <span id="xdx_90C_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20180430__20180501__us-gaap--CreditFacilityAxis__us-gaap--SecuredDebtMember_zniw2imzgvIj">one-month LIBOR</span> (subject to a LIBOR floor of <span id="xdx_905_ecustom--LiborFloorRate_iI_dp_c20180501__us-gaap--CreditFacilityAxis__us-gaap--SecuredDebtMember_zNdCgj9HmMG8">1.50</span>%) plus (ii) <span id="xdx_903_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_dp_c20180430__20180501__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zwDyyLP7pB0b">7.75</span>% per annum.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: #212529">On April 24, 2019, we terminated the Credit Agreement. A portion of the initial tranche of borrowing under the Financing Agreement in the amount of approximately $<span id="xdx_902_ecustom--RepaymentOfDebtWithNewCreditFacility_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--MidCapAgreementMember_zRCxWeLxaQee" title="Repayment of debt with new credit facility">81,661,000</span> was used to repay all amounts outstanding under the Credit Agreement, which included a prepayment fee of <span id="xdx_906_ecustom--PrepaymentFeePercentage_dp_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--MidCapAgreementMember_z1tr3iVx9Ax2" title="Prepayment fee percentage">4</span>%, a repayment fee of <span id="xdx_907_ecustom--RepaymentFeePercentage_dp_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--MidCapAgreementMember_zW5eRlDCh8gb" title="Repayment fee percentage">4</span>% and other fees and expenses payable to the lenders under the Credit Agreement. As a result of the termination of the Credit Agreement, we recorded $<span id="xdx_903_eus-gaap--GainsLossesOnExtinguishmentOfDebt_dxL_c20190101__20191231_zAdxzVLUPBZb" title="Loss on extinguishment of debt::XDX::-10%2C057%2C632"><span style="-sec-ix-hidden: xdx2ixbrl0904">10,057,632</span></span> in loss on extinguishment of debt in the accompanying consolidated financial statements. Interest on amounts borrowed under the Term Loan was due and payable monthly in arrears. Interest expense for the year ending December 31, 2019 related to the Credit Agreement was $<span id="xdx_90A_eus-gaap--InterestExpenseDebt_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--MidCapAgreementMember_zZu0N2x7r0pi">1,816,747</span>. During the year ended December 31, 2019, and prior to the repayment of the Credit Agreement, we amortized $<span id="xdx_907_eus-gaap--AmortizationOfFinancingCosts_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--MidCapAgreementMember_z6DStLq8Xyw7" title="Amortization of Debt Issuance Costs">120,146</span> of deferred financing fees <span style="color: black">as interest expense in our accompanying consolidated financial statements</span> and d<span style="color: black">uring the year ended December 31, 2018, we amortized $<span id="xdx_90A_eus-gaap--AmortizationOfFinancingCosts_c20180101__20181231_zEiH8OzHEhJ5">269,859</span>, of debt issuance costs as interest expense in our accompanying consolidated financial statements. </span></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: #212529; background-color: white">As of December 31, 2019, we had $<span id="xdx_901_eus-gaap--DebtInstrumentCarryingAmount_iI_c20191231__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_z9VcDs7KUOp4">200,000,000</span> in borrowings outstanding under the Financing Agreement, which are classified as long-term debt in the accompanying consolidated financial statements. During the year ended December 31, 2019, we incurred $<span id="xdx_90E_eus-gaap--PaymentsOfFinancingCosts_c20190101__20191231_zUmKALfTitQ4">6,652,270</span> in deferred financing fees related to the Financing Agreement. Deferred financing fees related to the entire Financing Agreement have been allocated pro rata between the funded and unfunded portions of each tranche. Allocated deferred financing fees related to the first tranche of borrowings of $<span id="xdx_906_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20191231_zr98Xubaf61j">6,101,513</span> have been reflected as a debt discount and are accreted to interest expense using the effective interest method. Deferred financing fees associated with unfunded tranches were deferred as assets until the respective tranche has been drawn. As of December 31, 2019, deferred financing fees related to the unfunded tranches were included in other current assets in the accompanying consolidated financial statements. During the year ended December 31, 2019, we amortized $<span id="xdx_902_eus-gaap--AmortizationOfFinancingCosts_c20190101__20191231__custom--DebtTrancheAxis__custom--TrancheOneMember_zlblebXkXWC4">736,156</span><span style="background-color: white"> of deferred financing fees related to the first tranche as interest expense in the accompanying consolidated financial statements. Interest on amounts borrowed under the Financing Agreement is due and payable quarterly in arrears. Interest expense for the year ended December 31, 2019 was $</span><span id="xdx_909_eus-gaap--InterestExpenseBorrowings_c20190101__20191231__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_zabZC7kgd36h">14,709,166</span><span style="background-color: white">. The overall effective interest rate under the Financing Agreement was approximately </span><span id="xdx_906_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_dp_c20191231_zQGVlNDMVn2e">11</span><span style="background-color: white">% as of December 31, </span>2019.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p id="xdx_89D_eus-gaap--ScheduleOfDebtTableTextBlock_zhYPUVgRaRm2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: #212529">As
of December 31, 2019 and 2018, the carrying value of our debt consisted of the following:</span></p>
<table border="0" cellpadding="0" cellspacing="0" style="margin-right: auto; margin-left: auto; float: none; width: 90%">

<tr>
<td style="vertical-align: top; padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" id="xdx_494_20191231_zlUsomLypRM8" style="vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b/></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" id="xdx_499_20181231_zzTEfz2tgvEe" style="vertical-align: top; padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b/></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="6" style="border-bottom: black 1pt none; border-top-style: none; border-right-style: none; border-left-style: none; border-bottom-style: solid; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>As of December
31,</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-bottom: black 1pt solid; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2019</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2018</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; width: 70%; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Financing Agreement</p>
</td>
<td style="width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 12%">
<p id="xdx_98E_eus-gaap--DebtInstrumentCarryingAmount_iI_c20191231__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_zbE9M3lpQTMk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">200,000,000</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 12%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#8212;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Credit Agreement</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#8212;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_98E_eus-gaap--DebtInstrumentCarryingAmount_iI_c20181231__us-gaap--LongtermDebtTypeAxis__custom--CreditAgreementMember_zphlZAFEh85c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">75,000,000</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_40C_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iNI_di_ze8D0Pviiowe" style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Debt discount and financing fees</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(5,365,357</p>
</td>
<td style="padding-bottom: 1pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(1,618,986</p>
</td>
<td style="padding-bottom: 1pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
</tr>
<tr id="xdx_40A_eus-gaap--LongTermDebtNoncurrent_iI_zm5RcpFdX4U3">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">TOTAL LONG-TERM DEBT</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">194,634,643</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">73,381,014</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>

</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6800169760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER CURRENT ASSETS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCurrentAssetsTextBlock', window );">OTHER CURRENT ASSETS</a></td>
<td class="text"><p id="xdx_803_eus-gaap--OtherCurrentAssetsTextBlock_zRNYmDDXc6Sd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b><span style="text-decoration: underline"><b>NOTE 4 &#8211; <span id="xdx_823_zdSaMndaGqag">OTHER CURRENT ASSETS</span></b></span></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p id="xdx_896_eus-gaap--ScheduleOfOtherCurrentAssetsTableTextBlock_zjwlCufIbUAf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Other current assets consist of the following:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="margin-right: auto; margin-left: auto; float: none; width: 70%">

<tr>
<td style="vertical-align: top; padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" id="xdx_499_20191231_zfyPdyJN7dKb" style="vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b/></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" id="xdx_49F_20181231_zAm9YV72nO92" style="border-right: Black medium none; border-left: Black medium none; padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b/></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="6" style="border-bottom: black 1pt solid; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>December 31,</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-bottom: black 1pt solid; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2019</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-right: Black medium none; border-bottom: Black 1pt solid; border-left: Black medium none; padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2018</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr id="xdx_400_ecustom--PrepaidSalesAndMarketingCostsCurrent_iI_maPEAOAz0Eh_zXRJw45hyjOi" style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; width: 64%; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Prepaid sales and marketing costs</p>
</td>
<td style="width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 15%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">1,583,698</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 15%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">5,148,789</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_400_eus-gaap--DeferredFinanceCostsCurrentNet_iI_maPEAOAz0Eh_z7DIMLHNXcG9">
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Debt financing fees on undrawn&#160;<span style="font-size: 10pt">tranches (Note 8)</span></p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span style="font-size: 10pt">550,757</span></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span style="font-size: 10pt">1,898,074</span></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_404_eus-gaap--PrepaidInsurance_iI_maPEAOAz0Eh_zW7ZnRxvUVCe" style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Prepaid insurance</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">1,812,135</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">790,465</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_40F_ecustom--PrepaidManufacturing_iI_maPEAOAz0Eh_zF5VxublHLfc">
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Prepaid manufacturing</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">2,595,721</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0684">&#8212;</span></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_40A_eus-gaap--OtherPrepaidExpenseCurrent_iI_maPEAOAz0Eh_zFDbJpAstKWb" style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Other prepaid costs</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">4,787,482</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">2,997,365</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_404_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_mtPEAOAz0Eh_zKXE2iVJ8S0d">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">TOTAL OTHER CURRENT ASSETS</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">11,329,793</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">10,834,693</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>

</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6796514816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORY (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Inventory consists of the following:</a></td>
<td class="text"><p id="xdx_89E_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zI6A9EX6leu8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Inventory consists of the following:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="margin-right: auto; margin-left: auto; float: none; width: 60%">

<tr>
<td style="vertical-align: top; padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" id="xdx_49B_20191231_zMjb20GpLqN8" style="vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b/></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" id="xdx_49F_20181231_znBjvoHo4Cn2" style="border-right: Black medium none; border-left: Black medium none; padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b/></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="6" style="border-bottom: black 1pt solid; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>December 31,</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-bottom: black 1pt solid; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2019</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-right: Black medium none; border-bottom: Black 1pt solid; border-left: Black medium none; padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2018</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr id="xdx_40C_eus-gaap--InventoryFinishedGoods_iI_maINzas5_zJI8TeByDyvk" style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; width: 64%; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Finished products</p>
</td>
<td style="width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 15%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">4,976,910</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 15%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">2,908,958</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_407_eus-gaap--InventoryWorkInProcess_iI_maINzas5_zL7THiYBMq0d">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Work in process</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">1,182,059</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">339,312</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_40B_eus-gaap--InventoryRawMaterialsAndSupplies_iI_maINzas5_zmfSP9XEzOJ1" style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Raw materials</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">5,701,747</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">19,400</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_40D_eus-gaap--InventoryNet_iTI_mtINzas5_zQw4JmfiOGD5">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">TOTAL INVENTORY</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">11,860,716</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">3,267,670</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>

</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6800162624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)</a></td>
<td class="text"><p id="xdx_80C_eus-gaap--QuarterlyFinancialInformationTextBlock_zMrP0NpM9FIb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b><span style="text-decoration: underline"><b>NOTE 14 &#8211; <span id="xdx_82E_z2svtgrXJTu7">SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)</span></b></span></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p id="xdx_896_eus-gaap--ScheduleOfQuarterlyFinancialInformationTableTextBlock_zEn63kaxapc7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Summarized quarterly financial data for fiscal years 2019 and 2018 is as follows:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; width: 100%">

<tr>
<td style="padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom">&#160;</td>
<td>&#160;</td>
<td style="vertical-align: top">&#160;</td>
<td id="xdx_497_20190101__20190331_zvWkYbBag85e" style="vertical-align: top">&#160;</td>
<td style="vertical-align: top">&#160;</td>
<td style="vertical-align: top">&#160;</td>
<td style="vertical-align: top">&#160;</td>
<td id="xdx_49C_20190401__20190630_zRMMfDXcFPna" style="vertical-align: top">&#160;</td>
<td style="vertical-align: top">&#160;</td>
<td style="vertical-align: top">&#160;</td>
<td style="vertical-align: top">&#160;</td>
<td id="xdx_49D_20190701__20190930_z4bm4UwCuShi" style="vertical-align: top">&#160;</td>
<td style="vertical-align: top">&#160;</td>
<td style="vertical-align: top">&#160;</td>
<td style="vertical-align: top">&#160;</td>
<td id="xdx_49D_20191001__20191231_zmCEIBgmbA5a" style="vertical-align: top">&#160;</td>
<td style="vertical-align: bottom; width: 1%">&#160;</td></tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="14" style="border-bottom: black 1pt solid; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2019</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><i>(In thousands,
except per share)</i></b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>First <br/>Quarter</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-right: Black medium none; border-bottom: Black 1pt solid; border-left: Black medium none; padding: 0pt 5.4pt; width: 13%; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Second Quarter<sup>(1)</sup></b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-right: Black medium none; border-bottom: Black 1pt solid; border-left: Black medium none; padding: 0pt 5.4pt; width: 13%; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Third <br/>Quarter<sup>(2)</sup></b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-right: Black medium none; border-bottom: Black 1pt solid; border-left: Black medium none; padding: 0pt 5.4pt; width: 13%; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Fourth Quarter</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr id="xdx_408_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zqinRDBQgOW3" style="background-color: #cceeff">
<td style="border-top: black 1pt solid; padding: 0pt 5.4pt; width: 40%; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Revenues</p>
</td>
<td style="width: 3%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 10%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">3,947</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 3%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 10%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">6,079</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 3%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 10%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">23,719</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 3%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 10%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">15,902</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_402_eus-gaap--GrossProfit_pn3n3_zBFlFQ2EDn5j">
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Gross profit</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">3,184</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">4,830</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">22,275</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">13,023</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_40D_eus-gaap--NetIncomeLoss_pn3n3_zdUt4Odpg7nj" style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Net loss</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(39,506</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(55,237</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(31,967</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(49,435</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_40E_eus-gaap--EarningsPerShareBasicAndDiluted_zrq0GfU2BD15" style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Loss per common share, basic and diluted</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(0.16</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(0.23</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(0.13</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(0.19</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; width: 100%">

<tr>
<td style="padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom">&#160;</td>
<td>&#160;</td>
<td style="vertical-align: top">&#160;</td>
<td id="xdx_49A_20180101__20180331_zxU5UFNBPt84" style="vertical-align: top">&#160;</td>
<td style="vertical-align: top">&#160;</td>
<td style="vertical-align: top">&#160;</td>
<td style="vertical-align: top">&#160;</td>
<td id="xdx_492_20180401__20180630_zQ4tjR4tcunj" style="vertical-align: top">&#160;</td>
<td style="vertical-align: top">&#160;</td>
<td style="vertical-align: top">&#160;</td>
<td style="vertical-align: top">&#160;</td>
<td id="xdx_49D_20180701__20180930_zeEuUP8H4Ijj" style="vertical-align: top">&#160;</td>
<td style="vertical-align: top">&#160;</td>
<td style="vertical-align: top">&#160;</td>
<td style="vertical-align: top">&#160;</td>
<td id="xdx_49D_20181001__20181231_zMiJBlQwGAw8" style="vertical-align: top">&#160;</td>
<td style="vertical-align: bottom; width: 1%">&#160;</td></tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="14" style="border-bottom: black 1pt solid; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2018</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><i>(In thousands,
except per share)</i></b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>First <br/>Quarter</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-right: Black medium none; border-bottom: Black 1pt solid; border-left: Black medium none; padding: 0pt 5.4pt; width: 13%; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Second Quarter</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-right: Black medium none; border-bottom: Black 1pt solid; border-left: Black medium none; padding: 0pt 5.4pt; width: 13%; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Third <br/>Quarter</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-right: Black medium none; border-bottom: Black 1pt solid; border-left: Black medium none; padding: 0pt 5.4pt; width: 13%; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Fourth Quarter</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr id="xdx_408_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zOdIA16Nbnk8" style="background-color: #cceeff">
<td style="border-top: black 1pt solid; padding: 0pt 5.4pt; width: 40%; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Revenues</p>
</td>
<td style="width: 3%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 10%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">3,773</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 3%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 10%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">3,763</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 3%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 10%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">3,474</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 3%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 10%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">5,089</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_402_eus-gaap--GrossProfit_pn3n3_zwxv5YtJecw3">
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Gross profit</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">3,139</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">3,309</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">2,775</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">4,139</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_40D_eus-gaap--NetIncomeLoss_pn3n3_zI3UO2OHCzL1" style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Net loss</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(24,402</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(33,219</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(35,605</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(39,391</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_40E_eus-gaap--EarningsPerShareBasicAndDiluted_zHw2xdXE9Tfh" style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Loss per common share, basic and diluted</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(0.11</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(0.15</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(0.16</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(0.17</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%">

<tr>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(1)</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">During the second quarter of 2019, we recorded $<span id="xdx_909_eus-gaap--GainsLossesOnExtinguishmentOfDebt_iN_pn3p0_dmi_c20190401__20190630_zxZ3LQ9oEMs4" title="Loss on extinguishment of debt">10.1 million</span> in loss on extinguishment of debt related to the repayment of the Credit Agreement. Refer to discussion in Note 8-Debt.</p>
</td>
</tr>

</table>
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; width: 100%">

<tr>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(2)</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">During the third quarter of 2019, we recorded $<span id="xdx_90A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_dm_c20190701__20190930__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember_zdrB7jeaTC48" title="Revenues">15.5 million</span> in license revenue related to the <span style="color: black">Theramex License Agreement</span>. Refer to discussion in Note 2-Summary of Significant Accounting Policies.</p>
</td>
</tr>

</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -URI http://asc.fasb.org/topic&amp;trid=2126967<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6808737456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER CURRENT LIABILITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock', window );">Other current liabilities consist of the following:</a></td>
<td class="text"><p id="xdx_89B_eus-gaap--OtherCurrentLiabilitiesTableTextBlock_zV63QVGAs9w6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Other current liabilities consist of the following:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="margin-right: auto; margin-left: auto; float: none; width: 80%">

<tr>
<td style="vertical-align: top; padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" id="xdx_491_20191231_zjFOD0PPjSWf" style="vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b/></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" id="xdx_499_20181231_zUKRCWRTVVHa" style="vertical-align: top; padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b/></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="6" style="border-bottom: black 1pt none; border-top-style: none; border-right-style: none; border-left-style: none; border-bottom-style: solid; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>December 31,</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-bottom: black 1pt solid; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2019</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2018</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr id="xdx_40E_eus-gaap--AccruedSalariesCurrent_iI_maOLCzU7z_zOuIA4I6TjVl" style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; width: 70%; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Accrued payroll, bonuses and commission costs</p>
</td>
<td style="width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 12%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">8,040,278</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 12%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">6,854,002</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_404_ecustom--SalesDiscountsReturnsAndAllowancesGoods1_iI_maOLCzU7z_zWEOrv5FWwFh">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Allowance for coupons and returns</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">10,316,298</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">5,294,120</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_404_eus-gaap--AccruedMarketingCostsCurrent_iI_maOLCzU7z_zzKoU8WkETQe" style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Accrued sales and marketing costs</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">3,285,662</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">2,288,028</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_40D_eus-gaap--AccruedVacationCurrent_iI_maOLCzU7z_zdVTD5Z7jHQ4">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Accrued compensated absences</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">1,463,878</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">1,178,110</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_408_ecustom--AllowanceForWholesaleDistributorFeesCurrent_iI_maOLCzU7z_zYhKDbjcucVf" style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Allowance for wholesale distributor fees</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">2,347,122</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">792,891</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_40B_eus-gaap--AccruedProfessionalFeesCurrent_iI_maOLCzU7z_zzjV5ZgsadF7">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Accrued legal and accounting expense</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">422,336</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">385,824</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_40B_ecustom--AccruedResearchAndDevelopment_iI_maOLCzU7z_zoBcexnUN7A7" style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Accrued research and development</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">1,049,603</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">388,675</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_400_eus-gaap--AccruedRentCurrent_iI_maOLCzU7z_zSS2ihVlbIv6">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Accrued rent</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0846">&#8212;</span></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">365,155</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_407_eus-gaap--OperatingLeaseLiabilityCurrent_iI_maOLCzU7z_zfwx69kp59ad" style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Operating lease liability</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">1,501,539</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0850">&#8212;</span></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_405_ecustom--AccruedRebates_iI_maOLCzU7z_zMCf1hCKBMif">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Accrued rebates</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">3,916,672</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">412,570</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_407_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_maOLCzU7z_zH8gZSYDqck8" style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Other accrued expenses</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">1,480,225</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">375,573</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_405_eus-gaap--OtherLiabilitiesCurrent_iTI_mtOLCzU7z_ziorxVunc4d3">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">TOTAL OTHER CURRENT LIABILITIES</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">33,823,613</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">18,334,948</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>

</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6800328128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The weighted average fair value per share of warrants issued and the assumptions used in the Black-Scholes Model during the years ended December 31, 2019, 2018, and 2017 are set forth in the table below. (Details) - Warrant [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WeightedAverageExercisePriceOtherThanOptions', window );">Weighted average exercise price</a></td>
<td class="nump">$ 5.63<span></span>
</td>
<td class="nump">$ 5.16<span></span>
</td>
<td class="nump">$ 6.83<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value</a></td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="nump">$ 2.79<span></span>
</td>
<td class="nump">$ 3.67<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.52%<span></span>
</td>
<td class="nump">2.36%<span></span>
</td>
<td class="nump">1.47%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">60.80%<span></span>
</td>
<td class="nump">62.12%<span></span>
</td>
<td class="nump">63.24%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_WeightedAverageExercisePriceOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of unvested equity-based compensation awards outstanding. Excludes stock and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_WeightedAverageExercisePriceOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6800169040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FIXED ASSETS, NET (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 415,193<span></span>
</td>
<td class="nump">$ 181,412<span></span>
</td>
<td class="nump">$ 141,601<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6805254720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other current liabilities consist of the following: (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued payroll, bonuses and commission costs</a></td>
<td class="nump">$ 8,040,278<span></span>
</td>
<td class="nump">$ 6,854,002<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_SalesDiscountsReturnsAndAllowancesGoods1', window );">Allowance for coupons and returns</a></td>
<td class="nump">10,316,298<span></span>
</td>
<td class="nump">5,294,120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedMarketingCostsCurrent', window );">Accrued sales and marketing costs</a></td>
<td class="nump">3,285,662<span></span>
</td>
<td class="nump">2,288,028<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedVacationCurrent', window );">Accrued compensated absences</a></td>
<td class="nump">1,463,878<span></span>
</td>
<td class="nump">1,178,110<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AllowanceForWholesaleDistributorFeesCurrent', window );">Allowance for wholesale distributor fees</a></td>
<td class="nump">2,347,122<span></span>
</td>
<td class="nump">792,891<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued legal and accounting expense</a></td>
<td class="nump">422,336<span></span>
</td>
<td class="nump">385,824<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AccruedResearchAndDevelopment', window );">Accrued research and development</a></td>
<td class="nump">1,049,603<span></span>
</td>
<td class="nump">388,675<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRentCurrent', window );">Accrued rent</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">365,155<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability</a></td>
<td class="nump">1,501,539<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AccruedRebates', window );">Accrued rebates</a></td>
<td class="nump">3,916,672<span></span>
</td>
<td class="nump">412,570<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued expenses</a></td>
<td class="nump">1,480,225<span></span>
</td>
<td class="nump">375,573<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">TOTAL OTHER CURRENT LIABILITIES</a></td>
<td class="nump">$ 33,823,613<span></span>
</td>
<td class="nump">$ 18,334,948<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AccruedRebates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable forrebates. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_AccruedRebates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AccruedResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for research and development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_AccruedResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AllowanceForWholesaleDistributorFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for wholesale distributor fees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_AllowanceForWholesaleDistributorFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_SalesDiscountsReturnsAndAllowancesGoods1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate allowance consisting of: (i) sales discounts given by the entity, including, but not limited to, early payments of accounts due, (ii) the total deduction from sales during the period arising from goods returned by customers (other than under warranty provisions), and (iii) price reductions (allowance, price protection agreements) given by the entity. Discounts, returns and allowances are a deduction from gross revenue in arriving at net revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_SalesDiscountsReturnsAndAllowancesGoods1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedMarketingCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for the marketing, trade and selling of the entity's goods and services.   Marketing costs would include expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services; costs of public relations and corporate promotions; and obligations incurred and payable for sales discounts, rebates, price protection programs, etc. offered to customers and under government programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedMarketingCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for contractual rent under lease arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedVacationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 25<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6409733&amp;loc=d3e19396-108361<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedVacationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6806299232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summarized quarterly financial data for fiscal years 2019 and 2018 is as follows: (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 15,902,000<span></span>
</td>
<td class="nump">$ 23,719,000<span></span>
</td>
<td class="nump">$ 6,079,000<span></span>
</td>
<td class="nump">$ 3,947,000<span></span>
</td>
<td class="nump">$ 5,089,000<span></span>
</td>
<td class="nump">$ 3,474,000<span></span>
</td>
<td class="nump">$ 3,763,000<span></span>
</td>
<td class="nump">$ 3,773,000<span></span>
</td>
<td class="nump">$ 49,646,937<span></span>
</td>
<td class="nump">$ 16,099,460<span></span>
</td>
<td class="nump">$ 16,777,713<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">13,023,000<span></span>
</td>
<td class="nump">22,275,000<span></span>
</td>
<td class="nump">4,830,000<span></span>
</td>
<td class="nump">3,184,000<span></span>
</td>
<td class="nump">4,139,000<span></span>
</td>
<td class="nump">2,775,000<span></span>
</td>
<td class="nump">3,309,000<span></span>
</td>
<td class="nump">3,139,000<span></span>
</td>
<td class="nump">43,312,352<span></span>
</td>
<td class="nump">13,361,808<span></span>
</td>
<td class="nump">14,140,770<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (49,435,000)<span></span>
</td>
<td class="num">$ (31,967,000)<span></span>
</td>
<td class="num">$ (55,237,000)<span></span>
</td>
<td class="num">$ (39,506,000)<span></span>
</td>
<td class="num">$ (39,391,000)<span></span>
</td>
<td class="num">$ (35,605,000)<span></span>
</td>
<td class="num">$ (33,219,000)<span></span>
</td>
<td class="num">$ (24,402,000)<span></span>
</td>
<td class="num">$ (176,144,999)<span></span>
</td>
<td class="num">$ (132,617,160)<span></span>
</td>
<td class="num">$ (76,925,380)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Loss per common share, basic and diluted</a></td>
<td class="num">$ (0.19)<span></span>
</td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (0.23)<span></span>
</td>
<td class="num">$ (0.16)<span></span>
</td>
<td class="num">$ (0.17)<span></span>
</td>
<td class="num">$ (0.16)<span></span>
</td>
<td class="num">$ (0.15)<span></span>
</td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="num">$ (0.72)<span></span>
</td>
<td class="num">$ (0.59)<span></span>
</td>
<td class="num">$ (0.37)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,057,632<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_LicenseAgreementTheramexMember', window );">License Agreement Theramex</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=txmd_LicenseAgreementTheramexMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=txmd_LicenseAgreementTheramexMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6792599408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>A reconciliation between taxes computed at the federal statutory rate and the consolidated effective tax rate is as follows: (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State tax rate, net of federal tax benefit</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Adjustment in valuation allowances</a></td>
<td class="num">(22.50%)<span></span>
</td>
<td class="num">(31.20%)<span></span>
</td>
<td class="nump">22.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent', window );">Excess stock benefits</a></td>
<td class="nump">0.20%<span></span>
</td>
<td class="nump">5.30%<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Federal income tax rate change</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(60.80%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Permanent and other differences</a></td>
<td class="num">(2.70%)<span></span>
</td>
<td class="num">(0.30%)<span></span>
</td>
<td class="num">(0.80%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Provision (benefit) for income taxes</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 740<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117330312&amp;loc=d3e23163-113944<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6807047504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The ranges of assumptions used in the Black-Scholes Model during the years ended December 31, 2019, 2018, and 2017 are set forth in the table below. (Details) - Share-based Payment Arrangement, Option [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 3.10<span></span>
</td>
<td class="nump">$ 5.45<span></span>
</td>
<td class="nump">$ 6.60<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value</a></td>
<td class="nump">$ 1.82<span></span>
</td>
<td class="nump">$ 3.24<span></span>
</td>
<td class="nump">$ 3.82<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate - minimum</a></td>
<td class="nump">1.64%<span></span>
</td>
<td class="nump">2.38%<span></span>
</td>
<td class="nump">1.84%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate - maximum</a></td>
<td class="nump">2.54%<span></span>
</td>
<td class="nump">2.89%<span></span>
</td>
<td class="nump">2.05%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Volatility - minimum</a></td>
<td class="nump">61.25%<span></span>
</td>
<td class="nump">59.45%<span></span>
</td>
<td class="nump">61.56%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Volatility - maximum</a></td>
<td class="nump">64.49%<span></span>
</td>
<td class="nump">64.04%<span></span>
</td>
<td class="nump">64.25%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Term</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 1 month 6 days<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Term</a></td>
<td class="text">6 years 6 months<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>60
<FILENAME>0001387131-20-002086-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001387131-20-002086-xbrl.zip
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M4&?2-C<$W82:&-B 7 &C;UGC%DWN@ KB@H;8Y,HOWQ /]$0L?5(0E$X5 7\
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M;4+-LUTU[[@.BLS/GICG7RX'2'7)3)0L5&Y**ON$IH.H2JE%R3FDHW9+\K1
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MAZ'^T>8/1&E67HK^T* Y=Q3GIA.*=7H]55KWUFSU56JQ>">8T]E%;?XF=F%
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M8<RFW ZV=W_;'I^]7HN-6<HG@FDQD6**0FE3:1@OBHIG&"R5M@S%]%SIW!4
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M$Y$6C*=DH:KLPR9LDOSX0EH0WTP>[R-8.&>R#O&U*V#/D)2_B C'K;GO[L>
M>L>:,;@WZR/]A#Q M4%%4:7)U8U$O$YMKHS%"SJ<@S(30=.G"HD<NO<>FI,
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MO5F*+CEU[]5@U2K6-_UE[M7!:-RC-]\RJHLW/,M\?# ?(:SBV\5_4$L#!!0
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MTDHRO89/W\GU+R 7ETW2_ 8B?Z*)+VYSU7R%\?#*MS^XV[Z;>H_(8(([5ZG
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MK6;NL*TK+)V:YNM0ZG$Y<Z%67_MQJP*"B9<"1Q*;S'1E5WBA+/Q>EW:XF))
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MA)@%F?XT&_]1MOUG^)<&^4\/XE\H_%]02P,$%     @ 2()84#PV5/X-M ,
MKU$C !,   !T>&UD+3$P:U\Q,C,Q,3DN:'1M[+UI<]M(MB#ZO2+J/V T71-V
M!"F3U&Z[_(+68JO*6EJ2[:H;-\*1!))DED& QB*)]>O?.2<S@00(4J),2B"%
MF=O=,@'D>O;U[?]W.W"M:QZ$PO=^7VNN-]8L[MF^([S>[VMQU*WOKOU_[W[]
MY6T_@O?@72_\?:T?1</7KU[=W-RLWVRL^T'O57-O;^_5+;ZS)E]Z?5OX7JO1
M:+[ZZ^33I=WG U877A@QS^;)1Z[POD\>'Y\FKW8"5V1>Q5_T)!NOQH:&IT[Z
M@?GR]BOY,/-J5/CJEGPUTJ^*T-]L-7>FK4.^D7QP.^G=)JX9=LC_>G_Q*7T]
M*GX_??55%# O[/K!@$5PASC25KW1JK>VC4'J(;<S \&_UWO^]9WC[-8WFGJ<
ML<O)[A0?=UB8G+C#<\>MYX0'./I>O=$T1@]X=^+@VZ_@J7XQCH*)+^Z]@J?)
MBV&]Q]@P>;G+P@Z]J!X4+ *>!+[+P\)OZ$G!1Y[O>?&@>$U.%+R*1D/^"EZJ
MPUL\$';RW=T?93^P_=B+@E'QJ:J'N+Z=[/K"(!K?#_Q8L)7H=N D[T9]'K A
MCR-AAP-GW?8']$6S!>\32>#,@?^U\/^]C43D\G=O7\G_A:<#'C$+1ZKS'[&X
M_GUMW_<B[D7U*]C9FF7+?_V^%O';Z)6D'*_@>S7HV_]3KUM'@KO.:^N21V^L
M4S;@KZU;Y_:-=7Q ?WQKM)K?/E_^UCKXT&Z?P__@XJQZ_;Y?;[S_AMO]-K[-
M;WJ;,XRVN45?-9J-YD,^W]K\Q@$O8!?P?X<>G.)H'XXG8.ZQY_#;/_GH6P/_
M7VMK9W-CEG'WC''; ^XY\)_HR&6];UWFAGR6H=K&4 >^'=-((K29>PY0ZCM'
M\%OX[>CO6<8\FCCFWYP%<L09[W6K:8RY'P=!9LA#SSE@$?\F'W^Z;-R>B,:_
M)__]_?<9IM@Y^/;7P5_?SN4@_[OO"I@C_-\K Y).#OZWU6@U_O='JP&O .?8
M:'[[UL2___Q?0.H>=]9AJ!GFW'X/P'[PK?E-<10Y-_PTRQBM;Y=]%G XTV_$
M0.4@(?TVRS@'N)9S-=;&V))^;O"M;X>?+[XULJ/"3[.,L??M/ [XMTUS)4/X
M9;9-AC^Z$2P$>(K:"_Q;C=#QG9$51B.7_[[6!5KVVFHVAI%U)0:PV5-^8UWX
M ^;5Y \UF"407:*:CKC6WSDB'+IL]-H"YL#IH;A]C020!T17Z9_"<;BGR"S^
M .^>2K8@:>AM=(&<\RCP!YJ>-YJ13W\W6T3;/=@=S,;%ZT+*LO8N)2UO7V6F
M^+EYI3#Q^QH((*\[/G!/YA'1,5>4H4EK[^CY7!>13C619JV]._K[4>9,:-K:
M.WQ]07-.HGEK[^KRY;G.*T!@ 'QI"<0TD -WQN'M2+@\V(<5]/P H.T3 _)G
MM6V;P\_PJV/1"U-7=10P&\52-;:2X%Z?#7$$T%4^<9 \+T2O'YUU/X>\'88\
M6LOLH1V>=6'=NQ/6O;NQ9L6>D.\""0.)""0TX8* $L1P='IU>B$/6-XGP3K"
MA?,X]3U;WM$L2VPVMQ>PQ'.0K#FLQ;F,?/O[%^;&O'!1$^Z[V=IYPD5-.JG6
M[@(6=<&ON1=SQ 449?&EKR+J[\=AY /$'M[:;HQJ,\(>_)]SQ6[7BK!H5V)1
MNOQO:H9OGX3-/0!>SP%V<0W_..&##@_&MK?;*/'V=I+M[3QT>\T%;.\#$U[X
MR<?%GWF'MXB4L0C[2)O/N@>\$]WOKO*+;;4V2[/8L9,?7^S6 A9[# L!"2\Z
MO!WB]3YP:1N+H+_'WC4L#(_MV .]CI_RJ#WP@TC\2S8..$O@D:@W TP"S1F(
M>%"X_'LPOM;&8LYV/ANX&XXW%L%<Y**!4BC8>,\]WA7%T'N?,]Y<!+.999%W
MG^/F(EC/+$N\&]4V]Q:P1.+4QV$8<^<@#H!@2?F:>#>H0_0DG)%A7/ (""%W
M#EG@P8AA,;]H[2P"=*?MAYZ=#?&K\/"6![8 ?KB8O2U$+)VVMS,TARUF+WN+
M$%O:SC^QI)#AE=]V'('O@';'A'/L[;.AB)A+=@HT33O[_@ 1B(CG!=HE0Q%Q
M)8W(0[C@MM_S:)0"N?/.HX )!KY'!SSI%!;!)TIV"O<%B$60\_UX$+NPM6M^
MV.UR&P0F(#^@;"*71% '>+?%T.7'GMSJ6;?M^(3+A2K&]JP7O-%8!)@O9E?C
M:U\$N0&A13(PE&CGC4\;C47@T\\L>0+Z35K^8S.OZ<QXLG)Z/YS>:"Y"_ID/
M,_[IO2U$UWL2TCWY*.Y&N(485TIV"O<$B(U%D/J[:<_/W-Y"].R?6?)LY')C
M$2CX<'*YEVQK[V$0M+DP\O\A8+#< GI9B$6+V=U6:U5(Q<\?Q2*4[KOQ;O*Z
M[R85VXNXO9]9\FRD8GLA'AU4C]%_P\+^-(/GG8:BC87H@?==WIU&HHV]>1(F
MC+-YK9:5]8G]Y!G.$ZD>ML@[3W)S(?K@@MP9FXU%J.0+<F=L-A8AB1(*Y8SL
MRANYWT?/]3T%G+'5-A>&\+.O]NZS78BS.;O0(^$QSP9@V/?#Z*'K;,T3NX@$
MG+.1%BYLD!<"C@XNU^5V% /C"7P@#=%(^3(?N.BM!3E; J16!US^[S'(.V$4
M"!NDP'V@:0]<Z_8BD R.T>;<"7$5GT!Z"L^Z^P"R#_6Z;.XN)@IAED7>?9*[
MBSY)5%0PYOVL2V3AD^_UKG@PF$AA[^%RVUR(T?YG%GWW.>\M0F[55&%.9&NN
MXE4:PC%,5GF_P[P;L^8J8CU\H7>>Z-9"Q"P=VX#ZQFD^HNS>2_LYN^'= 7D%
MJM(GYCEMSWD?"Q>#=J2*]"T,HF\GPA.#>%"L-&UM;:R-XRIQO'.749C!(?#$
M(=[=YY!W8_>3Z,(.SC=^-H!RMCVPVVE[V'S8'G86L(=+OQO=L(""GM2?!_R:
MNSY-3Q3D_G>S];!];3W]OJ;?U_;3WU?!Z1LBX06/XB#QK'WV0N:RCLO/@338
M@2#? RS9B6W@!^_.MT]F"665,F< %%$X)\R+N_"4;':S1#QN[R[$-6';\+%S
M@3<Z)5YU@NBPNQ#;YH20VFGKFW!FNUOE4<SO(8GM-3:S$?5>/'#\R.&V&#!W
MS5)_A+^OP;9"T?-^7ZOG]O>NV:@UMG9JVQNM!^U-NI[%-4_BD2Y8Q-%^"O*0
M*TBM(\OK^[SE]?#6YF$('ZC()4 E>^RZ[LE/FZV,SH=Y'G.YN?OL#G1JKP<O
M''H,U2KUSH-$*]C&Q@.W@3\;>2&X+0J8YB!&A_HE3,=\'5*>+4Q@4?+LZWZ
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MN"DMGQJW#2Z7"KFDV+G,IUP^6+YW@MR2TKPTFA[.#+]'+V0T0K>&[V'L0I8
MCNW[L4F?8=?9?@3C5_[>IP=G/P\8F'H&SPP>)N1%/ ] *-[\\X" )>.RCW5(
M#TAU?AZX\N2,L^1RUD\FG#\/("H5YUUV@*I8]Y.S[I*#D.+X%0LK"0LSA)B=
M1Y#T*@Y4<@[TQ/!0,9 G9R!/ P'+J_LM]) >4+?E>>#*DS/.Y?!D/+1ZSO,
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MP[R,^% =Z#< @V\G[%8,XA6QQS\ N(SSF ^@(VY=X/QR;OQGYHPK,)XS&%=
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M 25QA,6D:P.C#Y)_46Y$2LCN@/'IX4=??#?V(A905'80%L/S0;-S\.G+U==
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MI'WZ]EAI_]_R[\SWS)(14X?0Y,7L[A0FE<YQA6^9U0]0=?R_:#IK-KXST.U
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M7*?2C-6JP *"8;(XM.W3Y17-.N:I)=F.CID(<P9JS$AB.AM5#8T@#;@3"F#
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M[LR7V*GR)<H/X\NRBR2P!8GE1&$J+::ILL!T5QRC6PV%AB&I',A0.DSITUU
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M96,;H*[_:3;7MW/-;;94TSL2X,TV-UOK&[_)+@MDH $PLK% A.S54\O66O]
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MZ824&/(*0XGMA,<@PV.BN-*&!%WLPJGG-I]=%)EDFL G<(#?TRS69Z(RXL,
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M""J6'BD1,^:L/1$/+B]74RY0$([2/T./O*K1Q/(S:";-/!UEYA<R>"!H/D#
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MT;6?ZN")"B H08/2F09V'M3K46.<1709[3IDU.J6CZ6E[LJI)V7:#K?K3&&
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M@H7Y)@HT>'F\;?855!*Z5VG+B0AA/W/7[#86\?Y<?!?QX-(;.B7K _]; <W
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M\ -QH'%@@)UV5>=]/#AN39'&*'4V(>H,38Z2^821=F&\HV*9U7,E5Y<BRL3
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MT?#6",B]D6+2!&GG"_5=O825:F"@6^<DII4>FT_WVJ>,Y$ZB)%T%#>IM3%$
M\+6\NCAC$G[+938 XM\:W> ?CK_Z<K:F)<!GPQ^.'SP(_\*"^<-77]DO_&H0
M@+\P (V@287!$E^FG[Z:1])&Y5[T3P"A L=-9YDV1W&#;UYT(P/_\IM'-K(
MK)2V.GR1.?-Y<@0 (<@','T+G4%*Y<"ZE-@5='S12RTLS: ZC=PT(4*-"E0%
M)OZ?O2D=[?R-"YBM1QMH;G9K;;-1UTG<\JCOZ,)0*;1Z9BM:!C+AB\!G96>K
M .R57I)GFCZ9G\_C3BMY%;F)97729N6I0Q+(A6_-%( J9%K@7#$+I2:6Z1VL
M"A,;W=]$'(_.F?/(*?)Q'0'V;P9LK+N3I3/$EDQ\+NVIDY)S(FLJO@_:VBY=
M\&T8ILQG6(3:8D87H?Y(VPICWI56DN)<!^=N'M^O&8DPK)1>$NQ:![YI@E?#
M0&@,.+<VN8JRIF"R 3ED/4TNF'(?JA2?%VBD$'_<P]WXG]QBQ"ZVN7SHOF'.
M<TZ*IS +IFM!Y(4IV1G#E"V[N?,]#AD:9EL-6\=,&5LF-36- B)"B'1)X41$
M49O2ME@KJ(9E*UKQ3")5)UIRGJ77VS/A#?#MK!_2N[DG'!F-162$VF)(=Q4F
MB,GGN,G^?G]*R\)<_CXK,Z(.S9@Q]$!1924ZI<'V=Y#EG>=$S=BY!8WR>=U
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M900N4'2KX^'?0U66M[@CL3W;_/QS</3(R+P;FGRZTJ.1HDZ36)OE8(Z [<]
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M)F.6"U%ZC+K/DLZ]@;B3L.=:5Z<EQC)F]P_[1/DXSD7K'Z=RX&*<3EETV_Z
MTC'8YJAEG41 N(N0WFC5@ R3$0K+J2MH_LLUV?JCCNK0OO_6TV65'*@GWC]9
M?0(V?+!XSN19E'V(#\ &?V+P73YZ22I-C6QT!ZG@CHZ5=)?.X):04S (AI6"
M.X='(P.*.@!%=_& >YV]&_^83Z=R?\P;^@/>T+\:EI)(R)AB#/%1OP<M@!-:
M-62$.Y^DDP7QL]2* 6"@]ST@_\J3+CDF]][*,G/4@-D46XI\G*6H(=Z"'8^S
MPLLA6[W*J"ZSXC:KXV2>:M9I,>,ZWV$SFPI5&"2&7,XE91OHH[O@/@%5#F7
M^K)"H;-8P;721K3H[YJZ*$MT[IU90R$/2>=L2;_A(E[>@\90)^N^)8X(Q1A?
ME-%LE#DC!5@D=_.]B6,C/8,=%T9UP@B&U*\-05#M;C)*BWND)UTH,9*RDG-X
M]=W39^Y9D-JQ.GL\Y"^(C45-AB-[85KEX@!.,S,UCG0F61E/3\I3[A&(S/8B
MP*)T@Z6*-,HI+8P'0H5MT2QE'W<]23/7!$$K=@B)Z7)(;LJ,IN=#3)0]9#%^
MS)P[^O]]AJ6PN/P&CVF=+Z>>0;]OS_(O/TJZ)6TWT\GY<P&SB+:["Z&V2F1A
MD!63:+6-H0S]#4%2%J\L%<=0L>8LB<=$O^OI8WY;S:KXKA6$=BKBRX['A*;)
MTUGKSJ^&U[F+Y\0]P18^E!\G9TP8K+NX/[K-T1\1)2LXAU4A2C,\=XE6(WLU
M%K7A:^YQI"827B%UTL9X7>/JSMXG@CG\#C%[>5#, QV&X-7.Z/$4,'RTKQ^V
MH..OJAF@5"_LBMW@,?:OWN:#_#1M2"71@M+M==&VI92>AEZ7+/M?T\,B$LY*
MT?-_>7S9.0E HG/"WSWS,H-%"9DD^P>KFD:>A.,A&*!8A@1IL9!&*)$IR\)"
MU*YH17!'JOBJ_-SP6$KS,:1>4GK&?-80) Y4L8LL+6)F>G!IUZ2.I[QZ^B-5
M^:J1QSN@,;'W)1SG/QKG/?U;H+O"OB.TJV;X.?>F!G!PN@]IS(93@Y/OWE.;
M\XAQ* N1ZK8;=!-'+ KRY&T3%9V6Y,L:D-2<I98S>U)'?T),8%_\X?/X@NA$
M,<A4CF>EX+UK-H>;4 TFGSP\02^70K,X%8;(4?G:[L+I)T^.V[_[@24)*89:
M4639(TX^3W9Z*_^H**.T+9> !?8\ CBXE2+:THYI6-+&;8"0Z$H>IL/3)*2?
M+US()-!R_CH=L3HO-(%T4!T#"@\V=?H3*7%LRG:7@-83SX"DB[]M@3+)*MH8
M5TZ_T<PM/P-N1E>Q%R(&)?Q;C\'W[L1[+\[M'S8JS.X@%>+&9 &[W]-68I"U
M7?,Q1-FWZ=B%*W/ E9XP>48<]3@53YRA/",=+;!O]PE 8$R--<CVB8:PTO,F
M=C[.-@P[[)WDI.8)NZ#6 >4LR>_GEOZ$&1RHM(JLG4#)P%4=G00*>QE?D1G;
M=$\KJ R4X1T; #UBV^^MCP,O164])X[$.A--T32.M>KE8@^$SDNR?XHCWKQ^
M+)U198S7GEI;)T^N/6F<@BY75"FT/A Q7GC6@>6'P2++@M"!L[KT=UU,,$R:
M/AN>U(B696Y4O^'$8?U$ A)R6VJ+?$8HI8P8+RUMNE%69S;G+G,41JZH>_5Q
MU#(! ;[4CB%PX /QT=.&^<7+^N]]K>I@J_*VK*3O"\LKGJI20:T"]:&AV$LK
M@C)XX O442IR"1[G)KF?2R?1Y&O32\[KV-+$JJ6STS2^E_Z:2QR$RAB@R,<J
MM":,VJ)_#<NL0^N1$ *\-J6G8L!?HRSZ>OP#/FC.TV0G-C?FMS@I<XG\Q3A[
M80D'I5D\>6E.S74-TY:JSP(GWHC@X=H*S [L$NO\QH-4T)F[<91Q\@O9$RI%
MNI<U^)=?7=R,I8!5[R0%Q)=Q[%NY9=6D-6]:.#_4*VG5YWVT.:VD)1TDS>1>
M$VF&$K,/>P5X,_IB#UT']TU[?1WB-IEBD)V^2@H!P=XM*X[3(5# +2D'&UK0
M_5J+E)&%N216#/2&+[C_V-,1YY![CV;DWOW(O4<S<N_]7^4?RE/\+(;Z=7/-
MR0(CNN18<N!XEH2,7I=(R5,F_]D/2X[?H\]QEN0*F)Y:5-1+!JFC#_K9#\E8
MFVW62P[9D^ZOFJ;SJ./[>0=<:92$!:\$9Y^%S8,T#&ME Y.G#2;>T\SL?5$[
MU^$Z'.XH;="KFR"_7H?;YD#3C-XH<%"@K9%P5C='<;V*-B0*"LW,YR.CT*9S
M%%'N"/9/._()!Z?LFTYMWE+,J(<1!".50=[LM4DJ1) 5EB.4 &+0HLTG-U?!
M:8)QXO.1FT+K\>\^\L/W?:S0,\[B6\I.%YN#E/HLN$V9RC-M_4YYZ$PO_Z9Y
M@Y9]5=>(3TG",,5*6 ,Z=))H5'PJH<*Y3^IN2VF.++N!"PJ\UNG5#'N*O36:
MX1?O[I1\(Z()38. )Q++1RCF\Z; '#=>Z/I(A:O4,M1WW.SJ<#FMQA,6)/,A
MG3:.:7:DQ3H$V#IQ-.:A'W2H=X=^7>9%X#V*Z5\,^OC9@M-OA7&PZ]O;$!^=
M,@C@#RX<R)D@=Z2*DQ@*LWP6G94Z&_EL6MN7*0=PKIR1]DZ:)!\<%S8TA<!-
MB ?+[!,B)'OJX:,-4SY5P_)AXZ$O/=9<K0H0 H!6-4Q"Z\#D:Y82:"E5>TVM
M@=2**"AMS&F@_4]=6GY2!EAP!K7S3;Q0[>3R5%!]-UJ!O:A.WQ4MY1=EUIX0
MDRG]&2H, ZF 2^IAYO64A-]_CP>-K^PR[H4;R%3K.PSUEAF;_5)QN>2TS.@7
M/U%;[K=Q6OMTI#^-KY@+FHOGZ/TEIRC>[J=OGSY?HB<7[&Q)7!PX ]%?\^N3
M5S;[4_G[7J;)U+=Y74A*CUZ?),-*)-ZE_#E0&H+SEVG1T?@<M=O9-X1S1]47
M)U*QW"_N]C+C5W7:,D=PZ9;?/D;+)%=W0PC=AGI&EJXH38\AC^8W[Y*3/H>R
MXVLH'P72AC$<7[P,86_ P83F=UE#HZ#Q+\!-GRRTQY?)](57Y)5QSPG$">U]
M#C>C)LSS/44(DK7YZ-B&F2K<<(L/CET]NH>7'":278ON@-GC!""L\)*4HQUH
M=8*1)"=,*)7C7:G&D0M..4MW L5:":OA.K.5@P&[JJR8?48X\^83FBK:CE3$
MJ-?-+C!]RXJ62 MKAW<KRMWQ$Y;\XVE:]-&MZ[L8&S1L9<#GM*:S2?43:2::
M&PJ(XA4XW08@ FV9^!D^&A EO_Z<C(]F;J.7 .)U)N,Z:$:/)U(:M+*)B4XH
MZ=%1^\ONN@GQ_ZJRV\%8C^IG6OU@+6V\*"UUI+5>B':HG.,X\[C/7P1BGZ4-
MQ546.:Z5M"5#=;#NW[7JH+*MER\*IQR^-SG,=G';5'T\.=JCUR*+ZYK<L9M%
M_'4A1]BHG)<HKJTCZI:[[LA8"%L0[-V(DM9VQ.O!H>DL7>0%QDP UCB[1F-T
M6G]($%/77QP+SEWOML7OQ_G?:3;>!J$O#V9ZS+)\$,ZY"@[=XA,A>4[$"D)Y
M@H\_!;T$R .35JE=RF?FZXD>LVS*I@R)Y^RB\\R]NFS,IQCYUZ -I/9Z ,_!
M<L[^9GJ<H1OCQ?,2O8DY-U--CD-#KS.=BE3<Q4>U*WM[I$WAGPK077=.N\:8
M]&=Y>+W!KNSB<_&JK$*1,6GHAL!!N&$)*+(13?PC5_ X[T"),:YVJ+KO3=OT
M>ZXO9O*691TWUJU2/=X6+30MX_JC<X>91GMN,KE)\MW\X,QZ6RAI3$:C(&]F
MF&1Q']D/XK05>]GD3$HX>2X]6#RG77Q^%#9G1@R1[^#42?!A!X0?1UA+;M<6
M\$;-3ZJY^ M5\<DBEUWF@3HX(<AIZ_+0M,[SRRV\8N<%2ZSGM&*(?4C#9ZI*
M4^<@%DE+@OOMDLOR3*XAR,P=,50+^9#$5\@Q!F$L*M)O!/G).2(/V\PU7'+)
MTJ$174Z'=I.IX3,CQOS*L)V/[?UE1_Z68#^)$,G->Y/8@T?![Y^AD9I%#$-^
M+ND<=L&2ZTYW5#$#]CZKRB-_ >XA.B=,I(Z,,,5.\WY_+YXB0__DX( I9BA7
M ^?$^0!\Y0R#M.)@21BGET&&SL"$>*%/(,M.08-&COX(PC-YV3P,.^>/@A6!
MA3[0A3MTAX_F'':GO,$3-V!85^T;/@'O OE!G-V62[E';N#S5V:K*;C8.Q"!
M@9=+!>Z[#%:]G!RU"R2&Y_M!N(M3PFT2 ,>9EAS5E)3CV1/+H4EJ\76@0I4>
MQ/]F2ZVP)DZI9;F+='6RZYJ82K7 4:*&W [JV54G![Y\VV>74O'L^_.&2YXP
MO;\<=\-4ZI(=H>'E77=PEOTA7K?<V$^9>3DC?+8!:9^^XN2B#AJGLB174J#C
MP9O26@TP'?.S%'?BIPXVL6S=N$.?/+ZTWFS<MBC)&;5<97+AQ:N;&#^=B/$
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M*NE"F@SUKDQ1GZSWI(R4^,#D+" 7-^%RAOJ&8G$ZFSW!J^LGP8[7+XT_K>,
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MA 7PWTB%4WH'RH#,F#3 -M%X=?!+X5P#@L)6MEO.]&7''!6OTP'V'O_?A<U
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MV?Q61;GCK>?E?7;AL&W6?CCBD,2IH!1!7X<:<1Z9-9S.O_5L>M?TU0T=?%P
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MSGG3ED0">UA[[34\ZUDB8IY\K0H7Y]'P)@%3CJ($:"")3J*>0+D30&+"P&&
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M8D^R?;//CYA%""L +@UQ;,W P#] #@FQO,2\71TT%D (*HKC 5H'('87+V2
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M=SU?&;7H::&AF&,XD7=[(OUK/TWFQ.?-X.4ZS%G%SAT-$:%+RD[8S)I8LG5
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MUCJA]L&$PUM=;^*]6514.\5]$020X W'M8T+R9)V&PL%[6!7.I=%?]]2*9S
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M^>K?KSQC:KP@%.W\4.9%,?Q++IPC#PX6 ,O'Z7JO6RJ^JFI='"UV(X?9)D/
MIBFO#!D38!@0IE_Z#]>N;S4ZK15Q>^CHN)A@5A9EU5-T$C2EM:U%;#OLRB"%
M#-[O$WE1\'0\ZUHHW+G0.MZ?Y!+$=/:Q,C.T+W)R1E%R;#4&UL[7:O>N$Z8
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M:MZX-FZ@A]&/59FD.E6B U:8L4@[<Q8+/;TC_VMV("DC-')2I;D'QU<T4=\
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M1,D70,=(L$SL*]*@&FW097?9YE8$$0.Y!5V_"S@BU'\4?B9W>B6D47-98F5
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M:L8?^5<O?A!7%BUA#]WH<&D<O9,;;%2"6QU /;D-F:=_BI9@NG2/-W4#YYA
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M3P_/CH^C _K'V=EWJO/UUD!SQEI6F7N;)Y[6R**@%@%J^&9!'\Y^=^R&;K_
M.&2IFES&45O0I:+.I"/4I769FP8C9+N.)H-O"=<CHN!B6,^IH5P3O];505$
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M2,*J\E1]ZM^@PY?>8;K-O":"QBK@176=@$>$:;@T&R<")=*+9,UC![W9G86
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M2@U584E ^/*$!D@$L'!1VV5BLL:L<.2P=&R!_)M""J#N604+](= ?L:$FD[
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M/>&'LR#D6 JY).PZ%J(JER*:W*"?JOVI61(O*K\$]QXN#O@Q@3_&RQ#6)%G
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M8&]1*\8X3\B76>;C$ XU-4(#A9:J^&+A#'*A4'"%KM@R].'T$:85D18@ E(
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MHQXPY"6<4EC.F4!(M\+Y]GA3X&S#*G/M7P(+.?5O: AT3TJ\UZ:A7!,Z\"I
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M?["@-X*1@?025G0?SC:KP5D5IR\H&%Z;2NPS]MM W2QKZ0K;PB&94/@)!EU
M4^<8Q)<U@%2=%RQ(#1!4QJPQ,;Y31?AL+>BZ D" .2YMB)6WG64DP&[!,O([
M!KLUXFHSB@%K@]CK62%M=N?1'EEHU#+J45H<%!3[F:  %7" *O(PQ)!)8XM7
M@5 ;JH"1=@"^G5!1.>T]E?1'DB;'HA*BI=0G@JL;I\A_4Q0Y<\]HN@U92DDO
M5OQM<RS$4V^DW%V9.]/D(LD>-%+Q?2EG1S\Q+0UY^>V!\WA_R2-AZV)4+$J[
M6A @O-89_W-SA.B?] C!/^E&\,^7PF=E#25O(&T=:6U%PX@0+ZN4SC9U-53$
MBAMT5?&1I\X;HY-D'%^K++LN0?4OM9]L90<J[P4)I\V8KX,%U?CA''LR*\UC
M2 V9W#\,P*VHK>(5-)Q!A:Y5<=-@2J_=K.50!C"@R(B8JCNGT7V/H_O>BG%"
M6P[[W5^K__HGK;;KO,<>NZ1A,#&O3IZV^<!W207;,QP>D#0!]"N)-P!#4@8]
M0-T(C-6#H(<FL5/H[*-_(N,<I98.Z#A&2(-D2@44PMRHTY*:\,,T+IB_\@>(
M.\!L!_SQ!)TXM!%M(Z%L\YPZ;^$O.&/BE"JH*6W#$AA6<D_([.*$>B\%OCE9
M)<6/'N!)=K-D&+6D#S(]PT*]!99A0[4LNRD_IHHZN/:3)AK=I>%-^2XELUR:
MZ'@S28G0XZ?'E^Y;S/NSO+G.LR_Q$F8S[+:?_^Q\4=&'=VQLZ[OQ$B>O)^I'
M'$^3>DOSM!A:6*M,4.ZC; T"?\;$K>(NF 8$>O_'"BX8#T65TBR29_@A0248
M;F=&P A#AHD)5OD,2;160(4BK CECYW3H8X[4O4@X8=2&\8(W^J>>OI;!M5H
MQ2?7*O12:VZJ)Z-(D/1A"1QGNH/15CK8BD##^JJIZIZ!C"H/D$R!#^#[.%[G
M>2D&&]E/_W%PVMTZV_(OVIMG3L1V2@AYY*<<34IXD]8$>&#\>,]QW%1&U\B^
MQPJ< #$P*D4M^[JH[3P'P65B/:E\)'YQ7I"'A%/Y,)ROLM*K0@I5&E:77U"@
M2M[ G#LF)CE%E*$QH3'15U-XU]!QX;_0> S5,6L_EZM24EJL-&XJ'Z=^3"1U
M'?-J?I DB; *BHG=0U'QJ&"]5'/T#5HI>Y'2.:SG"=5A\4,K%@;M:M3>H/72
M.0<P5RBF;QC_P[:N5$'RP*LB+P]D!Q9E3H8L*H7"8"0,P807>:U =, PCB1%
M&V'+5S]!WQ.+7OAJH=FC --"4W1/BW H2TN+)Y05I]:8O/M"]KC'L&TJIFMC
M.#*1+H]D>"//#=T"LP#Y)AO[ZU'LKX_97!(1%FP6O)>LJ*&Z&R6@AJ[49Y8+
M =]XLQ X@4OG'7XUA4LR_8H6RD0\9VDZ0W0G(DK>13"A+&<,T3DV92%Q_,0&
M@PR9^4K5X$\OWIPK'>-J2BT3!R&MZFZQ_W?H$*(!I]^5)#Y&K\&/L]G)*VF$
M7Z 1[IQ9' A-+\''2$.NY3TV!K@N;Y,(X!BVL>!+%:DL)-#ZBK^/-[B-V+K1
M +M8'5WE"N&IE"BRPAFN:*_@VMCIRL\EI5,J30;RZ]QJ=>#"D.#2FA*Y@JQI
MY]],9?T>!I/DWY'>C+I8\#PYM2A5#X6TK@36?#]UZ->QS&(]?M9*2 ONP2L[
M\*J6NZD*DJ)70?VUU:8;DKJI6$3&7#5NN\S/N,H",A!AOL,(G$:Y;F)?)'ZS
M6)$-R%@A@TJ8AP$9O$&J%%^E-4:"_&K"66:-4\XW#CJB]BP3L+68AB#0D&3$
MZ(+IC^[S)ZNI<%9Z@VO [L05C!](B@B:/)R9>4R=NI)%2.O)X,A@,::EUHLD
MS"KB7!DG#Z,@2"8IBH!;$FN#H^JGY7PWI3*2_)(.*?X#X:M3"OC!4"08FYAM
MUG\+;60RB!1L6@*4X<\RUR-;/&/P8^%_"Q;Y LP&XA(H ':D^M(Q[&NKF-R&
MN5"W3ET(F&Z2).)7C,%I)SG/(XEV,K3E:!#IA=.JB'T>XO&<(:D"8H=SJK)1
MU6K,8%HH(-DVEE(!?JG<L, <8&.9[1H1?D5Q>L@/N4"JQ#+20-$W%!\F'7;3
MM,-ZFK_;;?;$E?,F7.Z@P>5NQ^4.&EQN_:7\6&;Q3D$N2/+7&""RI 4,V!FX
MX)H -F"O&FW8*V-<XY=E&$[SY(+6+#!!*U/!YLH(95=F=1FX\@YPP?ZY"N"]
M>&OAA3;1;C)G"C1I-1+WQGFJ*E#B! T".!NJN(92KJ%,+Z-'GXK0PIC:)4+$
MSLMWE P@RJQ%L$!&6&TZQ4NX'M"B5Q>"ONQ\0X^,Q@0J?PQMP4E#(^A&-LKV
M304*73:^H;[E7QG^&3TVNYMUE"6F(*=4(?*X"<6G<>H.$UIX8U#([Z(9(]>;
M@,)CB,];Q:*N@5X6/HO3<3M$&XKX4HTG#G3+$ U#L,J[F-F9S?5 24%S'A_C
M/*H>@QCI_VC:O31'LC3B@X?SP-==4#R!B=GU)M@]=]9X242HF<I&?NG/1S3K
MS=MTOYWL0S&CF0Q@*KI_^ZC]TTM'NE(36$]_F8+UK_ZUIJ=]N5,].P,;FM57
MRKQ:BTT-X^4Z:'?#L[V)RA_"T'%Q_^N']@]5;V=W[+Y>?O=1>UT][&T.;M6T
M-+G6:^3ENG$^$13E4*.UFLX?MT3<9FF_8&.@^@G,W2;UGMT94&6>\S]@^#RU
M^7DG'9I7^M0FUCGI/<V)_1$37SE2&1UV@NN5%[;DNDS CYZ>J/XEDXD0,[@Z
M]]9K\EKM]'Y:8^E]-/P[C/^Q;<Y-,Y5/]G[:;0/UUXOC0"/@AU]_W.VWK=*/
M"5\&AZKG]H==M]OKWV$(>\WA\:?L]OI]M^\-OIL9=]QNO^4.NYWO9L9MM]]N
MN:U^[[N9\=!M=?KNJ.,=>L;[Z-KK>9")6VC:+7ZT_L7M'+778IR9].@O:;[\
M]9GW'!PW^$?!?;.F7+&$.^WPZJ+N_GTENRV07/Z_?=^U:82W'/Z^OY*3X(JG
M[D%?U\R@$:2[O>YA[,;[U6;O%"6G:E#-"JU=7X4V;+FC]LCM=KO'*X9@38R.
M_2AU/7=X['/PAF[[V&7IT53:;<VS"L=\:^Y#/^9V6NY3GDSFLJQD$62VZ=;9
M7]/=.82R3_1C=]G8YZG*E>NZ_8'G>J,M9WCKENT^RN-?M+X[ +W7;VWQ?YLU
ML]9LY/:[';?3WA(7:M;,OIPZ;KO5==O=9M%V7[2>Z[4[;LO;$JJYRYH]C-E?
M'F%[[2UYB_13^T[["K]VIG$^#L4M D][/5%=4QW/;0][;FO?>VIET6Y_%(YL
MR<"J]?H#L&Z;%=MQQ7I=\,FZL&JC9L5VE#$P'UN]CCOH[:EMO]\E@SO=ZXW<
MT;YW^CXK9MU/\$\$#JG_*D'P3<E!J5*A I9_OP DJ_:AHFA"YRI:/ZV!'>W^
MPO(]#&_9< GO_EPY1HD&V[RYMWAJNP0RTT^]G3_,"8M]_=W=QWV?WOQ+1]E6
M;:_=:X^X"TJ<9T3PP P 030)EH6R-HLG%+YQIDH#B5O,OY$-UIP98G:YE[$A
M?, VB'X82EY)3?@32^Z[3@NAA^V.:PCIJE[$W</Y=W_XR60N,8OM+O(/;]^+
M]:>Z.9I/ZFBVC_=H6ND$N\VXW7:[V-09S]PR1/ZC.%H%\YXVYZ(Y%_I<=([[
M7%"Y/=9N13FV_.:[8%D5EX:O39)@C#4@(HRO3]D6^Z);6Z:.;%\.WYAS]P&[
MGWFA(3LQ&F-M<KXPU=L:O,#EV]0?0=?*W_'0W1I97V&,DLU<99U: ZEI3<1]
MU*.@;@VQ> _-DT\)5A-E-\[[8$+$($U9RB-U<J=2KI!W81?F#<6;B,7_^FC&
M-WZ(U"WR.5Q&IEI$( F?360\1GJ&0#(Z,,$<=9$C$D_5QPU;DX*=?$EEK05:
MPFMB=Y#OI+I09$10+61 :4C>&?R[T46*=;#O8@-+/[H,\'8]HYYAKJ%%J!%9
M;5/+9G2'3H">FXNFT1B/J3&*AH FL[DIJ!"\WN&47PM9NVWH5[3E0+R)YSYX
MJ,2#IU5*E),MC<PQ\2R[%"$<9GZ7Z0.KBNNX(2S3G\[ATH7?J9\GYN>Z)6W5
MK['>O6!M4' ,O6A%*HLCL<B!9;\828>W$-Q/:F6:H*CTY'JMGY1-8SJ;%_J]
M9W%FO'YXW#4QU]!ZD\:$)^JG!976$?GJ2/I%A;FS/)P%<.=.=8E]FA/9)=(9
MJRU(5[K@%/?$6O;BDK% EPPM6ZK*@8Z2&I='P= ';I.HG02J2H3R2':W/OOP
MX>/?WWP^4Y/R2U/:8S)K6=L42<)"L$&KAE-I+-,M2]_2L\<.'18CD%6\O<:K
M/':5<I0WTGMQR6;L1 ATSIOKZ'&H#E!5@<-(I"KXOUH-R_:Y9/DA<167(G'K
M=K-KBKAZ SL=TS=+12^)$BFL:IZ/!,DA"81YM.[,K+KJ6LI\WUX)!5+%2OI$
MHD=,Y\X,Z\:?N(VZB5MKV'!K;>?6&C;<6@>0\I7AU5'+(R\/]>TA^TFG<YK;
MZE&=)SK=='7HODZT/^7PBXJ&2 -=?!.3'/L45(1BD+=41*FYY/1OB?9K+"(Q
M"Y!A_T\*FJI/)T$RR1>8>IS@. VSN"_I??%Z(QLY#EUNS,<N3#%89(\DA<LN
M(69B3>JIHC\N>RW4"-!^L1-/)D@B:CP-Q<I/!)<5"_3$K[@Z'D%0)1=,(8WD
M=HT"N8744.<>#")@M-19(E^O/Q$Y-[301,.Z=P0> .JK:SJFS07\E%KWHC6:
MYN-_ZJ:SO#6RC^PLS#'0SC;C/+[&,\FF<01O"Y;<+A)9PH/+N3/%IMT9142M
M]A"8E9DDP5)V\%@RY:'0B1?3)!@Q!CF?^67H([T1=T>TT 9\E"<84IB")TON
M++50\:4!3%Q^&)=1W6.P];8,Y9X^N0->[^1N1<IVIPSC:FEU:WMN5@T'N9M6
M(6('2V%B!BH3"V=PMJ*Z])-W+D$Z?(85AL>_#*;PJF^+J=?ZZK>\]@]JJ'_C
M4*1/?8KPE/X-N^G(_WYM]9<]&\=YAAB=KW" /@?IUUWG>P]9T:>NT ]C$6+<
MFKQWU=(!([3(A?J-,N'AC?.CAY05'2I77,<=QWSDR .OC#MJ$"]I8RFZ8+V#
M^>WAH$?46FL!%\X-+@$*#4%:)+<]:&B\A;C5,?9!SHGF\<H/0E)AU%28+J!\
MB>\S+\)01$7KYF42,#D>75THO')TW+>!S#S9LRE(N5&;P+ZBPL;%8;=HF"'/
MDE+)IH$$L;MC2PS3 3T2 OMR?JQ\B^K+E#H3L,F#C-M4P7-2W3A:M7 R/V9&
M3&*"3V7[:075DT\1WY;<CDFVFI<-[XE.6#;PIOP$]?O#OM/ZV3Q0M4[V<^3^
M)'"H<7$*8"2P *B?V!7UT. -0S9!BY#3:MA!30N9EQ@4[96@7?[S].*TA'""
M/8LY@AW\6W"W.'P[F1+XS4B2Z<N]H'ZFU@(GV0P6.3:<R:IO TJ(RW*"$G)%
MJ894-AO4#TC!WTED3S\E<2>P&2=HY##Q,M(ABXRX%JUO\_3M%Q8$? 8&#)S!
M2Y)_=BRB*77OLOXT1:(,>P3H5!F39^DOT:3" T*^FN)E9J DC&C*Z_>:N\,Q
MV?$U[QV([ P[7ZY(/K5N< )XR918D.&.1NP9HCQC6&++)RL!T3BXN+D9*Z6^
ML$6 7 7=*8"2/VJO&L^J%K/@]-(9:('0:7>MW%(B*!6(<J?P5#9X6+>T</X(
MIN?^TH+PH@"/Q<3';JK&<2CH%/+U(S'AMH?4R21.DOB:0N7FT14 X5/G3(Z&
M?Z&;(*X#%+/Q/YDDN3#"[.LF[L^"YT[GA#KR.>_?O?KX&6XE.%V#TT'O)]<>
MOR\_ANLFYI:3IP-,M.(CX!F9O'($*TEZ2+_B(=9W])-ZI^W63]@@$A0K3$7'
M)BA+6XW85C?XYKFOWN\6.PDN0D5:T7>\4YC7%@U@<=*C'EGZ/#_91%?VAY;_
ME?G?./E;'HL>"=ZKE!<]]M/4.&/U=,:&I\?DC'6T,_96I^8N3%]JU*\7"%F@
M_T;;[;6?^8WW55^U\%DH%(YJ2R$MM2KDGRM[B&04?H??8>M+A:OASK_R VJ.
MQWV39<4,YLJ<MR>>;KE\QB&VS_0S9:Y7OY7>J%IZ\5M\J<03^$]?X:A!YX\Q
M0B>GU.CL1F??B\X>'97.[FJ=?:XM)SQ*KX/4RE_] TU=NP$NG-DSTX$&?V!4
MO@FV-;J]ONKC SC\C0YL=.#]Z,"SHU*"/:,$.97/QBJA%Z>8-&@463U&_$OP
MZQL,RS&, Z/\^JYQUFY=T"3B'UPQ?V3(ML\=MZW:>:J5H@2[W$$,KI[/ S%S
MWBCXCO-Q-@LF@DL6S.?&PI"?NXY@81#L9' H%QY +;GDLZ=&0B:VA"RUA#C/
MJ!(*O M&J^*C+DQ<^\TW&5,ZFU!DRAMUNL[G'%$$7L<_\7K/Q',,IWF]*?_'
M<YF!HB'A#/B?2^K( H.X$KJ!<-G30;OJ;9PL8(U/_GKJO%)EU90?$%KRW:VK
MMF;%< DHWC^E1[KKN]'NN'37(K'6'=U#$7$VAKM0SQ#P25MM%R.,A7JV:ERL
MUEUY<-?H8X8$D4KS\2+(K(AA84-@!3$4JGKNNCRX-,5_<I^IX-_X;^,>RL:5
M\H6$C>:M276JRXC!FW,GH:W&W^-DI*=)L5-,'TTF^2+G8@25 ,FQC[6L3HA+
MY\  R&ZY@[1E=B-(C,YB-RR:27@#@CR1G883<>E3KV*S]F9'G[CI5T?-#I?7
MN<DP$I4" I+DO47)9FN_62' [C47V&.(UQ<JO;_V$4AF)14X'2EW;F+OG E.
M)6KG%&"3E$",F0A!-;BR9$D!N1AGYJ=5?2*I<@&3R@Q?&\-'8? 5SSFEIDK?
M=_<;7Z,#'D,'O(M0M$ ,WB,ZPI<(E,AY4[9>E$';*( Z6+ 'N+FGL6!<*C:6
MQL0C'OP=#2V-L"F>[93SQ$L"@F:4]19)$LMJ7_BO6>+GTU/G3"N#]"8%#QW#
MYJ@_4/_,P7BX%B$]<R*"*VG*,#P(5=#$CS2"/8ZH3[?41H+"[XX_3N,PSY#7
M(%5 5YH<E8XI(),VBHM#H6C]0F2GSML\P?P )Q*F(H5=IO1K^0>+G'0I=;J6
MJ VUFI1?D,6O*2S8A"D+L@01.*G)1TB\OVY!BBM)C^4.YY3/%E.N,Y6&+?PL
M0 ,Z1:36*S'Q\U2WZ0[4F0ZM,XV1U# L#9X2%I8I7QB!O=!J3<M+:C^2>Z^[
MS@+^865$2 +D9(G=C&L(9BP,5&3@1S>N,H.YL&ZQ1!06H6.H-CJ6^&-DHV#I
M0E<$9%5D=#-9V[4JE-PKGK+H< RF2+F6"0)7R$6SH%:Z>(_+]+)Y$N>7<RD#
M>,'%B5XI_B/&I7G=%LLPH*4A_Y( :P$?%G-TGO@MMZG:;]14^VVO]ALUU7[U
ME_(ZVCE@R_VA#013@K(2T&D\O5H+7M'08V<K7:(-@-DCA#:+%$/Y03I7N4Z%
MYZ7_5K?;SFZ7ZUCQ1@YK%4):A=CB[#F]40879\\52GM7%S0@\B>.B4F;2A*"
M2#O#V'*6I6%"1QR4@UMV'!#H&ZV(BM<HNVJ)\$MS7U<A-GA)O\D)+/-D&:=L
M"?@3#.*9^_RWL[-/I^;X;)^K8N'C$DIM#I1,:32C[K-U? W49;TSG]\)-R9>
M";WSMUN(R^M"8;E4S'*,\"(5)R)5;L/Q]52%]6VM 4:Z'Q!4.4\8(4NQ<C](
MR%,T7AHX85'J3]@YPN^ VPMG/RC4X/C$./?R;LG61OP;\=]7_#==AQQ:*(@O
M11@XYX37>23P@D5,*UZM(L&,U2YW8<6M)\N.\!Q-)F))F24#M9)0^E#H8(:,
M(6%L.5A*F"T&F-"KIOL.QSH6^&."<%($I^*]?@[79A+\VR^<1\LRXB,+[\GB
M!-P:^,_FE#:GM#ZGU!BM,F!%!R\QB=%,%NX0XYT2=SI>_\J#5!)(Y4C/&B?V
MY52\F_C(3;:P5:U#23?\RT=C8I<<0]Q]Q!6LAYKL[I6M+5%^%\$KO[+CA:X;
MO9,3$"5MG*NA3)* I,])L7(37C!G;(DB@\TX6'J!+FU,^<B/R:4?V8H>O_P%
MSM3T&ODX\5<I0@B<9^<?+SX^K\I6JZZD^/=+QMB_3?R%N(Z3K\XS^*@#GFI5
M=,3,2+EKF&TH!<2+\?\]EQ8O121)-ZP:F@A.GU!KXX(LW2-C:B YBXV3<VUF
M.WU'KP;*UTZC!*Q9)S#'?L:>AJ;X<F\:@7 !E(_Q<[#G&"[U&]QW,":XOJ(,
M)/']^T]<%@VS0K,/SQ;<A4'*)%K+?!P&$]N&G 7)@H)0="TIL%.0Z)CE#,Z[
M>=9G\ZQ/_"P+^O\V0"*JBB#GQS5!SO60,TFBL%P*/TEE<X1'EHR5H/N&;,N@
MU61;MF9;!JTFVY*6Y!&^<I^D9)_??/KX^8OS\:WS[L/K-Y_>P/_WX8OS^<UO
M[RZ^O/G\YK7SZ<]7[]^=.V?GYQ___/#EW8??G+?O/O]Q5P*SAYSEW6^1JM$>
M8&"O8O!(&*<N_6:N@LWBR5>DHA%)6CI2X\1Y\2L2P23^DIC/TC]>8TN&R9U4
MX3U-;_.ZS]O%HR7U#9:@A$$D3N#*(0?$Z^*)6QG"20K.&8\#/X5+);K\]>,R
MB,A(C':_6V%\_&,YT%]>S-LKBU<IF(J/4MV]#/78]4J';:_:1^>9#RMZY4\1
MU\(5JC"CYY+1?9P&TP Y6U+G&;Z.C<OSE^<,T.#_?/WR^?IK5/?BTHZ!SE\9
M8#-:Z,XO8O'K/H;]+R_@!PPZF1[.Q] S!%]#3X\\(;2@8MYP5[V,4"HJ_X;@
M)(FRT2XX)N_@J"$,1EO/=S;#'G)5<1TJ"?W6B:@?IG%!3MVJ\!YU-]",37)#
MI#VGUM6RZ]!\2XGZBG78LS\C.@)4SY\^-]OVZ?SLXRN];ZX">&WN$J/>KU[,
MRRXQ]O0)$2"B 3JM)/N0A2&\<0Z_Z*T8)SF&8)D/IMW",&C"/CNHECPBXBJ"
M]\=&C7"N<$VHYEYUV2LB+B+N+![.[175%[.6QAO=G-2V<]BW.BERL]!_MIQZ
M5?>RXF;OGAW7<0%YJE"2:6KXVL,B+CB;KI>&4]Q,JR9E!R6G("T5"[W[HFDM
M0N%$/*V:/=]?XZC9KIP^R'3H&.-9ZO,Q%@4_D'XA5:)*[:E#MT9)$,O93$R)
M^\SB]PK]ZU3G^<%+@[%2 -;4Q\!(94](?< OBOQ@&N=@70#JD32GO10?(@=S
M(F_3R[F[YJ.WH1.=VI_*I=3-"9"NE?$#(L'R'YX\O0FK>\:4,JV,1OM$,WD]
M%T37=)L3=DTE >JF6WO1L0RKV<NCPR/C<\H8$TW&M-]AY*.MD2#(@L4P5#.0
M:W##Z)B+;R"HR ,BPV^4B9*!/?D &=4S^.*"^EFK+/2YH>57@5AFVK-V!Q^6
MYI.YHM4VF ^?2LHL9*])V$DM4R#<IE.Y$K[C-98Y",356!L_-LK<6"WW?8.\
M1A!1H"G-;?#Q/KM\^WOG3 &';Z,,CQF:M&N2EI'WMU^BW1%-SC/ON;,[B,.M
M1'&XAX!QJ#.:68!_6H&7SK/V\\V[6_=,^_HL>W&JMT^ZKTNXKZPEE:%VMJSG
MO>9$K>$4<R '2)+N: 58=1B<R%FMPUBM3UA_WK!N 0M:5#V-KG<HEEC J0:?
MBVJ-_RDF>NMPWXN)K.+-AMW*<I0677",4F+1+!:OV,-44\@JG/55$Z0;*RLG
MZ,6F!F-OFOE[BCJ]2%\XOWT^^_#%^?+[Q\\?OGS\@"F0)E9YQX&]1>?I/=@X
M A045G:]#4$73/WZ#KCL[]=PC+>NW1EX339I>S;):[))CR*XAX+N%09_'XQ:
MV\FSO"("X([+I@FP7AT5 59?$V!]),_YG2%N>1CJJ]T%X>&NX(UZ3<,&JH9<
M!27X&%D!ZA9?6"XXG,C=0JX>N9]84JN)(0@ (OPD(GIQ$&SPSXH9)?9'J&(;
MM&+B7\)G<^?=WZG%!;9B9DL43-H U&(HJ-Z[D%?ZP!^]IX^L,+YQ'&"%S\:@
M':\"BK+CJKY.\DOGC$. 62&)<_;A]9G)43%UCZ3"T;'%MW',%>;\F"FV3\ *
M;7Z2/;BW]L/&-\X7L*Z=3X6V4*GSY\692JRIW^'WK%021L=Q8$XJQ%?)G@-F
M.O=Q)@YR^ Q&:+H7A)ACT@V'C0.48IF\SXYC,'$H1V)\H:ZSF'"\P6O1/Z>Q
M;!_][H^_O_GO__X?&-/9&_""!4YW&H G<N6#\'"#*-BQE/->^*S"OK@\<QB7
MN%3N?DD0L&,5NKDAQHIUZ%PO('IF'Q,*O;Z*8^5@A'ZPX'9:RGVGZC8!7N#4
M'G=Q5]0?/_$KK90DMY6%$S*%)8L$*I&)8)H >/ +55*.'A;%J6>8*N2LE]DR
M'*K51Z)Z'_Q0^WQ(A41$4FI7IBA6LEDW;WYIQ*#\T!.VB9X*RXV.?4!S@2/8
M:>,+X7\[TOWYS_\XK$^Q;_?,PZJEDA@%J=7"%\^\N%:AMN(2,;< -C@AO_8J
MN(R3.$_A5W+;-; RQ,@1]TO#D&\&S\5(IVSB34^/U0ZI]HOXOM_];#(_^8?_
M;8$:",EM2F-%:%RWYTS!4..C+(,SZC@6!TPL_R#EZ#K[\KAH$:1P"R8X\B#[
MS__P+WVD32"9/'4N,*#LJT]E'P$_AV7U20/!E)?P9NJBHI0)#8?U#$ZP*-RD
MBC#(%'*JS$_"@/JP_^=_=%H.M70@1QS&E-PP <84%60PH8@*YCLEQQ?&,'0H
M=$7(UYQ$>#(>0'WZ3E=CS3-_$80W/V\S_%?CTBI^7#XGAY790US[!X\0L*-S
M&,A6E8DVT,O[Z>SS%^?=NW?WC] ZV)R^)V_B00AVO=:I6M.]O(Q[]R2&6DPU
MY,U=Y4F2(?5SQ=#O_$9]I3 H^0C^QD-YS0]@-AP$REY)VZGX2DG\[*N;":QL
M>*-NO" [B/FR@\2VE@S*2YC*M";(RZ<D_G9CFHA(A -2@R*P/4FQZ2/^\;.&
M'CA>]TQ9  5:!96;)620A(S\(82"ZMF8S(-C+>M34M'HVOUUK5=373O2NM8H
MV'.KS_GCJ=+C2I[43[\VRK)1ED>J+-OU5);MEE:6$I-XXWR\CD!^Y\&2V%8E
M=.85,4,R<2=]3B;-'T54QF?!E-_6.8"O8)SA@5I%-$JW4;I'NQV-TCVTTNW4
M5.EZIK&.5*^D.3'5 &HW+>C2+Q;JSY4]R-BKM*J1'S,^T.C7&NC7M%&PC8)]
M> 7;K:F";9NL@.ZQ;;,S" D6AZ=<!9.':F36:,]&>Q[O?MP>L]EN,)O;,9OM
M!K.Y:^;UG@1\S5UBVK=SAOGO#Y5@;JR@([&">C6U@KI6(F0>C -9GV4*ODUX
MYF(R%U.L6/[>+*&]Y-T2U!68STM'7F.3. S]90I_5O\J"?56P:637DF@*M^Z
M#HB4\HP/)E?/_.>W@&KOVL'Y@2<#AZ1"\M<>B?209^(1I.Q.JE-*X(/N3\4Y
MW4W>'G',S[S;')#'/PO5!R$1)9PT!AB_H1MT;C/75/X8'"2T/9VW)QY[2>4>
MOJ<.;["S^SY;Y^E.0OWXZWUKV3Z.41[3 C="];!"]:Q]G"KR0UQ5@^^DRBB0
M91V26$95G1/-2O$[U E2\P*Y^F\JGD70<_5['>2R(U\<XRJ0/^U )49X=BJ+
M$8G(XD,QK&N;O2(6< OG<;0]*%.PAQ[$_/&*AM?(#GSL8(GT*WZ^@US:7W\V
MOLVID>\?=7[:9'#??E1@0BM/\H!^XL$DJ@:&<_>G8[D$2D'7<3GH*B<T?.@)
M&1F[9:5P^0P_E9WP'F,K7L-]TNQ#81_ZC[(/(ITDP?*6\&6>Z"TUVW%LWL-N
MB._,$S'[KQ_F6;;\^<6+Z^OKTU1,3B_CJQ=GR62.7;U?B.FEG[P "\U_T>X-
MNIT7K5;+:WFC_G#0&K5:[6YO]&*2Q+/9_PZ_GHAOK7;+.YUGBQ]^;9]ZO[SP
M;W/DFJU:&>5?\O#&Z2.O0&M4][$>QXJ>(6.6AOQ^0B;0>.9\%K%%;>WXBSBZ
M=,Y1O)TWF,Q:)D&*#T%& M<Y^^/W#\Z9X5*CDC?\^P)+U:VBX#^"*"90\N_"
M#[,YC"I#<FCU'$5B^(?_3_!W+N;@6\E4.\PN7\KX'/RC49B/.LK;*TQOU/':
M/=";G>&HUWLQ%=\\HR?;C9X\G)Z,A.,QDWBK[H,]CB7=0U&B/E0Z[:):-5X@
MJW&2+[9HPHL8_&5+$7+_@0T_E8JRW2C*.HSR]HJRT^NWO&%K"/]N]_HOQ+=.
MIZWT9*?1DX<:Y<=)%F/3A7:/;,I!W<=['*NZQE#42M,P(KP.K@+-CU_2I:S)
M.HTFJ\,H[Z#)A@.OXWD>_M-#37;BM?[7&'W=1ID=U#GVAF3T>74?['$L:;71
M]X=(+I$=C(R]OP>9_X>88N.K]^_/W8+QAS^2G]M&('U3ZK=NH]_J,,H#N+2#
M7K??1I>VTV7EUFDB?P=6;DPIVGBTAQGE&>H,Q#602199/)]&A\DB&HE3((08
M?H%;^[$&ZS4:K ZC/*@&ZRD-UL3D&@U6WU':&NQ=9#4:;938<6[HG=W,7JO5
M[O3:&# [\902:P)F!QME],*O^Q"/8R'/)2&YP"PI=8#E$!AA/L%;W*39K/Z6
MV+L0'%%^ JNR?J/*ZC#* ]ACW9$W&KZ83L7,ZTZ4,FL"9HTRJ]LH7]U0W]RB
MT<7::-!HHSJ,\A"&56?0ZA8-JUZCBPXU2MW_W1N0A]BK^X"/8UG?!DF:L8FE
MB N-LK+[A+.V&C;:J@ZCO+.VZN"_^YAM[)Y(W$2WB<8WEE/M1ODV3A:*F)=;
MF0D.QR\6X.L1VY143:-&-=5AE%HU%50+A<D)Y]RN_Q2.8Z$;%7.@45K%1@0?
M96+P0)1-H$:Q/.HH#X&P:K>]CD18=5@U>:W&[&ET4NU&J<T>V\[YE(.8^ZEP
M_N$G"3)VRJ*?5F/YU&&4!U90;:V@R'CZ?W6?_G%L4J.A#C1*I:$^Q-')WW+0
M&=1(EQ751S:F##BT451UVKH[*ZI1J]7M=7N@J$8C%>P&/=5I]%2CI^HVRF*[
M:)EZPW)KJ:O@O[$-.+*D(WI=:JJFD+H6HSQ$G+OCD:;R6B<*=PZJJMNHJD95
MU6V4E4 G4%7MC:JJ*66NQ2CO#&?J=$:C4;O[8MKWO,&P.T7CRMA6O49A-0JK
M;J-$EB'G/1;Y?1'@#1K]9/<?)F55 </TFLKE6HSR(&&K3JM/-M;_#K3&ZC=A
M]4.-4K,P=)K:Y<.-<G-L/8N=]SYHM@]^EB=^F!9 FUY3E5R+4=Y9=\$-UNJ.
M6BLYP4&CO X6*!;C)/>3&Z?=)>W5KON CV19]\D0-M5[M1CE(0+OO5%'AK.,
M<S@DY_#_->[A049YMDR"4&FKAD7U(*.43720^T\E!5WL6HJA+J:)J8K3NROD
M,:_BB8\/B(I?.<<N$Y\2"\AU(5O=JF]]^?0;$0,&?IC=.._!$87!Z _CI?/N
M[\X7/\1>$LP^@R/[XL?%/TIUVJ#@:S'*PZI3@[<8->JT4:>U'N6G$,1:R)[>
M!%>]>1S%RFIRO6YM-&:MY.80_G*GWU8:<V@PM*TF/W&P47Z(K[C4<=@XS(=W
MF-\LEF%\0["T%8!:4T-4BU$>I+RQ/6IS2L+XR5X#]3_8*/_B1Q35ZS")?J?N
MXSV.5=T8S7.=($US,<7<Q*?0A_____Z?SO"E<Y:F,1A?F2AXJ>U;H&T;)58C
M)0;>Z;#;'Y6#?5Z[<4\/.,H+L<S8VFJSN36L^XB/8UU1DXF$^V;GRV5H.:C*
M/QV+[!H\SDH/E;[PMT]S/UGXSMDKJ=)N 1EI5%J-5%H'62<&"HYKZ;2F=.!P
MH_S#OY&>8V.4'6241G&!R05NY$P$V8:ZIU0K-IL_AT"]B.+)G-].G;=!%/P[
MB)6IUF!X:S'*PYIL)J'@=1N3[1[@<+W&7CO<*-\+]#1+EMFHYSG_XR_0U2SV
M:)/<JCI16F7!W=YF,VO1Z+;:Z+9AJ]7IMKP5=Y0K$QK5=I!1RF0ID^#WZS[:
MXUC3BWB678K0.81'>@Y' _$@CO1,+^(P)YNO@ ]I&*9K,<I#F'->=R!57KME
M=%Z_T7D'S"1@+UZ)#VE4WD%&^? J[Y8TUO!/?QP*]5]+-=6%GUP&H/-:9L67
MZDO_W\D)^,\BG/[L?/(OQ4N8]+]R$4W$S\Z@\]+YNQ_F\$_OY$3]8!I<J>>.
MXV0JDI-QG&7QXF?G5>B#V^[!@J9Q&$Q?.OS>$U"U/SO]9:;_H'X ?[.WR0R8
M]R:*887"';:H^*86OBD3WS*EZK&.3B0K;V\5WUY>#;4.+YTO-TM8@K/$'P>3
ME\X'?R%XK3[$L"J#COVC%^I7CEXPWAB]WB]@_2J6<@G/.QDGPO]Z,A:S.(%7
M^.&U?Y/>817UMN,75C;>'H@] YR9&?UN0D1B!^L<ADM_BGBE__JA]0/]-\CO
M1/VW?-!U,,WF>/):/[UTZ""GP;\%'\67CI2I21R&_C*%/ZM_%>9XVWM=OKNK
MWEQ[12<'/'SH 1_"P>F-!OT5!V=PZ\M>R<VQ[9WWX)M'O;\ZK5L'=(YUI?L/
MOM*?XF4>^C*,DT<3<#??!W#?I.(6M@%\X*P^L!C_::AT:C%*BY<9U9L%W1PV
MW,R''J5N5M$>-+#W T;'=)N*#_&IXV$Z#E-L3Z6XJ%&0CSG* W8 *MJ/HP;;
M<'C%VG0!.N0H*S'QZU ,KY( WO%*)%$P^=JT!:K1-AY6A5D$U$UU3Z/":C[*
MO538'\%D[HO0>1U'XE)3*39:K!:C/*P6,YP^;:_18HT6J_<H]]1BV60NPM#Y
M:^*G::/&ZK65AV6GL-184_]S</1!OXG2'6Z4*IU [!0EU(&[3VHA\1?BF_/[
MWYP__^J\#Q9!9KAC&QUWX%&:[$#;4\&KU:_=84)M[]3;F&3@J?GUE>OC.'TE
MND5TW>L]X.-8UHM\G ;3P$^:OI#WMC.6#NK<CP[J-#JHT4%'NZSG,9A5X ^"
M^OF-V%V_S.,DRN+(>?_^4Z.%#C1*HX4Z]V,)=1I+J-%"Q[NLYZ@J9J L5,/L
M\WD@9LZ;;V*24_./CS/X5"3.,D_27%+I?\Y#X7@=_\3K/O.?<S$T_:DWY3^Y
MSC*)%WEX24V/\F@*#T ;R^K&_>;;9.Y'E\(YFY .]$:=KMU7I-& !QIE00.V
M[T<#MAL-V&C AUW6PRJ\XE D!,T/'US[%<=15(6-]KN;]FO?C_W7-O9?HP4;
M+7BDRUI4B[:Z^_/TXO3\%)47?>1U>BVVTZ;Q$O6;_5WUI5&KK\)J%WXR]B.1
MGGS\%HH;I>_:K=9.1+B-CMM7Q]V+A=<V%EZCXQH==Z3+NE['><-&S3W13?=:
MWNF[#Q=-1=0A1]GTW#W0*/_[U>?WSKLHS7RLV7\=3W+"B)&T>IV7I%H"]?%4
M?3R-X9E1G#G^<BG\!+Y!7WR'- /^A,)VK_W,=V8!N*5C,?'S%!Z3I0Z]+O,O
M0:TEPD'(WQ1;^%X'V5P_(PPBP5]4[VLTV*..$C78Q?GOC09K-%@-1TF:XHO_
M+8[BQ8WSYELFHI2J*B=SL?"U2FMTR*..$G7(^=G[1H<T.J2&HURG0\[]<*+8
M*-X'T=<QDIHV&J46HT2-\OK-VT:C-!JEAJ-<IU%>BUD0!46%LN)^-9KE44>)
MFN7]V:M&LS2:I8:C7*=9WOMC$39*I:[;ADKET^<WC5(YL%(YCH$>QRC7J19D
MJP(-XF\Q6W:?9*-G[E'/=!L=TQ@N-1SE>0R'FWBC5Q-%;S%1]&R&?-<9)KO]
MM) ((N)P>)$/?YEBMNG-MWDP#C)X+_&![J-P?KD%1WA#[[QE;^] 9SSJ/_1@
MWT53Q&# 5WQ8_2A#2:04I -?!O&D%&><P&>+)=R ?A8G-\XRA%?!'ZEW+G_G
M],E>=?5G@T H#6@#W+]9,(7-0+ T* _X%/XQL74%9I5UYGKN8S\] 5NY"%C3
M@&K!-#5,0RS]!)X0WK PE!#3^$6-FL9."$&*QM$I*B8SA"P1?E9\TR46U\DD
MMP.6U%),,N8:#5(]C"!BY8=/?,)B57NY^A0GW'218%6P04+>-'/_2O!^)F(*
M"H-E"U5$&) 53-O[65RJ?,'%R5^==YE8./V6]VS\_)G7>GY*#-<56^X$#*?0
M HS"=AWGX=0)@Z\HD0RA((V4!71O8OL,15FK:'R"F;/,QV$P@5],@W02QJF8
M/EUY.A9#]RWIE[E(! K)T]^/H]F7/(F"=/Y=[(UDNMF#Z.91=X9.#*)?(ZV!
MN5ONPAF"8N4;6U_3YCIVX/]1]P>/NC^T1J1*@V@2)\LXH7HHW&M0W>,;T.0S
M^#<J[V<7;\[9"4$J\%:K=>+U!QWO^5.7AWTZ!1^Q/( ?Z7%'L%8C#YOD89_N
MJG65!Z^% A%SR>,-PE.IB-'1'),=CU3#8+/48-]S_N*PD9E-,M-] C*SVYW2
M)GGPO$8>-LE#[PG( ^B0OVD=\J_<3\ ODVJ$;A/96ZJU66C.\LL\S9Q.<_-L
MEYI]FMP>N=3T=I(:281\.ZGQ3N#_6JTG+S7[] FMH=0H--@5VJ?GSCLK(G21
MP693('&[;=L>-1IFNZSL0_):0UG9S4XQK<+:C?[8+A.C)R 3%R>=+3K"CW(J
MYNZ12'2J10+D88-(=#J=$V_8]X:C)R\37NL)",561?%QDL74<.%1?)K;).$W
M->KN-HVZMS?J[C:-NALDQXXZ\ Z)@D?#=6R^)(>[&-*L#&^5-, ;LMUIM_O#
MIW]#?A=I ^F'2T-ZC=74&-)2)(X\<_!97 9IEI1];_B/W=2'-J<VVMC;-8@W
M\@:=[T!<OHND@1(*9M%J\@9;9.(I) ZVRD2)6LUK-T*Q42B^H[S 5@LUO#%?
M;:R135)SY'F!?7 ,V\3&*)S![9V;[TATGD*:8$>%,]K) 1HU8K.#V#R%3,(&
ML;D0RTQJG9:T6S;*SH?X2C;T[31FS@XXS.\BYZ"OHOY=0BK?C4P\!;#V/BIE
MBR&C5<JP,8%WD)ZG$*/=(#U_^,EDKDS@+0EP@O*VFC#N#E)SY&'<O77.%A.X
MI',>V A>ER7?L$RIG66FA*K3*N:8_PDV?3"[*20I#T8[<-M,ZZXS,BGQ4B;]
MI6,E:P^9@/6"J+A^H9BM9./O<N[&OU*5J-<_5>LYWN?T'70D_,M@^E\_9-\6
M4Z_UU6^U_W_VOK0Y;65;^WNJ\A]T?$_>VKM*=C2 !$E.JC!@F\0&Q^!,7R@A
M-4:QD(@&#_SZ=W5+ H&%F20LX;[W[+TQ:.A>ZUECKUY=/ B',\U*M+TA4/]Q
MU:'N"Z03'6WPI6[BK>-PX5%1-Q.80=,RT5&>)_ \"YXK BK2(J#E14#%5U($
MM!7"?18D &;0J0NT>N)2F>28VXW39J5S?55OYVC<^=?=EY$C?K O:H-TZC:I
M1" -*:9G ^%.-'SQ'^W?R?$_RXYV])_G%SD$W4DT+VPLH?F]+FP$7BUY>P\Q
M#DP8?L#-*5S<R62@&'WLYN('D2,E_0O(DVWDF7 7>:#BN0/+UL?SC2=RQHL$
MG=L,E!%*^-6QQ-MIU%:#D.G#_!+X1J>+A>61V9@7J,S.6?VJ<EF_[C2J[8L:
MRS2:U:,-_..MF/WRA-BX$UV>AD[9->]*]^9=Z9>?VB?]\WOG/?S6 YXPIT?X
M3&5]K%N?WNM4)E=C\LL//89[E'.YX!PYU!Q<47!+R?;6X!SS%\T6[=9%S-A@
ME\46*P81TRAATM\P"!1ZR+#NPP"A#SZL=0]^,#."0('TTS/#&")X6208\9/J
MY%M5P?[SI.&B%;1O!+\1KO#;=J865] 0(E:9!,,[Q(GO#TSQJ(!?&7YIZS>#
MZ;?A,(5W\2FM?&C/9<[-^@0I9X$>.*\#;U=<ST9K+C*\6BB$L]CU5K:-![P!
MATJYYE#RPIH)>H"P5GU3N/(JVVM'PBN0U7PS*'E1+6:!'B"J.*^Y,S'-&0B>
MAN,QQ "'%3_I?P?B00IHF?=W_6=F@(K;)JGFL)11!,0QV;;N_<_"P0:2$!/
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M.]JGYO9;6C="M^ $.4(]Z@M37WC6%XZ(5NI%*"(K\@(KTD"2"L_K$)[DREA
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M':L97J3:XM24\J0^LYSNPA7NY\RQ')?E+ _-;NY'JF>CUN7)2\+312TB!%0
MJ #D2P!26?"29; &/"L6Z7H7%8B=[&PL2+0;"P5:=C6O:TUU[S9:5>0AILZ9
M5HW+2G#S@>"IK0#M8KJZQO:XZ8XU[:PCNP9G*[>OK(/H2@>H,(JI,?>*C:GJ
MT--4MBJC??YL$/SOXR?X3"UKX5GGER7UT>O_ =R[NHNG[8]D;40P_^A .7+O
MOWG-@,23_T73(26^P$HB/9EE'Q1"MH5B/9OY4ID1D <J"U06\BP+Z9S-PLEL
MJ2!0V:"RL8L,25&@&1(*M+PHX23R)3R'V]!*^5*P+W\VR_G==^'J^N+\VT/A
M]59_T&-:<JFCZ#$M%#69&-#+$XB"YB7=H1=IW[_S ):52@++E6A^A\K2;F+8
M<HYC6%I?OW>:-IDH=1,M^J);"IXY$F5X6QS>J _G7R\'N5N63[:+,3T'90%#
MTIU*ZI/(9H"Z0[*^0M"^'GRNZHE)Z:\F4$A32.\4TLF?]T,A32&=!J2W/KIA
M<:8HK<-19(GE"P6V7-Y!<\MD,4T/1Z$2MK&$;98AV'<ABNN7S6W0+[O>':OW
MY:O+CEJ1-"43_;+GB28<%7?4).OY-MKEQ+48F=G.]1AY*Z-97L] &5)ETYT#
MW,H-N.,[Q">R2Z"O79W?>H;R(!0FNP3JY+4@! 0FL<7_J5$\4VV\4^Z&(/,L
MC[=JR2E4'CVG73*T,D15!1GX?]=Q>+(N9BLVVDROP8(O5U2FJ$R]=IE*IV<#
MN,%BD6<%(84M"53&J(R]5*R^H9"EE B3RD6V(("8R2G$\&F+6?*I,"IA>9"P
M) 5LXQ;L+#R#Y84=G R\ ^L49,#>NPHP%3[!YU'XX*%BW^CFH6N-/C#<1R;X
M,QP<E]0P1NN]=I8>*@+^VAL/I3- ;]\H*MY9H9B/."W1MRS7M%RX"<)H!IZI
MPPMN;,4 [MBDVZ8[0 ["P")I8<7%K0YT4S%5'2YRPER)<[3I!).E*[SX/X>'
MS(F.#.T#<ZG<@.BVT5\/F2KZP)3XCPRI+OO B,SA8:BV-/UNU:1X=#(21NO<
M="2B5D?K"\,,E>;%P&?[4]KAEYT<1F<<SO4CTWD<P30KMM+3U8],$U2'3X^F
MA6=>C-[T/KP+_X(I^>D]D"2&.B.X_[!G(^7VL(= G\ C%>->>736)HS_:S"%
MD)-S+XZ.$(_<YU@46NN2-VEY6B+:+SV\3[W/G;/Z5>6R?MUI5-L7-?;MFT:S
M>L14FC6F?7W<;M0:E:M&O?WI?>]S=F=!;L.97O=AJ/4XKG P&6SO<[75;+?.
M&[5*IUY[^Z;=@?]>U)N=-M,Z8:J5]AES<M[ZD>T)QJ.(F"AXM&$$=I(89_PW
M7*>&?X<)<)$[[O*\T!VC1NWQ]'QP=ORK#,ZP-X0A/Y)+0#>$RIHY9*)D8Q91
M;3Y!K5J&H8P<D/KPTT?F7M?< 9XG]^Y@E3-/EA]M,B7(IKL&(O<G5-,:<CCV
MR9/%M'*U&[.R,.9[/^6;$T[[>7^[9;^?9X=!GQS/E!IF16G"E)+/E&]W?T<_
MS_2_I8=MVU#O'>EVP90*9H4\88KL,P65SCH__WX9CFZ*>6+*IQ7/>UI%]VUN
MZL,!]9*/S+8I05@XLBDMP)K@K_]WP///KXEN79VRO4/U"RFV/_*ZJ4$L%"[X
MLWC%_PGQ*3"2 8:8>5SXM1Z4Q.F2N$1)G#:)Y6>46'QOE"9RJXHSN+2M.QU4
MXO'CM8.TAMD:(5MQ@<X5U=7O=%='3J7GN#A]V-6/N^/&E2I)/\ZDH24N*2';
MOCSL13J:X$#*'SB)IIB3J]8%T[J$@+S3:)XRE6JG\;W1(>'W0D#3W:L[?R_=
MCDP92AGZFA@:9^#XA9NM=?AMJ#AJWQHYW7'[^ERWBU]JUU_[+]VV*TC%%8OO
M-C5X0O&HG)F]UV%F\5TVVH!,AK.#]>CU1R6\2U(T7]\VC#2XNWW9!A6!_(I
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M,W1X;I?/U-B'\^@NG*D_A>[<#%;TO$AU$'@3I!I<>%(H)"[<WO".?0* RCX
MX#@$P+!^TO^A7?S^4[O)()>/D^2RL+"+9PR7Y7W@<C7DLNE^,7_KJO?]U,@@
MEZM)<IE?+,O$<L:40^:?T;60T:V2UM?$K_97:9!!1M<29?1B<0Z3D3<V!,9Q
M;F"L1T!J1&R$UG8)JFM"J#2!4"D[$)JX!-[HVZ-;O-&_7B2O*Y[L2WQ9NU\0
MUK (Y7W@\L3NC\;#._MJJ#FM<@:YG*S=7WB46[Q%$/>!T1/3_WC]3;[\7FRK
MDI9!1B=K^A=N]%_!(KQ -@K&ZE<[H,_/;@04%VX$#$$KB,7N^%;6SOZ,.E\?
M:],=04EM$9R^Z!ABAE_<Q2,OE2[;:A+5$^EN'I37VSPXG6B].Y9^?[E2+[PO
M/ZK\9*(OOZV0@#P$SAR,HIPZZ8YM3J\]WBBF*QKIU[G,C6LGRP -$Y>76_;C
M\^N=_$QCG_A;NN,O%Q?7]OA6:#A\.M1*(Q,?3D='-*\>)<;48U]4'<TR([B)
M)(0G]>_8'["5>P8G(_&F R=(:BND-!9TL$860O'6!^O>K\E4+9P"MAD3X>PP
M+G8CB69R=5 DOZ!T//)0O'7A)JCWU,W@@^6YS!"Y@Z!<'=NOZ4#G[R5)6;]X
M_I ,R;\SNC2 'Z"'Z"=Y6[R."_80U]OVP"(@%T4NP.\D.?!#S;HWIU?@JR>;
MR#S3K^ E<Y[>ZUH,7MD-\[K:(NJ09SHJ4<DX:VOAK&]8:!R6_*('O/,#E[K;
MD^_T(:D+]C/ $*N!J)#M 4%&FR&%NGC=)!SV2QCXK(C%)ST150./N;31X;E?
MKSS1HZ#F/\^K'OTU:R%,)+^H^^V;J4A@H72>;'L(\:SB=3'M_[/WI,UI(]M^
M3U7^@U[NG5>9*MG#OB3S4H6WQ(YC.]Z3+Y1  F0+B6@QAE__^IQ>U!(2QMA@
ML#5U[PP&J9?3I\^^H L$PRVHM]_QE9'AA[X8U^B"VP1O)\]/08^A-B"$ >)L
M=<7L*$/C_;N689G&'4TY,, I1QYO46]@@,E"4@1ZP&*"V2_"O=8R;*-C^IO*
M/HW0I4/0K%="^5('>O\N9238)FP*G3.:YT"JU8@(^.#%)-BGH_\+\Y(8 )6'
MX.<%;0'$]^\D* )8($X"DS U+SW#ACT$'E:7$U+:O8?ES7J,5)LVH4WH3A+1
M& [.&<(>@C$2%P]Y:-K+$*'%"V$GK@.)>*,3"X*);1W"R!"VLX>6SCI$<WQY
M?GGD735.#[]6UCR&8L^\)RC3\#PC"XG >#0,,26RSSW>6  +"%MP 564'ZCK
M.N@'-,Q)!P$/: &$=L*=I+$+-*S-L-$YC;>71R;H#E)4+XQ\MT;404VO.J%>
MX,.VS#OJ)V>^^ %-=&=+HOYW(EQJILN( ^3HT<H<$)O R8GF12D&!+%"5J:\
M;$EV@V0ER!#9 +SA8A\X[:D;70A2R8ND$.$KI-N54E*GF;A2K]X%SG1H=HRF
M?G_X@/,C=1392"6>/B0P) ]M!:8%T2#<U.6Y_L;&*2R;/H]__S!MLQ_TN3WK
MX*Q8&Y:NG/O]JO!87W"8=#"9A(+ATZ?KG>M/GTZ*OV8O!U8NBJH1\GV$$XZ#
M<'>=0*C=RR"TNMW.;]W]<5&O"1!R:%4? ZW2AR^0-FC'H#4BC-;;5 XA7J0'
ME=LCPCJP4G$'# G'O9[#\]S(G^1V!?*QLO1%(BAPK+=@_+<LUE_)@A^F? XU
ME@4N_I E'4JM.%'".!S(!J5O:&T,EN%DR@V' $41P_!M*N%!7B1F4F@6!N>(
MH%/Q1MO1>5$!(J82!DZ)G;06I(C8W9R& TWN8G+A&)9$8--CLBB+]'=!Y')N
M($#( U,UR+JP"5#ZJ.),Y$Y9_D7Y&A&.SS4T+0MDTH#)BL@_=*#;VY)P)VW/
MD[(@,'L4N C"1R<P;/,5XTFPNBT*T?Z9@"X@P71:IP51V#3W(@;\J2O P^Z3
M2X,_8K!=E(NT-,]D<!L0E.$Y@6Q)4[E+AQPSU@S 0XX3O[T7)GYG#!#D0?YQ
M)\27;8#.8WB*I>?==N/LLC^ZF2"(Y<<0Q/*'+QW"F!_F'MOK#L H1VE=C;\/
M1_?[QEWY:1RE,HVCO$KE:=_V"6PA*)=J GL$-7WC$-3]Q.CT7+1&_?1WF^/;
MUK[=N]D:WQ\6UUQ="C>;Z4RA (!V"$UW!C[+Q\& ;6;Z["A[(J,G3/)5SD19
MFRV'_(?6/&F<;:G)#VT3;MYA/!R?;9QMJTJQG%.5N&$Q[<0\94/YZC@Z,EK@
MBIA$(5D+^;@P;)3G#31?B "):B#C@&QY@BNSW'++Z&)4>43R 8F&C2O))[1P
M!?B&71V51S0PL45!58*V06O[P'N$K[+,?LRYYVR8FHQ2EA\R7-?H,X[/=18\
M.OKL=)TP-,:)A8!2*R^&&NTADAOL4:FK02F(I75MDCL%RTB(DAX"DDU&290F
MRPCN>UY * _.X>TX?1 KVI"G-5%,\*C>,.[^%-S;"R.AF*")X[#%0D@X'6ES
MIL*"B8MXAN2MI *#A7IJZA;; U\[XC<M<,"WE11Z4GT J'N.:Q 2D@C3^_.?
MNO_#]XIN^6&8=NA CX<H6\&" %I,SX5C&V +%QOY>&88RI%#E)C*W]3,$NH2
M0BAGQ .2@5D&"=%@"*TU+;1C2S1"C>@SY#!<7F(I+ *XJ9R'!0%!!B=RU\#P
ML7H1:#PN-=P+R5QVP9DA$V,6+M2N^F!-0E5'L^T 16ZH'@.".]9/0Q==--4#
M\DC:-(."JC-@CM)<%W.X-4Q91(^:,+=C!LA+A;HL08X2,#QV=TQOX'B:==PY
M=.PNRD-49)AND):%\GF&:XZO<^[]SW:KM*W-4U=D"340PFT!XL-V-G _<9'J
ME<I2X46D?)I=%_1&(_^+&I^A2A66[4,03=Y=0B-:4$;0HG8&-!_$[C/<89JS
M&][C'BA3'I8GF/U*LS6F7&GE#/Q@:;0"7F*"D0JT 4@:"& LWZSC0#(7F>33
M,@^>A@S0 #7,C6X;ED70KTT6(OYFS13P;[:FH:G[/5A4[J_/BO3'!QISQ-IZ
MB<8-\?9<9(7A:S58U=)H(';[6,+2YK\?__N?>J5:?\R"E[]&R7T#T@30-;Q+
MFDVO95ALDM66([R^;<3V1#MFR#TS,GS,\/$9\!'"QACC34;*06_DL4QGEKN<
MH6:&FHM'34GJ )YOLU+:+L_0!JO*!+)"/ \X*'C?B0Q5,U1=/*IJ.D1O&G&4
M%?6]"<_O"S&Y[034PZRU_00,1K&9FP51-6:#\\IA!+WA%<^CWNG6* RR\S)T
MS]!],6L4!FQ>B!\MLM'()-,6\=D=@J8FK6%,"PFSHC#1BD_4AT\+D:,22![Q
M75946:+O&5IG:+V8-:)_Q?8W6/QL&!4'V A%YCJ6,^3EREB?!YU7#Z=5@$:T
MG5"[QQ\# HUF7S( \UCH1A]1&P-]P7AHV@$Z4^@;\1CA1+D&^[YD%R&[" M9
M8X1*(\[2("2L/&69MU#6" M0@2V/UE=D2"J"D3R(G(ODVNAHAX90GTZ,5=!,
M1!K+8^/O9K2\4V*$S^:#Z+]2:;"E&=)@:\WQGQ\')Q>%TY.2I2TP#;;>''=_
M_KDY&3F-VFEM]=-@:_.FP1::XX/+$_O732Z7Z];6, UVJSD>WAU<-8[=H[N3
MWM+38%<F6&2_(_LEF*^!*#G4A4E3)=';+])QP'D!Q ?KOX6O I>%8%W0NY@;
M@M B""\@RA.T]Q#IB#2V0CA,N*X%T0I., C9<=3)@2X4X=S ;*--Y9Q(![1W
M"&];)[MF(OX8'#R:J$E>@\Y"%FW*0<L48BN5CHG+$[()A88%>00H@>O& ")!
M;=Y%6'X2I'(*'LE=Q+H"8H%K>)X#4TCZ+#:?;^(FT+LB()93:9J-0$[(PW <
M0V1F2;-3#D-E?]@TQFKBHQ#PS](9:-E$\ H%&)M*_9A\+]*ZL<*VRU3J<!E.
M/ <B[HXR0=' EE&.A#<FD^#B3].^>I+7"D\U5+]#L-#2@9!5YF%X# >30CL'
MD><YDC'(!/0Y5K+RAH*&HA,%$"2(WLG@>0@L"<X]#!#":H^AQ8"&_T G+@PO
M %A(=@N*[C3T-Q*A1):O IS".Z*R /<^%$TF8K"I6R@Y0^<Q$#A]FI%+(<//
M'B*@NS2>R4*AE/P.\<_\#2CD28-^!Z*_CH@@BEV[Z/997)%T7"PY;RBJ2FJ4
M%/#60KQL4ALBN_TA%&,/Q^.77>E W@R=D";2I.$6WH@0I_"LPW>CBZ4A4X1,
ML5:1!,9.WZ YDEJ[QWM)1NJ2"I4"T(:(7!' 3EX]B#R3R41,Q\!PK:"%8>AT
M49O*&:R!+10%/]G(%9:\Q* 1SPOZ RHN\A VYK[R()0%6[BYSM#OJ>+['KE.
MJH3M'E%%6&P+] E5PLYP-+0<TJA8ASC<FP+T@@;B:Y$:G @@J29K6&Y:Y37^
M><(G&B!@U3USX(FEA659Z8S:G69:2&A%2(Y4W%716I#ISN#L0S*WQ_(#: HK
MSDDURPB@D+B%8'2EI%*#)Q^X#@$'[O/"UJ!WECG 0V.N<J1]X75-6'^/L ]R
M 51F:-0(CD.F ;K;^=PJ*]E*NR92^[K!8@&BO).EJ$&*/]TNU90AI@CS=(<:
M7#OY#8A/2F%TT< #*7T5PZ453&%(BNBCM<[@1?*I^L8S:,@! ";*( <QP^-I
M+[&0#[SL(!=T,-8ZFH['@[=4T<"+H"YYGG7PPB! ) 0=%P5PM/)U1-@&UCZ8
M"-Z@Z$DY\Q!Q,%&)= U"WI/()!;OC6X#;I8S1!TQ2G01#>.@H&B<O'VZ;Q98
M1XL+,UG"]*B\,X5NL]'D5=# M4D.Q0+:4K9#VQ%X.%0XEYHDMYJ>++ R#RT=
MG!P)E-5VF!"$IM?7WJ4W^7:(+FF\R6A86#L2O!Q$\RXG;POGB-"(3 K3IKE*
ME/1!<0!,4XI(D%SSD,ETY%;0FR BIF2"221\@C;H2,)H+VQV*T39A+4+=!."
M;S*>A0I+,@A,?EE9&#8&N\N!X>%KR:+7!&(3]L7%(P@)#</'R:ZP'$32;EYE
M>.<>.5ZT_AQW1$[#/KHW4 I/3)61LYQG>K\Y;O>OKH_.#_W[X_+ZE(""O5'3
M6#3E0]I?EBL#A9BB_6T8:#CWBL:$@ZBO)A4*E+X<:"/QC0O!Z6'N/XL<I?G*
M4+.><M8$?O:(B5B>;GPN$'+OF1!,@T8E?MLB.@[3C46.]0:NJ@\1(*R2"XJS
M$DQ4J>P55VO)G(=H0\D+K4LTBY8F[)E$6W3;O=$F10/E?"J'20 *B!LH\@K@
M04YN4G(*EV%KRD?R!.@U%MK'"5O'E(#:WVH4/#)@>$,&)O/SQL.T^RPR'YQ:
MQA1:<8;HW):&6C[D*!"4]; =:&A&P;."NOG*1PJQPM^;V06\,J!6CF]TB58Y
M-H099=)PQOPAD8IKL@1)FXJ 0@A(0X4'UA46:S=L,%.?>.7].X&4@$DHO%)K
M)21WU0H/)K))!/8'T3")WA8EJE+^6@T:])Y'KH0\?1?E9;@R/;/;,RC5<? :
MD@W\"1P?6QV;;68^HI81BJ),)1$MH%.@QW N_S>MQ,3,G_(T@>VT( ><U6P;
M!+YXJ_CW)DL%F!B7&GWH[:*%D:0^@:PS'Z$OAN'S WO_CMEYT'+)3UX/KYX6
M4@LJ/\)25#@C&I+N?7H)\9OZ?...W;CC5_()/WI-$>_P3 M$G_$#'D[TE(1^
M4#9)Z:]P>^CGBSV6>-?9NY6_L+<J0RC:]_2Q8]3!Z1W8M&$+.?:Y<!PX0HB*
M="?,7SDS7!X+!6GKA4=M_<.7Z!YA1YQI).XG 0IH>\"+*8BA=&>YQ55X5?A@
M(U4Q3,J[L X%S2,#+8G]10BD$W1[H:'+=9V6:-*'*PU:H&/Y)F:AB7[E<N&5
M)#&*A5,L]UR*CSR7),(7@67\9#8C.Q)^\15FW4_ETDF=DH28)9*!;2<%DZF5
MRG@,[W[+]L?S">-8:%N+6GPA=H2*'HQS$OUZ(RX%43>([&68RNI9@UR;-1AC
ML5(CT3<K;@C<5':B-N9T$S-FH3NL?=I_JS6U5BG1Z3P_&K8HI=+:(C]9#MBE
MUG0_27<"&?+X9/>T$5;&H0-,-:=/FJEF-)V_L-%\&;5(P&UVKMU/SY,M1TJ0
M)+_2'%^W=RO^KG5U%G16-!>6.@G)VHU7G_@ZW0?"# W,Y8%0\0$JDH9/10U9
M)QA%*TPSFSIH5P8M+Z;=IZDHG.>&46G<^4?> ;V"A2=!C0K?-5L!%<G!0BQ\
MS%[$R9S0ISQ.,-"$(%I(IJR,>=A-5W9,PZHHJX*M,C(\TT8I039LC7KKR8,T
M9E4.WH ( %3+R,^,3.,),#6+$B3R![7(R.4>PU@!&2R\\*T4',*<^ ;&$Y*%
M^I81/S8\#NK;Q$IM#^^-^GJH<PK6*C:'90MPG6!*YT]X' R;J$DSSR_O(AG&
MAJ"*29;-_%E)*^'1[I0/4)$#;.V)?C%::AC+GZQRCX_R#,&-]>;X1[EX?_FU
MVCC=*BXVN-$H_!@8!]]\<WL->GS4GQ#<.&BTZF>]W9V[X^H:!C>2D[K8NL[U
MQ]52KE]]P\&-R86;"%0>+E*5( 6 06^81AX[T$N9J+2::4O<4ADX-//&HQ4A
M35:E27P+!"Z10I$!6P8*[@0:&IHFF5^:","^&IK+:'Q8NV>C:03$/E^4 .;S
M1%B4Y.E^8,EAS2F,??3\"'7M00]@NFZSYSAZN&1.6EF,.Q3%@HJB+MU=.??7
MIK(=AM>P]?#\I'YH2V7D'_O\AB9&ED8B,3\GFA8HP@(Q=N(M:Y(19HY%4K%D
M*YXDZ%6$^5K,C"MTKQ GHLB@@<?)]4.O=(@PO+A<<DOE1$-!=&P:, :XAD6S
MF=Q@$.G/EJT'DM.)BC!BK6_YD,&'"47$E(ZA0V566F 6JZ;+8"1WF1!!<@YY
M[L<#/9B*R=!7!E7WH1PSC&7U1+(63:-267@!.R:'")4:#V1^G>KO&414;@&U
MW7;ZX%W%O1YCM&'#UO>Q.QY1"*#$:G+$P8ZD&<\Q6G/\NU+]>5"^[O\>=%=3
M:<9=;>"V%'E?;_A62@R7^L5"J/"ZCQT:K;M!67GD"0Q5ZK+:Z!%6CR4=-W3L
MB1 /FI;E$E[<,DT1ENI.,H;*[%V4-A ETG)&AE#!F.V/AHS?00U-7L)Z4SF;
M:1>B!N> Q= "&R*7%(.4?:=]._D-%@*$CEPT&A.D.#:--H0BI"H%('KS1?,$
M%VICLA!CO@OVW"!PB9A A(4!W"X4BD0D%DU-B*R>&@AH0+X]4N5(*V$%X%6S
M6<2NB&2$]>$$$&8!WZ "MG'6[D%KJXT?A&V!N(.P0)<0@+[OZ(:E\JKVD3>4
M'_0W#45:8T!M'_@"=10EB+G <>7;N'&&0)6_4N%$F9EYP,J=4F*DW E]'&?Q
M.!(P[C\(?-95@4=>Q\VSPMP@5S/%<XT=8M3H0T\>O63*G0-R 75A(>!-[W:C
M ]V8A1P#K$J=S($@FA3X"W5E!#H4=;ZGO"WM 615*1V 6LEID;?P>1#EE;'A
M0FX'/H;,]]S%VSXB8I:M@[D#A%(13<-E5D^./A<6+]F-%CK/-I5= 900$#B&
M("T<W:A8WAJQVPLF<!F.9M2XU+&"MH^1FX9&GD;.+UF[Y>4P1#ZVE0/-#L"J
M1*6Z*@IS+:.K\78E,"=TA(O,2Q-CI-43':7-*QQH& PE$B5H>,W @ !/P@-1
M+J5@E(;TJ"0X"%J$-1)]*4PB",5$[E8%89(F)@S @8%%_VTJD@ZQKXSKBT9Y
MJ)VE; $6E[P%VLE/WA-8$U-.39!Q*8DBLC.D+SP"5@X\EDUW\;.A20*\R=_D
MI7-X_DB,CX!H!)%*. D9U(O<4$Z9I*K#)J&E9L<D(T@67M:^@*PZ>N%@,+PB
MD3DA[X2?$^N5A540!YJITS0:/@HU++)V6B+- SLP^"QP=Z"-8N] B6AV$J W
MIW$E%B,732L3! TB< @JL!AE(/%"G8REY*A2F@D:D9/(G;0(/"XUA;Y1#IY,
MH/@12TDN 0MH:TL;GHRIGYA=[G\)R-Z"*:2$E5: V9&1O!_3)JN\@R6!\PR]
MATSIDFWCD98>9&K"K#7*^:5DQH:'CEY(BD&N"O@ N:;,&HRM)2G'Y*9K/PIP
MI&L/G6N;YZ#R=IW62!J/2T3H6D@P=R<.B2$0:?.R(ML)8IH2%]-"TI#.LW%-
M89.-&5:7VN,C;.7!Y" Y5IT6A8E+,(3IH$$+$#^)XLM.(?+_CF$"'$/S/FO6
MF< QJ/^7%Z5OG%THM%=XE?$LB<#0JC6BZ'P<^N3F4Y'2=]#A'<JJA &B'(\I
M5W[(6F8<3 RDTE>Y(02R/KAT=(Z.YZ'2#4QZ=N04-'0,XWUO$[T8\)\=)K8\
M98)OXJP<>2:V0J>E%P/6W'50O'2EUC$>==V 580(#-P^B+QS%)XT=FGEI=I8
M]YE@ -6N^*+%5L@ L.YRKKP!!?=/(#H05C9QD( \P-2D*%A6B7MB'\B1A0N'
MYEA&XFU-&MLG5 P6@$D6H2J[=)X-A:J6)])9'9%9=ODLK]/R< IY+H$!KV\S
M;GU%T'(;:\$;[NSN^,<-U!Q?UW_6S^_+9_M_YLEW6*7V(&SGRFEH8\YBKB'F
M.J3#VTHE5T%_" <6)L-S1&'Q[1Q7O$A<,[[IQ"E]31(;^]@F!+.2_#!MZ?T[
MULH0DP@M2TBC-+U<:M0EQ%*=9V#I5#3=Y N@)@T>$BE&H@V_A+V8I8"+D5GR
M]_MW)LWS_C@1Y$C^]7?82I%"9JA-) K&F#A_4M!4*NYJE*!37U%8E^?].[XM
M".X"^XPD1FTJ6RQ-8_8%RGT*-(L*IB TB>[BT1V\?T=C.2@HRS0>G.L<4Y;&
MIP5&Z+&6,&I$K? F+/;AH8HYW[\CY[?)B+M#=44CM#LP-HI(-L2QD)'JXJA9
ML3SL=0.W@]96UR@2V0:D:@)6HI(.T@7*H_+8N( $!$[M^8)KX<".9HVB! 2+
MHA>%]6^CE<A<!^M(D%/H8XH>9^;OWX56M/-0CR>/A@<J)F".,$_$V0-@-:X.
M,9,^UP"9@P2% 8O'3F"_:%FR>/^.F2 (DDT(&'1)T<Y!_,YQF88P<S+DAN<;
M W@2ZQ(**T2D:DQL0VA\(NAO#,RVT%X(YMA>A[8FF91WH"4@IT)X]?H\.0KA
M(KHT4R%A!IB8]OMW$1F+>A(3 ,&W+53&P)."='I2L7P%0.%]4C[F_^;%9$:1
MBQ$*I7PSA A]+,2>EBR>!)$(_==X%8C(8)^5C\6_8^4P$(BL;PLM<JY\+/V-
M035MGJP[\<S[=^S2SSPQR)$?RW]+^HD@DN0BJ+2J#]Y;T%:\J?M:Y1"<R@PA
M.+GFN)L?[IR=%T;EH]8"0W!JS?'QJ5W_]>=J/_<SO_HA./G<O#$XV\WQ;D\;
M79ZT+K_^7L,0G$9SO%W?LT?]3GWW:V%]0G!,K&M%D%V&X=R29CS(9DXIG@QS
M0JANVS6I5?*$23,@B\;%>?--2O8B<S:U85M$"F3)S30;*4QO'LA OC-]\.Q3
MBP&\O;?3V$#OQ1V^1X?ZI.S_N-R]OOZEAMR6>@5XX2'9L= S79W7/8$)P_#Y
MK?V#B\M&ZB",_7@&%.&)C5!'BQDWY_,W&D='QY>0!,!>39J[SDV.7#[@>4U2
M+2-+"VSPJ'0F1J1A$Y$1(<T3UD+6@" #?5YIN6@XAEI-8-4SVU$XBT,)CX+G
M8PW1]4?D>,ABIB'/6)H/G;U$NK2404\CW+1MLL)8:#!W[#0^*ZL'R6O \J+3
MI^=G1(MS")$M)MMBXBV7<)A_;NBDBA>1A26M96*_<C*Z[U"!*VTQ**L0$8N[
MKH6,SFV?HB03-QDK'8,:AWV(7%.@D-6 !HB#R!M8'=.RJ$^ )X@3BM;C$6[X
ME&= TK<?D7.BYN;($7#I"1U10U92C8M.:6"#THILSWC)M.C.)2$V>B!$HIUX
M(*HO4U%9#,[U&UENY0H%54CB4G/8PEJH0)O4J.! @; ."/%,YN0#AC9+GDN
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M*O!TZ$\3^,'(>W3OCT!M'IS'T0.J@;""3V#3$)HU[R\]%TS:/0(%@SJ# RX
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MIZXR61KK2\#)@&*)9ED!$YR #(HUWK@"SZIBA-D2W&X5+DH8=R%AT3+T;K1
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M//OFO4A>@$:9'A1<((\FE-@.JUE#N[1/RT03ND\:TX]2:MNP+(*LD/HF_AZ
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MN*U@UP[V;UX=;:@*VE!=.&VHJ-522:T5\Z^*-CS5&KD\_8A%4DU8%%:,D*W
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M@@KL:];@[(*<*OGA#'@&O$[XBPL"IS7"?MUW)KF6C@QJ<CN@CZHKD&X2<U^
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M0H8%;PD+C@S_WY:K_/,E(P%O[_"O#!",#'V#H0!9E]8UZ!^G1E\S;<X=0NJ
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M;."TA^!2(V^5"T4DV>5*&VS>+KU4975(.J.A]YP*/J8*O"HJJI?"^//ZM7L
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M;.(!_UF(("- +,1"WUK2# :;'[ N_>TS!SI8'5.2SPP4?4=3GKH:/,GSS59
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MPY%F=+8!;A_=R&QW;GS3<6-JD?;DIBC@]O?XJ3N-^3#D_/7U"Z#$8]\?P-?
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MAW?%X?.P;I]6<J>%VY=[=4;KQ'^)HBRW6A&:Q3EN6#$3-E]AW9=D'2A@SL,
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MRFA[>#"ROYGT-.-<L6EKO,:$A-37#<F4M2DJFB ==#-"O1?PLT=Q&3BZ[\!
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ME] !':O$B]=$B-.#FLIL.5-*0[C8H>("I6*<[X)PTF0*86)MXH//-;PBQER
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MA9LA7"@W6%HE-UA=+3<X-5S]\-[(R<WWLED(53*Q)?26';8^Z];BAM-YL%I
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MX=5 +C0?KCI#L95\L_K)?:7%D<'P)[8))NX?TY6MC@Y23V]C<!3+T760(SB
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M]#OQ: [:;$-F?<X'Z^&+O" PID#ODA\;) #L0A0D91N]9/#%QGE#DE5@8F-
M@0#[[3E0K00$6%RW,L[P\Z3<CJ5Y<SSAYDESL'&E:DK=/KX[+J8RJ!RC>9AE
M"^4"F\EP<26;W: *BJ=)E!\D6^\8+Q4L'1\^;Y5[1KO;_=44-U +&0-!)1@
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M:EU5'E'$<*8CJX(JRH*"?\"/)ATG""RT\,$,+'V@&<@81Q&/$,$<EHZ/;IL
MY%-G4N \MT?=F=CC?"#V^%)/;(W>"[UT)L6)S_HJG<:WPH4F01#'@@EKG(;3
MS 1 =:1I@:9B"7#B^+JY'90804=^Z/$8>3Q&'E\8*YCSX8V?GUCO5D,N==K=
M&&_\#X>/ME'&GRZ[TDWCY+8R6 V"/LJ@T3'*^%IBDO)AB^=.']\_BN=E5%S-
M<D193+X8MGC!%V!-A5559/)MPX0R04O&*=/5$QJ^7%Z.\FDQRF#@;DY ZRX,
MG@]#)_0C1D_=%7HJMW/TU*]$W5@>8WF,$G5C>8SE\?.I&Q3 9&<%,&2G4T#'
M1C99:?6%4I,_&Q6LM]9(8/,YB<_V.243C=TUQA*L'JN0)+.#CX/CZ1[04=I@
M$XEEI?]%^RC.[)7%!05]5M?.5;ML)O-L(L.QB1Q;V/]UQ%@+_E0M6&Y?^;06
MI-E$OI!,Y++I6 MB+=A7+5AN:_>4%A0*B4PAFTAQ00V7(\SO16-+?E9L65'K
MN@8@/;?(0((N]GA5*J$WI&@#V%4_'626&^=/[>N;KO&P$SRW-4/(V__[;RK_
ML\04\9RCU-0C/F@23:LS1QVV$XIBVY->_#!EA$4CUJ>]F4*$]6G=H#;6IWT3
MQEB?MJE/:X;'7T:?YL'731'[3,?I!T3 31P"FVX(3*+AZJA:?&V-!F?7;?DB
M*54?OT;)M:F9@A*^>R\Z!BJR4K;G:3>1^6U57'-L+L%F]@Q+/6JN.<)$^:*2
MOW:5-9E@<_E$,OD%"DRQY/])DK]^9367YQ+9[)XAV"T:/9[,BAX#>LKA4+):
M:4ERJV]X(>1) SV7KQ\*3]U]"!#OISO(1<= Q%GKC@S,'/B>I?OW?%Z(&6%0
MGEBO8KW:C%Y]0@ ;ZU7DA#+6JTWKU>[#X[U1JZ7#Y2HR[5*KQ-)JJQT?OYPV
M1:WR)G+=7C1*K"L=XIFLI.+GJ%&JI^X'W$[H%J<O@;03I!.+Q\E!2#I3)N?+
M8.?$NA+KRD*ZLC"H6ZPKL:Y\]O _65<61FC[NKJR/":;?B?W1OSUX"J7VPDF
MV]8@$L)Q?AX0TT:*C-YP -L33$;&_S.8OJ8C1I%?D#*$K['4:2;]_1TQ[[*B
MD"^Z2$6D!YYA=3JR*$,WE(YE6CH)A@G$CA,;:XR.,!='B, (0:CL-&7&/RCX
M&1)< [^Y&Q2\>)K!8J]9.M,6%,C7&*.'$.V[(ACXW6(OP0C,VW3UFND)@*.%
M5 89P'(9WXCOZ0JR:IBA+P, +?AM@ FL20Q2)?S[%*C1T2>@%GV">/R29_UZ
MI_J QP#$X,3MM&T3!]^^%W3:"H86[^)FS9:E!&A53\ JJ&K8^/IHZE>4/9&X
MK5"RIGI4XSA"M5R"4/;NJ''$=.S>G%T-.Q\5=LMA4I/V7@3#3$<]I!KR&S4\
M"NK*AD)-!?ZUKZG8R.FN(=# J,"309Z+E@VV=Z&U#887S01C6P<"V2&:1TS3
M^P//Z@60^W1-D,A=\'(%?=@]0@W'Q(V-&88D:A)*@*U4+*AI))BV91(+J\A]
MV;:->' 6P)--/T'4=, /-'U-20FN(*6GX] *;'G)QER\:?<\;9B":9F:/AR[
M&/ITB< (-LDF6SYPG4OE)M<QK-^/O?8!8\HFL-/IGFHXCW+'NHE&G'-&NM7V
M$1,(MJF@XW9$;\$( )P/,'-'K,F[K+'AL8:%\X=,\C<W>,]]%MVWU L\\(37
M&-T3#'*FQ%P(J@6 F]0 YX\8GNJ\#<N)K3;$&S)^!8!H"JJ@# W9M>9R?X!?
MX?QE*S\QXF"Z=;#Q C-P6DK  US\3@!0!,E'']!('<%7_YL4!M8G#/CA8(-X
M50(+A%]#@WE"9FQ:3,2+(CP;&X:Z]T*7"V7Z&MLMMZ1^L,9>9.Y3MU;_1OGH
MN1H;8O[\TYJ8S#R)VNA<-JK3K"M9V<GL)YT-:(;&]'$(C#\X$B:KQ"--AK(Z
MZB/!L. _JBM48R&G'=$:OB:"5$B-(^8!,0YA)'*GX)+'C5%]I6?[O@FIM(=F
MHV_B\ (3 _MID$FOO0Z67!U&^VK)NC?Z:0$V'(T@#I-*^D14,B.A2F9;(^6A
MVV?;1?F5S^\*Y'K#J+&WE,5U03>'35U0#2H21DDV1$4#9H<@Q;)IGUHO\936
MJ"NC]"4J98J#]F[18=OC(1EYD@1\)\;_!]84;/P5646S4XCV<;76+#/))$-*
M"<F?$^XOSV')>"Y=/**3ETKEMW!P?%N^XIOE$E/G;YN5<L,5L;:73?B^^8/"
MX?]R22[#%7XRTZMD[ST9@JF*REQ86#^Q/&<2S,41<RT _C,#1ZTU18%,6<):
M+F)G[5@DL#*".L0.#$>^PF"@R:K/B+4U09?@4N<V8F**@HGM)3A5;)^/F%."
M8RW33!_^ZZ4T!,"0K))!:-W5$;)MCFSV)A\#-@I* D*G0T(,H",>IW>53/&P
M53#J$/A:.O6A;<O 8FA@J\F'O($.AA0#=/0FHW<\I/80/U!" TC+\!5C$P3"
M%!W"X#$()%>031.!6<;9A$$,,;YRYB-<VN+QB<ACS1%3LG0GFA\B =\1FAR"
M_7;!DPEAB;UN8Q]$)^'.$3-/USYDL/'X/5.!17Z^!<+!%$Y6#&0 1_W7D,"A
MX 8.%(&W-=>@G0S]O_ ?LM%J&;IY>,@[+);*V*69PVLR:YP\R"DS/^@]9:I>
M\L#3\(E.>%Z4L>S$9G5F\IP"#+H5/.95MPAD$YB8"99EPP+7!#-F D)5_G^.
M-9Q@]P(.9S:[)].'+;#[M5XJ%K7+S+/ULA/&3F4?6V!L&G93S6(L4>8I[2RN
MRZ[)L'X+[.HTS-?7VX[^5.WNA%U3 ?T6V)5*9-/96>Q:3 L3D#P.:'ZI8(,/
M(3J.!ZP.?A@U]?#4-Z=?@YLH$"^!@RA8,F%,",UA)S=D(X?6 ![:E0'@EE"X
M+9ABC^ST-FDO@2$1I3<<7TCT"NPRP2\=T;"%X8,1^1UODB<U--UV*$Z0+UG$
MC;M>!=I.3#B68(/C1[JS<SFC+@QA(<#':3S_HH4S($ @J5"WLC5G,NJ7!Y=G
M];LW;L*9N+-T.#$@,CA'IA>9U*Q='=N0WLSZHFO;HV"F<BLR=6LNHS!\9/54
M>M#3.UOCU_:<0SZ_:5-SA&-G!C;#P8.\N+N/34K?ZD._%V)PG?R>QL8XD![@
M] Q-!,DX 9!H"DHB=J:JF8A)IA(0"N/@E]X+TD)[A'61*LK^5C*+E@).,1L+
MAO5T9;Z>5':SMKKY4@"F =05J6V^E8V7Y6H B]S>&IGJ=?=)[>MM,[G'R?_W
M;TDN-/M/M4:5^[PVRJ1YX5$\.#ZY:U2JY4:#*=:JQ7*U><LW*[5J7 4(6+IW
ME1NBB &V"J(N#X@AQ/Y:LJ >2):"#/1&EU^LP4"1D6XGQ^-N?9;EGQ+6.BVJ
M"UV4A-4&"ZKP<W+$J6><#*%[&C7Y7A,E>XA35SOV/\T7AV]GSZ?7RMP8=-:H
M%\S[[$>UY@QK0XL8H8M'?R6FV)/9)7M$++1:W^-.\UT+95!&NR^]/'1+-VIR
M!PRB(VO-']B&6!2$ED)91!SCK*QN]USJZ0B%\NDM=];M:@TS7^U] I]F#&U#
M*[&9<$[9U3G'?!J.823EM  6.H3%X0,>7ZUSCU1)TXV6),Y@VBB=O+I0+]CJ
M\V/>33_H$V  ;_09S*%GE</88'[TI1\3[UZIH_BA@40@Z+NF2P92IZ@Y04(3
MF!1:Q7 F@ 38@36>_4KCU<WPXN9FG$YXI6I#3B>O\3?JZ_G3R^_-V[3IFM1.
MG4XZM833*>^2/<LXG8MT[R[W>-9]N=P%@W;L=%+A+ IT.OE/Y=),I_/<*YU>
MZF?<J#^WX+L%/FW=Z<R(X)9S.J4%G<[4%A^K_SQ@^P/IZ5U8VYW,WJL3,6=B
M[W'83)@<7DO?D$.I-E3^JOC[9/0FN['!V,6,CJ_>N(I,%]1WZFN2X:6O)?4C
MMZ!^;)V1PE-*O1VAY^=>Z :HA?5M,]Q94B\U=9Y6NMN-9FA?[D_>GOR & ,I
MRHPJC*DQ[SU-00;6#"BQFKK<A@V3L):#+9TL*.:0&?0$S$2HJ/J_';^:;"ON
M";+*2+K5Q</1=-A8#$<SZ'$,V)Q%!N-_MXY,05;&7M#3C(%LDM4F;_,9'(R0
M3<NDN[ZH@N&\Q-VM -;9V6&VW*Z%2?T]G=;?HO.ZV6G53 T^0:K8P]Q[F51C
M3'?C%F%YME 5F;;R+FL,G!&&&H/D8_*^K36>K&PO(.-SZ8ES/IV.Y6!JO85?
MF#!+Q6N?3!@Y5Q\9E0>YDQ97)4QV8<(L9?,_F3!G8J>OW;U52MC9+TJ8^4[&
M)<RR5<[ 23N_SIG,.DYH[3G-2*+W=DXSPH'/FE,'N[B :&'^%^,+-C2Z\*2;
M^!5[?S-V)V3O!!Q!)&</9VTSF!?1[YL#N<ZG4ES[YK4K=&:G!6N4F??-=_#-
M$[DG<YGFF[0439)+TF2?W 9"OSL--5N[:"J[3!]WX3E63BYW5Y;]<G/=A:=9
MHVBP*8_CUAA,@H4_EJK9X17.=>H!7]-E=$A[.F3#GNNY1*W?EE4X\37FO3:W
MLAX-#^9$WJ=X]F[0$FJ==*N:OCFK9(07+LK6R:X.+S*GS4AR;IFEEL+>N?3E
MA"1_C6[.S+IZ>1-:J-Z9[=Z]) 3!V#J2$%3&3NU=,+.<-(SJ[?/4:_=18E.?
M[MUV+@V9H$[%$U7Q0*?DJ\LN7HH;VSSZ!U=M2XON4;@6+Y%A8+H7;:0%X,$L
M?S]UMB,S=K:#!AH1\^R!H9PS<]_$_4I;[UD?5N]!O^UYV:HSO?GG0^SK-NC)
MEY_#ZH=&"G/.^,S0VP13EQ5E@(70.?>XC"SQ>RI+,.<ZGO.8 -7>^9.'ZKF0
M6N \T8[D97J<*X-K<XEL;N;1HME2PL->=0/_+J(3I'?1DD8GNZ>",C5MO\08
M_=J)FFV^9<[G;EK<F<3,&/ :]H7+K2HY](2&H$LRK.*=(T$Q)ZNK<T0GO:>B
MXTR:SGG,TNC58C=5;I?T!4X0[TANPD:[^L'33&9EI^0<&5PL*LIO(BI*A4E9
M=%+95:*B84$>R1?**2KFUQ*U%9/8W05!R40VR7Y.$'2ZIZ(3% 25+90IEB3Y
MWN0B(R^;"X(R"38W\XSJ5F.@T,0KXG(R,P:2>OU<;=@0"K=S*V<[$YBMQ$#<
M[(/YVXV!N#T5G? 8Z$:[NWA^$1[T=#LR<K/I&(A+I-B91ZQGQD +1C^YM>U2
M+DRXHE.W7=XNG4B]ZUJN<C9\6B\W6[%>NRN[!&U]5L[-?FX@;D[NJ?#,B9N?
M3@612QHBK!I&17RV%#<7,H75!6@MKU;<4]D)]VHOO;IQIEXG+Y)S5XYV)C:;
M]VJ9U26&A$)UNO5[B',M57LC@S28.K^<\)SLJ? XD_?-O2Z,514??_<^LD]&
M^TJ,C S-&?3JHI1+KIR/'3&+8[SPK5'G\:K6+]_T'VZEG6"\_.?PD#F5D2+]
M8.I"%YO*!GJUL+0A>"'[DX'>?_ASBCD\Q)<S^)]?DOP6TA#F9++?H7\\V8#Q
M9,EZXR:64/W+G2 02 ^>_.FA?\K.9'\RH!8_&%X7VK+XDZEB^:4$J6HP<R[M
MO^M?YS;X">CXZU],DP#R#/ ##MLZ$EX.VPC+'GZFH+P+0V-IRM!?IQ@X]F+_
M"&'HE&6[6:#>!E20"Y_$JU+1#YXT'S2(']OZL<R#6J/>!7_>>1YTRV5YC^&#
MF&0J%#T(FQFQ<F8\7EIU(9T]."[6KJ\KS>MRM=E@^&H)0(2:E>I9N5K\0Y&$
M?S(3--T 7VH#:/P#F?(5@J.:@0!@7XV0,R&9R2% 0=(&$$KQC2*33W.A#0<*
M1TS#:ANFH-IHZH)]>%!SZ:H@@MD&/< .M<ZAA?^P^Q.1TWH3URDRQ8.DV)+@
MN;&%H+_1AD8:-&A"#!X__K=E4.A);-G@A"#MK>0B*-\-(!^%F<@VGIRO(8T0
M,"3:B6EB)$,:3^)YV:,@1Q0),AT *8/#(>V;<+ Q11MHJ1(T<V]FIG,%3 .N
M@"_(BR1[3,[6*#HJ[$'[]+FSZ$51[^EG:">%G*..]*:!,*0 >$1'O!_"!@R-
MM#S ?+L5 !Z?B2E@0+^(GBSV\ MQI*;+^ K2JD:FM$)>\PFW=X0Y-?QA@ADH
M%HC$T+V>0E"35\#K14 YE!+X1H->1Y\@DT 32R;,7T3X@W3$\)A;@1)'N@/8
MH-E 6&B (>M C""B#L,GOB"%$P2%T,Y+0#"[1$8-)%IVPUV*8XBGBX,V77N'
M*W32^,9FNR'T*=>=;C[4K@T]E6DC47 D!VZETX2F.WAVBBS*IH,V3@48JRRT
M6K"#8UNH(3: L[AOF(.DW]GD/-R>/I[TM(F4@HZI!#O\ ^#%801'.#X-?$SX
M+63, :2F-*-BY+\<#Y7:)& &?8FCC92;O(TC";OCI]X.SZ.MC.!!DV,A,.D!
M0_;=0M(*32<9A<UXSY+9740<<7,:J1C02\5NGV4W37GO(=45[2/J@IB^)LG8
MQMF9K=W(15:GFW $J!% : *?*.@E_=%Y&8P&]":$Q>XX'&FQQVHWRW-$RO=X
MOW)/CN-/=Z"4'H($X*44]?@-C?LN3, 331286\$$[W2*'R%+ H!&&)9 FRL)
MF.3JH0B-513"L4EO27CC>2'-;IE _4^*.EAL!Z& @[\F?5 DIT 2A(CDUAX$
M<J*>R&.MC>E#A;&)S5!+,J])I23%9E,LJ92DV!R;;(VD^VZZ8M0JZ;N"=P!X
MSOCQ ]TRQ8PT)77(9@]3+/T$I8GIDY^2I??QC;T#_^G4&?,X.,ZFIK)^*K2'
MY$&VJZVIS"EJZ]2OYQ-V.XKWR780JM<1@B)2NK8;_!7@P>"K'*%P+=,<^?">
MH5%SD!@7#X*6BW#HTX<_H7^DX\?'@'2Q6/#8'RL,ER7CSW[:^,')8I?J>Q6V
MBEYLV4985%40CVO!D>(LD6(L#W0!BUA:6Z3!LLGVLL.8.23N$H^W)IJ:M]C%
M)0DWG2_3GTR+A7E)2>;\"-X>/R6(:%7MC2[NV93[LXUPQ6,UW>8UQ6>;AV -
M53PXK_L@Y9T18J+]D:+M#HV9J" (VS*5=.KE=2008P38XI;QVC%MA'&6Y5JC
MJEG.\X.'"FMV/0.*HV_=OAL\^!PHK(!7A<&"LX<LM\RA#[?X"L,^.,YD$YC2
MH:57=\S&JP6!1P<AK^5DQR*H+J@/.4("=)=F$)X&:].'Y7W@E3!'),TF)G]>
MK;^DE9I^ROEV]),X',A(WS.3F!-OV1(=<XE,-KSCGX]Z/C]OMT(CEG&,9G:O
M-AS(@SV8@33E1<<POUJ'>DA1M 8RDL;I66#SX-TO+T9\KYG+FNJSUX' 9_V
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MEVLD/UZO[T\%,SMC[78)YD<F@UN#5%NW:MBLY9*)="YH"WB$)3G<B(UE=3-
M;/AR:Z0D&VRUJ#\DF\F=[-;"H\$2"W[Z>#:@33(4T,89/Y<JMD:7IV>7E=-J
M9Z!X$"";@KKQ7G3:&O5RQJ,QNBS)#[E-$&K+(#B9Y4!PQDAZWWE^EEA>5IN%
M \\-?C8\#A%D1W0F!,G/JFQKU$R]7 X'RNOO>G[[,ATPK@W#ZP3NU'6LX[5@
M6CK^[\R=GIDYQTGF/*TUXLX>,_=7E<'O["H1\I8.\S5)OSI%H0 )M+ $)^M5
M45:0BXO@02VX51+#1>^8B/Z-P.V+L!]X_#!_$,R&?:+?/G#5%A1R'L7H(63^
M^(0SEY]09\MLO\ZVDRH;S)/4V,BR#U-6R8D"1RR^?\-R$5@H6W)M K_ X=CT
MP\9J8(XBIPN\+UC4?G<N2P_#ZTQ5GETFFWC1HL',VFL@,R;HU:G<N0'4P&)&
MRDEW2X U^&$VWY'RAJ[A>+X!JQY]X:IV=54?J;VSUJC8Z-T6GMA'XW?&"P_6
MKXGE<I]0$X.C!O$>VU5K4AR[S<K>"BG1JC*^I7ULV6PBF\SMTYY8G^W@5[ =
M8-V;[]J4R1BTL^^_M<(MF(SHU8( LN+/7!??,[6UQ6L;VLHEDH5\(I/>;,%B
MRRIZLJJ*]G2$II3TN7M]WS1DX[%1V(A?_P0UYF(UWA<U!A'<CMOELM#2(P@R
M)1(\#5+DU(J*# V'I_3X_NXD6V5317'8BZ:6IF(MW1,M!?G:DI(64HE\8!?K
M2+ T2$E+JRJI_#;M;*O/:750YVKB8W9?G6TZ5N-]46,L@=M1XQ2737!L$.!$
M)%BZJ;R6!U2E4%V^-BJ%RW/>*K\E(ZBIS1[2$8&%VK:^SBM)?YH^;V)@^Z+O
M8Z*Z#:7/)]A4-E%([56FG%Q!Z5MR$RNZZ5/TQTLE5;N7V+O[Y%XZ[:8&.YO'
M%O#&L:ECC[X'&KX53YY)9//I1#JS5ZY\X?K7G4_DRQ\BOI0G&UQ;<K72DN36
MZ*%_4SM[2;[6;UXBJ+<PMQ_09< R*9@:]NC&%#9,K*P;5=:_U]#6,'G;ANIF
ML#_.)?+9_'YMM?MGOGJ?SC]C#['XZ/;UNG!:?GZ0E/1>NN7Z9'^3W3IE.SHF
MCY@*C0-#9P[_+FE66T&;CITWO8"]WMSL"V @A^2!SNX<^P?:^F;LEVC8KI7P
M&[:$#)5-9Q.9_&:MTZ=N[RWW1]I[ILUQ-QO9M3IWH%&!^L=B/V54WWNRB0Z.
M%VN"#I#>$_O]G)XY.E($&R846O[H"+I.&"8T";!W$4('BZGVLFRHARC3!P>?
M"4B_BGTE^Z#I%QY"<2UX9,OIDOW6[1\:RF3RB5PA_-"0GXNA7$L0&-^)-D5N
MRR2 +E8-+$*D29)J'E&A9()>,=[KCS0WHZ=HG:=)XP)BA$@(A=J'9KC!_!Y/
MX_%P>54BC1@4/[_S+K_SE-\&]W!^^R$H2A&-]2CP!C@_-PMX62";\VY#W_RZ
M3&:S^027"SH3;^."8EK-[+@<3J+)]LNCJTQ'>+H>\=UL:#.!Y6DQU=QX#5IP
MA03'AM(B06"N::<6Q=<5ZROW9=E&F\X*YJ$".-\6UHVZ#N;:'#)7LD@0OO\(
MLLZD#YBVNC:P% H'4,165905AT ,[^*;VSW Z+;XCF5:.F+ZL(?>Q&&BUPN.
MXK^38[?M(6/9N^A%D31FT#R8>"3V5#R0KFS#K'M-I][)TQA=&PH*V3;O]+\3
M[3.Z;D]W VL8].=NTT-N50T[UVP"/\T4U"Z!AR?GR# %Z>9\TNI/);$R\<T=
M JH/3>B(8R83^.*MC[:A8G5+%WO@:7V=F?]@Q9H?7#Z@[]](CQ$\%JN#[3Z-
M)<#[&8#8,?3:"AC0Z5%'6)7>D=T5\M62=1I8#AS"=[!W8HH"=EZDA0(#(/A]
MJ\^H3E>0[]\,K6-VD6+X Q>*4R_:K5AHH$L;V?9PUH5O=.]GW-M][5BF[\::
M3)L\. ,@6>7W;Z^ L$_/P,"SL%N#$ Q,"C3?]=J.]J'54]!$L3UPIQ<0'[@(
M]5YP1Z!/AIY$VJ _0A<.PD-T.(U]5']X/M?N[NI#P0,1\#W1X8WH/M,Q2G#X
M;$"?.K.;PC+#VSXZ488-BSW^^O[-;M8AR9T.%C\XI-1&YCM"]."2299=[+:\
MF%_OFJ5(M&T.L?R892Z[Y'&)L-E*R-<3L). 9W8LI2-C+RU]_^9TIC(LTC$$
MSE\Y8FXXG6==N1F7>Y]D3TCEM?UR5V$\'A(']?V;^Q '#T?%I&>\WBJT^XAA
M'R4SX*0 Q[H-V:=BUJS_ +A]ZNM.A6;3=A,0QV9ZO25+%GJ0S9ZLUE2RQ6$<
M8K.U[.-.AGA*J*OIPUJG@GV;<X7$?\A&J^7UZZ3SOB992VO4Z!7OY>;@[2XG
MN3HP@WJD.R([]USW:A28I0+V!%KCXU^]XIS-L(E\)A6F$3^_?X,]]>$,3Z_$
M\(K:@*.(TN?Q.WN7:U1+Q:MD\7EA?B<WQV\_ 7;'[G2"9=D$FPI-OBB[N7!V
MLRNRN]F3]4_DML3?E\[KOZ5N*K4PM[E-<MN=_TYU.YU*<(70WGV4V:EP9I=6
M9#;L-35[G\=M_K%^4\]W7HNEWL+<3FV2VQX!=L?N;"*=SB12;"B[:8@!NSVW
MP'&Y\YD,_\V?)^MO:4E))Q=F>'JC#'?FOTM^YS+Y1"$=:LN/OG^;+"^00%58
M(/M:*/D*2+?(& V2=_'5:NV^?,L[T:DP&9LV?<%Q )-(0.H^!/X@D2<T=A[@
M./@#T\5$>,P;BD@^(03E554#D%9'BOMBJ63\9NMF*?.)@>7XJ-8H\Z8+6$)#
M4RTLG3S):P*6EAQ)[4-O.YSVS) 2@[8?)%>Y4HUTP[\,U9$A%_S^C:3Y\(;U
M2UV[+IPXA9[/&_:7*-A=H2XMAHL(P5Z1/[E:9Y,$UG>PR^PC4BK&_W7K4++Z
MIBEOM,(,."[4I!!W,? HZ,!)8G,DJX(.52)+-\C>E[9E8(887A-3J'39?26P
MX?8_7U"'C$*8XST:/U8@198V4F3T-E9L 1]F8JK LE^G@[!/@9ZMV B$E+E=
M*TE6ERS%I"45NN*+;R$=JCT$G+@6OK1JU3J=PQ,;UJ<!L#X,K^L 7?>G5\5M
M^H0Z.UA>3KB+Y;;SD["N0!/7PS&D)*Q$'DFI>A!M@.MAL8D$:FYC8D5^@?@(
MJS6YR.E-Y2UB4<TQ'-4)U!8*/TBT/$2;R)*4 8]UN@>'ZI@BXR@2WSG$SQ4&
MLKMHC[_"XS&H#M+O\9]X3"*RIPE3<S4>SPC;#EA_TV--75Y3R_V!HI%%2V^1
M,U;0XP<[Z!QK=(T\6OE7IB#D=)MOT](\^K![L=L2:Z\:TS[=6A\TP_.?XXV[
MVTA%'9PV'3%WI&6W\ZLHZZ+5-TPP (:_?;=@JR5H)4FJ-"7!&%H?V:W&(3?S
M1NL?B8$@M ># N#.Y.W. G:"+EAH$%[[7\QH(C8=_C4&?U/S( )-Z.2,/7C)
M8FO$&]6KE_N;6\,'U+5->9L)J\F%PFH&GS];&3QS_8EN&2(SNQQ$IKL'^[.!
M,'=EMC8/9'E#VZ8KPU/'T?K;B =C5[)%7[%CL0>T1M=ZG:T.K@NGE?:V-,YM
MF+V(JVH?5VO-,I/TZI(3S;:Y<FO$&6]F5W^\:%JY@^-&^:I<;)9+S,T=?]LL
MWUX],:>5*E\M5O@KIL0W>>;ONRI_5ZK@:_YQK5'[>.SC[ES<YF7%ZT@_F^FS
M8$_]2[4K/:\U*JO9U(OP(0S$K>V?;EA]_+4\PA[YU1F:+Q3%B9Y -V:1(H^]
M9DUP2>V0.D]*AMX"]C[ C-I>!@<HBC PL!%U/GD(<BS[U]@?(=BB]L-]@W:^
ML3%,[8,RSK<4Q33D](RS?W^R6?S"W>/-P%;S'H!GKC6^QYM-P?:4MX>7I_:)
MT,UGT&::V._Z8F^"13JMM#O!;(IMC6ZOKSNE1_&TK@K[/L$2G5;.G6 !)IAN
M]]-W[T6KT9L#QKHO$\0:-W8,H5\L5TZZ_3:?V1 ' P C?;>NTXYC&L!V%V#!
MX5B^VQK(PA#"R708-/Y<=(F549=G!.]SYQ36BLP9A2LR8;P?DZH='NU;!/%X
M7^3YEWS\=P4JWYIEX$##2'S_ACY$-"!;(QFC)^@(!Y[R<20EGEM9X-<A]CHR
M?TJVW-+F?':$^M548)>CWZHPV8$E+8WTD23#!@'_6=O0XHGOD&[@_3,@QY.I
M4&KM7EKIUC[&$53#&AS_G80\U!H$&H18;&.QC8#8DCV*$T:6R"X7RVXLN]&6
M7;KCDOFBL4$0I$I^;)L;686%:F+1WF0'^[Z*9$<7TLL?]LH1G K$_Y.:PD=K
MH*;45&OT*JNWI9.;;NTAM33BRDQ(CAF2DV9G2,X6:W,VF:9@6"9$(Q4WN5T
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M($&$80$5QAS)D.DUQ'$,+T)4*:M (ST?TO$]V5@&.)4SP$/",,$'8>\5>89
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M@WJ^[.:5//N61GL?4..HZ+OA\0NJ)Z0 KG9:9"(!HQSLP=0E!A,FOF13\RI
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MJ-BC\?JP#ZBIYW1V&61K//3XM"2T8YKX=EN/'Z^$M:0K K_^/U!+ P04
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MHC;\.W+"QWWIKV^I"S[ZA-V.7/]^;_&7&C@LU9LM\21$6RAV2 H6T69#@D>
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MT["3 )7R  *CU\'!4@J0) PSY7*,HJ+5RA)'I&&KU)R]"M'2BY<\\"H/UE&
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MU\P**V]O-]253[T^6&4,@"NM7E NXI"*,4X4BYY3V-^$LPSNHRN5>'VH!+Q
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M)N#4RJG.&[2\'Y<*#9>3UL[6J5RF1FY,\G)O<0^1$GU6OI G_*TF\P\M;PZ
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M&+K'SW[._G-K$T1_\O\!4$L#!!0    ( $B"6% C)<N=F),  +<5"  5
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M5&&1UH"]U-=X74E\YR>DS]KFQU%9OJ7Z.DTVJJ]7I9+(9?X6/336RM(C'Y3
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MVIE!73N@.LD=REN6^3@-LOMMX.68R/_^W0>3:^LZ70=WV,W<$5QH5RO"X>P
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M\/4/(.JXCX9_8JGZW4F=_IR&.?G^:;+9%'&U9R0ZJ2B1LU772IAUO0N%0'!
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MZ@C40&[ 6S]F*DYYI1F_@7[E9P!(,YJ!&[<U;Q[<*5:.^T).'JVXDZT$=R7
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M]<-,.B ?80< B_5NFH9<H1'HW-8B5].<+J;B2H,R/"F- +I+K&S3$]!;:0@
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M'??0"H<TO;- $SX'%:C%#PU!VB>2Q_ ;[VU4S]OHP>AV>VZ8];F5$K3E&U/
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M@L=(FA:)9EY9KEOI6PS*2*+GBI%*-V2,%"J!9*0*J9J1F1?A]G-A5+'S2@=
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MVK6O:L:H"Z!3?\3!GN?$!238)YWH"V!:S"QNJ5<AKBX7)Y=7@-*AT%MM U:
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MX-P>DE#:.66,(<IWE:H;?67>C P%E=[>=V^&T*8ZB&WL7"/OEC0]V&K.5,*
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MR#<<,#\CJ"W0M1]VL+;,/DMO4[]1,VA=VID](5S'F;NG, W8 RW#>"C5<T-
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M6@U8S#:%*[JU6.OMZLC)(@!^I&Q*TK=/(9D7YR3N[E[<JAZ#YY<&#)1@5=0
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MHSHZN?2#E85U$#T3U#,+"OG230<\[$?RQT:A]$8@?Y/.*.BZ<X^NE/EO'/^
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MJ.\0: \D[6&=[EG2ML#HLZ1M/YPF2<LYL"?Z3D5MD?%];VM;X?1:W'884)/
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M3>H/.\C#ZM%E]U[9=3O,Z$VJWG;D074[I]:-#OX'ZNH=B6??" \IFV7?6N?
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MW&HJ'F'%94ZUM'+?JR^8:,V2PZ[$@*.,IMY JS*HW4DJ'&G% 9,2W,#Q5A]
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M"DT/K%^;D7;#=\WEYG(T^S@]NYP@Z8L?X]A_#,*045#7RF2*-&S&9JI"B*2
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ML)W3 6J+]>6J!@(<6YH6,]0?R"@KX>A>/0Z0C4,8VRZ;NHA<0.-AL5H)!V4
M4]21555JF,CT,M1II(S::Y1"-X8U;:8:N2?1<J!8R/)K9R!,SPPQ'2Q57T=,
MSXZ*Z1B$Z1B-N[ ;IN.C8GH.PO3<$-/!'GOOB.DYQN6*]/4BR+(%5!G'7'C
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MT6V$2H68A3M5/M>5#B-%'=LAH,-T)3U*.-C<%W%?62VMH,JV(TD''2HAN+V
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M[A(16*!U@?<WN, $@-KH"1UI'AO"@09G2^G\^+6(^SADK-.\OQ89[&9NPH/
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MF;IZ]M<3?9N #!L<<Z-$UAF;ACI26:UJ?QDS&)M-A%Y:I_Z5\,&+^",F']N
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M]]C<I8&\4<KV<7@?:$M4'VJD]TLQ^1?GJ[R/>5ZV"7;^GOK KZYC^V"Y#Q)
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M+3'-H%W\AO_?K4L)^\G_#U!+ P04    " !(@EA0[TSDP!M1   G<P  #@
M '1X;60Q,&LP,#$N:G!G[+P%5%Q=LC;<0"!H$C1(@" -:32X0Q*T&PN-!4_P
M!AH-#H$D!->F<4MP=PN:X$Z@<7=W=_[,.WYGYKTS\][[?=^_UA2+U9MSNIZJ
MLZMV56TYW([=S@$>0&3 ,@ T= # ^.</X'8+0"CE:&3I"D #W $  *(_+^T
M[CTWMC$T 1A_^WD%[782X / NG/G#N8=+$Q,+!RLG[]XV%A8V'CXN+AXN+CX
M#_!_H0?X]^X_N'\/GYB8A(28^!$5%=4CVC\1VMV[=PGP"<@?/""G)"4DI:3]
M5^GV&X 0&\T,/0T#C1" 3HB&08AVVP)H^:DV.@8:&AK@3W0'$QT#"^TN-MHO
M=P" O[R#]O/6 P#@YR?V75P\3"PLC-]Q_KQZ!Y,0BVZ B)@$J4[&%8%0C42I
M/5>AYX8.EKTEO?O&[GW)"P9>Z4^M_%^^V_/P&7Y(;9)D+#5R^-C\,$V*"6A,
M^%,4&MJ=GUV"B8'YBRZ_@R2DXR)ZKO*&FQC3+F* 'DKR_DO)]Q>&/*1[\_8?
M&!"26/NI3:J\I62W$P#\GWJB$V(0 B0 UWA..]L$D[40QS%%]M;FT(P"< 5$
MI3R2AT><^"F92)GSB?NC#X#IA,:RL:4'6%O3U\GMC[T%3'>W3H3NH-4*>)F5
M=#PF&*VMG-Q:89^K>EQ0MOC??7F\]E(L]#G NG=V?,L>&\/)^J;?*/P9U3\G
MZ9]BQB=^6]BDJ^J?(2V?MS\E+P?,.T-*PZX^\_P7<!=G_9WL?'6A3XQG<C]D
M=&4 FOH[Z?F*0CX1MH2/_:O][];^#RKU'^;_%>:[$EL0V?)#-P97FI%>8ZV/
M#,_ZC,=GNO?R=[W7.*K6 V5S9(_ :*: 7R/TY!P/CE:6U%;^-*@IVSB_:9R=
M!JV/$^.0!S:0!KVK],?#GU_B(\F\!TE%W-0_828)NH^NT.._/3?_F.H9X$6N
M1L[;]*<U/DA9A9@(2G'URH+5IT <^O*>OF^$*#=SW"(6[[@ =3V<;ETHI&=0
M2^@=D7\IWO=FD\_<ZBN?@9R46;S:HNG?78*O&#OUXM@I7>RCD!J LG( IAC+
MV;1;A?2%(W]Z2TY)05_I1($(D2L+;PIZ1QA:/+P8\QL^K6<TN=UIM&+IH*(U
MVQD1,BK3;/\!@?Z/CY]))<4_^,")EQ_W!%"D*:EPH':T?+#LEML12E1XP$B+
M#JVH:M(WM,Y^:.$$GX7.G&]6>PMR/Y&E^UET0,.S??QPI,PK)^'@A[9[$^C;
M]HL"=-F;CB#/ Y72@3BB:#EZ/DKY6I/J9X9?]P:XLN5=0=$79(ML<6<022>B
MG@:V5#05]!L]W$]::OY1_$G90$L;+L.NX7(G=A#4'Y'!U(?^]"&G?&#3N&3?
MEXH.?;A/=D>(9?$P(OE\3 ;#_%=-=<]LUZ:MD1W-S+%1 2H&D4B5PWOZJPR/
MQ&0"W PU+38S55\/S6N.-$U'\/4@0JV^L.=P5"#27&N)D1_ 47[F]ZPU:X,F
MF;X((L%6Z>R]_)EQA<M#%$XOR"9-.U\;/9U0"&P^P_/Y]JS0O:X(VL7A1^A@
M"(Z--D:AV ^8M4%!]L)DM>H)<,)^IAGTN:=4B:>NN_<GAAY"%994>>YFI$(/
M_<U#FNVY0YQRC)$%('"$B]2K9^ \]^*BI%DI<A@T3"HHQ>2K:>)6BW!%747"
M5["V.E(C8MRF \,HYMZ5"#2(;J@L,\,7.[=7WA63E. IO):@>M5:6T_C49KX
M=M:W9YP<O6UY*MG'\6\%^BCZ/U$34O<+GEC#9/EGW8;CL@OLF\NK79Y!IV>=
M*HS50(A5U+@?98I0#ONWP>FH\$6[1/@X6#M_+]D.+)KR =6$OAZ4IV\V@[X1
M\>K)RT1/*%.?U*BN0B:RDS^:%$<Z_!/"/XRM=DSPV:N^K^.7%ZUSDN;R3WP6
M'FEHXC>I /U"BDCEX1GLC&E-4DZ \ZO[3C$7U)0%U,ON+Q3:7X$(.I R4\@O
MK:!.@G1$L!\!D_2QWYZS]UM-O.EM>WSCI'D'%DNUIJRV<+^1]0IDE7TOHRMH
MG^Q#5UDU!O5DH[+>T _/."6_K6PS&FKIK# A.G@.5O (!)J];IMPT9-G&XM]
M[[*F7MVU:,BB(/)>S;EHBVEFC7&7)M<]X<1T8\*X=B#SQ]HW@%8!W!M9_[?1
M+U'AM-#[HCF6%;YI!0>2C!\9^! )CM0SR[[H-<HUF]O<&73<#&U/.%33GSG3
MOP@@>E"= _<1#&;9TU.B0><@>DR-M:!?)L],W=(LE4/)]P(DIQU0HSUI/J3X
MI-CL0:4BZ(SDM8"N?)B;^6E7GFHNQ'%M=S7@WNI@YJQ\Z#*/I9 0C%]G3QYD
M\ !/Y[OC)LID1N"S:.Q&#FI1QG>=74[#+DHP(T,&T?4<Q-K9Q2;XS%[NU,$U
MW*HO"!)",1+H\';#LHS:]8$JDS#5MQT,+<$%D@R@*(4!.=Y]IU&RHP$+Q<Y<
MNLHT_J\6;SZX)/%'T+&-^420@<ET+'CHT8*]G!S/BJ3B6ZH>,LAE@SJ*Y*"+
MTFIE#ES\K*9:(,?$T@JQ09739ZH#UZB9Z)P2%2&FJ^K#S@7F9:+!\5S68"'V
M-#BH>*@"T<OL<_.4+**0?2^[@&,D#IY>_D%>98"]'7O*%"L4E<O-:%L_/SXU
M/X\V>-E00\PQH&!B:D)Z\B4'6R#Z]!+)%0GR>F5J$KWLM^>]]6N#V$'"_1W?
MN3F>2,&%8<2&RC71,RWO7QWU/^D\RO1BE,&]6;*'_WP:XA8)R1:7^1"0T:&D
MQ>YT;:IJ365>'MC4]91D=3?TB&E7/CH3MI[='!^=04B)[+9BQS489A4$A]>J
MF@1HL?2G60/(' W<#V+A(_-5%%WO!<M,&;X.<<H.4'EF17\L@4&BYZ-I$^]H
MW1QS9H "S/CQ*93XH:^,%\V@R'HR23C[J8/?&S[$/DNWK5:S#Q;<?;S.W&DG
M]ZTY6VMV@:*"7=3Z/;;#<20H>D(KCD[:=["[>(\&_S''KMY"G=KF2#8RBTH5
MP?#=4(2[M(^;.HH=#AHF=GK2@]#;>W18=7+8^2YY7[P%/TO+.CU2@ 35J YB
M\H67"417R@UZB +HAJZW1P)6U@DU!J%7F'2MT;89)0POA.[,"U:XN-BZ1'OP
M>Z_OFJP5#NIF='R8%][(4:I/:[#HJ3[_2HVM\U7\X<=$<0!EW&F Z[AG_-NQ
M"-WL;N0Q-U4^<7K7BHQ+ $KE2<]@R*/>IN:F2#1%VEG,W2CT"F"N%1FOI%)P
MS"Q$K=.L-XKNB,K'M [1!:9(17W#L*39M['J2KBGFOY"FR7B<:(<0MNU%-9.
M<$VWE6 _E*!5'+30A"%U"_#0;&(7JV"Y0\VA%'BHO,Q..&ZJX"BJ6).E,>MK
M834HBY3V\[Y3TU['NE>M.A,Z](0-E&4DRYGO)LD=B";?%Q^T,>*3E%,<=!\;
M+Z'[76YY(!"SS43UQ_8+4,.UAK7MEQQ%[A@>^!+U5YOX,'K47)7/'J H;;B(
M_07I?GYO;A([BX4PK+>  T1RE,M"K9)#1IW;Y="D0OJ9A>-XKJ#CU#G93RLJ
M*4N=H8K%,$EJ(7PRK!(""W %\5@=7#%P=W&28#E.]NN':.>)8!70.2+EDJB[
MZ%Y5CGEW"RETR9-IR[PB4_)D$ $XB>\PK]_5#"/+/K8.(3V)5,IIF!>M2 C.
ML&$0E=(R]KN_-+<#V/KVZY[^[XR.;^/&@S!>9J L,K4XGV>^_.8!96B2,C^R
ML]5X GH8:,.?&&EP3R4JVL3C,8^:7*[MM.H3 1*I*+9!F33ZN9^*NV7O#T&
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M=*MKA< X%@&8A0A%N(M:;QVVPZ78(@EOMQ=GN2IC;SEJNDI1A'U\&(32WF"
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M>W[.#(LQ9B2>5B.[/J,,GN!ZRE[,W2YT,L-#]88?C<8O-"_8*3@@09?R/PT
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M@>+<5VQD2=Y/=L6NZY':R^#VB-@,,UX6#AU%#I%219RFS4[;&>E :)3I<]*
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MVJM4ZYQBO4+,TD?C$03,-IB.P/,.P'GN,7_9!I[_R)G+L"L.K1?(X[08)EV
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MZ:C <P1&[Y:)EUE6G_O"ZT&#!6ZTU:I-O!M%W.>G(<.5LWVFORL*+<H<HX.
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MD5=O3F"1Y=XDA.T\L8<#@B"LD)K<:A;<HFD7DW#6IX#QO\. Y>=U$B6B[EP
M^+%[,YAE47C\F9+Z%C"AMJT^4X[Q+\O_.W!\A4F[.,KEZ^IS0'9$@"*))K=F
ME(EO44'5]S),;_[? /Q;]"2P5JV?9Q^)5G?!EC<US>QBC6,MSR_1J+6^]PCP
M?T\GU$^=X" ^%X)(BRZH*FDWF0:%<>ZHR]-);ZS>_Y.:_ D.K6##N8Z9Q_6G
M2L9LT?FQA2Y2!L^VG;V_6?UO><NOPU'._'1O.Q#C\!PO3%O--+;P#6-29F3%
M#*8M.4'\;U $)\8^$NH]U3IDDJJ;@R"EDT&9HLP9(% YB")$(LV:^.^'^]_3
M(_6U.LWH&%?#*H*UTC?YI5-I&1FYX/87)%E+U3<:\E(?Z1D)LYI$'SU^<GIP
MV9ZFY"F-;MP.LM)\G!T YVV^GS^8F4C/E^#[0?F#B:F*=TG*KICO[C'EYM.M
MMV8C<+7#<:GUFB4C5^339(P=$]8EM*,_1[E'CIN%^A:.\UD\2N]X>CJ@V-E+
M@U.(0U<#_8,D(-$K2;FF2-XXBCFT9ZU7#<F]22!,=)W!' Z-'/A8901UY50'
M?S(W'U4E8\<V*[N(W)W.F*[#"I<<%L>[E-O50_1Q[(2#!P^9S-!)ZC8T!N&\
MZ6&/SYYY/OB3\+MT'GF:\4GJ6?2(*W7DIR_8Z:",6B:5^(YDT?)L1#><;]XD
MCD*G"3T0>-EPC_\(R82/'/JBF"0;8C@Y<,0,KHN98M"P14+*>Q"O; $#/#.*
M2RQ1O/$P M78(,5('805J*T@Y_5^)TP5QL")U9)W_QZ 5O7/\;W#H*9W.5,$
M4\V5$*R4'S[,UZ;K)M6N*&UIW@D%9PX&J64]73JU!>1\\K2Q1#GD2 DL#A.K
M2+/<]YF(=8K/#RMR&S;)Z+[/TA(5RX;FD]?JN3)8F%ZC>Q:Q.DK41?,A.W.#
M)(^G5!^X2I3.[XMP(O7S_48K]V?IG9??\O4I=5WZ599E8,-/!H<$M.PE#VE%
M>.PF("2)"(U'&?.=\W-H*KCG^J-Y_@S6] M*D?Q)1 GSP)'TYU9#EG:7"LBH
M'%P@(0/:*_3XG%WATQ*IS]UO,A]R2&F:J8<WLWKBR',2R\;,IX\;]N3IBZ:Q
M"@(\85E$B^9V3#)1Z4B9R/+@X()OK[G_I%&W^[<\31AR)'TP4R9P_DE'@JL?
M8SUP4CR7AX _/:F0%2W%MM@[W<^3TS+*2<\U.^?#T;)**%)+ZTA>RNJ\-J6\
M Q4M$ZDD&^2#"5>>8=\)<X8Y3 ^DBBZ8U8J=+#:R1PGA# ,)J2#XT<$+JE?#
MK[_]?^U<>SA4[=H?+SD4Q41%$9H9QF&4LPS)89AA',:AG))B,HZ9".F@&HP<
M8LR,9AP2AAD2R2%GB30CQ0PYRUE(A,[>W:[V5WOOK_?[]M[_?-?WQ_O\=5]K
MK>?W^]WWO:Y[K76MYW[XY\FLHH.TK:&Y0P8VNF^J(]$&;<"*B]8FJ.]RGOQ1
M[^+?QF]QZ/8Z;HC@2KWHT[*W41C,(HL#03UB6Z'8FT'#+3[\ WHR\RW)QFJH
M +0E:\@Q4RU?"7CV@[[-JKU+=@*:X-G*Y_-6\<8&D22;%-O,AV &2WL'=@D.
MTNT^V+8 6WXFR;X7IM-_TS.X446Z^/:@+IEC72:_ZN:" >),N>F*#L/>J:+C
M(YDE0D,'P0:%UXI1-JMJ^>!;9V?DB4]6@5&(*&AY>8PA/KBDZBCE"+2K^#Q(
MX?[3H1(@6BIY*!/OY*<AV8OP'>$["_B[7V6A=QJ/W>DZ<5X+7R0K@F-!PV=[
MK4S7"#=+W*PZ5<7B3'1;:S-.B-:N3CH.^UN@5<S[J$?B*$,!2(EL(EAZR"=3
M'2Z_/QT/*Z Y?0SAN;FO5RK<1\%+Q..:J>E(.11[#Y2SK_P#X!_6UN7=&8F^
MZ\FT9/9.9/+R<H>N*\ :N*2K#FJ\MP$(?@=OOFK9[GK[A8J%N[FZ?:9X--!+
MK4R8,G4T'4Z><9WP27,?Y8/H_'9]UWBFA/T@;[?C?K6:A=0)"2CTX2@H563\
M)X_RLAB[7B_.!N?L%[=!]*E\% ZKXZ;:NE+-@]3E=&+]Q-)@L</Q;O@:&?Z@
M/EE$$-ZJ]Y0O >&#B (Q@-90<Y>;88()&8)S3[#;@;AD]>(+=8KJ;D@HIJ+W
M*MO!-[>/P"VQ'N>[:&[^M_8O^9_$DC4ILY[UC^Z7W#;G>A "G"Q%.MP<L1,^
M7XLF^6KK4< ^C\Z[,N77.O>+T^F[(8Z0/ID$$,FB6IJ.7[4&]6,=,L($M]_1
MZ<V6T79UFAVY+M'>*%OO0D)E.Y1VXIU<D6XI?:"5O9&;)C'D A()Q ![?V57
MY'OYC?J/=QP47[35[Y,[D\SLGMQ75Z!6+BTM_R0IQLGQ3JG.T/DC'N?<J%-H
MEC\WIQ5+TCJT2R"YFW&FXFW1QKC8G\:?QO]+0UR5O*MR(;2+N%%@A7LNMME@
M*[.\@9#-PB1]'4)._\-6CP(R[]</7O_VK2W(L5MG>JW+? '$Q'PK_GQN&]<^
MPBNP^U3\KK=@LC2U- BW)3_>6\Q;D^Q EB&&+X'J' 4?#P<$K:M,V#6BF!S3
M?(9YIG'I*1+A?874:"7FY=LF7!#"BF[>%F:[T.'"GK?IC$?O6H2/O6 8O<0L
M=!>TE'1 \N")HE--E6HKPY?]'F,NFLDE6J8[XV[*4&Z'!5;WBO:U2[RV>5:X
M5Z/(K(Q[9W0TS2Q#$?Y1S G\#._=O)_*?,7LCKW5/LYA*ZJ=>"!;\P6 ]9I3
M==9-WVHH>D"DXP9QTB68DL:=P@L3*ZB44I>CIQZLQ"1'&[WTLFX^HBQFG)"8
MQ%8,QDM77G7+SVQ7$*1 $5><$U:CL^1U^R[,>D6N"X),\/!'6?1J1R^/\ YO
M/VN1<.4N#95.3X<JRN@]07&@AM070*/=829&QI6W&%4+4QY(68Q[$F9JME07
M2P,Z!Q3F[9LP?INKIW,AX,V<Y7%&C8PJUT-WIE;B/2>:@ ;=."R_Y/><0E^"
MP<0E4<T[N>=O/+.*ZCMDP3* '78<=CMI*%WH@9FD)V[)V6RSZD)RD(T!&1B$
MT,<:'0NU$)F>2B,<O!G4W[!W8U$42&=C[-/9#QY06OD;WT<XFK(XA-H08\XT
MTE-TAIYB5OFNEWSK5):B&PGEG*#CK3W G\$84UV4=4B()XXCPE6H3^+VA,YQ
MG)$#L^0ZK*O \%GE\KWB6Q8IYXOLF+;^90=N3QC1T?#\@YQ)>+"Z<$J-L[^L
MCH) R:7P&,/<;Y5VKU&35'/D&S\=I4KA\JGJ6!GL 3 J2H133B9/?W@N/*@>
MF3!RJW]!)[P=-U-Z\HYZ8WMT0^/8"J3?I7-;,;.AE9*/#D=7FB..22@3-Q3W
MA/HT/%U:"%'I]U_.\+$S?KTC^RGWK<KO3PM,?2<M=A04%V#B-I2<5FW2R?5R
M:J1/55 0)2.RC8.N\UX,Z^\Z8 P^T90P-(,]4K:$);U248,22V$EL$"JY'R'
M_M*#QRA7I1T(BO9TD@#I39K?*%1QY9CDDS+'XH_SB7@S\>Q8*]1,6Y1*J$56
M]YI/X5[G0ESXMAU;# G\S@?OVE[6T1%.+VJ,VL6R\0R6AEDSN]U#>:[ZG"6<
M !*$73T]XWI<E$6Q7I-+="PZ)CC;ZE&4W^<9561K'C?/S09U6:L&'3I",Q;8
M22!G%_#GW@^/U$2M6=:O@9&Y9D$R$FP]ZE1(9L#3=)5+BTX] Q30"J5Z@)]6
MX/EY:>MEP4(>AU$<'--3P.C,*<HY9W:JP'AXT*"!,$PFK Q[C\L#B^76R@@&
MZW[^VG=L4XEO!2LMP+5B6566CEW%/$R@*?X)R46I[BR UFB\2@[-LF&V973S
M%H/L,\;)M X)]312Z:?*"]ZTE0T3^3ZC>2]AY*UJESTS]ZURV&T8=Q*)SBQV
MD\3Z(Z>5U+BDE>BBX]O\<U:72R39UQ'A\:!Y'!8C)?7H&CD=PTM=3*RJP5=L
M]][073GZ6]C-R".LEPF%^L@$]YS>\/(;K^HFP$5Y!VN.!6'-+4D+FSL#RU<
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M9\/<CF,TL3A7Y65I_<YB-[;/5>T!EYUA0EVX(U?>]9PTC]= ,VVNFSKVLK>
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M&C[;?IH5V'4\WQ>8S2&34B? NYQ3N?K&XI(U5^Z/8HVP^3N*%$J:U@?4#VA
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M**%GZKZ0;]!*:-5KAU$,'#UB;9.BHF+)BW]=%;\G0,.H2]LLO^!?'[([Y!\
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MA'M_SBV=U^DQY_HFSO%H/,6-0I="+#?RV7:FD+-%M=43"FIH?\)J#[9J7^S
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M$IE*S,WZU94_;/-'W<0K@] CT:G"KHKK/HT]]4W!^?0S56@\(/"QJ(:&)TD
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MO]$#FI5:O_-]*9';?SM[]0 (V/4V]H&[7UY=L^O,LRC^,__\-,P?!.=ND<7
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MF$N_)1=0:@,5OCA\I55P1[E2S=X"L[S9)2A\9/^48Q9K(0"O%+OBA74'YN?
M4-&F?I@O2.Q&P-E"\O/)0K%90TDCM4E72'X, K>IOHTT/CU< /2D0$IVC(YY
M7#3H!$_7N3^&ZUH(^E:RX6^I01P3TQ<DTV&^LJ-XPD[4^[,[2..,X?WQ10#J
M#98TBX4? C5ND!;GU]H#H*S=N6(G&$L=2K5=*TZRIXG\(=7ER)/ 4U3;B7*W
M)5')_.(X1S:,"OE3@+UJ)/L#K8.T(N[?;Y7_XP,7'!(Y)S_3B,HD]"3+QX"=
MG!(\O=.*QPM%? 37A7U7B)OYI-#OP.<M1NM(KC;<81'!1EF5 1<*_1P6BUHM
MF_( *>J('YR=C1&[VEH)_FA18CEA ;A</URL\JWP05J:+[K2; C5I0N34F>8
M<*\X=!\ R491*Q_2"M\7:O3&\10(7\[4^^N%!02<VGWM0>QL)ZJL( ?T5ZA,
M9-1YOC/#]&$YD6P(*W0+J9U&<%V*HLQS+J2*=+M2[[<K)J"Z?HM.[9W7RXU[
MWT<;1F93<8MF6R/B_W^0[-*^P VDV<RI+"ZP""6\\*N,J1CO?HGCU3R\9FYP
MCWS64ZZPHL2TWXG,:5PLG=Q\=F%@<:^?X1B,:K?A-:0 799'KEVQ95Z#!506
M#7JS2DXC^<J&F4\? "[^T'RH5D&JG)[071,)30+$WU3-RS_+9"S^2G?J?/TR
MZ>H,_T^@9%BJZJ1*]!=Y'6UMY3%J^IY)F#Z[[?QR.!(>Z67(2+;6JI(SNKQ6
M-9VM]('Q^+O<'*W=N@(^E@UZF[/T"\+2&VJOWMHRH]6"FBR(I^"A':A7Q"53
MPKOQST5.-+"<P"OV>@\Y3[?I%KZ^$NWG2F.:R(:8QJ1<*F@YH@04<^CT1+ &
MO[N>^ZG?RL&<'K>_H3UONDEA=-V\M!G])[_G/H$^I>#K$^_^V^LG?76M%4Q-
MK</9*TUVTU Z^CK0R7PLVW9%0Q[<HD^2X876>%71S003C>QF*PG9VI["K]94
MQR'SV;5,O7MQO.ZSP2_=7=]<%%!R"$H4_.TY?MQ>U_=X-IM/;(BI[QN$CNGL
M#7^22P62&Z!-D],C,"\CN&1FF>D5PZ[ L.M/+>;I,8C;&-N]+,N3J"YHY8PA
MVZF8VZ4N2<U$QN3GR?E8E=3G6'E)1]JF^,/E4R2*BY7V0[7)RT6UUM5YIU9_
M2F)/@.FO-?R#9?T%PC$:([$>U6CYBJ&8)\]CIJS@J>/E'B2F7=#,#9IT7]F\
MF$S9$JEW?*^*\=K]5\BA(7Z-%),Q[8LFEN0$O4^?L'(.7Y8C'@ QD1)F-$_/
MQP<%[>J3[T35ZIVZ&JBSJOMA/Q*'5.5D,"46)*K'LM1@Y0)IJ5M=Q@D;MA.D
M',+Y!=7+"W\RO/O:X"\MTK#.WC=EGCP Q#_^!1.G3JX!L*3%2J-STQJHY= R
MW;M''()"4S)HJ3N5AZ)AP?:U\UOK(4X9S3'=DA1#B:XZZSG6#!UXE)KU)0?@
M>00(!FT+6\PZ-6I_&3-H(;3EI#"UAL"W]&PHO[8G$MA:>I.EET*U;.,[KJHZ
M,2U=' F2:%U-VV?G/M92DKNQT8V(J.D'BA4&+VY'%>QS]D!6A(6-B>D? &X/
M '*+\]U^IU0>"_C:J;3:8L1[MUF+WNH_K7-R\Q\H L=X7-?ZY) J6K@7#1I_
M8J[T+;1_)5NT ([+YXA<CP& :!EB[SNEN_S%/\'HV=D9L5V#C+YU%)6PKB,^
M>G!0:*@&D#D*H-=__TQ5',?S+$_'7&F]/ NS<+P-^)(/^*[4(]=%/4QW1_F3
M8M!T;KF\- ?QB\Z2E+@)29[[A-J^JAZDBHLT&2U,,W1#CXINN;_?3.TQB.)=
M8P^B1YA'-2%H0!\>N\"_^?.K';;":T'RC.<7U*J*F*6LV%?3V9SX&Q4"W@/>
MZ= XRCV#.V3S8-#T_KBC8X%/ZU>>[8:Q[X^H44E#]*Y[T(M55)?^C "O_D%0
MN-P VUS%-H[_89:3PZ<,[PJOSFC^00@#VZCI+VK)FOEV.50A/[&<?VO&[H<+
M(9Z>*'>QD^QD,*EAVCAXE*=VI];])=[Y-NQB^,"< <3\/(^)]#*SZB3[;5=
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M[5?K(VBAO/3 1&-M67QJ]#/RZ[W%A7,K5YM4RTB8T4H6)WBP!YPZ;CA43?D
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MVWL)O_*ANS5L#-JMAQST8!R?JNC)5_S!,TIB&MTS-$*H*WG.FY*6!+A;E^'
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M-+4OCUM^N@@-6(:99IE J=)VE5M%N-8G?_RR"&[>X=W:K5^XN#Y3V6OWNN8
MG8&P&'OO5[7W O;E,A;X6N?!<7]<Z,HZ=]F8]]=I -^G'MVSS+5ZU/1LD _7
M:4[X!*@S/\]^ !PC>!&)WZL23(*:Y(T9E^[&ZO>S;E\.[&_=3ZI HL;\^?V?
MJ@U>(]>8-BNP_0A3RC\#=*1E=(R! B5P+UX@>2]!GJAEPKMZ85:1V#:O+NGH
MU?UOGMI:H^?@S1EO<9/[39>UE"L!1)<3\\G94;",R8*S!6QN+62#!K'84#7+
M-R( R_O +)STV5F9;7NZ\DR3;5A^='AV=J"?=;HS.V^X7A THQN4KIIS6I2W
M:W$AI13V(>$4<NA<CKT^J[F4ZWUZGYP%*P_&PVS2>]'3"NP?[M,3 .99U=C@
MCF$Y'BWW!PVP;2>;-P-'CW;(O8E)IPRFTO8B!:99D/* ='K%D- [-B-]Y4YH
M8D ,JC[E6U\$:%1#G8C0&,1E$E);*B"RGC?F9<C'O1E2HZP,QC,1V0'5/X7Z
M33XG>O( "%C.FM$Q"7XQM)2S1,*2JC;3?\EX6 J,*Q$VBEJ,I2.@["RB36<M
M#=#I@H,BK-T"Y4,SU6KCV@,J10W"7 9#X+D1,&:ZO)+0IAX<?QDVV.*="?$@
M7Y=^ZLENUN[IA=0:OOUDI4 &4__X5=[*#)UC^.8*CW0XYI8*M\R:-/$J<6ES
MA4W/*&^:<CWG\>\HBG$2*-;8" :J>=1NX'K4ZA-EU JU6B*;T9)V64\^/0!
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M-" 1$[8<3_:[+H G30N2\=+UO%"E2*ONP=.[#)Z([,/KL>JVFYQQ;WM"/=@
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M-3%LB"EC+>E3B6N_%V69I%M?44%R^<>=L0;'E2J;5AWE\G8QC."K3",'_GX
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M39TQW>@2HZH@6EZ9<P[PCHYW6.CJG[$[-889"VJ5 \JK&.+IOL5D/V=_!MX
MJA4;ZCO;97F&+3[4L.GQ:7,V,>_W.0LW7G!*R)7K?N3'AIJ(P+>2"K=8Q<(]
M8QIH(]&K4XW'-YF^G(G :2Y(<(7@\G3EHY6*;]XIN@7OYBU KZL'K.OP*.+U
M3\L0T2:N4Z(Y3%COY')X0Y:-U MN+ZG-G\URJ3D.(;MMDEI1T= 4_ _C!72Y
M19S<J$C3X65I&[8,CTMZ?;*JF9C"W@"*:\M^J7="KELF.9'2MWT;JMS2MV%
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MFA9J1W4;73(0@P[KO\-)CW(F22>MB1_\B.< *GJO$]X0:>@9<2)2=9RNYX6
M^?WLS.B6X@H5UT"==(^PBX,*;*X-K^E!/4A;F_ Q6S6*AS2Y]/.[#[+CGZN:
MKUC?4>JB:"T\=]V^,4]E"](I'Z#SYV)ZKEQ'2)YX[:05&N[S@-ME.(73V^&P
M^ZBQQ&N]9=F6X_&C!]DQUN<^<_9OK=;>"&, W=W_^-TNZO@&'*O=%,1X:[$
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M/CDY]F*)M<=:A3I]4I+*/&9*!%F[$L16 S_J:^K&6+ #]X)+GR4[5NE)]?O
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M.$RK@4G>!?92'I5)_-_P)_(_> P]OZU9[X$5N)3?%_$1B1:B]<9QZ2FA97B
M5IC _W.'"O3(?3W(MX]+H$GC"S,_"W&743QGR$N4-^M;,5TI?NF,^0^-F<"R
MA9;=YR_VOSR6CR+7FI]CWDSJ?T^_!*;^!I_EJK81PJL_K+SZ.MZ^>;'']P\-
MX'E)PF>HL'38#^F_E?T>:A\ZONF\MU/T>)#A?\3]C[C_#\71^9QL!JL=)N_+
MJ\0IPHAI53!8T=LRK30G$I7SU./FG[G_!5!+ 0(4 Q0    ( $B"6%"U;IA'
M1AP  #D, 0 +              "  0    !E>#$P+3$X+FAT;5!+ 0(4 Q0
M   ( $B"6%" E&2T* ,  "P3   *              "  6\<  !E>#(Q+3$N
M:'1M4$L! A0#%     @ 2()84.OT@9.X P  A@X   H              ( !
MOQ\  &5X,C,M,2YH=&U02P$"% ,4    " !(@EA0G5->VK('   L+   "@
M            @ &?(P  97@S,2TQ+FAT;5!+ 0(4 Q0    ( $B"6%#"FR[%
MM@<  $HL   *              "  7DK  !E>#,Q+3(N:'1M4$L! A0#%
M  @ 2()84 >4<^1,!0  .AX   H              ( !5S,  &5X,S(M,2YH
M=&U02P$"% ,4    " !(@EA06F<*MD$%  #"&   "@              @ '+
M.   97@S,BTR+FAT;5!+ 0(4 Q0    ( $B"6%"-+#@4&1D  *AP   )
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M,#$Y,3(S,5]D968N>&UL4$L! A0#%     @ 2()84",ERYV8DP  MQ4( !4
M             ( !"H@$ '1X;60M,C Q.3$R,S%?;&%B+GAM;%!+ 0(4 Q0
M   ( $B"6%#Q0Z=*TE\  )(:!@ 5              "  =4;!0!T>&UD+3(P
M,3DQ,C,Q7W!R92YX;6Q02P$"% ,4    " !(@EA0[TSDP!M1   G<P  #@
M            @ ':>P4 ='AM9#$P:S P,2YJ<&=02P$"% ,4    " !(@EA0
M%6;UGQ:F   /P0  #@              @ $AS04 ='AM9#$P:S P,BYJ<&=0
52P4&     !  $ #$ P  8W,&

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6792379520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BUSINESS CONCENTRATIONS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfVendors', window );">Number of vendors - suppliers</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember', window );">Supplier Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">24.00%<span></span>
</td>
<td class="nump">43.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfVendors', window );">Number of vendors - suppliers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_SupplierTwoConcentrationRiskMember', window );">Supplier 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">27.00%<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_SupplierThreeConcentrationRiskMember', window );">Supplier 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Revenue Benchmark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfCustomers', window );">Number of customers - revenue</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_FourCustomersConcentrationRiskMember', window );">Four Customers Concentration Risk Member | Revenue Benchmark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">73.00%<span></span>
</td>
<td class="nump">76.00%<span></span>
</td>
<td class="nump">59.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationMcKessonCorporationRiskMember', window );">McKesson Corporation - Major Customer | Revenue Benchmark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 3,911,000<span></span>
</td>
<td class="nump">$ 1,610,000<span></span>
</td>
<td class="nump">$ 1,959,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationPillPackRiskMember', window );">PillPack - Major Customer | Revenue Benchmark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">12,676,000<span></span>
</td>
<td class="nump">5,075,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationAmerisourceBergenRiskMember', window );">AmerisourceBergen - Major Customer | Revenue Benchmark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">3,927,000<span></span>
</td>
<td class="nump">3,246,000<span></span>
</td>
<td class="nump">2,667,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationCardinalHealthRiskMember', window );">Cardinal Health - Major Customer | Revenue Benchmark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 4,551,000<span></span>
</td>
<td class="nump">$ 2,308,000<span></span>
</td>
<td class="nump">2,559,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationPharmacyInnovationsPaRiskMember', window );">Pharmacy Innovations PA - Major Customer | Revenue Benchmark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,715,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NumberOfCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of customers.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NumberOfCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NumberOfVendors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of vendors.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NumberOfVendors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13537-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_SupplierTwoConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=txmd_SupplierTwoConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_SupplierThreeConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=txmd_SupplierThreeConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_FourCustomersConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=txmd_FourCustomersConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationMcKessonCorporationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationMcKessonCorporationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationPillPackRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationPillPackRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationAmerisourceBergenRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationAmerisourceBergenRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationCardinalHealthRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationCardinalHealthRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationPharmacyInnovationsPaRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationPharmacyInnovationsPaRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6808804304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><p id="xdx_804_eus-gaap--IncomeTaxDisclosureTextBlock_zL6wTaqLV84c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b><span style="text-decoration: underline"><b>NOTE 10 &#8211; <span id="xdx_82E_z7q5de6Oj7qg">INCOME TAXES</span> </b></span></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p id="xdx_894_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zADi8hHgCXHf" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">For financial reporting purposes, income before taxes includes the following components:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="margin-right: auto; margin-left: auto; float: none; width: 90%">

<tr>
<td style="padding: 0pt; vertical-align: top"/>
<td><p style="margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-bottom: black 1pt solid; text-align: center; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>2019</b></p>
</td>
<td style="vertical-align: bottom"><p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td><p style="margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; text-align: center; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>2018</b></p>
</td>
<td style="vertical-align: bottom"><p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td><p style="margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; text-align: center; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>2017</b></p>
</td>
<td style="vertical-align: bottom"><p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr style="background-color: #cceeff">
<td style="padding: 0pt; width: 55%; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">United States</p>
</td>
<td style="width: 1%">
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; width: 1%; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="border-bottom: black 1pt solid; width: 12%; vertical-align: bottom">
<p id="xdx_98D_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_c20190101__20191231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zdcjS9MuxK97" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(176,144,999</p>
</td>
<td style="padding-bottom: 1pt; width: 1%; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
<td style="width: 1%">
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; width: 1%; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="border-bottom: black 1pt solid; width: 12%; vertical-align: bottom">
<p id="xdx_98B_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_c20180101__20181231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zZVgfVuMkwYi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(132,617,160</p>
</td>
<td style="padding-bottom: 1pt; width: 1%; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
<td style="width: 1%">
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; width: 1%; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="border-bottom: black 1pt solid; width: 12%; vertical-align: bottom">
<p id="xdx_98A_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_c20170101__20171231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zbqcESBZjJO9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(76,925,380</p>
</td>
<td style="padding-bottom: 1pt; width: 1%; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
</tr>
<tr>
<td style="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Total</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="border-bottom: black 2pt double; vertical-align: bottom">
<p id="xdx_986_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_c20190101__20191231_zA2uptl6PhHa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(176,144,999</p>
</td>
<td style="padding-bottom: 2pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="border-bottom: black 2pt double; vertical-align: bottom">
<p id="xdx_982_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_c20180101__20181231_zAAncojzdhd4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(132,617,160</p>
</td>
<td style="padding-bottom: 2pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="border-bottom: black 2pt double; vertical-align: bottom">
<p id="xdx_988_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_c20170101__20171231_zH3ExzahCWS5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(76,925,380</p>
</td>
<td style="padding-bottom: 2pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
</tr>

</table>
<p id="xdx_8AE_zhvkruLPKWMe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black; background-color: white">For the years ended December 31, 2019, 2018, and 2017, there was no provision for income taxes, current or deferred. At December 31, 2019, we had a federal net operating loss carry forward of approximately $<span id="xdx_90F_eus-gaap--OperatingLossCarryforwards_iI_c20191231__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--InternalRevenueServiceIRSMember_z8l9AyTYnsX3" title="Net operating loss carry forward">620,354,163</span>. Approximately $<span id="xdx_903_eus-gaap--OperatingLossCarryforwards_iI_c20191231__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--InternalRevenueServiceIRSMember__us-gaap--TaxPeriodAxis__custom--ExpirationPeriod20YearsMember_zSB1hNG2rK4b">338,775,332</span> of the federal net operating loss carry forward can be carried forward for <span id="xdx_90F_ecustom--NolCarryForwardPeriod_dt_c20190101__20191231__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--InternalRevenueServiceIRSMember__us-gaap--TaxPeriodAxis__custom--ExpirationPeriod20YearsMember_z7jOQqaAF0S8" title="NOL carry forward period">20 years</span> and will begin to expire in <span id="xdx_90F_ecustom--OperatingLossCarryforwardsExpirationYear_c20190101__20191231__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--InternalRevenueServiceIRSMember__us-gaap--TaxPeriodAxis__custom--ExpirationPeriod20YearsMember_zABw0O4Z2etk" title="NOL carry forward expiration year">2031</span>.&#160; The remaining $<span id="xdx_90A_eus-gaap--OperatingLossCarryforwards_iI_c20191231__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--InternalRevenueServiceIRSMember__us-gaap--TaxPeriodAxis__custom--ExpirationPeriodIndefiniteMember_zVwMshszB345">281,578,831</span> can be carried forward indefinitely.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p id="xdx_89F_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zoefKqWPnWmd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">A reconciliation between taxes computed at the federal statutory rate and the consolidated effective tax rate is as follows: </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="margin-right: auto; margin-left: auto; float: none; width: 90%">

<tr>
<td style="padding: 0pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" id="xdx_49B_20190101__20191231_zdXEdo8l0Qa5" style="border-bottom: black 1pt solid; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2019</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" id="xdx_49A_20180101__20181231_zx7mVGnraWRd" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2018</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" id="xdx_49A_20170101__20171231_ztGnIkT0Ayyf" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2017</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr id="xdx_40E_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_matax_zWW9DKxQYQX9" style="background-color: #cceeff">
<td style="padding: 0pt; width: 55%; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Federal statutory tax rate</p>
</td>
<td style="width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 10%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">21.0</p>
</td>
<td style="vertical-align: bottom; width: 3%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">%</p>
</td>
<td style="width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 10%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">21.0</p>
</td>
<td style="vertical-align: bottom; width: 3%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">%</p>
</td>
<td style="width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 10%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">34.0</p>
</td>
<td style="vertical-align: bottom; width: 3%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">%</p>
</td>
</tr>
<tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_matax_z9UZ52KqppS6">
<td style="padding: 0pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">State tax rate, net of federal tax benefit</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">4.0</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">%</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">5.2</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">%</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">5.0</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">%</p>
</td>
</tr>
<tr id="xdx_40E_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_matax_zMXUfxWLY9Yg" style="background-color: #cceeff">
<td style="padding: 0pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Adjustment in valuation allowances</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(22.5</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)%</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(31.2</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)%</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">22.6</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">%</p>
</td>
</tr>
<tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_dp_matax_zi11CB4dc9Q4">
<td style="padding: 0pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Excess stock benefits</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">0.2</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">%</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">5.3</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">%</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1220">&#8212;</span></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">%</p>
</td>
</tr>
<tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_dp_matax_z8hJGHsZqqnf" style="background-color: #cceeff">
<td style="padding: 0pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Federal income tax rate change</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">0</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">%</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1223">&#8212;</span></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">%</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(60.8</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)%</p>
</td>
</tr>
<tr id="xdx_40C_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_dp_matax_zltD2WQnmse2">
<td style="padding: 0pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Permanent and other differences</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(2.7</p>
</td>
<td style="padding-bottom: 1pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)%</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(0.3</p>
</td>
<td style="padding-bottom: 1pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)%</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(0.8</p>
</td>
<td style="padding-bottom: 1pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)%</p>
</td>
</tr>
<tr id="xdx_40C_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_dp0_mttax_zOznacZATEnc" style="background-color: #cceeff">
<td style="padding: 0pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Provision (benefit) for income taxes</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#8212;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#8212;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#8212;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>

</table>
<p id="xdx_8AE_zVKLUAFWiqjf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">Deferred income taxes result from temporary differences between the amount of assets and liabilities recognized for financial reporting and tax purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">&#160;</span></p>

<p id="xdx_89A_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zw9h4532cjri" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">The components of the net deferred income tax asset as of December 31, 2019, 2018, and 2017 are as follows:</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="margin-right: auto; margin-left: auto; float: none; width: 90%">

<tr>
<td style="padding: 0pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" id="xdx_492_20191231_zHBuwuSiDfbg" style="border-bottom: black 1pt solid; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2019</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" id="xdx_49A_20181231_zYKgdQSBRIp5" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2018</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" id="xdx_493_20171231_z7FXwxCHEeCg" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2017</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr id="xdx_409_eus-gaap--DeferredTaxAssetsNetAbstract_iB_zLYeykKKz84c">
<td style="padding: 0pt; width: 55%; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Deferred Income Tax Assets:</p>
</td>
<td style="width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 12%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 12%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 12%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_406_eus-gaap--DeferredTaxAssetsOtherLossCarryforwards_i01I_maDTAGz9uv_za087dA6m2l5" style="background-color: #cceeff">
<td style="padding: 0pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 16px">Net operating losses</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">180,520,709</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">140,891,764</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">99,596,321</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_40A_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_i01I_maDTAGz9uv_zESHYbMQgsW4">
<td style="padding: 0pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 16px">R&amp;D Credit</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">186,347</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">186,347</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">186,347</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_408_eus-gaap--DeferredTaxAssetsGross_i01TI_mtDTAGz9uv_maDTANzNCq_zpGMbiJ1dNX5" style="background-color: #cceeff">
<td style="padding: 0pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 16px">Total deferred income tax asset</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">180,707,056</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">141,078,111</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">99,782,668</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_40B_eus-gaap--DeferredTaxAssetsValuationAllowance_i01NI_di_msDTANzNCq_zBSejEMW9Ygf">
<td style="padding: 0pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 16px">Valuation allowance</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(180,707,056</p>
</td>
<td style="padding-bottom: 1pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(141,078,111</p>
</td>
<td style="padding-bottom: 1pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(99,782,668</p>
</td>
<td style="padding-bottom: 1pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
</tr>
<tr id="xdx_40B_eus-gaap--DeferredTaxAssetsNet_i01TI_d0_mtDTANzNCq_zkFTcoIvc2gh" style="background-color: #cceeff">
<td style="padding: 0pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Deferred income tax assets, net</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#8212;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#8212;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#8212;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>

</table>
<p id="xdx_8AE_zrUihzAMpL77" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">We believe that it is more likely than not that we will not generate sufficient future taxable income to realize the tax benefits related to the deferred tax assets on our balance sheet and as such, a valuation allowance has been established against the deferred tax assets for the period ended December 31, 2019.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black"><i><span style="color: black">Unrecognized Tax Benefits</span></i></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">As of the period ended December 31, 2019, we have no unrecognized tax benefits.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">On December 22, 2017, the U.S. federal government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act, or the Tax Act. The Tax Act makes broad and complex changes to the U.S. federal tax code, including, but not limited to reducing the U.S. federal corporate tax rate from <span id="xdx_90E_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_c20170101__20171231_zKlQ7fsuZXhb" title="Federal statutory tax rate">34</span> percent to <span id="xdx_90E_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_c20180101__20181231_zy9HW51Z2pw7">21</span> percent, effective January 1, 2018. As the result of our initial analysis of the impact of the Tax Act, we recorded a provisional amount of net tax expense of $<span id="xdx_900_eus-gaap--TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalIncomeTaxExpenseBenefit_dm_c20170101__20171231_zJ5V3RumQlxh" title="Tax Cuts and Jobs Act, provisional net tax expense">46.7 million</span> in 2017 related to the remeasurement of our deferred tax balances and other effects. We completed our accounting for the income tax effects of the Tax Act in 2018, and no material adjustments were required to the provisional amounts initially recorded.</span></p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6798341136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS, NET<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">INTANGIBLE ASSETS, NET</a></td>
<td class="text"><p id="xdx_806_eus-gaap--GoodwillAndIntangibleAssetsDisclosureTextBlock_zdGQyxM7RIa2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b><span style="text-decoration: underline"><b>NOTE 6 &#8211; <span id="xdx_827_zbdlCzYrVrkk">INTANGIBLE ASSETS, NET</span></b></span></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p id="xdx_89E_ecustom--ScheduleOfIntangibleAssetsTableTextBlock_zSsNxgQCmCKk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of December 31, 2019 and 2018:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; width: 100%">

<tr>
<td style="padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top">&#160;</td>
<td>&#160;</td>
<td style="border-top-style: none; border-right-style: none; border-left-style: none; vertical-align: top">&#160;</td>
<td style="border-top-style: none; border-right-style: none; border-left-style: none; vertical-align: top">&#160;</td>
<td style="border-top-style: none; border-right-style: none; border-left-style: none; vertical-align: top">&#160;</td>
<td style="border-top-style: none; border-right-style: none; border-left-style: none; vertical-align: top">&#160;</td>
<td style="border-top-style: none; border-right-style: none; border-left-style: none; vertical-align: top">&#160;</td>
<td style="border-top-style: none; border-right-style: none; border-left-style: none; vertical-align: top">&#160;</td>
<td style="border-top-style: none; border-right-style: none; border-left-style: none; vertical-align: top">&#160;</td>
<td style="border-top-style: none; border-right-style: none; border-left-style: none; vertical-align: top">&#160;</td>
<td style="border-top-style: none; border-right-style: none; border-left-style: none; vertical-align: top">&#160;</td>
<td style="border-top-style: none; border-right-style: none; border-left-style: none; vertical-align: top">&#160;</td>
<td style="border-top-style: none; border-right-style: none; border-left-style: none; vertical-align: top">&#160;</td>
<td style="border-top-style: none; border-right-style: none; border-left-style: none; vertical-align: top">&#160;</td>
<td style="border-top-style: none; border-right-style: none; border-left-style: none; vertical-align: top">&#160;</td>
<td style="border-top-style: none; border-right-style: none; border-left-style: none; vertical-align: top">&#160;</td>
<td style="vertical-align: bottom; width: 1%">&#160;</td></tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top"/>
<td><p style="margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="14" style="border-bottom: black 1pt none; border-top-style: none; border-right-style: none; border-left-style: none; border-bottom-style: solid; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>December 31,
2019</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; width: 40%; vertical-align: top"><b>&#160;</b></td>
<td><p style="margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-bottom: black 1pt solid; text-align: center; width: 10%; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Gross Carrying
Amount</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td style="width: 1%; width: 1%"><p style="margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-bottom: black 1pt solid; text-align: center; width: 10%; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Accumulated Amortization</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td style="width: 1%; width: 1%"><p style="margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-bottom: black 1pt solid; text-align: center; width: 10%; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Net<br/>Amount</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td style="width: 1%; width: 1%"><p style="margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-bottom: black 1pt solid; text-align: center; width: 10%; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Weighted-<br/>Average<br/>Remaining
Amortization<br/>Period (yrs.)</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; width: 40%; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Amortizable intangible assets:</p>
</td>
<td style="width: 3%">
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 10%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 3%">
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 10%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 3%">
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 10%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 3%">
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 10%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: rgb(204,238,255)">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Approved hormone</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: rgb(204,238,255)">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.15in; margin-top: 0pt; margin-bottom: 0pt">therapy drug</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: rgb(204,238,255)">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.15in; margin-top: 0pt; margin-bottom: 0pt">candidate patents</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zZ45m8aW3pgf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">3,463,082</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zvgJ9pOvKXK1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(478,983</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zrPdY8Onobyb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">2,984,099</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_dtY_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_z2oQJxvGOrE">13</span></p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: White">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Hormone therapy drug</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.15in; margin-top: 0pt; margin-bottom: 0pt">candidate patents</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: White">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.15in; margin-top: 0pt; margin-bottom: 0pt">(pending)</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20191231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_zGbZuhcyXZ41" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">1,979,299</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#8212;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20191231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_zw6A1cByWgMe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">1,979,299</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">n/a</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: rgb(204,238,255)">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Non-amortizable intangible</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: rgb(204,238,255)">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.15in; margin-top: 0pt; margin-bottom: 0pt">assets:</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: White">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Multiple trademarks</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_984_eus-gaap--IndefiniteLivedTrademarks_iI_c20191231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksForVitaminsSupplementsMember_znQmUqz0u694" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">294,813</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#8212;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_98A_eus-gaap--IndefiniteLivedIntangibleAssetsExcludingGoodwill_iI_c20191231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksForVitaminsSupplementsMember_zocGRvUhihv6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">294,813</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">indefinite</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: rgb(204,238,255)">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">TOTAL</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom">
<p id="xdx_984_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_c20191231_zrPXHNejo0C2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">5,737,194</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom">
<p id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_c20191231_zIYygBuIkRkd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(478,983</p>
</td>
<td style="padding-bottom: 2pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom">
<p id="xdx_98D_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20191231_zUtdcezNgmUh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">5,258,211</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; width: 100%">

<tr>
<td style="padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top">&#160;</td>
<td>&#160;</td>
<td style="border-top-style: none; border-right-style: none; border-left-style: none; border-image: initial; vertical-align: top">&#160;</td>
<td style="border-top-style: none; border-right-style: none; border-left-style: none; border-image: initial; vertical-align: top">&#160;</td>
<td style="border-top-style: none; border-right-style: none; border-left-style: none; border-image: initial; vertical-align: top">&#160;</td>
<td style="border-top-style: none; border-right-style: none; border-left-style: none; border-image: initial; vertical-align: top">&#160;</td>
<td style="border-top-style: none; border-right-style: none; border-left-style: none; border-image: initial; vertical-align: top">&#160;</td>
<td style="border-top-style: none; border-right-style: none; border-left-style: none; border-image: initial; vertical-align: top">&#160;</td>
<td style="border-top-style: none; border-right-style: none; border-left-style: none; border-image: initial; vertical-align: top">&#160;</td>
<td style="border-top-style: none; border-right-style: none; border-left-style: none; border-image: initial; vertical-align: top">&#160;</td>
<td style="border-top-style: none; border-right-style: none; border-left-style: none; border-image: initial; vertical-align: top">&#160;</td>
<td style="border-top-style: none; border-right-style: none; border-left-style: none; border-image: initial; vertical-align: top">&#160;</td>
<td style="border-top-style: none; border-right-style: none; border-left-style: none; border-image: initial; vertical-align: top">&#160;</td>
<td style="border-top-style: none; border-right-style: none; border-left-style: none; border-image: initial; vertical-align: top">&#160;</td>
<td style="border-top-style: none; border-right-style: none; border-left-style: none; border-image: initial; vertical-align: top">&#160;</td>
<td style="border-top-style: none; border-right-style: none; border-left-style: none; border-image: initial; vertical-align: top">&#160;</td>
<td style="vertical-align: bottom; width: 1%">&#160;</td></tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top"/>
<td><p style="margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="14" style="border-bottom: black 1pt solid; border-top-style: none; border-right-style: none; border-left-style: none; border-image: initial; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>December 31,
2018</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; text-align: center; vertical-align: top"><b>&#160;</b></td>
<td><p style="margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-bottom: black 1pt solid; text-align: center; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Gross Carrying
Amount</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td style="width: 1%; width: 1%"><p style="margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-bottom: black 1pt solid; text-align: center; width: 10%; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Accumulated Amortization</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td style="width: 1%; width: 1%"><p style="margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-bottom: black 1pt solid; text-align: center; width: 10%; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Net<br/>Amount</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td style="width: 1%; width: 1%"><p style="margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-bottom: black 1pt solid; text-align: center; width: 10%; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Weighted- Average<br/>Remaining
Amortization Period (yrs.)</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; width: 40%; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Amortizable intangible assets:</p>
</td>
<td style="width: 3%">
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 10%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 3%">
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 10%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 3%">
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 10%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 3%">
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 10%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">OPERA software patent</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--ComputerSoftwareIntangibleAssetMember_zuH4Ob72Oyq2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">31,951</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_c20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--ComputerSoftwareIntangibleAssetMember_zLmvoUYIi4ub" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(10,484</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--ComputerSoftwareIntangibleAssetMember_zaOasLYxHcb9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">21,467</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_dtY_c20180101__20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--ComputerSoftwareIntangibleAssetMember_zB2Ja4HDIBf8">10.75</span></p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Development costs of</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.15in; margin-top: 0pt; margin-bottom: 0pt">corporate website</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InternetDomainNamesMember_zSYk6Y2UUw96" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">91,743</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_c20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InternetDomainNamesMember_zHtL9OMHqBJ1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(91,743</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#8212;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">n/a</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: rgb(204,238,255)">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Approved hormone</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: rgb(204,238,255)">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.15in; margin-top: 0pt; margin-bottom: 0pt">therapy drug</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: rgb(204,238,255)">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.15in; margin-top: 0pt; margin-bottom: 0pt">candidate patents</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zO6DdncI1wfe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">2,234,129</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_c20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zawuCBN6mu5l" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(282,485</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zDHtmBT3FTW7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">1,951,644</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_dtY_c20180101__20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_z9dfucABmOri">14</span></p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: White">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Hormone therapy drug</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.15in; margin-top: 0pt; margin-bottom: 0pt">candidate patents</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: White">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.15in; margin-top: 0pt; margin-bottom: 0pt">(pending)</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20181231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_zhWshXYSDvVh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">1,855,279</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#8212;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20181231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_zUuP8vFYS5Fl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">1,855,279</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">n/a</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: rgb(204,238,255)">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Non-amortizable intangible</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: rgb(204,238,255)">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.15in; margin-top: 0pt; margin-bottom: 0pt">assets:</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: White">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Multiple trademarks</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_988_eus-gaap--IndefiniteLivedTrademarks_iI_c20181231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksForVitaminsSupplementsMember_zyYy112mUFnl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">264,289</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#8212;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_988_eus-gaap--IndefiniteLivedIntangibleAssetsExcludingGoodwill_iI_c20181231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksForVitaminsSupplementsMember_zvLuDgt0SQh7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">264,289</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">indefinite</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: rgb(204,238,255)">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">TOTAL</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom">
<p id="xdx_982_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_c20181231_z7iwKFoMeZTl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">4,477,391</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom">
<p id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_c20181231_zPbzzNlfWeZ2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(384,712</p>
</td>
<td style="padding-bottom: 2pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom">
<p id="xdx_984_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20181231_zNnLUsOkkZ89" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">4,092,679</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>

</table>
<p id="xdx_8AD_zQXuyGeRuVb8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">We capitalize external costs, consisting primarily of legal costs, related to securing our patents and trademarks. Once a patent is granted, we amortize the approved hormone therapy drug candidate patents using the straight-line method over the estimated useful life of approximately <span id="xdx_908_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zEe9VmrPiLYb">20</span> years, which is the life of intellectual property patents. If the patent is not granted, we write-off any capitalized patent costs at that time. Trademarks are perpetual and are not amortized. During the year ended December 31, 2019, we wrote off $<span id="xdx_909_eus-gaap--ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_c20190101__20191231_zAi4ok0xPne">78,864</span> in costs related to trademarks and patents, including the net carrying amount of the OPERA patent. </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">As of December 31, 2019, we had <span id="xdx_901_ecustom--NumberOfIssuedPatents_iI_uPure_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUSPatentsMember_zcAXHfpAAxz8">29</span> issued domestic &#160;patents and <span id="xdx_907_ecustom--NumberOfIssuedPatents_iI_uPure_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignPatentsMember_zmFxdUJsHDC">30</span> issued foreign patents, including: </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; width: 100%">

<tr>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">&#9679;</span></p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black"><span id="xdx_907_ecustom--NumberOfIssuedPatents_iI_uPure_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticPatentsBijuvaMember_zfHJygFwRv7h" title="Number of issued patents">12</span> domestic patents and <span id="xdx_908_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignPatentsBijuvaMember_zH34gBx8H73f">six</span> foreign patents that relate to BIJUVA as well as <span id="xdx_902_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticPatentsNonApprovedBijuvaMember_zuIweFRntojg">three</span> domestic patents that relate to estradiol and progesterone product candidates. These patents establish an important intellectual property foundation and are owned by us. The domestic patents will expire in 2032. The foreign patents will expire no earlier than 2032. In addition, we have pending patent applications relating to BIJUVA in the U.S., Argentina, Australia, Brazil, Canada, China, Europe, Israel, Japan, Mexico, New Zealand, Russia, South Africa, and South Korea; </span></p>
</td>
</tr>

</table>
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; width: 100%">

<tr>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">&#9679;</span></p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span id="xdx_90D_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUSPatentsImvexxyMember_zPub0tWlzhoj">Six</span><span style="color: black"> domestic patents (</span><span id="xdx_90F_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUSUtilityPatentsImvexxyMember_zeK62XpJvJ97">five</span> <span style="color: black">utility and <span id="xdx_905_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUSDesignPatentsImvexxyMember_zNiqvZkjaRL">one</span> design) and <span id="xdx_90D_ecustom--NumberOfIssuedPatents_iI_uPure_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignPatentsImvexxyMember_zYTzRR8sspCa">13</span> foreign patents (<span id="xdx_90A_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignUtilityPatentsImvexxyMember_zLRJQMRCTJW1">three</span> utility and <span id="xdx_905_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignDesignPatentsImvexxyMember_z8IZymKPqmu4">ten</span> design) that relate to IMVEXXY. These patents establish an important intellectual property foundation for IMVEXXY and are owned by us. The domestic patents will expire in 2032 or 2033. The foreign utility patents will expire no earlier than 2033. The foreign design patents provide protection expiring no earlier than 2025. In certain countries, the foreign design patents provide protection through at least 2037. In addition, we have pending patent applications related to IMVEXXY in the U.S., Argentina, Australia, Brazil, Canada, Europe, Israel, Japan, Mexico, New Zealand, Russia, South Africa, and South Korea; </span></p>
</td>
</tr>

</table>
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; width: 100%">

<tr>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">&#9679;</span></p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black"><span id="xdx_908_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUSPatentsTopicalCreamMember_zSE6pfEuadbc">One</span> domestic utility patent that relates to our topical-cream candidates, which is owned by us. The domestic patent will expire in 2035. We have pending patent applications with respect to our topical-cream candidates in the U.S., Argentina, Australia, Brazil, Canada, Europe, Israel, Japan, Mexico, Russia, South Africa, and South Korea; </span></p>
</td>
</tr>

</table>
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; width: 100%">

<tr>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">&#9679;</span></p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black"><span id="xdx_904_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUtilityPatentTransdermalPatchMember_z4tmsEJeDbqe">One</span> domestic utility patent and </span><span id="xdx_902_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignUtilityPatentTransdermalPatchMember_znk2ICZ9uEif">seven</span><span style="color: black"> foreign patents that relate to our transdermal-patch candidates, which are owned by us. The domestic utility patent will expire in 2032. The foreign patents will expire no earlier than 2033. We have pending patent applications with respect to our transdermal-patch candidates in the U.S., Brazil, Canada, Mexico, and South Africa; </span></p>
</td>
</tr>

</table>
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; width: 100%">

<tr>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">&#9679;</span></p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span id="xdx_909_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUtilityPatentTx009HRMember_zRjys56gHOK5">Three</span><span style="color: black"> domestic utility patents that relate to TX-009HR, a progesterone and estradiol product candidate, which are owned by us and will expire in 2037. We have pending patent applications with respect to TX-009HR in the U.S., Argentina, Australia, Brazil, Canada, Europe, Israel, Japan, Mexico, New Zealand, Russia, South Africa, and South Korea.</span></p>
</td>
</tr>

</table>
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; width: 100%">

<tr>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">&#9679;</span></p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span id="xdx_90D_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticPatentsProgesteroneFormulationsMember_zdkLx1njb5ng">Two</span><span style="color: black"> domestic and <span id="xdx_900_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignPatentsProgesteroneFormulationsMember_zEQ5E1kS3jW2">four</span> foreign patents that relate to formulations containing progesterone, which are owned by us. The domestic patent</span>s<span style="color: black"> will expire </span>between <span style="color: black">2032</span> and 2036<span style="color: black">. The foreign patents will expire no earlier than 2033. In addition, we have pending patent applications with respect formulations containing progesterone in the U.S., Argentina, Australia, Brazil, Canada, Europe, Israel, Japan, Mexico, Russia, South Africa, and South Korea; </span></p>
</td>
</tr>

</table>
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; width: 100%">

<tr>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">&#9679;</span></p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black"><span id="xdx_904_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUtilityPatentOperaMember_zOGUFxyameRe">One</span> domestic utility patent that relates to our OPERA information-technology platform, which is owned by us and will expire in 2031; </span></p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="background-color: white">Amortization expense was $<span id="xdx_90F_eus-gaap--AmortizationOfIntangibleAssets_c20190101__20191231_z7iwZ5ZuQTC9">197,593</span>, $<span id="xdx_908_eus-gaap--AmortizationOfIntangibleAssets_c20180101__20181231_z7N1ETmlU4z5">112,474</span>, and $<span id="xdx_90D_eus-gaap--AmortizationOfIntangibleAssets_c20170101__20171231_zKi5baRkOisj">71,516</span> for the years ended December 31, 2019, 2018, and 2017, respectively.</span></p>

<p id="xdx_897_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zrznKYBF3tWd" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="background-color: white">Estimated amortization expense, based on current patent cost being amortized, for the next five years is as follows:</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="margin-right: auto; margin-left: auto; float: none; width: 40%">

<tr>
<td style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; width: 49%; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Year Ending<br/>December
31,</b></p>
</td>
<td style="padding: 0pt 5.4pt; width: 2%; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td id="xdx_49E_20191231_zsxdHn6Z4B7k" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; vertical-align: top; width: 49%"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Estimated<br/>Amortization</b></p>
</td>
</tr>
<tr id="xdx_400_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_z5zAjuA6YVph" style="background-color: rgb(204,238,255)">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">2020</p>
</td>
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">$229,546</p>
</td>
</tr>
<tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_zggNowtaQ5kb" style="background-color: White">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">2021</p>
</td>
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">$229,546</p>
</td>
</tr>
<tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_zUDpMMLkGDl7" style="background-color: rgb(204,238,255)">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">2022</p>
</td>
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">$229,546</p>
</td>
</tr>
<tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_zlthq9FvAC15" style="background-color: White">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">2023</p>
</td>
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">$229,546</p>
</td>
</tr>
<tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_ztTQzfSmEsS7" style="background-color: rgb(204,238,255)">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">2024</p>
</td>
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">$229,546</p>
</td>
</tr>
<tr style="background-color: White">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>

</table>
<p id="xdx_8AB_zW8i29NaJY2f" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #212529"><span style="text-decoration: underline"><span style="color: #212529">License Agreement with the Population Council</span></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: #212529">On July 30, 2018, we entered into the Population Council License Agreement to commercialize ANNOVERA in the U.S. ANNOVERA became commercially available in the third quarter of 2019 and we expect the full commercial launch of ANNOVERA in the first quarter of 2020.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: #212529">Under the terms of the Population Council License Agreement, we paid the Population Council a milestone payment of $<span id="xdx_907_ecustom--MilestonePaymentUponFDAApproval_c20190701__20190930__srt--ProductOrServiceAxis__custom--AnnoveraMember__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreement1Member_zZi7oSOg8Tg1" title="Milestone payment upon FDA Approval">20,000,000</span> within 30 days following the approval by the FDA of the new drug application, or NDA, for ANNOVERA and $<span id="xdx_900_ecustom--MilestonePaymentsAfterReleaseOfFirstCommercialBatch_iI_c20190930__srt--ProductOrServiceAxis__custom--AnnoveraMember__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreement1Member_z1gyEedlxhHb" title="Milestone payments (payment after release of first commercial batch)">20,000,000</span> within 30 days following the first commercial batch release of ANNOVERA. Both milestone payments of $<span id="xdx_90F_eus-gaap--FinitelivedIntangibleAssetsAcquired1_c20190701__20190930__srt--ProductOrServiceAxis__custom--AnnoveraMember__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreement1Member_z24YlW0jZZ2c" title="License rights acquired">20,000,000</span> were recorded as license rights in the consolidated balance sheets. We started amortizing the license rights in the third quarter of 2019 once ANNOVERA became commercially available for use. The cost is amortized over the remaining useful life over which the license rights will contribute directly or indirectly to our cash flows, which is estimated to be the remaining patent life of the product, which expires in December 2032. The cost is amortized using the straight-line method as the pattern of economic benefit cannot be reliably determined. During the year ended December 31, 2019, we recorded $<span id="xdx_90F_eus-gaap--OtherAmortizationOfDeferredCharges_c20190101__20191231__srt--ProductOrServiceAxis__custom--AnnoveraMember__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreement1Member_z8S5vUF488U3" title="Amortization of Other Deferred Charges">778,692</span> in amortization expense related to the license fee which was recorded as a component of cost of sales.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: #212529">The
Population Council is also eligible to receive milestone payments and royalties from commercial sales of ANNOVERA. We are
responsible for marketing expenses related to the commercialization of ANNOVERA. In addition, we are required to pay the
Population Council, on a quarterly basis, step-based royalty payments based on annual net sales of ANNOVERA in the U.S. by
the Company and its affiliates and permitted licensees as follows: (i) if annual net sales are less than or equal to $<span id="xdx_902_ecustom--NetSalesAmountPerStepbasedRoyalty_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep1Member__srt--RangeAxis__srt--MaximumMember_zrTYygEARfQi" title="Net sales amount per step-based royalty">50,000,000</span>,
a royalty of <span id="xdx_90D_ecustom--RoyaltyPercent_dp_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep1Member_zkNUJsk4roz3" title="Royalty (percent)">5</span>%
of net sales; (ii) for annual net sales greater than $<span id="xdx_902_ecustom--NetSalesAmountPerStepbasedRoyalty_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep2Member__srt--RangeAxis__srt--MinimumMember_zpPxhCHKYSua">50,000,000</span>
and less than or equal to $<span id="xdx_903_ecustom--NetSalesAmountPerStepbasedRoyalty_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep2Member__srt--RangeAxis__srt--MaximumMember_zb8M2Ena4km4">150,000,000</span>,
a royalty of <span id="xdx_90D_ecustom--RoyaltyPercent_dp_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep2Member_zxZPuiOOFrC1">10</span>%
of such net sales; and (iii) for net sales greater than $<span id="xdx_903_ecustom--NetSalesAmountPerStepbasedRoyalty_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep3Member__srt--RangeAxis__srt--MinimumMember_zvrDgk1VqKRc">150,000,000</span>,
a royalty of <span id="xdx_903_ecustom--RoyaltyPercent_dp_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep3Member_zjcM4N5IFwbe">15</span>%
of such net sales. The annual royalty rate will be reduced to <span id="xdx_905_ecustom--AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent_dp_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreement1Member_zXXunlGnhwqf" title="Annual royalty rate reduction of initial rate during the six-month period from commercial sale of a generic equivalent">50</span>%
of the initial rate during the six-month period beginning on the date of the first arms-length commercial sale of a generic
equivalent of the one-year vaginal contraceptive system that is launched by a third party in the U.S., and thereafter will be
reduced to <span id="xdx_902_ecustom--AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent_dp_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreement1Member_zAfLDRuaPx5e" title="Annual royalty rate reduction of initial rate after the six-month period from commercial sale of a generic equivalent">20</span>%
of the initial rate. We are required to pay the Population Council milestone payments of $<span id="xdx_90A_ecustom--RequiredMilestonePaymentsUponCumulativeNetSalesOfSpecifiedLevels_dm_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreement1Member_z3WB7dveZctb" title="Required milestone payments upon cumulative net sales of specified levels">40
million</span> upon cumulative net sales of ANNOVERA in the U.S. by us and our affiliates and permitted sublicensees of each
of $<span id="xdx_902_ecustom--SpecifiedLevelOneOfCumulativeNetSalesForRequiredMilestonePayments_dm_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreement1Member_zPOga3TS5ZBa" title="Specified level one of cumulative net sales for required milestone payments">200
million</span>, $<span id="xdx_904_ecustom--SpecifiedLevelTwoOfCumulativeNetSalesForRequiredMilestonePayments_dm_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreement1Member_zRgYvIBzPUZa" title="Specified level two of cumulative net sales for required milestone payments">400
million</span> and $<span id="xdx_906_ecustom--SpecifiedLevelThreeOfCumulativeNetSalesForRequiredMilestonePayments_dm_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreement1Member_zwGmMDa1Sdvg" title="Specified level three of cumulative net sales for required milestone payments">1
billion</span>. The Population Council has agreed to perform and pay the costs and expenses associated with four
post-approval studies required by the FDA for ANNOVERA and we have agreed to perform and pay the costs and expenses
associated with a post approval study required by the FDA to measure risk for venous thromboembolism, provided that if the
costs and expenses associated with such post-approval study exceed $<span id="xdx_90A_ecustom--MaximumCostsAndExpensesForPostApprovalStudyToBePaid_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreement1Member_zagFFOU168tg" title="Maximum costs and expenses for post approval">20,000,000</span>,
half of such excess will be offset against royalties or other payments owed by us to the Population Council under the
Population Council License Agreement. We and the Population Council have agreed to form a joint product committee responsible
for overseeing activities under the Population Council License Agreement. We will be responsible for all aspects of
promotion, product positioning, pricing, education programs, publications, sales messages and any additional desired clinical
studies for the one-year vaginal contraceptive system, subject to oversight and decisions made by the joint product
committee. The Population Council License Agreement includes exclusive rights for us to negotiate co-development of two other
investigational vaginal contraceptive systems in development by the Population Council. </span></p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6805933392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other current assets consist of the following: (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrepaidSalesAndMarketingCostsCurrent', window );">Prepaid sales and marketing costs</a></td>
<td class="nump">$ 1,583,698<span></span>
</td>
<td class="nump">$ 5,148,789<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsCurrentNet', window );">Debt financing fees on undrawn&#160;tranches (Note 8)</a></td>
<td class="nump">550,757<span></span>
</td>
<td class="nump">1,898,074<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">1,812,135<span></span>
</td>
<td class="nump">790,465<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrepaidManufacturing', window );">Prepaid manufacturing</a></td>
<td class="nump">2,595,721<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other prepaid costs</a></td>
<td class="nump">4,787,482<span></span>
</td>
<td class="nump">2,997,365<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">TOTAL OTHER CURRENT ASSETS</a></td>
<td class="nump">$ 11,329,793<span></span>
</td>
<td class="nump">$ 10,834,693<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PrepaidManufacturing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid manufacturing costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_PrepaidManufacturing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PrepaidSalesAndMarketingCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It refers to the amount of prepaid sales and marketing costs incurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_PrepaidSalesAndMarketingCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsCurrentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs classified as current. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsCurrentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5865-108316<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6787-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6798341136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>THE COMPANY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">THE COMPANY</a></td>
<td class="text"><p id="xdx_80D_eus-gaap--NatureOfOperations_z13SIeAOJBxd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b><span style="text-decoration: underline"><b>NOTE 1 &#8211; <span id="xdx_822_zBs3fazlAubl">THE COMPANY</span></b></span></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">TherapeuticsMD,
Inc., a Nevada corporation, or TherapeuticsMD or the Company, has <span id="xdx_900_ecustom--NumberOfSubsidiaries_iI_dc_uPure_c20191231_zj683O4X4lTg" title="Number of subsidiaires">three</span> wholly owned subsidiaries, vitaMedMD, LLC, a Delaware
limited liability company, or VitaMed; BocaGreenMD, Inc., a Nevada corporation, or BocaGreen; and VitaCare Prescription Services,
Inc., a Florida corporation, or VitaCare. Unless the context otherwise requires, TherapeuticsMD, VitaMed, BocaGreen, and VitaCare
collectively are sometimes referred to as &#8220;our company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; or &#8220;us.&#8221;
TherapeuticsMD &#174;, vitaMedMD &#174;, BocaGreenMD &#174;, IMVEXXY &#174; and BIJUVA &#174; are registered trademarks of our
company and ANNOVERA&#8482; is a licensed trademark of our company. </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: black"><span style="text-decoration: underline"><span style="color: black">Nature of Business</span></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">We are a women&#8217;s healthcare company with a mission of creating and commercializing innovative products to support the lifespan of women from pregnancy prevention through menopause. At TherapeuticsMD, we combine entrepreneurial spirit, clinical expertise, and business leadership to develop and commercialize health solutions that enable new standards of care for women. Our solutions range from a patient-controlled, long-lasting contraceptive to advanced hormone therapy pharmaceutical products. We also manufacture and distribute branded and generic prescription prenatal vitamins under the vitaMedMD and BocaGreenMD brands. Our portfolio of products focused on women&#8217;s health allows us to efficiently leverage our sales and marketing plan to grow our recently approved products. During 2018, the U.S. Food and Drug Administration, or FDA, approval of our pharmaceutical products has transitioned our company from predominately focused on conducting research and development to one focused on commercializing our pharmaceutical products. In July 2018, we launched our FDA-approved product, IMVEXXY (estradiol vaginal inserts) for the treatment of moderate-to-severe dyspareunia (vaginal pain associated with sexual activity), a symptom of vulvar and vaginal atrophy, or VVA, due to menopause. In April 2019, we launched our FDA-approved product BIJUVA (estradiol and progesterone) capsules<span style="text-align: justify">, our hormone therapy combination of bio-identical 17&#223;-estradiol and bio-identical progesterone in a single, oral softgel capsule, for the treatment of moderate-to-severe vasomotor symptoms, or VMS, due to menopause in women with a uterus. In October 2019, we began a test and learn market introduction for our FDA-approved product ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system), the first and only patient-controlled, procedure-free, reversible prescription contraceptive option for women. We expect the full commercial launch of ANNOVERA in the first quarter of 2020. On July 30, 2018, we entered into an exclusive license agreement, or the Population Council License Agreement, with the Population Council, Inc., or the Population Council, to commercialize ANNOVERA in the U.S. In addition, on July 30, 2018, we entered into a license and supply agreement</span><span style="color: #212529">, or the Knight License Agreement,</span> with Knight Therapeutics Inc., or Knight, pursuant to which we granted Knight an exclusive license to commercialize IMVEXXY and BIJUVA in Canada and Israel. On June 6, 2019, we entered into an exclusive license and supply agreement, or the Theramex License Agreement, with Theramex HQ UK Limited, or Theramex, to commercialize BIJUVA and IMVEXXY outside of the U.S., excluding Canada and Israel, or the Theramex Territory. </span></p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6799739184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">For financial reporting purposes, income before taxes includes the following components:</a></td>
<td class="text"><p id="xdx_894_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zADi8hHgCXHf" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">For financial reporting purposes, income before taxes includes the following components:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="margin-right: auto; margin-left: auto; float: none; width: 90%">

<tr>
<td style="padding: 0pt; vertical-align: top"/>
<td><p style="margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-bottom: black 1pt solid; text-align: center; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>2019</b></p>
</td>
<td style="vertical-align: bottom"><p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td><p style="margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; text-align: center; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>2018</b></p>
</td>
<td style="vertical-align: bottom"><p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td><p style="margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; text-align: center; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>2017</b></p>
</td>
<td style="vertical-align: bottom"><p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr style="background-color: #cceeff">
<td style="padding: 0pt; width: 55%; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">United States</p>
</td>
<td style="width: 1%">
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; width: 1%; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="border-bottom: black 1pt solid; width: 12%; vertical-align: bottom">
<p id="xdx_98D_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_c20190101__20191231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zdcjS9MuxK97" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(176,144,999</p>
</td>
<td style="padding-bottom: 1pt; width: 1%; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
<td style="width: 1%">
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; width: 1%; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="border-bottom: black 1pt solid; width: 12%; vertical-align: bottom">
<p id="xdx_98B_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_c20180101__20181231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zZVgfVuMkwYi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(132,617,160</p>
</td>
<td style="padding-bottom: 1pt; width: 1%; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
<td style="width: 1%">
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; width: 1%; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="border-bottom: black 1pt solid; width: 12%; vertical-align: bottom">
<p id="xdx_98A_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_c20170101__20171231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zbqcESBZjJO9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(76,925,380</p>
</td>
<td style="padding-bottom: 1pt; width: 1%; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
</tr>
<tr>
<td style="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Total</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="border-bottom: black 2pt double; vertical-align: bottom">
<p id="xdx_986_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_c20190101__20191231_zA2uptl6PhHa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(176,144,999</p>
</td>
<td style="padding-bottom: 2pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="border-bottom: black 2pt double; vertical-align: bottom">
<p id="xdx_982_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_c20180101__20181231_zAAncojzdhd4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(132,617,160</p>
</td>
<td style="padding-bottom: 2pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
<td>
<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="border-bottom: black 2pt double; vertical-align: bottom">
<p id="xdx_988_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_c20170101__20171231_zH3ExzahCWS5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(76,925,380</p>
</td>
<td style="padding-bottom: 2pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
</tr>

</table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">A reconciliation between taxes computed at the federal statutory rate and the consolidated effective tax rate is as follows:</a></td>
<td class="text"><p id="xdx_89F_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zoefKqWPnWmd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">A reconciliation between taxes computed at the federal statutory rate and the consolidated effective tax rate is as follows: </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="margin-right: auto; margin-left: auto; float: none; width: 90%">

<tr>
<td style="padding: 0pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" id="xdx_49B_20190101__20191231_zdXEdo8l0Qa5" style="border-bottom: black 1pt solid; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2019</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" id="xdx_49A_20180101__20181231_zx7mVGnraWRd" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2018</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" id="xdx_49A_20170101__20171231_ztGnIkT0Ayyf" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2017</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr id="xdx_40E_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_matax_zWW9DKxQYQX9" style="background-color: #cceeff">
<td style="padding: 0pt; width: 55%; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Federal statutory tax rate</p>
</td>
<td style="width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 10%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">21.0</p>
</td>
<td style="vertical-align: bottom; width: 3%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">%</p>
</td>
<td style="width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 10%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">21.0</p>
</td>
<td style="vertical-align: bottom; width: 3%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">%</p>
</td>
<td style="width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 10%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">34.0</p>
</td>
<td style="vertical-align: bottom; width: 3%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">%</p>
</td>
</tr>
<tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_matax_z9UZ52KqppS6">
<td style="padding: 0pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">State tax rate, net of federal tax benefit</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">4.0</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">%</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">5.2</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">%</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">5.0</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">%</p>
</td>
</tr>
<tr id="xdx_40E_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_matax_zMXUfxWLY9Yg" style="background-color: #cceeff">
<td style="padding: 0pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Adjustment in valuation allowances</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(22.5</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)%</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(31.2</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)%</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">22.6</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">%</p>
</td>
</tr>
<tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_dp_matax_zi11CB4dc9Q4">
<td style="padding: 0pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Excess stock benefits</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">0.2</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">%</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">5.3</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">%</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1220">&#8212;</span></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">%</p>
</td>
</tr>
<tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_dp_matax_z8hJGHsZqqnf" style="background-color: #cceeff">
<td style="padding: 0pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Federal income tax rate change</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">0</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">%</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1223">&#8212;</span></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">%</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(60.8</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)%</p>
</td>
</tr>
<tr id="xdx_40C_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_dp_matax_zltD2WQnmse2">
<td style="padding: 0pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Permanent and other differences</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(2.7</p>
</td>
<td style="padding-bottom: 1pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)%</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(0.3</p>
</td>
<td style="padding-bottom: 1pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)%</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(0.8</p>
</td>
<td style="padding-bottom: 1pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)%</p>
</td>
</tr>
<tr id="xdx_40C_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_dp0_mttax_zOznacZATEnc" style="background-color: #cceeff">
<td style="padding: 0pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Provision (benefit) for income taxes</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#8212;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#8212;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#8212;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>

</table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">The components of the net deferred income tax asset as of December 31, 2019, 2018, and 2017 are as follows:</a></td>
<td class="text"><p id="xdx_89A_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zw9h4532cjri" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">The components of the net deferred income tax asset as of December 31, 2019, 2018, and 2017 are as follows:</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="margin-right: auto; margin-left: auto; float: none; width: 90%">

<tr>
<td style="padding: 0pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" id="xdx_492_20191231_zHBuwuSiDfbg" style="border-bottom: black 1pt solid; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2019</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" id="xdx_49A_20181231_zYKgdQSBRIp5" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2018</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" id="xdx_493_20171231_z7FXwxCHEeCg" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2017</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr id="xdx_409_eus-gaap--DeferredTaxAssetsNetAbstract_iB_zLYeykKKz84c">
<td style="padding: 0pt; width: 55%; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Deferred Income Tax Assets:</p>
</td>
<td style="width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 12%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 12%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 12%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_406_eus-gaap--DeferredTaxAssetsOtherLossCarryforwards_i01I_maDTAGz9uv_za087dA6m2l5" style="background-color: #cceeff">
<td style="padding: 0pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 16px">Net operating losses</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">180,520,709</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">140,891,764</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">99,596,321</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_40A_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_i01I_maDTAGz9uv_zESHYbMQgsW4">
<td style="padding: 0pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 16px">R&amp;D Credit</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">186,347</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">186,347</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">186,347</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_408_eus-gaap--DeferredTaxAssetsGross_i01TI_mtDTAGz9uv_maDTANzNCq_zpGMbiJ1dNX5" style="background-color: #cceeff">
<td style="padding: 0pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 16px">Total deferred income tax asset</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">180,707,056</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">141,078,111</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">99,782,668</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_40B_eus-gaap--DeferredTaxAssetsValuationAllowance_i01NI_di_msDTANzNCq_zBSejEMW9Ygf">
<td style="padding: 0pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 16px">Valuation allowance</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(180,707,056</p>
</td>
<td style="padding-bottom: 1pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(141,078,111</p>
</td>
<td style="padding-bottom: 1pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(99,782,668</p>
</td>
<td style="padding-bottom: 1pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
</tr>
<tr id="xdx_40B_eus-gaap--DeferredTaxAssetsNet_i01TI_d0_mtDTANzNCq_zkFTcoIvc2gh" style="background-color: #cceeff">
<td style="padding: 0pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Deferred income tax assets, net</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#8212;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#8212;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#8212;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>

</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6800274576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance for doubtful accounts</a></td>
<td class="nump">$ 904,040<span></span>
</td>
<td class="nump">$ 596,602<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, Shares Issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="nump">350,000,000<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued</a></td>
<td class="nump">271,177,076<span></span>
</td>
<td class="nump">240,462,439<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding</a></td>
<td class="nump">271,177,076<span></span>
</td>
<td class="nump">240,462,439<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=119407570&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118936363&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=119407570&amp;loc=SL82919249-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118955202&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6803374720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The following table provides information about disaggregated revenue by product mix for the years ended December 31, 2019, 2018, and 2017: (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">$ 15,902,000<span></span>
</td>
<td class="nump">$ 23,719,000<span></span>
</td>
<td class="nump">$ 6,079,000<span></span>
</td>
<td class="nump">$ 3,947,000<span></span>
</td>
<td class="nump">$ 5,089,000<span></span>
</td>
<td class="nump">$ 3,474,000<span></span>
</td>
<td class="nump">$ 3,763,000<span></span>
</td>
<td class="nump">$ 3,773,000<span></span>
</td>
<td class="nump">$ 49,646,937<span></span>
</td>
<td class="nump">$ 16,099,460<span></span>
</td>
<td class="nump">$ 16,777,713<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=txmd_PrescriptionVitaminsMember', window );">Prescription Vitamins [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,885,493<span></span>
</td>
<td class="nump">15,041,259<span></span>
</td>
<td class="nump">16,744,831<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=txmd_ImvexxyMember', window );">Imvexxy [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,252,045<span></span>
</td>
<td class="nump">1,058,201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=txmd_BijuvaMember', window );">BIJUVA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,836,443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=txmd_AnnoveraMember', window );">ANNOVERA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,166,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember', window );">License and Service [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,506,400<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=txmd_OtcProductsMember', window );">OTC Products [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,882<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=txmd_PrescriptionVitaminsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=txmd_PrescriptionVitaminsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=txmd_ImvexxyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=txmd_ImvexxyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=txmd_BijuvaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=txmd_BijuvaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=txmd_AnnoveraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=txmd_AnnoveraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=txmd_OtcProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=txmd_OtcProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6805308544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental lease information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Aug. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="nump">$ 10,109,154<span></span>
</td>
<td class="nump">$ 7,400,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Short-term operating lease liability (included in Other current liabilities)</a></td>
<td class="nump">1,501,539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liability</a></td>
<td class="nump">$ 9,145,049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining term</a></td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">8.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in the measurement of lease liabilities for operating lease</a></td>
<td class="nump">$ 1,164,234<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for lease obligation</a></td>
<td class="nump">$ 11,171,471<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6805692800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>The components of the net deferred income tax asset as of December 31, 2019, 2018, and 2017 are as follows: (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred Income Tax Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOtherLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">$ 180,520,709<span></span>
</td>
<td class="nump">$ 140,891,764<span></span>
</td>
<td class="nump">$ 99,596,321<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">R Credit</a></td>
<td class="nump">186,347<span></span>
</td>
<td class="nump">186,347<span></span>
</td>
<td class="nump">186,347<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred income tax asset</a></td>
<td class="nump">180,707,056<span></span>
</td>
<td class="nump">141,078,111<span></span>
</td>
<td class="nump">99,782,668<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(180,707,056)<span></span>
</td>
<td class="num">(141,078,111)<span></span>
</td>
<td class="num">(99,782,668)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred income tax assets, net</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOtherLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible loss carryforwards, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOtherLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6792382208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>A summary of activity under the 2009, 2012 and 2019 Plans and related information during the year ended December 31, 2019 is as follows: (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of shares under options, exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(102,546)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares under options, beginning</a></td>
<td class="nump">20,872,824<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, beginning</a></td>
<td class="nump">$ 4.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">5 years 10 months 2 days<span></span>
</td>
<td class="text">5 years 11 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, beginning</a></td>
<td class="nump">$ 12,239,876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares under options, granted</a></td>
<td class="nump">4,620,501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, granted</a></td>
<td class="nump">$ 3.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of shares under options, exercised</a></td>
<td class="num">(343,716)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, exercised</a></td>
<td class="nump">$ 0.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value, exercised</a></td>
<td class="nump">$ 1,426,828<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Number of shares under options, expired</a></td>
<td class="num">(26,375)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, expired</a></td>
<td class="nump">$ 5.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of shares under options, cancelled forfeited</a></td>
<td class="num">(93,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, cancelled forfeited</a></td>
<td class="nump">$ 5.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares under options, ending</a></td>
<td class="nump">25,030,234<span></span>
</td>
<td class="nump">20,872,824<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, ending</a></td>
<td class="nump">$ 4.65<span></span>
</td>
<td class="nump">$ 4.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, ending</a></td>
<td class="nump">$ 3,668,171<span></span>
</td>
<td class="nump">$ 12,239,876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of shares under options, vested and exercisable ending</a></td>
<td class="nump">18,025,819<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, vested and exercisable ending</a></td>
<td class="nump">$ 4.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual life, vested and exercisable</a></td>
<td class="text">4 years 7 months 13 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value, vested and exercisable ending</a></td>
<td class="nump">$ 3,319,621<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of shares under options, unvested ending</a></td>
<td class="nump">7,004,415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, unvested ending</a></td>
<td class="nump">$ 4.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms', window );">Weighted average remaining contractual life, unvested</a></td>
<td class="text">8 years 11 months 15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue', window );">Aggregate intrinsic value, unvested ending</a></td>
<td class="nump">$ 348,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for unvested options, in 'PnYnMnDTnHnMnS' format,</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire unvested shares reserved for issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options unvested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>txmd-10k_123119_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2019-01-31"
  xmlns:txmd="http://therapeuticsmd.com/20191231"
  xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="txmd-20191231.xsd" xlink:type="simple"/>
    <context id="From2019-01-01to2019-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2019-06-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <instant>2019-06-28</instant>
        </period>
    </context>
    <context id="AsOf2020-02-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <instant>2020-02-17</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2018-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2018-01-012018-12-31_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="From2017-01-012017-12-31_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_us-gaap_LicenseAndServiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2018-01-012018-12-31_us-gaap_LicenseAndServiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="From2017-01-012017-12-31_us-gaap_LicenseAndServiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="From2018-01-012018-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="From2017-01-012017-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2016-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="AsOf2016-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="AsOf2016-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="AsOf2016-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="From2017-01-012017-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="From2017-01-012017-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="From2017-01-012017-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2017-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="AsOf2017-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="AsOf2017-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="AsOf2017-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="From2018-01-012018-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="From2018-01-012018-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="From2018-01-012018-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2018-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="AsOf2018-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="AsOf2018-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_us-gaap_AccountsReceivableMember_custom_CustomerAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_us-gaap_AccountsReceivableMember_custom_CustomerBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_us-gaap_AccountsReceivableMember_custom_CustomerCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_us-gaap_AccountsReceivableMember_custom_CustomerDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2018-01-012018-12-31_us-gaap_AccountsReceivableMember_custom_CustomerAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="From2018-01-012018-12-31_us-gaap_AccountsReceivableMember_custom_CustomerBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="From2018-01-012018-12-31_us-gaap_AccountsReceivableMember_custom_CustomerCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_us-gaap_LandAndBuildingMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandAndBuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_us-gaap_LandAndBuildingMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandAndBuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_VitaminsAndImvexxyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:VitaminsAndImvexxyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_BijuvaAndAnnoveraMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:BijuvaAndAnnoveraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2018-07-302018-08-06_custom_SubscriptionAgreementKnightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">txmd:SubscriptionAgreementKnightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-30</startDate>
            <endDate>2018-08-06</endDate>
        </period>
    </context>
    <context id="AsOf2018-08-06_custom_SubscriptionAgreementKnightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">txmd:SubscriptionAgreementKnightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-08-06</instant>
        </period>
    </context>
    <context id="From2019-08-042019-08-05_custom_LicenseAgreementTheramexMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:LicenseAgreementTheramexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-04</startDate>
            <endDate>2019-08-05</endDate>
        </period>
    </context>
    <context id="From2019-08-032019-08-05_custom_LicenseAgreementTheramexMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:LicenseAgreementTheramexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-03</startDate>
            <endDate>2019-08-05</endDate>
        </period>
    </context>
    <context id="AsOf2019-06-06_custom_LicenseAgreementTheramexMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:LicenseAgreementTheramexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-06</instant>
        </period>
    </context>
    <context id="From2019-06-052019-06-06_custom_LicenseAgreementTheramexMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:LicenseAgreementTheramexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-05</startDate>
            <endDate>2019-06-06</endDate>
        </period>
    </context>
    <context id="From2019-06-052019-06-06_custom_LicenseAgreementTheramexMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:LicenseAgreementTheramexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-05</startDate>
            <endDate>2019-06-06</endDate>
        </period>
    </context>
    <context id="From2019-06-052019-06-06_custom_LicenseAgreementTheramexMember_custom_BijuvaAndAnnoveraMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:BijuvaAndAnnoveraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:LicenseAgreementTheramexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-05</startDate>
            <endDate>2019-06-06</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_PrescriptionVitaminsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:PrescriptionVitaminsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2018-01-012018-12-31_custom_PrescriptionVitaminsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:PrescriptionVitaminsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="From2017-01-012017-12-31_custom_PrescriptionVitaminsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:PrescriptionVitaminsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_ImvexxyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:ImvexxyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2018-01-012018-12-31_custom_ImvexxyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:ImvexxyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_BijuvaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:BijuvaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_AnnoveraMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:AnnoveraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2017-01-012017-12-31_custom_OtcProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:OtcProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2018-01-012018-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="From2017-01-012017-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2018-01-012018-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="From2017-01-012017-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2018-01-012018-12-31_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2019-01-02_us-gaap_AccountingStandardsUpdate201602Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-02</instant>
        </period>
    </context>
    <context id="AsOf2019-08-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <instant>2019-08-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2018-12-31_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_EquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2018-12-31_us-gaap_EquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2018-12-31_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2018-12-31_us-gaap_ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2018-12-31_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ApprovedHormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ApprovedHormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_HormoneTherapyDrugCandidatePatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">txmd:HormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_MultipleTrademarksForVitaminsSupplementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">txmd:MultipleTrademarksForVitaminsSupplementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2018-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="From2018-01-012018-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2018-12-31_us-gaap_InternetDomainNamesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InternetDomainNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="AsOf2018-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ApprovedHormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="From2018-01-012018-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ApprovedHormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2018-12-31_custom_HormoneTherapyDrugCandidatePatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">txmd:HormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="AsOf2018-12-31_custom_MultipleTrademarksForVitaminsSupplementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">txmd:MultipleTrademarksForVitaminsSupplementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_DomesticUSPatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticUSPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_ForeignPatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ForeignPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_DomesticPatentsBijuvaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticPatentsBijuvaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_ForeignPatentsBijuvaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ForeignPatentsBijuvaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_DomesticPatentsNonApprovedBijuvaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticPatentsNonApprovedBijuvaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_DomesticUSPatentsImvexxyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticUSPatentsImvexxyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_DomesticUSUtilityPatentsImvexxyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticUSUtilityPatentsImvexxyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_DomesticUSDesignPatentsImvexxyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticUSDesignPatentsImvexxyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_ForeignPatentsImvexxyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ForeignPatentsImvexxyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_ForeignUtilityPatentsImvexxyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ForeignUtilityPatentsImvexxyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_ForeignDesignPatentsImvexxyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ForeignDesignPatentsImvexxyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_DomesticUSPatentsTopicalCreamMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticUSPatentsTopicalCreamMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_DomesticUtilityPatentTransdermalPatchMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticUtilityPatentTransdermalPatchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_ForeignUtilityPatentTransdermalPatchMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ForeignUtilityPatentTransdermalPatchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_DomesticUtilityPatentTx009HRMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticUtilityPatentTx009HRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_DomesticPatentsProgesteroneFormulationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticPatentsProgesteroneFormulationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_ForeignPatentsProgesteroneFormulationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ForeignPatentsProgesteroneFormulationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_DomesticUtilityPatentOperaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticUtilityPatentOperaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="From2019-07-012019-09-30_custom_AnnoveraMember_custom_CouncilLicenseAgreement1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:AnnoveraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreement1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2019-09-30_custom_AnnoveraMember_custom_CouncilLicenseAgreement1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:AnnoveraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreement1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_AnnoveraMember_custom_CouncilLicenseAgreement1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:AnnoveraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreement1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_CouncilLicenseAgreementStep1Member_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreementStep1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_CouncilLicenseAgreementStep1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreementStep1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_CouncilLicenseAgreementStep2Member_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreementStep2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_CouncilLicenseAgreementStep2Member_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreementStep2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_CouncilLicenseAgreementStep2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreementStep2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_CouncilLicenseAgreementStep3Member_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreementStep3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_CouncilLicenseAgreementStep3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreementStep3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_CouncilLicenseAgreement1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreement1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2019-04-24_us-gaap_RevolvingCreditFacilityMember_custom_FinancingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-24</instant>
        </period>
    </context>
    <context id="From2019-04-232019-04-24_custom_FinancingAgreementMember_custom_TrancheOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="txmd:DebtTrancheAxis">txmd:TrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-23</startDate>
            <endDate>2019-04-24</endDate>
        </period>
    </context>
    <context id="AsOf2019-04-24_custom_FinancingAgreementMember_custom_TrancheTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="txmd:DebtTrancheAxis">txmd:TrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-24</instant>
        </period>
    </context>
    <context id="From2020-02-162020-02-18_custom_FinancingAgreementMember_custom_TrancheThreeMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="txmd:DebtTrancheAxis">txmd:TrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-16</startDate>
            <endDate>2020-02-18</endDate>
        </period>
    </context>
    <context id="From2019-10-012019-12-31_custom_ImvexxyBijuvaAndAnnoveraMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:ImvexxyBijuvaAndAnnoveraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-04-232019-04-24_custom_FinancingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-23</startDate>
            <endDate>2019-04-24</endDate>
        </period>
    </context>
    <context id="AsOf2019-04-24_custom_FinancingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-24</instant>
        </period>
    </context>
    <context id="From2019-04-232019-04-24_custom_FinancingAgreementMember_us-gaap_PrimeRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-23</startDate>
            <endDate>2019-04-24</endDate>
        </period>
    </context>
    <context id="AsOf2019-04-24_custom_FinancingAgreementMember_us-gaap_PrimeRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-24</instant>
        </period>
    </context>
    <context id="AsOf2019-04-24_custom_FinancingAgreementMember_custom_TrancheTwoThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="txmd:DebtTrancheAxis">txmd:TrancheTwoThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-24</instant>
        </period>
    </context>
    <context id="AsOf2018-05-01_us-gaap_SecuredDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-01</instant>
        </period>
    </context>
    <context id="From2018-04-302018-05-01_us-gaap_SecuredDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-30</startDate>
            <endDate>2018-05-01</endDate>
        </period>
    </context>
    <context id="From2018-04-302018-05-01_us-gaap_RevolvingCreditFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-30</startDate>
            <endDate>2018-05-01</endDate>
        </period>
    </context>
    <context id="From2019-04-232019-04-24_custom_MidCapAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:MidCapAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-23</startDate>
            <endDate>2019-04-24</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_MidCapAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:MidCapAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_FinancingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_TrancheOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="txmd:DebtTrancheAxis">txmd:TrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_FinancingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2018-12-31_custom_CreditAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="From2019-10-242019-10-29_custom_UnderwritingAgreementJPMorganChaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:UnderwritingAgreementJPMorganChaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-24</startDate>
            <endDate>2019-10-29</endDate>
        </period>
    </context>
    <context id="AsOf2019-10-29_custom_UnderwritingAgreementJPMorganChaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:UnderwritingAgreementJPMorganChaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-29</instant>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2018-08-012018-08-06_custom_UnderwritingAgreementGoldmanSachsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:UnderwritingAgreementGoldmanSachsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-08-01</startDate>
            <endDate>2018-08-06</endDate>
        </period>
    </context>
    <context id="AsOf2018-08-06_custom_UnderwritingAgreementGoldmanSachsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:UnderwritingAgreementGoldmanSachsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-08-06</instant>
        </period>
    </context>
    <context id="From2018-08-052018-08-06_custom_SubscriptionAgreementKnightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:SubscriptionAgreementKnightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-08-05</startDate>
            <endDate>2018-08-06</endDate>
        </period>
    </context>
    <context id="AsOf2018-08-06_custom_SubscriptionAgreementKnightMember819119062">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:SubscriptionAgreementKnightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-08-06</instant>
        </period>
    </context>
    <context id="From2018-01-012018-12-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="From2017-09-242017-09-25_custom_UnderwritingAgreementJPMorganChaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:UnderwritingAgreementJPMorganChaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-09-24</startDate>
            <endDate>2017-09-25</endDate>
        </period>
    </context>
    <context id="AsOf2017-09-28_custom_UnderwritingAgreementJPMorganChaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:UnderwritingAgreementJPMorganChaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-09-28</instant>
        </period>
    </context>
    <context id="From2017-09-262017-09-28_custom_UnderwritingAgreementJPMorganChaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:UnderwritingAgreementJPMorganChaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-09-26</startDate>
            <endDate>2017-09-28</endDate>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_WarrantsMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_WarrantsMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_OutsideConsultant2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:OutsideConsultant2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_OutsideConsultant2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:OutsideConsultant2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="From2018-01-012018-12-31_custom_OutsideConsultant2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:OutsideConsultant2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2018-12-31_custom_OutsideConsultant2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:OutsideConsultant2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="From2017-01-012017-12-31_custom_OutsideConsultant2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:OutsideConsultant2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2017-12-31_custom_OutsideConsultant2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:OutsideConsultant2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2018-01-012018-12-31_custom_WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="From2017-01-012017-12-31_custom_WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2018-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_WarrantsCashlessExerciseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantsCashlessExerciseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2017-01-012017-12-31_custom_WarrantsCashlessExerciseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantsCashlessExerciseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_LongTermIncentiveCompensationPlan2009Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:LongTermIncentiveCompensationPlan2009Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_NonQualified2012StockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:NonQualified2012StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_NonQualified2012StockIncentivePlanMember_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:NonQualified2012StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_Plan2019Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:Plan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_Plan2019Member_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:Plan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2018-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="AsOf2017-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2018-01-012018-12-31_us-gaap_EmployeeStockOptionMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="From2018-01-012018-12-31_us-gaap_EmployeeStockOptionMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="From2017-01-012017-12-31_us-gaap_EmployeeStockOptionMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="From2017-01-012017-12-31_us-gaap_EmployeeStockOptionMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2019-12-31_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="From2018-12-122018-12-13_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-12</startDate>
            <endDate>2018-12-13</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-07-292019-07-30_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-29</startDate>
            <endDate>2019-07-30</endDate>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_us-gaap_DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2018-01-012018-12-31_us-gaap_DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="From2017-01-012017-12-31_us-gaap_DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_InternalRevenueServiceIRSMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_InternalRevenueServiceIRSMember_custom_ExpirationPeriod20YearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">txmd:ExpirationPeriod20YearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_us-gaap_InternalRevenueServiceIRSMember_custom_ExpirationPeriod20YearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">txmd:ExpirationPeriod20YearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_InternalRevenueServiceIRSMember_custom_ExpirationPeriodIndefiniteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">txmd:ExpirationPeriodIndefiniteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_srt_AffiliatedEntityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2018-01-012018-12-31_srt_AffiliatedEntityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="From2017-01-012017-12-31_srt_AffiliatedEntityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2019-12-31_srt_AffiliatedEntityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2018-12-31_srt_AffiliatedEntityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_us-gaap_SupplierConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_SupplierTwoConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:SupplierTwoConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_SupplierThreeConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:SupplierThreeConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2018-01-012018-12-31_us-gaap_SupplierConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="From2018-01-012018-12-31_custom_SupplierTwoConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:SupplierTwoConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="From2018-01-012018-12-31_custom_SupplierThreeConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:SupplierThreeConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="From2017-01-012017-12-31_us-gaap_SupplierConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2018-01-012018-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="From2017-01-012017-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_us-gaap_SalesRevenueNetMember_custom_FourCustomersConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:FourCustomersConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2018-01-012018-12-31_us-gaap_SalesRevenueNetMember_custom_FourCustomersConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:FourCustomersConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="From2017-01-012017-12-31_us-gaap_SalesRevenueNetMember_custom_FourCustomersConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:FourCustomersConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationMcKessonCorporationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationMcKessonCorporationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationPillPackRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationPillPackRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationAmerisourceBergenRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationAmerisourceBergenRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationCardinalHealthRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationCardinalHealthRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2018-01-012018-12-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationMcKessonCorporationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationMcKessonCorporationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="From2018-01-012018-12-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationPillPackRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationPillPackRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="From2018-01-012018-12-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationAmerisourceBergenRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationAmerisourceBergenRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="From2018-01-012018-12-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationCardinalHealthRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationCardinalHealthRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="From2017-01-012017-12-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationAmerisourceBergenRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationAmerisourceBergenRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="From2017-01-012017-12-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationMcKessonCorporationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationMcKessonCorporationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="From2017-01-012017-12-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationCardinalHealthRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationCardinalHealthRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="From2017-01-012017-12-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationPharmacyInnovationsPaRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationPharmacyInnovationsPaRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="From2013-06-302013-07-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <startDate>2013-06-30</startDate>
            <endDate>2013-07-01</endDate>
        </period>
    </context>
    <context id="AsOf2018-10-02">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <instant>2018-10-02</instant>
        </period>
    </context>
    <context id="AsOf2019-08-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <instant>2019-08-01</instant>
        </period>
    </context>
    <context id="AsOf2019-06-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <instant>2019-06-01</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_CatalentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">txmd:CatalentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_AnnoveraMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">txmd:AnnoveraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="From2019-01-012019-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="From2019-04-012019-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="From2019-07-012019-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2019-10-012019-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2018-01-012018-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="From2018-04-012018-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="From2018-07-012018-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="From2018-10-012018-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="From2019-07-012019-09-30_custom_LicenseAgreementTheramexMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:LicenseAgreementTheramexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2020-02-162020-02-18_custom_FinancingAgreementMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-16</startDate>
            <endDate>2020-02-18</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="EUR">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2019-01-01to2019-12-31">0000025743</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2019-01-01to2019-12-31">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="From2019-01-01to2019-12-31">FY</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="From2019-01-01to2019-12-31">2019</dei:DocumentFiscalYearFocus>
    <dei:CurrentFiscalYearEndDate contextRef="From2019-01-01to2019-12-31">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityFilerCategory contextRef="From2019-01-01to2019-12-31" id="xdx2ixbrl0037">Large Accelerated Filer</dei:EntityFilerCategory>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2018-12-31"
      id="xdx2ixbrl0083"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2018-12-31"
      id="xdx2ixbrl0116"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2019-12-31"
      id="xdx2ixbrl0127"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2018-12-31"
      id="xdx2ixbrl0128"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2018-01-012018-12-31_us-gaap_LicenseAndServiceMember"
      id="xdx2ixbrl0180"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2017-01-012017-12-31_us-gaap_LicenseAndServiceMember"
      id="xdx2ixbrl0181"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2018-01-012018-12-31"
      id="xdx2ixbrl0224"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2017-01-012017-12-31"
      id="xdx2ixbrl0225"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestExpense
      contextRef="From2017-01-012017-12-31"
      id="xdx2ixbrl0233"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="From2019-01-01to2019-12-31"
      id="xdx2ixbrl0235"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="From2018-01-012018-12-31"
      id="xdx2ixbrl0236"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2019-01-01to2019-12-31"
      id="xdx2ixbrl0247"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2018-01-012018-12-31"
      id="xdx2ixbrl0248"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2017-01-012017-12-31"
      id="xdx2ixbrl0249"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2017-01-012017-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0276"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2017-01-012017-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0283"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2017-01-012017-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0290"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2017-01-012017-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0295"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2017-01-012017-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0297"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="AsOf2016-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0300"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="AsOf2016-12-31"
      id="xdx2ixbrl0303"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2017-01-012017-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0305"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2017-01-012017-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0306"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2018-01-012018-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0318"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2018-01-012018-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0324"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2018-01-012018-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0328"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2018-01-012018-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0330"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2018-01-012018-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0333"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2018-01-012018-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0334"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2019-01-012019-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0346"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2019-01-012019-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0352"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2019-01-012019-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0359"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-01-012019-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0362"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-01-012019-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0363"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherNoncashExpense
      contextRef="From2018-01-012018-12-31"
      id="xdx2ixbrl0395"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherNoncashExpense
      contextRef="From2017-01-012017-12-31"
      id="xdx2ixbrl0396"
      unitRef="USD"
      xsi:nil="true"/>
    <txmd:NoncashOperatingLeaseExpense
      contextRef="From2018-01-012018-12-31"
      id="xdx2ixbrl0399"
      unitRef="USD"
      xsi:nil="true"/>
    <txmd:NoncashOperatingLeaseExpense
      contextRef="From2017-01-012017-12-31"
      id="xdx2ixbrl0400"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2018-01-012018-12-31"
      id="xdx2ixbrl0407"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2017-01-012017-12-31"
      id="xdx2ixbrl0408"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherAmortizationOfDeferredCharges
      contextRef="From2018-01-012018-12-31"
      id="xdx2ixbrl0415"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherAmortizationOfDeferredCharges
      contextRef="From2017-01-012017-12-31"
      id="xdx2ixbrl0416"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="From2017-01-012017-12-31"
      id="xdx2ixbrl0420"
      unitRef="USD"
      xsi:nil="true"/>
    <txmd:PaymentsToAcquireIntellectualPropertyLicense
      contextRef="From2017-01-012017-12-31"
      id="xdx2ixbrl0456"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInRestrictedCash
      contextRef="From2017-01-012017-12-31"
      id="xdx2ixbrl0468"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="From2018-01-012018-12-31"
      id="xdx2ixbrl0487"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="From2017-01-012017-12-31"
      id="xdx2ixbrl0488"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt
      contextRef="From2019-01-01to2019-12-31"
      id="xdx2ixbrl0490"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt
      contextRef="From2017-01-012017-12-31"
      id="xdx2ixbrl0492"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="From2017-01-012017-12-31"
      id="xdx2ixbrl0496"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RepaymentsOfOtherLongTermDebt
      contextRef="From2018-01-012018-12-31"
      id="xdx2ixbrl0499"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RepaymentsOfOtherLongTermDebt
      contextRef="From2017-01-012017-12-31"
      id="xdx2ixbrl0500"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestPaidNet
      contextRef="From2017-01-012017-12-31"
      id="xdx2ixbrl0524"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="From2019-01-012019-12-31_us-gaap_LandAndBuildingMember_srt_MinimumMember"
      id="xdx2ixbrl0553">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="From2019-01-012019-12-31_us-gaap_LandAndBuildingMember_srt_MaximumMember"
      id="xdx2ixbrl0554">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="From2019-01-012019-12-31_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_srt_MinimumMember"
      id="xdx2ixbrl0555">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="From2019-01-012019-12-31_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_srt_MaximumMember"
      id="xdx2ixbrl0556">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <txmd:ReturnPeriodOfUnsalablePrescriptionProducts contextRef="From2019-01-012019-12-31_srt_MinimumMember">P6M</txmd:ReturnPeriodOfUnsalablePrescriptionProducts>
    <txmd:PrepaidManufacturing
      contextRef="AsOf2018-12-31"
      id="xdx2ixbrl0684"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AccruedRentCurrent
      contextRef="AsOf2019-12-31"
      id="xdx2ixbrl0846"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2018-12-31"
      id="xdx2ixbrl0850"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2019-01-01to2019-12-31"
      decimals="0"
      id="xdx2ixbrl0904"
      unitRef="USD">-10057632</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="From2017-01-012017-12-31"
      id="xdx2ixbrl1220"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="From2018-01-012018-12-31"
      id="xdx2ixbrl1223"
      unitRef="Pure"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2019-01-01to2019-12-31">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="From2019-01-01to2019-12-31">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="From2019-01-01to2019-12-31">2019-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="From2019-01-01to2019-12-31">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2019-01-01to2019-12-31">001-00100</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2019-01-01to2019-12-31">TherapeuticsMD, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2019-01-01to2019-12-31">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2019-01-01to2019-12-31">87-0233535</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2019-01-01to2019-12-31">951 Yamato Rd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2019-01-01to2019-12-31">Suite 220</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2019-01-01to2019-12-31">Boca Raton</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2019-01-01to2019-12-31">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2019-01-01to2019-12-31">33431</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2019-01-01to2019-12-31">(561)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2019-01-01to2019-12-31">961-1900</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2019-01-01to2019-12-31">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2019-01-01to2019-12-31">TXMD</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2019-01-01to2019-12-31">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2019-01-01to2019-12-31">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2019-01-01to2019-12-31">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2019-01-01to2019-12-31">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2019-01-01to2019-12-31">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntitySmallBusiness contextRef="From2019-01-01to2019-12-31">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2019-01-01to2019-12-31">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="From2019-01-01to2019-12-31">false</dei:EntityShellCompany>
    <txmd:EntityCommonStockHeldByNonaffiliates contextRef="AsOf2019-06-28" decimals="INF" unitRef="Shares">207399071</txmd:EntityCommonStockHeldByNonaffiliates>
    <dei:EntityPublicFloat contextRef="AsOf2019-06-28" decimals="0" unitRef="USD">539237585</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2020-02-17" decimals="INF" unitRef="Shares">271526176</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:Cash contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">160829713</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">161613077</us-gaap:Cash>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">904040</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">596602</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">24395958</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">11063821</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">11860716</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">3267670</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">11329793</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">10834693</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">208416180</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">186779261</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">2507775</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">472683</us-gaap:PropertyPlantAndEquipmentNet>
    <txmd:LicenseRights contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">39221308</txmd:LicenseRights>
    <txmd:LicenseRights contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">20000000</txmd:LicenseRights>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">5258211</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">4092679</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">10109154</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsMiscellaneousNoncurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">473009</us-gaap:OtherAssetsMiscellaneousNoncurrent>
    <us-gaap:OtherAssetsMiscellaneousNoncurrent contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">639301</us-gaap:OtherAssetsMiscellaneousNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">55061682</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">24731980</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">265985637</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">211983924</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">19181212</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">22743841</us-gaap:AccountsPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">33823613</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">18334948</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">53004825</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">41078789</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">194634643</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">73381014</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">9145049</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">256784517</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">114459803</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2019-12-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2018-12-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2019-12-31" decimals="INF" unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2018-12-31" decimals="INF" unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2019-12-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2018-12-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2019-12-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2018-12-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2019-12-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2018-12-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2019-12-31" decimals="INF" unitRef="Shares">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2018-12-31" decimals="INF" unitRef="Shares">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2019-12-31" decimals="INF" unitRef="Shares">271177076</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2019-12-31" decimals="INF" unitRef="Shares">271177076</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2018-12-31" decimals="INF" unitRef="Shares">240462439</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2018-12-31" decimals="INF" unitRef="Shares">240462439</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">271177</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">240463</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">704351222</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">616559938</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">-695421279</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">-519276280</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">9201120</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">97524121</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">265985637</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">211983924</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2019-01-012019-12-31_us-gaap_ProductMember"
      decimals="0"
      unitRef="USD">34140537</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2018-01-012018-12-31_us-gaap_ProductMember"
      decimals="0"
      unitRef="USD">16099460</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2017-01-012017-12-31_us-gaap_ProductMember"
      decimals="0"
      unitRef="USD">16777713</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2019-01-012019-12-31_us-gaap_LicenseAndServiceMember"
      decimals="0"
      unitRef="USD">15506400</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2019-01-01to2019-12-31"
      decimals="0"
      unitRef="USD">49646937</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">16099460</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2017-01-012017-12-31"
      decimals="0"
      unitRef="USD">16777713</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2019-01-01to2019-12-31"
      decimals="0"
      unitRef="USD">6334585</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">2737652</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2017-01-012017-12-31"
      decimals="0"
      unitRef="USD">2636943</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="From2019-01-01to2019-12-31"
      decimals="0"
      unitRef="USD">43312352</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">13361808</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2017-01-012017-12-31"
      decimals="0"
      unitRef="USD">14140770</us-gaap:GrossProfit>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2019-01-01to2019-12-31"
      decimals="0"
      unitRef="USD">174112612</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">115988954</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2017-01-012017-12-31"
      decimals="0"
      unitRef="USD">57703370</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2019-01-01to2019-12-31"
      decimals="0"
      unitRef="USD">19792212</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">27299138</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2017-01-012017-12-31"
      decimals="0"
      unitRef="USD">33852993</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2019-01-01to2019-12-31"
      decimals="0"
      unitRef="USD">612786</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">293886</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2017-01-012017-12-31"
      decimals="0"
      unitRef="USD">213117</us-gaap:DepreciationAndAmortization>
    <us-gaap:OperatingExpenses
      contextRef="From2019-01-01to2019-12-31"
      decimals="0"
      unitRef="USD">194517610</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">143581978</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2017-01-012017-12-31"
      decimals="0"
      unitRef="USD">91769480</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2019-01-01to2019-12-31"
      decimals="0"
      unitRef="USD">-151205258</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">-130220170</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2017-01-012017-12-31"
      decimals="0"
      unitRef="USD">-77628710</us-gaap:OperatingIncomeLoss>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2019-01-01to2019-12-31"
      decimals="0"
      unitRef="USD">-10057632</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:OtherNonoperatingIncome
      contextRef="From2019-01-01to2019-12-31"
      decimals="0"
      unitRef="USD">2500106</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">2280844</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="From2017-01-012017-12-31"
      decimals="0"
      unitRef="USD">695631</us-gaap:OtherNonoperatingIncome>
    <us-gaap:InterestExpense
      contextRef="From2019-01-01to2019-12-31"
      decimals="0"
      unitRef="USD">17382215</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">4677834</us-gaap:InterestExpense>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="From2017-01-012017-12-31"
      decimals="0"
      unitRef="USD">7699</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2019-01-01to2019-12-31"
      decimals="0"
      unitRef="USD">-24939741</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">-2396990</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2017-01-012017-12-31"
      decimals="0"
      unitRef="USD">703330</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2019-01-01to2019-12-31"
      decimals="0"
      unitRef="USD">-176144999</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">-132617160</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2017-01-012017-12-31"
      decimals="0"
      unitRef="USD">-76925380</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-01-01to2019-12-31"
      decimals="0"
      unitRef="USD">-176144999</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">-132617160</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2017-01-012017-12-31"
      decimals="0"
      unitRef="USD">-76925380</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="From2019-01-01to2019-12-31"
      decimals="INF"
      unitRef="USDPShares">-0.72</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="From2018-01-012018-12-31"
      decimals="INF"
      unitRef="USDPShares">-0.59</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="From2017-01-012017-12-31"
      decimals="INF"
      unitRef="USDPShares">-0.37</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="From2019-01-01to2019-12-31"
      decimals="INF"
      unitRef="Shares">246353318</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="From2018-01-012018-12-31"
      decimals="INF"
      unitRef="Shares">225026300</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="From2017-01-012017-12-31"
      decimals="INF"
      unitRef="Shares">205523288</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2016-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">196688222</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2016-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">196688</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2016-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">436995052</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2016-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-309702319</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2016-12-31" decimals="0" unitRef="USD">127489421</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2017-01-012017-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">12400000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2017-01-012017-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">12400</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2017-01-012017-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">68560235</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2017-01-012017-12-31"
      decimals="0"
      unitRef="USD">68572635</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2017-01-012017-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">102546</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2017-01-012017-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">103</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2017-01-012017-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">212512</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2017-01-012017-12-31"
      decimals="0"
      unitRef="USD">212615</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2017-01-012017-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">7238874</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2017-01-012017-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">7239</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2017-01-012017-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">3791760</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2017-01-012017-12-31"
      decimals="0"
      unitRef="USD">3798999</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2017-01-012017-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">6760425</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2017-01-012017-12-31"
      decimals="0"
      unitRef="USD">6760425</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="AsOf2016-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">31421</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="AsOf2016-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-31421</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:NetIncomeLoss
      contextRef="From2017-01-012017-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-76925380</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2017-01-012017-12-31"
      decimals="0"
      unitRef="USD">-76925380</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2017-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">216429642</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2017-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">216430</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2017-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">516351405</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2017-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-386659120</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2017-12-31" decimals="0" unitRef="USD">129908715</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2018-01-012018-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">18578430</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2018-01-012018-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">18578</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2018-01-012018-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">89889219</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">89907797</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2018-01-012018-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">5454367</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2018-01-012018-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">5455</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2018-01-012018-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">1660753</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">1666208</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2018-01-012018-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">8658561</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">8658561</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2018-01-012018-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-132617160</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">-132617160</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2018-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">240462439</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2018-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">240463</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2018-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">616559938</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2018-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-519276280</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">97524121</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2019-01-012019-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">29900000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2019-01-012019-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">29900</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2019-01-012019-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">77001358</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2019-01-01to2019-12-31"
      decimals="0"
      unitRef="USD">77031258</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="From2019-01-012019-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">814637</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2019-01-012019-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">814</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2019-01-012019-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">107842</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2019-01-01to2019-12-31"
      decimals="0"
      unitRef="USD">108656</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2019-01-012019-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">10682084</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2019-01-01to2019-12-31"
      decimals="0"
      unitRef="USD">10682084</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-01-012019-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-176144999</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-01-01to2019-12-31"
      decimals="0"
      unitRef="USD">-176144999</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2019-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">271177076</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">271177</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">704351222</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-695421279</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">9201120</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-01-01to2019-12-31"
      decimals="0"
      unitRef="USD">-176144999</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">-132617160</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2017-01-012017-12-31"
      decimals="0"
      unitRef="USD">-76925380</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="From2019-01-01to2019-12-31"
      decimals="0"
      unitRef="USD">415193</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">181412</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2017-01-012017-12-31"
      decimals="0"
      unitRef="USD">141601</us-gaap:Depreciation>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2019-01-01to2019-12-31"
      decimals="0"
      unitRef="USD">197593</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">112474</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2017-01-012017-12-31"
      decimals="0"
      unitRef="USD">71516</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:OtherNoncashExpense
      contextRef="From2019-01-01to2019-12-31"
      decimals="0"
      unitRef="USD">78864</us-gaap:OtherNoncashExpense>
    <txmd:NoncashOperatingLeaseExpense
      contextRef="From2019-01-01to2019-12-31"
      decimals="0"
      unitRef="USD">1062318</txmd:NoncashOperatingLeaseExpense>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="From2019-01-01to2019-12-31"
      decimals="0"
      unitRef="USD">307438</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">216022</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="From2017-01-012017-12-31"
      decimals="0"
      unitRef="USD">4206</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2019-01-01to2019-12-31"
      decimals="0"
      unitRef="USD">-10057632</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ShareBasedCompensation
      contextRef="From2019-01-01to2019-12-31"
      decimals="0"
      unitRef="USD">10693662</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">8661967</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2017-01-012017-12-31"
      decimals="0"
      unitRef="USD">6889323</us-gaap:ShareBasedCompensation>
    <us-gaap:OtherAmortizationOfDeferredCharges
      contextRef="From2019-01-01to2019-12-31"
      decimals="0"
      unitRef="USD">778692</us-gaap:OtherAmortizationOfDeferredCharges>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="From2019-01-01to2019-12-31"
      decimals="0"
      unitRef="USD">856302</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">269859</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2019-01-01to2019-12-31"
      decimals="0"
      unitRef="USD">13639575</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">6951041</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2017-01-012017-12-31"
      decimals="0"
      unitRef="USD">-167691</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2019-01-01to2019-12-31"
      decimals="0"
      unitRef="USD">8593046</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">1782312</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2017-01-012017-12-31"
      decimals="0"
      unitRef="USD">409037</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="From2019-01-01to2019-12-31"
      decimals="0"
      unitRef="USD">1880048</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">2657190</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="From2017-01-012017-12-31"
      decimals="0"
      unitRef="USD">4434130</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2019-01-01to2019-12-31"
      decimals="0"
      unitRef="USD">-3562629</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">18646241</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2017-01-012017-12-31"
      decimals="0"
      unitRef="USD">-3260914</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="From2019-01-01to2019-12-31"
      decimals="0"
      unitRef="USD">13675008</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">9107947</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="From2017-01-012017-12-31"
      decimals="0"
      unitRef="USD">1599510</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2019-01-01to2019-12-31"
      decimals="0"
      unitRef="USD">-165697595</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">-106811781</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2017-01-012017-12-31"
      decimals="0"
      unitRef="USD">-76155614</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <txmd:PaymentsToAcquireIntellectualPropertyLicense
      contextRef="From2019-01-01to2019-12-31"
      decimals="0"
      unitRef="USD">20000000</txmd:PaymentsToAcquireIntellectualPropertyLicense>
    <txmd:PaymentsToAcquireIntellectualPropertyLicense
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">20000000</txmd:PaymentsToAcquireIntellectualPropertyLicense>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2019-01-01to2019-12-31"
      decimals="0"
      unitRef="USD">1441989</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">1105407</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2017-01-012017-12-31"
      decimals="0"
      unitRef="USD">765291</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2019-01-01to2019-12-31"
      decimals="0"
      unitRef="USD">2450285</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">217040</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2017-01-012017-12-31"
      decimals="0"
      unitRef="USD">61817</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:IncreaseDecreaseInRestrictedCash
      contextRef="From2019-01-01to2019-12-31"
      decimals="0"
      unitRef="USD">20420</us-gaap:IncreaseDecreaseInRestrictedCash>
    <us-gaap:IncreaseDecreaseInRestrictedCash
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">175410</us-gaap:IncreaseDecreaseInRestrictedCash>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2019-01-01to2019-12-31"
      decimals="0"
      unitRef="USD">-23912694</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">-21497857</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2017-01-012017-12-31"
      decimals="0"
      unitRef="USD">-827108</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2019-01-01to2019-12-31"
      decimals="0"
      unitRef="USD">108656</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">1666208</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2017-01-012017-12-31"
      decimals="0"
      unitRef="USD">4011614</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2019-01-01to2019-12-31"
      decimals="0"
      unitRef="USD">77031258</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">89907797</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2017-01-012017-12-31"
      decimals="0"
      unitRef="USD">68572635</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="From2019-01-01to2019-12-31"
      decimals="0"
      unitRef="USD">200000000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">75000000</us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="From2019-01-01to2019-12-31"
      decimals="0"
      unitRef="USD">6652270</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">3786918</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:RepaymentsOfOtherLongTermDebt
      contextRef="From2019-01-01to2019-12-31"
      decimals="0"
      unitRef="USD">81660719</us-gaap:RepaymentsOfOtherLongTermDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2019-01-01to2019-12-31"
      decimals="0"
      unitRef="USD">188826925</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">162787087</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2017-01-012017-12-31"
      decimals="0"
      unitRef="USD">72584249</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2019-01-01to2019-12-31"
      decimals="0"
      unitRef="USD">-783364</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">34477449</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2017-01-012017-12-31"
      decimals="0"
      unitRef="USD">-4398473</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">161613077</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2017-12-31" decimals="0" unitRef="USD">127135628</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2016-12-31" decimals="0" unitRef="USD">131534101</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">160829713</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">161613077</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2017-12-31" decimals="0" unitRef="USD">127135628</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="From2019-01-01to2019-12-31"
      decimals="0"
      unitRef="USD">17787903</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">1890166</us-gaap:InterestPaidNet>
    <us-gaap:NatureOfOperations contextRef="From2019-01-01to2019-12-31">&lt;p id="xdx_80D_eus-gaap--NatureOfOperations_z13SIeAOJBxd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;b&gt;NOTE 1 &#x2013; &lt;span id="xdx_822_zBs3fazlAubl"&gt;THE COMPANY&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;TherapeuticsMD,
Inc., a Nevada corporation, or TherapeuticsMD or the Company, has &lt;span id="xdx_900_ecustom--NumberOfSubsidiaries_iI_dc_uPure_c20191231_zj683O4X4lTg" title="Number of subsidiaires"&gt;three&lt;/span&gt; wholly owned subsidiaries, vitaMedMD, LLC, a Delaware
limited liability company, or VitaMed; BocaGreenMD, Inc., a Nevada corporation, or BocaGreen; and VitaCare Prescription Services,
Inc., a Florida corporation, or VitaCare. Unless the context otherwise requires, TherapeuticsMD, VitaMed, BocaGreen, and VitaCare
collectively are sometimes referred to as &#x201c;our company,&#x201d; &#x201c;we,&#x201d; &#x201c;our,&#x201d; or &#x201c;us.&#x201d;
TherapeuticsMD &#xae;, vitaMedMD &#xae;, BocaGreenMD &#xae;, IMVEXXY &#xae; and BIJUVA &#xae; are registered trademarks of our
company and ANNOVERA&#x2122; is a licensed trademark of our company. &lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: black"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span style="color: black"&gt;Nature of Business&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;We are a women&#x2019;s healthcare company with a mission of creating and commercializing innovative products to support the lifespan of women from pregnancy prevention through menopause. At TherapeuticsMD, we combine entrepreneurial spirit, clinical expertise, and business leadership to develop and commercialize health solutions that enable new standards of care for women. Our solutions range from a patient-controlled, long-lasting contraceptive to advanced hormone therapy pharmaceutical products. We also manufacture and distribute branded and generic prescription prenatal vitamins under the vitaMedMD and BocaGreenMD brands. Our portfolio of products focused on women&#x2019;s health allows us to efficiently leverage our sales and marketing plan to grow our recently approved products. During 2018, the U.S. Food and Drug Administration, or FDA, approval of our pharmaceutical products has transitioned our company from predominately focused on conducting research and development to one focused on commercializing our pharmaceutical products. In July 2018, we launched our FDA-approved product, IMVEXXY (estradiol vaginal inserts) for the treatment of moderate-to-severe dyspareunia (vaginal pain associated with sexual activity), a symptom of vulvar and vaginal atrophy, or VVA, due to menopause. In April 2019, we launched our FDA-approved product BIJUVA (estradiol and progesterone) capsules&lt;span style="text-align: justify"&gt;, our hormone therapy combination of bio-identical 17&#xdf;-estradiol and bio-identical progesterone in a single, oral softgel capsule, for the treatment of moderate-to-severe vasomotor symptoms, or VMS, due to menopause in women with a uterus. In October 2019, we began a test and learn market introduction for our FDA-approved product ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system), the first and only patient-controlled, procedure-free, reversible prescription contraceptive option for women. We expect the full commercial launch of ANNOVERA in the first quarter of 2020. On July 30, 2018, we entered into an exclusive license agreement, or the Population Council License Agreement, with the Population Council, Inc., or the Population Council, to commercialize ANNOVERA in the U.S. In addition, on July 30, 2018, we entered into a license and supply agreement&lt;/span&gt;&lt;span style="color: #212529"&gt;, or the Knight License Agreement,&lt;/span&gt; with Knight Therapeutics Inc., or Knight, pursuant to which we granted Knight an exclusive license to commercialize IMVEXXY and BIJUVA in Canada and Israel. On June 6, 2019, we entered into an exclusive license and supply agreement, or the Theramex License Agreement, with Theramex HQ UK Limited, or Theramex, to commercialize BIJUVA and IMVEXXY outside of the U.S., excluding Canada and Israel, or the Theramex Territory. &lt;/span&gt;&lt;/p&gt;
</us-gaap:NatureOfOperations>
    <txmd:NumberOfSubsidiaries contextRef="AsOf2019-12-31" decimals="INF" unitRef="Pure">3</txmd:NumberOfSubsidiaries>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2019-01-01to2019-12-31">&lt;p id="xdx_808_eus-gaap--SignificantAccountingPoliciesTextBlock_zO2vOpZycVy9" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;b&gt;NOTE 2 &#x2013; &lt;span id="xdx_827_zZNBdZzlNhJd"&gt;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p id="xdx_840_eus-gaap--ConsolidationPolicyTextBlock_z9mbbq84TDpk" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="text-decoration: underline"&gt;Principles of Consolidation&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;The accompanying consolidated financial statements include the accounts of our company and our wholly owned subsidiaries, VitaMed, BocaGreen and VitaCare. All intercompany balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p id="xdx_84E_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zPuRMhgGn9n9" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: black"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span style="color: black"&gt;Cash&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;We maintain cash at financial institutions that at times may exceed the Federal Deposit Insurance Corporation, or the FDIC, insured limits of $&lt;span id="xdx_907_eus-gaap--CashFDICInsuredAmount_iI_c20191231_zArZMLyhjRi2" title="Federal insurance limits"&gt;250,000&lt;/span&gt; per bank. We have never experienced any losses related to these funds.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p id="xdx_842_eus-gaap--ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_z4vfyE0pmWgg" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: black"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span style="color: black"&gt;Trade Accounts Receivable and Allowance for Doubtful Accounts&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;Trade accounts receivable are customer obligations due under normal trade terms. We review accounts receivable for uncollectible accounts and credit card chargebacks and provide an allowance for doubtful accounts, which is based upon a review of outstanding receivables, historical collection information, and existing economic conditions. We evaluate trade accounts receivable aged more than 90 days for delinquency. We write off delinquent receivables against our allowance for doubtful accounts based on individual credit evaluations, the results of collection efforts, and specific circumstances of customers. We record recoveries of accounts previously written off when received as an increase in the allowance for doubtful accounts. To the extent data we use to calculate these estimates does not accurately reflect bad debts, adjustments to these reserves may be required. At December 31, 2019, four different customers represented &lt;span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_dp_c20190101__20191231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerAMember_zKF3b71cwfz1" title="Concentration risk"&gt;36&lt;/span&gt;%, &lt;span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_dp_c20190101__20191231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerBMember_zmEFfWdMZjDg"&gt;21&lt;/span&gt;%, &lt;span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_dp_c20190101__20191231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerCMember_zntJnZicuVGl"&gt;16&lt;/span&gt;% and &lt;span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_dp_c20190101__20191231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerDMember_zO8dfd3KrK6h"&gt;11&lt;/span&gt;% of our gross accounts receivable. At December 31, 2018, three different customers represented &lt;span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_dp_c20180101__20181231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerAMember_zupQyt5giKMl"&gt;42&lt;/span&gt;%, &lt;span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20180101__20181231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerBMember_zpzmvrRmdsO9"&gt;24&lt;/span&gt;% and &lt;span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_c20180101__20181231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerCMember_zyUQ7PV5Sc6d"&gt;13&lt;/span&gt;% of our gross accounts receivable.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;



&lt;p id="xdx_841_eus-gaap--InventoryPolicyTextBlock_zJMMUrzk2Is1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: black"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span style="color: black"&gt;Inventories&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;Inventories represent pharmaceutical products, packaged vitamins and raw materials which are valued at the lower of cost or net realizable value. Our pharmaceutical products are valued using first in first out method and our vitamins are valued using the average-cost method. We review our inventory for excess or obsolete inventory and write-down obsolete or otherwise unmarketable inventory to its estimated net realizable value. Obsolescence may occur due to product expiring or product improvements rendering previous versions obsolete.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span style="color: black"&gt;&lt;i&gt;Pre-Launch Inventory&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;Pre-launch
inventory costs associated with product candidates that have not yet received regulatory approval are capitalized if we
believe there is probable future commercial use and future economic benefit. If the probability of future commercial use and
future economic benefit cannot be reasonably determined, then pre-launch inventory costs associated with such product
candidates are expensed as research and development expenses during the period the costs are incurred. We have not
capitalized any pre-launch inventory to date.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p id="xdx_840_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zVTVNsWARLG6" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: black"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span style="color: black"&gt;Fixed Assets&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;We state fixed assets at cost, net of accumulated depreciation. We charge maintenance costs, which do not significantly extend the useful lives of the respective assets, and repair costs to operating expenses as incurred. We compute depreciation using the straight-line method over the estimated useful lives of the related assets, which range from &lt;span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dxL_c20190101__20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LandAndBuildingMember__srt--RangeAxis__srt--MinimumMember_zJS38w4WoxI7" title="Useful life of assets::XDX::P3Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0553"&gt;three&lt;/span&gt;&lt;/span&gt; to &lt;span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dxL_c20190101__20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LandAndBuildingMember__srt--RangeAxis__srt--MaximumMember_zlggfZdrMU98" title="::XDX::P7Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0554"&gt;seven&lt;/span&gt;&lt;/span&gt; years. Leasehold improvements are depreciated over the shorter of their useful life or the term of the lease.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;We capitalize software and software development costs incurred to create and acquire computer software for internal use, principally related to software coding and application development. We begin to capitalize software development costs when both the preliminary project stage is completed and it is probable that the software will be used as intended. Capitalized software costs include only external direct costs and services utilized in developing or obtaining computer software. Capitalized software costs are amortized on a straight-line basis when placed into service over the estimated useful life, generally &lt;span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dxL_c20190101__20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember__srt--RangeAxis__srt--MinimumMember_zld1rcASVmyj" title="::XDX::P5Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0555"&gt;five&lt;/span&gt;&lt;/span&gt; to &lt;span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dxL_c20190101__20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember__srt--RangeAxis__srt--MaximumMember_zbWzKwyxIev5" title="::XDX::P7Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0556"&gt;seven&lt;/span&gt;&lt;/span&gt; years.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p id="xdx_840_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zkbInhjBzxL3" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: black"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span style="color: black"&gt;Intangible Assets&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;We have adopted the provisions of Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, 350, &lt;i&gt;&lt;span style="color: black"&gt;Intangibles - Goodwill and Other&lt;/span&gt;&lt;/i&gt;, or ASC 350. Capitalized patent costs, net of accumulated amortization, include outside legal costs incurred for patent applications. In accordance with ASC 350, once a patent is granted, we amortize the capitalized patent costs over the remaining life of the patent using the straight-line method. If the patent is not granted, we write-off any capitalized patent costs at that time. As of December 31, 2019, we had &lt;span id="xdx_904_ecustom--NumberOfIssuedPatentsDomestic_iI_uPure_c20191231_zN9Aevq2rkUe" title="Number of issued patents domestic."&gt;29&lt;/span&gt; issued domestic, or U.S., patents and &lt;span id="xdx_907_ecustom--NumberOfIssuedPatentsForeign_iI_uPure_c20191231_zxTQdtMts3r5" title="Number of issued patents foreign"&gt;30&lt;/span&gt; issued foreign patents (See Note 6). We capitalize external costs, consisting primarily of legal costs, related to securing our trademarks. Trademarks are perpetual and are not amortized. We review intangible assets for impairment annually or when events or circumstances indicate that their carrying amount may not be recoverable.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p id="xdx_84C_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zX0rxQcb4Caj" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="text-decoration: underline"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;We review the carrying values of fixed assets and long-lived intangible assets to be held and used for impairment whenever events or changes in circumstances indicate that their carrying values may not be recoverable. Such events or circumstances may include, among others, the following:&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; width: 100%"&gt;

&lt;tr&gt;
&lt;td style="vertical-align: top; width: 18pt"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: top; width: 18pt"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&#x25cf;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;significant declines in an asset&#x2019;s market price;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; width: 100%"&gt;

&lt;tr&gt;
&lt;td style="vertical-align: top; width: 18pt"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: top; width: 18pt"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&#x25cf;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;significant deterioration in an asset&#x2019;s physical condition;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; width: 100%"&gt;

&lt;tr&gt;
&lt;td style="vertical-align: top; width: 18pt"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: top; width: 18pt"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&#x25cf;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;significant changes in the nature or extent of an asset&#x2019;s use or operation;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; width: 100%"&gt;

&lt;tr&gt;
&lt;td style="vertical-align: top; width: 18pt"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: top; width: 18pt"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&#x25cf;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;significant adverse changes in the business climate that could impact an asset&#x2019;s value, including adverse actions or assessments by regulators;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; width: 100%"&gt;

&lt;tr&gt;
&lt;td style="vertical-align: top; width: 18pt"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: top; width: 18pt"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&#x25cf;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;accumulation of costs significantly in excess of original expectations related to the acquisition or construction of an asset;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; width: 100%"&gt;

&lt;tr&gt;
&lt;td style="vertical-align: top; width: 18pt"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: top; width: 18pt"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&#x25cf;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;current-period operating or cash flow losses combined with a history of such losses or a forecast that demonstrates continuing losses associated with an asset&#x2019;s use; and&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; width: 100%"&gt;

&lt;tr&gt;
&lt;td style="vertical-align: top; width: 18pt"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: top; width: 18pt"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&#x25cf;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;expectations that it is more likely than not that an asset will be sold or otherwise disposed of significantly before the end of its previously estimated useful life.&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;If impairment indicators are present, we determine whether an impairment loss should be recognized by testing the applicable asset or asset group&#x2019;s carrying value for recoverability. This test requires long-lived assets to be grouped at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities, the determination of which requires judgment. We estimate the undiscounted future cash flows expected to be generated from the use and eventual disposal of the assets and compare that estimate to the respective carrying values in order to determine if such carrying values are recoverable. This assessment requires the exercise of judgment in assessing the future use of and projected value to be derived from the eventual disposal of the assets to be held and used. In our assessments, we also consider changes in asset utilization, including, if applicable, the temporary idling of capacity and the expected timing for placing this capacity back into production. If the carrying value of the assets is not recoverable, then we record a loss for the difference between the assets&#x2019; fair value and respective carrying values. We determine the fair value of the assets using an &#x201c;income approach&#x201d; based upon a forecast of all the expected discounted future net cash flows associated with the subject assets. Some of the more significant estimates and assumptions include market size and growth, market share, projected selling prices, manufacturing cost, and discount rate. We base estimates upon historical experience, our commercial relationships, market conditions, and available external information about future trends. We believe our current assumptions and estimates are reasonable and appropriate. Unanticipated events and changes in market conditions, however, could affect such estimates, resulting in the need for an impairment charge in future periods. There was no impairment of long-lived assets to be held and used during the years ended December 31, 2019, 2018, and 2017.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;We perform impairment tests for intangible assets with indefinite useful lives annually, in the fourth quarter, or more frequently if events occur or circumstances change that would more likely than not reduce the fair value of an intangible asset below its carrying value. The impairment test for assets with indefinite lives consists of a comparison of the fair value of the asset with its carrying amount. If the carrying amount of an intangible asset exceeds its fair value, an impairment loss is recognized in an amount equal to that excess. &lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: #212529"&gt;We also evaluate the remaining useful life of intangible assets subject to amortization on a periodic basis to determine whether events and circumstances would indicate impairment or warrant a revision to the remaining useful life. If the estimate of an intangible asset&#x2019;s remaining useful life is changed, we will amortize the remaining carrying value of the intangible asset prospectively over the revised remaining useful life.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p id="xdx_843_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zcmWXNTLtxO5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: black"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span style="color: black"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;Our financial instruments consist primarily of cash, accounts receivable, accounts payable, accrued expenses and long term debt. The carrying amount of cash, accounts receivable, accounts payable and accrued expenses approximates their fair value because of the short-term maturity of such instruments, which are considered Level 1 assets under the fair value hierarchy.&#160; T&lt;span style="color: #212529"&gt;he carrying amount for long-term debt as of December 31, 2019 and 2018 (as disclosed in Note 8), approximates fair value based on market activity for other debt instruments with similar characteristics and comparable risk (Level 2).&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;We
categorize our assets and liabilities that are valued at fair value on a recurring basis into a three-level fair value
hierarchy as defined by ASC 820, &lt;i&gt;&lt;span style="color: black"&gt;Fair Value Measurements&lt;/span&gt;&lt;/i&gt;, or ASC 820. The fair value
hierarchy gives the highest priority to quoted prices in active markets for identical assets and liabilities (Level 1) and
lowest priority to unobservable inputs (Level 3). Assets and liabilities recorded in the consolidated balance sheet at fair
value are categorized based on a hierarchy of inputs, as follows: &lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;
&lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 4%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify; width: 6%"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: justify; width: 90%"&gt;unadjusted quoted prices in active markets for identical assets or liabilities;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;quoted prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument; and&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;unobservable inputs for the assets or liabilities.&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;At December 31, 2019 and 2018, we had no assets or liabilities that were valued at fair value on a recurring basis.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;The fair value of indefinite-lived assets is measured on a non-recurring basis using significant unobservable inputs (Level 3) in connection with any required impairment test. During the year ended December 31, 2019, we wrote off $78,864 in costs related to trademarks and patents, including the net carrying amount of our OPERA software patent. There was no impairment of intangible assets during the years ended December 31, 2018, and 2017.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p id="xdx_845_eus-gaap--IncomeTaxPolicyTextBlock_zXcE6tElWSuf" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="text-decoration: underline"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;We account for income taxes under the asset and liability method. We recognize deferred tax assets and liabilities for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. We measure deferred tax assets and liabilities using enacted tax rates expected to apply to taxable income in the years in which the related temporary differences are expected to be recovered or settled. We recognize the effect on deferred tax assets and liabilities of a change in tax rates when the rate change is enacted. Valuation allowances are recorded to reduce deferred tax assets to the amount that will more likely than not be realized.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;In accordance with ASC 740, &lt;i&gt;&lt;span style="color: black"&gt;Income Taxes&lt;/span&gt;&lt;/i&gt;, we recognize the effect of uncertain income tax positions only if the positions are more likely than not of being sustained in an audit, based on the technical merits of the position. We measure recognized uncertain income tax positions using the largest amount that has a likelihood of being realized that is greater than 50%. Changes in recognition or measurement are reflected in the period in which those changes in judgment occur.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;We recognize both interest and penalties related to uncertain tax positions as part of the income tax provision. At December 31, 2019 and 2018, we had no tax positions relating to open tax returns that were considered to be uncertain.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;Our U.S. federal and state tax returns since 2011, which was the first year we generated net operating losses, remain open to examination.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p id="xdx_84D_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zZ67QJ5XmZpg" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="text-decoration: underline"&gt;Share-Based Compensation&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;We measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees are required to provide services. Share-based compensation arrangements include options, restricted stock, restricted stock units, performance-based awards, share appreciation rights, and employee share purchase plans. We amortize such compensation amounts, if any, over the respective service periods of the award. We use the Black-Scholes-Merton option pricing model, or the Black-Scholes Model, an acceptable model in accordance with ASC 718, Compensation-Stock Compensation, to value options. Option valuation models require the input of assumptions, including the expected life of the stock-based awards, the estimated stock price volatility, the risk-free interest rate, and the expected dividend yield. The risk-free interest rate assumption is based upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the term of the instrument. Estimated volatility is a measure of the amount by which our stock price is expected to fluctuate each year during the term of the award. On January 1, 2017, we began using our own stock price in our volatility calculation along with the other peer entities whose stock prices were publicly available that were similar to our company and in 2019 we started using only our own stock price in the volatility calculation. Our calculation of estimated volatility is based on historical stock prices over a period equal to the expected term of the awards. The average expected life of options is based on the contractual terms of the stock option using the simplified method. We utilize a dividend yield of zero based on the fact that we have never paid cash dividends and have no current intention to pay cash dividends. Calculating share-based compensation expense requires the input of highly subjective judgment and assumptions, estimates of expected life of the share-based award, stock price volatility and risk-free interest rates. The assumptions used in calculating the fair value of share-based awards represent our best estimates, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change and we use different assumptions, our share-based compensation expense could be materially different in the future. We recognize the compensation expense for share-based compensation granted based on the grant date fair value estimated in accordance with ASC 718. We generally recognize the compensation expense on a straight-line basis over the employee&#x2019;s requisite service period. Effective January 1, 2017, we account for forfeitures when they occur. On January 1, 2019, we adopted ASU 2018-07 which simplified the accounting for share-based payments to non-employees by aligning it with the accounting for share-based payments to employees, with certain exceptions. The new guidance expanded the scope of ASC 718 to include share-based payments granted to non-employees in exchange for goods or services used or consumed in an entity&#x2019;s own operations and superseded the guidance in ASC 505-50. Prior to January 1, 2019, equity instruments issued to non-employees were recorded on a fair value basis, as required by ASC 505, Equity - Based Payments to Non-Employees.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p id="xdx_845_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zX9Q9Tx5SIq5" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: black"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span style="color: black"&gt;Revenue Recognition&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;We
adopted ASC 606, &lt;i&gt;Revenue from Contracts with Customers&lt;/i&gt;, or ASC 606, on January 1, 2018 using the modified retrospective
method for all contracts not completed as of the date of adoption. ASC 606 states that a contract is considered &#x201c;completed&#x201d;
if all (or substantially all) of the revenue was recognized in accordance with revenue guidance that was in effect before the
date of initial application. Because all (or substantially all) of the revenue related to sales of our products was recognized
under ASC 605 prior to the date of initial application of the new standard, the contracts were considered completed under ASC
606. Based on our evaluation of ASC 606, we concluded that a cumulative adjustment was not necessary upon implementation of ASC
606 on January 1, 2018. In accordance with ASC 606, revenue is recognized when a customer obtains control of promised goods or
services. The amount of revenue recognized reflects the consideration to which we expect to be entitled to receive in exchange
for these goods or services. The provisions of ASC 606 include a five-step process by which we determine revenue recognition,
depicting the transfer of goods or services to customers in amounts reflecting the payment to which we expect to be entitled in
exchange for those goods or services. ASC 606 requires us to apply the following steps: (1) identify the contract with the customer;
(2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price
to the performance obligations in the contract; and (5) recognize revenue when, or as, we satisfy the performance obligation.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 36pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span style="color: black"&gt;&lt;i&gt;Prescription Products&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: #212529"&gt;As of December 31, 2019, our products consisted primarily of prescription vitamins and our FDA-approved products: IMVEXXY, which we began selling during the third quarter of 2018, and BIJUVA, which we began selling in the second quarter of 2019. We started selling ANNOVERA in the third quarter of 2019 and we expect the full commercial launch of ANNOVERA in the first quarter of 2020. We sell our name brand and generic prescription products primarily through wholesale distributors and retail pharmacies. We have one performance obligation related to prescription products sold through wholesale distributors, which is to transfer promised goods to a customer, and two performance obligations related to products sold through retail pharmacies, which are to: (1) transfer promised goods and (2) provide customer service for an immaterial fee. We treat shipping as a fulfillment activity rather than as a separate obligation. We recognize prescription revenue only when we satisfy performance obligations by transferring a promised good or service to a customer. A good or service is considered to be transferred when the customer receives the goods or service or obtains control. Control refers to the customer&#x2019;s ability to direct the use of, and obtain substantially all of the remaining benefits from, an asset. Based on our contracts, we invoice customers once our performance obligations have been satisfied, at which point payment is unconditional. We disclose receivables from contracts with customers separately in the statement of financial position. Payment for goods or services sold by us is typically due between 30 and 60 days after an invoice is sent to the customer. &lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: #212529"&gt;The transaction price of a contract is the amount of consideration which we expect to be entitled to in exchange for transferring promised goods or services to a customer. Prescription products are sold at fixed wholesale acquisition cost, or WAC, determined based on our list price. However, the total transaction price is variable as it is calculated net of estimated product returns, chargebacks, rebates, coupons, discounts and wholesaler fees. These estimates are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the customer) or a current liability (if the amount is payable to a party other than a customer). In order to determine the transaction price, we estimate the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract or each variable consideration. The estimated amount of variable consideration is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. In determining amounts of variable consideration to include in a contract&#x2019;s transaction price, we rely on our historical experience and other evidence that supports our qualitative assessment of whether revenue would be subject to a significant reversal. We consider all the facts and circumstances associated with both the risk of a revenue reversal arising from an uncertain future event and the magnitude of the reversal if that uncertain event were to occur. Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our original estimates, we will adjust these estimates, which would affect net product revenue and earnings in the period such changes in estimates become known. &lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: #212529"&gt;We accept returns of unsalable prescription products sold through wholesale distributors within a return period of &lt;span id="xdx_90B_ecustom--ReturnPeriodOfUnsalablePrescriptionProducts_dxH_c20190101__20191231__srt--RangeAxis__srt--MinimumMember_zwmQaTTYNKK" title="Return period of unsalable prescription products::XDX::P6M"&gt;six&lt;/span&gt; months prior to and up to &lt;span id="xdx_908_ecustom--ReturnPeriodOfUnsalablePrescriptionProducts_dtM_c20190101__20191231__srt--RangeAxis__srt--MaximumMember_zpQUNXhwWkQ1"&gt;12&lt;/span&gt; months following product expiration. Our vitamins and IMVEXXY currently have a shelf life of &lt;span id="xdx_907_ecustom--ShelfLifeOfPrescriptionProducts_dtM_c20190101__20191231__srt--ProductOrServiceAxis__custom--VitaminsAndImvexxyMember_zdk5medOaIY1" title="Shelf life of prescription products following product expiration"&gt;24&lt;/span&gt; months from the date of manufacture and BIJUVA and ANNOVERA currently have a shelf life of &lt;span id="xdx_905_ecustom--ShelfLifeOfPrescriptionProducts_dtM_c20190101__20191231__srt--ProductOrServiceAxis__custom--BijuvaAndAnnoveraMember_zykSpchkSjok"&gt;18&lt;/span&gt; months from the date of manufacture. We do not allow product returns for prescription products that have been dispensed to a patient. We estimate the amount of our product sales that may be returned by our customers and record this estimate as a reduction of revenue in the period the related product revenue is recognized. Where historical rates of return exist, we use history as a basis to establish a returns reserve for products shipped to wholesalers. For our newly launched products, for which the right of return exists but for which we currently do not have history of product returns, we estimate returns based on available industry data, our own sales information and our visibility into the inventory remaining in the distribution channel. At the end of each reporting period, we may decide to constrain revenue for product returns based on information from various sources, including channel inventory levels and dating and sell-through data, the expiration dates of products currently being shipped, price changes of competitive products and any introductions of generic products. We recognize the amount of expected returns as a refund liability, representing the obligation to return the customer&#x2019;s consideration. Since our returns primarily consist of expired and short dated products that will not be resold, we do not record a return asset for the right to recover the goods returned by the customer at the time of the initial sale (when recognition of revenue is deferred due to the anticipated return). Return estimates are recorded in accrued expenses and other current liabilities on the consolidated balance sheet.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: #212529"&gt;We offer various rebate and discount programs in an effort to maintain a competitive position in the marketplace and to promote sales and customer loyalty. We estimate the allowance for consumer rebates and coupons that we have offered based on our experience and industry averages, which is reviewed, and adjusted if necessary, on a quarterly basis. Estimates relating to these rebates and coupons are deducted from gross product revenues at the time the revenues are recognized. We record distributor fees based on amounts stated in contracts. Rebate and coupon estimates and distributor fees are recorded in accrued expenses and other current liabilities on the consolidated balance sheet. We estimate chargebacks based on number of units sold during the period taking into account prices stated in contracts and our historical experience. Estimates related to distributors fees, rebates, coupons and returns are disclosed in Note 7. We provide invoice discounts to our customers for prompt payment. Estimates relating to invoice discounts and chargebacks are deducted from gross product revenues at the time the revenues are recognized. &lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: #212529"&gt;As part of commercial launches for our FDA-approved prescription products, we introduced a co-pay assistance program for eligible enrolled patients whose out of pocket costs are reduced to a more affordable price. This allows patients to access the product at a reasonable cost and is in line with our responsible pricing approach. We reimburse pharmacies for this discount through third-party vendors. We consider certain payments as consideration paid to the customer and reflect such payments as a reduction of the transaction price as we do not receive a distinct good or service related to these payments. The variable consideration is estimated based on contract prices, the estimated percentage of patients that will utilize the copay assistance, the average assistance paid, the estimated levels of inventory in the distribution channel and the current level of prescriptions covered by patients&#x2019; insurance. Payers may change coverage levels for our prescription products positively or negatively, at any time up to the time that we have formally contracted coverage with the payer. As such, the net transaction price of our prescription products is susceptible to such changes in coverage levels, which are outside the influence of the Company. As a result, we constrain variable consideration for our prescription products to an amount that will not result in a significant revenue reversal in future periods. Our ability to estimate the net transaction price for our prescription products is constrained by our estimates of the amount to be paid for the co-pay assistance program which is directly related to the level of prescriptions paid for by insurance. As such, we record an accrual to reduce gross sales for the estimated co-pay and other patient assistance based on currently available third-party data and our internal analyses. We re-evaluate variable consideration each reporting period.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 36pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: #212529"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span style="color: #212529"&gt;&lt;i&gt;License Revenue&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: #212529"&gt;License
arrangements may consist of non-refundable upfront license fees, exclusive licensed rights to patented or patent pending
technology, and various performance or sales milestones and future product royalty payments. Some of these arrangements may
include multiple performance obligations. Non-refundable up-front fees that are not contingent on any future performance by
us, and do not require continuing involvement on our part, are recognized as revenue when the right to use functional IP is transferred to the customer.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #212529"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span style="color: #212529"&gt;License Agreement with Knight Therapeutics Inc.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: #212529"&gt;On July 30, 2018, we entered into the Knight License Agreement with Knight pursuant to which we granted Knight an exclusive license to commercialize IMVEXXY and BIJUVA in Canada and Israel. Pursuant to the terms of the Knight License Agreement, Knight will pay us a milestone fee upon first regulatory approval in Canada of each of IMVEXXY and BIJUVA, sales milestone fees based upon certain aggregate annual sales in Canada and Israel of each of IMVEXXY and BIJUVA and royalties based on aggregate annual sales of each of IMVEXXY and BIJUVA in Canada and Israel. Knight will be responsible for all regulatory and commercial activities in Canada and Israel related to IMVEXXY and BIJUVA. We may terminate the Knight License Agreement if Knight does not submit all regulatory applications, submissions and/or registrations required for regulatory approval to use and commercialize IMVEXXY and BIJUVA in Canada and Israel within certain specified time periods. We also may terminate the Knight License Agreement if Knight challenges our patents. Either party may terminate the Knight License Agreement for any material breach by the other party that is not cured within certain specified time periods or if the other party files for bankruptcy or other related matters. In connection with the Knight License Agreement, Knight entered into a subscription agreement with us, pursuant to which Knight purchased &lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20180730__20180806__us-gaap--SubsidiarySaleOfStockAxis__custom--SubscriptionAgreementKnightMember_zPi7HFxxKJK7"&gt;3,921,568&lt;/span&gt; shares of our Common Stock concurrent with the closing of the underwritten public offering of Common Stock on August 6, 2018 at a price of $&lt;span id="xdx_90C_eus-gaap--SaleOfStockPricePerShare_iI_c20180806__us-gaap--SubsidiarySaleOfStockAxis__custom--SubscriptionAgreementKnightMember_zA6xYqBlf9gh"&gt;5.10&lt;/span&gt;, for proceeds of $&lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20180730__20180806__us-gaap--SubsidiarySaleOfStockAxis__custom--SubscriptionAgreementKnightMember_zE3Vbx4PtVqb"&gt;20,000,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #212529"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span style="color: #212529"&gt;License Agreement with Theramex&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: #212529"&gt;On
June 6, 2019, we entered into the Theramex License Agreement with Theramex to commercialize BIJUVA and IMVEXXY in the &lt;span style="color: black"&gt;Theramex &lt;/span&gt;Territory.
Under the terms of the Theramex License Agreement, Theramex paid us EUR &lt;span id="xdx_90E_ecustom--CashUpfrontPaymentReceived_dm_uEUR_c20190804__20190805__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember_zhZ8Q0Jom5W"&gt;14
million&lt;/span&gt;, or $&lt;span id="xdx_904_ecustom--CashUpfrontPaymentReceived_uUSD_c20190803__20190805__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember_z1NgfBwzHIz7"&gt;15,506,400&lt;/span&gt;,
in cash as an upfront fee on August 5, 2019. Within thirty days of signing the Theramex License Agreement, we provided
Theramex the regulatory materials and clinical data that were necessary for Theramex to obtain marketing authorizations and
other applicable regulatory approvals for commercializing BIJUVA and IMVEXXY. We recognized the revenue related to the
upfront fee, which was a non-refundable payment, during the third quarter of 2019, at a point in time when Theramex was able
to use and benefit from the license which was when the knowledge transfer of regulatory documents occurred. We are eligible
to receive additional milestone payments comprised of (i) up to an aggregate of EUR &lt;span id="xdx_907_ecustom--RegulatoryMilestoneAdditionalPayment_iI_dm_uEUR_c20190606__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember__srt--RangeAxis__srt--MaximumMember_zebOAlMYfGdc"&gt;2
million&lt;/span&gt; in regulatory milestone payments based on regulatory approvals for BIJUVA and IMVEXXY in certain specified
markets and (ii) up to an aggregate of EUR &lt;span id="xdx_906_ecustom--SalesMilestonePaymentsInTranches_iI_dm_uEUR_c20190606__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember__srt--RangeAxis__srt--MaximumMember_zTkMgkY5IUa4"&gt;27.5
million&lt;/span&gt; in sales milestone payments to be paid in escalating tranches based on Theramex first attaining certain
aggregate annual net sales milestones of BIJUVA and IMVEXXY in the &lt;span style="color: black"&gt;Theramex &lt;/span&gt;Territory
ranging from EUR &lt;span id="xdx_90C_ecustom--AnnualNetSalesMilestone_dm_uEUR_c20190605__20190606__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember__srt--RangeAxis__srt--MinimumMember_z1X49D80mEN1" title="Sales milestone"&gt;25
million&lt;/span&gt; to EUR &lt;span id="xdx_909_ecustom--AnnualNetSalesMilestone_dm_uEUR_c20190605__20190606__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember__srt--RangeAxis__srt--MaximumMember_zfL5UAQPZVef"&gt;100
million&lt;/span&gt;. We are also entitled to receive quarterly royalty payments at a rate of &lt;span id="xdx_90D_ecustom--QuarterlyRoyaltyPaymentsPercentage_dp_c20190605__20190606__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember__srt--ProductOrServiceAxis__custom--BijuvaAndAnnoveraMember_zNWu2klcrb31" title="Quarterly royalty payments percentage"&gt;5&lt;/span&gt;% on net sales of BIJUVA and
IMVEXXY in the &lt;span style="color: black"&gt;Theramex &lt;/span&gt;Territory. Theramex is responsible for all regulatory
and commercial activities for BIJUVA and IMVEXXY in the &lt;span style="color: black"&gt;Theramex &lt;/span&gt;Territory. Theramex
may sublicense its rights to commercialize BIJUVA and IMVEXXY in the &lt;span style="color: black"&gt;Theramex &lt;/span&gt;Territory,
except for certain specified markets. We may terminate the Theramex License Agreement if Theramex does not submit
all regulatory applications, submissions and/or registrations required for regulatory approval to use and commercialize
BIJUVA and IMVEXXY within certain specified time periods. We also may terminate the Theramex License Agreement if
Theramex challenges our patents. Either party may terminate the Theramex License Agreement for any material breach by the
other party that is not cured within certain specified time periods or if the other party files for bankruptcy or other
related matters. &lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 36pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span style="color: black"&gt;&lt;i&gt;Disaggregation of revenue&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p id="xdx_890_eus-gaap--DisaggregationOfRevenueTableTextBlock_z8OEeqjDg4wl" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;The following table provides information about disaggregated revenue by product mix for the years ended December 31, 2019, 2018, and 2017:&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin-right: auto; margin-left: auto; float: none; width: 80%"&gt;

&lt;tr&gt;
&lt;td style="vertical-align: top; padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b/&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-right: Black medium none; border-left: Black medium none; padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b/&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-right: Black medium none; border-left: Black medium none; padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b/&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="10" style="border-bottom: black 1pt solid; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;For the Years
Ended December 31,&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: black 1pt solid; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-right: Black medium none; border-bottom: Black 1pt solid; border-left: Black medium none; padding: 0pt 5.4pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-right: Black medium none; border-bottom: Black 1pt solid; border-left: Black medium none; padding: 0pt 5.4pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; width: 55%; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;Prescription vitamins&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%"&gt;
&lt;p id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_zTCn7GWquVDa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;9,885,493&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%"&gt;
&lt;p id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180101__20181231__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_zeoacSq302Jd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;15,041,259&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%"&gt;
&lt;p id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20170101__20171231__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_zFufrbuEnuIj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;16,744,831&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;IMVEXXY&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ProductOrServiceAxis__custom--ImvexxyMember_zYDRVsbMXUX2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;16,252,045&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180101__20181231__srt--ProductOrServiceAxis__custom--ImvexxyMember_z6BPbXQEuVA8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;1,058,201&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#x2014;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;BIJUVA&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ProductOrServiceAxis__custom--BijuvaMember_zTDhU6TAWyd9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;1,836,443&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#x2014;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#x2014;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;ANNOVERA&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ProductOrServiceAxis__custom--AnnoveraMember_zNVeDXdoxc1h" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;6,166,556&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#x2014;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#x2014;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;License revenue&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ProductOrServiceAxis__us-gaap--LicenseAndServiceMember_zsZ6QSDNh8v1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;15,506,400&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#x2014;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#x2014;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;OTC products&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#x2014;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#x2014;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20170101__20171231__srt--ProductOrServiceAxis__custom--OtcProductsMember_zFoKtnjjbps5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;32,882&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 0pt 16px; text-indent: 0pt"&gt;Net revenue&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom"&gt;
&lt;p id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231_ziaaFJ1sWOfe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Net revenue"&gt;49,646,937&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom"&gt;
&lt;p id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180101__20181231_z38IF71YI67g" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;16,099,460&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom"&gt;
&lt;p id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20170101__20171231_zq8rzdspFESg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;16,777,713&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p id="xdx_8A1_z2enxXr8rRi1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: black"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span style="color: black"&gt;Shipping and Handling Costs&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;We expense all shipping and handling costs as incurred. We include these costs in cost of goods sold on the accompanying consolidated financial statements.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p id="xdx_84B_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zh34nsSoyXzj" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: black"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span style="color: black"&gt;Segment Reporting&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;We are managed and operated as &lt;span id="xdx_901_eus-gaap--NumberOfReportableSegments_dc_uPure_c20190101__20191231_zfTscoqBJ7ng" title="Number of operating segments"&gt;one&lt;/span&gt; business, which is focused on creating and commercializing products targeted exclusively for women. Our business operations are managed by a single management team that reports to the President of our company. We do not operate separate lines of business with respect to any of our products and we do not prepare discrete financial information with respect to separate products. All product sales are derived from sales in the United States. Accordingly, we view our business as one reportable operating segment.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;



&lt;p id="xdx_848_eus-gaap--CostOfSalesPolicyTextBlock_zBqUjo09XUGh" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: black"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span style="color: black"&gt;Cost of Sales &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;Cost
of sales includes the cost of inventory, manufacturing, manufacturing overhead and supply chain costs, and product shipping
and handling costs. The Population Council License Agreement requires payment of royalties based on the sale of future
products. Such royalties are recorded as a component of cost of sales. Additionally, the amortization of license fees or
milestone payments related to licensed products are classified as components of cost of sales to the extent such payments
become due in the future.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--AdvertisingCostsPolicyTextBlock_zwHL0Geta6pj" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="text-decoration: underline"&gt;Advertising Costs&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;We expense advertising costs when incurred. Advertising costs were $&lt;span id="xdx_900_eus-gaap--AdvertisingExpense_c20190101__20191231_zPOagYG9VJZh" title="Advertising costs"&gt;9,045,571&lt;/span&gt;, $&lt;span id="xdx_90C_eus-gaap--AdvertisingExpense_c20180101__20181231_zaOsot7eExva"&gt;1,682,746&lt;/span&gt; and $&lt;span id="xdx_900_eus-gaap--AdvertisingExpense_c20170101__20171231_zWaOTgdOA1Jf"&gt;448,288&lt;/span&gt; during the years ended December 31, 2019, 2018, and 2017, respectively.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--ResearchAndDevelopmentExpensePolicy_zIzh16fKypj9" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="text-decoration: underline"&gt;Research and Development Expenses&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;Research and development, or R&amp;amp;D, expenses include internal R&amp;amp;D activities, services of external contract research organizations, or CROs, costs of their clinical research sites, manufacturing, scale-up and validation costs, and other activities. Internal R&amp;amp;D activity expenses include laboratory supplies, salaries, benefits, and non-cash share-based compensation expenses. CRO activity expenses include preclinical laboratory experiments and clinical trial studies. Other activity expenses include regulatory consulting and other costs. The activities undertaken by our regulatory consultants that were classified as R&amp;amp;D expenses include assisting, consulting with, and advising our in-house staff with respect to various FDA submission processes, clinical trial processes, and scientific writing matters, including preparing protocols and FDA submissions. These consulting expenses were direct costs associated with preparing, reviewing, and undertaking work for our clinical trials and investigative drugs. We charge internal R&amp;amp;D activities and other activity expenses to operations as incurred. We make payments to CROs based on agreed-upon terms, which may include payments in advance of a study starting date. We expense nonrefundable advance payments for goods and services that will be used in future R&amp;amp;D activities when the activity has been performed or when the goods have been received rather than when the payment is made. We review and accrue CRO expenses and clinical trial study expenses based on services performed and rely on estimates of those costs applicable to the completion stage of a study as provided by CROs. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. We charge revisions to expenses in the period in which the facts that give rise to the revision become known.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p id="xdx_841_eus-gaap--EarningsPerSharePolicyTextBlock_zai2UEwH7ehf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="text-decoration: underline"&gt;Earnings Per Share&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;We calculate earnings per share, or EPS, in accordance with ASC 260, &lt;i&gt;&lt;span style="color: black"&gt;Earnings Per Share&lt;/span&gt;&lt;/i&gt;, which requires the computation and disclosure of two EPS amounts: basic and diluted. We compute basic EPS based on the weighted-average number of shares of common stock, par value $0.001 per share, or Common Stock, outstanding during the period. We compute diluted EPS based on the weighted-average number of shares of our Common Stock outstanding plus all potentially dilutive shares of our Common Stock outstanding during the period. Such potentially dilutive shares of our Common Stock consist of options, warrants and restricted stock awards and were excluded from the calculation of diluted earnings per share because their effect would have been anti-dilutive due to the net loss reported by us.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zjMWR87JAaTl" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;The table below presents potentially dilutive securities that could affect our calculation of diluted net loss per share allocable to common stockholders for the periods presented.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin-right: auto; margin-left: auto; float: none; width: 80%"&gt;

&lt;tr&gt;
&lt;td style="vertical-align: top; padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b/&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-right: Black medium none; border-left: Black medium none; padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b/&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-right: Black medium none; border-left: Black medium none; padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b/&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"/&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="10" style="border-bottom: black 1pt solid; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;As of December
31,&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: black 1pt solid; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-right: Black medium none; border-bottom: Black 1pt solid; border-left: Black medium none; padding: 0pt 5.4pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-right: Black medium none; border-bottom: Black 1pt solid; border-left: Black medium none; padding: 0pt 5.4pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; width: 55%; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;Stock options&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%"&gt;
&lt;p id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zwwment6okci" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;25,030,234&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%"&gt;
&lt;p id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z4Udu7FwKRBd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;20,872,824&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%"&gt;
&lt;p id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20170101__20171231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zLOgdFIRfWz1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;23,365,225&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;Warrants&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zn1G1tvZMjg2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;1,832,571&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20180101__20181231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zJuxJ8RNShMk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;3,007,571&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20170101__20171231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z1nPiuQRWDX3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;3,115,905&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;Restricted stock awards&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zed2bsYYVwWh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;1,240,000&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zIyxoJjJmrO6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;1,040,000&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#x2014;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom"&gt;
&lt;p id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20190101__20191231_zD9Rt6prp5r" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;28,102,805&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom"&gt;
&lt;p id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20180101__20181231_zP5dRly8IJff" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;24,920,395&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom"&gt;
&lt;p id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20170101__20171231_zBwVIKCXZx59" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;26,481,130&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;p id="xdx_8A5_znRoDQXLLwAh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p id="xdx_840_eus-gaap--ConcentrationRiskCreditRisk_z3qPnllrsXji" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="text-decoration: underline"&gt;Concentration of Credit Risk and other Risks and Uncertainties&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;Financial instruments that potentially expose us to concentrations of credit risk consist primarily of cash and trade accounts receivable. Cash is on deposit with financial institutions in the United States and these deposits generally exceed the amount of insurance provided by the FDIC. We have not experienced any historical losses on our deposits of cash.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;Concentration of credit risk with respect to our trade accounts receivable from our customers is primarily limited to drug wholesalers and retail pharmacy distributors. Credit is extended to our customers based on an evaluation of a customer&#x2019;s financial condition, and collateral is not required.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p id="xdx_84F_eus-gaap--UseOfEstimates_zsMyrC5LdsBg" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="text-decoration: underline"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;Our consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP. The preparation of these financial statements requires us to make significant estimates and judgments that affect the reported amounts of assets, liabilities, revenue, expenses, and related disclosure of contingent assets and liabilities. We evaluate our estimates, including those related to contingencies, on an ongoing basis. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ, at times in material amounts, from these estimates under different assumptions or conditions.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;



&lt;p id="xdx_84B_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zjxi7fQvxgc2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="text-decoration: underline"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="color: black"&gt;In August 2018, the FASB issued Accounting Standards Update, or ASU, 2018-13, which eliminates certain disclosure requirements for fair value measurements for all entities, requires public entities to disclose certain new information and modifies some disclosure requirements. The FASB developed the amendments to ASC 820 as part of its broader disclosure framework project, which aims to improve the effectiveness of disclosures in the notes to financial statements by focusing on requirements that clearly communicate the most important information to users of the financial statements. The new guidance is effective for all entities for fiscal years beginning after December 15, 2019 and for interim periods within those fiscal years. An entity is permitted to early adopt either the entire standard or only the provisions that eliminate or modify requirements. We do not expect that the adoption of this standard will have a material effect on our disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="color: black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="color: black"&gt;In June 2018, the FASB issued ASU 2018-07 to simplify the accounting for share-based payments to non-employees by aligning it with the accounting for share-based payments to employees, with certain exceptions. The new guidance expands the scope of ASC 718 to include share-based payments granted to non-employees in exchange for goods or services used or consumed in an entity&#x2019;s own operations and supersedes the guidance in ASC 505-50. The guidance is effective for public business entities in annual periods beginning after December 15, 2018, and interim periods within those annual periods. Early adoption is permitted, including in an interim period for which financial statements have not been issued, but not before an entity adopts ASC 606. We adopted this standard on January 1, 2019 and the adoption of this standard did not have a material effect on our consolidated financial statements. &lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="color: black"&gt;In February 2016, the FASB issued ASU 2016-02, Leases. This guidance requires lessees to record most leases on their balance sheets while recognizing expenses on their income statements in a manner similar to current accounting. The guidance also eliminates current real estate-specific provisions for all entities. For lessors, the guidance modifies the classification criteria and the accounting for sales-type and direct financing leases. The standard was effective for public business entities for annual periods beginning after December 15, 2018, and interim periods within those years. In July 2018, the FASB amended the new leases standard and issued ASU 2018-11, Leases, (Topic 842): Targeted Improvements to give entities another option for transition and to provide lessors with a practical expedient. We adopted ASU 2016-02 on January 1, 2019 utilizing the alternative transition method allowed for under ASU 2018-11 and we recorded a $&lt;span id="xdx_903_eus-gaap--OperatingLeaseRightOfUseAsset_iI_dm_c20190102__us-gaap--AdjustmentsForNewAccountingPronouncementsAxis__us-gaap--AccountingStandardsUpdate201602Member_zlV7DDjFbRp3" title="Right of use asset"&gt;3.8 million&lt;/span&gt; right of use asset and a $&lt;span id="xdx_903_eus-gaap--OperatingLeaseLiability_iI_dm_c20190102__us-gaap--AdjustmentsForNewAccountingPronouncementsAxis__us-gaap--AccountingStandardsUpdate201602Member_zthkuShkZZq9" title="Lease liability"&gt;4.1 million&lt;/span&gt; liability related to adoption of this standard. In addition, upon commencement of additional leased space in the third quarter of 2019 (as disclosed in Note 13), we recorded an additional $&lt;span id="xdx_903_eus-gaap--OperatingLeaseRightOfUseAsset_iI_dm_c20190831_zkKApmrsrDpd"&gt;7.4 million&lt;/span&gt; right of use asset and an additional $&lt;span id="xdx_90A_eus-gaap--OperatingLeaseLiability_iI_dm_c20190831_zd4NiSL1yiF4"&gt;7.2 million&lt;/span&gt; liability related to our new leased space. Comparative financial information was not adjusted and will continue to be reported under ASC 840. We also elected the transition relief package of practical expedients and as a result we did not assess (1) whether existing or expired contracts contain leases, (2) lease classification for any existing or expired leases, and (3) whether lease origination costs qualified as initial direct costs. We elected the short-term lease practical expedient by establishing an accounting policy to exclude leases with a term of 12 months or less. We elected not to separate lease components from non-lease components for our specified asset classes. Additionally, the adoption of the new standard resulted in increased disclosure requirements in our quarterly and annual filings. &lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants and the SEC did not, and are not expected to, have a material effect on our results of operations or financial position.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_850_zrLqpYk9J5Xh" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"/&gt;&lt;/p&gt;
</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2019-01-01to2019-12-31">&lt;p id="xdx_840_eus-gaap--ConsolidationPolicyTextBlock_z9mbbq84TDpk" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="text-decoration: underline"&gt;Principles of Consolidation&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;The accompanying consolidated financial statements include the accounts of our company and our wholly owned subsidiaries, VitaMed, BocaGreen and VitaCare. All intercompany balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2019-01-01to2019-12-31">&lt;p id="xdx_84E_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zPuRMhgGn9n9" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: black"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span style="color: black"&gt;Cash&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;We maintain cash at financial institutions that at times may exceed the Federal Deposit Insurance Corporation, or the FDIC, insured limits of $&lt;span id="xdx_907_eus-gaap--CashFDICInsuredAmount_iI_c20191231_zArZMLyhjRi2" title="Federal insurance limits"&gt;250,000&lt;/span&gt; per bank. We have never experienced any losses related to these funds.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashFDICInsuredAmount contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">250000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy contextRef="From2019-01-01to2019-12-31">&lt;p id="xdx_842_eus-gaap--ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_z4vfyE0pmWgg" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: black"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span style="color: black"&gt;Trade Accounts Receivable and Allowance for Doubtful Accounts&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;Trade accounts receivable are customer obligations due under normal trade terms. We review accounts receivable for uncollectible accounts and credit card chargebacks and provide an allowance for doubtful accounts, which is based upon a review of outstanding receivables, historical collection information, and existing economic conditions. We evaluate trade accounts receivable aged more than 90 days for delinquency. We write off delinquent receivables against our allowance for doubtful accounts based on individual credit evaluations, the results of collection efforts, and specific circumstances of customers. We record recoveries of accounts previously written off when received as an increase in the allowance for doubtful accounts. To the extent data we use to calculate these estimates does not accurately reflect bad debts, adjustments to these reserves may be required. At December 31, 2019, four different customers represented &lt;span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_dp_c20190101__20191231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerAMember_zKF3b71cwfz1" title="Concentration risk"&gt;36&lt;/span&gt;%, &lt;span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_dp_c20190101__20191231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerBMember_zmEFfWdMZjDg"&gt;21&lt;/span&gt;%, &lt;span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_dp_c20190101__20191231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerCMember_zntJnZicuVGl"&gt;16&lt;/span&gt;% and &lt;span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_dp_c20190101__20191231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerDMember_zO8dfd3KrK6h"&gt;11&lt;/span&gt;% of our gross accounts receivable. At December 31, 2018, three different customers represented &lt;span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_dp_c20180101__20181231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerAMember_zupQyt5giKMl"&gt;42&lt;/span&gt;%, &lt;span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20180101__20181231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerBMember_zpzmvrRmdsO9"&gt;24&lt;/span&gt;% and &lt;span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_c20180101__20181231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerCMember_zyUQ7PV5Sc6d"&gt;13&lt;/span&gt;% of our gross accounts receivable.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;



</us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2019-01-012019-12-31_us-gaap_AccountsReceivableMember_custom_CustomerAMember"
      decimals="INF"
      unitRef="Pure">0.36</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2019-01-012019-12-31_us-gaap_AccountsReceivableMember_custom_CustomerBMember"
      decimals="INF"
      unitRef="Pure">0.21</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2019-01-012019-12-31_us-gaap_AccountsReceivableMember_custom_CustomerCMember"
      decimals="INF"
      unitRef="Pure">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2019-01-012019-12-31_us-gaap_AccountsReceivableMember_custom_CustomerDMember"
      decimals="INF"
      unitRef="Pure">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2018-01-012018-12-31_us-gaap_AccountsReceivableMember_custom_CustomerAMember"
      decimals="INF"
      unitRef="Pure">0.42</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2018-01-012018-12-31_us-gaap_AccountsReceivableMember_custom_CustomerBMember"
      decimals="INF"
      unitRef="Pure">0.24</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2018-01-012018-12-31_us-gaap_AccountsReceivableMember_custom_CustomerCMember"
      decimals="INF"
      unitRef="Pure">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:InventoryPolicyTextBlock contextRef="From2019-01-01to2019-12-31">&lt;p id="xdx_841_eus-gaap--InventoryPolicyTextBlock_zJMMUrzk2Is1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: black"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span style="color: black"&gt;Inventories&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;Inventories represent pharmaceutical products, packaged vitamins and raw materials which are valued at the lower of cost or net realizable value. Our pharmaceutical products are valued using first in first out method and our vitamins are valued using the average-cost method. We review our inventory for excess or obsolete inventory and write-down obsolete or otherwise unmarketable inventory to its estimated net realizable value. Obsolescence may occur due to product expiring or product improvements rendering previous versions obsolete.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span style="color: black"&gt;&lt;i&gt;Pre-Launch Inventory&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;Pre-launch
inventory costs associated with product candidates that have not yet received regulatory approval are capitalized if we
believe there is probable future commercial use and future economic benefit. If the probability of future commercial use and
future economic benefit cannot be reasonably determined, then pre-launch inventory costs associated with such product
candidates are expensed as research and development expenses during the period the costs are incurred. We have not
capitalized any pre-launch inventory to date.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2019-01-01to2019-12-31">&lt;p id="xdx_840_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zVTVNsWARLG6" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: black"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span style="color: black"&gt;Fixed Assets&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;We state fixed assets at cost, net of accumulated depreciation. We charge maintenance costs, which do not significantly extend the useful lives of the respective assets, and repair costs to operating expenses as incurred. We compute depreciation using the straight-line method over the estimated useful lives of the related assets, which range from &lt;span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dxL_c20190101__20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LandAndBuildingMember__srt--RangeAxis__srt--MinimumMember_zJS38w4WoxI7" title="Useful life of assets::XDX::P3Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0553"&gt;three&lt;/span&gt;&lt;/span&gt; to &lt;span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dxL_c20190101__20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LandAndBuildingMember__srt--RangeAxis__srt--MaximumMember_zlggfZdrMU98" title="::XDX::P7Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0554"&gt;seven&lt;/span&gt;&lt;/span&gt; years. Leasehold improvements are depreciated over the shorter of their useful life or the term of the lease.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;We capitalize software and software development costs incurred to create and acquire computer software for internal use, principally related to software coding and application development. We begin to capitalize software development costs when both the preliminary project stage is completed and it is probable that the software will be used as intended. Capitalized software costs include only external direct costs and services utilized in developing or obtaining computer software. Capitalized software costs are amortized on a straight-line basis when placed into service over the estimated useful life, generally &lt;span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dxL_c20190101__20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember__srt--RangeAxis__srt--MinimumMember_zld1rcASVmyj" title="::XDX::P5Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0555"&gt;five&lt;/span&gt;&lt;/span&gt; to &lt;span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dxL_c20190101__20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember__srt--RangeAxis__srt--MaximumMember_zbWzKwyxIev5" title="::XDX::P7Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0556"&gt;seven&lt;/span&gt;&lt;/span&gt; years.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="From2019-01-01to2019-12-31">&lt;p id="xdx_840_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zkbInhjBzxL3" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: black"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span style="color: black"&gt;Intangible Assets&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;We have adopted the provisions of Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, 350, &lt;i&gt;&lt;span style="color: black"&gt;Intangibles - Goodwill and Other&lt;/span&gt;&lt;/i&gt;, or ASC 350. Capitalized patent costs, net of accumulated amortization, include outside legal costs incurred for patent applications. In accordance with ASC 350, once a patent is granted, we amortize the capitalized patent costs over the remaining life of the patent using the straight-line method. If the patent is not granted, we write-off any capitalized patent costs at that time. As of December 31, 2019, we had &lt;span id="xdx_904_ecustom--NumberOfIssuedPatentsDomestic_iI_uPure_c20191231_zN9Aevq2rkUe" title="Number of issued patents domestic."&gt;29&lt;/span&gt; issued domestic, or U.S., patents and &lt;span id="xdx_907_ecustom--NumberOfIssuedPatentsForeign_iI_uPure_c20191231_zxTQdtMts3r5" title="Number of issued patents foreign"&gt;30&lt;/span&gt; issued foreign patents (See Note 6). We capitalize external costs, consisting primarily of legal costs, related to securing our trademarks. Trademarks are perpetual and are not amortized. We review intangible assets for impairment annually or when events or circumstances indicate that their carrying amount may not be recoverable.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <txmd:NumberOfIssuedPatentsDomestic contextRef="AsOf2019-12-31" decimals="INF" unitRef="Pure">29</txmd:NumberOfIssuedPatentsDomestic>
    <txmd:NumberOfIssuedPatentsForeign contextRef="AsOf2019-12-31" decimals="INF" unitRef="Pure">30</txmd:NumberOfIssuedPatentsForeign>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="From2019-01-01to2019-12-31">&lt;p id="xdx_84C_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zX0rxQcb4Caj" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="text-decoration: underline"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;We review the carrying values of fixed assets and long-lived intangible assets to be held and used for impairment whenever events or changes in circumstances indicate that their carrying values may not be recoverable. Such events or circumstances may include, among others, the following:&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; width: 100%"&gt;

&lt;tr&gt;
&lt;td style="vertical-align: top; width: 18pt"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: top; width: 18pt"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&#x25cf;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;significant declines in an asset&#x2019;s market price;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; width: 100%"&gt;

&lt;tr&gt;
&lt;td style="vertical-align: top; width: 18pt"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: top; width: 18pt"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&#x25cf;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;significant deterioration in an asset&#x2019;s physical condition;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; width: 100%"&gt;

&lt;tr&gt;
&lt;td style="vertical-align: top; width: 18pt"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: top; width: 18pt"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&#x25cf;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;significant changes in the nature or extent of an asset&#x2019;s use or operation;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; width: 100%"&gt;

&lt;tr&gt;
&lt;td style="vertical-align: top; width: 18pt"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: top; width: 18pt"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&#x25cf;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;significant adverse changes in the business climate that could impact an asset&#x2019;s value, including adverse actions or assessments by regulators;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; width: 100%"&gt;

&lt;tr&gt;
&lt;td style="vertical-align: top; width: 18pt"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: top; width: 18pt"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&#x25cf;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;accumulation of costs significantly in excess of original expectations related to the acquisition or construction of an asset;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; width: 100%"&gt;

&lt;tr&gt;
&lt;td style="vertical-align: top; width: 18pt"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: top; width: 18pt"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&#x25cf;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;current-period operating or cash flow losses combined with a history of such losses or a forecast that demonstrates continuing losses associated with an asset&#x2019;s use; and&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; width: 100%"&gt;

&lt;tr&gt;
&lt;td style="vertical-align: top; width: 18pt"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: top; width: 18pt"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&#x25cf;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;expectations that it is more likely than not that an asset will be sold or otherwise disposed of significantly before the end of its previously estimated useful life.&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;If impairment indicators are present, we determine whether an impairment loss should be recognized by testing the applicable asset or asset group&#x2019;s carrying value for recoverability. This test requires long-lived assets to be grouped at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities, the determination of which requires judgment. We estimate the undiscounted future cash flows expected to be generated from the use and eventual disposal of the assets and compare that estimate to the respective carrying values in order to determine if such carrying values are recoverable. This assessment requires the exercise of judgment in assessing the future use of and projected value to be derived from the eventual disposal of the assets to be held and used. In our assessments, we also consider changes in asset utilization, including, if applicable, the temporary idling of capacity and the expected timing for placing this capacity back into production. If the carrying value of the assets is not recoverable, then we record a loss for the difference between the assets&#x2019; fair value and respective carrying values. We determine the fair value of the assets using an &#x201c;income approach&#x201d; based upon a forecast of all the expected discounted future net cash flows associated with the subject assets. Some of the more significant estimates and assumptions include market size and growth, market share, projected selling prices, manufacturing cost, and discount rate. We base estimates upon historical experience, our commercial relationships, market conditions, and available external information about future trends. We believe our current assumptions and estimates are reasonable and appropriate. Unanticipated events and changes in market conditions, however, could affect such estimates, resulting in the need for an impairment charge in future periods. There was no impairment of long-lived assets to be held and used during the years ended December 31, 2019, 2018, and 2017.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;We perform impairment tests for intangible assets with indefinite useful lives annually, in the fourth quarter, or more frequently if events occur or circumstances change that would more likely than not reduce the fair value of an intangible asset below its carrying value. The impairment test for assets with indefinite lives consists of a comparison of the fair value of the asset with its carrying amount. If the carrying amount of an intangible asset exceeds its fair value, an impairment loss is recognized in an amount equal to that excess. &lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: #212529"&gt;We also evaluate the remaining useful life of intangible assets subject to amortization on a periodic basis to determine whether events and circumstances would indicate impairment or warrant a revision to the remaining useful life. If the estimate of an intangible asset&#x2019;s remaining useful life is changed, we will amortize the remaining carrying value of the intangible asset prospectively over the revised remaining useful life.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2019-01-01to2019-12-31">&lt;p id="xdx_843_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zcmWXNTLtxO5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: black"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span style="color: black"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;Our financial instruments consist primarily of cash, accounts receivable, accounts payable, accrued expenses and long term debt. The carrying amount of cash, accounts receivable, accounts payable and accrued expenses approximates their fair value because of the short-term maturity of such instruments, which are considered Level 1 assets under the fair value hierarchy.&#160; T&lt;span style="color: #212529"&gt;he carrying amount for long-term debt as of December 31, 2019 and 2018 (as disclosed in Note 8), approximates fair value based on market activity for other debt instruments with similar characteristics and comparable risk (Level 2).&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;We
categorize our assets and liabilities that are valued at fair value on a recurring basis into a three-level fair value
hierarchy as defined by ASC 820, &lt;i&gt;&lt;span style="color: black"&gt;Fair Value Measurements&lt;/span&gt;&lt;/i&gt;, or ASC 820. The fair value
hierarchy gives the highest priority to quoted prices in active markets for identical assets and liabilities (Level 1) and
lowest priority to unobservable inputs (Level 3). Assets and liabilities recorded in the consolidated balance sheet at fair
value are categorized based on a hierarchy of inputs, as follows: &lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;
&lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 4%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify; width: 6%"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: justify; width: 90%"&gt;unadjusted quoted prices in active markets for identical assets or liabilities;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;quoted prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument; and&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;unobservable inputs for the assets or liabilities.&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;At December 31, 2019 and 2018, we had no assets or liabilities that were valued at fair value on a recurring basis.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;The fair value of indefinite-lived assets is measured on a non-recurring basis using significant unobservable inputs (Level 3) in connection with any required impairment test. During the year ended December 31, 2019, we wrote off $78,864 in costs related to trademarks and patents, including the net carrying amount of our OPERA software patent. There was no impairment of intangible assets during the years ended December 31, 2018, and 2017.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2019-01-01to2019-12-31">&lt;p id="xdx_845_eus-gaap--IncomeTaxPolicyTextBlock_zXcE6tElWSuf" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="text-decoration: underline"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;We account for income taxes under the asset and liability method. We recognize deferred tax assets and liabilities for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. We measure deferred tax assets and liabilities using enacted tax rates expected to apply to taxable income in the years in which the related temporary differences are expected to be recovered or settled. We recognize the effect on deferred tax assets and liabilities of a change in tax rates when the rate change is enacted. Valuation allowances are recorded to reduce deferred tax assets to the amount that will more likely than not be realized.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;In accordance with ASC 740, &lt;i&gt;&lt;span style="color: black"&gt;Income Taxes&lt;/span&gt;&lt;/i&gt;, we recognize the effect of uncertain income tax positions only if the positions are more likely than not of being sustained in an audit, based on the technical merits of the position. We measure recognized uncertain income tax positions using the largest amount that has a likelihood of being realized that is greater than 50%. Changes in recognition or measurement are reflected in the period in which those changes in judgment occur.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;We recognize both interest and penalties related to uncertain tax positions as part of the income tax provision. At December 31, 2019 and 2018, we had no tax positions relating to open tax returns that were considered to be uncertain.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;Our U.S. federal and state tax returns since 2011, which was the first year we generated net operating losses, remain open to examination.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2019-01-01to2019-12-31">&lt;p id="xdx_84D_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zZ67QJ5XmZpg" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="text-decoration: underline"&gt;Share-Based Compensation&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;We measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees are required to provide services. Share-based compensation arrangements include options, restricted stock, restricted stock units, performance-based awards, share appreciation rights, and employee share purchase plans. We amortize such compensation amounts, if any, over the respective service periods of the award. We use the Black-Scholes-Merton option pricing model, or the Black-Scholes Model, an acceptable model in accordance with ASC 718, Compensation-Stock Compensation, to value options. Option valuation models require the input of assumptions, including the expected life of the stock-based awards, the estimated stock price volatility, the risk-free interest rate, and the expected dividend yield. The risk-free interest rate assumption is based upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the term of the instrument. Estimated volatility is a measure of the amount by which our stock price is expected to fluctuate each year during the term of the award. On January 1, 2017, we began using our own stock price in our volatility calculation along with the other peer entities whose stock prices were publicly available that were similar to our company and in 2019 we started using only our own stock price in the volatility calculation. Our calculation of estimated volatility is based on historical stock prices over a period equal to the expected term of the awards. The average expected life of options is based on the contractual terms of the stock option using the simplified method. We utilize a dividend yield of zero based on the fact that we have never paid cash dividends and have no current intention to pay cash dividends. Calculating share-based compensation expense requires the input of highly subjective judgment and assumptions, estimates of expected life of the share-based award, stock price volatility and risk-free interest rates. The assumptions used in calculating the fair value of share-based awards represent our best estimates, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change and we use different assumptions, our share-based compensation expense could be materially different in the future. We recognize the compensation expense for share-based compensation granted based on the grant date fair value estimated in accordance with ASC 718. We generally recognize the compensation expense on a straight-line basis over the employee&#x2019;s requisite service period. Effective January 1, 2017, we account for forfeitures when they occur. On January 1, 2019, we adopted ASU 2018-07 which simplified the accounting for share-based payments to non-employees by aligning it with the accounting for share-based payments to employees, with certain exceptions. The new guidance expanded the scope of ASC 718 to include share-based payments granted to non-employees in exchange for goods or services used or consumed in an entity&#x2019;s own operations and superseded the guidance in ASC 505-50. Prior to January 1, 2019, equity instruments issued to non-employees were recorded on a fair value basis, as required by ASC 505, Equity - Based Payments to Non-Employees.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="From2019-01-01to2019-12-31">&lt;p id="xdx_845_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zX9Q9Tx5SIq5" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: black"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span style="color: black"&gt;Revenue Recognition&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;We
adopted ASC 606, &lt;i&gt;Revenue from Contracts with Customers&lt;/i&gt;, or ASC 606, on January 1, 2018 using the modified retrospective
method for all contracts not completed as of the date of adoption. ASC 606 states that a contract is considered &#x201c;completed&#x201d;
if all (or substantially all) of the revenue was recognized in accordance with revenue guidance that was in effect before the
date of initial application. Because all (or substantially all) of the revenue related to sales of our products was recognized
under ASC 605 prior to the date of initial application of the new standard, the contracts were considered completed under ASC
606. Based on our evaluation of ASC 606, we concluded that a cumulative adjustment was not necessary upon implementation of ASC
606 on January 1, 2018. In accordance with ASC 606, revenue is recognized when a customer obtains control of promised goods or
services. The amount of revenue recognized reflects the consideration to which we expect to be entitled to receive in exchange
for these goods or services. The provisions of ASC 606 include a five-step process by which we determine revenue recognition,
depicting the transfer of goods or services to customers in amounts reflecting the payment to which we expect to be entitled in
exchange for those goods or services. ASC 606 requires us to apply the following steps: (1) identify the contract with the customer;
(2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price
to the performance obligations in the contract; and (5) recognize revenue when, or as, we satisfy the performance obligation.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 36pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span style="color: black"&gt;&lt;i&gt;Prescription Products&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: #212529"&gt;As of December 31, 2019, our products consisted primarily of prescription vitamins and our FDA-approved products: IMVEXXY, which we began selling during the third quarter of 2018, and BIJUVA, which we began selling in the second quarter of 2019. We started selling ANNOVERA in the third quarter of 2019 and we expect the full commercial launch of ANNOVERA in the first quarter of 2020. We sell our name brand and generic prescription products primarily through wholesale distributors and retail pharmacies. We have one performance obligation related to prescription products sold through wholesale distributors, which is to transfer promised goods to a customer, and two performance obligations related to products sold through retail pharmacies, which are to: (1) transfer promised goods and (2) provide customer service for an immaterial fee. We treat shipping as a fulfillment activity rather than as a separate obligation. We recognize prescription revenue only when we satisfy performance obligations by transferring a promised good or service to a customer. A good or service is considered to be transferred when the customer receives the goods or service or obtains control. Control refers to the customer&#x2019;s ability to direct the use of, and obtain substantially all of the remaining benefits from, an asset. Based on our contracts, we invoice customers once our performance obligations have been satisfied, at which point payment is unconditional. We disclose receivables from contracts with customers separately in the statement of financial position. Payment for goods or services sold by us is typically due between 30 and 60 days after an invoice is sent to the customer. &lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: #212529"&gt;The transaction price of a contract is the amount of consideration which we expect to be entitled to in exchange for transferring promised goods or services to a customer. Prescription products are sold at fixed wholesale acquisition cost, or WAC, determined based on our list price. However, the total transaction price is variable as it is calculated net of estimated product returns, chargebacks, rebates, coupons, discounts and wholesaler fees. These estimates are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the customer) or a current liability (if the amount is payable to a party other than a customer). In order to determine the transaction price, we estimate the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract or each variable consideration. The estimated amount of variable consideration is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. In determining amounts of variable consideration to include in a contract&#x2019;s transaction price, we rely on our historical experience and other evidence that supports our qualitative assessment of whether revenue would be subject to a significant reversal. We consider all the facts and circumstances associated with both the risk of a revenue reversal arising from an uncertain future event and the magnitude of the reversal if that uncertain event were to occur. Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our original estimates, we will adjust these estimates, which would affect net product revenue and earnings in the period such changes in estimates become known. &lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: #212529"&gt;We accept returns of unsalable prescription products sold through wholesale distributors within a return period of &lt;span id="xdx_90B_ecustom--ReturnPeriodOfUnsalablePrescriptionProducts_dxH_c20190101__20191231__srt--RangeAxis__srt--MinimumMember_zwmQaTTYNKK" title="Return period of unsalable prescription products::XDX::P6M"&gt;six&lt;/span&gt; months prior to and up to &lt;span id="xdx_908_ecustom--ReturnPeriodOfUnsalablePrescriptionProducts_dtM_c20190101__20191231__srt--RangeAxis__srt--MaximumMember_zpQUNXhwWkQ1"&gt;12&lt;/span&gt; months following product expiration. Our vitamins and IMVEXXY currently have a shelf life of &lt;span id="xdx_907_ecustom--ShelfLifeOfPrescriptionProducts_dtM_c20190101__20191231__srt--ProductOrServiceAxis__custom--VitaminsAndImvexxyMember_zdk5medOaIY1" title="Shelf life of prescription products following product expiration"&gt;24&lt;/span&gt; months from the date of manufacture and BIJUVA and ANNOVERA currently have a shelf life of &lt;span id="xdx_905_ecustom--ShelfLifeOfPrescriptionProducts_dtM_c20190101__20191231__srt--ProductOrServiceAxis__custom--BijuvaAndAnnoveraMember_zykSpchkSjok"&gt;18&lt;/span&gt; months from the date of manufacture. We do not allow product returns for prescription products that have been dispensed to a patient. We estimate the amount of our product sales that may be returned by our customers and record this estimate as a reduction of revenue in the period the related product revenue is recognized. Where historical rates of return exist, we use history as a basis to establish a returns reserve for products shipped to wholesalers. For our newly launched products, for which the right of return exists but for which we currently do not have history of product returns, we estimate returns based on available industry data, our own sales information and our visibility into the inventory remaining in the distribution channel. At the end of each reporting period, we may decide to constrain revenue for product returns based on information from various sources, including channel inventory levels and dating and sell-through data, the expiration dates of products currently being shipped, price changes of competitive products and any introductions of generic products. We recognize the amount of expected returns as a refund liability, representing the obligation to return the customer&#x2019;s consideration. Since our returns primarily consist of expired and short dated products that will not be resold, we do not record a return asset for the right to recover the goods returned by the customer at the time of the initial sale (when recognition of revenue is deferred due to the anticipated return). Return estimates are recorded in accrued expenses and other current liabilities on the consolidated balance sheet.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: #212529"&gt;We offer various rebate and discount programs in an effort to maintain a competitive position in the marketplace and to promote sales and customer loyalty. We estimate the allowance for consumer rebates and coupons that we have offered based on our experience and industry averages, which is reviewed, and adjusted if necessary, on a quarterly basis. Estimates relating to these rebates and coupons are deducted from gross product revenues at the time the revenues are recognized. We record distributor fees based on amounts stated in contracts. Rebate and coupon estimates and distributor fees are recorded in accrued expenses and other current liabilities on the consolidated balance sheet. We estimate chargebacks based on number of units sold during the period taking into account prices stated in contracts and our historical experience. Estimates related to distributors fees, rebates, coupons and returns are disclosed in Note 7. We provide invoice discounts to our customers for prompt payment. Estimates relating to invoice discounts and chargebacks are deducted from gross product revenues at the time the revenues are recognized. &lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: #212529"&gt;As part of commercial launches for our FDA-approved prescription products, we introduced a co-pay assistance program for eligible enrolled patients whose out of pocket costs are reduced to a more affordable price. This allows patients to access the product at a reasonable cost and is in line with our responsible pricing approach. We reimburse pharmacies for this discount through third-party vendors. We consider certain payments as consideration paid to the customer and reflect such payments as a reduction of the transaction price as we do not receive a distinct good or service related to these payments. The variable consideration is estimated based on contract prices, the estimated percentage of patients that will utilize the copay assistance, the average assistance paid, the estimated levels of inventory in the distribution channel and the current level of prescriptions covered by patients&#x2019; insurance. Payers may change coverage levels for our prescription products positively or negatively, at any time up to the time that we have formally contracted coverage with the payer. As such, the net transaction price of our prescription products is susceptible to such changes in coverage levels, which are outside the influence of the Company. As a result, we constrain variable consideration for our prescription products to an amount that will not result in a significant revenue reversal in future periods. Our ability to estimate the net transaction price for our prescription products is constrained by our estimates of the amount to be paid for the co-pay assistance program which is directly related to the level of prescriptions paid for by insurance. As such, we record an accrual to reduce gross sales for the estimated co-pay and other patient assistance based on currently available third-party data and our internal analyses. We re-evaluate variable consideration each reporting period.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 36pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: #212529"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span style="color: #212529"&gt;&lt;i&gt;License Revenue&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: #212529"&gt;License
arrangements may consist of non-refundable upfront license fees, exclusive licensed rights to patented or patent pending
technology, and various performance or sales milestones and future product royalty payments. Some of these arrangements may
include multiple performance obligations. Non-refundable up-front fees that are not contingent on any future performance by
us, and do not require continuing involvement on our part, are recognized as revenue when the right to use functional IP is transferred to the customer.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #212529"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span style="color: #212529"&gt;License Agreement with Knight Therapeutics Inc.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: #212529"&gt;On July 30, 2018, we entered into the Knight License Agreement with Knight pursuant to which we granted Knight an exclusive license to commercialize IMVEXXY and BIJUVA in Canada and Israel. Pursuant to the terms of the Knight License Agreement, Knight will pay us a milestone fee upon first regulatory approval in Canada of each of IMVEXXY and BIJUVA, sales milestone fees based upon certain aggregate annual sales in Canada and Israel of each of IMVEXXY and BIJUVA and royalties based on aggregate annual sales of each of IMVEXXY and BIJUVA in Canada and Israel. Knight will be responsible for all regulatory and commercial activities in Canada and Israel related to IMVEXXY and BIJUVA. We may terminate the Knight License Agreement if Knight does not submit all regulatory applications, submissions and/or registrations required for regulatory approval to use and commercialize IMVEXXY and BIJUVA in Canada and Israel within certain specified time periods. We also may terminate the Knight License Agreement if Knight challenges our patents. Either party may terminate the Knight License Agreement for any material breach by the other party that is not cured within certain specified time periods or if the other party files for bankruptcy or other related matters. In connection with the Knight License Agreement, Knight entered into a subscription agreement with us, pursuant to which Knight purchased &lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20180730__20180806__us-gaap--SubsidiarySaleOfStockAxis__custom--SubscriptionAgreementKnightMember_zPi7HFxxKJK7"&gt;3,921,568&lt;/span&gt; shares of our Common Stock concurrent with the closing of the underwritten public offering of Common Stock on August 6, 2018 at a price of $&lt;span id="xdx_90C_eus-gaap--SaleOfStockPricePerShare_iI_c20180806__us-gaap--SubsidiarySaleOfStockAxis__custom--SubscriptionAgreementKnightMember_zA6xYqBlf9gh"&gt;5.10&lt;/span&gt;, for proceeds of $&lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20180730__20180806__us-gaap--SubsidiarySaleOfStockAxis__custom--SubscriptionAgreementKnightMember_zE3Vbx4PtVqb"&gt;20,000,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #212529"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span style="color: #212529"&gt;License Agreement with Theramex&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: #212529"&gt;On
June 6, 2019, we entered into the Theramex License Agreement with Theramex to commercialize BIJUVA and IMVEXXY in the &lt;span style="color: black"&gt;Theramex &lt;/span&gt;Territory.
Under the terms of the Theramex License Agreement, Theramex paid us EUR &lt;span id="xdx_90E_ecustom--CashUpfrontPaymentReceived_dm_uEUR_c20190804__20190805__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember_zhZ8Q0Jom5W"&gt;14
million&lt;/span&gt;, or $&lt;span id="xdx_904_ecustom--CashUpfrontPaymentReceived_uUSD_c20190803__20190805__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember_z1NgfBwzHIz7"&gt;15,506,400&lt;/span&gt;,
in cash as an upfront fee on August 5, 2019. Within thirty days of signing the Theramex License Agreement, we provided
Theramex the regulatory materials and clinical data that were necessary for Theramex to obtain marketing authorizations and
other applicable regulatory approvals for commercializing BIJUVA and IMVEXXY. We recognized the revenue related to the
upfront fee, which was a non-refundable payment, during the third quarter of 2019, at a point in time when Theramex was able
to use and benefit from the license which was when the knowledge transfer of regulatory documents occurred. We are eligible
to receive additional milestone payments comprised of (i) up to an aggregate of EUR &lt;span id="xdx_907_ecustom--RegulatoryMilestoneAdditionalPayment_iI_dm_uEUR_c20190606__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember__srt--RangeAxis__srt--MaximumMember_zebOAlMYfGdc"&gt;2
million&lt;/span&gt; in regulatory milestone payments based on regulatory approvals for BIJUVA and IMVEXXY in certain specified
markets and (ii) up to an aggregate of EUR &lt;span id="xdx_906_ecustom--SalesMilestonePaymentsInTranches_iI_dm_uEUR_c20190606__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember__srt--RangeAxis__srt--MaximumMember_zTkMgkY5IUa4"&gt;27.5
million&lt;/span&gt; in sales milestone payments to be paid in escalating tranches based on Theramex first attaining certain
aggregate annual net sales milestones of BIJUVA and IMVEXXY in the &lt;span style="color: black"&gt;Theramex &lt;/span&gt;Territory
ranging from EUR &lt;span id="xdx_90C_ecustom--AnnualNetSalesMilestone_dm_uEUR_c20190605__20190606__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember__srt--RangeAxis__srt--MinimumMember_z1X49D80mEN1" title="Sales milestone"&gt;25
million&lt;/span&gt; to EUR &lt;span id="xdx_909_ecustom--AnnualNetSalesMilestone_dm_uEUR_c20190605__20190606__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember__srt--RangeAxis__srt--MaximumMember_zfL5UAQPZVef"&gt;100
million&lt;/span&gt;. We are also entitled to receive quarterly royalty payments at a rate of &lt;span id="xdx_90D_ecustom--QuarterlyRoyaltyPaymentsPercentage_dp_c20190605__20190606__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember__srt--ProductOrServiceAxis__custom--BijuvaAndAnnoveraMember_zNWu2klcrb31" title="Quarterly royalty payments percentage"&gt;5&lt;/span&gt;% on net sales of BIJUVA and
IMVEXXY in the &lt;span style="color: black"&gt;Theramex &lt;/span&gt;Territory. Theramex is responsible for all regulatory
and commercial activities for BIJUVA and IMVEXXY in the &lt;span style="color: black"&gt;Theramex &lt;/span&gt;Territory. Theramex
may sublicense its rights to commercialize BIJUVA and IMVEXXY in the &lt;span style="color: black"&gt;Theramex &lt;/span&gt;Territory,
except for certain specified markets. We may terminate the Theramex License Agreement if Theramex does not submit
all regulatory applications, submissions and/or registrations required for regulatory approval to use and commercialize
BIJUVA and IMVEXXY within certain specified time periods. We also may terminate the Theramex License Agreement if
Theramex challenges our patents. Either party may terminate the Theramex License Agreement for any material breach by the
other party that is not cured within certain specified time periods or if the other party files for bankruptcy or other
related matters. &lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 36pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span style="color: black"&gt;&lt;i&gt;Disaggregation of revenue&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p id="xdx_890_eus-gaap--DisaggregationOfRevenueTableTextBlock_z8OEeqjDg4wl" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;The following table provides information about disaggregated revenue by product mix for the years ended December 31, 2019, 2018, and 2017:&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin-right: auto; margin-left: auto; float: none; width: 80%"&gt;

&lt;tr&gt;
&lt;td style="vertical-align: top; padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b/&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-right: Black medium none; border-left: Black medium none; padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b/&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-right: Black medium none; border-left: Black medium none; padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b/&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="10" style="border-bottom: black 1pt solid; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;For the Years
Ended December 31,&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: black 1pt solid; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-right: Black medium none; border-bottom: Black 1pt solid; border-left: Black medium none; padding: 0pt 5.4pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-right: Black medium none; border-bottom: Black 1pt solid; border-left: Black medium none; padding: 0pt 5.4pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; width: 55%; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;Prescription vitamins&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%"&gt;
&lt;p id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_zTCn7GWquVDa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;9,885,493&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%"&gt;
&lt;p id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180101__20181231__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_zeoacSq302Jd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;15,041,259&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%"&gt;
&lt;p id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20170101__20171231__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_zFufrbuEnuIj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;16,744,831&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;IMVEXXY&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ProductOrServiceAxis__custom--ImvexxyMember_zYDRVsbMXUX2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;16,252,045&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180101__20181231__srt--ProductOrServiceAxis__custom--ImvexxyMember_z6BPbXQEuVA8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;1,058,201&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#x2014;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;BIJUVA&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ProductOrServiceAxis__custom--BijuvaMember_zTDhU6TAWyd9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;1,836,443&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#x2014;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#x2014;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;ANNOVERA&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ProductOrServiceAxis__custom--AnnoveraMember_zNVeDXdoxc1h" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;6,166,556&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#x2014;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#x2014;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;License revenue&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ProductOrServiceAxis__us-gaap--LicenseAndServiceMember_zsZ6QSDNh8v1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;15,506,400&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#x2014;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#x2014;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;OTC products&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#x2014;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#x2014;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20170101__20171231__srt--ProductOrServiceAxis__custom--OtcProductsMember_zFoKtnjjbps5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;32,882&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 0pt 16px; text-indent: 0pt"&gt;Net revenue&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom"&gt;
&lt;p id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231_ziaaFJ1sWOfe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Net revenue"&gt;49,646,937&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom"&gt;
&lt;p id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180101__20181231_z38IF71YI67g" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;16,099,460&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom"&gt;
&lt;p id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20170101__20171231_zq8rzdspFESg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;16,777,713&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p id="xdx_8A1_z2enxXr8rRi1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: black"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span style="color: black"&gt;Shipping and Handling Costs&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;We expense all shipping and handling costs as incurred. We include these costs in cost of goods sold on the accompanying consolidated financial statements.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <txmd:ReturnPeriodOfUnsalablePrescriptionProducts contextRef="From2019-01-012019-12-31_srt_MaximumMember">P12M</txmd:ReturnPeriodOfUnsalablePrescriptionProducts>
    <txmd:ShelfLifeOfPrescriptionProducts contextRef="From2019-01-012019-12-31_custom_VitaminsAndImvexxyMember">P24M</txmd:ShelfLifeOfPrescriptionProducts>
    <txmd:ShelfLifeOfPrescriptionProducts contextRef="From2019-01-012019-12-31_custom_BijuvaAndAnnoveraMember">P18M</txmd:ShelfLifeOfPrescriptionProducts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2018-07-302018-08-06_custom_SubscriptionAgreementKnightMember"
      decimals="INF"
      unitRef="Shares">3921568</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2018-08-06_custom_SubscriptionAgreementKnightMember"
      decimals="INF"
      unitRef="USDPShares">5.10</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2018-07-302018-08-06_custom_SubscriptionAgreementKnightMember"
      decimals="0"
      unitRef="USD">20000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <txmd:CashUpfrontPaymentReceived
      contextRef="From2019-08-042019-08-05_custom_LicenseAgreementTheramexMember"
      decimals="0"
      unitRef="EUR">14000000</txmd:CashUpfrontPaymentReceived>
    <txmd:CashUpfrontPaymentReceived
      contextRef="From2019-08-032019-08-05_custom_LicenseAgreementTheramexMember"
      decimals="0"
      unitRef="USD">15506400</txmd:CashUpfrontPaymentReceived>
    <txmd:RegulatoryMilestoneAdditionalPayment
      contextRef="AsOf2019-06-06_custom_LicenseAgreementTheramexMember_srt_MaximumMember"
      decimals="0"
      unitRef="EUR">2000000</txmd:RegulatoryMilestoneAdditionalPayment>
    <txmd:SalesMilestonePaymentsInTranches
      contextRef="AsOf2019-06-06_custom_LicenseAgreementTheramexMember_srt_MaximumMember"
      decimals="0"
      unitRef="EUR">27500000</txmd:SalesMilestonePaymentsInTranches>
    <txmd:AnnualNetSalesMilestone
      contextRef="From2019-06-052019-06-06_custom_LicenseAgreementTheramexMember_srt_MinimumMember"
      decimals="0"
      unitRef="EUR">25000000</txmd:AnnualNetSalesMilestone>
    <txmd:AnnualNetSalesMilestone
      contextRef="From2019-06-052019-06-06_custom_LicenseAgreementTheramexMember_srt_MaximumMember"
      decimals="0"
      unitRef="EUR">100000000</txmd:AnnualNetSalesMilestone>
    <txmd:QuarterlyRoyaltyPaymentsPercentage
      contextRef="From2019-06-052019-06-06_custom_LicenseAgreementTheramexMember_custom_BijuvaAndAnnoveraMember"
      decimals="INF"
      unitRef="Pure">0.05</txmd:QuarterlyRoyaltyPaymentsPercentage>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="From2019-01-01to2019-12-31">&lt;p id="xdx_890_eus-gaap--DisaggregationOfRevenueTableTextBlock_z8OEeqjDg4wl" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;The following table provides information about disaggregated revenue by product mix for the years ended December 31, 2019, 2018, and 2017:&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin-right: auto; margin-left: auto; float: none; width: 80%"&gt;

&lt;tr&gt;
&lt;td style="vertical-align: top; padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b/&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-right: Black medium none; border-left: Black medium none; padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b/&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-right: Black medium none; border-left: Black medium none; padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b/&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="10" style="border-bottom: black 1pt solid; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;For the Years
Ended December 31,&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: black 1pt solid; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-right: Black medium none; border-bottom: Black 1pt solid; border-left: Black medium none; padding: 0pt 5.4pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-right: Black medium none; border-bottom: Black 1pt solid; border-left: Black medium none; padding: 0pt 5.4pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; width: 55%; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;Prescription vitamins&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%"&gt;
&lt;p id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_zTCn7GWquVDa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;9,885,493&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%"&gt;
&lt;p id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180101__20181231__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_zeoacSq302Jd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;15,041,259&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%"&gt;
&lt;p id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20170101__20171231__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_zFufrbuEnuIj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;16,744,831&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;IMVEXXY&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ProductOrServiceAxis__custom--ImvexxyMember_zYDRVsbMXUX2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;16,252,045&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180101__20181231__srt--ProductOrServiceAxis__custom--ImvexxyMember_z6BPbXQEuVA8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;1,058,201&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#x2014;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;BIJUVA&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ProductOrServiceAxis__custom--BijuvaMember_zTDhU6TAWyd9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;1,836,443&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#x2014;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#x2014;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;ANNOVERA&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ProductOrServiceAxis__custom--AnnoveraMember_zNVeDXdoxc1h" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;6,166,556&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#x2014;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#x2014;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;License revenue&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ProductOrServiceAxis__us-gaap--LicenseAndServiceMember_zsZ6QSDNh8v1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;15,506,400&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#x2014;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#x2014;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;OTC products&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#x2014;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#x2014;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20170101__20171231__srt--ProductOrServiceAxis__custom--OtcProductsMember_zFoKtnjjbps5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;32,882&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 0pt 16px; text-indent: 0pt"&gt;Net revenue&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom"&gt;
&lt;p id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231_ziaaFJ1sWOfe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Net revenue"&gt;49,646,937&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom"&gt;
&lt;p id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180101__20181231_z38IF71YI67g" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;16,099,460&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom"&gt;
&lt;p id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20170101__20171231_zq8rzdspFESg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;16,777,713&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2019-01-012019-12-31_custom_PrescriptionVitaminsMember"
      decimals="0"
      unitRef="USD">9885493</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2018-01-012018-12-31_custom_PrescriptionVitaminsMember"
      decimals="0"
      unitRef="USD">15041259</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2017-01-012017-12-31_custom_PrescriptionVitaminsMember"
      decimals="0"
      unitRef="USD">16744831</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2019-01-012019-12-31_custom_ImvexxyMember"
      decimals="0"
      unitRef="USD">16252045</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2018-01-012018-12-31_custom_ImvexxyMember"
      decimals="0"
      unitRef="USD">1058201</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2019-01-012019-12-31_custom_BijuvaMember"
      decimals="0"
      unitRef="USD">1836443</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2019-01-012019-12-31_custom_AnnoveraMember"
      decimals="0"
      unitRef="USD">6166556</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2019-01-012019-12-31_us-gaap_LicenseAndServiceMember"
      decimals="0"
      unitRef="USD">15506400</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2017-01-012017-12-31_custom_OtcProductsMember"
      decimals="0"
      unitRef="USD">32882</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2019-01-01to2019-12-31"
      decimals="0"
      unitRef="USD">49646937</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">16099460</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2017-01-012017-12-31"
      decimals="0"
      unitRef="USD">16777713</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="From2019-01-01to2019-12-31">&lt;p id="xdx_84B_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zh34nsSoyXzj" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: black"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span style="color: black"&gt;Segment Reporting&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;We are managed and operated as &lt;span id="xdx_901_eus-gaap--NumberOfReportableSegments_dc_uPure_c20190101__20191231_zfTscoqBJ7ng" title="Number of operating segments"&gt;one&lt;/span&gt; business, which is focused on creating and commercializing products targeted exclusively for women. Our business operations are managed by a single management team that reports to the President of our company. We do not operate separate lines of business with respect to any of our products and we do not prepare discrete financial information with respect to separate products. All product sales are derived from sales in the United States. Accordingly, we view our business as one reportable operating segment.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;



</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="From2019-01-01to2019-12-31"
      decimals="INF"
      unitRef="Pure">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:CostOfSalesPolicyTextBlock contextRef="From2019-01-01to2019-12-31">&lt;p id="xdx_848_eus-gaap--CostOfSalesPolicyTextBlock_zBqUjo09XUGh" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: black"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span style="color: black"&gt;Cost of Sales &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;Cost
of sales includes the cost of inventory, manufacturing, manufacturing overhead and supply chain costs, and product shipping
and handling costs. The Population Council License Agreement requires payment of royalties based on the sale of future
products. Such royalties are recorded as a component of cost of sales. Additionally, the amortization of license fees or
milestone payments related to licensed products are classified as components of cost of sales to the extent such payments
become due in the future.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

</us-gaap:CostOfSalesPolicyTextBlock>
    <us-gaap:AdvertisingCostsPolicyTextBlock contextRef="From2019-01-01to2019-12-31">&lt;p id="xdx_845_eus-gaap--AdvertisingCostsPolicyTextBlock_zwHL0Geta6pj" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="text-decoration: underline"&gt;Advertising Costs&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;We expense advertising costs when incurred. Advertising costs were $&lt;span id="xdx_900_eus-gaap--AdvertisingExpense_c20190101__20191231_zPOagYG9VJZh" title="Advertising costs"&gt;9,045,571&lt;/span&gt;, $&lt;span id="xdx_90C_eus-gaap--AdvertisingExpense_c20180101__20181231_zaOsot7eExva"&gt;1,682,746&lt;/span&gt; and $&lt;span id="xdx_900_eus-gaap--AdvertisingExpense_c20170101__20171231_zWaOTgdOA1Jf"&gt;448,288&lt;/span&gt; during the years ended December 31, 2019, 2018, and 2017, respectively.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:AdvertisingExpense
      contextRef="From2019-01-01to2019-12-31"
      decimals="0"
      unitRef="USD">9045571</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">1682746</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="From2017-01-012017-12-31"
      decimals="0"
      unitRef="USD">448288</us-gaap:AdvertisingExpense>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2019-01-01to2019-12-31">&lt;p id="xdx_845_eus-gaap--ResearchAndDevelopmentExpensePolicy_zIzh16fKypj9" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="text-decoration: underline"&gt;Research and Development Expenses&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;Research and development, or R&amp;amp;D, expenses include internal R&amp;amp;D activities, services of external contract research organizations, or CROs, costs of their clinical research sites, manufacturing, scale-up and validation costs, and other activities. Internal R&amp;amp;D activity expenses include laboratory supplies, salaries, benefits, and non-cash share-based compensation expenses. CRO activity expenses include preclinical laboratory experiments and clinical trial studies. Other activity expenses include regulatory consulting and other costs. The activities undertaken by our regulatory consultants that were classified as R&amp;amp;D expenses include assisting, consulting with, and advising our in-house staff with respect to various FDA submission processes, clinical trial processes, and scientific writing matters, including preparing protocols and FDA submissions. These consulting expenses were direct costs associated with preparing, reviewing, and undertaking work for our clinical trials and investigative drugs. We charge internal R&amp;amp;D activities and other activity expenses to operations as incurred. We make payments to CROs based on agreed-upon terms, which may include payments in advance of a study starting date. We expense nonrefundable advance payments for goods and services that will be used in future R&amp;amp;D activities when the activity has been performed or when the goods have been received rather than when the payment is made. We review and accrue CRO expenses and clinical trial study expenses based on services performed and rely on estimates of those costs applicable to the completion stage of a study as provided by CROs. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. We charge revisions to expenses in the period in which the facts that give rise to the revision become known.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2019-01-01to2019-12-31">&lt;p id="xdx_841_eus-gaap--EarningsPerSharePolicyTextBlock_zai2UEwH7ehf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="text-decoration: underline"&gt;Earnings Per Share&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;We calculate earnings per share, or EPS, in accordance with ASC 260, &lt;i&gt;&lt;span style="color: black"&gt;Earnings Per Share&lt;/span&gt;&lt;/i&gt;, which requires the computation and disclosure of two EPS amounts: basic and diluted. We compute basic EPS based on the weighted-average number of shares of common stock, par value $0.001 per share, or Common Stock, outstanding during the period. We compute diluted EPS based on the weighted-average number of shares of our Common Stock outstanding plus all potentially dilutive shares of our Common Stock outstanding during the period. Such potentially dilutive shares of our Common Stock consist of options, warrants and restricted stock awards and were excluded from the calculation of diluted earnings per share because their effect would have been anti-dilutive due to the net loss reported by us.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zjMWR87JAaTl" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;The table below presents potentially dilutive securities that could affect our calculation of diluted net loss per share allocable to common stockholders for the periods presented.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin-right: auto; margin-left: auto; float: none; width: 80%"&gt;

&lt;tr&gt;
&lt;td style="vertical-align: top; padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b/&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-right: Black medium none; border-left: Black medium none; padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b/&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-right: Black medium none; border-left: Black medium none; padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b/&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"/&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="10" style="border-bottom: black 1pt solid; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;As of December
31,&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: black 1pt solid; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-right: Black medium none; border-bottom: Black 1pt solid; border-left: Black medium none; padding: 0pt 5.4pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-right: Black medium none; border-bottom: Black 1pt solid; border-left: Black medium none; padding: 0pt 5.4pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; width: 55%; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;Stock options&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%"&gt;
&lt;p id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zwwment6okci" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;25,030,234&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%"&gt;
&lt;p id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z4Udu7FwKRBd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;20,872,824&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%"&gt;
&lt;p id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20170101__20171231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zLOgdFIRfWz1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;23,365,225&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;Warrants&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zn1G1tvZMjg2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;1,832,571&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20180101__20181231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zJuxJ8RNShMk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;3,007,571&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20170101__20171231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z1nPiuQRWDX3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;3,115,905&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;Restricted stock awards&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zed2bsYYVwWh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;1,240,000&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zIyxoJjJmrO6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;1,040,000&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#x2014;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom"&gt;
&lt;p id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20190101__20191231_zD9Rt6prp5r" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;28,102,805&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom"&gt;
&lt;p id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20180101__20181231_zP5dRly8IJff" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;24,920,395&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom"&gt;
&lt;p id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20170101__20171231_zBwVIKCXZx59" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;26,481,130&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;p id="xdx_8A5_znRoDQXLLwAh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2019-01-01to2019-12-31">&lt;p id="xdx_892_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zjMWR87JAaTl" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;The table below presents potentially dilutive securities that could affect our calculation of diluted net loss per share allocable to common stockholders for the periods presented.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin-right: auto; margin-left: auto; float: none; width: 80%"&gt;

&lt;tr&gt;
&lt;td style="vertical-align: top; padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b/&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-right: Black medium none; border-left: Black medium none; padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b/&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-right: Black medium none; border-left: Black medium none; padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b/&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"/&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="10" style="border-bottom: black 1pt solid; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;As of December
31,&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: black 1pt solid; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-right: Black medium none; border-bottom: Black 1pt solid; border-left: Black medium none; padding: 0pt 5.4pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-right: Black medium none; border-bottom: Black 1pt solid; border-left: Black medium none; padding: 0pt 5.4pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; width: 55%; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;Stock options&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%"&gt;
&lt;p id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zwwment6okci" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;25,030,234&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%"&gt;
&lt;p id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z4Udu7FwKRBd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;20,872,824&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%"&gt;
&lt;p id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20170101__20171231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zLOgdFIRfWz1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;23,365,225&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;Warrants&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zn1G1tvZMjg2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;1,832,571&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20180101__20181231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zJuxJ8RNShMk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;3,007,571&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20170101__20171231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z1nPiuQRWDX3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;3,115,905&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;Restricted stock awards&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zed2bsYYVwWh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;1,240,000&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zIyxoJjJmrO6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;1,040,000&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#x2014;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom"&gt;
&lt;p id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20190101__20191231_zD9Rt6prp5r" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;28,102,805&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom"&gt;
&lt;p id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20180101__20181231_zP5dRly8IJff" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;24,920,395&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom"&gt;
&lt;p id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20170101__20171231_zBwVIKCXZx59" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;26,481,130&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Shares">25030234</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2018-01-012018-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Shares">20872824</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2017-01-012017-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Shares">23365225</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2019-01-012019-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">1832571</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2018-01-012018-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">3007571</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2017-01-012017-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">3115905</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2019-01-012019-12-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="Shares">1240000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2018-01-012018-12-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="Shares">1040000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2019-01-01to2019-12-31"
      decimals="INF"
      unitRef="Shares">28102805</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2018-01-012018-12-31"
      decimals="INF"
      unitRef="Shares">24920395</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2017-01-012017-12-31"
      decimals="INF"
      unitRef="Shares">26481130</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2019-01-01to2019-12-31">&lt;p id="xdx_840_eus-gaap--ConcentrationRiskCreditRisk_z3qPnllrsXji" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="text-decoration: underline"&gt;Concentration of Credit Risk and other Risks and Uncertainties&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;Financial instruments that potentially expose us to concentrations of credit risk consist primarily of cash and trade accounts receivable. Cash is on deposit with financial institutions in the United States and these deposits generally exceed the amount of insurance provided by the FDIC. We have not experienced any historical losses on our deposits of cash.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;Concentration of credit risk with respect to our trade accounts receivable from our customers is primarily limited to drug wholesalers and retail pharmacy distributors. Credit is extended to our customers based on an evaluation of a customer&#x2019;s financial condition, and collateral is not required.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:UseOfEstimates contextRef="From2019-01-01to2019-12-31">&lt;p id="xdx_84F_eus-gaap--UseOfEstimates_zsMyrC5LdsBg" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="text-decoration: underline"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;Our consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP. The preparation of these financial statements requires us to make significant estimates and judgments that affect the reported amounts of assets, liabilities, revenue, expenses, and related disclosure of contingent assets and liabilities. We evaluate our estimates, including those related to contingencies, on an ongoing basis. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ, at times in material amounts, from these estimates under different assumptions or conditions.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;



</us-gaap:UseOfEstimates>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2019-01-01to2019-12-31">&lt;p id="xdx_84B_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zjxi7fQvxgc2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="text-decoration: underline"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="color: black"&gt;In August 2018, the FASB issued Accounting Standards Update, or ASU, 2018-13, which eliminates certain disclosure requirements for fair value measurements for all entities, requires public entities to disclose certain new information and modifies some disclosure requirements. The FASB developed the amendments to ASC 820 as part of its broader disclosure framework project, which aims to improve the effectiveness of disclosures in the notes to financial statements by focusing on requirements that clearly communicate the most important information to users of the financial statements. The new guidance is effective for all entities for fiscal years beginning after December 15, 2019 and for interim periods within those fiscal years. An entity is permitted to early adopt either the entire standard or only the provisions that eliminate or modify requirements. We do not expect that the adoption of this standard will have a material effect on our disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="color: black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="color: black"&gt;In June 2018, the FASB issued ASU 2018-07 to simplify the accounting for share-based payments to non-employees by aligning it with the accounting for share-based payments to employees, with certain exceptions. The new guidance expands the scope of ASC 718 to include share-based payments granted to non-employees in exchange for goods or services used or consumed in an entity&#x2019;s own operations and supersedes the guidance in ASC 505-50. The guidance is effective for public business entities in annual periods beginning after December 15, 2018, and interim periods within those annual periods. Early adoption is permitted, including in an interim period for which financial statements have not been issued, but not before an entity adopts ASC 606. We adopted this standard on January 1, 2019 and the adoption of this standard did not have a material effect on our consolidated financial statements. &lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="color: black"&gt;In February 2016, the FASB issued ASU 2016-02, Leases. This guidance requires lessees to record most leases on their balance sheets while recognizing expenses on their income statements in a manner similar to current accounting. The guidance also eliminates current real estate-specific provisions for all entities. For lessors, the guidance modifies the classification criteria and the accounting for sales-type and direct financing leases. The standard was effective for public business entities for annual periods beginning after December 15, 2018, and interim periods within those years. In July 2018, the FASB amended the new leases standard and issued ASU 2018-11, Leases, (Topic 842): Targeted Improvements to give entities another option for transition and to provide lessors with a practical expedient. We adopted ASU 2016-02 on January 1, 2019 utilizing the alternative transition method allowed for under ASU 2018-11 and we recorded a $&lt;span id="xdx_903_eus-gaap--OperatingLeaseRightOfUseAsset_iI_dm_c20190102__us-gaap--AdjustmentsForNewAccountingPronouncementsAxis__us-gaap--AccountingStandardsUpdate201602Member_zlV7DDjFbRp3" title="Right of use asset"&gt;3.8 million&lt;/span&gt; right of use asset and a $&lt;span id="xdx_903_eus-gaap--OperatingLeaseLiability_iI_dm_c20190102__us-gaap--AdjustmentsForNewAccountingPronouncementsAxis__us-gaap--AccountingStandardsUpdate201602Member_zthkuShkZZq9" title="Lease liability"&gt;4.1 million&lt;/span&gt; liability related to adoption of this standard. In addition, upon commencement of additional leased space in the third quarter of 2019 (as disclosed in Note 13), we recorded an additional $&lt;span id="xdx_903_eus-gaap--OperatingLeaseRightOfUseAsset_iI_dm_c20190831_zkKApmrsrDpd"&gt;7.4 million&lt;/span&gt; right of use asset and an additional $&lt;span id="xdx_90A_eus-gaap--OperatingLeaseLiability_iI_dm_c20190831_zd4NiSL1yiF4"&gt;7.2 million&lt;/span&gt; liability related to our new leased space. Comparative financial information was not adjusted and will continue to be reported under ASC 840. We also elected the transition relief package of practical expedients and as a result we did not assess (1) whether existing or expired contracts contain leases, (2) lease classification for any existing or expired leases, and (3) whether lease origination costs qualified as initial direct costs. We elected the short-term lease practical expedient by establishing an accounting policy to exclude leases with a term of 12 months or less. We elected not to separate lease components from non-lease components for our specified asset classes. Additionally, the adoption of the new standard resulted in increased disclosure requirements in our quarterly and annual filings. &lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants and the SEC did not, and are not expected to, have a material effect on our results of operations or financial position.&lt;/span&gt;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2019-01-02_us-gaap_AccountingStandardsUpdate201602Member"
      decimals="0"
      unitRef="USD">3800000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2019-01-02_us-gaap_AccountingStandardsUpdate201602Member"
      decimals="0"
      unitRef="USD">4100000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2019-08-31" decimals="0" unitRef="USD">7400000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability contextRef="AsOf2019-08-31" decimals="0" unitRef="USD">7200000</us-gaap:OperatingLeaseLiability>
    <us-gaap:InventoryDisclosureTextBlock contextRef="From2019-01-01to2019-12-31">&lt;p id="xdx_80F_eus-gaap--InventoryDisclosureTextBlock_zXRuhSKOS16e" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;b&gt;NOTE 3 &#x2013; &lt;span id="xdx_82E_zgeF1IYPHMS"&gt;INVENTORY&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p id="xdx_89E_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zI6A9EX6leu8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Inventory consists of the following:&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin-right: auto; margin-left: auto; float: none; width: 60%"&gt;

&lt;tr&gt;
&lt;td style="vertical-align: top; padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" id="xdx_49B_20191231_zMjb20GpLqN8" style="vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b/&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" id="xdx_49F_20181231_znBjvoHo4Cn2" style="border-right: Black medium none; border-left: Black medium none; padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b/&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="6" style="border-bottom: black 1pt solid; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: black 1pt solid; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-right: Black medium none; border-bottom: Black 1pt solid; border-left: Black medium none; padding: 0pt 5.4pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--InventoryFinishedGoods_iI_maINzas5_zJI8TeByDyvk" style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; width: 64%; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;Finished products&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 15%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;4,976,910&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 15%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;2,908,958&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_407_eus-gaap--InventoryWorkInProcess_iI_maINzas5_zL7THiYBMq0d"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;Work in process&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;1,182,059&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;339,312&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_40B_eus-gaap--InventoryRawMaterialsAndSupplies_iI_maINzas5_zmfSP9XEzOJ1" style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;Raw materials&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;5,701,747&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;19,400&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_40D_eus-gaap--InventoryNet_iTI_mtINzas5_zQw4JmfiOGD5"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"&gt;TOTAL INVENTORY&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;11,860,716&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;3,267,670&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="From2019-01-01to2019-12-31">&lt;p id="xdx_89E_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zI6A9EX6leu8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Inventory consists of the following:&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin-right: auto; margin-left: auto; float: none; width: 60%"&gt;

&lt;tr&gt;
&lt;td style="vertical-align: top; padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" id="xdx_49B_20191231_zMjb20GpLqN8" style="vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b/&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" id="xdx_49F_20181231_znBjvoHo4Cn2" style="border-right: Black medium none; border-left: Black medium none; padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b/&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="6" style="border-bottom: black 1pt solid; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: black 1pt solid; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-right: Black medium none; border-bottom: Black 1pt solid; border-left: Black medium none; padding: 0pt 5.4pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--InventoryFinishedGoods_iI_maINzas5_zJI8TeByDyvk" style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; width: 64%; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;Finished products&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 15%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;4,976,910&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 15%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;2,908,958&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_407_eus-gaap--InventoryWorkInProcess_iI_maINzas5_zL7THiYBMq0d"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;Work in process&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;1,182,059&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;339,312&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_40B_eus-gaap--InventoryRawMaterialsAndSupplies_iI_maINzas5_zmfSP9XEzOJ1" style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;Raw materials&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;5,701,747&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;19,400&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_40D_eus-gaap--InventoryNet_iTI_mtINzas5_zQw4JmfiOGD5"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"&gt;TOTAL INVENTORY&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;11,860,716&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;3,267,670&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryFinishedGoods contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">4976910</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">2908958</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryWorkInProcess contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">1182059</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">339312</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryRawMaterialsAndSupplies contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">5701747</us-gaap:InventoryRawMaterialsAndSupplies>
    <us-gaap:InventoryRawMaterialsAndSupplies contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">19400</us-gaap:InventoryRawMaterialsAndSupplies>
    <us-gaap:InventoryNet contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">11860716</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">3267670</us-gaap:InventoryNet>
    <us-gaap:OtherCurrentAssetsTextBlock contextRef="From2019-01-01to2019-12-31">&lt;p id="xdx_803_eus-gaap--OtherCurrentAssetsTextBlock_zRNYmDDXc6Sd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;b&gt;NOTE 4 &#x2013; &lt;span id="xdx_823_zdSaMndaGqag"&gt;OTHER CURRENT ASSETS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p id="xdx_896_eus-gaap--ScheduleOfOtherCurrentAssetsTableTextBlock_zjwlCufIbUAf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Other current assets consist of the following:&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin-right: auto; margin-left: auto; float: none; width: 70%"&gt;

&lt;tr&gt;
&lt;td style="vertical-align: top; padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" id="xdx_499_20191231_zfyPdyJN7dKb" style="vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b/&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" id="xdx_49F_20181231_zAm9YV72nO92" style="border-right: Black medium none; border-left: Black medium none; padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b/&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="6" style="border-bottom: black 1pt solid; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: black 1pt solid; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-right: Black medium none; border-bottom: Black 1pt solid; border-left: Black medium none; padding: 0pt 5.4pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_400_ecustom--PrepaidSalesAndMarketingCostsCurrent_iI_maPEAOAz0Eh_zXRJw45hyjOi" style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; width: 64%; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Prepaid sales and marketing costs&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 15%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;1,583,698&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 15%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;5,148,789&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_400_eus-gaap--DeferredFinanceCostsCurrentNet_iI_maPEAOAz0Eh_z7DIMLHNXcG9"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Debt financing fees on undrawn&#160;&lt;span style="font-size: 10pt"&gt;tranches (Note 8)&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;550,757&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,898,074&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--PrepaidInsurance_iI_maPEAOAz0Eh_zW7ZnRxvUVCe" style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Prepaid insurance&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;1,812,135&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;790,465&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_40F_ecustom--PrepaidManufacturing_iI_maPEAOAz0Eh_zF5VxublHLfc"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Prepaid manufacturing&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;2,595,721&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0684"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_40A_eus-gaap--OtherPrepaidExpenseCurrent_iI_maPEAOAz0Eh_zFDbJpAstKWb" style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Other prepaid costs&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;4,787,482&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;2,997,365&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_mtPEAOAz0Eh_zKXE2iVJ8S0d"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"&gt;TOTAL OTHER CURRENT ASSETS&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;11,329,793&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;10,834,693&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
</us-gaap:OtherCurrentAssetsTextBlock>
    <us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock contextRef="From2019-01-01to2019-12-31">&lt;p id="xdx_896_eus-gaap--ScheduleOfOtherCurrentAssetsTableTextBlock_zjwlCufIbUAf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Other current assets consist of the following:&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin-right: auto; margin-left: auto; float: none; width: 70%"&gt;

&lt;tr&gt;
&lt;td style="vertical-align: top; padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" id="xdx_499_20191231_zfyPdyJN7dKb" style="vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b/&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" id="xdx_49F_20181231_zAm9YV72nO92" style="border-right: Black medium none; border-left: Black medium none; padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b/&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="6" style="border-bottom: black 1pt solid; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: black 1pt solid; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-right: Black medium none; border-bottom: Black 1pt solid; border-left: Black medium none; padding: 0pt 5.4pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_400_ecustom--PrepaidSalesAndMarketingCostsCurrent_iI_maPEAOAz0Eh_zXRJw45hyjOi" style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; width: 64%; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Prepaid sales and marketing costs&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 15%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;1,583,698&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 15%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;5,148,789&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_400_eus-gaap--DeferredFinanceCostsCurrentNet_iI_maPEAOAz0Eh_z7DIMLHNXcG9"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Debt financing fees on undrawn&#160;&lt;span style="font-size: 10pt"&gt;tranches (Note 8)&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;550,757&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,898,074&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--PrepaidInsurance_iI_maPEAOAz0Eh_zW7ZnRxvUVCe" style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Prepaid insurance&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;1,812,135&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;790,465&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_40F_ecustom--PrepaidManufacturing_iI_maPEAOAz0Eh_zF5VxublHLfc"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Prepaid manufacturing&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;2,595,721&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0684"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_40A_eus-gaap--OtherPrepaidExpenseCurrent_iI_maPEAOAz0Eh_zFDbJpAstKWb" style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Other prepaid costs&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;4,787,482&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;2,997,365&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_mtPEAOAz0Eh_zKXE2iVJ8S0d"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"&gt;TOTAL OTHER CURRENT ASSETS&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;11,329,793&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;10,834,693&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
</us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock>
    <txmd:PrepaidSalesAndMarketingCostsCurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">1583698</txmd:PrepaidSalesAndMarketingCostsCurrent>
    <txmd:PrepaidSalesAndMarketingCostsCurrent contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">5148789</txmd:PrepaidSalesAndMarketingCostsCurrent>
    <us-gaap:DeferredFinanceCostsCurrentNet contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">550757</us-gaap:DeferredFinanceCostsCurrentNet>
    <us-gaap:DeferredFinanceCostsCurrentNet contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">1898074</us-gaap:DeferredFinanceCostsCurrentNet>
    <us-gaap:PrepaidInsurance contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">1812135</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">790465</us-gaap:PrepaidInsurance>
    <txmd:PrepaidManufacturing contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">2595721</txmd:PrepaidManufacturing>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">4787482</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">2997365</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">11329793</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">10834693</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2019-01-01to2019-12-31">&lt;p id="xdx_802_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zgpcaKalwq28" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;b&gt;NOTE 5 &#x2013; &lt;span id="xdx_82C_zBqY9axhRcNa"&gt;FIXED ASSETS, NET&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p id="xdx_89B_eus-gaap--PropertyPlantAndEquipmentTextBlock_zkVVpSXENsMa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Fixed assets, net consist of the following:&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin-right: auto; margin-left: auto; float: none; width: 70%"&gt;

&lt;tr&gt;
&lt;td style="vertical-align: top; padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" id="xdx_49F_20191231_zo6Y5dD1EH68" style="vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b/&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" id="xdx_49F_20181231_z6v1oWzlTnve" style="border-right: Black medium none; border-left: Black medium none; padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b/&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="6" style="border-bottom: black 1pt solid; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: black 1pt solid; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-right: Black medium none; border-bottom: Black 1pt solid; border-left: Black medium none; padding: 0pt 5.4pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; width: 64%; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Accounting system&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 15%"&gt;
&lt;p id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_z32a40lMwwJi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;301,096&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 15%"&gt;
&lt;p id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20181231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_zpnLXAPVVO9f" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;301,096&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Equipment&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zeGpIGjrLzE4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;1,619,646&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20181231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zKDf4Ta867He" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;490,576&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Furniture and fixtures&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_98B_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_ziLZ4fHvEgv6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;1,406,858&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20181231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zLgqLDpc7EO8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;116,542&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Computer hardware&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_982_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_z5rCbLMkY4i2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;80,211&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_989_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20181231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zz9tXHiawG8b" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;80,211&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Leasehold improvements&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;
&lt;p id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zsAmJrFQWzC9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;68,788&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;
&lt;p id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20181231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zaf7Hky3Dwz6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;37,888&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzht4_zdZloV6xL9N7"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"&gt;TOTAL FIXED ASSETS&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;3,476,599&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;1,026,313&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzht4_zHboRH6WJLq6" style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Accumulated depreciation&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;(968,824&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;(553,630&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_409_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzht4_z5pGWjrUNNpb"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"&gt;TOTAL FIXED ASSETS, NET&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;2,507,775&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;472,683&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;p id="xdx_8A0_zytXFyuyQPDb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Depreciation expense for the years ended December 31, 2019, 2018, and 2017 was $&lt;span id="xdx_90A_eus-gaap--Depreciation_c20190101__20191231_zyVSxuNunUb3" title="Depreciation expense"&gt;415,193&lt;/span&gt;, $&lt;span id="xdx_902_eus-gaap--Depreciation_c20180101__20181231_zft8t8kpKb9j"&gt;181,412&lt;/span&gt;, and $&lt;span id="xdx_909_eus-gaap--Depreciation_c20170101__20171231_zfY4ZFLq3AL1"&gt;141,601&lt;/span&gt;, respectively.&lt;/p&gt;
</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2019-01-01to2019-12-31">&lt;p id="xdx_89B_eus-gaap--PropertyPlantAndEquipmentTextBlock_zkVVpSXENsMa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Fixed assets, net consist of the following:&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin-right: auto; margin-left: auto; float: none; width: 70%"&gt;

&lt;tr&gt;
&lt;td style="vertical-align: top; padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" id="xdx_49F_20191231_zo6Y5dD1EH68" style="vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b/&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" id="xdx_49F_20181231_z6v1oWzlTnve" style="border-right: Black medium none; border-left: Black medium none; padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b/&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="6" style="border-bottom: black 1pt solid; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: black 1pt solid; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-right: Black medium none; border-bottom: Black 1pt solid; border-left: Black medium none; padding: 0pt 5.4pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; width: 64%; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Accounting system&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 15%"&gt;
&lt;p id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_z32a40lMwwJi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;301,096&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 15%"&gt;
&lt;p id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20181231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_zpnLXAPVVO9f" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;301,096&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Equipment&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zeGpIGjrLzE4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;1,619,646&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20181231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zKDf4Ta867He" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;490,576&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Furniture and fixtures&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_98B_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_ziLZ4fHvEgv6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;1,406,858&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20181231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zLgqLDpc7EO8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;116,542&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Computer hardware&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_982_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_z5rCbLMkY4i2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;80,211&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_989_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20181231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zz9tXHiawG8b" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;80,211&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Leasehold improvements&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;
&lt;p id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20191231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zsAmJrFQWzC9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;68,788&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;
&lt;p id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20181231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zaf7Hky3Dwz6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;37,888&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzht4_zdZloV6xL9N7"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"&gt;TOTAL FIXED ASSETS&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;3,476,599&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;1,026,313&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzht4_zHboRH6WJLq6" style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Accumulated depreciation&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;(968,824&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;(553,630&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_409_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzht4_z5pGWjrUNNpb"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"&gt;TOTAL FIXED ASSETS, NET&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;2,507,775&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;472,683&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2019-12-31_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"
      decimals="0"
      unitRef="USD">301096</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2018-12-31_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"
      decimals="0"
      unitRef="USD">301096</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2019-12-31_us-gaap_EquipmentMember"
      decimals="0"
      unitRef="USD">1619646</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2018-12-31_us-gaap_EquipmentMember"
      decimals="0"
      unitRef="USD">490576</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2019-12-31_us-gaap_FurnitureAndFixturesMember"
      decimals="0"
      unitRef="USD">1406858</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2018-12-31_us-gaap_FurnitureAndFixturesMember"
      decimals="0"
      unitRef="USD">116542</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2019-12-31_us-gaap_ComputerEquipmentMember"
      decimals="0"
      unitRef="USD">80211</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2018-12-31_us-gaap_ComputerEquipmentMember"
      decimals="0"
      unitRef="USD">80211</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2019-12-31_us-gaap_LeaseholdImprovementsMember"
      decimals="0"
      unitRef="USD">68788</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2018-12-31_us-gaap_LeaseholdImprovementsMember"
      decimals="0"
      unitRef="USD">37888</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">3476599</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">1026313</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">968824</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">553630</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">2507775</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">472683</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="From2019-01-01to2019-12-31"
      decimals="0"
      unitRef="USD">415193</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">181412</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2017-01-012017-12-31"
      decimals="0"
      unitRef="USD">141601</us-gaap:Depreciation>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="From2019-01-01to2019-12-31">&lt;p id="xdx_806_eus-gaap--GoodwillAndIntangibleAssetsDisclosureTextBlock_zdGQyxM7RIa2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;b&gt;NOTE 6 &#x2013; &lt;span id="xdx_827_zbdlCzYrVrkk"&gt;INTANGIBLE ASSETS, NET&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p id="xdx_89E_ecustom--ScheduleOfIntangibleAssetsTableTextBlock_zSsNxgQCmCKk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of December 31, 2019 and 2018:&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; width: 100%"&gt;

&lt;tr&gt;
&lt;td style="padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="border-top-style: none; border-right-style: none; border-left-style: none; vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top-style: none; border-right-style: none; border-left-style: none; vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top-style: none; border-right-style: none; border-left-style: none; vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top-style: none; border-right-style: none; border-left-style: none; vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top-style: none; border-right-style: none; border-left-style: none; vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top-style: none; border-right-style: none; border-left-style: none; vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top-style: none; border-right-style: none; border-left-style: none; vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top-style: none; border-right-style: none; border-left-style: none; vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top-style: none; border-right-style: none; border-left-style: none; vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top-style: none; border-right-style: none; border-left-style: none; vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top-style: none; border-right-style: none; border-left-style: none; vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top-style: none; border-right-style: none; border-left-style: none; vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top-style: none; border-right-style: none; border-left-style: none; vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top-style: none; border-right-style: none; border-left-style: none; vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"/&gt;
&lt;td&gt;&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="14" style="border-bottom: black 1pt none; border-top-style: none; border-right-style: none; border-left-style: none; border-bottom-style: solid; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;December 31,
2019&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom; width: 1%"&gt;&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; width: 40%; vertical-align: top"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
&lt;td&gt;&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center; width: 10%; vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;b&gt;Gross Carrying
Amount&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom; width: 1%"&gt;&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; width: 1%"&gt;&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center; width: 10%; vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;b&gt;Accumulated Amortization&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom; width: 1%"&gt;&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; width: 1%"&gt;&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center; width: 10%; vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;b&gt;Net&lt;br/&gt;Amount&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom; width: 1%"&gt;&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; width: 1%"&gt;&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center; width: 10%; vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;b&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining
Amortization&lt;br/&gt;Period (yrs.)&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom; width: 1%"&gt;&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; width: 40%; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Amortizable intangible assets:&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 3%"&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 3%"&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 3%"&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 3%"&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Approved hormone&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.15in; margin-top: 0pt; margin-bottom: 0pt"&gt;therapy drug&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.15in; margin-top: 0pt; margin-bottom: 0pt"&gt;candidate patents&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zZ45m8aW3pgf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;3,463,082&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zvgJ9pOvKXK1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;(478,983&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zrPdY8Onobyb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;2,984,099&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_dtY_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_z2oQJxvGOrE"&gt;13&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: White"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Hormone therapy drug&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.15in; margin-top: 0pt; margin-bottom: 0pt"&gt;candidate patents&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: White"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.15in; margin-top: 0pt; margin-bottom: 0pt"&gt;(pending)&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20191231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_zGbZuhcyXZ41" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;1,979,299&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#x2014;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20191231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_zw6A1cByWgMe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;1,979,299&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;n/a&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Non-amortizable intangible&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.15in; margin-top: 0pt; margin-bottom: 0pt"&gt;assets:&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: White"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Multiple trademarks&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_984_eus-gaap--IndefiniteLivedTrademarks_iI_c20191231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksForVitaminsSupplementsMember_znQmUqz0u694" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;294,813&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#x2014;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_98A_eus-gaap--IndefiniteLivedIntangibleAssetsExcludingGoodwill_iI_c20191231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksForVitaminsSupplementsMember_zocGRvUhihv6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;294,813&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;indefinite&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"&gt;TOTAL&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom"&gt;
&lt;p id="xdx_984_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_c20191231_zrPXHNejo0C2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;5,737,194&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom"&gt;
&lt;p id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_c20191231_zIYygBuIkRkd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;(478,983&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding-bottom: 2pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom"&gt;
&lt;p id="xdx_98D_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20191231_zUtdcezNgmUh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;5,258,211&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; width: 100%"&gt;

&lt;tr&gt;
&lt;td style="padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="border-top-style: none; border-right-style: none; border-left-style: none; border-image: initial; vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top-style: none; border-right-style: none; border-left-style: none; border-image: initial; vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top-style: none; border-right-style: none; border-left-style: none; border-image: initial; vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top-style: none; border-right-style: none; border-left-style: none; border-image: initial; vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top-style: none; border-right-style: none; border-left-style: none; border-image: initial; vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top-style: none; border-right-style: none; border-left-style: none; border-image: initial; vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top-style: none; border-right-style: none; border-left-style: none; border-image: initial; vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top-style: none; border-right-style: none; border-left-style: none; border-image: initial; vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top-style: none; border-right-style: none; border-left-style: none; border-image: initial; vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top-style: none; border-right-style: none; border-left-style: none; border-image: initial; vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top-style: none; border-right-style: none; border-left-style: none; border-image: initial; vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top-style: none; border-right-style: none; border-left-style: none; border-image: initial; vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top-style: none; border-right-style: none; border-left-style: none; border-image: initial; vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top-style: none; border-right-style: none; border-left-style: none; border-image: initial; vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"/&gt;
&lt;td&gt;&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="14" style="border-bottom: black 1pt solid; border-top-style: none; border-right-style: none; border-left-style: none; border-image: initial; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;December 31,
2018&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom; width: 1%"&gt;&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; text-align: center; vertical-align: top"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
&lt;td&gt;&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center; vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;b&gt;Gross Carrying
Amount&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom; width: 1%"&gt;&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; width: 1%"&gt;&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center; width: 10%; vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;b&gt;Accumulated Amortization&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom; width: 1%"&gt;&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; width: 1%"&gt;&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center; width: 10%; vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;b&gt;Net&lt;br/&gt;Amount&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom; width: 1%"&gt;&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; width: 1%"&gt;&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center; width: 10%; vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;b&gt;Weighted- Average&lt;br/&gt;Remaining
Amortization Period (yrs.)&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom; width: 1%"&gt;&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; width: 40%; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Amortizable intangible assets:&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 3%"&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 3%"&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 3%"&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 3%"&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;OPERA software patent&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--ComputerSoftwareIntangibleAssetMember_zuH4Ob72Oyq2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;31,951&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_c20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--ComputerSoftwareIntangibleAssetMember_zLmvoUYIi4ub" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;(10,484&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--ComputerSoftwareIntangibleAssetMember_zaOasLYxHcb9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;21,467&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_dtY_c20180101__20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--ComputerSoftwareIntangibleAssetMember_zB2Ja4HDIBf8"&gt;10.75&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Development costs of&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.15in; margin-top: 0pt; margin-bottom: 0pt"&gt;corporate website&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InternetDomainNamesMember_zSYk6Y2UUw96" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;91,743&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_c20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InternetDomainNamesMember_zHtL9OMHqBJ1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;(91,743&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#x2014;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;n/a&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Approved hormone&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.15in; margin-top: 0pt; margin-bottom: 0pt"&gt;therapy drug&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.15in; margin-top: 0pt; margin-bottom: 0pt"&gt;candidate patents&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zO6DdncI1wfe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;2,234,129&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_c20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zawuCBN6mu5l" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;(282,485&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zDHtmBT3FTW7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;1,951,644&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_dtY_c20180101__20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_z9dfucABmOri"&gt;14&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: White"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Hormone therapy drug&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.15in; margin-top: 0pt; margin-bottom: 0pt"&gt;candidate patents&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: White"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.15in; margin-top: 0pt; margin-bottom: 0pt"&gt;(pending)&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20181231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_zhWshXYSDvVh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;1,855,279&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#x2014;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20181231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_zUuP8vFYS5Fl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;1,855,279&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;n/a&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Non-amortizable intangible&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.15in; margin-top: 0pt; margin-bottom: 0pt"&gt;assets:&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: White"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Multiple trademarks&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_988_eus-gaap--IndefiniteLivedTrademarks_iI_c20181231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksForVitaminsSupplementsMember_zyYy112mUFnl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;264,289&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#x2014;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_988_eus-gaap--IndefiniteLivedIntangibleAssetsExcludingGoodwill_iI_c20181231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksForVitaminsSupplementsMember_zvLuDgt0SQh7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;264,289&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;indefinite&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"&gt;TOTAL&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom"&gt;
&lt;p id="xdx_982_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_c20181231_z7iwKFoMeZTl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;4,477,391&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom"&gt;
&lt;p id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_c20181231_zPbzzNlfWeZ2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;(384,712&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding-bottom: 2pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom"&gt;
&lt;p id="xdx_984_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20181231_zNnLUsOkkZ89" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;4,092,679&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;p id="xdx_8AD_zQXuyGeRuVb8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;We capitalize external costs, consisting primarily of legal costs, related to securing our patents and trademarks. Once a patent is granted, we amortize the approved hormone therapy drug candidate patents using the straight-line method over the estimated useful life of approximately &lt;span id="xdx_908_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zEe9VmrPiLYb"&gt;20&lt;/span&gt; years, which is the life of intellectual property patents. If the patent is not granted, we write-off any capitalized patent costs at that time. Trademarks are perpetual and are not amortized. During the year ended December 31, 2019, we wrote off $&lt;span id="xdx_909_eus-gaap--ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_c20190101__20191231_zAi4ok0xPne"&gt;78,864&lt;/span&gt; in costs related to trademarks and patents, including the net carrying amount of the OPERA patent. &lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;As of December 31, 2019, we had &lt;span id="xdx_901_ecustom--NumberOfIssuedPatents_iI_uPure_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUSPatentsMember_zcAXHfpAAxz8"&gt;29&lt;/span&gt; issued domestic &#160;patents and &lt;span id="xdx_907_ecustom--NumberOfIssuedPatents_iI_uPure_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignPatentsMember_zmFxdUJsHDC"&gt;30&lt;/span&gt; issued foreign patents, including: &lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; width: 100%"&gt;

&lt;tr&gt;
&lt;td style="vertical-align: top; width: 18pt"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: top; width: 18pt"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;&#x25cf;&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;&lt;span id="xdx_907_ecustom--NumberOfIssuedPatents_iI_uPure_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticPatentsBijuvaMember_zfHJygFwRv7h" title="Number of issued patents"&gt;12&lt;/span&gt; domestic patents and &lt;span id="xdx_908_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignPatentsBijuvaMember_zH34gBx8H73f"&gt;six&lt;/span&gt; foreign patents that relate to BIJUVA as well as &lt;span id="xdx_902_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticPatentsNonApprovedBijuvaMember_zuIweFRntojg"&gt;three&lt;/span&gt; domestic patents that relate to estradiol and progesterone product candidates. These patents establish an important intellectual property foundation and are owned by us. The domestic patents will expire in 2032. The foreign patents will expire no earlier than 2032. In addition, we have pending patent applications relating to BIJUVA in the U.S., Argentina, Australia, Brazil, Canada, China, Europe, Israel, Japan, Mexico, New Zealand, Russia, South Africa, and South Korea; &lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; width: 100%"&gt;

&lt;tr&gt;
&lt;td style="vertical-align: top; width: 18pt"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: top; width: 18pt"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;&#x25cf;&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span id="xdx_90D_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUSPatentsImvexxyMember_zPub0tWlzhoj"&gt;Six&lt;/span&gt;&lt;span style="color: black"&gt; domestic patents (&lt;/span&gt;&lt;span id="xdx_90F_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUSUtilityPatentsImvexxyMember_zeK62XpJvJ97"&gt;five&lt;/span&gt; &lt;span style="color: black"&gt;utility and &lt;span id="xdx_905_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUSDesignPatentsImvexxyMember_zNiqvZkjaRL"&gt;one&lt;/span&gt; design) and &lt;span id="xdx_90D_ecustom--NumberOfIssuedPatents_iI_uPure_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignPatentsImvexxyMember_zYTzRR8sspCa"&gt;13&lt;/span&gt; foreign patents (&lt;span id="xdx_90A_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignUtilityPatentsImvexxyMember_zLRJQMRCTJW1"&gt;three&lt;/span&gt; utility and &lt;span id="xdx_905_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignDesignPatentsImvexxyMember_z8IZymKPqmu4"&gt;ten&lt;/span&gt; design) that relate to IMVEXXY. These patents establish an important intellectual property foundation for IMVEXXY and are owned by us. The domestic patents will expire in 2032 or 2033. The foreign utility patents will expire no earlier than 2033. The foreign design patents provide protection expiring no earlier than 2025. In certain countries, the foreign design patents provide protection through at least 2037. In addition, we have pending patent applications related to IMVEXXY in the U.S., Argentina, Australia, Brazil, Canada, Europe, Israel, Japan, Mexico, New Zealand, Russia, South Africa, and South Korea; &lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; width: 100%"&gt;

&lt;tr&gt;
&lt;td style="vertical-align: top; width: 18pt"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: top; width: 18pt"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;&#x25cf;&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;&lt;span id="xdx_908_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUSPatentsTopicalCreamMember_zSE6pfEuadbc"&gt;One&lt;/span&gt; domestic utility patent that relates to our topical-cream candidates, which is owned by us. The domestic patent will expire in 2035. We have pending patent applications with respect to our topical-cream candidates in the U.S., Argentina, Australia, Brazil, Canada, Europe, Israel, Japan, Mexico, Russia, South Africa, and South Korea; &lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; width: 100%"&gt;

&lt;tr&gt;
&lt;td style="vertical-align: top; width: 18pt"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: top; width: 18pt"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;&#x25cf;&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;&lt;span id="xdx_904_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUtilityPatentTransdermalPatchMember_z4tmsEJeDbqe"&gt;One&lt;/span&gt; domestic utility patent and &lt;/span&gt;&lt;span id="xdx_902_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignUtilityPatentTransdermalPatchMember_znk2ICZ9uEif"&gt;seven&lt;/span&gt;&lt;span style="color: black"&gt; foreign patents that relate to our transdermal-patch candidates, which are owned by us. The domestic utility patent will expire in 2032. The foreign patents will expire no earlier than 2033. We have pending patent applications with respect to our transdermal-patch candidates in the U.S., Brazil, Canada, Mexico, and South Africa; &lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; width: 100%"&gt;

&lt;tr&gt;
&lt;td style="vertical-align: top; width: 18pt"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: top; width: 18pt"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;&#x25cf;&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span id="xdx_909_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUtilityPatentTx009HRMember_zRjys56gHOK5"&gt;Three&lt;/span&gt;&lt;span style="color: black"&gt; domestic utility patents that relate to TX-009HR, a progesterone and estradiol product candidate, which are owned by us and will expire in 2037. We have pending patent applications with respect to TX-009HR in the U.S., Argentina, Australia, Brazil, Canada, Europe, Israel, Japan, Mexico, New Zealand, Russia, South Africa, and South Korea.&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; width: 100%"&gt;

&lt;tr&gt;
&lt;td style="vertical-align: top; width: 18pt"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: top; width: 18pt"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;&#x25cf;&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span id="xdx_90D_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticPatentsProgesteroneFormulationsMember_zdkLx1njb5ng"&gt;Two&lt;/span&gt;&lt;span style="color: black"&gt; domestic and &lt;span id="xdx_900_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignPatentsProgesteroneFormulationsMember_zEQ5E1kS3jW2"&gt;four&lt;/span&gt; foreign patents that relate to formulations containing progesterone, which are owned by us. The domestic patent&lt;/span&gt;s&lt;span style="color: black"&gt; will expire &lt;/span&gt;between &lt;span style="color: black"&gt;2032&lt;/span&gt; and 2036&lt;span style="color: black"&gt;. The foreign patents will expire no earlier than 2033. In addition, we have pending patent applications with respect formulations containing progesterone in the U.S., Argentina, Australia, Brazil, Canada, Europe, Israel, Japan, Mexico, Russia, South Africa, and South Korea; &lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; width: 100%"&gt;

&lt;tr&gt;
&lt;td style="vertical-align: top; width: 18pt"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: top; width: 18pt"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;&#x25cf;&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;&lt;span id="xdx_904_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUtilityPatentOperaMember_zOGUFxyameRe"&gt;One&lt;/span&gt; domestic utility patent that relates to our OPERA information-technology platform, which is owned by us and will expire in 2031; &lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="background-color: white"&gt;Amortization expense was $&lt;span id="xdx_90F_eus-gaap--AmortizationOfIntangibleAssets_c20190101__20191231_z7iwZ5ZuQTC9"&gt;197,593&lt;/span&gt;, $&lt;span id="xdx_908_eus-gaap--AmortizationOfIntangibleAssets_c20180101__20181231_z7N1ETmlU4z5"&gt;112,474&lt;/span&gt;, and $&lt;span id="xdx_90D_eus-gaap--AmortizationOfIntangibleAssets_c20170101__20171231_zKi5baRkOisj"&gt;71,516&lt;/span&gt; for the years ended December 31, 2019, 2018, and 2017, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zrznKYBF3tWd" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="background-color: white"&gt;Estimated amortization expense, based on current patent cost being amortized, for the next five years is as follows:&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin-right: auto; margin-left: auto; float: none; width: 40%"&gt;

&lt;tr&gt;
&lt;td style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; width: 49%; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;Year Ending&lt;br/&gt;December
31,&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding: 0pt 5.4pt; width: 2%; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td id="xdx_49E_20191231_zsxdHn6Z4B7k" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; vertical-align: top; width: 49%"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;Estimated&lt;br/&gt;Amortization&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_400_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_z5zAjuA6YVph" style="background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"&gt;2020&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"&gt;$229,546&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_zggNowtaQ5kb" style="background-color: White"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"&gt;2021&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"&gt;$229,546&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_zUDpMMLkGDl7" style="background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"&gt;2022&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"&gt;$229,546&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_zlthq9FvAC15" style="background-color: White"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"&gt;2023&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"&gt;$229,546&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_ztTQzfSmEsS7" style="background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"&gt;2024&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"&gt;$229,546&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: White"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;p id="xdx_8AB_zW8i29NaJY2f" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #212529"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span style="color: #212529"&gt;License Agreement with the Population Council&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: #212529"&gt;On July 30, 2018, we entered into the Population Council License Agreement to commercialize ANNOVERA in the U.S. ANNOVERA became commercially available in the third quarter of 2019 and we expect the full commercial launch of ANNOVERA in the first quarter of 2020.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: #212529"&gt;Under the terms of the Population Council License Agreement, we paid the Population Council a milestone payment of $&lt;span id="xdx_907_ecustom--MilestonePaymentUponFDAApproval_c20190701__20190930__srt--ProductOrServiceAxis__custom--AnnoveraMember__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreement1Member_zZi7oSOg8Tg1" title="Milestone payment upon FDA Approval"&gt;20,000,000&lt;/span&gt; within 30 days following the approval by the FDA of the new drug application, or NDA, for ANNOVERA and $&lt;span id="xdx_900_ecustom--MilestonePaymentsAfterReleaseOfFirstCommercialBatch_iI_c20190930__srt--ProductOrServiceAxis__custom--AnnoveraMember__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreement1Member_z1gyEedlxhHb" title="Milestone payments (payment after release of first commercial batch)"&gt;20,000,000&lt;/span&gt; within 30 days following the first commercial batch release of ANNOVERA. Both milestone payments of $&lt;span id="xdx_90F_eus-gaap--FinitelivedIntangibleAssetsAcquired1_c20190701__20190930__srt--ProductOrServiceAxis__custom--AnnoveraMember__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreement1Member_z24YlW0jZZ2c" title="License rights acquired"&gt;20,000,000&lt;/span&gt; were recorded as license rights in the consolidated balance sheets. We started amortizing the license rights in the third quarter of 2019 once ANNOVERA became commercially available for use. The cost is amortized over the remaining useful life over which the license rights will contribute directly or indirectly to our cash flows, which is estimated to be the remaining patent life of the product, which expires in December 2032. The cost is amortized using the straight-line method as the pattern of economic benefit cannot be reliably determined. During the year ended December 31, 2019, we recorded $&lt;span id="xdx_90F_eus-gaap--OtherAmortizationOfDeferredCharges_c20190101__20191231__srt--ProductOrServiceAxis__custom--AnnoveraMember__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreement1Member_z8S5vUF488U3" title="Amortization of Other Deferred Charges"&gt;778,692&lt;/span&gt; in amortization expense related to the license fee which was recorded as a component of cost of sales.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: #212529"&gt;The
Population Council is also eligible to receive milestone payments and royalties from commercial sales of ANNOVERA. We are
responsible for marketing expenses related to the commercialization of ANNOVERA. In addition, we are required to pay the
Population Council, on a quarterly basis, step-based royalty payments based on annual net sales of ANNOVERA in the U.S. by
the Company and its affiliates and permitted licensees as follows: (i) if annual net sales are less than or equal to $&lt;span id="xdx_902_ecustom--NetSalesAmountPerStepbasedRoyalty_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep1Member__srt--RangeAxis__srt--MaximumMember_zrTYygEARfQi" title="Net sales amount per step-based royalty"&gt;50,000,000&lt;/span&gt;,
a royalty of &lt;span id="xdx_90D_ecustom--RoyaltyPercent_dp_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep1Member_zkNUJsk4roz3" title="Royalty (percent)"&gt;5&lt;/span&gt;%
of net sales; (ii) for annual net sales greater than $&lt;span id="xdx_902_ecustom--NetSalesAmountPerStepbasedRoyalty_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep2Member__srt--RangeAxis__srt--MinimumMember_zpPxhCHKYSua"&gt;50,000,000&lt;/span&gt;
and less than or equal to $&lt;span id="xdx_903_ecustom--NetSalesAmountPerStepbasedRoyalty_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep2Member__srt--RangeAxis__srt--MaximumMember_zb8M2Ena4km4"&gt;150,000,000&lt;/span&gt;,
a royalty of &lt;span id="xdx_90D_ecustom--RoyaltyPercent_dp_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep2Member_zxZPuiOOFrC1"&gt;10&lt;/span&gt;%
of such net sales; and (iii) for net sales greater than $&lt;span id="xdx_903_ecustom--NetSalesAmountPerStepbasedRoyalty_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep3Member__srt--RangeAxis__srt--MinimumMember_zvrDgk1VqKRc"&gt;150,000,000&lt;/span&gt;,
a royalty of &lt;span id="xdx_903_ecustom--RoyaltyPercent_dp_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep3Member_zjcM4N5IFwbe"&gt;15&lt;/span&gt;%
of such net sales. The annual royalty rate will be reduced to &lt;span id="xdx_905_ecustom--AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent_dp_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreement1Member_zXXunlGnhwqf" title="Annual royalty rate reduction of initial rate during the six-month period from commercial sale of a generic equivalent"&gt;50&lt;/span&gt;%
of the initial rate during the six-month period beginning on the date of the first arms-length commercial sale of a generic
equivalent of the one-year vaginal contraceptive system that is launched by a third party in the U.S., and thereafter will be
reduced to &lt;span id="xdx_902_ecustom--AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent_dp_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreement1Member_zAfLDRuaPx5e" title="Annual royalty rate reduction of initial rate after the six-month period from commercial sale of a generic equivalent"&gt;20&lt;/span&gt;%
of the initial rate. We are required to pay the Population Council milestone payments of $&lt;span id="xdx_90A_ecustom--RequiredMilestonePaymentsUponCumulativeNetSalesOfSpecifiedLevels_dm_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreement1Member_z3WB7dveZctb" title="Required milestone payments upon cumulative net sales of specified levels"&gt;40
million&lt;/span&gt; upon cumulative net sales of ANNOVERA in the U.S. by us and our affiliates and permitted sublicensees of each
of $&lt;span id="xdx_902_ecustom--SpecifiedLevelOneOfCumulativeNetSalesForRequiredMilestonePayments_dm_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreement1Member_zPOga3TS5ZBa" title="Specified level one of cumulative net sales for required milestone payments"&gt;200
million&lt;/span&gt;, $&lt;span id="xdx_904_ecustom--SpecifiedLevelTwoOfCumulativeNetSalesForRequiredMilestonePayments_dm_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreement1Member_zRgYvIBzPUZa" title="Specified level two of cumulative net sales for required milestone payments"&gt;400
million&lt;/span&gt; and $&lt;span id="xdx_906_ecustom--SpecifiedLevelThreeOfCumulativeNetSalesForRequiredMilestonePayments_dm_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreement1Member_zwGmMDa1Sdvg" title="Specified level three of cumulative net sales for required milestone payments"&gt;1
billion&lt;/span&gt;. The Population Council has agreed to perform and pay the costs and expenses associated with four
post-approval studies required by the FDA for ANNOVERA and we have agreed to perform and pay the costs and expenses
associated with a post approval study required by the FDA to measure risk for venous thromboembolism, provided that if the
costs and expenses associated with such post-approval study exceed $&lt;span id="xdx_90A_ecustom--MaximumCostsAndExpensesForPostApprovalStudyToBePaid_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreement1Member_zagFFOU168tg" title="Maximum costs and expenses for post approval"&gt;20,000,000&lt;/span&gt;,
half of such excess will be offset against royalties or other payments owed by us to the Population Council under the
Population Council License Agreement. We and the Population Council have agreed to form a joint product committee responsible
for overseeing activities under the Population Council License Agreement. We will be responsible for all aspects of
promotion, product positioning, pricing, education programs, publications, sales messages and any additional desired clinical
studies for the one-year vaginal contraceptive system, subject to oversight and decisions made by the joint product
committee. The Population Council License Agreement includes exclusive rights for us to negotiate co-development of two other
investigational vaginal contraceptive systems in development by the Population Council. &lt;/span&gt;&lt;/p&gt;
</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <txmd:ScheduleOfIntangibleAssetsTableTextBlock contextRef="From2019-01-01to2019-12-31">&lt;p id="xdx_89E_ecustom--ScheduleOfIntangibleAssetsTableTextBlock_zSsNxgQCmCKk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of December 31, 2019 and 2018:&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; width: 100%"&gt;

&lt;tr&gt;
&lt;td style="padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="border-top-style: none; border-right-style: none; border-left-style: none; vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top-style: none; border-right-style: none; border-left-style: none; vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top-style: none; border-right-style: none; border-left-style: none; vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top-style: none; border-right-style: none; border-left-style: none; vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top-style: none; border-right-style: none; border-left-style: none; vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top-style: none; border-right-style: none; border-left-style: none; vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top-style: none; border-right-style: none; border-left-style: none; vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top-style: none; border-right-style: none; border-left-style: none; vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top-style: none; border-right-style: none; border-left-style: none; vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top-style: none; border-right-style: none; border-left-style: none; vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top-style: none; border-right-style: none; border-left-style: none; vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top-style: none; border-right-style: none; border-left-style: none; vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top-style: none; border-right-style: none; border-left-style: none; vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top-style: none; border-right-style: none; border-left-style: none; vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"/&gt;
&lt;td&gt;&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="14" style="border-bottom: black 1pt none; border-top-style: none; border-right-style: none; border-left-style: none; border-bottom-style: solid; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;December 31,
2019&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom; width: 1%"&gt;&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; width: 40%; vertical-align: top"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
&lt;td&gt;&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center; width: 10%; vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;b&gt;Gross Carrying
Amount&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom; width: 1%"&gt;&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; width: 1%"&gt;&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center; width: 10%; vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;b&gt;Accumulated Amortization&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom; width: 1%"&gt;&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; width: 1%"&gt;&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center; width: 10%; vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;b&gt;Net&lt;br/&gt;Amount&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom; width: 1%"&gt;&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; width: 1%"&gt;&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center; width: 10%; vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;b&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining
Amortization&lt;br/&gt;Period (yrs.)&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom; width: 1%"&gt;&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; width: 40%; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Amortizable intangible assets:&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 3%"&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 3%"&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 3%"&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 3%"&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Approved hormone&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.15in; margin-top: 0pt; margin-bottom: 0pt"&gt;therapy drug&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.15in; margin-top: 0pt; margin-bottom: 0pt"&gt;candidate patents&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zZ45m8aW3pgf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;3,463,082&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zvgJ9pOvKXK1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;(478,983&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zrPdY8Onobyb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;2,984,099&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_dtY_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_z2oQJxvGOrE"&gt;13&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: White"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Hormone therapy drug&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.15in; margin-top: 0pt; margin-bottom: 0pt"&gt;candidate patents&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: White"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.15in; margin-top: 0pt; margin-bottom: 0pt"&gt;(pending)&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20191231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_zGbZuhcyXZ41" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;1,979,299&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#x2014;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20191231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_zw6A1cByWgMe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;1,979,299&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;n/a&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Non-amortizable intangible&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.15in; margin-top: 0pt; margin-bottom: 0pt"&gt;assets:&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: White"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Multiple trademarks&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_984_eus-gaap--IndefiniteLivedTrademarks_iI_c20191231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksForVitaminsSupplementsMember_znQmUqz0u694" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;294,813&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#x2014;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_98A_eus-gaap--IndefiniteLivedIntangibleAssetsExcludingGoodwill_iI_c20191231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksForVitaminsSupplementsMember_zocGRvUhihv6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;294,813&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;indefinite&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"&gt;TOTAL&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom"&gt;
&lt;p id="xdx_984_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_c20191231_zrPXHNejo0C2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;5,737,194&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom"&gt;
&lt;p id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_c20191231_zIYygBuIkRkd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;(478,983&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding-bottom: 2pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom"&gt;
&lt;p id="xdx_98D_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20191231_zUtdcezNgmUh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;5,258,211&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; width: 100%"&gt;

&lt;tr&gt;
&lt;td style="padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="border-top-style: none; border-right-style: none; border-left-style: none; border-image: initial; vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top-style: none; border-right-style: none; border-left-style: none; border-image: initial; vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top-style: none; border-right-style: none; border-left-style: none; border-image: initial; vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top-style: none; border-right-style: none; border-left-style: none; border-image: initial; vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top-style: none; border-right-style: none; border-left-style: none; border-image: initial; vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top-style: none; border-right-style: none; border-left-style: none; border-image: initial; vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top-style: none; border-right-style: none; border-left-style: none; border-image: initial; vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top-style: none; border-right-style: none; border-left-style: none; border-image: initial; vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top-style: none; border-right-style: none; border-left-style: none; border-image: initial; vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top-style: none; border-right-style: none; border-left-style: none; border-image: initial; vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top-style: none; border-right-style: none; border-left-style: none; border-image: initial; vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top-style: none; border-right-style: none; border-left-style: none; border-image: initial; vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top-style: none; border-right-style: none; border-left-style: none; border-image: initial; vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="border-top-style: none; border-right-style: none; border-left-style: none; border-image: initial; vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"/&gt;
&lt;td&gt;&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="14" style="border-bottom: black 1pt solid; border-top-style: none; border-right-style: none; border-left-style: none; border-image: initial; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;December 31,
2018&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom; width: 1%"&gt;&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; text-align: center; vertical-align: top"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
&lt;td&gt;&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center; vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;b&gt;Gross Carrying
Amount&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom; width: 1%"&gt;&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; width: 1%"&gt;&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center; width: 10%; vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;b&gt;Accumulated Amortization&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom; width: 1%"&gt;&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; width: 1%"&gt;&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center; width: 10%; vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;b&gt;Net&lt;br/&gt;Amount&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom; width: 1%"&gt;&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; width: 1%"&gt;&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center; width: 10%; vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;b&gt;Weighted- Average&lt;br/&gt;Remaining
Amortization Period (yrs.)&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom; width: 1%"&gt;&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; width: 40%; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Amortizable intangible assets:&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 3%"&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 3%"&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 3%"&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 3%"&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;OPERA software patent&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--ComputerSoftwareIntangibleAssetMember_zuH4Ob72Oyq2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;31,951&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_c20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--ComputerSoftwareIntangibleAssetMember_zLmvoUYIi4ub" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;(10,484&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--ComputerSoftwareIntangibleAssetMember_zaOasLYxHcb9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;21,467&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_dtY_c20180101__20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--ComputerSoftwareIntangibleAssetMember_zB2Ja4HDIBf8"&gt;10.75&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Development costs of&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.15in; margin-top: 0pt; margin-bottom: 0pt"&gt;corporate website&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InternetDomainNamesMember_zSYk6Y2UUw96" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;91,743&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_c20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InternetDomainNamesMember_zHtL9OMHqBJ1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;(91,743&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#x2014;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;n/a&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Approved hormone&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.15in; margin-top: 0pt; margin-bottom: 0pt"&gt;therapy drug&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.15in; margin-top: 0pt; margin-bottom: 0pt"&gt;candidate patents&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zO6DdncI1wfe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;2,234,129&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_c20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zawuCBN6mu5l" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;(282,485&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zDHtmBT3FTW7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;1,951,644&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_dtY_c20180101__20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_z9dfucABmOri"&gt;14&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: White"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Hormone therapy drug&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.15in; margin-top: 0pt; margin-bottom: 0pt"&gt;candidate patents&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: White"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.15in; margin-top: 0pt; margin-bottom: 0pt"&gt;(pending)&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20181231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_zhWshXYSDvVh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;1,855,279&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#x2014;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20181231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_zUuP8vFYS5Fl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;1,855,279&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;n/a&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Non-amortizable intangible&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.15in; margin-top: 0pt; margin-bottom: 0pt"&gt;assets:&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: White"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Multiple trademarks&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_988_eus-gaap--IndefiniteLivedTrademarks_iI_c20181231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksForVitaminsSupplementsMember_zyYy112mUFnl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;264,289&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#x2014;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_988_eus-gaap--IndefiniteLivedIntangibleAssetsExcludingGoodwill_iI_c20181231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksForVitaminsSupplementsMember_zvLuDgt0SQh7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;264,289&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;indefinite&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"&gt;TOTAL&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom"&gt;
&lt;p id="xdx_982_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_c20181231_z7iwKFoMeZTl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;4,477,391&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom"&gt;
&lt;p id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_c20181231_zPbzzNlfWeZ2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;(384,712&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding-bottom: 2pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom"&gt;
&lt;p id="xdx_984_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20181231_zNnLUsOkkZ89" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;4,092,679&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
</txmd:ScheduleOfIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2019-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember"
      decimals="0"
      unitRef="USD">3463082</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2019-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember"
      decimals="0"
      unitRef="USD">478983</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2019-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember"
      decimals="0"
      unitRef="USD">2984099</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 contextRef="From2019-01-012019-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember">P13Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2019-12-31_custom_HormoneTherapyDrugCandidatePatentsMember"
      decimals="0"
      unitRef="USD">1979299</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2019-12-31_custom_HormoneTherapyDrugCandidatePatentsMember"
      decimals="0"
      unitRef="USD">1979299</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedTrademarks
      contextRef="AsOf2019-12-31_custom_MultipleTrademarksForVitaminsSupplementsMember"
      decimals="0"
      unitRef="USD">294813</us-gaap:IndefiniteLivedTrademarks>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="AsOf2019-12-31_custom_MultipleTrademarksForVitaminsSupplementsMember"
      decimals="0"
      unitRef="USD">294813</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">5737194</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">478983</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">5258211</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2018-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember"
      decimals="0"
      unitRef="USD">31951</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2018-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember"
      decimals="0"
      unitRef="USD">10484</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2018-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember"
      decimals="0"
      unitRef="USD">21467</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 contextRef="From2018-01-012018-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember">P10Y9M</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2018-12-31_us-gaap_InternetDomainNamesMember"
      decimals="0"
      unitRef="USD">91743</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2018-12-31_us-gaap_InternetDomainNamesMember"
      decimals="0"
      unitRef="USD">91743</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2018-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember"
      decimals="0"
      unitRef="USD">2234129</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2018-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember"
      decimals="0"
      unitRef="USD">282485</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2018-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember"
      decimals="0"
      unitRef="USD">1951644</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 contextRef="From2018-01-012018-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember">P14Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2018-12-31_custom_HormoneTherapyDrugCandidatePatentsMember"
      decimals="0"
      unitRef="USD">1855279</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2018-12-31_custom_HormoneTherapyDrugCandidatePatentsMember"
      decimals="0"
      unitRef="USD">1855279</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedTrademarks
      contextRef="AsOf2018-12-31_custom_MultipleTrademarksForVitaminsSupplementsMember"
      decimals="0"
      unitRef="USD">264289</us-gaap:IndefiniteLivedTrademarks>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="AsOf2018-12-31_custom_MultipleTrademarksForVitaminsSupplementsMember"
      decimals="0"
      unitRef="USD">264289</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">4477391</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">384712</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">4092679</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2019-01-012019-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="From2019-01-01to2019-12-31"
      decimals="0"
      unitRef="USD">78864</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <txmd:NumberOfIssuedPatents
      contextRef="AsOf2019-12-31_custom_DomesticUSPatentsMember"
      decimals="INF"
      unitRef="Pure">29</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="AsOf2019-12-31_custom_ForeignPatentsMember"
      decimals="INF"
      unitRef="Pure">30</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="AsOf2019-12-31_custom_DomesticPatentsBijuvaMember"
      decimals="INF"
      unitRef="Pure">12</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="AsOf2019-12-31_custom_ForeignPatentsBijuvaMember"
      decimals="INF"
      unitRef="Pure">6</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="AsOf2019-12-31_custom_DomesticPatentsNonApprovedBijuvaMember"
      decimals="INF"
      unitRef="Pure">3</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="AsOf2019-12-31_custom_DomesticUSPatentsImvexxyMember"
      decimals="INF"
      unitRef="Pure">6</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="AsOf2019-12-31_custom_DomesticUSUtilityPatentsImvexxyMember"
      decimals="INF"
      unitRef="Pure">5</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="AsOf2019-12-31_custom_DomesticUSDesignPatentsImvexxyMember"
      decimals="INF"
      unitRef="Pure">1</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="AsOf2019-12-31_custom_ForeignPatentsImvexxyMember"
      decimals="INF"
      unitRef="Pure">13</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="AsOf2019-12-31_custom_ForeignUtilityPatentsImvexxyMember"
      decimals="INF"
      unitRef="Pure">3</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="AsOf2019-12-31_custom_ForeignDesignPatentsImvexxyMember"
      decimals="INF"
      unitRef="Pure">10</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="AsOf2019-12-31_custom_DomesticUSPatentsTopicalCreamMember"
      decimals="INF"
      unitRef="Pure">1</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="AsOf2019-12-31_custom_DomesticUtilityPatentTransdermalPatchMember"
      decimals="INF"
      unitRef="Pure">1</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="AsOf2019-12-31_custom_ForeignUtilityPatentTransdermalPatchMember"
      decimals="INF"
      unitRef="Pure">7</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="AsOf2019-12-31_custom_DomesticUtilityPatentTx009HRMember"
      decimals="INF"
      unitRef="Pure">3</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="AsOf2019-12-31_custom_DomesticPatentsProgesteroneFormulationsMember"
      decimals="INF"
      unitRef="Pure">2</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="AsOf2019-12-31_custom_ForeignPatentsProgesteroneFormulationsMember"
      decimals="INF"
      unitRef="Pure">4</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="AsOf2019-12-31_custom_DomesticUtilityPatentOperaMember"
      decimals="INF"
      unitRef="Pure">1</txmd:NumberOfIssuedPatents>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2019-01-01to2019-12-31"
      decimals="0"
      unitRef="USD">197593</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">112474</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2017-01-012017-12-31"
      decimals="0"
      unitRef="USD">71516</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="From2019-01-01to2019-12-31">&lt;p id="xdx_897_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zrznKYBF3tWd" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="background-color: white"&gt;Estimated amortization expense, based on current patent cost being amortized, for the next five years is as follows:&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin-right: auto; margin-left: auto; float: none; width: 40%"&gt;

&lt;tr&gt;
&lt;td style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; width: 49%; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;Year Ending&lt;br/&gt;December
31,&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding: 0pt 5.4pt; width: 2%; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td id="xdx_49E_20191231_zsxdHn6Z4B7k" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; vertical-align: top; width: 49%"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;Estimated&lt;br/&gt;Amortization&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_400_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_z5zAjuA6YVph" style="background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"&gt;2020&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"&gt;$229,546&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_zggNowtaQ5kb" style="background-color: White"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"&gt;2021&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"&gt;$229,546&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_zUDpMMLkGDl7" style="background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"&gt;2022&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"&gt;$229,546&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_zlthq9FvAC15" style="background-color: White"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"&gt;2023&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"&gt;$229,546&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_ztTQzfSmEsS7" style="background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"&gt;2024&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"&gt;$229,546&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: White"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">229546</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">229546</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">229546</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">229546</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">229546</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <txmd:MilestonePaymentUponFDAApproval
      contextRef="From2019-07-012019-09-30_custom_AnnoveraMember_custom_CouncilLicenseAgreement1Member"
      decimals="0"
      unitRef="USD">20000000</txmd:MilestonePaymentUponFDAApproval>
    <txmd:MilestonePaymentsAfterReleaseOfFirstCommercialBatch
      contextRef="AsOf2019-09-30_custom_AnnoveraMember_custom_CouncilLicenseAgreement1Member"
      decimals="0"
      unitRef="USD">20000000</txmd:MilestonePaymentsAfterReleaseOfFirstCommercialBatch>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="From2019-07-012019-09-30_custom_AnnoveraMember_custom_CouncilLicenseAgreement1Member"
      decimals="0"
      unitRef="USD">20000000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:OtherAmortizationOfDeferredCharges
      contextRef="From2019-01-012019-12-31_custom_AnnoveraMember_custom_CouncilLicenseAgreement1Member"
      decimals="0"
      unitRef="USD">778692</us-gaap:OtherAmortizationOfDeferredCharges>
    <txmd:NetSalesAmountPerStepbasedRoyalty
      contextRef="From2019-01-012019-12-31_custom_CouncilLicenseAgreementStep1Member_srt_MaximumMember"
      decimals="0"
      unitRef="USD">50000000</txmd:NetSalesAmountPerStepbasedRoyalty>
    <txmd:RoyaltyPercent
      contextRef="From2019-01-012019-12-31_custom_CouncilLicenseAgreementStep1Member"
      decimals="INF"
      unitRef="Pure">0.05</txmd:RoyaltyPercent>
    <txmd:NetSalesAmountPerStepbasedRoyalty
      contextRef="From2019-01-012019-12-31_custom_CouncilLicenseAgreementStep2Member_srt_MinimumMember"
      decimals="0"
      unitRef="USD">50000000</txmd:NetSalesAmountPerStepbasedRoyalty>
    <txmd:NetSalesAmountPerStepbasedRoyalty
      contextRef="From2019-01-012019-12-31_custom_CouncilLicenseAgreementStep2Member_srt_MaximumMember"
      decimals="0"
      unitRef="USD">150000000</txmd:NetSalesAmountPerStepbasedRoyalty>
    <txmd:RoyaltyPercent
      contextRef="From2019-01-012019-12-31_custom_CouncilLicenseAgreementStep2Member"
      decimals="INF"
      unitRef="Pure">0.10</txmd:RoyaltyPercent>
    <txmd:NetSalesAmountPerStepbasedRoyalty
      contextRef="From2019-01-012019-12-31_custom_CouncilLicenseAgreementStep3Member_srt_MinimumMember"
      decimals="0"
      unitRef="USD">150000000</txmd:NetSalesAmountPerStepbasedRoyalty>
    <txmd:RoyaltyPercent
      contextRef="From2019-01-012019-12-31_custom_CouncilLicenseAgreementStep3Member"
      decimals="INF"
      unitRef="Pure">0.15</txmd:RoyaltyPercent>
    <txmd:AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent
      contextRef="From2019-01-012019-12-31_custom_CouncilLicenseAgreement1Member"
      decimals="INF"
      unitRef="Pure">0.50</txmd:AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent>
    <txmd:AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent
      contextRef="From2019-01-012019-12-31_custom_CouncilLicenseAgreement1Member"
      decimals="INF"
      unitRef="Pure">0.20</txmd:AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent>
    <txmd:RequiredMilestonePaymentsUponCumulativeNetSalesOfSpecifiedLevels
      contextRef="From2019-01-012019-12-31_custom_CouncilLicenseAgreement1Member"
      decimals="0"
      unitRef="USD">40000000</txmd:RequiredMilestonePaymentsUponCumulativeNetSalesOfSpecifiedLevels>
    <txmd:SpecifiedLevelOneOfCumulativeNetSalesForRequiredMilestonePayments
      contextRef="From2019-01-012019-12-31_custom_CouncilLicenseAgreement1Member"
      decimals="0"
      unitRef="USD">200000000</txmd:SpecifiedLevelOneOfCumulativeNetSalesForRequiredMilestonePayments>
    <txmd:SpecifiedLevelTwoOfCumulativeNetSalesForRequiredMilestonePayments
      contextRef="From2019-01-012019-12-31_custom_CouncilLicenseAgreement1Member"
      decimals="0"
      unitRef="USD">400000000</txmd:SpecifiedLevelTwoOfCumulativeNetSalesForRequiredMilestonePayments>
    <txmd:SpecifiedLevelThreeOfCumulativeNetSalesForRequiredMilestonePayments
      contextRef="From2019-01-012019-12-31_custom_CouncilLicenseAgreement1Member"
      decimals="0"
      unitRef="USD">1000000000</txmd:SpecifiedLevelThreeOfCumulativeNetSalesForRequiredMilestonePayments>
    <txmd:MaximumCostsAndExpensesForPostApprovalStudyToBePaid
      contextRef="From2019-01-012019-12-31_custom_CouncilLicenseAgreement1Member"
      decimals="0"
      unitRef="USD">20000000</txmd:MaximumCostsAndExpensesForPostApprovalStudyToBePaid>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="From2019-01-01to2019-12-31">&lt;p id="xdx_805_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_zjt8xYAJDmTd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;b&gt;NOTE 7 &#x2013; &lt;span id="xdx_82F_zx9XuzG1nPx2"&gt;OTHER CURRENT LIABILITIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p id="xdx_89B_eus-gaap--OtherCurrentLiabilitiesTableTextBlock_zV63QVGAs9w6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Other current liabilities consist of the following:&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin-right: auto; margin-left: auto; float: none; width: 80%"&gt;

&lt;tr&gt;
&lt;td style="vertical-align: top; padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" id="xdx_491_20191231_zjFOD0PPjSWf" style="vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b/&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" id="xdx_499_20181231_zUKRCWRTVVHa" style="vertical-align: top; padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b/&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="6" style="border-bottom: black 1pt none; border-top-style: none; border-right-style: none; border-left-style: none; border-bottom-style: solid; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: black 1pt solid; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_40E_eus-gaap--AccruedSalariesCurrent_iI_maOLCzU7z_zOuIA4I6TjVl" style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; width: 70%; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;Accrued payroll, bonuses and commission costs&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;8,040,278&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;6,854,002&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_404_ecustom--SalesDiscountsReturnsAndAllowancesGoods1_iI_maOLCzU7z_zWEOrv5FWwFh"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;Allowance for coupons and returns&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;10,316,298&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;5,294,120&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--AccruedMarketingCostsCurrent_iI_maOLCzU7z_zzKoU8WkETQe" style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;Accrued sales and marketing costs&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;3,285,662&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;2,288,028&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_40D_eus-gaap--AccruedVacationCurrent_iI_maOLCzU7z_zdVTD5Z7jHQ4"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;Accrued compensated absences&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;1,463,878&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;1,178,110&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_408_ecustom--AllowanceForWholesaleDistributorFeesCurrent_iI_maOLCzU7z_zYhKDbjcucVf" style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;Allowance for wholesale distributor fees&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;2,347,122&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;792,891&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_40B_eus-gaap--AccruedProfessionalFeesCurrent_iI_maOLCzU7z_zzjV5ZgsadF7"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;Accrued legal and accounting expense&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;422,336&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;385,824&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_40B_ecustom--AccruedResearchAndDevelopment_iI_maOLCzU7z_zoBcexnUN7A7" style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;Accrued research and development&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;1,049,603&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;388,675&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_400_eus-gaap--AccruedRentCurrent_iI_maOLCzU7z_zSS2ihVlbIv6"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;Accrued rent&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0846"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;365,155&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_407_eus-gaap--OperatingLeaseLiabilityCurrent_iI_maOLCzU7z_zfwx69kp59ad" style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;Operating lease liability&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;1,501,539&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0850"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_405_ecustom--AccruedRebates_iI_maOLCzU7z_zMCf1hCKBMif"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;Accrued rebates&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;3,916,672&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;412,570&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_407_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_maOLCzU7z_zH8gZSYDqck8" style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;Other accrued expenses&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;1,480,225&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;375,573&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_405_eus-gaap--OtherLiabilitiesCurrent_iTI_mtOLCzU7z_ziorxVunc4d3"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"&gt;TOTAL OTHER CURRENT LIABILITIES&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;33,823,613&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;18,334,948&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:OtherCurrentLiabilitiesTableTextBlock contextRef="From2019-01-01to2019-12-31">&lt;p id="xdx_89B_eus-gaap--OtherCurrentLiabilitiesTableTextBlock_zV63QVGAs9w6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Other current liabilities consist of the following:&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin-right: auto; margin-left: auto; float: none; width: 80%"&gt;

&lt;tr&gt;
&lt;td style="vertical-align: top; padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" id="xdx_491_20191231_zjFOD0PPjSWf" style="vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b/&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" id="xdx_499_20181231_zUKRCWRTVVHa" style="vertical-align: top; padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b/&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="6" style="border-bottom: black 1pt none; border-top-style: none; border-right-style: none; border-left-style: none; border-bottom-style: solid; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: black 1pt solid; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_40E_eus-gaap--AccruedSalariesCurrent_iI_maOLCzU7z_zOuIA4I6TjVl" style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; width: 70%; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;Accrued payroll, bonuses and commission costs&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;8,040,278&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;6,854,002&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_404_ecustom--SalesDiscountsReturnsAndAllowancesGoods1_iI_maOLCzU7z_zWEOrv5FWwFh"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;Allowance for coupons and returns&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;10,316,298&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;5,294,120&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--AccruedMarketingCostsCurrent_iI_maOLCzU7z_zzKoU8WkETQe" style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;Accrued sales and marketing costs&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;3,285,662&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;2,288,028&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_40D_eus-gaap--AccruedVacationCurrent_iI_maOLCzU7z_zdVTD5Z7jHQ4"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;Accrued compensated absences&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;1,463,878&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;1,178,110&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_408_ecustom--AllowanceForWholesaleDistributorFeesCurrent_iI_maOLCzU7z_zYhKDbjcucVf" style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;Allowance for wholesale distributor fees&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;2,347,122&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;792,891&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_40B_eus-gaap--AccruedProfessionalFeesCurrent_iI_maOLCzU7z_zzjV5ZgsadF7"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;Accrued legal and accounting expense&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;422,336&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;385,824&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_40B_ecustom--AccruedResearchAndDevelopment_iI_maOLCzU7z_zoBcexnUN7A7" style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;Accrued research and development&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;1,049,603&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;388,675&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_400_eus-gaap--AccruedRentCurrent_iI_maOLCzU7z_zSS2ihVlbIv6"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;Accrued rent&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0846"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;365,155&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_407_eus-gaap--OperatingLeaseLiabilityCurrent_iI_maOLCzU7z_zfwx69kp59ad" style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;Operating lease liability&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;1,501,539&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0850"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_405_ecustom--AccruedRebates_iI_maOLCzU7z_zMCf1hCKBMif"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;Accrued rebates&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;3,916,672&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;412,570&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_407_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_maOLCzU7z_zH8gZSYDqck8" style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;Other accrued expenses&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;1,480,225&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;375,573&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_405_eus-gaap--OtherLiabilitiesCurrent_iTI_mtOLCzU7z_ziorxVunc4d3"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"&gt;TOTAL OTHER CURRENT LIABILITIES&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;33,823,613&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;18,334,948&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
</us-gaap:OtherCurrentLiabilitiesTableTextBlock>
    <us-gaap:AccruedSalariesCurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">8040278</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">6854002</us-gaap:AccruedSalariesCurrent>
    <txmd:SalesDiscountsReturnsAndAllowancesGoods1 contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">10316298</txmd:SalesDiscountsReturnsAndAllowancesGoods1>
    <txmd:SalesDiscountsReturnsAndAllowancesGoods1 contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">5294120</txmd:SalesDiscountsReturnsAndAllowancesGoods1>
    <us-gaap:AccruedMarketingCostsCurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">3285662</us-gaap:AccruedMarketingCostsCurrent>
    <us-gaap:AccruedMarketingCostsCurrent contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">2288028</us-gaap:AccruedMarketingCostsCurrent>
    <us-gaap:AccruedVacationCurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">1463878</us-gaap:AccruedVacationCurrent>
    <us-gaap:AccruedVacationCurrent contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">1178110</us-gaap:AccruedVacationCurrent>
    <txmd:AllowanceForWholesaleDistributorFeesCurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">2347122</txmd:AllowanceForWholesaleDistributorFeesCurrent>
    <txmd:AllowanceForWholesaleDistributorFeesCurrent contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">792891</txmd:AllowanceForWholesaleDistributorFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">422336</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">385824</us-gaap:AccruedProfessionalFeesCurrent>
    <txmd:AccruedResearchAndDevelopment contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">1049603</txmd:AccruedResearchAndDevelopment>
    <txmd:AccruedResearchAndDevelopment contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">388675</txmd:AccruedResearchAndDevelopment>
    <us-gaap:AccruedRentCurrent contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">365155</us-gaap:AccruedRentCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">1501539</us-gaap:OperatingLeaseLiabilityCurrent>
    <txmd:AccruedRebates contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">3916672</txmd:AccruedRebates>
    <txmd:AccruedRebates contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">412570</txmd:AccruedRebates>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">1480225</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">375573</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">33823613</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">18334948</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LongTermDebtTextBlock contextRef="From2019-01-01to2019-12-31">&lt;p id="xdx_805_eus-gaap--LongTermDebtTextBlock_zSiEv2AIkhag" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;b&gt;NOTE 8 &#x2013; &lt;span id="xdx_826_zaOePHCOSkxk"&gt;DEBT&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: #212529"&gt;On April 24, 2019, we entered into a Financing Agreement, as amended on December 27, 2019, or the Financing Agreement, with TPG Specialty Lending, Inc., as administrative agent, or the Administrative Agent, various lenders from time to time party thereto, and certain of our subsidiaries party thereto from time to time as guarantors, which provides us with a $&lt;span id="xdx_904_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20190424__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_ztKq30bxEfr9"&gt;300,000,000&lt;/span&gt; first lien secured term loan credit facility, or the Facility. The Facility provides for availability to us in three tranches: (i) $&lt;span id="xdx_909_eus-gaap--ProceedsFromLinesOfCredit_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__custom--DebtTrancheAxis__custom--TrancheOneMember_zi0swcfjdzkc"&gt;200,000,000&lt;/span&gt; was drawn upon entering into the Financing Agreement; (ii) $&lt;span id="xdx_90A_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__custom--DebtTrancheAxis__custom--TrancheTwoMember_z9hMwRzstg49"&gt;50,000,000&lt;/span&gt; will be available to us in the Administrative Agent&#x2019;s sole and absolute discretion either contemporaneously with the delivery of our financial statements for the fiscal quarter ending June 30, 2020 or at such earlier date as the Administrative Agent shall have consented to; and (iii) $&lt;span id="xdx_909_eus-gaap--ProceedsFromLinesOfCredit_c20200216__20200218__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__custom--DebtTrancheAxis__custom--TrancheThreeMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_znOd6IYgJich"&gt;50,000,000&lt;/span&gt; was drawn on February 18, 2020 following our achievement of more than $&lt;span id="xdx_90A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20191001__20191231__srt--ProductOrServiceAxis__custom--ImvexxyBijuvaAndAnnoveraMember__srt--RangeAxis__srt--MinimumMember_zfv3TjGl8LZ1" title="Net revenue"&gt;11,000,000&lt;/span&gt; in net revenues from IMVEXXY, BIJUVA and ANNOVERA for the fourth quarter of 2019. Borrowings under the Facility accrue interest at either (i) &lt;span id="xdx_90B_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zKJYtF79CaQd"&gt;3-month LIBOR&lt;/span&gt; plus &lt;span id="xdx_902_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_dp_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zp1LBXSYs8ve"&gt;7.75&lt;/span&gt;%, subject to a LIBOR floor of &lt;span id="xdx_902_ecustom--LiborFloorRate_iI_dp_c20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zOd7HYmfzNdi" title="LIBOR floor rate"&gt;2.70&lt;/span&gt;% or (ii) the &lt;span id="xdx_90A_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__us-gaap--VariableRateAxis__us-gaap--PrimeRateMember_zjeOahoIjjzg"&gt;prime rate&lt;/span&gt; plus &lt;span id="xdx_908_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_dp_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__us-gaap--VariableRateAxis__us-gaap--PrimeRateMember_z7ZeM62wYHf9"&gt;6.75&lt;/span&gt;%, subject to a prime rate floor of &lt;span id="xdx_901_ecustom--LiborFloorRate_iI_dp_c20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__us-gaap--VariableRateAxis__us-gaap--PrimeRateMember_zm98sOE82Djj"&gt;5.2&lt;/span&gt;% as selected by us. Interest on amounts borrowed under the Facility is payable quarterly. The outstanding principal amount of the Facility is payable in &lt;span id="xdx_903_ecustom--NumberOfInstallmentPayments_iI_dc_uPure_c20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zo00bHzWivZ7" title="Number of quarterly principal installment payments"&gt;four&lt;/span&gt; equal quarterly installments beginning on June 30, 2023, with the Facility maturing on March 31, 2024. We have the right to prepay borrowings under the Facility in whole or in part at any time, subject to a prepayment fee on the principal amount being prepaid of (i) &lt;span id="xdx_908_ecustom--PrepaymentFeeForFirstTwoYearsFundingPercent_dp_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zBKqDSL2LShj" title="Prepayment fee for first two years funding (percent)"&gt;30.0&lt;/span&gt;% for the first two years following the initial funding date of the applicable borrowing, (ii) &lt;span id="xdx_900_ecustom--PrepaymentFeeThirdYearFundingPercent_dp_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zXjZ1JE5xuIi" title="Prepayment fee third year funding (percent)"&gt;5.0&lt;/span&gt;% for the third year following the initial funding date of the applicable borrowing, (iii) &lt;span id="xdx_90E_ecustom--PrepaymentFeeFourthYearFundingPercent_dp_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_z072mbMfrW8h" title="Prepayment fee fourth year funding (percent)"&gt;3.0&lt;/span&gt;% for the fourth year following the initial funding date of the applicable borrowing and (iv) &lt;span id="xdx_902_ecustom--PrepaymentFeeFifthYearFundingPercent_dp_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_z5dW3FwW1X3c" title="Prepayment fee fifth year funding (percent)"&gt;1.0&lt;/span&gt;% for the fifth year following the initial funding date of the applicable borrowing but prior to March 31, 2024. In connection with the initial borrowing under the Facility, we paid, for the benefit of the lenders, a facility fee equal to &lt;span id="xdx_90E_ecustom--FacilityFeePaidPercent_dp_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_z1LrXhir0wBk" title="Facility fee paid (percent)"&gt;2.5&lt;/span&gt;% of the initial amount borrowed and will be required to pay such a facility fee in connection with any subsequent borrowings under the Facility. We are also required to pay the Administrative Agent and the lenders an annual administrative fee in addition to other fees and expenses. The Financing Agreement contains customary mandatory prepayments, restrictions and covenants applicable to us that are customary for financings of this type. Among other requirements, we are required to (i) maintain a minimum unrestricted cash balance of $&lt;span id="xdx_90E_ecustom--MinimumCashBalanceRequirementUnderCreditAgreement_iI_c20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zcVtCOGqCjMc" title="Minimum cash balance requirement under credit agreement"&gt;50,000,000&lt;/span&gt;, which will increase to $&lt;span id="xdx_90C_ecustom--MinimumCashBalanceRequirementUnderCreditAgreement_iI_c20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__custom--DebtTrancheAxis__custom--TrancheTwoThreeMember_zapjg0M2A454"&gt;60,000,000&lt;/span&gt; if we draw either the second or third tranche of the Facility, and (ii) achieve certain minimum consolidated net revenue amounts attributable to commercial sales of our IMVEXXY, BIJUVA and ANNOVERA products beginning with the fiscal quarter ending December 31, 2020. The Financing Agreement also includes other representations, warranties, indemnities and events of default that are customary for financings of this type, including an event of default relating to a change of control of the Company. Upon or after an event of default, the Administrative Agent and the lenders may declare all or a portion of our obligations under the Financing Agreement to be immediately due and payable and exercise other rights and remedies provided for under the Financing Agreement. The obligations of our company and its subsidiaries under the Financing Agreement are secured, subject to customary permitted liens and other agreed upon exceptions, by a first priority perfected security interest in all existing and after acquired assets of our company and its subsidiaries. The obligations under the Financing Agreement will be guaranteed by each of our future direct and indirect subsidiaries, subject to certain exceptions. &lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: #212529"&gt;On May 1, 2018, we entered into a Credit and Security Agreement, or the Credit Agreement, with MidCap Financial Trust, or MidCap, as agent, or Agent, and as lender, and the additional lenders party thereto from time to time (together with MidCap as a lender, the Lenders), as amended. The Credit Agreement provided a secured term loan facility in an aggregate principal amount of up to $&lt;span id="xdx_90B_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20180501__us-gaap--CreditFacilityAxis__us-gaap--SecuredDebtMember_zthRxExVWBUe"&gt;200,000,000&lt;/span&gt;, or the Term Loan. Under the terms of the Credit Agreement, the Term Loan was available to be made in &lt;span id="xdx_902_ecustom--NumberOfTranchesUnderTermLoanFacility_iI_dc_uPure_c20180501__us-gaap--CreditFacilityAxis__us-gaap--SecuredDebtMember_zPPGETTdoyd1" title="Number of tranches under term loan facility"&gt;three&lt;/span&gt; separate tranches, with each tranche to be made available to us, at our option, upon our achievement of certain milestones. Amounts borrowed under the Term Loan bore interest at a rate equal to the sum of (i) &lt;span id="xdx_90C_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20180430__20180501__us-gaap--CreditFacilityAxis__us-gaap--SecuredDebtMember_zniw2imzgvIj"&gt;one-month LIBOR&lt;/span&gt; (subject to a LIBOR floor of &lt;span id="xdx_905_ecustom--LiborFloorRate_iI_dp_c20180501__us-gaap--CreditFacilityAxis__us-gaap--SecuredDebtMember_zNdCgj9HmMG8"&gt;1.50&lt;/span&gt;%) plus (ii) &lt;span id="xdx_903_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_dp_c20180430__20180501__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zwDyyLP7pB0b"&gt;7.75&lt;/span&gt;% per annum.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: #212529"&gt;On April 24, 2019, we terminated the Credit Agreement. A portion of the initial tranche of borrowing under the Financing Agreement in the amount of approximately $&lt;span id="xdx_902_ecustom--RepaymentOfDebtWithNewCreditFacility_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--MidCapAgreementMember_zRCxWeLxaQee" title="Repayment of debt with new credit facility"&gt;81,661,000&lt;/span&gt; was used to repay all amounts outstanding under the Credit Agreement, which included a prepayment fee of &lt;span id="xdx_906_ecustom--PrepaymentFeePercentage_dp_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--MidCapAgreementMember_z1tr3iVx9Ax2" title="Prepayment fee percentage"&gt;4&lt;/span&gt;%, a repayment fee of &lt;span id="xdx_907_ecustom--RepaymentFeePercentage_dp_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--MidCapAgreementMember_zW5eRlDCh8gb" title="Repayment fee percentage"&gt;4&lt;/span&gt;% and other fees and expenses payable to the lenders under the Credit Agreement. As a result of the termination of the Credit Agreement, we recorded $&lt;span id="xdx_903_eus-gaap--GainsLossesOnExtinguishmentOfDebt_dxL_c20190101__20191231_zAdxzVLUPBZb" title="Loss on extinguishment of debt::XDX::-10%2C057%2C632"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0904"&gt;10,057,632&lt;/span&gt;&lt;/span&gt; in loss on extinguishment of debt in the accompanying consolidated financial statements. Interest on amounts borrowed under the Term Loan was due and payable monthly in arrears. Interest expense for the year ending December 31, 2019 related to the Credit Agreement was $&lt;span id="xdx_90A_eus-gaap--InterestExpenseDebt_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--MidCapAgreementMember_zZu0N2x7r0pi"&gt;1,816,747&lt;/span&gt;. During the year ended December 31, 2019, and prior to the repayment of the Credit Agreement, we amortized $&lt;span id="xdx_907_eus-gaap--AmortizationOfFinancingCosts_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--MidCapAgreementMember_z6DStLq8Xyw7" title="Amortization of Debt Issuance Costs"&gt;120,146&lt;/span&gt; of deferred financing fees &lt;span style="color: black"&gt;as interest expense in our accompanying consolidated financial statements&lt;/span&gt; and d&lt;span style="color: black"&gt;uring the year ended December 31, 2018, we amortized $&lt;span id="xdx_90A_eus-gaap--AmortizationOfFinancingCosts_c20180101__20181231_zEiH8OzHEhJ5"&gt;269,859&lt;/span&gt;, of debt issuance costs as interest expense in our accompanying consolidated financial statements. &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: #212529; background-color: white"&gt;As of December 31, 2019, we had $&lt;span id="xdx_901_eus-gaap--DebtInstrumentCarryingAmount_iI_c20191231__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_z9VcDs7KUOp4"&gt;200,000,000&lt;/span&gt; in borrowings outstanding under the Financing Agreement, which are classified as long-term debt in the accompanying consolidated financial statements. During the year ended December 31, 2019, we incurred $&lt;span id="xdx_90E_eus-gaap--PaymentsOfFinancingCosts_c20190101__20191231_zUmKALfTitQ4"&gt;6,652,270&lt;/span&gt; in deferred financing fees related to the Financing Agreement. Deferred financing fees related to the entire Financing Agreement have been allocated pro rata between the funded and unfunded portions of each tranche. Allocated deferred financing fees related to the first tranche of borrowings of $&lt;span id="xdx_906_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20191231_zr98Xubaf61j"&gt;6,101,513&lt;/span&gt; have been reflected as a debt discount and are accreted to interest expense using the effective interest method. Deferred financing fees associated with unfunded tranches were deferred as assets until the respective tranche has been drawn. As of December 31, 2019, deferred financing fees related to the unfunded tranches were included in other current assets in the accompanying consolidated financial statements. During the year ended December 31, 2019, we amortized $&lt;span id="xdx_902_eus-gaap--AmortizationOfFinancingCosts_c20190101__20191231__custom--DebtTrancheAxis__custom--TrancheOneMember_zlblebXkXWC4"&gt;736,156&lt;/span&gt;&lt;span style="background-color: white"&gt; of deferred financing fees related to the first tranche as interest expense in the accompanying consolidated financial statements. Interest on amounts borrowed under the Financing Agreement is due and payable quarterly in arrears. Interest expense for the year ended December 31, 2019 was $&lt;/span&gt;&lt;span id="xdx_909_eus-gaap--InterestExpenseBorrowings_c20190101__20191231__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_zabZC7kgd36h"&gt;14,709,166&lt;/span&gt;&lt;span style="background-color: white"&gt;. The overall effective interest rate under the Financing Agreement was approximately &lt;/span&gt;&lt;span id="xdx_906_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_dp_c20191231_zQGVlNDMVn2e"&gt;11&lt;/span&gt;&lt;span style="background-color: white"&gt;% as of December 31, &lt;/span&gt;2019.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p id="xdx_89D_eus-gaap--ScheduleOfDebtTableTextBlock_zhYPUVgRaRm2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: #212529"&gt;As
of December 31, 2019 and 2018, the carrying value of our debt consisted of the following:&lt;/span&gt;&lt;/p&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin-right: auto; margin-left: auto; float: none; width: 90%"&gt;

&lt;tr&gt;
&lt;td style="vertical-align: top; padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" id="xdx_494_20191231_zlUsomLypRM8" style="vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b/&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" id="xdx_499_20181231_zzTEfz2tgvEe" style="vertical-align: top; padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b/&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="6" style="border-bottom: black 1pt none; border-top-style: none; border-right-style: none; border-left-style: none; border-bottom-style: solid; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;As of December
31,&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: black 1pt solid; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; width: 70%; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;Financing Agreement&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%"&gt;
&lt;p id="xdx_98E_eus-gaap--DebtInstrumentCarryingAmount_iI_c20191231__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_zbE9M3lpQTMk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;200,000,000&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#x2014;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;Credit Agreement&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#x2014;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_98E_eus-gaap--DebtInstrumentCarryingAmount_iI_c20181231__us-gaap--LongtermDebtTypeAxis__custom--CreditAgreementMember_zphlZAFEh85c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;75,000,000&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iNI_di_ze8D0Pviiowe" style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;Debt discount and financing fees&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;(5,365,357&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;(1,618,986&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_40A_eus-gaap--LongTermDebtNoncurrent_iI_zm5RcpFdX4U3"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"&gt;TOTAL LONG-TERM DEBT&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;194,634,643&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;73,381,014&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
</us-gaap:LongTermDebtTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="AsOf2019-04-24_us-gaap_RevolvingCreditFacilityMember_custom_FinancingAgreementMember"
      decimals="0"
      unitRef="USD">300000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="From2019-04-232019-04-24_custom_FinancingAgreementMember_custom_TrancheOneMember"
      decimals="0"
      unitRef="USD">200000000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="AsOf2019-04-24_custom_FinancingAgreementMember_custom_TrancheTwoMember"
      decimals="0"
      unitRef="USD">50000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="From2020-02-162020-02-18_custom_FinancingAgreementMember_custom_TrancheThreeMember_us-gaap_SubsequentEventMember"
      decimals="0"
      unitRef="USD">50000000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2019-10-012019-12-31_custom_ImvexxyBijuvaAndAnnoveraMember_srt_MinimumMember"
      decimals="0"
      unitRef="USD">11000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:DebtInstrumentDescriptionOfVariableRateBasis contextRef="From2019-04-232019-04-24_custom_FinancingAgreementMember">3-month LIBOR</us-gaap:DebtInstrumentDescriptionOfVariableRateBasis>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="From2019-04-232019-04-24_custom_FinancingAgreementMember"
      decimals="INF"
      unitRef="Pure">0.0775</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <txmd:LiborFloorRate
      contextRef="AsOf2019-04-24_custom_FinancingAgreementMember"
      decimals="INF"
      unitRef="Pure">0.0270</txmd:LiborFloorRate>
    <us-gaap:DebtInstrumentDescriptionOfVariableRateBasis contextRef="From2019-04-232019-04-24_custom_FinancingAgreementMember_us-gaap_PrimeRateMember">prime rate</us-gaap:DebtInstrumentDescriptionOfVariableRateBasis>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="From2019-04-232019-04-24_custom_FinancingAgreementMember_us-gaap_PrimeRateMember"
      decimals="INF"
      unitRef="Pure">0.0675</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <txmd:LiborFloorRate
      contextRef="AsOf2019-04-24_custom_FinancingAgreementMember_us-gaap_PrimeRateMember"
      decimals="INF"
      unitRef="Pure">0.052</txmd:LiborFloorRate>
    <txmd:NumberOfInstallmentPayments
      contextRef="AsOf2019-04-24_custom_FinancingAgreementMember"
      decimals="INF"
      unitRef="Pure">4</txmd:NumberOfInstallmentPayments>
    <txmd:PrepaymentFeeForFirstTwoYearsFundingPercent
      contextRef="From2019-04-232019-04-24_custom_FinancingAgreementMember"
      decimals="INF"
      unitRef="Pure">0.300</txmd:PrepaymentFeeForFirstTwoYearsFundingPercent>
    <txmd:PrepaymentFeeThirdYearFundingPercent
      contextRef="From2019-04-232019-04-24_custom_FinancingAgreementMember"
      decimals="INF"
      unitRef="Pure">0.050</txmd:PrepaymentFeeThirdYearFundingPercent>
    <txmd:PrepaymentFeeFourthYearFundingPercent
      contextRef="From2019-04-232019-04-24_custom_FinancingAgreementMember"
      decimals="INF"
      unitRef="Pure">0.030</txmd:PrepaymentFeeFourthYearFundingPercent>
    <txmd:PrepaymentFeeFifthYearFundingPercent
      contextRef="From2019-04-232019-04-24_custom_FinancingAgreementMember"
      decimals="INF"
      unitRef="Pure">0.010</txmd:PrepaymentFeeFifthYearFundingPercent>
    <txmd:FacilityFeePaidPercent
      contextRef="From2019-04-232019-04-24_custom_FinancingAgreementMember"
      decimals="INF"
      unitRef="Pure">0.025</txmd:FacilityFeePaidPercent>
    <txmd:MinimumCashBalanceRequirementUnderCreditAgreement
      contextRef="AsOf2019-04-24_custom_FinancingAgreementMember"
      decimals="0"
      unitRef="USD">50000000</txmd:MinimumCashBalanceRequirementUnderCreditAgreement>
    <txmd:MinimumCashBalanceRequirementUnderCreditAgreement
      contextRef="AsOf2019-04-24_custom_FinancingAgreementMember_custom_TrancheTwoThreeMember"
      decimals="0"
      unitRef="USD">60000000</txmd:MinimumCashBalanceRequirementUnderCreditAgreement>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="AsOf2018-05-01_us-gaap_SecuredDebtMember"
      decimals="0"
      unitRef="USD">200000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <txmd:NumberOfTranchesUnderTermLoanFacility
      contextRef="AsOf2018-05-01_us-gaap_SecuredDebtMember"
      decimals="INF"
      unitRef="Pure">3</txmd:NumberOfTranchesUnderTermLoanFacility>
    <us-gaap:DebtInstrumentDescriptionOfVariableRateBasis contextRef="From2018-04-302018-05-01_us-gaap_SecuredDebtMember">one-month LIBOR</us-gaap:DebtInstrumentDescriptionOfVariableRateBasis>
    <txmd:LiborFloorRate
      contextRef="AsOf2018-05-01_us-gaap_SecuredDebtMember"
      decimals="INF"
      unitRef="Pure">0.0150</txmd:LiborFloorRate>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="From2018-04-302018-05-01_us-gaap_RevolvingCreditFacilityMember"
      decimals="INF"
      unitRef="Pure">0.0775</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <txmd:RepaymentOfDebtWithNewCreditFacility
      contextRef="From2019-04-232019-04-24_custom_MidCapAgreementMember"
      decimals="0"
      unitRef="USD">81661000</txmd:RepaymentOfDebtWithNewCreditFacility>
    <txmd:PrepaymentFeePercentage
      contextRef="From2019-04-232019-04-24_custom_MidCapAgreementMember"
      decimals="INF"
      unitRef="Pure">0.04</txmd:PrepaymentFeePercentage>
    <txmd:RepaymentFeePercentage
      contextRef="From2019-04-232019-04-24_custom_MidCapAgreementMember"
      decimals="INF"
      unitRef="Pure">0.04</txmd:RepaymentFeePercentage>
    <us-gaap:InterestExpenseDebt
      contextRef="From2019-01-012019-12-31_custom_MidCapAgreementMember"
      decimals="0"
      unitRef="USD">1816747</us-gaap:InterestExpenseDebt>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="From2019-01-012019-12-31_custom_MidCapAgreementMember"
      decimals="0"
      unitRef="USD">120146</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">269859</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2019-12-31_custom_FinancingAgreementMember"
      decimals="0"
      unitRef="USD">200000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="From2019-01-01to2019-12-31"
      decimals="0"
      unitRef="USD">6652270</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">6101513</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="From2019-01-012019-12-31_custom_TrancheOneMember"
      decimals="0"
      unitRef="USD">736156</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:InterestExpenseBorrowings
      contextRef="From2019-01-012019-12-31_custom_FinancingAgreementMember"
      decimals="0"
      unitRef="USD">14709166</us-gaap:InterestExpenseBorrowings>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="AsOf2019-12-31" decimals="INF" unitRef="Pure">0.11</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:ScheduleOfDebtTableTextBlock contextRef="From2019-01-01to2019-12-31">&lt;p id="xdx_89D_eus-gaap--ScheduleOfDebtTableTextBlock_zhYPUVgRaRm2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: #212529"&gt;As
of December 31, 2019 and 2018, the carrying value of our debt consisted of the following:&lt;/span&gt;&lt;/p&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin-right: auto; margin-left: auto; float: none; width: 90%"&gt;

&lt;tr&gt;
&lt;td style="vertical-align: top; padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" id="xdx_494_20191231_zlUsomLypRM8" style="vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b/&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" id="xdx_499_20181231_zzTEfz2tgvEe" style="vertical-align: top; padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b/&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="6" style="border-bottom: black 1pt none; border-top-style: none; border-right-style: none; border-left-style: none; border-bottom-style: solid; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;As of December
31,&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: black 1pt solid; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; width: 70%; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;Financing Agreement&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%"&gt;
&lt;p id="xdx_98E_eus-gaap--DebtInstrumentCarryingAmount_iI_c20191231__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_zbE9M3lpQTMk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;200,000,000&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#x2014;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;Credit Agreement&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#x2014;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_98E_eus-gaap--DebtInstrumentCarryingAmount_iI_c20181231__us-gaap--LongtermDebtTypeAxis__custom--CreditAgreementMember_zphlZAFEh85c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;75,000,000&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iNI_di_ze8D0Pviiowe" style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;Debt discount and financing fees&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;(5,365,357&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;(1,618,986&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_40A_eus-gaap--LongTermDebtNoncurrent_iI_zm5RcpFdX4U3"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"&gt;TOTAL LONG-TERM DEBT&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;194,634,643&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;73,381,014&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2019-12-31_custom_FinancingAgreementMember"
      decimals="0"
      unitRef="USD">200000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2018-12-31_custom_CreditAgreementMember"
      decimals="0"
      unitRef="USD">75000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">5365357</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">1618986</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebtNoncurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">194634643</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">73381014</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2019-01-01to2019-12-31">&lt;p id="xdx_80C_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zr1lbX2Y9D4d" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;b&gt;NOTE 9 &#x2013; &lt;span id="xdx_82E_zBXGNpIYmxl4"&gt;STOCKHOLDERS&#x2019; EQUITY&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="text-decoration: underline"&gt;Preferred Stock&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;At December 31, 2019, we had &lt;span id="xdx_905_eus-gaap--PreferredStockSharesAuthorized_iI_c20191231_zTOAgJVpXB2g"&gt;10,000,000&lt;/span&gt; shares of Preferred Stock, par value $&lt;span id="xdx_902_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20191231_zq0hLf08FHNg"&gt;0.001&lt;/span&gt;, authorized for issuance, of which &lt;span id="xdx_906_eus-gaap--PreferredStockSharesIssued_iI_do_c20191231_zHQwzEDAM63k"&gt;&lt;span id="xdx_907_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20191231_zmy7r9Nyhwn1"&gt;no&lt;/span&gt;&lt;/span&gt; shares of Preferred Stock were issued or outstanding.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="text-decoration: underline"&gt;Common Stock&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;At December 31, 2019, we had &lt;span id="xdx_901_eus-gaap--CommonStockSharesAuthorized_iI_c20191231_zPs3uhMuk7Ij"&gt;350,000,000&lt;/span&gt; shares of Common Stock authorized for issuance, of which &lt;span id="xdx_908_eus-gaap--CommonStockSharesIssued_iI_c20191231_zTuOXU3PkOVg"&gt;&lt;span id="xdx_90A_eus-gaap--CommonStockSharesOutstanding_iI_c20191231_zWdNBpqcNWx8"&gt;271,177,076&lt;/span&gt;&lt;/span&gt; shares of&#160; Common Stock were issued and outstanding.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span style="color: black"&gt;&lt;i&gt;Issuances During 2019&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;On October 24, 2019, we entered into an underwriting agreement with J.P. Morgan Securities LLC, as representative of the underwriters, relating to an underwritten public offering of &lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20191024__20191029__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementJPMorganChaseMember_zzhYHMosfdY1"&gt;26,000,000&lt;/span&gt; shares of our Common Stock at a public offering price of $&lt;span id="xdx_90A_eus-gaap--SharesIssuedPricePerShare_iI_c20191029__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementJPMorganChaseMember_zAjg4lFbLlf1"&gt;2.75&lt;/span&gt; per share. We granted the underwriters an option, exercisable for a period of &lt;span id="xdx_901_ecustom--PeriodExercisableUnderwritersOption_dt_c20191024__20191029__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementJPMorganChaseMember_zkPs2rK7it54" title="Period exercisable underwriters option"&gt;30 days&lt;/span&gt;, to purchase up to &lt;span id="xdx_904_ecustom--UnderwritersOptionGrantedInPeriodShares_c20191024__20191029__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementJPMorganChaseMember_zyOo1tRWgXP5" title="Underwriters option granted in period shares"&gt;3,900,000&lt;/span&gt; additional shares of Common Stock, which was exercised in full. The net proceeds to us from the offering were approximately $&lt;span id="xdx_907_ecustom--ProceedsFromIssuancePublicOffering_c20191024__20191029__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementJPMorganChaseMember_zSAbRt90BdY"&gt;77,031,000&lt;/span&gt;, after deducting the underwriting discount and offering expenses payable by us. The offering closed on October 29, 2019. &lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;During the year ended December 31, 2019, certain individuals exercised stock options to purchase an aggregate of &lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zxMNGDGgvUGf"&gt;331,619&lt;/span&gt; shares of Common Stock for $&lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zMfvCCpwzZV9"&gt;108,656&lt;/span&gt; in cash.&#160; Also, during the year ended December 31, 2019, stock options to purchase an aggregate of &lt;span id="xdx_901_ecustom--NumberOfStockOptionsExercisedInCashlessExercise_c20190101__20191231_z7Ts4oYk1wC7" title="Number of stock options exercised in cashless exercise (in shares)"&gt;12,097&lt;/span&gt; shares of Common Stock were exercised pursuant to the options&#x2019; cashless exercise provisions, which resulted in &lt;span id="xdx_90D_ecustom--NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares_c20190101__20191231_zjDIqaErDoVk" title="Number of common stock issued during period for stock options exercised in cashless exercise (in shares)"&gt;11,834&lt;/span&gt; shares of Common Stock being issued.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span style="color: black"&gt;&lt;i&gt;Issuances During 2018&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;On August 1, 2018, we entered into an underwriting agreement with Goldman Sachs &amp;amp; Co. LLC, as representative of the underwriters, relating to an underwritten public offering of &lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20180801__20180806__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementGoldmanSachsMember_zDGtMyIi9AQd"&gt;12,745,098&lt;/span&gt; shares of our Common Stock at a price of $&lt;span id="xdx_909_eus-gaap--SharesIssuedPricePerShare_iI_c20180806__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementGoldmanSachsMember_zYGCWawnhbJd"&gt;5.10&lt;/span&gt; per share. We granted the underwriters an option, exercisable for a period of &lt;span id="xdx_906_ecustom--PeriodExercisableUnderwritersOption_dt_c20180801__20180806__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementGoldmanSachsMember_zVsKieBFw9di"&gt;30 days&lt;/span&gt;, to purchase up to &lt;span id="xdx_90E_ecustom--UnderwritersOptionGrantedInPeriodShares_c20180801__20180806__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementGoldmanSachsMember_zqVUpBiKm7Rf"&gt;1,911,764&lt;/span&gt; additional shares of Common Stock. On August 2, 2018, the underwriters exercised the option in full. The net proceeds to us from the offering, including the exercise of the option to purchase additional shares, were approximately $&lt;span id="xdx_90D_ecustom--ProceedsFromIssuancePublicOffering_c20180801__20180806__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementGoldmanSachsMember_zgBjkcLXYwjh"&gt;69,908,000&lt;/span&gt;, after deducting the underwriting discount and offering expenses payable by us. The offering closed on August 6, 2018. In connection with the Knight License Agreement, on August 6, 2018, Knight entered into a subscription agreement with us, pursuant to which Knight purchased &lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20180805__20180806__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementKnightMember_zNIGC8ShI0o7"&gt;3,921,568&lt;/span&gt; of shares of our Common Stock concurrently with the closing of the underwritten public offering of Common Stock at a price of $&lt;span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_c20180806__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementKnightMember_za7hGPU9otw1"&gt;5.10&lt;/span&gt;, for proceeds to us of $&lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20180805__20180806__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementKnightMember_zRHfKZ7dNtr5"&gt;20,000,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;During the year ended December 31, 2018, certain individuals exercised stock options to purchase an aggregate of &lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zHiowcES30lj"&gt;5,444,526&lt;/span&gt; shares of Common Stock for $&lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z36gE29D3pWf"&gt;1,666,208&lt;/span&gt; in cash. Also, during the year ended December 31, 2018, stock options to purchase an aggregate of &lt;span id="xdx_90C_ecustom--NumberOfStockOptionsExercisedInCashlessExercise_c20180101__20181231_zDVr4ebv9s65"&gt;10,000&lt;/span&gt; shares of Common Stock were exercised pursuant to the options&#x2019; cashless exercise provisions, wherein &lt;span id="xdx_90C_ecustom--NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares_c20180101__20181231_zhbndHLPqPIk"&gt;9,841&lt;/span&gt; shares of Common Stock were issued.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span style="color: black"&gt;&lt;i&gt;Issuances During 2017&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;On September 25, 2017, we entered into an underwriting agreement with J.P. Morgan Securities LLC relating to an underwritten public offering of &lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20170924__20170925__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementJPMorganChaseMember_zl9ka8C4mkWg"&gt;12,400,000&lt;/span&gt; shares of our Common Stock at a price of $&lt;span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_c20170928__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementJPMorganChaseMember_z8vw2S1Nm17l"&gt;5.55&lt;/span&gt; per share. The net proceeds to us from the offering were approximately $&lt;span id="xdx_909_ecustom--ProceedsFromIssuancePublicOffering_c20170926__20170928__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementJPMorganChaseMember_z9zXHJcsmL3e"&gt;68,573,000&lt;/span&gt;, after deducting estimated offering expenses payable by us. The offering closed on September 28, 2017 and we issued &lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20170926__20170928__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementJPMorganChaseMember_zstftbLH5yVi"&gt;12,400,000&lt;/span&gt; shares of Common Stock.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;During the year ended December 31, 2017, certain individuals exercised stock options to purchase an aggregate of &lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20170101__20171231_zVXD8ygZBgl7"&gt;102,546&lt;/span&gt; shares of Common Stock for $&lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_c20170101__20171231_zHUJqh1806O2"&gt;212,615&lt;/span&gt; in cash.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="text-decoration: underline"&gt;Warrants to Purchase Common Stock&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;As of December 31, 2019, we had warrants outstanding to purchase an aggregate of &lt;span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstanding_iI_c20191231_zprfMzJQxKz5"&gt;1,832,571&lt;/span&gt; shares of Common Stock with a weighted-average contractual remaining life of approximately &lt;span id="xdx_90B_ecustom--WarrantsAndRightsWeightedAverageContractualRemainingLife_dtY_c20190101__20191231_zIkIuyjKCTgk" title="Weighted-average contractual remaining life"&gt;1.95&lt;/span&gt; years, and exercise prices ranging from $&lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20191231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__srt--RangeAxis__srt--MinimumMember_zhCByUX9fQF7"&gt;0.24&lt;/span&gt; to $&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20191231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__srt--RangeAxis__srt--MaximumMember_z22OGQ9JMSV"&gt;8.20&lt;/span&gt; per share, resulting in a weighted average exercise price of $&lt;span id="xdx_902_ecustom--WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice_iI_c20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zPwuUL5vRlt7" title="Weighted average exercise price of warrants (in dollars per share)"&gt;2.62&lt;/span&gt; per share.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;The valuation methodology used to determine the fair value of our warrants is the Black-Scholes Model. The Black-Scholes Model requires the use of a number of assumptions, including volatility of the stock price, the risk-free interest rate, dividend yield and the term of the warrant. During the year ended December 31, 2019, we granted warrants to purchase an aggregate of &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_ziSNle1y4PYe" title="Warrants granted"&gt;75,000&lt;/span&gt; shares of Common Stock to outside consultants which vest ratably over a &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtM_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zyKQ8jRcazDd" title="Warrants vesting period"&gt;12&lt;/span&gt;-month period and have an expiration date of &lt;span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20191231__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zSvqSCMF2X54" title="Warrants expiration date"&gt;February 13, 2024&lt;/span&gt;. During the year ended December 31, 2018, we granted warrants to purchase an aggregate of &lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20180101__20181231__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_z0HEhH7p5PG8"&gt;175,000&lt;/span&gt; shares of Common Stock to outside consultants which vest ratably over a &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtM_c20180101__20181231__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zBb69z51ovd1"&gt;12&lt;/span&gt;-month period and have an expiration date of &lt;span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20181231__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zMvAlTL440fh"&gt;March 15, 2023&lt;/span&gt;. During the year ended December 31, 2017, we granted warrants to purchase an aggregate of &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20170101__20171231__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zg7KzW5gyPkk"&gt;125,000&lt;/span&gt; shares of Common Stock to outside consultants which vest ratably over a &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtM_c20170101__20171231__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zNLaO6dpnahg"&gt;12&lt;/span&gt;-month period and have an expiration date of &lt;span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20171231__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zvVlHAs2Dvpj"&gt;March 15, 2022&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;We recorded share-based compensation expense related to warrants previously issued of $&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensation_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zi8eIr5qpsQ6"&gt;254,970&lt;/span&gt;, $&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensation_c20180101__20181231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_z83PpEbF6tGg"&gt;494,136&lt;/span&gt;, and $&lt;span id="xdx_905_eus-gaap--ShareBasedCompensation_c20170101__20171231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zbXY56uq74e5"&gt;313,271&lt;/span&gt; for the years ended December 31, 2019, 2018 and 2017, respectively, in the accompanying consolidated financial statements. At December 31, 2019, total unrecognized estimated compensation expense related to unvested warrants was approximately $&lt;span id="xdx_909_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20191231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zh1okmWOz9y6"&gt;26,446&lt;/span&gt; which is expected to be recognized over weighted-average period of &lt;span id="xdx_903_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zDGx8e3Shs69"&gt;0.1&lt;/span&gt; years.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p id="xdx_89E_ecustom--ScheduleOfWarrantRollForwardTableTextBlock_zOwm3dSdLZ89" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;i&gt;Summary of our Warrant activity during the year ended December 31, 2019:&lt;/i&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; width: 100%"&gt;

&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;Number of Shares
Under Warrants&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom; width: 1%"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom; width: 1%"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; width: 13%; vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;Weighted Average
Exercise Price&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom; width: 1%"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom; width: 1%"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; width: 13%; vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;Weighted Average
Remaining Contractual Life in Years&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom; width: 1%"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom; width: 1%"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; width: 13%; vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;Aggregate Intrinsic
Value&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom; width: 1%"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; width: 40%; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Balance at December 31, 2018&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 3%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%"&gt;
&lt;p id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zzsiNoEzQ4Jk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Number of shares under warrants outstanding beginning"&gt;3,007,571&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 3%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%"&gt;
&lt;p id="xdx_984_ecustom--WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice_iS_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z5INwx1jqVf5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Weighted average exercise price warrants outstanding beginning"&gt;2.78&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 3%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20180101__20181231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zxjwyr8ZK2H1" title="Weighted average remaining contractual life, warrants outstanding"&gt;1.58&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 3%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%"&gt;
&lt;p id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iS_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z0MUPG1iCvga" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Aggregate intrinsic value, warrants outstanding beginning"&gt;4,826,403&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 16px"&gt;Granted&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zdeXaontc7rh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Number of shares under warrants granted"&gt;75,000&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_987_ecustom--WarrantsGrantedOtherThanOptionsWeightedAverageExercisePrice_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z5RsyebWvcFl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Weighted average exercise price warrants granted"&gt;5.63&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 16px"&gt;Exercised&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zmBuFPFCyj0j" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Number of shares under warrants exercised"&gt;(1,250,000&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_984_ecustom--WarrantsExercisedOtherThanOptionsWeightedAverageExercisePrice_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zbvjQGVArDqj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Weighted average exercise price warrants exercised"&gt;3.20&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z5B44HXAAYx4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Aggregate intrinsic value, warrants exercised"&gt;2,420,000&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 16px"&gt;Expired&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#x2014;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#x2014;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#x2014;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 16px"&gt;Cancelled/Forfeited&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#x2014;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#x2014;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#x2014;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Balance at December 31, 2019&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zHJWqHZEIubc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Number of shares under warrants outstanding ending"&gt;1,832,571&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_98D_ecustom--WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice_iE_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zodK7rurjHp1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Weighted average exercise price warrants outstanding ending"&gt;2.62&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zebKN0rLMd8k"&gt;1.95&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iE_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z6mE2IQurG9l" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Aggregate intrinsic value, warrants outstanding ending"&gt;2,447,929&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Vested and Exercisable at December 31, 2019&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zPmH3SiLrHOg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Number of shares under warrants vested and exercisable ending"&gt;1,820,071&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_986_ecustom--WarrantsOutstandingVestedAndExercisable_iE_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zSPukOwepEHb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Weighted average exercise price warrants vested and exercisable ending"&gt;2.60&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&lt;span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExercisableWeightedAverageRemainingContractualTerms_dtY_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z1B6TVrIP1s6" title="Weighted average remaining contractual life, vested and exercisable ending"&gt;1.90&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue_iE_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zXaS840m905d" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Aggregate intrinsic value, vested and exercisable ending"&gt;2,447,929&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Unvested at December 31, 2019&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zSGOyx4fGjaa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Number of shares under warrants unvested ending"&gt;12,500&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_98C_ecustom--WarrantsUnvestedWeightedAverageExercisePrice_iE_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zB54OIysC6p" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Weighted average exercise price warrants unvested ending"&gt;5.63&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&lt;span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms_dtY_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zBJ5gIVdV1C2" title="Weighted average remaining contractual life, warrants unvested ending"&gt;9.13&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#x2014;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;p id="xdx_8AE_zd4TbJcoRQbj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p id="xdx_890_ecustom--ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock_zZ8D5rUScNI1" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;The weighted average fair value per share of warrants issued and the assumptions used in the Black-Scholes Model during the years ended December 31, 2019, 2018, and 2017 are set forth in the table below.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin-right: auto; margin-left: auto; float: none; width: 80%"&gt;

&lt;tr&gt;
&lt;td style="padding: 0pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" id="xdx_496_20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zG5JtLMRyJz3" style="border-bottom: black 1pt solid; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" id="xdx_496_20180101__20181231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zxQ5G1Vw01fk" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" id="xdx_49C_20170101__20171231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zyNqzjHzKqhc" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_405_ecustom--WeightedAverageExercisePriceOtherThanOptions_zuNoq8ji79a8" style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt; width: 55%; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Weighted average exercise price&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 3%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;5.63&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 3%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;5.16&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 3%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;6.83&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_40A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_zP3RmzYosxR3"&gt;
&lt;td style="padding: 0pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Weighted average grant date fair value&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;3.00&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;2.79&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;3.67&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_409_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_za8qxKPEG6y3" style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Risk-free interest rate&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;2.52&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;%&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;2.36&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;%&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;1.47&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;%&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_zYjoJ5E78zph"&gt;
&lt;td style="padding: 0pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Volatility&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;60.8&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;%&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;62.12&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;%&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;63.24&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;%&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Term (in years)&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zftNEFwHtlHk" title="Term"&gt;5&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20180101__20181231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zunPuguZCAy5"&gt;5&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20170101__20171231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zMZ3YxBRyp91"&gt;5&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_406_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_zoarFoj8iWm9"&gt;
&lt;td style="padding: 0pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Dividend yield&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;0.00&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;%&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;0.00&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;%&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;0.00&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;%&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;p id="xdx_8A2_zF5PmUHoAiBa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&lt;span style="color: black"&gt;&lt;i&gt;Warrant exercises&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;During the year ended December 31, 2019, warrants to purchase an aggregate of &lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zYwnH775sK0j" title="Warrants exercised"&gt;1,250,000&lt;/span&gt; shares of Common Stock were exercised pursuant to the warrants&#x2019; cashless exercise provisions, which resulted in &lt;span id="xdx_90F_ecustom--NumberOfStockIssuedInCashlessExerciseOfWarrants_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsCashlessExerciseMember_zcLcDd2VOyBf" title="Number of stock issued in cashless exercise of warrants"&gt;471,184&lt;/span&gt; shares of Common Stock being issued. During the year ended December 31, 2018, &lt;span id="xdx_90F_ecustom--NumberOfStockIssuedInCashlessExerciseOfWarrants_do_c20180101__20181231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zus9aF77sbfd"&gt;no&lt;/span&gt; warrants were exercised.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;During the year ended December 31, 2017, certain individuals exercised warrants to purchase an aggregate of &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20170101__20171231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zAKZFvqTBQMd"&gt;2,476,666&lt;/span&gt; shares of Common Stock for $&lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueOther_c20170101__20171231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zWNlfkzO8DL1" title="Shares issued for exercise of warrants, net"&gt;3,798,999&lt;/span&gt; in cash. In addition, during the year ended December 31, 2017, certain individuals exercised warrants to purchase an aggregate of &lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20170101__20171231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsCashlessExerciseMember_zPTJ96mXW0se"&gt;6,590,000&lt;/span&gt; shares of Common Stock pursuant to the warrants&#x2019; cashless exercise provisions, which resulted in &lt;span id="xdx_900_ecustom--NumberOfStockIssuedInCashlessExerciseOfWarrants_c20170101__20171231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsCashlessExerciseMember_z2jrqc8PYIUl"&gt;4,762,208&lt;/span&gt; shares of Common Stock being issued.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: black"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span style="color: black"&gt;Options to Purchase Common Stock of the Company&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;In 2009, we adopted the 2009 Long Term Incentive Compensation Plan, or the 2009 Plan, to provide financial incentives to employees, directors, advisers, and consultants of our company who are able to contribute towards the creation of or who have created stockholder value by providing them stock options and other stock and cash incentives, or the Awards. As of December 31, 2019, there were non-qualified stock options to purchase an aggregate of &lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20191231__us-gaap--PlanNameAxis__custom--LongTermIncentiveCompensationPlan2009Member_zA9WJyJtOZnf"&gt;15,017,759&lt;/span&gt; shares of Common Stock outstanding under the 2009 Plan. Effective upon our adoption of the TherapeuticsMD, Inc. 2019 Stock Incentive Plan, or the 2019 Plan, on June 20, 2019, no future awards may be made under the 2009 Plan. &lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;In 2012, we adopted the 2012 Stock Incentive Plan, or the 2012 Plan, a non-qualified plan that was amended in August 2013. The 2012 Plan was designed to serve as an incentive for retaining qualified and competent key employees, officers, directors, and certain consultants and advisors of our company. As of December 31, 2019, there were non-qualified stock options to purchase an aggregate of &lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20191231__us-gaap--PlanNameAxis__custom--NonQualified2012StockIncentivePlanMember_zdi2FH3pvyx6"&gt;6,316,474&lt;/span&gt; shares of Common Stock outstanding and an aggregate of &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20191231__us-gaap--PlanNameAxis__custom--NonQualified2012StockIncentivePlanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zjwuaexHuYlb"&gt;1,040,000&lt;/span&gt; restricted stock awards under the 2012 Plan. Effective upon our adoption of the 2019 Plan, no future awards may be made under the 2012 Plan. &lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;On June 20, 2019, we adopted the 2019 Plan to serve as an incentive for retaining qualified and competent key employees, officers, directors, and certain consultants and advisors of our company. The Awards available under the 2019 Plan consist of stock options, stock appreciation rights, restricted stock, restricted stock units, performance stock, performance units, and other stock or cash awards as described in the 2019 Plan. Generally, the options vest annually over four years or as determined by our board of directors, upon each option grant. Options may be exercised by paying the price for shares or on a cashless exercise basis after they have vested and prior to the specified expiration date provided and applicable exercise conditions are met, if any. The expiration date is generally ten years from the date the option is issued. &lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;As of December 31, 2019, there were &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20191231__us-gaap--PlanNameAxis__custom--Plan2019Member_z3hKaGDLkKI"&gt;13,599,382&lt;/span&gt; shares of Common Stock available for issuance under the 2019 Plan, consisting of (i) &lt;span id="xdx_90E_ecustom--PlanAwardsNumberOfNewShares_iI_c20191231__us-gaap--PlanNameAxis__custom--Plan2019Member_zTQ3oZu0sPsf" title="Plan awards number of new shares"&gt;11,103,999&lt;/span&gt; new shares, (ii) &lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20191231__us-gaap--PlanNameAxis__custom--NonQualified2012StockIncentivePlanMember_z91vULZqs2He"&gt;2,395,333&lt;/span&gt; unallocated shares previously available for issuance under the 2012 Plan that were not then subject to outstanding &#x201c;Awards&#x201d; (as defined in the 2012 Plan), and (iii) &lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20191231__us-gaap--PlanNameAxis__custom--LongTermIncentiveCompensationPlan2009Member_zr71Tt1aKAD"&gt;100,050&lt;/span&gt; unallocated shares previously available for issuance under the 2009 Plan that were not then subject to outstanding &#x201c;Awards&#x201d; (as defined in the 2009 Plan). Any shares subject to outstanding options or other equity &#x201c;Awards&#x201d; under the 2019 Plan, the 2012 Plan and the 2009 Plan that are forfeited, expire or otherwise terminate without issuance of the underlying shares, or if any such Award is settled for cash or otherwise does not result in the issuance of all or a portion of the shares subject to such Award (other than shares tendered or withheld in connection with the exercise of an Award or the satisfaction of withholding tax liabilities), the shares to which those Awards were subject, shall, to the extent of such forfeiture, expiration, termination, cash settlement or non-issuance, again be available for delivery with respect to Awards under the 2019 Plan. As of December 31, 2019, there were non-qualified stock options to purchase &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20191231__us-gaap--PlanNameAxis__custom--Plan2019Member_zPNlniOuGUG7"&gt;3,696,001&lt;/span&gt; shares of Common Stock outstanding under the 2019 Plan and &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20191231__us-gaap--PlanNameAxis__custom--Plan2019Member__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zKf9prgmmQbc"&gt;200,000&lt;/span&gt; restricted stock awards outstanding under the 2019 Plan.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;The valuation methodology used to determine the fair value of stock options is the Black-Scholes Model. The Black-Scholes Model requires the use of a number of assumptions including volatility of the stock price, the risk-free interest rate, and the expected life of the stock options.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zCEi1KljRvq9" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;The ranges of assumptions used in the Black-Scholes Model during the years ended December 31, 2019, 2018, and 2017 are set forth in the table below.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin-right: auto; margin-left: auto; float: none; width: 90%"&gt;

&lt;tr&gt;
&lt;td style="padding: 0pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" id="xdx_49C_20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zjKyY1ZaOy42" style="border-bottom: black 1pt solid; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" id="xdx_497_20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z58HCy3xTEeg" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" id="xdx_49C_20170101__20171231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zqVe4ECcgasl" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt; width: 55%; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Weighted average exercise price&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zgkqeDYPMqIg" title="Weighted average exercise price"&gt;3.10&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zFo2BcoH7fjj"&gt;5.45&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20171231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zbG85QwG2Ocb"&gt;6.60&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_zc1CMM4er3qi"&gt;
&lt;td style="padding: 0pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Weighted average grant date fair value&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;1.82&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;3.24&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;3.82&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Risk-free interest rate&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_dp_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z72SaZuA7mYf" title="Risk-free interest rate - minimum"&gt;1.64&lt;/span&gt;-&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_dp_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zMBIDOEQmA3g" title="Risk-free interest rate - maximum"&gt;2.54&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;%&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_dp_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zWMdjkfx1yJ5"&gt;2.38&lt;/span&gt;-&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_dp_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zber2qjmMZ7h"&gt;2.89&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;%&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_dp_c20170101__20171231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zQKM7FnmrT82"&gt;1.84&lt;/span&gt;-&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_dp_c20170101__20171231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zPWhETmvYVph"&gt;2.05&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;%&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Volatility&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_dp_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zvNe48pIuEr3" title="Volatility - minimum"&gt;61.25&lt;/span&gt;-&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_dp_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zPSoEKeatYTa" title="Volatility - maximum"&gt;64.49&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;%&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_dp_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zgeecMMVU1w"&gt;59.45&lt;/span&gt;-&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_dp_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zTEHa0V1Z9Of"&gt;64.04&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;%&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_dp_c20170101__20171231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zWtayHZ5UV75"&gt;61.56&lt;/span&gt;-&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_dp_c20170101__20171231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zoMIKAINnb18"&gt;64.25&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;%&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Term (in years)&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zqaof0desl1f" title="Term"&gt;5.5&lt;/span&gt;-&lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zZGWEqvOCNH2"&gt;6.5&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_z9Gj3SsGjeLf"&gt;5.1&lt;/span&gt;-&lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_z3js9QZdKgci"&gt;6.25&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20170101__20171231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_z0KPl6IbB7Mk"&gt;5.5&lt;/span&gt;-&lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20170101__20171231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zewgrtLkYuD5"&gt;6.25&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_zzaNpbW6kdKi"&gt;
&lt;td style="padding: 0pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Dividend yield&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;0.00&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;%&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;0.00&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;%&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;0.00&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;%&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;p id="xdx_8A1_zfVnekqikrOe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zqkCBu3wAa76" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;A summary of activity under the 2009, 2012 and 2019 Plans and related information during the year ended December 31, 2019 is as follows:&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; width: 100%"&gt;

&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;Number of Shares
Under Options&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom; width: 1%"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom; width: 1%"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; width: 13%; vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;Weighted Average
Exercise Price&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom; width: 1%"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom; width: 1%"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; width: 13%; vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;Weighted Average
Remaining Contractual Life in Years&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom; width: 1%"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom; width: 1%"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; width: 13%; vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;Aggregate Intrinsic
Value&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom; width: 1%"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; width: 40%; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Balance at December 31, 2018&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 3%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%"&gt;
&lt;p id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z1WbCCkctj24" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Number of shares under options, beginning"&gt;20,872,824&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 3%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%"&gt;
&lt;p id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zbL3OIGB26O6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Weighted average exercise price, beginning"&gt;4.93&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 3%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zEKbZ2w6uHi1" title="Weighted average remaining contractual life"&gt;5.94&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 3%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%"&gt;
&lt;p id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zzIu12iiUYNh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Aggregate intrinsic value, beginning"&gt;12,239,876&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 16px"&gt;Granted&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z14SZQE1hUE2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Number of shares under options, granted"&gt;4,620,501&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z3iADKoLUTN3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Weighted average exercise price, granted"&gt;3.10&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 16px"&gt;Exercised&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zvxmSZSdljxe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Number of shares under options, exercised"&gt;(343,716&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zs2Pw0YxQ17i" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Weighted average exercise price, exercised"&gt;0.32&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zNKbPT57DNg1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Aggregate intrinsic value, exercised"&gt;1,426,828&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 16px"&gt;Expired&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z3ZQUPGssbIb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Number of shares under options, expired"&gt;(26,375&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zqBowh4gmwK2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Weighted average exercise price, expired"&gt;5.57&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 16px"&gt;Cancelled/Forfeited&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;
&lt;p id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zo67pKgkpwuf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Number of shares under options, cancelled forfeited"&gt;(93,000&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_znaQMmEOcu31" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Weighted average exercise price, cancelled forfeited"&gt;5.16&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Balance at December 31, 2019&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zT5qwoFAhF85" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Number of shares under options, ending"&gt;25,030,234&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zrkPEZKJ1B2k" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Weighted average exercise price, ending"&gt;4.65&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zwnfeDj2mMFa"&gt;5.84&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zEN2HI5oFGGd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Aggregate intrinsic value, ending"&gt;3,668,171&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Vested and Exercisable at December 31, 2019&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zXjGY5zRJRXg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Number of shares under options, vested and exercisable ending"&gt;18,025,819&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zf7B2nc4VWn7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Weighted average exercise price, vested and exercisable ending"&gt;4.88&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zGU2IlSsl7Pb" title="Weighted average remaining contractual life, vested and exercisable"&gt;4.62&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zstAPNlwDEl3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Aggregate intrinsic value, vested and exercisable ending"&gt;3,319,621&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Unvested at December 31, 2019&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zhRoTf6JPxce" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Number of shares under options, unvested ending"&gt;7,004,415&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_iE_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z0meePN4hQb4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Weighted average exercise price, unvested ending"&gt;4.05&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&lt;span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms_dtY_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zO4CzDUTSACc" title="Weighted average remaining contractual life, unvested"&gt;8.96&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue_iE_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zKiil2Vlg8Bk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Aggregate intrinsic value, unvested ending"&gt;348,550&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;p id="xdx_8A9_zHz2fz1qH2h3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;At December 31, 2019, our outstanding options had exercise prices ranging from $&lt;span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice_iI_c20191231__srt--RangeAxis__srt--MinimumMember_zjJKNZmujqd8" title="Range - exercise price of options"&gt;0.19&lt;/span&gt; to $&lt;span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice_iI_c20191231__srt--RangeAxis__srt--MaximumMember_zFiacbDPeo4"&gt;8.92&lt;/span&gt; per share. Share-based compensation expense related to options recognized in our results of operations for the years ended December 31, 2019, 2018, and 2017 was approximately $&lt;span id="xdx_909_eus-gaap--AllocatedShareBasedCompensationExpense_c20190101__20191231_zuudtJB3bdZc"&gt;8,798,707&lt;/span&gt;, $&lt;span id="xdx_902_eus-gaap--AllocatedShareBasedCompensationExpense_c20180101__20181231_zDGum8ymDev8"&gt;8,091,294&lt;/span&gt;, and $&lt;span id="xdx_908_eus-gaap--AllocatedShareBasedCompensationExpense_c20170101__20171231_zGiej39Pfm6"&gt;6,447,154&lt;/span&gt;, respectively, and it is based on awards vested. At December 31, 2019, total unrecognized estimated compensation expense related to unvested options was approximately $&lt;span id="xdx_906_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_c20191231_z2Ux47Ts9Ou6"&gt;11,460,000&lt;/span&gt;, which may be adjusted for future changes in forfeitures. This cost is expected to be recognized over a weighted-average period of &lt;span id="xdx_904_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zlAyk1aeJjwg"&gt;2.4&lt;/span&gt; years. No tax benefit was realized due to a continued pattern of operating losses.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: black"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span style="color: black"&gt;Restricted Stock&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;Restricted stock awards granted under our 2009, 2012 and 2019 Plans entitle the holder to receive, at the end of vesting period, a specified number of shares of our Common Stock. Share-based compensation expense is measured by the market value of our Common Stock on the day of the grant. The shares vest ratably over the period specified in the grant. There is no partial vesting and any unvested portion is forfeited.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: #212529"&gt;On
December 13, 2018, we granted an aggregate of &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20181212__20181213__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zgyqMYPzPxZ8"&gt;1,040,000&lt;/span&gt;
restricted stock units to certain executive employees which will vest at the end of the third year. The grant date fair
value was $&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20181212__20181213__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zk4XlYgflu0j"&gt;4.06&lt;/span&gt;
per unit. At December 31, 2019, &lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zJKhH2kS0VNa"&gt;150,000&lt;/span&gt;
of those restricted stock units vested due to an employment termination.&#160; On July 30, 2019, we granted an aggregate of &lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20190729__20190730__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zUL9Y3i4m4w7"&gt;200,000&lt;/span&gt;
restricted stock units to certain executive employees which will vest on January 31, 2022. The grant date fair value
was $&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20190729__20190730__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zpo5CUmdIRlk"&gt;2.18&lt;/span&gt;
per unit. During the year ended December 31, 2019 and 2018, we recorded $&lt;span id="xdx_90F_eus-gaap--RestrictedStockExpense_c20190101__20191231_zymqTdrvGDi9"&gt;1,628,407&lt;/span&gt;
and $&lt;span id="xdx_901_eus-gaap--RestrictedStockExpense_c20180101__20181231_z3CUBmKVNeYc"&gt;73,132&lt;/span&gt;, respectively,
in share-based compensation expense related to restricted stock units. At December 31, 2019, total unrecognized
estimated compensation expense related to unvested restricted stock units was approximately $&lt;span id="xdx_903_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_iI_c20191231_zKm9R7UpC4d5"&gt;2,711,000&lt;/span&gt;,
which may be adjusted for future changes in forfeitures. This cost is expected to be recognized over a
weighted-average period of &lt;span id="xdx_909_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zHYC7rxV3Vnj"&gt;2.0&lt;/span&gt;
years. At December 31, 2019, we had &lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zBExi3hHJUia"&gt;1,240,000&lt;/span&gt;
restricted stock awards outstanding.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: black"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span style="color: black"&gt;Cash-Settled Stock Appreciation Rights (SARs)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;On July 1, 2018, we issued cash-settled SARs to certain consultants and employees. The SARs plan year began on July 1, 2018 and ended on or immediately following June 30, 2019. SARs were granted with a grant price equal to the market value of a share of our Common Stock on the date of grant. Cash-settled SARs provided for the cash payment of the excess of the fair market value of our Common Stock on June 30, 2019 over the grant price. Cash-settled SARs have no effect on dilutive shares or shares outstanding as any appreciation of our Common Stock over the grant price is paid in cash and not in Common Stock. &lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;Cash
settled SARs were recorded in our consolidated balance sheets as a liability until the date of exercise. The fair value of each
SAR award was estimated using the Black-Scholes valuation model. In accordance with ASC Topic 718, &lt;i&gt;Stock Compensation&lt;/i&gt;,
the fair value of each SAR award was recalculated at the end of each reporting period and the liability and expense adjusted based
on the new fair value and the percent vested. At June 30, 2019, the fair market value of our Common Stock was lower than the grant
price of the SARs and, as a result, the recorded liability was reversed and no cash payment was made.&lt;/span&gt;&lt;/p&gt;
</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2019-12-31" decimals="INF" unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2019-12-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2019-12-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2019-12-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2019-12-31" decimals="INF" unitRef="Shares">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2019-12-31" decimals="INF" unitRef="Shares">271177076</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2019-12-31" decimals="INF" unitRef="Shares">271177076</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2019-10-242019-10-29_custom_UnderwritingAgreementJPMorganChaseMember"
      decimals="INF"
      unitRef="Shares">26000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2019-10-29_custom_UnderwritingAgreementJPMorganChaseMember"
      decimals="INF"
      unitRef="USDPShares">2.75</us-gaap:SharesIssuedPricePerShare>
    <txmd:PeriodExercisableUnderwritersOption contextRef="From2019-10-242019-10-29_custom_UnderwritingAgreementJPMorganChaseMember">P30D</txmd:PeriodExercisableUnderwritersOption>
    <txmd:UnderwritersOptionGrantedInPeriodShares
      contextRef="From2019-10-242019-10-29_custom_UnderwritingAgreementJPMorganChaseMember"
      decimals="INF"
      unitRef="Shares">3900000</txmd:UnderwritersOptionGrantedInPeriodShares>
    <txmd:ProceedsFromIssuancePublicOffering
      contextRef="From2019-10-242019-10-29_custom_UnderwritingAgreementJPMorganChaseMember"
      decimals="0"
      unitRef="USD">77031000</txmd:ProceedsFromIssuancePublicOffering>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2019-01-012019-12-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">331619</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2019-01-012019-12-31_us-gaap_StockOptionMember"
      decimals="0"
      unitRef="USD">108656</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <txmd:NumberOfStockOptionsExercisedInCashlessExercise
      contextRef="From2019-01-01to2019-12-31"
      decimals="INF"
      unitRef="Shares">12097</txmd:NumberOfStockOptionsExercisedInCashlessExercise>
    <txmd:NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares
      contextRef="From2019-01-01to2019-12-31"
      decimals="INF"
      unitRef="Shares">11834</txmd:NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2018-08-012018-08-06_custom_UnderwritingAgreementGoldmanSachsMember"
      decimals="INF"
      unitRef="Shares">12745098</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2018-08-06_custom_UnderwritingAgreementGoldmanSachsMember"
      decimals="INF"
      unitRef="USDPShares">5.10</us-gaap:SharesIssuedPricePerShare>
    <txmd:PeriodExercisableUnderwritersOption contextRef="From2018-08-012018-08-06_custom_UnderwritingAgreementGoldmanSachsMember">P30D</txmd:PeriodExercisableUnderwritersOption>
    <txmd:UnderwritersOptionGrantedInPeriodShares
      contextRef="From2018-08-012018-08-06_custom_UnderwritingAgreementGoldmanSachsMember"
      decimals="INF"
      unitRef="Shares">1911764</txmd:UnderwritersOptionGrantedInPeriodShares>
    <txmd:ProceedsFromIssuancePublicOffering
      contextRef="From2018-08-012018-08-06_custom_UnderwritingAgreementGoldmanSachsMember"
      decimals="0"
      unitRef="USD">69908000</txmd:ProceedsFromIssuancePublicOffering>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2018-08-052018-08-06_custom_SubscriptionAgreementKnightMember"
      decimals="INF"
      unitRef="Shares">3921568</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2018-08-06_custom_SubscriptionAgreementKnightMember819119062"
      decimals="INF"
      unitRef="USDPShares">5.10</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2018-08-052018-08-06_custom_SubscriptionAgreementKnightMember"
      decimals="0"
      unitRef="USD">20000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2018-01-012018-12-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">5444526</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2018-01-012018-12-31_us-gaap_StockOptionMember"
      decimals="0"
      unitRef="USD">1666208</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <txmd:NumberOfStockOptionsExercisedInCashlessExercise
      contextRef="From2018-01-012018-12-31"
      decimals="INF"
      unitRef="Shares">10000</txmd:NumberOfStockOptionsExercisedInCashlessExercise>
    <txmd:NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares
      contextRef="From2018-01-012018-12-31"
      decimals="INF"
      unitRef="Shares">9841</txmd:NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2017-09-242017-09-25_custom_UnderwritingAgreementJPMorganChaseMember"
      decimals="INF"
      unitRef="Shares">12400000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2017-09-28_custom_UnderwritingAgreementJPMorganChaseMember"
      decimals="INF"
      unitRef="USDPShares">5.55</us-gaap:SharesIssuedPricePerShare>
    <txmd:ProceedsFromIssuancePublicOffering
      contextRef="From2017-09-262017-09-28_custom_UnderwritingAgreementJPMorganChaseMember"
      decimals="0"
      unitRef="USD">68573000</txmd:ProceedsFromIssuancePublicOffering>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2017-09-262017-09-28_custom_UnderwritingAgreementJPMorganChaseMember"
      decimals="INF"
      unitRef="Shares">12400000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2017-01-012017-12-31"
      decimals="INF"
      unitRef="Shares">102546</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2017-01-012017-12-31"
      decimals="0"
      unitRef="USD">212615</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:WarrantsAndRightsOutstanding contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">1832571</us-gaap:WarrantsAndRightsOutstanding>
    <txmd:WarrantsAndRightsWeightedAverageContractualRemainingLife contextRef="From2019-01-01to2019-12-31">P1Y11M12D</txmd:WarrantsAndRightsWeightedAverageContractualRemainingLife>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2019-12-31_custom_WarrantsMember_srt_MinimumMember"
      decimals="INF"
      unitRef="USDPShares">0.24</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2019-12-31_custom_WarrantsMember_srt_MaximumMember"
      decimals="INF"
      unitRef="USDPShares">8.20</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <txmd:WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice
      contextRef="AsOf2019-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="USDPShares">2.62</txmd:WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2019-01-012019-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">75000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="From2019-01-012019-12-31_custom_OutsideConsultant2Member">P12M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate contextRef="AsOf2019-12-31_custom_OutsideConsultant2Member">2024-02-13</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2018-01-012018-12-31_custom_OutsideConsultant2Member"
      decimals="INF"
      unitRef="Shares">175000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="From2018-01-012018-12-31_custom_OutsideConsultant2Member">P12M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate contextRef="AsOf2018-12-31_custom_OutsideConsultant2Member">2023-03-15</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2017-01-012017-12-31_custom_OutsideConsultant2Member"
      decimals="INF"
      unitRef="Shares">125000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="From2017-01-012017-12-31_custom_OutsideConsultant2Member">P12M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate contextRef="AsOf2017-12-31_custom_OutsideConsultant2Member">2022-03-15</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ShareBasedCompensation
      contextRef="From2019-01-012019-12-31_custom_WarrantsMember"
      decimals="0"
      unitRef="USD">254970</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2018-01-012018-12-31_custom_WarrantsMember"
      decimals="0"
      unitRef="USD">494136</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2017-01-012017-12-31_custom_WarrantsMember"
      decimals="0"
      unitRef="USD">313271</us-gaap:ShareBasedCompensation>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="AsOf2019-12-31_custom_WarrantsMember"
      decimals="0"
      unitRef="USD">26446</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="From2019-01-012019-12-31_custom_WarrantsMember">P0Y1M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <txmd:ScheduleOfWarrantRollForwardTableTextBlock contextRef="From2019-01-01to2019-12-31">&lt;p id="xdx_89E_ecustom--ScheduleOfWarrantRollForwardTableTextBlock_zOwm3dSdLZ89" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;i&gt;Summary of our Warrant activity during the year ended December 31, 2019:&lt;/i&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; width: 100%"&gt;

&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;Number of Shares
Under Warrants&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom; width: 1%"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom; width: 1%"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; width: 13%; vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;Weighted Average
Exercise Price&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom; width: 1%"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom; width: 1%"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; width: 13%; vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;Weighted Average
Remaining Contractual Life in Years&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom; width: 1%"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom; width: 1%"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; width: 13%; vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;Aggregate Intrinsic
Value&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom; width: 1%"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; width: 40%; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Balance at December 31, 2018&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 3%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%"&gt;
&lt;p id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zzsiNoEzQ4Jk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Number of shares under warrants outstanding beginning"&gt;3,007,571&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 3%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%"&gt;
&lt;p id="xdx_984_ecustom--WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice_iS_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z5INwx1jqVf5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Weighted average exercise price warrants outstanding beginning"&gt;2.78&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 3%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20180101__20181231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zxjwyr8ZK2H1" title="Weighted average remaining contractual life, warrants outstanding"&gt;1.58&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 3%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%"&gt;
&lt;p id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iS_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z0MUPG1iCvga" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Aggregate intrinsic value, warrants outstanding beginning"&gt;4,826,403&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 16px"&gt;Granted&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zdeXaontc7rh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Number of shares under warrants granted"&gt;75,000&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_987_ecustom--WarrantsGrantedOtherThanOptionsWeightedAverageExercisePrice_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z5RsyebWvcFl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Weighted average exercise price warrants granted"&gt;5.63&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 16px"&gt;Exercised&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zmBuFPFCyj0j" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Number of shares under warrants exercised"&gt;(1,250,000&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_984_ecustom--WarrantsExercisedOtherThanOptionsWeightedAverageExercisePrice_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zbvjQGVArDqj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Weighted average exercise price warrants exercised"&gt;3.20&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z5B44HXAAYx4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Aggregate intrinsic value, warrants exercised"&gt;2,420,000&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 16px"&gt;Expired&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#x2014;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#x2014;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#x2014;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 16px"&gt;Cancelled/Forfeited&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#x2014;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#x2014;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#x2014;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Balance at December 31, 2019&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zHJWqHZEIubc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Number of shares under warrants outstanding ending"&gt;1,832,571&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_98D_ecustom--WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice_iE_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zodK7rurjHp1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Weighted average exercise price warrants outstanding ending"&gt;2.62&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zebKN0rLMd8k"&gt;1.95&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iE_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z6mE2IQurG9l" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Aggregate intrinsic value, warrants outstanding ending"&gt;2,447,929&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Vested and Exercisable at December 31, 2019&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zPmH3SiLrHOg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Number of shares under warrants vested and exercisable ending"&gt;1,820,071&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_986_ecustom--WarrantsOutstandingVestedAndExercisable_iE_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zSPukOwepEHb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Weighted average exercise price warrants vested and exercisable ending"&gt;2.60&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&lt;span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExercisableWeightedAverageRemainingContractualTerms_dtY_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z1B6TVrIP1s6" title="Weighted average remaining contractual life, vested and exercisable ending"&gt;1.90&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue_iE_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zXaS840m905d" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Aggregate intrinsic value, vested and exercisable ending"&gt;2,447,929&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Unvested at December 31, 2019&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zSGOyx4fGjaa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Number of shares under warrants unvested ending"&gt;12,500&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_98C_ecustom--WarrantsUnvestedWeightedAverageExercisePrice_iE_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zB54OIysC6p" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Weighted average exercise price warrants unvested ending"&gt;5.63&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&lt;span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms_dtY_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zBJ5gIVdV1C2" title="Weighted average remaining contractual life, warrants unvested ending"&gt;9.13&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#x2014;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
</txmd:ScheduleOfWarrantRollForwardTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2018-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">3007571</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <txmd:WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice
      contextRef="AsOf2018-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="USDPShares">2.78</txmd:WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="From2018-01-012018-12-31_us-gaap_WarrantMember">P1Y6M29D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="AsOf2018-12-31_us-gaap_WarrantMember"
      decimals="0"
      unitRef="USD">4826403</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2019-01-012019-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">75000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <txmd:WarrantsGrantedOtherThanOptionsWeightedAverageExercisePrice
      contextRef="From2019-01-012019-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="USDPShares">5.63</txmd:WarrantsGrantedOtherThanOptionsWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2019-01-012019-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">1250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <txmd:WarrantsExercisedOtherThanOptionsWeightedAverageExercisePrice
      contextRef="From2019-01-012019-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="USDPShares">3.20</txmd:WarrantsExercisedOtherThanOptionsWeightedAverageExercisePrice>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue
      contextRef="From2019-01-012019-12-31_us-gaap_WarrantMember"
      decimals="0"
      unitRef="USD">2420000</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2019-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">1832571</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <txmd:WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice
      contextRef="AsOf2019-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="USDPShares">2.62</txmd:WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="From2019-01-012019-12-31_us-gaap_WarrantMember">P1Y11M12D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="AsOf2019-12-31_us-gaap_WarrantMember"
      decimals="0"
      unitRef="USD">2447929</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber
      contextRef="AsOf2019-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">1820071</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber>
    <txmd:WarrantsOutstandingVestedAndExercisable
      contextRef="AsOf2019-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="USDPShares">2.60</txmd:WarrantsOutstandingVestedAndExercisable>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExercisableWeightedAverageRemainingContractualTerms contextRef="From2019-01-012019-12-31_us-gaap_WarrantMember">P1Y10M24D</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExercisableWeightedAverageRemainingContractualTerms>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue
      contextRef="AsOf2019-12-31_us-gaap_WarrantMember"
      decimals="0"
      unitRef="USD">2447929</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2019-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">12500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <txmd:WarrantsUnvestedWeightedAverageExercisePrice
      contextRef="AsOf2019-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="USDPShares">5.63</txmd:WarrantsUnvestedWeightedAverageExercisePrice>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms contextRef="From2019-01-012019-12-31_us-gaap_WarrantMember">P9Y1M17D</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms>
    <txmd:ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock contextRef="From2019-01-01to2019-12-31">&lt;p id="xdx_890_ecustom--ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock_zZ8D5rUScNI1" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;The weighted average fair value per share of warrants issued and the assumptions used in the Black-Scholes Model during the years ended December 31, 2019, 2018, and 2017 are set forth in the table below.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin-right: auto; margin-left: auto; float: none; width: 80%"&gt;

&lt;tr&gt;
&lt;td style="padding: 0pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" id="xdx_496_20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zG5JtLMRyJz3" style="border-bottom: black 1pt solid; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" id="xdx_496_20180101__20181231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zxQ5G1Vw01fk" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" id="xdx_49C_20170101__20171231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zyNqzjHzKqhc" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_405_ecustom--WeightedAverageExercisePriceOtherThanOptions_zuNoq8ji79a8" style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt; width: 55%; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Weighted average exercise price&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 3%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;5.63&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 3%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;5.16&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 3%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;6.83&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_40A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_zP3RmzYosxR3"&gt;
&lt;td style="padding: 0pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Weighted average grant date fair value&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;3.00&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;2.79&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;3.67&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_409_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_za8qxKPEG6y3" style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Risk-free interest rate&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;2.52&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;%&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;2.36&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;%&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;1.47&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;%&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_zYjoJ5E78zph"&gt;
&lt;td style="padding: 0pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Volatility&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;60.8&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;%&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;62.12&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;%&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;63.24&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;%&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Term (in years)&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zftNEFwHtlHk" title="Term"&gt;5&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20180101__20181231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zunPuguZCAy5"&gt;5&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20170101__20171231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zMZ3YxBRyp91"&gt;5&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_406_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_zoarFoj8iWm9"&gt;
&lt;td style="padding: 0pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Dividend yield&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;0.00&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;%&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;0.00&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;%&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;0.00&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;%&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
</txmd:ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock>
    <txmd:WeightedAverageExercisePriceOtherThanOptions
      contextRef="From2019-01-012019-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="USDPShares">5.63</txmd:WeightedAverageExercisePriceOtherThanOptions>
    <txmd:WeightedAverageExercisePriceOtherThanOptions
      contextRef="From2018-01-012018-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="USDPShares">5.16</txmd:WeightedAverageExercisePriceOtherThanOptions>
    <txmd:WeightedAverageExercisePriceOtherThanOptions
      contextRef="From2017-01-012017-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="USDPShares">6.83</txmd:WeightedAverageExercisePriceOtherThanOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2019-01-012019-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="USDPShares">3.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2018-01-012018-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="USDPShares">2.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2017-01-012017-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="USDPShares">3.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2019-01-012019-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Pure">0.0252</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2018-01-012018-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Pure">0.0236</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2017-01-012017-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Pure">0.0147</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2019-01-012019-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Pure">0.608</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2018-01-012018-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Pure">0.6212</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2017-01-012017-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Pure">0.6324</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2019-01-012019-12-31_us-gaap_WarrantMember">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2018-01-012018-12-31_us-gaap_WarrantMember">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2017-01-012017-12-31_us-gaap_WarrantMember">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2019-01-012019-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2018-01-012018-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2017-01-012017-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2019-01-012019-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">1250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <txmd:NumberOfStockIssuedInCashlessExerciseOfWarrants
      contextRef="From2019-01-012019-12-31_custom_WarrantsCashlessExerciseMember"
      decimals="INF"
      unitRef="Shares">471184</txmd:NumberOfStockIssuedInCashlessExerciseOfWarrants>
    <txmd:NumberOfStockIssuedInCashlessExerciseOfWarrants
      contextRef="From2018-01-012018-12-31_custom_WarrantsMember"
      decimals="INF"
      unitRef="Shares">0</txmd:NumberOfStockIssuedInCashlessExerciseOfWarrants>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2017-01-012017-12-31_custom_WarrantsMember"
      decimals="INF"
      unitRef="Shares">2476666</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2017-01-012017-12-31_custom_WarrantsMember"
      decimals="0"
      unitRef="USD">3798999</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2017-01-012017-12-31_custom_WarrantsCashlessExerciseMember"
      decimals="INF"
      unitRef="Shares">6590000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <txmd:NumberOfStockIssuedInCashlessExerciseOfWarrants
      contextRef="From2017-01-012017-12-31_custom_WarrantsCashlessExerciseMember"
      decimals="INF"
      unitRef="Shares">4762208</txmd:NumberOfStockIssuedInCashlessExerciseOfWarrants>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2019-12-31_custom_LongTermIncentiveCompensationPlan2009Member"
      decimals="INF"
      unitRef="Shares">15017759</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2019-12-31_custom_NonQualified2012StockIncentivePlanMember"
      decimals="INF"
      unitRef="Shares">6316474</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2019-12-31_custom_NonQualified2012StockIncentivePlanMember_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="Shares">1040000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2019-12-31_custom_Plan2019Member"
      decimals="INF"
      unitRef="Shares">13599382</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <txmd:PlanAwardsNumberOfNewShares
      contextRef="AsOf2019-12-31_custom_Plan2019Member"
      decimals="INF"
      unitRef="Shares">11103999</txmd:PlanAwardsNumberOfNewShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2019-12-31_custom_NonQualified2012StockIncentivePlanMember"
      decimals="INF"
      unitRef="Shares">2395333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2019-12-31_custom_LongTermIncentiveCompensationPlan2009Member"
      decimals="INF"
      unitRef="Shares">100050</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2019-12-31_custom_Plan2019Member"
      decimals="INF"
      unitRef="Shares">3696001</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2019-12-31_custom_Plan2019Member_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="Shares">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2019-01-01to2019-12-31">&lt;p id="xdx_895_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zCEi1KljRvq9" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;The ranges of assumptions used in the Black-Scholes Model during the years ended December 31, 2019, 2018, and 2017 are set forth in the table below.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin-right: auto; margin-left: auto; float: none; width: 90%"&gt;

&lt;tr&gt;
&lt;td style="padding: 0pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" id="xdx_49C_20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zjKyY1ZaOy42" style="border-bottom: black 1pt solid; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" id="xdx_497_20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z58HCy3xTEeg" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" id="xdx_49C_20170101__20171231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zqVe4ECcgasl" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt; width: 55%; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Weighted average exercise price&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zgkqeDYPMqIg" title="Weighted average exercise price"&gt;3.10&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zFo2BcoH7fjj"&gt;5.45&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20171231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zbG85QwG2Ocb"&gt;6.60&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_zc1CMM4er3qi"&gt;
&lt;td style="padding: 0pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Weighted average grant date fair value&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;1.82&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;3.24&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;3.82&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Risk-free interest rate&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_dp_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z72SaZuA7mYf" title="Risk-free interest rate - minimum"&gt;1.64&lt;/span&gt;-&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_dp_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zMBIDOEQmA3g" title="Risk-free interest rate - maximum"&gt;2.54&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;%&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_dp_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zWMdjkfx1yJ5"&gt;2.38&lt;/span&gt;-&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_dp_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zber2qjmMZ7h"&gt;2.89&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;%&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_dp_c20170101__20171231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zQKM7FnmrT82"&gt;1.84&lt;/span&gt;-&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_dp_c20170101__20171231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zPWhETmvYVph"&gt;2.05&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;%&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Volatility&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_dp_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zvNe48pIuEr3" title="Volatility - minimum"&gt;61.25&lt;/span&gt;-&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_dp_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zPSoEKeatYTa" title="Volatility - maximum"&gt;64.49&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;%&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_dp_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zgeecMMVU1w"&gt;59.45&lt;/span&gt;-&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_dp_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zTEHa0V1Z9Of"&gt;64.04&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;%&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_dp_c20170101__20171231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zWtayHZ5UV75"&gt;61.56&lt;/span&gt;-&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_dp_c20170101__20171231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zoMIKAINnb18"&gt;64.25&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;%&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Term (in years)&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zqaof0desl1f" title="Term"&gt;5.5&lt;/span&gt;-&lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zZGWEqvOCNH2"&gt;6.5&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_z9Gj3SsGjeLf"&gt;5.1&lt;/span&gt;-&lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_z3js9QZdKgci"&gt;6.25&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20170101__20171231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_z0KPl6IbB7Mk"&gt;5.5&lt;/span&gt;-&lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20170101__20171231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zewgrtLkYuD5"&gt;6.25&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_zzaNpbW6kdKi"&gt;
&lt;td style="padding: 0pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Dividend yield&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;0.00&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;%&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;0.00&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;%&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;0.00&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;%&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2019-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="USDPShares">3.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2018-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="USDPShares">5.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2017-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="USDPShares">6.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="USDPShares">1.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2018-01-012018-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="USDPShares">3.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2017-01-012017-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="USDPShares">3.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Pure">0.0164</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Pure">0.0254</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="From2018-01-012018-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Pure">0.0238</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="From2018-01-012018-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Pure">0.0289</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="From2017-01-012017-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Pure">0.0184</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="From2017-01-012017-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Pure">0.0205</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Pure">0.6125</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Pure">0.6449</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="From2018-01-012018-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Pure">0.5945</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="From2018-01-012018-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Pure">0.6404</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="From2017-01-012017-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Pure">0.6156</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="From2017-01-012017-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Pure">0.6425</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember_srt_MinimumMember">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember_srt_MaximumMember">P6Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2018-01-012018-12-31_us-gaap_EmployeeStockOptionMember_srt_MinimumMember">P5Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2018-01-012018-12-31_us-gaap_EmployeeStockOptionMember_srt_MaximumMember">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2017-01-012017-12-31_us-gaap_EmployeeStockOptionMember_srt_MinimumMember">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2017-01-012017-12-31_us-gaap_EmployeeStockOptionMember_srt_MaximumMember">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2018-01-012018-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2017-01-012017-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2019-01-01to2019-12-31">&lt;p id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zqkCBu3wAa76" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;A summary of activity under the 2009, 2012 and 2019 Plans and related information during the year ended December 31, 2019 is as follows:&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; width: 100%"&gt;

&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;Number of Shares
Under Options&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom; width: 1%"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom; width: 1%"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; width: 13%; vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;Weighted Average
Exercise Price&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom; width: 1%"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom; width: 1%"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; width: 13%; vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;Weighted Average
Remaining Contractual Life in Years&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom; width: 1%"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom; width: 1%"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; width: 13%; vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;Aggregate Intrinsic
Value&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom; width: 1%"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; width: 40%; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Balance at December 31, 2018&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 3%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%"&gt;
&lt;p id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z1WbCCkctj24" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Number of shares under options, beginning"&gt;20,872,824&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 3%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%"&gt;
&lt;p id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zbL3OIGB26O6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Weighted average exercise price, beginning"&gt;4.93&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 3%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zEKbZ2w6uHi1" title="Weighted average remaining contractual life"&gt;5.94&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 3%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%"&gt;
&lt;p id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zzIu12iiUYNh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Aggregate intrinsic value, beginning"&gt;12,239,876&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 16px"&gt;Granted&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z14SZQE1hUE2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Number of shares under options, granted"&gt;4,620,501&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z3iADKoLUTN3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Weighted average exercise price, granted"&gt;3.10&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 16px"&gt;Exercised&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zvxmSZSdljxe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Number of shares under options, exercised"&gt;(343,716&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zs2Pw0YxQ17i" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Weighted average exercise price, exercised"&gt;0.32&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zNKbPT57DNg1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Aggregate intrinsic value, exercised"&gt;1,426,828&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 16px"&gt;Expired&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z3ZQUPGssbIb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Number of shares under options, expired"&gt;(26,375&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zqBowh4gmwK2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Weighted average exercise price, expired"&gt;5.57&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 16px"&gt;Cancelled/Forfeited&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;
&lt;p id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zo67pKgkpwuf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Number of shares under options, cancelled forfeited"&gt;(93,000&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_znaQMmEOcu31" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Weighted average exercise price, cancelled forfeited"&gt;5.16&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Balance at December 31, 2019&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zT5qwoFAhF85" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Number of shares under options, ending"&gt;25,030,234&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zrkPEZKJ1B2k" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Weighted average exercise price, ending"&gt;4.65&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zwnfeDj2mMFa"&gt;5.84&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zEN2HI5oFGGd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Aggregate intrinsic value, ending"&gt;3,668,171&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Vested and Exercisable at December 31, 2019&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zXjGY5zRJRXg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Number of shares under options, vested and exercisable ending"&gt;18,025,819&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zf7B2nc4VWn7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Weighted average exercise price, vested and exercisable ending"&gt;4.88&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zGU2IlSsl7Pb" title="Weighted average remaining contractual life, vested and exercisable"&gt;4.62&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zstAPNlwDEl3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Aggregate intrinsic value, vested and exercisable ending"&gt;3,319,621&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Unvested at December 31, 2019&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zhRoTf6JPxce" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Number of shares under options, unvested ending"&gt;7,004,415&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_iE_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z0meePN4hQb4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Weighted average exercise price, unvested ending"&gt;4.05&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&lt;span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms_dtY_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zO4CzDUTSACc" title="Weighted average remaining contractual life, unvested"&gt;8.96&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue_iE_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zKiil2Vlg8Bk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Aggregate intrinsic value, unvested ending"&gt;348,550&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2018-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Shares">20872824</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2018-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="USDPShares">4.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2018-01-012018-12-31_us-gaap_EmployeeStockOptionMember">P5Y11M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2018-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      unitRef="USD">12239876</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Shares">4620501</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="USDPShares">3.10</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Shares">343716</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="USDPShares">0.32</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      unitRef="USD">1426828</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Shares">26375</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="USDPShares">5.57</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Shares">93000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="USDPShares">5.16</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2019-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Shares">25030234</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2019-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="USDPShares">4.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember">P5Y10M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2019-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      unitRef="USD">3668171</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="AsOf2019-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Shares">18025819</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2019-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="USDPShares">4.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember">P4Y7M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2019-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      unitRef="USD">3319621</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="AsOf2019-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Shares">7004415</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2019-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="USDPShares">4.05</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms contextRef="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember">P8Y11M15D</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue
      contextRef="AsOf2019-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      unitRef="USD">348550</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice
      contextRef="AsOf2019-12-31_srt_MinimumMember"
      decimals="INF"
      unitRef="USDPShares">0.19</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice
      contextRef="AsOf2019-12-31_srt_MaximumMember"
      decimals="INF"
      unitRef="USDPShares">8.92</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2019-01-01to2019-12-31"
      decimals="0"
      unitRef="USD">8798707</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">8091294</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2017-01-012017-12-31"
      decimals="0"
      unitRef="USD">6447154</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">11460000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember">P2Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2018-12-122018-12-13_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="Shares">1040000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2018-12-122018-12-13_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="USDPShares">4.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="From2019-01-012019-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="Shares">150000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2019-07-292019-07-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="Shares">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2019-07-292019-07-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="USDPShares">2.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:RestrictedStockExpense
      contextRef="From2019-01-01to2019-12-31"
      decimals="0"
      unitRef="USD">1628407</us-gaap:RestrictedStockExpense>
    <us-gaap:RestrictedStockExpense
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">73132</us-gaap:RestrictedStockExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">2711000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="From2019-01-012019-12-31_us-gaap_RestrictedStockUnitsRSUMember">P2Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2019-12-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="Shares">1240000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2019-01-01to2019-12-31">&lt;p id="xdx_804_eus-gaap--IncomeTaxDisclosureTextBlock_zL6wTaqLV84c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;b&gt;NOTE 10 &#x2013; &lt;span id="xdx_82E_z7q5de6Oj7qg"&gt;INCOME TAXES&lt;/span&gt; &lt;/b&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p id="xdx_894_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zADi8hHgCXHf" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;For financial reporting purposes, income before taxes includes the following components:&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin-right: auto; margin-left: auto; float: none; width: 90%"&gt;

&lt;tr&gt;
&lt;td style="padding: 0pt; vertical-align: top"/&gt;
&lt;td&gt;&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center; vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; text-align: center; vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; text-align: center; vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt; width: 55%; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;United States&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%"&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; width: 1%; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; width: 12%; vertical-align: bottom"&gt;
&lt;p id="xdx_98D_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_c20190101__20191231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zdcjS9MuxK97" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;(176,144,999&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; width: 1%; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%"&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; width: 1%; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; width: 12%; vertical-align: bottom"&gt;
&lt;p id="xdx_98B_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_c20180101__20181231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zZVgfVuMkwYi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;(132,617,160&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; width: 1%; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%"&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; width: 1%; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; width: 12%; vertical-align: bottom"&gt;
&lt;p id="xdx_98A_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_c20170101__20171231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zbqcESBZjJO9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;(76,925,380&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; width: 1%; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Total&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p id="xdx_986_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_c20190101__20191231_zA2uptl6PhHa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;(176,144,999&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding-bottom: 2pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p id="xdx_982_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_c20180101__20181231_zAAncojzdhd4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;(132,617,160&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding-bottom: 2pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p id="xdx_988_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_c20170101__20171231_zH3ExzahCWS5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;(76,925,380&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding-bottom: 2pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;p id="xdx_8AE_zhvkruLPKWMe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black; background-color: white"&gt;For the years ended December 31, 2019, 2018, and 2017, there was no provision for income taxes, current or deferred. At December 31, 2019, we had a federal net operating loss carry forward of approximately $&lt;span id="xdx_90F_eus-gaap--OperatingLossCarryforwards_iI_c20191231__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--InternalRevenueServiceIRSMember_z8l9AyTYnsX3" title="Net operating loss carry forward"&gt;620,354,163&lt;/span&gt;. Approximately $&lt;span id="xdx_903_eus-gaap--OperatingLossCarryforwards_iI_c20191231__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--InternalRevenueServiceIRSMember__us-gaap--TaxPeriodAxis__custom--ExpirationPeriod20YearsMember_zSB1hNG2rK4b"&gt;338,775,332&lt;/span&gt; of the federal net operating loss carry forward can be carried forward for &lt;span id="xdx_90F_ecustom--NolCarryForwardPeriod_dt_c20190101__20191231__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--InternalRevenueServiceIRSMember__us-gaap--TaxPeriodAxis__custom--ExpirationPeriod20YearsMember_z7jOQqaAF0S8" title="NOL carry forward period"&gt;20 years&lt;/span&gt; and will begin to expire in &lt;span id="xdx_90F_ecustom--OperatingLossCarryforwardsExpirationYear_c20190101__20191231__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--InternalRevenueServiceIRSMember__us-gaap--TaxPeriodAxis__custom--ExpirationPeriod20YearsMember_zABw0O4Z2etk" title="NOL carry forward expiration year"&gt;2031&lt;/span&gt;.&#160; The remaining $&lt;span id="xdx_90A_eus-gaap--OperatingLossCarryforwards_iI_c20191231__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--InternalRevenueServiceIRSMember__us-gaap--TaxPeriodAxis__custom--ExpirationPeriodIndefiniteMember_zVwMshszB345"&gt;281,578,831&lt;/span&gt; can be carried forward indefinitely.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p id="xdx_89F_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zoefKqWPnWmd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;A reconciliation between taxes computed at the federal statutory rate and the consolidated effective tax rate is as follows: &lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin-right: auto; margin-left: auto; float: none; width: 90%"&gt;

&lt;tr&gt;
&lt;td style="padding: 0pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" id="xdx_49B_20190101__20191231_zdXEdo8l0Qa5" style="border-bottom: black 1pt solid; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" id="xdx_49A_20180101__20181231_zx7mVGnraWRd" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" id="xdx_49A_20170101__20171231_ztGnIkT0Ayyf" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_40E_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_matax_zWW9DKxQYQX9" style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt; width: 55%; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Federal statutory tax rate&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;21.0&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;%&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;21.0&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;%&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;34.0&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;%&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_matax_z9UZ52KqppS6"&gt;
&lt;td style="padding: 0pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;State tax rate, net of federal tax benefit&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;4.0&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;%&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;5.2&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;%&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;5.0&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;%&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_40E_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_matax_zMXUfxWLY9Yg" style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Adjustment in valuation allowances&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;(22.5&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;)%&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;(31.2&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;)%&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;22.6&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;%&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_dp_matax_zi11CB4dc9Q4"&gt;
&lt;td style="padding: 0pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Excess stock benefits&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;0.2&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;%&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;5.3&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;%&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1220"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;%&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_dp_matax_z8hJGHsZqqnf" style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Federal income tax rate change&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;0&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;%&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1223"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;%&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;(60.8&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;)%&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_dp_matax_zltD2WQnmse2"&gt;
&lt;td style="padding: 0pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Permanent and other differences&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;(2.7&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;)%&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;(0.3&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;)%&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;(0.8&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;)%&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_dp0_mttax_zOznacZATEnc" style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Provision (benefit) for income taxes&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#x2014;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#x2014;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#x2014;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;p id="xdx_8AE_zVKLUAFWiqjf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;Deferred income taxes result from temporary differences between the amount of assets and liabilities recognized for financial reporting and tax purposes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zw9h4532cjri" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;The components of the net deferred income tax asset as of December 31, 2019, 2018, and 2017 are as follows:&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin-right: auto; margin-left: auto; float: none; width: 90%"&gt;

&lt;tr&gt;
&lt;td style="padding: 0pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" id="xdx_492_20191231_zHBuwuSiDfbg" style="border-bottom: black 1pt solid; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" id="xdx_49A_20181231_zYKgdQSBRIp5" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" id="xdx_493_20171231_z7FXwxCHEeCg" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_409_eus-gaap--DeferredTaxAssetsNetAbstract_iB_zLYeykKKz84c"&gt;
&lt;td style="padding: 0pt; width: 55%; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Deferred Income Tax Assets:&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_406_eus-gaap--DeferredTaxAssetsOtherLossCarryforwards_i01I_maDTAGz9uv_za087dA6m2l5" style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 16px"&gt;Net operating losses&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;180,520,709&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;140,891,764&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;99,596,321&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_40A_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_i01I_maDTAGz9uv_zESHYbMQgsW4"&gt;
&lt;td style="padding: 0pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 16px"&gt;R&amp;amp;D Credit&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;186,347&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;186,347&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;186,347&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsGross_i01TI_mtDTAGz9uv_maDTANzNCq_zpGMbiJ1dNX5" style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 16px"&gt;Total deferred income tax asset&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;180,707,056&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;141,078,111&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;99,782,668&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_40B_eus-gaap--DeferredTaxAssetsValuationAllowance_i01NI_di_msDTANzNCq_zBSejEMW9Ygf"&gt;
&lt;td style="padding: 0pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 16px"&gt;Valuation allowance&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;(180,707,056&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;(141,078,111&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;(99,782,668&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_40B_eus-gaap--DeferredTaxAssetsNet_i01TI_d0_mtDTANzNCq_zkFTcoIvc2gh" style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Deferred income tax assets, net&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#x2014;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#x2014;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#x2014;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;p id="xdx_8AE_zrUihzAMpL77" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;We believe that it is more likely than not that we will not generate sufficient future taxable income to realize the tax benefits related to the deferred tax assets on our balance sheet and as such, a valuation allowance has been established against the deferred tax assets for the period ended December 31, 2019.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;&lt;i&gt;&lt;span style="color: black"&gt;Unrecognized Tax Benefits&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;As of the period ended December 31, 2019, we have no unrecognized tax benefits.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;On December 22, 2017, the U.S. federal government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act, or the Tax Act. The Tax Act makes broad and complex changes to the U.S. federal tax code, including, but not limited to reducing the U.S. federal corporate tax rate from &lt;span id="xdx_90E_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_c20170101__20171231_zKlQ7fsuZXhb" title="Federal statutory tax rate"&gt;34&lt;/span&gt; percent to &lt;span id="xdx_90E_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_c20180101__20181231_zy9HW51Z2pw7"&gt;21&lt;/span&gt; percent, effective January 1, 2018. As the result of our initial analysis of the impact of the Tax Act, we recorded a provisional amount of net tax expense of $&lt;span id="xdx_900_eus-gaap--TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalIncomeTaxExpenseBenefit_dm_c20170101__20171231_zJ5V3RumQlxh" title="Tax Cuts and Jobs Act, provisional net tax expense"&gt;46.7 million&lt;/span&gt; in 2017 related to the remeasurement of our deferred tax balances and other effects. We completed our accounting for the income tax effects of the Tax Act in 2018, and no material adjustments were required to the provisional amounts initially recorded.&lt;/span&gt;&lt;/p&gt;
</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="From2019-01-01to2019-12-31">&lt;p id="xdx_894_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zADi8hHgCXHf" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;For financial reporting purposes, income before taxes includes the following components:&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin-right: auto; margin-left: auto; float: none; width: 90%"&gt;

&lt;tr&gt;
&lt;td style="padding: 0pt; vertical-align: top"/&gt;
&lt;td&gt;&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center; vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; text-align: center; vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; text-align: center; vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt; width: 55%; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;United States&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%"&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; width: 1%; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; width: 12%; vertical-align: bottom"&gt;
&lt;p id="xdx_98D_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_c20190101__20191231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zdcjS9MuxK97" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;(176,144,999&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; width: 1%; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%"&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; width: 1%; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; width: 12%; vertical-align: bottom"&gt;
&lt;p id="xdx_98B_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_c20180101__20181231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zZVgfVuMkwYi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;(132,617,160&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; width: 1%; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%"&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; width: 1%; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; width: 12%; vertical-align: bottom"&gt;
&lt;p id="xdx_98A_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_c20170101__20171231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zbqcESBZjJO9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;(76,925,380&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; width: 1%; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Total&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p id="xdx_986_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_c20190101__20191231_zA2uptl6PhHa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;(176,144,999&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding-bottom: 2pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p id="xdx_982_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_c20180101__20181231_zAAncojzdhd4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;(132,617,160&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding-bottom: 2pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p id="xdx_988_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_c20170101__20171231_zH3ExzahCWS5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;(76,925,380&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding-bottom: 2pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="From2019-01-012019-12-31_us-gaap_DomesticCountryMember"
      decimals="0"
      unitRef="USD">-176144999</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="From2018-01-012018-12-31_us-gaap_DomesticCountryMember"
      decimals="0"
      unitRef="USD">-132617160</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="From2017-01-012017-12-31_us-gaap_DomesticCountryMember"
      decimals="0"
      unitRef="USD">-76925380</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="From2019-01-01to2019-12-31"
      decimals="0"
      unitRef="USD">-176144999</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">-132617160</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="From2017-01-012017-12-31"
      decimals="0"
      unitRef="USD">-76925380</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2019-12-31_us-gaap_InternalRevenueServiceIRSMember"
      decimals="0"
      unitRef="USD">620354163</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2019-12-31_us-gaap_InternalRevenueServiceIRSMember_custom_ExpirationPeriod20YearsMember"
      decimals="0"
      unitRef="USD">338775332</us-gaap:OperatingLossCarryforwards>
    <txmd:NolCarryForwardPeriod contextRef="From2019-01-012019-12-31_us-gaap_InternalRevenueServiceIRSMember_custom_ExpirationPeriod20YearsMember">P20Y</txmd:NolCarryForwardPeriod>
    <txmd:OperatingLossCarryforwardsExpirationYear contextRef="From2019-01-012019-12-31_us-gaap_InternalRevenueServiceIRSMember_custom_ExpirationPeriod20YearsMember">2031</txmd:OperatingLossCarryforwardsExpirationYear>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2019-12-31_us-gaap_InternalRevenueServiceIRSMember_custom_ExpirationPeriodIndefiniteMember"
      decimals="0"
      unitRef="USD">281578831</us-gaap:OperatingLossCarryforwards>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2019-01-01to2019-12-31">&lt;p id="xdx_89F_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zoefKqWPnWmd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;A reconciliation between taxes computed at the federal statutory rate and the consolidated effective tax rate is as follows: &lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin-right: auto; margin-left: auto; float: none; width: 90%"&gt;

&lt;tr&gt;
&lt;td style="padding: 0pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" id="xdx_49B_20190101__20191231_zdXEdo8l0Qa5" style="border-bottom: black 1pt solid; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" id="xdx_49A_20180101__20181231_zx7mVGnraWRd" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" id="xdx_49A_20170101__20171231_ztGnIkT0Ayyf" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_40E_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_matax_zWW9DKxQYQX9" style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt; width: 55%; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Federal statutory tax rate&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;21.0&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;%&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;21.0&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;%&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;34.0&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;%&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_matax_z9UZ52KqppS6"&gt;
&lt;td style="padding: 0pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;State tax rate, net of federal tax benefit&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;4.0&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;%&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;5.2&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;%&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;5.0&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;%&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_40E_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_matax_zMXUfxWLY9Yg" style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Adjustment in valuation allowances&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;(22.5&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;)%&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;(31.2&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;)%&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;22.6&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;%&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_dp_matax_zi11CB4dc9Q4"&gt;
&lt;td style="padding: 0pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Excess stock benefits&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;0.2&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;%&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;5.3&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;%&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1220"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;%&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_dp_matax_z8hJGHsZqqnf" style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Federal income tax rate change&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;0&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;%&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1223"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;%&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;(60.8&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;)%&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_dp_matax_zltD2WQnmse2"&gt;
&lt;td style="padding: 0pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Permanent and other differences&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;(2.7&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;)%&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;(0.3&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;)%&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;(0.8&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;)%&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_dp0_mttax_zOznacZATEnc" style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Provision (benefit) for income taxes&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#x2014;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#x2014;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#x2014;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2019-01-01to2019-12-31"
      decimals="INF"
      unitRef="Pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2018-01-012018-12-31"
      decimals="INF"
      unitRef="Pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2017-01-012017-12-31"
      decimals="INF"
      unitRef="Pure">0.340</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2019-01-01to2019-12-31"
      decimals="INF"
      unitRef="Pure">0.040</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2018-01-012018-12-31"
      decimals="INF"
      unitRef="Pure">0.052</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2017-01-012017-12-31"
      decimals="INF"
      unitRef="Pure">0.050</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2019-01-01to2019-12-31"
      decimals="INF"
      unitRef="Pure">-0.225</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2018-01-012018-12-31"
      decimals="INF"
      unitRef="Pure">-0.312</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2017-01-012017-12-31"
      decimals="INF"
      unitRef="Pure">0.226</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="From2019-01-01to2019-12-31"
      decimals="INF"
      unitRef="Pure">0.002</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="From2018-01-012018-12-31"
      decimals="INF"
      unitRef="Pure">0.053</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="From2019-01-01to2019-12-31"
      decimals="INF"
      unitRef="Pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="From2017-01-012017-12-31"
      decimals="INF"
      unitRef="Pure">-0.608</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="From2019-01-01to2019-12-31"
      decimals="INF"
      unitRef="Pure">-0.027</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="From2018-01-012018-12-31"
      decimals="INF"
      unitRef="Pure">-0.003</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="From2017-01-012017-12-31"
      decimals="INF"
      unitRef="Pure">-0.008</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2019-01-01to2019-12-31"
      decimals="INF"
      unitRef="Pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2018-01-012018-12-31"
      decimals="INF"
      unitRef="Pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2017-01-012017-12-31"
      decimals="INF"
      unitRef="Pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2019-01-01to2019-12-31">&lt;p id="xdx_89A_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zw9h4532cjri" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;The components of the net deferred income tax asset as of December 31, 2019, 2018, and 2017 are as follows:&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin-right: auto; margin-left: auto; float: none; width: 90%"&gt;

&lt;tr&gt;
&lt;td style="padding: 0pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" id="xdx_492_20191231_zHBuwuSiDfbg" style="border-bottom: black 1pt solid; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" id="xdx_49A_20181231_zYKgdQSBRIp5" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" id="xdx_493_20171231_z7FXwxCHEeCg" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_409_eus-gaap--DeferredTaxAssetsNetAbstract_iB_zLYeykKKz84c"&gt;
&lt;td style="padding: 0pt; width: 55%; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Deferred Income Tax Assets:&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_406_eus-gaap--DeferredTaxAssetsOtherLossCarryforwards_i01I_maDTAGz9uv_za087dA6m2l5" style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 16px"&gt;Net operating losses&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;180,520,709&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;140,891,764&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;99,596,321&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_40A_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_i01I_maDTAGz9uv_zESHYbMQgsW4"&gt;
&lt;td style="padding: 0pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 16px"&gt;R&amp;amp;D Credit&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;186,347&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;186,347&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;186,347&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsGross_i01TI_mtDTAGz9uv_maDTANzNCq_zpGMbiJ1dNX5" style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 16px"&gt;Total deferred income tax asset&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;180,707,056&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;141,078,111&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;99,782,668&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_40B_eus-gaap--DeferredTaxAssetsValuationAllowance_i01NI_di_msDTANzNCq_zBSejEMW9Ygf"&gt;
&lt;td style="padding: 0pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 16px"&gt;Valuation allowance&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;(180,707,056&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;(141,078,111&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;(99,782,668&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_40B_eus-gaap--DeferredTaxAssetsNet_i01TI_d0_mtDTANzNCq_zkFTcoIvc2gh" style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Deferred income tax assets, net&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#x2014;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#x2014;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#x2014;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOtherLossCarryforwards contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">180520709</us-gaap:DeferredTaxAssetsOtherLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOtherLossCarryforwards contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">140891764</us-gaap:DeferredTaxAssetsOtherLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOtherLossCarryforwards contextRef="AsOf2017-12-31" decimals="0" unitRef="USD">99596321</us-gaap:DeferredTaxAssetsOtherLossCarryforwards>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">186347</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">186347</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="AsOf2017-12-31" decimals="0" unitRef="USD">186347</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsGross contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">180707056</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">141078111</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="AsOf2017-12-31" decimals="0" unitRef="USD">99782668</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">180707056</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">141078111</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2017-12-31" decimals="0" unitRef="USD">99782668</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet contextRef="AsOf2017-12-31" decimals="0" unitRef="USD">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2017-01-012017-12-31"
      decimals="INF"
      unitRef="Pure">0.34</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2018-01-012018-12-31"
      decimals="INF"
      unitRef="Pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalIncomeTaxExpenseBenefit
      contextRef="From2017-01-012017-12-31"
      decimals="0"
      unitRef="USD">46700000</us-gaap:TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalIncomeTaxExpenseBenefit>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2019-01-01to2019-12-31">&lt;p id="xdx_804_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zgie4KeD5Cpb" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span style="color: black"&gt;&lt;b&gt;NOTE 11 &#x2013; &lt;span id="xdx_826_zjDJXeBkIIZa"&gt;RELATED PARTIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: #212529; background-color: white"&gt;In July 2015, J. Martin Carroll, a director of our company, was appointed to the board of directors of Catalent, Inc. From time to time, we have entered into agreements with Catalent, Inc. and its affiliates, or Catalent, in the normal course of business. Agreements with Catalent have been reviewed by independent directors of our Company, or a committee consisting of independent directors of our company, since July 2015. During the years ended December 31, 2019, 2018 and 2017, we were billed by Catalent approximately $&lt;span id="xdx_908_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20190101__20191231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--AffiliatedEntityMember_zKi3t8phY5Nb" title="Amount billed"&gt;6,101,000&lt;/span&gt;, &lt;span style="background-color: white"&gt;$&lt;/span&gt;&lt;span id="xdx_904_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20180101__20181231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--AffiliatedEntityMember_zqPDCCoK5juk"&gt;4,111,000&lt;/span&gt; and $&lt;span id="xdx_90C_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20170101__20171231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--AffiliatedEntityMember_zfStqqRfrYNg"&gt;3,646,000&lt;/span&gt;&lt;span style="background-color: white"&gt;, respectively, for manufacturing activities related to our clinical trials, scale-up, registration batches, stability and validation testing.&#160; As of December 31, 2019 and 2018, there were amounts due to Catalent of approximately $&lt;/span&gt;&lt;span id="xdx_906_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_c20191231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--AffiliatedEntityMember_zKzmEpKGPUv2" title="Amounts due to related party"&gt;35,000&lt;/span&gt;&lt;span style="background-color: white"&gt; and $&lt;/span&gt;&lt;span id="xdx_902_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_c20181231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--AffiliatedEntityMember_z9yX0r34phrf"&gt;88,000&lt;/span&gt;&lt;span style="background-color: white"&gt;, respectively. In addition, we have minimum purchase requirements in place with Catalent as disclosed in Note 13, Commitments and Contingencies.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty
      contextRef="From2019-01-012019-12-31_srt_AffiliatedEntityMember"
      decimals="0"
      unitRef="USD">6101000</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty
      contextRef="From2018-01-012018-12-31_srt_AffiliatedEntityMember"
      decimals="0"
      unitRef="USD">4111000</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty
      contextRef="From2017-01-012017-12-31_srt_AffiliatedEntityMember"
      decimals="0"
      unitRef="USD">3646000</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:AccountsPayableRelatedPartiesCurrent
      contextRef="AsOf2019-12-31_srt_AffiliatedEntityMember"
      decimals="0"
      unitRef="USD">35000</us-gaap:AccountsPayableRelatedPartiesCurrent>
    <us-gaap:AccountsPayableRelatedPartiesCurrent
      contextRef="AsOf2018-12-31_srt_AffiliatedEntityMember"
      decimals="0"
      unitRef="USD">88000</us-gaap:AccountsPayableRelatedPartiesCurrent>
    <us-gaap:ConcentrationRiskDisclosureTextBlock contextRef="From2019-01-01to2019-12-31">&lt;p id="xdx_804_eus-gaap--ConcentrationRiskDisclosureTextBlock_ztnMgYnmrbt1" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span style="color: black"&gt;&lt;b&gt;NOTE
12 &#x2013; &lt;span id="xdx_823_zIV8oz54AaXc"&gt;BUSINESS CONCENTRATIONS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;We purchase our prescription products from several suppliers with approximately &lt;span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20190101__20191231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_z4ACyvGjFMlg"&gt;24&lt;/span&gt;%, &lt;span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20190101__20191231__us-gaap--ConcentrationRiskByTypeAxis__custom--SupplierTwoConcentrationRiskMember_z5oVDkWgDQn1"&gt;27&lt;/span&gt;% and &lt;span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20190101__20191231__us-gaap--ConcentrationRiskByTypeAxis__custom--SupplierThreeConcentrationRiskMember_zv7GggoSt8Nh"&gt;35&lt;/span&gt;% of our purchases supplied by &lt;span id="xdx_90C_ecustom--NumberOfVendors_dc_uPure_c20190101__20191231_z41LJnJ0NjX8" title="Number of vendors - suppliers"&gt;three&lt;/span&gt; vendors each, respectively, during the year ended December 31, 2019, &lt;span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20180101__20181231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_z8oAQnqHYkZ1"&gt;43&lt;/span&gt;%, &lt;span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20180101__20181231__us-gaap--ConcentrationRiskByTypeAxis__custom--SupplierTwoConcentrationRiskMember_zJ4hU7XGgkK1"&gt;33&lt;/span&gt;% and &lt;span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20180101__20181231__us-gaap--ConcentrationRiskByTypeAxis__custom--SupplierThreeConcentrationRiskMember_zjhDFKrG2zmk"&gt;24&lt;/span&gt;% of our purchases supplied by &lt;span id="xdx_90D_ecustom--NumberOfVendors_dc_uPure_c20180101__20181231_zumjp0mpdYwa"&gt;three&lt;/span&gt; vendors each, respectively, during the year ended December 31, 2018, and &lt;span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20170101__20171231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zNSnALCZBzvi" title="Concentration risk"&gt;100&lt;/span&gt;% of our purchases supplied by &lt;span id="xdx_907_ecustom--NumberOfVendors_dc_uPure_c20170101__20171231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zaY3nRzejjhe"&gt;one&lt;/span&gt; vendor for the year ended December 31, 2017.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;We sell our prescription products to wholesale distributors, specialty pharmacies, specialty distributors, and chain drug stores that generally sell products to retail pharmacies, hospitals, and other institutional customers. During each of the years ended December 31, 2019, 2018 and 2017, &lt;span id="xdx_90F_ecustom--NumberOfCustomers_dc_uPure_c20190101__20191231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z1X1VboSYu6h" title="Number of customers - revenue"&gt;&lt;span id="xdx_90A_ecustom--NumberOfCustomers_dc_uPure_c20180101__20181231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zi7PzsIWif4c" title="Number of customers - revenue"&gt;&lt;span id="xdx_906_ecustom--NumberOfCustomers_dc_uPure_c20170101__20171231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zGcfmoUvIDsk" title="Number of customers - revenue"&gt;four&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; customers each accounted for more than &lt;span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20190101__20191231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zM8332bQqgaf" title="Concentration risk"&gt;&lt;span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_dp_c20180101__20181231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zATBihi25Tvd" title="Concentration risk"&gt;&lt;span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_c20170101__20171231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zeeZfSn6OJTl" title="Concentration risk"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;% of our total prescription revenues. Prescription revenue from the four customers combined accounted for approximately &lt;span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_c20190101__20191231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--FourCustomersConcentrationRiskMember_zruN4QGI5ak2" title="Concentration risk"&gt;73&lt;/span&gt;%, &lt;span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20180101__20181231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--FourCustomersConcentrationRiskMember_z8MeQGtPnKQa"&gt;76&lt;/span&gt;%, and &lt;span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_c20170101__20171231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--FourCustomersConcentrationRiskMember_zzPbH3qgXd03"&gt;59&lt;/span&gt;% of our prescription revenue for the years ended December 31, 2019, 2018 and 2017, respectively.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;During the year ended December 31, 2019, McKesson Corporation accounted for approximately $&lt;span id="xdx_905_eus-gaap--Revenues_c20190101__20191231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationMcKessonCorporationRiskMember_zPhuxuhWrRhf" title="Revenues"&gt;3,911,000&lt;/span&gt; of our prescription revenue, Pillpack, Inc. accounted for approximately $&lt;span id="xdx_90A_eus-gaap--Revenues_c20190101__20191231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationPillPackRiskMember_zPOwABWNHa3g"&gt;12,676,000&lt;/span&gt; of our prescription revenue, AmerisourceBergen accounted for approximately $&lt;span id="xdx_906_eus-gaap--Revenues_c20190101__20191231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationAmerisourceBergenRiskMember_zsmOBn6Tv5Hh"&gt;3,927,000&lt;/span&gt; of our prescription revenue and Cardinal Health accounted for approximately $&lt;span id="xdx_904_eus-gaap--Revenues_c20190101__20191231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationCardinalHealthRiskMember_zPrNCg3EbDrd"&gt;4,551,000&lt;/span&gt; of our prescription revenue.&#160; During the year ended December 31, 2018, McKesson Corporation accounted for approximately $&lt;span id="xdx_903_eus-gaap--Revenues_c20180101__20181231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationMcKessonCorporationRiskMember_zy9iziJlFeC8"&gt;1,610,000&lt;/span&gt; of our prescription revenue, Pillpack, Inc. accounted for approximately $&lt;span id="xdx_90F_eus-gaap--Revenues_c20180101__20181231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationPillPackRiskMember_zEue5CDdiVt2"&gt;5,075,000&lt;/span&gt; of our prescription revenue, AmerisourceBergen accounted for approximately $&lt;span id="xdx_905_eus-gaap--Revenues_c20180101__20181231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationAmerisourceBergenRiskMember_zdhm7OySa9Ra"&gt;3,246,000&lt;/span&gt; of our prescription revenue and Cardinal Health accounted for approximately $&lt;span id="xdx_902_eus-gaap--Revenues_c20180101__20181231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationCardinalHealthRiskMember_zQoUJjkaWr4b"&gt;2,308,000&lt;/span&gt; of our prescription revenue. During the year ended December 31, 2017, AmerisourceBergen accounted for approximately $&lt;span id="xdx_907_eus-gaap--Revenues_c20170101__20171231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationAmerisourceBergenRiskMember_zBdhMO7IGyYh"&gt;2,667,000&lt;/span&gt; of our prescription revenue; McKesson Corporation accounted for approximately $&lt;span id="xdx_901_eus-gaap--Revenues_c20170101__20171231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationMcKessonCorporationRiskMember_zYFac21scak2"&gt;1,959,000&lt;/span&gt; of our prescription revenue; Cardinal Health accounted for approximately $&lt;span id="xdx_90C_eus-gaap--Revenues_c20170101__20171231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationCardinalHealthRiskMember_zkhPsGnM1J13"&gt;2,559,000&lt;/span&gt; of our prescription revenue and Pharmacy Innovations PA accounted for approximately $&lt;span id="xdx_90B_eus-gaap--Revenues_c20170101__20171231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationPharmacyInnovationsPaRiskMember_zsXZhx6YsbLc"&gt;2,715,000&lt;/span&gt; of our prescription revenue. &lt;/span&gt;&lt;/p&gt;
</us-gaap:ConcentrationRiskDisclosureTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2019-01-012019-12-31_us-gaap_SupplierConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.24</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2019-01-012019-12-31_custom_SupplierTwoConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.27</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2019-01-012019-12-31_custom_SupplierThreeConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.35</us-gaap:ConcentrationRiskPercentage1>
    <txmd:NumberOfVendors
      contextRef="From2019-01-01to2019-12-31"
      decimals="INF"
      unitRef="Pure">3</txmd:NumberOfVendors>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2018-01-012018-12-31_us-gaap_SupplierConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.43</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2018-01-012018-12-31_custom_SupplierTwoConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.33</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2018-01-012018-12-31_custom_SupplierThreeConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.24</us-gaap:ConcentrationRiskPercentage1>
    <txmd:NumberOfVendors
      contextRef="From2018-01-012018-12-31"
      decimals="INF"
      unitRef="Pure">3</txmd:NumberOfVendors>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2017-01-012017-12-31_us-gaap_SupplierConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">1</us-gaap:ConcentrationRiskPercentage1>
    <txmd:NumberOfVendors
      contextRef="From2017-01-012017-12-31_us-gaap_SupplierConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">1</txmd:NumberOfVendors>
    <txmd:NumberOfCustomers
      contextRef="From2019-01-012019-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">4</txmd:NumberOfCustomers>
    <txmd:NumberOfCustomers
      contextRef="From2018-01-012018-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">4</txmd:NumberOfCustomers>
    <txmd:NumberOfCustomers
      contextRef="From2017-01-012017-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">4</txmd:NumberOfCustomers>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2019-01-012019-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2018-01-012018-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2017-01-012017-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2019-01-012019-12-31_us-gaap_SalesRevenueNetMember_custom_FourCustomersConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.73</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2018-01-012018-12-31_us-gaap_SalesRevenueNetMember_custom_FourCustomersConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.76</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2017-01-012017-12-31_us-gaap_SalesRevenueNetMember_custom_FourCustomersConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.59</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:Revenues
      contextRef="From2019-01-012019-12-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationMcKessonCorporationRiskMember"
      decimals="0"
      unitRef="USD">3911000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2019-01-012019-12-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationPillPackRiskMember"
      decimals="0"
      unitRef="USD">12676000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2019-01-012019-12-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationAmerisourceBergenRiskMember"
      decimals="0"
      unitRef="USD">3927000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2019-01-012019-12-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationCardinalHealthRiskMember"
      decimals="0"
      unitRef="USD">4551000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2018-01-012018-12-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationMcKessonCorporationRiskMember"
      decimals="0"
      unitRef="USD">1610000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2018-01-012018-12-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationPillPackRiskMember"
      decimals="0"
      unitRef="USD">5075000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2018-01-012018-12-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationAmerisourceBergenRiskMember"
      decimals="0"
      unitRef="USD">3246000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2018-01-012018-12-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationCardinalHealthRiskMember"
      decimals="0"
      unitRef="USD">2308000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2017-01-012017-12-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationAmerisourceBergenRiskMember"
      decimals="0"
      unitRef="USD">2667000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2017-01-012017-12-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationMcKessonCorporationRiskMember"
      decimals="0"
      unitRef="USD">1959000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2017-01-012017-12-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationCardinalHealthRiskMember"
      decimals="0"
      unitRef="USD">2559000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2017-01-012017-12-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationPharmacyInnovationsPaRiskMember"
      decimals="0"
      unitRef="USD">2715000</us-gaap:Revenues>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2019-01-01to2019-12-31">&lt;p id="xdx_80A_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zhJAHfjpgEEi" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span style="color: black"&gt;&lt;b&gt;NOTE 13 &#x2013; &lt;span id="xdx_82A_zcIGsXKuPa46"&gt;COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: black"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span style="color: black"&gt;Operating Leases&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: #212529"&gt;We adopted ASC 842 effective January 1, 2019. Substantially all our operating lease right-of-use assets and operating lease liabilities represent leases for office space used to conduct our business. Upon adoption, we recognized a right-of-use asset and a lease liability for all leases that have commenced as of January 1, 2019. The right-of-use assets represent the right to use the leased asset for the lease term. The lease liabilities represent the present value of the lease payments under the lease. The right-of-use asset is initially measured at cost, which primarily comprises the initial amount of the lease liability, plus any initial direct costs incurred, less any lease incentives received. All right-of-use assets are reviewed for impairment. The lease liability is initially measured at the present value of the lease payments, discounted using our secured incremental borrowing rate for the same term as the underlying lease because the rates are not implicit in the leases. Some of our leases contain variable lease payments, including payments based on an index or rate. Variable lease payments based on an index or rate are initially measured using the index or rate in effect at lease commencement. Additional payments based on the change in an index or rate, or payments based on a change in our portion of the operating expenses are recorded as a period expense when incurred. Lease modifications result in remeasurement of the lease liability. Included in lease expense are any variable lease payments incurred in the period that were not included in the initial lease liability.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: #212529"&gt;We lease administrative office space in Boca Raton, Florida pursuant to a non-cancelable operating lease that commenced on July 1, 2013 and originally provided for a &lt;span id="xdx_90E_ecustom--CapitalLeaseObligationsTerm_dtM_c20130630__20130701_zdVg4IsOI4U9" title="Non-cancelable operating lease term"&gt;63&lt;/span&gt;-month term. On February 18, 2015, we entered into an agreement with the same lessors to lease additional administrative office space in the same location, pursuant to an addendum to such lease. In addition, on April 26, 2016, we entered into an agreement with the same lessors to lease additional administrative office space in the same location. This agreement was effective beginning May 1, 2016 and extended the original expiration of the lease term to October 31, 2021. On October 4, 2016, we entered into an agreement with the same lessors to lease additional administrative office space in the same location, pursuant to an addendum to such lease. This addendum became effective beginning November 1, 2016.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: #212529"&gt;In October 2018, we entered into a lease for new corporate offices in Boca Raton, Florida. The lease includes &lt;span id="xdx_90F_ecustom--NetRentableAreaLease_iI_usqft_c20181002_zNtE8ApWI0tg" title="Net rentable area"&gt;56,212&lt;/span&gt; rentable square feet, or the full premises, of which the lease on &lt;span id="xdx_90C_ecustom--RentedAreaLease_iI_usqft_c20181002_zAHNPk4lOrF2" title="Rented area lease"&gt;7,561&lt;/span&gt; square feet commenced in 2018 and the lease on the remaining &lt;span id="xdx_907_ecustom--AdditionalAreaOfLeaseOccupied_iI_usqft_c20190801_zKJzAhT76tnj" title="Additional area of lease occupied"&gt;48,651&lt;/span&gt; square feet commenced in August 2019, or the full premises commencement date. The lease will expire &lt;span id="xdx_902_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dt_c20190801_zCw6gyvl9XJ5"&gt;11 years&lt;/span&gt; after the full premises commencement date, unless terminated earlier in accordance with the terms of the lease. We have the option to extend the term of the lease for &lt;span id="xdx_908_ecustom--LesseeFinanceLeaseExistenceOfOptionToExtendNumber_dc_uPure_c20190101__20191231_zfGD4K7SGNJg" title="Number of options to extend lease"&gt;two&lt;/span&gt; additional consecutive periods of &lt;span id="xdx_907_eus-gaap--LesseeFinanceLeaseRenewalTerm1_iI_dt_c20191231_z1H6WTPH41m4" title="Lease renewal term"&gt;five years&lt;/span&gt;. The extension option is not included in the determination of the lease term as it is not reasonably certain to be exercised. The term of the lease includes escalating rent and free rent periods. We are also responsible for certain other operating costs under the lease, including electricity and utility expenses. In June 2019, we entered into an agreement with the same lessors to lease additional &lt;span id="xdx_905_ecustom--LesseeOperatingLeaseLeaseNotYetCommencedArea_iI_usqft_c20190601_zVHqmxRLq306" title="Lease not yet commenced (area)"&gt;6,536&lt;/span&gt; square feet of administrative office space in the same location, pursuant to an addendum to such lease, which is expected to commence as soon as the first quarter of 2020.&lt;/span&gt;&lt;/p&gt;
&lt;p id="xdx_897_ecustom--ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock_z48rBQgEI9Lj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin-right: auto; margin-left: auto; float: none; width: 80%"&gt;

&lt;tr&gt;
&lt;td style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;b&gt;&lt;span id="xdx_8BC_zTCvqPmJs8xf"&gt;Supplemental lease information&lt;/span&gt; at December 31, 2019&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; width: 85%; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Right-of-use asset&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%"&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%"&gt;
&lt;p id="xdx_984_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20191231_z8a7pYazUhbk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Right-of-use asset"&gt;10,109,154&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Short-term operating lease liability (included in Other current liabilities)&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_985_eus-gaap--OperatingLeaseLiabilityCurrent_iI_c20191231_zERKcgVqrAr9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Short-term operating lease liability (included in Other current liabilities)"&gt;1,501,539&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Long-term operating lease liability&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_98D_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_c20191231_zjW5hGBbmrn3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Long-term operating lease liability"&gt;9,145,049&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Weighted average remaining term&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_987_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dt_c20191231_zbwYMEXG2Mhg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Weighted average remaining term"&gt;9 Years&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Weighted average discount rate&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_987_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20191231_zSn2Lds4H9O3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Weighted average discount rate"&gt;8.25&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;%&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin-right: auto; margin-left: auto; float: none; width: 80%"&gt;

&lt;tr&gt;
&lt;td style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;b&gt;Supplemental cash flow information for the year ended&lt;/b&gt;&lt;br/&gt;
&lt;b&gt;December 31, 2019&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; width: 85%; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Cash paid for amounts included in the measurement of lease liabilities for operating lease&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%"&gt;
&lt;p id="xdx_989_eus-gaap--OperatingLeasePayments_c20190101__20191231_zSvPYRerMxW8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Cash paid for amounts included in the measurement of lease liabilities for operating lease"&gt;&lt;span style="font-size: 10pt"&gt;1,164,234&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Right-of-use assets obtained in exchange for lease obligation&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_982_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_c20190101__20191231_z7S1xqMVFat6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Right-of-use assets obtained in exchange for lease obligation"&gt;11,171,471&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;p id="xdx_8AE_zl1S0NCrW1T1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;


&lt;p id="xdx_895_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_z2GX5VLIpZ6e" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: #212529"&gt;The following table reconciles the undiscounted cash flows for all operating leases at December 31, 2019 to the operating lease liabilities recorded on the balance sheet:&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin-right: auto; margin-left: auto; float: none; width: 50%"&gt;

&lt;tr&gt;
&lt;td style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;Years Ending December
31,&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" id="xdx_49A_20191231_zoZfKDWyM5Ni" style="vertical-align: top"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPznhG_zCShR9Y0XsZ5" style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; width: 77%; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;2020&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%"&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 20%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;1,566,617&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPznhG_zpb6wZo9RsZ5"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;2021&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;2,198,541&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPznhG_zjgMVTsisXS9" style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;2022&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;1,262,302&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPznhG_zVUB6N03Ccyh"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;2023&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;1,293,859&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_maLOLLPznhG_zNj4npP2OcX6" style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;2024&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;1,326,206&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_maLOLLPznhG_zMsI9KHAuEv1"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Thereafter&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;8,036,931&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPznhG_zXKl3OVd0UV1" style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Total undiscounted lease payments&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;15,684,456&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zWmQOGk1qPQk"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Less: imputed interest&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;(5,037,868&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iI_zRqM9FEjWdl4" style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Present value of lease payments&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;10,646,588&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;p id="xdx_8AE_zEmzow5b22Q7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: #212529; background-color: white"&gt;During the year ended December 31, 2019, operating lease expense related to our real estate leases was $&lt;span id="xdx_900_eus-gaap--OperatingLeaseExpense_c20190101__20191231_z4qcml6WorJ4" title="Operating lease expense"&gt;1,558,794&lt;/span&gt;&lt;span style="background-color: white"&gt;, and variable lease expense was insignificant.&#160; &lt;/span&gt;&lt;span style="color: black"&gt;The rental expense during the years ended December 31, 2018 and 2017 was $&lt;span id="xdx_901_eus-gaap--LeaseAndRentalExpense_c20180101__20181231_zs2WHRxallCe" title="Rental expense"&gt;1,068,275&lt;/span&gt; and $&lt;span id="xdx_90B_eus-gaap--LeaseAndRentalExpense_c20170101__20171231_zL5faYMzAg6d"&gt;1,029,205&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: black"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span style="color: black"&gt;Intellectual Property Licenses&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;The Population Council License Agreement provides for future milestone payments to be paid by us for access to certain technologies. In addition, we pay royalties as a percent of revenue as described in Note 6, Intangible Assets, to these consolidated financial statements.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: black"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span style="color: black"&gt;Purchase Commitments&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: #212529; background-color: white"&gt;We
have manufacturing and supply agreements whereby we are required to purchase from Catalent a minimum number of
softgels during the first contract year and a higher number of softgels after the first contract year. If the minimum order
quantities of specific products are not met, we are required to pay Catalent &lt;span id="xdx_90B_ecustom--SignificantSupplyCommitmentPercentagePayable_iI_dp_c20191231_zPWjHoUUPya8" title="Significant supply commitment percentage payable"&gt;50&lt;/span&gt;%
of the difference between the total amount we would have paid to Catalent if the minimum requirement had been fulfilled
and the sum of all purchases of our products from Catalent during the contract year. Minimum purchase commitments for
Catalent for the next five years are as follows: 2020 &#x2013; $&lt;span id="xdx_906_eus-gaap--RecordedUnconditionalPurchaseObligationDueWithinOneYear_iI_c20191231__us-gaap--RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis__custom--CatalentMember_zShCViTpvU7d" title="Minimum purchase commitment, 2020"&gt;5,650,853&lt;/span&gt;;
2021 &#x2013; $&lt;span id="xdx_904_eus-gaap--RecordedUnconditionalPurchaseObligationDueInSecondYear_iI_c20191231__us-gaap--RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis__custom--CatalentMember_z6U7SNDCL1Cj" title="Minimum purchase commitment, 2021"&gt;4,000,035&lt;/span&gt;;
2022 &#x2013; $&lt;span id="xdx_900_eus-gaap--RecordedUnconditionalPurchaseObligationDueInThirdYear_iI_c20191231__us-gaap--RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis__custom--CatalentMember_zdAVDHPZdg33" title="Minimum purchase commitment, 2022"&gt;5,643,291&lt;/span&gt;;
2023 &#x2013; $&lt;span id="xdx_90D_eus-gaap--RecordedUnconditionalPurchaseObligationDueInFourthYear_iI_c20191231__us-gaap--RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis__custom--CatalentMember_zAXPQP8fqCDh" title="Minimum purchase commitment, 2023"&gt;6,445,301&lt;/span&gt;
and 2024 &#x2013; $&lt;span id="xdx_90D_eus-gaap--RecordedUnconditionalPurchaseObligationDueInFifthYear_iI_c20191231__us-gaap--RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis__custom--CatalentMember_zZAH1Pv4dl41" title="Minimum purchase commitment, 2024"&gt;6,758,945&lt;/span&gt;.
In addition, we have a manufacturing and supply agreement whereby we are required to purchase a minimum number of units of
ANNOVERA during a contract year. The minimum purchase commitment for ANNOVERA for 2020 is approximately $&lt;span id="xdx_904_eus-gaap--RecordedUnconditionalPurchaseObligationDueWithinOneYear_iI_c20191231__us-gaap--RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis__custom--AnnoveraMember_zmcDDsZ0PtD5"&gt;1,049,750&lt;/span&gt;.
As of December 31, 2019, we have met our minimum purchase commitments with our manufacturers related to fiscal
year 2019.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: #212529; background-color: white"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"/&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: black"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span style="color: black"&gt;Legal Proceedings&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;From time to time, we are involved in litigation and proceedings in the ordinary course of business. We are not currently involved in any legal proceeding that we believe would have a material effect on our consolidated financial condition, results of operations, or cash flows.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: black"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span style="color: black"&gt;Off-Balance Sheet Arrangements&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;As of December 31, 2019, 2018, and 2017, we had no off-balance sheet arrangements that have had or are reasonably likely to have current or future effects on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; color: black"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span style="color: black"&gt;Employment Agreements&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: black"&gt;We have entered into employment agreements with certain of our executives that provide for compensation and certain other benefits. Under certain circumstances, including a change in control, some of these agreements provide for severance or other payments, if those circumstances occur during the term of the employment agreement.&lt;/span&gt;&lt;/p&gt;
</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <txmd:CapitalLeaseObligationsTerm contextRef="From2013-06-302013-07-01">P63M</txmd:CapitalLeaseObligationsTerm>
    <txmd:NetRentableAreaLease contextRef="AsOf2018-10-02" decimals="INF" unitRef="sqft">56212</txmd:NetRentableAreaLease>
    <txmd:RentedAreaLease contextRef="AsOf2018-10-02" decimals="INF" unitRef="sqft">7561</txmd:RentedAreaLease>
    <txmd:AdditionalAreaOfLeaseOccupied contextRef="AsOf2019-08-01" decimals="INF" unitRef="sqft">48651</txmd:AdditionalAreaOfLeaseOccupied>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="AsOf2019-08-01">P11Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <txmd:LesseeFinanceLeaseExistenceOfOptionToExtendNumber
      contextRef="From2019-01-01to2019-12-31"
      decimals="INF"
      unitRef="Pure">2</txmd:LesseeFinanceLeaseExistenceOfOptionToExtendNumber>
    <us-gaap:LesseeFinanceLeaseRenewalTerm1 contextRef="AsOf2019-12-31">P5Y</us-gaap:LesseeFinanceLeaseRenewalTerm1>
    <txmd:LesseeOperatingLeaseLeaseNotYetCommencedArea contextRef="AsOf2019-06-01" decimals="INF" unitRef="sqft">6536</txmd:LesseeOperatingLeaseLeaseNotYetCommencedArea>
    <txmd:ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock contextRef="From2019-01-01to2019-12-31">&lt;p id="xdx_897_ecustom--ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock_z48rBQgEI9Lj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin-right: auto; margin-left: auto; float: none; width: 80%"&gt;

&lt;tr&gt;
&lt;td style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;b&gt;&lt;span id="xdx_8BC_zTCvqPmJs8xf"&gt;Supplemental lease information&lt;/span&gt; at December 31, 2019&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; width: 85%; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Right-of-use asset&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%"&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%"&gt;
&lt;p id="xdx_984_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20191231_z8a7pYazUhbk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Right-of-use asset"&gt;10,109,154&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Short-term operating lease liability (included in Other current liabilities)&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_985_eus-gaap--OperatingLeaseLiabilityCurrent_iI_c20191231_zERKcgVqrAr9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Short-term operating lease liability (included in Other current liabilities)"&gt;1,501,539&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Long-term operating lease liability&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_98D_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_c20191231_zjW5hGBbmrn3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Long-term operating lease liability"&gt;9,145,049&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Weighted average remaining term&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_987_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dt_c20191231_zbwYMEXG2Mhg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Weighted average remaining term"&gt;9 Years&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Weighted average discount rate&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_987_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20191231_zSn2Lds4H9O3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Weighted average discount rate"&gt;8.25&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;%&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin-right: auto; margin-left: auto; float: none; width: 80%"&gt;

&lt;tr&gt;
&lt;td style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;b&gt;Supplemental cash flow information for the year ended&lt;/b&gt;&lt;br/&gt;
&lt;b&gt;December 31, 2019&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; width: 85%; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Cash paid for amounts included in the measurement of lease liabilities for operating lease&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%"&gt;
&lt;p id="xdx_989_eus-gaap--OperatingLeasePayments_c20190101__20191231_zSvPYRerMxW8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Cash paid for amounts included in the measurement of lease liabilities for operating lease"&gt;&lt;span style="font-size: 10pt"&gt;1,164,234&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Right-of-use assets obtained in exchange for lease obligation&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p id="xdx_982_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_c20190101__20191231_z7S1xqMVFat6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Right-of-use assets obtained in exchange for lease obligation"&gt;11,171,471&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
</txmd:ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">10109154</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">1501539</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">9145049</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2019-12-31">P9Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="AsOf2019-12-31" decimals="INF" unitRef="Pure">0.0825</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeasePayments
      contextRef="From2019-01-01to2019-12-31"
      decimals="0"
      unitRef="USD">1164234</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="From2019-01-01to2019-12-31"
      decimals="0"
      unitRef="USD">11171471</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2019-01-01to2019-12-31">&lt;p id="xdx_895_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_z2GX5VLIpZ6e" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: #212529"&gt;The following table reconciles the undiscounted cash flows for all operating leases at December 31, 2019 to the operating lease liabilities recorded on the balance sheet:&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin-right: auto; margin-left: auto; float: none; width: 50%"&gt;

&lt;tr&gt;
&lt;td style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;Years Ending December
31,&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" id="xdx_49A_20191231_zoZfKDWyM5Ni" style="vertical-align: top"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPznhG_zCShR9Y0XsZ5" style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; width: 77%; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;2020&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%"&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 20%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;1,566,617&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPznhG_zpb6wZo9RsZ5"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;2021&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;2,198,541&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPznhG_zjgMVTsisXS9" style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;2022&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;1,262,302&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPznhG_zVUB6N03Ccyh"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;2023&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;1,293,859&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_maLOLLPznhG_zNj4npP2OcX6" style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;2024&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;1,326,206&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_maLOLLPznhG_zMsI9KHAuEv1"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Thereafter&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;8,036,931&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPznhG_zXKl3OVd0UV1" style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Total undiscounted lease payments&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;15,684,456&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zWmQOGk1qPQk"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Less: imputed interest&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;(5,037,868&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iI_zRqM9FEjWdl4" style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Present value of lease payments&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;10,646,588&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">1566617</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">2198541</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">1262302</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">1293859</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">1326206</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">8036931</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">15684456</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">5037868</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">10646588</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2019-01-01to2019-12-31"
      decimals="0"
      unitRef="USD">1558794</us-gaap:OperatingLeaseExpense>
    <us-gaap:LeaseAndRentalExpense
      contextRef="From2018-01-012018-12-31"
      decimals="0"
      unitRef="USD">1068275</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense
      contextRef="From2017-01-012017-12-31"
      decimals="0"
      unitRef="USD">1029205</us-gaap:LeaseAndRentalExpense>
    <txmd:SignificantSupplyCommitmentPercentagePayable contextRef="AsOf2019-12-31" decimals="INF" unitRef="Pure">0.50</txmd:SignificantSupplyCommitmentPercentagePayable>
    <us-gaap:RecordedUnconditionalPurchaseObligationDueWithinOneYear
      contextRef="AsOf2019-12-31_custom_CatalentMember"
      decimals="0"
      unitRef="USD">5650853</us-gaap:RecordedUnconditionalPurchaseObligationDueWithinOneYear>
    <us-gaap:RecordedUnconditionalPurchaseObligationDueInSecondYear
      contextRef="AsOf2019-12-31_custom_CatalentMember"
      decimals="0"
      unitRef="USD">4000035</us-gaap:RecordedUnconditionalPurchaseObligationDueInSecondYear>
    <us-gaap:RecordedUnconditionalPurchaseObligationDueInThirdYear
      contextRef="AsOf2019-12-31_custom_CatalentMember"
      decimals="0"
      unitRef="USD">5643291</us-gaap:RecordedUnconditionalPurchaseObligationDueInThirdYear>
    <us-gaap:RecordedUnconditionalPurchaseObligationDueInFourthYear
      contextRef="AsOf2019-12-31_custom_CatalentMember"
      decimals="0"
      unitRef="USD">6445301</us-gaap:RecordedUnconditionalPurchaseObligationDueInFourthYear>
    <us-gaap:RecordedUnconditionalPurchaseObligationDueInFifthYear
      contextRef="AsOf2019-12-31_custom_CatalentMember"
      decimals="0"
      unitRef="USD">6758945</us-gaap:RecordedUnconditionalPurchaseObligationDueInFifthYear>
    <us-gaap:RecordedUnconditionalPurchaseObligationDueWithinOneYear
      contextRef="AsOf2019-12-31_custom_AnnoveraMember"
      decimals="0"
      unitRef="USD">1049750</us-gaap:RecordedUnconditionalPurchaseObligationDueWithinOneYear>
    <us-gaap:QuarterlyFinancialInformationTextBlock contextRef="From2019-01-01to2019-12-31">&lt;p id="xdx_80C_eus-gaap--QuarterlyFinancialInformationTextBlock_zMrP0NpM9FIb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;b&gt;NOTE 14 &#x2013; &lt;span id="xdx_82E_z2svtgrXJTu7"&gt;SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p id="xdx_896_eus-gaap--ScheduleOfQuarterlyFinancialInformationTableTextBlock_zEn63kaxapc7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Summarized quarterly financial data for fiscal years 2019 and 2018 is as follows:&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; width: 100%"&gt;

&lt;tr&gt;
&lt;td style="padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_497_20190101__20190331_zvWkYbBag85e" style="vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_49C_20190401__20190630_zRMMfDXcFPna" style="vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_49D_20190701__20190930_z4bm4UwCuShi" style="vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_49D_20191001__20191231_zmCEIBgmbA5a" style="vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="14" style="border-bottom: black 1pt solid; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom; width: 1%"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;&lt;i&gt;(In thousands,
except per share)&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;First &lt;br/&gt;Quarter&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom; width: 1%"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom; width: 1%"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-right: Black medium none; border-bottom: Black 1pt solid; border-left: Black medium none; padding: 0pt 5.4pt; width: 13%; vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;Second Quarter&lt;sup&gt;(1)&lt;/sup&gt;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom; width: 1%"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom; width: 1%"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-right: Black medium none; border-bottom: Black 1pt solid; border-left: Black medium none; padding: 0pt 5.4pt; width: 13%; vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;Third &lt;br/&gt;Quarter&lt;sup&gt;(2)&lt;/sup&gt;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom; width: 1%"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom; width: 1%"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-right: Black medium none; border-bottom: Black 1pt solid; border-left: Black medium none; padding: 0pt 5.4pt; width: 13%; vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;Fourth Quarter&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom; width: 1%"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_408_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zqinRDBQgOW3" style="background-color: #cceeff"&gt;
&lt;td style="border-top: black 1pt solid; padding: 0pt 5.4pt; width: 40%; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Revenues&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 3%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;3,947&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 3%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;6,079&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 3%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;23,719&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 3%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;15,902&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--GrossProfit_pn3n3_zBFlFQ2EDn5j"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Gross profit&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;3,184&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;4,830&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;22,275&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;13,023&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_40D_eus-gaap--NetIncomeLoss_pn3n3_zdUt4Odpg7nj" style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Net loss&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;(39,506&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;(55,237&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;(31,967&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;(49,435&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_40E_eus-gaap--EarningsPerShareBasicAndDiluted_zrq0GfU2BD15" style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Loss per common share, basic and diluted&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;(0.16&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;(0.23&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;(0.13&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;(0.19&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; width: 100%"&gt;

&lt;tr&gt;
&lt;td style="padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_49A_20180101__20180331_zxU5UFNBPt84" style="vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_492_20180401__20180630_zQ4tjR4tcunj" style="vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_49D_20180701__20180930_zeEuUP8H4Ijj" style="vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_49D_20181001__20181231_zMiJBlQwGAw8" style="vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="14" style="border-bottom: black 1pt solid; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom; width: 1%"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;&lt;i&gt;(In thousands,
except per share)&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;First &lt;br/&gt;Quarter&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom; width: 1%"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom; width: 1%"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-right: Black medium none; border-bottom: Black 1pt solid; border-left: Black medium none; padding: 0pt 5.4pt; width: 13%; vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;Second Quarter&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom; width: 1%"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom; width: 1%"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-right: Black medium none; border-bottom: Black 1pt solid; border-left: Black medium none; padding: 0pt 5.4pt; width: 13%; vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;Third &lt;br/&gt;Quarter&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom; width: 1%"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom; width: 1%"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-right: Black medium none; border-bottom: Black 1pt solid; border-left: Black medium none; padding: 0pt 5.4pt; width: 13%; vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;Fourth Quarter&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom; width: 1%"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_408_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zOdIA16Nbnk8" style="background-color: #cceeff"&gt;
&lt;td style="border-top: black 1pt solid; padding: 0pt 5.4pt; width: 40%; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Revenues&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 3%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;3,773&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 3%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;3,763&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 3%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;3,474&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 3%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;5,089&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--GrossProfit_pn3n3_zwxv5YtJecw3"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Gross profit&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;3,139&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;3,309&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;2,775&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;4,139&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_40D_eus-gaap--NetIncomeLoss_pn3n3_zI3UO2OHCzL1" style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Net loss&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;(24,402&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;(33,219&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;(35,605&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;(39,391&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_40E_eus-gaap--EarningsPerShareBasicAndDiluted_zHw2xdXE9Tfh" style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Loss per common share, basic and diluted&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;(0.11&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;(0.15&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;(0.16&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;(0.17&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%"&gt;

&lt;tr&gt;
&lt;td style="vertical-align: top; width: 18pt"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: top; width: 18pt"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;(1)&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;During the second quarter of 2019, we recorded $&lt;span id="xdx_909_eus-gaap--GainsLossesOnExtinguishmentOfDebt_iN_pn3p0_dmi_c20190401__20190630_zxZ3LQ9oEMs4" title="Loss on extinguishment of debt"&gt;10.1 million&lt;/span&gt; in loss on extinguishment of debt related to the repayment of the Credit Agreement. Refer to discussion in Note 8-Debt.&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; width: 100%"&gt;

&lt;tr&gt;
&lt;td style="vertical-align: top; width: 18pt"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: top; width: 18pt"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;(2)&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;During the third quarter of 2019, we recorded $&lt;span id="xdx_90A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_dm_c20190701__20190930__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember_zdrB7jeaTC48" title="Revenues"&gt;15.5 million&lt;/span&gt; in license revenue related to the &lt;span style="color: black"&gt;Theramex License Agreement&lt;/span&gt;. Refer to discussion in Note 2-Summary of Significant Accounting Policies.&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
</us-gaap:QuarterlyFinancialInformationTextBlock>
    <us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock contextRef="From2019-01-01to2019-12-31">&lt;p id="xdx_896_eus-gaap--ScheduleOfQuarterlyFinancialInformationTableTextBlock_zEn63kaxapc7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Summarized quarterly financial data for fiscal years 2019 and 2018 is as follows:&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; width: 100%"&gt;

&lt;tr&gt;
&lt;td style="padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_497_20190101__20190331_zvWkYbBag85e" style="vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_49C_20190401__20190630_zRMMfDXcFPna" style="vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_49D_20190701__20190930_z4bm4UwCuShi" style="vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_49D_20191001__20191231_zmCEIBgmbA5a" style="vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="14" style="border-bottom: black 1pt solid; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom; width: 1%"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;&lt;i&gt;(In thousands,
except per share)&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;First &lt;br/&gt;Quarter&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom; width: 1%"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom; width: 1%"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-right: Black medium none; border-bottom: Black 1pt solid; border-left: Black medium none; padding: 0pt 5.4pt; width: 13%; vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;Second Quarter&lt;sup&gt;(1)&lt;/sup&gt;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom; width: 1%"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom; width: 1%"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-right: Black medium none; border-bottom: Black 1pt solid; border-left: Black medium none; padding: 0pt 5.4pt; width: 13%; vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;Third &lt;br/&gt;Quarter&lt;sup&gt;(2)&lt;/sup&gt;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom; width: 1%"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom; width: 1%"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-right: Black medium none; border-bottom: Black 1pt solid; border-left: Black medium none; padding: 0pt 5.4pt; width: 13%; vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;Fourth Quarter&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom; width: 1%"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_408_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zqinRDBQgOW3" style="background-color: #cceeff"&gt;
&lt;td style="border-top: black 1pt solid; padding: 0pt 5.4pt; width: 40%; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Revenues&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 3%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;3,947&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 3%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;6,079&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 3%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;23,719&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 3%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;15,902&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--GrossProfit_pn3n3_zBFlFQ2EDn5j"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Gross profit&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;3,184&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;4,830&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;22,275&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;13,023&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_40D_eus-gaap--NetIncomeLoss_pn3n3_zdUt4Odpg7nj" style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Net loss&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;(39,506&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;(55,237&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;(31,967&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;(49,435&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_40E_eus-gaap--EarningsPerShareBasicAndDiluted_zrq0GfU2BD15" style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Loss per common share, basic and diluted&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;(0.16&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;(0.23&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;(0.13&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;(0.19&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; width: 100%"&gt;

&lt;tr&gt;
&lt;td style="padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_49A_20180101__20180331_zxU5UFNBPt84" style="vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_492_20180401__20180630_zQ4tjR4tcunj" style="vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_49D_20180701__20180930_zeEuUP8H4Ijj" style="vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_49D_20181001__20181231_zMiJBlQwGAw8" style="vertical-align: top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="14" style="border-bottom: black 1pt solid; vertical-align: top"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom; width: 1%"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;&lt;i&gt;(In thousands,
except per share)&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;First &lt;br/&gt;Quarter&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom; width: 1%"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom; width: 1%"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-right: Black medium none; border-bottom: Black 1pt solid; border-left: Black medium none; padding: 0pt 5.4pt; width: 13%; vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;Second Quarter&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom; width: 1%"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom; width: 1%"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-right: Black medium none; border-bottom: Black 1pt solid; border-left: Black medium none; padding: 0pt 5.4pt; width: 13%; vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;Third &lt;br/&gt;Quarter&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom; width: 1%"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom; width: 1%"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" style="border-right: Black medium none; border-bottom: Black 1pt solid; border-left: Black medium none; padding: 0pt 5.4pt; width: 13%; vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;Fourth Quarter&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: bottom; width: 1%"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_408_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zOdIA16Nbnk8" style="background-color: #cceeff"&gt;
&lt;td style="border-top: black 1pt solid; padding: 0pt 5.4pt; width: 40%; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Revenues&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 3%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;3,773&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 3%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;3,763&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 3%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;3,474&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 3%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;5,089&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--GrossProfit_pn3n3_zwxv5YtJecw3"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Gross profit&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;3,139&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;3,309&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;2,775&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;4,139&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_40D_eus-gaap--NetIncomeLoss_pn3n3_zI3UO2OHCzL1" style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Net loss&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;(24,402&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;(33,219&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;(35,605&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;(39,391&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr id="xdx_40E_eus-gaap--EarningsPerShareBasicAndDiluted_zHw2xdXE9Tfh" style="background-color: #cceeff"&gt;
&lt;td style="padding: 0pt 5.4pt; vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;Loss per common share, basic and diluted&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;(0.11&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;(0.15&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;(0.16&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"&gt;(0.17&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;)&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%"&gt;

&lt;tr&gt;
&lt;td style="vertical-align: top; width: 18pt"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: top; width: 18pt"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;(1)&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;During the second quarter of 2019, we recorded $&lt;span id="xdx_909_eus-gaap--GainsLossesOnExtinguishmentOfDebt_iN_pn3p0_dmi_c20190401__20190630_zxZ3LQ9oEMs4" title="Loss on extinguishment of debt"&gt;10.1 million&lt;/span&gt; in loss on extinguishment of debt related to the repayment of the Credit Agreement. Refer to discussion in Note 8-Debt.&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; width: 100%"&gt;

&lt;tr&gt;
&lt;td style="vertical-align: top; width: 18pt"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: top; width: 18pt"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;(2)&lt;/p&gt;
&lt;/td&gt;
&lt;td style="vertical-align: top"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;During the third quarter of 2019, we recorded $&lt;span id="xdx_90A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_dm_c20190701__20190930__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember_zdrB7jeaTC48" title="Revenues"&gt;15.5 million&lt;/span&gt; in license revenue related to the &lt;span style="color: black"&gt;Theramex License Agreement&lt;/span&gt;. Refer to discussion in Note 2-Summary of Significant Accounting Policies.&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
</us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2019-01-012019-03-31"
      decimals="-3"
      unitRef="USD">3947000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2019-04-012019-06-30"
      decimals="-3"
      unitRef="USD">6079000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2019-07-012019-09-30"
      decimals="-3"
      unitRef="USD">23719000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2019-10-012019-12-31"
      decimals="-3"
      unitRef="USD">15902000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:GrossProfit
      contextRef="From2019-01-012019-03-31"
      decimals="-3"
      unitRef="USD">3184000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2019-04-012019-06-30"
      decimals="-3"
      unitRef="USD">4830000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2019-07-012019-09-30"
      decimals="-3"
      unitRef="USD">22275000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2019-10-012019-12-31"
      decimals="-3"
      unitRef="USD">13023000</us-gaap:GrossProfit>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-01-012019-03-31"
      decimals="-3"
      unitRef="USD">-39506000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-04-012019-06-30"
      decimals="-3"
      unitRef="USD">-55237000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-07-012019-09-30"
      decimals="-3"
      unitRef="USD">-31967000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-10-012019-12-31"
      decimals="-3"
      unitRef="USD">-49435000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="From2019-01-012019-03-31"
      decimals="INF"
      unitRef="USDPShares">-0.16</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="From2019-04-012019-06-30"
      decimals="INF"
      unitRef="USDPShares">-0.23</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="From2019-07-012019-09-30"
      decimals="INF"
      unitRef="USDPShares">-0.13</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="From2019-10-012019-12-31"
      decimals="INF"
      unitRef="USDPShares">-0.19</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2018-01-012018-03-31"
      decimals="-3"
      unitRef="USD">3773000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2018-04-012018-06-30"
      decimals="-3"
      unitRef="USD">3763000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2018-07-012018-09-30"
      decimals="-3"
      unitRef="USD">3474000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2018-10-012018-12-31"
      decimals="-3"
      unitRef="USD">5089000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:GrossProfit
      contextRef="From2018-01-012018-03-31"
      decimals="-3"
      unitRef="USD">3139000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2018-04-012018-06-30"
      decimals="-3"
      unitRef="USD">3309000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2018-07-012018-09-30"
      decimals="-3"
      unitRef="USD">2775000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2018-10-012018-12-31"
      decimals="-3"
      unitRef="USD">4139000</us-gaap:GrossProfit>
    <us-gaap:NetIncomeLoss
      contextRef="From2018-01-012018-03-31"
      decimals="-3"
      unitRef="USD">-24402000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2018-04-012018-06-30"
      decimals="-3"
      unitRef="USD">-33219000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2018-07-012018-09-30"
      decimals="-3"
      unitRef="USD">-35605000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2018-10-012018-12-31"
      decimals="-3"
      unitRef="USD">-39391000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="From2018-01-012018-03-31"
      decimals="INF"
      unitRef="USDPShares">-0.11</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="From2018-04-012018-06-30"
      decimals="INF"
      unitRef="USDPShares">-0.15</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="From2018-07-012018-09-30"
      decimals="INF"
      unitRef="USDPShares">-0.16</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="From2018-10-012018-12-31"
      decimals="INF"
      unitRef="USDPShares">-0.17</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2019-04-012019-06-30"
      decimals="-3"
      unitRef="USD">-10100000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2019-07-012019-09-30_custom_LicenseAgreementTheramexMember"
      decimals="-3"
      unitRef="USD">15500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2019-01-01to2019-12-31">&lt;p id="xdx_807_eus-gaap--SubsequentEventsTextBlock_z4Sms2OiHi83" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;b&gt;NOTE 15 &#x2013; &lt;span id="xdx_822_zIc69mhC26cg"&gt;SUBSEQUENT EVENTS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="color: #212529"&gt;On February 18, 2020, we received $&lt;span id="xdx_906_eus-gaap--ProceedsFromLinesOfCredit_c20200216__20200218__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z4ARTyqNNAG5" title="Proceeds from Financing Agreement"&gt;50,000,000&lt;/span&gt; under the Financing Agreement following our achievement of more than $&lt;span id="xdx_901_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20191001__20191231__srt--ProductOrServiceAxis__custom--ImvexxyBijuvaAndAnnoveraMember__srt--RangeAxis__srt--MinimumMember_zrZC4J9F7YIi" title="Net revenue"&gt;11,000,000&lt;/span&gt; in net revenues from IMVEXXY, BIJUVA and ANNOVERA for the fourth quarter of 2019 (refer to discussion in Note 8-Debt).&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="From2020-02-162020-02-18_custom_FinancingAgreementMember_us-gaap_SubsequentEventMember"
      decimals="0"
      unitRef="USD">50000000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2019-10-012019-12-31_custom_ImvexxyBijuvaAndAnnoveraMember_srt_MinimumMember"
      decimals="0"
      unitRef="USD">11000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6800218144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTIES</a></td>
<td class="text"><p id="xdx_804_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zgie4KeD5Cpb" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><b><span style="text-decoration: underline"><span style="color: black"><b>NOTE 11 &#8211; <span id="xdx_826_zjDJXeBkIIZa">RELATED PARTIES</span></b></span></span></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: #212529; background-color: white">In July 2015, J. Martin Carroll, a director of our company, was appointed to the board of directors of Catalent, Inc. From time to time, we have entered into agreements with Catalent, Inc. and its affiliates, or Catalent, in the normal course of business. Agreements with Catalent have been reviewed by independent directors of our Company, or a committee consisting of independent directors of our company, since July 2015. During the years ended December 31, 2019, 2018 and 2017, we were billed by Catalent approximately $<span id="xdx_908_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20190101__20191231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--AffiliatedEntityMember_zKi3t8phY5Nb" title="Amount billed">6,101,000</span>, <span style="background-color: white">$</span><span id="xdx_904_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20180101__20181231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--AffiliatedEntityMember_zqPDCCoK5juk">4,111,000</span> and $<span id="xdx_90C_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20170101__20171231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--AffiliatedEntityMember_zfStqqRfrYNg">3,646,000</span><span style="background-color: white">, respectively, for manufacturing activities related to our clinical trials, scale-up, registration batches, stability and validation testing.&#160; As of December 31, 2019 and 2018, there were amounts due to Catalent of approximately $</span><span id="xdx_906_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_c20191231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--AffiliatedEntityMember_zKzmEpKGPUv2" title="Amounts due to related party">35,000</span><span style="background-color: white"> and $</span><span id="xdx_902_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_c20181231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--AffiliatedEntityMember_z9yX0r34phrf">88,000</span><span style="background-color: white">, respectively. In addition, we have minimum purchase requirements in place with Catalent as disclosed in Note 13, Commitments and Contingencies.</span></span></p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6808767536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER CURRENT LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">OTHER CURRENT LIABILITIES</a></td>
<td class="text"><p id="xdx_805_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_zjt8xYAJDmTd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b><span style="text-decoration: underline"><b>NOTE 7 &#8211; <span id="xdx_82F_zx9XuzG1nPx2">OTHER CURRENT LIABILITIES</span></b></span></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p id="xdx_89B_eus-gaap--OtherCurrentLiabilitiesTableTextBlock_zV63QVGAs9w6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Other current liabilities consist of the following:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="margin-right: auto; margin-left: auto; float: none; width: 80%">

<tr>
<td style="vertical-align: top; padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" id="xdx_491_20191231_zjFOD0PPjSWf" style="vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b/></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" id="xdx_499_20181231_zUKRCWRTVVHa" style="vertical-align: top; padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b/></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="6" style="border-bottom: black 1pt none; border-top-style: none; border-right-style: none; border-left-style: none; border-bottom-style: solid; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>December 31,</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-bottom: black 1pt solid; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2019</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2018</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr id="xdx_40E_eus-gaap--AccruedSalariesCurrent_iI_maOLCzU7z_zOuIA4I6TjVl" style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; width: 70%; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Accrued payroll, bonuses and commission costs</p>
</td>
<td style="width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 12%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">8,040,278</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 12%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">6,854,002</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_404_ecustom--SalesDiscountsReturnsAndAllowancesGoods1_iI_maOLCzU7z_zWEOrv5FWwFh">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Allowance for coupons and returns</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">10,316,298</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">5,294,120</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_404_eus-gaap--AccruedMarketingCostsCurrent_iI_maOLCzU7z_zzKoU8WkETQe" style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Accrued sales and marketing costs</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">3,285,662</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">2,288,028</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_40D_eus-gaap--AccruedVacationCurrent_iI_maOLCzU7z_zdVTD5Z7jHQ4">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Accrued compensated absences</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">1,463,878</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">1,178,110</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_408_ecustom--AllowanceForWholesaleDistributorFeesCurrent_iI_maOLCzU7z_zYhKDbjcucVf" style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Allowance for wholesale distributor fees</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">2,347,122</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">792,891</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_40B_eus-gaap--AccruedProfessionalFeesCurrent_iI_maOLCzU7z_zzjV5ZgsadF7">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Accrued legal and accounting expense</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">422,336</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">385,824</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_40B_ecustom--AccruedResearchAndDevelopment_iI_maOLCzU7z_zoBcexnUN7A7" style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Accrued research and development</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">1,049,603</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">388,675</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_400_eus-gaap--AccruedRentCurrent_iI_maOLCzU7z_zSS2ihVlbIv6">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Accrued rent</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0846">&#8212;</span></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">365,155</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_407_eus-gaap--OperatingLeaseLiabilityCurrent_iI_maOLCzU7z_zfwx69kp59ad" style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Operating lease liability</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">1,501,539</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0850">&#8212;</span></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_405_ecustom--AccruedRebates_iI_maOLCzU7z_zMCf1hCKBMif">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Accrued rebates</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">3,916,672</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">412,570</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_407_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_maOLCzU7z_zH8gZSYDqck8" style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Other accrued expenses</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">1,480,225</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">375,573</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_405_eus-gaap--OtherLiabilitiesCurrent_iTI_mtOLCzU7z_ziorxVunc4d3">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">TOTAL OTHER CURRENT LIABILITIES</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">33,823,613</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">18,334,948</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>

</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6792383728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (176,144,999)<span></span>
</td>
<td class="num">$ (132,617,160)<span></span>
</td>
<td class="num">$ (76,925,380)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation of fixed assets</a></td>
<td class="nump">415,193<span></span>
</td>
<td class="nump">181,412<span></span>
</td>
<td class="nump">141,601<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">197,593<span></span>
</td>
<td class="nump">112,474<span></span>
</td>
<td class="nump">71,516<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashExpense', window );">Write off of patent and trademark cost</a></td>
<td class="nump">78,864<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NoncashOperatingLeaseExpense', window );">Non-cash operating lease expense</a></td>
<td class="nump">1,062,318<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for doubtful accounts</a></td>
<td class="nump">307,438<span></span>
</td>
<td class="nump">216,022<span></span>
</td>
<td class="nump">4,206<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss of extinguishment of debt</a></td>
<td class="nump">10,057,632<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">10,693,662<span></span>
</td>
<td class="nump">8,661,967<span></span>
</td>
<td class="nump">6,889,323<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAmortizationOfDeferredCharges', window );">Amortization of intellectual property license fee</a></td>
<td class="nump">778,692<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of deferred financing costs</a></td>
<td class="nump">856,302<span></span>
</td>
<td class="nump">269,859<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(13,639,575)<span></span>
</td>
<td class="num">(6,951,041)<span></span>
</td>
<td class="nump">167,691<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(8,593,046)<span></span>
</td>
<td class="num">(1,782,312)<span></span>
</td>
<td class="num">(409,037)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="num">(1,880,048)<span></span>
</td>
<td class="num">(2,657,190)<span></span>
</td>
<td class="num">(4,434,130)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(3,562,629)<span></span>
</td>
<td class="nump">18,646,241<span></span>
</td>
<td class="num">(3,260,914)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="nump">13,675,008<span></span>
</td>
<td class="nump">9,107,947<span></span>
</td>
<td class="nump">1,599,510<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(165,697,595)<span></span>
</td>
<td class="num">(106,811,781)<span></span>
</td>
<td class="num">(76,155,614)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PaymentsToAcquireIntellectualPropertyLicense', window );">Payment for intellectual property license</a></td>
<td class="num">(20,000,000)<span></span>
</td>
<td class="num">(20,000,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Patent costs</a></td>
<td class="num">(1,441,989)<span></span>
</td>
<td class="num">(1,105,407)<span></span>
</td>
<td class="num">(765,291)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of fixed assets</a></td>
<td class="num">(2,450,285)<span></span>
</td>
<td class="num">(217,040)<span></span>
</td>
<td class="num">(61,817)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInRestrictedCash', window );">Payment of security deposit</a></td>
<td class="num">(20,420)<span></span>
</td>
<td class="num">(175,410)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(23,912,694)<span></span>
</td>
<td class="num">(21,497,857)<span></span>
</td>
<td class="num">(827,108)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of options and warrants</a></td>
<td class="nump">108,656<span></span>
</td>
<td class="nump">1,666,208<span></span>
</td>
<td class="nump">4,011,614<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of common stock, net of costs</a></td>
<td class="nump">77,031,258<span></span>
</td>
<td class="nump">89,907,797<span></span>
</td>
<td class="nump">68,572,635<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from Financing Agreement</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt', window );">Proceeds from Credit Agreement</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Payment of deferred financing fees</a></td>
<td class="num">(6,652,270)<span></span>
</td>
<td class="num">(3,786,918)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfOtherLongTermDebt', window );">Repayment of Credit Agreement</a></td>
<td class="num">(81,660,719)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">188,826,925<span></span>
</td>
<td class="nump">162,787,087<span></span>
</td>
<td class="nump">72,584,249<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">(Decrease) increase in cash</a></td>
<td class="num">(783,364)<span></span>
</td>
<td class="nump">34,477,449<span></span>
</td>
<td class="num">(4,398,473)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, beginning of period</a></td>
<td class="nump">161,613,077<span></span>
</td>
<td class="nump">127,135,628<span></span>
</td>
<td class="nump">131,534,101<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, end of period</a></td>
<td class="nump">160,829,713<span></span>
</td>
<td class="nump">161,613,077<span></span>
</td>
<td class="nump">127,135,628<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">$ 17,787,903<span></span>
</td>
<td class="nump">$ 1,890,166<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NoncashOperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to operating lease costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NoncashOperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PaymentsToAcquireIntellectualPropertyLicense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outlow for payments to acquir intellectual property license.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_PaymentsToAcquireIntellectualPropertyLicense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInRestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow for the increase (decrease) associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInRestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAmortizationOfDeferredCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization of other deferred costs recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAmortizationOfDeferredCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense or loss included in net income that result in no cash flow, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of long-term debt classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=119407570&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfOtherLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for the payment of debt classified as other, maturing after one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfOtherLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6800242304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ScheduleOfWarrantRollForwardTableTextBlock', window );">Summary of our Warrant activity during the year ended December 31, 2019:</a></td>
<td class="text"><p id="xdx_89E_ecustom--ScheduleOfWarrantRollForwardTableTextBlock_zOwm3dSdLZ89" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><i>Summary of our Warrant activity during the year ended December 31, 2019:</i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; width: 100%">

<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Number of Shares
Under Warrants</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; width: 13%; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Weighted Average
Exercise Price</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; width: 13%; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Weighted Average
Remaining Contractual Life in Years</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; width: 13%; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Aggregate Intrinsic
Value</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; width: 40%; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Balance at December 31, 2018</p>
</td>
<td style="width: 3%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 10%">
<p id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zzsiNoEzQ4Jk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Number of shares under warrants outstanding beginning">3,007,571</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 3%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 10%">
<p id="xdx_984_ecustom--WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice_iS_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z5INwx1jqVf5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Weighted average exercise price warrants outstanding beginning">2.78</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 3%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 10%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20180101__20181231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zxjwyr8ZK2H1" title="Weighted average remaining contractual life, warrants outstanding">1.58</span></p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 3%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 10%">
<p id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iS_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z0MUPG1iCvga" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Aggregate intrinsic value, warrants outstanding beginning">4,826,403</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 16px">Granted</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zdeXaontc7rh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Number of shares under warrants granted">75,000</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_987_ecustom--WarrantsGrantedOtherThanOptionsWeightedAverageExercisePrice_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z5RsyebWvcFl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Weighted average exercise price warrants granted">5.63</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 16px">Exercised</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zmBuFPFCyj0j" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Number of shares under warrants exercised">(1,250,000</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_984_ecustom--WarrantsExercisedOtherThanOptionsWeightedAverageExercisePrice_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zbvjQGVArDqj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Weighted average exercise price warrants exercised">3.20</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z5B44HXAAYx4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Aggregate intrinsic value, warrants exercised">2,420,000</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 16px">Expired</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#8212;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#8212;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#8212;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 16px">Cancelled/Forfeited</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#8212;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#8212;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#8212;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Balance at December 31, 2019</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 2pt double; vertical-align: bottom">
<p id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zHJWqHZEIubc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Number of shares under warrants outstanding ending">1,832,571</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_98D_ecustom--WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice_iE_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zodK7rurjHp1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Weighted average exercise price warrants outstanding ending">2.62</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zebKN0rLMd8k">1.95</span></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iE_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z6mE2IQurG9l" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Aggregate intrinsic value, warrants outstanding ending">2,447,929</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Vested and Exercisable at December 31, 2019</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zPmH3SiLrHOg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Number of shares under warrants vested and exercisable ending">1,820,071</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_986_ecustom--WarrantsOutstandingVestedAndExercisable_iE_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zSPukOwepEHb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Weighted average exercise price warrants vested and exercisable ending">2.60</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExercisableWeightedAverageRemainingContractualTerms_dtY_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z1B6TVrIP1s6" title="Weighted average remaining contractual life, vested and exercisable ending">1.90</span></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue_iE_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zXaS840m905d" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Aggregate intrinsic value, vested and exercisable ending">2,447,929</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Unvested at December 31, 2019</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zSGOyx4fGjaa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Number of shares under warrants unvested ending">12,500</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_98C_ecustom--WarrantsUnvestedWeightedAverageExercisePrice_iE_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zB54OIysC6p" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Weighted average exercise price warrants unvested ending">5.63</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms_dtY_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zBJ5gIVdV1C2" title="Weighted average remaining contractual life, warrants unvested ending">9.13</span></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#8212;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>

</table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock', window );">The weighted average fair value per share of warrants issued and the assumptions used in the Black-Scholes Model during the years ended December 31, 2019, 2018, and 2017 are set forth in the table below.</a></td>
<td class="text"><p id="xdx_890_ecustom--ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock_zZ8D5rUScNI1" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">The weighted average fair value per share of warrants issued and the assumptions used in the Black-Scholes Model during the years ended December 31, 2019, 2018, and 2017 are set forth in the table below.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="margin-right: auto; margin-left: auto; float: none; width: 80%">

<tr>
<td style="padding: 0pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" id="xdx_496_20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zG5JtLMRyJz3" style="border-bottom: black 1pt solid; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2019</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" id="xdx_496_20180101__20181231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zxQ5G1Vw01fk" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2018</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" id="xdx_49C_20170101__20171231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zyNqzjHzKqhc" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2017</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr id="xdx_405_ecustom--WeightedAverageExercisePriceOtherThanOptions_zuNoq8ji79a8" style="background-color: #cceeff">
<td style="padding: 0pt; width: 55%; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Weighted average exercise price</p>
</td>
<td style="width: 3%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 10%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">5.63</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 3%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 10%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">5.16</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 3%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 10%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">6.83</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_40A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_zP3RmzYosxR3">
<td style="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Weighted average grant date fair value</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">3.00</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">2.79</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">3.67</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_409_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_za8qxKPEG6y3" style="background-color: #cceeff">
<td style="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Risk-free interest rate</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">2.52</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">%</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">2.36</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">%</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">1.47</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">%</p>
</td>
</tr>
<tr id="xdx_404_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_zYjoJ5E78zph">
<td style="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Volatility</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">60.8</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">%</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">62.12</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">%</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">63.24</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">%</p>
</td>
</tr>
<tr style="background-color: #cceeff">
<td style="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Term (in years)</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190101__20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zftNEFwHtlHk" title="Term">5</span></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20180101__20181231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zunPuguZCAy5">5</span></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20170101__20171231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zMZ3YxBRyp91">5</span></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_406_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_zoarFoj8iWm9">
<td style="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Dividend yield</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">0.00</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">%</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">0.00</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">%</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">0.00</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">%</p>
</td>
</tr>

</table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">The ranges of assumptions used in the Black-Scholes Model during the years ended December 31, 2019, 2018, and 2017 are set forth in the table below.</a></td>
<td class="text"><p id="xdx_895_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zCEi1KljRvq9" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">The ranges of assumptions used in the Black-Scholes Model during the years ended December 31, 2019, 2018, and 2017 are set forth in the table below.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="margin-right: auto; margin-left: auto; float: none; width: 90%">

<tr>
<td style="padding: 0pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" id="xdx_49C_20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zjKyY1ZaOy42" style="border-bottom: black 1pt solid; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2019</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" id="xdx_497_20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z58HCy3xTEeg" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2018</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" id="xdx_49C_20170101__20171231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zqVe4ECcgasl" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2017</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr style="background-color: #cceeff">
<td style="padding: 0pt; width: 55%; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Weighted average exercise price</p>
</td>
<td style="width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 12%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zgkqeDYPMqIg" title="Weighted average exercise price">3.10</span></p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 12%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zFo2BcoH7fjj">5.45</span></p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 12%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20171231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zbG85QwG2Ocb">6.60</span></p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_402_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_zc1CMM4er3qi">
<td style="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Weighted average grant date fair value</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">1.82</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">3.24</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">3.82</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: #cceeff">
<td style="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Risk-free interest rate</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_dp_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z72SaZuA7mYf" title="Risk-free interest rate - minimum">1.64</span>-<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_dp_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zMBIDOEQmA3g" title="Risk-free interest rate - maximum">2.54</span></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">%</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_dp_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zWMdjkfx1yJ5">2.38</span>-<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_dp_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zber2qjmMZ7h">2.89</span></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">%</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_dp_c20170101__20171231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zQKM7FnmrT82">1.84</span>-<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_dp_c20170101__20171231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zPWhETmvYVph">2.05</span></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">%</p>
</td>
</tr>
<tr>
<td style="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Volatility</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_dp_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zvNe48pIuEr3" title="Volatility - minimum">61.25</span>-<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_dp_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zPSoEKeatYTa" title="Volatility - maximum">64.49</span></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">%</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_dp_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zgeecMMVU1w">59.45</span>-<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_dp_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zTEHa0V1Z9Of">64.04</span></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">%</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_dp_c20170101__20171231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zWtayHZ5UV75">61.56</span>-<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_dp_c20170101__20171231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zoMIKAINnb18">64.25</span></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">%</p>
</td>
</tr>
<tr style="background-color: #cceeff">
<td style="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Term (in years)</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zqaof0desl1f" title="Term">5.5</span>-<span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zZGWEqvOCNH2">6.5</span></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_z9Gj3SsGjeLf">5.1</span>-<span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_z3js9QZdKgci">6.25</span></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20170101__20171231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_z0KPl6IbB7Mk">5.5</span>-<span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20170101__20171231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zewgrtLkYuD5">6.25</span></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_403_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_zzaNpbW6kdKi">
<td style="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Dividend yield</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">0.00</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">%</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">0.00</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">%</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">0.00</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">%</p>
</td>
</tr>

</table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">A summary of activity under the 2009, 2012 and 2019 Plans and related information during the year ended December 31, 2019 is as follows:</a></td>
<td class="text"><p id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zqkCBu3wAa76" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: black">A summary of activity under the 2009, 2012 and 2019 Plans and related information during the year ended December 31, 2019 is as follows:</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; width: 100%">

<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Number of Shares
Under Options</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; width: 13%; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Weighted Average
Exercise Price</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; width: 13%; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Weighted Average
Remaining Contractual Life in Years</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; width: 13%; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Aggregate Intrinsic
Value</b></p>
</td>
<td style="width: 1%; vertical-align: bottom; width: 1%"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; width: 40%; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Balance at December 31, 2018</p>
</td>
<td style="width: 3%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 10%">
<p id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z1WbCCkctj24" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Number of shares under options, beginning">20,872,824</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 3%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 10%">
<p id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zbL3OIGB26O6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Weighted average exercise price, beginning">4.93</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 3%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 10%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zEKbZ2w6uHi1" title="Weighted average remaining contractual life">5.94</span></p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 3%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 10%">
<p id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zzIu12iiUYNh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Aggregate intrinsic value, beginning">12,239,876</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 16px">Granted</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z14SZQE1hUE2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Number of shares under options, granted">4,620,501</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z3iADKoLUTN3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Weighted average exercise price, granted">3.10</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 16px">Exercised</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zvxmSZSdljxe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Number of shares under options, exercised">(343,716</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zs2Pw0YxQ17i" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Weighted average exercise price, exercised">0.32</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zNKbPT57DNg1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Aggregate intrinsic value, exercised">1,426,828</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 16px">Expired</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z3ZQUPGssbIb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Number of shares under options, expired">(26,375</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zqBowh4gmwK2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Weighted average exercise price, expired">5.57</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 16px">Cancelled/Forfeited</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zo67pKgkpwuf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Number of shares under options, cancelled forfeited">(93,000</p>
</td>
<td style="padding-bottom: 1pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_znaQMmEOcu31" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Weighted average exercise price, cancelled forfeited">5.16</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Balance at December 31, 2019</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 2pt double; vertical-align: bottom">
<p id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zT5qwoFAhF85" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Number of shares under options, ending">25,030,234</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zrkPEZKJ1B2k" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Weighted average exercise price, ending">4.65</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zwnfeDj2mMFa">5.84</span></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zEN2HI5oFGGd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Aggregate intrinsic value, ending">3,668,171</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Vested and Exercisable at December 31, 2019</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zXjGY5zRJRXg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Number of shares under options, vested and exercisable ending">18,025,819</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zf7B2nc4VWn7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Weighted average exercise price, vested and exercisable ending">4.88</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zGU2IlSsl7Pb" title="Weighted average remaining contractual life, vested and exercisable">4.62</span></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zstAPNlwDEl3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Aggregate intrinsic value, vested and exercisable ending">3,319,621</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Unvested at December 31, 2019</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zhRoTf6JPxce" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Number of shares under options, unvested ending">7,004,415</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_iE_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z0meePN4hQb4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Weighted average exercise price, unvested ending">4.05</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms_dtY_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zO4CzDUTSACc" title="Weighted average remaining contractual life, unvested">8.96</span></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue_iE_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zKiil2Vlg8Bk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right" title="Aggregate intrinsic value, unvested ending">348,550</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>

</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of warrants, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ScheduleOfWarrantRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for warrants that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of warrants that were granted, exercised, forfeited, and expired during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ScheduleOfWarrantRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6814804752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 160,829,713<span></span>
</td>
<td class="nump">$ 161,613,077<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net of allowance for doubtful accounts of $904,040 and $596,602, respectively</a></td>
<td class="nump">24,395,958<span></span>
</td>
<td class="nump">11,063,821<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">11,860,716<span></span>
</td>
<td class="nump">3,267,670<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">11,329,793<span></span>
</td>
<td class="nump">10,834,693<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">208,416,180<span></span>
</td>
<td class="nump">186,779,261<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed assets, net</a></td>
<td class="nump">2,507,775<span></span>
</td>
<td class="nump">472,683<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsAbstract', window );"><strong>Other Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_LicenseRights', window );">License rights, net</a></td>
<td class="nump">39,221,308<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">5,258,211<span></span>
</td>
<td class="nump">4,092,679<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use asset</a></td>
<td class="nump">10,109,154<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsMiscellaneousNoncurrent', window );">Other assets</a></td>
<td class="nump">473,009<span></span>
</td>
<td class="nump">639,301<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Total other assets</a></td>
<td class="nump">55,061,682<span></span>
</td>
<td class="nump">24,731,980<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">265,985,637<span></span>
</td>
<td class="nump">211,983,924<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">19,181,212<span></span>
</td>
<td class="nump">22,743,841<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">33,823,613<span></span>
</td>
<td class="nump">18,334,948<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">53,004,825<span></span>
</td>
<td class="nump">41,078,789<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Long-Term Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">194,634,643<span></span>
</td>
<td class="nump">73,381,014<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability</a></td>
<td class="nump">9,145,049<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">256,784,517<span></span>
</td>
<td class="nump">114,459,803<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock - par value $0.001; 10,000,000 shares authorized; no shares issued and outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock - par value $0.001; 350,000,000 shares authorized: 271,177,076 and 240,462,439 issued and outstanding, respectively</a></td>
<td class="nump">271,177<span></span>
</td>
<td class="nump">240,463<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">704,351,222<span></span>
</td>
<td class="nump">616,559,938<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(695,421,279)<span></span>
</td>
<td class="num">(519,276,280)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">9,201,120<span></span>
</td>
<td class="nump">97,524,121<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 265,985,637<span></span>
</td>
<td class="nump">$ 211,983,924<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_LicenseRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of license rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_LicenseRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4428-111522<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116846819&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsMiscellaneousNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other miscellaneous assets expected to be realized or consumed after one year or normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsMiscellaneousNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6800134064">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>THE COMPANY (Details Narrative)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfSubsidiaries', window );">Number of subsidiaires</a></td>
<td class="nump">3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NumberOfSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of subsidiaires for period reported.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NumberOfSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6678561120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory consists of the following: (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished products</a></td>
<td class="nump">$ 4,976,910<span></span>
</td>
<td class="nump">$ 2,908,958<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in process</a></td>
<td class="nump">1,182,059<span></span>
</td>
<td class="nump">339,312<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsAndSupplies', window );">Raw materials</a></td>
<td class="nump">5,701,747<span></span>
</td>
<td class="nump">19,400<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">TOTAL INVENTORY</a></td>
<td class="nump">$ 11,860,716<span></span>
</td>
<td class="nump">$ 3,267,670<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116846819&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsAndSupplies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(4),(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsAndSupplies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6799884928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">As of December 31, 2019 and 2018, the carrying value of our debt consisted of the following:</a></td>
<td class="text"><p id="xdx_89D_eus-gaap--ScheduleOfDebtTableTextBlock_zhYPUVgRaRm2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="color: #212529">As
of December 31, 2019 and 2018, the carrying value of our debt consisted of the following:</span></p>
<table border="0" cellpadding="0" cellspacing="0" style="margin-right: auto; margin-left: auto; float: none; width: 90%">

<tr>
<td style="vertical-align: top; padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" id="xdx_494_20191231_zlUsomLypRM8" style="vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b/></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" id="xdx_499_20181231_zzTEfz2tgvEe" style="vertical-align: top; padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b/></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="6" style="border-bottom: black 1pt none; border-top-style: none; border-right-style: none; border-left-style: none; border-bottom-style: solid; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>As of December
31,</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-bottom: black 1pt solid; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2019</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-bottom: black 1pt solid; padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2018</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; width: 70%; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Financing Agreement</p>
</td>
<td style="width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 12%">
<p id="xdx_98E_eus-gaap--DebtInstrumentCarryingAmount_iI_c20191231__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_zbE9M3lpQTMk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">200,000,000</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 12%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#8212;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Credit Agreement</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&#8212;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p id="xdx_98E_eus-gaap--DebtInstrumentCarryingAmount_iI_c20181231__us-gaap--LongtermDebtTypeAxis__custom--CreditAgreementMember_zphlZAFEh85c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">75,000,000</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_40C_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iNI_di_ze8D0Pviiowe" style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Debt discount and financing fees</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(5,365,357</p>
</td>
<td style="padding-bottom: 1pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">(1,618,986</p>
</td>
<td style="padding-bottom: 1pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">)</p>
</td>
</tr>
<tr id="xdx_40A_eus-gaap--LongTermDebtNoncurrent_iI_zm5RcpFdX4U3">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">TOTAL LONG-TERM DEBT</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">194,634,643</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">73,381,014</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>

</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6814262064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER CURRENT ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock', window );">Other current assets consist of the following:</a></td>
<td class="text"><p id="xdx_896_eus-gaap--ScheduleOfOtherCurrentAssetsTableTextBlock_zjwlCufIbUAf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Other current assets consist of the following:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="margin-right: auto; margin-left: auto; float: none; width: 70%">

<tr>
<td style="vertical-align: top; padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" id="xdx_499_20191231_zfyPdyJN7dKb" style="vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b/></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" id="xdx_49F_20181231_zAm9YV72nO92" style="border-right: Black medium none; border-left: Black medium none; padding-top: 0pt; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b/></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="6" style="border-bottom: black 1pt solid; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>December 31,</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-bottom: black 1pt solid; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2019</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
<td colspan="2" style="border-right: Black medium none; border-bottom: Black 1pt solid; border-left: Black medium none; padding: 0pt 5.4pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>2018</b></p>
</td>
<td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>
</td>
</tr>
<tr id="xdx_400_ecustom--PrepaidSalesAndMarketingCostsCurrent_iI_maPEAOAz0Eh_zXRJw45hyjOi" style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; width: 64%; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Prepaid sales and marketing costs</p>
</td>
<td style="width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 15%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">1,583,698</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="vertical-align: bottom; width: 15%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">5,148,789</p>
</td>
<td style="vertical-align: bottom; width: 1%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_400_eus-gaap--DeferredFinanceCostsCurrentNet_iI_maPEAOAz0Eh_z7DIMLHNXcG9">
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Debt financing fees on undrawn&#160;<span style="font-size: 10pt">tranches (Note 8)</span></p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span style="font-size: 10pt">550,757</span></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span style="font-size: 10pt">1,898,074</span></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_404_eus-gaap--PrepaidInsurance_iI_maPEAOAz0Eh_zW7ZnRxvUVCe" style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Prepaid insurance</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">1,812,135</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">790,465</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_40F_ecustom--PrepaidManufacturing_iI_maPEAOAz0Eh_zF5VxublHLfc">
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Prepaid manufacturing</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">2,595,721</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0684">&#8212;</span></p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_40A_eus-gaap--OtherPrepaidExpenseCurrent_iI_maPEAOAz0Eh_zFDbJpAstKWb" style="background-color: #cceeff">
<td style="padding: 0pt 5.4pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Other prepaid costs</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">4,787,482</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">2,997,365</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>
<tr id="xdx_404_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_mtPEAOAz0Eh_zKXE2iVJ8S0d">
<td style="padding: 0pt 5.4pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">TOTAL OTHER CURRENT ASSETS</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">11,329,793</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">$</p>
</td>
<td style="border-top: black 1pt solid; border-bottom: black 2pt double; border-left-style: none; border-right-style: none; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">10,834,693</p>
</td>
<td style="vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
</tr>

</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6808838368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p id="xdx_807_eus-gaap--SubsequentEventsTextBlock_z4Sms2OiHi83" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b><span style="text-decoration: underline"><b>NOTE 15 &#8211; <span id="xdx_822_zIc69mhC26cg">SUBSEQUENT EVENTS</span></b></span></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="color: #212529">On February 18, 2020, we received $<span id="xdx_906_eus-gaap--ProceedsFromLinesOfCredit_c20200216__20200218__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z4ARTyqNNAG5" title="Proceeds from Financing Agreement">50,000,000</span> under the Financing Agreement following our achievement of more than $<span id="xdx_901_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20191001__20191231__srt--ProductOrServiceAxis__custom--ImvexxyBijuvaAndAnnoveraMember__srt--RangeAxis__srt--MinimumMember_zrZC4J9F7YIi" title="Net revenue">11,000,000</span> in net revenues from IMVEXXY, BIJUVA and ANNOVERA for the fourth quarter of 2019 (refer to discussion in Note 8-Debt).</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6786851536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fixed assets, net consist of the following: (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">TOTAL FIXED ASSETS</a></td>
<td class="nump">$ 3,476,599<span></span>
</td>
<td class="nump">$ 1,026,313<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="num">(968,824)<span></span>
</td>
<td class="num">(553,630)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">TOTAL FIXED ASSETS, NET</a></td>
<td class="nump">2,507,775<span></span>
</td>
<td class="nump">472,683<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Software and Software Development Costs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">TOTAL FIXED ASSETS</a></td>
<td class="nump">301,096<span></span>
</td>
<td class="nump">301,096<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">TOTAL FIXED ASSETS</a></td>
<td class="nump">1,619,646<span></span>
</td>
<td class="nump">490,576<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">TOTAL FIXED ASSETS</a></td>
<td class="nump">1,406,858<span></span>
</td>
<td class="nump">116,542<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">TOTAL FIXED ASSETS</a></td>
<td class="nump">80,211<span></span>
</td>
<td class="nump">80,211<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">TOTAL FIXED ASSETS</a></td>
<td class="nump">$ 68,788<span></span>
</td>
<td class="nump">$ 37,888<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6819313776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS, NET (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of Intangible Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,593<span></span>
</td>
<td class="nump">$ 112,474<span></span>
</td>
<td class="nump">$ 71,516<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAmortizationOfDeferredCharges', window );">Amortization of Other Deferred Charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 778,692<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreement1Member', window );">Council License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent', window );">Annual royalty rate reduction of initial rate during the six-month period from commercial sale of a generic equivalent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent', window );">Annual royalty rate reduction of initial rate after the six-month period from commercial sale of a generic equivalent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_RequiredMilestonePaymentsUponCumulativeNetSalesOfSpecifiedLevels', window );">Required milestone payments upon cumulative net sales of specified levels</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_SpecifiedLevelOneOfCumulativeNetSalesForRequiredMilestonePayments', window );">Specified level one of cumulative net sales for required milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_SpecifiedLevelTwoOfCumulativeNetSalesForRequiredMilestonePayments', window );">Specified level two of cumulative net sales for required milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_SpecifiedLevelThreeOfCumulativeNetSalesForRequiredMilestonePayments', window );">Specified level three of cumulative net sales for required milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid', window );">Maximum costs and expenses for post approval</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreementStep1Member', window );">Council License Agreement Step 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_RoyaltyPercent', window );">Royalty (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreementStep1Member', window );">Council License Agreement Step 1 | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NetSalesAmountPerStepbasedRoyalty', window );">Net sales amount per step-based royalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreementStep2Member', window );">Council License Agreement Step 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_RoyaltyPercent', window );">Royalty (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreementStep2Member', window );">Council License Agreement Step 2 | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NetSalesAmountPerStepbasedRoyalty', window );">Net sales amount per step-based royalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreementStep2Member', window );">Council License Agreement Step 2 | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NetSalesAmountPerStepbasedRoyalty', window );">Net sales amount per step-based royalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreementStep3Member', window );">Council License Agreement Step 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_RoyaltyPercent', window );">Royalty (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreementStep3Member', window );">Council License Agreement Step 3 | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NetSalesAmountPerStepbasedRoyalty', window );">Net sales amount per step-based royalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=txmd_AnnoveraMember', window );">ANNOVERA [Member] | Council License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_MilestonePaymentUponFDAApproval', window );">Milestone payment upon FDA Approval</a></td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch', window );">Milestone payments (payment after release of first commercial batch)</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">License rights acquired</a></td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAmortizationOfDeferredCharges', window );">Amortization of Other Deferred Charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 778,692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember', window );">Approved Hormone Therapy Drug Candidate Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-Lived Intangible Asset, Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUSPatentsMember', window );">Domestic US Patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignPatentsMember', window );">Foreign Patents Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticPatentsBijuvaMember', window );">Domestic Patents BIJUVA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignPatentsBijuvaMember', window );">Foreign Patents BIJUVA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticPatentsNonApprovedBijuvaMember', window );">Domestic Patents NonApproved BIJUVA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUSPatentsImvexxyMember', window );">Domestic US Patents IMVEXXY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUSUtilityPatentsImvexxyMember', window );">Domestic US Utility Patents IMVEXXY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUSDesignPatentsImvexxyMember', window );">Domestic US Design Patents IMVEXXY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignPatentsImvexxyMember', window );">Foreign Patents IMVEXXY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignUtilityPatentsImvexxyMember', window );">Foreign Utility Patents IMVEXXY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignDesignPatentsImvexxyMember', window );">Foreign Design Patents IMVEXXY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUSPatentsTopicalCreamMember', window );">Domestic US Patents Topical Cream</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUtilityPatentTransdermalPatchMember', window );">Domestic Utility Patent Transdermal Patch</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignUtilityPatentTransdermalPatchMember', window );">Foreign Utility Patent Transdermal Patch</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUtilityPatentTx009HRMember', window );">Domestic Utility Patent TX009HR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticPatentsProgesteroneFormulationsMember', window );">Domestic Patents Progesterone Formulations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignPatentsProgesteroneFormulationsMember', window );">Foreign Patents Progesterone Formulations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUtilityPatentOperaMember', window );">Domestic Utility Patent Opera</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The reduction in royalty rate of initial rate six-months after the first arms-length commercial sale of a generic equivalent of the one-year vaginal contraceptive system that is launched by a third party in the U.S.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The reduction in royalty rate of the initial rate during the six-month period beginning on the date of the first arms-length commercial sale of a generic equivalent of the one-year vaginal contraceptive system that is launched by a third party in the U.S.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum amount of costs and expenses associated with a post approval study required by the FDA to measure risk for venous thromboembolism to be paid by the Company before any such excess will be offset against royalties or other payments owed by us to the Population Council under the Council License Agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_MilestonePaymentUponFDAApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of milestone payments upon FDA approval.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_MilestonePaymentUponFDAApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of milestone payments payable after release of first commercial batch.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NetSalesAmountPerStepbasedRoyalty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net sales amount as defined in license agreement for step-based royalty payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NetSalesAmountPerStepbasedRoyalty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NumberOfIssuedPatents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of issued patents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NumberOfIssuedPatents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_RequiredMilestonePaymentsUponCumulativeNetSalesOfSpecifiedLevels">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of required milestone payments upon cumulative net sales of specified levels by the company and affiliates and permitted sublicensees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_RequiredMilestonePaymentsUponCumulativeNetSalesOfSpecifiedLevels</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_RoyaltyPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percent of the net sales to be paid as royalty per license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_RoyaltyPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_SpecifiedLevelOneOfCumulativeNetSalesForRequiredMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The first level of net sales by the company and affiliates and permitted sublicensees related to required milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_SpecifiedLevelOneOfCumulativeNetSalesForRequiredMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_SpecifiedLevelThreeOfCumulativeNetSalesForRequiredMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The third level of net sales by the company and affiliates and permitted sublicensees related to required milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_SpecifiedLevelThreeOfCumulativeNetSalesForRequiredMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_SpecifiedLevelTwoOfCumulativeNetSalesForRequiredMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The second level of net sales by the company and affiliates and permitted sublicensees related to required milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_SpecifiedLevelTwoOfCumulativeNetSalesForRequiredMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinitelivedIntangibleAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinitelivedIntangibleAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAmortizationOfDeferredCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization of other deferred costs recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAmortizationOfDeferredCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreement1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreement1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreementStep1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreementStep1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreementStep2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreementStep2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreementStep3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreementStep3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=txmd_AnnoveraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=txmd_AnnoveraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUSPatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUSPatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignPatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignPatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticPatentsBijuvaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticPatentsBijuvaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignPatentsBijuvaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignPatentsBijuvaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticPatentsNonApprovedBijuvaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticPatentsNonApprovedBijuvaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUSPatentsImvexxyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUSPatentsImvexxyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUSUtilityPatentsImvexxyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUSUtilityPatentsImvexxyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUSDesignPatentsImvexxyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUSDesignPatentsImvexxyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignPatentsImvexxyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignPatentsImvexxyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignUtilityPatentsImvexxyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignUtilityPatentsImvexxyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignDesignPatentsImvexxyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignDesignPatentsImvexxyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUSPatentsTopicalCreamMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUSPatentsTopicalCreamMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUtilityPatentTransdermalPatchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUtilityPatentTransdermalPatchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignUtilityPatentTransdermalPatchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignUtilityPatentTransdermalPatchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUtilityPatentTx009HRMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUtilityPatentTx009HRMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticPatentsProgesteroneFormulationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticPatentsProgesteroneFormulationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignPatentsProgesteroneFormulationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignPatentsProgesteroneFormulationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUtilityPatentOperaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUtilityPatentOperaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6806360592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of our Warrant activity during the year ended December 31, 2019: (Details) - Warrant [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of shares under warrants outstanding beginning</a></td>
<td class="nump">3,007,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice', window );">Weighted average exercise price warrants outstanding beginning</a></td>
<td class="nump">$ 2.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted average remaining contractual life, warrants outstanding</a></td>
<td class="text">1 year 11 months 12 days<span></span>
</td>
<td class="text">1 year 6 months 29 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate intrinsic value, warrants outstanding beginning</a></td>
<td class="nump">$ 4,826,403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Number of shares under warrants granted</a></td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsGrantedOtherThanOptionsWeightedAverageExercisePrice', window );">Weighted average exercise price warrants granted</a></td>
<td class="nump">$ 5.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Number of shares under warrants exercised</a></td>
<td class="num">(1,250,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsExercisedOtherThanOptionsWeightedAverageExercisePrice', window );">Weighted average exercise price warrants exercised</a></td>
<td class="nump">$ 3.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value, warrants exercised</a></td>
<td class="nump">$ 2,420,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of shares under warrants outstanding ending</a></td>
<td class="nump">1,832,571<span></span>
</td>
<td class="nump">3,007,571<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice', window );">Weighted average exercise price warrants outstanding ending</a></td>
<td class="nump">$ 2.62<span></span>
</td>
<td class="nump">$ 2.78<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate intrinsic value, warrants outstanding ending</a></td>
<td class="nump">$ 2,447,929<span></span>
</td>
<td class="nump">$ 4,826,403<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber', window );">Number of shares under warrants vested and exercisable ending</a></td>
<td class="nump">1,820,071<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsOutstandingVestedAndExercisable', window );">Weighted average exercise price warrants vested and exercisable ending</a></td>
<td class="nump">$ 2.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExercisableWeightedAverageRemainingContractualTerms', window );">Weighted average remaining contractual life, vested and exercisable ending</a></td>
<td class="text">1 year 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue', window );">Aggregate intrinsic value, vested and exercisable ending</a></td>
<td class="nump">$ 2,447,929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares under warrants unvested ending</a></td>
<td class="nump">12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsUnvestedWeightedAverageExercisePrice', window );">Weighted average exercise price warrants unvested ending</a></td>
<td class="nump">$ 5.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms', window );">Weighted average remaining contractual life, warrants unvested ending</a></td>
<td class="text">9 years 1 month 17 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for unvested equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format,</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExercisableWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested and exercisable equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format,</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedExercisableWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which vested non option equity instruments outstanding as of the balance sheet date can be currently converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of warrants vested and exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on warrants exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_WarrantsExercisedOtherThanOptionsWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which warrant holders can acquire shares of common stock with respect to warrants that were exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_WarrantsExercisedOtherThanOptionsWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_WarrantsGrantedOtherThanOptionsWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which warrant holders can acquire shares of common stock by exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_WarrantsGrantedOtherThanOptionsWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which warrant holders can acquire the shares reserved for issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_WarrantsOutstandingVestedAndExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which warrant holders can acquire shares reserved for issuance, for fully vested and exercisable warrants outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_WarrantsOutstandingVestedAndExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_WarrantsUnvestedWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which warrant holders can acquire the shares reserved for issuance on warrants outstanding and unvested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_WarrantsUnvestedWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6800499392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 18, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from Financing Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,902,000<span></span>
</td>
<td class="nump">$ 23,719,000<span></span>
</td>
<td class="nump">$ 6,079,000<span></span>
</td>
<td class="nump">$ 3,947,000<span></span>
</td>
<td class="nump">$ 5,089,000<span></span>
</td>
<td class="nump">$ 3,474,000<span></span>
</td>
<td class="nump">$ 3,763,000<span></span>
</td>
<td class="nump">$ 3,773,000<span></span>
</td>
<td class="nump">$ 49,646,937<span></span>
</td>
<td class="nump">$ 16,099,460<span></span>
</td>
<td class="nump">$ 16,777,713<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=txmd_ImvexxyBijuvaAndAnnoveraMember', window );">IMVEXXY, BIJUVA and ANNOVERA [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementMember', window );">Financing Agreement [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from Financing Agreement</a></td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=txmd_ImvexxyBijuvaAndAnnoveraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=txmd_ImvexxyBijuvaAndAnnoveraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
